<SEC-DOCUMENT>0000200406-22-000086.txt : 20221027
<SEC-HEADER>0000200406-22-000086.hdr.sgml : 20221027
<ACCEPTANCE-DATETIME>20221027160259
ACCESSION NUMBER:		0000200406-22-000086
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20221002
FILED AS OF DATE:		20221027
DATE AS OF CHANGE:		20221027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		221337293

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>jnj-20221002.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:33652491-8200-4ac3-aad3-f4f6756ccdbe,g:4fa62845-cfde-4969-940e-970c42754004,d:5a494e6be84b467a8d7a1188e54512ab--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:jnj="http://www.jnj.com/20221002" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20221002</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80L2ZyYWc6NjBiZDQ5MjM1ZmM5NDcxODhlMjE1YmFmM2E0YjY4YTUvdGFibGU6ZDIxZDE0NWY0NjM1NGNlNThkMjA0MmU3NTFiN2I1OGMvdGFibGVyYW5nZTpkMjFkMTQ1ZjQ2MzU0Y2U1OGQyMDQyZTc1MWI3YjU4Y180LTEtMS0xLTc3NDA3_4e0bdbc1-6386-4ea3-80c0-a863172e8863">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80L2ZyYWc6NjBiZDQ5MjM1ZmM5NDcxODhlMjE1YmFmM2E0YjY4YTUvdGFibGU6ZDIxZDE0NWY0NjM1NGNlNThkMjA0MmU3NTFiN2I1OGMvdGFibGVyYW5nZTpkMjFkMTQ1ZjQ2MzU0Y2U1OGQyMDQyZTc1MWI3YjU4Y181LTEtMS0xLTc3NDA3_0f269ab4-e9e8-4b18-931d-056d439b83c5">1/1</ix:nonNumeric><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80L2ZyYWc6NjBiZDQ5MjM1ZmM5NDcxODhlMjE1YmFmM2E0YjY4YTUvdGFibGU6ZDIxZDE0NWY0NjM1NGNlNThkMjA0MmU3NTFiN2I1OGMvdGFibGVyYW5nZTpkMjFkMTQ1ZjQ2MzU0Y2U1OGQyMDQyZTc1MWI3YjU4Y185LTEtMS0xLTc3NDA3_6bbd45ea-a228-4c3f-9657-66e94d9147b7">2022</ix:nonNumeric><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80L2ZyYWc6NjBiZDQ5MjM1ZmM5NDcxODhlMjE1YmFmM2E0YjY4YTUvdGFibGU6ZDIxZDE0NWY0NjM1NGNlNThkMjA0MmU3NTFiN2I1OGMvdGFibGVyYW5nZTpkMjFkMTQ1ZjQ2MzU0Y2U1OGQyMDQyZTc1MWI3YjU4Y18xMC0xLTEtMS03NzQwNw_ff6a6dc1-5088-499d-bdb4-f4f012ebb010">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80L2ZyYWc6NjBiZDQ5MjM1ZmM5NDcxODhlMjE1YmFmM2E0YjY4YTUvdGFibGU6ZDIxZDE0NWY0NjM1NGNlNThkMjA0MmU3NTFiN2I1OGMvdGFibGVyYW5nZTpkMjFkMTQ1ZjQ2MzU0Y2U1OGQyMDQyZTc1MWI3YjU4Y18xMS0xLTEtMS03NzQwNw_6f531b40-a31a-4576-8b56-376a4b916fe8">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20221002.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1079dea4094854a0d8215a7b7bee77_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5474370380a497b82e6a430f952af34_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12fdbd4684c2453789af8d70324bc71a_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4072dbe684f043559e6b3816abcc50e8_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414d244f8d08480fb66a8026c8d80ad4_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a83e7272e834e8fae6c7fe265b3be1b_I20221021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i88a45c1864b841c3bd10c2ba6038465e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00b96c9b90b442fab76aafa9fe0f84c0_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b472a7b024e4350a7efccb19639fe5d_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i897e4f04cc0743dab9335bb279413316_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i761acbf210e54d4fb1c6163ec297f3bf_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58e73c0430be475c963749b0d5dfc1f0_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69a1c834e78d4ae6845c115cb37b55cc_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e381efb52944e08881f1e2b2dbd0e62_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia001762d1dae4d37bc5d624881fae1f7_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46a1b195ff7d410ba97f45f6c00f9cdb_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9083e68f134a6b959f8e81ba70dca0_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17402ff8071d436f8f5e04dfd2b0c961_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3af518980d74cf485a8c59539fbb189_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ceeba3817c74be08a112b20898f78ce_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib60c35086bcc4c329bbe423674e693a9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04a23e81d62c4182843a25a386d3c871_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a4a604382b3438899182204e090fce2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71751112fea74037b276e2ca1d6230b8_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d8e299561a467d8fbca5be63ecf1db_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d3b5d7c62914a7d86c97bf6c03bc15e_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if04a9117c60243599ca157246ed62b82_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2841ce9e4bda45d8adf1dbed8d0ebb98_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc527a1e93694a149099814a6a780f3f_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i627a7e7e8917482ea7ed3fcf4e5c6e7c_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if42495605efa42b5bb22a39f20c44adb_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i922b7adff7f14b97a51ffc13b9d0eb2d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic763a721f63241119bc153b39881a917_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic42e25ee27d54341885e6febcb82d781_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4184dedf017492f81476885b7412820_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58afd10b08ae473ebc46006082b2cec6_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50585c37981c4ff18094df49a0252cde_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a790e2ad784bd7ad2cc7889a2256a0_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e846d19941748ce9cbcf17a4f318405_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7466db7fb3de4e73b837ebe5f0b10609_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c66231e52f741d58eefd24bb80b245b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d5a9d98b51145fda780e8e3cb899d96_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5af1680d3ee24b0db79fec7b602aee32_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i360f555817294c969083b2da5b0c7012_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia39a746470bc4c38bb1c35c5afbcd727_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i784f48887ba4406090c0c953b964f651_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba060ae7e2bf4658880cd1a19b71adf6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i543c0b5db3074157b1c389cc2cb0ab48_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15558a3176fc43799fe21d45d80bca2a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2612dc9b393420aae1223b600b75635_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2af979d2806348c99fb689ce6819de96_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0536181aa78447d784d738349332b35e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i661087c5259246cfa115e122efa6dcaf_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i235a103d58c546b8837d113d0020a52e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica2f1087d4384fb0b48f876aae358e67_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i813f5728d4834e4081f50346c8257c32_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cb8f0f0413e458aa5d67d5e5470970a_D20221001-20221027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcf057d296c84d089ec6d58708ea1502_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if32850109bc44a7fbb02840853387b1a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fbdf34d70c14edbb7715d0150857e3d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7787b0e8db0d4969ac6e93a11454dd47_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i470f1742dc564aceade9de615023f5d9_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i522547423bad464f84afd2d37c47a86d_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21aa856799804b82aa87e91511e1349b_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id36c39c3a9764cb68cde96d61776f981_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dbbb67dd9c940368c9c692b2970e944_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i957a0b8f238643b5a7f04ec25dd1ade7_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c547b36424143b69e5081413c4fdc53_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i717dee1c18bf45e493386905d911c3e8_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62511374dce64f139252ff8bd59a8db6_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a64086e3de14779a155947b262f6215_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1c84b4bb409475ca45e6496196a8bfe_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7879ef9eb79f474c8938fb5e9a08e0c1_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd146d7e5a948cb9bea7e9644188230_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0995bad590ed43e0bd73dc14bc4125a2_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d9447c402644708f5027054c7c807d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f7c9ef50ebc4fa19a9a1d74ac4d6b69_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i888f5820c4ce448da471f2eeb67baf91_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5a1bf6a5e0a43f89bd6a0e1d76c50bb_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee5060692494cee9c6f548b6e07c2a1_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica35d2547f134655985b599491b5d2de_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027b98ae63404a32b51e156b3616bcf5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieceea25b4808416c866a84c9e93d2bc5_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4346ff30c79f4cb6889ccfc5de69e800_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic14f778c18a3446c9134ffdea15dbf34_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dc12c5833b246768b8eb8a92f87ba5b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07d3d9443f8444bbaf8ea1e69ddb15bb_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72dbeff9573f40a5b9ba376ad81d5398_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb87a9281a92433d81c4a3ab6ffcf38e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f92be1d7860435ab1166cf51a2c9ada_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i699ea2f9280641c6a2c2ca9ae65c2e9e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9571f8c7ed824bd7907d0dc67ac2cbfc_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78647d618ebb4323997e495ab6b689d1_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6804eaf6e9a2498bb21b278580ca9ca0_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i132eac11468e4392b097dc2bcb6b935b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7950a50b27c4ebdb91385e119fda9f5_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89a2ff3d08834c418a9d5c5493adff6e_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc16a1145204ef7b053987f85b7f51d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98263d9f7f8641fd9e965fa50bc0532a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82b29d715d9741d3abce2df4d39b309e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4f312e218c94f0da6a1676afa932315_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fde6866da6845ffa717894b879f8c97_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7366275be3ae410893ecf9408865b9c7_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0b992f36af4511aa5daeaab0f6fbab_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8378ff8e008a4098af1366d8ed328c04_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0757ae310f7c40a68adf9115fdf4e04f_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i773b6479d1f84dd099a271d67f39d97b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f6aac49f1e34f848da45a55d588af8d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98dd0e4104d64d1e9e04143dee5c8d7b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30c2531c320b4c429410121c99424073_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if365333f1f9d4429b45bb40e00408696_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02b8db1fe34e46ee8c685ab4da2008f5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e443c797bce44b8904549f48d8fc7a7_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i425df44efbe4432dafc49cc44a80a0c5_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc5be715bb3247109709d1a846e794a0_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971a920aa5d64f5992b34b4dddba6c81_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7500ee5f78d14a669d9868e1d786c583_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a948b4810449dda6fec2b6273bb8cb_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eecf9b0d2d34ad7af622fbf637bcea6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac33f410fd64a498d0320619c400fc0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if68cb6de6b7547ddbd0a239ef2261809_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd364fbacd784c248996002106d412f1_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e79e3afda2d4ff4b9c9715fed272c0d_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idced9fd0a0dc40e2962f7034fb149e25_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cfd0ec8b28f4d61aef0be150644a052_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa79f363437b49b18f54f6dfea462a0c_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f939a4ef544f199f0a9ba9f0486f0e_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29be9feba45c4fbf8a5331a5258734dc_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20d1c20c564471ca693f0dbf7e3e2b7_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531bee53a47b496db85de6734c8b4ba1_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35ef3a7f91694f4784dabed8656e3e52_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891a31716b3c4d33862563ef6041c58c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i234b580d2ab945b7a1da2967b50f2f0b_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c2c6e50b3414bb7b581acb7b2ddf236_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4b5f475cfa74c208c0321112d12da5e_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide20e84875b34943bcfaf3c9ae95202b_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b950c0556549258d0b61b677f0b680_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe5347877f646f8a69accb4b750d574_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic472125573384b52b4aa88304af5b630_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ff0963b4e07465bbef6c78a5da86146_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7792ddd751e74a3fa36de680b670123a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42bf0720b1074baa96eb44f6c995dbfc_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7912b942d37f465fb3e53088b7761ba5_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2000357e194a441e9534374b54cbc72a_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c24b49746b4613b703772fdfe9f6eb_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd7f9d1ac03a4e2ea6d1d353ef976c71_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bb2d4354806473f89aeaf974654c5d0_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i370583126d5b4bab94e9ead51c975ebf_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee255d90708413cb5622bce2a34a5eb_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba8c6cab16ef4288b07b2a65d72b7ca7_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e59de01264548d093d60627efe88e9d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10d2e79904b6488a85d7505ca382bbc1_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i487741e9485f4d4989b2d9bdd6959f03_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f8bb4709c5441d49ce49132893c52de_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eba85641ea146e5bc22ff998e193635_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185112cfdae241938bc5001036d374c8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5777045ad8034f0ba971fbea4fe60d05_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8c1c1667b484cd296b17f3e255a344c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65ea7c0fbd54a3d9557ee7eb1a25b7c_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6bb3d370ef04b7d8291df862fee2c4e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2db0b7f18904840b6133ca100157ba1_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97ce603cf39f42638ed7c1c786b7b5cf_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedd9f71bda284795aea57b0e3717a2fd_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09ae709d11a747f5bcc44c920b026868_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i995da9ebcbab4f4db89d58d96f77b4f5_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd6461d92f04ed69ce2217f18942c36_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b27f2a754554e6dafba78c082f6f40b_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if177366e6dce47ec8b19785b5a66cc57_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i606547907f3f4875acafd89bf36f7292_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47c3297a283649f18a41e3b7ce1b4275_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a1fe51dbd41434cacb992b4b627a3a1_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5794f5fa77224cff877efb7f11be88a9_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8788e8f33a374f91990206b3e2c99555_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ae9a8d6d144029b31ac56599a2c97d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b0e63e41f6a4d339367644bfc21181c_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib372927ab7a04736879231296a9857fc_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe72fcc581ba4b3aa24c4cf87da552b5_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9edf61dadd24a7a89bfd4eb35fdb595_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5ec42981eb24a7b8f39e90fcfcb3b97_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7787c920b4fa4851a091b1d05760f26c_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9abd0ce724b48d1878bcaa4742736aa_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13455fb6580c486fa719cf5f9b78801a_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17df52d9c169494fb0dbcfa0f99740fa_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf68b60de7014cf2a3fbb8410bc3a9bd_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f13cabfbd6e4267a7040e78e38ec939_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91092ba038134ef4a95f7a6d01647908_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e55b859d5454474b61a342f2ab11b53_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01e0e3590e6e48db894610a47ecd29c5_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57a26835dc1c47168bfb6605e72bd3bf_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e80c564ea64f3fbe9520902829f8e1_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12c14427081a4db2aa89c55987a2b503_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dab1f127dfc4cc180ee120f93e8d77b_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a3800ae61df48de8d071ba58133741a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id965e9daba4e49939bc440149dcc9a39_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15f41a6eac24347aff0d98e523e6a33_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i298d351dbfee46d79686114bc7415cde_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bfc8f6514464a3799d65367ae9e9037_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacffb22cdad9443a846f401be599d84d_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07d551fd651b44dc8ea8cbf5d62affe2_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3f1d898f0d04ab99472e9d1769191c9_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic52ecafdfee4446badc41ecd13c9f2a2_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i980e7f0f06314813b0a382c339d86df1_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9006cebe9baf49098f28b71ba8b0b364_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e6b7c5e255f431184d25955b77d4780_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0157c2d40621415cb530f8b4f529c1d8_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09041d6f39a84ccea0a739091619c846_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i262548be13894c1896c025888251703e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5de5b6e1d4334a008a1d9c060b09147b_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870bf42cc2f24c9ca6e75df10312d19f_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94e04502c4854e9099be4395f58835e5_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d2496e033944a6858188b916c2ec78_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i2b4f83eb2b694aaebcf4695cd84e55b9_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70cc3db8241b44bdadd5529cad658578_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i030634cc2bab40ba860c6310273384f3_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="ida226c289b3d44c98e6aca58fd729233_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ed802dd203a43d3afa9f1915bf381d2_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38954d1e3098492e806481f25cf864c8_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8507feada10d4116ae4715be0f83f61b_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic33663885e724dba955223059c45014c_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3220255239e4430e8bc071481c23af70_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ac596ef8054dd9bec84c0c13239c57_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i463dccc9a3684c049eac0a5bb39ebf77_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f76f6e1c7584e90bdce33b5939f49fe_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4e881a6337c48eba78aa5737f820648_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9913e7637b4fefad4d9411b1e57dda_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c801bf0bfb74c4fb7e197403e0c19da_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e9ef1c58573413fb263475037c7df0f_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec007660d14f41158b78244410752ef6_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib01c6007919844dc8a0fff621af91ba7_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cefb1e606b8454bbae8580ad29ba4e9_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd59161e160443be992c19c3e552de73_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46bc9af826d04e288de22182a64ee453_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0955f4509fed4180a52c8b18fe4c4b13_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5267d6a76fd344b9aae4d32ffcdb89ea_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1f362e68c5546b8b0891c1e060d692e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a74be7a73c41d79f6e2392d1d60ea0_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1bec1f0d9314920bb56531e382e7cdc_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3efd972e13344cdb42226b639f85eea_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f419a473f34fb29199544a2c8cb16f_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81460a08681c4e40ab454eff67450960_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78f4c5055c844c61bdbada64f0290039_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa22322ad88f4cfebf3bdcb75ad25975_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06fdae26fcfd4a60b871ade74a542ac4_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32266ba4f72e43a792a31e7faa9148b2_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id940c82927a641158fe648918accafc9_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if847a21b92f348a0b7a4025c882fc0e2_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6a26673c434118a68c645642b3fbc4_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f89bf72f2ba4b478472d343bdeec569_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29078fb071994051bd63d8f4587eb909_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8851eff20e5145c5bca1a1ee92617a5e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i477c86f7309842dfb55248451d3efa39_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ca4d871cf6b437582cda14e89bb594b_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c7dc65157e44d3aba2a140b03b946b1_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib89592a0e11e4753b648c5e3cc03ee9e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36742f2d0f1f4ab8a7597150249a02bf_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i733cb704b7674b0e9a24cc4ab884180a_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae69d4e77db7465fb0571ca12ef0fff2_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4ff5147e1a54074a2362ad5feee7c65_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia452af2ce27e4af2a660f83bf6fbda90_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b7612a89a5a4d3e9fddec30bc11ee22_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8534a543c9964871863c7e4c16232cb4_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a53e2b415aa46dba827a399ff3c0318_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23e399c422d04b4c9802c29f75c01f77_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i515258d897424d1d91d0dd5e6ba17edb_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ec40d315b946f2b9c6a729deef3a36_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f6e82e7b82a4263986c8f5f799e01aa_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331180abea9a4581bd4f74309a491129_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a76440ea8554d14aface7459e0c118e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id71489b63d304114b1ee5ae439e5265d_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f32d63a3ac54710b81b92f90e389147_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04beb44383334787802dafc265394766_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ab907b696a4139a072f00b70bbda49_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i725d5d1c65b54fe9961ae484ef90be5e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i165e3f370fbf46ed93bf4cce9e54727f_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i428e006eac404991b3e3d872ddd1c1f7_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b9310bb6dc4450490632d0116946ede_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id11fe423cd3a474cb70088616178415a_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36a4cef5d4f402fbd7eac9f85a18b17_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86512b1f50de4ad88f542164448d26c1_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff6bcf8520fa4057a7f4a5589d4684d2_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2b9b9e93ec74f2b850cf4cacc8bbe2b_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12550a2b68084f8b9214b4faeb85013d_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6f68f74915492181e040fe2b309c71_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic72911776cd542c5852cd1d5ca05062f_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e72ec4950db4ec699a1131d9548a556_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic668dba37a974482a824018731b483bc_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i955013ec18f9497e9a9c99fee52c731e_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fe780e81ace4f5c8b98dcf4b0ac0e21_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7deba806ae124861960bbc06843762d7_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0861e096ce334fdfae380bc7f0d69b72_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbdbc1ee962e45f7901626232a02576c_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffbcba0a9b874fb6b9472d4fa8d72638_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333dd5feeee74afbb5ad0dc46eb323e0_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0422e59a7ebf4c4cbf75f1140ecc88d0_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ebbcfaca4140c38e6ed48542fbd4de_D20220103-20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i017db5ac595541f0b302582a410ea26d_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd1b1fcff0145219d7fb406847ea584_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d211681392d483b8f62c60a8d8a4dc2_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if235130eab4e408b92fb2c43ccb98f42_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d60d3f4537d4080a89795d512b26b9e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if38fd805a6f8420da833524d3340a063_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04fab62da2c141f888b893afab6164da_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i332809e8f61c44149c2e4659a135fe38_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff704175779c4e83903efe4bb1b1eb21_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i206b36fcd5884efc8e2d9f8f10a5a918_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i096b7900f5fe4d45964781506fef7cd4_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d64a67a236a4c7e9d6dae0c1d2fd34a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i944bc08bbd494170a723fa335d775693_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0857a3c31a28448189abbe9edefd142c_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfb9d5a6b7ad47d78a2e5ef496f4cbb9_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib49ea28b1f6a4233b9e391f4fe2d7695_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08ec2d8a0db84c62aeaf6386e449a7e3_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cde6a52268347428b5037069103d820_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia74220ebf81e4065a938588bde5498e7_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78fcb0fd89d14eb6b29ffdbd3720e7ce_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54a459b3600145d3b4107cf4bdccf257_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i941ed2c1db534253af22569d7910ede8_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f1d220f585f4dec831f31a5f9ce8adf_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aeb275ad1f442feafbe9c4c30a972b6_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec58864a102d428fba3c283afdd1c086_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63196f90176a4d4c89a11a247847a7d2_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib10849b3cb49478ebbdfac543124e1cb_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i343ce984f8d243c99d19169f2ce469e8_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie94a7099ba6b469abec25cbdb9df79c3_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c7b7f8b4fa541888ad11c59317e305b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i110338127fd4477e9581eeb21a88403b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba3692bbfa0746ad97c0e05cf2f74b81_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib155353bba1e4367acb4afc65093ac17_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c11083b6fd4c70b63123ebd3184bcc_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59bf5576de564479ab33549d72205efb_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b06f4a72c54053ab762b36aa11132f_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie061b083973e42d4885e9f9780a30d24_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id127890eb1d746d2b41f02aec9b35a5a_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i028f7b0cc1fe4417b3829de872b9bff7_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20bbf2239aa6444fa5e65541167d42d9_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6217c9284834a96aba0480663c6c29a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fc1b31fec9043679c9a24c4e7d7eb15_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i728ae91795a049659be1d1a2f8f086d6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i197d29cb3728490aa880fe1b2febaf85_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8a1658b7674fd480d2da4366870996_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8200dc57bcf946c89ace0088bd07514a_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c3e6ddd1e342c29393fe34fb925065_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf3eefd4fdc4df398da4efb9abc13be_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31d505d43664fc6a37a1a6f7390b6d9_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f6eab93c9b4d1fb2d19580cedc8b4c_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4fadfd175984a22b86dc24c89dc4bc0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15720a18344e469886257608fa371d4b_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a609c570d4247459662c095f2834797_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5be2488acb464b53b616386ec7557fd2_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbb0f442da954722b1c33088aa5d0bc2_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b5a875d8089486c8f44852cabb6ecfd_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i211cbd1cb10f4ee7839006b5eaa4a2bd_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i258122d0b65d4169b5b5519e4d8d5074_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29c2eb559dcd4387b1033c88491e2a2e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0235b711c804ebfa7876a02dd285bb1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec063ee8c3a4470694b6e73255290c52_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04db1cf7ec4e45bba56bc0d72ea66e02_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2286d04e2f4ee5b108615874070bf9_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd220bba8484f9ab20dffe40805100c_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ebc82e0cc7a43579e7cb5d5261ff68b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie05209c75c064c149e32ca91f101c128_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60597d445fdd471dbefd75d06e9d49b6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59769c19cc641d08a4a75d12515d22c_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadaaf79391e243ce9580a4a5f82c3c1e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40537dd17e641f18a84d3dae0e1e91e_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id74e23c5a1ea4a3fa4324f3cbebba2ec_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57dad0479d5f408586720d9c4f156c48_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6571e3bbe1c5478088cde974f1a794ff_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cf927e34f9e49f0abbbe3cd9b236507_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa1da1546f194c1fb0e2caecfe484dff_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if82e78c4579b4156b6cdbcf7c3cee740_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0699f62151e4b32a947734f89b31cdd_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117745a3dd684de8974772ece9648d65_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9a0c60f81b457091ed4cdfdfcafa87_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85433357f9bb4fba8f50ce185075b2a3_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76af37281c8f42adacabdb80e1047e01_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f4bdb37dc4b4d47be92fde1fbb37bab_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia378214014c14267bb7dedcdfdfa66ce_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa62c7427744e21ad6b4c38c6a07153_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59345d38f1c4186b66ae8cc16f7a721_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e80efcfa77b44a5b447cd4080557081_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie501da18e9c84dbdb77d1e9fce501b01_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic34261d9fecc4b469fbfc7320a06ad74_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38e077f4d7ef4d1ba0449d563d1247a0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8bba328151b4f589a73606eb0809caf_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b41c4b48d4d43e0a26a3b93522fd773_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c2d3a271be74fd9aea5facb617f9860_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4f833113f7041289bb2eb913b130ebf_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e5cf3b01a84cb493dc2721b5a74b79_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320bb566db254466ba9c6a695628a6b0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e5886c2fb184bac9cd7ffe1b974ffb7_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i755b8f931470497ba00724a368f9cdbe_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c1d5e55ddc144bc825a5b127870993d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44a1dbe5705741b68a24e0e337ef63e8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc8e23dcc91d417896dc4ffb5479cb12_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11459a5bbd884b9cbcefb0dd8cc442ec_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3cc1f7e1fa54ceb9ccc93da93684bef_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i676de123fa744973b1d51400eabfad36_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58528c896007432da65d8fa36f867e8e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i050bad26138643da94080c24dc214a0b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ebea684bc144c3ab6b069f307243b39_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ab2943111a45ddb4c3689d0f23f0b8_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c86dfc4bbb843088a0478dacfdda4eb_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie710509f29a84a6798f07d16fdf4bc25_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if36c2d2204694bd1b65beb048a38a087_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27e0991470e3476189d1336285252c30_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9da5926e9f140999d1bba65c342a33e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i601cd15753894e97b054f81a710b6ce8_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f5d0786855c4f85a8c2679f03a458e6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fb4bb0a29804fc68f9bc363715532c3_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id807a25e86074bc39f2d148f8a84be6e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14c31eac278e41a1ba118b6c025d1f7a_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7e206e166a4e58afbaf397873c5618_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab929e3264374872bb7f54c68dd062ca_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eab22cd2cda488aa69b38e14ab9166f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib47f7963286445b1827fe6925d9837a5_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29e7b4c0a8e04fc7a1fb4736a9fc92a4_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7967609999b541f2b29b2c6ce68ddbc8_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac3cb68f0c34215a382d7031670ff23_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6bd3d8de975456d820b150c1d106f90_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b4fc3995b69496ca407948b3dea092c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic73b319201054f529e8ccf164554f568_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf4f4567b834309abf4b2ff42315882_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b43ed5dbcd543d9ae7b7fd7bb075ab7_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c16c4c7023f4f0790700efabacf60f9_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f027f36faa4af1b4f6e944c1417488_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0afbd5dc3a754753a394dd6670fce509_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc5345a5249f40379024f3ef934dd3db_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2ca59e69a743e88208410ceda1bcba_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib294a903194d4a7187902c709f695b44_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67974f0f7a1245e7809b5204fc2509b6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3db40e6bab3440fbc146528ac4ef7a0_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6202780aca5740c78cbc6ab6252f4036_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifff14a1f8c334b9aadadb7babbfdd924_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a6027ed50842c6972d5eee3da4c9c6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5b800af44314d97bc6e07ab8f06ffb3_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id938e01bb77e45deb2dd767caac9cdff_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60bca8e9e03447268cf3bf5aee0f765e_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c5c096bdb6c47b695ac4b997e09e315_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea479d1c88df4fae9e4ce67cffee6742_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i618dbaeeb2c24741aa3cbe519fe58c50_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8086f446324048e2a9c8937b0ced6d84_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b22d7a7eb564fce9cb4052d7a41c913_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i059e1b1f3a53490db3d19ba632df2180_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0008e6798c040f696f04e80c67a9f1f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec6ee4cea0654427bd1841c05b22220d_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db6efcbef124e2cbfa8b06aaf5015e1_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab89cc409f64d07bce8e87a8fdf95c7_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6fc771e5cf47a7964910a8424d9aa6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b5a3ff0712432c9a8b2bec26f39b4d_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic969d91a8c6340d49f4ca9c6d0a168bd_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i611a544e7fed48459222bd6dba1e2fff_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i532f597a8ed14fc5aaa5997db648cfba_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5a81309c93e40bbb6520a059a567fc9_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75bc3e4b7f0f4bebbec4aa452e444d00_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i045bb0bb60d64408bc746a0b601e9798_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73cbadc80e7d49bfab612db1296213d4_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02219b77430640bcb4d575751528f347_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0e29062c8fe44fd9b3dc53b1dcfddc0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade60d9fbc69468ea53b4630449ae23d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48d8585ed15e4dd9b2a5802f367ad706_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6578cdec5d474fb61356ea6723f969_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i539ed9db6fc4408cb8bf66316e3d162b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i113f00d20dd64c9c8ec5149aaec8e0e2_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14d2acd0bff348a696db84de99c97bfb_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i438b4b2bfa6b4080af4749683d1d6535_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e88b65375c744c690cb9f2531ad1947_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i777a5ad66b154207965e26b2bac930d7_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20227083c87e481eacfb2dd925179f5b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5446bf9970a24b6b937fb2036be6ff7c_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4543179c68d4c82a76af5e632f3aa8b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id59930ef089148a392af915228263641_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c253c52c7ee4f25a276574c0adf9fe3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if48bf4caae12427a934bf19365269a73_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e97e36903074830b97a3f886bbda733_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94fa08b8cbd0498cb485bc7b48711e3b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff2bdce36f584334bc4721f3d6131a87_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5acf2a6ea8034d3e9b7d7074924ada01_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14747989f826463ca3488654f17be9f5_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a1127e192c04223a462719cdaa10ae0_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55656c2263544ef8b6e0bad424c168b7_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0d1ddf2bf748eb9fb05773730d69a5_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if490f8f38569467da82013ec07af4dc0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fcbba0ef29f4f6fbad46f21014a1b89_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd0faf0da5f04c0992e10094b3f8e97c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6191e64a17bc461c9838efdd458364cf_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc6597880ac74bf48cc5795eaf19e569_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf91d92c233a4dbfa5243a026f870176_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icddabaad4cf84f18995b0dfd4ec27309_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1a722add33f4a4e970219beb9128bbc_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbb9d283788741abb9be248c18d56115_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba72ecd0fd3b47c6b352e266260fc5cf_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib213aac39dd14e45914c3a0c2bf6713c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d296b6dadd4d958ffe5990c80d6a0c_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83db602d21fc49c098bf5479b3b020f9_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf51711c9fc9401ea85ff7dab87f84e2_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i413c6a3f140542e58e400aa2f983c6e5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67e44ed2293b4d0ca08120085f5e960d_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b33e65c46b4a568b37f7326d33ae1e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4345727efc2f4029a0ed4bd19dcf7bfd_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i054f2ca9d0cb4fb8b157c2706a23ca76_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76df4b1c1d904841a08d373dc471035c_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46fb64831ae740e8819f320229d29799_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i374469fd1fe84b23986b0e14cfccfc49_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bbe137b43fd4b918335c8497edf70c1_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32c68d6e42284bbfb401b21b31fe0f06_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8189ee4e82488592a6e11bb1a45d3a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e3265b7db3479d856ade508a46ed66_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7faac73e2f23406cb8eb7dbe1944acdf_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b2795880e984fa283bc3a164283cb1c_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e3eb5daefce43a7ace1a8549cc00d5c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53e3c10757fd42b993341c8066c8b790_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4d204cb63f34d5f990c71beecdb6abb_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifef1f530ace84a29a6481dcddde7acf2_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1aab6ee7734aaa9c1c053a59b47312_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aea2bc286e74c24ab2637ca0d209a3c_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58f24b47415f48b0885b0d7c10967969_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic305652d07704e98ba5feacfb2d5f00d_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33a0efdb63c04fa69e366975a05bb13f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i177dc85392db469a8c1db91c948cdd05_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied3e8bd6206b4ee5a70504f5d9b66667_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9610be906255476eab03ae58f21e9645_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8979440d00f14555833df82de8200c08_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af5e8ef63074a068a23d526b83f8c0f_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a94a1625b94c1e93bba0b6e6b48f6e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe25061e631e414e92da52fa72c80da1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i976e2778a2084719a4234e95ad13c666_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecbfb31a552f4de39c19d87cb748cc94_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1202469d66404db95107a79c2868a0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd1abaa86844d559d8ce0f5cf23ff7c_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa1aba1c6e8477da278328f0b8c7659_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa25cbf4d9754df6ba84b4ef2d383458_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedfbfd4bd41c4c5187cf6e182e899660_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1612b190f4f14f649d1d8aaf00cdd1c6_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968f6b90e0d24fbf8745420b22f191a9_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaec7a45f95d444fc9c23636a25fc71b4_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie877d3091b2a412cada21c76c157025a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i823acd2fea2640ddb3d3f3ab09a21a0a_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac2c5b49a0b14b7886ce8b9cb93667c8_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieba37868d4ab40a494a8932e5c195ce0_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0705f1796374a95b4f177ad23d8fa53_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5b2ee0a4ccb47b689fde9e511d136bc_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id289d5f0f10e4ee799a2e6ea8bd1d88f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cd7004acb80425580aeab7c75bcb925_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b2cb42ee1f24a339b3c00347bb66920_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf202bcc43b74c6e97e4400e94a50ef9_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib390ee20bcf14042acab18119fdcb669_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11dfd015a75b4884aaf7606edf7f9f0a_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a4897765d040e2aef60f9e024a65d8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ead4e3e50cf4bfeba22c28a2397048c_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa16021f57ab4f1caa859b2705fd46a2_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0e31c64d572445bb6085f0d2c49ea4b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd460e77c2eb4aa3be50b1cdf64ac81d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca3698a549d4feda795428aba1c8625_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49a96dfb6d88408fb4483ed241d5e788_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i137cde1513484ea6a0ba43bca08f33f7_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab5433d88374b8f9bd823c575a7a039_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d7a58a2310f449cafcd3b8351c93cfe_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e55ac0a94064596be5e7888ac1c9bec_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie09bdbc4c576474ba2cece696d19cb68_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf94af89fe14fea8f4a33af0a883c1a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79c0238a6fff4c91bf6b829e1e0e6892_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad2fa156fe5432eb82a37c862ef94fb_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a7b092ca9844859eac9399e8268977_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62f741d423224f489272cc2103a2be77_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac7374616114d02b1ef9e3af61e8c95_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4365f12a95234c7dbbcbde1b929baee3_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe1eed427e824c31a74eb9fd41fbaa1e_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie11b64a00633401683a6ce25e6f615fb_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9968c0bccd0448c9a01e166ab918a984_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b46d64b60414934aca49f64ba9e5f60_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1580db90b0e48cc893c81fb2540cb41_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a0e4c73916450babe25165d391d6bc_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide5f51b2ac144660a667a5fef9ab26d4_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a52f1a99905452fb46ab62760965f86_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a2a628c1fc440eca687de37f708aa8c_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52da69a2389c48eb9e42c1a2ea47bd75_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66a7d12f22764dbb8759a742d94eb8a2_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93952a8fa3ba416a91d3216edf3a66f8_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e8caf499784ae398f716cde9975425_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i451f3c5eff7745599f90d0af11f4f4cf_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia582797f6e464aa9a43e5e6175ed4fdc_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8801d5f445ea486381246f9557e84830_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08dd8fcd4d2a45b99b04b6d5af0eb436_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78d8a32d310f4f73ad47b98c02d07725_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eccfe1cbc774b868af74e3ecf7e96d1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab744bf1ae1c4732bff2f6dbcb6177c9_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i983dfa5746394727b4076b1302b725e3_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524e2edfc08f4a5580c142b4fbe47bdf_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b57f9e060b40b7a959c01f75f2cdb8_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e84d1337fdb4905ba98011e4e8bd221_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5b869f0296461f9fd2b132c207af88_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76cd338bc7d045b684ffef7f072eb708_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f93a1e291fb4f21aa74bf605526f3d4_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57185a1089ea4d859905b073688fb56b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122d085eabad46eb96a300589fd4bb3d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89657990d309468383c0be47dae23813_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59754740b9fc4cf0ae2c2c849165f4c0_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic879ca2153fb4a0088c7ee21b8bb666f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibae451029e5d4bd580e6089d7352e564_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf29bc608704deab5ec4bfc9c1166f5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f1ff4ca321f4e6fa0ef4ae8850e39b3_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70cf1523502f4cf5ba39389cb696eb37_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b56bacf950743f084cba59a7fa25e7a_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i081f0f428e784cab8f9d016f92effd83_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5cd7d0017649089af560975f3138e1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475fdfe52a874f96855bebe87d3bcdf4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87898be332414773b484d0dc62a17a36_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia552b1bea3ed45ea9d9428a49f4aa36d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dc593f363ef47a58da8ed226cc81f6d_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5273b9790a9456bbdf4c45498aaef2f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47cb84e4eff645bc93a43e37e94a9db3_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6dde9f39bec4bea8b20aa1d494c72cf_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01a4a90d5035473fbeccea2782bd2c3b_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42adb27c042b423eb963af60ecdd4f28_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027553a8069f4b20b245dc5aa1b7f00d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6c8c3e6d5948d28dd9796e3ca9f2a0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72692a16cfbd4625a23c6c13e5c4a89a_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b6abfbb54c2428e827e225364933220_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55a933b2468c47028feef151e8eca9a6_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09e27f9730db43f6a2ad23e6cf8a28d5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77060b346f464d5d94e95a340469f8c1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i272627f13bc84d4cbe6effb2975aca80_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1544200114ae4509a452b21c7cda8113_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37417b84faf544e388d7fbea6710dde8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd68e44359f480b9c73e8e0717f39b5_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c2e5afe5f447d98cdb95e255a91e36_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia610c33820924e2887785db9deee9d33_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id90c807d7bb242bdb981d10b3fe54eb6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i694546fb28354b728eb7a664114dcc64_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c8924e9eaec4b2dbfbc45f97506d991_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d326425f4074d3aa5f72ef541b7d36a_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3a634db09b3472284861b507d5c1114_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibba42e341ee7416abbbe3661f587439e_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13b890bcafd74f788a55c0ebe94e5632_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505a0ebef84644338a169d2b6209fbd0_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ddfba15a2041d88d410a99ac1e926a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i033591a445a5468693248831071b5242_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da56618ab654c42b05e7ce3d95c93fb_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c5a4918db2e4440a13d121f8cffb4d5_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5604fe07056d43b898f627ac12fe4ae3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i400f6ad312e1418a8315ea7c4ca60914_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80d4fa554f9c42f2b2dbef32f68ab0dc_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eecfc49d16b42a8a21357eaf2267e33_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cb87af3cab043ca8decf206c6b249b3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cfd9c7ab83c419bbf61049f45186a29_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i028ed305b9b440838647dbf947fce3c2_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5014237d9c1c451999919bf6eec12ab2_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63b1476e16fc4757b5fe6b377ec00a8b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b55351b3e714b4196d956f493f5fbfe_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i494b3dcc71a9471bbb64838967bf211f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d1982faddbe4e81a502b33e94996bba_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1677f52df4334218aa0a0cb8d77df066_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf32b8dec40e4c26a1275c9cbeb2cab9_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0075c921c1a3418087cbff16476429bb_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i642b7fdb6d7141198e59206a87715ca1_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaec24b62e56f4c749ad066b0f5814893_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a58f759a804eeea68e4f6cf19f54cc_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d2e948664e48509acc9a46d147acd6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9034ae3630be4f90ac8759f73c9d84ee_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia01a0e267e3d49408ae383c295013155_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b9230ef516443ccad9d26677a66975e_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i900204896d434dda8fac86bae0cf2c69_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id112e58fd1da4992aaabcf75b671635a_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69daef85a2cd4f0698981e2468d08268_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a8f26f579b45d49451e22987cfe043_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a917baf2b146579258ed0bd76a5682_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ffc7cf3c884b2296b9598791625833_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c8f9a3dd9c847dc8c25bf43d101da5a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ddcdd029114904a3d37f67d1a5375f_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e00716790544c2aa2782fbaa642b291_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d366ba8634843b7952c594a0298644e_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80589dad11a143ef83bed73c9c636e0d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a27bbab26194f368e984c6efeac7dbf_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id541227fbffe4cb58cbf08c74d640a31_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35536d5c87534fd7904edf6033b8d2fb_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab3102676df483cb94d5771c3340715_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61e739cf89e04a2ab85cbf458333e420_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a347180bf99437b8e59ccf9b456e939_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7c91bc046b54947b056276f205609b5_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d1d755fe864e0aa2bc11b07fb588d5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i861cea3736ba431ea19399c9d74f4a1e_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0643a60ebf034a56a19d98183b76d940_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0d3bc436e1940458257e25f0366f0fd_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee986d724e44b098461eac0f89dfb0a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3461941dfba467a82a64d0fe6a92726_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27b82c53a0dc4b3abae2328362331d7b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib052e84cde5f4591ac72582a42239b41_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bd7ffd7738b4d259f17a9f3eed5fe8f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847dce3495ea4ca1a4c5ecbdcdeb9266_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id846e2e0c92e48e1a68009c7f0c3ec3d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7e140ec784341c3bdaa6b9e35a220ad_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9bdd1c6bdaa4f278e3d75778bc8098e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic62f68f5cbaa47839c0b6b490a8f2c4f_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b53f572aa44e899c6d9df9aab6646f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bba86c6d32b4bb1a8652b8dd4c5851d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09aa7aa2a79a46fe942e1eab7057a546_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c58cf190dba4d119b64a72bea44dee8_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib35fad42d0e6463995e0600e17c5c1b5_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5565a9f7ec554e8cabd71fcaee639311_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f344311b3cf48939c39240aac35200c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefa33272c8bd4721a74234b17b990694_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87579025231469fb10ceb2f4c7cfdcb_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if99ca9d34e85413ab54b2210dcdfb7fd_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9e7cfafb6474ef2948dd5e06029902a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia860b7d96f0447f392f5eeac7875c1a1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2cef51b9a6c41d794a7883c2331934f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2605c867ea164850b491768230077fdb_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73ebd1cbb69f4706bf7449a515a56452_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b836292a904483a2495cd84486214a_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ae4efec9bc24e5c832eb9b323983513_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i881f037a08664e86b329cb3e8bac41e3_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i876e020ffc28486eb2cba4c856c63d96_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cad11a8c56443738c97c90053bcf485_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icad2abe11b5d441f84340fceedeecb5f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10b4ecc9ffe3480b8f5dd56a9cd5aa6a_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca30d47d5784736873c33392dc4ae62_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea669ae399404c9ca5423bd557cf0873_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b3c8d3f2fb24fcf990880e0ff513c1f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i244e58e9444a4e3d9e577108f15d8bd8_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e4b71f563c40d697c20b57f2ac67af_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13674b49cf2b434d99ece35b1733ccb9_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a01e2a70a145dfb1adbbc859b6dd82_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea4a942c29b64296a578054f8bb63c6e_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i838ec4506aac4839afabb56c89fe75de_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43cb13f6753d4651a135658fc71c6eff_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4942e0be0534752a71e7f1ada41cc70_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05be66fafb444a8080fecb6fcd302e95_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida875fcca159482f83502993ab5d5e4e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34bb5f16f5ad400fbb4ffb0ed9d46048_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07c17c915a040be98c96fe359fecfd2_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdaa89f4a1441e29f7642f5b666eb27_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de0a5cf540d4fee9c40859ef3796bdc_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8138f8e21ac94faf9fe88ce25877aed5_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5898c52cfe945779c5143c8df491534_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68c5d8ed136a4c20816e313a4c90b13b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3e5afc3d50e4e4ca0a187ad6b9f1a6c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37eb67f7b144c5eb518c4948cf96145_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85dda44763ba4414829f3605a73753e0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9b58f0b50e427692c9798179519c8c_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf9944934bf44f41a5d848a08016534f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a4e187060bf4b56af8469e2457ad148_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53914db7b6994764b67ebd82cd5d70b1_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29e6c0eadbf94d859fbb92d57ca15229_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbec97fb95be414cb2b89e264202246c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0297066eac1245ce913a0df991220e7d_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5b7a4bbda24f7f9fcc5b69ed4a9435_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i722ea23e5f924f16a6e6c00652075eba_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if177d277829c4cf39e15833c514ec56f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29aa768ec65741dc949cd342666e4f34_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife790b9884ac4cabbd776e36f99b03af_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ad125a62b6946b1b33566216a51ed56_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie42b6679085b4580b95eb6119e492e4c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6e27d7094e94cc8af96f23c67b17244_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fbc058d591f475e80e0b7c6171f743d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i305a29aa90b04a249642618470269a81_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i065d4da56934430d83b7760ca1e819d3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i564acf556d06473886229ffaf87f0863_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8bde317222d4d88bda353d061dbd018_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ceeea82fd7e49d6a825cf5247584a5e_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a5ce8f1fae8494f9167e95a0acaaeb6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03f7fb6c7a194120a4df7e29ac654467_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bb546e3766343bf9f6063a3941899a5_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f10cfdf4b7c497b8b6044b5b86bf524_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i818389fdcd8e4be3bf8813b2e25a407d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f381374d0cb4d7d863372ef4c0e1356_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d82aed0673478d9b0ab5456d859fc6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i680f6194af6c4f068b01fc50ebebf2bc_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e4a4d3e8ab4d7eb48f7cc386ceeb8c_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i499f24d8dbf843af8dd118f4348d0ab6_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib458d25a886746158cfacde3445cd6fc_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0430caf022a942bdb0f6cdbd46b04bac_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7ef391ad36744e5a7cca822a0d2390d_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8778f377a1564158aa09c4c776f50a1e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc078949f249451895be35c4a94e683e_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i577a1cff490044bfa62a9e2f3af70a8a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa3a87266183456fa1a996407ff90f9d_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7df5dd26fd074767b958cd1516adf6ea_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fe5ed9c09394a3ead9cf56afedcc350_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i392724c4d2c743918e9611261847ffc2_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff24f989dc2649e0a841bfefa2388270_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5f74ff91d6b439183caba093e33753e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bd824b5eee841079ac4190b0b4c2ded_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id063a0459cf44210877c1484ef7c45a0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cbfd51374014b128d8615d36bec5484_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aa376f5433c40de98c137cab1b41421_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i038004c2490c4105b96321ee95665011_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5f92f7db04a4642b0601560adc62b41_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe31a46ec13474db2f9953a95a8ebf1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24e24057824445669dc06fd3fa613c19_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bf3746768844207b9687743172b8829_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b31eb5bc05146f6bd4d2d78e8fda6ff_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4170b6c793743a092f6c56a49529637_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i092927032fbf41288117417bd83c8d33_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2847269390c248719305140d646fb64d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7be44d585f94dd1b4e8bdccd9f72fcd_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cd97ec22af24e1aaafd19a24d6e9286_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0dde31e99e496dbedc1e0f945ca70e_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9417a55ca564c889c26bac785e05477_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ae91066041f4be1b8f92b78864de25f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i974d64a21e4f41528433f1336946ceed_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f9110d30d29404584bef97cc4a24dd1_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9cd6cfa9d6a40558ceef771622f76b4_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbc22c2972644793b32196e789568db5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7c3c999eaef4151b4669dc63eb4030a_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3e2207be87140cab8ceaa62aa0d6044_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9429a289df048cfa5ab4fdd10126b5b_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd65d3eab964c75adc84d3231cdbf0d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cae4423d64f4d4bbfe2cbf8df84e736_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a87b0c3795491d8cb754d008abe491_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26b3f7fda8dc45a4acd129a76f977cd3_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7efc4792ae7f465ab37467091fef4a2d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97fdcab14626459db0701cecead7f119_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i855d5f8389ac44e5abf80391fa0ee110_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d6094b282dc44208ebf68078e1e3b34_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic907c783f0ed4d86bdb6abb9d2580af7_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3281cef57f094b31b7cdacddcdaf74a8_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1d05e3bda784d0d9ae066ae87e26eae_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib707a9c98f6b4c618112fba387110572_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic13deb7b513e4e2281a5b9c7dcd54fb8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief2452e5e77d4264a2a230717da020d1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95095593fff6463d893fd017b40967ea_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ce74ed131d46019830ea323390afd8_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb897375b8384ad0bed6f189fe441473_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7368c2116cf4338b2809934b019406f_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i372b1bcd430544318ad85558939c89df_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ec4f3ba11ea4d6b88b6d131ffd28198_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe322b23cff240edbba0ccd9e2b833c8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34035b45a76f4ade91be1a7e5f2dd59f_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic700316f668447918923186ca5e57289_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58690ca930484006850c26e283195c51_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a3ef38541d04372a83ca49403db6011_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a94b325e9bc4923bb6d5064b162cbb1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia30996795fa94ea6b9c7db00253f7c7c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbc66fc1dfb74e039295ae639e9205c3_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47a2e3c8bb504b308a68c7504052a8cc_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b794e63d907423bbad6d7dfdc91be50_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33bcbb3a06994413a39168066fba21c0_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i391427c923714920834b2e9cb41cb698_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b326613e99b4043bfe3af2bbeeaf963_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37b0ad3859c844e399e58cadb8404920_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0f540aabca4cbb8e8011d5ced8cbfb_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c8bf7911a294fd5a9711bf309527dd7_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic13b79cce02e4ae4924831ae4711540f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19ef6dc106bc4d7d871aedead8e03203_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3d9e613aba94a1f9b967f1b8b04148b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51efdf97f2214c34a66a193a4ee00409_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f710c786d345ffab2ccc1e077da0e5_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b737de8e7ed48e9a0f1e473c0fd11b0_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa68cd0ebbc649f8b1944c6452cf157c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e651723831f48ba8112b343beaff0d3_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic19353844d9d42988aefc5611b61c81a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc3559fd0b124045a8fa153a444ef33e_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c4456bb5034d83b9f17294fc378c0a_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5d3558da8644e909594aa8c7e4e0083_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00b3e8006e23428f8b7ee7417c102c09_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1039c0aa59334e18b5a49bf9c2b74e02_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b1416bbe0bf416081fe7ae31939518b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d4e80547494117a247653eb23d938e_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c7c7b4a1930485390375e2d3bbb3a2f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76779eb2bfad4ee1a6a2508e4e75218c_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09bb019661ae4ed0a5e67d8131209bf2_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c0711b6e2e4a6087c73758e3f91243_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28e3fcd890c242319befd0f7388bfe2e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic42e396c0efc43a3ba71cd4831b384c8_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d0c0d174e1e465a968649b402f5cea1_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac832e9cf5c414d856dd7230794b701_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida2ad956ed734c17a0b3ce03be3fff11_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d9be1e0153f4553b7b041b59504358d_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d8758d185d4148b85cbe1809fe78e2_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e826c2f1324a59aedd22ebe1aca2e6_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b09107775e49eaa9df473cb669c97e_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad0196cb82f94a8ea79748ba42931837_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02b2071e56d747afbf128fec4a955609_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6af84b75578249b38eb94570b45c8bcf_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i366a7d5e35604a52910d0f6633b551b3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i640f5e27e4594136be6910021459b067_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d78c321af554254b32b1e3a8a1d3694_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaff737262fdb484bbf75e5931817a490_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c366e52f34f4c939ba9bb069bc96cea_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49dade5fbc6447ae87c04ac20252f3ee_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9c2927f6ad471d81601e63f54fc36f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d94242030db4c6e972f72cfbfe05464_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i158baf5a07fa408c826b2c8d54778c21_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i358c3cd12c24472787b2a36a2550e8c6_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a772c8416cf49df88d756da5e9a094d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02c59bee76a743e19c22b2e772f8d973_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i201e6e46d1c74819a9acfb688922322f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b398a883ec74c3eba875c513b5d8cd2_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifafc57d6cd754d72bbe14c0919d17e1f_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i623b6ae349b44bf9b2853ebb6769281d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i123867d1543d46d9afd6cedaa87c7ed3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia200d3ae9c054b709c7195a311b6c9e3_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie23f74e989df418392f516e411c8ba59_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9146e1200a7f49d3ac965e4dc89a064c_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17622e1e5cdf4287a5ce27533de69c09_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15889f3752b64ea98aa7f132f768a0d1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e93bc594b454595aa61c0a479afcfcf_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40e55fe351984553bed44ba01eed5ad0_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie132afb6984b4e4d956e2c5e87394126_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d49f0375714f51b3b624836cc6d325_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f897a88b0e9498e84e0922c6ac778a3_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibba76952fd2b4a519af20462218629da_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae82913ec44462fb96a4ca814d6a702_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eba42d826fe467a9b5e86014b866bdb_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ec2459bfe446ec8682b17c888295b8_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529501a1b6e049f08c8a55b366fc992d_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf01c838f2074a85932e153dd373f7b0_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2e6ad455cb48d9b9bb5b16d05ff610_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if60b072dec854b1e8dfb55dd85a8118b_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647abea8193b4b739d73a6331f0863b4_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7de7cde1f8a4671978be90e6b0c20b6_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57af817119fa4ecd8f610dbcbd0f3ac1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c3910a76f84ce297ae66994c95a35c_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4cfbdab95a0435dbfa671be6d271f63_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i643bc69b32254fa0bbda0732674f0a17_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e56281ecec14a7c80ff8779c1ca8f17_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25009198d573425d8e230b1a71881f95_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8fe8d12a2fd4f01b02c290b548244b4_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9452da93d10a4670896f05edcac90904_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba3e034faa2643de9e74a65652cc9170_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38bfe15254ae44efae8441525503c832_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc4c09ce590a442181ad6662947c8fe7_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90e9c507ad5b4f6c9505f100acae883a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a34e43a1f6446ecbcaa76509bae0457_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i074ce9c3c7514a87bf8e13428ff46900_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd2f05005c0f428383f2f6685296745f_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353ce076e41d4fed82b475f2741cafd1_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f05af96e15a40369cfe4cd4140d6449_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ffe02d809844979135aec3c5ba4751_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if191b6e468a3476aa02636eb2412f60b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i331c19f370344f7baf99003b536c4f3e_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d61b35824144f9bcdad8d927f11908_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68cff4026c6244d2acead47809054223_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id982a81309df49e9b1b002ff1ac41cae_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie667e5b01edb4ec3a359b1a4b8416940_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadb11728d759451d965568df87db85d8_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf94b8f123d04272bb4b90c496e51b83_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i815bc18a28fc42afa083e798ae8e6b32_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9b9a440e17401eaa071454d7751a0d_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f75366413fe46b586eb415473747dec_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea81eebb8464de781937770e40b4cf8_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf724f9760f04a4d97e3362a30a8c490_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5394d3d3ed644aaadfbfd8d6956ee4a_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bb2fc4834df4cee928c01c8ffe451e8_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f562eb61574b4a8135f7a6ff000d61_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffded04d2e5b4de28d6c73c949492aa9_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a2695569614474a9334e8de4bd04385_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfb750d153444cfbb2321cb34524ef38_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied1e8cdc798340419a8c42b1446f8a47_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifadac292feaa4f469fb02f86ff949995_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i072ffc473a074bf6b2765979c610418b_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied5e809531a04e8ebd37dbed6ad36ab8_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc46250604114f8e80b3e470ae4babdb_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4268f03b6cf41eb89ecb7ae077eb9e3_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72c1a76dec8d49eaa40c1cca89c0bc8d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c67e57cd4f489992a696a230aaba42_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c08f0957c7d4b9e8e627867718f4458_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i990e1ccf4a544e3caa982783ffee28fe_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5068794590a54e5988087731a2a8b4d4_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c47fac364494aed96246540e7b4f7c7_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aa4e83b89284abc892194a08d7295b2_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia79ea739fc2a40d89f2755e7e4a01102_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5891042222334a28a0bb7a5e271806af_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21a2cce4e35d4c1297c84a76cb27a899_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66d27784d12d4bb18f3912c082fcae16_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3d5cdd413d4757984bddf6f14322bd_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i751be87313594bb993858ae3c749f84d_D20210104-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf347773ad54fb88be2e997e4827221_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="brand"><xbrli:measure>jnj:brand</xbrli:measure></xbrli:unit><xbrli:context id="idc76602e6fb84b0a862455dca71e8bba_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed71c93d9694050bbc60255c39761e2_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>jnj:claimant</xbrli:measure></xbrli:unit><xbrli:context id="id4a164f8c9e84a87a27b9958b9f63142_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eea6ea68542417790d4a54103e549ae_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08773cd5b344ed58f2677261b44e9de_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eb4e32762af4828a35d4453122c0f42_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c421f92c4fe44b480312cbb61c76537_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i494bb8f36e6b4d348f07972031b000b3_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida7fb50fd03e447e8bfba4781b1f21c6_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id34d8d00dc95419c9bd7f8538f501612_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ElmironMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20d66d03f67b4697b74d7d5b092b023a_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>jnj:patient</xbrli:measure></xbrli:unit><xbrli:context id="icdd65a25b656477ea5bb46da7f0655dc_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cases"><xbrli:measure>jnj:cases</xbrli:measure></xbrli:unit><xbrli:context id="i57f785ad2f34433aa2271007ab8726b8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc38c671bd94c1891fa4b65bac8ec0b_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e63d8a7e74e42f6a4a9d28176f31ee4_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i135a75e1eac047bcb5100f4e1292998c_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i699c1217087e4147b4a39954f40ee65c_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7c3ce8a2b94702bf75c6781069843d_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b18def56e5244478a2952bec11e5335_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c83f6e3f6e543809b38536c601fde43_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb28f8306622475282cfa3ad654e30a5_D20220301-20220322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jnj:RasmussenInstrumentsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5473d8ddcca64b71b3e429a13c5bf85d_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i533d6a68961b4cbc8e82491aa88f91f5_D20191230-20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf0bc69e2f514d4f8022cfc52f98c981_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54e00e15c6a4438da0eb288d0b6da9f6_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>jnj:claim</xbrli:measure></xbrli:unit><xbrli:context id="i0cc5049a65cc4fe3b6242125d5b8d5c0_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i438940227a2a4ff395f3e492e755ecde_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id67cae946c154573ad2500e94ad849da_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2b36aba9e54f04a044b6f392d0eac4_I20150430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ContactLensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icacdc0678d9f4679bbb4b670b539eae6_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9e691f551214439bf1ee3b313e022c3_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ca0be8b6078437fbd42287a1c403587_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife72459bccf34924aabd0acb8e60d652_D20220704-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-04</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i690d9c2e2c884662976264e7af01ba35_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93e937c11c7436bacd6ccaeacdf0cb6_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28209dc3607348dbb3171ab6afdd3dea_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe9fcf4dbc843569a9d49299bde3c5a_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie51585f5aa3d424c9d17456abcf75390_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6262632abd6a46d5a6a2555c388ca348_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3d9ff58f127499cb7a03cc08f3f4dbf_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bfabbf7068d43948d05ef08e73d9679_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4425d96eacb04e7696f85e7eaea16821_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72c4525bf37f4e2aa7ae0c4f54cbf866_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57839c019e9745718882687e73ce9e18_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb01ffbc16f648fb954f806b9df10064_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339ac2517af5425bb6f6bd7a62b270be_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea736a79ff947c586d1da1d7bcb9f18_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i923ad899b5ec4870933079c36fc15f9a_D20220103-20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7802b4bc08714bbfa6723a15254942f7_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199a6c4996a1468e956555f0edbf4206_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8caf79efe14c4c99b6b144f88b0704f5_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic114825b023e4671a3b06ef6426697c5_I20221002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-02</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5a494e6be84b467a8d7a1188e54512ab_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDY2_1557fbb8-924d-44bb-95d5-6db2f8f771bb">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6ZDU2MGNiZjI5ZWVjNDgzNWFlM2Y2N2Q4MGY4NGRhZWQvdGFibGVyYW5nZTpkNTYwY2JmMjllZWM0ODM1YWUzZjY3ZDgwZjg0ZGFlZF8xLTAtMS0xLTc3NDA3_21afd2b6-f2e9-4e05-910c-53a0bc4be673">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarterly Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">for the quarterly period ended <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8xMjI_14650054-42b4-4ed2-b8fe-c559ee608c9d">October 2, 2022</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6ZDI4OWQyZmFlZDc3NDZkOGJiNzA3YjFjNjRhMDUxNmYvdGFibGVyYW5nZTpkMjg5ZDJmYWVkNzc0NmQ4YmI3MDdiMWM2NGEwNTE2Zl8xLTAtMS0xLTc3NDA3_d6473cff-2261-40cb-8da3-766b5d42dcd8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934<br/>for the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDU4_bb81f31d-3ad3-4f6f-9290-c9d8d5431597">1-3215</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDU5_a7cb4631-e7b6-422d-a062-50371df33000">Johnson &amp; Johnson</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6ZGI3Y2EyYjA0OTZiNDIwMmJlYWI1YTI2ZDc1MWM1YmQvdGFibGVyYW5nZTpkYjdjYTJiMDQ5NmI0MjAyYmVhYjVhMjZkNzUxYzViZF8wLTAtMS0xLTc3NDA3_9fc746a2-8244-478c-8cf6-48fa25eecaba">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6ZGI3Y2EyYjA0OTZiNDIwMmJlYWI1YTI2ZDc1MWM1YmQvdGFibGVyYW5nZTpkYjdjYTJiMDQ5NmI0MjAyYmVhYjVhMjZkNzUxYzViZF8wLTItMS0xLTc3NDA3_ea51dded-70d5-4fac-8db6-b93a624fad4a">22-1024240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDYw_3a92e286-b9d6-4abc-b65f-95856ca90bf0">One Johnson &amp; Johnson Plaza</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDYx_f670e3ef-0c65-4d9d-9cb7-7396eae6b9fb">New Brunswick</ix:nonNumeric>, <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDYy_4b51fc6e-7b3c-4995-9519-0cbd44fca0bd">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDY3_470692a4-d513-49d7-aec7-7bfb951aac0d">08933</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDYz_7075e8ec-0397-4a82-b59b-22430e6e7a93">732</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDY0_00fd9958-534a-4f53-8b24-8bfd45bf675a">524-0400</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDU3_0d130ac7-33f1-4397-879a-390beaf67fc9">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDY4_e514cc87-04ae-44f1-a4ff-70a8dc21309c">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MjNkMDgwYzZiODZiNDBmMWI1OWYwMjBkMGJmNmRlZGEvdGFibGVyYW5nZToyM2QwODBjNmI4NmI0MGYxYjU5ZjAyMGQwYmY2ZGVkYV8wLTEtMS0xLTc3NDA3_4c24e7a2-6f45-4ba6-a6db-dbba0d40e45d">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MjNkMDgwYzZiODZiNDBmMWI1OWYwMjBkMGJmNmRlZGEvdGFibGVyYW5nZToyM2QwODBjNmI4NmI0MGYxYjU5ZjAyMGQwYmY2ZGVkYV8xLTQtMS0xLTc3NDA3_d55204be-fd2c-49e7-868c-55f90e92b447">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MjNkMDgwYzZiODZiNDBmMWI1OWYwMjBkMGJmNmRlZGEvdGFibGVyYW5nZToyM2QwODBjNmI4NmI0MGYxYjU5ZjAyMGQwYmY2ZGVkYV8yLTItMS0xLTc3NDA3_144a0534-7133-4403-b362-6cd1b4eeba8f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If&#160;an&#160;emerging&#160;growth&#160;company,&#160;indicated&#160;by&#160;check&#160;mark&#160;if&#160;the&#160;registrant&#160;has&#160;elected&#160;not&#160;to&#160;use&#160;the&#160;extended&#160;transition period&#160;for&#160;complying with&#160;any&#160;new&#160;or&#160;revised&#160;financial&#160;accounting&#160;standards&#160;provided pursuant&#160;to&#160;Section&#160;13(a)&#160;of&#160;the&#160;Exchange&#160;Act. &#9744;</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDY1_b82be262-3ff4-4eb3-91bd-6a00024b6f69">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(b) OF THE ACT</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3d1079dea4094854a0d8215a7b7bee77_D20220103-20221002" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8xLTAtMS0xLTc3NDA3_83557c98-e8ec-4521-b2e2-103f32a707d9">Common Stock, Par Value $1.00</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3d1079dea4094854a0d8215a7b7bee77_D20220103-20221002" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8xLTEtMS0xLTc3NDA3_89a01ea6-6459-4684-89fd-44785be11465">JNJ</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3d1079dea4094854a0d8215a7b7bee77_D20220103-20221002" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8xLTItMS0xLTc3NDA3_192ac3fd-f921-47a1-b557-189228c644e7">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia5474370380a497b82e6a430f952af34_D20220103-20221002" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8yLTAtMS0xLTc3NDA3_801cd21d-1dae-4c6f-b645-337bfe8e45f4">0.650% Notes Due May 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia5474370380a497b82e6a430f952af34_D20220103-20221002" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8yLTEtMS0xLTc3NDA3_6a6868c9-5dec-448c-b37f-2c52b5ecbf22">JNJ24C</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia5474370380a497b82e6a430f952af34_D20220103-20221002" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8yLTItMS0xLTc3NDA3_61bf9641-1f78-4432-abec-e8c71f5a5059">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12fdbd4684c2453789af8d70324bc71a_D20220103-20221002" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8zLTAtMS0xLTc3NDA3_1ec62f34-3917-4efa-8497-215177cf2e93">5.50% Notes Due November 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12fdbd4684c2453789af8d70324bc71a_D20220103-20221002" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8zLTEtMS0xLTc3NDA3_8e745d2e-978d-4aca-9800-ec79e7a99e97">JNJ24BP</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12fdbd4684c2453789af8d70324bc71a_D20220103-20221002" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8zLTItMS0xLTc3NDA3_201ae211-5238-43fe-9821-7c3efdc1c526">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4072dbe684f043559e6b3816abcc50e8_D20220103-20221002" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF80LTAtMS0xLTc3NDA3_8c59902f-60dd-434a-8372-4b95e282955c">1.150% Notes Due November 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4072dbe684f043559e6b3816abcc50e8_D20220103-20221002" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF80LTEtMS0xLTc3NDA3_a850e828-c7a0-44b6-b1eb-409c6e175562">JNJ28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4072dbe684f043559e6b3816abcc50e8_D20220103-20221002" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF80LTItMS0xLTc3NDA3_3b6da2af-2240-4848-a52b-7ebe06dad884">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i414d244f8d08480fb66a8026c8d80ad4_D20220103-20221002" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF81LTAtMS0xLTc3NDA3_ad797585-80d6-4139-8364-8b8e3cedd275">1.650% Notes Due May 2035</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i414d244f8d08480fb66a8026c8d80ad4_D20220103-20221002" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF81LTEtMS0xLTc3NDA3_b31e70de-998f-45bc-bace-749d74e60bb2">JNJ35</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i414d244f8d08480fb66a8026c8d80ad4_D20220103-20221002" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF81LTItMS0xLTc3NDA3_ab512680-7909-494c-bef8-4f104464d5bc">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2022, <ix:nonFraction unitRef="shares" contextRef="i4a83e7272e834e8fae6c7fe265b3be1b_I20221021" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8xOTk2_e44b3ba7-e15c-4873-b269-869c0e410cff">2,614,483,607</ix:nonFraction> shares of Common Stock, $1.00 par value, were outstanding.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_7"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_13">Part I &#8212; Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_16">Item&#160;1. Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_19">Consolidated Balance Sheets &#8212; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_19">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_19"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_19">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_19">, 2022 and January 2, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25">Consolidated Statements of Earnings for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25">Third</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25"> Quarters Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25">, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25">, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_25">2</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28">Consolidated Statements of Earnings for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28">, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28">, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_28">3</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31">Consolidated Statements of Comprehensive Income for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31">Third</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31"> Quarters and Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31">, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31">, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_31">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37">Consolidated Statements of Equity for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37">Third</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37"> Quarters and Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37"> 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37">, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37">, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_37">5</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43">Consolidated Statements of Cash Flows for the Fiscal </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43">, 2022 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43">October</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43">, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_43">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_46">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_46">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_103">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_103">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_106">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_106">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_109">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_109">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_112">Part II &#8212; Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_112">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_115">Item&#160;1 - Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_115">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_118">Item&#160;2 - Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_118">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_121">Item&#160;6 - Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_121">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_124">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a494e6be84b467a8d7a1188e54512ab_124">68</a></span></div></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Johnson &amp; Johnson's other publicly available documents contain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward-looking statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.&#160;Management and representatives of Johnson &amp; Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements do not relate strictly to historical or current facts and reflect management&#8217;s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company's strategy for growth; product development activities; regulatory approvals; market position and expenditures.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company&#8217;s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Development, Market Success and Competition</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company&#8217;s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increasingly aggressive and frequent challenges to the Company&#8217;s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Allegations that the Company&#8217;s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company&#8217;s ability to sell the products in question and require the payment of money damages and future royalties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Liability, Litigation and Regulatory Activity</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Compliance with local regulations and laws that may restrict the Company&#8217;s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union&#8217;s Medical Devices Regulation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Company&#8217;s Strategic Initiatives, Healthcare Market Trends and the Planned Separation of the Company&#8217;s Consumer Health Business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s ability to consummate the planned separation of the Company&#8217;s Consumer Health business on a timely basis or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company&#8217;s ability to successfully separate the Company&#8217;s Consumer Health business and realize the anticipated benefits from the planned separation; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The New Consumer Health Company&#8217;s ability to succeed as a standalone publicly traded company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Economic Conditions, Financial Markets and Operating Internationally</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market conditions and the possibility that the Company&#8217;s share repurchase program may be delayed, suspended or discontinued;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of global public health crises and pandemics, including the novel coronavirus (COVID-19) pandemic;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes to global climate, extreme weather and natural disasters that could affect demand for the Company&#8217;s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company&#8217;s products and operations; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Supply Chain and Operations </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Interruptions and breaches of the Company&#8217;s information technology systems or those of the Company&#8217;s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company&#8217;s products; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. </span></div><div><span><br/></span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022, for a description of certain risks that could, among other things, cause the Company&#8217;s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;I &#8212; FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions Except Share and Per Share Data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:69.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMy0yLTEtMS03NzQwNw_87103184-e019-49ff-92cc-f2716cd6db40">11,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMy00LTEtMS03NzQwNw_59835106-299b-450d-a3f8-3b4deb3d6ca1">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNC0yLTEtMS03NzQwNw_9eddc708-d75f-4d2e-81d9-d5e9d7be3e67">22,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNC00LTEtMS03NzQwNw_df457282-85da-4476-a7ae-d4729a580110">17,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, trade, less allowances $<ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNS0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmE4Y2MyMDQ1Zjg2YjQ4NThiMjhjZmUzZjg3M2QyOGI1XzQ4_db0a988c-a9f0-48fc-b342-ae73ea582a48">201</ix:nonFraction> (2021, $<ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNS0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmE4Y2MyMDQ1Zjg2YjQ4NThiMjhjZmUzZjg3M2QyOGI1XzU4_c236d4c3-e9f4-46f5-a6ff-6c96422fff03">230</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNS0yLTEtMS03NzQwNw_166592de-6cf0-4885-854b-91b2fa77db96">15,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNS00LTEtMS03NzQwNw_7de6833f-2cb4-4bfa-af78-cc7d2455d494">15,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNi0yLTEtMS03NzQwNw_8fcfe02d-e954-4a93-89d2-fadd69c84553">11,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNi00LTEtMS03NzQwNw_8ca633e4-f7c4-4a01-818d-66f7a8795189">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNy0yLTEtMS03NzQwNw_f3c91f56-3de4-4649-be69-cf01791a841e">3,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNy00LTEtMS03NzQwNw_02cba2f9-1e58-460b-92cf-91b6dfc6bf4b">3,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfOS0yLTEtMS03NzQwNw_f7b59207-a029-43d1-86a4-4dbc6c96d962">65,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfOS00LTEtMS03NzQwNw_405dadee-e7cf-46b2-b016-5a3892ff5768">60,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment at cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTAtMi0xLTEtNzc0MDc_c2a06ceb-4ded-4910-8828-812e63d225d4">46,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTAtNC0xLTEtNzc0MDc_b97d8fc2-1666-4673-b1ae-0dd51aa565bd">47,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTEtMi0xLTEtNzc0MDc_3a274bb7-cfa2-4b5d-bfee-419c082672ef">28,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTEtNC0xLTEtNzc0MDc_04e00fe0-0cfe-4255-965f-ebf682f86bba">28,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTItMi0xLTEtNzc0MDc_fe37fec7-5da4-47fc-9487-d218a61269bc">18,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTItNC0xLTEtNzc0MDc_84044f85-e1eb-446b-ab6d-cf10395bf784">18,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTMtMi0xLTEtNzc0MDc_135469e4-53c9-4c04-86d2-355cd267577a">40,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTMtNC0xLTEtNzc0MDc_015a7663-8638-41ca-836c-d7191b80dcee">46,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTQtMi0xLTEtNzc0MDc_dba52113-fa6a-4709-982a-bf3cc8f3bb7c">33,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTQtNC0xLTEtNzc0MDc_f4af2b30-a432-4032-abdb-a5c1a19f6f8b">35,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTUtMi0xLTEtNzc0MDc_a066e56e-476d-4e25-839f-8e28041232f3">9,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTUtNC0xLTEtNzc0MDc_7439ecfa-799a-4c5e-8839-b92ff8847b98">10,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTYtMi0xLTEtNzc0MDc_04140cb0-b802-4c90-ad7c-f159fee5f4ef">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTYtNC0xLTEtNzc0MDc_39e37e67-9809-4f5d-ba2b-8dda461b921e">10,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTctMi0xLTEtNzc0MDc_749f7a4b-d4bd-4642-90ee-ffe4d27f2845">175,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTctNC0xLTEtNzc0MDc_d950d475-eaa8-4982-a708-9d5593b9488c">182,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans and notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjAtMi0xLTEtNzc0MDc_4f5a69c7-2ed3-4d28-bee4-9a169d70a49f">4,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjAtNC0xLTEtNzc0MDc_876ec6c8-35bc-412c-8c19-faf9dbb44eb4">3,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjEtMi0xLTEtNzc0MDc_8bd9a4fb-5dfb-433d-b3d6-89a5a17bf781">10,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjEtNC0xLTEtNzc0MDc_1e856972-33eb-4eee-8641-dcaee24efb9c">11,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjItMi0xLTEtNzc0MDc_cadaf813-c621-40b8-b2ce-41d56f8d9161">11,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjItNC0xLTEtNzc0MDc_829025f6-9a93-4a14-9d0f-a6f9b98898db">13,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, returns and promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjMtMi0xLTEtNzc0MDc_a2b5129a-9bd7-43d9-8ede-167c125b1265">14,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjMtNC0xLTEtNzc0MDc_2e47e8f4-1efc-4d63-a50d-0eca76016a50">12,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjQtMi0xLTEtNzc0MDc_668d4c33-33c3-4c85-9f6a-8a28c986c6d7">3,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjQtNC0xLTEtNzc0MDc_053f6283-409b-45fe-b4fb-afa57b23c284">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjUtMi0xLTEtNzc0MDc_d9f37115-7e45-4519-9bb9-5d4f036d0a50">1,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjUtNC0xLTEtNzc0MDc_d5e299b0-46c3-4070-bbd9-4b0fff86a7be">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjYtMi0xLTEtNzc0MDc_a108383d-d176-41ca-bfc8-afa8fd0038f4">45,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjYtNC0xLTEtNzc0MDc_7b8de311-60bd-44e8-8981-6b41eba1a8c2">45,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjctMi0xLTEtNzc0MDc_8edbbaf0-e601-4554-b54d-a5a4736f81e0">27,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjctNC0xLTEtNzc0MDc_a34a94b0-c9db-49a6-8cf3-3c77d21efeb7">29,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjgtMi0xLTEtNzc0MDc_81580457-3499-4fc2-ba9a-652ccf3f085a">4,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjgtNC0xLTEtNzc0MDc_68b35dc9-fb82-4ee3-b2ac-bc3ef6151207">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations (Note 6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjktMi0xLTEtNzc0MDc_240859d2-6261-4e1f-878c-4480d837a102">8,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjktNC0xLTEtNzc0MDc_04eacb96-8b8a-424e-b906-06258e2a1436">8,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term taxes payable (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzAtMi0xLTEtNzc0MDc_7f8da704-816c-433c-b35f-5902d844be1a">4,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzAtNC0xLTEtNzc0MDc_bb55b820-67d0-4f18-9a21-f48041128418">5,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzEtMi0xLTEtNzc0MDc_e3ead9bc-8f38-49d9-bf28-98f544cbd132">9,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzEtNC0xLTEtNzc0MDc_834a8424-428c-4e93-99f5-8b19cb772d58">10,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzItMi0xLTEtNzc0MDc_2d461f9c-d881-4725-a486-17740fae7c42">100,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzItNC0xLTEtNzc0MDc_ce2e508e-1210-4879-8c8b-37a340e2fed8">107,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzMtMi0xLTEtNzc0MDc_863fd9a3-5203-4203-80f7-f62980b7c3ec"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzMtNC0xLTEtNzc0MDc_ff805182-f9c5-43a6-a166-ddd1433924e9"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl8yOQ_a6194ed0-5405-43d6-8151-38837ce4ce05"><ix:nonFraction unitRef="usdPerShare" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl8yOQ_f0b9d193-96f9-4e2e-b2ed-b0ce923ff973">1.00</ix:nonFraction></ix:nonFraction> per share (authorized <ix:nonFraction unitRef="shares" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl81NA_2259623f-e44c-41a2-8e0a-3822f851ca9d"><ix:nonFraction unitRef="shares" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl81NA_5d64467d-b4d0-4af0-8c71-353a673700ff">4,320,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl83Mg_5d42feea-0e6f-4c72-b4b4-4ae29f48e828"><ix:nonFraction unitRef="shares" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl83Mg_b903eca1-d5a6-4506-93c3-1f2fc86c6bd0">3,119,843,000</ix:nonFraction></ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMi0xLTEtNzc0MDc_71a55487-09a8-4104-9aea-3bde6e5d1d5d">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtNC0xLTEtNzc0MDc_70b7cc9f-0ff6-437b-b1d2-d170cf489373">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss) (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzYtMi0xLTEtNzc0MDc_f2a6f407-b57d-4ce6-9b87-3e0f4bcfc282">15,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzYtNC0xLTEtNzc0MDc_b61439ac-91a8-4fac-a8a1-56e8bb43a0d9">13,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzctMi0xLTEtNzc0MDc_38591a74-0544-40f6-b7a1-25da3a6e902e">127,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzctNC0xLTEtNzc0MDc_cdfd2e67-bb96-4eba-b28e-49757d57303c">123,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: common stock held in treasury, at cost (<ix:nonFraction unitRef="shares" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzgtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxMDFiM2M0YmU5NzU0NGVhODU0N2I1MmI0Mzk3M2FkMl81MA_bb84033f-fddb-4dd3-bd5c-4f790459aaa2">502,961,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzgtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxMDFiM2M0YmU5NzU0NGVhODU0N2I1MmI0Mzk3M2FkMl81Nw_4e502b37-ee9d-4766-986f-8eabdb01be55">490,878,000</ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzgtMi0xLTEtNzc0MDc_29a1861b-5dc6-46cd-8ee4-85ef83bce80e">41,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzgtNC0xLTEtNzc0MDc_2f588495-ba51-4042-9aeb-798e57aee85d">39,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzktMi0xLTEtNzc0MDc_732360cb-5617-4c97-8d61-0f1c002ecb3b">74,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzktNC0xLTEtNzc0MDc_23147768-22c7-4963-9c67-aa9371c0562f">74,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNDAtMi0xLTEtNzc0MDc_21ff570f-8597-4fe2-a9e8-6c3f8b500556">175,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNDAtNC0xLTEtNzc0MDc_5bc8d362-4041-410a-b8a3-79f448b7e741">182,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars &amp; Shares in Millions Except Per Share Amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:54.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMi0yLTEtMS03NzQwNw_e7669b04-6474-401f-9296-cb15f791ebcf">23,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMi00LTEtMS03NzQwNw_52c10e84-3916-4fa7-8eb1-c5167d51dd08">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMi02LTEtMS03NzQwNw_59f130b2-a18e-4dc9-8568-85a6680c290f">23,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMi04LTEtMS03NzQwNw_a378741a-7b96-4a16-9348-b3c5f7bb5ffa">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMy0yLTEtMS03NzQwNw_91bb2ab7-1652-4524-a1e4-a2b19aae9d98">7,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMy00LTEtMS03NzQwNw_2b50eec0-d653-4060-ab9e-7bf02991f0bc">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMy02LTEtMS03NzQwNw_df82bc12-7f4d-47b8-93e4-65a0083aa18a">7,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMy04LTEtMS03NzQwNw_e6d78e3c-f9a1-4729-b59d-c8b739614e53">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNC0yLTEtMS03NzQwNw_008c0253-7cc2-4d52-94fb-d6644c324400">15,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNC00LTEtMS03NzQwNw_5a3f08ec-f631-4f03-8d58-59474bd34da3">67.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNC02LTEtMS03NzQwNw_b133490c-2358-4795-a2e8-058134964364">16,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNC04LTEtMS03NzQwNw_1e7de4c4-3c6b-4eee-b7bb-a25a02170957">68.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNS0yLTEtMS03NzQwNw_9f66543b-a186-4f8e-a1ee-1bfadada4e86">6,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNS00LTEtMS03NzQwNw_8c3a5670-59f2-448e-a678-835bb5c7f6cb">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNS02LTEtMS03NzQwNw_0ba0a223-b08d-47e9-850e-ba2b51dd8746">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNS04LTEtMS03NzQwNw_5939f352-b128-4e0a-b78d-81a260653d1a">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNi0yLTEtMS03NzQwNw_6fa74cba-f71d-4913-a0c4-27f2bbaf9baa">3,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNi00LTEtMS03NzQwNw_2b622228-5811-40fc-a99c-ddf706f705d4">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNi02LTEtMS03NzQwNw_a0f854b9-6215-4d3e-8d43-9acdd3c05454">3,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNi04LTEtMS03NzQwNw_442311df-3285-4ee5-8ee9-a6e8c54a80a4">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNy0yLTEtMS03NzQwNw_d6e26cfa-091e-4836-8ff8-73a8827b593e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNy00LTEtMS03NzQwNw_fa36dbf1-e04b-468e-90ef-14f600995a37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNy02LTEtMS03NzQwNw_12d909b0-981f-4334-a17d-166ad9119dfa">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNy04LTEtMS03NzQwNw_e4672b65-e46f-4276-b14d-a634c143eb16">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOC0yLTEtMS03NzQwNw_b65067aa-f27a-4a68-acd3-6abcef660606">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOC00LTEtMS03NzQwNw_6e97430b-4e7e-4e00-a6a2-012ffb0aee6a">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOC02LTEtMS03NzQwNw_3131b186-861a-45ce-bfd9-61ea73b349ed">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOC04LTEtMS03NzQwNw_23e811e5-2259-4871-aa18-7e325e0655c1">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOS0yLTEtMS03NzQwNw_99d77481-2a6a-40fe-b80f-19234ecea244">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOS00LTEtMS03NzQwNw_66b1aa6c-1756-4dee-947d-1c46decf1316">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOS02LTEtMS03NzQwNw_f334f432-3b73-406f-9f83-031e54491ce7">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOS04LTEtMS03NzQwNw_30821169-ee6e-40b5-af85-218c3503a24f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTAtMi0xLTEtNzc0MDc_4c074f55-0479-4df4-bb86-96c588213115">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTAtNC0xLTEtNzc0MDc_ed05f75e-a475-4252-add3-b704084faf06">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTAtNi0xLTEtNzc0MDc_93b07f1b-8dbb-46f2-af55-623982eb1c22">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTAtOC0xLTEtNzc0MDc_3c565883-9fa4-4ecb-8091-bfdd83f44df4">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTEtMi0xLTEtNzc0MDc_d8ece78a-c54e-4098-a4b3-c187dd2273e0">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTEtNC0xLTEtNzc0MDc_67ac033f-1635-49b7-80f8-45cad8bb5945">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTEtNi0xLTEtNzc0MDc_f0fb4a6d-540a-4178-a689-4aa6093d50b2">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTEtOC0xLTEtNzc0MDc_51ee9268-9bbf-4a18-ae65-dde5b9533b22">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTItMi0xLTEtNzc0MDc_ffc1b3f1-f2fc-4f46-bb97-5e9164e3b1f1">5,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTItNC0xLTEtNzc0MDc_4f4e4e15-7264-4c3d-82ba-7ad1936d718d">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTItNi0xLTEtNzc0MDc_b3e1bfb8-6cbd-4e20-ac43-10e76d4b9645">3,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTItOC0xLTEtNzc0MDc_1d49ad83-df2e-42f8-bcae-f8da6401d4d0">16.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTMtMi0xLTEtNzc0MDc_cad8236b-a1ab-4173-9978-a42cf2eed74e">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTMtNC0xLTEtNzc0MDc_6ee5fc51-5f9b-43ab-9cf4-829a8c977721">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTMtNi0xLTEtNzc0MDc_b297863b-f219-4d54-94b7-ee6bcdc1e016">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTMtOC0xLTEtNzc0MDc_5b1f8c29-6d2a-43b7-b6d4-57c8d4576bcb">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTQtMi0xLTEtNzc0MDc_b7474ca7-cc8c-4e4b-b7b6-1e1256c59f61">4,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTQtNC0xLTEtNzc0MDc_72c9609b-7c50-4948-b18b-18d9d6d4d220">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTQtNi0xLTEtNzc0MDc_fb744b19-805d-40b5-8de5-0d15a4d3d54c">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTQtOC0xLTEtNzc0MDc_e12e7e76-f0aa-42e0-853b-02e84e14419a">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS PER SHARE (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTctMi0xLTEtNzc0MDc_f9012076-c601-4018-8e27-b21858348250">1.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTctNi0xLTEtNzc0MDc_698c2e6c-250b-443c-8484-36156cbd03a8">1.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTgtMi0xLTEtNzc0MDc_04d648b3-0408-4560-8459-5d8f13cbfc34">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTgtNi0xLTEtNzc0MDc_ae2cd20b-779c-4e6f-a380-f23638a5ecb5">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVG. SHARES OUTSTANDING</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMjEtMi0xLTEtNzc0MDc_7e7da13a-2a06-4713-9999-036e9b8f956a">2,627.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMjEtNi0xLTEtNzc0MDc_b0583c0a-7e7a-4260-809c-1f60c8b591fb">2,632.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMjItMi0xLTEtNzc0MDc_612fcda8-71ce-41bd-8691-d8eb524f5111">2,661.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMjItNi0xLTEtNzc0MDc_cfccc64b-6147-4a37-98b7-18a11c7a18f6">2,674.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_28"></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars &amp; Shares in Millions Except Per Share Amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:283.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNC0yLTEtMS03NzQwNw_f5a2ec24-f815-4ed4-9851-11c79c8c3ada">71,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNC00LTEtMS03NzQwNw_8ec4b547-eede-4745-819b-f10e2b8d3ed9">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNC02LTEtMS03NzQwNw_e5b866e2-b172-4658-8178-2914c5852061">68,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNC04LTEtMS03NzQwNw_445626d7-05b7-425a-89d8-1dc0c95dc68c">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNS0yLTEtMS03NzQwNw_8897d550-3c21-41ce-91bb-f6cd4be75cdf">23,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNS00LTEtMS03NzQwNw_46ccf2bb-b353-44f9-a725-879969389750">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNS02LTEtMS03NzQwNw_900fd153-87d0-4b49-911c-66e7b71c78cd">21,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNS04LTEtMS03NzQwNw_7603cd11-1946-4e1b-9b7a-e8e9ba96e0a5">31.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNi0yLTEtMS03NzQwNw_47e44759-d38e-48ce-978f-6e10d7e74d70">47,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNi00LTEtMS03NzQwNw_cd108292-7b5f-4aae-84ad-8aef632976cd">67.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNi02LTEtMS03NzQwNw_a6772f8e-0748-4c71-9b13-343fb76ffbe4">47,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNi04LTEtMS03NzQwNw_a21a4d55-a7c2-4edb-b0e6-bcd1048e723e">68.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNy0yLTEtMS03NzQwNw_bb6193c7-ba6b-4df7-a39a-e1a27f332ede">18,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNy00LTEtMS03NzQwNw_ee0f9227-9c9c-4da2-ae45-b2fcc960ae8e">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNy02LTEtMS03NzQwNw_5ea13cd2-9328-452a-818e-01e99a24f382">17,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNy04LTEtMS03NzQwNw_625d5796-90de-49c3-a427-749f8a6cd36c">25.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOC0yLTEtMS03NzQwNw_c9505f97-fab0-4446-b53f-c4d0f7cff0ce">10,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOC00LTEtMS03NzQwNw_2569f713-362d-4705-b28e-e0a7efd07659">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOC02LTEtMS03NzQwNw_0828cad7-c7d4-45eb-896a-5ac2bfb04f98">9,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOC04LTEtMS03NzQwNw_0482be19-1070-45bb-a74f-0ba97fd794d9">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOS0yLTEtMS03NzQwNw_ba8b3b88-7c90-4fb9-87a7-1cbede5fb593">610</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOS00LTEtMS03NzQwNw_78a683ec-906b-4f7b-b0cc-a2b7e838225e">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOS02LTEtMS03NzQwNw_d13a1e74-5745-4b6d-b3ef-8c6bf9745869">900</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOS04LTEtMS03NzQwNw_f449112c-7a05-470e-a86d-18cccc66932f">1.3</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTAtMi0xLTEtNzc0MDc_e6a318f7-b651-4c8b-a950-bec1bd675c1d">236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTAtNC0xLTEtNzc0MDc_5bb5fb16-9248-4b56-bdd1-8f027b0fbee7">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTAtNi0xLTEtNzc0MDc_22f027af-aca3-483c-b2fb-2faa65219719">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTAtOC0xLTEtNzc0MDc_227579b0-51d8-4143-94cb-25d8a24ad3b0">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTEtMi0xLTEtNzc0MDc_50c391d2-97da-42f4-afad-1b191f658ecd">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTEtNC0xLTEtNzc0MDc_f24ea554-2b27-4b46-b534-77af4dc2a5f0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTEtNi0xLTEtNzc0MDc_ee882c2d-a591-44f1-adec-9e70f416c0e1">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTEtOC0xLTEtNzc0MDc_b93b7144-2bb0-4e20-af9e-a75acc9a52be">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTItMi0xLTEtNzc0MDc_3d266828-ca78-43bd-a549-fe1dec0990b3">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTItNC0xLTEtNzc0MDc_2b297fa7-4ffa-498e-abfe-8ac5573b2a79">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTItNi0xLTEtNzc0MDc_2f00dd84-3824-40c8-9402-05ca56a6f201">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTItOC0xLTEtNzc0MDc_8c73213a-392e-490e-844c-b5673a099660">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTMtMi0xLTEtNzc0MDc_0a020613-fa1b-461a-9395-23bd2c9cce43">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTMtNC0xLTEtNzc0MDc_bd66958f-5bd2-4dfb-adbb-183e536ef0d2">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTMtNi0xLTEtNzc0MDc_ffdb22f1-98af-4c43-9a7e-a807902d182a">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTMtOC0xLTEtNzc0MDc_e745979b-c91f-4032-8032-d98bf48e0c1d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTQtMi0xLTEtNzc0MDc_8ff1c250-5417-4a37-8c8f-6844cd067d8d">17,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTQtNC0xLTEtNzc0MDc_948f914b-ddcc-4508-8c13-b34a20627f31">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTQtNi0xLTEtNzc0MDc_fdf1d23d-f750-49d6-aa7e-a01e7d506a2f">17,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTQtOC0xLTEtNzc0MDc_2da939e4-76dc-45ee-ab19-886303f42570">26.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTUtMi0xLTEtNzc0MDc_c4100f43-c18c-4cfa-a5d7-0cf246ea8c5a">3,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTUtNC0xLTEtNzc0MDc_4e7c1248-cb28-4d6b-b45a-d868058d74e0">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTUtNi0xLTEtNzc0MDc_1b6fff84-ae67-428e-832b-e64538ec710d">1,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTUtOC0xLTEtNzc0MDc_cd9af93b-7763-4c41-a4be-e1220c042e79">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTYtMi0xLTEtNzc0MDc_75037e60-c6da-4b97-86c6-7b536a9d9306">14,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTYtNC0xLTEtNzc0MDc_05a4386e-5c7c-44ff-9f35-f4c38377e474">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTYtNi0xLTEtNzc0MDc_6a03cc3c-8486-46fd-8b12-4552698747b2">16,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTYtOC0xLTEtNzc0MDc_27896a8c-7a49-4a65-8850-04977ea12c3c">23.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS PER SHARE (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTktMi0xLTEtNzc0MDc_72032aae-227c-468e-90f8-3ba688e2399e">5.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTktNi0xLTEtNzc0MDc_c0143160-ef21-4091-8e43-caec981347d7">6.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjAtMi0xLTEtNzc0MDc_298e37c3-4c61-4e98-9e79-bfa727b12766">5.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjAtNi0xLTEtNzc0MDc_6bbf739b-0e2e-4712-b377-0a869bf98cea">6.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVG. SHARES OUTSTANDING</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjMtMi0xLTEtNzc0MDc_2b7b7575-df7e-4cd2-bc1e-0ed3b3a52411">2,628.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjMtNi0xLTEtNzc0MDc_709486ab-d7c5-4ab1-8733-ff96d5e71a9e">2,632.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjQtMi0xLTEtNzc0MDc_d632d07c-28f7-4be1-acbc-9f8fb0acc3a0">2,667.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjQtNi0xLTEtNzc0MDc_d6fc6f2f-1347-4276-a0b2-ac8e3213bfb2">2,674.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See Notes to Consolidated Financial Statements</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMy0xLTEtMS03NzQwNw_110560c9-a79d-4d68-941c-3c0cbaac40d7">4,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMy0zLTEtMS03NzQwNw_700b268b-7d22-4fd0-9e88-367918aa8419">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMy01LTEtMS03NzQwNw_0a9c1e71-74fa-4abd-9c1d-a89ce6d3b602">14,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMy03LTEtMS03NzQwNw_836dfb9a-6fa5-454e-a294-38c85b147fc1">16,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfNi0xLTEtMS03NzQwNw_b82184fe-beb3-4ec7-a5bd-09389826e487">1,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfNi0zLTEtMS03NzQwNw_72144488-f179-47b9-9259-48ec48053837">382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfNi01LTEtMS03NzQwNw_02136c81-8bc5-46fd-b9d1-888dcfb33c4f">1,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfNi03LTEtMS03NzQwNw_28704fa4-6b2a-4ae8-a84f-f2c24357dcf9">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized holding gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfOS0xLTEtMS03NzQwNw_c8c8d7c4-de35-46a0-be4f-e9dbea7bf221">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfOS0zLTEtMS03NzQwNw_6bf01c41-3889-4c96-9f9e-840d374da1ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfOS01LTEtMS03NzQwNw_4ca80f36-7318-4c5a-8a14-2526735dfd03">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfOS03LTEtMS03NzQwNw_35ccf82c-4a14-4127-a24a-4857a0785ec1">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTAtMS0xLTEtNzc0MDc_5e0947e7-61a0-418b-b449-96699b9b1126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTAtMy0xLTEtNzc0MDc_5e2a0b0e-c78e-485d-a555-e294902c5dfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTAtNS0xLTEtNzc0MDc_ecbd9a70-cd50-4451-a7b5-c43bee25841e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTAtNy0xLTEtNzc0MDc_f9b1cc33-180d-4d25-b58d-021cbe0a7f83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTItMS0xLTEtNzc0MDc_c417de3c-31ee-45a9-8da1-3e5469f485e2">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTItMy0xLTEtNzc0MDc_9174a654-830f-436e-9101-308a13324f2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTItNS0xLTEtNzc0MDc_42e6895a-e8ea-49c4-bc22-e7de6e823630">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTItNy0xLTEtNzc0MDc_9e1f9bb2-e9af-4695-8f27-772b4ef6dcf6">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior service cost amortization during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTUtMS0xLTEtNzc0MDc_83f98b5c-16e1-4e67-bb85-6cf33e5e88c5">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTUtMy0xLTEtNzc0MDc_1bda04de-b68c-4e79-967c-40accd1136ba">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTUtNS0xLTEtNzc0MDc_7c09e143-066d-4935-927d-0b833de3b201">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTUtNy0xLTEtNzc0MDc_c9cc537c-4f75-4385-afca-ada814340e56">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Gain (loss) amortization during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTYtMS0xLTEtNzc0MDc_9bee777a-74ac-4428-bc98-8674530886b8">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTYtMy0xLTEtNzc0MDc_bd824ef0-ab90-46ea-982b-52101fd1f63f">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTYtNS0xLTEtNzc0MDc_72e06459-1837-4e5a-aa50-a63e6f0302ba">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTYtNy0xLTEtNzc0MDc_b8b6751f-884c-4ec4-ad84-7641fd0a3079">822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTgtMS0xLTEtNzc0MDc_a026f745-e032-49f6-9f53-54c131d3d4b5">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTgtMy0xLTEtNzc0MDc_d0eaccdf-5ee9-415f-8aae-0c644e3812ee">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTgtNS0xLTEtNzc0MDc_62100389-3d69-489b-822f-221dd731b421">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTgtNy0xLTEtNzc0MDc_aaaab364-16c2-4b88-b08b-08eab07493f3">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives &amp; hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjEtMS0xLTEtNzc0MDc_58cc26a1-6c3f-48ab-a177-041f057d08c5">204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjEtMy0xLTEtNzc0MDc_115cdd30-e9dd-4ab6-a278-6a94ed778e99">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjEtNS0xLTEtNzc0MDc_dc94b9ea-b95a-4606-af1c-5d49e36e8463">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjEtNy0xLTEtNzc0MDc_0e157cc5-7b09-4c64-9d63-32a81e6efdee">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjItMS0xLTEtNzc0MDc_939408bf-98af-4a7a-b4f2-49fd4b33567b">105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjItMy0xLTEtNzc0MDc_9ba8821a-cb68-46d8-a45a-ab8e7784279d">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjItNS0xLTEtNzc0MDc_3cf73413-78ae-48b6-bc7c-1f6f8b910737">332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjItNy0xLTEtNzc0MDc_bcf5b53d-0c71-4d5b-8de0-aab1a60c0bf4">576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjMtMS0xLTEtNzc0MDc_da59a21b-3ba8-4793-9edd-388dd3ee80a7">309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjMtMy0xLTEtNzc0MDc_dc2fca47-aef4-405b-8145-8109707a8e70">166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjMtNS0xLTEtNzc0MDc_4c53123c-1ef4-4d08-a969-8e7966359dda">586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjMtNy0xLTEtNzc0MDc_617ed074-5c38-420f-9648-7195058dbe93">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjUtMS0xLTEtNzc0MDc_10efc6f1-826f-400a-aeef-251d4170bf7b">1,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjUtMy0xLTEtNzc0MDc_9e20df94-8f55-4f4b-90fe-d49544c23bbd">315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjUtNS0xLTEtNzc0MDc_8101384f-c5da-47cf-b219-7d3f6ce1fd37">2,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjUtNy0xLTEtNzc0MDc_099db2f6-61f2-4932-aef7-b9f319d337bc">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjctMS0xLTEtNzc0MDc_88c3e5a2-b438-44d0-8d51-54f3fe639c54">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjctMy0xLTEtNzc0MDc_9f49de67-6216-4848-a513-e0a6ca152b30">3,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjctNS0xLTEtNzc0MDc_91db4f11-13e8-49cd-bded-b43c15ac8146">12,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjctNy0xLTEtNzc0MDc_30a737cb-acc2-46c0-bbe1-85738bcd56d8">15,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income for the fiscal third quarter were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzE2MA_c28bf0c1-2384-40bf-8778-d8ee2814908e">181</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzE3NQ_ca01e69a-53c9-48f1-9f0f-94e16b8d7f76">86</ix:nonFraction> million; Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzI0NA_14bebd82-371a-46d2-8c3a-2e354b6bf03a">33</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzI2MA_d3472a9b-911a-4860-953c-3c78bbe47c78">65</ix:nonFraction> million; Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzI5NQ_c164548f-3a49-401d-bb2c-7eee168f3632">82</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzMxMQ_e0736f9e-a586-4e8e-bcb0-74e9929957d0">43</ix:nonFraction> million.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income for the fiscal nine months were as follows for 2022 and 2021, respectively: Foreign Currency Translation: $<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzE1Ng_1dfb214e-9691-4932-b735-75b15c2cc516">859</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzE3Mg_2d64fa4f-cba3-4c53-978b-b42ea20d3d30">315</ix:nonFraction> million; Securities: $<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzE5Nw_16fec028-03e5-43fa-9744-23654cd0f8a2">9</ix:nonFraction> million in 2022; Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzI0Mg_b900b322-dc59-44ae-8ac0-a51a609de560">98</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzI1OA_f22a90b3-f014-4d55-90ad-f68e893ef043">197</ix:nonFraction> million; Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzI5Mw_d4c70296-4122-4102-b758-52b9ce957296">155</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzMwOQ_5b133280-05cb-4a4c-a4d6-f4fef5645bb8">167</ix:nonFraction> million.</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Third Quarter Ended October&#160;2, 2022 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, July 3, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b96c9b90b442fab76aafa9fe0f84c0_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMS0xLTEtMS03NzQwNw_b60eb3fa-f435-43f2-babe-fe7d6a3c2f9e">76,357</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b472a7b024e4350a7efccb19639fe5d_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMS0zLTEtMS03NzQwNw_33dda6d0-b7ab-490a-8047-f269b29760d9">126,216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i897e4f04cc0743dab9335bb279413316_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMS01LTEtMS03NzQwNw_2d718c72-5494-47be-9494-967ec42ab1fe">13,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i761acbf210e54d4fb1c6163ec297f3bf_I20220703" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMS03LTEtMS03NzQwNw_85aaf8bd-69b7-47f5-84a4-5b01db4883c0">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58e73c0430be475c963749b0d5dfc1f0_I20220703" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMS05LTEtMS03NzQwNw_5cd09265-8938-437b-b748-07a1216260f6">39,136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMi0xLTEtMS03NzQwNw_a363907b-7bf8-4e6c-8171-10be47d123f3">4,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a1c834e78d4ae6845c115cb37b55cc_D20220704-20221002" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMi0zLTEtMS03NzQwNw_cefdba05-0f4a-4d10-98cd-5f6c355ebfa1">4,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMy0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjFkMGRmNTA3MzkwZTQzYmJiOTU0MDdkOTU5YmIwMmI1XzI2_eb64f03c-5c4f-4f81-907e-ef844ab7e7bc">1.13</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMy0xLTEtMS03NzQwNw_d059f147-a6cb-4023-8cec-c77636748eb6">2,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69a1c834e78d4ae6845c115cb37b55cc_D20220704-20221002" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMy0zLTEtMS03NzQwNw_cef42521-5be4-4725-83b5-0176af07a933">2,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNC0xLTEtMS03NzQwNw_a66bfd5f-7ad4-4e0e-a55a-b952cac1f975">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a1c834e78d4ae6845c115cb37b55cc_D20220704-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNC0zLTEtMS03NzQwNw_91c15446-5ce0-4ea0-acf2-28a651b16b44">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381efb52944e08881f1e2b2dbd0e62_D20220704-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNC05LTEtMS03NzQwNw_952aa9f5-c840-49cb-be70-72c7f2754665">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNS0xLTEtMS03NzQwNw_224ba15c-6311-40a9-aa3a-4f56e673b1e7">2,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381efb52944e08881f1e2b2dbd0e62_D20220704-20221002" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNS05LTEtMS03NzQwNw_5d08aa82-aef7-4771-bef3-fe869ff25fa6">2,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNy0xLTEtMS03NzQwNw_4ccb0dfa-eb7d-41e5-b940-3ee15a9b010c">1,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia001762d1dae4d37bc5d624881fae1f7_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNy01LTEtMS03NzQwNw_4198631f-cfd7-414b-8dee-f93163bcdab2">1,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, October 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfOC0xLTEtMS03NzQwNw_ef95f7c1-2a6a-4d84-b495-5b598bb25371">74,599</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a1b195ff7d410ba97f45f6c00f9cdb_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfOC0zLTEtMS03NzQwNw_eaf2cc51-15ca-4744-bd9b-5e3ca42afc63">127,917</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a9083e68f134a6b959f8e81ba70dca0_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfOC01LTEtMS03NzQwNw_ca397452-07f1-4a2d-926a-6db23d5e1ea4">15,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17402ff8071d436f8f5e04dfd2b0c961_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfOC03LTEtMS03NzQwNw_040906d5-435e-45f9-83f7-5476bcad6607">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3af518980d74cf485a8c59539fbb189_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfOC05LTEtMS03NzQwNw_ead86e1f-85f4-4813-8d66-410325d1b8a4">41,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Nine Months Ended October&#160;2, 2022</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMy0xLTEtMS03NzQwNw_9a9e10fc-b1f0-48d7-9d96-87cea1c23610">74,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ceeba3817c74be08a112b20898f78ce_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMy0zLTEtMS03NzQwNw_e03ccdce-c330-4a68-8caa-b7c790a15d75">123,060</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib60c35086bcc4c329bbe423674e693a9_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMy01LTEtMS03NzQwNw_97f1be44-533c-4b65-9714-d8aa9a1446a6">13,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04a23e81d62c4182843a25a386d3c871_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMy03LTEtMS03NzQwNw_8a6db7ee-8ca9-4dd4-b6a6-9b13f549c355">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a4a604382b3438899182204e090fce2_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMy05LTEtMS03NzQwNw_5bc089b4-8ee3-4c50-a806-66b4012aac01">39,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNC0xLTEtMS03NzQwNw_aaabac85-0dca-4278-93af-1eba5a3ece27">14,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71751112fea74037b276e2ca1d6230b8_D20220103-20221002" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNC0zLTEtMS03NzQwNw_41709fb4-14b9-41bf-95d1-d56673f3753b">14,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNS0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjFiMDlhYjc5NTRhMTQyYmRhMWJiODI4MjcyN2Q1NjJiXzI2_0baee691-25fa-4bb8-a2fe-1f1eb50b0d38">3.32</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNS0xLTEtMS03NzQwNw_383a967d-ce41-42b2-9233-9a274ded4566">8,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71751112fea74037b276e2ca1d6230b8_D20220103-20221002" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNS0zLTEtMS03NzQwNw_642d558a-0c81-406f-9e34-cd2352d9dcd3">8,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNi0xLTEtMS03NzQwNw_a086730d-9be0-4d5f-8540-04fcee732143">1,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71751112fea74037b276e2ca1d6230b8_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNi0zLTEtMS03NzQwNw_b7f58f14-e066-4a97-a08d-17546152ab51">836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d8e299561a467d8fbca5be63ecf1db_D20220103-20221002" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNi05LTEtMS03NzQwNw_a3a23227-81ca-4af1-b7ab-d5e2c9498ecb">2,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNy0xLTEtMS03NzQwNw_0a1fa4ae-560d-4b30-8fc8-d50414838314">4,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67d8e299561a467d8fbca5be63ecf1db_D20220103-20221002" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNy05LTEtMS03NzQwNw_c1ff493a-682d-4a8f-a6fa-22767a53a73a">4,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfOS0xLTEtMS03NzQwNw_59ebd771-21f2-44ee-a2c9-94fb2442a8f1">2,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d3b5d7c62914a7d86c97bf6c03bc15e_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfOS01LTEtMS03NzQwNw_25d20126-5b61-4e26-80e3-8f146bdd0827">2,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, October 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMTAtMS0xLTEtNzc0MDc_de20bd48-0964-4cdc-87a2-fe5e8b371bf6">74,599</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a1b195ff7d410ba97f45f6c00f9cdb_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMTAtMy0xLTEtNzc0MDc_a48223bb-0840-440b-8b9b-6e0b6cfb4e67">127,917</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a9083e68f134a6b959f8e81ba70dca0_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMTAtNS0xLTEtNzc0MDc_e012660f-da08-4695-9f8c-5263de88aba3">15,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17402ff8071d436f8f5e04dfd2b0c961_I20221002" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMTAtNy0xLTEtNzc0MDc_3f3ffabe-861a-49b2-87ee-346607f89ef0">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3af518980d74cf485a8c59539fbb189_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMTAtOS0xLTEtNzc0MDc_605ab8e3-4381-4b97-8eac-3e1186c2a0fc">41,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Third Quarter Ended October&#160;3, 2021 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:37.985%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, July 4, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04a9117c60243599ca157246ed62b82_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMS0xLTEtMS03NzQwNw_e6abf1c9-7d43-48fd-b53b-c1414b844aa6">69,580</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2841ce9e4bda45d8adf1dbed8d0ebb98_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMS0zLTEtMS03NzQwNw_f896e826-a67e-4cad-8610-4d5e0fea9ea4">120,154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc527a1e93694a149099814a6a780f3f_I20210704" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMS01LTEtMS03NzQwNw_28bdd847-38ba-4192-a0af-d858fd011297">15,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i627a7e7e8917482ea7ed3fcf4e5c6e7c_I20210704" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMS03LTEtMS03NzQwNw_55acaac4-fd0b-456f-bc8e-a06a66dc73aa">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if42495605efa42b5bb22a39f20c44adb_I20210704" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMS05LTEtMS03NzQwNw_11eb6088-4512-4533-b6cb-5c2e262b1a51">38,594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMy0xLTEtMS03NzQwNw_1a2838e2-d89b-4611-9187-6a4250be9505">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922b7adff7f14b97a51ffc13b9d0eb2d_D20210705-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMy0zLTEtMS03NzQwNw_07a55c4b-1107-45f8-a23a-41e6efd42542">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmRiYmY1ZjM3YTgzNTRiNTE4OTM5MzEzZjYyOGZiMTVjXzI2_4c0c0fe1-6c07-47a9-97dd-e7c9ed6dfd37">1.06</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNC0xLTEtMS03NzQwNw_c4322b5e-66fe-4f30-9a2e-6cd450d92c31">2,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i922b7adff7f14b97a51ffc13b9d0eb2d_D20210705-20211003" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNC0zLTEtMS03NzQwNw_254c7b3d-577a-45e4-b972-e7b3f5dee9f5">2,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNS0xLTEtMS03NzQwNw_13a86886-981d-4d84-92c2-7ff92a245090">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922b7adff7f14b97a51ffc13b9d0eb2d_D20210705-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNS0zLTEtMS03NzQwNw_03598dd8-21cf-487a-b848-be4310c1c34e">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic763a721f63241119bc153b39881a917_D20210705-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNS05LTEtMS03NzQwNw_e6df1df4-751c-436a-aa50-bb8a1128c703">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNi0xLTEtMS03NzQwNw_651f72d4-5a89-4930-b924-980a483b2fbf">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic763a721f63241119bc153b39881a917_D20210705-20211003" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNi05LTEtMS03NzQwNw_bdc45345-5579-4541-b33e-4fa41f541ef2">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOC0xLTEtMS03NzQwNw_1a659c88-2c84-470b-8ec0-aa1f9cf226a6">315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic42e25ee27d54341885e6febcb82d781_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOC01LTEtMS03NzQwNw_6eb141b8-7530-49da-a8b4-74d2982930c0">315</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, October 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4184dedf017492f81476885b7412820_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOS0xLTEtMS03NzQwNw_c73ddf12-b975-4fcc-b225-e14918a0a51f">70,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58afd10b08ae473ebc46006082b2cec6_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOS0zLTEtMS03NzQwNw_1df9b6b2-4500-4928-b8d8-45cb9e5b3107">121,092</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50585c37981c4ff18094df49a0252cde_I20211003" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOS01LTEtMS03NzQwNw_5e951084-bd89-4585-9708-2c7299b02cb3">15,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a790e2ad784bd7ad2cc7889a2256a0_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOS03LTEtMS03NzQwNw_ea8aed71-ee74-45ca-bec7-ccda69962527">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e846d19941748ce9cbcf17a4f318405_I20211003" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOS05LTEtMS03NzQwNw_93de1509-9bc1-4fc5-9228-b3b2df7c02d5">38,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal Nine Months Ended  October&#160;3, 2021</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, January 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7466db7fb3de4e73b837ebe5f0b10609_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMy0xLTEtMS03NzQwNw_24ce7470-8260-4d6b-b315-839d717f3491">63,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c66231e52f741d58eefd24bb80b245b_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMy0zLTEtMS03NzQwNw_93f41593-c31f-4c7e-b911-3ef69bb87194">113,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d5a9d98b51145fda780e8e3cb899d96_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMy01LTEtMS03NzQwNw_ca683c5c-4849-4711-830e-5ffafe810654">15,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af1680d3ee24b0db79fec7b602aee32_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMy03LTEtMS03NzQwNw_e504a033-8b8e-4fa1-9cda-426ea2178fdb">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i360f555817294c969083b2da5b0c7012_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMy05LTEtMS03NzQwNw_cd9a3420-8897-4099-ba3a-ce49ab75c310">38,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNS0xLTEtMS03NzQwNw_077ca4ea-f352-4c33-87f4-191e72cd281e">16,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39a746470bc4c38bb1c35c5afbcd727_D20210104-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNS0zLTEtMS03NzQwNw_a64b9063-20e7-48aa-8abc-d9a6676ffb76">16,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjdkY2M4M2E2MTFmODQxYjFiODMxZWY0MTMzYmFiYTJiXzI2_317aea22-5e9d-46b7-adf3-3ee0c19d1171">3.13</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNi0xLTEtMS03NzQwNw_69e642e4-5464-426e-8380-f85e02a01d77">8,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia39a746470bc4c38bb1c35c5afbcd727_D20210104-20211003" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNi0zLTEtMS03NzQwNw_f8667112-f0cc-4f02-9f45-76c416277e7d">8,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNy0xLTEtMS03NzQwNw_d9831973-49cb-4e47-82e0-40d61ecca7dd">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia39a746470bc4c38bb1c35c5afbcd727_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNy0zLTEtMS03NzQwNw_aae8aeac-6b06-4f98-bf1d-543786e45966">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i784f48887ba4406090c0c953b964f651_D20210104-20211003" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNy05LTEtMS03NzQwNw_79bd4418-d796-431e-b575-524ba1560e26">2,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfOC0xLTEtMS03NzQwNw_5e7dc7f0-c0b3-424d-993e-f3d81e9f44da">2,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i784f48887ba4406090c0c953b964f651_D20210104-20211003" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfOC05LTEtMS03NzQwNw_5494f380-90db-46d1-82ba-a341f6b3b021">2,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTAtMS0xLTEtNzc0MDc_ee7d3f39-1076-4a92-ab57-48e00c9da7e8">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba060ae7e2bf4658880cd1a19b71adf6_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTAtNS0xLTEtNzc0MDc_17ad68f5-2ba3-434a-ace3-e547e6447ad1">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, October 3, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4184dedf017492f81476885b7412820_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTEtMS0xLTEtNzc0MDc_2f4d6965-a0fc-4032-b51f-b52caa1e9b60">70,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58afd10b08ae473ebc46006082b2cec6_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTEtMy0xLTEtNzc0MDc_29135590-59b8-428e-9084-c6815806bb95">121,092</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50585c37981c4ff18094df49a0252cde_I20211003" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTEtNS0xLTEtNzc0MDc_e737f642-273d-4f2b-a0ed-2c95c645fa97">15,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4a790e2ad784bd7ad2cc7889a2256a0_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTEtNy0xLTEtNzc0MDc_51f68bc7-db25-4e99-bdd1-637b02d3804d">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e846d19941748ce9cbcf17a4f318405_I20211003" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTEtOS0xLTEtNzc0MDc_d36b1e6b-4aa3-42f3-a715-df3a7910c61c">38,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_43"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMy0yLTEtMS03NzQwNw_d77ae4a8-cbb0-441a-99a9-b339b2590c87">14,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMy00LTEtMS03NzQwNw_f0a20d36-1767-42fa-8091-4d9f3e764ee9">16,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNS0yLTEtMS03NzQwNw_4239dc7d-73b2-488c-8ae9-1fd1e61015ef">5,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNS00LTEtMS03NzQwNw_df124ac5-d52a-462e-b453-22c0b84f2389">5,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNi0yLTEtMS03NzQwNw_be652b45-27dc-414f-b4e6-c718eb9ef56a">925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNi00LTEtMS03NzQwNw_9bb28ad1-115c-46f4-8162-c0b937846756">920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-downs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfOS0yLTEtMS03NzQwNw_01634787-8cf8-40c5-ab0f-a05926ae8bb6">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfOS00LTEtMS03NzQwNw_30076e63-6b86-42b5-84df-50ddf28190ef">964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets/businesses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTEtMi0xLTEtNzc0MDc_013e1a28-be40-4106-b350-33462d23440f">213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTEtNC0xLTEtNzc0MDc_0b3c2ca7-52c4-4b5d-a71c-c7ee8c0a8261">601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTMtMi0xLTEtNzc0MDc_5bed5f71-6286-4199-8b23-3cf14dbdaaa5">2,488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTMtNC0xLTEtNzc0MDc_5a1c5942-f792-4cd3-b901-518a6b5b76fb">2,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit losses and accounts receivable allowances </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTQtMi0xLTEtNzc0MDc_853d4d83-d2bc-4853-8096-b04562bb097c">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTQtNC0xLTEtNzc0MDc_99bb2354-da9e-4c27-a2ac-8cdbacee8bcc">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTYtMi0xLTEtNzc0MDc_01297cc6-332a-45e1-addc-c1857b56125d">1,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTYtNC0xLTEtNzc0MDc_c32c1ca1-66f3-44c1-9201-f105041fbe85">1,818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTctMi0xLTEtNzc0MDc_a11524f0-66bc-47be-b967-2b59bd8987e1">1,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTctNC0xLTEtNzc0MDc_6b5fef3b-dd61-49b0-8793-a6292efa754e">1,178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTgtMi0xLTEtNzc0MDc_ec06f2cb-92ab-4821-879b-4d22011e7104">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTgtNC0xLTEtNzc0MDc_f77e944e-c3e6-405f-a823-e0668b41abe4">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in other current and non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTktMi0xLTEtNzc0MDc_de669004-52b4-487f-818c-bfda666b193f">4,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTktNC0xLTEtNzc0MDc_2854eaee-9629-4f49-a3cc-1adeb0257734">2,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in other current and non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjAtMi0xLTEtNzc0MDc_a39ee4e1-3ba2-4cb3-96e1-52ffa97d6d32">4,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjAtNC0xLTEtNzc0MDc_d08b996f-3ecf-43ae-98b6-8ce8f67db110">1,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjItMi0xLTEtNzc0MDc_a226c4c5-d71f-4356-bf26-816da0b42b92">15,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjItNC0xLTEtNzc0MDc_30c550cf-6f65-4ac4-a12d-c1bf45f4eeaf">17,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjUtMi0xLTEtNzc0MDc_e8b579f8-3d0f-4cfd-8d6a-f43ecc081c95">2,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjUtNC0xLTEtNzc0MDc_024399f4-6a55-4c09-9f73-9087a32436a5">2,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the disposal of assets/businesses, net (Note 10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjYtMi0xLTEtNzc0MDc_0e4678a8-009d-44ed-94bc-b4def033cb05">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjYtNC0xLTEtNzc0MDc_ca025bd3-01af-4bd3-8adc-d3358a8ed60a">666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjctMi0xLTEtNzc0MDc_dbb05eb3-167f-4d0a-a693-c1d761e7ad83">522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjctNC0xLTEtNzc0MDc_be49d969-98e3-48ae-91db-2f7fa5d4b8cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjgtMi0xLTEtNzc0MDc_a7d849c3-7135-4e32-921c-0f3733e1927a">31,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjgtNC0xLTEtNzc0MDc_add9ecbf-c223-4572-8d48-cab344188c7e">18,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjktMi0xLTEtNzc0MDc_f5a68bc6-7529-472e-a9d9-710a8c2c3539">26,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjktNC0xLTEtNzc0MDc_7e46d6a7-e1a2-4af0-b60c-3aaaad7aa9d3">16,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzAtMi0xLTEtNzc0MDc_5b8e0c50-f19d-4813-9280-6a087ee34172">305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzAtNC0xLTEtNzc0MDc_af07be19-f734-4373-8a4c-179092485e3d">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (primarily licenses and milestones)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzEtMi0xLTEtNzc0MDc_f245e816-320b-4090-b1fd-4b6a520a5288">208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzEtNC0xLTEtNzc0MDc_d10241e4-e77e-4aff-86b4-c0f939c6ddab">414</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH USED BY INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzMtMi0xLTEtNzc0MDc_593db909-57fd-4d35-94bf-953ecb5ef604">7,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzMtNC0xLTEtNzc0MDc_ce9ea83c-71fc-46ce-a927-4e860369b80a">3,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzYtMi0xLTEtNzc0MDc_aecf976c-1aee-4695-a179-c47febe354b8">8,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzYtNC0xLTEtNzc0MDc_0cbc91b1-0103-4a46-8c60-ed8173b2f005">8,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzctMi0xLTEtNzc0MDc_d6b2ef40-1741-4fd4-ab3e-2408d71381c7">4,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzctNC0xLTEtNzc0MDc_d1a16085-c6a8-491c-b71b-e98f1f943da8">2,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzgtMi0xLTEtNzc0MDc_57dcd356-acd8-4025-a14c-4ef7de8a421b">7,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzgtNC0xLTEtNzc0MDc_3231a6ac-9ea9-4e38-bb1a-1f1adf266f31">1,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzktMi0xLTEtNzc0MDc_35717fb1-1e2b-4ba7-84ef-4fc5adc10c92">4,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzktNC0xLTEtNzc0MDc_bec73b7a-d88a-499c-80e2-96c618d14154">821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDAtMi0xLTEtNzc0MDc_8889a16a-793b-4b4a-904d-e163f950ea78">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDAtNC0xLTEtNzc0MDc_1da4b78f-ce4d-4fc9-a11d-fb8517cb88bc">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDEtMi0xLTEtNzc0MDc_7a060f8d-9e43-4b3a-81a7-75f4885d926a">2,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDEtNC0xLTEtNzc0MDc_0ed92207-e8ed-4c67-93ca-23a812b9ae32">1,452</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDItMi0xLTEtNzc0MDc_1a1b796c-0eb4-4692-97e8-c37318b47d80">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDItNC0xLTEtNzc0MDc_f77339ce-2e74-48d7-931b-1912e232070b">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDMtMi0xLTEtNzc0MDc_18107803-efc3-4942-91c9-857c685cb61b">1,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDMtNC0xLTEtNzc0MDc_e5ce003b-3fc9-40cc-aac2-dcff6b68b75c">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDQtMi0xLTEtNzc0MDc_9acc224c-c3bb-4569-92d2-f322615e3356">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDQtNC0xLTEtNzc0MDc_dbc0b915-0af8-4768-9dbe-d0cb17f52ee9">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH USED BY FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDYtMi0xLTEtNzc0MDc_1561ac3d-1493-4fb2-8457-0e4d2185a157">10,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDYtNC0xLTEtNzc0MDc_b819f7a2-0156-440e-b36f-6fb6f44c449d">10,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDgtMi0xLTEtNzc0MDc_23967340-a438-4284-81ab-fb7da664afd6">431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDgtNC0xLTEtNzc0MDc_f2d3836e-f851-4336-aa97-69a0550882b3">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease)/Increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDktMi0xLTEtNzc0MDc_d4e2f038-1b0e-4993-8fa4-876a5851c535">3,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDktNC0xLTEtNzc0MDc_79aab141-1ee6-47ef-8566-0a5e110168cf">3,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash equivalents, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTAtMi0xLTEtNzc0MDc_b4db5bd0-8a44-49cb-9d0c-7b26e7aaa1ac">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7466db7fb3de4e73b837ebe5f0b10609_I20210103" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTAtNC0xLTEtNzc0MDc_f22a585a-5086-4a7c-a230-1da646609a7e">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS, END OF PERIOD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTEtMi0xLTEtNzc0MDc_c86c259a-d954-4976-9bb9-0f25c211bee3">11,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4184dedf017492f81476885b7412820_I20211003" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTEtNC0xLTEtNzc0MDc_ae6706f2-9f0c-4f40-aec3-3668c5e470aa">17,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTgtMi0xLTEtNzc0MDc_75f04ea6-31a8-41db-87bf-1f921327f324">620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTgtNC0xLTEtNzc0MDc_7491c08f-2485-4562-8041-aae42b101c88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed and noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTktMi0xLTEtNzc0MDc_60115e45-9538-4725-b75b-ec63ad9e0590">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTktNC0xLTEtNzc0MDc_38d92255-b650-4cb6-90fa-63d8f284b17b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNjAtMi0xLTEtNzc0MDc_35315050-79f3-43b8-b7ed-ddc93b27e551">522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNjAtNC0xLTEtNzc0MDc_5734cece-0717-4ede-83eb-dfc06b96bff8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 1 &#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80OS9mcmFnOjUzNjYzMGY1OGIwZTRjZDZiNGQ4MGRmNDFmMzc0ODA0L3RleHRyZWdpb246NTM2NjMwZjU4YjBlNGNkNmI0ZDgwZGY0MWYzNzQ4MDRfMjczOA_853d0cec-7463-4576-a10d-74a421dbf33a" continuedAt="i1b5994e7e5b0472aa240b55493960703" escape="true">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i1b5994e7e5b0472aa240b55493960703"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80OS9mcmFnOjUzNjYzMGY1OGIwZTRjZDZiNGQ4MGRmNDFmMzc0ODA0L3RleHRyZWdpb246NTM2NjMwZjU4YjBlNGNkNmI0ZDgwZGY0MWYzNzQ4MDRfMjcyOQ_07e51840-3ed6-4264-8ff2-12456321ca63" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October&#160;2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended October&#160;2, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div></ix:nonNumeric><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80OS9mcmFnOjUzNjYzMGY1OGIwZTRjZDZiNGQ4MGRmNDFmMzc0ODA0L3RleHRyZWdpb246NTM2NjMwZjU4YjBlNGNkNmI0ZDgwZGY0MWYzNzQ4MDRfMjczNg_12f62725-e8d5-4e79-a7e9-4b49c38a38bb" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. </span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal third quarter of 2022.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Not Adopted as of October 2, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) &#8211; Disclosure of Supplier Finance Program Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity&#8217;s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80OS9mcmFnOjUzNjYzMGY1OGIwZTRjZDZiNGQ4MGRmNDFmMzc0ODA0L3RleHRyZWdpb246NTM2NjMwZjU4YjBlNGNkNmI0ZDgwZGY0MWYzNzQ4MDRfMjczMA_2f4ec82a-586d-4136-aa3e-f4d8d0026ad4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_52"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 2 &#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RleHRyZWdpb246OTljODVmZmE4OWQzNGQ5ZGIwYjNiZTQzNDNiODYzNDBfMzY_64cc3147-39d7-4831-b94b-c09a8bf0a559" continuedAt="ic0faf0660c674383a0a019da26157675" escape="true">INVENTORIES </ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ic0faf0660c674383a0a019da26157675"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RleHRyZWdpb246OTljODVmZmE4OWQzNGQ5ZGIwYjNiZTQzNDNiODYzNDBfMzE_c2c20f35-df21-4e41-b2d4-91a903a43518" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:51.896%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMS0yLTEtMS03NzQwNw_f017fc8b-1ca7-4c03-a103-2e1f7cf15a60">1,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMS00LTEtMS03NzQwNw_32edaca2-d4af-47e5-9b91-056aec4e9729">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMi0yLTEtMS03NzQwNw_4174c7c7-bc25-4138-bdb2-939540c4d921">2,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMi00LTEtMS03NzQwNw_633a912f-2f18-4c97-9307-0065efc21aaa">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMy0yLTEtMS03NzQwNw_88160913-5ee0-4ae3-b87d-55bcfaa361a2">7,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMy00LTEtMS03NzQwNw_ee0eeeda-e937-4a10-9e27-aa58eff4c8bc">6,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfNC0yLTEtMS03NzQwNw_51b2b64c-25e2-4fc7-8675-f308263b1101">11,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfNC00LTEtMS03NzQwNw_fb797332-7aa1-4fb0-861b-36d93822a4a0">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 3 &#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMjA2MQ_9f6f37bf-ed33-4705-969d-8a22e22fe45b" continuedAt="ibe1bff124d4c484189e97390e34b061e" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ibe1bff124d4c484189e97390e34b061e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMjA1OA_7aa14ccb-dbf1-41c4-8a66-774855fb7c4f" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:61.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543c0b5db3074157b1c389cc2cb0ab48_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMi0yLTEtMS03NzQwNw_3af32b75-3ee2-492f-97ad-0968cf179608">35,132</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15558a3176fc43799fe21d45d80bca2a_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMi00LTEtMS03NzQwNw_e38a9e1d-e598-4b3f-aa92-ab021036e98a">38,572</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i543c0b5db3074157b1c389cc2cb0ab48_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMy0yLTEtMS03NzQwNw_7827fc05-ea07-47df-ad76-4e27090234cb">20,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15558a3176fc43799fe21d45d80bca2a_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMy00LTEtMS03NzQwNw_07d5f736-42bf-41a7-90cf-4a5809327872">20,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543c0b5db3074157b1c389cc2cb0ab48_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNC0yLTEtMS03NzQwNw_f18eff10-af44-4013-b99d-23a1cba7daa8">15,016</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15558a3176fc43799fe21d45d80bca2a_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNC00LTEtMS03NzQwNw_930efde1-8e8d-4a85-b418-fdee75a05c1c">18,484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2612dc9b393420aae1223b600b75635_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNS0yLTEtMS03NzQwNw_d89d44af-11f5-4d91-b9af-d9b9b83c9ffc">22,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af979d2806348c99fb689ce6819de96_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNS00LTEtMS03NzQwNw_e534b5a0-18e2-4da1-a147-eeb5c3a6954b">23,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2612dc9b393420aae1223b600b75635_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNi0yLTEtMS03NzQwNw_5439ed32-2d81-406d-9ec6-bfb5b82971b2">12,406</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2af979d2806348c99fb689ce6819de96_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNi00LTEtMS03NzQwNw_22b860be-00d2-4d2d-866e-06a50f3a1023">11,925</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2612dc9b393420aae1223b600b75635_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNy0yLTEtMS03NzQwNw_0da9c2ef-244d-4bd2-a5ca-194eff090299">9,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af979d2806348c99fb689ce6819de96_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNy00LTEtMS03NzQwNw_40128cd4-880f-40e2-a89f-c23a3ea704b5">11,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0536181aa78447d784d738349332b35e_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfOS0yLTEtMS03NzQwNw_db04d4ab-6921-4803-8fd6-7b3a83c8f0bf">6,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i661087c5259246cfa115e122efa6dcaf_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfOS00LTEtMS03NzQwNw_4ecc8abd-2953-489b-8081-7503a788d2ad">6,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235a103d58c546b8837d113d0020a52e_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTAtMi0xLTEtNzc0MDc_0a76b79a-8e5d-4a5a-afe4-3ab059e43636">8,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica2f1087d4384fb0b48f876aae358e67_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTAtNC0xLTEtNzc0MDc_e1d64ac0-c513-4692-b9c5-9b16904d983f">9,837</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTEtMi0xLTEtNzc0MDc_24a4627b-1817-4d20-92bf-3a5739f0fcc5">15,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTEtNC0xLTEtNzc0MDc_7d83def3-551f-476c-badb-9dc9d4ee56e4">16,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTItMi0xLTEtNzc0MDc_20121d8d-8006-48f9-898e-c0fc5c7b06be">40,336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTItNC0xLTEtNzc0MDc_68b7e9a6-3090-46c5-99cd-79e5c9726bd7">46,392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The change in intangible assets with definite lives is primarily the result of currency translation effects.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="i813f5728d4834e4081f50346c8257c32_D20220103-20221002" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfNjE1_63d60b12-b1f5-4649-bfdb-691b944fcde7">0.6</ix:nonFraction>&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, subsequent to the fiscal third quarter, additional information regarding efficacy of the HS indication became available which led the Company to the decision to terminate the development of bermekimab for HS. The Company will record a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i9cb8f0f0413e458aa5d67d5e5470970a_D20221001-20221027" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMjc0ODc3OTA3MTk5OA_f8b4119f-cc9d-47ce-82cf-87836b727d21">0.2</ix:nonFraction>&#160;billion in the fiscal fourth quarter related to this impairment.  The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMjA2MA_61625a08-f90a-4841-be12-a1fcdf543987" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of October&#160;2, 2022 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:39.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcf057d296c84d089ec6d58708ea1502_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMS0yLTEtMS03NzQwNw_67bfc192-cbb3-4e6d-9409-8f3d227dd64b">9,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if32850109bc44a7fbb02840853387b1a_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMS00LTEtMS03NzQwNw_7ba241bc-1df8-415a-98e3-b5fe55f19fe4">10,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbdf34d70c14edbb7715d0150857e3d_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMS02LTEtMS03NzQwNw_d028fcd1-102f-4809-b7b2-3a3ea8c1f40d">14,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMS04LTEtMS03NzQwNw_cfced1ea-1783-4f60-8df6-8517c44f3735">35,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7787b0e8db0d4969ac6e93a11454dd47_D20220103-20221002" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMi0yLTEtMS03NzQwNw_ac8f88e8-b22d-4468-a547-329c435888c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i470f1742dc564aceade9de615023f5d9_D20220103-20221002" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMi00LTEtMS03NzQwNw_69ac9856-ae2d-49ab-b925-7709f1164ece">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMi02LTEtMS03NzQwNw_3c294d00-315e-4a4e-a0da-16ed829ad79f">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMi04LTEtMS03NzQwNw_3bc7d5c2-efc3-4273-a563-fa72452b2575">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7787b0e8db0d4969ac6e93a11454dd47_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNC0yLTEtMS03NzQwNw_86aaf039-ec33-4f5d-aead-a3f25259ef9f">1,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i470f1742dc564aceade9de615023f5d9_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNC00LTEtMS03NzQwNw_5ce6ef15-ec6a-4e47-b2a3-4efe358dcef5">920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNC02LTEtMS03NzQwNw_262954d4-5c95-4529-9ac8-2c199dd40f86">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNC04LTEtMS03NzQwNw_f4f5ded5-1e65-43a3-9373-fb11f23d8a02">2,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at October 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522547423bad464f84afd2d37c47a86d_I20221002" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNS0yLTEtMS03NzQwNw_2aaa6f11-0b11-45fd-bda4-f08b3e4eb3f7">8,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21aa856799804b82aa87e91511e1349b_I20221002" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNS00LTEtMS03NzQwNw_11672cc6-9b75-4769-b4d9-dc8aec8631fd">9,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36c39c3a9764cb68cde96d61776f981_I20221002" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNS02LTEtMS03NzQwNw_5cc6c9e8-0b4a-4b29-8650-18bbaa1f37cc">14,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNS04LTEtMS03NzQwNw_507a2262-6f26-41e2-a897-5a6a04b3bd22">33,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is <ix:nonNumeric contextRef="i6dbbb67dd9c940368c9c692b2970e944_D20220103-20221002" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTMzMQ_30e7e4cb-9331-4693-8977-dc8559f21d2e">12</ix:nonNumeric> years. The weighted average amortization period for customer relationships and other intangible assets is <ix:nonNumeric contextRef="i957a0b8f238643b5a7f04ec25dd1ade7_D20220103-20221002" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTQ0MA_a8fb9773-5e06-4cc2-90ca-16f218bb76d8">21</ix:nonNumeric> years. The amortization expense of amortizable intangible assets included in cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTU0Ng_81a88ca1-13c5-4b6a-b550-188cd02e8772">1.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTU1Mw_dc3432a5-bec1-4c22-90fc-92f968c76f70">1.1</ix:nonFraction>&#160;billion for the fiscal third quarters ended October&#160;2, 2022 and October&#160;3, 2021, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTY4OA_5c1a18ea-d034-4d91-8c94-6b6d5510f9ee">3.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTY5NQ_0d46a2e7-5a0d-4afa-9072-04c541945b55">3.6</ix:nonFraction>&#160;billion for the fiscal nine months ended October&#160;2, 2022 and October&#160;3, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMjA3OA_dd642aef-5e3a-4a37-8785-968dfc46507a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"></td><td style="width:18.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjBlODA0ODA2Y2RjNjRjYjY5YzYwMmY5NGRiMTU0NjcwL3RhYmxlcmFuZ2U6MGU4MDQ4MDZjZGM2NGNiNjljNjAyZjk0ZGIxNTQ2NzBfMi0wLTEtMS03NzQwNw_442d7336-c985-4d02-8515-bc9be502156c">4,300</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjBlODA0ODA2Y2RjNjRjYjY5YzYwMmY5NGRiMTU0NjcwL3RhYmxlcmFuZ2U6MGU4MDQ4MDZjZGM2NGNiNjljNjAyZjk0ZGIxNTQ2NzBfMi0yLTEtMS03NzQwNw_b5ee6294-192e-46fa-b611-435ae6ec6a5e">4,300</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjBlODA0ODA2Y2RjNjRjYjY5YzYwMmY5NGRiMTU0NjcwL3RhYmxlcmFuZ2U6MGU4MDQ4MDZjZGM2NGNiNjljNjAyZjk0ZGIxNTQ2NzBfMi00LTEtMS03NzQwNw_67dc700d-69d3-4828-96e6-56ad3f67749c">4,100</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjBlODA0ODA2Y2RjNjRjYjY5YzYwMmY5NGRiMTU0NjcwL3RhYmxlcmFuZ2U6MGU4MDQ4MDZjZGM2NGNiNjljNjAyZjk0ZGIxNTQ2NzBfMi02LTEtMS03NzQwNw_facb7df8-2214-4507-be33-9a601ca631c8">3,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjBlODA0ODA2Y2RjNjRjYjY5YzYwMmY5NGRiMTU0NjcwL3RhYmxlcmFuZ2U6MGU4MDQ4MDZjZGM2NGNiNjljNjAyZjk0ZGIxNTQ2NzBfMi04LTEtMS03NzQwNw_be466696-b5d6-4be9-9026-66f8d1ad1bf5">2,800</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 4 &#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2MzY_89e6cb3f-5df0-4c14-9652-4a5911294f51" continuedAt="ib3ba3cf2fc9b4a1f897a90b96b60fe54" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib3ba3cf2fc9b4a1f897a90b96b60fe54" continuedAt="i62b08b85de514439be8d76092ceb70d8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October&#160;2, 2022, the cumulative amount of cash collateral received by the Company under the CSA amounted to $<ix:nonFraction unitRef="usd" contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002" decimals="-6" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTY1MQ_28e7241f-fb86-4186-ab0c-d980552d672d">0.8</ix:nonFraction> billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjMxNg_e3b8cc74-4d11-48c5-ada6-03838e4b59ad">47.1</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="i1c547b36424143b69e5081413c4fdc53_I20221002" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjMyMA_f931adee-54fc-43e7-b90f-bc26849df999">36.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i717dee1c18bf45e493386905d911c3e8_I20221002" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjMyNw_455c82f5-27a6-4a4f-aa0d-6ac5d284671d">10.0</ix:nonFraction>&#160;billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="i62511374dce64f139252ff8bd59a8db6_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjUwMg_96920d38-906d-4e89-b41c-651133bd3ffa">45.8</ix:nonFraction> billion,  $<ix:nonFraction unitRef="usd" contextRef="i8a64086e3de14779a155947b262f6215_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjUwNw_8be9d7c3-e5b4-46cf-a958-abbc70db6d34">37.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ib1c84b4bb409475ca45e6496196a8bfe_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjUxNA_cbd46eb2-e80f-402d-b5af-795d2fc192a2">10.0</ix:nonFraction> billion respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;2, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $<ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfNDY0NA_1a2a2ba5-c27e-4981-a9da-346ec8c1fd7d">922</ix:nonFraction>&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfNDkwMg_0a29a671-e772-4dbb-bbe7-edf3cb5b1a73">next 12 months</ix:nonNumeric> as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfNTA2Mw_076c82b7-058a-4b29-bfad-02ce50db6ed6">18</ix:nonNumeric> months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="i62b08b85de514439be8d76092ceb70d8" continuedAt="i0622759c91d94d74acea5b208229c6ce"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2ODA_3fb1d9aa-86bf-43f7-9eaa-2c72e23a8562" continuedAt="i99de1e601ebc4895882ff852e666f6da" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2022 and 2021, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7879ef9eb79f474c8938fb5e9a08e0c1_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy0xLTEtMS03NzQwNw_8223593a-6e47-4639-9028-654b94311d4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd146d7e5a948cb9bea7e9644188230_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy0yLTEtMS03NzQwNw_253f87fc-f5ba-4e92-9dc5-d05418742c13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0995bad590ed43e0bd73dc14bc4125a2_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy0zLTEtMS03NzQwNw_ec197f8e-d1c1-42a5-90ef-4e376968cb53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28d9447c402644708f5027054c7c807d_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy00LTEtMS03NzQwNw_01927ff9-9fd1-43b0-90ab-21ae448acfe7">322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f7c9ef50ebc4fa19a9a1d74ac4d6b69_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy01LTEtMS03NzQwNw_8e7f1d90-0e57-470f-ab38-df04162dce71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i888f5820c4ce448da471f2eeb67baf91_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy02LTEtMS03NzQwNw_07f2244b-1e90-4057-94b2-364a108cf80c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a1bf6a5e0a43f89bd6a0e1d76c50bb_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy03LTEtMS03NzQwNw_f968fed9-47ec-4c70-a9dd-7cc8b5d31cab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee5060692494cee9c6f548b6e07c2a1_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy04LTEtMS03NzQwNw_3b5b6c79-d28e-4040-b1c0-ee494155ebe8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica35d2547f134655985b599491b5d2de_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy05LTEtMS03NzQwNw_ea83f3ec-5b54-4578-854e-39be072edfd7">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027b98ae63404a32b51e156b3616bcf5_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy0xMC0xLTEtNzc0MDc_5079ea2a-b278-4c5a-8542-76816925a968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7879ef9eb79f474c8938fb5e9a08e0c1_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC0xLTEtMS03NzQwNw_8ed1dc86-e9f7-48b7-bcc1-cff021a69319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd146d7e5a948cb9bea7e9644188230_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC0yLTEtMS03NzQwNw_c528ca0a-6180-469e-be1c-7f8ca3bbd99a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0995bad590ed43e0bd73dc14bc4125a2_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC0zLTEtMS03NzQwNw_d8131e72-b32d-44ef-9133-a96ce9818e94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d9447c402644708f5027054c7c807d_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC00LTEtMS03NzQwNw_e579948c-84b2-4c44-a43e-9241c07ccb27">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f7c9ef50ebc4fa19a9a1d74ac4d6b69_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC01LTEtMS03NzQwNw_71f2c5a7-7c4b-4142-9519-800cd1a111d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i888f5820c4ce448da471f2eeb67baf91_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC02LTEtMS03NzQwNw_04abbb7f-7d25-4443-8a2d-63290bb94005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a1bf6a5e0a43f89bd6a0e1d76c50bb_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC03LTEtMS03NzQwNw_5d8c3f9e-9372-4846-acc7-3047b0418083">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee5060692494cee9c6f548b6e07c2a1_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC04LTEtMS03NzQwNw_c8335e74-4416-477f-a000-9095fb1bf574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica35d2547f134655985b599491b5d2de_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC05LTEtMS03NzQwNw_e22ee133-96a9-4d3e-88e7-287b3d401721">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027b98ae63404a32b51e156b3616bcf5_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC0xMC0xLTEtNzc0MDc_3a3a85b6-b9fd-498b-b515-86418b154420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieceea25b4808416c866a84c9e93d2bc5_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItMS0xLTEtNzc0MDc_d2915ef4-577e-4499-9831-94c982abfe7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4346ff30c79f4cb6889ccfc5de69e800_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItMi0xLTEtNzc0MDc_0118b64b-c54d-428f-a7b6-ecdd2aea360f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14f778c18a3446c9134ffdea15dbf34_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItMy0xLTEtNzc0MDc_f9a565e9-44fc-409c-9329-4e7de8dca57c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dc12c5833b246768b8eb8a92f87ba5b_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItNC0xLTEtNzc0MDc_4afeceee-72f0-4419-bb5d-4ef600d33cc0">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d3d9443f8444bbaf8ea1e69ddb15bb_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItNS0xLTEtNzc0MDc_53452e43-19b1-45c2-b4a1-47b8c9b5fd03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72dbeff9573f40a5b9ba376ad81d5398_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItNi0xLTEtNzc0MDc_772dec44-cf62-4d03-828b-a6f3fcbeb43e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb87a9281a92433d81c4a3ab6ffcf38e_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItNy0xLTEtNzc0MDc_7ecb050d-8abf-4da9-b311-b8c7533baa8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f92be1d7860435ab1166cf51a2c9ada_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItOC0xLTEtNzc0MDc_a5969ab6-c2cd-40e7-b7f5-993b6f017811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699ea2f9280641c6a2c2ca9ae65c2e9e_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItOS0xLTEtNzc0MDc_9eb9cccc-eb69-487a-b906-c0809d956989">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9571f8c7ed824bd7907d0dc67ac2cbfc_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItMTAtMS0xLTc3NDA3_21c6af1d-54f5-4e88-b37c-c670694dd854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieceea25b4808416c866a84c9e93d2bc5_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtMS0xLTEtNzc0MDc_99b0b57d-3eb5-4e87-a89e-80d34509567c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4346ff30c79f4cb6889ccfc5de69e800_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtMi0xLTEtNzc0MDc_18542194-2944-448d-9a1c-315db14a9ffb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14f778c18a3446c9134ffdea15dbf34_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtMy0xLTEtNzc0MDc_ef59538d-db03-4283-aa74-3b462e4712a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dc12c5833b246768b8eb8a92f87ba5b_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtNC0xLTEtNzc0MDc_789ede97-25b0-4e64-9e2d-1956ae330d45">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d3d9443f8444bbaf8ea1e69ddb15bb_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtNS0xLTEtNzc0MDc_92164361-2f93-4292-8841-9519bad8f936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72dbeff9573f40a5b9ba376ad81d5398_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtNi0xLTEtNzc0MDc_97aeec12-84fa-4f2d-a557-c9922b338254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb87a9281a92433d81c4a3ab6ffcf38e_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtNy0xLTEtNzc0MDc_2df63db5-d322-42ba-a33e-8f0dba817c92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f92be1d7860435ab1166cf51a2c9ada_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtOC0xLTEtNzc0MDc_887eaa22-4d5e-4320-9ef7-619b5bc7535f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699ea2f9280641c6a2c2ca9ae65c2e9e_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtOS0xLTEtNzc0MDc_eca66ad3-fc6d-427b-bd97-ba2410cfedba">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9571f8c7ed824bd7907d0dc67ac2cbfc_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtMTAtMS0xLTc3NDA3_eb4b4e56-8b63-4a00-a735-4529c27ba8d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78647d618ebb4323997e495ab6b689d1_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctMS0xLTEtNzc0MDc_32157a9a-f22a-43cc-b763-92009ac63ee0">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6804eaf6e9a2498bb21b278580ca9ca0_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctMi0xLTEtNzc0MDc_c9c321ea-31fa-40ee-97f5-0d64ebc8a7a2">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132eac11468e4392b097dc2bcb6b935b_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctMy0xLTEtNzc0MDc_2ae2c51d-8293-4f29-be52-a0cab97bcd5d">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7950a50b27c4ebdb91385e119fda9f5_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctNC0xLTEtNzc0MDc_6b60fcce-203d-47f2-b6a5-87a9b9e08970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a2ff3d08834c418a9d5c5493adff6e_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctNS0xLTEtNzc0MDc_00987ae9-3f1e-4c3b-a5d5-0579dde3d320">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcc16a1145204ef7b053987f85b7f51d_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctNi0xLTEtNzc0MDc_5c82757a-8835-4050-8ff5-feefe14c2f81">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98263d9f7f8641fd9e965fa50bc0532a_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctNy0xLTEtNzc0MDc_7c67528c-e0b9-4e57-ab87-1723e756d3d5">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b29d715d9741d3abce2df4d39b309e_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctOC0xLTEtNzc0MDc_295a4983-e1dc-432d-8ef2-4a9c6990a3a8">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f312e218c94f0da6a1676afa932315_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctOS0xLTEtNzc0MDc_50e83a23-41cb-4fa3-9748-5a8759993bd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fde6866da6845ffa717894b879f8c97_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctMTAtMS0xLTc3NDA3_0d971727-74e2-4c81-902c-ebcca56a3a5b">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78647d618ebb4323997e495ab6b689d1_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtMS0xLTEtNzc0MDc_80b43298-16f4-41e6-88e0-c0c494b6acf8">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6804eaf6e9a2498bb21b278580ca9ca0_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtMi0xLTEtNzc0MDc_67ce7382-c60c-40f9-a111-f37c654011be">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132eac11468e4392b097dc2bcb6b935b_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtMy0xLTEtNzc0MDc_c7dc21e0-2e6c-4bc4-b402-a03990d0d9de">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7950a50b27c4ebdb91385e119fda9f5_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtNC0xLTEtNzc0MDc_b983987e-017d-4bbf-a2b8-e941a240139a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a2ff3d08834c418a9d5c5493adff6e_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtNS0xLTEtNzc0MDc_19ac987a-18fd-42bb-8676-6b08ed9339f0">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcc16a1145204ef7b053987f85b7f51d_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtNi0xLTEtNzc0MDc_1e989e3d-95c1-42a2-a147-41e110780d78">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98263d9f7f8641fd9e965fa50bc0532a_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtNy0xLTEtNzc0MDc_81abddd1-40a6-4e25-b64e-f85152d95525">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b29d715d9741d3abce2df4d39b309e_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtOC0xLTEtNzc0MDc_26babf0d-8511-48e6-8622-dc70acaf4415">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4f312e218c94f0da6a1676afa932315_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtOS0xLTEtNzc0MDc_8ec6bb73-40bd-4e7d-8db1-22af5cd8d33d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fde6866da6845ffa717894b879f8c97_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtMTAtMS0xLTc3NDA3_092a07bf-3ba3-4ceb-95d0-fc74138b3690">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7366275be3ae410893ecf9408865b9c7_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtMS0xLTEtNzc0MDc_025b5214-0ee2-4dc0-8b3f-38cc6c1180e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0b992f36af4511aa5daeaab0f6fbab_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtMi0xLTEtNzc0MDc_0afffff8-17eb-4e45-b3e6-f4b4becc723f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8378ff8e008a4098af1366d8ed328c04_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtMy0xLTEtNzc0MDc_1015aa2f-9122-4381-91dc-edd1f2c86679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0757ae310f7c40a68adf9115fdf4e04f_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtNC0xLTEtNzc0MDc_66c4c53e-a66e-41e4-bb9a-79d82d285ad6">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i773b6479d1f84dd099a271d67f39d97b_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtNS0xLTEtNzc0MDc_f7c870cd-def5-4696-88d0-c7df3d00b757">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6aac49f1e34f848da45a55d588af8d_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtNi0xLTEtNzc0MDc_a2918abe-78ee-4f73-b2ab-6fa0d7402af6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i98dd0e4104d64d1e9e04143dee5c8d7b_D20210705-20211003" xsi:nil="true" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtNy0xLTEtNzc0MDc_30d13d53-5b77-481f-b944-5dbacc38c00a"></ix:nonFraction></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c2531c320b4c429410121c99424073_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtOC0xLTEtNzc0MDc_54a97734-31a1-4d95-9664-21bdba1aee49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if365333f1f9d4429b45bb40e00408696_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtOS0xLTEtNzc0MDc_800f2a78-02b2-4175-b720-01513f8d9dd0">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b8db1fe34e46ee8c685ab4da2008f5_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtMTAtMS0xLTc3NDA3_e0fb1252-52c3-40c1-b62f-62930049066d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7366275be3ae410893ecf9408865b9c7_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtMS0xLTEtNzc0MDc_cf651b1c-edb9-4df6-8815-370bd4b53fca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c0b992f36af4511aa5daeaab0f6fbab_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtMi0xLTEtNzc0MDc_fa47fb8e-5443-42c5-870f-72c3e77e3a86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8378ff8e008a4098af1366d8ed328c04_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtMy0xLTEtNzc0MDc_f2f29b61-372a-4927-b251-4713bfd1c9b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0757ae310f7c40a68adf9115fdf4e04f_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtNC0xLTEtNzc0MDc_29784c4f-53ae-493d-bd41-7068d0351015">205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i773b6479d1f84dd099a271d67f39d97b_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtNS0xLTEtNzc0MDc_de27e918-d3ad-4693-985f-05a117df09c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6aac49f1e34f848da45a55d588af8d_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtNi0xLTEtNzc0MDc_b575a435-ccfe-41c7-ae08-808f72d7dce0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98dd0e4104d64d1e9e04143dee5c8d7b_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtNy0xLTEtNzc0MDc_f2ec6a60-6b33-44d2-a8d8-de480e988abb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c2531c320b4c429410121c99424073_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtOC0xLTEtNzc0MDc_2fd4a2ae-f3d2-4058-adcb-3d58398adbcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if365333f1f9d4429b45bb40e00408696_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtOS0xLTEtNzc0MDc_18af4b3b-5c1a-49b8-b474-f5156c319c4c">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b8db1fe34e46ee8c685ab4da2008f5_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtMTAtMS0xLTc3NDA3_e3e6044a-6fad-4df2-ae32-830c84192e9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i0622759c91d94d74acea5b208229c6ce" continuedAt="i21c06e0d11c942f5812f68683aabbcf2"><ix:continuation id="i99de1e601ebc4895882ff852e666f6da" continuedAt="i711fa694fbaa4afabf29269563b788e7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2022 and 2021, net of tax:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e443c797bce44b8904549f48d8fc7a7_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy0xLTEtMS03NzQwNw_89670d35-9e1c-4dfb-a3ea-96d88f68c02c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425df44efbe4432dafc49cc44a80a0c5_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy0yLTEtMS03NzQwNw_5c6e558c-8dd3-4195-b7fb-4bf91e410bfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5be715bb3247109709d1a846e794a0_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy0zLTEtMS03NzQwNw_f2a96ed4-1d86-4f64-9e00-273f7217f6c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i971a920aa5d64f5992b34b4dddba6c81_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy00LTEtMS03NzQwNw_f929399c-8aba-4aa9-8665-5c0a2a32964d">1,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7500ee5f78d14a669d9868e1d786c583_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy01LTEtMS03NzQwNw_5c909717-d114-484c-9502-9b6a898173c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a948b4810449dda6fec2b6273bb8cb_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy02LTEtMS03NzQwNw_6a8f7471-3445-4218-bbdc-6361c79aaad2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eecf9b0d2d34ad7af622fbf637bcea6_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy03LTEtMS03NzQwNw_301b3546-abc6-49dc-adbd-334efa7ae29f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33f410fd64a498d0320619c400fc0_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy04LTEtMS03NzQwNw_3e82efcd-ab4d-4f27-9037-192449b95456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if68cb6de6b7547ddbd0a239ef2261809_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy05LTEtMS03NzQwNw_f9832778-f0d3-4419-b4fb-56820ac87658">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd364fbacd784c248996002106d412f1_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy0xMC0xLTEtNzc0MDc_b6cbbd5c-831d-4470-ab5b-0354fa64f9d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e443c797bce44b8904549f48d8fc7a7_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC0xLTEtMS03NzQwNw_88009eea-d429-4b8c-ba81-f2a1f18caa48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425df44efbe4432dafc49cc44a80a0c5_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC0yLTEtMS03NzQwNw_75296205-b481-40e0-a4ff-b77bb024ba77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5be715bb3247109709d1a846e794a0_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC0zLTEtMS03NzQwNw_de1a0322-9baa-41ce-a445-f2b5546167b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971a920aa5d64f5992b34b4dddba6c81_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC00LTEtMS03NzQwNw_0b459bf5-a536-4c29-8618-4300701be1fa">1,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7500ee5f78d14a669d9868e1d786c583_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC01LTEtMS03NzQwNw_ef8ee1b9-2519-4aea-afa4-0ac9f6221623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a948b4810449dda6fec2b6273bb8cb_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC02LTEtMS03NzQwNw_adcee368-a3b5-408e-91ef-c41670c972f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eecf9b0d2d34ad7af622fbf637bcea6_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC03LTEtMS03NzQwNw_f9efe592-bca7-42a9-a575-c5b7ef3f43be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac33f410fd64a498d0320619c400fc0_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC04LTEtMS03NzQwNw_18f57eb9-b5dd-4fb4-b089-a6e934c09f6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68cb6de6b7547ddbd0a239ef2261809_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC05LTEtMS03NzQwNw_68e42078-6a5f-451d-ad7b-d68dce091074">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd364fbacd784c248996002106d412f1_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC0xMC0xLTEtNzc0MDc_e7b40d6c-ff76-478e-b001-562e1b6b7c63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e79e3afda2d4ff4b9c9715fed272c0d_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItMS0xLTEtNzc0MDc_6bd90fe1-0296-4951-b800-d1de3d866663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idced9fd0a0dc40e2962f7034fb149e25_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItMi0xLTEtNzc0MDc_e8a471dd-7647-46f9-a52f-6c9a197c231a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfd0ec8b28f4d61aef0be150644a052_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItMy0xLTEtNzc0MDc_99c56c21-5431-4161-9605-b48ecd7ca9de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa79f363437b49b18f54f6dfea462a0c_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItNC0xLTEtNzc0MDc_e03d242f-df30-42ca-8efa-358ec987dbe0">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f939a4ef544f199f0a9ba9f0486f0e_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItNS0xLTEtNzc0MDc_e8a2cd69-303d-4b2e-9487-f1134538ac92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29be9feba45c4fbf8a5331a5258734dc_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItNi0xLTEtNzc0MDc_34e9331c-0c91-4c8f-992c-fd50f224e3d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20d1c20c564471ca693f0dbf7e3e2b7_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItNy0xLTEtNzc0MDc_d6334635-7c48-4581-af8e-8d2bf345c479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531bee53a47b496db85de6734c8b4ba1_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItOC0xLTEtNzc0MDc_449b0d90-4db7-452a-af53-5ba9e1109be2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef3a7f91694f4784dabed8656e3e52_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItOS0xLTEtNzc0MDc_2f792b40-1645-48dd-ba74-deb16e69bd47">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891a31716b3c4d33862563ef6041c58c_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItMTAtMS0xLTc3NDA3_93fdd91c-a811-4826-832d-913bf9194552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e79e3afda2d4ff4b9c9715fed272c0d_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtMS0xLTEtNzc0MDc_217050dc-fd55-4faf-b68d-45e13ec653e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idced9fd0a0dc40e2962f7034fb149e25_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtMi0xLTEtNzc0MDc_176cb356-ea16-4296-a0ce-517eac1b2fbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfd0ec8b28f4d61aef0be150644a052_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtMy0xLTEtNzc0MDc_cbb167c8-2c3b-459f-b8e5-7fafa5da272f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa79f363437b49b18f54f6dfea462a0c_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtNC0xLTEtNzc0MDc_68381f6a-946a-4517-b701-93aeaf821500">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f939a4ef544f199f0a9ba9f0486f0e_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtNS0xLTEtNzc0MDc_0954ab03-88c8-46c5-afd2-c2037e118847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29be9feba45c4fbf8a5331a5258734dc_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtNi0xLTEtNzc0MDc_0b880418-eaad-4c7d-9d41-5b858f97dd86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20d1c20c564471ca693f0dbf7e3e2b7_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtNy0xLTEtNzc0MDc_08281b0a-044f-4b49-b4b9-66bf36e54c0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531bee53a47b496db85de6734c8b4ba1_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtOC0xLTEtNzc0MDc_1fb9b33a-64c0-4b14-99a6-61eaf5fbcff4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef3a7f91694f4784dabed8656e3e52_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtOS0xLTEtNzc0MDc_38e8647c-e022-4430-a306-12002cc43e3c">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891a31716b3c4d33862563ef6041c58c_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtMTAtMS0xLTc3NDA3_0d4af285-af98-4e73-88a1-1ed806667c88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i234b580d2ab945b7a1da2967b50f2f0b_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctMS0xLTEtNzc0MDc_9ef30bde-216f-4f74-8a28-1f777042f51c">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c2c6e50b3414bb7b581acb7b2ddf236_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctMi0xLTEtNzc0MDc_dac552b6-dfca-45d7-bdb2-ae12f13563c0">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4b5f475cfa74c208c0321112d12da5e_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctMy0xLTEtNzc0MDc_84a83dc2-032d-4ab1-94da-50c1012d4c21">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide20e84875b34943bcfaf3c9ae95202b_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctNC0xLTEtNzc0MDc_14f602ee-8618-4a25-a917-e8ae6573ba13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29b950c0556549258d0b61b677f0b680_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctNS0xLTEtNzc0MDc_23db3eb4-9cfb-455f-8396-bfc890595402">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe5347877f646f8a69accb4b750d574_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctNi0xLTEtNzc0MDc_6dc5a955-2282-4f91-989e-f59fea778da0">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic472125573384b52b4aa88304af5b630_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctNy0xLTEtNzc0MDc_071441c2-159d-46ce-9b05-b1a835b9d323">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ff0963b4e07465bbef6c78a5da86146_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctOC0xLTEtNzc0MDc_5e1a8503-765d-4b73-8e83-124aa6b157ce">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7792ddd751e74a3fa36de680b670123a_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctOS0xLTEtNzc0MDc_a0484325-7bb8-4331-b045-82e9d7271b0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42bf0720b1074baa96eb44f6c995dbfc_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctMTAtMS0xLTc3NDA3_162f66b5-5a09-4e08-aecd-6a08c6150cb2">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i234b580d2ab945b7a1da2967b50f2f0b_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtMS0xLTEtNzc0MDc_59efcf37-1389-445f-a114-1df247f974d4">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c2c6e50b3414bb7b581acb7b2ddf236_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtMi0xLTEtNzc0MDc_4349c131-0103-49d2-bc19-de6f16b52498">153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4b5f475cfa74c208c0321112d12da5e_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtMy0xLTEtNzc0MDc_9fefdc5f-6b0b-4f05-bcec-73c301be377c">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide20e84875b34943bcfaf3c9ae95202b_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtNC0xLTEtNzc0MDc_af913719-4a66-40b9-9681-4531b30f7798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29b950c0556549258d0b61b677f0b680_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtNS0xLTEtNzc0MDc_309ca1b3-6b4e-4931-b879-06ef35208b03">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbe5347877f646f8a69accb4b750d574_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtNi0xLTEtNzc0MDc_8cc5ce6c-0ab5-4d53-bc8c-d0e38acffeb3">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic472125573384b52b4aa88304af5b630_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtNy0xLTEtNzc0MDc_d87319c0-1325-4f41-b78f-4a2eda90fc5b">398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ff0963b4e07465bbef6c78a5da86146_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtOC0xLTEtNzc0MDc_9aa51e5c-35ae-4135-997b-e120d6f19cb7">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7792ddd751e74a3fa36de680b670123a_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtOS0xLTEtNzc0MDc_b50b7007-8cc3-4174-b14e-fe794b6bb08f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42bf0720b1074baa96eb44f6c995dbfc_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtMTAtMS0xLTc3NDA3_8cc8e338-04d7-4250-a87a-90eac1365248">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7912b942d37f465fb3e53088b7761ba5_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtMS0xLTEtNzc0MDc_3fd926c1-99e1-409e-877f-2f0b022ff7c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2000357e194a441e9534374b54cbc72a_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtMi0xLTEtNzc0MDc_1ddf0bfa-ec02-4a73-9aec-713b921ac2ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6c24b49746b4613b703772fdfe9f6eb_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtMy0xLTEtNzc0MDc_21390b4d-06f8-4660-924f-e57b36fc1314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7f9d1ac03a4e2ea6d1d353ef976c71_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtNC0xLTEtNzc0MDc_6ff7077d-9dba-4ef4-96a5-0ba1bbfb1772">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bb2d4354806473f89aeaf974654c5d0_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtNS0xLTEtNzc0MDc_116294df-c98a-41b2-b799-3973fb690077">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370583126d5b4bab94e9ead51c975ebf_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtNi0xLTEtNzc0MDc_be40fa52-52a9-4206-8bd4-9390630dbb44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee255d90708413cb5622bce2a34a5eb_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtNy0xLTEtNzc0MDc_64628083-a56b-465f-bb1d-e1415425d7c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8c6cab16ef4288b07b2a65d72b7ca7_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtOC0xLTEtNzc0MDc_746a07a5-3421-4149-b1e3-dda3c1887fc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e59de01264548d093d60627efe88e9d_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtOS0xLTEtNzc0MDc_652cabc4-e904-4ef1-a92b-12ff29b87f71">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d2e79904b6488a85d7505ca382bbc1_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtMTAtMS0xLTc3NDA3_6ffab85c-a388-4478-86a3-0c71d0a72231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7912b942d37f465fb3e53088b7761ba5_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtMS0xLTEtNzc0MDc_a60b318c-4bc7-4f04-978b-1684ae5c5f08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2000357e194a441e9534374b54cbc72a_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtMi0xLTEtNzc0MDc_a584aca1-429d-4349-833b-5f3f47ea4ed0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6c24b49746b4613b703772fdfe9f6eb_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtMy0xLTEtNzc0MDc_fb0d2801-cc3c-4349-b0d4-8195f5d959f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd7f9d1ac03a4e2ea6d1d353ef976c71_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtNC0xLTEtNzc0MDc_3ab4af8c-e3de-4ea0-8940-d218a106e0cd">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bb2d4354806473f89aeaf974654c5d0_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtNS0xLTEtNzc0MDc_1d2f435d-35f2-45d7-889c-f8df33e93633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370583126d5b4bab94e9ead51c975ebf_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtNi0xLTEtNzc0MDc_27251cfc-5457-4983-8edd-15b2ca065bca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee255d90708413cb5622bce2a34a5eb_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtNy0xLTEtNzc0MDc_20abeabb-4e65-4c67-9e1c-53dc49a6b3b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8c6cab16ef4288b07b2a65d72b7ca7_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtOC0xLTEtNzc0MDc_470e3d00-1042-4079-89ee-4bb69df3d35f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e59de01264548d093d60627efe88e9d_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtOS0xLTEtNzc0MDc_48eefb3a-1e88-423d-b0f2-bef1ade82d39">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d2e79904b6488a85d7505ca382bbc1_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtMTAtMS0xLTc3NDA3_59d4a89e-db23-4e4a-aeb9-30d6df8d8651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i21c06e0d11c942f5812f68683aabbcf2" continuedAt="i7db9fbebe2bf4f95a1a85c9294a72f1c"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2Mzg_9c35d5a1-6efe-43b7-b4a5-3c48d6066deb" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  October&#160;2, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i487741e9485f4d4989b2d9bdd6959f03_I20221002" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmQ1NmRiZmVhOThkOTRhYTk5Y2VhZmZiODFmMDUyZjFlL3RhYmxlcmFuZ2U6ZDU2ZGJmZWE5OGQ5NGFhOTljZWFmZmI4MWYwNTJmMWVfNC0yLTEtMS03NzQwNw_0fb4bee9-5151-4e24-86cc-2a781cc40261">8,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8bb4709c5441d49ce49132893c52de_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmQ1NmRiZmVhOThkOTRhYTk5Y2VhZmZiODFmMDUyZjFlL3RhYmxlcmFuZ2U6ZDU2ZGJmZWE5OGQ5NGFhOTljZWFmZmI4MWYwNTJmMWVfNC00LTEtMS03NzQwNw_931d53d2-14ea-43a9-bee1-0d7c1f6a18d9">9,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i487741e9485f4d4989b2d9bdd6959f03_I20221002" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmQ1NmRiZmVhOThkOTRhYTk5Y2VhZmZiODFmMDUyZjFlL3RhYmxlcmFuZ2U6ZDU2ZGJmZWE5OGQ5NGFhOTljZWFmZmI4MWYwNTJmMWVfNC02LTEtMS03NzQwNw_b35745d3-f126-492b-969c-641d7cdad854">1,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f8bb4709c5441d49ce49132893c52de_I20220102" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmQ1NmRiZmVhOThkOTRhYTk5Y2VhZmZiODFmMDUyZjFlL3RhYmxlcmFuZ2U6ZDU2ZGJmZWE5OGQ5NGFhOTljZWFmZmI4MWYwNTJmMWVfNC04LTEtMS03NzQwNw_21861e01-7ab5-44fc-be22-49e4f247e06e">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2ODE_4aaad050-8a03-41fc-877b-b7bbcacf5e92" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2022 and 2021: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:24.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eba85641ea146e5bc22ff998e193635_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjJhOWY5MGQ0ZWE3NTQ5ZmJhYjBkN2I5NDA5ZDdjZDE3L3RhYmxlcmFuZ2U6MmE5ZjkwZDRlYTc1NDlmYmFiMGQ3Yjk0MDlkN2NkMTdfNC00LTEtMS03NzQwNw_2b3e1867-1313-44df-a386-eceeb61d4f85">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i185112cfdae241938bc5001036d374c8_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjJhOWY5MGQ0ZWE3NTQ5ZmJhYjBkN2I5NDA5ZDdjZDE3L3RhYmxlcmFuZ2U6MmE5ZjkwZDRlYTc1NDlmYmFiMGQ3Yjk0MDlkN2NkMTdfNC02LTEtMS03NzQwNw_32e797fd-c8c9-46f3-96bf-58320094c520">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5777045ad8034f0ba971fbea4fe60d05_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjJhOWY5MGQ0ZWE3NTQ5ZmJhYjBkN2I5NDA5ZDdjZDE3L3RhYmxlcmFuZ2U6MmE5ZjkwZDRlYTc1NDlmYmFiMGQ3Yjk0MDlkN2NkMTdfNC03LTEtMS03NzQwNw_5b49c984-2759-4050-9e04-809b251af658">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8c1c1667b484cd296b17f3e255a344c_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjJhOWY5MGQ0ZWE3NTQ5ZmJhYjBkN2I5NDA5ZDdjZDE3L3RhYmxlcmFuZ2U6MmE5ZjkwZDRlYTc1NDlmYmFiMGQ3Yjk0MDlkN2NkMTdfNC05LTEtMS03NzQwNw_1409d59e-e470-4b18-a1ab-5522f21b9d75">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="i711fa694fbaa4afabf29269563b788e7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal third quarters ended in 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfMy0yLTEtMS03NzQwNw_dbd3e2a8-2a54-415d-86de-3732f7730724">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfMy00LTEtMS03NzQwNw_dfb20e11-bbb9-49e8-9aaf-63545e09c6ed">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if65ea7c0fbd54a3d9557ee7eb1a25b7c_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfMy04LTEtMS03NzQwNw_6e6cb5ea-26ef-4a73-adae-41e4eef6d580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6bb3d370ef04b7d8291df862fee2c4e_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfMy0xMC0xLTEtNzc0MDc_a2bb3a9e-33dd-4d73-a5fd-33e88b450fc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2db0b7f18904840b6133ca100157ba1_D20220704-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfNC0yLTEtMS03NzQwNw_70b05344-9f06-4ee6-ba1a-3731752cf6ce">261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97ce603cf39f42638ed7c1c786b7b5cf_D20210705-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfNC00LTEtMS03NzQwNw_41590c0f-06a0-4f2e-9eb4-dca228338a3a">141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd9f71bda284795aea57b0e3717a2fd_D20220704-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfNC04LTEtMS03NzQwNw_76ef9c81-074d-45ae-bbd4-704a156334c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ae709d11a747f5bcc44c920b026868_D20210705-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfNC0xMC0xLTEtNzc0MDc_fdd6cfef-636d-4e91-9338-ae1ca5bd7b75">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal nine months ended in 2022 and 2021</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:24.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.265%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfMy0yLTEtMS03NzQwNw_06a37b2d-9cc8-4b9a-89c6-9c0b54b5c946">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfMy00LTEtMS03NzQwNw_c6706464-0c0b-4da9-bb42-d2e509c3dbdc">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995da9ebcbab4f4db89d58d96f77b4f5_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfMy04LTEtMS03NzQwNw_8ab446c4-3df4-493b-b6fc-878036f2e05b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bd6461d92f04ed69ce2217f18942c36_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfMy0xMC0xLTEtNzc0MDc_8c86c43a-63b4-465d-b9e0-ebdd0a2e3d14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b27f2a754554e6dafba78c082f6f40b_D20220103-20221002" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfNC0yLTEtMS03NzQwNw_b47a9da8-4982-4d00-af27-87e54310c57a">1,134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if177366e6dce47ec8b19785b5a66cc57_D20210104-20211003" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfNC00LTEtMS03NzQwNw_f0d0d0a8-1047-498a-81f7-3900a0cbeee2">432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i606547907f3f4875acafd89bf36f7292_D20220103-20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfNC04LTEtMS03NzQwNw_68f3064a-962c-47a4-9abd-c646c3121852">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c3297a283649f18a41e3b7ce1b4275_D20210104-20211003" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfNC0xMC0xLTEtNzc0MDc_71eb4cc1-8713-4984-88f6-4e9099cc208a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i7db9fbebe2bf4f95a1a85c9294a72f1c" continuedAt="i849fea66861b4fe5ac9e20c88d4a95d5"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2NTI_4e9d233a-96a0-4d5d-9578-211ed269134b" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:26.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.009%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1fe51dbd41434cacb992b4b627a3a1_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfMi0yLTEtMS03NzQwNw_14702c63-99b3-4c2b-a2b5-83655e5da57b">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5794f5fa77224cff877efb7f11be88a9_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfMi00LTEtMS03NzQwNw_e6c1edd4-04e7-4a94-88d6-652f8c1613e9">607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5794f5fa77224cff877efb7f11be88a9_D20220103-20221002" decimals="-6" sign="-" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfMi02LTEtMS03NzQwNw_79821abb-3a81-4ec8-8d09-1e5c76612c4d">755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8788e8f33a374f91990206b3e2c99555_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfMi04LTEtMS03NzQwNw_3858bfcd-e3d5-47ad-a94d-b9ffab185878">522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8788e8f33a374f91990206b3e2c99555_I20221002" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfMi0xMC0xLTEtNzc0MDc_181e9897-17d1-4864-8c60-2197fdcb29a0">522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ae9a8d6d144029b31ac56599a2c97d_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfNC0yLTEtMS03NzQwNw_4b73fc8e-64c1-4398-bd45-e38830aabcb5">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b0e63e41f6a4d339367644bfc21181c_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfNC00LTEtMS03NzQwNw_b7377f30-9317-49f6-8961-ac90aeebcaf6">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b0e63e41f6a4d339367644bfc21181c_D20220103-20221002" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfNC02LTEtMS03NzQwNw_bde3057a-da0f-45a0-bb72-29b69740e2e5">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib372927ab7a04736879231296a9857fc_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfNC04LTEtMS03NzQwNw_8c31e282-4141-4b26-a3ea-3c5ed16434bd">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib372927ab7a04736879231296a9857fc_I20221002" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfNC0xMC0xLTEtNzc0MDc_693d83b8-51d3-4f98-902f-c93e9f101644">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity investments without readily determinable market values, there was a decrease of $<ix:nonFraction unitRef="usd" contextRef="i2b0e63e41f6a4d339367644bfc21181c_D20220103-20221002" decimals="-6" sign="-" name="jnj:EquityFairValueAdjustmentImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfNjcyOQ_e6cdce8e-a4b4-4452-b3e7-43f3cfafee06">29</ix:nonFraction> million in the fair value reflected in net income as a result of impairments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal third quarter ended October&#160;2, 2022, the Company sold all its equity investments in argenx SE for proceeds of $<ix:nonFraction unitRef="usd" contextRef="ibe72fcc581ba4b3aa24c4cf87da552b5_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjE5OTAyMzI2ODEwNA_525450c3-7852-4188-9fd5-276960ec50dc">0.6</ix:nonFraction>&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i849fea66861b4fe5ac9e20c88d4a95d5" continuedAt="i3d4139a964e24744a2df7ce8dabdb811"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE3MDI_da5537d5-82f9-4a21-98d8-ef608997b713" continuedAt="if733a2a304af48fc8b354d65a6e7ebfa" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of October&#160;2, 2022 and January&#160;2, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:48.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9edf61dadd24a7a89bfd4eb35fdb595_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNC0yLTEtMS03NzQwNw_34522b34-9f71-4692-9736-067171efb28f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5ec42981eb24a7b8f39e90fcfcb3b97_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNC00LTEtMS03NzQwNw_482827d1-9241-4bd1-a6f3-4956c6e752ec">1,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7787c920b4fa4851a091b1d05760f26c_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNC02LTEtMS03NzQwNw_3f3a8500-e869-499e-afdc-08e58bccbf2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNC04LTEtMS03NzQwNw_f12a67ff-1bf7-41f8-88e5-05a0b4350fb1">1,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9abd0ce724b48d1878bcaa4742736aa_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNC0xMC0xLTEtNzc0MDc_51ac9ce7-23ab-4fb4-8e21-2711ce3b16d1">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13455fb6580c486fa719cf5f9b78801a_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNS0yLTEtMS03NzQwNw_a503a8e2-f829-46ef-ac2c-9bfc619f9657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17df52d9c169494fb0dbcfa0f99740fa_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNS00LTEtMS03NzQwNw_5fd9007f-eff8-4125-a0b2-1bfbb5fcf1a9">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf68b60de7014cf2a3fbb8410bc3a9bd_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNS02LTEtMS03NzQwNw_33ad4657-f165-43ce-a0ba-2a57ca306506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f13cabfbd6e4267a7040e78e38ec939_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNS04LTEtMS03NzQwNw_fa3e2256-54dd-48c9-a2cc-1f1fc93c11ab">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91092ba038134ef4a95f7a6d01647908_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNS0xMC0xLTEtNzc0MDc_1016411b-d08d-476c-9725-975bd94710db">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e55b859d5454474b61a342f2ab11b53_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNy0yLTEtMS03NzQwNw_95eed028-6cc6-46ee-aaeb-ba7a4d77a92a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e0e3590e6e48db894610a47ecd29c5_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNy00LTEtMS03NzQwNw_88a7360b-6c36-4e0f-8474-23a90d8532cd">4,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNy02LTEtMS03NzQwNw_49d45a08-a64f-4aa0-b97e-6ff9f839b6bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNy04LTEtMS03NzQwNw_9db7a870-6934-473e-a88e-0c268a7abc4b">4,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a26835dc1c47168bfb6605e72bd3bf_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNy0xMC0xLTEtNzc0MDc_a5d8773e-a352-46ed-abb9-e9de5f3c594a">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9edf61dadd24a7a89bfd4eb35fdb595_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfOS0yLTEtMS03NzQwNw_023560ad-bdc8-47eb-b1db-7ec7156e2892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5ec42981eb24a7b8f39e90fcfcb3b97_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfOS00LTEtMS03NzQwNw_20cfdaf5-3b3b-4cc2-be47-0999d6649b02">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7787c920b4fa4851a091b1d05760f26c_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfOS02LTEtMS03NzQwNw_7b680ad8-2658-4ba0-8669-1b1f50a8479c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfOS04LTEtMS03NzQwNw_ed158d29-f350-4839-8d2f-9a7caa9f4fb0">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9abd0ce724b48d1878bcaa4742736aa_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfOS0xMC0xLTEtNzc0MDc_eead4f55-d7ba-4ec0-bc39-9ebe4d6dc06d">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13455fb6580c486fa719cf5f9b78801a_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTAtMi0xLTEtNzc0MDc_c461be11-678e-4d4e-89f9-8081c2cf3b9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17df52d9c169494fb0dbcfa0f99740fa_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTAtNC0xLTEtNzc0MDc_5c608119-8c88-4d65-bd09-5b400e8dc1d2">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf68b60de7014cf2a3fbb8410bc3a9bd_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTAtNi0xLTEtNzc0MDc_d059c771-27ec-4d2d-9c30-1ab0cb09ca53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f13cabfbd6e4267a7040e78e38ec939_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTAtOC0xLTEtNzc0MDc_f65976cf-9bb3-49ff-ba74-259d0429ef75">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91092ba038134ef4a95f7a6d01647908_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTAtMTAtMS0xLTc3NDA3_cd781155-1cf2-4578-97e5-6207fef46763">979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e55b859d5454474b61a342f2ab11b53_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTItMi0xLTEtNzc0MDc_f04f5d06-932a-4369-bd78-189f77cc7e37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e0e3590e6e48db894610a47ecd29c5_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTItNC0xLTEtNzc0MDc_c6b1623b-3b19-48cd-80f6-67c56e380baf">3,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTItNi0xLTEtNzc0MDc_41a4c69f-23e3-4f51-9b49-458f180d0e18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTItOC0xLTEtNzc0MDc_f68c242b-0406-4c2a-a9a4-d3881910b57f">3,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a26835dc1c47168bfb6605e72bd3bf_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTItMTAtMS0xLTc3NDA3_77684a4d-5db4-4d71-8305-77ac88d592e5">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9edf61dadd24a7a89bfd4eb35fdb595_I20221002" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTUtMi0xLTEtNzc0MDc_6bbf0de3-670b-44bb-b60f-81fd88e3b42b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5ec42981eb24a7b8f39e90fcfcb3b97_I20221002" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTUtNC0xLTEtNzc0MDc_0776a2de-e7da-49d9-a0d0-30049070a7a8">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7787c920b4fa4851a091b1d05760f26c_I20221002" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTUtNi0xLTEtNzc0MDc_6ecdbf39-6f2f-41c4-8374-3d97e3ed3434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTUtOC0xLTEtNzc0MDc_70908b88-d206-4ddd-93c6-927b30744dce">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9abd0ce724b48d1878bcaa4742736aa_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTUtMTAtMS0xLTc3NDA3_f6de4d8d-08cf-460e-91f8-805c37540a01">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9edf61dadd24a7a89bfd4eb35fdb595_I20221002" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTctMi0xLTEtNzc0MDc_4906dba3-6cb4-4697-b619-92856f1f6dbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5ec42981eb24a7b8f39e90fcfcb3b97_I20221002" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTctNC0xLTEtNzc0MDc_d336cf42-6d81-4d7d-811c-bed968895ff0">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7787c920b4fa4851a091b1d05760f26c_I20221002" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTctNi0xLTEtNzc0MDc_091c1f91-4537-402a-b8c8-090d4fc09ef4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTctOC0xLTEtNzc0MDc_a3eb0089-a90b-410f-9b10-8eb5303e940a">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9abd0ce724b48d1878bcaa4742736aa_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTctMTAtMS0xLTc3NDA3_7ab98916-5694-4dbf-bfc9-fd4d82315cc5">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e55b859d5454474b61a342f2ab11b53_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTktMi0xLTEtNzc0MDc_5819d7d6-d778-4bd5-954e-99be18413b3e">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e0e3590e6e48db894610a47ecd29c5_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTktNC0xLTEtNzc0MDc_1a81273c-b389-4aae-ad88-5568ac3a902f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTktNi0xLTEtNzc0MDc_9a370408-95fa-4006-9c5a-fab590ec1338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTktOC0xLTEtNzc0MDc_cdc5f7c4-a72c-4dbd-8c17-14ed156dc6a3">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTktMTAtMS0xLTc3NDA3_55a99c1b-b28b-4979-9257-02442f9a9d1e">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e55b859d5454474b61a342f2ab11b53_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjAtMi0xLTEtNzc0MDc_2109db0b-9b55-483c-b05b-7c0b7637a9f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e0e3590e6e48db894610a47ecd29c5_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjAtNC0xLTEtNzc0MDc_75a0a63b-993e-415c-b4d4-49ade5414f83">22,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjAtNi0xLTEtNzc0MDc_bb9503ad-2f13-4332-808e-0518e4d5791f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjAtOC0xLTEtNzc0MDc_cffeb7d5-c84d-4721-8663-5f6aeaa2ccff">22,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjAtMTAtMS0xLTc3NDA3_eb9cc727-1005-4f07-8271-ebe7b41eb8d8">19,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e55b859d5454474b61a342f2ab11b53_I20221002" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjItMi0xLTEtNzc0MDc_26e7571a-5674-486a-9210-01395f16723a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e0e3590e6e48db894610a47ecd29c5_I20221002" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjItNC0xLTEtNzc0MDc_98bf727c-78af-47d9-84eb-0daaefd4204e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjItNi0xLTEtNzc0MDc_12bc1c19-abda-4bb1-89c8-e53de8bd9809">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjItOC0xLTEtNzc0MDc_f925e83c-9afe-48ce-8dfd-02baf8226f5b">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjItMTAtMS0xLTc3NDA3_11cad7d6-bbb2-4040-8c9a-b5d2b698b197">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfMi0yLTEtMS03NzQwNw_125a2ac5-63b3-4016-8db7-cd546006e368">4,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfMi00LTEtMS03NzQwNw_4e6d2cf7-ccc4-4445-a550-dd24571b0b9d">1,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfMy0yLTEtMS03NzQwNw_b3b4ba01-953a-449d-94c7-72806d52783c">4,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfMy00LTEtMS03NzQwNw_702fb190-85fe-44ac-b338-529c17ea73a7">1,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNC0yLTEtMS03NzQwNw_7431bfe0-ec8e-41ba-8384-b4a92be0362b">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNC00LTEtMS03NzQwNw_8c03a22d-0757-4e49-bdaf-6d7db0c3c486">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNi0yLTEtMS03NzQwNw_143c784d-ace3-4140-bee0-8b1b1e13eb0c">3,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNi00LTEtMS03NzQwNw_9263177f-78a1-428f-a150-7f7a6e2189ac">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNy0yLTEtMS03NzQwNw_f6af8a52-c092-400f-8e47-c27f77838f78">3,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNy00LTEtMS03NzQwNw_d646bc49-2632-4775-9b6e-db53b6f17fa8">1,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfOC0yLTEtMS03NzQwNw_e11e2435-924c-4c01-9a50-c3e5fd2fdfec">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfOC00LTEtMS03NzQwNw_a1e36792-d3bf-4b1c-a0b8-bbbf7d12dd38">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><ix:continuation id="i3d4139a964e24744a2df7ce8dabdb811" continuedAt="i1f41f73de3934ea181cf9e678956b4ed"><ix:continuation id="if733a2a304af48fc8b354d65a6e7ebfa" continuedAt="i3cf2bd3058c14c5aa231bb3e8f5d3866"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration for each of the fiscal nine months ended is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"></td><td style="width:41.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfMy0yLTEtMS03NzQwNw_29862f22-4b89-47c2-a388-951d937a3723">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7466db7fb3de4e73b837ebe5f0b10609_I20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfMy00LTEtMS03NzQwNw_cba9b616-656f-43de-ba04-aea470bf428f">633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNC0yLTEtMS03NzQwNw_d4a53770-cd40-4523-a208-afea61fa6ac7">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNC00LTEtMS03NzQwNw_287d4364-3b49-4709-bc7e-cfc66506596a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNS0yLTEtMS03NzQwNw_c507c220-6c70-4e14-ad37-4cbfad7c977b">89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNS00LTEtMS03NzQwNw_61620eb2-f5a6-4c22-9ecc-310183ab00d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNi0yLTEtMS03NzQwNw_d1e7bf02-8b58-4832-a1ad-0b2d93ab55a6">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNi00LTEtMS03NzQwNw_15c89d91-fca9-42fc-9410-b431377d9663">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNy0yLTEtMS03NzQwNw_756db0ed-63e1-434f-9be0-cb3ad7f45cee">525</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4184dedf017492f81476885b7412820_I20211003" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNy00LTEtMS03NzQwNw_e84809b8-9da9-4809-81c6-29df01de783b">613</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $<ix:nonFraction unitRef="usd" contextRef="i38e80c564ea64f3fbe9520902829f8e1_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTA4NA_b78ef0f0-c346-4448-a630-9081f50c4c0c">1,884</ix:nonFraction> million, which are classified as Level 1 and contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i12c14427081a4db2aa89c55987a2b503_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTE1Mg_41b9bab7-8f2b-400d-b383-5606c5522568">533</ix:nonFraction> million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $<ix:nonFraction unitRef="usd" contextRef="i0dab1f127dfc4cc180ee120f93e8d77b_I20221002" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTQwOA_91da519b-883c-496c-a26c-0cd7c50be8b7">507</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4a3800ae61df48de8d071ba58133741a_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTQyMw_0f839a28-68ae-4144-a004-a56eb2061bde">520</ix:nonFraction> million, classified as non-current other liabilities as of October&#160;2, 2022 and January&#160;2, 2022, respectively.  Includes $<ix:nonFraction unitRef="usd" contextRef="id965e9daba4e49939bc440149dcc9a39_I20221002" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTUyMA_baa95c2d-f089-4beb-a6db-8d57a77de24c">18</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if15f41a6eac24347aff0d98e523e6a33_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTUzNQ_88a9a0e2-2515-4767-aa1b-c375f6af0d3f">13</ix:nonFraction> million classified as current liabilities as of October&#160;2, 2022 and January&#160;2, 2022, respectively.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i3cf2bd3058c14c5aa231bb3e8f5d3866" continuedAt="i1fc51eebab744a4b82d9f075183e5484">           (6)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1fc51eebab744a4b82d9f075183e5484">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.</ix:continuation> </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2ODk_0f1693f4-4939-4043-bf78-b7487218fc54" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of October&#160;2, 2022 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:30.762%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/( Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMS0xLTEtMS03NzQwNw_e89f47c4-6107-4293-a4be-d4ed2965131f">4,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMS01LTEtMS03NzQwNw_17ab715c-09cc-4d62-92dd-1947b0c39f69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMS03LTEtMS03NzQwNw_0baa273b-1bed-48a6-8e5d-111b72cff342">4,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMS05LTEtMS03NzQwNw_587c8e12-0102-41d8-bcf2-cf34f3e03deb">4,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMS0xMS0xLTEtNzc0MDc_8d10fca8-8aac-4461-90ec-d75cf55a4a3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMy0xLTEtMS03NzQwNw_d8c110af-274f-4388-92f7-56f26ff9ff9a">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002" sign="-" xsi:nil="true" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMy01LTEtMS03NzQwNw_2e1a433d-8435-4a43-8edf-4a91301dbad5"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMy03LTEtMS03NzQwNw_c53f4eca-8d4d-42ec-af1e-ed3d1339f303">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMy05LTEtMS03NzQwNw_b5fe09c9-f7e7-4a12-986e-3b5acdddcf43">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMy0xMS0xLTEtNzc0MDc_14bb8e13-6a44-4e8a-a672-27d95a069b0a">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNC0xLTEtMS03NzQwNw_7816c183-fba0-47eb-851e-91e6efaa1681">2,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNC01LTEtMS03NzQwNw_b18707be-c286-42d4-b1e9-0fdbda918cab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNC03LTEtMS03NzQwNw_d9ccfd88-7fba-4ce5-bb1e-314004cf5539">2,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNC05LTEtMS03NzQwNw_76df08a3-e3fc-4c2f-8f72-8d866790d05c">2,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNC0xMS0xLTEtNzc0MDc_b35d74e4-5d03-4d04-a2aa-2403ae6d7c0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298d351dbfee46d79686114bc7415cde_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNi0xLTEtMS03NzQwNw_b6d4ed92-9e06-41d6-bb33-d9b329de6c89">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i298d351dbfee46d79686114bc7415cde_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNi01LTEtMS03NzQwNw_accef0d4-0b12-42a2-8fe7-a04d2bca897e">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298d351dbfee46d79686114bc7415cde_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNi03LTEtMS03NzQwNw_155dd513-1657-47bb-8da1-29bee7d0ef47">2,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i298d351dbfee46d79686114bc7415cde_I20221002" xsi:nil="true" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNi05LTEtMS03NzQwNw_c986dcc6-04dc-4db7-9968-e27c24e0c73e"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298d351dbfee46d79686114bc7415cde_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNi0xMS0xLTEtNzc0MDc_16b81e7b-0ff1-4db8-8fad-a8926334bc1e">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNy0xLTEtMS03NzQwNw_dce57bb0-a7ed-449e-a8ff-5a9cdee1c152">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNy01LTEtMS03NzQwNw_7632e851-866a-4447-a3e4-6b30f5bfd888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNy03LTEtMS03NzQwNw_754ccd6b-1efa-4519-bcb8-7113baae0e46">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNy05LTEtMS03NzQwNw_4107175b-66ef-48ea-8235-7ac9c3817e70">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNy0xMS0xLTEtNzc0MDc_b0b2fe73-5562-4b8c-bf6d-f2f940a0a003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfc8f6514464a3799d65367ae9e9037_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOC0xLTEtMS03NzQwNw_97f9c578-6e34-4175-baf7-6e0bc5e44f1a">928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfc8f6514464a3799d65367ae9e9037_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOC01LTEtMS03NzQwNw_9835c1ef-b6f1-45da-958b-37321d8ab130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfc8f6514464a3799d65367ae9e9037_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOC03LTEtMS03NzQwNw_9e14080d-e17f-4851-a4a6-034beeaa2e90">928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfc8f6514464a3799d65367ae9e9037_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOC05LTEtMS03NzQwNw_b79eaf7e-2966-4301-b49b-a25792ff4bd5">928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfc8f6514464a3799d65367ae9e9037_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOC0xMS0xLTEtNzc0MDc_5c797441-b77c-4c03-ad00-c5fcf4775940">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacffb22cdad9443a846f401be599d84d_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOS0xLTEtMS03NzQwNw_67c90087-1ac6-438e-92ad-0f3db5f45ffc">11,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacffb22cdad9443a846f401be599d84d_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOS01LTEtMS03NzQwNw_8a0dfae0-3753-4d89-b544-160b64953099">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacffb22cdad9443a846f401be599d84d_I20221002" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOS03LTEtMS03NzQwNw_8ff23838-764d-4950-a09c-34741c2f1aa9">11,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacffb22cdad9443a846f401be599d84d_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOS05LTEtMS03NzQwNw_48d7adc1-1ca0-40dc-bbcf-437d57e028c2">9,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacffb22cdad9443a846f401be599d84d_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOS0xMS0xLTEtNzc0MDc_745959d9-1647-4fc5-b1d0-28c50a09a731">2,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d551fd651b44dc8ea8cbf5d62affe2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTItMS0xLTEtNzc0MDc_18db9e1b-e39c-48ab-983c-a4bb43250956">21,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07d551fd651b44dc8ea8cbf5d62affe2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTItNS0xLTEtNzc0MDc_ebffa19b-b785-4d56-a245-971ea4108bc6">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d551fd651b44dc8ea8cbf5d62affe2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTItNy0xLTEtNzc0MDc_9792bfe5-18fb-4347-9ab7-f0ab7b7501e6">21,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f1d898f0d04ab99472e9d1769191c9_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTItOS0xLTEtNzc0MDc_44cd1be3-2628-4054-8257-b9994ef26d87">2,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3f1d898f0d04ab99472e9d1769191c9_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTItMTEtMS0xLTc3NDA3_4a4677ff-5bb1-4a82-9aa2-643190e6ca75">19,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic52ecafdfee4446badc41ecd13c9f2a2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTQtMS0xLTEtNzc0MDc_8233e231-c836-4a0d-a5eb-af755047b7c7">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic52ecafdfee4446badc41ecd13c9f2a2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTQtNS0xLTEtNzc0MDc_8a7332fd-6068-4c2a-9085-37c9e53482e1">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic52ecafdfee4446badc41ecd13c9f2a2_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTQtNy0xLTEtNzc0MDc_e092b877-665b-408c-88bd-0aaf14df5c1a">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i980e7f0f06314813b0a382c339d86df1_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTQtOS0xLTEtNzc0MDc_c4dabbb2-a4b3-4cff-87f8-d70b3f99e803">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i980e7f0f06314813b0a382c339d86df1_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTQtMTEtMS0xLTc3NDA3_58cb0a09-1097-4173-a063-248cd9d62c38">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTUtMS0xLTEtNzc0MDc_ee60af32-b3a9-4501-85e9-f0c5593ea9e7">22,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTUtNS0xLTEtNzc0MDc_4cf75330-294a-49cd-acca-207984bb37cb">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTUtNy0xLTEtNzc0MDc_1a606e16-8878-424b-955c-6da9ad2975c8">22,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTUtOS0xLTEtNzc0MDc_2f7761a1-56aa-4914-aefe-175c07ff4e88">2,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTUtMTEtMS0xLTc3NDA3_a0d99d95-1002-4cd9-82b4-0df30f49ed28">19,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTYtMS0xLTEtNzc0MDc_71b3848e-83b4-44c1-b783-7b2cd4e18c24">34,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTYtNS0xLTEtNzc0MDc_f2533de6-128d-4253-a335-2b375ecaa24a">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTYtNy0xLTEtNzc0MDc_e1b92c3a-2cde-4d46-af7a-1e52288e2b24">34,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTYtOS0xLTEtNzc0MDc_67bca0da-1309-46ab-b55f-c4e783f8b8e9">11,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTYtMTEtMS0xLTc3NDA3_d2415f8d-c67f-42e4-9ee5-6b3b9bda313a">22,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i1f41f73de3934ea181cf9e678956b4ed" continuedAt="i3651ccb49bcf47f9aa0afa7c069f4aec"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the fiscal year ended January&#160;2, 2022 the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2NTA_0d7f2ab6-b2a1-49be-ad21-e85e0b931c62" escape="true">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2Njk_e023e9c2-c7e4-4717-bd5c-5d9de6a86226" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of October&#160;2, 2022 are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"></td><td style="width:43.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMS0yLTEtMS03NzQwNw_452d2632-ae94-4591-9c61-c414e3916681">22,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMS00LTEtMS03NzQwNw_fb414c27-241b-4bc5-a8ba-a8e79b0cb253">22,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMi0yLTEtMS03NzQwNw_135850c4-0dec-410c-b26c-1320748bdedc">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMi00LTEtMS03NzQwNw_8e8798d1-480a-4cba-b57f-bcb33f46c758">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMy0yLTEtMS03NzQwNw_04f2b6a9-d0b9-466c-a6be-93e3c06d5421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMy00LTEtMS03NzQwNw_d9e8ca81-0970-4cff-9010-8040dc911c64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfNC0yLTEtMS03NzQwNw_d9aa4266-f7ec-4af1-93ae-015db0c600af">22,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfNC00LTEtMS03NzQwNw_029f56d2-e737-4521-aead-e1c15dd90634">22,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i3651ccb49bcf47f9aa0afa7c069f4aec" continuedAt="i634e2f08dd074bd1be000b531e0dc30b"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2NjA_6b0245e9-222a-48aa-be2e-ee7f8503e1eb" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October&#160;2, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.259%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9006cebe9baf49098f28b71ba8b0b364_I20221002" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNC0yLTEtMS03NzQwNw_3dfc95c4-ded7-4198-a519-30052389b7f8">4,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6b7c5e255f431184d25955b77d4780_I20221002" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNC00LTEtMS03NzQwNw_07a45922-9a04-4475-944d-541590340d05">4,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0157c2d40621415cb530f8b4f529c1d8_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNy0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmI5ZjcxMTMxZTJmODQwMzk4NWQ1ODE1NjhjMDMxYmUxXzQ_15bf2977-b8ed-4ce8-b141-809654e46626">6.73</ix:nonFraction>% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09041d6f39a84ccea0a739091619c846_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNy0yLTEtMS03NzQwNw_8520ba88-8133-4478-a724-5aeef0894128">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262548be13894c1896c025888251703e_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNy00LTEtMS03NzQwNw_036ecc0f-e93a-4b1b-985d-17352e8a4d67">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5de5b6e1d4334a008a1d9c060b09147b_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfOC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmZmZTc3NzMzNGM4YTRiYTRiYTRkY2E0YjhiMTk5ZjcwXzQ_b0b7ee92-ff5d-48af-800e-01b410f7ecf8">3.375</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870bf42cc2f24c9ca6e75df10312d19f_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfOC0yLTEtMS03NzQwNw_3c47e0b4-659e-4398-aa74-58c609eb1a91">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e04502c4854e9099be4395f58835e5_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfOC00LTEtMS03NzQwNw_d068f133-d5a1-43b7-a207-6154264488f7">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9d2496e033944a6858188b916c2ec78_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo4MDU1Y2ZlZTJkMjY0ZTdhOWVlMWVmOTJkYjY1YzIzZV80_7b0cebc7-c1f5-4878-aa3f-39178af5b813">0.650</ix:nonFraction>% Notes due 2024 (<ix:nonFraction unitRef="eur" contextRef="ie9d2496e033944a6858188b916c2ec78_I20221002" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo4MDU1Y2ZlZTJkMjY0ZTdhOWVlMWVmOTJkYjY1YzIzZV8yMw_9d12f485-1729-4866-b7ba-239435dfacdc">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="ie9d2496e033944a6858188b916c2ec78_I20221002" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo4MDU1Y2ZlZTJkMjY0ZTdhOWVlMWVmOTJkYjY1YzIzZV8zMw_f0fba65a-b82b-4126-93de-e1fa8e807d60">0.9712</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4f83eb2b694aaebcf4695cd84e55b9_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTAtMi0xLTEtNzc0MDc_a9cfcc38-b4df-41ed-bc8c-7ac442e95d85">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70cc3db8241b44bdadd5529cad658578_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTAtNC0xLTEtNzc0MDc_a2a6b76d-880e-4b5c-9a37-4e94b733a7f9">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i030634cc2bab40ba860c6310273384f3_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTEtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjowZDI1ZjdlMGE5YzQ0NmU0ODE5NWU3MTdiNDFjZWM2NF80_be68491a-82f5-481c-91f8-772d46324dbe">5.50</ix:nonFraction>% Notes due 2024 (<ix:nonFraction unitRef="gbp" contextRef="i030634cc2bab40ba860c6310273384f3_I20221002" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTEtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjowZDI1ZjdlMGE5YzQ0NmU0ODE5NWU3MTdiNDFjZWM2NF8yMw_04fbe35a-f093-4770-891e-9cef1e817af0">500</ix:nonFraction>MM GBP <ix:nonFraction unitRef="number" contextRef="i030634cc2bab40ba860c6310273384f3_I20221002" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTEtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjowZDI1ZjdlMGE5YzQ0NmU0ODE5NWU3MTdiNDFjZWM2NF8zMg_b5514766-46df-4971-9004-a39ac7c2e020">1.0908</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida226c289b3d44c98e6aca58fd729233_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTEtMi0xLTEtNzc0MDc_c2dca628-9e07-42e0-bb6d-bfdd29fdb9b8">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed802dd203a43d3afa9f1915bf381d2_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTEtNC0xLTEtNzc0MDc_1309b618-69ca-4204-9657-386288b06925">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38954d1e3098492e806481f25cf864c8_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTItMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxMTdhN2JlYTA4YTA0ZTI5YjNmNTQ1MGIwM2Q2NGQwY180_8a1f866d-fa2c-4a3b-ac1f-2dfa99d9a254">2.625</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8507feada10d4116ae4715be0f83f61b_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTItMi0xLTEtNzc0MDc_cc42b064-4982-46a0-b50e-7b6d585f1fc0">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33663885e724dba955223059c45014c_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTItNC0xLTEtNzc0MDc_4682649c-d047-44e7-b329-452b63d9666d">721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.550% Notes due 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3220255239e4430e8bc071481c23af70_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTMtMi0xLTEtNzc0MDc_b83ccf56-7368-4772-98d1-b60bdaae18fe">922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ac596ef8054dd9bec84c0c13239c57_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTMtNC0xLTEtNzc0MDc_1c3654a8-8902-4f46-88b9-faf8e078c969">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i463dccc9a3684c049eac0a5bb39ebf77_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjowMGYzYWM5YzEwNzM0YjEwYmEwN2JkMjk4ZTk5ZGM5Zl80_a32a1c83-1438-4e13-abe9-96445284a9b0">2.45</ix:nonFraction>% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f76f6e1c7584e90bdce33b5939f49fe_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTUtMi0xLTEtNzc0MDc_5b14d7c3-69f4-492d-883f-02893e81696c">1,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4e881a6337c48eba78aa5737f820648_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTUtNC0xLTEtNzc0MDc_ce1d3b03-41c0-481b-9914-b588dc90f738">1,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf9913e7637b4fefad4d9411b1e57dda_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTYtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjplZDVhZWY1MWJhMWM0NmE1YThhYWIwOTZmMDA3MmIzMV80_e2c3082d-bb63-4844-8efa-691ab08e6489">2.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c801bf0bfb74c4fb7e197403e0c19da_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTYtMi0xLTEtNzc0MDc_68040224-2629-4741-9a9a-3c64d11e7826">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9ef1c58573413fb263475037c7df0f_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTYtNC0xLTEtNzc0MDc_c568f926-574f-442e-8542-5ac69b46f571">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec007660d14f41158b78244410752ef6_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTgtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo2OWJmYWFkODg0MGY0NjI1YjBiZWMxNTYzYzk1ZTJkYV80_d52a9e55-4e14-4371-abc0-c4a562aa7804">0.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01c6007919844dc8a0fff621af91ba7_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTgtMi0xLTEtNzc0MDc_23d3fc82-3140-44f6-830b-cc3cfb8074c9">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cefb1e606b8454bbae8580ad29ba4e9_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTgtNC0xLTEtNzc0MDc_9b4f477f-4a58-42d3-b194-3a4cfd22ceb8">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd59161e160443be992c19c3e552de73_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTktMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo3YTQwZDIxNDg2YWU0Y2I3ODVmNWVkYmI5MTkzNTA2M180_a8f5931d-d4b0-4dff-85e3-2f87c9ce271b">2.90</ix:nonFraction>%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46bc9af826d04e288de22182a64ee453_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTktMi0xLTEtNzc0MDc_7fa321ab-e5c5-4036-a398-cd1c87a648ab">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0955f4509fed4180a52c8b18fe4c4b13_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTktNC0xLTEtNzc0MDc_3c07f727-63b4-4999-9de8-3f13d1cb3111">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5267d6a76fd344b9aae4d32ffcdb89ea_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjplOWY1MTQ3Y2I3ZDk0Y2VmYjNkMjg0MDY2OTU0MDJjY180_1a9ad378-7a14-4432-a326-75536399c4a4">1.150</ix:nonFraction>% Notes due 2028 (<ix:nonFraction unitRef="eur" contextRef="i5267d6a76fd344b9aae4d32ffcdb89ea_I20221002" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjplOWY1MTQ3Y2I3ZDk0Y2VmYjNkMjg0MDY2OTU0MDJjY18yMw_a71e0de7-8500-4c19-9081-8406b9c9bc63">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="i5267d6a76fd344b9aae4d32ffcdb89ea_I20221002" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjplOWY1MTQ3Y2I3ZDk0Y2VmYjNkMjg0MDY2OTU0MDJjY18zMw_b022d3ec-2310-4e86-9a8a-b5ed2cc09bea">0.9712</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f362e68c5546b8b0891c1e060d692e_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjAtMi0xLTEtNzc0MDc_b08c0748-54e0-4dee-aa4a-8f4532f52105">724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a74be7a73c41d79f6e2392d1d60ea0_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjAtNC0xLTEtNzc0MDc_57c5a3f3-d722-4dd1-b7e9-1a33f88260d1">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1bec1f0d9314920bb56531e382e7cdc_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjEtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo0NDViNjY4M2M2NjQ0MDE5YTU2MTA2YzkzYTA1N2Y2ZV80_4f43af8e-6189-4689-bd9b-60005e28e53c">6.95</ix:nonFraction>% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3efd972e13344cdb42226b639f85eea_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjEtMi0xLTEtNzc0MDc_0c98503d-d48b-4d4f-a16a-a8115a9f5900">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f419a473f34fb29199544a2c8cb16f_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjEtNC0xLTEtNzc0MDc_471e23f1-c9da-4908-b9d5-c22059367723">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81460a08681c4e40ab454eff67450960_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjItMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpiNWJkZDgxMWM0OTI0MTdjYTBlOWEyMDUxNzhiZGJlM180_86293598-ae61-4dfa-8e9f-dfd059a5408c">1.30</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f4c5055c844c61bdbada64f0290039_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjItMi0xLTEtNzc0MDc_f9f61326-2f22-48e3-9704-cc093ba0127f">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa22322ad88f4cfebf3bdcb75ad25975_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjItNC0xLTEtNzc0MDc_8843941b-73f0-4907-86ee-9635d70f6046">1,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06fdae26fcfd4a60b871ade74a542ac4_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjMtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo4ZTg2ODk0MDVmNjI0ZjRhYjNmODg0NDMwNDVhNGFhNV80_362bedf7-b1a0-4464-b37b-1d31f54ada1d">4.95</ix:nonFraction>% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32266ba4f72e43a792a31e7faa9148b2_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjMtMi0xLTEtNzc0MDc_35e400d2-ea39-4643-9e59-1622524b365a">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id940c82927a641158fe648918accafc9_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjMtNC0xLTEtNzc0MDc_47c6d73b-c8f9-4f6b-ae02-4df31986143a">507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if847a21b92f348a0b7a4025c882fc0e2_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjQtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo5NDUyN2U3NTMxMjE0ODY2ODc4OGM3M2JhZTMzMDU4OV80_73d65011-4875-4b18-9465-0feba2c43dff">4.375</ix:nonFraction>% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6a26673c434118a68c645642b3fbc4_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjQtMi0xLTEtNzc0MDc_b07c01f5-0aee-4d55-90c3-8e02cdb23338">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f89bf72f2ba4b478472d343bdeec569_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjQtNC0xLTEtNzc0MDc_e5d5d048-3870-4ee2-8441-5d8746213d5c">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29078fb071994051bd63d8f4587eb909_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoyZThlOTk0MThlMWU0NWY0YmUxZmU0YWM4ZTY1MDkzZV80_8c1e40c4-f2ee-4c5e-906f-8ec1a3eb880f">1.650</ix:nonFraction>% Notes due 2035 (<ix:nonFraction unitRef="usd" contextRef="i29078fb071994051bd63d8f4587eb909_I20221002" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoyZThlOTk0MThlMWU0NWY0YmUxZmU0YWM4ZTY1MDkzZV8yMw_37c1dbdd-d621-47e5-a629-458e4771b55a">1.5</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="i29078fb071994051bd63d8f4587eb909_I20221002" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoyZThlOTk0MThlMWU0NWY0YmUxZmU0YWM4ZTY1MDkzZV8zMg_049baf8a-f1a7-4060-a424-39519f91058b">0.9712</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29078fb071994051bd63d8f4587eb909_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjUtMi0xLTEtNzc0MDc_6e432337-169f-4b5c-ba77-1b9eeb6c37a9">1,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8851eff20e5145c5bca1a1ee92617a5e_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjUtNC0xLTEtNzc0MDc_aa05ab9f-848e-4ea1-b29d-e0f2f420132e">1,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i477c86f7309842dfb55248451d3efa39_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjYtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxYTk1ZTAyMTJmMTA0N2E3YWY5Nzk4MjI2Yjc2YTQ1Ml80_efc8e399-c0a5-42b7-a93e-926226160777">3.55</ix:nonFraction>% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ca4d871cf6b437582cda14e89bb594b_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjYtMi0xLTEtNzc0MDc_0849ef83-c939-4ee8-8695-230b6731bd79">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7dc65157e44d3aba2a140b03b946b1_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjYtNC0xLTEtNzc0MDc_7adcf267-63e0-42f7-b377-1b1af8257417">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib89592a0e11e4753b648c5e3cc03ee9e_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjctMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxYjFhMDQ1OGFkNDE0NjBhYjY1NzA1ZGZjNGM1ZGMxYV80_8e5e7f5c-4a9a-4641-a375-84f628655e85">5.95</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36742f2d0f1f4ab8a7597150249a02bf_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjctMi0xLTEtNzc0MDc_72632a99-c00f-4d62-9722-514056af4e3a">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733cb704b7674b0e9a24cc4ab884180a_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjctNC0xLTEtNzc0MDc_ca72fe71-2358-4d57-baae-c41b60151acd">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae69d4e77db7465fb0571ca12ef0fff2_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjgtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoyOGIxMWQ4M2Y1Mjg0NGM5YWNkOWFhNmQxN2U0OTJkMF80_8def504b-3f23-46c2-92f4-fb33f4c5ae12">3.625</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4ff5147e1a54074a2362ad5feee7c65_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjgtMi0xLTEtNzc0MDc_3ab64fdb-902f-46e2-9c7b-c85efed0ba86">1,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia452af2ce27e4af2a660f83bf6fbda90_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjgtNC0xLTEtNzc0MDc_c6f30371-2cbf-4011-8796-5aace8fb229f">1,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b7612a89a5a4d3e9fddec30bc11ee22_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjktMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjozZWNiYWUxMjlhYWY0ZGFmYjc4NzcxNzU0ZDhlMWJhZV80_ac5e3ba3-8312-4c45-90aa-74e09859ee29">3.40</ix:nonFraction>%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8534a543c9964871863c7e4c16232cb4_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjktMi0xLTEtNzc0MDc_3b90a500-edcc-49a1-869c-d69ccb948358">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a53e2b415aa46dba827a399ff3c0318_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjktNC0xLTEtNzc0MDc_aa29a10b-2743-4f4d-ad97-298e4216b0ab">822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23e399c422d04b4c9802c29f75c01f77_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo5OWJmZjA3ZWMwN2U0NzhlYjQwOTFhOGY0YTZiMzM1MF80_0fcd1d26-cd74-4ec9-97f4-1c5b55594b8c">5.85</ix:nonFraction>% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515258d897424d1d91d0dd5e6ba17edb_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzAtMi0xLTEtNzc0MDc_0e3bde78-fe2a-42e0-adcc-0193135abe74">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ec40d315b946f2b9c6a729deef3a36_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzAtNC0xLTEtNzc0MDc_54391f99-603b-422b-ac4a-d8bbdf02ba92">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f6e82e7b82a4263986c8f5f799e01aa_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzEtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpiZThhMTk0YjlkMGU0NzQ5OTBlNTVmOGVjMjIwNGNhYV80_3f523171-7895-4c2f-bb25-484187d1600d">4.50</ix:nonFraction>% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331180abea9a4581bd4f74309a491129_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzEtMi0xLTEtNzc0MDc_c3807ad1-ea79-40c6-a157-2b668240e3c0">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a76440ea8554d14aface7459e0c118e_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzEtNC0xLTEtNzc0MDc_c6ee3c6c-94ab-43fe-b9aa-0b1e97417b86">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id71489b63d304114b1ee5ae439e5265d_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzItMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjplNDY4M2Y5NzI0MGQ0N2RhOWY1OTkxZWZjMzFiZjQ5N180_20854e30-1f1f-419a-8f59-306a86389133">2.10</ix:nonFraction>% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f32d63a3ac54710b81b92f90e389147_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzItMi0xLTEtNzc0MDc_fac2a18b-2ef6-454d-9e50-e940e4b0434b">827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04beb44383334787802dafc265394766_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzItNC0xLTEtNzc0MDc_7b27940d-2c61-42bc-bf54-6dddb4e7e768">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8ab907b696a4139a072f00b70bbda49_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzMtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo3NTBhZTExYjMyYWQ0OTBhOTBjMjljMmRiNWRhMjU3ZV80_05e28d5c-984d-4a42-9011-da56f20ff9d3">4.85</ix:nonFraction>% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i725d5d1c65b54fe9961ae484ef90be5e_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzMtMi0xLTEtNzc0MDc_52f79f06-bbca-410f-8d31-0f1a73f27eeb">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165e3f370fbf46ed93bf4cce9e54727f_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzMtNC0xLTEtNzc0MDc_f2603218-0d7a-4304-ae29-571991b87020">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i428e006eac404991b3e3d872ddd1c1f7_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzQtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo0YTk0NjQxM2MyMzU0ZDkyOTA0MTJhNTQyMDJhMjljZl80_1dc53928-f6b0-4dd7-b324-1134c791c9ee">4.50</ix:nonFraction>% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b9310bb6dc4450490632d0116946ede_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzQtMi0xLTEtNzc0MDc_e114f258-1121-457f-b5bb-91c826263ece">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id11fe423cd3a474cb70088616178415a_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzQtNC0xLTEtNzc0MDc_25050221-e82b-438b-8a5c-ff37377bd378">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia36a4cef5d4f402fbd7eac9f85a18b17_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo4NmQ5Zjk3MmE4ZGQ0ZTZjOTAyOGQ0YTA3ZTA5MzY5YV80_9a7df79b-ff71-4482-9a93-f9c26e6f631b">3.70</ix:nonFraction>% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86512b1f50de4ad88f542164448d26c1_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzUtMi0xLTEtNzc0MDc_3d86ada1-c94c-45ec-a35a-3a58576293d6">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6bcf8520fa4057a7f4a5589d4684d2_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzUtNC0xLTEtNzc0MDc_ae0d5bff-e0f1-4a90-a318-634920c28510">1,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia2b9b9e93ec74f2b850cf4cacc8bbe2b_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzYtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpmZTg2OGRkZjM3OGI0YjdkOWYxMDNlZjNkNzZiNTU5Yl80_5d7bdedf-cfc2-4119-8c37-2387fb53a767">3.75</ix:nonFraction>% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12550a2b68084f8b9214b4faeb85013d_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzYtMi0xLTEtNzc0MDc_2e065bbf-4a03-4e32-b666-54a95c798a38">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6f68f74915492181e040fe2b309c71_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzYtNC0xLTEtNzc0MDc_4d71d918-255c-4ba7-a348-3022579382dc">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic72911776cd542c5852cd1d5ca05062f_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzctMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoyZmNhMGE5OTYzM2M0NmFhYjlkOGU1MTczOTFhYTU3Zl80_78762afb-a544-4ace-8835-2bc945b7309a">3.50</ix:nonFraction>% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e72ec4950db4ec699a1131d9548a556_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzctMi0xLTEtNzc0MDc_6affa024-256a-4f31-9708-e9e782aa87d7">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic668dba37a974482a824018731b483bc_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzctNC0xLTEtNzc0MDc_c00541ca-6c26-44fe-8fb6-0c207239ac28">593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i955013ec18f9497e9a9c99fee52c731e_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzgtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxZjRhOTMzNzg0MTQ0MzQ0ODA0ZWNlZDI2ZWI4MzkyNF80_7d34eeed-687a-400e-b56b-892f58f99727">2.25</ix:nonFraction>% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe780e81ace4f5c8b98dcf4b0ac0e21_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzgtMi0xLTEtNzc0MDc_502b4678-241a-48b2-85e0-97c577890e5d">809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7deba806ae124861960bbc06843762d7_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzgtNC0xLTEtNzc0MDc_b99db3b4-4079-4b08-a16e-5c1bba8bfa1b">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0861e096ce334fdfae380bc7f0d69b72_I20221002" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzktMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYmJkOTVhYjUwNzE0NWY2OTk5NTE5NDE1Njg0YTNmZl80_a1a68f78-c51e-4889-a534-5513629b3b91">2.45</ix:nonFraction>% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdbc1ee962e45f7901626232a02576c_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzktMi0xLTEtNzc0MDc_8444d36b-e7c7-4945-abc0-e15f81fd9bd1">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffbcba0a9b874fb6b9472d4fa8d72638_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzktNC0xLTEtNzc0MDc_54ddc3c0-5e0a-49dd-bf79-7d1bdb953757">619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333dd5feeee74afbb5ad0dc46eb323e0_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNDAtMi0xLTEtNzc0MDc_1cc03be9-1435-4a25-b901-ebeafeda39d6">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0422e59a7ebf4c4cbf75f1140ecc88d0_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNDAtNC0xLTEtNzc0MDc_d465494d-aa47-48aa-8c01-68158e852bc2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9006cebe9baf49098f28b71ba8b0b364_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNDEtMi0xLTEtNzc0MDc_04bc1b3e-1306-4d5e-b3e4-8512bac37a17">27,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6b7c5e255f431184d25955b77d4780_I20221002" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNDEtNC0xLTEtNzc0MDc_d3d140db-f244-49c8-a41a-c79cb98ea602">24,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is <ix:nonFraction unitRef="number" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTExOTE_572ec12f-2d1d-4c62-9f8a-9aee0af3f741">3.06</ix:nonFraction>%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the estimated fair value over the carrying value of debt was $<ix:nonFraction unitRef="usd" contextRef="ic8ebbcfaca4140c38e6ed48542fbd4de_D20220103-20220703" decimals="-8" name="jnj:ExcessOfFairValueOverCarryingValueOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTEyNzE_abc507f5-1c67-4d11-af11-84c8b4a9fa32">3.2</ix:nonFraction> billion at January 2, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of October&#160;2, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i017db5ac595541f0b302582a410ea26d_I20221002" decimals="-8" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTEzMzg_78827c3f-bbb4-4581-9f6d-b96c7704bf75">3.9</ix:nonFraction>&#160;billion of commercial paper which has a weighted average interest rate of <ix:nonFraction unitRef="number" contextRef="i017db5ac595541f0b302582a410ea26d_I20221002" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE0MDc_dc530ec7-f7b0-416a-b403-682652aeb41a">2.88</ix:nonFraction>% and a weighted average maturity of approximately <ix:nonNumeric contextRef="i0dd1b1fcff0145219d7fb406847ea584_D20220103-20221002" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE0NTk_5120d5e0-00e0-48f2-8556-ace8c5dd932d">three months</ix:nonNumeric>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i634e2f08dd074bd1be000b531e0dc30b">Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</ix:continuation></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_67"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 5 &#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMzA4Nw_8455da33-12db-4c01-bcf1-dd79a2652a0c" continuedAt="iaf473f6fd9b14ccaa743f29edebce30e" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iaf473f6fd9b14ccaa743f29edebce30e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal nine months of 2022 and 2021 were <ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTIz_7939717d-a06b-4d21-a643-8d93415c85a5">17.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTMw_93391cb6-62f4-4973-b0f9-8dfebf5aa290">10.0</ix:nonFraction>%, respectively. This increase in the consolidated tax rate as compared to the prior year fiscal nine months is primarily due to the Company reorganizing the ownership structure of certain wholly-owned international subsidiaries in the second fiscal quarter of 2021.  As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with the applicable local regulations. Accordingly, the Company recorded a local deferred tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="ie4184dedf017492f81476885b7412820_I20211003" decimals="-8" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfNjI4_d30cc084-c0af-4e3c-b6b1-8fa6d86550c0">2.3</ix:nonFraction>&#160;billion which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $<ix:nonFraction unitRef="usd" contextRef="ie4184dedf017492f81476885b7412820_I20211003" decimals="-8" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfNzM4_4fb45e3c-594c-422e-ba3f-60879bfbaaf1">1.7</ix:nonFraction>&#160;billion. The net impact of this reorganization was an approximate $<ix:nonFraction unitRef="usd" contextRef="ie4184dedf017492f81476885b7412820_I20211003" decimals="-8" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfNzk4_26e01f16-d95c-4f25-b52b-329ff6ef640e">0.6</ix:nonFraction>&#160;billion net benefit or a <ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfODE4_6a390a63-9f2e-41a3-92e0-c6545e63c1e3">3.4</ix:nonFraction>% decrease to the effective tax rate of the fiscal nine months of 2021. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally, the following items had an unfavorable impact to the Company&#8217;s year-to-date effective tax rate as compared to the same period in the prior fiscal year:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">as part of the planned separation of the Company&#8217;s Consumer Health business (for further information see Note 1 in the Company's Annual Report on Form 10-K for the fiscal year ended January 2, 2022) the Company has recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-8" name="us-gaap:IncreaseDecreaseInIncomeTaxes" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTY0OTI2NzQ1NTk0MA_8ac47b0f-4241-4918-9283-11af1049306e">0.4</ix:nonFraction>&#160;billion in net incremental tax costs which increased the rate by approximately <ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:IncrementalIncreaseDecreaseInTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTY0OTI2NzQ1NTk1NA_18febf4a-2a5b-474c-8aa6-ca884d09af2f">2.0</ix:nonFraction>% for the fiscal nine months of 2022 </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">certain one-time favorable tax items that occurred during the fiscal nine months of  2021 and resulted in an approximate <ix:nonFraction unitRef="number" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="2" name="jnj:OneTimeFavorableTaxItemPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTY0OTI2NzQ1NTk2MA_74518c5a-94d1-4bc3-93c3-62969baab1a8">1.0</ix:nonFraction>% benefit to the effective tax rate, but were not repeated in fiscal 2022 </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.53pt">In the fiscal third quarter of 2021 the Company had accrued additional Talc expenses of $<ix:nonFraction unitRef="usd" contextRef="i7d211681392d483b8f62c60a8d8a4dc2_D20210705-20211003" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc0Mg_4adec178-8de3-4229-8dbb-befc4312b8a3">1.4</ix:nonFraction>&#160;billion at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="i7d211681392d483b8f62c60a8d8a4dc2_D20210705-20211003" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc1Ng_fcf629b8-b99b-495c-a058-84974c808b87">23.5</ix:nonFraction>% and $<ix:nonFraction unitRef="usd" contextRef="if235130eab4e408b92fb2c43ccb98f42_D20210705-20211003" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc2Mw_20174b9f-82e6-4094-9228-72afabc3a518">0.8</ix:nonFraction>&#160;billion for the Risperdal Gynecomastia settlement at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="if235130eab4e408b92fb2c43ccb98f42_D20210705-20211003" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc3Nw_6c91ec85-4a92-45b5-952d-3230dfd265eb">16.4</ix:nonFraction>%. (See note 11 to the Consolidated Financial Statements for more details)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">in the fiscal third quarter of 2021 the Company recorded a partial IPR&amp;D charge of $<ix:nonFraction unitRef="usd" contextRef="i5d60d3f4537d4080a89795d512b26b9e_D20210705-20211003" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc4NA_177f703e-5b9d-4e6e-9e72-3b59bb75693a">0.9</ix:nonFraction>&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of <ix:nonFraction unitRef="number" contextRef="i5d60d3f4537d4080a89795d512b26b9e_D20210705-20211003" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc5OA_ba8abdec-c100-4f60-b187-c1d79dc29cc6">22.4</ix:nonFraction>%</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during the first three fiscal quarters of 2022 and 2021.  The Company&#8217;s 2022 tax rate benefited primarily from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022, the impairment of bermekimab for AD IPR&amp;D (for further information see Note 3 of the Consolidated Financial Statements) and changes in the fair value of securities in the Company&#8217;s investment portfolio, both recorded at the U.S. statutory rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of October&#160;2, 2022, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTk4Mg_1a5e6b30-65e7-4afd-98b8-3c03aee950bf">3.8</ix:nonFraction> billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016.  In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 6 &#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RleHRyZWdpb246ZGYxNDUyZDI2M2Y1NGEzZjlhOTljOTNiNDlmY2NlNGJfMTAwNA_47dcc6e6-cdad-4c80-8631-53b9fbf605d3" continuedAt="iebfb7a5ed4274f739f0149f4eb8cf946" escape="true">PENSIONS AND OTHER BENEFIT PLANS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iebfb7a5ed4274f739f0149f4eb8cf946"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RleHRyZWdpb246ZGYxNDUyZDI2M2Y1NGEzZjlhOTljOTNiNDlmY2NlNGJfMTAxNg_62a9c25f-7815-4883-8cbf-324fe03b940c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:32.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy0yLTEtMS03NzQwNw_1dca604d-ffc8-4825-b2a1-5b6433e875b5">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy00LTEtMS03NzQwNw_81d03e0f-959d-4fd0-9996-10e5bbc25c49">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy02LTEtMS03NzQwNw_fe3ea17e-686d-4356-be0c-c5c83828e7de">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy04LTEtMS03NzQwNw_4766061c-f29f-4bea-8e9a-b9bb040deef7">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy0xMC0xLTEtNzc0MDc_7354d9b5-ef13-412d-b065-b3b5406246a6">953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy0xMi0xLTEtNzc0MDc_e912c6d6-0568-4614-9ffd-680e8a983c07">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy0xNC0xLTEtNzc0MDc_567ec81c-2262-4fdb-b1bd-36b2191e4d8a">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy0xNi0xLTEtNzc0MDc_5eaaa277-cbac-4d40-884e-a5a1859448fc">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC0yLTEtMS03NzQwNw_313c247b-b361-41f3-b6e9-9426d657997d">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC00LTEtMS03NzQwNw_ce2c4ef6-4ef3-4490-bcb0-df1174cba705">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC02LTEtMS03NzQwNw_00ffb3ad-febb-4bf1-9ed2-a6a603ad98d5">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC04LTEtMS03NzQwNw_63a20f24-adad-47c0-abaf-7731c547bafc">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC0xMC0xLTEtNzc0MDc_b327d9b6-54db-4a29-88f5-d5278a9f0ede">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC0xMi0xLTEtNzc0MDc_19aa52ce-ec5c-4e78-8a71-8ec878ee1739">578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC0xNC0xLTEtNzc0MDc_23361908-7c50-4f78-aaf1-24b5326cc200">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC0xNi0xLTEtNzc0MDc_e9e79bc4-1833-42d3-93e8-ebd126cacdcf">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS0yLTEtMS03NzQwNw_110c5e08-1f1a-47e8-8314-b5d9aabe8cd8">683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS00LTEtMS03NzQwNw_d5a6c5a3-7695-46be-bc2e-c7f00d227a7c">661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS02LTEtMS03NzQwNw_5fa38641-f7bf-4456-99c6-6041648daae5">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS04LTEtMS03NzQwNw_3d5c08b0-54f7-489d-ab01-9adfff742356">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS0xMC0xLTEtNzc0MDc_ada40638-fb2f-45bb-9c53-8881a723337f">2,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS0xMi0xLTEtNzc0MDc_c070c080-8358-47a2-b8fd-0c47778306ae">1,988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS0xNC0xLTEtNzc0MDc_2fae021b-f289-4e63-add8-47c6d2812cc2">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS0xNi0xLTEtNzc0MDc_52747841-cecb-4579-b8e3-441ff8b2ef62">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi0yLTEtMS03NzQwNw_2da52b26-7426-425b-855d-4696eaf7f680">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi00LTEtMS03NzQwNw_cd12e8d9-6058-4f39-bc33-c9baed4dabfa">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi02LTEtMS03NzQwNw_28771d16-8a87-4578-bd41-18e03b537567">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi04LTEtMS03NzQwNw_6bb42ead-7301-4479-a77c-b615b21c0543">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi0xMC0xLTEtNzc0MDc_0bf56a18-e908-48db-b626-739661015d86">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi0xMi0xLTEtNzc0MDc_dfb119ee-7318-4feb-add2-b0ef3ec2b787">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi0xNC0xLTEtNzc0MDc_4d6882b8-3a7d-45c1-9499-d6aa2fd7a26c">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi0xNi0xLTEtNzc0MDc_f6450eb5-163d-4fab-945c-36a0873af351">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC0yLTEtMS03NzQwNw_47571c9c-b332-4fd5-8ba4-f14db207dab6">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC00LTEtMS03NzQwNw_57adbb03-c6c8-46e1-9923-c6d3f4a1f4f3">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC02LTEtMS03NzQwNw_be22b183-f703-4111-95eb-da82ffbff562">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC04LTEtMS03NzQwNw_c5588e31-2a52-4a60-9732-9f5cb9a76288">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC0xMC0xLTEtNzc0MDc_906bfc16-e799-48d3-9254-61cfba034a00">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC0xMi0xLTEtNzc0MDc_dad822b8-bc4e-42cc-8e5c-8f8f4af33b8d">944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC0xNC0xLTEtNzc0MDc_fd1a080e-4b1a-487d-9ec0-cfa69e8d5620">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC0xNi0xLTEtNzc0MDc_7bd4e1b2-789b-4db0-8ebd-9ad6f3d39ffe">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS0yLTEtMS03NzQwNw_b45d9277-a249-445b-836a-a0d9ee67e208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS00LTEtMS03NzQwNw_a6ce0cb0-f2d1-4b36-a160-2291d3dc5542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS02LTEtMS03NzQwNw_8ef0bb4b-a345-4f49-8aef-5a60edf744cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS04LTEtMS03NzQwNw_7d02cb42-5ae8-4f61-ad47-f2c75b6e041c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS0xMC0xLTEtNzc0MDc_e86cec9c-c8db-42f7-9663-4b4e796169ed">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS0xMi0xLTEtNzc0MDc_762c2ea8-875a-4317-94d6-ca66bc221603">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS0xNC0xLTEtNzc0MDc_f490b084-2d72-4ea2-952d-4fa3030d5f7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS0xNi0xLTEtNzc0MDc_467eb590-ad97-4b1d-a86f-4fdafa48baac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtMi0xLTEtNzc0MDc_8cadabdc-4544-49e5-98e8-8b92d78f5f67">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtNC0xLTEtNzc0MDc_c1819070-3819-4231-943e-102a468c1aab">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtNi0xLTEtNzc0MDc_025e8c6e-8243-444c-9aa8-470e583bee70">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtOC0xLTEtNzc0MDc_2c0a7dd4-9730-4157-b609-906bca8b2213">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtMTAtMS0xLTc3NDA3_22430dac-0267-4919-9e76-c681b4b458f4">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtMTItMS0xLTc3NDA3_769fc4be-df2c-46ff-9310-d618295665a5">418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtMTQtMS0xLTc3NDA3_c5867b62-9758-455f-ba7c-5b69c11bba2c">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtMTYtMS0xLTc3NDA3_58182d51-f616-44ce-b97d-32b3eca066e1">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal nine months ended October&#160;2, 2022, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i332809e8f61c44149c2e4659a135fe38_D20220103-20221002" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RleHRyZWdpb246ZGYxNDUyZDI2M2Y1NGEzZjlhOTljOTNiNDlmY2NlNGJfNzQy_b8de06c1-68bc-4e5d-9cba-c386dbd4a24d">82</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff704175779c4e83903efe4bb1b1eb21_D20220103-20221002" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RleHRyZWdpb246ZGYxNDUyZDI2M2Y1NGEzZjlhOTljOTNiNDlmY2NlNGJfNzQ5_39c29ef7-afef-4330-a749-426a0534a7df">15</ix:nonFraction> million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div></ix:continuation><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_73"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 7 &#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RleHRyZWdpb246MmNiZWE3YmExMmQ2NDJhMDljNDI3Y2FlMTViNzk4N2RfOTMy_802221b7-a344-4a1a-a388-0a38041f25a2" continuedAt="ibf2918d522d54d8f81b4b5899236b391" escape="true">ACCUMULATED OTHER COMPREHENSIVE INCOME</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ibf2918d522d54d8f81b4b5899236b391"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RleHRyZWdpb246MmNiZWE3YmExMmQ2NDJhMDljNDI3Y2FlMTViNzk4N2RfOTMw_edcf0a04-c448-4bb6-b3c0-7af18a2719a7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.991%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i206b36fcd5884efc8e2d9f8f10a5a918_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNC0yLTEtMS03NzQwNw_e3d23e1b-fec6-47e1-a177-061a95a66fa1">10,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i096b7900f5fe4d45964781506fef7cd4_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNC00LTEtMS03NzQwNw_e354f69b-0e0c-4a2f-8671-12d1651652ab">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d64a67a236a4c7e9d6dae0c1d2fd34a_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNC02LTEtMS03NzQwNw_7ae94870-7339-4f62-ab7e-8281e3ec5df5">2,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i944bc08bbd494170a723fa335d775693_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNC04LTEtMS03NzQwNw_fbd7767d-9fd8-45e4-b36b-806664831a2d">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib60c35086bcc4c329bbe423674e693a9_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNC0xMC0xLTEtNzc0MDc_788c3654-d35f-4a5e-b5ce-fd5bfeaf6b99">13,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNS0yLTEtMS03NzQwNw_02136c81-8bc5-46fd-b9d1-888dcfb33c4f">1,957</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNS00LTEtMS03NzQwNw_42e6895a-e8ea-49c4-bc22-e7de6e823630">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNS02LTEtMS03NzQwNw_62100389-3d69-489b-822f-221dd731b421">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNS04LTEtMS03NzQwNw_4c53123c-1ef4-4d08-a969-8e7966359dda">586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNS0xMC0xLTEtNzc0MDc_8101384f-c5da-47cf-b219-7d3f6ce1fd37">2,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0857a3c31a28448189abbe9edefd142c_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNy0yLTEtMS03NzQwNw_dc397e7a-12c3-4461-b78d-a00655dfca79">11,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfb9d5a6b7ad47d78a2e5ef496f4cbb9_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNy00LTEtMS03NzQwNw_d4cdde95-87d0-4fbf-8582-56196220dd35">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib49ea28b1f6a4233b9e391f4fe2d7695_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNy02LTEtMS03NzQwNw_2794d45e-3ef4-4828-a96a-43db10d0deec">2,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08ec2d8a0db84c62aeaf6386e449a7e3_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNy04LTEtMS03NzQwNw_7a8ae12b-e25e-4bab-9ef4-6500a82d6d4e">922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a9083e68f134a6b959f8e81ba70dca0_I20221002" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNy0xMC0xLTEtNzc0MDc_309534e3-4b1d-45be-a6e2-cf565b76dd18">15,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 8 &#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RleHRyZWdpb246ZjRjMThlYWYxNjNmNDYzZDk2ZjE0NjE3NWJlZDk4NWFfODA0_9f746c6b-25be-4cc2-9b63-c4b93a3681a1" continuedAt="iae32781cec3646ebab7610f42f520a1b" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iae32781cec3646ebab7610f42f520a1b" continuedAt="ia1df6985f62746cba1a1b3d211287d68"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RleHRyZWdpb246ZjRjMThlYWYxNjNmNDYzZDk2ZjE0NjE3NWJlZDk4NWFfODIx_8b01bc34-ea25-42b2-9666-f2ab524e22e0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:53.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMi0yLTEtMS03NzQwNw_f9012076-c601-4018-8e27-b21858348250">1.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMi00LTEtMS03NzQwNw_befd3460-b7bb-47bd-bb58-fd64f8af4adf">1.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMi02LTEtMS03NzQwNw_c2de6305-39f2-4d47-af45-976cb7be90fc">5.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMi04LTEtMS03NzQwNw_6f17ac4b-4655-4cff-9daf-f2698c2dba32">6.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMy0yLTEtMS03NzQwNw_7e7da13a-2a06-4713-9999-036e9b8f956a">2,627.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMy00LTEtMS03NzQwNw_b58a4c69-0a8e-4d5e-9908-e250f853225d">2,632.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMy02LTEtMS03NzQwNw_21f4461c-44b1-4800-bbe9-20c35b5a91c5">2,628.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMy04LTEtMS03NzQwNw_d71b869c-3b47-4327-a9b5-acc94742c3cc">2,632.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNC0yLTEtMS03NzQwNw_01f3f65e-b157-4007-b3d8-14891b278750">140.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNC00LTEtMS03NzQwNw_75638a4b-82df-4487-93d1-ab8f84063ea2">138.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNC02LTEtMS03NzQwNw_0dffcb94-164d-47b4-88d7-9f21dfb42867">141.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNC04LTEtMS03NzQwNw_d33a5482-b96d-459f-ad42-f342b6fee314">139.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNS0yLTEtMS03NzQwNw_32b0027a-13ad-4fee-a410-43cd86d6f2de">106.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNS00LTEtMS03NzQwNw_0e4e70d5-51f3-4471-a7ce-10ab7a7051d4">96.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNS02LTEtMS03NzQwNw_82ad045a-d6c3-45c0-89d6-d23bd429e62b">102.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNS04LTEtMS03NzQwNw_d1ff37f6-3992-4f2f-890a-35e28dde5f26">96.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNy0yLTEtMS03NzQwNw_612fcda8-71ce-41bd-8691-d8eb524f5111">2,661.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNy00LTEtMS03NzQwNw_8576be8a-46fc-448b-a0ab-aa1d39dcaf0d">2,674.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNy02LTEtMS03NzQwNw_2f0d206b-c5e4-430c-bd9b-2d28c427f01f">2,667.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNy04LTEtMS03NzQwNw_4d04a57d-ac9d-4ea8-895d-a50d61114329">2,674.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfOC0yLTEtMS03NzQwNw_04d648b3-0408-4560-8459-5d8f13cbfc34">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfOC00LTEtMS03NzQwNw_309612bd-7dfc-478e-a31b-b1664696b854">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfOC02LTEtMS03NzQwNw_f53ed9e2-2b9c-476c-8228-0495c015f18a">5.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfOC04LTEtMS03NzQwNw_f4cd8903-b7e2-4222-8265-cb9ac6064684">6.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The diluted net earnings per share calculation for both the fiscal third quarter ended October&#160;2, 2022 and October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock. </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ia1df6985f62746cba1a1b3d211287d68">The diluted net earnings per share calculation for the fiscal nine months ended October&#160;2, 2022 and October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.327%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 9 &#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzU4OA_39778cbe-64ee-4e31-b28a-1c7eccebc75a" continuedAt="i6eec714b437a4d01ae275ac71b677b23" escape="true">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6eec714b437a4d01ae275ac71b677b23" continuedAt="i155c220611f249cbb762b0a1f955b718"><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="jnj:SalesBySegmentOfBusinessTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzYwMg_55361f1d-bb2b-4d3b-a749-98594f3d8b6a" continuedAt="i75c15b96de6c4fb28db4291f6d7aff7b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cde6a52268347428b5037069103d820_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS0yLTEtMS03NzQwNw_59413411-829c-47f7-ae4b-aac3f5332e92">695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia74220ebf81e4065a938588bde5498e7_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS00LTEtMS03NzQwNw_9f004705-6b38-4eaf-b14b-d69cce79949e">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7cde6a52268347428b5037069103d820_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS02LTEtMS03NzQwNw_42a71c50-5438-4a40-9870-b0062aad3542">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fcb0fd89d14eb6b29ffdbd3720e7ce_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS04LTEtMS03NzQwNw_e2d67109-f7de-4a12-9df8-b05dadf04b83">2,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a459b3600145d3b4107cf4bdccf257_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS0xMC0xLTEtNzc0MDc_ef8b9ceb-91f4-4535-a428-e3bca447d41e">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78fcb0fd89d14eb6b29ffdbd3720e7ce_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS0xMi0xLTEtNzc0MDc_f9470d28-83b5-4f3e-bfb1-3eb0766be26e">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i941ed2c1db534253af22569d7910ede8_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi0yLTEtMS03NzQwNw_fdb1bef5-06e9-4237-96e9-ced9cfc8933c">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f1d220f585f4dec831f31a5f9ce8adf_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi00LTEtMS03NzQwNw_7b23c3d2-c23d-47c6-83f3-b0c8428003e3">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i941ed2c1db534253af22569d7910ede8_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi02LTEtMS03NzQwNw_7a52a8b9-3e4f-45d6-8c63-a309d8bd0967">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aeb275ad1f442feafbe9c4c30a972b6_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi04LTEtMS03NzQwNw_1db87aea-5f2d-406c-9542-ed8051d585bc">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec58864a102d428fba3c283afdd1c086_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi0xMC0xLTEtNzc0MDc_228d8f2f-6be3-4878-a0d0-79bcc6f91662">2,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9aeb275ad1f442feafbe9c4c30a972b6_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi0xMi0xLTEtNzc0MDc_739a5433-0b9d-49cb-967f-0d372b87c2e5">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63196f90176a4d4c89a11a247847a7d2_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy0yLTEtMS03NzQwNw_c0b12b4e-801c-49f4-beef-2a64ed9a36d2">1,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib10849b3cb49478ebbdfac543124e1cb_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy00LTEtMS03NzQwNw_2b860998-6891-4fe8-b107-7f26415d9dc8">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i63196f90176a4d4c89a11a247847a7d2_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy02LTEtMS03NzQwNw_ed8a513a-631f-4351-8a25-bc9e0eb4405b">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343ce984f8d243c99d19169f2ce469e8_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy04LTEtMS03NzQwNw_9da5adf0-3eaf-447b-8280-f7469db9efca">4,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94a7099ba6b469abec25cbdb9df79c3_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy0xMC0xLTEtNzc0MDc_f0048b70-6b4a-4ac1-b3be-493a2f788898">4,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i343ce984f8d243c99d19169f2ce469e8_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy0xMi0xLTEtNzc0MDc_58fc3880-a7a8-4e12-91e7-a4ae9d2a421b">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c7b7f8b4fa541888ad11c59317e305b_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS0yLTEtMS03NzQwNw_1a4e5c64-6942-4614-85c1-436c22b63f6d">591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110338127fd4477e9581eeb21a88403b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS00LTEtMS03NzQwNw_d5e4f6a1-5e45-44e4-9d99-79405fbc1124">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c7b7f8b4fa541888ad11c59317e305b_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS02LTEtMS03NzQwNw_49278a8c-db08-46bc-bc6c-781825ae067b">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3692bbfa0746ad97c0e05cf2f74b81_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS04LTEtMS03NzQwNw_0fbfbdd8-bb49-4fb3-a161-195524e2847c">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib155353bba1e4367acb4afc65093ac17_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS0xMC0xLTEtNzc0MDc_b3af86f2-6374-43b4-9db7-145d31d000bb">1,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iba3692bbfa0746ad97c0e05cf2f74b81_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS0xMi0xLTEtNzc0MDc_60b82335-384d-4f48-8824-e6aa67ff20cf">5.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c11083b6fd4c70b63123ebd3184bcc_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtMi0xLTEtNzc0MDc_bbccca33-32a2-47f2-8253-8e133f256fc5">535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59bf5576de564479ab33549d72205efb_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtNC0xLTEtNzc0MDc_aef9d247-9d52-43ca-a9dc-b0f861d6555f">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id8c11083b6fd4c70b63123ebd3184bcc_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtNi0xLTEtNzc0MDc_90e893db-e185-4280-9ddf-fc04512a9add">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b06f4a72c54053ab762b36aa11132f_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtOC0xLTEtNzc0MDc_97a4f5e9-8075-4fd9-a848-37e4440b3971">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie061b083973e42d4885e9f9780a30d24_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtMTAtMS0xLTc3NDA3_6e20173b-1f8e-4389-9bf4-79f47eeaf652">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i92b06f4a72c54053ab762b36aa11132f_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtMTItMS0xLTc3NDA3_471e7678-d4af-4fff-97c2-8c746c1c3f2c">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id127890eb1d746d2b41f02aec9b35a5a_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtMi0xLTEtNzc0MDc_8d0202cf-7814-407f-9f74-dae132db1f83">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028f7b0cc1fe4417b3829de872b9bff7_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtNC0xLTEtNzc0MDc_d41fb1ea-c45c-4ca3-ba02-f2f1b385b1a4">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id127890eb1d746d2b41f02aec9b35a5a_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtNi0xLTEtNzc0MDc_9f0d28c1-c2f3-45dc-b18b-51f0444ae30a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20bbf2239aa6444fa5e65541167d42d9_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtOC0xLTEtNzc0MDc_3a3e9671-052d-4f57-88c2-e9ccf0154850">3,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6217c9284834a96aba0480663c6c29a_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtMTAtMS0xLTc3NDA3_e09177ba-ee10-43d8-b464-0460de19fe89">3,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i20bbf2239aa6444fa5e65541167d42d9_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtMTItMS0xLTc3NDA3_799abeb3-71c5-4cf0-91f9-a271406eaaec">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc1b31fec9043679c9a24c4e7d7eb15_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtMi0xLTEtNzc0MDc_a48e9090-5d45-4507-b683-a2cc970a8e0a">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728ae91795a049659be1d1a2f8f086d6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtNC0xLTEtNzc0MDc_bb950bbc-8cd6-49c0-a15d-8fe02f68c1bc">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4fc1b31fec9043679c9a24c4e7d7eb15_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtNi0xLTEtNzc0MDc_cfddb3c5-5742-4360-8584-785dc066e8cc">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197d29cb3728490aa880fe1b2febaf85_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtOC0xLTEtNzc0MDc_f6e40d46-5207-40c9-8786-c918aa976d8b">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc8a1658b7674fd480d2da4366870996_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtMTAtMS0xLTc3NDA3_854e2157-10da-4e26-b367-bab2900d7150">478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i197d29cb3728490aa880fe1b2febaf85_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtMTItMS0xLTc3NDA3_84f292da-cb92-400e-81d6-dd7daaafab30">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8200dc57bcf946c89ace0088bd07514a_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtMi0xLTEtNzc0MDc_e1147286-b09c-49d4-bdfb-79cf2e59a8f9">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c3e6ddd1e342c29393fe34fb925065_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtNC0xLTEtNzc0MDc_a15945f9-3d6a-43fc-b0d9-e9aee683c298">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8200dc57bcf946c89ace0088bd07514a_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtNi0xLTEtNzc0MDc_fcbb6fd8-7829-4e58-8f1e-7c5cdce83e55">12.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf3eefd4fdc4df398da4efb9abc13be_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtOC0xLTEtNzc0MDc_6f4b24ab-293b-4be2-a953-9421c74e1a55">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie31d505d43664fc6a37a1a6f7390b6d9_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtMTAtMS0xLTc3NDA3_6f74d880-e86b-4891-b4b5-c4d201e934c2">762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icaf3eefd4fdc4df398da4efb9abc13be_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtMTItMS0xLTc3NDA3_ae879925-04bc-4a25-9995-9af62fd1841d">12.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f6eab93c9b4d1fb2d19580cedc8b4c_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtMi0xLTEtNzc0MDc_babb0ded-1ff0-429c-b5b8-3b00f860c2ce">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4fadfd175984a22b86dc24c89dc4bc0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtNC0xLTEtNzc0MDc_c95dd050-a8b9-450c-b81c-684eda001353">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1f6eab93c9b4d1fb2d19580cedc8b4c_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtNi0xLTEtNzc0MDc_e603d4a0-2398-41a1-9445-aaa12e5df721">5.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15720a18344e469886257608fa371d4b_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtOC0xLTEtNzc0MDc_ae10b3e3-bc08-4337-8bfa-95191a04b844">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a609c570d4247459662c095f2834797_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtMTAtMS0xLTc3NDA3_11e12e2f-6e98-4627-853c-b7eed80e790d">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i15720a18344e469886257608fa371d4b_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtMTItMS0xLTc3NDA3_e9b1a0c6-432c-4d66-8305-29153602b945">8.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be2488acb464b53b616386ec7557fd2_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctMi0xLTEtNzc0MDc_74219e21-c734-49e2-b469-b2871b4bd366">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb0f442da954722b1c33088aa5d0bc2_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctNC0xLTEtNzc0MDc_9774b12e-7ae8-4190-92b6-506953826ffb">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5be2488acb464b53b616386ec7557fd2_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctNi0xLTEtNzc0MDc_41e07552-5f3b-44e1-8d5b-f98aa0e8214d">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b5a875d8089486c8f44852cabb6ecfd_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctOC0xLTEtNzc0MDc_9e627362-f253-4c8b-b0d9-06543c2b8e4c">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i211cbd1cb10f4ee7839006b5eaa4a2bd_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctMTAtMS0xLTc3NDA3_e898c9b7-b97c-45fe-a04f-e7836028c527">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9b5a875d8089486c8f44852cabb6ecfd_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctMTItMS0xLTc3NDA3_8e5362a9-8832-4d56-a17e-1a1992da2fa4">8.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258122d0b65d4169b5b5519e4d8d5074_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtMi0xLTEtNzc0MDc_cdcafa1f-42ab-4e58-af22-d4969211cd13">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c2eb559dcd4387b1033c88491e2a2e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtNC0xLTEtNzc0MDc_530d6762-d52a-4051-aaf3-3b3f9b802507">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i258122d0b65d4169b5b5519e4d8d5074_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtNi0xLTEtNzc0MDc_74cd8681-9464-40e7-b7e0-d9d4a89bb853">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0235b711c804ebfa7876a02dd285bb1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtOC0xLTEtNzc0MDc_6be96a6b-0c7c-4114-aecb-fb0f4ff7bd72">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec063ee8c3a4470694b6e73255290c52_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtMTAtMS0xLTc3NDA3_258a888c-cf23-4204-add2-16d3bdf57dfb">879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie0235b711c804ebfa7876a02dd285bb1_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtMTItMS0xLTc3NDA3_0a283013-1641-4c16-8dd8-f64b89d72567">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04db1cf7ec4e45bba56bc0d72ea66e02_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktMi0xLTEtNzc0MDc_342a9295-e9da-420c-b205-dfe85d1f4a8e">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f2286d04e2f4ee5b108615874070bf9_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktNC0xLTEtNzc0MDc_6bbdf6fa-070e-4b43-bc6b-ef38f5993f78">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i04db1cf7ec4e45bba56bc0d72ea66e02_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktNi0xLTEtNzc0MDc_27839314-58a4-471f-a3cd-72e4e3b7f8c3">4.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dd220bba8484f9ab20dffe40805100c_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktOC0xLTEtNzc0MDc_040e47c0-f840-49a2-be0e-d5b70c622e96">1,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebc82e0cc7a43579e7cb5d5261ff68b_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktMTAtMS0xLTc3NDA3_e9039079-ecf2-468c-a2ad-a446ac6afc70">1,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5dd220bba8484f9ab20dffe40805100c_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktMTItMS0xLTc3NDA3_7bfb3d80-1c30-431b-bbb7-41125465a56c">5.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05209c75c064c149e32ca91f101c128_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtMi0xLTEtNzc0MDc_3ccc7044-c7d7-42b4-87db-c2c51300b6b1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60597d445fdd471dbefd75d06e9d49b6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtNC0xLTEtNzc0MDc_e3865dc8-2975-4b27-9311-683b25e214ae">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie05209c75c064c149e32ca91f101c128_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtNi0xLTEtNzc0MDc_0b32d4b3-fe25-4e62-9424-e0d335b9c384">22.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59769c19cc641d08a4a75d12515d22c_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtOC0xLTEtNzc0MDc_87f82f8e-58a7-4847-89a2-a5cee3e528be">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadaaf79391e243ce9580a4a5f82c3c1e_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtMTAtMS0xLTc3NDA3_95ad487e-96d0-4a81-9616-a37e83a757fe">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie59769c19cc641d08a4a75d12515d22c_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtMTItMS0xLTc3NDA3_c0cc72f7-b729-47cb-8942-be51aa121b8b">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40537dd17e641f18a84d3dae0e1e91e_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItMi0xLTEtNzc0MDc_314037b5-455a-4fa4-b625-4a86b2f1c47a">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id74e23c5a1ea4a3fa4324f3cbebba2ec_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItNC0xLTEtNzc0MDc_3126b015-a2b2-400f-b1c2-9d594ffd43bf">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie40537dd17e641f18a84d3dae0e1e91e_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItNi0xLTEtNzc0MDc_c1b4ed39-a872-4fd4-8544-c4409b18a124">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57dad0479d5f408586720d9c4f156c48_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItOC0xLTEtNzc0MDc_efbfbf2b-4de3-4641-bf58-f307cc389755">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6571e3bbe1c5478088cde974f1a794ff_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItMTAtMS0xLTc3NDA3_e3c3dc46-d410-47f1-8d46-3a527d60fc3a">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i57dad0479d5f408586720d9c4f156c48_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItMTItMS0xLTc3NDA3_a4a3d232-58b2-4e40-ba0d-f6efe9956e75">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cf927e34f9e49f0abbbe3cd9b236507_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtMi0xLTEtNzc0MDc_5c042d3e-8b84-467a-8b6a-a57138b3a6e5">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa1da1546f194c1fb0e2caecfe484dff_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtNC0xLTEtNzc0MDc_ffa5fb2e-4c67-4ea8-aea3-94625172899a">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7cf927e34f9e49f0abbbe3cd9b236507_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtNi0xLTEtNzc0MDc_04afb899-58b7-43df-85dd-db24ecb64cd7">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if82e78c4579b4156b6cdbcf7c3cee740_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtOC0xLTEtNzc0MDc_e3478ab8-0522-4a38-aa19-14cc4859c0f9">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0699f62151e4b32a947734f89b31cdd_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtMTAtMS0xLTc3NDA3_a6560930-33e0-4033-ba3b-200f316b3288">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if82e78c4579b4156b6cdbcf7c3cee740_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtMTItMS0xLTc3NDA3_e28636cf-605e-47d5-a9d5-0ba2cab0220b">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117745a3dd684de8974772ece9648d65_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtMi0xLTEtNzc0MDc_f3268367-3737-4965-9011-25b9e0721c32">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b9a0c60f81b457091ed4cdfdfcafa87_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtNC0xLTEtNzc0MDc_f1cc2c81-862c-4651-b3c0-d5e634cef9c5">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i117745a3dd684de8974772ece9648d65_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtNi0xLTEtNzc0MDc_0d8930fb-e79e-4aa8-9679-dadba48f79f7">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85433357f9bb4fba8f50ce185075b2a3_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtOC0xLTEtNzc0MDc_815c2d1e-2528-43bc-8a4a-5c4c753b96a7">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76af37281c8f42adacabdb80e1047e01_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtMTAtMS0xLTc3NDA3_3572a242-c48e-4ff1-9d1f-5d1c0778b0ce">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i85433357f9bb4fba8f50ce185075b2a3_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtMTItMS0xLTc3NDA3_84071c53-0b24-4f3c-94ce-86f2508e40a0">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f4bdb37dc4b4d47be92fde1fbb37bab_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtMi0xLTEtNzc0MDc_e60c679f-d7c4-4ed3-8b0f-f4b3b3c0616e">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia378214014c14267bb7dedcdfdfa66ce_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtNC0xLTEtNzc0MDc_caca1ea8-18cb-4ac5-a45b-1ecd30d11fee">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2f4bdb37dc4b4d47be92fde1fbb37bab_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtNi0xLTEtNzc0MDc_1026add4-4662-45f2-9b07-0d8d14b92180">11.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa62c7427744e21ad6b4c38c6a07153_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtOC0xLTEtNzc0MDc_f26efdfe-4634-42bf-8fd2-3a94e8735832">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59345d38f1c4186b66ae8cc16f7a721_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtMTAtMS0xLTc3NDA3_86dba171-5256-43aa-ba30-b956320551bd">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5fa62c7427744e21ad6b4c38c6a07153_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtMTItMS0xLTc3NDA3_4367beb7-2700-484c-b89f-d7b46414e7e5">8.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e80efcfa77b44a5b447cd4080557081_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctMi0xLTEtNzc0MDc_73c86cc1-7adf-43eb-b79b-caf8fafb2a6d">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie501da18e9c84dbdb77d1e9fce501b01_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctNC0xLTEtNzc0MDc_4acef47a-36f5-4413-9078-e47b2e2c5dc2">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0e80efcfa77b44a5b447cd4080557081_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctNi0xLTEtNzc0MDc_6c29965d-5433-4cf5-8a8d-f09c0df5c6c5">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34261d9fecc4b469fbfc7320a06ad74_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctOC0xLTEtNzc0MDc_ca43f135-afbd-49b2-8519-976eea5e5a54">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38e077f4d7ef4d1ba0449d563d1247a0_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctMTAtMS0xLTc3NDA3_48ffae35-1520-4513-8593-e89c5ef6e69f">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic34261d9fecc4b469fbfc7320a06ad74_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctMTItMS0xLTc3NDA3_b3d96eaf-51ff-4c06-920e-b68cafe232df">6.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8bba328151b4f589a73606eb0809caf_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktMi0xLTEtNzc0MDc_eee7fce0-8b52-4f4e-8096-e6beec03f8eb">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b41c4b48d4d43e0a26a3b93522fd773_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktNC0xLTEtNzc0MDc_54f6e8b2-de92-43cb-97b9-a29b22d7e9f3">1,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8bba328151b4f589a73606eb0809caf_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktNi0xLTEtNzc0MDc_f0d4ec57-7d89-4273-8d84-11f29a802f1b">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c2d3a271be74fd9aea5facb617f9860_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktOC0xLTEtNzc0MDc_b76a9afe-1d83-4e90-93db-7471a961df1e">4,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4f833113f7041289bb2eb913b130ebf_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktMTAtMS0xLTc3NDA3_50b6734e-1f46-4726-83ad-35fb20bfab17">4,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7c2d3a271be74fd9aea5facb617f9860_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktMTItMS0xLTc3NDA3_8b686e19-751d-41fd-a429-cfd97a787437">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e5cf3b01a84cb493dc2721b5a74b79_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtMi0xLTEtNzc0MDc_2e89c608-498c-4779-bded-ccf11a2fcb08">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320bb566db254466ba9c6a695628a6b0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtNC0xLTEtNzc0MDc_5833723b-5cf2-468f-832b-8a241ba54f54">2,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i20e5cf3b01a84cb493dc2721b5a74b79_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtNi0xLTEtNzc0MDc_91b1aff2-d506-46f3-af83-41b2cc7c72c1">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5886c2fb184bac9cd7ffe1b974ffb7_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtOC0xLTEtNzc0MDc_bdc0a319-21ff-4d1d-8484-3a920bfa94c7">6,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i755b8f931470497ba00724a368f9cdbe_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtMTAtMS0xLTc3NDA3_e664e9b8-400d-4c31-9a02-b67afd237119">6,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e5886c2fb184bac9cd7ffe1b974ffb7_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtMTItMS0xLTc3NDA3_63161ca3-7c32-4a96-93a7-9300152cdc94">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1d5e55ddc144bc825a5b127870993d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtMi0xLTEtNzc0MDc_d7ad69de-6e0c-48ad-8a2f-8d32959408e9">3,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44a1dbe5705741b68a24e0e337ef63e8_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtNC0xLTEtNzc0MDc_4010399e-40fc-44fb-9ed2-8ecbcdd7b2c1">3,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1c1d5e55ddc144bc825a5b127870993d_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtNi0xLTEtNzc0MDc_7f5248ff-cf1d-4217-9ea9-3d457770367a">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7787b0e8db0d4969ac6e93a11454dd47_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtOC0xLTEtNzc0MDc_9507c010-8439-4b52-b985-1836e2d95c8b">11,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc8e23dcc91d417896dc4ffb5479cb12_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtMTAtMS0xLTc3NDA3_bbf99355-12e4-432f-ab59-3930eb7d5c1d">11,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7787b0e8db0d4969ac6e93a11454dd47_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtMTItMS0xLTc3NDA3_236d866e-4f23-4a1b-a8c6-eafe60da4ea4">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i155c220611f249cbb762b0a1f955b718" continuedAt="i5e5c5d57a51840d6a001027f603bbac7"><ix:continuation id="i75c15b96de6c4fb28db4291f6d7aff7b" continuedAt="if1f0eb7b861e47eca36d715ecc366645"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11459a5bbd884b9cbcefb0dd8cc442ec_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtMi0xLTEtNzc0MDc_a837e592-24eb-4fef-af89-0d97abe1b90d">2,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3cc1f7e1fa54ceb9ccc93da93684bef_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtNC0xLTEtNzc0MDc_95c5dce4-6e98-4041-8bd5-73b8bfdbcca2">2,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11459a5bbd884b9cbcefb0dd8cc442ec_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtNi0xLTEtNzc0MDc_c686bee2-6ee4-44c6-88e2-628cec507bcd">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676de123fa744973b1d51400eabfad36_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtOC0xLTEtNzc0MDc_b1389ada-1de3-49a9-9a2c-6c63d8914c28">8,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58528c896007432da65d8fa36f867e8e_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtMTAtMS0xLTc3NDA3_7e983e16-0b0b-4e1f-a165-d2ec300a85b9">7,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i676de123fa744973b1d51400eabfad36_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtMTItMS0xLTc3NDA3_99fdb9b9-91b2-4274-80d3-4e92a4969a80">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050bad26138643da94080c24dc214a0b_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctMi0xLTEtNzc0MDc_9e9be918-d635-441d-97a4-fcc184cade99">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ebea684bc144c3ab6b069f307243b39_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctNC0xLTEtNzc0MDc_839a7b16-57ca-4fec-9908-8bd4c7a13d76">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i050bad26138643da94080c24dc214a0b_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctNi0xLTEtNzc0MDc_7f2df336-94a9-4020-9d13-407390dee5ea">4.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9ab2943111a45ddb4c3689d0f23f0b8_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctOC0xLTEtNzc0MDc_f5dc9dbe-8081-467a-8510-672358d9b8c9">4,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c86dfc4bbb843088a0478dacfdda4eb_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctMTAtMS0xLTc3NDA3_95a47a86-de54-4bf5-83d4-5099e7b9628e">4,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9ab2943111a45ddb4c3689d0f23f0b8_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctMTItMS0xLTc3NDA3_981962d8-2634-47b1-8313-814a4ce3b089">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie710509f29a84a6798f07d16fdf4bc25_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtMi0xLTEtNzc0MDc_5b4210fb-dd1d-4d48-ba59-6a906e6f3f26">4,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if36c2d2204694bd1b65beb048a38a087_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtNC0xLTEtNzc0MDc_0c780254-b978-4433-9a13-1e28079247b2">4,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie710509f29a84a6798f07d16fdf4bc25_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtNi0xLTEtNzc0MDc_bb659963-7858-4e70-8067-a1ced1bb981e">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27e0991470e3476189d1336285252c30_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtOC0xLTEtNzc0MDc_8aa6c302-342b-423d-a218-7393ef9e7422">12,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9da5926e9f140999d1bba65c342a33e_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtMTAtMS0xLTc3NDA3_50c0fed8-eeb4-4b6a-98d4-11f9b2cc31f1">12,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i27e0991470e3476189d1336285252c30_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtMTItMS0xLTc3NDA3_290d9523-b6fe-4158-b0ac-2bf3617c023c">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i601cd15753894e97b054f81a710b6ce8_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtMi0xLTEtNzc0MDc_6ab38b0a-7745-4a8b-bb27-c67addaf781a">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f5d0786855c4f85a8c2679f03a458e6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtNC0xLTEtNzc0MDc_a5bc51c8-ba8f-4c8d-9447-4d1037269f7a">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i601cd15753894e97b054f81a710b6ce8_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtNi0xLTEtNzc0MDc_a807058d-dfa7-429a-88e8-628104fff1ce">27.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fb4bb0a29804fc68f9bc363715532c3_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtOC0xLTEtNzc0MDc_63436432-8ed0-44cb-ab8e-4601d5758862">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id807a25e86074bc39f2d148f8a84be6e_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtMTAtMS0xLTc3NDA3_07a534c9-e359-42c0-b030-e8d69edf28af">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2fb4bb0a29804fc68f9bc363715532c3_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtMTItMS0xLTc3NDA3_7712e95a-4e2a-4ccd-af69-6dffa11803e1">27.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c31eac278e41a1ba118b6c025d1f7a_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtMi0xLTEtNzc0MDc_7b0235b8-aaf5-45ef-82e5-d15da1584c44">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7e206e166a4e58afbaf397873c5618_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtNC0xLTEtNzc0MDc_f0640957-2582-440e-a7fd-0c73a6d24e6b">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i14c31eac278e41a1ba118b6c025d1f7a_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtNi0xLTEtNzc0MDc_985b4f05-16c7-47b1-a87e-7baab1c48154">16.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab929e3264374872bb7f54c68dd062ca_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtOC0xLTEtNzc0MDc_f44ea88a-0726-4697-9641-af53bb8c4319">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eab22cd2cda488aa69b38e14ab9166f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtMTAtMS0xLTc3NDA3_fa85c70a-5262-4b3e-a834-979b0c5063ab">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iab929e3264374872bb7f54c68dd062ca_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtMTItMS0xLTc3NDA3_a2254e24-dc7b-405d-aa5f-331300ce5a49">17.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47f7963286445b1827fe6925d9837a5_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItMi0xLTEtNzc0MDc_4764cd7b-0ff9-46fe-bede-6458fa718a56">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e7b4c0a8e04fc7a1fb4736a9fc92a4_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItNC0xLTEtNzc0MDc_1310f2a2-1b10-46e2-b859-fe5a7528a784">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib47f7963286445b1827fe6925d9837a5_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItNi0xLTEtNzc0MDc_eb56d570-92d7-4d21-8dba-c156dee1bbfa">27.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7967609999b541f2b29b2c6ce68ddbc8_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItOC0xLTEtNzc0MDc_2f40955c-5cab-4636-a987-9abd794f60d1">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac3cb68f0c34215a382d7031670ff23_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItMTAtMS0xLTc3NDA3_754b161b-d169-414b-ac16-22455773cd3d">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7967609999b541f2b29b2c6ce68ddbc8_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItMTItMS0xLTc3NDA3_d2a44334-0174-48b5-b358-4f1e1e32ad85">16.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bd3d8de975456d820b150c1d106f90_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtMi0xLTEtNzc0MDc_580407f6-3235-449f-ad43-196bd77d72c8">558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4fc3995b69496ca407948b3dea092c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtNC0xLTEtNzc0MDc_724db83f-ab4b-458a-9b06-ee3442f26212">761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia6bd3d8de975456d820b150c1d106f90_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtNi0xLTEtNzc0MDc_9b4b21f0-3413-4ed5-bd86-9eff8910610a">26.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73b319201054f529e8ccf164554f568_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtOC0xLTEtNzc0MDc_1ce92dd4-fb7f-490b-acdb-e71a25638d89">1,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf4f4567b834309abf4b2ff42315882_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtMTAtMS0xLTc3NDA3_b97e2ba5-a36a-4f44-a5d4-cd9915128743">2,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic73b319201054f529e8ccf164554f568_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtMTItMS0xLTc3NDA3_18348597-bd9c-4b6a-b3c2-0d1ef15412ad">23.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b43ed5dbcd543d9ae7b7fd7bb075ab7_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtMi0xLTEtNzc0MDc_defe4e0e-78d3-4640-a280-33ddfea29328">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c16c4c7023f4f0790700efabacf60f9_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtNC0xLTEtNzc0MDc_de9c122c-5bed-460d-a3a6-71e786453a0a">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b43ed5dbcd543d9ae7b7fd7bb075ab7_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtNi0xLTEtNzc0MDc_d8a5e396-61aa-45bf-96a1-1c3533dc0ffa">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35f027f36faa4af1b4f6e944c1417488_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtOC0xLTEtNzc0MDc_b43657aa-1e70-4986-996c-9acf48d345d2">886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0afbd5dc3a754753a394dd6670fce509_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtMTAtMS0xLTc3NDA3_1a1bf7a5-657c-4cc7-8133-ba5e3f864728">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35f027f36faa4af1b4f6e944c1417488_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtMTItMS0xLTc3NDA3_42a84120-d5df-4103-914f-b1c76eb1a32b">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc5345a5249f40379024f3ef934dd3db_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtMi0xLTEtNzc0MDc_d81b63ed-effa-4e68-b244-25c488ed4d16">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2ca59e69a743e88208410ceda1bcba_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtNC0xLTEtNzc0MDc_6280f48d-43ce-4e19-99a8-b88840af4004">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifc5345a5249f40379024f3ef934dd3db_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtNi0xLTEtNzc0MDc_fa3b738b-4571-4501-b8ff-3daec54242ca">10.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib294a903194d4a7187902c709f695b44_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtOC0xLTEtNzc0MDc_46e1b6ef-234b-4f83-b42d-778af207dbec">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67974f0f7a1245e7809b5204fc2509b6_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtMTAtMS0xLTc3NDA3_2e925e51-f81c-473f-9f40-9a76068f1550">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib294a903194d4a7187902c709f695b44_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtMTItMS0xLTc3NDA3_4465ca52-9c63-4723-87e7-b581df07e98d">9.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3db40e6bab3440fbc146528ac4ef7a0_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctMi0xLTEtNzc0MDc_fa42dc83-651a-4eb2-bb8d-bab8a817ef75">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6202780aca5740c78cbc6ab6252f4036_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctNC0xLTEtNzc0MDc_7e6b31d4-d023-41ed-98cd-83721c74d46c">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3db40e6bab3440fbc146528ac4ef7a0_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctNi0xLTEtNzc0MDc_54dd8940-95bf-46e6-bd43-ce637829f35b">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifff14a1f8c334b9aadadb7babbfdd924_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctOC0xLTEtNzc0MDc_ff3c0c87-bea1-4c62-bf9c-eb740f079f38">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a6027ed50842c6972d5eee3da4c9c6_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctMTAtMS0xLTc3NDA3_27cc52d5-a9d8-4ec5-b6d3-e4ea4a8d322a">1,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifff14a1f8c334b9aadadb7babbfdd924_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctMTItMS0xLTc3NDA3_ae907ef5-def6-4ed4-9625-f92ba70b31f9">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5b800af44314d97bc6e07ab8f06ffb3_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktMi0xLTEtNzc0MDc_5ae1e1d8-1efc-4fd3-8f53-23e5fcc88a46">1,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id938e01bb77e45deb2dd767caac9cdff_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktNC0xLTEtNzc0MDc_eb5dd764-166b-47a1-9c57-4ba274819899">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5b800af44314d97bc6e07ab8f06ffb3_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktNi0xLTEtNzc0MDc_a0985353-228a-4ae6-abc9-d7acc4f6a056">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bca8e9e03447268cf3bf5aee0f765e_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktOC0xLTEtNzc0MDc_8c3480a0-f954-4720-9a12-8e7e88c71ca6">4,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c5c096bdb6c47b695ac4b997e09e315_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktMTAtMS0xLTc3NDA3_8d4ef654-e481-40da-a208-d722a341be43">4,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60bca8e9e03447268cf3bf5aee0f765e_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktMTItMS0xLTc3NDA3_d27162cb-3157-4297-a81f-95bd6c447bd3">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea479d1c88df4fae9e4ce67cffee6742_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtMi0xLTEtNzc0MDc_cda29a62-b4d4-418f-b6cb-299e832be683">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i618dbaeeb2c24741aa3cbe519fe58c50_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtNC0xLTEtNzc0MDc_30e30dcd-4acd-402c-b05f-cddc833eacc2">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iea479d1c88df4fae9e4ce67cffee6742_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtNi0xLTEtNzc0MDc_7e551b6e-1ad0-4e3e-8850-6633b8f6f7e1">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8086f446324048e2a9c8937b0ced6d84_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtOC0xLTEtNzc0MDc_0d8a293e-3e8e-4026-9e45-afdba5a6aad0">2,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b22d7a7eb564fce9cb4052d7a41c913_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtMTAtMS0xLTc3NDA3_528e4874-6258-4b8b-99e2-d726d1fb8239">2,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8086f446324048e2a9c8937b0ced6d84_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtMTItMS0xLTc3NDA3_a991d0e7-9c4b-4b7b-b81e-ebfb01df6e83">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i059e1b1f3a53490db3d19ba632df2180_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtMi0xLTEtNzc0MDc_d6d4e47e-c35c-4b41-b6ad-2372a7d4f9c2">2,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0008e6798c040f696f04e80c67a9f1f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtNC0xLTEtNzc0MDc_4292bd4b-d834-4ef1-b293-834e7991bab7">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i059e1b1f3a53490db3d19ba632df2180_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtNi0xLTEtNzc0MDc_e8998345-365a-4f3d-94a8-398e1fbaf73c">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6ee4cea0654427bd1841c05b22220d_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtOC0xLTEtNzc0MDc_6839f0a2-e247-414f-9a48-a649fa640b97">7,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db6efcbef124e2cbfa8b06aaf5015e1_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtMTAtMS0xLTc3NDA3_9f5f0e26-d754-4ba0-bad3-7f9fe9a84813">6,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec6ee4cea0654427bd1841c05b22220d_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtMTItMS0xLTc3NDA3_756b4260-e9b0-4b43-a530-86ac32435e60">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab89cc409f64d07bce8e87a8fdf95c7_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtMi0xLTEtNzc0MDc_40fc483c-f1ab-4507-8893-b7fa09f4e87e">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6fc771e5cf47a7964910a8424d9aa6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtNC0xLTEtNzc0MDc_a98f745f-048c-4145-87b0-628d1ede27a2">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ab89cc409f64d07bce8e87a8fdf95c7_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtNi0xLTEtNzc0MDc_1c2816ae-0b3c-4f5d-8192-c2111f55a47d">40.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b5a3ff0712432c9a8b2bec26f39b4d_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtOC0xLTEtNzc0MDc_7b8b801f-ac90-4d6e-9b03-ae16b5195c1e">1,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic969d91a8c6340d49f4ca9c6d0a168bd_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtMTAtMS0xLTc3NDA3_02adb906-808e-4861-bb15-bdea206eaece">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9b5a3ff0712432c9a8b2bec26f39b4d_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtMTItMS0xLTc3NDA3_c4fa9928-5e53-45a2-abd9-f3de5a85a48e">33.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i611a544e7fed48459222bd6dba1e2fff_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtMi0xLTEtNzc0MDc_96df341a-4d82-48ed-b95a-50bedfef1589">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i532f597a8ed14fc5aaa5997db648cfba_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtNC0xLTEtNzc0MDc_02f282e2-20cc-4e5f-abe6-02fb5b1e76a1">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i611a544e7fed48459222bd6dba1e2fff_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtNi0xLTEtNzc0MDc_5d66b278-31b7-4d64-9e6c-bb3a3447efd7">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a81309c93e40bbb6520a059a567fc9_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtOC0xLTEtNzc0MDc_4d7c5f70-e788-4c46-9f61-e514c6cd79b9">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75bc3e4b7f0f4bebbec4aa452e444d00_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtMTAtMS0xLTc3NDA3_07e25301-183b-47cf-84c8-45ec9b4e411b">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5a81309c93e40bbb6520a059a567fc9_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtMTItMS0xLTc3NDA3_83c42ee2-1e9a-4132-8d07-961c5a566b5a">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045bb0bb60d64408bc746a0b601e9798_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtMi0xLTEtNzc0MDc_4dcde3da-5e81-4022-b2e8-1df9d80d7ebf">729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73cbadc80e7d49bfab612db1296213d4_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtNC0xLTEtNzc0MDc_02516780-cbf3-4d54-9194-d3c8b53d01e4">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i045bb0bb60d64408bc746a0b601e9798_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtNi0xLTEtNzc0MDc_c2ab594d-cb99-4e2e-bab3-4c3c157caaa6">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02219b77430640bcb4d575751528f347_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtOC0xLTEtNzc0MDc_f6b25e07-cb9a-4990-be1f-69e7baee6319">1,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0e29062c8fe44fd9b3dc53b1dcfddc0_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtMTAtMS0xLTc3NDA3_7b1f02ea-cb42-4877-9e1f-f209defbef6a">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02219b77430640bcb4d575751528f347_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtMTItMS0xLTc3NDA3_a14680d0-58e8-4460-b624-cd09af6a66ba">33.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade60d9fbc69468ea53b4630449ae23d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTctMi0xLTEtNzc0MDc_45b6c98e-ae16-485e-9878-2bc49f2ad7f8">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48d8585ed15e4dd9b2a5802f367ad706_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTctNC0xLTEtNzc0MDc_ebcb1f7b-b8b0-4df8-a42b-4f5570bffd26">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f6578cdec5d474fb61356ea6723f969_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTctOC0xLTEtNzc0MDc_a5dd101d-de5f-4b7f-8b7f-fca50b922c3f">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i539ed9db6fc4408cb8bf66316e3d162b_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTctMTAtMS0xLTc3NDA3_c751bf29-eb6e-409f-9859-4cbbaeea96ea">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1f6578cdec5d474fb61356ea6723f969_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTctMTItMS0xLTc3NDA3_3bdd1c77-28fb-4d63-be72-18af7c2fd38b">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i113f00d20dd64c9c8ec5149aaec8e0e2_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTgtMi0xLTEtNzc0MDc_f70dcbc5-1d03-44a0-88cd-116724f26d54">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d2acd0bff348a696db84de99c97bfb_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTgtNC0xLTEtNzc0MDc_c45eece1-3e2a-471e-9a5a-7477b298d5db">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438b4b2bfa6b4080af4749683d1d6535_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTgtOC0xLTEtNzc0MDc_c984d639-6e30-4ce7-a66c-89fd0904bba4">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e88b65375c744c690cb9f2531ad1947_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTgtMTAtMS0xLTc3NDA3_fe32225e-f811-4157-9db0-746e501e92cd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777a5ad66b154207965e26b2bac930d7_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTktMi0xLTEtNzc0MDc_f6b868c4-c3bf-4867-8c54-d705b20bcee0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20227083c87e481eacfb2dd925179f5b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTktNC0xLTEtNzc0MDc_fd8e1245-868b-4226-8b03-e7c262796247">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5446bf9970a24b6b937fb2036be6ff7c_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTktOC0xLTEtNzc0MDc_730f31f0-706c-4570-867b-dfbeeaca0f02">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4543179c68d4c82a76af5e632f3aa8b_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTktMTAtMS0xLTc3NDA3_3795aa56-8daf-46fb-b80c-19c08d372adf">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5446bf9970a24b6b937fb2036be6ff7c_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTktMTItMS0xLTc3NDA3_e470e269-21d7-4414-98f0-39529d4e5914">19.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id59930ef089148a392af915228263641_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItMi0xLTEtNzc0MDc_47368de9-84fc-4338-980b-9dad9d191bf1">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c253c52c7ee4f25a276574c0adf9fe3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItNC0xLTEtNzc0MDc_b2825b21-7a08-4448-aec8-86511d9833b5">679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id59930ef089148a392af915228263641_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItNi0xLTEtNzc0MDc_d24f025b-fa03-49be-b78a-f3f310100fcc">42.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48bf4caae12427a934bf19365269a73_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItOC0xLTEtNzc0MDc_316772e8-17ce-4a59-8119-4cbdb0c20781">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e97e36903074830b97a3f886bbda733_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItMTAtMS0xLTc3NDA3_5e367d68-88b4-4cc4-a995-6f84953096cc">1,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if48bf4caae12427a934bf19365269a73_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItMTItMS0xLTc3NDA3_7c807d2e-e262-4302-81a7-c643a346a415">22.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94fa08b8cbd0498cb485bc7b48711e3b_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtMi0xLTEtNzc0MDc_53be8a00-0096-4fae-bcd7-0a767a8b57cc">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2bdce36f584334bc4721f3d6131a87_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtNC0xLTEtNzc0MDc_a46f9a62-29ab-4d9c-9503-eec7ff8e6ff7">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94fa08b8cbd0498cb485bc7b48711e3b_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtNi0xLTEtNzc0MDc_f74cdf86-9c39-4246-a8f0-076a01cc2bf6">29.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5acf2a6ea8034d3e9b7d7074924ada01_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtOC0xLTEtNzc0MDc_6015893c-9657-4dc2-b7af-ed54f6852083">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14747989f826463ca3488654f17be9f5_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtMTAtMS0xLTc3NDA3_a40d8d39-bd65-44c3-b2c1-904ad7901e87">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5acf2a6ea8034d3e9b7d7074924ada01_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtMTItMS0xLTc3NDA3_bc0c6489-65e7-420e-82fc-679664619290">50.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1127e192c04223a462719cdaa10ae0_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtMi0xLTEtNzc0MDc_01695cc6-13a9-4f07-ba28-a97f0d8cc7b7">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55656c2263544ef8b6e0bad424c168b7_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtNC0xLTEtNzc0MDc_b9028e9c-92e8-4a81-abc2-e1e7ff1b12f7">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4a1127e192c04223a462719cdaa10ae0_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtNi0xLTEtNzc0MDc_29ba9019-4769-413c-b3eb-753320f014bf">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0d1ddf2bf748eb9fb05773730d69a5_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtOC0xLTEtNzc0MDc_96898518-30bd-4278-ad09-421e7b8bc22f">3,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if490f8f38569467da82013ec07af4dc0_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtMTAtMS0xLTc3NDA3_253d5bd4-900e-4ac6-ae61-03e58773c940">3,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f0d1ddf2bf748eb9fb05773730d69a5_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtMTItMS0xLTc3NDA3_67c76d88-b2af-4adb-8382-f519019dafcf">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fcbba0ef29f4f6fbad46f21014a1b89_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjYtMi0xLTEtNzc0MDc_8b6ce3a5-604b-4052-b892-75e5893674fa">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd0faf0da5f04c0992e10094b3f8e97c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjYtNC0xLTEtNzc0MDc_8231d942-6654-4a10-a648-96064e38f568">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6191e64a17bc461c9838efdd458364cf_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjYtOC0xLTEtNzc0MDc_4797a437-1a20-4d30-b557-29dfb0242e41">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc6597880ac74bf48cc5795eaf19e569_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjYtMTAtMS0xLTc3NDA3_58b10de5-69e9-426d-b67d-4604269f54af">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6191e64a17bc461c9838efdd458364cf_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjYtMTItMS0xLTc3NDA3_e29450b7-1a3f-45c0-992e-b7598f65ceae">71.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf91d92c233a4dbfa5243a026f870176_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjctMi0xLTEtNzc0MDc_888821c2-5622-4d53-b041-a65e849ddf45">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icddabaad4cf84f18995b0dfd4ec27309_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjctNC0xLTEtNzc0MDc_5ed94443-07a4-4247-9ff1-581705cccade">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1a722add33f4a4e970219beb9128bbc_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjctOC0xLTEtNzc0MDc_8aeef6be-5f94-4f39-8175-8bc2d00887cd">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb9d283788741abb9be248c18d56115_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjctMTAtMS0xLTc3NDA3_a4a7de14-d29a-4cfc-8d71-b0f6c7af866c">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba72ecd0fd3b47c6b352e266260fc5cf_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjgtMi0xLTEtNzc0MDc_aece5654-f77e-4d16-809d-67e8d7b5ef4b">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib213aac39dd14e45914c3a0c2bf6713c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjgtNC0xLTEtNzc0MDc_4509bc1c-cf94-4e14-99d2-8ab4710bd408">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iba72ecd0fd3b47c6b352e266260fc5cf_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjgtNi0xLTEtNzc0MDc_33376d9b-3755-4d39-b84e-d647a25c65a7">2.7</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d296b6dadd4d958ffe5990c80d6a0c_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjgtOC0xLTEtNzc0MDc_0c21881b-4bdc-4f87-b649-9765fca826f0">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83db602d21fc49c098bf5479b3b020f9_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjgtMTAtMS0xLTc3NDA3_61b5dc6b-5828-4d9f-b3c4-a3a258a57c12">766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf51711c9fc9401ea85ff7dab87f84e2_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtMi0xLTEtNzc0MDc_29aed3a1-c8a0-44d4-8824-e2026525e6ae">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i413c6a3f140542e58e400aa2f983c6e5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtNC0xLTEtNzc0MDc_3a629e62-a970-4c2a-99b7-a49cbfef05ab">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icf51711c9fc9401ea85ff7dab87f84e2_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtNi0xLTEtNzc0MDc_64fc13de-a325-4e3d-8dad-45c3f5b53382">27.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67e44ed2293b4d0ca08120085f5e960d_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtOC0xLTEtNzc0MDc_1140684e-46a7-420d-b6f9-0e257a6457e2">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b33e65c46b4a568b37f7326d33ae1e_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtMTAtMS0xLTc3NDA3_89589aac-a892-41d1-99fd-03bf9ec53d00">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i67e44ed2293b4d0ca08120085f5e960d_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtMTItMS0xLTc3NDA3_33b60f80-5a5c-477c-83a4-2c15e0be2b90">14.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4345727efc2f4029a0ed4bd19dcf7bfd_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtMi0xLTEtNzc0MDc_6a2a6626-96cc-4ba1-8d1f-cbd9dcbc9fda">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054f2ca9d0cb4fb8b157c2706a23ca76_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtNC0xLTEtNzc0MDc_b0aa9c6d-2bce-43ac-8379-68346a1f4caa">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4345727efc2f4029a0ed4bd19dcf7bfd_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtNi0xLTEtNzc0MDc_10a53e5b-8094-4c4a-9b2d-a17cbd716ff5">4.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76df4b1c1d904841a08d373dc471035c_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtOC0xLTEtNzc0MDc_a69f9606-97b4-441c-86fd-4588e4ee7c3f">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46fb64831ae740e8819f320229d29799_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtMTAtMS0xLTc3NDA3_140c268d-0a3c-4d8f-b2f1-e1535100ee28">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i76df4b1c1d904841a08d373dc471035c_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtMTItMS0xLTc3NDA3_95dd87ab-042f-484c-967a-c4745be902a7">5.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374469fd1fe84b23986b0e14cfccfc49_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItMi0xLTEtNzc0MDc_5e2c23ce-a6a9-454e-abdf-c9571c2a1375">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bbe137b43fd4b918335c8497edf70c1_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItNC0xLTEtNzc0MDc_f5cb3dd3-2fa4-47d0-a529-f69ca9172b8e">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i374469fd1fe84b23986b0e14cfccfc49_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItNi0xLTEtNzc0MDc_55c23dda-5ea9-440b-a641-7b53a9150591">5.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c68d6e42284bbfb401b21b31fe0f06_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItOC0xLTEtNzc0MDc_e10e61a4-848b-42f8-882b-edad1ced569a">718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife8189ee4e82488592a6e11bb1a45d3a_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItMTAtMS0xLTc3NDA3_95bcbc52-71a7-4f4e-af05-4cffb4367ef0">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i32c68d6e42284bbfb401b21b31fe0f06_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItMTItMS0xLTc3NDA3_bd0d84d1-f947-4395-b06d-4bb642052226">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e3265b7db3479d856ade508a46ed66_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtMi0xLTEtNzc0MDc_1256cbaf-a2f7-4873-b75b-6e11a1c3d31d">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7faac73e2f23406cb8eb7dbe1944acdf_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtNC0xLTEtNzc0MDc_d18a9d54-3f08-4a18-aad8-35eae62fb6fd">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i84e3265b7db3479d856ade508a46ed66_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtNi0xLTEtNzc0MDc_b8f89818-48fc-433c-9f85-1d771edb1feb">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2795880e984fa283bc3a164283cb1c_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtOC0xLTEtNzc0MDc_da50c09c-890f-4e48-8558-ecf4bf8a827a">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e3eb5daefce43a7ace1a8549cc00d5c_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtMTAtMS0xLTc3NDA3_6a280055-c372-46b1-b522-9860287f63ce">1,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2b2795880e984fa283bc3a164283cb1c_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtMTItMS0xLTc3NDA3_4f3ddd2e-d60d-40f2-9e8b-d3831475e7a0">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53e3c10757fd42b993341c8066c8b790_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtMi0xLTEtNzc0MDc_d3fda435-0492-4fda-8b09-f932b96cf509">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d204cb63f34d5f990c71beecdb6abb_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtNC0xLTEtNzc0MDc_7ac67ad9-ada9-4edb-8461-1005a8b6b9d0">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i53e3c10757fd42b993341c8066c8b790_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtNi0xLTEtNzc0MDc_3289ec07-f42f-42c0-8992-b56cd397fb63">17.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef1f530ace84a29a6481dcddde7acf2_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtOC0xLTEtNzc0MDc_a3eedb7d-82c3-4a6e-a0ec-8b6fbbb5ecf2">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb1aab6ee7734aaa9c1c053a59b47312_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtMTAtMS0xLTc3NDA3_ad2b657e-5c80-4204-9b0c-9a1f174d2a2d">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifef1f530ace84a29a6481dcddde7acf2_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtMTItMS0xLTc3NDA3_1c2d7e8e-dd15-4c2d-8ef6-899a579a0079">19.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aea2bc286e74c24ab2637ca0d209a3c_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtMi0xLTEtNzc0MDc_bbb1f125-0833-45c5-9876-aa658d931ac2">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58f24b47415f48b0885b0d7c10967969_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtNC0xLTEtNzc0MDc_e7732a68-812d-45f8-bb76-b00bf1260567">517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7aea2bc286e74c24ab2637ca0d209a3c_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtNi0xLTEtNzc0MDc_d5bb0e8a-5781-4f4b-8915-73938387e548">6.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic305652d07704e98ba5feacfb2d5f00d_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtOC0xLTEtNzc0MDc_04dc15a4-47ef-484f-beb9-c2dcdddaef20">1,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a0efdb63c04fa69e366975a05bb13f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtMTAtMS0xLTc3NDA3_30e2e8f5-1540-4e57-afca-99ec96322f76">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic305652d07704e98ba5feacfb2d5f00d_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtMTItMS0xLTc3NDA3_0ff2f79e-fea5-4484-af83-c405b3d9ca3e">7.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i5e5c5d57a51840d6a001027f603bbac7" continuedAt="ie447a7f70853414a8a8fc2bb81bcfcd0"><ix:continuation id="if1f0eb7b861e47eca36d715ecc366645" continuedAt="i26230647f4e54d4d9ac990296afa8fe5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i177dc85392db469a8c1db91c948cdd05_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtMi0xLTEtNzc0MDc_f489b4e6-6f4a-432b-b1af-ecbd1a606e8f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3e8bd6206b4ee5a70504f5d9b66667_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtNC0xLTEtNzc0MDc_e2c2b124-58ef-4ced-9c42-bd47f0fc795c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i177dc85392db469a8c1db91c948cdd05_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtNi0xLTEtNzc0MDc_c545c1c4-704d-4ea8-8e13-791d53bad3f0">46.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9610be906255476eab03ae58f21e9645_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtOC0xLTEtNzc0MDc_6d3e93bb-67a9-47cc-9338-6e0564354001">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8979440d00f14555833df82de8200c08_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtMTAtMS0xLTc3NDA3_3834d242-7a17-4c1d-8ffc-1e8249c79c71">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9610be906255476eab03ae58f21e9645_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtMTItMS0xLTc3NDA3_ecb6bb25-88b6-4cf4-b0d4-67d310a6c268">57.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af5e8ef63074a068a23d526b83f8c0f_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtMi0xLTEtNzc0MDc_6b69c364-b219-4eef-9ca1-34dbb96a0740">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a94a1625b94c1e93bba0b6e6b48f6e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtNC0xLTEtNzc0MDc_43c9d68d-b773-4612-bba7-2af9b52ae5e7">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5af5e8ef63074a068a23d526b83f8c0f_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtNi0xLTEtNzc0MDc_a7d9d6b9-a76e-42a1-a935-40088a7b58d1">17.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25061e631e414e92da52fa72c80da1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtOC0xLTEtNzc0MDc_e4fa116b-118d-46c2-b5c2-ff1b8f3d8e05">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i976e2778a2084719a4234e95ad13c666_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtMTAtMS0xLTc3NDA3_ca7a3f55-9d5c-4706-b714-5c010db1d520">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibe25061e631e414e92da52fa72c80da1_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtMTItMS0xLTc3NDA3_2211dd7a-ccca-43bb-8d14-527ec329a83d">5.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecbfb31a552f4de39c19d87cb748cc94_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItMi0xLTEtNzc0MDc_f6949069-dc98-4cff-b340-9d88c991a821">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1202469d66404db95107a79c2868a0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItNC0xLTEtNzc0MDc_eda126e3-8efe-463e-bef0-214c8493f4d6">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iecbfb31a552f4de39c19d87cb748cc94_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItNi0xLTEtNzc0MDc_8eb67f87-973d-4222-98b9-03dd3fd5b17f">22.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd1abaa86844d559d8ce0f5cf23ff7c_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItOC0xLTEtNzc0MDc_1c8d0d93-da31-4041-aa94-4fd675d26719">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa1aba1c6e8477da278328f0b8c7659_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItMTAtMS0xLTc3NDA3_c9df8f2e-0057-41a4-a693-e8ee3744485d">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3dd1abaa86844d559d8ce0f5cf23ff7c_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItMTItMS0xLTc3NDA3_68168bc5-0d73-4fba-90f2-ae6fc6b179ae">14.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa25cbf4d9754df6ba84b4ef2d383458_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtMi0xLTEtNzc0MDc_808358a3-7ff4-4324-bf80-e30387986627">919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfbfd4bd41c4c5187cf6e182e899660_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtNC0xLTEtNzc0MDc_93326aa5-3669-47a9-bc12-0c2a24e25941">835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa25cbf4d9754df6ba84b4ef2d383458_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtNi0xLTEtNzc0MDc_ff337655-8c07-4939-ad7b-5b877e839527">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1612b190f4f14f649d1d8aaf00cdd1c6_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtOC0xLTEtNzc0MDc_f84a56b7-b1d0-45fd-ac8a-b8427efa3704">2,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968f6b90e0d24fbf8745420b22f191a9_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtMTAtMS0xLTc3NDA3_2bb08870-2e25-4457-b49b-c8e860d24d9a">2,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1612b190f4f14f649d1d8aaf00cdd1c6_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtMTItMS0xLTc3NDA3_48e43ccc-5b0b-4812-86da-72c1ec5e907d">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec7a45f95d444fc9c23636a25fc71b4_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtMi0xLTEtNzc0MDc_22f5cd97-1912-40a4-a09f-9d0bf3d57252">763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie877d3091b2a412cada21c76c157025a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtNC0xLTEtNzc0MDc_22725b53-eb28-48f9-b867-4853d882fc8c">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaec7a45f95d444fc9c23636a25fc71b4_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtNi0xLTEtNzc0MDc_869491bd-eca1-4228-ae5c-747532224e79">9.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823acd2fea2640ddb3d3f3ab09a21a0a_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtOC0xLTEtNzc0MDc_5c77b5d1-b47e-4574-bea9-b6de56dca8ba">2,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2c5b49a0b14b7886ce8b9cb93667c8_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtMTAtMS0xLTc3NDA3_444692fc-9fa9-4254-93bc-9c7323ecc9f7">2,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i823acd2fea2640ddb3d3f3ab09a21a0a_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtMTItMS0xLTc3NDA3_4550e0ae-0198-4886-815d-d8e054370b72">9.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba37868d4ab40a494a8932e5c195ce0_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctMi0xLTEtNzc0MDc_12dff2e9-ad91-47d5-b860-d87ce60e1be9">1,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0705f1796374a95b4f177ad23d8fa53_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctNC0xLTEtNzc0MDc_b6510c5d-646e-4821-8be2-e46ef9f02862">1,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieba37868d4ab40a494a8932e5c195ce0_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctNi0xLTEtNzc0MDc_40e92951-f719-4ee8-96a3-9016a6a9f33b">0.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b2ee0a4ccb47b689fde9e511d136bc_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctOC0xLTEtNzc0MDc_df7324c4-0e27-4936-8f57-b1dd22ceb1b6">5,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id289d5f0f10e4ee799a2e6ea8bd1d88f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctMTAtMS0xLTc3NDA3_acebab13-d5ac-4fb2-962c-5067a4fd0fa2">5,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id5b2ee0a4ccb47b689fde9e511d136bc_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctMTItMS0xLTc3NDA3_929bdf37-8b40-4013-b6af-8143adf84357">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd7004acb80425580aeab7c75bcb925_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktMi0xLTEtNzc0MDc_333954a5-b672-4e15-9586-ff7ae79280e6">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2cb42ee1f24a339b3c00347bb66920_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktNC0xLTEtNzc0MDc_e28b2e7a-a2bf-4f9d-831e-931236729932">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cd7004acb80425580aeab7c75bcb925_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktNi0xLTEtNzc0MDc_eb3735c7-b1a4-4160-8eae-7d087ef0f976">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf202bcc43b74c6e97e4400e94a50ef9_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktOC0xLTEtNzc0MDc_41ace2e4-00cb-4617-84fe-5dd148e32e0e">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib390ee20bcf14042acab18119fdcb669_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktMTAtMS0xLTc3NDA3_d1298dd1-7b24-4119-86bf-728d16695a18">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idf202bcc43b74c6e97e4400e94a50ef9_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktMTItMS0xLTc3NDA3_b23565f8-90f8-4f55-9496-0757e3005d1c">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11dfd015a75b4884aaf7606edf7f9f0a_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtMi0xLTEtNzc0MDc_788b1e76-0b16-402b-9112-a8f5e97f4e24">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45a4897765d040e2aef60f9e024a65d8_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtNC0xLTEtNzc0MDc_388945ca-27bc-4d38-9be1-33fe53dcced2">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i11dfd015a75b4884aaf7606edf7f9f0a_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtNi0xLTEtNzc0MDc_d6f3eac1-5ede-4605-a793-a230718548ea">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ead4e3e50cf4bfeba22c28a2397048c_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtOC0xLTEtNzc0MDc_52b32043-256c-483c-9415-eb844493ec44">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa16021f57ab4f1caa859b2705fd46a2_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtMTAtMS0xLTc3NDA3_1f76a271-58d7-4902-8146-1b8613dd09b3">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ead4e3e50cf4bfeba22c28a2397048c_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtMTItMS0xLTc3NDA3_449074a0-cc5d-48f9-9b98-af9a2661b112">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0e31c64d572445bb6085f0d2c49ea4b_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtMi0xLTEtNzc0MDc_835d2d21-7cac-4145-a472-b505bf57abc1">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd460e77c2eb4aa3be50b1cdf64ac81d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtNC0xLTEtNzc0MDc_5fb72534-981b-4188-80ea-8c3aa5b9a996">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia0e31c64d572445bb6085f0d2c49ea4b_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtNi0xLTEtNzc0MDc_58d1a9b7-3c80-4090-8685-ab26285f1447">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icca3698a549d4feda795428aba1c8625_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtOC0xLTEtNzc0MDc_64341a2b-0557-4c24-8d93-b37d43fe896e">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a96dfb6d88408fb4483ed241d5e788_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtMTAtMS0xLTc3NDA3_a52ce96b-019d-4dbe-97d4-f2a2fcb90062">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icca3698a549d4feda795428aba1c8625_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtMTItMS0xLTc3NDA3_7755f128-2a1c-4fd0-a304-44d58fa7d028">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i137cde1513484ea6a0ba43bca08f33f7_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtMi0xLTEtNzc0MDc_c7f243be-14ce-4082-9099-30d79881a505">684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab5433d88374b8f9bd823c575a7a039_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtNC0xLTEtNzc0MDc_89d5ce76-e101-4dc4-9226-6c95644e4723">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i137cde1513484ea6a0ba43bca08f33f7_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtNi0xLTEtNzc0MDc_258d2f27-82d7-4253-8a36-76ef48a93a4b">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7a58a2310f449cafcd3b8351c93cfe_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtOC0xLTEtNzc0MDc_b5b2d816-f010-4efb-a553-d60afe6401b6">2,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e55ac0a94064596be5e7888ac1c9bec_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtMTAtMS0xLTc3NDA3_2757dea4-9ffc-430f-aa27-644341e30a3e">1,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d7a58a2310f449cafcd3b8351c93cfe_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtMTItMS0xLTc3NDA3_c91f4295-e737-4c30-8ded-eeace5ca5e52">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09bdbc4c576474ba2cece696d19cb68_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtMi0xLTEtNzc0MDc_62b82a76-ebaa-4a26-bb8d-8f0bc972dbb8">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf94af89fe14fea8f4a33af0a883c1a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtNC0xLTEtNzc0MDc_3466a044-dbb6-4ab8-8b4f-215570584248">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie09bdbc4c576474ba2cece696d19cb68_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtNi0xLTEtNzc0MDc_f13b102a-4601-444b-bdd5-845df9ca2255">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79c0238a6fff4c91bf6b829e1e0e6892_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtOC0xLTEtNzc0MDc_cd0f1d01-682f-49a2-82a1-9ced9735df9c">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad2fa156fe5432eb82a37c862ef94fb_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtMTAtMS0xLTc3NDA3_a5d8a634-7494-41b0-8a4b-c193cfb94416">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i79c0238a6fff4c91bf6b829e1e0e6892_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtMTItMS0xLTc3NDA3_12c6a435-2a3a-46fd-8ff2-cff4564c45ee">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45a7b092ca9844859eac9399e8268977_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtMi0xLTEtNzc0MDc_e280ccd5-ecd5-4407-874f-9cbd5ddb9ccc">1,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f741d423224f489272cc2103a2be77_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtNC0xLTEtNzc0MDc_b4498783-1e86-4734-9ae2-7cb6fff1188d">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45a7b092ca9844859eac9399e8268977_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtNi0xLTEtNzc0MDc_f0bd6415-e8ea-4ae6-8087-120841df53d1">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac7374616114d02b1ef9e3af61e8c95_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtOC0xLTEtNzc0MDc_2741a272-2e05-4f48-b308-223c25e2da6f">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4365f12a95234c7dbbcbde1b929baee3_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtMTAtMS0xLTc3NDA3_9ef81c1e-e8d6-4828-bac6-46b3685e648b">2,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ac7374616114d02b1ef9e3af61e8c95_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtMTItMS0xLTc3NDA3_329c6dd2-af7d-4526-a739-757b8d94ce6e">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1eed427e824c31a74eb9fd41fbaa1e_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctMi0xLTEtNzc0MDc_701b5593-cc67-47d1-94e6-ebc0499e26a2">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11b64a00633401683a6ce25e6f615fb_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctNC0xLTEtNzc0MDc_21afcaf4-5a2b-4849-815d-aab94e7ffc1a">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibe1eed427e824c31a74eb9fd41fbaa1e_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctNi0xLTEtNzc0MDc_7ed676c0-b375-4d94-8354-e0cadef89638">6.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9968c0bccd0448c9a01e166ab918a984_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctOC0xLTEtNzc0MDc_460e7383-612e-4ec1-8562-d05073f2830d">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b46d64b60414934aca49f64ba9e5f60_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctMTAtMS0xLTc3NDA3_ff1ec17a-ae1a-4903-954d-f21d927ec842">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9968c0bccd0448c9a01e166ab918a984_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctMTItMS0xLTc3NDA3_43796aba-6920-4bef-b974-0f4100e860f8">7.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1580db90b0e48cc893c81fb2540cb41_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtMi0xLTEtNzc0MDc_9b36aa4b-c96f-4c9d-a39f-fef74cd21e0e">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22a0e4c73916450babe25165d391d6bc_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtNC0xLTEtNzc0MDc_a75a2202-d335-4abe-bea5-8f14bf7b31de">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib1580db90b0e48cc893c81fb2540cb41_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtNi0xLTEtNzc0MDc_22deb5a8-6bd4-4336-b2d7-c76c30f5d895">24.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5f51b2ac144660a667a5fef9ab26d4_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtOC0xLTEtNzc0MDc_126fb367-6ae0-48d6-b14a-6b745df1c42b">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a52f1a99905452fb46ab62760965f86_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtMTAtMS0xLTc3NDA3_1d21f116-90b8-4b17-8106-0b0f3db722e1">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide5f51b2ac144660a667a5fef9ab26d4_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtMTItMS0xLTc3NDA3_19330906-0457-46ec-8400-6cdd53998e55">26.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2a628c1fc440eca687de37f708aa8c_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktMi0xLTEtNzc0MDc_71ec06e7-abc3-4076-a13d-6894a05fc1e5">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52da69a2389c48eb9e42c1a2ea47bd75_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktNC0xLTEtNzc0MDc_90a46f9e-53a8-4cb9-b573-842b84d1a45f">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8a2a628c1fc440eca687de37f708aa8c_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktNi0xLTEtNzc0MDc_5bd0151d-ff35-444f-82ce-b3d9385daa1a">14.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a7d12f22764dbb8759a742d94eb8a2_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktOC0xLTEtNzc0MDc_21bfd868-37b1-4c2d-ace2-0bdc84d65f25">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93952a8fa3ba416a91d3216edf3a66f8_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktMTAtMS0xLTc3NDA3_ce3e271b-0223-4d5e-a6b6-caa65dd9d871">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i66a7d12f22764dbb8759a742d94eb8a2_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktMTItMS0xLTc3NDA3_96934a77-5965-4a04-870e-4d08accdd6bd">17.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e8caf499784ae398f716cde9975425_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTItMS0xLTc3NDA3_48673073-917f-483c-aa33-def7924d7c5b">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451f3c5eff7745599f90d0af11f4f4cf_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTQtMS0xLTc3NDA3_ffe6b00c-7f5f-43d1-895d-5fa60412d07f">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3e8caf499784ae398f716cde9975425_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTYtMS0xLTc3NDA3_88e23ce5-d2bf-4439-9760-2bbede28a0af">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia582797f6e464aa9a43e5e6175ed4fdc_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTgtMS0xLTc3NDA3_3af971b8-bb78-42a6-af45-219e2e2d090f">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8801d5f445ea486381246f9557e84830_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTEwLTEtMS03NzQwNw_28e11162-fb92-4851-bcfb-e4eb8ed7a4ff">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia582797f6e464aa9a43e5e6175ed4fdc_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTEyLTEtMS03NzQwNw_8b028469-25d6-4aec-9572-b62a82e3baa7">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08dd8fcd4d2a45b99b04b6d5af0eb436_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTItMS0xLTc3NDA3_fbe3eb00-9051-4ef2-9e56-42f63434b99f">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d8a32d310f4f73ad47b98c02d07725_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTQtMS0xLTc3NDA3_bfef3121-2151-4ee2-bb7e-92ef04cfdcfe">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i08dd8fcd4d2a45b99b04b6d5af0eb436_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTYtMS0xLTc3NDA3_b48232e2-0d3c-4954-a1e0-dd9be5c9277b">17.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eccfe1cbc774b868af74e3ecf7e96d1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTgtMS0xLTc3NDA3_855eeca2-3fc2-491c-a027-1d4af3cf06bf">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab744bf1ae1c4732bff2f6dbcb6177c9_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTEwLTEtMS03NzQwNw_d696a5fe-445e-4874-954f-e66f8b03ed31">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1eccfe1cbc774b868af74e3ecf7e96d1_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTEyLTEtMS03NzQwNw_dfd84226-2bb1-4260-b820-9e2191987683">16.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983dfa5746394727b4076b1302b725e3_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTItMS0xLTc3NDA3_37c34a36-fc15-48ce-b77f-abfda35fb74b">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524e2edfc08f4a5580c142b4fbe47bdf_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTQtMS0xLTc3NDA3_e6971af1-eae6-4dda-af61-4380a3670ce4">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i983dfa5746394727b4076b1302b725e3_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTYtMS0xLTc3NDA3_684291d8-6f42-4a3f-85f9-fb5050c9bd18">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b57f9e060b40b7a959c01f75f2cdb8_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTgtMS0xLTc3NDA3_b689dae6-6ba7-4d41-b5e8-5c2714591092">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e84d1337fdb4905ba98011e4e8bd221_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTEwLTEtMS03NzQwNw_21c758af-d7dc-46f2-a614-f5c913903ab8">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib1b57f9e060b40b7a959c01f75f2cdb8_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTEyLTEtMS03NzQwNw_956c8cf6-5353-4de0-8241-cb6f27dc4c02">7.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5b869f0296461f9fd2b132c207af88_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTItMS0xLTc3NDA3_d214af7d-4e88-4fdc-81bf-8c4fd7ddf8ed">1,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76cd338bc7d045b684ffef7f072eb708_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTQtMS0xLTc3NDA3_8167dfef-993f-41c2-a515-6148ca65d237">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e5b869f0296461f9fd2b132c207af88_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTYtMS0xLTc3NDA3_16c3e3eb-301c-4519-b53c-4ec17e1d95fa">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f93a1e291fb4f21aa74bf605526f3d4_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTgtMS0xLTc3NDA3_3aeeb45a-40ec-4c81-aacd-ce1cbcc44619">5,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57185a1089ea4d859905b073688fb56b_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTEwLTEtMS03NzQwNw_7c4636a9-9e27-4c82-a251-6a67fee584ac">4,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f93a1e291fb4f21aa74bf605526f3d4_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTEyLTEtMS03NzQwNw_9e1d2eeb-2d73-4c92-b86f-22fd86ce80a8">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122d085eabad46eb96a300589fd4bb3d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTItMS0xLTc3NDA3_6533568b-230c-44d5-b75b-75a9787dd620">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89657990d309468383c0be47dae23813_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTQtMS0xLTc3NDA3_de527da9-c737-4ac5-a91d-c098d4f04533">2,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i122d085eabad46eb96a300589fd4bb3d_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTYtMS0xLTc3NDA3_27d0c423-304c-48ad-9cf0-712c69df04f4">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59754740b9fc4cf0ae2c2c849165f4c0_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTgtMS0xLTc3NDA3_27c9666f-1475-4705-a1c3-30290963e8ca">6,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic879ca2153fb4a0088c7ee21b8bb666f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTEwLTEtMS03NzQwNw_fea86ad9-c0f3-4881-83c8-a4623e44c0a2">6,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i59754740b9fc4cf0ae2c2c849165f4c0_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTEyLTEtMS03NzQwNw_9202e584-a112-48c6-8425-2feb89bc1132">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae451029e5d4bd580e6089d7352e564_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTItMS0xLTc3NDA3_98be3939-c0e0-4a8d-ab14-954241c02eea">4,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf29bc608704deab5ec4bfc9c1166f5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTQtMS0xLTc3NDA3_ca46f7f3-f5be-49fd-be9f-e66592cee528">3,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibae451029e5d4bd580e6089d7352e564_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTYtMS0xLTc3NDA3_06a1738b-f655-4f69-99b6-a78c10d3d1df">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1ff4ca321f4e6fa0ef4ae8850e39b3_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTgtMS0xLTc3NDA3_c3905425-e31c-4ff0-837a-df6a10f25fa8">12,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70cf1523502f4cf5ba39389cb696eb37_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTEwLTEtMS03NzQwNw_28b709af-2d42-44b4-b615-6330e08029a6">10,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f1ff4ca321f4e6fa0ef4ae8850e39b3_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTEyLTEtMS03NzQwNw_50d036af-c305-4661-9483-0bdce0b18f37">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b56bacf950743f084cba59a7fa25e7a_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTItMS0xLTc3NDA3_03d3f669-1492-43c3-a9cb-5900aa0f71a7">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081f0f428e784cab8f9d016f92effd83_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTQtMS0xLTc3NDA3_bde6be23-13ca-4874-9ec4-47b584d66741">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b56bacf950743f084cba59a7fa25e7a_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTYtMS0xLTc3NDA3_8ecaf0c6-4e43-4620-ac5c-dae1a3d273df">30.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5cd7d0017649089af560975f3138e1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTgtMS0xLTc3NDA3_39c46373-4d28-49e1-bb0b-6cff1247892b">3,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475fdfe52a874f96855bebe87d3bcdf4_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTEwLTEtMS03NzQwNw_8e39a05d-0be4-4943-a123-6a4de6e52e64">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c5cd7d0017649089af560975f3138e1_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTEyLTEtMS03NzQwNw_6ce8e65a-782e-4c4b-9599-de5c2f15cbb5">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87898be332414773b484d0dc62a17a36_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTItMS0xLTc3NDA3_23314db0-e01a-4dc4-8ae0-8130f724c1a1">955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia552b1bea3ed45ea9d9428a49f4aa36d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTQtMS0xLTc3NDA3_5fb90ada-8ec1-4c1a-b27b-6941052c0104">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87898be332414773b484d0dc62a17a36_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTYtMS0xLTc3NDA3_708dde4d-6199-48ee-8ebf-6b94ee19b1c4">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dc593f363ef47a58da8ed226cc81f6d_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTgtMS0xLTc3NDA3_2612f869-e935-4c49-ad1e-40244aab656c">2,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5273b9790a9456bbdf4c45498aaef2f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTEwLTEtMS03NzQwNw_3afc5a25-0d40-4ca5-8dfb-3349db3e98da">2,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6dc593f363ef47a58da8ed226cc81f6d_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTEyLTEtMS03NzQwNw_3d62dee7-7cb0-4315-9620-fe9a17a6436c">36.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47cb84e4eff645bc93a43e37e94a9db3_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTItMS0xLTc3NDA3_8e75c137-9852-4fde-9d61-e89a2d5908b7">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6dde9f39bec4bea8b20aa1d494c72cf_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTQtMS0xLTc3NDA3_3a61e633-fc61-429a-94b9-0b729667f803">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i47cb84e4eff645bc93a43e37e94a9db3_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTYtMS0xLTc3NDA3_696014d7-df05-45dd-9865-c2950e78cdfc">29.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01a4a90d5035473fbeccea2782bd2c3b_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTgtMS0xLTc3NDA3_f80eee1c-2149-458c-b474-2d1de51b91ab">5,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42adb27c042b423eb963af60ecdd4f28_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTEwLTEtMS03NzQwNw_f60af198-5fbe-445c-905e-bbf5b742dfd6">4,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01a4a90d5035473fbeccea2782bd2c3b_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTEyLTEtMS03NzQwNw_2d30d891-c3b4-49e6-aaa8-b9b625840489">34.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027553a8069f4b20b245dc5aa1b7f00d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTItMS0xLTc3NDA3_287f142b-7f35-4ec5-bdb0-0e2b90a14056">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6c8c3e6d5948d28dd9796e3ca9f2a0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTQtMS0xLTc3NDA3_211f067f-7f58-465f-80b3-9411e23b76ce">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i027553a8069f4b20b245dc5aa1b7f00d_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTYtMS0xLTc3NDA3_f7bb5c41-e0ed-4df8-805d-55997268d18e">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72692a16cfbd4625a23c6c13e5c4a89a_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTgtMS0xLTc3NDA3_ac4a8dd8-f7db-4ee4-a7ab-52956cdeae6f">693</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b6abfbb54c2428e827e225364933220_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTEwLTEtMS03NzQwNw_f2782d0e-8461-4d4e-9841-c5ab12cd1c97">578</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72692a16cfbd4625a23c6c13e5c4a89a_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTEyLTEtMS03NzQwNw_e807403e-396f-4c87-9e5a-e212875d9263">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a933b2468c47028feef151e8eca9a6_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE1LTItMS0xLTc3NDA3_5e09de0f-4206-4087-895f-da474b8f9078">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09e27f9730db43f6a2ad23e6cf8a28d5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE1LTQtMS0xLTc3NDA3_c64141db-737c-43b1-9971-498295b50c9d">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77060b346f464d5d94e95a340469f8c1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE1LTgtMS0xLTc3NDA3_8aacf51e-bffc-4b42-b072-dea5badff64e">647</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i272627f13bc84d4cbe6effb2975aca80_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE1LTEwLTEtMS03NzQwNw_02417707-2282-4ac3-95d4-c90cad35f187">329</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1544200114ae4509a452b21c7cda8113_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTItMS0xLTc3NDA3_c22f5687-6fb2-43cb-8bdc-f58f574a72f3">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37417b84faf544e388d7fbea6710dde8_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTQtMS0xLTc3NDA3_bcf94185-eb52-46f1-a302-b5c4b7b6756f">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1544200114ae4509a452b21c7cda8113_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTYtMS0xLTc3NDA3_d87ece80-d296-4576-9d3b-c604ebcd3202">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd68e44359f480b9c73e8e0717f39b5_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTgtMS0xLTc3NDA3_98cc1356-3f79-4aa8-8910-58e458eca8b9">1,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c2e5afe5f447d98cdb95e255a91e36_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTEwLTEtMS03NzQwNw_3a99b534-daad-496a-a79c-9b5bed46228a">907</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcd68e44359f480b9c73e8e0717f39b5_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTEyLTEtMS03NzQwNw_cd7cb7f1-8789-4bcd-a0da-4a659c9c9a37">47.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia610c33820924e2887785db9deee9d33_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTItMS0xLTc3NDA3_0234758e-347d-40ca-b683-049239750663">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90c807d7bb242bdb981d10b3fe54eb6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTQtMS0xLTc3NDA3_be799c6e-85cf-458b-b538-66d54118db28">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia610c33820924e2887785db9deee9d33_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTYtMS0xLTc3NDA3_c062cd81-7af4-4a34-bc57-691fa4c1b149">14.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i694546fb28354b728eb7a664114dcc64_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTgtMS0xLTc3NDA3_dcbb3bd6-5c2d-4e87-bc9b-5cc40ed9b855">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c8924e9eaec4b2dbfbc45f97506d991_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTEwLTEtMS03NzQwNw_416ebf96-c735-4384-96a5-bff5f2084d42">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i694546fb28354b728eb7a664114dcc64_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTEyLTEtMS03NzQwNw_b30733b8-be6c-4f74-b5e8-890f8c7ba811">18.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d326425f4074d3aa5f72ef541b7d36a_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTItMS0xLTc3NDA3_d78cf9e2-aa47-4d8e-982c-c4bae48714bb">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a634db09b3472284861b507d5c1114_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTQtMS0xLTc3NDA3_a1c7a277-be6b-4452-bb68-a2c961ddc66a">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4d326425f4074d3aa5f72ef541b7d36a_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTYtMS0xLTc3NDA3_55d25271-a8b1-4117-8ef4-d9ab2c12891a">14.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba42e341ee7416abbbe3661f587439e_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTgtMS0xLTc3NDA3_4d8cd4e7-b1ae-4e67-baed-c46b7f7537bf">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13b890bcafd74f788a55c0ebe94e5632_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTEwLTEtMS03NzQwNw_3612d35b-c93b-4fda-9a90-312bc79fe64f">1,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibba42e341ee7416abbbe3661f587439e_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTEyLTEtMS03NzQwNw_26eaa90e-5751-4129-8340-7d46c688cb76">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505a0ebef84644338a169d2b6209fbd0_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTItMS0xLTc3NDA3_2576fffa-8034-4e79-a4fd-4d9d417acb17">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ddfba15a2041d88d410a99ac1e926a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTQtMS0xLTc3NDA3_fe03e4b8-1df3-4912-9228-da26ac0b6b23">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i505a0ebef84644338a169d2b6209fbd0_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTYtMS0xLTc3NDA3_ee504c8a-78f1-47ee-82dd-7388425ca8d7">14.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i033591a445a5468693248831071b5242_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTgtMS0xLTc3NDA3_508135d0-1f2f-439d-8ba7-86cda0f377b8">2,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7da56618ab654c42b05e7ce3d95c93fb_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTEwLTEtMS03NzQwNw_f4f8a39b-33d6-412e-a847-354532a71e92">3,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i033591a445a5468693248831071b5242_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTEyLTEtMS03NzQwNw_c4066696-d018-49f2-86f3-d99de4e8cbf9">11.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5a4918db2e4440a13d121f8cffb4d5_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTItMS0xLTc3NDA3_e545b6f8-2b4d-455a-b99d-180d319ac5ef">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5604fe07056d43b898f627ac12fe4ae3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTQtMS0xLTc3NDA3_86d2a40b-8df6-4238-825f-6e0312219a85">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5c5a4918db2e4440a13d121f8cffb4d5_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTYtMS0xLTc3NDA3_e6dc1394-7707-4d7b-bd89-ae0c1e6f82be">33.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400f6ad312e1418a8315ea7c4ca60914_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTgtMS0xLTc3NDA3_f77e75a0-7f42-4e30-b7ac-7f65f7807d45">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d4fa554f9c42f2b2dbef32f68ab0dc_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTEwLTEtMS03NzQwNw_5bfa69dd-2c1d-46d1-886d-b44e4c957733">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i400f6ad312e1418a8315ea7c4ca60914_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTEyLTEtMS03NzQwNw_b1577bff-4f53-4dae-8733-588ba1b6622e">43.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eecfc49d16b42a8a21357eaf2267e33_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTItMS0xLTc3NDA3_cbdc47fd-6c4d-40a3-b5c3-81068826cfe4">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb87af3cab043ca8decf206c6b249b3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTQtMS0xLTc3NDA3_3fd574a9-9e22-471e-a01c-85c32a7d8de8">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0eecfc49d16b42a8a21357eaf2267e33_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTYtMS0xLTc3NDA3_6cafda5e-5747-47ac-ac59-dc241b4fcfcc">15.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cfd9c7ab83c419bbf61049f45186a29_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTgtMS0xLTc3NDA3_ded03fa5-407c-4a6c-8a06-1f8f3380ab01">1,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028ed305b9b440838647dbf947fce3c2_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTEwLTEtMS03NzQwNw_be42f362-ded4-448c-bf1d-436bb13a5810">1,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9cfd9c7ab83c419bbf61049f45186a29_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTEyLTEtMS03NzQwNw_3dcad1c0-cce6-4dbb-9418-39bca020373d">12.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5014237d9c1c451999919bf6eec12ab2_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTItMS0xLTc3NDA3_acda469a-4753-461f-b094-41eed4869b66">456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b1476e16fc4757b5fe6b377ec00a8b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTQtMS0xLTc3NDA3_f7be6355-fb9c-4998-8c79-98f102c14138">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5014237d9c1c451999919bf6eec12ab2_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTYtMS0xLTc3NDA3_e8d8d080-283d-4aeb-85cf-d3584eb6f4e6">16.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b55351b3e714b4196d956f493f5fbfe_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTgtMS0xLTc3NDA3_578c338a-f210-4790-9f1a-ac2b7680ca21">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i494b3dcc71a9471bbb64838967bf211f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTEwLTEtMS03NzQwNw_d0902220-d9c0-4656-938e-4a452be8bda3">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5b55351b3e714b4196d956f493f5fbfe_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTEyLTEtMS03NzQwNw_ab8ba990-5c79-4b42-a4cf-c0dc091f1ba0">14.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="ie447a7f70853414a8a8fc2bb81bcfcd0" continuedAt="i7a233380fa534adebcd628534e5f533e"><ix:continuation id="i26230647f4e54d4d9ac990296afa8fe5" continuedAt="i968d093b8f2143a3aa9c57820f65a4ab"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d1982faddbe4e81a502b33e94996bba_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI3LTItMS0xLTc3NDA3_e3a14ccb-6865-4d23-a48e-e14908056178">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1677f52df4334218aa0a0cb8d77df066_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI3LTQtMS0xLTc3NDA3_c14cb655-ef00-4d3e-b072-466c0bc19fba">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf32b8dec40e4c26a1275c9cbeb2cab9_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI3LTgtMS0xLTc3NDA3_e340695d-9537-4580-8a22-fe46afaf9f60">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0075c921c1a3418087cbff16476429bb_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI3LTEwLTEtMS03NzQwNw_11eca9c6-c206-407d-95df-bfc1ac27fd71">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i642b7fdb6d7141198e59206a87715ca1_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTItMS0xLTc3NDA3_244eaea4-67e4-40bc-8f19-fc7c5f9bbb5e">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec24b62e56f4c749ad066b0f5814893_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTQtMS0xLTc3NDA3_c7115bdc-9eec-44c1-92c3-191e39d4c257">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i642b7fdb6d7141198e59206a87715ca1_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTYtMS0xLTc3NDA3_a98fc5b6-43fa-4af9-8aaa-914b005c9d38">32.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9a58f759a804eeea68e4f6cf19f54cc_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTgtMS0xLTc3NDA3_c866ac00-8fd5-4550-a5ed-3ca856679c1e">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d2e948664e48509acc9a46d147acd6_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTEwLTEtMS03NzQwNw_37332820-7e5e-4690-964b-13c1ceec07c7">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie9a58f759a804eeea68e4f6cf19f54cc_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTEyLTEtMS03NzQwNw_8fa0c22c-713b-4831-886b-29cfed3e886f">37.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9034ae3630be4f90ac8759f73c9d84ee_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTItMS0xLTc3NDA3_f91aa134-d844-459b-b87b-0d2a11c217cc">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia01a0e267e3d49408ae383c295013155_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTQtMS0xLTc3NDA3_7a823a65-edef-4359-8079-dd4227445437">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9034ae3630be4f90ac8759f73c9d84ee_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTYtMS0xLTc3NDA3_bd740b6d-bd0e-4ba3-8385-ff398d27601b">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9230ef516443ccad9d26677a66975e_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTgtMS0xLTc3NDA3_14172523-c3c0-4e9b-b79f-f9f4c1003637">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900204896d434dda8fac86bae0cf2c69_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTEwLTEtMS03NzQwNw_e979e815-c2d0-41b0-97e5-d01f8a03c160">428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7b9230ef516443ccad9d26677a66975e_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTEyLTEtMS03NzQwNw_38a7dc33-3315-413c-851b-669c6af55694">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id112e58fd1da4992aaabcf75b671635a_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTItMS0xLTc3NDA3_3511f5ee-dd7f-4c17-b845-38e773e59ac6">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69daef85a2cd4f0698981e2468d08268_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTQtMS0xLTc3NDA3_b46bd0f0-41a8-4865-8107-d298d1515695">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id112e58fd1da4992aaabcf75b671635a_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTYtMS0xLTc3NDA3_0c3c3efe-48e7-4b31-951e-197455468209">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a8f26f579b45d49451e22987cfe043_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTgtMS0xLTc3NDA3_ddf15e6c-ea0a-4e54-9d68-771f7da8ccca">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a917baf2b146579258ed0bd76a5682_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTEwLTEtMS03NzQwNw_9245d2e1-9d97-46da-90e8-eb2156864507">1,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i77a8f26f579b45d49451e22987cfe043_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTEyLTEtMS03NzQwNw_ccde8a03-b75b-4031-ac1b-2404c045b747">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70ffc7cf3c884b2296b9598791625833_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTItMS0xLTc3NDA3_3938836d-477a-4202-9771-859e2f863feb">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c8f9a3dd9c847dc8c25bf43d101da5a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTQtMS0xLTc3NDA3_c54c9968-c3d3-42a0-a994-b8c9c04b6de4">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i70ffc7cf3c884b2296b9598791625833_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTYtMS0xLTc3NDA3_114dbbf2-aea0-44d0-b490-01bec53f2994">3.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ddcdd029114904a3d37f67d1a5375f_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTgtMS0xLTc3NDA3_f3d76392-afda-48b6-880b-222ebce54cf0">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e00716790544c2aa2782fbaa642b291_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTEwLTEtMS03NzQwNw_305ee796-2803-49be-98b0-c4355d667943">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i01ddcdd029114904a3d37f67d1a5375f_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTEyLTEtMS03NzQwNw_e1658095-92b1-4e84-983d-77ae77b63195">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d366ba8634843b7952c594a0298644e_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTItMS0xLTc3NDA3_392adf84-2e4d-4a19-bc7f-34f00990ccf4">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80589dad11a143ef83bed73c9c636e0d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTQtMS0xLTc3NDA3_3045cced-73b6-4df6-abdd-ab69c913288a">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4d366ba8634843b7952c594a0298644e_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTYtMS0xLTc3NDA3_d6a3a0ee-c230-4e1c-807d-afa27eb5556f">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a27bbab26194f368e984c6efeac7dbf_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTgtMS0xLTc3NDA3_ada063bb-ad5c-43fd-9be0-d031010e8c83">2,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id541227fbffe4cb58cbf08c74d640a31_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTEwLTEtMS03NzQwNw_283a79cc-f8d2-41eb-b8dd-11d685193b2c">2,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8a27bbab26194f368e984c6efeac7dbf_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTEyLTEtMS03NzQwNw_fb9a5d5d-eda3-46bd-914d-60a042a4587a">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35536d5c87534fd7904edf6033b8d2fb_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTItMS0xLTc3NDA3_e761b49e-4eb5-4900-8bfb-857f84de24a6">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab3102676df483cb94d5771c3340715_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTQtMS0xLTc3NDA3_9bd28808-e53a-4e9f-b8a1-ddab81281ee5">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i35536d5c87534fd7904edf6033b8d2fb_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTYtMS0xLTc3NDA3_4dbfaeca-369e-429a-bf33-b567d34547bd">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61e739cf89e04a2ab85cbf458333e420_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTgtMS0xLTc3NDA3_2bc1bbf9-c80e-472e-a075-6d1f2a79983f">827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a347180bf99437b8e59ccf9b456e939_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTEwLTEtMS03NzQwNw_72434eff-9e67-46df-8e8c-e34f035aa965">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i61e739cf89e04a2ab85cbf458333e420_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTEyLTEtMS03NzQwNw_5daebafe-bd0f-4c55-aa32-c23b04644619">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c91bc046b54947b056276f205609b5_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTItMS0xLTc3NDA3_0613b1d3-0cc1-42b9-96a1-ae5fef344c91">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d1d755fe864e0aa2bc11b07fb588d5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTQtMS0xLTc3NDA3_cab83dad-0471-41d9-8c5d-90a2d70bd9cd">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib7c91bc046b54947b056276f205609b5_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTYtMS0xLTc3NDA3_d33885c0-69ac-488f-8ff8-285954e9afe4">4.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861cea3736ba431ea19399c9d74f4a1e_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTgtMS0xLTc3NDA3_e4195035-91d1-49e7-a00f-be8ab91512e2">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0643a60ebf034a56a19d98183b76d940_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTEwLTEtMS03NzQwNw_bbb13930-8869-4ff1-ae99-a2ccef1be885">510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i861cea3736ba431ea19399c9d74f4a1e_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTEyLTEtMS03NzQwNw_7f084ced-c4a1-4bc1-b88c-1a5867dd73ed">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d3bc436e1940458257e25f0366f0fd_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTItMS0xLTc3NDA3_7241e281-c8c9-4c12-8eb4-6a9453ca1035">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee986d724e44b098461eac0f89dfb0a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTQtMS0xLTc3NDA3_5eae7404-9c11-4ca5-aa09-45128e57a8a2">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie0d3bc436e1940458257e25f0366f0fd_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTYtMS0xLTc3NDA3_a4157344-d8ea-4cfe-a237-1f7daab7b707">3.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3461941dfba467a82a64d0fe6a92726_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTgtMS0xLTc3NDA3_daca405b-e0dc-4167-9999-7ede50bacd38">1,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27b82c53a0dc4b3abae2328362331d7b_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTEwLTEtMS03NzQwNw_a86add6f-cda7-480b-a1d0-5303880eee12">1,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie3461941dfba467a82a64d0fe6a92726_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTEyLTEtMS03NzQwNw_638012cb-848f-4f82-9e19-72f0589b893a">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib052e84cde5f4591ac72582a42239b41_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTItMS0xLTc3NDA3_dc228651-234a-4d8e-90b9-8cda101577e5">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd7ffd7738b4d259f17a9f3eed5fe8f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTQtMS0xLTc3NDA3_6deba91d-4c53-4fb2-9a47-1e7cd8ceee72">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib052e84cde5f4591ac72582a42239b41_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTYtMS0xLTc3NDA3_364ef25e-f32a-486c-8655-187b77c7a5b5">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847dce3495ea4ca1a4c5ecbdcdeb9266_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTgtMS0xLTc3NDA3_f41ffb41-70a1-481b-87d2-4a7b2b9aed51">824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id846e2e0c92e48e1a68009c7f0c3ec3d_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTEwLTEtMS03NzQwNw_6461d6a2-450d-4aff-b467-b8a0830e2be5">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i847dce3495ea4ca1a4c5ecbdcdeb9266_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTEyLTEtMS03NzQwNw_e51184ea-a268-4de4-85e2-680af4b35963">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e140ec784341c3bdaa6b9e35a220ad_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTItMS0xLTc3NDA3_2d8e9b06-e3be-4ddb-b4b5-8672c55c1e4b">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9bdd1c6bdaa4f278e3d75778bc8098e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTQtMS0xLTc3NDA3_efb19cbe-e43f-4c96-b3fd-4aab6df40105">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7e140ec784341c3bdaa6b9e35a220ad_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTYtMS0xLTc3NDA3_e1e26adc-6321-4357-8b08-45978d4a9b68">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62f68f5cbaa47839c0b6b490a8f2c4f_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTgtMS0xLTc3NDA3_f817a614-6369-4e47-89b2-022132315c34">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b53f572aa44e899c6d9df9aab6646f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTEwLTEtMS03NzQwNw_71c565ad-f339-438c-8b20-330e2634b7dc">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic62f68f5cbaa47839c0b6b490a8f2c4f_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTEyLTEtMS03NzQwNw_cef64399-9474-4d5b-bde3-df1b8fa4b03c">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bba86c6d32b4bb1a8652b8dd4c5851d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTItMS0xLTc3NDA3_e1cd5d82-e08b-4f75-ab59-eddfe72053cd">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09aa7aa2a79a46fe942e1eab7057a546_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTQtMS0xLTc3NDA3_d531da8d-27a3-47ac-bc2c-e1ac95ed335a">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9bba86c6d32b4bb1a8652b8dd4c5851d_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTYtMS0xLTc3NDA3_4140bb6a-c20e-4c33-b451-e5026879d07c">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c58cf190dba4d119b64a72bea44dee8_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTgtMS0xLTc3NDA3_5c23778a-ad52-4f00-a202-b36b0ba4048d">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35fad42d0e6463995e0600e17c5c1b5_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTEwLTEtMS03NzQwNw_05de47d6-eed3-45bd-b2e6-35e966d9546b">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c58cf190dba4d119b64a72bea44dee8_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTEyLTEtMS03NzQwNw_4325afc0-1a0a-46a9-b0cd-bf8c334fd112">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5565a9f7ec554e8cabd71fcaee639311_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTItMS0xLTc3NDA3_caf402d7-4639-4ded-8e6b-ba03aec291ed">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f344311b3cf48939c39240aac35200c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTQtMS0xLTc3NDA3_2b5567e7-3c8a-48a9-a55e-b2af1cab17bc">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5565a9f7ec554e8cabd71fcaee639311_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTYtMS0xLTc3NDA3_4becd5d5-974d-465b-8fd5-3cac01f0b023">29.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa33272c8bd4721a74234b17b990694_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTgtMS0xLTc3NDA3_17185166-fcde-4c9e-915f-dddc091bcacf">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87579025231469fb10ceb2f4c7cfdcb_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTEwLTEtMS03NzQwNw_4db9d07b-a803-43aa-9993-1d520875a6b3">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iefa33272c8bd4721a74234b17b990694_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTEyLTEtMS03NzQwNw_fd965fff-05fd-4519-aea3-809902e6dc75">31.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99ca9d34e85413ab54b2210dcdfb7fd_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTItMS0xLTc3NDA3_fdd7205a-3ebb-485b-b24e-fe3b1b130169">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e7cfafb6474ef2948dd5e06029902a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTQtMS0xLTc3NDA3_653bc627-e3e1-467e-bff1-12ee11182aa4">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if99ca9d34e85413ab54b2210dcdfb7fd_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTYtMS0xLTc3NDA3_25691fd5-21e0-46b1-85b6-4ebcd27239dd">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia860b7d96f0447f392f5eeac7875c1a1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTgtMS0xLTc3NDA3_549f1649-5c77-4446-8097-8015105a7e59">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2cef51b9a6c41d794a7883c2331934f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTEwLTEtMS03NzQwNw_adb468f6-1d89-4a52-842e-6bc6c4fde406">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia860b7d96f0447f392f5eeac7875c1a1_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTEyLTEtMS03NzQwNw_d2d7e20a-310c-48a2-8f52-00dab75bb075">13.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2605c867ea164850b491768230077fdb_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTItMS0xLTc3NDA3_bce076f7-4bcf-49a5-833e-8c73fd3b20a7">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73ebd1cbb69f4706bf7449a515a56452_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTQtMS0xLTc3NDA3_bb7ce1c4-7321-4a44-b63a-8165b25a8f86">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2605c867ea164850b491768230077fdb_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTYtMS0xLTc3NDA3_12f680f4-842c-4538-9eff-6ccf87de50c9">22.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b836292a904483a2495cd84486214a_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTgtMS0xLTc3NDA3_120fc276-f680-4bc5-97ab-3ebc614a8337">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae4efec9bc24e5c832eb9b323983513_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTEwLTEtMS03NzQwNw_da43cb3a-66f8-4391-af83-9cc01a5ddf9b">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i67b836292a904483a2495cd84486214a_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTEyLTEtMS03NzQwNw_76370a1f-27d4-4dd8-93b8-e06c773d324b">20.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i881f037a08664e86b329cb3e8bac41e3_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTItMS0xLTc3NDA3_5c768719-7d0e-43f6-82ec-df6508130207">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i876e020ffc28486eb2cba4c856c63d96_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTQtMS0xLTc3NDA3_e95cdfc6-0894-4834-87fc-6503ad535300">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i881f037a08664e86b329cb3e8bac41e3_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTYtMS0xLTc3NDA3_0a646aff-c97f-4806-a226-c9c8a46f3caf">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cad11a8c56443738c97c90053bcf485_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTgtMS0xLTc3NDA3_24fc8f65-f233-4ae5-8b97-9fa9d7901456">2,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icad2abe11b5d441f84340fceedeecb5f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTEwLTEtMS03NzQwNw_51efd61a-914a-48f4-bb47-ad5eb20f6bbf">2,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7cad11a8c56443738c97c90053bcf485_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTEyLTEtMS03NzQwNw_4c88fe83-1d6d-432d-a9c3-931baf01eabf">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10b4ecc9ffe3480b8f5dd56a9cd5aa6a_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTItMS0xLTc3NDA3_4f8299fb-8e08-427a-a07f-7094c514591b">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icca30d47d5784736873c33392dc4ae62_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTQtMS0xLTc3NDA3_9f7cdd5c-7743-4409-a4e5-adfa70e9c8c6">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i10b4ecc9ffe3480b8f5dd56a9cd5aa6a_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTYtMS0xLTc3NDA3_68274191-fd36-43ac-a30d-2a1458dedbea">17.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea669ae399404c9ca5423bd557cf0873_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTgtMS0xLTc3NDA3_d7aa8853-8dc7-4868-9de9-21fc7bb03ed7">651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3c8d3f2fb24fcf990880e0ff513c1f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTEwLTEtMS03NzQwNw_2b132ee5-539e-499b-a63b-ed24df92ba41">727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iea669ae399404c9ca5423bd557cf0873_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTEyLTEtMS03NzQwNw_1efe1136-8242-4411-8adf-a72bafeb9aba">10.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i244e58e9444a4e3d9e577108f15d8bd8_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTItMS0xLTc3NDA3_517c518f-f206-4b08-8d9d-584fff8d2896">1,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e4b71f563c40d697c20b57f2ac67af_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTQtMS0xLTc3NDA3_8f839337-a6b7-45f6-a429-48cf78d63c84">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i244e58e9444a4e3d9e577108f15d8bd8_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTYtMS0xLTc3NDA3_e1415e55-1510-49a6-8630-9789904b4e6f">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13674b49cf2b434d99ece35b1733ccb9_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTgtMS0xLTc3NDA3_9ef79ea3-a9a6-4226-ab81-48770c34ae3a">2,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a01e2a70a145dfb1adbbc859b6dd82_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTEwLTEtMS03NzQwNw_79652551-2c80-41db-bfe1-69777dcbbddc">3,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i13674b49cf2b434d99ece35b1733ccb9_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTEyLTEtMS03NzQwNw_383116c8-aa53-436d-80b6-eaa899a9226d">6.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea4a942c29b64296a578054f8bb63c6e_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTItMS0xLTc3NDA3_6302ca0d-1870-4566-9261-44de90b5056c">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838ec4506aac4839afabb56c89fe75de_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTQtMS0xLTc3NDA3_fb31f829-13fe-423a-b2e2-9f7b30e6c26c">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea4a942c29b64296a578054f8bb63c6e_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTYtMS0xLTc3NDA3_bd1341ae-a1e4-480c-8412-51567796d9f6">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43cb13f6753d4651a135658fc71c6eff_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTgtMS0xLTc3NDA3_cd55ceab-a4b2-4195-ae3d-dbbeb3ccd196">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4942e0be0534752a71e7f1ada41cc70_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTEwLTEtMS03NzQwNw_b51feedc-6008-4062-9cf2-23e331c59150">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43cb13f6753d4651a135658fc71c6eff_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTEyLTEtMS03NzQwNw_2faed52e-996e-4d51-bab2-a241593d7c7d">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05be66fafb444a8080fecb6fcd302e95_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTItMS0xLTc3NDA3_0c9becb0-9bf9-42ba-b26f-5537cd579930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida875fcca159482f83502993ab5d5e4e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTQtMS0xLTc3NDA3_88643bdc-9f4f-40d5-827e-7a26b714f8ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05be66fafb444a8080fecb6fcd302e95_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTYtMS0xLTc3NDA3_5e711fd2-fe5e-4b10-9f14-f66fb5f76b76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bb5f16f5ad400fbb4ffb0ed9d46048_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTgtMS0xLTc3NDA3_f9cbe219-ce06-4ff9-bb42-6187073833f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07c17c915a040be98c96fe359fecfd2_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTEwLTEtMS03NzQwNw_3e58969a-8383-47db-aa59-9d1e8e7501f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34bb5f16f5ad400fbb4ffb0ed9d46048_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTEyLTEtMS03NzQwNw_5866727e-55c7-46bc-8f10-3ea584e8efa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdaa89f4a1441e29f7642f5b666eb27_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTItMS0xLTc3NDA3_04ab2642-05a7-4094-839d-4dee942e3324">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de0a5cf540d4fee9c40859ef3796bdc_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTQtMS0xLTc3NDA3_648973f2-f967-426e-a13d-8f5d990e6097">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cdaa89f4a1441e29f7642f5b666eb27_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTYtMS0xLTc3NDA3_90fe365c-b7af-462d-b022-13cc631dcbde">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8138f8e21ac94faf9fe88ce25877aed5_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTgtMS0xLTc3NDA3_279bc62e-2b1e-4fbf-bda4-b2321267a99b">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5898c52cfe945779c5143c8df491534_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTEwLTEtMS03NzQwNw_e11644aa-6751-4f5a-b570-041bd2560493">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8138f8e21ac94faf9fe88ce25877aed5_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTEyLTEtMS03NzQwNw_e29c9627-15f7-46d5-9665-c61db1cbc6b8">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA / INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68c5d8ed136a4c20816e313a4c90b13b_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTItMS0xLTc3NDA3_4ed1fefc-8fb3-4549-a686-63a3554aa6d3">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e5afc3d50e4e4ca0a187ad6b9f1a6c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTQtMS0xLTc3NDA3_b31756bb-4a91-4165-94dc-07a42628cc3c">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i68c5d8ed136a4c20816e313a4c90b13b_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTYtMS0xLTc3NDA3_bb7001f2-888a-4151-b7ca-e97993ed55d9">25.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie37eb67f7b144c5eb518c4948cf96145_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTgtMS0xLTc3NDA3_ce2b778b-0ca3-4b0a-8daf-5fd72ddc8492">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85dda44763ba4414829f3605a73753e0_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTEwLTEtMS03NzQwNw_7c547968-084d-42bb-9d7d-2476c9c6d48a">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie37eb67f7b144c5eb518c4948cf96145_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTEyLTEtMS03NzQwNw_e290d45c-c166-421a-b237-5ad520aaf6eb">34.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9b58f0b50e427692c9798179519c8c_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTItMS0xLTc3NDA3_56e7f97b-8c71-489c-a5c7-02ad4c7d171f">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf9944934bf44f41a5d848a08016534f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTQtMS0xLTc3NDA3_60c4a047-ce44-4dc3-a2c3-52088461dbbf">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e9b58f0b50e427692c9798179519c8c_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTYtMS0xLTc3NDA3_4d70f9a8-edc0-4e62-88e4-3415270fedd1">11.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4e187060bf4b56af8469e2457ad148_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTgtMS0xLTc3NDA3_d8092904-78e2-40c5-925d-a37570c250bf">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53914db7b6994764b67ebd82cd5d70b1_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTEwLTEtMS03NzQwNw_d0d89fb7-ce76-4fd1-bf6b-bc7226040e1f">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8a4e187060bf4b56af8469e2457ad148_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTEyLTEtMS03NzQwNw_31569bdc-5795-4ce7-97fe-7ed0f81b912e">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e6c0eadbf94d859fbb92d57ca15229_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTItMS0xLTc3NDA3_948e08a9-a2e8-4984-ac58-fb361df640d3">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbec97fb95be414cb2b89e264202246c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTQtMS0xLTc3NDA3_5aae144a-d10e-4b5d-aed9-05bf14f6ef59">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i29e6c0eadbf94d859fbb92d57ca15229_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTYtMS0xLTc3NDA3_37c4bc9b-1d0b-4543-88e0-9736e1008c8d">18.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0297066eac1245ce913a0df991220e7d_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTgtMS0xLTc3NDA3_6bfe21e1-2d7d-481e-a6a3-bf07fe7601dc">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5b7a4bbda24f7f9fcc5b69ed4a9435_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTEwLTEtMS03NzQwNw_cfb577af-68c6-47e3-b972-b020a7244dc7">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0297066eac1245ce913a0df991220e7d_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTEyLTEtMS03NzQwNw_45a2ebf1-6857-4740-8956-558fd2d7226c">19.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722ea23e5f924f16a6e6c00652075eba_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTItMS0xLTc3NDA3_6b4f5241-f65d-4023-aa59-a109483a6a45">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if177d277829c4cf39e15833c514ec56f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTQtMS0xLTc3NDA3_7ee684cd-377c-405f-b474-4d7db431ea2a">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i722ea23e5f924f16a6e6c00652075eba_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTYtMS0xLTc3NDA3_776e7f55-123e-4ec7-a2ad-7e97a48d344c">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29aa768ec65741dc949cd342666e4f34_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTgtMS0xLTc3NDA3_b3903ef0-7aaf-4bb8-ab0f-1fbeb33a8325">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife790b9884ac4cabbd776e36f99b03af_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTEwLTEtMS03NzQwNw_6c8fc756-ec09-4715-9400-58ca866fc88d">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i29aa768ec65741dc949cd342666e4f34_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTEyLTEtMS03NzQwNw_881b739e-18e4-43b5-b987-89d2a9440ea8">12.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad125a62b6946b1b33566216a51ed56_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTItMS0xLTc3NDA3_982e70ba-98a1-4111-936d-161ffd7d4702">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie42b6679085b4580b95eb6119e492e4c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTQtMS0xLTc3NDA3_3f5ab6a8-7108-411a-87cf-3e3f7d687134">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8ad125a62b6946b1b33566216a51ed56_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTYtMS0xLTc3NDA3_237d6184-999b-4131-8690-13a2fd9c96cd">20.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e27d7094e94cc8af96f23c67b17244_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTgtMS0xLTc3NDA3_c14e7ce8-9114-4fc3-8e25-f328c6e254b7">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fbc058d591f475e80e0b7c6171f743d_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTEwLTEtMS03NzQwNw_2a96f201-d388-4834-a107-b51d63cc3976">533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if6e27d7094e94cc8af96f23c67b17244_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTEyLTEtMS03NzQwNw_78c8c6a1-b717-433e-9b48-1b0322a3186d">14.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305a29aa90b04a249642618470269a81_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTItMS0xLTc3NDA3_9f6d6125-c8ff-4bc5-bb72-94533cac0023">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065d4da56934430d83b7760ca1e819d3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTQtMS0xLTc3NDA3_310a0ae6-4411-4e59-bdaf-8d268a2eee45">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i305a29aa90b04a249642618470269a81_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTYtMS0xLTc3NDA3_695c22f2-9519-4a5f-9599-2251d8e8eb3e">12.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564acf556d06473886229ffaf87f0863_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTgtMS0xLTc3NDA3_f2b18eb4-cfc3-4326-8afd-a58929d6f7c9">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8bde317222d4d88bda353d061dbd018_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTEwLTEtMS03NzQwNw_366b1f59-d009-4e30-a0bd-1162f0d8378b">869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i564acf556d06473886229ffaf87f0863_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTEyLTEtMS03NzQwNw_8c172611-c6a4-4f0c-aa48-f1e95c860ee1">13.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ceeea82fd7e49d6a825cf5247584a5e_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTItMS0xLTc3NDA3_468f30d8-4c4d-4e16-b087-dba79f7b0c70">7,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5ce8f1fae8494f9167e95a0acaaeb6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTQtMS0xLTc3NDA3_0c3a6499-b4e4-4796-9085-9ce34da713ca">7,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ceeea82fd7e49d6a825cf5247584a5e_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTYtMS0xLTc3NDA3_6b1a0b57-6dd5-449b-900b-b10fcd4faadd">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f7fb6c7a194120a4df7e29ac654467_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTgtMS0xLTc3NDA3_4a9c197d-9e38-49d1-93cb-f07329ba3998">21,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb546e3766343bf9f6063a3941899a5_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTEwLTEtMS03NzQwNw_d4fa4b6e-35a8-4c85-8f35-8b792c129818">20,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03f7fb6c7a194120a4df7e29ac654467_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTEyLTEtMS03NzQwNw_336c24d9-c73d-4294-b53d-4c41871758bc">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f10cfdf4b7c497b8b6044b5b86bf524_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTItMS0xLTc3NDA3_359980ba-fe71-4a52-abf0-08655e170e8b">5,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818389fdcd8e4be3bf8813b2e25a407d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTQtMS0xLTc3NDA3_6eeb4330-672d-49c9-a209-1746c3e12b5d">5,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f10cfdf4b7c497b8b6044b5b86bf524_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTYtMS0xLTc3NDA3_ddadbc47-dd0a-43c1-9175-069505637450">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f381374d0cb4d7d863372ef4c0e1356_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTgtMS0xLTc3NDA3_26f6e2e5-2494-4d88-a6e8-ee4836ec2297">18,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d82aed0673478d9b0ab5456d859fc6_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTEwLTEtMS03NzQwNw_9969d362-8df0-475f-a9be-739057125396">16,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f381374d0cb4d7d863372ef4c0e1356_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTEyLTEtMS03NzQwNw_882551d9-17ef-4c81-844a-601bca10fd20">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i680f6194af6c4f068b01fc50ebebf2bc_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTItMS0xLTc3NDA3_d11b99a6-415b-46d4-b841-4a6672aa9447">13,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e4a4d3e8ab4d7eb48f7cc386ceeb8c_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTQtMS0xLTc3NDA3_bbe1691e-1011-492a-930e-3a8506fe5fc8">12,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i680f6194af6c4f068b01fc50ebebf2bc_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTYtMS0xLTc3NDA3_fa0ac1c6-8c37-429e-9019-5f6b609bc4ea">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i470f1742dc564aceade9de615023f5d9_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTgtMS0xLTc3NDA3_7c390e92-87f0-401b-aef2-931db7f9279e">39,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499f24d8dbf843af8dd118f4348d0ab6_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTEwLTEtMS03NzQwNw_5f9988cf-636a-4a27-a525-52a6dd5a0a7d">37,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i470f1742dc564aceade9de615023f5d9_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTEyLTEtMS03NzQwNw_14f04e7a-b33e-4fe7-9f0e-6f8b18ded687">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i7a233380fa534adebcd628534e5f533e" continuedAt="i749b6da3dcd34b2ebc3d8fe02f1c29f1"><ix:continuation id="i968d093b8f2143a3aa9c57820f65a4ab" continuedAt="ib2efdde4d62f43dba2e63e3f22daecea"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib458d25a886746158cfacde3445cd6fc_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTItMS0xLTc3NDA3_735039ea-04d6-47d5-8627-5330bf5ef52a">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0430caf022a942bdb0f6cdbd46b04bac_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTQtMS0xLTc3NDA3_3d88f6a1-d97f-41d9-8d76-5c26bb44009d">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib458d25a886746158cfacde3445cd6fc_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTYtMS0xLTc3NDA3_c938e0ee-dc78-4091-ac0c-8811d3ba30f3">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ef391ad36744e5a7cca822a0d2390d_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTgtMS0xLTc3NDA3_b2a002ed-f7fb-444c-9286-5155950c51a4">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8778f377a1564158aa09c4c776f50a1e_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTEwLTEtMS03NzQwNw_ee19f447-6a93-4cec-8e9f-8c4d20e91225">1,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7ef391ad36744e5a7cca822a0d2390d_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTEyLTEtMS03NzQwNw_8c48d3e1-fa25-4af3-972c-b9cb0cfdd2ca">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc078949f249451895be35c4a94e683e_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTItMS0xLTc3NDA3_0442f9c8-9c4d-4508-b94c-b1d0b3380816">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577a1cff490044bfa62a9e2f3af70a8a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTQtMS0xLTc3NDA3_25ed1f9a-ad48-4a0d-8dce-0a4581fee68e">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc078949f249451895be35c4a94e683e_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTYtMS0xLTc3NDA3_48a76f98-e913-4fff-9aa0-ce9ae56dbf20">0.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3a87266183456fa1a996407ff90f9d_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTgtMS0xLTc3NDA3_7c38dfe4-ebcf-45b5-af8b-0a4fa9666547">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df5dd26fd074767b958cd1516adf6ea_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTEwLTEtMS03NzQwNw_35a013dd-21d8-4019-8396-30e45443fa6d">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa3a87266183456fa1a996407ff90f9d_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTEyLTEtMS03NzQwNw_ce8eebdb-c334-49e4-b7d5-6fe47ec07271">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe5ed9c09394a3ead9cf56afedcc350_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTItMS0xLTc3NDA3_8532c240-20b7-4c5f-9a27-6b47ff54d410">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392724c4d2c743918e9611261847ffc2_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTQtMS0xLTc3NDA3_ebd5dfd8-6dba-44e3-ae42-d3a197d6e7c7">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2fe5ed9c09394a3ead9cf56afedcc350_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTYtMS0xLTc3NDA3_766c4779-5f5f-4563-a669-121940604f3a">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff24f989dc2649e0a841bfefa2388270_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTgtMS0xLTc3NDA3_e7af085f-0f28-481c-ad04-afa92e868459">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f74ff91d6b439183caba093e33753e_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTEwLTEtMS03NzQwNw_e379c65a-0254-4b69-b2a8-8d47028e3650">2,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff24f989dc2649e0a841bfefa2388270_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTEyLTEtMS03NzQwNw_3fdd1a73-d7c1-4d58-ae87-a3504775eaed">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd824b5eee841079ac4190b0b4c2ded_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTItMS0xLTc3NDA3_15d584d4-dcda-464e-9b03-69c0e1cf9d78">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id063a0459cf44210877c1484ef7c45a0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTQtMS0xLTc3NDA3_0301ee3b-249d-49ad-bb07-c4c888dce78e">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3bd824b5eee841079ac4190b0b4c2ded_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTYtMS0xLTc3NDA3_c2da1b79-bb2b-438c-8fd5-83ed30d91aaa">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cbfd51374014b128d8615d36bec5484_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTgtMS0xLTc3NDA3_44699a29-0719-4657-9626-f2c8975976a5">3,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aa376f5433c40de98c137cab1b41421_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTEwLTEtMS03NzQwNw_cf4ad064-c03d-4564-8765-239eb7aff4a8">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cbfd51374014b128d8615d36bec5484_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTEyLTEtMS03NzQwNw_7098b416-3fe4-4c26-82b6-3c9ba2bcb4b1">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i038004c2490c4105b96321ee95665011_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTItMS0xLTc3NDA3_a24f60b7-a19b-4fa5-a568-7d53b819cdc7">785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5f92f7db04a4642b0601560adc62b41_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTQtMS0xLTc3NDA3_0948852e-cc32-4f93-a987-ba1a7de0ad8b">843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i038004c2490c4105b96321ee95665011_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTYtMS0xLTc3NDA3_0753a207-561d-43e8-98d7-f0115fbb71b2">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe31a46ec13474db2f9953a95a8ebf1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTgtMS0xLTc3NDA3_5b0fd4f9-bd13-4211-8e6e-ee358ac9ced3">2,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e24057824445669dc06fd3fa613c19_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTEwLTEtMS03NzQwNw_d06bb938-c23f-4971-91e4-f219d1607f26">2,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iffe31a46ec13474db2f9953a95a8ebf1_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTEyLTEtMS03NzQwNw_7178ecee-a6d9-4605-b1ec-c2e3189a3c55">4.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bf3746768844207b9687743172b8829_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTItMS0xLTc3NDA3_a51a46d6-1cae-44aa-bfc7-7346dc1eef85">2,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b31eb5bc05146f6bd4d2d78e8fda6ff_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTQtMS0xLTc3NDA3_e3c4ac7c-f222-496e-9d7e-1b2ca6e224d4">2,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9bf3746768844207b9687743172b8829_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTYtMS0xLTc3NDA3_bee470b8-3cbc-470e-acb2-b6db50f320f5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4170b6c793743a092f6c56a49529637_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTgtMS0xLTc3NDA3_318422ef-0832-4684-bcd1-3364a4651359">6,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092927032fbf41288117417bd83c8d33_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTEwLTEtMS03NzQwNw_f4c419c6-bf2a-4adf-98f7-e9c488f823d0">6,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4170b6c793743a092f6c56a49529637_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTEyLTEtMS03NzQwNw_3b3544a6-faa4-4922-bf36-9a6acf51b724">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2847269390c248719305140d646fb64d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTItMS0xLTc3NDA3_5d98d112-932b-46fe-bc45-411cb76eb3ae">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7be44d585f94dd1b4e8bdccd9f72fcd_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTQtMS0xLTc3NDA3_6ef1adb2-86c8-4d39-bf73-43bbf6f46ce2">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2847269390c248719305140d646fb64d_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTYtMS0xLTc3NDA3_09ef40b2-186d-45de-87ee-fc152ce5b807">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd97ec22af24e1aaafd19a24d6e9286_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTgtMS0xLTc3NDA3_a39fe74e-c0f2-48b1-ab54-9f6297dfdb64">693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0dde31e99e496dbedc1e0f945ca70e_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTEwLTEtMS03NzQwNw_5d959bb7-5c1e-4e0f-a14c-db3b881cb3f4">651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8cd97ec22af24e1aaafd19a24d6e9286_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTEyLTEtMS03NzQwNw_db2b5215-fa1a-4aef-b2ea-e66b76c10bb1">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9417a55ca564c889c26bac785e05477_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTItMS0xLTc3NDA3_573ec7b4-e53a-4def-932a-e8715a772764">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae91066041f4be1b8f92b78864de25f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTQtMS0xLTc3NDA3_75633c37-8fad-44e3-bd66-fc02000856ae">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib9417a55ca564c889c26bac785e05477_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTYtMS0xLTc3NDA3_5adb204e-e500-485c-97c7-d8ce001f7283">15.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974d64a21e4f41528433f1336946ceed_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTgtMS0xLTc3NDA3_03c289e7-d780-452a-a668-7853f0a412af">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f9110d30d29404584bef97cc4a24dd1_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTEwLTEtMS03NzQwNw_4e7ac24f-02cd-487f-a2de-9e60b3524a5f">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i974d64a21e4f41528433f1336946ceed_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTEyLTEtMS03NzQwNw_6b37614d-af77-4c23-b104-ae71c60473e5">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9cd6cfa9d6a40558ceef771622f76b4_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTItMS0xLTc3NDA3_2084a9e1-173d-408d-9b09-4d51d018803e">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbc22c2972644793b32196e789568db5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTQtMS0xLTc3NDA3_0536de5a-6d20-4407-8bd9-3c233dd45776">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic9cd6cfa9d6a40558ceef771622f76b4_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTYtMS0xLTc3NDA3_e5bd93ca-5174-4e66-94bd-79984e4fd807">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7c3c999eaef4151b4669dc63eb4030a_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTgtMS0xLTc3NDA3_1793e12d-a2a9-4203-8179-60bc9c00540e">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3e2207be87140cab8ceaa62aa0d6044_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTEwLTEtMS03NzQwNw_eeba0878-b84d-4c4c-9716-367e5eab513b">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7c3c999eaef4151b4669dc63eb4030a_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTEyLTEtMS03NzQwNw_282533c4-0d88-49e2-b3f3-2309949a67f4">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9429a289df048cfa5ab4fdd10126b5b_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTItMS0xLTc3NDA3_27ca44e4-be71-4c43-9f54-05a2e6e8a8cf">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd65d3eab964c75adc84d3231cdbf0d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTQtMS0xLTc3NDA3_71da9903-bd01-4f1e-8d09-129ed260b85f">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9429a289df048cfa5ab4fdd10126b5b_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTYtMS0xLTc3NDA3_cb9ed2f2-7d02-4fe1-93c0-960df50f39c7">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cae4423d64f4d4bbfe2cbf8df84e736_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTgtMS0xLTc3NDA3_1d699ee8-11e3-4e0a-b1ce-ebcc27229cf5">620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a87b0c3795491d8cb754d008abe491_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTEwLTEtMS03NzQwNw_00bf82c3-3e14-4324-8964-9b62ba74ba97">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5cae4423d64f4d4bbfe2cbf8df84e736_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTEyLTEtMS03NzQwNw_b2071c6e-dc8d-4159-a3d7-dc263943d54b">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3f7fda8dc45a4acd129a76f977cd3_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTItMS0xLTc3NDA3_fcace501-bb51-4b0b-a865-e916d52f5cdc">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7efc4792ae7f465ab37467091fef4a2d_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTQtMS0xLTc3NDA3_536d3199-f1c2-487e-bae2-770e49a77cc0">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i26b3f7fda8dc45a4acd129a76f977cd3_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTYtMS0xLTc3NDA3_cacfcb1d-bb4e-41ba-b0c8-1f0b8d2bb8a0">12.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97fdcab14626459db0701cecead7f119_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTgtMS0xLTc3NDA3_0051e27f-4adc-4dad-adf3-b96967d90b4f">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855d5f8389ac44e5abf80391fa0ee110_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTEwLTEtMS03NzQwNw_c777d6ef-533d-4da8-9446-10b770915950">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i97fdcab14626459db0701cecead7f119_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTEyLTEtMS03NzQwNw_01e51fa6-7dcc-4a30-bffb-b2bf823bfedd">4.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d6094b282dc44208ebf68078e1e3b34_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTItMS0xLTc3NDA3_968a7298-f731-431a-8f91-8d4e3658465c">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic907c783f0ed4d86bdb6abb9d2580af7_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTQtMS0xLTc3NDA3_6ab17021-b72e-45df-b74b-f84994abbaa7">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d6094b282dc44208ebf68078e1e3b34_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTYtMS0xLTc3NDA3_de5b641b-e5fd-49de-b435-62afaf1ec73a">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3281cef57f094b31b7cdacddcdaf74a8_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTgtMS0xLTc3NDA3_3b05cfa2-9b1f-4965-ac58-7dbfa748ea7a">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d05e3bda784d0d9ae066ae87e26eae_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTEwLTEtMS03NzQwNw_05639c6c-180a-43c9-83c6-e5e3d86b500b">983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3281cef57f094b31b7cdacddcdaf74a8_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTEyLTEtMS03NzQwNw_f6e198b6-588d-462f-b35b-0edb7ce2ffaa">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib707a9c98f6b4c618112fba387110572_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTItMS0xLTc3NDA3_d72dddaf-bbf9-4166-b264-f7a37db61e34">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic13deb7b513e4e2281a5b9c7dcd54fb8_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTQtMS0xLTc3NDA3_31f2592e-dfff-4d7f-b0ac-537e67dc2072">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib707a9c98f6b4c618112fba387110572_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTYtMS0xLTc3NDA3_6d04bfb4-5b8c-4d3d-89af-90392489793c">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2452e5e77d4264a2a230717da020d1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTgtMS0xLTc3NDA3_84c7a1f1-e5cd-4b3a-b3b1-3c0960b45e55">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95095593fff6463d893fd017b40967ea_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTEwLTEtMS03NzQwNw_2d790786-1fd0-40a4-9542-a9878b7004be">1,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief2452e5e77d4264a2a230717da020d1_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTEyLTEtMS03NzQwNw_c677d293-7fd0-4eba-82b9-222ba4e8ed46">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ce74ed131d46019830ea323390afd8_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTItMS0xLTc3NDA3_d1f1a0d2-e126-45f4-8f61-5fccd975f163">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb897375b8384ad0bed6f189fe441473_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTQtMS0xLTc3NDA3_c8892014-50e0-4c0c-9c63-62b6b22b639e">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0ce74ed131d46019830ea323390afd8_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTYtMS0xLTc3NDA3_42ac3194-dd30-4d08-a311-b5f755720dbd">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7368c2116cf4338b2809934b019406f_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTgtMS0xLTc3NDA3_92619ad5-92e9-42e5-b311-aa3e6866de26">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i372b1bcd430544318ad85558939c89df_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTEwLTEtMS03NzQwNw_3f11a529-b49d-4959-8b0c-bb697cb18c74">805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id7368c2116cf4338b2809934b019406f_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTEyLTEtMS03NzQwNw_c009be18-8b48-4b5d-8934-aec62c5d1be4">7.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec4f3ba11ea4d6b88b6d131ffd28198_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTItMS0xLTc3NDA3_a167598c-9215-4048-865d-b84e9d45d2f8">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe322b23cff240edbba0ccd9e2b833c8_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTQtMS0xLTc3NDA3_e4fcc5b7-5ed4-46c6-86bc-0dfc4bee707e">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ec4f3ba11ea4d6b88b6d131ffd28198_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTYtMS0xLTc3NDA3_e0c00f7e-8240-4ee3-9346-497673c93608">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34035b45a76f4ade91be1a7e5f2dd59f_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTgtMS0xLTc3NDA3_ddbc4127-1d21-4a0d-a77c-9b8344871396">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic700316f668447918923186ca5e57289_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTEwLTEtMS03NzQwNw_648c16b7-96a1-49c6-b387-60d2748c7867">2,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34035b45a76f4ade91be1a7e5f2dd59f_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTEyLTEtMS03NzQwNw_2741b38e-3eec-4a44-be6f-b2431053cb28">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58690ca930484006850c26e283195c51_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTItMS0xLTc3NDA3_4fe66eb7-6ce2-47ed-bd9d-c9cce3b9cdb0">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a3ef38541d04372a83ca49403db6011_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTQtMS0xLTc3NDA3_ef22f886-a7a4-4069-bd2d-586023897de2">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58690ca930484006850c26e283195c51_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTYtMS0xLTc3NDA3_cba10df8-4304-4c1e-b09d-2a0a53fb6041">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a94b325e9bc4923bb6d5064b162cbb1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTgtMS0xLTc3NDA3_73b9ffae-4516-4a00-970e-37801fc879f1">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia30996795fa94ea6b9c7db00253f7c7c_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTEwLTEtMS03NzQwNw_b481aa32-62c6-49e0-a211-59439a455062">1,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8a94b325e9bc4923bb6d5064b162cbb1_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTEyLTEtMS03NzQwNw_530c917d-01a4-4d06-91d5-9f27d6a277e9">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc66fc1dfb74e039295ae639e9205c3_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTItMS0xLTc3NDA3_9f658e3c-63db-470a-9db6-22f4fcc6ea22">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47a2e3c8bb504b308a68c7504052a8cc_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTQtMS0xLTc3NDA3_85809c7c-a94e-4e90-9d40-7af8112f7035">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="icbc66fc1dfb74e039295ae639e9205c3_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTYtMS0xLTc3NDA3_0989e131-3b2f-48cf-97ba-641369622531">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b794e63d907423bbad6d7dfdc91be50_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTgtMS0xLTc3NDA3_9bca8211-819a-4820-aa1c-03378c5909d1">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33bcbb3a06994413a39168066fba21c0_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTEwLTEtMS03NzQwNw_35c91964-25cb-43eb-9dcb-47772767b31d">952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8b794e63d907423bbad6d7dfdc91be50_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTEyLTEtMS03NzQwNw_cc0a0b97-95e8-439d-bb3d-206519073e3a">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i391427c923714920834b2e9cb41cb698_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTItMS0xLTc3NDA3_18cf1fdf-d27e-4c9d-b740-9b6fffd26aef">708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b326613e99b4043bfe3af2bbeeaf963_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTQtMS0xLTc3NDA3_0a5d433c-5829-4b59-ba04-51ba4a278113">706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i391427c923714920834b2e9cb41cb698_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTYtMS0xLTc3NDA3_132de5f6-61ed-4e83-88b2-347af736e560">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b0ad3859c844e399e58cadb8404920_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTgtMS0xLTc3NDA3_b1f85878-0d2b-4f8c-a6ae-ae7510d31f9f">2,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b0f540aabca4cbb8e8011d5ced8cbfb_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTEwLTEtMS03NzQwNw_def3e8d5-f9bd-4a1d-8d4b-fa7f31e7e437">2,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i37b0ad3859c844e399e58cadb8404920_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTEyLTEtMS03NzQwNw_aca8562e-ff1d-47ec-847a-05e1eeda0ad2">2.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8bf7911a294fd5a9711bf309527dd7_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTItMS0xLTc3NDA3_589527b5-cc26-4525-8b8d-114f59e4e8b1">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic13b79cce02e4ae4924831ae4711540f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTQtMS0xLTc3NDA3_902dc25a-b865-4cb4-9b91-2108dbfb72ac">948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c8bf7911a294fd5a9711bf309527dd7_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTYtMS0xLTc3NDA3_3c705cb9-8df4-41b6-a33a-5e06aee4c507">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19ef6dc106bc4d7d871aedead8e03203_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTgtMS0xLTc3NDA3_133df480-0d48-4945-a637-88ad2a0dbf20">2,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d9e613aba94a1f9b967f1b8b04148b_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTEwLTEtMS03NzQwNw_3a6cfb3b-4f9d-4ed3-ab1c-786ee8fc4eca">2,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i19ef6dc106bc4d7d871aedead8e03203_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTEyLTEtMS03NzQwNw_d54cd679-2982-4545-b711-736278d8ff43">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51efdf97f2214c34a66a193a4ee00409_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTItMS0xLTc3NDA3_81982296-b61c-400d-b7e0-d4de0b41bff9">1,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f710c786d345ffab2ccc1e077da0e5_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTQtMS0xLTc3NDA3_7c22415f-a99b-4073-b5ad-d64a6f167b4f">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i51efdf97f2214c34a66a193a4ee00409_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTYtMS0xLTc3NDA3_564c3c11-5a8c-4653-b49a-ce8a7eca2686">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b737de8e7ed48e9a0f1e473c0fd11b0_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTgtMS0xLTc3NDA3_67a7d3de-a67a-49e0-95c3-695bc82b29a4">4,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa68cd0ebbc649f8b1944c6452cf157c_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTEwLTEtMS03NzQwNw_293d1269-2c37-40c9-85a7-05e38cc5ed18">4,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0b737de8e7ed48e9a0f1e473c0fd11b0_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTEyLTEtMS03NzQwNw_8dd54ffa-5f71-4107-9869-b404246ec0a9">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e651723831f48ba8112b343beaff0d3_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTItMS0xLTc3NDA3_5fe918b6-73f7-4084-ab4c-a2e38404e1b8">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic19353844d9d42988aefc5611b61c81a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTQtMS0xLTc3NDA3_b60bc6ce-d77c-454f-88b0-f9319f0d28a5">2,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e651723831f48ba8112b343beaff0d3_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTYtMS0xLTc3NDA3_3d9fde95-0f52-41d8-8120-4d607519cd0d">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3559fd0b124045a8fa153a444ef33e_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTgtMS0xLTc3NDA3_d3b630c8-353a-4b1d-ae0f-f5e4d2fd522b">7,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38c4456bb5034d83b9f17294fc378c0a_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTEwLTEtMS03NzQwNw_d753d475-2933-48ff-b4b0-d90e34e7e321">7,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc3559fd0b124045a8fa153a444ef33e_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTEyLTEtMS03NzQwNw_b8087cd3-36db-4ad5-b20d-6226eb326aec">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5d3558da8644e909594aa8c7e4e0083_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTItMS0xLTc3NDA3_732ee62a-d1a2-49bc-80b5-0cd7f3d2585c">457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b3e8006e23428f8b7ee7417c102c09_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTQtMS0xLTc3NDA3_54e2f815-ec97-49d6-ab79-7d5d0cec9db8">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia5d3558da8644e909594aa8c7e4e0083_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTYtMS0xLTc3NDA3_f6af0c82-afe7-4fbb-a271-f7b8322df038">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1039c0aa59334e18b5a49bf9c2b74e02_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTgtMS0xLTc3NDA3_6d320bb8-ca46-40d0-8a08-a31c166ff845">1,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1416bbe0bf416081fe7ae31939518b_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTEwLTEtMS03NzQwNw_90a20301-79d6-4572-8ef2-6427f467b155">1,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1039c0aa59334e18b5a49bf9c2b74e02_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTEyLTEtMS03NzQwNw_7f6121ff-b60b-4bdf-b730-f32d1b4f1084">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d4e80547494117a247653eb23d938e_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTItMS0xLTc3NDA3_432354da-eb72-433f-b97e-a79cb0b73f4d">701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7c7b4a1930485390375e2d3bbb3a2f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTQtMS0xLTc3NDA3_22eafc17-32d1-4724-bfbe-a997f4ba2279">705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib3d4e80547494117a247653eb23d938e_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTYtMS0xLTc3NDA3_fc2bf70b-d1a6-4ada-a256-b3cd8be8a03c">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76779eb2bfad4ee1a6a2508e4e75218c_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTgtMS0xLTc3NDA3_a21db887-422e-45e5-963f-65b30085c957">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bb019661ae4ed0a5e67d8131209bf2_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTEwLTEtMS03NzQwNw_abc107ec-0b78-4dfe-b80a-a29e87d7165f">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76779eb2bfad4ee1a6a2508e4e75218c_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTEyLTEtMS03NzQwNw_4e2e2bb3-bfee-4fb5-86a5-47d1be0d0808">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c0711b6e2e4a6087c73758e3f91243_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTItMS0xLTc3NDA3_a4df08a6-7e76-44a1-9d0d-1ccc1bc7f22a">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e3fcd890c242319befd0f7388bfe2e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTQtMS0xLTc3NDA3_d2861147-a246-4fc7-b39d-796362a231b3">1,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70c0711b6e2e4a6087c73758e3f91243_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTYtMS0xLTc3NDA3_fb34db29-bf93-4ea8-9f84-b154f0e21346">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42e396c0efc43a3ba71cd4831b384c8_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTgtMS0xLTc3NDA3_866e50f5-6b73-47a2-a6a6-31277cca7c54">3,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d0c0d174e1e465a968649b402f5cea1_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTEwLTEtMS03NzQwNw_800bfd4a-6e49-42d2-aa1b-04a4367fad23">3,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic42e396c0efc43a3ba71cd4831b384c8_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTEyLTEtMS03NzQwNw_feaa171d-149a-4b25-995e-ab9b778fcd89">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac832e9cf5c414d856dd7230794b701_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTItMS0xLTc3NDA3_63511e63-349d-4f8f-9563-ac99ae99708d">527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida2ad956ed734c17a0b3ce03be3fff11_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTQtMS0xLTc3NDA3_3925248b-6406-435c-9cfb-9d657856d2e6">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ac832e9cf5c414d856dd7230794b701_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTYtMS0xLTc3NDA3_2b1679f0-4755-4584-bf20-66c80d800a9c">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d9be1e0153f4553b7b041b59504358d_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTgtMS0xLTc3NDA3_33ba11fa-daef-44dd-aa9d-4941378c85b7">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d8758d185d4148b85cbe1809fe78e2_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTEwLTEtMS03NzQwNw_19f17a8b-faf0-4028-b90d-83004cac17b3">1,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2d9be1e0153f4553b7b041b59504358d_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTEyLTEtMS03NzQwNw_ce0ac28f-b791-4770-8de9-65ffd483abdf">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e826c2f1324a59aedd22ebe1aca2e6_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTItMS0xLTc3NDA3_7cce9b42-5d89-4915-9378-dd70d93b2f43">737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b09107775e49eaa9df473cb669c97e_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTQtMS0xLTc3NDA3_4d3eb1b9-6044-43a0-b474-8f392144c087">752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib7e826c2f1324a59aedd22ebe1aca2e6_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTYtMS0xLTc3NDA3_fba80c76-d779-4a32-84e8-ec057bf3c49c">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad0196cb82f94a8ea79748ba42931837_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTgtMS0xLTc3NDA3_6f5008af-6e03-4916-bbeb-fe475050b8a9">2,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b2071e56d747afbf128fec4a955609_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTEwLTEtMS03NzQwNw_fead43dd-93ae-48d3-96a6-fe0dec40a1a2">2,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iad0196cb82f94a8ea79748ba42931837_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTEyLTEtMS03NzQwNw_7d60187e-d650-4cd2-8152-a9198e412995">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6af84b75578249b38eb94570b45c8bcf_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTItMS0xLTc3NDA3_4542a229-016d-4df9-b325-b1d8793828e0">1,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i366a7d5e35604a52910d0f6633b551b3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTQtMS0xLTc3NDA3_702c68f5-40f6-4150-b4a4-cdd557a6d22f">1,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6af84b75578249b38eb94570b45c8bcf_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTYtMS0xLTc3NDA3_5bb8135b-0992-4898-9adc-d38ed856aaef">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i640f5e27e4594136be6910021459b067_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTgtMS0xLTc3NDA3_6dcaf866-bf59-4bf3-adb3-652ae1061ca0">3,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d78c321af554254b32b1e3a8a1d3694_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTEwLTEtMS03NzQwNw_fb4925a9-4304-4a25-b047-207df35b7bc5">3,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i640f5e27e4594136be6910021459b067_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTEyLTEtMS03NzQwNw_f9a72543-f77d-4d3e-ab75-7d2fc0043302">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaff737262fdb484bbf75e5931817a490_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTItMS0xLTc3NDA3_b4d39a0a-c606-4ff1-b9b5-3187bdaebac8">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c366e52f34f4c939ba9bb069bc96cea_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTQtMS0xLTc3NDA3_94aa6c5e-f13f-4f4e-8209-b10f31d866fe">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaff737262fdb484bbf75e5931817a490_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTYtMS0xLTc3NDA3_cf729e36-e84d-4cc2-926f-37eb65b03218">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49dade5fbc6447ae87c04ac20252f3ee_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTgtMS0xLTc3NDA3_00496c5f-9b60-4bf1-a68c-41bd36fcc496">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9c2927f6ad471d81601e63f54fc36f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTEwLTEtMS03NzQwNw_b31bedc7-4bca-4c84-b656-bec05b075e14">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i49dade5fbc6447ae87c04ac20252f3ee_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTEyLTEtMS03NzQwNw_d2dbe143-c509-4cfd-8c15-850d3e46f1be">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d94242030db4c6e972f72cfbfe05464_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTItMS0xLTc3NDA3_dc98364a-a3f4-44b1-bbd4-cee2b61b5363">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i158baf5a07fa408c826b2c8d54778c21_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTQtMS0xLTc3NDA3_f61f1977-71fe-4acf-853d-457a245f4813">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5d94242030db4c6e972f72cfbfe05464_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTYtMS0xLTc3NDA3_d0dc4731-ad11-4967-869d-66ee27e7482f">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358c3cd12c24472787b2a36a2550e8c6_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTgtMS0xLTc3NDA3_1d82ae60-b668-4798-8cae-dfb45c6c4805">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a772c8416cf49df88d756da5e9a094d_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTEwLTEtMS03NzQwNw_74f79d01-2f11-4d7e-a55f-b3f63b15e825">2,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i358c3cd12c24472787b2a36a2550e8c6_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTEyLTEtMS03NzQwNw_214d0de1-b3d5-4d4e-898f-00462e64568f">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c59bee76a743e19c22b2e772f8d973_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTItMS0xLTc3NDA3_fec98f45-f794-495b-987b-1382578a5deb">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201e6e46d1c74819a9acfb688922322f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTQtMS0xLTc3NDA3_aa2c7583-06fa-4d5d-9f04-a915b532beaa">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02c59bee76a743e19c22b2e772f8d973_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTYtMS0xLTc3NDA3_07810b2d-b596-4e40-a4e4-090886951a34">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b398a883ec74c3eba875c513b5d8cd2_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTgtMS0xLTc3NDA3_b6b78c76-897a-4abb-a360-c7e9a45410ee">3,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifafc57d6cd754d72bbe14c0919d17e1f_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTEwLTEtMS03NzQwNw_acd15deb-9033-4be3-bef6-8fd7b82bd010">3,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b398a883ec74c3eba875c513b5d8cd2_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTEyLTEtMS03NzQwNw_430f1b19-6534-4654-b84b-225bf75cfb37">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i623b6ae349b44bf9b2853ebb6769281d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTItMS0xLTc3NDA3_f141a941-6fae-40e6-845f-354db5f454ab">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123867d1543d46d9afd6cedaa87c7ed3_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTQtMS0xLTc3NDA3_119228a1-a2b9-4835-8ec4-d61fa9d7216f">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i623b6ae349b44bf9b2853ebb6769281d_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTYtMS0xLTc3NDA3_59cdba0d-cc15-4272-87f9-a810719c0c85">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia200d3ae9c054b709c7195a311b6c9e3_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTgtMS0xLTc3NDA3_47540613-c85d-4f95-b5c6-a1aeaa0459d9">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23f74e989df418392f516e411c8ba59_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTEwLTEtMS03NzQwNw_91289273-4f97-4a82-b029-7c53cdaff945">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia200d3ae9c054b709c7195a311b6c9e3_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTEyLTEtMS03NzQwNw_9fa42715-a6ef-4dbc-bad1-c3d141169ebf">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9146e1200a7f49d3ac965e4dc89a064c_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTItMS0xLTc3NDA3_8147fa6c-8d5d-4f29-bcd3-2355b2b22b3d">503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17622e1e5cdf4287a5ce27533de69c09_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTQtMS0xLTc3NDA3_f990ab97-29a8-4b36-910b-81302b45bd60">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9146e1200a7f49d3ac965e4dc89a064c_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTYtMS0xLTc3NDA3_5e124fbd-23b8-4eb7-8788-2cbc7314e3a3">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15889f3752b64ea98aa7f132f768a0d1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTgtMS0xLTc3NDA3_74641b74-21af-4e8e-baa7-b8ef5ecc56ac">1,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e93bc594b454595aa61c0a479afcfcf_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTEwLTEtMS03NzQwNw_f6f994d8-486c-4c71-8397-beed00afd6c8">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15889f3752b64ea98aa7f132f768a0d1_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTEyLTEtMS03NzQwNw_a5b07beb-5372-46d8-b5ea-a38565a809ae">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40e55fe351984553bed44ba01eed5ad0_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTItMS0xLTc3NDA3_f218c5df-39d5-43c7-8b36-6f52efcfd207">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie132afb6984b4e4d956e2c5e87394126_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTQtMS0xLTc3NDA3_260e347f-f85d-4265-b868-adcd622783f0">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40e55fe351984553bed44ba01eed5ad0_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTYtMS0xLTc3NDA3_8c9232fb-66d1-4d6d-ad0e-da82be6daeb4">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04d49f0375714f51b3b624836cc6d325_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTgtMS0xLTc3NDA3_39636d8b-5cf1-4d32-9e40-60386f5b1603">2,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f897a88b0e9498e84e0922c6ac778a3_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTEwLTEtMS03NzQwNw_f593fd93-045a-4609-a02a-d00d770765a4">2,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04d49f0375714f51b3b624836cc6d325_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTEyLTEtMS03NzQwNw_15d90354-8dad-4746-a57d-5393404f0be8">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i749b6da3dcd34b2ebc3d8fe02f1c29f1" continuedAt="i96be2c99c29447ab86d4b51283391fec"><ix:continuation id="ib2efdde4d62f43dba2e63e3f22daecea"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba76952fd2b4a519af20462218629da_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTItMS0xLTc3NDA3_1c3072c7-ddda-4a9a-abb1-72e942392317">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae82913ec44462fb96a4ca814d6a702_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTQtMS0xLTc3NDA3_1b84f543-f918-4928-8d34-cbb3c1471268">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibba76952fd2b4a519af20462218629da_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTYtMS0xLTc3NDA3_397974ce-a3a6-4225-a5b1-ad3ffad3057a">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eba42d826fe467a9b5e86014b866bdb_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTgtMS0xLTc3NDA3_0608606f-c606-49a9-898b-4a3a659e399f">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ec2459bfe446ec8682b17c888295b8_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTEwLTEtMS03NzQwNw_c390aa6e-cf46-496b-a1fd-1183efebd1a8">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8eba42d826fe467a9b5e86014b866bdb_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTEyLTEtMS03NzQwNw_3a7cddec-99ef-497a-a4a0-276f190ec0c6">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i529501a1b6e049f08c8a55b366fc992d_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTItMS0xLTc3NDA3_03d31dff-ac9a-4967-a79c-aefcac9735d0">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf01c838f2074a85932e153dd373f7b0_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTQtMS0xLTc3NDA3_7f98afdf-d143-42ea-bfcb-3c97f74d939f">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i529501a1b6e049f08c8a55b366fc992d_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTYtMS0xLTc3NDA3_ce4ec366-62eb-4750-b55c-839baf74af76">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2e6ad455cb48d9b9bb5b16d05ff610_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTgtMS0xLTc3NDA3_64bab64f-6c85-47df-9563-a03002a44ccf">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if60b072dec854b1e8dfb55dd85a8118b_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTEwLTEtMS03NzQwNw_72c54545-88ed-4a14-9d7c-e0ee268ac0b1">577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a2e6ad455cb48d9b9bb5b16d05ff610_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTEyLTEtMS03NzQwNw_38758470-3258-4dff-a154-5cdd4a59c882">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i647abea8193b4b739d73a6331f0863b4_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTItMS0xLTc3NDA3_5fdbd7c4-fb25-4a0b-8690-774063dfa662">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de7cde1f8a4671978be90e6b0c20b6_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTQtMS0xLTc3NDA3_6d910608-010f-44ff-9817-e43dbfd74b24">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i647abea8193b4b739d73a6331f0863b4_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTYtMS0xLTc3NDA3_f5bce298-7d17-4638-999d-e033d2d1ba4d">3.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57af817119fa4ecd8f610dbcbd0f3ac1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTgtMS0xLTc3NDA3_72b42ae8-1af0-4c5d-923f-f15bdab116de">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c3910a76f84ce297ae66994c95a35c_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTEwLTEtMS03NzQwNw_bab3dbf1-ad3a-45a5-aa43-3424f1378790">910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57af817119fa4ecd8f610dbcbd0f3ac1_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTEyLTEtMS03NzQwNw_0e0d0fcd-2ad8-4d7b-b119-f8769ea1a700">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4cfbdab95a0435dbfa671be6d271f63_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTItMS0xLTc3NDA3_6d5afd70-6383-4676-b5d1-5ce606e84b02">3,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i643bc69b32254fa0bbda0732674f0a17_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTQtMS0xLTc3NDA3_92c0931f-3304-47ea-a11b-682e4129f029">3,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4cfbdab95a0435dbfa671be6d271f63_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTYtMS0xLTc3NDA3_e9336e9d-e9cd-40f0-980e-8c64236dc684">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e56281ecec14a7c80ff8779c1ca8f17_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTgtMS0xLTc3NDA3_76ad3076-73dc-4875-9b99-212e32819055">9,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25009198d573425d8e230b1a71881f95_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTEwLTEtMS03NzQwNw_1a68d5e9-2928-4740-b8be-45058458d609">9,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e56281ecec14a7c80ff8779c1ca8f17_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTEyLTEtMS03NzQwNw_7e951af0-ec4b-409b-a2e0-5d115044a5ce">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fe8d12a2fd4f01b02c290b548244b4_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTItMS0xLTc3NDA3_40e62fad-9bef-4b40-ba75-6a192afa924e">3,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9452da93d10a4670896f05edcac90904_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTQtMS0xLTc3NDA3_a5a1f79a-642f-47a8-a927-fef088cda6a7">3,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id8fe8d12a2fd4f01b02c290b548244b4_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTYtMS0xLTc3NDA3_e14f3a81-514a-4225-b71e-8e9f2fdf428f">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3e034faa2643de9e74a65652cc9170_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTgtMS0xLTc3NDA3_b802a6a8-f340-4247-bc2f-e48ac6667455">10,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38bfe15254ae44efae8441525503c832_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTEwLTEtMS03NzQwNw_3b60d84b-6405-4d36-8ea5-0f3fc66f213d">10,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iba3e034faa2643de9e74a65652cc9170_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTEyLTEtMS03NzQwNw_d3f45b19-b2dc-4472-b557-5673e1510b69">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc4c09ce590a442181ad6662947c8fe7_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTItMS0xLTc3NDA3_3a336d22-eab0-43fb-bbec-34fb45349935">6,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e9c507ad5b4f6c9505f100acae883a_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTQtMS0xLTc3NDA3_33cf323c-4d4c-473c-8f7f-32a72daaf2dc">6,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc4c09ce590a442181ad6662947c8fe7_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTYtMS0xLTc3NDA3_c6600fae-8a1b-4b41-9b3d-568624d6b1e7">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTgtMS0xLTc3NDA3_6f7fec80-a804-4f22-bfd7-2612873922bc">20,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a34e43a1f6446ecbcaa76509bae0457_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTEwLTEtMS03NzQwNw_bb074d11-0d38-4e01-afcf-b04961fa6442">20,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTEyLTEtMS03NzQwNw_a1b32d37-8055-437c-907c-bf969a208647">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074ce9c3c7514a87bf8e13428ff46900_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTItMS0xLTc3NDA3_0d8595b8-38d7-493c-8bae-26a98ee8755c">12,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd2f05005c0f428383f2f6685296745f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTQtMS0xLTc3NDA3_c620747b-16d8-41c0-b558-99cf02a75496">11,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i074ce9c3c7514a87bf8e13428ff46900_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTYtMS0xLTc3NDA3_476878fa-166c-43ec-b434-5e78b560a1ab">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353ce076e41d4fed82b475f2741cafd1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTgtMS0xLTc3NDA3_b36b98b8-8e6f-414e-8cf4-ed8106a74488">36,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f05af96e15a40369cfe4cd4140d6449_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTEwLTEtMS03NzQwNw_ac938dfa-0b51-48d9-9b8e-a3350f371257">34,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i353ce076e41d4fed82b475f2741cafd1_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTEyLTEtMS03NzQwNw_3bce7cfb-f0d3-45d7-a70d-3f06a2b99aa4">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ffe02d809844979135aec3c5ba4751_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTItMS0xLTc3NDA3_928a7b8f-fe25-47b9-ab53-f6880a1ec2bb">11,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if191b6e468a3476aa02636eb2412f60b_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTQtMS0xLTc3NDA3_80a0c12d-7769-41eb-8106-3975390413c4">11,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if5ffe02d809844979135aec3c5ba4751_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTYtMS0xLTc3NDA3_8c099f03-5b13-4e19-adb7-3fa07740cbc7">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i331c19f370344f7baf99003b536c4f3e_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTgtMS0xLTc3NDA3_e2cfc12b-a846-4821-8d01-748254f3b2f3">35,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d61b35824144f9bcdad8d927f11908_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTEwLTEtMS03NzQwNw_9e525c48-ee45-48cd-91b3-3c08f7b91794">33,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i331c19f370344f7baf99003b536c4f3e_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTEyLTEtMS03NzQwNw_1702f11b-9afc-42d1-8633-37bca21d4ec8">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTItMS0xLTc3NDA3_7e81da3e-ecd4-460f-baa8-8bbacbfe3bf9">23,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTQtMS0xLTc3NDA3_3e7bf816-cc0d-43c5-b45a-afed8da4d0a9">23,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTYtMS0xLTc3NDA3_81d50106-d8f0-49cc-a9fa-7bde49fff754">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTgtMS0xLTc3NDA3_7212cc7f-b7b5-4436-94e4-470cf7fbae40">71,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTEwLTEtMS03NzQwNw_d88e4a0a-3620-4e37-ba3e-d06170ce4eec">68,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTEyLTEtMS03NzQwNw_917de753-caba-4a07-ab98-71cf22e55bab">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Approximately $<ix:nonFraction unitRef="usd" contextRef="i68cff4026c6244d2acead47809054223_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTU2_3a2eac7c-236a-4bc6-810a-3737ca16d27e">0.1</ix:nonFraction>&#160;billion in the fiscal third quarter of 2021 and $<ix:nonFraction unitRef="usd" contextRef="id982a81309df49e9b1b002ff1ac41cae_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjAw_fcfac2c3-4997-4744-bd4c-eb945f9c3f05">0.3</ix:nonFraction>&#160;billion in the fiscal nine months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Previously referred to as Medical Devices</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzU4MQ_bb944dd9-50fb-4125-adfa-ab1475a7f5cf" continuedAt="i9177044bd8c1443c92893c23eefb664d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:36.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie667e5b01edb4ec3a359b1a4b8416940_D20220704-20221002" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMi0yLTEtMS03NzQwNw_0d0c6d94-2dea-4606-8455-3bceb8ae8903">809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadb11728d759451d965568df87db85d8_D20210705-20211003" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMi00LTEtMS03NzQwNw_99b087a2-dcc7-4bb5-b379-6cbe3327fffd">577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf94b8f123d04272bb4b90c496e51b83_D20220103-20221002" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMi04LTEtMS03NzQwNw_5ce7bcfb-70da-41ec-af0f-00dc2ed18f28">2,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815bc18a28fc42afa083e798ae8e6b32_D20210104-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMi0xMC0xLTEtNzc0MDc_93e610e7-5281-4ab9-bdda-b495d1306b85">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy0yLTEtMS03NzQwNw_44e23931-ff1b-4bf8-9a3c-894c13542da4">4,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f9b9a440e17401eaa071454d7751a0d_D20210705-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy00LTEtMS03NzQwNw_a1e83c5f-4584-47b5-b49d-c1cf24014ffd">4,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy02LTEtMS03NzQwNw_6f6deb1e-217b-4322-b0b2-afd9d3f2b315">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy04LTEtMS03NzQwNw_5f71b284-bd8d-4159-9a07-1a0dd6bdc6d0">12,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea81eebb8464de781937770e40b4cf8_D20210104-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy0xMC0xLTEtNzc0MDc_8b566601-5178-4aa6-8853-876e517f96a7">13,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy0xMi0xLTEtNzc0MDc_2269d154-397c-4c8d-8653-578a796b7857">7.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf724f9760f04a4d97e3362a30a8c490_D20220704-20221002" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNC0yLTEtMS03NzQwNw_2ccc212a-8a3d-41b2-bbc1-3ed20e8940f0">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5394d3d3ed644aaadfbfd8d6956ee4a_D20210705-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNC00LTEtMS03NzQwNw_38b62ca6-c570-4cca-89c3-cc35ebfd3362">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb2fc4834df4cee928c01c8ffe451e8_D20220103-20221002" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNC04LTEtMS03NzQwNw_261826bb-614e-4e75-b08e-2ad7a77cd6f7">3,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f562eb61574b4a8135f7a6ff000d61_D20210104-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNC0xMC0xLTEtNzc0MDc_14830d07-6778-48f0-a924-5a1c2f6dbd07">3,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6bb2fc4834df4cee928c01c8ffe451e8_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNC0xMi0xLTEtNzc0MDc_df88b7d8-f0ef-4aa1-83c8-f512b26c255a">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffded04d2e5b4de28d6c73c949492aa9_D20220704-20221002" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS0yLTEtMS03NzQwNw_47cb199b-f46b-4077-bb1b-a4399d6f7cc4">6,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a2695569614474a9334e8de4bd04385_D20210705-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS00LTEtMS03NzQwNw_db1210cb-3697-441f-829f-14f290730c58">4,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iffded04d2e5b4de28d6c73c949492aa9_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS02LTEtMS03NzQwNw_fe85f93e-bb55-45a5-a3c3-363094a0d2ac">52.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb750d153444cfbb2321cb34524ef38_D20220103-20221002" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS04LTEtMS03NzQwNw_b10c4b8f-8831-4c5f-af33-c2474ab6570d">18,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied1e8cdc798340419a8c42b1446f8a47_D20210104-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS0xMC0xLTEtNzc0MDc_762cfeea-d95e-42b6-9d1d-28f23825ed81">18,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfb750d153444cfbb2321cb34524ef38_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS0xMi0xLTEtNzc0MDc_0f43fa08-8f4a-46b7-bd14-a2bce4aa8f00">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifadac292feaa4f469fb02f86ff949995_D20220704-20221002" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNi0yLTEtMS03NzQwNw_74e745ea-6af8-421b-8899-333e0e244fec">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072ffc473a074bf6b2765979c610418b_D20210705-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNi00LTEtMS03NzQwNw_06fac315-d71a-403a-9f08-7fbc68384eed">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5e809531a04e8ebd37dbed6ad36ab8_D20220103-20221002" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNi04LTEtMS03NzQwNw_aabf5515-e2c3-4e15-b89e-0e5555a91a51">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc46250604114f8e80b3e470ae4babdb_D20210104-20211003" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNi0xMC0xLTEtNzc0MDc_a332a9f2-dd41-48c6-92d0-2d2172fa1113">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie667e5b01edb4ec3a359b1a4b8416940_D20220704-20221002" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNy0yLTEtMS03NzQwNw_16f36248-376d-4987-a252-18917b305113">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb11728d759451d965568df87db85d8_D20210705-20211003" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNy00LTEtMS03NzQwNw_688db27d-67c3-41ac-b5d0-a8c6615f311d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf94b8f123d04272bb4b90c496e51b83_D20220103-20221002" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNy04LTEtMS03NzQwNw_0f3e8ba0-5dc2-4f68-b496-814930aa5e6f">619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815bc18a28fc42afa083e798ae8e6b32_D20210104-20211003" decimals="-6" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNy0xMC0xLTEtNzc0MDc_420d666b-de79-4ed9-acd7-7d6137f8468b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC0yLTEtMS03NzQwNw_e623c46e-3d9e-4e2f-aad3-8e7d478eb90a">5,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC00LTEtMS03NzQwNw_62272d25-0194-43b4-920f-cd3a1eb4bdc2">3,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC02LTEtMS03NzQwNw_19fd099e-8a0a-447b-922d-1ee4f05782fc">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC04LTEtMS03NzQwNw_6896312d-021c-4028-a49c-c05a5a99ca7c">17,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC0xMC0xLTEtNzc0MDc_f971c5af-bd98-4612-ab0f-579d47fea24e">17,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC0xMi0xLTEtNzc0MDc_662ce76b-17b5-4846-8df4-9ee171da6588">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*The 2021 fiscal third  quarter and nine months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">**Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ie667e5b01edb4ec3a359b1a4b8416940_D20220704-20221002" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfOTIz_6e0edee6-ac74-40af-9a60-a74f987f7637">0.1</ix:nonFraction> billion in both the fiscal third quarter of 2022 and 2021 and $<ix:nonFraction unitRef="usd" contextRef="i815bc18a28fc42afa083e798ae8e6b32_D20210104-20211003" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfOTYy_177d1333-c7ca-4f89-9cf8-4c15725682d2"><ix:nonFraction unitRef="usd" contextRef="iaf94b8f123d04272bb4b90c496e51b83_D20220103-20221002" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfOTYy_5969c358-81d7-47e6-b32d-e67ed808c360">0.3</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal nine months of 2022 and 2021. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="iaf94b8f123d04272bb4b90c496e51b83_D20220103-20221002" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTAyMQ_f13e0418-588c-464d-83d7-41420e689f71">0.1</ix:nonFraction>&#160;billion in the fiscal nine months of 2022. Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="iadb11728d759451d965568df87db85d8_D20210705-20211003" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDQwNg_35c84ec8-cc90-4ad3-8c6e-1b332929bbed">1.4</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i815bc18a28fc42afa083e798ae8e6b32_D20210104-20211003" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDQyMA_3d4cd530-36f6-4e9e-bcf8-9de3d54b7822">1.5</ix:nonFraction>&#160;billion in the fiscal three months and fiscal nine months of 2021, respectively, primarily for talc related costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $<ix:nonFraction unitRef="usd" contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002" decimals="-8" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTE4Ng_85caabfa-013b-4fec-92d5-37ecf84394f9">0.6</ix:nonFraction>&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTI5Ng_f2de774a-7d7f-421d-92ba-a5bf888ff18c">0.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i1f9b9a440e17401eaa071454d7751a0d_D20210705-20211003" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTMwMw_a6d08831-ec96-4068-aaff-261f0e2d0750">0.8</ix:nonFraction>&#160;billion in the fiscal third quarter of 2022 and 2021, respectively. Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTM4Mw_2def5e4c-cd3d-40b0-8a9d-1f652e06b29b">2.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="idea81eebb8464de781937770e40b4cf8_D20210104-20211003" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTM5MA_4235d194-b60d-4bbd-b206-2b08803eb1a8">2.5</ix:nonFraction>&#160;billion in the fiscal nine months of 2022 and 2021, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i813f5728d4834e4081f50346c8257c32_D20220103-20221002" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTY0OTI2NzQ0NjY3NQ_63d60b12-b1f5-4649-bfdb-691b944fcde7">0.6</ix:nonFraction>&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i96be2c99c29447ab86d4b51283391fec"><ix:continuation id="i9177044bd8c1443c92893c23eefb664d" continuedAt="iec3a000ad47e4297a07cca66b425690b"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A loss of $<ix:nonFraction unitRef="usd" contextRef="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002" decimals="-8" sign="-" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTkxNg_4e5ce5af-7e5d-4dba-a261-33dc135ff8ec">0.2</ix:nonFraction>&#160;billion and a gain of $<ix:nonFraction unitRef="usd" contextRef="i1f9b9a440e17401eaa071454d7751a0d_D20210705-20211003" decimals="-8" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTkzMw_10fd8a05-11d8-4810-8e2a-d3abd7948671">0.1</ix:nonFraction>&#160;billion related to the change in the fair value of securities in the fiscal third quarter of 2022 and 2021, respectively. A loss of $<ix:nonFraction unitRef="usd" contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002" decimals="-8" sign="-" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjA0Mg_aa8c636c-dee9-440b-9eee-57c0be2756a6"><ix:nonFraction unitRef="usd" contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002" decimals="-8" sign="-" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjA0Mg_bc50538d-b337-43b8-8b2b-42f5ee8a3c69">0.7</ix:nonFraction></ix:nonFraction>&#160;billion and a gain of $<ix:nonFraction unitRef="usd" contextRef="idea81eebb8464de781937770e40b4cf8_D20210104-20211003" decimals="-8" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjA1OQ_53099f78-9c37-47b8-b4b1-0763eb33541d">0.2</ix:nonFraction>&#160;billion related to the change in the fair value of securities in the fiscal nine months of 2022 and 2021, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine supply network related costs of $<ix:nonFraction unitRef="usd" contextRef="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002" decimals="-8" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjIwNw_b3a22ed7-2f8e-409f-b089-f2f85a957ace">0.4</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002" decimals="-8" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDM2NA_d7825f34-997d-4739-9590-b835462d5749">0.7</ix:nonFraction>&#160;billion in the fiscal third quarter and fiscal nine months 2022, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ia4268f03b6cf41eb89ecb7ae077eb9e3_D20210705-20211003" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDM3OA_158c6d5b-44fc-44b3-bb93-4c4cc98144c7">0.8</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i72c1a76dec8d49eaa40c1cca89c0bc8d_D20210104-20211003" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDM5Mg_2f2c409d-ec37-4e57-a391-7124b7f80e47">0.7</ix:nonFraction>&#160;billion in the fiscal third quarter and fiscal nine months of 2021, respectively, primarily related to Risperdal Gynecomastia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal third quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $<ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-8" name="jnj:AmountPrepaidAndDueToManufacturers" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjgyMQ_e75e6913-58b6-4d27-aeef-03c485580615">0.5</ix:nonFraction>&#160;billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i6bb2fc4834df4cee928c01c8ffe451e8_D20220103-20221002" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzEzNw_25e58bea-a425-43c6-ab65-0b04bc6a6460"><ix:nonFraction unitRef="usd" contextRef="idf724f9760f04a4d97e3362a30a8c490_D20220704-20221002" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzEzNw_5b3a19e7-b716-4b21-93c6-f16a52cf0be0">0.2</ix:nonFraction></ix:nonFraction>&#160;billion in  the fiscal third quarter of 2022. Litigation expense of $0.5 billion in fiscal nine months of 2022, primarily pelvic mesh related costs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzI3Ng_685f4c52-69ce-4e91-8d0d-23210a84d4a9">0.1</ix:nonFraction> billion in both the fiscal third quarter of 2022 and 2021 and $<ix:nonFraction unitRef="usd" contextRef="i4a34e43a1f6446ecbcaa76509bae0457_D20210104-20211003" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzI4Mw_061bdfb2-ffe5-49ce-ad81-265f78331bdb"><ix:nonFraction unitRef="usd" contextRef="i4a34e43a1f6446ecbcaa76509bae0457_D20210104-20211003" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzI4Mw_a09db157-68bc-4beb-b745-d86005d64774">0.2</ix:nonFraction></ix:nonFraction>&#160;billion in the fiscal nine months of 2022 and 2021, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ia5394d3d3ed644aaadfbfd8d6956ee4a_D20210705-20211003" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzM2NA_65ba53c9-4169-48d6-98a9-1a5a74d5d15a"><ix:nonFraction unitRef="usd" contextRef="idf724f9760f04a4d97e3362a30a8c490_D20220704-20221002" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzM2NA_c617d353-959e-4867-88f8-ffd98cc3f558">0.3</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal third quarter of 2022 and 2021 and $<ix:nonFraction unitRef="usd" contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzQwMw_5fb45733-a071-4668-90a7-63d198fbb563"><ix:nonFraction unitRef="usd" contextRef="i4a34e43a1f6446ecbcaa76509bae0457_D20210104-20211003" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzQwMw_927c9d7a-7046-4a96-9870-40f6d5528d84">0.8</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal nine months of 2022 and 2021.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes an in-process research and development expense of $<ix:nonFraction unitRef="usd" contextRef="ia5394d3d3ed644aaadfbfd8d6956ee4a_D20210705-20211003" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDQzNA_22fe40b1-b00a-4a1b-bc5b-c75e32023c75"><ix:nonFraction unitRef="usd" contextRef="i29f562eb61574b4a8135f7a6ff000d61_D20210104-20211003" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDQzNA_ddd32f36-bdc6-4541-8955-4c82d4f8c9fd">0.9</ix:nonFraction></ix:nonFraction>&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021.</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="iec3a000ad47e4297a07cca66b425690b" continuedAt="i00c6291af36a41dbb82c1e1c36bf0f55">(4)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i00c6291af36a41dbb82c1e1c36bf0f55"> Amounts not allocated to segments include interest income/expense and general corporate income/expense.</ix:continuation> </span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzYwMQ_7d0b7900-bb3b-45e1-8d3e-9ea9cca15029" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:30.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i074ce9c3c7514a87bf8e13428ff46900_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi0yLTEtMS03NzQwNw_5db1b413-0e98-47c2-b03e-509997306ccf">12,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd2f05005c0f428383f2f6685296745f_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi00LTEtMS03NzQwNw_52dc14cd-ce30-4acf-bf34-2ba4fbc5e02c">11,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i074ce9c3c7514a87bf8e13428ff46900_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi02LTEtMS03NzQwNw_3149c0f3-282d-42b4-b2f3-9b7c5d61895d">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353ce076e41d4fed82b475f2741cafd1_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi04LTEtMS03NzQwNw_f087ea79-304e-4bef-87a0-6e62b42dbb56">36,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f05af96e15a40369cfe4cd4140d6449_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi0xMC0xLTEtNzc0MDc_ee35cdd7-1e20-497a-97c0-7181a7d1b712">34,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i353ce076e41d4fed82b475f2741cafd1_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi0xMi0xLTEtNzc0MDc_c33ba4cf-d799-44f4-993f-3b9a861946ed">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c67e57cd4f489992a696a230aaba42_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy0yLTEtMS03NzQwNw_34f27675-a396-46b3-baae-d8bd98eb48b0">5,524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c08f0957c7d4b9e8e627867718f4458_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy00LTEtMS03NzQwNw_3702beb3-0605-486f-98b9-95cf321d4518">5,587</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if3c67e57cd4f489992a696a230aaba42_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy02LTEtMS03NzQwNw_3614204c-8e73-4c36-9699-e27354efe537">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i990e1ccf4a544e3caa982783ffee28fe_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy04LTEtMS03NzQwNw_f7db8fb0-7e63-4a89-ba8c-18941b367cc0">17,633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5068794590a54e5988087731a2a8b4d4_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy0xMC0xLTEtNzc0MDc_064b07ac-698a-4025-846e-aaf5a2ebbd15">16,669</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i990e1ccf4a544e3caa982783ffee28fe_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy0xMi0xLTEtNzc0MDc_92d85196-bb1e-4b91-b97a-09a9271b4d68">5.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c47fac364494aed96246540e7b4f7c7_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC0yLTEtMS03NzQwNw_854cecb4-f60b-4226-99fd-bdf253c61026">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aa4e83b89284abc892194a08d7295b2_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC00LTEtMS03NzQwNw_957db391-8aee-4ad8-8610-24285c043b10">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c47fac364494aed96246540e7b4f7c7_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC02LTEtMS03NzQwNw_1ec9b3c1-0ccd-4240-bac7-71db8bb66eed">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia79ea739fc2a40d89f2755e7e4a01102_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC04LTEtMS03NzQwNw_2c649352-30d1-48b0-89df-8b24f2245c3d">4,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5891042222334a28a0bb7a5e271806af_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC0xMC0xLTEtNzc0MDc_85e8bac0-e8b3-4a10-a087-33f50e5e4d87">4,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia79ea739fc2a40d89f2755e7e4a01102_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC0xMi0xLTEtNzc0MDc_7833e27a-3ca5-46f3-b8a3-8b675524fbcf">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a2cce4e35d4c1297c84a76cb27a899_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS0yLTEtMS03NzQwNw_e6f5848a-52a2-411d-873f-997870be8137">4,252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d27784d12d4bb18f3912c082fcae16_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS00LTEtMS03NzQwNw_1bfead8d-2d81-493f-a20e-95b921b8c4f6">4,288</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i21a2cce4e35d4c1297c84a76cb27a899_D20220704-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS02LTEtMS03NzQwNw_107adf4e-251b-4de2-8a97-56d3d2208533">0.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3d5cdd413d4757984bddf6f14322bd_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS04LTEtMS03NzQwNw_c9eb3823-8d4c-4985-adff-136c9498abaf">12,960</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i751be87313594bb993858ae3c749f84d_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS0xMC0xLTEtNzc0MDc_82bc4fbe-95fb-4ee5-b16b-99809109ae41">13,018</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1b3d5cdd413d4757984bddf6f14322bd_D20220103-20221002" decimals="3" sign="-" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS0xMi0xLTEtNzc0MDc_1d87bed9-0362-4208-8b6d-cc2f3d206892">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi0yLTEtMS03NzQwNw_86680c64-86b4-4189-be86-2561f0e75c9a">23,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi00LTEtMS03NzQwNw_82febc5b-2974-4001-8e70-05a382ef8288">23,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi02LTEtMS03NzQwNw_cd4005c9-4bc2-4b74-a918-f36908251cf4">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi04LTEtMS03NzQwNw_7d491886-ffcc-4dae-9870-9e1f6b0ec408">71,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi0xMC0xLTEtNzc0MDc_8d9f6e1e-0e74-42c6-8ec2-3757279bd35e">68,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi0xMi0xLTEtNzc0MDc_79cc2d8a-d297-4407-bd29-69788d4bbdd7">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 10&#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84Mi9mcmFnOjFiNjEzYjZhNGZlMTQxOTliYmFhYTZiM2U0MmYyYTRmL3RleHRyZWdpb246MWI2MTNiNmE0ZmUxNDE5OWJiYWFhNmIzZTQyZjJhNGZfNDE4_adad86d3-529d-4100-b7c7-95863b660f89" continuedAt="iabc620c684e4426c869f5c95f8eeeea0" escape="true">ACQUISITIONS AND DIVESTITURES</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="iabc620c684e4426c869f5c95f8eeeea0" continuedAt="i065f28ae34424d5480dfdc7faf086128">There were no material acquisitions or divestitures in the fiscal first, second or third quarter of 2022. </ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i065f28ae34424d5480dfdc7faf086128">During the first fiscal quarter of 2021, in separate transactions, the Company divested <ix:nonFraction unitRef="brand" contextRef="i1cf347773ad54fb88be2e997e4827221_I20210404" decimals="INF" name="jnj:NumberOfBrands" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84Mi9mcmFnOjFiNjEzYjZhNGZlMTQxOTliYmFhYTZiM2U0MmYyYTRmL3RleHRyZWdpb246MWI2MTNiNmE0ZmUxNDE5OWJiYWFhNmIzZTQyZjJhNGZfMjUw_5a7fc2d0-7e16-4cd3-930c-b4e4326e5f29">two</ix:nonFraction> brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $<ix:nonFraction unitRef="usd" contextRef="idc76602e6fb84b0a862455dca71e8bba_D20210104-20210404" decimals="-8" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84Mi9mcmFnOjFiNjEzYjZhNGZlMTQxOTliYmFhYTZiM2U0MmYyYTRmL3RleHRyZWdpb246MWI2MTNiNmE0ZmUxNDE5OWJiYWFhNmIzZTQyZjJhNGZfNDA4_c8ccbe33-f53b-4024-894d-f22141bca6e2">0.6</ix:nonFraction>&#160;billion.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 11 &#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfOTkzNTI_2c45093d-657a-4fd9-89eb-668392ff2c0a" continuedAt="i9ec634cc04194d9c901351821ba69005" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9ec634cc04194d9c901351821ba69005" continuedAt="i3d1213b50529483bb8ca51d4c9f832d4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of  October&#160;2, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; XARELTO; body powders containing talc, primarily JOHNSON&#8217;S Baby Powder; INVOKANA; and ETHICON PHYSIOMESH Flexible Composite Mesh. As of October&#160;2, 2022, in the United States there were approximately <ix:nonFraction unitRef="claimant" contextRef="i7ed71c93d9694050bbc60255c39761e2_I20221002" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDM4Nw_3d0adc07-e42b-4b9c-81b5-663bfc812dff">180</ix:nonFraction> plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; <ix:nonFraction unitRef="claimant" contextRef="id4a164f8c9e84a87a27b9958b9f63142_I20221002" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDU0OQ_2a375b64-ad9f-4160-a8ef-52dcc967eec3">1,400</ix:nonFraction> with respect to the PINNACLE Acetabular Cup System; <ix:nonFraction unitRef="claimant" contextRef="i5eea6ea68542417790d4a54103e549ae_I20221002" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDYwNA_29c139b6-1fb1-44e8-bb33-b1495aae69a9">9,400</ix:nonFraction> with respect to pelvic meshes; <ix:nonFraction unitRef="claimant" contextRef="ie08773cd5b344ed58f2677261b44e9de_I20221002" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDYzOA_a0f9dafe-bc22-44cb-b4f5-6087be5487c8">1,500</ix:nonFraction> with respect to RISPERDAL; <ix:nonFraction unitRef="claimant" contextRef="i6eb4e32762af4828a35d4453122c0f42_I20221002" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDY2OA_6121b1f8-1954-48ca-b04c-7b7ee0c6b0c8">600</ix:nonFraction> with respect to XARELTO; <ix:nonFraction unitRef="claimant" contextRef="i7c421f92c4fe44b480312cbb61c76537_I20221002" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDY5Ng_247c2f0c-db6a-4422-a989-ba96f6ff8d93">40,300</ix:nonFraction> with respect to body powders containing talc; <ix:nonFraction unitRef="claimant" contextRef="i494bb8f36e6b4d348f07972031b000b3_I20221002" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDc0NQ_19919991-261b-4d02-b569-0568bbd92514">5</ix:nonFraction> with respect to INVOKANA;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> <ix:nonFraction unitRef="claimant" contextRef="ida7fb50fd03e447e8bfba4781b1f21c6_I20221002" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDc3NQ_ba46afb7-761a-4094-b5e4-bf3b594aacf9">4,800</ix:nonFraction> with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; and <ix:nonFraction unitRef="claimant" contextRef="id34d8d00dc95419c9bd7f8538f501612_I20221002" decimals="INF" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDg0Mg_8e7a47b0-ab1c-46fa-b9e7-b90170950f48">1,900</ix:nonFraction> with respect to ELMIRON. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i3d1213b50529483bb8ca51d4c9f832d4" continuedAt="ib46474bc9b534f57b8d1c987913d19c0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than <ix:nonFraction unitRef="patient" contextRef="i20d66d03f67b4697b74d7d5b092b023a_I20221002" decimals="0" name="jnj:Numberofpatientsinsettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjE4OQ_4db8cee7-7f71-47c3-8698-4a45a0a50b7e">10,000</ix:nonFraction> claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. Prior to 2019, several adverse verdicts had been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia  and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. In September 2022, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia, pending Federal Court approval. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately <ix:nonFraction unitRef="cases" contextRef="icdd65a25b656477ea5bb46da7f0655dc_I20210531" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTIzMDQ_37083326-e47a-43d1-8df2-29747c365f3c">3,600</ix:nonFraction> Physiomesh cases (covering approximately <ix:nonFraction unitRef="claimant" contextRef="icdd65a25b656477ea5bb46da7f0655dc_I20210531" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTIzNDg_67deaa2f-5724-4500-919a-514a60a4f24e">4,300</ix:nonFraction> plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes <ix:nonFraction unitRef="cases" contextRef="i57f785ad2f34433aa2271007ab8726b8_I20210930" decimals="0" name="jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTI0ODg_a4c7c768-a1c3-4829-a264-9a01222d99d3">3,729</ix:nonFraction> cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of October 2022, there are approximately <ix:nonFraction unitRef="cases" contextRef="i5bc38c671bd94c1891fa4b65bac8ec0b_I20221002" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfOTkzNDg_03cb8227-e560-422f-a439-79d72c16c123">154</ix:nonFraction> active cases subject to these orders which are being reviewed and evaluated. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="ib46474bc9b534f57b8d1c987913d19c0" continuedAt="if6557c7883cd47cebcf672df9351e6a1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $<ix:nonFraction unitRef="usd" contextRef="i6e63d8a7e74e42f6a4a9d28176f31ee4_D20191001-20191031" decimals="-9" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTQ3ODI_cde3de10-c9f2-45bc-8b10-cfc307a9cb9f">8.0</ix:nonFraction>&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $<ix:nonFraction unitRef="usd" contextRef="i135a75e1eac047bcb5100f4e1292998c_D20200101-20200131" decimals="-5" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTQ4NjQ_6f24f4d0-c4e1-40f7-ba1a-2447ea338d7e">6.8</ix:nonFraction>&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp; Johnson announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $<ix:nonFraction unitRef="usd" contextRef="i699c1217087e4147b4a39954f40ee65c_D20180701-20180731" decimals="-8" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTcxMTI_420d2d8b-59f6-4cbd-ae37-3740e8a2808b">4.7</ix:nonFraction>&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No. ED 207476 (Mo. App.), reducing the overall award to  $<ix:nonFraction unitRef="usd" contextRef="icf7c3ce8a2b94702bf75c6781069843d_D20200601-20200630" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTcyMTI_5ebaf890-c17d-44b8-8026-7decaebea20f">2.1</ix:nonFraction>&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i4b18def56e5244478a2952bec11e5335_D20210601-20210630" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTc1MzQ_bfc6ce51-3488-425e-84ee-a27b4363a5da">2.5</ix:nonFraction>&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="if6557c7883cd47cebcf672df9351e6a1" continuedAt="i95c7903aedcb44f9a95ca304c4f18dcc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. The briefing and oral argument on the appeal were completed in September 2022. While the New Jersey Bankruptcy Court&#8217;s order effectively stays all of the Company&#8217;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $<ix:nonFraction unitRef="usd" contextRef="i8c83f6e3f6e543809b38536c601fde43_D20211001-20211031" decimals="-9" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMjE0MTM_a94e63a5-33b9-4857-89ce-6db6757f73a3">2</ix:nonFraction>&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $<ix:nonFraction unitRef="usd" contextRef="i8c83f6e3f6e543809b38536c601fde43_D20211001-20211031" decimals="-9" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMjE1MTA_326c2105-4efb-47bd-8cd3-b719d4747f64">2</ix:nonFraction>&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that J&amp;J fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by Johnson &amp; Johnson&#8217;s then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In July 2022, Imerys filed a motion in the Imerys Bankruptcy to stay the Edley Class Action, which was denied in August 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#8217;s insurers (the Mediation Parties) agreed to engage in mediation. The term of the mediation ended in September 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC)  (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i95c7903aedcb44f9a95ca304c4f18dcc" continuedAt="i528be41792854599b1f244791ae952bf"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#8220;talc-related claims&#8221; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiff&#8217;s motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#8217;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record.  In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action. Plaintiff has appealed the Bankruptcy Court&#8217;s order.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery. In July 2022, the Court denied Plaintiff&#8217;s discovery motion. In August 2022, the Court reopened Johnson &amp; Johnson&#8217;s motion to dismiss. In lieu of opposing, Plaintiff made a motion to voluntarily dismiss the case, which the Court granted in October 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i528be41792854599b1f244791ae952bf" continuedAt="ie51e9f1a05d947679eeb489be9d2863b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument. In September 2022, the Third Circuit affirmed the dismissal of Plaintiffs&#8217; amended complaint.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. The appeal continues to be held in abeyance, with the Company being required to file periodic status updates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MedTech</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos.  6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447);  and 9,452,276 </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ie51e9f1a05d947679eeb489be9d2863b" continuedAt="i03b28950995a4a7d94a7e69c78ac8f16"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(&#8217;276) based on Auris&#8217; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the  &#8217;056,  &#8217;447, &#8217;276 and &#8217;906 patents.  In December 2019, the USPTO  denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the  &#8217;447,  and &#8217;906 patents and denied review of the &#8217;276 patent. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris appealed, and  in April 2022, the United States Court of Appeals for the Federal Circuit vacated the decision that the &#8217;447 patent was not invalid and remanded the decision  to the USPTO for further review.  In May 2022, the United States Court of Appeals for the Federal Circuit confirmed the ruling that claim 53 of the &#8217;906 patent was not invalid, vacated the decision that the remaining claims of the &#8217;906 patent were not invalid and remanded the decision  to the USPTO for further review. Auris filed a request for reexamination of the &#8217;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in September 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 (&#8217;234) and 9,713,537 (&#8217;537) by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. Trial is scheduled to begin in December 2022. In June 2022, DePuy filed potentially dispositive summary judgment motions that the &#8217;234 patent is invalid as anticipated and the &#8217;537 patent is not infringed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 (&#8217;180) and 10,517,583 (&#8217;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#8217;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#8217;180 patent, and awarding damages in the amount of $<ix:nonFraction unitRef="usd" contextRef="icb28f8306622475282cfa3ad654e30a5_D20220301-20220322" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDEzNDA_4adac001-14e9-42af-b192-adbec78e1a3c">20</ix:nonFraction>&#160;million. DePuy challenged the verdict in its post-trial motions. In July 2022, a hearing was held on the post-trial motions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company&#8217;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#8217;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2019, Janssen Inc., Janssen Oncology, Inc., and BTG International Ltd. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#8217;s Laboratories Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision. The appeal hearing took place in September 2022. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In April 2021, July 2021 and April 2022, respectively, Apotex, DRL and Pharmascience initiated Statements of Claim under Section 8 of the Patented Medicines (Notice of Compliance) Regulations against Janssen seeking damages in respect of those parties generic Zytiga tablets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> Trials against Apotex and DRL are scheduled for June 2023. A trial date for the Pharmascience action has not been set.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i03b28950995a4a7d94a7e69c78ac8f16" continuedAt="i273fb91c73e84be29a94a0d7246bdc0e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#8217;310). The following generic drug companies are named defendants:  Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. In August 2022, after receiving a second notice letter from Mylan regarding the same ANDA, JPI and Bayer filed a second patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan. In September 2022, Mylan moved to dismiss the second lawsuit. In September 2022, the MDL panel transferred the second lawsuit to the District of Delaware. No trial date has been set for these two lawsuits. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Partes Review (IPR) with the United States Patent and Trademark Office (USPTO), seeking to invalidate the &#8217;310 patent. In August 2022, the Patent Trial and Appeal Board issued a decision instituting IPR.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022, InvaGen Pharmaceuticals, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#8217;310 patent. Also in September 2022, Teva Pharmaceuticals USA, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022, JPI, Bayer, and Bayer Intellectual Property GmbH (BIP) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against USV Private Limited (USV), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg, 10 mg, 15 mg, and 20 mg) before the expiration of the '310 patent and United States Patent No. 9,539,218 (&#8217;218). JPI, Bayer, and BIP are seeking an order enjoining USV from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent, and its generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, JPI, Bayer AG, and BIP </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mankind Pharma Limited (Mankind), who filed an ANDA seeking approval to market generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. JPI, Bayer AG, and BIP are seeking an order enjoining Mankind from marketing its generic versions of XARELTO before the expiration of the &#8217;218 patent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Sandoz stipulated to infringement of the &#8217;770 patent.  Trial against Sandoz on the issue of validity concluded in February 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Sandoz appealed the decision. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Apotex stipulated to validity of the &#8217;770 patent.  Trial against Apotex on the issue of infringement concluded in March 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Apotex appealed the decision.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i273fb91c73e84be29a94a0d7246bdc0e" continuedAt="ide4f954a0d14458f990c23e1a64e9ad6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of United States Patent No. 9,439,906 (&#8217;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#8217;s favor. Teva has appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. A trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. The action has been consolidated with the November 2020 action for trial, which took place in July 2022. In August 2022, the Court issued a decision finding the claims of the&#8217;335 patent are not invalid. Pharmascience appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#8217;s filing of an ANDS (original ANDS) seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Janssen Canada initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex in response to Apotex&#8217;s Notice of Allegation of invalidity with respect to the original ANDS and in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ide4f954a0d14458f990c23e1a64e9ad6" continuedAt="iea38895834ea41f3b661ce87aaf79e27"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of United States Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(546 mg). Trial is scheduled to begin in November 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. The trial is scheduled to begin in July 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SYMTUZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of United States Patent Nos. 10,039,718 (the &#8217;718 patent) and 10,786,518 (the &#8217;518 patent). Janssen is seeking an order enjoining Lupin from marketing its generic version of SYMTUZA before the expiration of the &#8217;718 and &#8217;518 patents. The trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ERLEADA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of United States Patent No. 9,481,663 (the &#8217;663 patent). In August 2022, Janssen and SKI filed a first amended complaint against Lupin adding U.S. Patent Nos. 9,884,054 (the &#8217;054 </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="iea38895834ea41f3b661ce87aaf79e27" continuedAt="i1782ebb4136d40b382e25632a2df0e62"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">patent), 10,052,314 (&#8217;314), 10,702,508 (&#8217;508) and 10,849,888 (&#8217;888) to the suit. Janssen and SKI are seeking an order enjoining Lupin from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents. In August 2022, Janssen and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Janssen and SKI initiated a patent infringement lawsuit in United States District Court for the District of New Jersey against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited (collectively, Zydus), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents. Janssen and SKI are seeking an order enjoining Zydus from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Janssen, The Regents of the University of California (UC), and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Sandoz Inc. (Sandoz), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663 patent and United States Patent Nos. 8,445,507 (&#8217;507), 8,802,689 (&#8217;689), 9,338,159 (&#8217;159), and 9,987,261 (&#8217;261).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, Janssen, UC, and SKI filed a first amended complaint against Sandoz adding the &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents to the suit.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Janssen, UC, and SKI are seeking an order enjoining Sandoz from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;689, &#8217;159, &#8217;261, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">District Court for the Districts of New Jersey and Delaware against Eugia Pharma Specialities Limited, Aurobindo Pharma USA, Inc., and Auromedics Pharma LLC (collectively, Eugia), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the &#8217;663, &#8217;507, &#8217;689, &#8217;159 and &#8217;261 patents. Janssen, UC, and SKI are seeking an order enjoining Eugia from marketing its generic version of ERLEADA before the expiration of the &#8217;663,&#8217;507, &#8217;689, &#8217;159, and &#8217;261 patents. In September 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Hetero Labs Limited Unit V and Hetero USA, Inc. (collectively, Hetero), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507,&#8217;054, &#8217;314,&#8217;508, and&#8217;888 patents. Janssen, UC, and SKI are seeking an order enjoining Hetero from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">UPTRAVI </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, Actelion Pharmaceuticals Ltd, and Janssen Inc. (collectively, Janssen) and Nippon Shinyaku Co. (Nippon Shinyaku) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. in response to Sandoz&#8217;s filing of an ANDS seeking approval to market generic versions of UPTRAVI before the expiration of Canadian Patent Nos. 2,731,370 and 2,764,475. In this lawsuit, Janssen and Nippon Shinyaku are seeking an order enjoining Sandoz from marketing its generic version of UPTRAVI before the expiration of the relevant patents. A trial date has not been set.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Other Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#8217; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#8217; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in response to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution. The parties exchanged opening briefs in July 2022 and responsive briefs in September 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i1782ebb4136d40b382e25632a2df0e62" continuedAt="ib78e16ca2e934d53af2e155483f81d75"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to <ix:nonFraction unitRef="claimant" contextRef="i5473d8ddcca64b71b3e429a13c5bf85d_I20221002" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjYwNDI_b923734e-cb9e-4bfc-afcb-9945330a2945">3,500</ix:nonFraction> lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &amp; Johnson, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $<ix:nonFraction unitRef="usd" contextRef="i533d6a68961b4cbc8e82491aa88f91f5_D20191230-20200628" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjg0MDY_81af66d6-1de0-472d-9ef1-ce5b1677c30e">465</ix:nonFraction>&#160;million. Johnson &amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#8217;s judgment and directed entry of judgment for Defendants. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#8217; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $<ix:nonFraction unitRef="usd" contextRef="icf0bc69e2f514d4f8022cfc52f98c981_I20191031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjk0MzI_c6fa804d-5ccb-48de-a644-7ed845b2671a">4</ix:nonFraction>&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $<ix:nonFraction unitRef="usd" contextRef="i54e00e15c6a4438da0eb288d0b6da9f6_I20201031" decimals="-9" name="jnj:LossContingencyEstimateOfAdditionalPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjk1NzI_5ce93c39-8b7c-4873-a4a3-3256f095a511">1</ix:nonFraction>&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of  $<ix:nonFraction unitRef="usd" contextRef="i54e00e15c6a4438da0eb288d0b6da9f6_I20201031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjk3MzM_671d4e05-456c-4b3f-b03e-3a967782025a">5</ix:nonFraction>&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement is expected to be paid by the end of fiscal year 2022, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ib78e16ca2e934d53af2e155483f81d75" continuedAt="i79b075c5fc514300b6a612a29eb982c3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022. Also in April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions. In September 2022, the Company also reached a settlement agreement with the State of New Hampshire and its participating subdivisions. Consequently, by September 2022, the Company had settled the opioid claims advanced by all states except Washington.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are approximately <ix:nonFraction unitRef="claim" contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNzEzODI_c2dc7e4b-a22e-4964-8fb6-252c132b3848">60</ix:nonFraction> cases remaining post-settlement in various state courts. There are approximately <ix:nonFraction unitRef="claim" contextRef="i0cc5049a65cc4fe3b6242125d5b8d5c0_I20221002" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNzE0NjY_ceab4332-9458-4fd1-845c-5c931cdcc4c6">860</ix:nonFraction> remaining federal cases against Johnson &amp; Johnson and JPI coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020.  By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted Johnson &amp; Johnson&#8217;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state court&#8217;s dismissal order.   </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i79b075c5fc514300b6a612a29eb982c3" continuedAt="i13a410ddf60c4a6eba1b57833f2542bb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">denied. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#8217;s dismissal of the case to the First Circuit. The briefing on the appeal will be complete by the end of October 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for May 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $<ix:nonFraction unitRef="usd" contextRef="i438940227a2a4ff395f3e492e755ecde_D20200101-20200131" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNzk1ODM_0a87bc30-4dd6-46d3-b6a0-55f1c5d563cf">344</ix:nonFraction>&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $<ix:nonFraction unitRef="usd" contextRef="i438940227a2a4ff395f3e492e755ecde_D20200101-20200131" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNzk3NDc_46f6b19b-a4eb-4d69-847d-a4f23e8919c2">344</ix:nonFraction>&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $<ix:nonFraction unitRef="usd" contextRef="id67cae946c154573ad2500e94ad849da_D20220401-20220430" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNzk5MTk_6781da46-ae45-4baa-88b5-c4f3c4def073">302</ix:nonFraction>&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company&#8217;s petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. The Company plans to petition for review by the United States Supreme Court.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#8217;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI&#8217;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#8217;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting as barred by the stay arising from the LTL Bankruptcy Case, referenced above, while the State argued that the stay did not apply. In January 2022, the Court granted the State&#8217;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. The temporary stay expired in May 2022. LTL thereafter moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#8217;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#8217;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#8217;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexico&#8217;s discovery obligations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i13a410ddf60c4a6eba1b57833f2542bb" continuedAt="ic2cde81baf234bf4bc24b6f8bfcfe6d4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to mediation of their claims in the LTL Bankruptcy Case.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, Johnson &amp; Johnson and Janssen Products, LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over <ix:nonFraction unitRef="claim" contextRef="i1d2b36aba9e54f04a044b6f392d0eac4_I20150430" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfODgwNjU_4a138fe7-aae3-4256-92fc-494d2e01f5da">30</ix:nonFraction> putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. This case was settled in March 2022. The Court approved the settlement in October 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022, subject to Court approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The complaint seeks damages and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ic2cde81baf234bf4bc24b6f8bfcfe6d4" continuedAt="ia7c3ed5fd8674cb3b2bc650f78958cad"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. This case was settled in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022. Genmab has moved for early disposition of the arbitration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In February 2022, defendants petitioned for rehearing en banc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. In September 2022, the Court granted in part and denied in part plaintiff&#8217;s motion for class certification. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#8217;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ia7c3ed5fd8674cb3b2bc650f78958cad"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (&#8220;EBSI&#8221;) with the American Arbitration Association, alleging that EBSI breached the parties&#8217; Manufacturing Services Agreement for the Company&#8217;s COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In July 2022, Emergent filed its answering statement and counterclaims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequent to the quarter, in October 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Merck Sharp &amp; Dohme Corp. with the American Arbitration Association pursuant to the Parties&#8217; agreements relating to production of drug substance and drug product for Johnson &amp; Johnson&#8217;s COVID-19 vaccine. Also in October 2022, Merck filed its answer and counterclaims.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in May 2021, multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">putative </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">class actions were filed in state and federal courts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(California, Florida, New York, and New Jersey)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the affirmative promotion of those products as &#8220;safe&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and, in at least one case, alleging a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strict liability manufacturing defect and failure to warn </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claims, asserting that the named plaintiffs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> suffered unspecified injuries as a result of alleged exposure to benzene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 12&#8212; <ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMjU5OQ_7962f0f3-b900-4282-a3fd-9bc8d00cc579" continuedAt="i100f2332b15f4f09a08633654f2cac1c" escape="true">RESTRUCTURING</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i100f2332b15f4f09a08633654f2cac1c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal third quarter of 2022, the Company recorded a net pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="icacdc0678d9f4679bbb4b670b539eae6_D20220704-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfNjY0_d7c94527-b77e-4bd9-80a8-1989dba1ea06">123</ix:nonFraction> million, which is included on the following lines of the Consolidated Statement of Earnings, $<ix:nonFraction unitRef="usd" contextRef="ia9e691f551214439bf1ee3b313e022c3_D20220704-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfNzUy_cc96ba85-747c-40d9-a6ce-83fcab407002">82</ix:nonFraction> million in restructuring, $<ix:nonFraction unitRef="usd" contextRef="i9ca0be8b6078437fbd42287a1c403587_D20220704-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfNzcz_48930e17-cf6f-4790-95da-d1d0c5d7db3c">13</ix:nonFraction> million in cost of products sold and $<ix:nonFraction unitRef="usd" contextRef="ife72459bccf34924aabd0acb8e60d652_D20220704-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfODA1_6e26083f-b4ff-4950-83b6-64af444775c5">28</ix:nonFraction> million in other (income) expense, net.  In the fiscal nine months of 2022, the Company recorded a net pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i690d9c2e2c884662976264e7af01ba35_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfOTA1_1b80022d-2704-4c01-b7db-01e9816b0aa5">323</ix:nonFraction>&#160;million, which is included on the following lines of the Consolidated Statement of Earnings, $<ix:nonFraction unitRef="usd" contextRef="ia93e937c11c7436bacd6ccaeacdf0cb6_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfOTkz_2788e860-5d6e-411e-b611-095a089df7f6">237</ix:nonFraction>&#160;million in restructuring, $<ix:nonFraction unitRef="usd" contextRef="i28209dc3607348dbb3171ab6afdd3dea_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTAxNA_7042a77d-1050-4262-aabb-2cd1b8362b53"><ix:nonFraction unitRef="usd" contextRef="i28209dc3607348dbb3171ab6afdd3dea_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTAxNA_734b103c-86d5-45e9-a40b-f12a7905febb">46</ix:nonFraction></ix:nonFraction>&#160;million in cost of products sold and $<ix:nonFraction unitRef="usd" contextRef="i4fe9fcf4dbc843569a9d49299bde3c5a_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTA0Ng_6c613ae8-9f40-4f39-906e-cc73dc245d3e">40</ix:nonFraction>&#160;million in other (income) expense, net. Total project costs of approximately $<ix:nonFraction unitRef="usd" contextRef="ie51585f5aa3d424c9d17456abcf75390_I20221002" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTExOA_a64932df-dca0-4578-9c28-9f3156c34cf4">2.1</ix:nonFraction> billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In total, the Company expects the Global Supply Chain actions to generate approximately $<ix:nonFraction unitRef="usd" contextRef="i6262632abd6a46d5a6a2555c388ca348_I20221002" decimals="-8" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTM0Ng_3c2fabcd-684f-4f80-80d6-8f1619b0bc57">0.7</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="ib3d9ff58f127499cb7a03cc08f3f4dbf_I20221002" decimals="-8" name="jnj:RestructuringandRelatedCostExpectedFutureSavings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTM1Mg_1128f430-2dca-460c-98d3-a1422e234d71">0.8</ix:nonFraction> billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i6262632abd6a46d5a6a2555c388ca348_I20221002" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTUyMA_470dcde2-e45a-43c1-a8e4-cf093e43d5fe">2.2</ix:nonFraction> billion to $<ix:nonFraction unitRef="usd" contextRef="ib3d9ff58f127499cb7a03cc08f3f4dbf_I20221002" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTUyNg_a5dad99c-51d6-47bc-97b2-3daf0078e3ec">2.3</ix:nonFraction> billion by the completion of the program in December 2022. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMjYwNQ_eeb87794-4fd9-42eb-b099-7fff7256ca94" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:32.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bfabbf7068d43948d05ef08e73d9679_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfMS0xLTEtMS03NzQwNw_bc87d09f-fe17-4e7a-9af3-0dc4637f4640">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4425d96eacb04e7696f85e7eaea16821_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfMS0yLTEtMS03NzQwNw_f09548b0-36ae-4d83-ae40-0aaa41b2712b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c4525bf37f4e2aa7ae0c4f54cbf866_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfMS00LTEtMS03NzQwNw_5b98ce1d-3543-4ed7-be1e-918e1cc4112d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57839c019e9745718882687e73ce9e18_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfMS01LTEtMS03NzQwNw_ab98a15d-e8a8-40a0-a73c-19a5583f8730">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb01ffbc16f648fb954f806b9df10064_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNC0xLTEtMS03NzQwNw_f8238d89-3f1c-4449-9cd9-99251a7d84f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i339ac2517af5425bb6f6bd7a62b270be_D20220103-20221002" decimals="-6" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNC0yLTEtMS03NzQwNw_08c40136-6d30-406a-ab72-b2c0664ae535">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea736a79ff947c586d1da1d7bcb9f18_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNC00LTEtMS03NzQwNw_ea133571-63f1-415d-a8ea-4262859ecfac">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923ad899b5ec4870933079c36fc15f9a_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNC01LTEtMS03NzQwNw_9573001d-4e96-4e1a-9ddf-766f52aac4c2">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb01ffbc16f648fb954f806b9df10064_D20220103-20221002" decimals="-6" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNS0xLTEtMS03NzQwNw_37cf2a59-7675-49ec-807a-1391feaeb615">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339ac2517af5425bb6f6bd7a62b270be_D20220103-20221002" decimals="-6" sign="-" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNS0yLTEtMS03NzQwNw_901db085-d384-461a-847a-08b6aa486705">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ea736a79ff947c586d1da1d7bcb9f18_D20220103-20221002" decimals="-6" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNS00LTEtMS03NzQwNw_32b1e306-8ee5-4667-8fc2-acbfdadd0a1b">317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i923ad899b5ec4870933079c36fc15f9a_D20220103-20221002" decimals="-6" name="jnj:PaymentsForRestructuringNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNS01LTEtMS03NzQwNw_fb04d5a8-fb70-410b-a8b5-e4e3d6fa0056">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb01ffbc16f648fb954f806b9df10064_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNi0xLTEtMS03NzQwNw_ab1a26db-988f-4dbb-8d4a-86b27c1af8c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i339ac2517af5425bb6f6bd7a62b270be_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNi0yLTEtMS03NzQwNw_610cfa35-bc3a-45be-aca2-bffb6577b012">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ea736a79ff947c586d1da1d7bcb9f18_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNi00LTEtMS03NzQwNw_be982d82-df62-4404-a3b9-4bbe5f63ebd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i923ad899b5ec4870933079c36fc15f9a_D20220103-20221002" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNi01LTEtMS03NzQwNw_d9aaeef4-acec-4cac-ba8f-d9ef8bf2596c">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, October 2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7802b4bc08714bbfa6723a15254942f7_I20221002" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfOS0xLTEtMS03NzQwNw_fb63fe06-7c57-413f-a899-bc523597c24f">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199a6c4996a1468e956555f0edbf4206_I20221002" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfOS0yLTEtMS03NzQwNw_4cf8639b-a42b-4534-a160-48b998c3fc17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8caf79efe14c4c99b6b144f88b0704f5_I20221002" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfOS00LTEtMS03NzQwNw_7c17eab2-4d2a-47ef-bcd1-2366b7cc2f6b">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic114825b023e4671a3b06ef6426697c5_I20221002" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfOS01LTEtMS03NzQwNw_6fa7f4b2-4dd8-4eb9-a3ab-decf6954944d">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_103"></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Consolidated Sales</span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal nine months of 2022, worldwide sales were $71.2 billion, a total increase of 3.3%, including an operational increase of 7.9% as compared to 2021 fiscal nine months sales of $69.0 billion. Currency fluctuations had a negative impact of 4.6% for the fiscal nine months of 2022. In the fiscal nine months of 2022, the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative 0.2%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S. companies were $36.1 billion in the fiscal nine months of 2022, which represented an increase of 3.1% as compared to the prior year. In the fiscal nine months of 2022, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a negative 0.1%.  Sales by international companies were $35.2 billion, an increase of 3.5%, including an operational increase of 12.9%, and a negative currency impact of 9.4% as compared to the fiscal nine months sales of 2021. In the fiscal nine months of 2022, the net impact of acquisitions and divestitures on the international operational sales growth was a negative 0.2%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal nine months of 2022, sales by companies in Europe achieved growth of 5.8%, which included an operational increase of 18.2% and a negative currency impact of 12.4%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 6.7%, which included an operational increase of 9.6%, and a negative currency impact of 2.9%. Sales by companies in the Asia-Pacific, Africa region experienced a decline of 0.4%, including an operational increase of 7.2% offset by a negative currency impact of 7.6%.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20221002_g1.jpg" alt="jnj-20221002_g1.jpg" style="height:268px;margin-bottom:5pt;vertical-align:text-bottom;width:355px"/><img src="jnj-20221002_g2.jpg" alt="jnj-20221002_g2.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"/></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal third quarter of 2022, worldwide sales were $23.8 billion, a total increase of 1.9%, which included operational growth of 8.1%  and a negative currency impact of 6.2% as compared to 2021 fiscal third quarter sales of $23.3 billion. In the fiscal third quarter of 2022, the net impact of acquisitions and divestitures on worldwide operational sales growth was a negative 0.1%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S. companies were $12.5 billion in the fiscal third quarter of 2022, which represented an increase of 4.1% as compared to the prior year. In the fiscal third quarter of 2022, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a negative 0.1%.  Sales by international companies were $11.3 billion, a total decrease of 0.3%, which included operational growth of 12.3% offset by a negative currency impact of 12.6%. In the fiscal third quarter of 2022, the net impact of acquisitions and divestitures on the international operational sales growth was a negative 0.1%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal third quarter of 2022, sales by companies in Europe experienced a decline of 1.1%, which included operational growth of 14.5% offset by a negative currency impact of 15.6%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 4.1%, including operational growth of 9.1% and a negative currency impact of 5.0%. Sales by companies in the Asia-Pacific, Africa region experienced a decline of 0.9%, including operational growth of 10.5% offset by a negative currency impact of 11.4%.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20221002_g3.jpg" alt="jnj-20221002_g3.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/><img src="jnj-20221002_g4.jpg" alt="jnj-20221002_g4.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"/></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Sales by Business Segments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health segment sales in the fiscal nine months of 2022 were $11.2 billion, a decrease of 1.1% as compared to the same period a year ago, including operational growth of 2.6% offset by a negative currency impact of 3.7%. U.S. Consumer Health segment sales decreased by 1.7%.  International Consumer Health segment sales decreased by 0.6%, including operational growth of 6.0% offset by a negative currency impact of 6.6%.  In the fiscal nine months of 2022, the net impact of acquisitions and divestitures on the Consumer Health segment operational sales growth was a negative 0.5%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Consumer Health Franchise Sales* &#8212; Fiscal Nine Months Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:42.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,186</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first fiscal nine months of 2021, approximately $0.3 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consumer Health segment sales in the fiscal third quarter of 2022 were $3.8 billion, a decrease of 0.4% as compared to the same period a year ago, including operational growth of 4.7% offset by a negative currency impact of 5.1%. U.S. Consumer Health segment sales increased by 2.1%. International Consumer Health segment sales decreased by 2.3% including operational growth of 6.7% offset by a negative currency impact of 9.0%. In the fiscal third quarter of 2022, the net impact of acquisitions and divestitures on the Consumer Health segment operational sales growth was a negative 0.1%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Major Consumer Health Franchise Sales* &#8212; Fiscal Third Quarter Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:43.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,795</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,812</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal third quarter of 2021, approximately $0.1 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OTC franchise achieved operational growth of 7.2% as compared to the prior year fiscal third quarter. The growth was driven by price actions and increased Cough/Cold/Flu and pediatric fever incidences as well as category recovery. This was partially offset by U.S. supply constraints.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skin Health/Beauty franchise achieved operational growth of 5.0% as compared to the prior year fiscal third quarter. The growth was driven by price actions, market growth and increased demand outside the U.S. for NEUTROGENA and AVEENO due to strong new product introductions.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oral Care franchise experienced an operational decline of 0.7% as compared to the prior year fiscal third quarter. The decline was driven by softer consumption in China, category deceleration in the EMEA and Latin America regions, and suspension of personal care products in Russia. This was partially offset by price actions in the U.S.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Baby Care franchise achieved operational growth of 1.6% as compared to the prior year fiscal third quarter. The growth was driven by price actions, market growth and AVEENO Baby facial cream relaunch in the Asia Pacific region. This was partially offset by competitive pressures in the U.S. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Women&#8217;s Health franchise achieved operational growth of 7.9% as compared to the prior year fiscal third quarter primarily driven by continued strong performance in India, price actions, and lapping prior year supply disruption due to flooding in EMEA.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Wound Care/Other franchise experienced an operational decline of 2.5% as compared to the prior year fiscal third quarter primarily driven by timing of club sales in Canada, U.S. market declines and lapping prior year strong COVID-19 related demand. This was partially offset by price actions primarily in the U.S.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business (Kenvue as the name for the planned New Consumer Health Company), with the intention to create a new, publicly traded company. The Company is targeting completion of the planned separation in 18 to 24 months after the initial announcement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment sales in the fiscal nine months of 2022 were $39.4 billion, an increase of 5.2% as compared to the same period a year ago, with an operational increase of 10.2% and a negative currency impact of 5.0%. U.S. Pharmaceutical sales increased 3.4% as compared to the same period a year ago. International Pharmaceutical sales increased by 7.3%, including operational growth of 18.5% and a negative currency impact of 11.2%.  In the fiscal nine months of 2022, the net impact of acquisitions and divestitures on the Pharmaceutical segment operational sales growth was a negative 0.1%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Pharmaceutical Therapeutic Area Sales** &#8212; Fiscal Nine Months Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:48.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.017%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,817</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI/ SIMPONI ARIA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,908</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,394</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT/rilpivirine</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PREZISTA/ PREZCOBIX/ REZOLSTA/ SYMTUZA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,156</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA/methylphenidate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;RISPERDAL CONSTA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,056</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,770</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA/ abiraterone acetate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,547</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,599</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,916</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVOKANA/ INVOKAMET</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1,2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal nine months of 2021, approximately $0.3 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pharmaceutical segment sales in the fiscal third quarter of 2022 were $13.2 billion, an increase of 2.6% as compared to the same period a year ago, including an operational increase of 9.0% and a negative currency impact of 6.4%. U.S. Pharmaceutical sales increased 3.0% as compared to the same period a year ago. International Pharmaceutical sales increased by 2.0%, including operational growth of 16.7% and a negative currency impact of 14.7%. In the fiscal third quarter of 2022, the net impact of acquisitions and divestitures on the Pharmaceutical segment operational sales growth was a negative 0.2%. Adjustments to previous sales reserve estimates were approximately $0.1 billion unfavorable in the fiscal third quarter of 2022 and approximately $0.2 billion favorable in the fiscal third quarter of 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Pharmaceutical Therapeutic Area Sales** &#8212; Fiscal Third Quarter Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:47.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,287</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI/ SIMPONI ARIA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT/rilpivirine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PREZISTA/ PREZCOBIX/ REZOLSTA/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,681</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA/ methylphenidate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;RISPERDAL CONSTA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,064</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,665</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA/ abiraterone acetate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,034</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,041</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVOKANA/ INVOKAMET</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1,2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,214</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,882</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal third quarter of 2021, approximately $0.1 billion of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunology products achieved operational growth of 5.6% as compared to the same period a year ago driven by market growth and share gains of STELARA (ustekinumab) in Crohn's disease and Ulcerative Colitis partially offset by a net unfavorable adjustment to previous sales reserves. Additionally, strong growth of TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(guselkumab) was due to market growth and  share gains in Psoriasis and Psoriatic Arthritis. This was partially offset by lower sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(infliximab) due to biosimilar competition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The latest expiring United States composition of matter patent for STELARA (ustekinumab) will expire in September 2023. STELARA (ustekinumab) U.S. sales in fiscal 2021 were approximately $5.9 billion. The expiration of a product patent or loss of market exclusivity is likely to result in a reduction in sales.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease products achieved operational growth of 3.8% as compared to the same period a year ago. Growth was primarily driven by the contribution of the COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This was partially offset by lower sales of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and PREZCOBIX/REZOLSTA (darunavir/cobicistat) due to increased competition and loss of exclusivity of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in certain countries outside the U.S. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience products achieved operational sales growth of 5.9% as compared to the same period a year ago. Growth of Paliperidone long-acting injectables INVEGA SUSTENNA/XEPLION (paliperidone palmitate) and INVEGA TRINZA/TREVICTA was due to new patient starts and persistence of treatment as well as the launch of INVEGA HAFYERA. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology products achieved operational sales growth of 20.0% as compared to the same period a year ago. Contributors to the growth were strong sales of DARZALEX (daratumumab) driven by share gains in all regions, continued strong market growth, and uptake of the subcutaneous formulation and the continued global launch uptake of ERLEADA (apalutamide). IMBRUVICA (ibrutinib) sales declined due to competitive pressures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pulmonary Hypertension achieved operational sales growth of 3.0% as compared to the same period a year ago. Sales growth was due to demand and share gains from UPTRAVI (selexipag) and OPSUMIT (macitentan) partially offset by COVID-19 related market constraints and unfavorable patient mix in OPSUMIT (macitentan) as well as continued declines in Other Pulmonary Hypertension.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular / Metabolism / Other products achieved operational growth of 1.4% as compared to the same period a year ago. The growth of XARELTO (rivaroxaban) was primarily driven by volume growth and share gains. The decline in sales of INVOKANA/INVOKAMET (canagliflozin) were due to continued share erosion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Starting in the second quarter of fiscal 2022, the Company updated its policy so that no end customer will be permitted direct delivery of product to a location other than the billing location. The updated policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Company&#8217;s drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain unlimited contract pharmacy arrangements under policy exceptions. The Company will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy update has discount and volume implications in the current year and going forward. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech*</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment sales in the fiscal nine months of 2022 were $20.7 billion, an increase of 2.2% as compared to the same period a year ago, with an operational increase of 6.6% and a negative currency impact of 4.4%. U.S. MedTech sales increased 4.9%. International MedTech sales decreased by 0.1%, including an operational increase of 8.2% offset by a negative currency impact of 8.3%. In the fiscal nine months of 2022, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was negative 0.1%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major MedTech Franchise Sales &#8212; Fiscal Nine Months Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:228.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,299</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,440</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,433</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,704</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,517</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,952</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total MedTech Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,651</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Previously referred to as Medical Devices</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment sales in the fiscal third quarter of 2022 were $6.8 billion, an increase of 2.1% as compared to the same period a year ago, which included operational growth of 8.1% and a negative currency impact of 6.0%. U.S. MedTech sales increased 7.7%. International MedTech sales decreased by 2.9%, including operational growth of 8.5% offset by a negative currency impact of 11.4%. In the fiscal third quarter of 2022, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was negligible.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Major MedTech Franchise Sales &#8212; Fiscal Third Quarter Ended</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:235.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,422</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,405</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,095</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,093</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,206</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">957</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total MedTech Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,782</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Previously referred to as Medical Devices</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Surgery franchise achieved operational sales growth of 7.1% as compared to the prior year fiscal third quarter. The operational growth in Advanced Surgery was primarily driven by the following: Endocutter market recovery and new products partially offset by competitive pressures in the U.S.; Biosurgery market recovery, market expansion efforts and the success of new products partially offset by strong U.S. market demand in the prior year for infection prevention products; and Energy products driven by new product penetration coupled with competitive supply challenges partially offset by competitive pressures. The operational growth in General Surgery was primarily driven by market recovery and technology penetration. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Orthopaedics franchise achieved operational sales growth of 4.7% as compared to the prior year fiscal third quarter. The operational growth in hips reflects procedure recovery, continued strength from the portfolio including ACTIS Stem and PINNACLE Dual Mobility, driven by KINCISE and VELYS Hip Navigation and momentum in the U.S. Ambulatory Surgery Center channel. This was partially offset by impacts of volume-based procurement in China and the timing of tenders outside the U.S. The operational growth in knees was primarily driven by procedure recovery, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. This was partially offset by impacts of volume-based procurement in China and timing of tenders outside the U.S. The operational growth in Trauma was driven by market recovery and the uptake of new products. The operational growth in Spine, Sports &amp; Other reflects procedure recovery and the benefit from new products in Spine, Sports, Shoulders and VELYS Digital Solutions. This was partially offset by competitive pressures in Spine. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vision franchise achieved operational sales growth of 8.6% as compared to the prior year fiscal third quarter. The Contact Lenses/Other operational growth was primarily driven by market recovery, price actions, commercial execution and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new products as well as the benefit of stocking in the U.S. related to new product launches. The Surgical operational growth was primarily driven by the success of new products mostly offset by global supply challenges, a high prior year comparison in Refractive lenses and timing of stocking in ASPAC.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Interventional Solutions franchise achieved operational sales growth of 17.7% as compared to the prior year fiscal third quarter. The double digit growth in all regions was driven by continued market recovery, new product performance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and commercial execution.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANALYSIS OF CONSOLIDATED EARNINGS BEFORE PROVISION FOR TAXES ON INCOME </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings before provision for taxes on income for the fiscal nine months of 2022 was $17.5 billion representing 24.6% of sales as compared to $17.9 billion in the fiscal nine months of 2021, representing 26.0% of sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings before provision for taxes on income for the fiscal third quarter of 2022 was $5.8 billion representing 24.5% of sales as compared to $3.8 billion in the fiscal third quarter of 2021, representing 16.5% of sales. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="text-align:center"><img src="jnj-20221002_g5.jpg" alt="jnj-20221002_g5.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="jnj-20221002_g6.jpg" alt="jnj-20221002_g6.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Nine months Q3 2022 versus Fiscal Nine months Q3 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.15pt">Commodity inflation in the MedTech and Consumer Health segments</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Currency in the Pharmaceutical segment</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Favorable segment mix with a higher percentage of sales coming from the Pharmaceutical segment</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain benefits in the MedTech and Consumer Health segments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset amortization expense included in cost of products sold for the fiscal nine months of 2022 and 2021 was $3.2&#160;billion and $3.6&#160;billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q3 2022 versus Q3 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Commodity inflation in the MedTech and Consumer Health segments</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Currency in the Pharmaceutical segment</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain benefits in the MedTech and Consumer Health segments</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The intangible asset amortization expense included in cost of products sold for the fiscal third quarters of 2022 and 2021 was $1.0 billion and $1.1&#160;billion, respectively. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, Marketing and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><img src="jnj-20221002_g7.jpg" alt="jnj-20221002_g7.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="jnj-20221002_g8.jpg" alt="jnj-20221002_g8.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Nine months Q3 2022 versus Fiscal Nine months Q3 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased spending to support product launches in the MedTech segment</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Q3 2022 versus Q3 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Investment prioritization in the Consumer Health segment</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Leveraging of marketing expense spending in the MedTech segment </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research and Development Expense</span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20221002_g9.jpg" alt="jnj-20221002_g9.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><img src="jnj-20221002_g10.jpg" alt="jnj-20221002_g10.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Nine months Q3 2022 versus Fiscal Nine months Q3 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">General portfolio progression in the Pharmaceutical segment</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased investment across multiple franchises in the MedTech segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q3 2022 versus Q3 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">General portfolio progression in the Pharmaceutical segment</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased investment across multiple franchises in the MedTech segment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-Process Research and Development (IPR&amp;D)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.  In the fiscal third quarter and fiscal nine months of 2021, the Company recorded a partial IPR&amp;D charge of $0.9 billion primarily related to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, subsequent to the fiscal third quarter, additional information regarding efficacy of the HS indication became available which led the Company to the decision to terminate the development of bermekimab for HS. The Company will record a charge of approximately $0.2 billion in the fiscal fourth quarter related to this impairment.  The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Interest (Income) Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest (income) expense in the first fiscal nine months of 2022 was a net interest income of $137 million as compared to interest expense of $83 million in the same period a year ago primarily due to higher rates of interest earned on cash balances. Interest (income) expense in the fiscal third quarter of 2022 was a net interest income of $99 million as compared to interest expense of $7 million in the same period a year ago primarily due to higher rates of interest earned on cash balances. The balance of cash, cash equivalents and current marketable securities was $34.1&#160;billion at the end of the fiscal third quarter of 2022 as compared to $31.0 billion at the end of the fiscal third quarter of 2021. The Company&#8217;s debt position was $32.0 billion as of October&#160;2, 2022 as compared to $33.9 billion the same period a year ago. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income) Expense, Net*</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Nine months Q3 2022 versus Fiscal Nine months Q3 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal nine months of 2022 was unfavorable by $0.2 billion as compared to the prior year primarily due to the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Nine Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the fair value of securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 Vaccine related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, integration and divestiture related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plan related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> Primarily related to pelvic mesh in the fiscal nine months of 2022 and talc and Risperdal Gynecomastia in the fiscal nine months of 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily related to divestiture gains of two pharmaceutical brands outside the U.S. in the fiscal nine months of 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q3 2022 versus Q3 2021</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal third quarter of 2022 was favorable by $1.4 billion as compared to the prior year primarily due to the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Third Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the fair value of securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 Vaccine related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plan related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Primarily related to pelvic mesh in the fiscal third quarter of 2022 and talc and Risperdal Gynecomastia in the fiscal third quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before tax by segment of business for the fiscal nine months were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:31.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,592&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,237&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expenses not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,524&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,940&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consumer Health segment income before tax as a percent of sales in the fiscal nine months of 2022 was 20.4% versus 10.0% for the same period a year ago. The increase in the income before tax as a percent of sales in the fiscal nine months of 2022 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower litigation expense, primarily talc ($0.1 billion in 2022 vs. $1.5 billion in 2021)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supply chain benefits in 2022</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Commodity inflation in 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment income before tax as a percent of sales in the fiscal nine months of 2022 was 32.0% versus 36.5% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal nine months of 2022 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An IPR&amp;D charge of $0.6 billion in 2022 related to bermekimab (JnJ-77474462), an investigational drug for the treatment of AD and Hidradenitis Suppurativa (HS) </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $0.6 billion in 2021, primarily related to divestiture gains of two pharmaceutical brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable changes in the fair value of securities ($0.7 billion loss in 2022 vs. $0.2 billion gain in 2021)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine supply network related costs of $0.7 billion in 2022</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased Research &amp; Development investment for general portfolio progression </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable currency in Cost of Products Sold </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Litigation related expense of $0.7 billion in 2021, primarily related to Risperdal Gynecomastia</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower intangible asset amortization expense ($2.2 billion in 2022 vs. $2.5 billion in 2021)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment income before tax as a percent of sales in the fiscal nine months of 2022 was 18.1% versus 18.8% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal nine months of 2022 was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher litigation related expense ($0.5 billion in 2022 vs. income of $0.1 billion in 2021)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Commodity inflation in 2022</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased selling, marketing and administrative spending to support product launches</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased investment in Research &amp; Development </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain benefits in 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">An IPR&amp;D charge of $0.9 billion in 2021 related to the general surgery offering in digital robotics (Ottava) acquired&#160;&#160;&#160;&#160;with the Auris Health acquisition in 2019</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income (loss) before tax by segment of business for the fiscal third quarters were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:32.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expenses not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior year income before tax has been reclassified as Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consumer Health segment income (loss) before tax as a percent of sales in the fiscal third quarter of 2022 was 21.3% versus (15.1)% for the same period a year ago. The increase in the income before tax as a percent of sales in the fiscal third quarter of 2022 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower litigation expense primarily talc </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supply chain benefits in 2022</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Commodity inflation in 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment income before tax as a percent of sales in the fiscal third quarter of 2022 was 32.2% versus 32.6% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal third quarter as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable changes in the fair value of securities ($0.2 billion loss in 2022 vs. $0.1 billion gain in 2021)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine supply network related costs of $0.4 billion in 2022</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable currency in Cost of Products Sold</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased Research &amp; Development investment for general portfolio progression </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation related expense of $0.8 billion in 2021, primarily related to Risperdal</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment income before tax as a percent of sales in the fiscal third quarter of 2022 was 16.6% versus 6.4% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal third quarter was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">An IPR&amp;D charge of $0.9 billion in 2021 related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain benefits in 2022</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Leveraging of marketing expense</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Commodity Inflation in 2022</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased investment in Research &amp; Development </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation related expense of $0.2 billion in 2022</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                                     </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018, the Company announced plans to implement actions across its Global Supply Chain that are intended to enable the Company to focus resources and increase investments in critical capabilities, technologies and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">solutions necessary to manufacture and supply its product portfolio of the future, enhance agility and drive growth. The Company expects these supply chain actions will include expanding its use of strategic collaborations, and bolstering its initiatives to reduce complexity, improving cost-competitiveness, enhancing capabilities and optimizing its network.&#160;Discussions regarding specific future actions are ongoing and are subject to all relevant consultation requirements before they are finalized. In total, the Company expects these actions to generate approximately $0.7 to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.2 to $2.3 billion by the completion of the program in December 2022. In the first fiscal nine months of 2022, the Company recorded a net pre-tax charge of $323&#160;million, which is included on the following lines of the Consolidated Statement of Earnings, $237&#160;million in restructuring, $46&#160;million in cost of products sold and $40&#160;million in other (income) expense, net. In the first fiscal nine months of 2021, the Company recorded a pre-tax charge of $333 million, which is included on the following lines of the Consolidated Statement of Earnings, $169 million in restructuring, $65 million in cost of products sold and $99 million in other (income) expense, net. In the fiscal third quarter of 2022, the Company recorded a net pre-tax charge of $123 million, which is included on the following lines of the Consolidated Statement of Earnings, $82 million in restructuring, $13 million in cost of products sold and $28 million in other (income) expense, net. In the fiscal third quarter of 2021, the Company recorded a pre-tax charge of $121 million, which is included on the following lines of the Consolidated Statement of Earnings, $60 million in restructuring, $18 million in cost of products sold and $43 million in other (income) expense, net. Restructuring charges of approximately $2.1 billion have been recorded since the restructuring was announced. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;12 to the Consolidated Financial Statements for additional details related to the restructuring.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Taxes on Income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rate for the fiscal nine months of 2022 was 17.7% in 2022 and 10.0% in 2021. The Company will continue to incur additional international tax related expenses until the legal separation of the Consumer Health business. </span></div><div style="margin-top:2.7pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-top:2.7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For discussion related to the fiscal nine months of 2022 provision for taxes refer to Note&#160;5 to the Consolidated Financial Statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20221002_g11.jpg" alt="jnj-20221002_g11.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:193px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><img src="jnj-20221002_g12.jpg" alt="jnj-20221002_g12.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><img src="jnj-20221002_g13.jpg" alt="jnj-20221002_g13.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:193px"/></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents were $11.4 billion at the end of the fiscal third quarter of 2022 as compared with $14.5 billion at the end of fiscal year 2021. The primary sources and uses of cash that contributed to the $3.1&#160;billion decrease were:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:21.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2021 Cash and cash equivalents balance</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash generated from operating activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by investing activities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by financing activities</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">effect of exchange rate and rounding</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3 2022 Cash and cash equivalents balance</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company had $22.7 billion in marketable securities at the end of the fiscal third quarter of 2022 and $17.1 billion at the end of fiscal year 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operations of $15.8&#160;billion was the result of:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs partially offset by the deferred tax provision, net gain on sale of assets/businesses and credit losses and accounts receivable allowances </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts receivable and inventories </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts payable and accrued liabilities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in other current and non-current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in other current and non-current liabilities</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow from operations</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities use of $8.0 billion of cash was primarily used for:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">additions to property, plant and equipment</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from the disposal of assets/businesses, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">acquisitions, net of cash acquired and other</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net purchases of investments</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">credit support agreements activity, net</span></td></tr><tr><td style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other and rounding</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for investing activities</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities use of $10.6 billion of cash was primarily used for: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">dividends to shareholders </span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">repurchase of common stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net proceeds from short and long term debt</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from stock options exercised/employee withholding tax on stock awards, net</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">credit support agreements activity, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other and rounding</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for financing activities</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2022, the Company secured a new 364-day Credit Facility. Total credit available to the Company approximates $10&#160;billion, which expires on September&#160;7, 2023.  Interest charged on borrowings under the credit line agreement is based on either Term Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreement are not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of October&#160;2, 2022, the Company's cash, cash equivalents and marketable securities was approximately $34.1 billion and approximately $32.0 billion of notes payable and long-term debt for a net cash position of $2.1 billion as compared to the prior year net debt position of $2.9 billion. Considering recent market conditions and the on-going COVID-19 pandemic, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's approximate $0.5 billion in contractual supply commitments associated with its development of the COVID-19 vaccine, the remaining balance to be paid on the agreement to settle opioid litigation for approximately $2.8 billion and the establishment of the $2.0 billion trust for talc related liabilities (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable. </span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's Common Stock. Share repurchases may be made at management&#8217;s discretion from time to time on the open market or through privately negotiated transactions.  The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for general corporate purposes. The Company intends to finance the share repurchase program through available cash. Through September 30, 2022, $2.0 billion has been repurchased under the program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal nine months of 2022, the Company paid approximately $2.1 billion to the U.S. Treasury which included $0.8 billion related to the current installment due on foreign undistributed earnings as part of the TCJA charge (see Note 1 to the Consolidated Financial Statements in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January 2, 2022) and $1.3 billion primarily related to the normal estimated payments for the fiscal nine months of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fiscal third quarter ended October 2, 2022, the Company sold all of its shares in argenx SE for proceeds of $0.6 billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2022, the Board of Directors declared a regular cash dividend of $1.13 per share, payable on September 6, 2022 to shareholders of record as of August 23, 2022. The Company expects to continue the practice of paying regular quarterly cash dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 19, 2022, the Board of Directors declared a regular cash dividend of $1.13 per share, payable on December 6, 2022 to shareholders of record as of November 22, 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OTHER INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic and Market Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 considerations and business continuity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered various internal and external factors in assessing the potential impact of COVID-19 on its business and financial results based upon information available at this time, as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Operating Model: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a diversified business model across the healthcare industry with flexibility designed into its manufacturing, research and development clinical operations and commercial capabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Supply Chain: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to leverage its global manufacturing footprint and dual-source capabilities while closely monitoring and maintaining critical inventory at major distribution centers away from high-risk areas to ensure adequate and effective distribution. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business Continuity: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The robust, active business continuity plans across the Company's network have been instrumental in preparing the Company for events like COVID-19 and the ability to meet the majority of patient and consumer needs remains uninterrupted.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Workforce: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has put procedures in place to protect its essential workforce in manufacturing, distribution, commercial and research operations while ensuring appropriate remote working protocols have been established for other employees. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Liquidity:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's high-quality credit rating allows the Company superior access to the financial capital markets for the foreseeable future. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Domestic and Foreign Legislation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will continue to assess and evaluate the on-going global legislative efforts to combat the COVID-19 impact on economies and the sectors in which it participates. Currently, the recent legislative acts put in place are not expected to have a material impact on the Company&#8217;s operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal third quarter of 2022, amounts paid for services to be delivered</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.5 billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the global progress on vaccine development and distribution as well as the amount of existing global supply, the Company is modifying its COVID-19 vaccine research programs and manufacturing capacity to levels that meet all customer contractual commitments which will result in incremental costs for the year. The Company continues to evaluate the global demand for the COVID-19 vaccine and its related supply.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to evaluate and monitor both its internal and external supply arrangements. The Company has established a global vaccine supply network, where, in addition to its internal manufacturing site in Leiden, the Netherlands, ten other manufacturing sites have been involved in the production of the vaccine across different countries and continents. The Company does not believe that a disruption relating to vaccine manufacturing, or the resulting delay would have a material financial impact on the Company&#8217;s consolidated financial statements or results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russia-Ukraine War</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the long-term implications of Russia&#8217;s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal third quarter and nine months of 2022, including accounts receivable or inventory reserves, was not material. As of both the 2021 fiscal year ending January 2, 2022, and the fiscal third quarter ending October 2, 2022, the business of the Company&#8217;s Ukraine subsidiaries represented less than 1% of the Company&#8217;s consolidated assets and revenues. As of both the 2021 fiscal year ending January 2, 2022, and the fiscal third quarter ending October 2, 2022, the business of the Company&#8217;s Russian subsidiaries represented less than 1% of the Company&#8217;s consolidated assets and represented 1% of revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In early March, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. Additionally, at the end of March, the Company made the decision to suspend supply of personal care products in Russia.  The Company continued to supply its other products throughout the third quarter as patients rely on many of the products for healthcare purposes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela and Argentina as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. Beginning in the fiscal second quarter of 2022, the Company accounted for operations in Turkey as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This did not have a material impact on the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.&#160;This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings.&#160; The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, as a result of the current global economic downturn, may continue to impact the Company&#8217;s businesses.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also operates in an environment increasingly hostile to intellectual property rights. Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the FDA or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue will be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also a risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;3 &#8212; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the Company&#8217;s assessment of its sensitivity to market risk since its presentation set forth in Item&#160;7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; in its Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;4 &#8212; CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs.&#160;Duato and Wolk concluded that, as of the end of the period covered by this report, the Company&#8217;s disclosure controls and procedures were effective.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Internal control. During the period covered by this report, there were no changes in the Company&#8217;s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company has not experienced any material impact to its internal controls over financial reporting despite the fact that many of its employees are working remotely due to the COVID-19 pandemic. The Company proactively took actions to re-evaluate and refine its financial reporting process through additional monitoring controls to provide reasonable assurance that the financial results are reported accurately and timely. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part II &#8212; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to Note 11 included in Part&#160;I, Item&#160;1, Financial Statements (unaudited) &#8212; Notes to Consolidated Financial Statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i5a494e6be84b467a8d7a1188e54512ab_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</span></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's Common Stock. Share repurchases may be made at management&#8217;s discretion from time to time on the open market or through privately negotiated transactions.  The repurchase program has no time limit and may be suspended for periods or discontinued at any time. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to Common Stock purchases by the Company during the fiscal third quarter of 2022. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal third quarter.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:503.25pt"><tr><td style="width:1.0pt"></td><td style="width:210.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:90.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:57pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Month Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Avg. Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 4, 2022 through July 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 1, 2022 through August 28, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 29, 2022 through October 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,382,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,232,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,042,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,232,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,207,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;During the fiscal third quarter of 2022, the Company repurchased an aggregate of 13,042,285 shares of Johnson &amp; Johnson Common Stock in open-market transactions, of which 12,232,285 shares were purchased pursuant to the repurchase program that was publicly announced on September 14, 2022, and of which 810,000 shares were purchased as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;2, 2022, an aggregate of 12,232,285 shares were purchased for a total of $2.0 billion since the inception of the repurchase program announced on September 14, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;2, 2022, the maximum number of shares that may yet be purchased under the plan is 18,207,721 based on the closing price of Johnson &amp; Johnson Common Stock on the New York Stock Exchange on September 30, 2022 of $163.36 per share.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;6 &#8212; EXHIBITS</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20223qex311ceocertificati.htm">Exhibit&#160;31.1  </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20223qex312cfocertificati.htm">Exhibit&#160;31.2 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Financial Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20223qex321ceocertificati.htm">Exhibit&#160;32.1 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div style="text-indent:11.25pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20223qex322cfocertificati.htm">Exhibit&#160;32.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certification of Chief Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 101: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i5a494e6be84b467a8d7a1188e54512ab_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:51.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JOHNSON &amp; JOHNSON<br/>(Registrant)&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: October 27, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/ J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer (Principal Financial Officer)&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: October 27, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/&#160;R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controller (Principal Accounting Officer)&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a20223qex311ceocertificati.htm
<DESCRIPTION>EX-31.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i60df5695cbd64210bcd592f953d5cf5e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joaquin Duato, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended October&#160;2, 2022 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Joaquin Duato</font></div><div style="padding-left:288pt"><font style="color:#7d7d7d;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">__________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joaquin Duato </font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;   October&#160;27, 2022</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a20223qex312cfocertificati.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i31b410c3574e4824ba379321f556ab0c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph J. Wolk, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended October&#160;2, 2022 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Joseph J. Wolk</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">______________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph J. Wolk</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; October&#160;27, 2022</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a20223qex321ceocertificati.htm
<DESCRIPTION>EX-32.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia6877ab1c0a941e9aa8e3fb9eb2bf991_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.1</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Joaquin Duato, the Chief Executive Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:11pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended October 2, 2022 (the&#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joaquin Duato</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;padding-right:38.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;  October&#160;27, 2022</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a20223qex322cfocertificati.htm
<DESCRIPTION>EX-32.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idda2c50916dc41fb8eb4ac05b427514b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.2</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended October 2, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Dated&#58;  October&#160;27, 2022</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>jnj-20221002.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:33652491-8200-4ac3-aad3-f4f6756ccdbe,g:4fa62845-cfde-4969-940e-970c42754004-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20221002" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.jnj.com/20221002">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20221002_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20221002_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20221002_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20221002_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.jnj.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEarnings" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings">
        <link:definition>1003004 - Statement - Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1006007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>1007008 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1008009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.jnj.com/role/Inventories">
        <link:definition>2103102 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2106103 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.jnj.com/role/FairValueMeasurements">
        <link:definition>2112104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.jnj.com/role/IncomeTaxes">
        <link:definition>2124105 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlans" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans">
        <link:definition>2126106 - Disclosure - Pensions and Other Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncome" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome">
        <link:definition>2130107 - Disclosure - Accumulated Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.jnj.com/role/EarningsPerShare">
        <link:definition>2133108 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreas" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas">
        <link:definition>2136109 - Disclosure - Segments of Business and Geographic Areas</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures">
        <link:definition>2141110 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.jnj.com/role/LegalProceedings">
        <link:definition>2144111 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.jnj.com/role/Restructuring">
        <link:definition>2146112 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.jnj.com/role/InventoriesTables">
        <link:definition>2304301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2307302 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.jnj.com/role/FairValueMeasurementsTables">
        <link:definition>2313303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansTables" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables">
        <link:definition>2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeTables" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables">
        <link:definition>2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.jnj.com/role/EarningsPerShareTables">
        <link:definition>2334306 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasTables" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables">
        <link:definition>2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.jnj.com/role/RestructuringTables">
        <link:definition>2347308 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.jnj.com/role/InventoriesDetails">
        <link:definition>2405401 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2408402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillGoodwillBySegmentDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
        <link:definition>2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails">
        <link:definition>2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2414406 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofDerivativeActivityDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails">
        <link:definition>2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDerivativesBalanceSheetLocationDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails">
        <link:definition>2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
        <link:definition>2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
        <link:definition>2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
        <link:definition>2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
        <link:definition>2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails">
        <link:definition>2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
        <link:definition>2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.jnj.com/role/IncomeTaxesDetails">
        <link:definition>2425416 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails">
        <link:definition>2429418 - Disclosure - Pensions and Other Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.jnj.com/role/EarningsPerShareDetails">
        <link:definition>2435420 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
        <link:definition>2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
        <link:definition>2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
        <link:definition>2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails">
        <link:definition>2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails">
        <link:definition>2443425 - Disclosure - Business Combinations and Divestitures - Schedule of Pro Forma Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsDetails" roleURI="http://www.jnj.com/role/LegalProceedingsDetails">
        <link:definition>2445426 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails">
        <link:definition>2448427 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringScheduleofRestructuringReserveDetails" roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails">
        <link:definition>2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jnj_PercentageChangeInSalesBySegmentOfBusiness" abstract="false" name="PercentageChangeInSalesBySegmentOfBusiness" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A1.150NotesDue2028Member" abstract="true" name="A1.150NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesDomain" abstract="true" name="LitigationSettlementByCompaniesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyReserveEstablishedWithinTrust" abstract="false" name="LossContingencyReserveEstablishedWithinTrust" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_Restructuringchargepercenttosales" abstract="false" name="Restructuringchargepercenttosales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_IMBRUVICAMember" abstract="true" name="IMBRUVICAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentImpairmentLoss" abstract="false" name="EquityFairValueAdjustmentImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EDURANTrilpivirineMember" abstract="true" name="EDURANTrilpivirineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentInProcessPercentToSales" abstract="false" name="ResearchAndDevelopmentInProcessPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EvraAndDoxilMember" abstract="true" name="EvraAndDoxilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PelvicMeshesMember" abstract="false" name="PelvicMeshesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_MedicalDevicesMember" abstract="true" name="MedicalDevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" abstract="true" name="PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DARZALEXMember" abstract="true" name="DARZALEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" abstract="false" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_CONCERTAMethylphenidateMember" abstract="true" name="CONCERTAMethylphenidateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ADVANCEDMember" abstract="true" name="ADVANCEDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProductLiabilityContingencyNumberOfClaimant" abstract="false" name="ProductLiabilityContingencyNumberOfClaimant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_A5.85Debenturesdue2038Member" abstract="true" name="A5.85Debenturesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SurgeryMember" abstract="true" name="SurgeryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ZYTIGAMember" abstract="true" name="ZYTIGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PaymentsForRestructuringNet" abstract="false" name="PaymentsForRestructuringNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_XareltoMember" abstract="true" name="XareltoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_GENERALMember" abstract="true" name="GENERALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.50Debenturesdue2040Member" abstract="true" name="A4.50Debenturesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" abstract="true" name="INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConsumerMember" abstract="true" name="ConsumerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SimponiSimponiAriaMember" abstract="true" name="SimponiSimponiAriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RasmussenInstrumentsLLCMember" abstract="true" name="RasmussenInstrumentsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AmountPrepaidAndDueToManufacturers" abstract="false" name="AmountPrepaidAndDueToManufacturers" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithoutReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SURGICALMember" abstract="true" name="SURGICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InfectiousDiseasesMember" abstract="true" name="InfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NotesDuePeriodFifteenMember" abstract="true" name="NotesDuePeriodFifteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OrthopaedicsMember" abstract="true" name="OrthopaedicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.85Notesdue2041Member" abstract="true" name="A4.85Notesdue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A210NotesDue2040Member" abstract="true" name="A210NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IncomeTaxExpenseBenefitPercentToSales" abstract="false" name="IncomeTaxExpenseBenefitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_WomensHealthMember" abstract="true" name="WomensHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A095NotesDue2027Member" abstract="true" name="A095NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" abstract="false" name="SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_A3.75Notesdue2047Member" abstract="true" name="A3.75Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ElmironMember" abstract="true" name="ElmironMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AccruedRebatesReturnsAndPromotions" abstract="false" name="AccruedRebatesReturnsAndPromotions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SalesRevenueGoodsNetPercentToSales" abstract="false" name="SalesRevenueGoodsNetPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_SupplyChainMember" abstract="true" name="SupplyChainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_HIPSMember" abstract="true" name="HIPSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SellingGeneralAndAdministrativeExpensePercentToSales" abstract="false" name="SellingGeneralAndAdministrativeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A3.375Notesdue2023Member" abstract="true" name="A3.375Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RestructuringandRelatedCostExpectedFutureSavings" abstract="false" name="RestructuringandRelatedCostExpectedFutureSavings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CONTACTLENSESOTHERMember" abstract="true" name="CONTACTLENSESOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.900Notesdue2028Member" abstract="true" name="A2.900Notesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2250NotesDue2050Member" abstract="true" name="A2250NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SurgicalMeshProductsMarketingMember" abstract="true" name="SurgicalMeshProductsMarketingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.400Notesdue2038Member" abstract="true" name="A3.400Notesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OPSUMITMember" abstract="true" name="OPSUMITMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.95Debenturesdue2033Member" abstract="true" name="A4.95Debenturesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.45Notesdue2026Member" abstract="true" name="A2.45Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AsiaPacificAfricaMember" abstract="true" name="AsiaPacificAfricaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherNonOperatingIncomeExpensePercentToSales" abstract="false" name="OtherNonOperatingIncomeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_SPINEOTHERMember" abstract="true" name="SPINEOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_StelaraMember" abstract="true" name="StelaraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TalcMember" abstract="true" name="TalcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A1.650NotesDue2035Member" abstract="true" name="A1.650NotesDue2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PulmonaryHypertensionMember" abstract="true" name="PulmonaryHypertensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterestExpensePercentToSales" abstract="false" name="InterestExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A5.95Notesdue2037Member" abstract="true" name="A5.95Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DePuyASRU.S.Member" abstract="true" name="DePuyASRU.S.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterventionalSolutionsMember" abstract="true" name="InterventionalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OTHERNEUROSCIENCEMember" abstract="true" name="OTHERNEUROSCIENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SalesBySegmentOfBusinessTableTextBlock" abstract="false" name="SalesBySegmentOfBusinessTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_OtherInfectiousDiseasesMember" abstract="true" name="OtherInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NumberOfBrands" abstract="false" name="NumberOfBrands" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_BabyPowderMember" abstract="true" name="BabyPowderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_UPTRAVIMember" abstract="true" name="UPTRAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RisperdalMember" abstract="true" name="RisperdalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" abstract="true" name="OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BeautyMember" abstract="true" name="BeautyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TRAUMAMember" abstract="true" name="TRAUMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.50Notesdue2043Member" abstract="true" name="A4.50Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" abstract="true" name="CONSUMERHEALTHAndPHARMACEUTICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInOperatingIncomeLoss" abstract="false" name="PercentageChangeInOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_PinnacleAcetabularCupSystemMember" abstract="false" name="PinnacleAcetabularCupSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2450NotesDue2060Member" abstract="true" name="A2450NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InvokanaMember" abstract="true" name="InvokanaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InvestmentIncomeInterestPercentToSales" abstract="false" name="InvestmentIncomeInterestPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_InterestIncomeExpenseNetMember" abstract="true" name="InterestIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_INVOKANAINVOKAMETMember" abstract="true" name="INVOKANAINVOKAMETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.375Notesdue2033Member" abstract="true" name="A4.375Notesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" abstract="false" name="EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BabyCareMember" abstract="true" name="BabyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_KNEESMember" abstract="true" name="KNEESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.625Notesdue2025Member" abstract="true" name="A2.625Notesdue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" abstract="false" name="LossContingencyNumberOfClaimsWithinSettlementAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_LossContingencyEstimateOfAdditionalPossibleLoss" abstract="false" name="LossContingencyEstimateOfAdditionalPossibleLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A3.55Notesdue2036Member" abstract="true" name="A3.55Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CostOfGoodsSoldPercentToSales" abstract="false" name="CostOfGoodsSoldPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="jnj_ExcessOfFairValueOverCarryingValueOfDebt" abstract="false" name="ExcessOfFairValueOverCarryingValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AsrMember" abstract="false" name="AsrMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_GrossProfitPercentToSales" abstract="false" name="GrossProfitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_AurisHealthMember" abstract="true" name="AurisHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OTCMember" abstract="true" name="OTCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OralCareMember" abstract="true" name="OralCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OneTimeFavorableTaxItemPercent" abstract="false" name="OneTimeFavorableTaxItemPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_WesternHemisphereExcludingUSMember" abstract="true" name="WesternHemisphereExcludingUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PhysiomeshMember" abstract="true" name="PhysiomeshMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_UNITEDSTATESExportsMember" abstract="true" name="UNITEDSTATESExportsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A6.95Notesdue2029Member" abstract="true" name="A6.95Notesdue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IncrementalIncreaseDecreaseInTaxes" abstract="false" name="IncrementalIncreaseDecreaseInTaxes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A5.50NotesDue2024Member" abstract="true" name="A5.50NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_Numberofpatientsinsettlement" abstract="false" name="Numberofpatientsinsettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_A3.500Notesdue2048Member" abstract="true" name="A3.500Notesdue2048Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AssetWriteoffMember" abstract="true" name="AssetWriteoffMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A6.73Debenturesdue2023Member" abstract="true" name="A6.73Debenturesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BermekimabMember" abstract="true" name="BermekimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A1300NotesDue2030Member" abstract="true" name="A1300NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.625Notesdue2037Member" abstract="true" name="A3.625Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CardiovascularMetabolismOtherMember" abstract="true" name="CardiovascularMetabolismOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesAxis" abstract="true" name="LitigationSettlementByCompaniesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_EquityInvestmentRollForward" abstract="true" name="EquityInvestmentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_ContactLensesMember" abstract="true" name="ContactLensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A0550NotesDue2025Member" abstract="true" name="A0550NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OpioidMember" abstract="true" name="OpioidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RISPERDALCONSTAMember" abstract="true" name="RISPERDALCONSTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_VisionMember" abstract="true" name="VisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NetIncomeAttributableToParentPercentToSales" abstract="false" name="NetIncomeAttributableToParentPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A3.70Notesdue2046Member" abstract="true" name="A3.70Notesdue2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherIncomeExpenseNetMember" abstract="true" name="OtherIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" abstract="false" name="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ERLEADAMember" abstract="true" name="ERLEADAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A0.650NotesDue2024Member" abstract="true" name="A0.650NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LegalProceedingTextualsAbstract" abstract="true" name="LegalProceedingTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_WoundCareandOtherMember" abstract="true" name="WoundCareandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PurchasedInProcessResearchAndDevelopmentMember" abstract="true" name="PurchasedInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesByGeographicArea" abstract="false" name="PercentageChangeInSalesByGeographicArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PatentsAndTrademarksMember" abstract="true" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_A2.95Notesdue2027Member" abstract="true" name="A2.95Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>jnj-20221002_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:33652491-8200-4ac3-aad3-f4f6756ccdbe,g:4fa62845-cfde-4969-940e-970c42754004-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_28b91219-742e-4463-b80d-ba84f895edb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b85a56ad-3896-421b-86e2-aaa9f6f33e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_28b91219-742e-4463-b80d-ba84f895edb3" xlink:to="loc_us-gaap_LiabilitiesCurrent_b85a56ad-3896-421b-86e2-aaa9f6f33e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e80f4e0d-cbf3-47c2-bb19-37f8d1cbc11b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_28b91219-742e-4463-b80d-ba84f895edb3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e80f4e0d-cbf3-47c2-bb19-37f8d1cbc11b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_61366588-7479-4fc9-9de3-55c62299de71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_28b91219-742e-4463-b80d-ba84f895edb3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_61366588-7479-4fc9-9de3-55c62299de71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_183ad17c-166a-4dbc-8f75-6469dfddea21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_28b91219-742e-4463-b80d-ba84f895edb3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_183ad17c-166a-4dbc-8f75-6469dfddea21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_67232add-4269-4f72-ac63-92b25debf087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_28b91219-742e-4463-b80d-ba84f895edb3" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_67232add-4269-4f72-ac63-92b25debf087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f470adfb-6c6f-4bd3-92fc-76d9eea24b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_28b91219-742e-4463-b80d-ba84f895edb3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f470adfb-6c6f-4bd3-92fc-76d9eea24b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_13bc0340-4776-4b85-89fd-7b9cd379a4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_f30792f4-5f08-451c-9f01-3bb96150c520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_13bc0340-4776-4b85-89fd-7b9cd379a4f3" xlink:to="loc_us-gaap_ShortTermBorrowings_f30792f4-5f08-451c-9f01-3bb96150c520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a028a62-e678-4bd8-852b-6a685b2da34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_13bc0340-4776-4b85-89fd-7b9cd379a4f3" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a028a62-e678-4bd8-852b-6a685b2da34b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e484b7c7-dfb3-4b05-9f39-0d47d47c3c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_13bc0340-4776-4b85-89fd-7b9cd379a4f3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e484b7c7-dfb3-4b05-9f39-0d47d47c3c6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_70d64dd6-2222-485f-8a44-c562348358a3" xlink:href="jnj-20221002.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_13bc0340-4776-4b85-89fd-7b9cd379a4f3" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_70d64dd6-2222-485f-8a44-c562348358a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5cbfcc8-1cb6-497b-958a-34cac601f7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_13bc0340-4776-4b85-89fd-7b9cd379a4f3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5cbfcc8-1cb6-497b-958a-34cac601f7a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_dde137af-609e-4e14-92ed-63d2b9f21f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_13bc0340-4776-4b85-89fd-7b9cd379a4f3" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_dde137af-609e-4e14-92ed-63d2b9f21f96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a36aae2e-a473-4d95-a816-fc0fdf53174c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2995de3f-244c-43d7-94b9-9a29157aa3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a36aae2e-a473-4d95-a816-fc0fdf53174c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2995de3f-244c-43d7-94b9-9a29157aa3fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3df6c589-255e-40e9-b2f8-d404d653c9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a36aae2e-a473-4d95-a816-fc0fdf53174c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3df6c589-255e-40e9-b2f8-d404d653c9a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e68bce9-a627-471e-a8b2-39060a803a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2cfed8de-7f4d-4777-b1f7-c6f755a0494e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e68bce9-a627-471e-a8b2-39060a803a39" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2cfed8de-7f4d-4777-b1f7-c6f755a0494e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_040d1dde-9e27-4c41-94ec-1cdf13bdc812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e68bce9-a627-471e-a8b2-39060a803a39" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_040d1dde-9e27-4c41-94ec-1cdf13bdc812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0fb7aac3-a0b9-4fa9-9552-69bed03e643e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e68bce9-a627-471e-a8b2-39060a803a39" xlink:to="loc_us-gaap_CommonStockValue_0fb7aac3-a0b9-4fa9-9552-69bed03e643e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_bdb800d7-aefc-4c3e-95b5-0f350bbcbb46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e68bce9-a627-471e-a8b2-39060a803a39" xlink:to="loc_us-gaap_TreasuryStockValue_bdb800d7-aefc-4c3e-95b5-0f350bbcbb46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_849be09a-5873-4962-9d5f-4081e05248fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f3908e8b-4ccc-4840-9bf4-8abb1abc000e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_849be09a-5873-4962-9d5f-4081e05248fa" xlink:to="loc_us-gaap_Liabilities_f3908e8b-4ccc-4840-9bf4-8abb1abc000e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc964f59-82cd-4691-9b2d-6a0de18e3cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_849be09a-5873-4962-9d5f-4081e05248fa" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fc964f59-82cd-4691-9b2d-6a0de18e3cfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bbba4bec-c4c7-439c-9048-465266a72e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_849be09a-5873-4962-9d5f-4081e05248fa" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bbba4bec-c4c7-439c-9048-465266a72e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d769cd4c-fe3b-40ab-ac4d-4cdd6805419e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_38ce652b-43ba-4d60-8cc9-e37df6941d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d769cd4c-fe3b-40ab-ac4d-4cdd6805419e" xlink:to="loc_us-gaap_AssetsCurrent_38ce652b-43ba-4d60-8cc9-e37df6941d2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_df2d36ac-559a-4d1a-85b0-42f3ed9b54c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d769cd4c-fe3b-40ab-ac4d-4cdd6805419e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_df2d36ac-559a-4d1a-85b0-42f3ed9b54c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_33c889ea-6155-457d-ab36-b6f4a3aa4d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d769cd4c-fe3b-40ab-ac4d-4cdd6805419e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_33c889ea-6155-457d-ab36-b6f4a3aa4d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a4031841-f8cb-4cd3-8e94-adf2d7d2dd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d769cd4c-fe3b-40ab-ac4d-4cdd6805419e" xlink:to="loc_us-gaap_Goodwill_a4031841-f8cb-4cd3-8e94-adf2d7d2dd3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_434422bb-ff25-40c0-b7a0-481437b4c8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d769cd4c-fe3b-40ab-ac4d-4cdd6805419e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_434422bb-ff25-40c0-b7a0-481437b4c8e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ebb3d12b-24b8-42c5-9644-e4e02cb8af49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d769cd4c-fe3b-40ab-ac4d-4cdd6805419e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ebb3d12b-24b8-42c5-9644-e4e02cb8af49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4b6d9afb-ebe4-44bf-b5c5-dd07263354be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fa360e2-138f-4770-9755-18667413aff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4b6d9afb-ebe4-44bf-b5c5-dd07263354be" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fa360e2-138f-4770-9755-18667413aff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_84967f14-0dbb-4643-9e2a-999254e4b7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4b6d9afb-ebe4-44bf-b5c5-dd07263354be" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_84967f14-0dbb-4643-9e2a-999254e4b7ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_81882e0a-0144-4573-953e-39dabde5b111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4b6d9afb-ebe4-44bf-b5c5-dd07263354be" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_81882e0a-0144-4573-953e-39dabde5b111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1c794d28-ea07-402d-81cb-6433223492fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4b6d9afb-ebe4-44bf-b5c5-dd07263354be" xlink:to="loc_us-gaap_InventoryNet_1c794d28-ea07-402d-81cb-6433223492fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c30f36f2-7024-428b-bf35-ef9e76a347ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4b6d9afb-ebe4-44bf-b5c5-dd07263354be" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c30f36f2-7024-428b-bf35-ef9e76a347ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_6c506d2d-f3c4-4745-8796-ac6a83532790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e488591f-b130-4d6b-9d47-802b4890e11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_6c506d2d-f3c4-4745-8796-ac6a83532790" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e488591f-b130-4d6b-9d47-802b4890e11a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5be24b99-d677-4e9e-840f-4acd9ba62880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_6c506d2d-f3c4-4745-8796-ac6a83532790" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5be24b99-d677-4e9e-840f-4acd9ba62880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f17f73b3-d517-4ad7-994f-7b832425c977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e852904f-4101-4879-abed-46343be8a3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f17f73b3-d517-4ad7-994f-7b832425c977" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e852904f-4101-4879-abed-46343be8a3e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_2e21a3bd-75c0-4ec3-9eb0-33da5d7d6a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f17f73b3-d517-4ad7-994f-7b832425c977" xlink:to="loc_us-gaap_GrossProfit_2e21a3bd-75c0-4ec3-9eb0-33da5d7d6a4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7a920aed-6682-4c2b-8272-de4ed241ece8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f17f73b3-d517-4ad7-994f-7b832425c977" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7a920aed-6682-4c2b-8272-de4ed241ece8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8913cfa8-1224-4bb0-b395-3f33705873fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f17f73b3-d517-4ad7-994f-7b832425c977" xlink:to="loc_us-gaap_RestructuringCharges_8913cfa8-1224-4bb0-b395-3f33705873fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c86bf397-50c1-482e-8ae6-def67d5db125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f17f73b3-d517-4ad7-994f-7b832425c977" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c86bf397-50c1-482e-8ae6-def67d5db125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_113ac9c4-f877-47ba-bbd5-ef9333c14c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f17f73b3-d517-4ad7-994f-7b832425c977" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_113ac9c4-f877-47ba-bbd5-ef9333c14c0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d91351f8-592f-4662-aa4b-83c13738dd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f17f73b3-d517-4ad7-994f-7b832425c977" xlink:to="loc_us-gaap_InterestExpense_d91351f8-592f-4662-aa4b-83c13738dd4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9fe1c160-bd8c-46b2-9c94-2f68422e160f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f17f73b3-d517-4ad7-994f-7b832425c977" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9fe1c160-bd8c-46b2-9c94-2f68422e160f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_4221d629-3847-4c0b-9ca2-3796a8e82dbc" xlink:href="jnj-20221002.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_2abff7e8-01e4-41ea-9cd2-bd6b932b7f59" xlink:href="jnj-20221002.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_4221d629-3847-4c0b-9ca2-3796a8e82dbc" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_2abff7e8-01e4-41ea-9cd2-bd6b932b7f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_4329f546-de1a-48ad-9348-8369e8c3a799" xlink:href="jnj-20221002.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_4221d629-3847-4c0b-9ca2-3796a8e82dbc" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_4329f546-de1a-48ad-9348-8369e8c3a799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49a39052-8b3f-461a-9a18-649708e090d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3510ab26-3b1b-4b5c-84fb-91ad6e729c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_49a39052-8b3f-461a-9a18-649708e090d7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3510ab26-3b1b-4b5c-84fb-91ad6e729c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9d288bc1-3158-420c-8c1f-b7674d5dda23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_49a39052-8b3f-461a-9a18-649708e090d7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9d288bc1-3158-420c-8c1f-b7674d5dda23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_79510860-64aa-4035-8b3a-8907579b98ea" xlink:href="jnj-20221002.xsd#jnj_GrossProfitPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_a1e1a1af-922d-4c28-8d30-97293cdb44fb" xlink:href="jnj-20221002.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_79510860-64aa-4035-8b3a-8907579b98ea" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_a1e1a1af-922d-4c28-8d30-97293cdb44fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_d8c5fcda-c0aa-429d-a591-90fe7142ed07" xlink:href="jnj-20221002.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_79510860-64aa-4035-8b3a-8907579b98ea" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_d8c5fcda-c0aa-429d-a591-90fe7142ed07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_1d7173e1-3072-43e7-95c6-60c2875878fd" xlink:href="jnj-20221002.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_d2b04dd9-7f74-4bcf-9129-878f4fc9081b" xlink:href="jnj-20221002.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_1d7173e1-3072-43e7-95c6-60c2875878fd" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_d2b04dd9-7f74-4bcf-9129-878f4fc9081b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_ef8c546d-5fd4-47b1-ae20-930f2f558412" xlink:href="jnj-20221002.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_1d7173e1-3072-43e7-95c6-60c2875878fd" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_ef8c546d-5fd4-47b1-ae20-930f2f558412" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_141fc820-c227-47ba-a396-3e16b22cf846" xlink:href="jnj-20221002.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_1d7173e1-3072-43e7-95c6-60c2875878fd" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_141fc820-c227-47ba-a396-3e16b22cf846" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_c20f6c2c-1a27-4189-9aa9-e211abf16cd4" xlink:href="jnj-20221002.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_1d7173e1-3072-43e7-95c6-60c2875878fd" xlink:to="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_c20f6c2c-1a27-4189-9aa9-e211abf16cd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_22f6fc01-0fe6-4284-b280-4c235a75d8d0" xlink:href="jnj-20221002.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_1d7173e1-3072-43e7-95c6-60c2875878fd" xlink:to="loc_jnj_Restructuringchargepercenttosales_22f6fc01-0fe6-4284-b280-4c235a75d8d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_fb2cb136-d3a6-4359-84a6-c5398a1f66d9" xlink:href="jnj-20221002.xsd#jnj_InterestExpensePercentToSales"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_1d7173e1-3072-43e7-95c6-60c2875878fd" xlink:to="loc_jnj_InterestExpensePercentToSales_fb2cb136-d3a6-4359-84a6-c5398a1f66d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_ea95c9a5-500a-4038-9042-b146ec82e0a5" xlink:href="jnj-20221002.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_1d7173e1-3072-43e7-95c6-60c2875878fd" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_ea95c9a5-500a-4038-9042-b146ec82e0a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_2ab2523d-df2e-4afe-91f0-c0b5ee5438e4" xlink:href="jnj-20221002.xsd#jnj_GrossProfitPercentToSales"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_1d7173e1-3072-43e7-95c6-60c2875878fd" xlink:to="loc_jnj_GrossProfitPercentToSales_2ab2523d-df2e-4afe-91f0-c0b5ee5438e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_88295ca1-f11f-45c3-b2e0-0ebbd36b684c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_f7dc08d4-aa9e-47ad-b44c-bc57222ca406" xlink:href="jnj-20221002.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_88295ca1-f11f-45c3-b2e0-0ebbd36b684c" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_f7dc08d4-aa9e-47ad-b44c-bc57222ca406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_aedfdff8-d2bf-4e84-a85b-401dad879ef1" xlink:href="jnj-20221002.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_88295ca1-f11f-45c3-b2e0-0ebbd36b684c" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_aedfdff8-d2bf-4e84-a85b-401dad879ef1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a560bcd5-03cd-4470-b187-a88f0918f331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_286102b9-4a5d-43d1-93dd-901c0f78740f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a560bcd5-03cd-4470-b187-a88f0918f331" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_286102b9-4a5d-43d1-93dd-901c0f78740f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_681c3c66-6144-43b1-8730-fd2c18d583fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a560bcd5-03cd-4470-b187-a88f0918f331" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_681c3c66-6144-43b1-8730-fd2c18d583fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_cdf4b4d2-bc8e-4fcd-bfc5-65212838f88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a560bcd5-03cd-4470-b187-a88f0918f331" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_cdf4b4d2-bc8e-4fcd-bfc5-65212838f88b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1c17cc05-72cc-4bd2-b0f3-cffd336ae6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a560bcd5-03cd-4470-b187-a88f0918f331" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1c17cc05-72cc-4bd2-b0f3-cffd336ae6a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f80a1e93-cce4-471f-b3c3-bc44d87297d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b5eae0f2-d449-4094-9dbf-f65d9524c4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f80a1e93-cce4-471f-b3c3-bc44d87297d6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b5eae0f2-d449-4094-9dbf-f65d9524c4a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_71ec2e71-433c-4eac-9d8b-ea4fb8bccbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f80a1e93-cce4-471f-b3c3-bc44d87297d6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_71ec2e71-433c-4eac-9d8b-ea4fb8bccbb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5828d7a8-0b20-458f-857b-e5e0fc4a0aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ca66aea6-02cb-4c04-b406-a8d123b44263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5828d7a8-0b20-458f-857b-e5e0fc4a0aeb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ca66aea6-02cb-4c04-b406-a8d123b44263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_70ae4ce1-85c1-417d-bc81-c7fa9d4d720f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5828d7a8-0b20-458f-857b-e5e0fc4a0aeb" xlink:to="loc_us-gaap_NetIncomeLoss_70ae4ce1-85c1-417d-bc81-c7fa9d4d720f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9b1c0a9f-60d0-47c3-93ce-3c4e579cb48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_d5b58b87-cb5e-45df-a4fb-1d0e4a3b20a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9b1c0a9f-60d0-47c3-93ce-3c4e579cb48b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_d5b58b87-cb5e-45df-a4fb-1d0e4a3b20a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_b9a16f75-474b-41db-9ff7-9d6174e845d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9b1c0a9f-60d0-47c3-93ce-3c4e579cb48b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_b9a16f75-474b-41db-9ff7-9d6174e845d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58de1ce3-74cb-46d7-a11e-baa308202fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b20dd54-70dd-4b94-9c4a-539a950e28c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58de1ce3-74cb-46d7-a11e-baa308202fdf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b20dd54-70dd-4b94-9c4a-539a950e28c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dcc26312-c80d-46b2-a831-f9bb2767ec1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58de1ce3-74cb-46d7-a11e-baa308202fdf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dcc26312-c80d-46b2-a831-f9bb2767ec1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7fd214e4-e026-40da-af79-0e5cb5a738bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58de1ce3-74cb-46d7-a11e-baa308202fdf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7fd214e4-e026-40da-af79-0e5cb5a738bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9875a3b2-f127-44ec-89c1-188c2da365ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58de1ce3-74cb-46d7-a11e-baa308202fdf" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9875a3b2-f127-44ec-89c1-188c2da365ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3ac3e522-c506-4753-a354-2803fd1606e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_d85a06f1-52b0-4599-94ba-57256ccade54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3ac3e522-c506-4753-a354-2803fd1606e1" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_d85a06f1-52b0-4599-94ba-57256ccade54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_07531297-1243-4471-8f6a-f58cc7ed6a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3ac3e522-c506-4753-a354-2803fd1606e1" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_07531297-1243-4471-8f6a-f58cc7ed6a94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_784091c7-0600-49c9-9772-09a5073a518b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_NetIncomeLoss_784091c7-0600-49c9-9772-09a5073a518b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bc6be841-2e44-4a77-a05f-c2ebc4afb45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bc6be841-2e44-4a77-a05f-c2ebc4afb45f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_559a39cc-73b2-4e6a-886d-48f34c3c17cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_ShareBasedCompensation_559a39cc-73b2-4e6a-886d-48f34c3c17cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_7d2036e2-f850-436e-85f1-fa954189d97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_AssetImpairmentCharges_7d2036e2-f850-436e-85f1-fa954189d97f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_ca1754ad-c785-43a6-8f14-d8e1404e7669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_ca1754ad-c785-43a6-8f14-d8e1404e7669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d86be7b5-901d-4417-a8e3-cb0f47519a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d86be7b5-901d-4417-a8e3-cb0f47519a6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c014a19e-093e-4f00-b975-371fa6a25c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c014a19e-093e-4f00-b975-371fa6a25c41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6baaada1-f437-4e62-8d5b-ff5addef632a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6baaada1-f437-4e62-8d5b-ff5addef632a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8a69b907-face-4725-85c0-fc24f7447ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8a69b907-face-4725-85c0-fc24f7447ba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0bd3f4be-77c2-4ddc-a2c3-077aabbe15ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0bd3f4be-77c2-4ddc-a2c3-077aabbe15ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cb671e77-71bc-4a55-9428-c801458ffbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_cb671e77-71bc-4a55-9428-c801458ffbbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ac80d49b-5a1a-45db-b474-459fef3a0671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90ab0aa7-9c71-4714-a071-2159567c9f6d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ac80d49b-5a1a-45db-b474-459fef3a0671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bebcf9c9-631c-40cc-ae54-24df041b0cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_1f30c588-5244-4946-bf96-d91550af2ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bebcf9c9-631c-40cc-ae54-24df041b0cfc" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_1f30c588-5244-4946-bf96-d91550af2ab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4c7ff4f7-9513-4503-8d75-22aca5cef566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bebcf9c9-631c-40cc-ae54-24df041b0cfc" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4c7ff4f7-9513-4503-8d75-22aca5cef566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_17065fae-2100-4e9a-9125-c0af1ee71e79" xlink:href="jnj-20221002.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bebcf9c9-631c-40cc-ae54-24df041b0cfc" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_17065fae-2100-4e9a-9125-c0af1ee71e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_3cd2d7df-418d-458a-ac1c-2759c7dc9c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bebcf9c9-631c-40cc-ae54-24df041b0cfc" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_3cd2d7df-418d-458a-ac1c-2759c7dc9c6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_bee8c5f8-d1af-4cb4-902f-4192bb92439a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bebcf9c9-631c-40cc-ae54-24df041b0cfc" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_bee8c5f8-d1af-4cb4-902f-4192bb92439a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d5f0750c-2b69-445f-afc1-09da6b139382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bebcf9c9-631c-40cc-ae54-24df041b0cfc" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d5f0750c-2b69-445f-afc1-09da6b139382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_f150ca2a-ed2c-48c0-986a-0ae5a38f139b" xlink:href="jnj-20221002.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bebcf9c9-631c-40cc-ae54-24df041b0cfc" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_f150ca2a-ed2c-48c0-986a-0ae5a38f139b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_821d1a0c-6ca2-410e-9754-edf0fb0f3bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bebcf9c9-631c-40cc-ae54-24df041b0cfc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_821d1a0c-6ca2-410e-9754-edf0fb0f3bee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b2a46cef-9f03-4092-9133-f6d677718b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bebcf9c9-631c-40cc-ae54-24df041b0cfc" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_b2a46cef-9f03-4092-9133-f6d677718b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edb8e6af-92dd-4a81-9ac6-dc0c0de036d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e7b9ace6-1c01-4b7e-9d6c-d271f822fa91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edb8e6af-92dd-4a81-9ac6-dc0c0de036d2" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_e7b9ace6-1c01-4b7e-9d6c-d271f822fa91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37b7b8d3-e1e9-4e41-875b-a74a84c1a2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edb8e6af-92dd-4a81-9ac6-dc0c0de036d2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37b7b8d3-e1e9-4e41-875b-a74a84c1a2d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_da9f0d5e-5142-4355-9465-d2da3891150a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edb8e6af-92dd-4a81-9ac6-dc0c0de036d2" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_da9f0d5e-5142-4355-9465-d2da3891150a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f9207c3d-5020-464d-9ce8-c0dc861b93a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edb8e6af-92dd-4a81-9ac6-dc0c0de036d2" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f9207c3d-5020-464d-9ce8-c0dc861b93a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_5be2f4fd-e1d3-4911-865f-af538cbe4327" xlink:href="jnj-20221002.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edb8e6af-92dd-4a81-9ac6-dc0c0de036d2" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_5be2f4fd-e1d3-4911-865f-af538cbe4327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_33375526-7c24-48dc-b7e1-c7717968ebba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edb8e6af-92dd-4a81-9ac6-dc0c0de036d2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_33375526-7c24-48dc-b7e1-c7717968ebba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_ac2fa0af-a264-4d90-8ecf-adb345b5aae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edb8e6af-92dd-4a81-9ac6-dc0c0de036d2" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_ac2fa0af-a264-4d90-8ecf-adb345b5aae3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_938e5ea5-5937-4156-91bf-48a937d869b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_353aaf81-2e6a-4b42-b6ef-714f8d653b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_938e5ea5-5937-4156-91bf-48a937d869b8" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_353aaf81-2e6a-4b42-b6ef-714f8d653b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_aca53db8-dce9-4f6d-ad6c-79c22fcf43a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_938e5ea5-5937-4156-91bf-48a937d869b8" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_aca53db8-dce9-4f6d-ad6c-79c22fcf43a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b2e7fbc6-7c0c-445c-9b35-8ce338477c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_938e5ea5-5937-4156-91bf-48a937d869b8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b2e7fbc6-7c0c-445c-9b35-8ce338477c3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_28fe5e54-a5d1-4a46-99f6-4f41f43527cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_09a16a77-2f89-47c7-828a-41a6d683a307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_28fe5e54-a5d1-4a46-99f6-4f41f43527cb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_09a16a77-2f89-47c7-828a-41a6d683a307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5501a8a1-6eb0-47b8-a8d1-b5165cf36497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_28fe5e54-a5d1-4a46-99f6-4f41f43527cb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5501a8a1-6eb0-47b8-a8d1-b5165cf36497" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_220dc976-1836-4e78-b939-a1015e2abc29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_233170fd-7e33-435d-b8de-536ef47879af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_220dc976-1836-4e78-b939-a1015e2abc29" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_233170fd-7e33-435d-b8de-536ef47879af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_d6f8a393-def3-42ec-81fc-2b3d73269954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_220dc976-1836-4e78-b939-a1015e2abc29" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_d6f8a393-def3-42ec-81fc-2b3d73269954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_cc6e263e-f298-43ae-bc8c-3783ff830c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c5cb0739-ca5f-4676-b218-a44edd4ce5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_cc6e263e-f298-43ae-bc8c-3783ff830c9a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c5cb0739-ca5f-4676-b218-a44edd4ce5c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_7fc516ff-809f-4a6a-a951-93bda64bf557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_cc6e263e-f298-43ae-bc8c-3783ff830c9a" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_7fc516ff-809f-4a6a-a951-93bda64bf557" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_248f533c-af4a-4077-9527-ff8cd1f20bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_a51e54e3-5a5b-48ff-86a5-684de3792b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_248f533c-af4a-4077-9527-ff8cd1f20bb4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_a51e54e3-5a5b-48ff-86a5-684de3792b16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_26c32413-1825-4523-adb2-e979dd19a020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_248f533c-af4a-4077-9527-ff8cd1f20bb4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_26c32413-1825-4523-adb2-e979dd19a020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1dcc0001-415e-4e42-9daf-6e5ee6ddcdae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6d23a338-cada-4523-ab4c-378c2b11bbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1dcc0001-415e-4e42-9daf-6e5ee6ddcdae" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6d23a338-cada-4523-ab4c-378c2b11bbe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_83b8a18d-ffac-4a58-bf97-dae7d1fb9cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1dcc0001-415e-4e42-9daf-6e5ee6ddcdae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_83b8a18d-ffac-4a58-bf97-dae7d1fb9cc1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4c85c961-0057-4a56-89f3-fa93549ddb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6884d675-16f4-4adb-879f-9d49adee8cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4c85c961-0057-4a56-89f3-fa93549ddb58" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6884d675-16f4-4adb-879f-9d49adee8cb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_103693ab-4695-43bc-b292-13c383158a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4c85c961-0057-4a56-89f3-fa93549ddb58" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_103693ab-4695-43bc-b292-13c383158a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_11ea591e-a069-4f0a-9770-0b63aaf00382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_4c85c961-0057-4a56-89f3-fa93549ddb58" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_11ea591e-a069-4f0a-9770-0b63aaf00382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_a8351783-6dd7-4ab4-a627-5f239ba412e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_55b33de6-f25f-4106-acc8-5d8246d0d528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_a8351783-6dd7-4ab4-a627-5f239ba412e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_55b33de6-f25f-4106-acc8-5d8246d0d528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_efd5a86e-050a-4adf-b16b-4b91eab6e489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_a8351783-6dd7-4ab4-a627-5f239ba412e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_efd5a86e-050a-4adf-b16b-4b91eab6e489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_0ae80f0c-dc0f-49b3-aff6-8ab1a1141026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_a8351783-6dd7-4ab4-a627-5f239ba412e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_0ae80f0c-dc0f-49b3-aff6-8ab1a1141026" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_323f1d77-74c2-497f-93c4-d7da70c9b97a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_8a8a8067-67ce-4bbc-ac93-5f52ff37c46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_323f1d77-74c2-497f-93c4-d7da70c9b97a" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_8a8a8067-67ce-4bbc-ac93-5f52ff37c46d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_e9668f8b-b5b4-4b52-a3cb-8d2316259792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_323f1d77-74c2-497f-93c4-d7da70c9b97a" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_e9668f8b-b5b4-4b52-a3cb-8d2316259792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a6e30613-f981-4a55-859f-4632c6b4a8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_323f1d77-74c2-497f-93c4-d7da70c9b97a" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a6e30613-f981-4a55-859f-4632c6b4a8aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_dd6b0b38-ed59-44b3-915c-5f8e757a4d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_323f1d77-74c2-497f-93c4-d7da70c9b97a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_dd6b0b38-ed59-44b3-915c-5f8e757a4d15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_340fef11-27b8-4e50-94c2-70324d4f245a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_323f1d77-74c2-497f-93c4-d7da70c9b97a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_340fef11-27b8-4e50-94c2-70324d4f245a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_05a1519b-e79f-4608-b6f8-32051c545be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_323f1d77-74c2-497f-93c4-d7da70c9b97a" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_05a1519b-e79f-4608-b6f8-32051c545be4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb1ad231-f259-4151-8018-b41295b99c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a14e44e-cb31-47c9-9a17-1e459316f848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb1ad231-f259-4151-8018-b41295b99c30" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a14e44e-cb31-47c9-9a17-1e459316f848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ef41fa00-0ce7-45d4-a686-f2d9f09f1efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb1ad231-f259-4151-8018-b41295b99c30" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ef41fa00-0ce7-45d4-a686-f2d9f09f1efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_d81cb024-83f8-4a8f-be44-2e1674ca1d1a" xlink:href="jnj-20221002.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb1ad231-f259-4151-8018-b41295b99c30" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_d81cb024-83f8-4a8f-be44-2e1674ca1d1a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>jnj-20221002_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:33652491-8200-4ac3-aad3-f4f6756ccdbe,g:4fa62845-cfde-4969-940e-970c42754004-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20221002.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended" id="i1551e3c9039c4a31bb0a5a4340b1f958_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_023b2125-06d3-47dd-aee7-bfb218e9dacc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentType_023b2125-06d3-47dd-aee7-bfb218e9dacc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7c435626-76b0-47df-b993-e5ab290b1298" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentQuarterlyReport_7c435626-76b0-47df-b993-e5ab290b1298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9f626652-1d47-451d-97dc-060e626bedad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentPeriodEndDate_9f626652-1d47-451d-97dc-060e626bedad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e5bae366-3c86-4dce-a4ed-60299325e829" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentTransitionReport_e5bae366-3c86-4dce-a4ed-60299325e829" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f301d1fb-ceb2-40fd-a6ce-f5f6686eb0ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityFileNumber_f301d1fb-ceb2-40fd-a6ce-f5f6686eb0ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e8ab7e26-e780-4b18-8929-9e94265e747f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityRegistrantName_e8ab7e26-e780-4b18-8929-9e94265e747f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_78866a15-d9cd-4689-ba75-a204addf2ce0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityIncorporationStateCountryCode_78866a15-d9cd-4689-ba75-a204addf2ce0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_120a1f05-b89c-4097-9458-310460dfaedf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityTaxIdentificationNumber_120a1f05-b89c-4097-9458-310460dfaedf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_24398342-a92b-42b4-9855-a32d82ec4c4a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityAddressAddressLine1_24398342-a92b-42b4-9855-a32d82ec4c4a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0e87f2e4-62ca-4045-a5a2-dcd82e875c15" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityAddressCityOrTown_0e87f2e4-62ca-4045-a5a2-dcd82e875c15" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4a24c9a7-af69-4bca-97e8-ef565996fcec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityAddressStateOrProvince_4a24c9a7-af69-4bca-97e8-ef565996fcec" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ffb5c6fb-166a-46c3-b965-24994ab2712d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityAddressPostalZipCode_ffb5c6fb-166a-46c3-b965-24994ab2712d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8bc763e7-df34-4b06-b6b6-e4b8931bd5cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_CityAreaCode_8bc763e7-df34-4b06-b6b6-e4b8931bd5cd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3eb1e9b1-d071-4499-8eda-94f6caa262c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_LocalPhoneNumber_3eb1e9b1-d071-4499-8eda-94f6caa262c8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8437f2d0-031c-4cd1-86de-da663f96c949" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityCurrentReportingStatus_8437f2d0-031c-4cd1-86de-da663f96c949" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e8dd68df-04fc-4ec4-8c09-37b6566c3d55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityInteractiveDataCurrent_e8dd68df-04fc-4ec4-8c09-37b6566c3d55" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_fa531bdf-4469-4fdb-adf0-b08697934683" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityFilerCategory_fa531bdf-4469-4fdb-adf0-b08697934683" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2644ca7c-c972-4e1c-b645-738c872cb3f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntitySmallBusiness_2644ca7c-c972-4e1c-b645-738c872cb3f1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_269f85c6-c124-490a-bbf5-352b44ed3a37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityEmergingGrowthCompany_269f85c6-c124-490a-bbf5-352b44ed3a37" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e14a6a7e-99ce-4b04-a034-acab5173cb56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityShellCompany_e14a6a7e-99ce-4b04-a034-acab5173cb56" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f7605d3d-23ea-40e5-a066-080bd961bc92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_Security12bTitle_f7605d3d-23ea-40e5-a066-080bd961bc92" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3b746f00-b356-417e-9849-8a9f5c9960bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_TradingSymbol_3b746f00-b356-417e-9849-8a9f5c9960bb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_873e5200-baab-4ed3-b804-7eb1c733c84a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_SecurityExchangeName_873e5200-baab-4ed3-b804-7eb1c733c84a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3022525c-cad1-468f-9014-0312843ebd76" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3022525c-cad1-468f-9014-0312843ebd76" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4089b260-e326-4f65-9b0d-b285f8a1ecf3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityCentralIndexKey_4089b260-e326-4f65-9b0d-b285f8a1ecf3" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a2119503-6cdd-4d63-9674-c31757ae969d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_CurrentFiscalYearEndDate_a2119503-6cdd-4d63-9674-c31757ae969d" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b3f5300e-a883-4cd0-be31-43adff55bce5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentFiscalYearFocus_b3f5300e-a883-4cd0-be31-43adff55bce5" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11d7288b-727a-49aa-a0dc-27ce5ba3a7bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11d7288b-727a-49aa-a0dc-27ce5ba3a7bb" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1776563f-20b8-4552-b344-c689610e19f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_AmendmentFlag_1776563f-20b8-4552-b344-c689610e19f8" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_20ff3c44-5512-4505-8182-c59a38b3d15c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntitiesTable_20ff3c44-5512-4505-8182-c59a38b3d15c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e212e209-d25a-4604-a637-b82e1b8a2bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_20ff3c44-5512-4505-8182-c59a38b3d15c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e212e209-d25a-4604-a637-b82e1b8a2bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e212e209-d25a-4604-a637-b82e1b8a2bb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e212e209-d25a-4604-a637-b82e1b8a2bb0" xlink:to="loc_us-gaap_ClassOfStockDomain_e212e209-d25a-4604-a637-b82e1b8a2bb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e212e209-d25a-4604-a637-b82e1b8a2bb0" xlink:to="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bb95fa71-3c4e-4d0a-8fce-9348d7f96758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:to="loc_us-gaap_CommonStockMember_bb95fa71-3c4e-4d0a-8fce-9348d7f96758" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_2b078fc9-572b-4359-b744-b0167bbfd163" xlink:href="jnj-20221002.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:to="loc_jnj_A0.650NotesDue2024Member_2b078fc9-572b-4359-b744-b0167bbfd163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_9f1e832c-1515-45f9-8593-ddf3af3a55b5" xlink:href="jnj-20221002.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:to="loc_jnj_A5.50NotesDue2024Member_9f1e832c-1515-45f9-8593-ddf3af3a55b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_7af73fbb-0e90-40b0-835c-cb2baaa41e8c" xlink:href="jnj-20221002.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:to="loc_jnj_A1.150NotesDue2028Member_7af73fbb-0e90-40b0-835c-cb2baaa41e8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_0c563682-0616-4a8d-ba49-8df7a598edc9" xlink:href="jnj-20221002.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:to="loc_jnj_A1.650NotesDue2035Member_0c563682-0616-4a8d-ba49-8df7a598edc9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="i34f4c063b72e4f438c5dade921f753dc_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4e06ce24-82b7-42b4-84a3-b9ad1552fdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4e06ce24-82b7-42b4-84a3-b9ad1552fdfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c9a90cf-2308-4f90-8a64-83a260a88178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_NetIncomeLoss_4c9a90cf-2308-4f90-8a64-83a260a88178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_a2634409-173f-4b52-86c0-f5f302523fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_DividendsCommonStockCash_a2634409-173f-4b52-86c0-f5f302523fba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_8c5088a7-488c-45e3-b92f-818285461b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_8c5088a7-488c-45e3-b92f-818285461b25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7345a4fa-4293-4fe6-bde7-acc91b48631a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7345a4fa-4293-4fe6-bde7-acc91b48631a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_66d2952e-8fa8-48ab-bc70-c9900002d5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_66d2952e-8fa8-48ab-bc70-c9900002d5ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ff546d4-a643-4bb0-aa3e-85a459bddd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7197847d-f1d3-4ff5-9e2a-c5898db398c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_StatementTable_7197847d-f1d3-4ff5-9e2a-c5898db398c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2007c5bb-d868-4ff0-9576-929e7ae34ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7197847d-f1d3-4ff5-9e2a-c5898db398c3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2007c5bb-d868-4ff0-9576-929e7ae34ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2007c5bb-d868-4ff0-9576-929e7ae34ba6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2007c5bb-d868-4ff0-9576-929e7ae34ba6" xlink:to="loc_us-gaap_EquityComponentDomain_2007c5bb-d868-4ff0-9576-929e7ae34ba6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2007c5bb-d868-4ff0-9576-929e7ae34ba6" xlink:to="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_04408683-2c50-4457-ac2e-b5f25c57474f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:to="loc_us-gaap_RetainedEarningsMember_04408683-2c50-4457-ac2e-b5f25c57474f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d90c0dc7-876f-4e2a-b5f1-ec655edd1fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d90c0dc7-876f-4e2a-b5f1-ec655edd1fb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7f69d8fc-a983-4fed-8fb7-ccee292afbef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:to="loc_us-gaap_CommonStockMember_7f69d8fc-a983-4fed-8fb7-ccee292afbef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_4f8e62da-9024-449a-85ed-0e398ac91932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:to="loc_us-gaap_TreasuryStockMember_4f8e62da-9024-449a-85ed-0e398ac91932" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="i4c567207aea4436996e24e7a4d15f5e8_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_3c0b9548-2a98-42db-bd85-45665d5dabf0" xlink:href="jnj-20221002.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1409d633-7a3a-4cb5-9343-d630939a0afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_3c0b9548-2a98-42db-bd85-45665d5dabf0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1409d633-7a3a-4cb5-9343-d630939a0afc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bd3bf86d-f577-43b1-bef9-faccae354096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1409d633-7a3a-4cb5-9343-d630939a0afc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bd3bf86d-f577-43b1-bef9-faccae354096" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0a37d028-0820-47e6-85af-2607e179f5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bd3bf86d-f577-43b1-bef9-faccae354096" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0a37d028-0820-47e6-85af-2607e179f5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4394b1e2-8ba9-42f7-9ce5-33a690f034a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bd3bf86d-f577-43b1-bef9-faccae354096" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4394b1e2-8ba9-42f7-9ce5-33a690f034a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cf8bd8c8-577b-4160-b665-7469f7a60d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bd3bf86d-f577-43b1-bef9-faccae354096" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cf8bd8c8-577b-4160-b665-7469f7a60d92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_7db654b3-f1bb-450b-8910-627fe8ad447d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1409d633-7a3a-4cb5-9343-d630939a0afc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_7db654b3-f1bb-450b-8910-627fe8ad447d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4d38dd32-3e0b-435c-b10e-73962bfc8fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_7db654b3-f1bb-450b-8910-627fe8ad447d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4d38dd32-3e0b-435c-b10e-73962bfc8fad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_91ed1253-c51b-4dde-bcc1-0b958fde7edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_7db654b3-f1bb-450b-8910-627fe8ad447d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_91ed1253-c51b-4dde-bcc1-0b958fde7edb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3b85fa2d-a0b3-442a-8f67-c853e7900d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_3c0b9548-2a98-42db-bd85-45665d5dabf0" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3b85fa2d-a0b3-442a-8f67-c853e7900d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:href="jnj-20221002.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_3c0b9548-2a98-42db-bd85-45665d5dabf0" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b057cf3e-7b69-444d-a858-cf3ffbe5daa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b057cf3e-7b69-444d-a858-cf3ffbe5daa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b057cf3e-7b69-444d-a858-cf3ffbe5daa0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b057cf3e-7b69-444d-a858-cf3ffbe5daa0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b057cf3e-7b69-444d-a858-cf3ffbe5daa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9627088b-a156-41cf-b23c-89b267b1675d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b057cf3e-7b69-444d-a858-cf3ffbe5daa0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9627088b-a156-41cf-b23c-89b267b1675d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_ab15769c-f7d4-4760-b248-aaeb3c08e6ec" xlink:href="jnj-20221002.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9627088b-a156-41cf-b23c-89b267b1675d" xlink:to="loc_jnj_PatentsAndTrademarksMember_ab15769c-f7d4-4760-b248-aaeb3c08e6ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_a45dd351-95c3-4775-8e83-2121b6ed9166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9627088b-a156-41cf-b23c-89b267b1675d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_a45dd351-95c3-4775-8e83-2121b6ed9166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf334391-2f5f-41ad-ac21-a3dd1fce0d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9627088b-a156-41cf-b23c-89b267b1675d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf334391-2f5f-41ad-ac21-a3dd1fce0d14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6474bbb3-94d1-4598-aa88-bba83ed4ebdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6474bbb3-94d1-4598-aa88-bba83ed4ebdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6474bbb3-94d1-4598-aa88-bba83ed4ebdb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6474bbb3-94d1-4598-aa88-bba83ed4ebdb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6474bbb3-94d1-4598-aa88-bba83ed4ebdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_973c5e04-9768-4af1-b3dd-febb1cf37873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6474bbb3-94d1-4598-aa88-bba83ed4ebdb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_973c5e04-9768-4af1-b3dd-febb1cf37873" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_85545e52-968d-4dd5-b0bb-108a3bbb50d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_973c5e04-9768-4af1-b3dd-febb1cf37873" xlink:to="loc_us-gaap_TrademarksMember_85545e52-968d-4dd5-b0bb-108a3bbb50d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_b28e4b4e-7dc6-438b-b0c9-1c8e3ef0a9ac" xlink:href="jnj-20221002.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_973c5e04-9768-4af1-b3dd-febb1cf37873" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_b28e4b4e-7dc6-438b-b0c9-1c8e3ef0a9ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_79305854-57c0-44a5-a0d2-1c7d85389192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_79305854-57c0-44a5-a0d2-1c7d85389192" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_79305854-57c0-44a5-a0d2-1c7d85389192_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79305854-57c0-44a5-a0d2-1c7d85389192" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_79305854-57c0-44a5-a0d2-1c7d85389192_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5bc4370-50a6-4c7b-8963-fc24aff53a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79305854-57c0-44a5-a0d2-1c7d85389192" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5bc4370-50a6-4c7b-8963-fc24aff53a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_76b0cc1d-75fe-452c-b7bb-495b8e55a79b" xlink:href="jnj-20221002.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5bc4370-50a6-4c7b-8963-fc24aff53a97" xlink:to="loc_jnj_BermekimabMember_76b0cc1d-75fe-452c-b7bb-495b8e55a79b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d7664358-3dd9-4e37-b5d9-77828b4385e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d7664358-3dd9-4e37-b5d9-77828b4385e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d7664358-3dd9-4e37-b5d9-77828b4385e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d7664358-3dd9-4e37-b5d9-77828b4385e6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d7664358-3dd9-4e37-b5d9-77828b4385e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8341e4f2-71e8-443e-9a7c-bfcc663ad6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d7664358-3dd9-4e37-b5d9-77828b4385e6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8341e4f2-71e8-443e-9a7c-bfcc663ad6a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_374cb6f0-4acf-48fb-b880-eb874509e94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8341e4f2-71e8-443e-9a7c-bfcc663ad6a5" xlink:to="loc_us-gaap_SubsequentEventMember_374cb6f0-4acf-48fb-b880-eb874509e94c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended" id="i812455ce86eb4a638fcede37fb4be24e_IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_7db06f4f-05f9-4990-a31f-4d0ed5cdfb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_750ebe9e-0d10-4576-94e7-7e27cdda2b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_7db06f4f-05f9-4990-a31f-4d0ed5cdfb7f" xlink:to="loc_us-gaap_GoodwillRollForward_750ebe9e-0d10-4576-94e7-7e27cdda2b4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_101f4d8c-81c9-4099-9dc2-45a7e5bc95ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_750ebe9e-0d10-4576-94e7-7e27cdda2b4d" xlink:to="loc_us-gaap_Goodwill_101f4d8c-81c9-4099-9dc2-45a7e5bc95ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_48a19418-7a00-4f7c-9100-3fcb3012ddb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_750ebe9e-0d10-4576-94e7-7e27cdda2b4d" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_48a19418-7a00-4f7c-9100-3fcb3012ddb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_22bcd881-df81-44c8-b2b3-a6e4f58902e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_750ebe9e-0d10-4576-94e7-7e27cdda2b4d" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_22bcd881-df81-44c8-b2b3-a6e4f58902e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3c90df07-9cb6-4838-a80d-b203f2c48ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7d2d2c18-09e3-4d33-ab3d-08db3516d927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_7db06f4f-05f9-4990-a31f-4d0ed5cdfb7f" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7d2d2c18-09e3-4d33-ab3d-08db3516d927" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8b9aa5d1-2f86-4099-ae9f-db0ea1878b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7d2d2c18-09e3-4d33-ab3d-08db3516d927" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8b9aa5d1-2f86-4099-ae9f-db0ea1878b14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8b9aa5d1-2f86-4099-ae9f-db0ea1878b14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b9aa5d1-2f86-4099-ae9f-db0ea1878b14" xlink:to="loc_us-gaap_SegmentDomain_8b9aa5d1-2f86-4099-ae9f-db0ea1878b14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e9cbb59e-1f4a-4fab-9cbd-399cf3e46742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b9aa5d1-2f86-4099-ae9f-db0ea1878b14" xlink:to="loc_us-gaap_SegmentDomain_e9cbb59e-1f4a-4fab-9cbd-399cf3e46742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_c0b6273a-02cf-4dab-9c7b-1febb0b1beb2" xlink:href="jnj-20221002.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e9cbb59e-1f4a-4fab-9cbd-399cf3e46742" xlink:to="loc_jnj_ConsumerMember_c0b6273a-02cf-4dab-9c7b-1febb0b1beb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_6c6df398-76cd-4962-ab7d-135f08c4d161" xlink:href="jnj-20221002.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e9cbb59e-1f4a-4fab-9cbd-399cf3e46742" xlink:to="loc_jnj_PharmaceuticalMember_6c6df398-76cd-4962-ab7d-135f08c4d161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_366783b6-1bbd-45af-8c48-875221075a4b" xlink:href="jnj-20221002.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e9cbb59e-1f4a-4fab-9cbd-399cf3e46742" xlink:to="loc_jnj_MedicalDevicesMember_366783b6-1bbd-45af-8c48-875221075a4b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="ibcda77db05b84aa69b5d8985f1a6fd1b_IntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0a289837-75be-4ff2-9683-8998f1f7497c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_191f1da9-5265-4099-a609-b3856224b4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0a289837-75be-4ff2-9683-8998f1f7497c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_191f1da9-5265-4099-a609-b3856224b4f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6a1892e8-03f4-4eaf-a408-bdc3a365336f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0a289837-75be-4ff2-9683-8998f1f7497c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6a1892e8-03f4-4eaf-a408-bdc3a365336f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f8c264ae-1e08-4c08-9bd2-3ef6764494b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0a289837-75be-4ff2-9683-8998f1f7497c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f8c264ae-1e08-4c08-9bd2-3ef6764494b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15168541-8290-4a2c-a551-d80942b90522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f8c264ae-1e08-4c08-9bd2-3ef6764494b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15168541-8290-4a2c-a551-d80942b90522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15168541-8290-4a2c-a551-d80942b90522_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15168541-8290-4a2c-a551-d80942b90522" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_15168541-8290-4a2c-a551-d80942b90522_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a09832ad-b88d-4df0-9c6b-ec2b2a1234e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15168541-8290-4a2c-a551-d80942b90522" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a09832ad-b88d-4df0-9c6b-ec2b2a1234e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_54c46f2b-0420-42fb-a17b-3c67f0a20def" xlink:href="jnj-20221002.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a09832ad-b88d-4df0-9c6b-ec2b2a1234e1" xlink:to="loc_jnj_PatentsAndTrademarksMember_54c46f2b-0420-42fb-a17b-3c67f0a20def" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e9014add-6ead-4804-8156-8a567eb358bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a09832ad-b88d-4df0-9c6b-ec2b2a1234e1" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e9014add-6ead-4804-8156-8a567eb358bc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i89b143d8721141f7b01aca791c387e8b_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_3ec46d00-1845-42f0-ad04-67c03ef590e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_3ec46d00-1845-42f0-ad04-67c03ef590e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2d70d89d-e06f-4215-afcd-cf5be657f1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2d70d89d-e06f-4215-afcd-cf5be657f1d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_cb4e03ab-c0cd-4908-91a7-392b41607a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_cb4e03ab-c0cd-4908-91a7-392b41607a8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_3f192c81-8c83-4796-8971-86b340a58e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_3f192c81-8c83-4796-8971-86b340a58e4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_3dffd967-1561-4a4a-98b8-ceeadd1560aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_3dffd967-1561-4a4a-98b8-ceeadd1560aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_76039188-754d-4f29-8977-492a9a8e6361" xlink:href="jnj-20221002.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_76039188-754d-4f29-8977-492a9a8e6361" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_e3bbb7bc-4404-4389-a0af-cfc0c30ffa91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_EquityFairValueAdjustment_e3bbb7bc-4404-4389-a0af-cfc0c30ffa91" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_de1dfb22-eb6a-4d43-b0bc-97e16b3f688b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_de1dfb22-eb6a-4d43-b0bc-97e16b3f688b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_8c0d87c0-4cb7-42ce-a2d5-3fdffed724ae" xlink:href="jnj-20221002.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_8c0d87c0-4cb7-42ce-a2d5-3fdffed724ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_db17961c-82b6-48f4-b489-eef3f75c9f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_ShortTermBorrowings_db17961c-82b6-48f4-b489-eef3f75c9f75" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_777bc7be-1209-48fc-8ff2-274fc3ebc9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_777bc7be-1209-48fc-8ff2-274fc3ebc9ac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_25cc3fcc-1fa7-48c3-92ae-02d74fda3c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_DebtInstrumentTerm_25cc3fcc-1fa7-48c3-92ae-02d74fda3c6e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_172cc7d4-2de9-4db9-899e-36431465977b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_172cc7d4-2de9-4db9-899e-36431465977b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_172cc7d4-2de9-4db9-899e-36431465977b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_172cc7d4-2de9-4db9-899e-36431465977b" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_172cc7d4-2de9-4db9-899e-36431465977b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a9b061a4-c171-4e40-bd14-5640a3a0180c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_172cc7d4-2de9-4db9-899e-36431465977b" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a9b061a4-c171-4e40-bd14-5640a3a0180c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_d62d7bd6-6373-4d61-a2c9-f9ee289d3136" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a9b061a4-c171-4e40-bd14-5640a3a0180c" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_d62d7bd6-6373-4d61-a2c9-f9ee289d3136" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4c343980-a67f-49c0-a0e2-c9eacb7eb937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4c343980-a67f-49c0-a0e2-c9eacb7eb937" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c343980-a67f-49c0-a0e2-c9eacb7eb937_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c343980-a67f-49c0-a0e2-c9eacb7eb937" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c343980-a67f-49c0-a0e2-c9eacb7eb937_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6c74155a-a5da-4de0-96e7-72ea763c50a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c343980-a67f-49c0-a0e2-c9eacb7eb937" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6c74155a-a5da-4de0-96e7-72ea763c50a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_1c495cd3-9274-478c-94c3-2232dbbeb5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6c74155a-a5da-4de0-96e7-72ea763c50a3" xlink:to="loc_us-gaap_EquitySecuritiesMember_1c495cd3-9274-478c-94c3-2232dbbeb5bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_62a0027a-5de8-40de-a8e2-08387e57ac75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_62a0027a-5de8-40de-a8e2-08387e57ac75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_62a0027a-5de8-40de-a8e2-08387e57ac75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_62a0027a-5de8-40de-a8e2-08387e57ac75" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_62a0027a-5de8-40de-a8e2-08387e57ac75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b377014d-5700-4633-a424-2482c22cacd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_62a0027a-5de8-40de-a8e2-08387e57ac75" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b377014d-5700-4633-a424-2482c22cacd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_53d468db-d26d-46cf-bec5-4f31c579b77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b377014d-5700-4633-a424-2482c22cacd6" xlink:to="loc_us-gaap_ForeignExchangeContractMember_53d468db-d26d-46cf-bec5-4f31c579b77b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_9da6b686-36bd-428f-a3d7-9f3c69aec88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b377014d-5700-4633-a424-2482c22cacd6" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_9da6b686-36bd-428f-a3d7-9f3c69aec88b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8c803644-0038-4984-b8cc-5f86d6152906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b377014d-5700-4633-a424-2482c22cacd6" xlink:to="loc_us-gaap_InterestRateSwapMember_8c803644-0038-4984-b8cc-5f86d6152906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_8b1436bf-b53e-4c5e-b8e4-553f8e92caae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_8b1436bf-b53e-4c5e-b8e4-553f8e92caae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8b1436bf-b53e-4c5e-b8e4-553f8e92caae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8b1436bf-b53e-4c5e-b8e4-553f8e92caae" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8b1436bf-b53e-4c5e-b8e4-553f8e92caae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_b3429f95-1d42-4113-9437-d1f17ae3b23c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8b1436bf-b53e-4c5e-b8e4-553f8e92caae" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_b3429f95-1d42-4113-9437-d1f17ae3b23c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7c3c27f7-e892-46be-97d2-1f421003d1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_b3429f95-1d42-4113-9437-d1f17ae3b23c" xlink:to="loc_us-gaap_CommercialPaperMember_7c3c27f7-e892-46be-97d2-1f421003d1b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended" id="id936963a28ed4b54a49020787a27e9af_FairValueMeasurementsSummaryofDerivativeActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbcabdae-9692-4350-a8eb-183138ca969e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_ee4d343d-1f58-4de5-b0c6-e9896b19b10b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbcabdae-9692-4350-a8eb-183138ca969e" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_ee4d343d-1f58-4de5-b0c6-e9896b19b10b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_fcc0513c-dd37-4bd6-abc6-474697d05c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbcabdae-9692-4350-a8eb-183138ca969e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_fcc0513c-dd37-4bd6-abc6-474697d05c9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_96f2c4f5-f646-4c0c-8780-0c8655833275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbcabdae-9692-4350-a8eb-183138ca969e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_96f2c4f5-f646-4c0c-8780-0c8655833275" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ff5a3632-5fdf-4eb0-bcfa-1957a5c97f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbcabdae-9692-4350-a8eb-183138ca969e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ff5a3632-5fdf-4eb0-bcfa-1957a5c97f11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9aaba60e-bbde-4c58-ba07-2884fb0ba1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ff5a3632-5fdf-4eb0-bcfa-1957a5c97f11" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9aaba60e-bbde-4c58-ba07-2884fb0ba1f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_9aaba60e-bbde-4c58-ba07-2884fb0ba1f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9aaba60e-bbde-4c58-ba07-2884fb0ba1f7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_9aaba60e-bbde-4c58-ba07-2884fb0ba1f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ca476510-ada3-4768-823e-340c549eda12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9aaba60e-bbde-4c58-ba07-2884fb0ba1f7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ca476510-ada3-4768-823e-340c549eda12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_73ec480e-009a-4698-94c3-b53dfa3dfdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ca476510-ada3-4768-823e-340c549eda12" xlink:to="loc_us-gaap_FairValueHedgingMember_73ec480e-009a-4698-94c3-b53dfa3dfdc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_4041a9ca-64e5-49bb-8f6e-ecaea307aa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ca476510-ada3-4768-823e-340c549eda12" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_4041a9ca-64e5-49bb-8f6e-ecaea307aa2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_09a9b3c0-36c4-4f55-9a8e-f04fa46a69d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ca476510-ada3-4768-823e-340c549eda12" xlink:to="loc_us-gaap_CashFlowHedgingMember_09a9b3c0-36c4-4f55-9a8e-f04fa46a69d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_435ad025-8a0a-4385-ab29-fc95ddd4a198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ff5a3632-5fdf-4eb0-bcfa-1957a5c97f11" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_435ad025-8a0a-4385-ab29-fc95ddd4a198" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_435ad025-8a0a-4385-ab29-fc95ddd4a198_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_435ad025-8a0a-4385-ab29-fc95ddd4a198" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_435ad025-8a0a-4385-ab29-fc95ddd4a198_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_435ad025-8a0a-4385-ab29-fc95ddd4a198" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_07974d1c-8887-4db5-87c0-5856fb39f4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:to="loc_us-gaap_InterestRateContractMember_07974d1c-8887-4db5-87c0-5856fb39f4a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ffbccd94-0abd-41f7-8de9-e3a703277c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ffbccd94-0abd-41f7-8de9-e3a703277c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_4c98b9c5-1583-4f9a-9551-59a3eab46634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_4c98b9c5-1583-4f9a-9551-59a3eab46634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_169105ad-8bc6-49c4-8d4e-f38fcd10f25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:to="loc_us-gaap_InterestRateSwapMember_169105ad-8bc6-49c4-8d4e-f38fcd10f25e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_ec5609ea-3e4c-4829-a2f5-c7ec07a987d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_ec5609ea-3e4c-4829-a2f5-c7ec07a987d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_150a1eb6-a1f8-426a-b70f-4d149693eaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ff5a3632-5fdf-4eb0-bcfa-1957a5c97f11" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_150a1eb6-a1f8-426a-b70f-4d149693eaf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_150a1eb6-a1f8-426a-b70f-4d149693eaf7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_150a1eb6-a1f8-426a-b70f-4d149693eaf7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_150a1eb6-a1f8-426a-b70f-4d149693eaf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_150a1eb6-a1f8-426a-b70f-4d149693eaf7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_bdade803-041d-4050-9aaa-a425741314c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:to="loc_us-gaap_SalesMember_bdade803-041d-4050-9aaa-a425741314c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_fd608c5d-291c-4d50-bf44-3be6a1b2c2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:to="loc_us-gaap_CostOfSalesMember_fd608c5d-291c-4d50-bf44-3be6a1b2c2d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1c151362-6e1a-4f82-8022-ef04b6d7caa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1c151362-6e1a-4f82-8022-ef04b6d7caa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_302d2d4d-e259-4c2d-8a08-26b23c676fc3" xlink:href="jnj-20221002.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_302d2d4d-e259-4c2d-8a08-26b23c676fc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_0bfdf39d-b0c8-4120-9ac1-dba9e0fd10d7" xlink:href="jnj-20221002.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_0bfdf39d-b0c8-4120-9ac1-dba9e0fd10d7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsDerivativesBalanceSheetLocationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="extended" id="i477b70b839084849b2b342a42b8cb799_FairValueMeasurementsDerivativesBalanceSheetLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_ff7b754c-3877-4e2c-a35a-c2d1547e5850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a80f3246-db87-4758-af8d-46ad26b1e7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ff7b754c-3877-4e2c-a35a-c2d1547e5850" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a80f3246-db87-4758-af8d-46ad26b1e7ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_fe91f3bb-2601-4665-a969-c04ff414cf95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ff7b754c-3877-4e2c-a35a-c2d1547e5850" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_fe91f3bb-2601-4665-a969-c04ff414cf95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_efc33891-ba2f-4b72-af0c-f86e2d843a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_ff7b754c-3877-4e2c-a35a-c2d1547e5850" xlink:to="loc_us-gaap_DerivativeTable_efc33891-ba2f-4b72-af0c-f86e2d843a9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cba27ebe-b06e-4e64-904a-468931821193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_efc33891-ba2f-4b72-af0c-f86e2d843a9c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cba27ebe-b06e-4e64-904a-468931821193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cba27ebe-b06e-4e64-904a-468931821193_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cba27ebe-b06e-4e64-904a-468931821193" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cba27ebe-b06e-4e64-904a-468931821193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_99c64ada-0ca4-4e16-8912-9c4c7425d596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cba27ebe-b06e-4e64-904a-468931821193" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_99c64ada-0ca4-4e16-8912-9c4c7425d596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_f18d31ea-fb5b-4a01-aa71-2dfd418d0ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_99c64ada-0ca4-4e16-8912-9c4c7425d596" xlink:to="loc_us-gaap_LongTermDebtMember_f18d31ea-fb5b-4a01-aa71-2dfd418d0ffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2969dbbe-e46a-411c-9c88-5fc576896540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_efc33891-ba2f-4b72-af0c-f86e2d843a9c" xlink:to="loc_us-gaap_HedgingDesignationAxis_2969dbbe-e46a-411c-9c88-5fc576896540" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2969dbbe-e46a-411c-9c88-5fc576896540_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_2969dbbe-e46a-411c-9c88-5fc576896540" xlink:to="loc_us-gaap_HedgingDesignationDomain_2969dbbe-e46a-411c-9c88-5fc576896540_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_79d457c3-9dfb-4016-9c27-05048246975e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_2969dbbe-e46a-411c-9c88-5fc576896540" xlink:to="loc_us-gaap_HedgingDesignationDomain_79d457c3-9dfb-4016-9c27-05048246975e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2f87a189-f7a4-4818-90d0-9b31c7c5307b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_79d457c3-9dfb-4016-9c27-05048246975e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2f87a189-f7a4-4818-90d0-9b31c7c5307b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i4c798d5db4fa4d9a81b794ade258e8f4_FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1aa7cdaa-26f1-4af9-a206-9d70dd8339e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_380c641e-790c-4020-8a55-b86e452d2dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1aa7cdaa-26f1-4af9-a206-9d70dd8339e3" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_380c641e-790c-4020-8a55-b86e452d2dde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90811a61-d8cb-4bea-83a3-401a15f1366e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1aa7cdaa-26f1-4af9-a206-9d70dd8339e3" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90811a61-d8cb-4bea-83a3-401a15f1366e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_63bf38fe-26e9-4c71-8695-7776f993170f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90811a61-d8cb-4bea-83a3-401a15f1366e" xlink:to="loc_us-gaap_HedgingDesignationAxis_63bf38fe-26e9-4c71-8695-7776f993170f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_63bf38fe-26e9-4c71-8695-7776f993170f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_63bf38fe-26e9-4c71-8695-7776f993170f" xlink:to="loc_us-gaap_HedgingDesignationDomain_63bf38fe-26e9-4c71-8695-7776f993170f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f9b6792c-cfa6-4e4e-b081-a9ff3ed29513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_63bf38fe-26e9-4c71-8695-7776f993170f" xlink:to="loc_us-gaap_HedgingDesignationDomain_f9b6792c-cfa6-4e4e-b081-a9ff3ed29513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_961743c8-53a5-4866-883a-bab16f3fa2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f9b6792c-cfa6-4e4e-b081-a9ff3ed29513" xlink:to="loc_us-gaap_NondesignatedMember_961743c8-53a5-4866-883a-bab16f3fa2cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_74238876-3fdc-4315-8428-1ce1562b8466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90811a61-d8cb-4bea-83a3-401a15f1366e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_74238876-3fdc-4315-8428-1ce1562b8466" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_74238876-3fdc-4315-8428-1ce1562b8466_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_74238876-3fdc-4315-8428-1ce1562b8466" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_74238876-3fdc-4315-8428-1ce1562b8466_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f84bb8a2-b50a-4b4c-a1e7-9e8ba5e6c358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_74238876-3fdc-4315-8428-1ce1562b8466" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f84bb8a2-b50a-4b4c-a1e7-9e8ba5e6c358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_93d85692-2917-48d8-b183-001872752371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f84bb8a2-b50a-4b4c-a1e7-9e8ba5e6c358" xlink:to="loc_us-gaap_ForeignExchangeContractMember_93d85692-2917-48d8-b183-001872752371" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7d69e06f-5f19-481f-9202-eded5e01f4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90811a61-d8cb-4bea-83a3-401a15f1366e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7d69e06f-5f19-481f-9202-eded5e01f4b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d69e06f-5f19-481f-9202-eded5e01f4b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7d69e06f-5f19-481f-9202-eded5e01f4b4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d69e06f-5f19-481f-9202-eded5e01f4b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20ce88e5-6a32-4b12-98d7-1cd22307b169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7d69e06f-5f19-481f-9202-eded5e01f4b4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20ce88e5-6a32-4b12-98d7-1cd22307b169" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_df55433e-33ee-411c-940f-b22e6c0d8c88" xlink:href="jnj-20221002.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_20ce88e5-6a32-4b12-98d7-1cd22307b169" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_df55433e-33ee-411c-940f-b22e6c0d8c88" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="i80b04ad62533471fb8749b8627ecf0dd_FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_af0691d6-b40f-40bf-a52e-2c9421a97fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_7953708b-6c1a-4007-87c7-fef568855fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_af0691d6-b40f-40bf-a52e-2c9421a97fa4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_7953708b-6c1a-4007-87c7-fef568855fd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_c19e050b-2d0d-4cd9-8118-d2554acae0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_af0691d6-b40f-40bf-a52e-2c9421a97fa4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_c19e050b-2d0d-4cd9-8118-d2554acae0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f569b13a-9e0f-440a-8695-d31e10aef4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_af0691d6-b40f-40bf-a52e-2c9421a97fa4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f569b13a-9e0f-440a-8695-d31e10aef4de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c4c63adb-670a-4130-bd84-32466542f0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f569b13a-9e0f-440a-8695-d31e10aef4de" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c4c63adb-670a-4130-bd84-32466542f0f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c4c63adb-670a-4130-bd84-32466542f0f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c4c63adb-670a-4130-bd84-32466542f0f5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c4c63adb-670a-4130-bd84-32466542f0f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bc586b9b-1b72-419c-989a-a834d382b99d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c4c63adb-670a-4130-bd84-32466542f0f5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bc586b9b-1b72-419c-989a-a834d382b99d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_b4e186be-c776-4f67-8ecb-50c107c3c0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bc586b9b-1b72-419c-989a-a834d382b99d" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_b4e186be-c776-4f67-8ecb-50c107c3c0aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_928bf3b8-05d4-42c5-9c54-b1ff122ea03b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f569b13a-9e0f-440a-8695-d31e10aef4de" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_928bf3b8-05d4-42c5-9c54-b1ff122ea03b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_928bf3b8-05d4-42c5-9c54-b1ff122ea03b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_928bf3b8-05d4-42c5-9c54-b1ff122ea03b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_928bf3b8-05d4-42c5-9c54-b1ff122ea03b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5d36715d-94ac-4694-8181-e0226c21f277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_928bf3b8-05d4-42c5-9c54-b1ff122ea03b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5d36715d-94ac-4694-8181-e0226c21f277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_165a0242-01d1-4afa-9805-b9e4a2ee441c" xlink:href="jnj-20221002.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5d36715d-94ac-4694-8181-e0226c21f277" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_165a0242-01d1-4afa-9805-b9e4a2ee441c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended" id="i44d3a420f5c742f6bdabf41ccb7e062a_FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_80ff6a6e-ca07-457c-a688-8b8a619f85dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_80ff6a6e-ca07-457c-a688-8b8a619f85dc" xlink:to="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_9055beb7-627d-4b9f-bb0f-119eef70b56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_9055beb7-627d-4b9f-bb0f-119eef70b56c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5fdacfe5-63c0-45e7-927c-31debb6a858c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5fdacfe5-63c0-45e7-927c-31debb6a858c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_c49b0302-fe46-45e5-bd8f-78ce8cc83d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_us-gaap_EquityFairValueAdjustment_c49b0302-fe46-45e5-bd8f-78ce8cc83d4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_517bb0ca-e9fd-4818-bec7-85363286edef" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_517bb0ca-e9fd-4818-bec7-85363286edef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_391eb994-7e91-466f-990b-e1086e4b628f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_2b97f05e-9126-4ed5-9afc-8bfecde71ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_58ebc535-29be-4c10-8941-c1db17ebde30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_58ebc535-29be-4c10-8941-c1db17ebde30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_101173f1-b8b9-4fe2-96f6-016b6e75e6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_80ff6a6e-ca07-457c-a688-8b8a619f85dc" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_101173f1-b8b9-4fe2-96f6-016b6e75e6da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_691a5bda-16ee-4338-bfe2-16de78a2af15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_101173f1-b8b9-4fe2-96f6-016b6e75e6da" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_691a5bda-16ee-4338-bfe2-16de78a2af15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_691a5bda-16ee-4338-bfe2-16de78a2af15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_691a5bda-16ee-4338-bfe2-16de78a2af15" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_691a5bda-16ee-4338-bfe2-16de78a2af15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_785bd17d-2e06-4965-abdd-c01ff40334ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_691a5bda-16ee-4338-bfe2-16de78a2af15" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_785bd17d-2e06-4965-abdd-c01ff40334ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_fe055187-7f9a-493e-8afc-95201aa8678c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_785bd17d-2e06-4965-abdd-c01ff40334ca" xlink:to="loc_us-gaap_EquitySecuritiesMember_fe055187-7f9a-493e-8afc-95201aa8678c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4a23ea7f-f367-4807-a24e-2ac0bbd6543a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_101173f1-b8b9-4fe2-96f6-016b6e75e6da" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4a23ea7f-f367-4807-a24e-2ac0bbd6543a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4a23ea7f-f367-4807-a24e-2ac0bbd6543a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4a23ea7f-f367-4807-a24e-2ac0bbd6543a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_4a23ea7f-f367-4807-a24e-2ac0bbd6543a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f2208a09-efb6-49dc-af2a-a54b89019790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4a23ea7f-f367-4807-a24e-2ac0bbd6543a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f2208a09-efb6-49dc-af2a-a54b89019790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5f5d01d2-ad11-4772-9be2-cb13add23f41" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f2208a09-efb6-49dc-af2a-a54b89019790" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5f5d01d2-ad11-4772-9be2-cb13add23f41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_074fce4a-07a5-499c-94eb-2dc32f1288c4" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f2208a09-efb6-49dc-af2a-a54b89019790" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_074fce4a-07a5-499c-94eb-2dc32f1288c4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended" id="i66936a0b982e4939b4951a29dd9cd1d4_FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_097b7d1a-9793-4798-a289-693769369d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_097b7d1a-9793-4798-a289-693769369d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_d99ab10f-c1a7-4fd5-8e89-eb63673da538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_d99ab10f-c1a7-4fd5-8e89-eb63673da538" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_02e64078-7d62-4f17-a072-748498399489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_02e64078-7d62-4f17-a072-748498399489" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_3a31c1b6-090c-453e-b8fd-73ff59f5722e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_3a31c1b6-090c-453e-b8fd-73ff59f5722e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_162166e1-620b-4a6a-8d27-e54bfece775f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_162166e1-620b-4a6a-8d27-e54bfece775f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82c8aac5-b44f-4966-b229-391ecab0688b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82c8aac5-b44f-4966-b229-391ecab0688b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_269f633f-515b-4709-910d-0704890cbe77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_269f633f-515b-4709-910d-0704890cbe77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_39df2b3b-b5e2-4a5a-b132-3e4a7b4f0379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_39df2b3b-b5e2-4a5a-b132-3e4a7b4f0379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_2a20ae15-443f-430a-a8a2-86ec55c453b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_2a20ae15-443f-430a-a8a2-86ec55c453b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6356c585-750b-4e35-95a1-668c2fd5e6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeAssets_6356c585-750b-4e35-95a1-668c2fd5e6d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3aad65fe-7f44-4ecb-9680-700c7e188e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3aad65fe-7f44-4ecb-9680-700c7e188e3a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_0eb02fc1-5f40-451f-ac6b-6f055d34cd30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_0eb02fc1-5f40-451f-ac6b-6f055d34cd30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1d390170-38bb-4dc4-bd24-49b60bfcff78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeLiabilities_1d390170-38bb-4dc4-bd24-49b60bfcff78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_02a511a2-bb8d-4f72-85a4-0cd5066b453d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_02a511a2-bb8d-4f72-85a4-0cd5066b453d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_64bd732d-6e1c-4685-b4ad-355ff80b0b45" xlink:href="jnj-20221002.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_64bd732d-6e1c-4685-b4ad-355ff80b0b45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4b9f4e34-f8d2-4f0e-8716-ada0123c2f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4b9f4e34-f8d2-4f0e-8716-ada0123c2f38" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15653af7-ec20-4863-885c-b625f91307ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15653af7-ec20-4863-885c-b625f91307ed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bf1cc182-cb96-4be7-b975-2c6c913dcd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_32d89bd0-edbe-46cd-90c8-1ef03793feb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_32d89bd0-edbe-46cd-90c8-1ef03793feb6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_720718e0-bde2-411f-a7aa-4c4c121f40f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_720718e0-bde2-411f-a7aa-4c4c121f40f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_720718e0-bde2-411f-a7aa-4c4c121f40f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_720718e0-bde2-411f-a7aa-4c4c121f40f9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_720718e0-bde2-411f-a7aa-4c4c121f40f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7945e9ce-bd9d-4400-b2de-47026a64be89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_720718e0-bde2-411f-a7aa-4c4c121f40f9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7945e9ce-bd9d-4400-b2de-47026a64be89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1c70e06a-f52f-4694-897c-816d960d6a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7945e9ce-bd9d-4400-b2de-47026a64be89" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1c70e06a-f52f-4694-897c-816d960d6a81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_334312b4-2a21-4820-823a-e917de2c9506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7945e9ce-bd9d-4400-b2de-47026a64be89" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_334312b4-2a21-4820-823a-e917de2c9506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_80a8deb1-1862-4185-8de0-757ea3100137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7945e9ce-bd9d-4400-b2de-47026a64be89" xlink:to="loc_us-gaap_LongTermDebtMember_80a8deb1-1862-4185-8de0-757ea3100137" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c2cad9e7-73a3-474b-a635-eda13ee741a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c2cad9e7-73a3-474b-a635-eda13ee741a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c2cad9e7-73a3-474b-a635-eda13ee741a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c2cad9e7-73a3-474b-a635-eda13ee741a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c2cad9e7-73a3-474b-a635-eda13ee741a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53dfc41-652d-497a-aff6-bc69b8e46d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c2cad9e7-73a3-474b-a635-eda13ee741a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53dfc41-652d-497a-aff6-bc69b8e46d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_ebabcfa8-ab0f-48d4-85cd-3afd126f5f81" xlink:href="jnj-20221002.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53dfc41-652d-497a-aff6-bc69b8e46d72" xlink:to="loc_jnj_AurisHealthMember_ebabcfa8-ab0f-48d4-85cd-3afd126f5f81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_49cb5bc1-f03c-4820-aa6c-5e7cb7a1002e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_InvestmentTypeAxis_49cb5bc1-f03c-4820-aa6c-5e7cb7a1002e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_49cb5bc1-f03c-4820-aa6c-5e7cb7a1002e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_49cb5bc1-f03c-4820-aa6c-5e7cb7a1002e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_49cb5bc1-f03c-4820-aa6c-5e7cb7a1002e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ad0a50a4-0eff-4e79-8f85-3582ebcb0b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_49cb5bc1-f03c-4820-aa6c-5e7cb7a1002e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ad0a50a4-0eff-4e79-8f85-3582ebcb0b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_20b8b637-59d7-4936-94bf-ee5d60279242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ad0a50a4-0eff-4e79-8f85-3582ebcb0b57" xlink:to="loc_us-gaap_EquitySecuritiesMember_20b8b637-59d7-4936-94bf-ee5d60279242" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5a9ae5c0-a11b-42f4-99c9-00535f05f786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5a9ae5c0-a11b-42f4-99c9-00535f05f786" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5a9ae5c0-a11b-42f4-99c9-00535f05f786_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5a9ae5c0-a11b-42f4-99c9-00535f05f786" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5a9ae5c0-a11b-42f4-99c9-00535f05f786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d256b6d2-ae69-4013-a971-f89d151c01be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5a9ae5c0-a11b-42f4-99c9-00535f05f786" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d256b6d2-ae69-4013-a971-f89d151c01be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_f248aaa4-d40a-44c8-aa0d-8ef5a9b28d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d256b6d2-ae69-4013-a971-f89d151c01be" xlink:to="loc_us-gaap_InterestRateContractMember_f248aaa4-d40a-44c8-aa0d-8ef5a9b28d6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0ae8f9a7-c865-4b53-8150-ecd10724a401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d256b6d2-ae69-4013-a971-f89d151c01be" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0ae8f9a7-c865-4b53-8150-ecd10724a401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_d71bd646-9bfc-498b-94db-4e5f4b57d509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d256b6d2-ae69-4013-a971-f89d151c01be" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_d71bd646-9bfc-498b-94db-4e5f4b57d509" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d02bedb-dc21-4d95-b158-c546b341bb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d02bedb-dc21-4d95-b158-c546b341bb52" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d02bedb-dc21-4d95-b158-c546b341bb52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d02bedb-dc21-4d95-b158-c546b341bb52" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d02bedb-dc21-4d95-b158-c546b341bb52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90ca92a2-f215-4d24-a434-6d64356125c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d02bedb-dc21-4d95-b158-c546b341bb52" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90ca92a2-f215-4d24-a434-6d64356125c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_47e5a653-3f33-48b0-8bb3-966ff3e13ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90ca92a2-f215-4d24-a434-6d64356125c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_47e5a653-3f33-48b0-8bb3-966ff3e13ca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_37421012-5b96-4904-aede-d184e9b51817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90ca92a2-f215-4d24-a434-6d64356125c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_37421012-5b96-4904-aede-d184e9b51817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_74c873a2-9a3f-4c9a-a02e-c2d8e11ba3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90ca92a2-f215-4d24-a434-6d64356125c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_74c873a2-9a3f-4c9a-a02e-c2d8e11ba3b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4d324c4b-976a-4982-80e3-61c3c13c1f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4d324c4b-976a-4982-80e3-61c3c13c1f9c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4d324c4b-976a-4982-80e3-61c3c13c1f9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4d324c4b-976a-4982-80e3-61c3c13c1f9c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4d324c4b-976a-4982-80e3-61c3c13c1f9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_cc08c22b-a4e5-433f-80fa-df7e5472cb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4d324c4b-976a-4982-80e3-61c3c13c1f9c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_cc08c22b-a4e5-433f-80fa-df7e5472cb96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_dca2ddae-8d0b-4e18-a355-4fbc9a7293b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_cc08c22b-a4e5-433f-80fa-df7e5472cb96" xlink:to="loc_us-gaap_FairValueHedgingMember_dca2ddae-8d0b-4e18-a355-4fbc9a7293b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2bd99df2-ee54-4a42-b815-adc8e41f0870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2bd99df2-ee54-4a42-b815-adc8e41f0870" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2bd99df2-ee54-4a42-b815-adc8e41f0870_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2bd99df2-ee54-4a42-b815-adc8e41f0870" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2bd99df2-ee54-4a42-b815-adc8e41f0870_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3846b060-5436-44e5-840c-b4280aa8d704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2bd99df2-ee54-4a42-b815-adc8e41f0870" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3846b060-5436-44e5-840c-b4280aa8d704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b3779629-5f2d-4a85-b90b-81b777792e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3846b060-5436-44e5-840c-b4280aa8d704" xlink:to="loc_us-gaap_EquitySecuritiesMember_b3779629-5f2d-4a85-b90b-81b777792e58" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="i59cb084fc3164fb7b08f9e31f2804495_FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_3a996b1f-e3f3-4dc0-8025-274bccae4bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_88589c8e-a9ef-4297-a7b9-eb8becbe1622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3a996b1f-e3f3-4dc0-8025-274bccae4bcc" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_88589c8e-a9ef-4297-a7b9-eb8becbe1622" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_115ae4af-ecba-4df5-909d-d083266f5c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_88589c8e-a9ef-4297-a7b9-eb8becbe1622" xlink:to="loc_us-gaap_HeldToMaturitySecurities_115ae4af-ecba-4df5-909d-d083266f5c02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_fa66ff64-c758-48c8-a4fe-e9a4b101033d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_88589c8e-a9ef-4297-a7b9-eb8becbe1622" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_fa66ff64-c758-48c8-a4fe-e9a4b101033d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_999bd5ad-15d0-4208-8130-fe2d83ba0813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_88589c8e-a9ef-4297-a7b9-eb8becbe1622" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_999bd5ad-15d0-4208-8130-fe2d83ba0813" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a2be47f-0665-4c25-adf2-874ebfb2d507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3a996b1f-e3f3-4dc0-8025-274bccae4bcc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a2be47f-0665-4c25-adf2-874ebfb2d507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b2ebcf0e-1ba9-4b25-baa7-2b42f91a4735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a2be47f-0665-4c25-adf2-874ebfb2d507" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b2ebcf0e-1ba9-4b25-baa7-2b42f91a4735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b3a2e222-206b-4097-bea2-5ceab6d569f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a2be47f-0665-4c25-adf2-874ebfb2d507" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b3a2e222-206b-4097-bea2-5ceab6d569f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_592bbd9f-300b-4ef2-9882-4f1ca9e86e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a2be47f-0665-4c25-adf2-874ebfb2d507" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_592bbd9f-300b-4ef2-9882-4f1ca9e86e84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3a996b1f-e3f3-4dc0-8025-274bccae4bcc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_964fbb4c-528f-4f9b-8e40-c9821d165b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_964fbb4c-528f-4f9b-8e40-c9821d165b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_dc326126-4330-4edf-85c5-13dd568ab150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_dc326126-4330-4edf-85c5-13dd568ab150" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_9d44606f-bc4d-462d-aac7-b273791bb747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_9d44606f-bc4d-462d-aac7-b273791bb747" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_46e5573a-1de3-4c21-b5c3-89d7c4a4fe6f" xlink:href="jnj-20221002.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_46e5573a-1de3-4c21-b5c3-89d7c4a4fe6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_db8c0502-074f-43c3-ad9c-9ce7e173d970" xlink:href="jnj-20221002.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_db8c0502-074f-43c3-ad9c-9ce7e173d970" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_67a63903-cb7e-413e-af94-964640cf55ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3a996b1f-e3f3-4dc0-8025-274bccae4bcc" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_67a63903-cb7e-413e-af94-964640cf55ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_eb2cf4dd-5e37-4fa8-abe5-1a7807e87301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_67a63903-cb7e-413e-af94-964640cf55ea" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_eb2cf4dd-5e37-4fa8-abe5-1a7807e87301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_eb2cf4dd-5e37-4fa8-abe5-1a7807e87301_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_eb2cf4dd-5e37-4fa8-abe5-1a7807e87301" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_eb2cf4dd-5e37-4fa8-abe5-1a7807e87301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a5a5e66d-3756-49c2-ac0a-416f3aa2dc43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_eb2cf4dd-5e37-4fa8-abe5-1a7807e87301" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a5a5e66d-3756-49c2-ac0a-416f3aa2dc43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_47901bd2-eb40-4310-a4ea-4ec1f4a60ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a5a5e66d-3756-49c2-ac0a-416f3aa2dc43" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_47901bd2-eb40-4310-a4ea-4ec1f4a60ea2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_fa4aa352-350c-45e2-b2ca-db48385f96ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a5a5e66d-3756-49c2-ac0a-416f3aa2dc43" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_fa4aa352-350c-45e2-b2ca-db48385f96ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ccf411ac-859e-435d-aad6-c5fb1a49daf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_67a63903-cb7e-413e-af94-964640cf55ea" xlink:to="loc_us-gaap_InvestmentTypeAxis_ccf411ac-859e-435d-aad6-c5fb1a49daf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ccf411ac-859e-435d-aad6-c5fb1a49daf2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_ccf411ac-859e-435d-aad6-c5fb1a49daf2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ccf411ac-859e-435d-aad6-c5fb1a49daf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_ccf411ac-859e-435d-aad6-c5fb1a49daf2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_04d1d8a3-d7f1-4b0b-8fab-add4c936e15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_CashMember_04d1d8a3-d7f1-4b0b-8fab-add4c936e15d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_4dcc3182-7f81-48d6-a40b-c9ffa511a865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_4dcc3182-7f81-48d6-a40b-c9ffa511a865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ce09936b-45e7-4235-96fb-5a019dfcc493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ce09936b-45e7-4235-96fb-5a019dfcc493" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_17e39efe-e03f-4724-bd95-9420cb9a2172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_17e39efe-e03f-4724-bd95-9420cb9a2172" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_482d3727-86e8-4ee8-8eb3-cdc43ec3e098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_482d3727-86e8-4ee8-8eb3-cdc43ec3e098" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_b392355e-aeaa-4e00-ba56-0df374e114b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_BankTimeDepositsMember_b392355e-aeaa-4e00-ba56-0df374e114b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8ba44bd5-fc82-45b8-bdaa-8239d992027f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8ba44bd5-fc82-45b8-bdaa-8239d992027f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ead8d65a-d593-4c8b-b285-de1eeeadfdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_67a63903-cb7e-413e-af94-964640cf55ea" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ead8d65a-d593-4c8b-b285-de1eeeadfdec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ead8d65a-d593-4c8b-b285-de1eeeadfdec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ead8d65a-d593-4c8b-b285-de1eeeadfdec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ead8d65a-d593-4c8b-b285-de1eeeadfdec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cafb2f3-d61d-4acc-92a2-c760f13c7ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ead8d65a-d593-4c8b-b285-de1eeeadfdec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cafb2f3-d61d-4acc-92a2-c760f13c7ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_e55028f7-da7a-428c-b3ef-d1069b164481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cafb2f3-d61d-4acc-92a2-c760f13c7ead" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_e55028f7-da7a-428c-b3ef-d1069b164481" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_667331a0-f444-4103-bea8-d37c02234147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cafb2f3-d61d-4acc-92a2-c760f13c7ead" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_667331a0-f444-4103-bea8-d37c02234147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_47693012-8da5-438c-b1df-2782930a2e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cafb2f3-d61d-4acc-92a2-c760f13c7ead" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_47693012-8da5-438c-b1df-2782930a2e81" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended" id="i53204c979da548f8884fbb6b30a87a69_FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24c5ea2-2622-47dd-b79e-f174db801049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24c5ea2-2622-47dd-b79e-f174db801049" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_84dcafd7-8fef-4cf0-89f9-f64a61129017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_84dcafd7-8fef-4cf0-89f9-f64a61129017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_e589ea81-27d5-49b4-a33b-b8f89108a1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_84dcafd7-8fef-4cf0-89f9-f64a61129017" xlink:to="loc_us-gaap_ShortTermBorrowings_e589ea81-27d5-49b4-a33b-b8f89108a1e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_5f3fc2aa-b8d7-41b7-a4e7-5dbf97de40bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_5f3fc2aa-b8d7-41b7-a4e7-5dbf97de40bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2bc7f919-4a97-4132-8d59-b93ef4e3b102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_5f3fc2aa-b8d7-41b7-a4e7-5dbf97de40bb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2bc7f919-4a97-4132-8d59-b93ef4e3b102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fcd257de-cb62-4523-a769-a30936a79bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fcd257de-cb62-4523-a769-a30936a79bfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8c72d7fd-b8e9-419c-a591-3ab4aa802651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8c72d7fd-b8e9-419c-a591-3ab4aa802651" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_b5dd2d47-680e-46f9-ad86-02ec8839ee3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_b5dd2d47-680e-46f9-ad86-02ec8839ee3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_76980449-67af-46af-a611-75d544ebee6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24c5ea2-2622-47dd-b79e-f174db801049" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_76980449-67af-46af-a611-75d544ebee6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_89cfdbba-3865-4bed-98be-092712a6c600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_76980449-67af-46af-a611-75d544ebee6e" xlink:to="loc_us-gaap_DebtInstrumentAxis_89cfdbba-3865-4bed-98be-092712a6c600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_89cfdbba-3865-4bed-98be-092712a6c600_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_89cfdbba-3865-4bed-98be-092712a6c600" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_89cfdbba-3865-4bed-98be-092712a6c600_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_89cfdbba-3865-4bed-98be-092712a6c600" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_47fea8f5-4486-4d3a-bf83-140c863054ed" xlink:href="jnj-20221002.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_47fea8f5-4486-4d3a-bf83-140c863054ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_03ba06fd-58fe-4cd3-a497-38db57487e96" xlink:href="jnj-20221002.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.375Notesdue2023Member_03ba06fd-58fe-4cd3-a497-38db57487e96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_9c0260a0-11f1-4d56-bae1-a84acd95fad9" xlink:href="jnj-20221002.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A0.650NotesDue2024Member_9c0260a0-11f1-4d56-bae1-a84acd95fad9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_847343c6-238a-4e67-8b19-2045080d90af" xlink:href="jnj-20221002.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A5.50NotesDue2024Member_847343c6-238a-4e67-8b19-2045080d90af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_db82ee49-bd48-4bf5-ac0c-72862ac41f98" xlink:href="jnj-20221002.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2.625Notesdue2025Member_db82ee49-bd48-4bf5-ac0c-72862ac41f98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_952e88b2-c937-4898-bf60-c6dca9509ccd" xlink:href="jnj-20221002.xsd#jnj_A0550NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A0550NotesDue2025Member_952e88b2-c937-4898-bf60-c6dca9509ccd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_1ec7fe24-918d-4c94-a4f3-56df953862db" xlink:href="jnj-20221002.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2.45Notesdue2026Member_1ec7fe24-918d-4c94-a4f3-56df953862db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_a1a2219a-a0fc-4b23-9899-841d1a453b6e" xlink:href="jnj-20221002.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2.95Notesdue2027Member_a1a2219a-a0fc-4b23-9899-841d1a453b6e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_d3071828-b7fa-44fd-99c5-925e414b86f3" xlink:href="jnj-20221002.xsd#jnj_A095NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A095NotesDue2027Member_d3071828-b7fa-44fd-99c5-925e414b86f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_e6c1fcd6-2bbd-4b99-8e68-ca67d1fb7c63" xlink:href="jnj-20221002.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2.900Notesdue2028Member_e6c1fcd6-2bbd-4b99-8e68-ca67d1fb7c63" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_967ec95d-0b31-441c-8245-1b21a99383b6" xlink:href="jnj-20221002.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A1.150NotesDue2028Member_967ec95d-0b31-441c-8245-1b21a99383b6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_16430ef6-43e2-4b94-907b-607c3a2c4cd1" xlink:href="jnj-20221002.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A6.95Notesdue2029Member_16430ef6-43e2-4b94-907b-607c3a2c4cd1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_ec9f398f-7fa5-4266-927a-44746abe32bc" xlink:href="jnj-20221002.xsd#jnj_A1300NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A1300NotesDue2030Member_ec9f398f-7fa5-4266-927a-44746abe32bc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_d301a942-448a-4345-a505-46b4732144c7" xlink:href="jnj-20221002.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_d301a942-448a-4345-a505-46b4732144c7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_4c93acc7-8b33-42ca-ab4c-bfc86eb4b39d" xlink:href="jnj-20221002.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A4.375Notesdue2033Member_4c93acc7-8b33-42ca-ab4c-bfc86eb4b39d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_e252ab84-62ea-49d0-b521-098870f4315d" xlink:href="jnj-20221002.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A1.650NotesDue2035Member_e252ab84-62ea-49d0-b521-098870f4315d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_91f7ff6e-632f-461b-b62f-2670b257553c" xlink:href="jnj-20221002.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.55Notesdue2036Member_91f7ff6e-632f-461b-b62f-2670b257553c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_834b670a-ac15-4ea0-9082-add3c6670013" xlink:href="jnj-20221002.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A5.95Notesdue2037Member_834b670a-ac15-4ea0-9082-add3c6670013" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_bd9a9bf9-8cea-46b6-8189-e13f3e499272" xlink:href="jnj-20221002.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.625Notesdue2037Member_bd9a9bf9-8cea-46b6-8189-e13f3e499272" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_f7c864a1-6a4a-4e74-bb44-4579fc35b1b1" xlink:href="jnj-20221002.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.400Notesdue2038Member_f7c864a1-6a4a-4e74-bb44-4579fc35b1b1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_1ef80614-99bb-4b50-8a8a-3ddebc0662ff" xlink:href="jnj-20221002.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_1ef80614-99bb-4b50-8a8a-3ddebc0662ff" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_0666a3e1-268a-4006-b428-d85cfcd3275e" xlink:href="jnj-20221002.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_0666a3e1-268a-4006-b428-d85cfcd3275e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_480e6f88-4c93-44b2-98cb-4fc3c46abd3d" xlink:href="jnj-20221002.xsd#jnj_A210NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A210NotesDue2040Member_480e6f88-4c93-44b2-98cb-4fc3c46abd3d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_b019efe2-4cb8-4c69-aa19-ef1fa726111e" xlink:href="jnj-20221002.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A4.85Notesdue2041Member_b019efe2-4cb8-4c69-aa19-ef1fa726111e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_46b1c8f6-3d07-49ef-9dff-9af13bf3161f" xlink:href="jnj-20221002.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A4.50Notesdue2043Member_46b1c8f6-3d07-49ef-9dff-9af13bf3161f" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_ad6c79b9-a3c4-403a-9afc-32293e03fc6f" xlink:href="jnj-20221002.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.70Notesdue2046Member_ad6c79b9-a3c4-403a-9afc-32293e03fc6f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_fd607e03-57ce-4d18-b140-cc5665c53584" xlink:href="jnj-20221002.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.75Notesdue2047Member_fd607e03-57ce-4d18-b140-cc5665c53584" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_b097ebfc-edd8-4ca6-bfea-08598bb3fd93" xlink:href="jnj-20221002.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.500Notesdue2048Member_b097ebfc-edd8-4ca6-bfea-08598bb3fd93" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_ba07fab6-946b-4b6c-bcaa-fdb1efb2a4be" xlink:href="jnj-20221002.xsd#jnj_A2250NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2250NotesDue2050Member_ba07fab6-946b-4b6c-bcaa-fdb1efb2a4be" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_789d448b-9b65-4150-9a61-8e4d33c2eaba" xlink:href="jnj-20221002.xsd#jnj_A2450NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2450NotesDue2060Member_789d448b-9b65-4150-9a61-8e4d33c2eaba" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_34b01aeb-6941-41a6-86a5-f7fccef4b608" xlink:href="jnj-20221002.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_34b01aeb-6941-41a6-86a5-f7fccef4b608" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_8172387d-4509-4871-a56b-2a4c4adfd4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_76980449-67af-46af-a611-75d544ebee6e" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_8172387d-4509-4871-a56b-2a4c4adfd4a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8172387d-4509-4871-a56b-2a4c4adfd4a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8172387d-4509-4871-a56b-2a4c4adfd4a9" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8172387d-4509-4871-a56b-2a4c4adfd4a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_eef7ec76-0f30-4380-bea7-3664f520e14a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8172387d-4509-4871-a56b-2a4c4adfd4a9" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_eef7ec76-0f30-4380-bea7-3664f520e14a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2fe2b2d1-4d43-4d25-b2c6-862598b941a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_eef7ec76-0f30-4380-bea7-3664f520e14a" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2fe2b2d1-4d43-4d25-b2c6-862598b941a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_f2935a70-611e-4e16-bb66-d8ce3f04a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2fe2b2d1-4d43-4d25-b2c6-862598b941a2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_f2935a70-611e-4e16-bb66-d8ce3f04a6e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_06e88b1b-67f0-4813-9669-9e5108e43d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2fe2b2d1-4d43-4d25-b2c6-862598b941a2" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_06e88b1b-67f0-4813-9669-9e5108e43d55" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended" id="i6a5a4a54e8ec4989bbad550f991d20f6_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_57d0f201-4bed-4830-adf3-72b44fe2278f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_57d0f201-4bed-4830-adf3-72b44fe2278f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncrementalIncreaseDecreaseInTaxes_8b085bd8-3143-4587-bc6d-b6b0b6674aaa" xlink:href="jnj-20221002.xsd#jnj_IncrementalIncreaseDecreaseInTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_jnj_IncrementalIncreaseDecreaseInTaxes_8b085bd8-3143-4587-bc6d-b6b0b6674aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OneTimeFavorableTaxItemPercent_116bad73-bf69-4fd1-b134-777acfdf5844" xlink:href="jnj-20221002.xsd#jnj_OneTimeFavorableTaxItemPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_jnj_OneTimeFavorableTaxItemPercent_116bad73-bf69-4fd1-b134-777acfdf5844" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_0ea186e5-08d3-4138-8081-3b307855f00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_us-gaap_LitigationSettlementExpense_0ea186e5-08d3-4138-8081-3b307855f00a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_dba00106-b26f-4077-b227-70ea2d867878" xlink:href="jnj-20221002.xsd#jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_dba00106-b26f-4077-b227-70ea2d867878" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9557625f-9519-4e3c-8415-add1f3018432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9557625f-9519-4e3c-8415-add1f3018432" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_5e8becb9-8e7b-4067-88a5-88f2c43b1bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_5e8becb9-8e7b-4067-88a5-88f2c43b1bf8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e42f8fd4-3359-4b3d-8140-638d8626f226" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:to="loc_srt_LitigationCaseAxis_e42f8fd4-3359-4b3d-8140-638d8626f226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e42f8fd4-3359-4b3d-8140-638d8626f226_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_e42f8fd4-3359-4b3d-8140-638d8626f226" xlink:to="loc_srt_LitigationCaseTypeDomain_e42f8fd4-3359-4b3d-8140-638d8626f226_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c21fb7ea-6c88-470e-afcb-619f315f1f71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_e42f8fd4-3359-4b3d-8140-638d8626f226" xlink:to="loc_srt_LitigationCaseTypeDomain_c21fb7ea-6c88-470e-afcb-619f315f1f71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_c514c123-e87a-4bb9-8919-a968a0bbd1af" xlink:href="jnj-20221002.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c21fb7ea-6c88-470e-afcb-619f315f1f71" xlink:to="loc_jnj_TalcMember_c514c123-e87a-4bb9-8919-a968a0bbd1af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_afdbd375-a88e-4945-a35b-a6005b732cf4" xlink:href="jnj-20221002.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c21fb7ea-6c88-470e-afcb-619f315f1f71" xlink:to="loc_jnj_RisperdalMember_afdbd375-a88e-4945-a35b-a6005b732cf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_48f1aa79-d80e-4173-9481-99c0e4e0a4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_48f1aa79-d80e-4173-9481-99c0e4e0a4e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_48f1aa79-d80e-4173-9481-99c0e4e0a4e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_48f1aa79-d80e-4173-9481-99c0e4e0a4e2" xlink:to="loc_us-gaap_SegmentDomain_48f1aa79-d80e-4173-9481-99c0e4e0a4e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_be3c9e0b-e906-421c-8b09-643a9b8d6554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_48f1aa79-d80e-4173-9481-99c0e4e0a4e2" xlink:to="loc_us-gaap_SegmentDomain_be3c9e0b-e906-421c-8b09-643a9b8d6554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_6000b78e-017e-418f-b6c1-9a650c6e3155" xlink:href="jnj-20221002.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_be3c9e0b-e906-421c-8b09-643a9b8d6554" xlink:to="loc_jnj_ConsumerMember_6000b78e-017e-418f-b6c1-9a650c6e3155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b81dabff-3655-4cd0-91f2-fc995612e0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b81dabff-3655-4cd0-91f2-fc995612e0e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b81dabff-3655-4cd0-91f2-fc995612e0e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b81dabff-3655-4cd0-91f2-fc995612e0e6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b81dabff-3655-4cd0-91f2-fc995612e0e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc6ee97c-8d7e-4e83-8ea7-dcfe39b97ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b81dabff-3655-4cd0-91f2-fc995612e0e6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc6ee97c-8d7e-4e83-8ea7-dcfe39b97ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_5741d63e-14f7-4ca4-86a0-c0950ea355f9" xlink:href="jnj-20221002.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc6ee97c-8d7e-4e83-8ea7-dcfe39b97ec4" xlink:to="loc_jnj_AurisHealthMember_5741d63e-14f7-4ca4-86a0-c0950ea355f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_708ea334-a336-4ccf-9743-deee0f2ca839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_708ea334-a336-4ccf-9743-deee0f2ca839" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_708ea334-a336-4ccf-9743-deee0f2ca839_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_708ea334-a336-4ccf-9743-deee0f2ca839" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_708ea334-a336-4ccf-9743-deee0f2ca839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f38297c-64f1-4fa7-95b5-21c147b84c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_708ea334-a336-4ccf-9743-deee0f2ca839" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f38297c-64f1-4fa7-95b5-21c147b84c69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_6ee98f7b-825f-4f08-8adc-58df97cd0367" xlink:href="jnj-20221002.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f38297c-64f1-4fa7-95b5-21c147b84c69" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_6ee98f7b-825f-4f08-8adc-58df97cd0367" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i74780ed6d1a046e9b4ad4507c401e5e8_PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_45f7670c-4ecb-43ba-ba3d-a82983ce691b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_45f7670c-4ecb-43ba-ba3d-a82983ce691b" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_dc46711a-3c83-4d64-9e6b-8af87d5dacd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_dc46711a-3c83-4d64-9e6b-8af87d5dacd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_930575ab-f5a8-405b-9f71-d134d3cfb2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_930575ab-f5a8-405b-9f71-d134d3cfb2e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3214d9fa-24c8-45d2-989f-9c78a62c55d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3214d9fa-24c8-45d2-989f-9c78a62c55d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_7fed389d-eb3c-40da-bf6a-8d110b62a50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_7fed389d-eb3c-40da-bf6a-8d110b62a50f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_18cb2f19-fd75-498b-8866-660c2bbdefec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_18cb2f19-fd75-498b-8866-660c2bbdefec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_532b65e4-7954-4363-9bc7-85fbbf6746b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_532b65e4-7954-4363-9bc7-85fbbf6746b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1af88eb9-4347-422b-8440-d567a1a6ebc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1af88eb9-4347-422b-8440-d567a1a6ebc6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0faeaa94-8378-4cce-9ae5-e85934cbcf93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_45f7670c-4ecb-43ba-ba3d-a82983ce691b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0faeaa94-8378-4cce-9ae5-e85934cbcf93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_624f892c-32fe-4e27-acc9-6677f185a9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0faeaa94-8378-4cce-9ae5-e85934cbcf93" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_624f892c-32fe-4e27-acc9-6677f185a9e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_624f892c-32fe-4e27-acc9-6677f185a9e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_624f892c-32fe-4e27-acc9-6677f185a9e6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_624f892c-32fe-4e27-acc9-6677f185a9e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3593f32c-b971-42a3-9112-a1c12290e094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_624f892c-32fe-4e27-acc9-6677f185a9e6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3593f32c-b971-42a3-9112-a1c12290e094" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_bbb563a1-bc6d-4b36-83c4-536a931d64db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3593f32c-b971-42a3-9112-a1c12290e094" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_bbb563a1-bc6d-4b36-83c4-536a931d64db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2e02da94-a048-48d9-9bcc-6302c0be7136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3593f32c-b971-42a3-9112-a1c12290e094" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2e02da94-a048-48d9-9bcc-6302c0be7136" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended" id="i62e3c98e749b4b04910c902fc8713a30_PensionsandOtherBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_04dbb8bc-4f18-4b44-9198-2a085c3c666c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_f37f43c1-d213-42a0-b8dd-dc5f29597a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_04dbb8bc-4f18-4b44-9198-2a085c3c666c" xlink:to="loc_us-gaap_PensionContributions_f37f43c1-d213-42a0-b8dd-dc5f29597a71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f96ef185-29e2-42f1-8b9e-72f7c3d25ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_04dbb8bc-4f18-4b44-9198-2a085c3c666c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f96ef185-29e2-42f1-8b9e-72f7c3d25ec9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_84099d51-4e4e-46ae-a986-863a8d5ddaae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f96ef185-29e2-42f1-8b9e-72f7c3d25ec9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_84099d51-4e4e-46ae-a986-863a8d5ddaae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_84099d51-4e4e-46ae-a986-863a8d5ddaae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_84099d51-4e4e-46ae-a986-863a8d5ddaae" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_84099d51-4e4e-46ae-a986-863a8d5ddaae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5f362014-f2eb-40a1-89e8-7403a1ede6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_84099d51-4e4e-46ae-a986-863a8d5ddaae" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5f362014-f2eb-40a1-89e8-7403a1ede6a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f7bf40b4-84ea-4601-9ff5-157e472abf07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5f362014-f2eb-40a1-89e8-7403a1ede6a8" xlink:to="loc_us-gaap_DomesticPlanMember_f7bf40b4-84ea-4601-9ff5-157e472abf07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_22b99d7d-3c1e-4466-8e84-c2b228ad3f51" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_f7bf40b4-84ea-4601-9ff5-157e472abf07" xlink:to="loc_country_US_22b99d7d-3c1e-4466-8e84-c2b228ad3f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f31688a3-e9e7-4e92-bd37-5ba039120d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5f362014-f2eb-40a1-89e8-7403a1ede6a8" xlink:to="loc_us-gaap_ForeignPlanMember_f31688a3-e9e7-4e92-bd37-5ba039120d8d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="ib070ada434684b5987cc2af799ab3623_AccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14208de8-277b-4169-bc66-54380e1b4380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_14060afe-3067-4ea3-9b15-14375d93d7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14208de8-277b-4169-bc66-54380e1b4380" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_14060afe-3067-4ea3-9b15-14375d93d7b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ea2d10b-4932-4f9a-a3f2-e2fa6a639767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_14060afe-3067-4ea3-9b15-14375d93d7b1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ea2d10b-4932-4f9a-a3f2-e2fa6a639767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3cd083ce-7c17-4d61-ad8b-8fa82e27f6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_14060afe-3067-4ea3-9b15-14375d93d7b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3cd083ce-7c17-4d61-ad8b-8fa82e27f6c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0ea6af9-d499-4a4c-a807-ecb1af5e976d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e58f471f-8b54-40e3-a040-b38f2b2a5c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14208de8-277b-4169-bc66-54380e1b4380" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e58f471f-8b54-40e3-a040-b38f2b2a5c8a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cf1d62d2-37dd-4666-b3fe-26bcb030d074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e58f471f-8b54-40e3-a040-b38f2b2a5c8a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cf1d62d2-37dd-4666-b3fe-26bcb030d074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cf1d62d2-37dd-4666-b3fe-26bcb030d074_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf1d62d2-37dd-4666-b3fe-26bcb030d074" xlink:to="loc_us-gaap_EquityComponentDomain_cf1d62d2-37dd-4666-b3fe-26bcb030d074_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf1d62d2-37dd-4666-b3fe-26bcb030d074" xlink:to="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e0c6f530-ec72-49d5-8e6a-a8ff8299ccf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e0c6f530-ec72-49d5-8e6a-a8ff8299ccf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f6d6eb9f-d938-4592-894d-822cc95c0ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f6d6eb9f-d938-4592-894d-822cc95c0ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c7b628f9-2d0e-4f12-b25e-1a8ab2972c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c7b628f9-2d0e-4f12-b25e-1a8ab2972c32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9049a0c6-b4ed-44c3-93bd-c41867a2f621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9049a0c6-b4ed-44c3-93bd-c41867a2f621" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cad70467-471c-44f4-b32a-d3a9134504a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cad70467-471c-44f4-b32a-d3a9134504a8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended" id="ic6fca199c95a4f8a92e2cc521775bc7b_SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_fd47a9a3-a99b-4454-aa22-0779900ace09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c8ae9a15-1238-4b8a-9cfc-0fe66f9d3e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_fd47a9a3-a99b-4454-aa22-0779900ace09" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c8ae9a15-1238-4b8a-9cfc-0fe66f9d3e35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_633d47ca-b5fe-495f-9596-a8c12b658abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c8ae9a15-1238-4b8a-9cfc-0fe66f9d3e35" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_633d47ca-b5fe-495f-9596-a8c12b658abc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_4cc4ae32-4aeb-4347-8d3f-5514ab1079a9" xlink:href="jnj-20221002.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c8ae9a15-1238-4b8a-9cfc-0fe66f9d3e35" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_4cc4ae32-4aeb-4347-8d3f-5514ab1079a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_fd47a9a3-a99b-4454-aa22-0779900ace09" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d87648b5-b1bd-4b2b-a442-5153a92f0472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d87648b5-b1bd-4b2b-a442-5153a92f0472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d87648b5-b1bd-4b2b-a442-5153a92f0472_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d87648b5-b1bd-4b2b-a442-5153a92f0472" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d87648b5-b1bd-4b2b-a442-5153a92f0472_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4d44493-f699-42ce-9f67-216fccca5800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d87648b5-b1bd-4b2b-a442-5153a92f0472" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4d44493-f699-42ce-9f67-216fccca5800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d975c6c9-e0c7-4476-a40c-0a31ebfdd2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d975c6c9-e0c7-4476-a40c-0a31ebfdd2a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d975c6c9-e0c7-4476-a40c-0a31ebfdd2a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d975c6c9-e0c7-4476-a40c-0a31ebfdd2a9" xlink:to="loc_us-gaap_SegmentDomain_d975c6c9-e0c7-4476-a40c-0a31ebfdd2a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d975c6c9-e0c7-4476-a40c-0a31ebfdd2a9" xlink:to="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_357c8ac4-9be5-400c-9fff-78a209ee0e37" xlink:href="jnj-20221002.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:to="loc_jnj_ConsumerMember_357c8ac4-9be5-400c-9fff-78a209ee0e37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_91a9ebf0-cbd6-409f-b4e9-fcfbeab492d4" xlink:href="jnj-20221002.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:to="loc_jnj_PharmaceuticalMember_91a9ebf0-cbd6-409f-b4e9-fcfbeab492d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_43764cc3-6a21-4a6e-8a03-055c3e588c7a" xlink:href="jnj-20221002.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:to="loc_jnj_MedicalDevicesMember_43764cc3-6a21-4a6e-8a03-055c3e588c7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b4b17338-b3e3-4821-8ee1-a7043aee451e" xlink:href="jnj-20221002.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b4b17338-b3e3-4821-8ee1-a7043aee451e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_36ebab44-7e01-45e7-8459-3ff1511722ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:to="loc_us-gaap_SubsegmentsAxis_36ebab44-7e01-45e7-8459-3ff1511722ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_36ebab44-7e01-45e7-8459-3ff1511722ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_36ebab44-7e01-45e7-8459-3ff1511722ab" xlink:to="loc_us-gaap_SubsegmentsDomain_36ebab44-7e01-45e7-8459-3ff1511722ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_36ebab44-7e01-45e7-8459-3ff1511722ab" xlink:to="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_28db8103-2b83-4b23-aa88-42789096820f" xlink:href="jnj-20221002.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_ImmunologyMember_28db8103-2b83-4b23-aa88-42789096820f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_df1adb2e-056e-4540-8799-03480d9ccc9a" xlink:href="jnj-20221002.xsd#jnj_InfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_InfectiousDiseasesMember_df1adb2e-056e-4540-8799-03480d9ccc9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_4330ee7d-9b56-4572-b759-6ba021d19234" xlink:href="jnj-20221002.xsd#jnj_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_NeuroscienceMember_4330ee7d-9b56-4572-b759-6ba021d19234" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_57e4e7e5-5f00-4511-9db8-5e734b078dcf" xlink:href="jnj-20221002.xsd#jnj_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_OncologyMember_57e4e7e5-5f00-4511-9db8-5e734b078dcf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_7ef7ecf0-aaaa-4146-860d-c70c169fd5d6" xlink:href="jnj-20221002.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_PulmonaryHypertensionMember_7ef7ecf0-aaaa-4146-860d-c70c169fd5d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_c4650c16-5bf8-44c2-921e-0915303e45e6" xlink:href="jnj-20221002.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_c4650c16-5bf8-44c2-921e-0915303e45e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_6a8e77dd-14b2-417f-b875-f2e30b6276e0" xlink:href="jnj-20221002.xsd#jnj_InterventionalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_InterventionalSolutionsMember_6a8e77dd-14b2-417f-b875-f2e30b6276e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_1e7f3152-8126-42c3-afdf-59872b627b61" xlink:href="jnj-20221002.xsd#jnj_OrthopaedicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_OrthopaedicsMember_1e7f3152-8126-42c3-afdf-59872b627b61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_b93cae8f-a3da-4a2e-afdf-0fe73c06c083" xlink:href="jnj-20221002.xsd#jnj_SurgeryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_SurgeryMember_b93cae8f-a3da-4a2e-afdf-0fe73c06c083" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_82f61d4a-3ccc-4405-bd67-d2ba86ae7e04" xlink:href="jnj-20221002.xsd#jnj_VisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_VisionMember_82f61d4a-3ccc-4405-bd67-d2ba86ae7e04" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_02eabe35-91fe-4e21-9a43-60eff813d616" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:to="loc_srt_ProductOrServiceAxis_02eabe35-91fe-4e21-9a43-60eff813d616" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_02eabe35-91fe-4e21-9a43-60eff813d616_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_02eabe35-91fe-4e21-9a43-60eff813d616" xlink:to="loc_srt_ProductsAndServicesDomain_02eabe35-91fe-4e21-9a43-60eff813d616_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_02eabe35-91fe-4e21-9a43-60eff813d616" xlink:to="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_9b795038-bbda-4283-8751-392a213af885" xlink:href="jnj-20221002.xsd#jnj_OTCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OTCMember_9b795038-bbda-4283-8751-392a213af885" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_f87513a8-d4dc-4580-ad81-eea5b6345757" xlink:href="jnj-20221002.xsd#jnj_BeautyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_BeautyMember_f87513a8-d4dc-4580-ad81-eea5b6345757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_b39c9cdd-010f-4b67-ad87-b95fa1bc4cb4" xlink:href="jnj-20221002.xsd#jnj_OralCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OralCareMember_b39c9cdd-010f-4b67-ad87-b95fa1bc4cb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_feb8504d-c567-41c7-8c58-e5cbf0f59340" xlink:href="jnj-20221002.xsd#jnj_BabyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_BabyCareMember_feb8504d-c567-41c7-8c58-e5cbf0f59340" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_6693875c-0805-448b-8f50-542b0b2e7d6b" xlink:href="jnj-20221002.xsd#jnj_WomensHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_WomensHealthMember_6693875c-0805-448b-8f50-542b0b2e7d6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_f9361960-17b0-44ce-bb63-a502c6e81bb4" xlink:href="jnj-20221002.xsd#jnj_WoundCareandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_WoundCareandOtherMember_f9361960-17b0-44ce-bb63-a502c6e81bb4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_11b3bec6-c59b-4537-a05c-3b62dd36147d" xlink:href="jnj-20221002.xsd#jnj_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_RemicadeMember_11b3bec6-c59b-4537-a05c-3b62dd36147d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_3babae05-1bf3-44b7-a0ad-1572568087e0" xlink:href="jnj-20221002.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_SimponiSimponiAriaMember_3babae05-1bf3-44b7-a0ad-1572568087e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_4c04fe5c-6ef8-4eb8-ada5-ca989c8c5c22" xlink:href="jnj-20221002.xsd#jnj_StelaraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_StelaraMember_4c04fe5c-6ef8-4eb8-ada5-ca989c8c5c22" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_4dea79ac-94ab-4550-a941-e48278a647ed" xlink:href="jnj-20221002.xsd#jnj_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_TremfyaMember_4dea79ac-94ab-4550-a941-e48278a647ed" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_2aec88ca-24cd-4ed1-9dc5-37ec27c5dc79" xlink:href="jnj-20221002.xsd#jnj_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OtherImmunologyMember_2aec88ca-24cd-4ed1-9dc5-37ec27c5dc79" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_d823e6c4-a479-4322-9117-c29c6d59b5b8" xlink:href="jnj-20221002.xsd#jnj_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_COVID19Member_d823e6c4-a479-4322-9117-c29c6d59b5b8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_1de4da18-0228-40ae-96be-0f660c9625b1" xlink:href="jnj-20221002.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_EDURANTrilpivirineMember_1de4da18-0228-40ae-96be-0f660c9625b1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_ee3b390b-440a-40a4-b7e4-b461a2d97305" xlink:href="jnj-20221002.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_ee3b390b-440a-40a4-b7e4-b461a2d97305" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_c4449a71-154c-479b-92db-0a6f9b6fbc90" xlink:href="jnj-20221002.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_c4449a71-154c-479b-92db-0a6f9b6fbc90" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_db04c191-6835-4a13-9c8e-00d160fb2f93" xlink:href="jnj-20221002.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_db04c191-6835-4a13-9c8e-00d160fb2f93" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_3309fdd7-7b39-4b9a-b821-5f150d3a0dc2" xlink:href="jnj-20221002.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_3309fdd7-7b39-4b9a-b821-5f150d3a0dc2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_eff1b8cc-fe45-47fd-91ec-8d1f222183ee" xlink:href="jnj-20221002.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_RISPERDALCONSTAMember_eff1b8cc-fe45-47fd-91ec-8d1f222183ee" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_f12dd828-af16-4fcf-839a-e056488c3c45" xlink:href="jnj-20221002.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_f12dd828-af16-4fcf-839a-e056488c3c45" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_a478fa2a-b990-419a-b3ef-fb52e8ef0989" xlink:href="jnj-20221002.xsd#jnj_DARZALEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_DARZALEXMember_a478fa2a-b990-419a-b3ef-fb52e8ef0989" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_85f8c1a5-c5c2-4f1d-a7ad-4069d5797350" xlink:href="jnj-20221002.xsd#jnj_ERLEADAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_ERLEADAMember_85f8c1a5-c5c2-4f1d-a7ad-4069d5797350" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_fa235ba4-e5a1-4368-951c-a5a5b9912d19" xlink:href="jnj-20221002.xsd#jnj_IMBRUVICAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_IMBRUVICAMember_fa235ba4-e5a1-4368-951c-a5a5b9912d19" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_56261101-9fa2-482f-9fe1-60fffddcf422" xlink:href="jnj-20221002.xsd#jnj_ZYTIGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_ZYTIGAMember_56261101-9fa2-482f-9fe1-60fffddcf422" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_94e2a531-3b1b-48f1-898d-02520c23f224" xlink:href="jnj-20221002.xsd#jnj_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OtherOncologyMember_94e2a531-3b1b-48f1-898d-02520c23f224" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_4b9ccdd4-070d-4ded-bea0-69aa332008ec" xlink:href="jnj-20221002.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OPSUMITMember_4b9ccdd4-070d-4ded-bea0-69aa332008ec" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_ac29a4e8-efb5-409e-9741-bfd505601b33" xlink:href="jnj-20221002.xsd#jnj_UPTRAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_UPTRAVIMember_ac29a4e8-efb5-409e-9741-bfd505601b33" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_1c46faf5-8d60-4233-9ca0-37d03ab5c5d2" xlink:href="jnj-20221002.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_XareltoMember_1c46faf5-8d60-4233-9ca0-37d03ab5c5d2" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_96eb70f5-358c-4330-af41-e747382679b6" xlink:href="jnj-20221002.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_96eb70f5-358c-4330-af41-e747382679b6" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_41ad3425-7d93-4967-857f-602749aa2f6f" xlink:href="jnj-20221002.xsd#jnj_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OtherMember_41ad3425-7d93-4967-857f-602749aa2f6f" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_3bc890cd-420a-4a06-a10e-603363590151" xlink:href="jnj-20221002.xsd#jnj_HIPSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_HIPSMember_3bc890cd-420a-4a06-a10e-603363590151" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_fac765a6-0907-4502-9d9b-bf435672209b" xlink:href="jnj-20221002.xsd#jnj_KNEESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_KNEESMember_fac765a6-0907-4502-9d9b-bf435672209b" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_6c8557aa-2a81-4ad7-8978-6c207fd27280" xlink:href="jnj-20221002.xsd#jnj_TRAUMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_TRAUMAMember_6c8557aa-2a81-4ad7-8978-6c207fd27280" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_8d39afd5-dcc2-4007-85fb-94231907c810" xlink:href="jnj-20221002.xsd#jnj_SPINEOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_SPINEOTHERMember_8d39afd5-dcc2-4007-85fb-94231907c810" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_f0c3afd9-4440-4d5c-8d9a-affbe94d41ab" xlink:href="jnj-20221002.xsd#jnj_ADVANCEDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_ADVANCEDMember_f0c3afd9-4440-4d5c-8d9a-affbe94d41ab" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_95703f41-358d-411e-a9fa-5cc480fb33b4" xlink:href="jnj-20221002.xsd#jnj_GENERALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_GENERALMember_95703f41-358d-411e-a9fa-5cc480fb33b4" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_493659a4-dfa2-453f-a988-968122a004da" xlink:href="jnj-20221002.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_493659a4-dfa2-453f-a988-968122a004da" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_c42da33c-80f2-4d8c-8583-40ff71891151" xlink:href="jnj-20221002.xsd#jnj_SURGICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_SURGICALMember_c42da33c-80f2-4d8c-8583-40ff71891151" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c3fc43c4-b621-4878-9378-1f4792b3ec04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:to="loc_srt_StatementGeographicalAxis_c3fc43c4-b621-4878-9378-1f4792b3ec04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c3fc43c4-b621-4878-9378-1f4792b3ec04_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c3fc43c4-b621-4878-9378-1f4792b3ec04" xlink:to="loc_srt_SegmentGeographicalDomain_c3fc43c4-b621-4878-9378-1f4792b3ec04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c3fc43c4-b621-4878-9378-1f4792b3ec04" xlink:to="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_815fbb05-aa3a-4539-be55-d64831532dd7" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:to="loc_country_CN_815fbb05-aa3a-4539-be55-d64831532dd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2ba36e70-9c45-44f1-88b7-804a37f32832" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:to="loc_country_US_2ba36e70-9c45-44f1-88b7-804a37f32832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_f3fa4069-4f4f-44b4-b8f6-ba519ae08a92" xlink:href="jnj-20221002.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:to="loc_jnj_UNITEDSTATESExportsMember_f3fa4069-4f4f-44b4-b8f6-ba519ae08a92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b5a09504-a66c-4f8f-8f2a-c4e22b6992db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:to="loc_us-gaap_NonUsMember_b5a09504-a66c-4f8f-8f2a-c4e22b6992db" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended" id="i79c3f89d0f8649bf84d67f8de9492a1a_SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f2c0c2de-6809-4082-9e31-19d02265f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_OperatingIncomeLoss_f2c0c2de-6809-4082-9e31-19d02265f72f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_28fcd59d-0726-432d-a6c6-fa1319c0dbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_BusinessExitCosts1_28fcd59d-0726-432d-a6c6-fa1319c0dbb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b406d508-0350-424b-96ff-f43335bacbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b406d508-0350-424b-96ff-f43335bacbe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_f2454a39-8c7d-4a0c-bd57-f1e4cf491b8f" xlink:href="jnj-20221002.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_f2454a39-8c7d-4a0c-bd57-f1e4cf491b8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_c4ffd201-6fae-4f96-9f55-394b624f8fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_AdjustmentForAmortization_c4ffd201-6fae-4f96-9f55-394b624f8fb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_1d8b9227-f5c0-4a34-a720-7cfaa145d07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_1d8b9227-f5c0-4a34-a720-7cfaa145d07f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_7e23f834-2c4e-46e4-a525-893fef570ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_7e23f834-2c4e-46e4-a525-893fef570ff2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_f21c9f9b-d1af-4600-90bb-acc7daabf401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_SuppliesExpense_f21c9f9b-d1af-4600-90bb-acc7daabf401" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers_711d2b17-b0c0-4c97-a311-e7afbf990ede" xlink:href="jnj-20221002.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_jnj_AmountPrepaidAndDueToManufacturers_711d2b17-b0c0-4c97-a311-e7afbf990ede" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fcbb3aaa-0a3c-41f0-92ba-93f1cbb800c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_RestructuringCharges_fcbb3aaa-0a3c-41f0-92ba-93f1cbb800c0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_deed8f7d-d4d0-4d43-b1b9-3bb75c7f8c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_LitigationSettlementExpense_deed8f7d-d4d0-4d43-b1b9-3bb75c7f8c8b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_473a7c31-66c9-4556-ad4a-75de70cf2e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_473a7c31-66c9-4556-ad4a-75de70cf2e5c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_afb51e5f-27a9-4ab0-bf05-446f2cdce3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_afb51e5f-27a9-4ab0-bf05-446f2cdce3c0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1dc1a0cc-2491-47da-b477-1f1db241a43d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:to="loc_srt_ConsolidationItemsAxis_1dc1a0cc-2491-47da-b477-1f1db241a43d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1dc1a0cc-2491-47da-b477-1f1db241a43d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_1dc1a0cc-2491-47da-b477-1f1db241a43d" xlink:to="loc_srt_ConsolidationItemsDomain_1dc1a0cc-2491-47da-b477-1f1db241a43d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_478c2118-27d5-4061-ad73-dc238588392f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_1dc1a0cc-2491-47da-b477-1f1db241a43d" xlink:to="loc_srt_ConsolidationItemsDomain_478c2118-27d5-4061-ad73-dc238588392f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_6c60fd01-3b86-4ab3-9a48-6d716abf9d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_478c2118-27d5-4061-ad73-dc238588392f" xlink:to="loc_us-gaap_OperatingSegmentsMember_6c60fd01-3b86-4ab3-9a48-6d716abf9d61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2cc24c6b-6118-4393-ba76-e63363e33864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_478c2118-27d5-4061-ad73-dc238588392f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2cc24c6b-6118-4393-ba76-e63363e33864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_08f16b4f-2186-460b-950c-638ed6dec307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_08f16b4f-2186-460b-950c-638ed6dec307" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_08f16b4f-2186-460b-950c-638ed6dec307_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_08f16b4f-2186-460b-950c-638ed6dec307" xlink:to="loc_us-gaap_SegmentDomain_08f16b4f-2186-460b-950c-638ed6dec307_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_08f16b4f-2186-460b-950c-638ed6dec307" xlink:to="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_8222190d-5871-419b-80c6-378c0bba4c23" xlink:href="jnj-20221002.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:to="loc_jnj_ConsumerMember_8222190d-5871-419b-80c6-378c0bba4c23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_ea603a6b-4e65-4690-a455-80e669b7f897" xlink:href="jnj-20221002.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:to="loc_jnj_PharmaceuticalMember_ea603a6b-4e65-4690-a455-80e669b7f897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_a7e15a6c-1bf0-413c-af0c-5880e0fc83a6" xlink:href="jnj-20221002.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:to="loc_jnj_MedicalDevicesMember_a7e15a6c-1bf0-413c-af0c-5880e0fc83a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_abf70157-a2ef-4dba-bad1-acca8085dd98" xlink:href="jnj-20221002.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_abf70157-a2ef-4dba-bad1-acca8085dd98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8760f6cc-f922-4a00-8f5d-32b77302890c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8760f6cc-f922-4a00-8f5d-32b77302890c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8760f6cc-f922-4a00-8f5d-32b77302890c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8760f6cc-f922-4a00-8f5d-32b77302890c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8760f6cc-f922-4a00-8f5d-32b77302890c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27ef5750-a859-433b-b866-6e9320227070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8760f6cc-f922-4a00-8f5d-32b77302890c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27ef5750-a859-433b-b866-6e9320227070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_96b03d17-673e-4d56-b9c2-4b8e558ed0b6" xlink:href="jnj-20221002.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27ef5750-a859-433b-b866-6e9320227070" xlink:to="loc_jnj_BermekimabMember_96b03d17-673e-4d56-b9c2-4b8e558ed0b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_600fd8d7-391d-4a1c-b5b7-b0e3d324e316" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:to="loc_srt_LitigationCaseAxis_600fd8d7-391d-4a1c-b5b7-b0e3d324e316" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_600fd8d7-391d-4a1c-b5b7-b0e3d324e316_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_600fd8d7-391d-4a1c-b5b7-b0e3d324e316" xlink:to="loc_srt_LitigationCaseTypeDomain_600fd8d7-391d-4a1c-b5b7-b0e3d324e316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d9cd2f81-194b-42d3-8867-ab97558a6222" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_600fd8d7-391d-4a1c-b5b7-b0e3d324e316" xlink:to="loc_srt_LitigationCaseTypeDomain_d9cd2f81-194b-42d3-8867-ab97558a6222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_fc66db19-b60d-437b-bdc7-00d52bf2c0b1" xlink:href="jnj-20221002.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d9cd2f81-194b-42d3-8867-ab97558a6222" xlink:to="loc_jnj_RisperdalMember_fc66db19-b60d-437b-bdc7-00d52bf2c0b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7f760724-8e6a-419d-93a4-0ce828037682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7f760724-8e6a-419d-93a4-0ce828037682" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f760724-8e6a-419d-93a4-0ce828037682_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7f760724-8e6a-419d-93a4-0ce828037682" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7f760724-8e6a-419d-93a4-0ce828037682_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_520fc01e-952b-4fde-b90e-a816cc0632ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7f760724-8e6a-419d-93a4-0ce828037682" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_520fc01e-952b-4fde-b90e-a816cc0632ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_dfbb99bc-51ca-4050-b03a-7293a5277fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_520fc01e-952b-4fde-b90e-a816cc0632ff" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_dfbb99bc-51ca-4050-b03a-7293a5277fa7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended" id="id7aafff6b2364e91938578b34cb6621a_SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bdef0fa4-aca2-4c61-a85f-73493776b384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_7605881f-a87d-4853-ae8b-d1a970b83add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bdef0fa4-aca2-4c61-a85f-73493776b384" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_7605881f-a87d-4853-ae8b-d1a970b83add" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_184acb39-cd31-4c94-a7be-a917ee1f8b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_7605881f-a87d-4853-ae8b-d1a970b83add" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_184acb39-cd31-4c94-a7be-a917ee1f8b9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_cf0c48ad-625e-492e-bba1-7ddb681a906b" xlink:href="jnj-20221002.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_7605881f-a87d-4853-ae8b-d1a970b83add" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_cf0c48ad-625e-492e-bba1-7ddb681a906b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7ef0dd9b-7238-40ed-98b2-f0b9e49eec1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bdef0fa4-aca2-4c61-a85f-73493776b384" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7ef0dd9b-7238-40ed-98b2-f0b9e49eec1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bdc0b03d-4727-4fea-8404-70937606c4e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7ef0dd9b-7238-40ed-98b2-f0b9e49eec1e" xlink:to="loc_srt_StatementGeographicalAxis_bdc0b03d-4727-4fea-8404-70937606c4e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bdc0b03d-4727-4fea-8404-70937606c4e6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bdc0b03d-4727-4fea-8404-70937606c4e6" xlink:to="loc_srt_SegmentGeographicalDomain_bdc0b03d-4727-4fea-8404-70937606c4e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bdc0b03d-4727-4fea-8404-70937606c4e6" xlink:to="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c4907d7e-6439-4f0a-a0f7-b0156ff8eeb1" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:to="loc_country_US_c4907d7e-6439-4f0a-a0f7-b0156ff8eeb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_c198768a-41c7-4c25-ab40-a804a1f9ef26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:to="loc_srt_EuropeMember_c198768a-41c7-4c25-ab40-a804a1f9ef26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_c4458988-1603-4488-9f8a-32132c69526c" xlink:href="jnj-20221002.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_c4458988-1603-4488-9f8a-32132c69526c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_2b6db516-618f-4aa5-b043-6fab9bd57ab0" xlink:href="jnj-20221002.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:to="loc_jnj_AsiaPacificAfricaMember_2b6db516-618f-4aa5-b043-6fab9bd57ab0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended" id="i76514c3d28a34c73bc8bc7411ad67da8_AcquisitionsandDivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_567eec53-8b0a-4251-baa6-557eb1865a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfBrands_eb5ecd70-23bc-4821-9530-7e8f1ab5c7a6" xlink:href="jnj-20221002.xsd#jnj_NumberOfBrands"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_567eec53-8b0a-4251-baa6-557eb1865a87" xlink:to="loc_jnj_NumberOfBrands_eb5ecd70-23bc-4821-9530-7e8f1ab5c7a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_47b596d7-20a1-4233-97dd-b8f51b7f140e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_567eec53-8b0a-4251-baa6-557eb1865a87" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_47b596d7-20a1-4233-97dd-b8f51b7f140e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22735793-5e1f-4464-b716-1d4c3c97221c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_567eec53-8b0a-4251-baa6-557eb1865a87" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22735793-5e1f-4464-b716-1d4c3c97221c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beace95b-d72c-4716-a20e-0b82ec182ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22735793-5e1f-4464-b716-1d4c3c97221c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beace95b-d72c-4716-a20e-0b82ec182ba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_beace95b-d72c-4716-a20e-0b82ec182ba4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beace95b-d72c-4716-a20e-0b82ec182ba4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_beace95b-d72c-4716-a20e-0b82ec182ba4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_329ff6ff-f21a-48d6-ab5b-8a6ae0e44b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beace95b-d72c-4716-a20e-0b82ec182ba4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_329ff6ff-f21a-48d6-ab5b-8a6ae0e44b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_099437c5-534f-48d1-aabd-9bfecfd8e199" xlink:href="jnj-20221002.xsd#jnj_EvraAndDoxilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_329ff6ff-f21a-48d6-ab5b-8a6ae0e44b24" xlink:to="loc_jnj_EvraAndDoxilMember_099437c5-534f-48d1-aabd-9bfecfd8e199" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#LegalProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended" id="i309fab0468504d1eade666e00bb1864a_LegalProceedingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5ad704c8-dbd9-4855-9a57-2a1b3322d6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:href="jnj-20221002.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5ad704c8-dbd9-4855-9a57-2a1b3322d6fe" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_7be8652c-fb1b-42fe-8572-dd3c12fc8b81" xlink:href="jnj-20221002.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_7be8652c-fb1b-42fe-8572-dd3c12fc8b81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_2c7da553-f045-4856-b534-270c2375e369" xlink:href="jnj-20221002.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_jnj_Numberofpatientsinsettlement_2c7da553-f045-4856-b534-270c2375e369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_9daca0ad-3021-4698-a37e-db16f68b7692" xlink:href="jnj-20221002.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_9daca0ad-3021-4698-a37e-db16f68b7692" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_68dae74d-e3a0-4644-808a-98c2ae00cc91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_68dae74d-e3a0-4644-808a-98c2ae00cc91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_a6dff0ed-7d15-44ed-b958-adb52506d9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_a6dff0ed-7d15-44ed-b958-adb52506d9f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_0d56493e-3c6a-4a0d-b1c0-9938d5868024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_0d56493e-3c6a-4a0d-b1c0-9938d5868024" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_98ca6889-a11b-4c82-8789-8ca82a3a43ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_98ca6889-a11b-4c82-8789-8ca82a3a43ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_73ece054-2ba2-48a7-b6bb-a067043d9933" xlink:href="jnj-20221002.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_73ece054-2ba2-48a7-b6bb-a067043d9933" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_29ea6a5b-60b4-4d27-b3ce-0ec8d928ec38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_29ea6a5b-60b4-4d27-b3ce-0ec8d928ec38" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f07bcc8b-d56a-471e-bbb4-6cfdabef4804" xlink:href="jnj-20221002.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f07bcc8b-d56a-471e-bbb4-6cfdabef4804" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_5ad704c8-dbd9-4855-9a57-2a1b3322d6fe" xlink:to="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d9616b38-b04b-401b-b21e-26b01c2df740" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_srt_LitigationCaseAxis_d9616b38-b04b-401b-b21e-26b01c2df740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d9616b38-b04b-401b-b21e-26b01c2df740_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_d9616b38-b04b-401b-b21e-26b01c2df740" xlink:to="loc_srt_LitigationCaseTypeDomain_d9616b38-b04b-401b-b21e-26b01c2df740_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_d9616b38-b04b-401b-b21e-26b01c2df740" xlink:to="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_2348d51f-fccc-47a3-8037-50f70fd02ff4" xlink:href="jnj-20221002.xsd#jnj_DePuyASRU.S.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:to="loc_jnj_DePuyASRU.S.Member_2348d51f-fccc-47a3-8037-50f70fd02ff4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_b39a4889-386a-4cf5-ae68-596496206b19" xlink:href="jnj-20221002.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:to="loc_jnj_RisperdalMember_b39a4889-386a-4cf5-ae68-596496206b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_9b22c391-caed-4a5c-9672-300dae8f2073" xlink:href="jnj-20221002.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:to="loc_jnj_BabyPowderMember_9b22c391-caed-4a5c-9672-300dae8f2073" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_a12de088-e1d9-4919-8540-c05c63334e6a" xlink:href="jnj-20221002.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_a12de088-e1d9-4919-8540-c05c63334e6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_e6314ce7-b8e3-4c62-b7f1-adadd7b09058" xlink:href="jnj-20221002.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_e6314ce7-b8e3-4c62-b7f1-adadd7b09058" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_48d8a18a-7829-47b8-931b-a0431d80b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_us-gaap_LitigationStatusAxis_48d8a18a-7829-47b8-931b-a0431d80b7a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_48d8a18a-7829-47b8-931b-a0431d80b7a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_48d8a18a-7829-47b8-931b-a0431d80b7a5" xlink:to="loc_us-gaap_LitigationStatusDomain_48d8a18a-7829-47b8-931b-a0431d80b7a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ea103dd6-d514-4529-baf4-1411226a6924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_48d8a18a-7829-47b8-931b-a0431d80b7a5" xlink:to="loc_us-gaap_LitigationStatusDomain_ea103dd6-d514-4529-baf4-1411226a6924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_d2dbbb9a-26e0-41cb-b80f-ceccd94d1987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_ea103dd6-d514-4529-baf4-1411226a6924" xlink:to="loc_us-gaap_SettledLitigationMember_d2dbbb9a-26e0-41cb-b80f-ceccd94d1987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_d24d54c6-b1e0-492f-a409-1a8000ad745d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_ea103dd6-d514-4529-baf4-1411226a6924" xlink:to="loc_us-gaap_JudicialRulingMember_d24d54c6-b1e0-492f-a409-1a8000ad745d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f3838efa-a49e-487e-a494-35c5215dbbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_ea103dd6-d514-4529-baf4-1411226a6924" xlink:to="loc_us-gaap_PendingLitigationMember_f3838efa-a49e-487e-a494-35c5215dbbaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4df5603-1749-4c4c-90bb-e6c7a5d99d37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_srt_ProductOrServiceAxis_e4df5603-1749-4c4c-90bb-e6c7a5d99d37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e4df5603-1749-4c4c-90bb-e6c7a5d99d37_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e4df5603-1749-4c4c-90bb-e6c7a5d99d37" xlink:to="loc_srt_ProductsAndServicesDomain_e4df5603-1749-4c4c-90bb-e6c7a5d99d37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e4df5603-1749-4c4c-90bb-e6c7a5d99d37" xlink:to="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_4413bf2b-cd03-43fc-ad5e-6b7e7ed03ecd" xlink:href="jnj-20221002.xsd#jnj_AsrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_AsrMember_4413bf2b-cd03-43fc-ad5e-6b7e7ed03ecd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_51b33b76-4470-4cea-b390-4ca0c3d04f24" xlink:href="jnj-20221002.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_51b33b76-4470-4cea-b390-4ca0c3d04f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_59d0f5b8-3cca-426f-b4b7-680a38383ac6" xlink:href="jnj-20221002.xsd#jnj_PelvicMeshesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_PelvicMeshesMember_59d0f5b8-3cca-426f-b4b7-680a38383ac6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_24494520-396f-4cf8-a383-d32abfea2e26" xlink:href="jnj-20221002.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_RisperdalMember_24494520-396f-4cf8-a383-d32abfea2e26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_57a33001-aedf-49ef-8b70-4a5d6161a1ef" xlink:href="jnj-20221002.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_XareltoMember_57a33001-aedf-49ef-8b70-4a5d6161a1ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_adc25290-971c-4399-925d-ba0e0823128b" xlink:href="jnj-20221002.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_TalcMember_adc25290-971c-4399-925d-ba0e0823128b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_2f0530e3-c7a8-4350-9d9f-1436973d9fdc" xlink:href="jnj-20221002.xsd#jnj_InvokanaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_InvokanaMember_2f0530e3-c7a8-4350-9d9f-1436973d9fdc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_5f120d0b-7557-4cc2-a2ff-2a0aa5cea514" xlink:href="jnj-20221002.xsd#jnj_PhysiomeshMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_PhysiomeshMember_5f120d0b-7557-4cc2-a2ff-2a0aa5cea514" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_bb8d1622-af54-4407-b96c-3e34c4981dd7" xlink:href="jnj-20221002.xsd#jnj_OpioidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_OpioidMember_bb8d1622-af54-4407-b96c-3e34c4981dd7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember_67492c25-2f59-47d6-8a2a-fe2dfd9365e3" xlink:href="jnj-20221002.xsd#jnj_ContactLensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_ContactLensesMember_67492c25-2f59-47d6-8a2a-fe2dfd9365e3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember_e246d4db-e21c-4a15-a2e8-089d50f10211" xlink:href="jnj-20221002.xsd#jnj_ElmironMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_ElmironMember_e246d4db-e21c-4a15-a2e8-089d50f10211" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_3336cffc-c7ff-4a31-a645-bbfd6277a071" xlink:href="jnj-20221002.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_3336cffc-c7ff-4a31-a645-bbfd6277a071" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_3336cffc-c7ff-4a31-a645-bbfd6277a071_default" xlink:href="jnj-20221002.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_3336cffc-c7ff-4a31-a645-bbfd6277a071" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_3336cffc-c7ff-4a31-a645-bbfd6277a071_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_6bb83383-4c5c-481c-9b89-fc2621e5cd65" xlink:href="jnj-20221002.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_3336cffc-c7ff-4a31-a645-bbfd6277a071" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_6bb83383-4c5c-481c-9b89-fc2621e5cd65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_233be48b-d2cb-40f9-945e-4cbfdd93e93d" xlink:href="jnj-20221002.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_6bb83383-4c5c-481c-9b89-fc2621e5cd65" xlink:to="loc_jnj_RisperdalMember_233be48b-d2cb-40f9-945e-4cbfdd93e93d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_574ed954-4b39-4fe3-b3ea-24ac8c1097f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_574ed954-4b39-4fe3-b3ea-24ac8c1097f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_574ed954-4b39-4fe3-b3ea-24ac8c1097f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_574ed954-4b39-4fe3-b3ea-24ac8c1097f6" xlink:to="loc_us-gaap_LossContingencyNatureDomain_574ed954-4b39-4fe3-b3ea-24ac8c1097f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_452d8c8a-1d6a-4485-946c-78ba0bbe62a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_574ed954-4b39-4fe3-b3ea-24ac8c1097f6" xlink:to="loc_us-gaap_LossContingencyNatureDomain_452d8c8a-1d6a-4485-946c-78ba0bbe62a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_51c1f350-9bb9-48bc-a4dd-d5f9a688beba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_452d8c8a-1d6a-4485-946c-78ba0bbe62a2" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_51c1f350-9bb9-48bc-a4dd-d5f9a688beba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6e8293e4-c7f0-4697-9b05-569723145fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6e8293e4-c7f0-4697-9b05-569723145fbe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6e8293e4-c7f0-4697-9b05-569723145fbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6e8293e4-c7f0-4697-9b05-569723145fbe" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6e8293e4-c7f0-4697-9b05-569723145fbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c7bdc7c7-1b3b-4df7-a262-686ae28a21f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6e8293e4-c7f0-4697-9b05-569723145fbe" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c7bdc7c7-1b3b-4df7-a262-686ae28a21f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4fa3ddc2-810d-4d9e-a3f2-23bb97cb83af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c7bdc7c7-1b3b-4df7-a262-686ae28a21f8" xlink:to="loc_us-gaap_SubsequentEventMember_4fa3ddc2-810d-4d9e-a3f2-23bb97cb83af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7f8c6ebb-48a8-4453-931d-f68f0595bc0c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_srt_CounterpartyNameAxis_7f8c6ebb-48a8-4453-931d-f68f0595bc0c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7f8c6ebb-48a8-4453-931d-f68f0595bc0c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7f8c6ebb-48a8-4453-931d-f68f0595bc0c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7f8c6ebb-48a8-4453-931d-f68f0595bc0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b17cff7-589c-49ae-baa3-f505458aeea4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7f8c6ebb-48a8-4453-931d-f68f0595bc0c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b17cff7-589c-49ae-baa3-f505458aeea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RasmussenInstrumentsLLCMember_537a444a-9725-4131-b3c3-e5aa7f3335ea" xlink:href="jnj-20221002.xsd#jnj_RasmussenInstrumentsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b17cff7-589c-49ae-baa3-f505458aeea4" xlink:to="loc_jnj_RasmussenInstrumentsLLCMember_537a444a-9725-4131-b3c3-e5aa7f3335ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="i84bd9b6d86e4473baa6a5c9678bbfb43_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8242617e-4559-4629-8737-85be063638e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:to="loc_us-gaap_RestructuringCharges_8242617e-4559-4629-8737-85be063638e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3911e6dd-2b9c-407a-95bc-2c1e96490863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3911e6dd-2b9c-407a-95bc-2c1e96490863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_febed525-b6d0-4dc2-b10b-54913fb0d5ba" xlink:href="jnj-20221002.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_febed525-b6d0-4dc2-b10b-54913fb0d5ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_3c339728-c7ca-478b-ba0b-c791a8d8c343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_3c339728-c7ca-478b-ba0b-c791a8d8c343" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c1b8a55f-e890-4f62-b2c1-f3c042e618f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c1b8a55f-e890-4f62-b2c1-f3c042e618f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c1b8a55f-e890-4f62-b2c1-f3c042e618f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c1b8a55f-e890-4f62-b2c1-f3c042e618f9" xlink:to="loc_us-gaap_SegmentDomain_c1b8a55f-e890-4f62-b2c1-f3c042e618f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_598b145b-0a19-42fd-89cd-b5fcc4893517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c1b8a55f-e890-4f62-b2c1-f3c042e618f9" xlink:to="loc_us-gaap_SegmentDomain_598b145b-0a19-42fd-89cd-b5fcc4893517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_9e5b671f-30ff-43b6-9148-dcaa012d9498" xlink:href="jnj-20221002.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_598b145b-0a19-42fd-89cd-b5fcc4893517" xlink:to="loc_jnj_MedicalDevicesMember_9e5b671f-30ff-43b6-9148-dcaa012d9498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_423c2e42-56e4-4f6c-81c6-9b6e988ec066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:to="loc_us-gaap_RestructuringPlanAxis_423c2e42-56e4-4f6c-81c6-9b6e988ec066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_423c2e42-56e4-4f6c-81c6-9b6e988ec066_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_423c2e42-56e4-4f6c-81c6-9b6e988ec066" xlink:to="loc_us-gaap_RestructuringPlanDomain_423c2e42-56e4-4f6c-81c6-9b6e988ec066_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d6da946f-c7de-4cea-a751-089169ff12e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_423c2e42-56e4-4f6c-81c6-9b6e988ec066" xlink:to="loc_us-gaap_RestructuringPlanDomain_d6da946f-c7de-4cea-a751-089169ff12e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_cc9a4b98-8716-43b7-8db1-724da4e810b2" xlink:href="jnj-20221002.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_d6da946f-c7de-4cea-a751-089169ff12e9" xlink:to="loc_jnj_SupplyChainMember_cc9a4b98-8716-43b7-8db1-724da4e810b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_be22e1f9-8ae7-4cb4-9ce1-4db4ffb7c44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_be22e1f9-8ae7-4cb4-9ce1-4db4ffb7c44d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_be22e1f9-8ae7-4cb4-9ce1-4db4ffb7c44d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_be22e1f9-8ae7-4cb4-9ce1-4db4ffb7c44d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_be22e1f9-8ae7-4cb4-9ce1-4db4ffb7c44d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2768b1b3-866d-4528-a6dc-4f6194d7d55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_be22e1f9-8ae7-4cb4-9ce1-4db4ffb7c44d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2768b1b3-866d-4528-a6dc-4f6194d7d55d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_6726cf12-f6c3-450e-825b-236c1baa945d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2768b1b3-866d-4528-a6dc-4f6194d7d55d" xlink:to="loc_us-gaap_RestructuringChargesMember_6726cf12-f6c3-450e-825b-236c1baa945d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_639d562b-a99f-4f59-8a98-94aae023cd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2768b1b3-866d-4528-a6dc-4f6194d7d55d" xlink:to="loc_us-gaap_CostOfSalesMember_639d562b-a99f-4f59-8a98-94aae023cd3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_ce1bf650-7ae1-44f4-bd5c-2e81f5111af8" xlink:href="jnj-20221002.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2768b1b3-866d-4528-a6dc-4f6194d7d55d" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_ce1bf650-7ae1-44f4-bd5c-2e81f5111af8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_645d95e0-a930-4200-a942-69338e6ef531" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:to="loc_srt_RangeAxis_645d95e0-a930-4200-a942-69338e6ef531" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_645d95e0-a930-4200-a942-69338e6ef531_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_645d95e0-a930-4200-a942-69338e6ef531" xlink:to="loc_srt_RangeMember_645d95e0-a930-4200-a942-69338e6ef531_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ae14ab6-1941-4197-81cc-af1212734a16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_645d95e0-a930-4200-a942-69338e6ef531" xlink:to="loc_srt_RangeMember_6ae14ab6-1941-4197-81cc-af1212734a16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c065d941-c5d3-4452-997b-7629843c25f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6ae14ab6-1941-4197-81cc-af1212734a16" xlink:to="loc_srt_MaximumMember_c065d941-c5d3-4452-997b-7629843c25f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9a046559-730e-4f08-b1d7-9d3031aec28c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6ae14ab6-1941-4197-81cc-af1212734a16" xlink:to="loc_srt_MinimumMember_9a046559-730e-4f08-b1d7-9d3031aec28c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended" id="i9b235e0be4d84f16834ad084a10511f8_RestructuringScheduleofRestructuringReserveDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_51946a3d-0e56-4d0e-9d7e-9610cfcfbbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_51946a3d-0e56-4d0e-9d7e-9610cfcfbbab" xlink:to="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_049c6aa9-cd08-417f-927d-4fc3dbaf86da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:to="loc_us-gaap_RestructuringReserve_049c6aa9-cd08-417f-927d-4fc3dbaf86da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2e3e4dd1-ee75-4b79-9f75-00e4a608270c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:to="loc_us-gaap_RestructuringCharges_2e3e4dd1-ee75-4b79-9f75-00e4a608270c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsForRestructuringNet_9757c9b5-7766-4b91-b99a-acaad6a9525f" xlink:href="jnj-20221002.xsd#jnj_PaymentsForRestructuringNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:to="loc_jnj_PaymentsForRestructuringNet_9757c9b5-7766-4b91-b99a-acaad6a9525f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9e38ecf2-8c83-4b48-9cd6-67315c03d43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9e38ecf2-8c83-4b48-9cd6-67315c03d43e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_85f9e951-3ea5-449a-aae7-898fb2b67b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_365df539-e579-4569-9088-82f3762f295c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_51946a3d-0e56-4d0e-9d7e-9610cfcfbbab" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_365df539-e579-4569-9088-82f3762f295c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_7f960aa6-beef-4f12-8c8e-7bd064907cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_365df539-e579-4569-9088-82f3762f295c" xlink:to="loc_us-gaap_RestructuringPlanAxis_7f960aa6-beef-4f12-8c8e-7bd064907cc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_7f960aa6-beef-4f12-8c8e-7bd064907cc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_7f960aa6-beef-4f12-8c8e-7bd064907cc5" xlink:to="loc_us-gaap_RestructuringPlanDomain_7f960aa6-beef-4f12-8c8e-7bd064907cc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_341c4df5-8742-46cf-90c8-22a9d7916b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_7f960aa6-beef-4f12-8c8e-7bd064907cc5" xlink:to="loc_us-gaap_RestructuringPlanDomain_341c4df5-8742-46cf-90c8-22a9d7916b95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_78bad654-7fa9-4c7d-b178-ecf3a2419730" xlink:href="jnj-20221002.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_341c4df5-8742-46cf-90c8-22a9d7916b95" xlink:to="loc_jnj_MedicalDevicesMember_78bad654-7fa9-4c7d-b178-ecf3a2419730" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_3348e447-372e-4eb0-b7d4-e11f7a23ce86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_365df539-e579-4569-9088-82f3762f295c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_3348e447-372e-4eb0-b7d4-e11f7a23ce86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3348e447-372e-4eb0-b7d4-e11f7a23ce86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3348e447-372e-4eb0-b7d4-e11f7a23ce86" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3348e447-372e-4eb0-b7d4-e11f7a23ce86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_9c606bc0-6e42-4f82-8b12-36b67facb39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3348e447-372e-4eb0-b7d4-e11f7a23ce86" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_9c606bc0-6e42-4f82-8b12-36b67facb39e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_9eb84957-e942-4662-becc-b7fbce643680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9c606bc0-6e42-4f82-8b12-36b67facb39e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_9eb84957-e942-4662-becc-b7fbce643680" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_fad5a194-46f0-483f-acf5-e643a5c9df80" xlink:href="jnj-20221002.xsd#jnj_AssetWriteoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9c606bc0-6e42-4f82-8b12-36b67facb39e" xlink:to="loc_jnj_AssetWriteoffMember_fad5a194-46f0-483f-acf5-e643a5c9df80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_35546694-45ba-40a2-a208-f69cd723a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9c606bc0-6e42-4f82-8b12-36b67facb39e" xlink:to="loc_us-gaap_OtherRestructuringMember_35546694-45ba-40a2-a208-f69cd723a7b9" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>jnj-20221002_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:33652491-8200-4ac3-aad3-f4f6756ccdbe,g:4fa62845-cfde-4969-940e-970c42754004-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0a27f1ca-f6b5-48fb-a676-e4866f93bf10_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_208d71c4-e8aa-49a8-93b7-4e0ad3b6417d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_b038071c-458a-4cd3-b67a-9d0e1c534359_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_b5dda011-9ad8-4ea6-91cd-087a19f8c5ac_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses and accounts receivable allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_318f0399-cdaa-4a3f-ad36-3233c30e9e61_terseLabel_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_label_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_documentation_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:href="jnj-20221002.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:to="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyPowderMember_326636fc-c1d0-4887-b56f-1ae61e3e9e99_terseLabel_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder</link:label>
    <link:label id="lab_jnj_BabyPowderMember_label_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:label id="lab_jnj_BabyPowderMember_documentation_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember" xlink:href="jnj-20221002.xsd#jnj_BabyPowderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyPowderMember" xlink:to="lab_jnj_BabyPowderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_00f5b82b-6415-4969-ace8-6c2e0c816ad4_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b98979f2-0a75-4ecc-8db1-31713de6cbbf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_b580466e-e391-41ca-8d5c-46835e9da94e_terseLabel_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value (6)</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_label_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:href="jnj-20221002.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:to="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerMember_72d14ae3-b5ad-47f0-86ad-132a846d1d9a_terseLabel_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH (1)</link:label>
    <link:label id="lab_jnj_ConsumerMember_label_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer [Member]</link:label>
    <link:label id="lab_jnj_ConsumerMember_documentation_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember" xlink:href="jnj-20221002.xsd#jnj_ConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerMember" xlink:to="lab_jnj_ConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DARZALEXMember_d714a726-e986-43ae-a1c1-604b93fb5319_terseLabel_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX</link:label>
    <link:label id="lab_jnj_DARZALEXMember_label_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:label id="lab_jnj_DARZALEXMember_documentation_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember" xlink:href="jnj-20221002.xsd#jnj_DARZALEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DARZALEXMember" xlink:to="lab_jnj_DARZALEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_95a4678e-499e-4dbc-9b8a-b89f83cef2df_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ADVANCEDMember_15c1ef74-b307-433e-a191-fb09d6e503eb_terseLabel_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_label_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_documentation_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember" xlink:href="jnj-20221002.xsd#jnj_ADVANCEDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ADVANCEDMember" xlink:to="lab_jnj_ADVANCEDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_78e92ebf-f9e4-4038-ae9f-ea9d17115284_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b35894d7-3769-4843-82f4-205f081c2afe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_9ce768d3-2a6f-4bae-b993-83dc4e5f0d4c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, impairment losses, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_f50d7db3-ceca-4cba-944a-f340eeb07ed0_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5d894f6b-877c-495c-a37a-1fd5c16168ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_798131dc-8f11-4f16-bcbc-b5af68b3223f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_ed210069-a6c2-490f-b6fa-1a31f70cf593_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_8112bc37-0300-45a0-aeac-1b294adf39fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_eb5ae542-b750-4f6b-9859-59c256c6e1b3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_8a1e79c8-9c4f-490c-b0a8-32214d1d1c41_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_label_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in operating income loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:href="jnj-20221002.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:to="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_50bfe262-3383-48dd-9e19-b54774a38e35_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_2e7c1042-1cfa-4cbb-a941-ccd89fc17fc0_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply network costs</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_345888d6-a32e-4663-855c-b553dccf60f6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_d73e1f26-88ff-418b-8990-2f55f02ac8d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b49d387d-b231-404b-84cd-99a17f7ffbad_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_40b6c4af-2d01-47a4-a6be-cc1083f75947_terseLabel_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_label_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_documentation_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member" xlink:href="jnj-20221002.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.75Notesdue2047Member" xlink:to="lab_jnj_A3.75Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d0e04f93-ebb4-4c5a-ab60-e9c694b794dc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (primarily licenses and milestones)</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6c9004b4-1d29-4d37-9ae9-1a5d44a9575d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncrementalIncreaseDecreaseInTaxes_ef05b29b-11d8-4388-a37a-054571341114_terseLabel_en-US" xlink:label="lab_jnj_IncrementalIncreaseDecreaseInTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental change to income tax rate (percent)</link:label>
    <link:label id="lab_jnj_IncrementalIncreaseDecreaseInTaxes_label_en-US" xlink:label="lab_jnj_IncrementalIncreaseDecreaseInTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Increase (Decrease) In Taxes</link:label>
    <link:label id="lab_jnj_IncrementalIncreaseDecreaseInTaxes_documentation_en-US" xlink:label="lab_jnj_IncrementalIncreaseDecreaseInTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Increase (Decrease) In Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncrementalIncreaseDecreaseInTaxes" xlink:href="jnj-20221002.xsd#jnj_IncrementalIncreaseDecreaseInTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncrementalIncreaseDecreaseInTaxes" xlink:to="lab_jnj_IncrementalIncreaseDecreaseInTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d19d1039-800c-4fb6-9e4c-fce47945a303_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionContributions_47895bea-0a4b-4abc-ad90-dc8b7b34e451_terseLabel_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to pension plans</link:label>
    <link:label id="lab_us-gaap_PensionContributions_label_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionContributions" xlink:to="lab_us-gaap_PensionContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1d5b8875-97c1-4c58-aa77-dffe6257c275_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_bd407596-bd90-4af3-8023-9d71f81b551d_terseLabel_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES / OTHER</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_label_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_documentation_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember" xlink:href="jnj-20221002.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONTACTLENSESOTHERMember" xlink:to="lab_jnj_CONTACTLENSESOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_3e317380-71bb-4584-bcfa-bbf055cc8b7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_619712bd-b639-4be4-bbf1-3fc022e581e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_b1189373-101a-4ecc-8bf0-9e693dbeb747_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e53a4d6a-99be-4d72-b2d6-86b73c9d8236_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_d929b62a-37f6-4106-b56b-46728fd9eb49_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_bb8a500d-f0f9-4852-98f1-76ab4f65a3e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_257aab4e-0055-4d53-ab66-f779668d90a6_negatedTerseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:href="jnj-20221002.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_397a1790-43d5-4c22-81b5-333539c04270_negatedTerseLabel_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: shares which could be repurchased under treasury stock method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_label_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Which Could Be Repurchased Under Treasury Stock Method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_documentation_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:href="jnj-20221002.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:to="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_88f85aef-0c5d-445a-969e-3add8cb42d43_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_HIPSMember_3cf22e98-d976-4ac7-8d76-f2ffc0a42872_terseLabel_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS</link:label>
    <link:label id="lab_jnj_HIPSMember_label_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:label id="lab_jnj_HIPSMember_documentation_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember" xlink:href="jnj-20221002.xsd#jnj_HIPSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_HIPSMember" xlink:to="lab_jnj_HIPSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_50cc2c33-40ba-4f8f-99ec-c582370659fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_f520aea4-f17b-43b6-ac23-7a0f404b536d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange rate</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_257acda3-3d38-45fe-a2e0-4571fad4ad22_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4cf8403d-90e2-41ba-973e-2776b50003d8_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a3550a5a-a103-4d49-9b95-8a6f7b373c44_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c6fde218-eb41-4700-a1e9-9edf2f7c2f6d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_2d42664d-627e-497a-9075-761b72602ce0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_3b857f01-9859-4cf7-8d9c-e0641ccce82c_verboseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due May 2035</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_08abc8db-5221-490d-ad28-3a131d3d960a_terseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes due 2035 (1.5B Euro 0.9712)</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_label_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_documentation_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member" xlink:href="jnj-20221002.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.650NotesDue2035Member" xlink:to="lab_jnj_A1.650NotesDue2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_a99e1385-e90a-4340-8ff6-3dcb85654285_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost/(credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c5050926-0efb-485e-a4de-8423a83a6734_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_96174033-61c9-44f0-8584-2fbc62db3959_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_43b81724-418b-44da-9e3d-a2c567d656cb_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:href="jnj-20221002.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ade11f15-e6e4-48bf-92fc-2949a3ebd4f3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_59c6dea0-eb4b-4fb2-b098-bef37e6dbd69_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims within settlement agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_label_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_documentation_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:href="jnj-20221002.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:to="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentRollForward_37313cfb-8031-4aba-b8c3-0273618786c4_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_label_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentRollForward" xlink:to="lab_jnj_EquityInvestmentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_ffaada95-2f88-4589-97e0-6ae69094dfdb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_92da3043-f9d2-4b5b-9ce6-b7b891d8385d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of basic net earnings per share to diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_fb9bcb7a-f48a-49a4-8636-0cc59f0e6101_terseLabel_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_label_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_documentation_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember" xlink:href="jnj-20221002.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTHERNEUROSCIENCEMember" xlink:to="lab_jnj_OTHERNEUROSCIENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_a593ddf9-0754-4efe-b842-6dc0fcfd3390_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_f794ac89-e2a1-4714-9f38-ce8d231c08d5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PhysiomeshMember_4704cdf7-03df-458e-9abb-0d770f1ce11f_terseLabel_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_label_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_documentation_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember" xlink:href="jnj-20221002.xsd#jnj_PhysiomeshMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PhysiomeshMember" xlink:to="lab_jnj_PhysiomeshMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_c410ed02-f1b1-4000-b400-e27baa9c5f06_terseLabel_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_label_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_documentation_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement" xlink:href="jnj-20221002.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Numberofpatientsinsettlement" xlink:to="lab_jnj_Numberofpatientsinsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e15b5353-5e33-43fb-9c01-5d1eb1326b0f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3f1a95bf-43b5-4788-82f7-4f2e0502a605_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_b8fefaff-4a11-4049-8e89-c1f25d392492_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_155f44e1-612b-471a-95f2-f8d882634eda_terseLabel_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_label_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_documentation_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member" xlink:href="jnj-20221002.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.95Notesdue2029Member" xlink:to="lab_jnj_A6.95Notesdue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ab2a02e5-9fe2-4ad9-9fdb-6cabfbb74137_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with definite lives:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_61144269-f6ff-4f4c-a94a-d847cbf360d0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_57b8a5c4-1fc5-4c91-886e-43b5ad52579c_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information, Revenue for Reportable Segment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_9e550532-392f-4fe8-80d1-c104454436a1_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_bc812074-f332-49c9-bf45-c6f27dc7e8e7_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_08919a97-1b12-40be-b33f-5981e0952e36_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvokanaMember_ca8e628f-d383-4567-938a-6108a1e96d67_terseLabel_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana</link:label>
    <link:label id="lab_jnj_InvokanaMember_label_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:label id="lab_jnj_InvokanaMember_documentation_en-US" xlink:label="lab_jnj_InvokanaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Invokana [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember" xlink:href="jnj-20221002.xsd#jnj_InvokanaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvokanaMember" xlink:to="lab_jnj_InvokanaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_c59d6c70-736a-4272-b539-f9bb78391b5c_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_2019ed20-0d4c-4296-afbd-b3d93c7c1eaa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7382f726-6636-4848-bd37-90dafcd3fac9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_118fd493-f323-41ad-b61a-a213afb13348_terseLabel_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S.</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_label_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_documentation_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember" xlink:href="jnj-20221002.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WesternHemisphereExcludingUSMember" xlink:to="lab_jnj_WesternHemisphereExcludingUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6b5fa155-f4a3-4611-b8f6-1bf71a99d0d4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets for identical assets and liabilities Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b3280dcf-67a2-4d8e-8532-a01d90444988_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_cf1abec4-af5b-400c-98ca-f4fecf35882f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_bde2f3a4-9b63-44b8-9ef1-3ac6a440ae4b_terseLabel_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income percent to sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_label_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income Interest Percent To Sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_documentation_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income interest percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:href="jnj-20221002.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:to="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_90c61552-bd47-4fad-966c-4606450b0896_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e8c52495-a7be-4255-a7e0-1e84601b63a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for Sale Securities Maturities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_18f97bd4-c334-4911-957e-66f8a288a3f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_6fd626b4-33ce-4517-bb39-e4e1ca3b8d8a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_a3a33971-9ba0-45df-be6e-123f56c4f1f3_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_1999fc16-d2a8-447b-a7b0-87cd1c6e43f3_terseLabel_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net percent to sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Operating Income Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non operating income expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:href="jnj-20221002.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:to="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_42d85262-0ae3-45b4-8be6-7867ed45771b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring estimated cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BeautyMember_242bde77-5c5c-4787-9e83-a97fd3e3e55a_terseLabel_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin Health/Beauty</link:label>
    <link:label id="lab_jnj_BeautyMember_label_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:label id="lab_jnj_BeautyMember_documentation_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember" xlink:href="jnj-20221002.xsd#jnj_BeautyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BeautyMember" xlink:to="lab_jnj_BeautyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4b5d2c31-b6ac-4d56-83fa-3edc9a1f1ff2_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note 4)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4d502afd-d5ff-42c3-8d6d-f3e2a10ec6c5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_43fd6296-c3f6-44b4-87df-15d68b8dac7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_6ba43aec-f6fa-4693-98a3-9397b2df3465_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0ad37ac9-d078-46db-8ddb-9fcdb3eff970_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_COVID19Member_79e623f2-32f6-46c5-a6ee-154faa2b8a92_terseLabel_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_jnj_COVID19Member_label_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_jnj_COVID19Member_documentation_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member" xlink:href="jnj-20221002.xsd#jnj_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_COVID19Member" xlink:to="lab_jnj_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_298316e4-769c-41ca-8f67-c388d0b5c01d_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits(1)</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_a8705406-742a-45fc-9354-3d8e13749466_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposal of assets/businesses, net (Note 10)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_d12d191c-bf86-48b4-bfd6-927c06086b31_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0a2c1ed3-f1a7-45bb-a4f1-43bb356c8a50_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_fa60a64f-6a66-4642-a259-5bf939e21a09_terseLabel_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL [Member]</link:label>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_label_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL [Member]</link:label>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_documentation_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:href="jnj-20221002.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:to="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NumberOfBrands_d43524ce-8a73-4fd3-ba6b-b6a1e7a32aba_terseLabel_en-US" xlink:label="lab_jnj_NumberOfBrands" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Brands</link:label>
    <link:label id="lab_jnj_NumberOfBrands_label_en-US" xlink:label="lab_jnj_NumberOfBrands" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Brands</link:label>
    <link:label id="lab_jnj_NumberOfBrands_documentation_en-US" xlink:label="lab_jnj_NumberOfBrands" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Brands</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfBrands" xlink:href="jnj-20221002.xsd#jnj_NumberOfBrands"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NumberOfBrands" xlink:to="lab_jnj_NumberOfBrands" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_18287b42-6046-4264-b9db-ff6be225c2c5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c2b873e8-ae9a-4b52-ae9a-e6deeca15b57_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_7cb64cbb-ce7c-4a44-b904-fe07b50697f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_17384e73-c7a4-47f2-84ee-2d313e5cd906_terseLabel_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member" xlink:href="jnj-20221002.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.375Notesdue2023Member" xlink:to="lab_jnj_A3.375Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4d370948-a9ca-4712-a4cf-a856725a14da_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b48c2fb6-2db4-4906-b15a-53b2718f75a2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DePuyASRU.S.Member_be59547a-efa0-4cd3-9468-094c4b7507d8_terseLabel_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S.</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_label_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_documentation_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member" xlink:href="jnj-20221002.xsd#jnj_DePuyASRU.S.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DePuyASRU.S.Member" xlink:to="lab_jnj_DePuyASRU.S.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A095NotesDue2027Member_1176ad49-475a-41a5-915c-e7b3f19a58fe_terseLabel_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_label_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_documentation_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member" xlink:href="jnj-20221002.xsd#jnj_A095NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A095NotesDue2027Member" xlink:to="lab_jnj_A095NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_83618d7c-4f55-4218-9e2c-e504664613f7_terseLabel_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_label_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_documentation_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:href="jnj-20221002.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:to="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_c40dd8ed-2b69-4ebd-a21e-6a0ca2057922_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_727a292d-cf4c-49f7-adca-91a7f2ca1db4_negatedLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_afac8c4c-6afb-4904-a0f3-e43a5f8c2caa_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_13cd01ac-8d0e-4365-8743-7331358be7e8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_250b7282-5f94-439c-8fed-bcf384bb27bb_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development in process percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">research and development in process percent to sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:href="jnj-20221002.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:to="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_8c6074fb-3420-475d-b058-0c05ea538763_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Business Segments</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_22ab45a2-116c-4881-bdee-4dfc62e2bc6b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SupplyChainMember_b29f6131-932a-44ac-bc16-2a3a19fc9524_terseLabel_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:label id="lab_jnj_SupplyChainMember_label_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain [Member]</link:label>
    <link:label id="lab_jnj_SupplyChainMember_documentation_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember" xlink:href="jnj-20221002.xsd#jnj_SupplyChainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SupplyChainMember" xlink:to="lab_jnj_SupplyChainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_59ea98eb-08ce-4f40-9ff4-7ea864785202_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_89b6daba-2ca1-426e-a43c-9a512a9f37fb_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_24f06835-1308-43e6-b221-c709ebc5e4a4_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_85ce301a-f903-4bde-bde7-5f93db4669f5_terseLabel_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member" xlink:href="jnj-20221002.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.375Notesdue2033Member" xlink:to="lab_jnj_A4.375Notesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4a63471c-c820-4e45-a7fd-2c2675a4c05c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_850faaa3-b532-4adc-be36-1cae1c26c5ab_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_2229452d-31fe-4b51-911a-d1a4703ab400_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_78c84369-7535-4f8a-af0c-e5be1ec5ff58_terseLabel_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_label_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing [Member]</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_documentation_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:href="jnj-20221002.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:to="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_cbee828c-85e2-4b75-8916-4890f24f0f66_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_702e0cd0-0ff1-4e4c-8902-62db70fc59b9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Fair Value Reflected in Net Income</link:label>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_57251cc3-638c-45dc-ad0b-fe14ee20173a_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. sovereign securities(1)</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1782cf21-b7fa-4945-99e1-f54b04a9285f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_20290b85-6274-4983-99db-0862f4c3ef59_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_85b5f797-52d6-4a77-a3d0-9565ca1a86ea_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_941ca8ad-38d4-4446-a0ab-7a4713203744_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a09fe1c5-3849-4a85-a372-44d7e36d7740_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4971b88a-cc7d-4c3f-937a-7daf2c68803c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_241de419-ae90-4072-9136-f7354c8649bf_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1300NotesDue2030Member_9e1881d4-a755-48c4-954b-861b84b83c63_terseLabel_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_label_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030 [Member]</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_documentation_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member" xlink:href="jnj-20221002.xsd#jnj_A1300NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1300NotesDue2030Member" xlink:to="lab_jnj_A1300NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_35c95d48-76e7-4b40-a9b9-47813bbc50e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit plans:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_4a0dfa88-bec8-410b-a9ee-2e173f6096d1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_da9aaef4-53dd-475f-82e8-9fd35fd60aec_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations (Note 6)</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_eb7a0740-7d67-48bc-8744-3fff4758eadf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_11353bbe-1748-42be-b3b7-60c3daeaa8f1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_067e4436-5ae3-4a3d-b93d-0cd6d0a58584_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_83c928cd-b9f1-48f3-8201-0c35c4b430d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7f9d41e2-f744-4793-ac68-b017be7979fc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED BY FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_64d23a19-9e20-4c2f-9749-f1440e6fd2a7_totalLabel_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income percent to sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:href="jnj-20221002.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:to="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4a33f59f-b9e2-4687-88da-8b658be1421b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c9ee3a11-1910-4320-abe7-64322c39228d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_8900474a-0c87-426f-99d0-664bf04902a6_terseLabel_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular / Metabolism / Other</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_label_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_documentation_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember" xlink:href="jnj-20221002.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CardiovascularMetabolismOtherMember" xlink:to="lab_jnj_CardiovascularMetabolismOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9eafd20e-918c-4cc7-bf90-46174581d631_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4cab1de6-f6c4-4f82-80de-46be02677a8e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide income before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8561012a-7171-40ec-b128-2f5a003bc6bb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_be0b9ee9-c0a7-46b8-a927-2ddc8217ad2e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f769de2a-e1bb-404f-99b4-08295869ef28_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_13b72d40-b5c8-4ffc-89a3-d1d48f9195b3_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_d1e51c32-02f4-4813-8772-50a4950a9733_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_3ee51ab3-a687-41df-b2f7-23da1dc75808_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_3581a798-7dc2-4387-8cfb-2ff4edf2edf6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_bdc07453-b6cc-402f-9549-4a26a23966af_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_634d8ace-3636-4641-8517-572c4501b807_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_15fe51da-2057-44bf-a974-c74c0276d4f3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_a0edfe55-40db-48d5-968d-0c538095335f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_089c9e28-bd19-42f8-bdc1-f9cd82615dc0_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:href="jnj-20221002.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_27f4a727-5c7e-4b87-a0ac-aba1acc12327_terseLabel_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals)</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_label_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals) [Abstract]</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_documentation_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding Textuals Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract" xlink:href="jnj-20221002.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalProceedingTextualsAbstract" xlink:to="lab_jnj_LegalProceedingTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_31067378-4ed0-4a46-bd5c-5a464dc39999_terseLabel_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_label_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_documentation_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:href="jnj-20221002.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:to="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_5ddf9757-44a5-4259-8f12-c119c5eaede8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_62263551-72ae-4776-a17f-7c86a8891bba_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_f248b67c-0ea7-4cfd-8d32-9e2e05d055e9_verboseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates, returns and promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_label_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_documentation_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:href="jnj-20221002.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:to="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_d3397a62-dd80-49a4-b478-93a25b987022_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_70d146b9-73d1-422e-86be-60c6f114944f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_e44b80e6-a941-4ffe-b186-07807e58dcae_terseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:href="jnj-20221002.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:to="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyCareMember_c0b6e079-c93b-4b12-beaa-47e76b21fb44_terseLabel_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care</link:label>
    <link:label id="lab_jnj_BabyCareMember_label_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:label id="lab_jnj_BabyCareMember_documentation_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember" xlink:href="jnj-20221002.xsd#jnj_BabyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyCareMember" xlink:to="lab_jnj_BabyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_157d7359-4a73-4f54-bb6f-0a6215e3b8ae_terseLabel_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_label_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System [Member]</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_documentation_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular cup system.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:href="jnj-20221002.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:to="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxes_7641b5c2-5eb1-4718-b7cd-59c75581413f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental tax costs related to restructuring</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_0bc84867-7685-484f-bf2d-6007049c70f0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_491dc861-0f19-43d6-affb-abd490babe5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_aab6a24a-e18d-468a-9c31-42676bf43419_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_c8cd84c9-33dd-406b-a823-e592333b54bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled non cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_3bf2497c-3baa-494f-968e-2b1bd2f1b2bd_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_0262018a-a8e7-4b2b-b0e5-3d2252b624fe_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_49672236-b0f2-488b-b16a-7c476c0dc0ca_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_93938bc9-7b01-40ae-a569-ee35c701fd26_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_baac0c88-b6b2-46bd-ab6f-72f84999c1e5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_11083613-11ac-4c12-a723-d31bf49dc8e3_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_46d4929c-b02c-4c77-8eda-160658968ad9_terseLabel_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_label_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_documentation_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member" xlink:href="jnj-20221002.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Debenturesdue2040Member" xlink:to="lab_jnj_A4.50Debenturesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_14fd13c5-74d0-42bd-827d-21efe2f567cc_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member" xlink:href="jnj-20221002.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2036Member" xlink:to="lab_jnj_A3.55Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_8bb76620-83ee-4436-b25b-d7c131b126e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income on derivatives, after tax</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_38576abb-66a8-4316-9fc3-fffeedc52851_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TalcMember_9a708c82-beba-48ff-aa4f-7090f8931a40_terseLabel_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc</link:label>
    <link:label id="lab_jnj_TalcMember_label_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:label id="lab_jnj_TalcMember_documentation_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember" xlink:href="jnj-20221002.xsd#jnj_TalcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TalcMember" xlink:to="lab_jnj_TalcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_f8c380f0-443a-418d-b53b-cb33433b7fa4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0b17ed66-8749-445e-860d-5945696a9bae_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_363f15f9-5f26-4a34-8765-78b31ccf44ac_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_1460bd57-5ad1-4977-a005-f1e0d3fc02d2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_524dddbc-c2a1-4250-b4bf-99b99f1d02fd_terseLabel_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_label_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member" xlink:href="jnj-20221002.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.85Debenturesdue2038Member" xlink:to="lab_jnj_A5.85Debenturesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_75c5d3eb-2559-4c88-bd8b-a05b64c5800d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6590abeb-e4b6-410a-b637-77df3656ec22_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c5216ab8-721e-45db-8ef7-5666f16c0fab_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00a292bb-e031-4ea1-b1aa-c90268b2cdf9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_e2e4e5a8-1171-4805-8fde-3ba010e8f813_terseLabel_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIMPONI / SIMPONI ARIA</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_label_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_documentation_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember" xlink:href="jnj-20221002.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SimponiSimponiAriaMember" xlink:to="lab_jnj_SimponiSimponiAriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PelvicMeshesMember_4985b5a3-f4ad-415b-8e71-5b0281c7780a_terseLabel_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_label_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes [Member]</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_documentation_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic meshes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember" xlink:href="jnj-20221002.xsd#jnj_PelvicMeshesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PelvicMeshesMember" xlink:to="lab_jnj_PelvicMeshesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_25114148-8f31-47c5-8e78-0f271e38b700_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1c9ef6d9-4029-4906-afa8-6cec6c03f992_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_010ce5a6-30eb-4550-a226-f7034d811a0a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_bd5b085b-50d4-4136-98aa-ee51058264d4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3cd2a845-094a-4d60-a3cc-30d99beb8fe6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b0fe0a96-f232-4f87-bd50-3365bc86a482_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_XareltoMember_95c8975c-2e39-4c5b-b043-5f8d1dc15774_terseLabel_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XARELTO</link:label>
    <link:label id="lab_jnj_XareltoMember_label_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:label id="lab_jnj_XareltoMember_documentation_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember" xlink:href="jnj-20221002.xsd#jnj_XareltoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_XareltoMember" xlink:to="lab_jnj_XareltoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_e5ca6157-27da-4f2b-ae48-64a518483248_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eb82863c-4bcc-40d5-b9f9-c3f9eafc9a9c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b92a087-1d5a-49cd-936f-a3ef01d41b8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_b14e0a6c-a973-49f5-8f2f-a8fc16ec20f3_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4473eddf-0643-4619-b2d7-bcdb4a1f02ad_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_15086ade-f065-4866-994a-afbddc0eb01f_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fc0dc375-2632-467e-919a-95c22e0186d4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f42cef26-677f-42d0-b8ca-4e78873e7078_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_57a54dc6-13cc-4b18-ba09-05a41fd760ee_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member" xlink:href="jnj-20221002.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2026Member" xlink:to="lab_jnj_A2.45Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_7722bf75-cc16-4637-b8da-07b27895d34e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7e6ebd27-9ccb-4d59-b0fa-cbdd1fa1e74a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RasmussenInstrumentsLLCMember_731be4fd-8d76-4499-8490-707088744fa1_terseLabel_en-US" xlink:label="lab_jnj_RasmussenInstrumentsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rasmussen Instruments, LLC</link:label>
    <link:label id="lab_jnj_RasmussenInstrumentsLLCMember_label_en-US" xlink:label="lab_jnj_RasmussenInstrumentsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rasmussen Instruments, LLC [Member]</link:label>
    <link:label id="lab_jnj_RasmussenInstrumentsLLCMember_documentation_en-US" xlink:label="lab_jnj_RasmussenInstrumentsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rasmussen Instruments, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RasmussenInstrumentsLLCMember" xlink:href="jnj-20221002.xsd#jnj_RasmussenInstrumentsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RasmussenInstrumentsLLCMember" xlink:to="lab_jnj_RasmussenInstrumentsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_6dd8565e-bafa-41c4-9a5f-d9cf7f1d33b5_terseLabel_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_label_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_documentation_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member" xlink:href="jnj-20221002.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Notesdue2043Member" xlink:to="lab_jnj_A4.50Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_0fd92d2e-9ba0-4d59-884c-039c4459a4d2_terseLabel_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income percent to sales</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense Benefit Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense benefit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:href="jnj-20221002.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:to="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_182cbc53-f15c-4539-bd86-021800d97772_terseLabel_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers percent to sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_label_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue Goods Net Percent To Sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_documentation_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue goods net percentage to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:href="jnj-20221002.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:to="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_69438b9f-bf30-4b60-b56b-48e50c79747f_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_92156cc3-1acf-4c90-99e3-219aa9c86f0d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide effective income tax rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_f00bfd77-936b-4972-a73c-fc14ef3ed023_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales/ Purchases/Other</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_label_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:to="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d2484e55-bb68-4e68-80bc-74172e36d551_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_6ce7f2ad-2892-4951-b169-9fd306e269fa_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ZYTIGAMember_bbd266bc-0dd2-468d-8bed-729b1b2e4332_terseLabel_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA / abiraterone acetate</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_label_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_documentation_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember" xlink:href="jnj-20221002.xsd#jnj_ZYTIGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ZYTIGAMember" xlink:to="lab_jnj_ZYTIGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c0000f63-0c6f-4664-9892-54605269dac8_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_04688053-25bd-43a2-80a8-3f408d998523_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0c261259-4d6f-4f29-8470-851f43e46769_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_2f9b51d9-1739-4d9b-98f7-5510514f784d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges recorded to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_a1deba10-3766-453f-ab04-1a9efa259ef0_verboseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:href="jnj-20221002.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:to="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_70655945-9afd-4833-ba88-a3fa8a1d8d92_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_567eca64-2984-4beb-906e-01b025e5c77b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_46409520-178d-4566-941d-d7124f124549_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_81d6d260-f0d4-4f46-81bb-924a5fd5165c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_6a078505-850a-4c35-a484-7bc318a56c43_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_a9c340bc-4d34-401d-8d83-44aa1d7f9e08_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_bc45a63c-7b33-4117-b95e-43b3d3f790b2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4b511bf1-352d-4ef6-b720-8dfdfd5f36b8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_061675b3-9707-40ff-9b77-533e755982e1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_c5a45c1f-da42-443d-8c19-5dde2bfdaf05_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_a379597d-71c0-4de9-bff8-28e77bfdd842_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_7f3091b9-b9af-4ece-839a-3deb90e68324_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Axis]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:href="jnj-20221002.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:to="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7434c23b-0817-43bc-b8ac-2d37668753d2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PharmaceuticalMember_939834a1-81fe-4a51-8307-192eb5c606d5_terseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PHARMACEUTICAL(1)</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_label_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_documentation_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember" xlink:href="jnj-20221002.xsd#jnj_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PharmaceuticalMember" xlink:to="lab_jnj_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_d0e7bb61-ffd9-4d7e-a8ec-9c527f0dd594_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c309d073-e708-4cc6-85fa-5cb00b5d5979_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_15019638-9b7a-4802-8b3e-dad14a41ff13_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_0e6c4829-cbab-4861-b95e-6486eb6618e5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Amount</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_d6b8065e-e78f-45e0-8f5a-113386180ce3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ba96f6c5-d892-4fa8-85c2-9e2a740c3246_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_7bffca45-fff4-43cf-8289-f6a6ffac81cd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_6e8b73a9-23eb-4909-9484-587892be19fc_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by geographic area.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:href="jnj-20221002.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:to="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgeryMember_b7a4d5e7-d9cc-408f-a2ec-11c264d0c7de_terseLabel_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery</link:label>
    <link:label id="lab_jnj_SurgeryMember_label_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:label id="lab_jnj_SurgeryMember_documentation_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember" xlink:href="jnj-20221002.xsd#jnj_SurgeryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgeryMember" xlink:to="lab_jnj_SurgeryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_d46ed8a5-de82-498a-9691-08e82116c7bc_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-Maturity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_a6889e8d-e50d-4867-9548-9a9146866036_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0185be35-fa92-4096-ac0f-636c214e0168_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_2ca3b060-c2b0-4fe0-8f71-6c4196518333_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_77efc797-42de-4653-98fc-4c3ee07f6be6_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RemicadeMember_75b26cd3-c5fc-45ff-9aa6-15b2a580caff_terseLabel_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REMICADE</link:label>
    <link:label id="lab_jnj_RemicadeMember_label_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_jnj_RemicadeMember_documentation_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember" xlink:href="jnj-20221002.xsd#jnj_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RemicadeMember" xlink:to="lab_jnj_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2a636f7a-bae2-41ea-823f-fe424be1e6aa_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c9ffd1fd-64d0-4fda-8788-163a246a30cb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_410c3718-20a0-44bf-aff1-bf8b4f4a030b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_170f0101-9654-489a-89bd-2a4df38c281a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_27b1d6c4-8d99-4e7f-b6fa-a4ea206ca3d7_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum length of time for hedge exposure</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TremfyaMember_66c96315-678c-4384-9cbf-eda7a32bbc6c_terseLabel_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TREMFYA</link:label>
    <link:label id="lab_jnj_TremfyaMember_label_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_jnj_TremfyaMember_documentation_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfaya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember" xlink:href="jnj-20221002.xsd#jnj_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TremfyaMember" xlink:to="lab_jnj_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_c3d411c1-38a6-4576-9c4e-717224cd4443_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_710e24bf-5b5b-48ca-ba66-a8a9065bb240_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_1fb42844-c86e-453d-9450-b883fcbe60b8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_1e78d665-c962-40e7-8eb2-81fb6be89a81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_053b3ea7-a704-417b-b0f6-83d1bcea8755_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PaymentsForRestructuringNet_0566efbd-8939-48fe-b5c8-b12db425e104_negatedTerseLabel_en-US" xlink:label="lab_jnj_PaymentsForRestructuringNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settlements</link:label>
    <link:label id="lab_jnj_PaymentsForRestructuringNet_label_en-US" xlink:label="lab_jnj_PaymentsForRestructuringNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Net</link:label>
    <link:label id="lab_jnj_PaymentsForRestructuringNet_documentation_en-US" xlink:label="lab_jnj_PaymentsForRestructuringNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsForRestructuringNet" xlink:href="jnj-20221002.xsd#jnj_PaymentsForRestructuringNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PaymentsForRestructuringNet" xlink:to="lab_jnj_PaymentsForRestructuringNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_cd1f2862-17dc-44c1-b90d-81dfa8ec7eb9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ElmironMember_04b75cce-6110-44b0-9170-39f2e999dc01_terseLabel_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron</link:label>
    <link:label id="lab_jnj_ElmironMember_label_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron [Member]</link:label>
    <link:label id="lab_jnj_ElmironMember_documentation_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember" xlink:href="jnj-20221002.xsd#jnj_ElmironMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ElmironMember" xlink:to="lab_jnj_ElmironMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_baa7a542-9056-408d-bcbf-c2128be1bc44_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_db628c9a-6892-4b0d-a323-b52e749fb418_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par Value $1.00</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_bf0f8c67-f4d9-4f7f-b245-b7a035f71014_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued Amount</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NeuroscienceMember_6b47257b-6851-43be-a163-21bb0347e082_terseLabel_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_label_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_documentation_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember" xlink:href="jnj-20221002.xsd#jnj_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NeuroscienceMember" xlink:to="lab_jnj_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_b5484d44-4381-4489-9be3-9bbc862f388b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_f6ad7969-e73f-476f-8af0-068939b89f43_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1a15db43-245d-486e-9468-5219d79543b5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_bfd66327-65b4-4b18-a24c-189bf94755fb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_384adba7-6503-4299-b3e0-38684d67d0cd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_56f03911-5bca-4257-9521-cef09c7c7ad0_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_509a0062-a06b-45c1-bf5c-18fb6babcd5a_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_59123d60-3dee-43e2-9741-b68cf09cf9aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_eed4e407-f3d3-4cc5-84be-29314109e4fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_f8a4e52e-b0ba-4a9a-862d-cc6bf0107cd4_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d67241b6-5616-4589-a550-3cff1ccfcc34_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5eb8e3d8-c003-4736-b620-50b2fb8462b4_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5a827c78-2efb-44aa-b4e4-d0519a7a9d6c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_aab55072-3939-4e8c-92c3-3ed3c346fe3d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Accumulated OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_29faaf3d-5bd2-4ace-8daa-8b3d0dfbcdf2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_85ade323-7dfc-4d15-a063-a1836bd8112e_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_91690406-79d1-4408-9f14-d519982358f8_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate for legal expense (percent)</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:href="jnj-20221002.xsd#jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_db424d48-24a5-42e4-ba7f-27cef58d3083_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_eb6823cc-295b-4fda-b201-72445bb31a2f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4651876e-a195-437d-9da5-391def85f2b6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, trade, less allowances $201 (2021, $230)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6f51b717-d3e1-4817-ac3f-28e8eec95103_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_6198936b-f2c8-417f-908f-e7c8b52c844a_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Gov't securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_39e0f3eb-b19f-4575-9ac5-62b1fee63f0a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VisionMember_d15ce909-27f4-4677-9e8b-e6b8e985de51_terseLabel_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision</link:label>
    <link:label id="lab_jnj_VisionMember_label_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision [Member]</link:label>
    <link:label id="lab_jnj_VisionMember_documentation_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember" xlink:href="jnj-20221002.xsd#jnj_VisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VisionMember" xlink:to="lab_jnj_VisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_93e9bf12-ae9b-416c-b49d-3de52ece0354_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_73120da3-f028-47b7-b421-9c3945ec18d5_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3878f161-142e-4995-8422-564e97128dfa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_93c14bfb-abc9-4247-84d1-4d968cbdb1cb_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_4147e167-946b-4154-87b9-d9b0e5fbe440_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9ebb8a30-9988-4b43-a029-d3574e3655b9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_de319169-184a-4f0e-9a2c-780ef696321b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_2fd4f7e6-a14c-43f0-b0c7-4f6745684be6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets/businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GENERALMember_60c07d37-c89e-4ead-92cf-be7f485561f2_terseLabel_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL</link:label>
    <link:label id="lab_jnj_GENERALMember_label_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:label id="lab_jnj_GENERALMember_documentation_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember" xlink:href="jnj-20221002.xsd#jnj_GENERALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GENERALMember" xlink:to="lab_jnj_GENERALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_05965a7d-7b89-43d9-8169-4ecdeab99fe1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_25c3fe30-d9c3-41e1-8704-9e4952f411d2_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0d7d5bff-d5aa-4ba5-a354-1aa2173b9a15_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, marketing and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_2b37290e-4362-485d-9e89-c0c08a26e6b1_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_e5dbd501-70bb-4a32-b991-d27f242227a8_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_97d0f4c4-f0b6-4a9c-aa5d-0efda2198bd3_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_27a10502-b1e0-46c2-bb59-f8977a746321_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66495a27-9fa6-439d-ae34-3be714878984_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c670754d-4d90-4968-87fd-ccb6f10ccebb_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_9138d66b-9b49-41b9-b22c-4f1749f05bde_terseLabel_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Notes due 2048</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_label_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_documentation_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member" xlink:href="jnj-20221002.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.500Notesdue2048Member" xlink:to="lab_jnj_A3.500Notesdue2048Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_16cd6fb8-933e-4c6f-8a41-03702040dc9c_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0550NotesDue2025Member_c0ed3186-51f3-412f-85e7-aa6a35ce8e86_terseLabel_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_label_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_documentation_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member" xlink:href="jnj-20221002.xsd#jnj_A0550NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0550NotesDue2025Member" xlink:to="lab_jnj_A0550NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_228690b3-a1fb-47d1-8063-915bb97d5fc3_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment, impairment loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:href="jnj-20221002.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:to="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_0ffdef36-4731-4113-82db-fe0803b2f59d_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f5ef08c7-7b42-49e0-9579-0e8afc028b34_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f355ad99-4a23-4992-9622-bbac32275c49_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_2a329871-7ed9-4cbb-9f12-4ad6b8faf2f8_terseLabel_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_label_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_documentation_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales" xlink:href="jnj-20221002.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Restructuringchargepercenttosales" xlink:to="lab_jnj_Restructuringchargepercenttosales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_48a8bb52-4b63-4b96-a6cc-ab987d900a05_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Segment Operating Income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_fd51f221-fe03-4aa4-b69b-309630af8897_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_a1d68c92-3143-4b79-86f5-4dca67e08222_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0dce6729-ef5b-44ce-b7f3-ac8a3138add5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New and Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_cb83160f-6360-459b-819f-52f811fda63d_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5c379953-e204-42eb-b9b9-98f4f3931063_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_d2e9ac9a-2436-4ba7-8eef-174d82ee5d28_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_251074cd-e36d-4a99-8090-3d92291d49cf_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Note 3)</link:label>
    <link:label id="lab_us-gaap_Goodwill_6eba4f0e-3c50-4e03-b38a-4f2a7129f4ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Beginning of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_67cdc811-5a90-4879-830e-7f6c80b988f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill End of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_bce1c3aa-baa8-44c3-a8f1-8e7d0eee5a99_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPINEOTHERMember_2dfc9c5f-112f-452e-b250-5305f9551f6a_terseLabel_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE, SPORTS &amp; OTHER</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_label_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_documentation_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember" xlink:href="jnj-20221002.xsd#jnj_SPINEOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPINEOTHERMember" xlink:to="lab_jnj_SPINEOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_fe821a98-7cef-4c81-900d-679d66f9bfb1_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_4fb977da-78fb-48c3-b353-e67defd510f3_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:href="jnj-20221002.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_3e37b834-1672-49d8-85e4-c938b3c5972f_terseLabel_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold percent to sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_label_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold Percent To Sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_documentation_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:href="jnj-20221002.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:to="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_81c8c183-33bb-4686-9130-37679e7d7bcd_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0f0aec34-4d59-46fb-9b61-06b566c5e24e_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ea5a2169-c2f0-4507-92d8-04c85b6f8ebf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_22b49e47-c948-46ac-8b66-6d67175c0e64_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_d8eea74d-0093-4833-8791-11ac6876b945_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_7a9f0030-f8f3-44c9-82f4-9b0f0d4b6a22_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b04752c1-d426-40a0-8ae8-0240d62dc70f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c4c0b8ce-0a28-44b0-a319-4b99aa4b3626_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c421e537-3a16-4096-9e62-0c9a6052ff16_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3e5031ef-c7ef-46ee-8052-5a415e8695de_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImmunologyMember_f67f10c2-c61b-453a-b241-c97e06de777f_terseLabel_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_jnj_ImmunologyMember_label_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_jnj_ImmunologyMember_documentation_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember" xlink:href="jnj-20221002.xsd#jnj_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImmunologyMember" xlink:to="lab_jnj_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8ff246fb-bac8-4651-bd83-2e80c50d2bf5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_0a605047-574b-48f1-9226-9083acc4ba08_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1c9a267d-e7bf-4f3c-ba45-0a02361d6c4a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44da2209-98cb-495f-bbfa-06baf992e473_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_e4003172-38d7-46a7-8fa6-99303ef782b8_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e7893afc-4b42-457f-845c-da811a475bd1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_a5799692-0e73-4b1f-ad91-03a784feb837_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_17109915-6d69-4961-be2b-c677c89457d8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_db9b814c-9276-45d2-b8c9-cf736a43333e_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_77558357-f965-439c-a4a2-337fc427a9b7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_eb858f8e-6858-4af2-ac5b-eff06a3e2525_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_d1f8ef25-6bdc-4430-a9a8-015983d6650f_verboseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of foreign exchange contracts into earnings, period</link:label>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_label_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Reclassification of Cash Flow Hedge Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:to="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_1e13ff63-6fec-45de-90ae-c0e55e85e3ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Equity Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_797a67fd-2be1-4e45-b729-fb8162d94daa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_8a9d1b73-4be4-402b-860f-d5eae4442731_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:href="jnj-20221002.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_8dbeee03-3f58-4fc8-a6f8-1469d407c1f3_terseLabel_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="jnj-20221002.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_03afb4a5-80a6-4208-a2cb-4afae5d00a98_verboseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_56e61675-be21-4c61-b292-b326b4526403_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes due 2028 (750MM Euro 0.9712)</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member" xlink:href="jnj-20221002.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDue2028Member" xlink:to="lab_jnj_A1.150NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_cc7d0dca-72b7-49c9-816c-32f0a8a044c0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_5a07d73e-6cd3-4c26-b50f-ec596c77866f_verboseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_d41b480a-c7c7-444a-b598-680cec6194f0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_29656b3e-c79e-4093-99c0-acc8af968ab1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_a6c33b82-d693-4348-8bf5-930108de2ac3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_bbe1b852-9927-4b4f-bd94-5299056705b6_terseLabel_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT / rilpivirine</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_label_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_documentation_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember" xlink:href="jnj-20221002.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EDURANTrilpivirineMember" xlink:to="lab_jnj_EDURANTrilpivirineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_bb4ab5b9-d9de-4f33-a4bf-84e9da89c401_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_22f789fb-7499-480d-9dc4-741a0ffe538a_verboseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due May 2024</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_ede83489-600c-4443-b071-d6cfcfe1345a_terseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes due 2024 (750MM Euro 0.9712)</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member" xlink:href="jnj-20221002.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.650NotesDue2024Member" xlink:to="lab_jnj_A0.650NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_78201da3-7cdd-4e73-af7d-91c0406900c8_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of additional possible loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_label_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_documentation_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:href="jnj-20221002.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:to="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3b3273ce-3358-4423-9690-91aa6acf5f68_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bad860fa-7cc0-48ea-8852-cc1f794ecae4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_dd600016-ab69-4aaf-a6f3-25d6638f867b_negatedTerseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in effective tax rate (percent)</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:href="jnj-20221002.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_441e38ff-91ec-4121-b8ab-abf1fd9d4542_terseLabel_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount prepaid and due to manufacturers</link:label>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_label_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Prepaid and Due to Manufacturers</link:label>
    <link:label id="lab_jnj_AmountPrepaidAndDueToManufacturers_documentation_en-US" xlink:label="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Prepaid and Due to Manufacturers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers" xlink:href="jnj-20221002.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AmountPrepaidAndDueToManufacturers" xlink:to="lab_jnj_AmountPrepaidAndDueToManufacturers" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WomensHealthMember_55e0c0e9-6816-4b76-8f93-24a88db7debe_terseLabel_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health</link:label>
    <link:label id="lab_jnj_WomensHealthMember_label_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:label id="lab_jnj_WomensHealthMember_documentation_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember" xlink:href="jnj-20221002.xsd#jnj_WomensHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WomensHealthMember" xlink:to="lab_jnj_WomensHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8aab80d2-da6f-413b-a744-aa6a9b01d19e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_08ecf890-7d86-4521-a33b-af654b9344b5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d841c98e-c542-4553-ae51-4a141db04b3b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4dddc524-0b8a-40fb-9775-c13f4c06f1fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IMBRUVICAMember_6791789b-10e3-4dc7-a849-ba56aff44492_terseLabel_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_label_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_documentation_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember" xlink:href="jnj-20221002.xsd#jnj_IMBRUVICAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IMBRUVICAMember" xlink:to="lab_jnj_IMBRUVICAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_808f8ddd-e34f-45d8-bf7e-14cbbceb4f5b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; Hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2250NotesDue2050Member_bb772cf3-864f-4196-9be2-a51b48cf42c4_terseLabel_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2050</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_label_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050 [Member]</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_documentation_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member" xlink:href="jnj-20221002.xsd#jnj_A2250NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2250NotesDue2050Member" xlink:to="lab_jnj_A2250NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_a72411e9-6643-42fb-a834-3313cf3469d0_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_757798cf-0f17-4669-8549-23d9310ff5d7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4af731d3-acbb-446c-bb06-4aab34678eb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_32d93286-4913-46cb-a387-b6ea9b0c97b1_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1df68a4c-02b3-4e94-b11a-6ddfa44ae57d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9ae38ae5-a634-4e51-9c0a-7857a3a0b355_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Weighted-Average Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8aa215d2-6d65-426e-8646-3c6fdcf07d00_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED BY INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_174a1e13-28e6-4ad4-bec1-f93ce344dc64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_96c88ece-8115-4cf8-95b2-557d0e7915c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_dc680f68-bb51-475f-a16b-80dab6b7e278_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_75144aea-7d20-4d35-84b2-e868ec577aa3_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f8293ceb-069a-4a00-a45c-9ee56fba8913_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c13fbfb9-3c15-4ca2-bd48-1f4ed223ac27_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_be725904-2cc5-44c1-8e14-00c38ca807ea_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OralCareMember_c6aa47ac-f411-470c-9474-47298b09035d_terseLabel_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care</link:label>
    <link:label id="lab_jnj_OralCareMember_label_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:label id="lab_jnj_OralCareMember_documentation_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember" xlink:href="jnj-20221002.xsd#jnj_OralCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OralCareMember" xlink:to="lab_jnj_OralCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_115caf85-baa8-4434-ac25-bb1cbb879b74_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_a32950f6-f300-4c57-95fa-015aa36d93ac_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OPSUMITMember_b544b070-f769-4d5c-b31f-d60d213f90c0_terseLabel_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT</link:label>
    <link:label id="lab_jnj_OPSUMITMember_label_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:label id="lab_jnj_OPSUMITMember_documentation_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember" xlink:href="jnj-20221002.xsd#jnj_OPSUMITMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OPSUMITMember" xlink:to="lab_jnj_OPSUMITMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_67fd0716-a45c-4927-9b60-a4edd31d9a71_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="jnj-20221002.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_284775c4-4834-43ea-bf3d-9bb390bf6af1_verboseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f6501987-ba62-4dc2-be8e-99e0bfeee663_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Profit by Segment of Business</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_3850a8f2-f1f7-4db0-b9e9-ad56422b4a44_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cae2e522-04ba-46c0-9045-b03f446b4d76_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64c60861-22c8-404b-8891-20355cd2d77c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1be6c53d-0c13-4393-814a-e58050cfd1f9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a55dbc79-3db2-4dbe-a6b8-58487cdc7e51_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Current Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_5bbe25f4-ed3f-41b5-88fd-30726a39fffc_verboseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_359b1323-2c45-4dd6-8739-9e650505b1ca_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6cac58c1-e958-491b-af7b-b6f42aefcd2f_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property and intangibles</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_cdd2e07a-0512-4c1c-8221-ccc604670a52_terseLabel_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90%&#160;Notes due 2028</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_label_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_documentation_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member" xlink:href="jnj-20221002.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.900Notesdue2028Member" xlink:to="lab_jnj_A2.900Notesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_ee5f30b0-0910-4ed6-a651-a9b419ccf95e_terseLabel_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Exports</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_label_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_documentation_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember" xlink:href="jnj-20221002.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UNITEDSTATESExportsMember" xlink:to="lab_jnj_UNITEDSTATESExportsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_a8fbc725-b516-4897-9d25-1531195d490e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AssetWriteoffMember_b9be161b-2726-49a6-bd53-4a17fcdf9159_terseLabel_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-offs/Sales</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_label_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_documentation_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember" xlink:href="jnj-20221002.xsd#jnj_AssetWriteoffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AssetWriteoffMember" xlink:to="lab_jnj_AssetWriteoffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_d0925cc9-aaeb-41ed-9550-baa0860de255_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f4415436-b6bf-4c67-ae0c-608bf9a59742_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_300542a4-0d58-4fb1-ac83-aaa17a02453d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_23c00b7a-a907-4702-8dd2-4ea601b29180_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsrMember_63f5c865-7cdf-4331-ab2e-2438fc742aa1_terseLabel_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR</link:label>
    <link:label id="lab_jnj_AsrMember_label_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR [Member]</link:label>
    <link:label id="lab_jnj_AsrMember_documentation_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember" xlink:href="jnj-20221002.xsd#jnj_AsrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsrMember" xlink:to="lab_jnj_AsrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_4cb2b896-dee2-4860-9cd1-0d7a9b13c2ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7933eaa7-f189-464b-991b-d782e483e9a4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_efbe5021-9dc5-4a42-b4ac-ef229221a206_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of the estimated fair value over the carrying value of debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Fair Value Over Carrying Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of fair value over carrying value of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:href="jnj-20221002.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:to="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GrossProfitPercentToSales_9dd16c99-09d3-48d5-9a99-856eddc1c085_totalLabel_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_label_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_documentation_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales" xlink:href="jnj-20221002.xsd#jnj_GrossProfitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GrossProfitPercentToSales" xlink:to="lab_jnj_GrossProfitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d946471-72cc-4edc-a4f6-246bbf713503_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_34bd810e-5e5f-4907-a35b-b772ba2d6512_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b7a8a192-9390-457f-9f2d-bfacfc0e6b4b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_86c27a1b-776b-4a3a-9260-e158339d259f_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve established</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_label_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_documentation_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:href="jnj-20221002.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:to="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_d493891c-7977-4cb3-b3d1-5e563b1d8e50_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_4b18e542-57dc-46d0-baff-8dc6db802744_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_7fce0279-18a8-41d2-89dc-a604a1ee5149_terseLabel_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member" xlink:href="jnj-20221002.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.95Debenturesdue2033Member" xlink:to="lab_jnj_A4.95Debenturesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_KNEESMember_13a9eccf-e40d-4793-a273-55f7276e3b39_terseLabel_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES</link:label>
    <link:label id="lab_jnj_KNEESMember_label_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:label id="lab_jnj_KNEESMember_documentation_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember" xlink:href="jnj-20221002.xsd#jnj_KNEESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_KNEESMember" xlink:to="lab_jnj_KNEESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_4456967b-297f-4623-86ff-7cefce8546b1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_df302030-1b40-4b33-b767-ba2fd96b448d_terseLabel_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling marketing and administrative expenses percent to sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling general and administrative expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:href="jnj-20221002.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:to="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_e958f4af-f935-4117-bb2e-478a6c0232b0_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_8600c051-4563-41cf-bc8d-53f0ee180a4e_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: common stock held in treasury, at cost (502,961,000 and 490,878,000 shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_9cc8a6d0-6d3b-4fb5-96a3-f4375f3cffbb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1ee0224d-d550-4335-a7d0-cf63a6623abe_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_abdf22e1-42b0-45df-817c-b35d3c55250f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3d8c9aba-dbec-4986-86d9-23ef268e4521_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_797e413e-8060-41fc-9c8c-184e7aae8eb5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f6c7508a-e40e-4a10-9e9e-2e44a3db7286_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fc911ad2-9e33-4b1c-bacf-f51d9c84e0d1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1995083a-a69f-4b81-8c7d-f942801e8789_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a2c38a02-0d66-4e6a-a798-a80d339e4b49_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9a53693c-6b9a-45fa-9e77-2fd146652401_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_9ff83f5b-55fc-4d60-aac3-8ec6e9a336cc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fbe25870-c972-41a5-a104-517e7ffc28d0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ef5787b7-74bd-497c-a2c6-3612dc6e73db_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss) (Note 7)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_39b5dc4d-7670-4704-b555-da72406741a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_0de05bdc-b432-47a6-8111-d8e44b128f5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Derivatives not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4e15ae2c-9170-4030-8046-2e5a728fa414_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_248751f8-afe9-4d72-82fb-aaecf3b3fc33_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ad65d4ca-802e-478f-861f-e245c5a2783d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_0a6e664d-9174-4ff3-8a14-711a3dc4a8ad_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_4cb2b1f7-b076-4212-9359-e73e8c2412d5_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency, number of claimants</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_label_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingency Number Of Claimant</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency number of claimant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:href="jnj-20221002.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:to="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9dafd7df-00eb-4347-a42c-695de8e5852b_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_fb2c2c19-4d6f-4135-8212-396cdaacb739_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_8b14aec6-d80d-4bcd-b3bc-fbba5ede5970_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_c4f35939-0b95-435d-9586-53af812f211d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_e427b52f-98cb-4862-8087-3acd33cc8214_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation/Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c8879f03-5aef-4afe-9726-ab129d1cf455_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_22ed092e-7502-4898-aef5-109ddc85835b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_ea476bd2-6a56-4d32-a897-0a7c8c335006_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_6f7a5d79-6166-45e3-b2f9-80e23d1ef032_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_d6b353f7-38a2-450a-8956-313d3445485c_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by geographic area</link:label>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments, Geographical Areas [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_011dd19c-9415-41ee-b2b6-953828efac57_terseLabel_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA / INVOKAMET</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_label_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_documentation_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember" xlink:href="jnj-20221002.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVOKANAINVOKAMETMember" xlink:to="lab_jnj_INVOKANAINVOKAMETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_7dad471a-8f5a-4390-b55f-60b4dddd1a16_terseLabel_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40%&#160;Notes due 2038</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_label_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member" xlink:href="jnj-20221002.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.400Notesdue2038Member" xlink:to="lab_jnj_A3.400Notesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AurisHealthMember_f0370ba2-d7d6-45a4-8454-60b91f053ea5_terseLabel_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:label id="lab_jnj_AurisHealthMember_label_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health [Member]</link:label>
    <link:label id="lab_jnj_AurisHealthMember_documentation_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember" xlink:href="jnj-20221002.xsd#jnj_AurisHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AurisHealthMember" xlink:to="lab_jnj_AurisHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_82a1a96a-8813-4024-a621-e4d44e8d00c4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_f668b488-19f3-4f4a-a73b-95a33d0230cf_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and notes payable</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_703126c1-0b1a-4db8-b942-635418d7cc5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3fd7da1e-1166-494b-bd45-bb6f111656fe_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e7dec4bb-aad9-4b6c-99d6-8517f1a2b588_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4d4e8f1a-ec2b-4670-9ca6-3094a49699ec_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_71ea37fe-f397-43e5-8a4b-9992512fcd13_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_f592b10d-a75e-40f9-8ea1-2dbbef4115b2_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_label_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Loaned or Sold under Agreements to Repurchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:to="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_b60c5031-e12a-4622-8cec-ec3fa923332b_terseLabel_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_label_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due Period Fifteen Member</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_documentation_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes due period fifteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember" xlink:href="jnj-20221002.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NotesDuePeriodFifteenMember" xlink:to="lab_jnj_NotesDuePeriodFifteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_0ee98fa1-d8bb-4dd5-be35-e1d91d665d31_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_641d8052-aead-4db1-8d13-e16a71373ea3_terseLabel_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_label_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business [Table Text Block]</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_documentation_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:href="jnj-20221002.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:to="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_2d132e76-9008-4608-9688-363b9d6b64c5_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments of Business and Geographic Areas</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_258df2cb-3055-4046-b309-86b302deb6dd_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_7a566dad-aa0e-4f7f-86e3-f923bce91502_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_5509b3d7-728c-4d98-b91a-1733438ec1a0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Income on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_dd74ea76-c7a2-41b5-876b-be45add69e52_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_fa3d5e61-8ba4-4d74-b422-1a469b6870d7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_aa05708f-81ba-4700-8259-b683d2676484_verboseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due November 2024</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_ede038cc-34e9-42ee-9b08-6e30b55d318a_terseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes due 2024 (500MM GBP 1.0908)</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member" xlink:href="jnj-20221002.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.50NotesDue2024Member" xlink:to="lab_jnj_A5.50NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_36d17fc6-507c-4ead-b3cc-5658ad5c8398_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_287d05a9-f48d-4f3a-96ac-f6168bb38576_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_54612df6-5b88-4960-b69f-625fbfad3701_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9032df52-2f81-4e44-8342-172a41cc09ee_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RisperdalMember_8c872065-fa13-4988-aeba-aad17b113f28_terseLabel_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal</link:label>
    <link:label id="lab_jnj_RisperdalMember_label_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal [Member]</link:label>
    <link:label id="lab_jnj_RisperdalMember_documentation_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember" xlink:href="jnj-20221002.xsd#jnj_RisperdalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RisperdalMember" xlink:to="lab_jnj_RisperdalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_fce7eca2-8191-42c2-8c02-7717aa458527_terseLabel_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_label_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_documentation_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member" xlink:href="jnj-20221002.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.70Notesdue2046Member" xlink:to="lab_jnj_A3.70Notesdue2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ac061a5a-f7dd-48e9-b5bb-80ab5c4466df_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVG. SHARES OUTSTANDING</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_818575fd-a613-4e7e-b596-dbf4e7328b9d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Note 2)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_8407320a-8de8-4ef6-b3d6-f63870852449_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e30bb63b-ec5e-4472-92bf-0399e39be9c0_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_9bd7b598-103e-436f-ba07-ce3eb8e98e1b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring (Note 12)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_1a5f4ea6-67e2-40cd-9bbf-c37f929709d6_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MedicalDevicesMember_e7bce310-743f-45c6-9bb9-4b00cfa01102_verboseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MedTech</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_1edc925b-bd19-4e61-9d2c-a9f55af264ef_terseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEDTECH(3)</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_label_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_documentation_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember" xlink:href="jnj-20221002.xsd#jnj_MedicalDevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MedicalDevicesMember" xlink:to="lab_jnj_MedicalDevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e5a55973-7848-4e5e-86ec-94b2be481e0b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_36c90c5e-b4ab-4548-8e11-914f2b87816b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherOncologyMember_e0924f2d-38d4-4eba-a429-60f4788fd788_terseLabel_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER ONCOLOGY</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_label_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_documentation_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember" xlink:href="jnj-20221002.xsd#jnj_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherOncologyMember" xlink:to="lab_jnj_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_d24e2da5-39c5-428f-9a5a-7fa5a858a6ed_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3c24a646-c2da-4812-b9b3-1ca846edca2d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_12a0f72e-d22e-4274-9e4c-9b9a9ec60100_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Liability Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_adcd1a4f-3427-4a66-b70f-844aeba8ec88_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b8495c1f-65bd-43f5-bed7-c936c60f9def_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_6ed392ec-a1cb-4edd-b0dd-86baece80c6c_terseLabel_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_label_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member" xlink:href="jnj-20221002.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.73Debenturesdue2023Member" xlink:to="lab_jnj_A6.73Debenturesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_3603bbf6-3f1b-4504-8a48-22f4eea6d57e_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_c2e0bda7-0d17-4fd2-a5cb-6b66c4613113_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ERLEADAMember_25fd8dff-cfa9-488e-82c5-49cc85f0853f_terseLabel_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:label id="lab_jnj_ERLEADAMember_label_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA [Member]</link:label>
    <link:label id="lab_jnj_ERLEADAMember_documentation_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember" xlink:href="jnj-20221002.xsd#jnj_ERLEADAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ERLEADAMember" xlink:to="lab_jnj_ERLEADAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_98cd73e5-d71d-4588-b183-0223e0ebd7dd_terseLabel_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_label_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_documentation_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember" xlink:href="jnj-20221002.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PatentsAndTrademarksMember" xlink:to="lab_jnj_PatentsAndTrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b81eb91e-b13e-450c-b0f4-b5ce7c7dbfb7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_fe5a755b-bc14-4cd9-a1af-f385ea468fea_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_e7ab4883-9bd4-4936-a7c9-090569d066bf_terseLabel_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member" xlink:href="jnj-20221002.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.625Notesdue2037Member" xlink:to="lab_jnj_A3.625Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_060519ba-b1ee-4b34-b98a-58497c3499da_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with indefinite lives:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_82ebd765-d944-410f-ade8-0e11140382f2_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on disposition of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9726e233-edcd-4e50-9878-618f09cc0d39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_6fe0b007-39c1-41ed-82bd-692f3c044f5c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherImmunologyMember_055fd877-b727-42aa-a758-2a51a5658d28_terseLabel_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER IMMUNOLOGY</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_label_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_documentation_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember" xlink:href="jnj-20221002.xsd#jnj_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherImmunologyMember" xlink:to="lab_jnj_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_8ffd2833-ab5b-40e7-a45b-89c1564a8df0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_2884ac75-0582-4fda-b1f2-14416e0ecddf_terseLabel_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_label_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_documentation_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember" xlink:href="jnj-20221002.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RISPERDALCONSTAMember" xlink:to="lab_jnj_RISPERDALCONSTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BermekimabMember_9f09c7e7-5ade-4f8b-bbfa-4881f2958fb9_terseLabel_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:label id="lab_jnj_BermekimabMember_label_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:label id="lab_jnj_BermekimabMember_documentation_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember" xlink:href="jnj-20221002.xsd#jnj_BermekimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BermekimabMember" xlink:to="lab_jnj_BermekimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_b0d51479-f768-4801-9e41-bd4cb1c2b445_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_2be7e41b-7490-4d21-a67f-5ae9db47c1c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_727e2bc1-9f20-472e-9c70-0735081cea96_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_90a6c753-2558-46f6-97c3-7c9e1d8b6595_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de642acc-c818-46b9-8c85-ae4509fa46d4_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_3b7ff2d7-ba90-418c-ae2d-2d79742c7752_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EvraAndDoxilMember_5cf7be54-bc85-4eca-902f-27db31878473_terseLabel_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_label_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil [Member]</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_documentation_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember" xlink:href="jnj-20221002.xsd#jnj_EvraAndDoxilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EvraAndDoxilMember" xlink:to="lab_jnj_EvraAndDoxilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_50e03e66-5036-4b3c-ae0d-cfcc7a2fdb8d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_af362b3b-076b-4435-acef-4a3490e0c432_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0768fdbd-90fa-41b9-ad80-1f657f44335c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_28b210a9-96ec-43ae-93e7-5315a1b36974_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_77eb71df-0235-4a14-9266-98a3c7dbbe8e_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_320768f4-03aa-48e4-9c71-3a1c02ce8489_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goods in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_f6c3f69e-0195-4269-9a8d-6d1f15a85f4c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_eae0354a-5e36-4fce-841c-724361d529a8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterventionalSolutionsMember_2ddbebf1-3fb1-43aa-a8c7-5332fd6261ac_verboseLabel_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_label_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_documentation_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember" xlink:href="jnj-20221002.xsd#jnj_InterventionalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterventionalSolutionsMember" xlink:to="lab_jnj_InterventionalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_06d97a1b-fe3e-4536-bb4d-0503fe05f2f2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_dc573c56-6862-4a25-8711-e8576cd028c4_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_05d8e8bb-9c30-4aae-9930-f9be3996c638_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_75b72a54-d423-40ec-b49d-6540bf58c5d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestExpensePercentToSales_6ac60e97-4205-40b4-89ec-ee6961c252d5_terseLabel_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized percent to sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_label_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales" xlink:href="jnj-20221002.xsd#jnj_InterestExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestExpensePercentToSales" xlink:to="lab_jnj_InterestExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_bf6f3190-d6d2-4ee8-abc3-7d6ed558be73_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_d7c8d8d4-4b77-442d-b866-8d885f7cbd0b_verboseLabel_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_label_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_documentation_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:href="jnj-20221002.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:to="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_81ba2800-822e-4964-9922-39110081c147_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_9bbcd627-588e-4f23-8540-e26eab5b0471_terseLabel_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects</link:label>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_label_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DamagesFromProductDefectsMember" xlink:to="lab_us-gaap_DamagesFromProductDefectsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_014e15b1-79cf-4aed-92cb-cf7c71b97aac_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential shares exercisable under stock option plans</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_ae934bed-2953-41a2-bbb5-1c4dacb76b72_verboseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_fb780bc3-9452-49e7-b141-b7ffdc0309f4_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_ce01ed32-8c0c-4335-a743-d4658eba0447_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_316517d6-94b0-43d2-b0b6-2f68bc1dd331_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d45900ec-a38a-483d-88ef-76e71977bc18_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_13676e04-f258-4be3-9101-d1b32f122f40_terseLabel_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_label_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_documentation_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member" xlink:href="jnj-20221002.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.95Notesdue2027Member" xlink:to="lab_jnj_A2.95Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_37f9169f-efa5-4762-a040-fe6e5a6354b5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired (Note 10)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_13858f2d-e071-4c9e-bb98-07d15e2a670c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_a04c369d-d499-4d44-9ec0-18fe2f34e62c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ff4b91a2-83f6-4e23-9823-7dc79cbd444d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_3537c7a1-2587-4bc0-b66e-4124a80e36a4_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_23dc5a95-743c-4397-85c8-982607ddacc2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_45f8fd44-efa4-4351-b5ca-fd93e45aa8ae_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_357f57b6-f45d-465b-a83c-07c16e5ff1cd_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d164b6ad-66a9-4008-a287-c9d849489008_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net (Note 3)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_f2041c2e-0970-4a92-aa74-2786739c829e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets - net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpioidMember_9092a89a-5aa8-4596-aa90-f20d5ac31f60_terseLabel_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:label id="lab_jnj_OpioidMember_label_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">opioid [Member]</link:label>
    <link:label id="lab_jnj_OpioidMember_documentation_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember" xlink:href="jnj-20221002.xsd#jnj_OpioidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpioidMember" xlink:to="lab_jnj_OpioidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2450NotesDue2060Member_139d8a40-5b5d-4ecb-aa82-11a4aa7261f7_terseLabel_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2060</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_label_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060 [Member]</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_documentation_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member" xlink:href="jnj-20221002.xsd#jnj_A2450NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2450NotesDue2060Member" xlink:to="lab_jnj_A2450NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_15860b5b-5416-4acd-aab7-936056015c9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_f292c9ee-f91d-4b19-85ec-7831a28ae548_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_3088cf54-19df-4ee5-890c-35ad4d600863_terseLabel_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_label_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_documentation_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member" xlink:href="jnj-20221002.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.85Notesdue2041Member" xlink:to="lab_jnj_A4.85Notesdue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6fb4fc35-b840-47d6-ad76-0297d1ba78e5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_2fc36575-0e19-4e48-baad-5da44b2b58e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_fe3d9c94-f586-40c7-843f-7e8a6da04217_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term taxes payable (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherMember_e764c1be-6e33-48a5-a363-c6dc51573bd4_terseLabel_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_OtherMember_label_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_jnj_OtherMember_documentation_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember" xlink:href="jnj-20221002.xsd#jnj_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherMember" xlink:to="lab_jnj_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0522f629-e2ef-49cb-8fda-00b841b5a026_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_4f635446-1ac5-4387-b8d7-8ac562d9834b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_13d88698-1d95-4516-906b-f52aa0bae959_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_394d1096-7208-48fc-9c2a-b87451c530ee_verboseLabel_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income)/Interest expense, net</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember" xlink:href="jnj-20221002.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestIncomeExpenseNetMember" xlink:to="lab_jnj_InterestIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_8c124d97-7bc0-4c0d-bc02-a229ec6e247c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities(1)</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_77e2cc44-4cc3-4520-a730-7595e2593ee1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_5708bd0c-2ace-47ea-8a99-d6e806370c34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Asset Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_84657b19-4ade-4e02-9298-8e1acee1b65a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TRAUMAMember_5d4f0ff7-4658-466d-b9f9-c428ce62c7c1_terseLabel_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA</link:label>
    <link:label id="lab_jnj_TRAUMAMember_label_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:label id="lab_jnj_TRAUMAMember_documentation_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember" xlink:href="jnj-20221002.xsd#jnj_TRAUMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TRAUMAMember" xlink:to="lab_jnj_TRAUMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_798a4133-be9f-448a-a387-045ec949962c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_42bed92b-179b-4684-90da-d2b652934dbd_terseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_50a734fc-1c35-45cc-b523-4e178f390240_verboseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember" xlink:href="jnj-20221002.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherIncomeExpenseNetMember" xlink:to="lab_jnj_OtherIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f51ca977-bd00-4f24-8c77-406b22e16659_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_a7973d94-ec80-4a39-97ef-00bfa57b0761_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral already posted, aggregate fair value</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_19d14f97-4c4a-4624-8e3e-86fe7bb3f269_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_90023ed0-7670-44b4-a648-d29bc7ede02c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0bd5d169-ff11-4f05-8d6a-1a618303b13e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OncologyMember_9058e263-d4cc-42af-ae50-1a466ae6f801_terseLabel_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_jnj_OncologyMember_label_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_jnj_OncologyMember_documentation_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember" xlink:href="jnj-20221002.xsd#jnj_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OncologyMember" xlink:to="lab_jnj_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_7a5e58b2-e0e9-41b5-8fb9-76d14b528e60_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities at fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Detail [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_5c2282ab-e542-4f22-9e19-c339501a5980_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_fb0ed369-05de-4581-acbf-114ed68d3433_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_b0fd4ccf-4af1-4133-9df3-0b6d4cf82c2b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3d9ad07b-de1b-42b5-ac16-df81c4adf544_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2b754a64-1ff2-4a88-a2f3-dea56db847c9_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTCMember_439d13d3-5eb5-424e-b217-d83e8b659d73_terseLabel_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_label_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_documentation_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember" xlink:href="jnj-20221002.xsd#jnj_OTCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTCMember" xlink:to="lab_jnj_OTCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ac629ecd-2d47-4b5f-a38d-7fecee617500_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_76587666-389e-41a5-a807-7404e9dfd806_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_85b2c3cf-945b-4aaf-9565-89b07df051e5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_e13e1b64-9a59-470a-add5-e24d7a9c02ee_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_49ddc36a-69df-4760-8c9f-bb6f255e43ef_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense Excluding Acquired In Process Cost Percent To Sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense excluding acquired in process cost percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:href="jnj-20221002.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:to="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5fab2915-4233-47ba-9a69-29ea792b404a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_0504914d-6201-406d-94d4-8ab0f4290278_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_51468115-bd09-4311-8465-bfc8cd6b96cb_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_283ea881-538b-4712-9c54-d81ad575fa78_terseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:href="jnj-20221002.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_fa497ac0-5c2a-40ff-af61-8ab9e25a10a4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_5abcc28b-55cc-454f-8ed6-312febacd836_terseLabel_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member" xlink:href="jnj-20221002.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.95Notesdue2037Member" xlink:to="lab_jnj_A5.95Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_3a6efb44-af2c-4dc5-a292-a3e7c1db37d7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1701c4ba-11a4-40ef-ac60-72bcb1de8d4a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_237f3ef6-9007-4f20-b52d-518c228cae49_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_d3d10a4e-01cc-48f3-9b75-f0a76f3fd956_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_b2772783-7424-4f0b-8bd2-f02c0d25c848_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ec750fe7-423e-450b-bdf0-f76bcb01ba2f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_2bff3aaf-35df-4696-a9bc-bcf5be03e4aa_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A210NotesDue2040Member_9722ad82-32ac-492c-9f35-56385c3dff6c_terseLabel_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_label_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_documentation_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member" xlink:href="jnj-20221002.xsd#jnj_A210NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A210NotesDue2040Member" xlink:to="lab_jnj_A210NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_5d49e16e-83d6-4437-8406-98b194f3dca8_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Domain]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:href="jnj-20221002.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:to="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_d542fc38-f208-41b8-8d57-65ef30c121ef_terseLabel_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA / methylphenidate</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_label_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_documentation_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember" xlink:href="jnj-20221002.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONCERTAMethylphenidateMember" xlink:to="lab_jnj_CONCERTAMethylphenidateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7afedf78-5c21-4359-9368-7aa60909c82b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StelaraMember_015ce04c-7612-4a80-ad2d-2a95190920a5_terseLabel_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STELARA</link:label>
    <link:label id="lab_jnj_StelaraMember_label_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:label id="lab_jnj_StelaraMember_documentation_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember" xlink:href="jnj-20221002.xsd#jnj_StelaraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StelaraMember" xlink:to="lab_jnj_StelaraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SURGICALMember_90fb00b7-096c-4fa0-8bc3-c4133f164ed0_terseLabel_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL</link:label>
    <link:label id="lab_jnj_SURGICALMember_label_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:label id="lab_jnj_SURGICALMember_documentation_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember" xlink:href="jnj-20221002.xsd#jnj_SURGICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SURGICALMember" xlink:to="lab_jnj_SURGICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_b2e05016-32b2-422a-a773-99cc5861bbf9_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments and settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_c9ce502c-2511-493a-bab3-97141e20ff36_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4a76db1-b4d9-4e07-8150-01c301d41035_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease)/Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_bf1597d4-877e-4bb7-90ff-840846c62812_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OrthopaedicsMember_ec6bb319-49dc-4cdc-904c-aa6c8e490cd4_terseLabel_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_label_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_documentation_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember" xlink:href="jnj-20221002.xsd#jnj_OrthopaedicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OrthopaedicsMember" xlink:to="lab_jnj_OrthopaedicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_34e5a6ce-3be7-4d2a-a677-91bec548b9a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_b1d511b3-246f-4c73-91d5-207adc2a5d1f_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_17cb7d31-b293-4b96-bc67-c32560aa30ed_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InfectiousDiseasesMember_e5dba56c-da2e-442c-8321-763d5fceddac_terseLabel_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember" xlink:href="jnj-20221002.xsd#jnj_InfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InfectiousDiseasesMember" xlink:to="lab_jnj_InfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_198f794e-5842-4875-9b0e-4c4b3fc8a1ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_233c6e11-2477-411c-8407-2225f3a7bdb4_terseLabel_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_label_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_documentation_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember" xlink:href="jnj-20221002.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PulmonaryHypertensionMember" xlink:to="lab_jnj_PulmonaryHypertensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23c32b4b-117e-4393-a830-eb0f27993bd5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_51931a8f-2ef8-4819-949b-2eb1d739f87c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a8c19a99-83df-4797-bdd2-cab92969ec9d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0ec4e1b3-f5f0-4edc-b841-53fbc420b898_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_13e60d3a-10d3-48d6-b0ea-a5b0cd13e52b_totalLabel_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings percent to sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_label_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_documentation_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:href="jnj-20221002.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:to="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OneTimeFavorableTaxItemPercent_efa82271-9ea0-4a92-b8a4-81015c648241_terseLabel_en-US" xlink:label="lab_jnj_OneTimeFavorableTaxItemPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable tax event (percent)</link:label>
    <link:label id="lab_jnj_OneTimeFavorableTaxItemPercent_label_en-US" xlink:label="lab_jnj_OneTimeFavorableTaxItemPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Favorable Tax Item,Percent</link:label>
    <link:label id="lab_jnj_OneTimeFavorableTaxItemPercent_documentation_en-US" xlink:label="lab_jnj_OneTimeFavorableTaxItemPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Favorable Tax Item,Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OneTimeFavorableTaxItemPercent" xlink:href="jnj-20221002.xsd#jnj_OneTimeFavorableTaxItemPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OneTimeFavorableTaxItemPercent" xlink:to="lab_jnj_OneTimeFavorableTaxItemPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1dfcba94-086f-4e03-ae20-60b09d8d8545_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_1a65d818-8ad4-400c-9870-9af87008db81_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d19f0637-1dec-4bb4-aa27-ca53ef14f496_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_fea1b6af-1b3b-4df3-b56d-e4d0a293f709_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_833ed5c8-db9f-445b-8722-8ba64e6e57c6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_291bbca1-ac1c-4e6e-b465-8bf687d51672_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_83b43092-b12b-433b-a19c-3ce1a9be29c9_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent Change (as a percent)</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:href="jnj-20221002.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:to="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_7bd477f0-e44d-4c32-a2a5-fd543b4f945e_terseLabel_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625% Notes due 2025</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_label_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_documentation_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member" xlink:href="jnj-20221002.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.625Notesdue2025Member" xlink:to="lab_jnj_A2.625Notesdue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18890797-570b-4fa2-9740-e8a5839be5e4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_8dc7b1d0-8ca2-4953-a483-9992c71fc05b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_26868142-dfe8-451e-92dc-e22920f9ef70_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate on non-current debt</link:label>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_08a5c6b6-07f7-4f75-b546-4c1305e3e34f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JudicialRulingMember_178046db-20e6-43ea-bfa8-88b42adf79de_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember" xlink:to="lab_us-gaap_JudicialRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_5b989609-cc58-44ea-a4b9-8588fe258ea2_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_979ddd68-18c2-41e3-9236-a1feb6ab2414_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_19a60a64-2096-42c4-84ef-7455b77c1e78_terseLabel_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_label_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_documentation_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember" xlink:href="jnj-20221002.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsiaPacificAfricaMember" xlink:to="lab_jnj_AsiaPacificAfricaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b563e8b8-4418-48ba-b5ac-9be5e205bf4f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_3ed1c1d4-95c6-49de-bb80-74c4ec806df9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UPTRAVIMember_acd13f6d-930f-4860-8c73-f52a3c6f8c3a_terseLabel_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_label_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_documentation_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember" xlink:href="jnj-20221002.xsd#jnj_UPTRAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UPTRAVIMember" xlink:to="lab_jnj_UPTRAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2100f89f-0cdb-47e5-b159-5b31625660fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WoundCareandOtherMember_cdf98f1e-08b4-46ed-9088-24bd289f7575_terseLabel_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care/Other</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_label_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_documentation_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember" xlink:href="jnj-20221002.xsd#jnj_WoundCareandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WoundCareandOtherMember" xlink:to="lab_jnj_WoundCareandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7567fe53-5a45-43d9-80dd-d29f09920dcc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_6c4f43e2-c96e-44b8-9174-e37bac68847e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_349681d0-00c1-4195-8ea3-f85ca4e78cc7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_fec18aa0-e74f-41ee-be76-9c61127d0ae2_terseLabel_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INFECTIOUS DISEASES(</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember" xlink:href="jnj-20221002.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherInfectiousDiseasesMember" xlink:to="lab_jnj_OtherInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_36422af4-4b1a-47dc-825e-838406e98bfc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_675d32a6-b494-4f25-b0ab-953f998b6fcc_terseLabel_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost savings expected</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_label_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:label id="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings_documentation_en-US" xlink:label="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Future Savings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:href="jnj-20221002.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:to="lab_jnj_RestructuringandRelatedCostExpectedFutureSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_573a3a13-e530-44fd-a159-8d0c74b0bdd4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_fa24e53f-b678-4a0b-a2e1-05d9d2eb5fef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_89c2d795-6226-49a6-ad89-8b2a1da00178_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ContactLensesMember_93bf7efc-b6d6-4e49-b80f-9c8cfc054a82_terseLabel_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses</link:label>
    <link:label id="lab_jnj_ContactLensesMember_label_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses [Member]</link:label>
    <link:label id="lab_jnj_ContactLensesMember_documentation_en-US" xlink:label="lab_jnj_ContactLensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Lenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember" xlink:href="jnj-20221002.xsd#jnj_ContactLensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ContactLensesMember" xlink:to="lab_jnj_ContactLensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_a3b13f42-bd93-413e-91f0-026adb0d8614_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>jnj-20221002_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:33652491-8200-4ac3-aad3-f4f6756ccdbe,g:4fa62845-cfde-4969-940e-970c42754004-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20221002.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8d506aa9-80eb-4d13-bccd-bba7bab6aaf7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_20ff3c44-5512-4505-8182-c59a38b3d15c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8d506aa9-80eb-4d13-bccd-bba7bab6aaf7" xlink:to="loc_dei_EntitiesTable_20ff3c44-5512-4505-8182-c59a38b3d15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e212e209-d25a-4604-a637-b82e1b8a2bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_20ff3c44-5512-4505-8182-c59a38b3d15c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e212e209-d25a-4604-a637-b82e1b8a2bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e212e209-d25a-4604-a637-b82e1b8a2bb0" xlink:to="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bb95fa71-3c4e-4d0a-8fce-9348d7f96758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:to="loc_us-gaap_CommonStockMember_bb95fa71-3c4e-4d0a-8fce-9348d7f96758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_2b078fc9-572b-4359-b744-b0167bbfd163" xlink:href="jnj-20221002.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:to="loc_jnj_A0.650NotesDue2024Member_2b078fc9-572b-4359-b744-b0167bbfd163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_9f1e832c-1515-45f9-8593-ddf3af3a55b5" xlink:href="jnj-20221002.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:to="loc_jnj_A5.50NotesDue2024Member_9f1e832c-1515-45f9-8593-ddf3af3a55b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_7af73fbb-0e90-40b0-835c-cb2baaa41e8c" xlink:href="jnj-20221002.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:to="loc_jnj_A1.150NotesDue2028Member_7af73fbb-0e90-40b0-835c-cb2baaa41e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_0c563682-0616-4a8d-ba49-8df7a598edc9" xlink:href="jnj-20221002.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1f77af33-6c6b-494e-8f2b-11d70d8a440a" xlink:to="loc_jnj_A1.650NotesDue2035Member_0c563682-0616-4a8d-ba49-8df7a598edc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_20ff3c44-5512-4505-8182-c59a38b3d15c" xlink:to="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_023b2125-06d3-47dd-aee7-bfb218e9dacc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentType_023b2125-06d3-47dd-aee7-bfb218e9dacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7c435626-76b0-47df-b993-e5ab290b1298" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentQuarterlyReport_7c435626-76b0-47df-b993-e5ab290b1298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9f626652-1d47-451d-97dc-060e626bedad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentPeriodEndDate_9f626652-1d47-451d-97dc-060e626bedad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e5bae366-3c86-4dce-a4ed-60299325e829" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentTransitionReport_e5bae366-3c86-4dce-a4ed-60299325e829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f301d1fb-ceb2-40fd-a6ce-f5f6686eb0ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityFileNumber_f301d1fb-ceb2-40fd-a6ce-f5f6686eb0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e8ab7e26-e780-4b18-8929-9e94265e747f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityRegistrantName_e8ab7e26-e780-4b18-8929-9e94265e747f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_78866a15-d9cd-4689-ba75-a204addf2ce0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityIncorporationStateCountryCode_78866a15-d9cd-4689-ba75-a204addf2ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_120a1f05-b89c-4097-9458-310460dfaedf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityTaxIdentificationNumber_120a1f05-b89c-4097-9458-310460dfaedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_24398342-a92b-42b4-9855-a32d82ec4c4a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityAddressAddressLine1_24398342-a92b-42b4-9855-a32d82ec4c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0e87f2e4-62ca-4045-a5a2-dcd82e875c15" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityAddressCityOrTown_0e87f2e4-62ca-4045-a5a2-dcd82e875c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4a24c9a7-af69-4bca-97e8-ef565996fcec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityAddressStateOrProvince_4a24c9a7-af69-4bca-97e8-ef565996fcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ffb5c6fb-166a-46c3-b965-24994ab2712d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityAddressPostalZipCode_ffb5c6fb-166a-46c3-b965-24994ab2712d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8bc763e7-df34-4b06-b6b6-e4b8931bd5cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_CityAreaCode_8bc763e7-df34-4b06-b6b6-e4b8931bd5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3eb1e9b1-d071-4499-8eda-94f6caa262c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_LocalPhoneNumber_3eb1e9b1-d071-4499-8eda-94f6caa262c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8437f2d0-031c-4cd1-86de-da663f96c949" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityCurrentReportingStatus_8437f2d0-031c-4cd1-86de-da663f96c949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e8dd68df-04fc-4ec4-8c09-37b6566c3d55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityInteractiveDataCurrent_e8dd68df-04fc-4ec4-8c09-37b6566c3d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_fa531bdf-4469-4fdb-adf0-b08697934683" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityFilerCategory_fa531bdf-4469-4fdb-adf0-b08697934683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2644ca7c-c972-4e1c-b645-738c872cb3f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntitySmallBusiness_2644ca7c-c972-4e1c-b645-738c872cb3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_269f85c6-c124-490a-bbf5-352b44ed3a37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityEmergingGrowthCompany_269f85c6-c124-490a-bbf5-352b44ed3a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e14a6a7e-99ce-4b04-a034-acab5173cb56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityShellCompany_e14a6a7e-99ce-4b04-a034-acab5173cb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f7605d3d-23ea-40e5-a066-080bd961bc92" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_Security12bTitle_f7605d3d-23ea-40e5-a066-080bd961bc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3b746f00-b356-417e-9849-8a9f5c9960bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_TradingSymbol_3b746f00-b356-417e-9849-8a9f5c9960bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_873e5200-baab-4ed3-b804-7eb1c733c84a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_SecurityExchangeName_873e5200-baab-4ed3-b804-7eb1c733c84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3022525c-cad1-468f-9014-0312843ebd76" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3022525c-cad1-468f-9014-0312843ebd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4089b260-e326-4f65-9b0d-b285f8a1ecf3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_EntityCentralIndexKey_4089b260-e326-4f65-9b0d-b285f8a1ecf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a2119503-6cdd-4d63-9674-c31757ae969d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_CurrentFiscalYearEndDate_a2119503-6cdd-4d63-9674-c31757ae969d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b3f5300e-a883-4cd0-be31-43adff55bce5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentFiscalYearFocus_b3f5300e-a883-4cd0-be31-43adff55bce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11d7288b-727a-49aa-a0dc-27ce5ba3a7bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11d7288b-727a-49aa-a0dc-27ce5ba3a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1776563f-20b8-4552-b344-c689610e19f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_77c9a616-edeb-483e-8ae2-7d2e901eb8de" xlink:to="loc_dei_AmendmentFlag_1776563f-20b8-4552-b344-c689610e19f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_455bcbcc-7809-496d-a6a1-cbd5cfb1225f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5af8a176-1bc7-422e-82a8-a23cc8b2cf7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_455bcbcc-7809-496d-a6a1-cbd5cfb1225f" xlink:to="loc_us-gaap_AssetsAbstract_5af8a176-1bc7-422e-82a8-a23cc8b2cf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_dcbb5ff8-8a8e-4114-a1e5-0b871ff2da62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5af8a176-1bc7-422e-82a8-a23cc8b2cf7b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_dcbb5ff8-8a8e-4114-a1e5-0b871ff2da62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b37885ec-ee76-4399-acf8-9e411ded34ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcbb5ff8-8a8e-4114-a1e5-0b871ff2da62" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b37885ec-ee76-4399-acf8-9e411ded34ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_f1c694f1-ebff-42c6-b9fe-f36a4733323d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcbb5ff8-8a8e-4114-a1e5-0b871ff2da62" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_f1c694f1-ebff-42c6-b9fe-f36a4733323d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_da1ac7aa-b7b0-42d4-abf4-8324d242af46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcbb5ff8-8a8e-4114-a1e5-0b871ff2da62" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_da1ac7aa-b7b0-42d4-abf4-8324d242af46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ffaa26f4-a785-42d1-97f9-5b64c05b3fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcbb5ff8-8a8e-4114-a1e5-0b871ff2da62" xlink:to="loc_us-gaap_InventoryNet_ffaa26f4-a785-42d1-97f9-5b64c05b3fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a1ec28b-f189-4e9e-931a-e0c17078ba05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcbb5ff8-8a8e-4114-a1e5-0b871ff2da62" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a1ec28b-f189-4e9e-931a-e0c17078ba05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3225c2cd-f187-4bc8-8263-5e76b5d05485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcbb5ff8-8a8e-4114-a1e5-0b871ff2da62" xlink:to="loc_us-gaap_AssetsCurrent_3225c2cd-f187-4bc8-8263-5e76b5d05485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9f53f7d4-44c2-43ec-8949-2302e87ce88f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5af8a176-1bc7-422e-82a8-a23cc8b2cf7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9f53f7d4-44c2-43ec-8949-2302e87ce88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4e1396da-3ec8-4a7c-94df-23750c4633b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5af8a176-1bc7-422e-82a8-a23cc8b2cf7b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4e1396da-3ec8-4a7c-94df-23750c4633b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1152aa06-ed6d-40be-a2e1-ef4f17d5632d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5af8a176-1bc7-422e-82a8-a23cc8b2cf7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1152aa06-ed6d-40be-a2e1-ef4f17d5632d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1d6bb9ae-f218-4d2c-9fdb-679825b18ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5af8a176-1bc7-422e-82a8-a23cc8b2cf7b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1d6bb9ae-f218-4d2c-9fdb-679825b18ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b7c15b74-c334-4ca3-95ce-251b5c71ceb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5af8a176-1bc7-422e-82a8-a23cc8b2cf7b" xlink:to="loc_us-gaap_Goodwill_b7c15b74-c334-4ca3-95ce-251b5c71ceb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_56733e9f-87d5-4d43-9013-2c49930070ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5af8a176-1bc7-422e-82a8-a23cc8b2cf7b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_56733e9f-87d5-4d43-9013-2c49930070ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_57416e07-e4a6-4121-8ca9-2b470663f804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5af8a176-1bc7-422e-82a8-a23cc8b2cf7b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_57416e07-e4a6-4121-8ca9-2b470663f804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d1a93361-581c-4940-b31b-5748caa4dd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5af8a176-1bc7-422e-82a8-a23cc8b2cf7b" xlink:to="loc_us-gaap_Assets_d1a93361-581c-4940-b31b-5748caa4dd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_455bcbcc-7809-496d-a6a1-cbd5cfb1225f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8133acb9-6aed-420b-8ebb-291651c3162f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8133acb9-6aed-420b-8ebb-291651c3162f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_c9cc4bea-2596-488f-b054-85f1c41e074b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8133acb9-6aed-420b-8ebb-291651c3162f" xlink:to="loc_us-gaap_ShortTermBorrowings_c9cc4bea-2596-488f-b054-85f1c41e074b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0f1caba9-71e4-4dab-9395-fb62f86c52e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8133acb9-6aed-420b-8ebb-291651c3162f" xlink:to="loc_us-gaap_AccountsPayableCurrent_0f1caba9-71e4-4dab-9395-fb62f86c52e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8207a2a2-3943-4fe0-ac40-ea3b641ceeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8133acb9-6aed-420b-8ebb-291651c3162f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8207a2a2-3943-4fe0-ac40-ea3b641ceeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_48eb6ceb-af2e-4cf9-9ff9-7450eb9add9f" xlink:href="jnj-20221002.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8133acb9-6aed-420b-8ebb-291651c3162f" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_48eb6ceb-af2e-4cf9-9ff9-7450eb9add9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e97c811a-e3d9-4776-8c41-70860332683f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8133acb9-6aed-420b-8ebb-291651c3162f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e97c811a-e3d9-4776-8c41-70860332683f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_e4893083-6c12-4d63-bd86-a567e1af280b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8133acb9-6aed-420b-8ebb-291651c3162f" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_e4893083-6c12-4d63-bd86-a567e1af280b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2b1eee65-225e-4180-97cd-f344829a2ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8133acb9-6aed-420b-8ebb-291651c3162f" xlink:to="loc_us-gaap_LiabilitiesCurrent_2b1eee65-225e-4180-97cd-f344829a2ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_bd0f597e-df74-462a-bb3f-02743a37106c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_bd0f597e-df74-462a-bb3f-02743a37106c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fb8764f6-9259-4a39-8786-d8c93674e9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fb8764f6-9259-4a39-8786-d8c93674e9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_43dd1127-ee3c-4e08-a827-962a4d91b161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_43dd1127-ee3c-4e08-a827-962a4d91b161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3d56701e-164d-4ad2-9bd2-15b91f301d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3d56701e-164d-4ad2-9bd2-15b91f301d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c1465643-c07e-4e96-9bfe-8ce3321da0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c1465643-c07e-4e96-9bfe-8ce3321da0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_690b71bb-7248-4980-a36b-4180beb03d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:to="loc_us-gaap_Liabilities_690b71bb-7248-4980-a36b-4180beb03d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cd9075e1-c2ed-402a-a34f-21599905586f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cd9075e1-c2ed-402a-a34f-21599905586f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_39a3143f-210d-45a5-b2f0-cea8a92e4960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:to="loc_us-gaap_StockholdersEquityAbstract_39a3143f-210d-45a5-b2f0-cea8a92e4960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fa1f0cac-463a-4ed5-bcda-a4e41943c445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_39a3143f-210d-45a5-b2f0-cea8a92e4960" xlink:to="loc_us-gaap_CommonStockValue_fa1f0cac-463a-4ed5-bcda-a4e41943c445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e49eff34-0447-407e-9f2c-fa1b118b8fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_39a3143f-210d-45a5-b2f0-cea8a92e4960" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e49eff34-0447-407e-9f2c-fa1b118b8fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0196eeef-d3d4-4a14-8307-57ceff1d4f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_39a3143f-210d-45a5-b2f0-cea8a92e4960" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0196eeef-d3d4-4a14-8307-57ceff1d4f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d3e88d51-9d97-4ce1-a335-3b29cbd87645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_39a3143f-210d-45a5-b2f0-cea8a92e4960" xlink:to="loc_us-gaap_TreasuryStockValue_d3e88d51-9d97-4ce1-a335-3b29cbd87645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9920b197-6d26-4103-92e6-f86c601066b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_39a3143f-210d-45a5-b2f0-cea8a92e4960" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9920b197-6d26-4103-92e6-f86c601066b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_628f393c-1f9a-4495-ade6-7b79e48a314d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64187f3e-7c1f-4e24-8fe4-b3f8c52e61fd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_628f393c-1f9a-4495-ade6-7b79e48a314d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_dcc7092b-9557-46aa-b734-0dfcacfa7d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2cba07d2-f28c-4dcd-93d2-d052e21af534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dcc7092b-9557-46aa-b734-0dfcacfa7d4a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2cba07d2-f28c-4dcd-93d2-d052e21af534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d6d91c91-6ea3-4bb4-8911-a2658b8b3c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2cba07d2-f28c-4dcd-93d2-d052e21af534" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d6d91c91-6ea3-4bb4-8911-a2658b8b3c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_49171000-94e8-401a-97c1-386fee32c577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_dcc7092b-9557-46aa-b734-0dfcacfa7d4a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_49171000-94e8-401a-97c1-386fee32c577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a3307b48-7162-4bab-a510-045bb71a42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_49171000-94e8-401a-97c1-386fee32c577" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a3307b48-7162-4bab-a510-045bb71a42e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_441c315d-7934-4111-a9f7-bf198592283d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_49171000-94e8-401a-97c1-386fee32c577" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_441c315d-7934-4111-a9f7-bf198592283d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f104449b-465f-4b59-b54d-350d4de5d1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_49171000-94e8-401a-97c1-386fee32c577" xlink:to="loc_us-gaap_CommonStockSharesIssued_f104449b-465f-4b59-b54d-350d4de5d1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_55e6eb51-77c4-4b27-9e0a-352f21fae7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_49171000-94e8-401a-97c1-386fee32c577" xlink:to="loc_us-gaap_TreasuryStockShares_55e6eb51-77c4-4b27-9e0a-352f21fae7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3265610c-0e6f-4076-af22-25e33416b30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3265610c-0e6f-4076-af22-25e33416b30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_e440d97d-7b64-4133-8ff2-b59ecbd3bc06" xlink:href="jnj-20221002.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_e440d97d-7b64-4133-8ff2-b59ecbd3bc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b62498e8-7712-4e44-a1df-e15298be35d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b62498e8-7712-4e44-a1df-e15298be35d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_ba88f2c5-f8c5-4fb4-8d07-3703040bb96e" xlink:href="jnj-20221002.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_ba88f2c5-f8c5-4fb4-8d07-3703040bb96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_13e5248a-8eb0-4e0a-a17a-2ef7236fb9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_GrossProfit_13e5248a-8eb0-4e0a-a17a-2ef7236fb9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_ab18a024-5ca7-43d9-b8ef-a6f5d9c0b810" xlink:href="jnj-20221002.xsd#jnj_GrossProfitPercentToSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_GrossProfitPercentToSales_ab18a024-5ca7-43d9-b8ef-a6f5d9c0b810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_254cf8ad-33cb-4de8-bc17-a17604683efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_254cf8ad-33cb-4de8-bc17-a17604683efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_deffa7b4-08de-4513-8673-125058a986ec" xlink:href="jnj-20221002.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_deffa7b4-08de-4513-8673-125058a986ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f946704f-f1f8-4f95-86a9-9a5a1f5c4099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f946704f-f1f8-4f95-86a9-9a5a1f5c4099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_4779b794-6563-4af4-9bfa-43c024d2d995" xlink:href="jnj-20221002.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_4779b794-6563-4af4-9bfa-43c024d2d995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_cb3a7080-4fb2-44f5-83d6-1521af28e1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_cb3a7080-4fb2-44f5-83d6-1521af28e1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_b2b5b554-65a2-4f7c-865e-79483159e1f1" xlink:href="jnj-20221002.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_b2b5b554-65a2-4f7c-865e-79483159e1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7f972b77-c683-46eb-b879-4016cd2a2db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7f972b77-c683-46eb-b879-4016cd2a2db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_08adb4ef-fcbc-40f7-bd80-e4be5ce2a5ed" xlink:href="jnj-20221002.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_08adb4ef-fcbc-40f7-bd80-e4be5ce2a5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_da7d725b-9a8c-4248-b670-156e2ac3d3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_InterestExpense_da7d725b-9a8c-4248-b670-156e2ac3d3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_784b46bb-1a75-4e8b-80cb-272311246a4f" xlink:href="jnj-20221002.xsd#jnj_InterestExpensePercentToSales"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_InterestExpensePercentToSales_784b46bb-1a75-4e8b-80cb-272311246a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_76a7ffb0-6fa4-4777-9d43-ddd2374ab935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_76a7ffb0-6fa4-4777-9d43-ddd2374ab935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_0c5bd22d-5cdb-4182-948e-3979d2acdce1" xlink:href="jnj-20221002.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_0c5bd22d-5cdb-4182-948e-3979d2acdce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fe24f1b3-96c6-48a6-bf1d-e26ba23b4f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_RestructuringCharges_fe24f1b3-96c6-48a6-bf1d-e26ba23b4f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_f8f0aa8a-27aa-4ad4-92ab-57438f3ddea1" xlink:href="jnj-20221002.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_Restructuringchargepercenttosales_f8f0aa8a-27aa-4ad4-92ab-57438f3ddea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d437e8f-4a28-411d-9ad5-8acb7165177e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d437e8f-4a28-411d-9ad5-8acb7165177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_08f79c69-f26a-4003-b6dd-4c80f246b81b" xlink:href="jnj-20221002.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_08f79c69-f26a-4003-b6dd-4c80f246b81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ae23c53d-2365-4de1-aaf0-41cdfdf396d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ae23c53d-2365-4de1-aaf0-41cdfdf396d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_add98b31-a2a9-42df-b5a5-8b375cd00662" xlink:href="jnj-20221002.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_add98b31-a2a9-42df-b5a5-8b375cd00662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4f503ab5-46a6-4d82-b2bb-429ad1b136df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_NetIncomeLoss_4f503ab5-46a6-4d82-b2bb-429ad1b136df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_d5699283-34ac-4fef-ae74-2300117a5776" xlink:href="jnj-20221002.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_jnj_NetIncomeAttributableToParentPercentToSales_d5699283-34ac-4fef-ae74-2300117a5776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b5f396f9-9242-4a1b-bc2e-ad201c0bc50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_EarningsPerShareAbstract_b5f396f9-9242-4a1b-bc2e-ad201c0bc50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_693ad652-1723-49fb-885f-e5ce4e9bf036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b5f396f9-9242-4a1b-bc2e-ad201c0bc50b" xlink:to="loc_us-gaap_EarningsPerShareBasic_693ad652-1723-49fb-885f-e5ce4e9bf036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_75330732-a296-483b-a314-4ffc795be26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b5f396f9-9242-4a1b-bc2e-ad201c0bc50b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_75330732-a296-483b-a314-4ffc795be26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3b34063d-9187-424b-9624-c0664732d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e7894d40-a17d-4401-8888-0ad09b656a27" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3b34063d-9187-424b-9624-c0664732d59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_54b197ed-6dae-4959-8618-b28fcf9cd812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3b34063d-9187-424b-9624-c0664732d59e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_54b197ed-6dae-4959-8618-b28fcf9cd812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_45b95b04-771d-4f2e-b413-901f30c8a1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3b34063d-9187-424b-9624-c0664732d59e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_45b95b04-771d-4f2e-b413-901f30c8a1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0cc5dc0b-5fac-4aaa-bcc3-e943b401297e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11f7bc17-2c04-4286-9386-a9c095b34393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0cc5dc0b-5fac-4aaa-bcc3-e943b401297e" xlink:to="loc_us-gaap_NetIncomeLoss_11f7bc17-2c04-4286-9386-a9c095b34393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cd7176b3-17d8-4c1f-9348-b6da1098bcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0cc5dc0b-5fac-4aaa-bcc3-e943b401297e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cd7176b3-17d8-4c1f-9348-b6da1098bcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_8c9e709e-2fc1-4826-a2b3-07441a0a9f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cd7176b3-17d8-4c1f-9348-b6da1098bcc0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_8c9e709e-2fc1-4826-a2b3-07441a0a9f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_cb1d23e9-d74d-4fd3-9bb8-fbc62b0fa5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cd7176b3-17d8-4c1f-9348-b6da1098bcc0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_cb1d23e9-d74d-4fd3-9bb8-fbc62b0fa5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bc5c9adc-98ae-4f2a-97c6-24a3519a47a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_cb1d23e9-d74d-4fd3-9bb8-fbc62b0fa5f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bc5c9adc-98ae-4f2a-97c6-24a3519a47a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_a1f8d6dc-a310-4cc8-a10e-d88219df95dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_cb1d23e9-d74d-4fd3-9bb8-fbc62b0fa5f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_a1f8d6dc-a310-4cc8-a10e-d88219df95dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_120f385a-929e-40f8-bd7a-0d7296e91546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_cb1d23e9-d74d-4fd3-9bb8-fbc62b0fa5f0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_120f385a-929e-40f8-bd7a-0d7296e91546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_3383722d-7c2b-4408-9cb1-ce6ed7efdff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cd7176b3-17d8-4c1f-9348-b6da1098bcc0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_3383722d-7c2b-4408-9cb1-ce6ed7efdff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_27c3f730-5ff0-4229-8459-d485115eafdd" xlink:href="jnj-20221002.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_3383722d-7c2b-4408-9cb1-ce6ed7efdff6" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_27c3f730-5ff0-4229-8459-d485115eafdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_ead0a4de-763f-46d6-b750-8ef028afe4d9" xlink:href="jnj-20221002.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_3383722d-7c2b-4408-9cb1-ce6ed7efdff6" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_ead0a4de-763f-46d6-b750-8ef028afe4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_16a61425-2457-4107-abf2-7aea48fb1282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_3383722d-7c2b-4408-9cb1-ce6ed7efdff6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_16a61425-2457-4107-abf2-7aea48fb1282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_3586a168-672b-47e4-a665-11a1af9568b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cd7176b3-17d8-4c1f-9348-b6da1098bcc0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_3586a168-672b-47e4-a665-11a1af9568b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_f7e1c835-f384-46f5-ac14-92428d5bec62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_3586a168-672b-47e4-a665-11a1af9568b3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_f7e1c835-f384-46f5-ac14-92428d5bec62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_31dc9651-85d2-45af-b170-64ea008d1029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_3586a168-672b-47e4-a665-11a1af9568b3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_31dc9651-85d2-45af-b170-64ea008d1029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_14e9f1e5-c72e-4c07-886c-d1c1c74d0156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_3586a168-672b-47e4-a665-11a1af9568b3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_14e9f1e5-c72e-4c07-886c-d1c1c74d0156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5136067e-a096-4e6b-b208-55ded56a696a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0cc5dc0b-5fac-4aaa-bcc3-e943b401297e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5136067e-a096-4e6b-b208-55ded56a696a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_650b638f-09f4-4a1b-b2e8-759d8151bdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0cc5dc0b-5fac-4aaa-bcc3-e943b401297e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_650b638f-09f4-4a1b-b2e8-759d8151bdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4b6e5f9c-e867-4b83-8606-79d623c98250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_b4a11065-459c-4fa0-b848-d54899b0f37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4b6e5f9c-e867-4b83-8606-79d623c98250" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_b4a11065-459c-4fa0-b848-d54899b0f37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ad0a259f-8bcf-4d47-b807-23ccfa2aa3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4b6e5f9c-e867-4b83-8606-79d623c98250" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_ad0a259f-8bcf-4d47-b807-23ccfa2aa3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_3c7b71bd-8cf3-47b6-95ff-bc26b2b29dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4b6e5f9c-e867-4b83-8606-79d623c98250" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_3c7b71bd-8cf3-47b6-95ff-bc26b2b29dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_8cfd1032-3bcd-4261-ab45-95bc55f1d95d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4b6e5f9c-e867-4b83-8606-79d623c98250" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_8cfd1032-3bcd-4261-ab45-95bc55f1d95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_397c85e1-0d7a-4fc2-b177-a74e89f85810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7197847d-f1d3-4ff5-9e2a-c5898db398c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_397c85e1-0d7a-4fc2-b177-a74e89f85810" xlink:to="loc_us-gaap_StatementTable_7197847d-f1d3-4ff5-9e2a-c5898db398c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2007c5bb-d868-4ff0-9576-929e7ae34ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7197847d-f1d3-4ff5-9e2a-c5898db398c3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2007c5bb-d868-4ff0-9576-929e7ae34ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2007c5bb-d868-4ff0-9576-929e7ae34ba6" xlink:to="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_04408683-2c50-4457-ac2e-b5f25c57474f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:to="loc_us-gaap_RetainedEarningsMember_04408683-2c50-4457-ac2e-b5f25c57474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d90c0dc7-876f-4e2a-b5f1-ec655edd1fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d90c0dc7-876f-4e2a-b5f1-ec655edd1fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7f69d8fc-a983-4fed-8fb7-ccee292afbef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:to="loc_us-gaap_CommonStockMember_7f69d8fc-a983-4fed-8fb7-ccee292afbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_4f8e62da-9024-449a-85ed-0e398ac91932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_42289290-b0e9-4a3b-b331-3cbd62f795c4" xlink:to="loc_us-gaap_TreasuryStockMember_4f8e62da-9024-449a-85ed-0e398ac91932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7197847d-f1d3-4ff5-9e2a-c5898db398c3" xlink:to="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4e06ce24-82b7-42b4-84a3-b9ad1552fdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4e06ce24-82b7-42b4-84a3-b9ad1552fdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4c9a90cf-2308-4f90-8a64-83a260a88178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_NetIncomeLoss_4c9a90cf-2308-4f90-8a64-83a260a88178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_a2634409-173f-4b52-86c0-f5f302523fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_DividendsCommonStockCash_a2634409-173f-4b52-86c0-f5f302523fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_8c5088a7-488c-45e3-b92f-818285461b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_8c5088a7-488c-45e3-b92f-818285461b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7345a4fa-4293-4fe6-bde7-acc91b48631a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_7345a4fa-4293-4fe6-bde7-acc91b48631a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_66d2952e-8fa8-48ab-bc70-c9900002d5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_66d2952e-8fa8-48ab-bc70-c9900002d5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ff546d4-a643-4bb0-aa3e-85a459bddd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7e6ceda8-65da-4ab4-912b-e3ee56f0180b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ff546d4-a643-4bb0-aa3e-85a459bddd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3a139ecd-9b92-4778-895e-4219558ebe1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_698b7b6c-356d-4a34-9c60-1f1ce713c2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3a139ecd-9b92-4778-895e-4219558ebe1e" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_698b7b6c-356d-4a34-9c60-1f1ce713c2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20221002.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2c2fa8ef-08a6-458a-a1fe-1e31cc00ee44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c13e8483-a219-42f6-a6ad-e96ae63ae74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2c2fa8ef-08a6-458a-a1fe-1e31cc00ee44" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c13e8483-a219-42f6-a6ad-e96ae63ae74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_487bc4a2-2528-4220-a26c-ea2895bfdcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c13e8483-a219-42f6-a6ad-e96ae63ae74a" xlink:to="loc_us-gaap_NetIncomeLoss_487bc4a2-2528-4220-a26c-ea2895bfdcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f48ecb58-766f-4873-ac12-59c61f077c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c13e8483-a219-42f6-a6ad-e96ae63ae74a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f48ecb58-766f-4873-ac12-59c61f077c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dec9526d-390f-495d-be3d-a308ed01af53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f48ecb58-766f-4873-ac12-59c61f077c00" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dec9526d-390f-495d-be3d-a308ed01af53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f6c79dc7-1fe0-4dfd-8c26-65f088b23e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f48ecb58-766f-4873-ac12-59c61f077c00" xlink:to="loc_us-gaap_ShareBasedCompensation_f6c79dc7-1fe0-4dfd-8c26-65f088b23e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_354409ba-53dd-40a3-8d9c-a9a58e4f3134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f48ecb58-766f-4873-ac12-59c61f077c00" xlink:to="loc_us-gaap_AssetImpairmentCharges_354409ba-53dd-40a3-8d9c-a9a58e4f3134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_9fbb9340-dc90-46f9-a4de-dcd48038b7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f48ecb58-766f-4873-ac12-59c61f077c00" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_9fbb9340-dc90-46f9-a4de-dcd48038b7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af7fb962-a4f1-41b6-8899-48b2c57cbcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f48ecb58-766f-4873-ac12-59c61f077c00" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af7fb962-a4f1-41b6-8899-48b2c57cbcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_247deaf4-0931-47ea-8d97-e2b3b81cd710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f48ecb58-766f-4873-ac12-59c61f077c00" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_247deaf4-0931-47ea-8d97-e2b3b81cd710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ae617d4-55f7-4395-a773-33888504401d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c13e8483-a219-42f6-a6ad-e96ae63ae74a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ae617d4-55f7-4395-a773-33888504401d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_faefdd5e-4836-4004-9b70-02c6b6773c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ae617d4-55f7-4395-a773-33888504401d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_faefdd5e-4836-4004-9b70-02c6b6773c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b309b5e9-3eca-44cb-9b15-fd9a8926cf00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ae617d4-55f7-4395-a773-33888504401d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b309b5e9-3eca-44cb-9b15-fd9a8926cf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e4b2e64a-e3b7-4ce5-a9e6-27d7f0839e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ae617d4-55f7-4395-a773-33888504401d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e4b2e64a-e3b7-4ce5-a9e6-27d7f0839e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_fddcf050-a533-481a-8252-cfb065bb49d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ae617d4-55f7-4395-a773-33888504401d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_fddcf050-a533-481a-8252-cfb065bb49d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f1a3d3ca-ed21-45c0-91f1-0a9c80933755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ae617d4-55f7-4395-a773-33888504401d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f1a3d3ca-ed21-45c0-91f1-0a9c80933755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d3a45e55-8854-4362-aef9-981b5facba84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c13e8483-a219-42f6-a6ad-e96ae63ae74a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d3a45e55-8854-4362-aef9-981b5facba84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_42a75ac7-5cb4-4a33-aa1a-caa72d7117ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2c2fa8ef-08a6-458a-a1fe-1e31cc00ee44" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_42a75ac7-5cb4-4a33-aa1a-caa72d7117ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_34161241-3172-4bf9-a063-d3034698240a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_42a75ac7-5cb4-4a33-aa1a-caa72d7117ad" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_34161241-3172-4bf9-a063-d3034698240a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_943afcd2-c13d-4041-863d-1046998b7c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_42a75ac7-5cb4-4a33-aa1a-caa72d7117ad" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_943afcd2-c13d-4041-863d-1046998b7c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_15936a97-10b3-4b9d-a7fb-e248d3c88b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_42a75ac7-5cb4-4a33-aa1a-caa72d7117ad" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_15936a97-10b3-4b9d-a7fb-e248d3c88b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_d1188bda-1d7d-41cf-b5ff-d6f4d38c09ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_42a75ac7-5cb4-4a33-aa1a-caa72d7117ad" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_d1188bda-1d7d-41cf-b5ff-d6f4d38c09ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_77ccb804-584e-4251-a1bd-9647b7b9c363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_42a75ac7-5cb4-4a33-aa1a-caa72d7117ad" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_77ccb804-584e-4251-a1bd-9647b7b9c363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_ce7d6551-8346-4607-848a-cdc1f5b56b20" xlink:href="jnj-20221002.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_42a75ac7-5cb4-4a33-aa1a-caa72d7117ad" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_ce7d6551-8346-4607-848a-cdc1f5b56b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a50de0bb-4d49-44be-8863-cc711eb81afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_42a75ac7-5cb4-4a33-aa1a-caa72d7117ad" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a50de0bb-4d49-44be-8863-cc711eb81afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_625518b2-2168-4447-9160-c830c933c8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_42a75ac7-5cb4-4a33-aa1a-caa72d7117ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_625518b2-2168-4447-9160-c830c933c8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2c2fa8ef-08a6-458a-a1fe-1e31cc00ee44" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_556abfcd-e4eb-44c7-aab4-4e8b31b6cffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_556abfcd-e4eb-44c7-aab4-4e8b31b6cffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a72bbff6-6742-495e-8b7d-d71fe531a07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a72bbff6-6742-495e-8b7d-d71fe531a07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_729bde80-24a7-41a7-a9ee-6836ee91c23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_729bde80-24a7-41a7-a9ee-6836ee91c23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_fe435e62-fef4-4eba-a771-98b126702ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_fe435e62-fef4-4eba-a771-98b126702ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b0187518-216c-4b83-bde0-5c60a5573c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_b0187518-216c-4b83-bde0-5c60a5573c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_0df8eb8c-d271-42ed-af3d-b1e111bd9814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_0df8eb8c-d271-42ed-af3d-b1e111bd9814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_ee3d4d55-f876-45f3-a352-b4f998cd5f5a" xlink:href="jnj-20221002.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_ee3d4d55-f876-45f3-a352-b4f998cd5f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_87dd0fac-435e-4e93-b816-e9ec952d0450" xlink:href="jnj-20221002.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_87dd0fac-435e-4e93-b816-e9ec952d0450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_91934aa9-55c7-493d-b629-ad38245eaf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_91934aa9-55c7-493d-b629-ad38245eaf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff86cac9-60b4-49c7-857d-6c2a62879665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a9eb2624-e1fe-4897-8768-03f142cee05a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff86cac9-60b4-49c7-857d-6c2a62879665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6632b6a-155d-498e-9c2e-4f7c80e9a38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2c2fa8ef-08a6-458a-a1fe-1e31cc00ee44" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6632b6a-155d-498e-9c2e-4f7c80e9a38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b77b13d6-5b23-49d1-b6be-ab7f66666277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2c2fa8ef-08a6-458a-a1fe-1e31cc00ee44" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b77b13d6-5b23-49d1-b6be-ab7f66666277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa7fed77-0c98-4f48-97b5-4130c760cead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2c2fa8ef-08a6-458a-a1fe-1e31cc00ee44" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa7fed77-0c98-4f48-97b5-4130c760cead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_da63f594-d533-4209-8296-292307e2232c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2c2fa8ef-08a6-458a-a1fe-1e31cc00ee44" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_da63f594-d533-4209-8296-292307e2232c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_6f7d254a-4bb0-4c84-9b8a-b4b0fa24d60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2c2fa8ef-08a6-458a-a1fe-1e31cc00ee44" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_6f7d254a-4bb0-4c84-9b8a-b4b0fa24d60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_27f252b0-3f9c-4560-a062-b6668fb8eb07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_6f7d254a-4bb0-4c84-9b8a-b4b0fa24d60d" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_27f252b0-3f9c-4560-a062-b6668fb8eb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_c52c464f-a320-4e5d-9292-59fa95759c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_6f7d254a-4bb0-4c84-9b8a-b4b0fa24d60d" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_c52c464f-a320-4e5d-9292-59fa95759c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_b1db8e9d-4804-4e9b-9305-79b90466b241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_6f7d254a-4bb0-4c84-9b8a-b4b0fa24d60d" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_b1db8e9d-4804-4e9b-9305-79b90466b241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20221002.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_211275f2-75bc-4bdf-b903-4edd1328b079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b4252e19-6cbe-4097-bd27-c07f60a18dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_211275f2-75bc-4bdf-b903-4edd1328b079" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b4252e19-6cbe-4097-bd27-c07f60a18dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20221002.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7996af37-83cd-4bde-b918-b0c44cb1671b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_c11184ec-5202-4d17-a2ef-52697c717a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7996af37-83cd-4bde-b918-b0c44cb1671b" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_c11184ec-5202-4d17-a2ef-52697c717a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20221002.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9c18bde8-ff7e-4bd1-a3ea-392fe195ee81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_76b9c58c-6047-4a61-9a94-2ae4777c6334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9c18bde8-ff7e-4bd1-a3ea-392fe195ee81" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_76b9c58c-6047-4a61-9a94-2ae4777c6334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_96244995-9655-4deb-add5-80539d6bde54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_de409828-b375-4145-a7b5-0abb5bc0cfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_96244995-9655-4deb-add5-80539d6bde54" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_de409828-b375-4145-a7b5-0abb5bc0cfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20221002.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_da3b1337-f049-4bdc-a9ed-f27a7f4b8417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4c7b8058-f311-4423-b3ae-578484cce751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_da3b1337-f049-4bdc-a9ed-f27a7f4b8417" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4c7b8058-f311-4423-b3ae-578484cce751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20221002.xsd#PensionsandOtherBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fd263a48-896e-4874-8490-5b82edaa9ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_065f82f5-6496-4535-8a38-c869db2a5bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fd263a48-896e-4874-8490-5b82edaa9ebf" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_065f82f5-6496-4535-8a38-c869db2a5bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20221002.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dabf620d-2c15-4402-8afe-e2a8c64effb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_afaab284-bd3b-4bff-b30f-d3882aa3d014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dabf620d-2c15-4402-8afe-e2a8c64effb1" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_afaab284-bd3b-4bff-b30f-d3882aa3d014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20221002.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_742e92de-5c70-49f0-896e-1cc996a05f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c9700c6b-d6eb-41f1-8b0c-786f2cb333de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_742e92de-5c70-49f0-896e-1cc996a05f42" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c9700c6b-d6eb-41f1-8b0c-786f2cb333de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20221002.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5731d9aa-f1c9-4963-a76f-c7c0dcd2b757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_b35bcdb8-4134-4df3-8cd1-e794230791e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5731d9aa-f1c9-4963-a76f-c7c0dcd2b757" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_b35bcdb8-4134-4df3-8cd1-e794230791e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20221002.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_06c703d0-6f5c-481d-af82-1703a2760a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6289062f-906d-4d44-8e76-5218cef54876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_06c703d0-6f5c-481d-af82-1703a2760a88" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_6289062f-906d-4d44-8e76-5218cef54876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20221002.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_683e7c06-b213-4756-b59d-910e5f5c428f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_8cb9d3c3-9c0b-4108-a6d6-944d41b2bb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_683e7c06-b213-4756-b59d-910e5f5c428f" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_8cb9d3c3-9c0b-4108-a6d6-944d41b2bb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20221002.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a3e9d09c-90b5-4704-84e3-7ad98978c233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_93197929-243d-4cd6-b78c-1694bdba0784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a3e9d09c-90b5-4704-84e3-7ad98978c233" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_93197929-243d-4cd6-b78c-1694bdba0784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20221002.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2ac2db81-858e-484f-87a5-260c6dc6e1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_86649791-354c-436b-8426-4828dfb04c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ac2db81-858e-484f-87a5-260c6dc6e1d5" xlink:to="loc_us-gaap_UseOfEstimates_86649791-354c-436b-8426-4828dfb04c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ecede7d2-4b70-4dbf-adbc-96ea356e9642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ac2db81-858e-484f-87a5-260c6dc6e1d5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ecede7d2-4b70-4dbf-adbc-96ea356e9642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5ecf5c57-6b0a-41b2-b1b8-a5f2c8ab864c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ac2db81-858e-484f-87a5-260c6dc6e1d5" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5ecf5c57-6b0a-41b2-b1b8-a5f2c8ab864c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6709ed6e-91af-427b-96ef-33ede550934f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ac2db81-858e-484f-87a5-260c6dc6e1d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6709ed6e-91af-427b-96ef-33ede550934f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20221002.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5795c421-438f-4c4d-9be5-79be2904b05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6715b451-513c-4504-8a35-132cb5c2bccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5795c421-438f-4c4d-9be5-79be2904b05a" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6715b451-513c-4504-8a35-132cb5c2bccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20221002.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8ddd4912-5fef-4ab4-af1b-f98098ce407c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_b64c37de-3c66-4aab-8ea3-7dfe3e85c6fd" xlink:href="jnj-20221002.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8ddd4912-5fef-4ab4-af1b-f98098ce407c" xlink:to="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_b64c37de-3c66-4aab-8ea3-7dfe3e85c6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_76c3662b-0ae1-4e55-b8d1-d8bf34a9ebfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8ddd4912-5fef-4ab4-af1b-f98098ce407c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_76c3662b-0ae1-4e55-b8d1-d8bf34a9ebfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_6f455998-54c3-422c-a6ea-94e872ba9d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8ddd4912-5fef-4ab4-af1b-f98098ce407c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_6f455998-54c3-422c-a6ea-94e872ba9d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0fa965fd-896a-4130-975e-91c87fe0e5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2deb0676-eb24-47d8-9bb1-947140e5e806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0fa965fd-896a-4130-975e-91c87fe0e5bd" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2deb0676-eb24-47d8-9bb1-947140e5e806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_167fc7d9-4819-440b-8a42-4a03b0fd1014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0fa965fd-896a-4130-975e-91c87fe0e5bd" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_167fc7d9-4819-440b-8a42-4a03b0fd1014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_c4273cc5-2a86-41d1-b9c9-22af00d0d8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0fa965fd-896a-4130-975e-91c87fe0e5bd" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_c4273cc5-2a86-41d1-b9c9-22af00d0d8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_c51511a3-586d-4833-bb19-a54b761be7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0fa965fd-896a-4130-975e-91c87fe0e5bd" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_c51511a3-586d-4833-bb19-a54b761be7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_cca5a3e2-4cdc-4bd4-9bc2-3b06f7effe79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0fa965fd-896a-4130-975e-91c87fe0e5bd" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_cca5a3e2-4cdc-4bd4-9bc2-3b06f7effe79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5cdd0dfa-8ce5-4f86-a238-09138df69243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0fa965fd-896a-4130-975e-91c87fe0e5bd" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5cdd0dfa-8ce5-4f86-a238-09138df69243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6088997b-bc6a-4562-8c06-de569e9d2797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0fa965fd-896a-4130-975e-91c87fe0e5bd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6088997b-bc6a-4562-8c06-de569e9d2797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_a95f5479-60ad-4b50-99c3-f57fe3fecf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0fa965fd-896a-4130-975e-91c87fe0e5bd" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_a95f5479-60ad-4b50-99c3-f57fe3fecf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20221002.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4f6da1a7-dc2b-4cf3-b0df-ee5f43b12bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_26e1cd00-681a-4802-b21e-31da000cadc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4f6da1a7-dc2b-4cf3-b0df-ee5f43b12bc4" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_26e1cd00-681a-4802-b21e-31da000cadc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="jnj-20221002.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_59e717e6-16d0-4650-834d-e728bc158762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b7cacd19-d6b2-4550-9594-2d095e68d95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_59e717e6-16d0-4650-834d-e728bc158762" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b7cacd19-d6b2-4550-9594-2d095e68d95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20221002.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f811515c-e744-4a4f-b75f-692960804e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c9ee58d0-cffc-4bc3-af64-0159e46c8a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f811515c-e744-4a4f-b75f-692960804e9b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c9ee58d0-cffc-4bc3-af64-0159e46c8a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20221002.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b96350d2-0990-4722-8834-2d7f2e8a7dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_921994c9-3140-45ad-9534-2ffaf96f623b" xlink:href="jnj-20221002.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b96350d2-0990-4722-8834-2d7f2e8a7dcc" xlink:to="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_921994c9-3140-45ad-9534-2ffaf96f623b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_a9e3de39-7849-409c-ae64-fbf90b264487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b96350d2-0990-4722-8834-2d7f2e8a7dcc" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_a9e3de39-7849-409c-ae64-fbf90b264487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_6416f7a0-cf7c-4685-ab61-cc77bf90deb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b96350d2-0990-4722-8834-2d7f2e8a7dcc" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_6416f7a0-cf7c-4685-ab61-cc77bf90deb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20221002.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2ae19cb2-2581-42b8-a21b-65c1c6a5e5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ff999ce7-3292-441f-8170-1541942e4fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_2ae19cb2-2581-42b8-a21b-65c1c6a5e5dc" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_ff999ce7-3292-441f-8170-1541942e4fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9c4b54f8-ea26-4f64-9603-9df8e193e975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_8666ec95-b427-4d21-a816-973db27ee0db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9c4b54f8-ea26-4f64-9603-9df8e193e975" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_8666ec95-b427-4d21-a816-973db27ee0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_466f7223-78af-43c4-8236-4aa44a0b557e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9c4b54f8-ea26-4f64-9603-9df8e193e975" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_466f7223-78af-43c4-8236-4aa44a0b557e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7b44a9f4-a843-4c82-9c15-9eddce2b3a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9c4b54f8-ea26-4f64-9603-9df8e193e975" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7b44a9f4-a843-4c82-9c15-9eddce2b3a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8f736138-fc4a-4991-bb9e-97a039df8437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9c4b54f8-ea26-4f64-9603-9df8e193e975" xlink:to="loc_us-gaap_InventoryNet_8f736138-fc4a-4991-bb9e-97a039df8437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25b58ae4-66af-4ae7-8fe2-4019f95ab758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:href="jnj-20221002.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25b58ae4-66af-4ae7-8fe2-4019f95ab758" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b057cf3e-7b69-444d-a858-cf3ffbe5daa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b057cf3e-7b69-444d-a858-cf3ffbe5daa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9627088b-a156-41cf-b23c-89b267b1675d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b057cf3e-7b69-444d-a858-cf3ffbe5daa0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9627088b-a156-41cf-b23c-89b267b1675d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_ab15769c-f7d4-4760-b248-aaeb3c08e6ec" xlink:href="jnj-20221002.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9627088b-a156-41cf-b23c-89b267b1675d" xlink:to="loc_jnj_PatentsAndTrademarksMember_ab15769c-f7d4-4760-b248-aaeb3c08e6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_a45dd351-95c3-4775-8e83-2121b6ed9166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9627088b-a156-41cf-b23c-89b267b1675d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_a45dd351-95c3-4775-8e83-2121b6ed9166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf334391-2f5f-41ad-ac21-a3dd1fce0d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9627088b-a156-41cf-b23c-89b267b1675d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf334391-2f5f-41ad-ac21-a3dd1fce0d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6474bbb3-94d1-4598-aa88-bba83ed4ebdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6474bbb3-94d1-4598-aa88-bba83ed4ebdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_973c5e04-9768-4af1-b3dd-febb1cf37873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6474bbb3-94d1-4598-aa88-bba83ed4ebdb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_973c5e04-9768-4af1-b3dd-febb1cf37873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_85545e52-968d-4dd5-b0bb-108a3bbb50d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_973c5e04-9768-4af1-b3dd-febb1cf37873" xlink:to="loc_us-gaap_TrademarksMember_85545e52-968d-4dd5-b0bb-108a3bbb50d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_b28e4b4e-7dc6-438b-b0c9-1c8e3ef0a9ac" xlink:href="jnj-20221002.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_973c5e04-9768-4af1-b3dd-febb1cf37873" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_b28e4b4e-7dc6-438b-b0c9-1c8e3ef0a9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_79305854-57c0-44a5-a0d2-1c7d85389192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_79305854-57c0-44a5-a0d2-1c7d85389192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5bc4370-50a6-4c7b-8963-fc24aff53a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79305854-57c0-44a5-a0d2-1c7d85389192" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5bc4370-50a6-4c7b-8963-fc24aff53a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_76b0cc1d-75fe-452c-b7bb-495b8e55a79b" xlink:href="jnj-20221002.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5bc4370-50a6-4c7b-8963-fc24aff53a97" xlink:to="loc_jnj_BermekimabMember_76b0cc1d-75fe-452c-b7bb-495b8e55a79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d7664358-3dd9-4e37-b5d9-77828b4385e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d7664358-3dd9-4e37-b5d9-77828b4385e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8341e4f2-71e8-443e-9a7c-bfcc663ad6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d7664358-3dd9-4e37-b5d9-77828b4385e6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8341e4f2-71e8-443e-9a7c-bfcc663ad6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_374cb6f0-4acf-48fb-b880-eb874509e94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8341e4f2-71e8-443e-9a7c-bfcc663ad6a5" xlink:to="loc_us-gaap_SubsequentEventMember_374cb6f0-4acf-48fb-b880-eb874509e94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_3c0b9548-2a98-42db-bd85-45665d5dabf0" xlink:href="jnj-20221002.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_595b5e08-0924-4eb3-a024-c30c971920d5" xlink:to="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_3c0b9548-2a98-42db-bd85-45665d5dabf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1409d633-7a3a-4cb5-9343-d630939a0afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_3c0b9548-2a98-42db-bd85-45665d5dabf0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1409d633-7a3a-4cb5-9343-d630939a0afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bd3bf86d-f577-43b1-bef9-faccae354096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1409d633-7a3a-4cb5-9343-d630939a0afc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bd3bf86d-f577-43b1-bef9-faccae354096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0a37d028-0820-47e6-85af-2607e179f5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bd3bf86d-f577-43b1-bef9-faccae354096" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0a37d028-0820-47e6-85af-2607e179f5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4394b1e2-8ba9-42f7-9ce5-33a690f034a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bd3bf86d-f577-43b1-bef9-faccae354096" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4394b1e2-8ba9-42f7-9ce5-33a690f034a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cf8bd8c8-577b-4160-b665-7469f7a60d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bd3bf86d-f577-43b1-bef9-faccae354096" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cf8bd8c8-577b-4160-b665-7469f7a60d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_7db654b3-f1bb-450b-8910-627fe8ad447d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_1409d633-7a3a-4cb5-9343-d630939a0afc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_7db654b3-f1bb-450b-8910-627fe8ad447d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4d38dd32-3e0b-435c-b10e-73962bfc8fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_7db654b3-f1bb-450b-8910-627fe8ad447d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4d38dd32-3e0b-435c-b10e-73962bfc8fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_91ed1253-c51b-4dde-bcc1-0b958fde7edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_7db654b3-f1bb-450b-8910-627fe8ad447d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_91ed1253-c51b-4dde-bcc1-0b958fde7edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3b85fa2d-a0b3-442a-8f67-c853e7900d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_3c0b9548-2a98-42db-bd85-45665d5dabf0" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3b85fa2d-a0b3-442a-8f67-c853e7900d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1fc6891-0cab-48ea-853e-099b0357af39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_7d2d2c18-09e3-4d33-ab3d-08db3516d927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1fc6891-0cab-48ea-853e-099b0357af39" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_7d2d2c18-09e3-4d33-ab3d-08db3516d927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8b9aa5d1-2f86-4099-ae9f-db0ea1878b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7d2d2c18-09e3-4d33-ab3d-08db3516d927" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8b9aa5d1-2f86-4099-ae9f-db0ea1878b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e9cbb59e-1f4a-4fab-9cbd-399cf3e46742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b9aa5d1-2f86-4099-ae9f-db0ea1878b14" xlink:to="loc_us-gaap_SegmentDomain_e9cbb59e-1f4a-4fab-9cbd-399cf3e46742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_c0b6273a-02cf-4dab-9c7b-1febb0b1beb2" xlink:href="jnj-20221002.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e9cbb59e-1f4a-4fab-9cbd-399cf3e46742" xlink:to="loc_jnj_ConsumerMember_c0b6273a-02cf-4dab-9c7b-1febb0b1beb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_6c6df398-76cd-4962-ab7d-135f08c4d161" xlink:href="jnj-20221002.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e9cbb59e-1f4a-4fab-9cbd-399cf3e46742" xlink:to="loc_jnj_PharmaceuticalMember_6c6df398-76cd-4962-ab7d-135f08c4d161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_366783b6-1bbd-45af-8c48-875221075a4b" xlink:href="jnj-20221002.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e9cbb59e-1f4a-4fab-9cbd-399cf3e46742" xlink:to="loc_jnj_MedicalDevicesMember_366783b6-1bbd-45af-8c48-875221075a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_7db06f4f-05f9-4990-a31f-4d0ed5cdfb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_7d2d2c18-09e3-4d33-ab3d-08db3516d927" xlink:to="loc_us-gaap_GoodwillLineItems_7db06f4f-05f9-4990-a31f-4d0ed5cdfb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_750ebe9e-0d10-4576-94e7-7e27cdda2b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_7db06f4f-05f9-4990-a31f-4d0ed5cdfb7f" xlink:to="loc_us-gaap_GoodwillRollForward_750ebe9e-0d10-4576-94e7-7e27cdda2b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_101f4d8c-81c9-4099-9dc2-45a7e5bc95ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_750ebe9e-0d10-4576-94e7-7e27cdda2b4d" xlink:to="loc_us-gaap_Goodwill_101f4d8c-81c9-4099-9dc2-45a7e5bc95ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_48a19418-7a00-4f7c-9100-3fcb3012ddb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_750ebe9e-0d10-4576-94e7-7e27cdda2b4d" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_48a19418-7a00-4f7c-9100-3fcb3012ddb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_22bcd881-df81-44c8-b2b3-a6e4f58902e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_750ebe9e-0d10-4576-94e7-7e27cdda2b4d" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_22bcd881-df81-44c8-b2b3-a6e4f58902e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3c90df07-9cb6-4838-a80d-b203f2c48ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_750ebe9e-0d10-4576-94e7-7e27cdda2b4d" xlink:to="loc_us-gaap_Goodwill_3c90df07-9cb6-4838-a80d-b203f2c48ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9ed9a888-3e42-4a64-8625-ab28feac6f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f8c264ae-1e08-4c08-9bd2-3ef6764494b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9ed9a888-3e42-4a64-8625-ab28feac6f4b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f8c264ae-1e08-4c08-9bd2-3ef6764494b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15168541-8290-4a2c-a551-d80942b90522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f8c264ae-1e08-4c08-9bd2-3ef6764494b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15168541-8290-4a2c-a551-d80942b90522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a09832ad-b88d-4df0-9c6b-ec2b2a1234e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_15168541-8290-4a2c-a551-d80942b90522" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a09832ad-b88d-4df0-9c6b-ec2b2a1234e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_54c46f2b-0420-42fb-a17b-3c67f0a20def" xlink:href="jnj-20221002.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a09832ad-b88d-4df0-9c6b-ec2b2a1234e1" xlink:to="loc_jnj_PatentsAndTrademarksMember_54c46f2b-0420-42fb-a17b-3c67f0a20def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_e9014add-6ead-4804-8156-8a567eb358bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a09832ad-b88d-4df0-9c6b-ec2b2a1234e1" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_e9014add-6ead-4804-8156-8a567eb358bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0a289837-75be-4ff2-9683-8998f1f7497c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f8c264ae-1e08-4c08-9bd2-3ef6764494b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0a289837-75be-4ff2-9683-8998f1f7497c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_191f1da9-5265-4099-a609-b3856224b4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0a289837-75be-4ff2-9683-8998f1f7497c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_191f1da9-5265-4099-a609-b3856224b4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6a1892e8-03f4-4eaf-a408-bdc3a365336f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0a289837-75be-4ff2-9683-8998f1f7497c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6a1892e8-03f4-4eaf-a408-bdc3a365336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_68e9a491-68e3-4441-9eff-efa84f44719c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c97b072c-44a9-44c8-96ed-0821f36cf354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_68e9a491-68e3-4441-9eff-efa84f44719c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c97b072c-44a9-44c8-96ed-0821f36cf354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_43dd8570-3c3b-4744-b50f-a9ee5f8c9ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_68e9a491-68e3-4441-9eff-efa84f44719c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_43dd8570-3c3b-4744-b50f-a9ee5f8c9ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cefcee75-cf48-4c8a-bb64-8cb66db9b4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_68e9a491-68e3-4441-9eff-efa84f44719c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cefcee75-cf48-4c8a-bb64-8cb66db9b4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d988e681-215c-4f98-b739-4aaa3547e818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_68e9a491-68e3-4441-9eff-efa84f44719c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d988e681-215c-4f98-b739-4aaa3547e818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a7c39cc1-d9c4-4593-a6d7-1dd0e2e68ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_68e9a491-68e3-4441-9eff-efa84f44719c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a7c39cc1-d9c4-4593-a6d7-1dd0e2e68ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_36182d10-fea5-419d-a136-b7861c333d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_36182d10-fea5-419d-a136-b7861c333d90" xlink:to="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_172cc7d4-2de9-4db9-899e-36431465977b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_172cc7d4-2de9-4db9-899e-36431465977b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a9b061a4-c171-4e40-bd14-5640a3a0180c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_172cc7d4-2de9-4db9-899e-36431465977b" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a9b061a4-c171-4e40-bd14-5640a3a0180c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_d62d7bd6-6373-4d61-a2c9-f9ee289d3136" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_a9b061a4-c171-4e40-bd14-5640a3a0180c" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_d62d7bd6-6373-4d61-a2c9-f9ee289d3136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_4c343980-a67f-49c0-a0e2-c9eacb7eb937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_4c343980-a67f-49c0-a0e2-c9eacb7eb937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6c74155a-a5da-4de0-96e7-72ea763c50a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_4c343980-a67f-49c0-a0e2-c9eacb7eb937" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6c74155a-a5da-4de0-96e7-72ea763c50a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_1c495cd3-9274-478c-94c3-2232dbbeb5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6c74155a-a5da-4de0-96e7-72ea763c50a3" xlink:to="loc_us-gaap_EquitySecuritiesMember_1c495cd3-9274-478c-94c3-2232dbbeb5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_62a0027a-5de8-40de-a8e2-08387e57ac75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_62a0027a-5de8-40de-a8e2-08387e57ac75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b377014d-5700-4633-a424-2482c22cacd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_62a0027a-5de8-40de-a8e2-08387e57ac75" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b377014d-5700-4633-a424-2482c22cacd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_53d468db-d26d-46cf-bec5-4f31c579b77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b377014d-5700-4633-a424-2482c22cacd6" xlink:to="loc_us-gaap_ForeignExchangeContractMember_53d468db-d26d-46cf-bec5-4f31c579b77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_9da6b686-36bd-428f-a3d7-9f3c69aec88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b377014d-5700-4633-a424-2482c22cacd6" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_9da6b686-36bd-428f-a3d7-9f3c69aec88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8c803644-0038-4984-b8cc-5f86d6152906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b377014d-5700-4633-a424-2482c22cacd6" xlink:to="loc_us-gaap_InterestRateSwapMember_8c803644-0038-4984-b8cc-5f86d6152906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_8b1436bf-b53e-4c5e-b8e4-553f8e92caae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_8b1436bf-b53e-4c5e-b8e4-553f8e92caae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_b3429f95-1d42-4113-9437-d1f17ae3b23c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8b1436bf-b53e-4c5e-b8e4-553f8e92caae" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_b3429f95-1d42-4113-9437-d1f17ae3b23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7c3c27f7-e892-46be-97d2-1f421003d1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_b3429f95-1d42-4113-9437-d1f17ae3b23c" xlink:to="loc_us-gaap_CommercialPaperMember_7c3c27f7-e892-46be-97d2-1f421003d1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0a01687b-93eb-411b-9dbd-1cd42262bc6d" xlink:to="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_3ec46d00-1845-42f0-ad04-67c03ef590e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_3ec46d00-1845-42f0-ad04-67c03ef590e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_2d70d89d-e06f-4215-afcd-cf5be657f1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_DerivativeNotionalAmount_2d70d89d-e06f-4215-afcd-cf5be657f1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_cb4e03ab-c0cd-4908-91a7-392b41607a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_cb4e03ab-c0cd-4908-91a7-392b41607a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_3f192c81-8c83-4796-8971-86b340a58e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_3f192c81-8c83-4796-8971-86b340a58e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_3dffd967-1561-4a4a-98b8-ceeadd1560aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_3dffd967-1561-4a4a-98b8-ceeadd1560aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_76039188-754d-4f29-8977-492a9a8e6361" xlink:href="jnj-20221002.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_76039188-754d-4f29-8977-492a9a8e6361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_e3bbb7bc-4404-4389-a0af-cfc0c30ffa91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_EquityFairValueAdjustment_e3bbb7bc-4404-4389-a0af-cfc0c30ffa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_de1dfb22-eb6a-4d43-b0bc-97e16b3f688b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_de1dfb22-eb6a-4d43-b0bc-97e16b3f688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_8c0d87c0-4cb7-42ce-a2d5-3fdffed724ae" xlink:href="jnj-20221002.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_8c0d87c0-4cb7-42ce-a2d5-3fdffed724ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_db17961c-82b6-48f4-b489-eef3f75c9f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_ShortTermBorrowings_db17961c-82b6-48f4-b489-eef3f75c9f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_777bc7be-1209-48fc-8ff2-274fc3ebc9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_777bc7be-1209-48fc-8ff2-274fc3ebc9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_25cc3fcc-1fa7-48c3-92ae-02d74fda3c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c086f8d3-fad6-4f1a-9fed-ab4c0c0a657c" xlink:to="loc_us-gaap_DebtInstrumentTerm_25cc3fcc-1fa7-48c3-92ae-02d74fda3c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0aefdcdf-6a00-461c-9a91-16ccfc018b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ff5a3632-5fdf-4eb0-bcfa-1957a5c97f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0aefdcdf-6a00-461c-9a91-16ccfc018b3f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ff5a3632-5fdf-4eb0-bcfa-1957a5c97f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9aaba60e-bbde-4c58-ba07-2884fb0ba1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ff5a3632-5fdf-4eb0-bcfa-1957a5c97f11" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9aaba60e-bbde-4c58-ba07-2884fb0ba1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ca476510-ada3-4768-823e-340c549eda12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9aaba60e-bbde-4c58-ba07-2884fb0ba1f7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ca476510-ada3-4768-823e-340c549eda12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_73ec480e-009a-4698-94c3-b53dfa3dfdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ca476510-ada3-4768-823e-340c549eda12" xlink:to="loc_us-gaap_FairValueHedgingMember_73ec480e-009a-4698-94c3-b53dfa3dfdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_4041a9ca-64e5-49bb-8f6e-ecaea307aa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ca476510-ada3-4768-823e-340c549eda12" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_4041a9ca-64e5-49bb-8f6e-ecaea307aa2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_09a9b3c0-36c4-4f55-9a8e-f04fa46a69d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_ca476510-ada3-4768-823e-340c549eda12" xlink:to="loc_us-gaap_CashFlowHedgingMember_09a9b3c0-36c4-4f55-9a8e-f04fa46a69d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_435ad025-8a0a-4385-ab29-fc95ddd4a198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ff5a3632-5fdf-4eb0-bcfa-1957a5c97f11" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_435ad025-8a0a-4385-ab29-fc95ddd4a198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_435ad025-8a0a-4385-ab29-fc95ddd4a198" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_07974d1c-8887-4db5-87c0-5856fb39f4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:to="loc_us-gaap_InterestRateContractMember_07974d1c-8887-4db5-87c0-5856fb39f4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ffbccd94-0abd-41f7-8de9-e3a703277c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ffbccd94-0abd-41f7-8de9-e3a703277c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_4c98b9c5-1583-4f9a-9551-59a3eab46634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_4c98b9c5-1583-4f9a-9551-59a3eab46634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_169105ad-8bc6-49c4-8d4e-f38fcd10f25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:to="loc_us-gaap_InterestRateSwapMember_169105ad-8bc6-49c4-8d4e-f38fcd10f25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_ec5609ea-3e4c-4829-a2f5-c7ec07a987d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5df6e233-c069-49f2-84c2-0f07f63ffe9e" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_ec5609ea-3e4c-4829-a2f5-c7ec07a987d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_150a1eb6-a1f8-426a-b70f-4d149693eaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ff5a3632-5fdf-4eb0-bcfa-1957a5c97f11" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_150a1eb6-a1f8-426a-b70f-4d149693eaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_150a1eb6-a1f8-426a-b70f-4d149693eaf7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_bdade803-041d-4050-9aaa-a425741314c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:to="loc_us-gaap_SalesMember_bdade803-041d-4050-9aaa-a425741314c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_fd608c5d-291c-4d50-bf44-3be6a1b2c2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:to="loc_us-gaap_CostOfSalesMember_fd608c5d-291c-4d50-bf44-3be6a1b2c2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1c151362-6e1a-4f82-8022-ef04b6d7caa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1c151362-6e1a-4f82-8022-ef04b6d7caa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_302d2d4d-e259-4c2d-8a08-26b23c676fc3" xlink:href="jnj-20221002.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_302d2d4d-e259-4c2d-8a08-26b23c676fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_0bfdf39d-b0c8-4120-9ac1-dba9e0fd10d7" xlink:href="jnj-20221002.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e0859667-e41d-4de9-a72e-63490f9bbdfa" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_0bfdf39d-b0c8-4120-9ac1-dba9e0fd10d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbcabdae-9692-4350-a8eb-183138ca969e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ff5a3632-5fdf-4eb0-bcfa-1957a5c97f11" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbcabdae-9692-4350-a8eb-183138ca969e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_ee4d343d-1f58-4de5-b0c6-e9896b19b10b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbcabdae-9692-4350-a8eb-183138ca969e" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_ee4d343d-1f58-4de5-b0c6-e9896b19b10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_fcc0513c-dd37-4bd6-abc6-474697d05c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbcabdae-9692-4350-a8eb-183138ca969e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_fcc0513c-dd37-4bd6-abc6-474697d05c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_96f2c4f5-f646-4c0c-8780-0c8655833275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_dbcabdae-9692-4350-a8eb-183138ca969e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_96f2c4f5-f646-4c0c-8780-0c8655833275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsDerivativesBalanceSheetLocationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bd140bb7-2bfb-452f-ab27-c370c9c7c348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_efc33891-ba2f-4b72-af0c-f86e2d843a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bd140bb7-2bfb-452f-ab27-c370c9c7c348" xlink:to="loc_us-gaap_DerivativeTable_efc33891-ba2f-4b72-af0c-f86e2d843a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cba27ebe-b06e-4e64-904a-468931821193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_efc33891-ba2f-4b72-af0c-f86e2d843a9c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cba27ebe-b06e-4e64-904a-468931821193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_99c64ada-0ca4-4e16-8912-9c4c7425d596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cba27ebe-b06e-4e64-904a-468931821193" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_99c64ada-0ca4-4e16-8912-9c4c7425d596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_f18d31ea-fb5b-4a01-aa71-2dfd418d0ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_99c64ada-0ca4-4e16-8912-9c4c7425d596" xlink:to="loc_us-gaap_LongTermDebtMember_f18d31ea-fb5b-4a01-aa71-2dfd418d0ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2969dbbe-e46a-411c-9c88-5fc576896540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_efc33891-ba2f-4b72-af0c-f86e2d843a9c" xlink:to="loc_us-gaap_HedgingDesignationAxis_2969dbbe-e46a-411c-9c88-5fc576896540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_79d457c3-9dfb-4016-9c27-05048246975e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_2969dbbe-e46a-411c-9c88-5fc576896540" xlink:to="loc_us-gaap_HedgingDesignationDomain_79d457c3-9dfb-4016-9c27-05048246975e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2f87a189-f7a4-4818-90d0-9b31c7c5307b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_79d457c3-9dfb-4016-9c27-05048246975e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2f87a189-f7a4-4818-90d0-9b31c7c5307b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_ff7b754c-3877-4e2c-a35a-c2d1547e5850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_efc33891-ba2f-4b72-af0c-f86e2d843a9c" xlink:to="loc_us-gaap_DerivativeLineItems_ff7b754c-3877-4e2c-a35a-c2d1547e5850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a80f3246-db87-4758-af8d-46ad26b1e7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ff7b754c-3877-4e2c-a35a-c2d1547e5850" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a80f3246-db87-4758-af8d-46ad26b1e7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_fe91f3bb-2601-4665-a969-c04ff414cf95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ff7b754c-3877-4e2c-a35a-c2d1547e5850" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_fe91f3bb-2601-4665-a969-c04ff414cf95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9f823eb0-0842-4727-bbb9-ed63497dbed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90811a61-d8cb-4bea-83a3-401a15f1366e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9f823eb0-0842-4727-bbb9-ed63497dbed5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90811a61-d8cb-4bea-83a3-401a15f1366e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_63bf38fe-26e9-4c71-8695-7776f993170f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90811a61-d8cb-4bea-83a3-401a15f1366e" xlink:to="loc_us-gaap_HedgingDesignationAxis_63bf38fe-26e9-4c71-8695-7776f993170f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f9b6792c-cfa6-4e4e-b081-a9ff3ed29513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_63bf38fe-26e9-4c71-8695-7776f993170f" xlink:to="loc_us-gaap_HedgingDesignationDomain_f9b6792c-cfa6-4e4e-b081-a9ff3ed29513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_961743c8-53a5-4866-883a-bab16f3fa2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f9b6792c-cfa6-4e4e-b081-a9ff3ed29513" xlink:to="loc_us-gaap_NondesignatedMember_961743c8-53a5-4866-883a-bab16f3fa2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_74238876-3fdc-4315-8428-1ce1562b8466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90811a61-d8cb-4bea-83a3-401a15f1366e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_74238876-3fdc-4315-8428-1ce1562b8466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f84bb8a2-b50a-4b4c-a1e7-9e8ba5e6c358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_74238876-3fdc-4315-8428-1ce1562b8466" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f84bb8a2-b50a-4b4c-a1e7-9e8ba5e6c358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_93d85692-2917-48d8-b183-001872752371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f84bb8a2-b50a-4b4c-a1e7-9e8ba5e6c358" xlink:to="loc_us-gaap_ForeignExchangeContractMember_93d85692-2917-48d8-b183-001872752371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7d69e06f-5f19-481f-9202-eded5e01f4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90811a61-d8cb-4bea-83a3-401a15f1366e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7d69e06f-5f19-481f-9202-eded5e01f4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_20ce88e5-6a32-4b12-98d7-1cd22307b169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7d69e06f-5f19-481f-9202-eded5e01f4b4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_20ce88e5-6a32-4b12-98d7-1cd22307b169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_df55433e-33ee-411c-940f-b22e6c0d8c88" xlink:href="jnj-20221002.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_20ce88e5-6a32-4b12-98d7-1cd22307b169" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_df55433e-33ee-411c-940f-b22e6c0d8c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1aa7cdaa-26f1-4af9-a206-9d70dd8339e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_90811a61-d8cb-4bea-83a3-401a15f1366e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1aa7cdaa-26f1-4af9-a206-9d70dd8339e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_380c641e-790c-4020-8a55-b86e452d2dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_1aa7cdaa-26f1-4af9-a206-9d70dd8339e3" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_380c641e-790c-4020-8a55-b86e452d2dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_273aa255-9101-4a51-925c-af412603b916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f569b13a-9e0f-440a-8695-d31e10aef4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_273aa255-9101-4a51-925c-af412603b916" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f569b13a-9e0f-440a-8695-d31e10aef4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c4c63adb-670a-4130-bd84-32466542f0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f569b13a-9e0f-440a-8695-d31e10aef4de" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c4c63adb-670a-4130-bd84-32466542f0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bc586b9b-1b72-419c-989a-a834d382b99d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c4c63adb-670a-4130-bd84-32466542f0f5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bc586b9b-1b72-419c-989a-a834d382b99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_b4e186be-c776-4f67-8ecb-50c107c3c0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_bc586b9b-1b72-419c-989a-a834d382b99d" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_b4e186be-c776-4f67-8ecb-50c107c3c0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_928bf3b8-05d4-42c5-9c54-b1ff122ea03b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f569b13a-9e0f-440a-8695-d31e10aef4de" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_928bf3b8-05d4-42c5-9c54-b1ff122ea03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5d36715d-94ac-4694-8181-e0226c21f277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_928bf3b8-05d4-42c5-9c54-b1ff122ea03b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5d36715d-94ac-4694-8181-e0226c21f277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_165a0242-01d1-4afa-9805-b9e4a2ee441c" xlink:href="jnj-20221002.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5d36715d-94ac-4694-8181-e0226c21f277" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_165a0242-01d1-4afa-9805-b9e4a2ee441c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_af0691d6-b40f-40bf-a52e-2c9421a97fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f569b13a-9e0f-440a-8695-d31e10aef4de" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_af0691d6-b40f-40bf-a52e-2c9421a97fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_7953708b-6c1a-4007-87c7-fef568855fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_af0691d6-b40f-40bf-a52e-2c9421a97fa4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_7953708b-6c1a-4007-87c7-fef568855fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_c19e050b-2d0d-4cd9-8118-d2554acae0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_af0691d6-b40f-40bf-a52e-2c9421a97fa4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_c19e050b-2d0d-4cd9-8118-d2554acae0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_85a31de0-26f5-4cab-ad70-9e9dcd5239d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_101173f1-b8b9-4fe2-96f6-016b6e75e6da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_85a31de0-26f5-4cab-ad70-9e9dcd5239d5" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_101173f1-b8b9-4fe2-96f6-016b6e75e6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_691a5bda-16ee-4338-bfe2-16de78a2af15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_101173f1-b8b9-4fe2-96f6-016b6e75e6da" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_691a5bda-16ee-4338-bfe2-16de78a2af15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_785bd17d-2e06-4965-abdd-c01ff40334ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_691a5bda-16ee-4338-bfe2-16de78a2af15" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_785bd17d-2e06-4965-abdd-c01ff40334ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_fe055187-7f9a-493e-8afc-95201aa8678c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_785bd17d-2e06-4965-abdd-c01ff40334ca" xlink:to="loc_us-gaap_EquitySecuritiesMember_fe055187-7f9a-493e-8afc-95201aa8678c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4a23ea7f-f367-4807-a24e-2ac0bbd6543a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_101173f1-b8b9-4fe2-96f6-016b6e75e6da" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4a23ea7f-f367-4807-a24e-2ac0bbd6543a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f2208a09-efb6-49dc-af2a-a54b89019790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4a23ea7f-f367-4807-a24e-2ac0bbd6543a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f2208a09-efb6-49dc-af2a-a54b89019790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5f5d01d2-ad11-4772-9be2-cb13add23f41" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f2208a09-efb6-49dc-af2a-a54b89019790" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5f5d01d2-ad11-4772-9be2-cb13add23f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_074fce4a-07a5-499c-94eb-2dc32f1288c4" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f2208a09-efb6-49dc-af2a-a54b89019790" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_074fce4a-07a5-499c-94eb-2dc32f1288c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_80ff6a6e-ca07-457c-a688-8b8a619f85dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_101173f1-b8b9-4fe2-96f6-016b6e75e6da" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_80ff6a6e-ca07-457c-a688-8b8a619f85dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_80ff6a6e-ca07-457c-a688-8b8a619f85dc" xlink:to="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_9055beb7-627d-4b9f-bb0f-119eef70b56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_9055beb7-627d-4b9f-bb0f-119eef70b56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5fdacfe5-63c0-45e7-927c-31debb6a858c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5fdacfe5-63c0-45e7-927c-31debb6a858c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_c49b0302-fe46-45e5-bd8f-78ce8cc83d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_us-gaap_EquityFairValueAdjustment_c49b0302-fe46-45e5-bd8f-78ce8cc83d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_517bb0ca-e9fd-4818-bec7-85363286edef" xlink:href="jnj-20221002.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_517bb0ca-e9fd-4818-bec7-85363286edef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_391eb994-7e91-466f-990b-e1086e4b628f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_391eb994-7e91-466f-990b-e1086e4b628f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_2b97f05e-9126-4ed5-9afc-8bfecde71ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_2b97f05e-9126-4ed5-9afc-8bfecde71ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_58ebc535-29be-4c10-8941-c1db17ebde30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_9a237dd8-2a5e-498a-b6c3-dc2794ffcc67" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_58ebc535-29be-4c10-8941-c1db17ebde30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a5f2014c-42a8-42da-94c6-81f1dc7f34a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a5f2014c-42a8-42da-94c6-81f1dc7f34a3" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_720718e0-bde2-411f-a7aa-4c4c121f40f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_720718e0-bde2-411f-a7aa-4c4c121f40f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7945e9ce-bd9d-4400-b2de-47026a64be89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_720718e0-bde2-411f-a7aa-4c4c121f40f9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7945e9ce-bd9d-4400-b2de-47026a64be89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1c70e06a-f52f-4694-897c-816d960d6a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7945e9ce-bd9d-4400-b2de-47026a64be89" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_1c70e06a-f52f-4694-897c-816d960d6a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_334312b4-2a21-4820-823a-e917de2c9506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7945e9ce-bd9d-4400-b2de-47026a64be89" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_334312b4-2a21-4820-823a-e917de2c9506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_80a8deb1-1862-4185-8de0-757ea3100137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7945e9ce-bd9d-4400-b2de-47026a64be89" xlink:to="loc_us-gaap_LongTermDebtMember_80a8deb1-1862-4185-8de0-757ea3100137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c2cad9e7-73a3-474b-a635-eda13ee741a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c2cad9e7-73a3-474b-a635-eda13ee741a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53dfc41-652d-497a-aff6-bc69b8e46d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c2cad9e7-73a3-474b-a635-eda13ee741a8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53dfc41-652d-497a-aff6-bc69b8e46d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_ebabcfa8-ab0f-48d4-85cd-3afd126f5f81" xlink:href="jnj-20221002.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a53dfc41-652d-497a-aff6-bc69b8e46d72" xlink:to="loc_jnj_AurisHealthMember_ebabcfa8-ab0f-48d4-85cd-3afd126f5f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_49cb5bc1-f03c-4820-aa6c-5e7cb7a1002e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_InvestmentTypeAxis_49cb5bc1-f03c-4820-aa6c-5e7cb7a1002e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ad0a50a4-0eff-4e79-8f85-3582ebcb0b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_49cb5bc1-f03c-4820-aa6c-5e7cb7a1002e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ad0a50a4-0eff-4e79-8f85-3582ebcb0b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_20b8b637-59d7-4936-94bf-ee5d60279242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ad0a50a4-0eff-4e79-8f85-3582ebcb0b57" xlink:to="loc_us-gaap_EquitySecuritiesMember_20b8b637-59d7-4936-94bf-ee5d60279242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5a9ae5c0-a11b-42f4-99c9-00535f05f786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5a9ae5c0-a11b-42f4-99c9-00535f05f786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d256b6d2-ae69-4013-a971-f89d151c01be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5a9ae5c0-a11b-42f4-99c9-00535f05f786" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d256b6d2-ae69-4013-a971-f89d151c01be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_f248aaa4-d40a-44c8-aa0d-8ef5a9b28d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d256b6d2-ae69-4013-a971-f89d151c01be" xlink:to="loc_us-gaap_InterestRateContractMember_f248aaa4-d40a-44c8-aa0d-8ef5a9b28d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0ae8f9a7-c865-4b53-8150-ecd10724a401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d256b6d2-ae69-4013-a971-f89d151c01be" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0ae8f9a7-c865-4b53-8150-ecd10724a401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_d71bd646-9bfc-498b-94db-4e5f4b57d509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d256b6d2-ae69-4013-a971-f89d151c01be" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_d71bd646-9bfc-498b-94db-4e5f4b57d509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d02bedb-dc21-4d95-b158-c546b341bb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d02bedb-dc21-4d95-b158-c546b341bb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90ca92a2-f215-4d24-a434-6d64356125c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2d02bedb-dc21-4d95-b158-c546b341bb52" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90ca92a2-f215-4d24-a434-6d64356125c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_47e5a653-3f33-48b0-8bb3-966ff3e13ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90ca92a2-f215-4d24-a434-6d64356125c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_47e5a653-3f33-48b0-8bb3-966ff3e13ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_37421012-5b96-4904-aede-d184e9b51817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90ca92a2-f215-4d24-a434-6d64356125c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_37421012-5b96-4904-aede-d184e9b51817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_74c873a2-9a3f-4c9a-a02e-c2d8e11ba3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90ca92a2-f215-4d24-a434-6d64356125c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_74c873a2-9a3f-4c9a-a02e-c2d8e11ba3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4d324c4b-976a-4982-80e3-61c3c13c1f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4d324c4b-976a-4982-80e3-61c3c13c1f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_cc08c22b-a4e5-433f-80fa-df7e5472cb96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4d324c4b-976a-4982-80e3-61c3c13c1f9c" xlink:to="loc_us-gaap_HedgingRelationshipDomain_cc08c22b-a4e5-433f-80fa-df7e5472cb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_dca2ddae-8d0b-4e18-a355-4fbc9a7293b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_cc08c22b-a4e5-433f-80fa-df7e5472cb96" xlink:to="loc_us-gaap_FairValueHedgingMember_dca2ddae-8d0b-4e18-a355-4fbc9a7293b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2bd99df2-ee54-4a42-b815-adc8e41f0870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2bd99df2-ee54-4a42-b815-adc8e41f0870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3846b060-5436-44e5-840c-b4280aa8d704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2bd99df2-ee54-4a42-b815-adc8e41f0870" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3846b060-5436-44e5-840c-b4280aa8d704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b3779629-5f2d-4a85-b90b-81b777792e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3846b060-5436-44e5-840c-b4280aa8d704" xlink:to="loc_us-gaap_EquitySecuritiesMember_b3779629-5f2d-4a85-b90b-81b777792e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b3348c03-a8e3-49e0-a83c-3c3d81cc9b56" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_097b7d1a-9793-4798-a289-693769369d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_097b7d1a-9793-4798-a289-693769369d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_d99ab10f-c1a7-4fd5-8e89-eb63673da538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_d99ab10f-c1a7-4fd5-8e89-eb63673da538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_02e64078-7d62-4f17-a072-748498399489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_02e64078-7d62-4f17-a072-748498399489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_3a31c1b6-090c-453e-b8fd-73ff59f5722e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_3a31c1b6-090c-453e-b8fd-73ff59f5722e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_162166e1-620b-4a6a-8d27-e54bfece775f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_162166e1-620b-4a6a-8d27-e54bfece775f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82c8aac5-b44f-4966-b229-391ecab0688b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82c8aac5-b44f-4966-b229-391ecab0688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_269f633f-515b-4709-910d-0704890cbe77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_1fb186f4-ee10-4d68-b845-e88d099224e6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_269f633f-515b-4709-910d-0704890cbe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_39df2b3b-b5e2-4a5a-b132-3e4a7b4f0379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_39df2b3b-b5e2-4a5a-b132-3e4a7b4f0379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_2a20ae15-443f-430a-a8a2-86ec55c453b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_2a20ae15-443f-430a-a8a2-86ec55c453b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6356c585-750b-4e35-95a1-668c2fd5e6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeAssets_6356c585-750b-4e35-95a1-668c2fd5e6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3aad65fe-7f44-4ecb-9680-700c7e188e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_3aad65fe-7f44-4ecb-9680-700c7e188e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_0eb02fc1-5f40-451f-ac6b-6f055d34cd30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_0eb02fc1-5f40-451f-ac6b-6f055d34cd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_1d390170-38bb-4dc4-bd24-49b60bfcff78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_DerivativeLiabilities_1d390170-38bb-4dc4-bd24-49b60bfcff78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_02a511a2-bb8d-4f72-85a4-0cd5066b453d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_02a511a2-bb8d-4f72-85a4-0cd5066b453d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_64bd732d-6e1c-4685-b4ad-355ff80b0b45" xlink:href="jnj-20221002.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_64bd732d-6e1c-4685-b4ad-355ff80b0b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4b9f4e34-f8d2-4f0e-8716-ada0123c2f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4b9f4e34-f8d2-4f0e-8716-ada0123c2f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15653af7-ec20-4863-885c-b625f91307ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_15653af7-ec20-4863-885c-b625f91307ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bf1cc182-cb96-4be7-b975-2c6c913dcd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bf1cc182-cb96-4be7-b975-2c6c913dcd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_32d89bd0-edbe-46cd-90c8-1ef03793feb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b8cb3502-fd64-4115-8dde-c74bc82e3a7c" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_32d89bd0-edbe-46cd-90c8-1ef03793feb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_24af0ff9-d52e-4bf7-ac42-8e66fab4ce92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_67a63903-cb7e-413e-af94-964640cf55ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_24af0ff9-d52e-4bf7-ac42-8e66fab4ce92" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_67a63903-cb7e-413e-af94-964640cf55ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_eb2cf4dd-5e37-4fa8-abe5-1a7807e87301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_67a63903-cb7e-413e-af94-964640cf55ea" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_eb2cf4dd-5e37-4fa8-abe5-1a7807e87301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a5a5e66d-3756-49c2-ac0a-416f3aa2dc43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_eb2cf4dd-5e37-4fa8-abe5-1a7807e87301" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a5a5e66d-3756-49c2-ac0a-416f3aa2dc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_47901bd2-eb40-4310-a4ea-4ec1f4a60ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a5a5e66d-3756-49c2-ac0a-416f3aa2dc43" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_47901bd2-eb40-4310-a4ea-4ec1f4a60ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_fa4aa352-350c-45e2-b2ca-db48385f96ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a5a5e66d-3756-49c2-ac0a-416f3aa2dc43" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_fa4aa352-350c-45e2-b2ca-db48385f96ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ccf411ac-859e-435d-aad6-c5fb1a49daf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_67a63903-cb7e-413e-af94-964640cf55ea" xlink:to="loc_us-gaap_InvestmentTypeAxis_ccf411ac-859e-435d-aad6-c5fb1a49daf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_ccf411ac-859e-435d-aad6-c5fb1a49daf2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_04d1d8a3-d7f1-4b0b-8fab-add4c936e15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_CashMember_04d1d8a3-d7f1-4b0b-8fab-add4c936e15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_4dcc3182-7f81-48d6-a40b-c9ffa511a865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_4dcc3182-7f81-48d6-a40b-c9ffa511a865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ce09936b-45e7-4235-96fb-5a019dfcc493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ce09936b-45e7-4235-96fb-5a019dfcc493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_17e39efe-e03f-4724-bd95-9420cb9a2172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_17e39efe-e03f-4724-bd95-9420cb9a2172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_482d3727-86e8-4ee8-8eb3-cdc43ec3e098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_482d3727-86e8-4ee8-8eb3-cdc43ec3e098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_b392355e-aeaa-4e00-ba56-0df374e114b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_BankTimeDepositsMember_b392355e-aeaa-4e00-ba56-0df374e114b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8ba44bd5-fc82-45b8-bdaa-8239d992027f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_72424c2e-38a1-4a1c-92b3-20491a98a10e" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8ba44bd5-fc82-45b8-bdaa-8239d992027f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ead8d65a-d593-4c8b-b285-de1eeeadfdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_67a63903-cb7e-413e-af94-964640cf55ea" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ead8d65a-d593-4c8b-b285-de1eeeadfdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cafb2f3-d61d-4acc-92a2-c760f13c7ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ead8d65a-d593-4c8b-b285-de1eeeadfdec" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cafb2f3-d61d-4acc-92a2-c760f13c7ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_e55028f7-da7a-428c-b3ef-d1069b164481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cafb2f3-d61d-4acc-92a2-c760f13c7ead" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_e55028f7-da7a-428c-b3ef-d1069b164481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_667331a0-f444-4103-bea8-d37c02234147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cafb2f3-d61d-4acc-92a2-c760f13c7ead" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_667331a0-f444-4103-bea8-d37c02234147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_47693012-8da5-438c-b1df-2782930a2e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cafb2f3-d61d-4acc-92a2-c760f13c7ead" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_47693012-8da5-438c-b1df-2782930a2e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_3a996b1f-e3f3-4dc0-8025-274bccae4bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_67a63903-cb7e-413e-af94-964640cf55ea" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_3a996b1f-e3f3-4dc0-8025-274bccae4bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_88589c8e-a9ef-4297-a7b9-eb8becbe1622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3a996b1f-e3f3-4dc0-8025-274bccae4bcc" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_88589c8e-a9ef-4297-a7b9-eb8becbe1622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_115ae4af-ecba-4df5-909d-d083266f5c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_88589c8e-a9ef-4297-a7b9-eb8becbe1622" xlink:to="loc_us-gaap_HeldToMaturitySecurities_115ae4af-ecba-4df5-909d-d083266f5c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_fa66ff64-c758-48c8-a4fe-e9a4b101033d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_88589c8e-a9ef-4297-a7b9-eb8becbe1622" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_fa66ff64-c758-48c8-a4fe-e9a4b101033d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_999bd5ad-15d0-4208-8130-fe2d83ba0813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_88589c8e-a9ef-4297-a7b9-eb8becbe1622" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_999bd5ad-15d0-4208-8130-fe2d83ba0813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a2be47f-0665-4c25-adf2-874ebfb2d507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3a996b1f-e3f3-4dc0-8025-274bccae4bcc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a2be47f-0665-4c25-adf2-874ebfb2d507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b2ebcf0e-1ba9-4b25-baa7-2b42f91a4735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a2be47f-0665-4c25-adf2-874ebfb2d507" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b2ebcf0e-1ba9-4b25-baa7-2b42f91a4735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b3a2e222-206b-4097-bea2-5ceab6d569f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a2be47f-0665-4c25-adf2-874ebfb2d507" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b3a2e222-206b-4097-bea2-5ceab6d569f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_592bbd9f-300b-4ef2-9882-4f1ca9e86e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_0a2be47f-0665-4c25-adf2-874ebfb2d507" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_592bbd9f-300b-4ef2-9882-4f1ca9e86e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_3a996b1f-e3f3-4dc0-8025-274bccae4bcc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_964fbb4c-528f-4f9b-8e40-c9821d165b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_964fbb4c-528f-4f9b-8e40-c9821d165b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_dc326126-4330-4edf-85c5-13dd568ab150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_dc326126-4330-4edf-85c5-13dd568ab150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_9d44606f-bc4d-462d-aac7-b273791bb747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_9d44606f-bc4d-462d-aac7-b273791bb747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_46e5573a-1de3-4c21-b5c3-89d7c4a4fe6f" xlink:href="jnj-20221002.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_46e5573a-1de3-4c21-b5c3-89d7c4a4fe6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_db8c0502-074f-43c3-ad9c-9ce7e173d970" xlink:href="jnj-20221002.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_a0e4a294-d7c2-46fe-b84e-6e1ee1c28d44" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_db8c0502-074f-43c3-ad9c-9ce7e173d970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ac5aa514-6864-43ca-a4fd-7738985d7bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9e72c9-f355-4fd8-be33-6ce06878bbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ac5aa514-6864-43ca-a4fd-7738985d7bf3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9e72c9-f355-4fd8-be33-6ce06878bbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9f5360be-e911-45a7-8499-efaa5b583b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9e72c9-f355-4fd8-be33-6ce06878bbf0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9f5360be-e911-45a7-8499-efaa5b583b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_710e7d79-7334-40e1-b4e1-83094125ed4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9e72c9-f355-4fd8-be33-6ce06878bbf0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_710e7d79-7334-40e1-b4e1-83094125ed4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_88b99869-64dd-4735-b4c3-a74db55ca988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9e72c9-f355-4fd8-be33-6ce06878bbf0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_88b99869-64dd-4735-b4c3-a74db55ca988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_b5ddb4eb-b498-4596-9f77-e1eff592f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9e72c9-f355-4fd8-be33-6ce06878bbf0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_b5ddb4eb-b498-4596-9f77-e1eff592f1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_1688bcb4-b79c-4603-9b53-0ee067af62ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ac5aa514-6864-43ca-a4fd-7738985d7bf3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_1688bcb4-b79c-4603-9b53-0ee067af62ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_230f87aa-eb4e-4459-9be8-4b3f0a1151cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_1688bcb4-b79c-4603-9b53-0ee067af62ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_230f87aa-eb4e-4459-9be8-4b3f0a1151cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4bad9193-3e60-46fe-b126-d5bd55724e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_1688bcb4-b79c-4603-9b53-0ee067af62ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4bad9193-3e60-46fe-b126-d5bd55724e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1a0eb425-3e1b-4f7f-af88-fa4e6e5efe11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_1688bcb4-b79c-4603-9b53-0ee067af62ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1a0eb425-3e1b-4f7f-af88-fa4e6e5efe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_49b7a86b-4402-4367-adbb-2d7334051bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_1688bcb4-b79c-4603-9b53-0ee067af62ce" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_49b7a86b-4402-4367-adbb-2d7334051bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b051ef47-3dda-4ed2-8d77-e6e6650bdfa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_76980449-67af-46af-a611-75d544ebee6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b051ef47-3dda-4ed2-8d77-e6e6650bdfa3" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_76980449-67af-46af-a611-75d544ebee6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_89cfdbba-3865-4bed-98be-092712a6c600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_76980449-67af-46af-a611-75d544ebee6e" xlink:to="loc_us-gaap_DebtInstrumentAxis_89cfdbba-3865-4bed-98be-092712a6c600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_89cfdbba-3865-4bed-98be-092712a6c600" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_47fea8f5-4486-4d3a-bf83-140c863054ed" xlink:href="jnj-20221002.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_47fea8f5-4486-4d3a-bf83-140c863054ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_03ba06fd-58fe-4cd3-a497-38db57487e96" xlink:href="jnj-20221002.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.375Notesdue2023Member_03ba06fd-58fe-4cd3-a497-38db57487e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_9c0260a0-11f1-4d56-bae1-a84acd95fad9" xlink:href="jnj-20221002.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A0.650NotesDue2024Member_9c0260a0-11f1-4d56-bae1-a84acd95fad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_847343c6-238a-4e67-8b19-2045080d90af" xlink:href="jnj-20221002.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A5.50NotesDue2024Member_847343c6-238a-4e67-8b19-2045080d90af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_db82ee49-bd48-4bf5-ac0c-72862ac41f98" xlink:href="jnj-20221002.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2.625Notesdue2025Member_db82ee49-bd48-4bf5-ac0c-72862ac41f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_952e88b2-c937-4898-bf60-c6dca9509ccd" xlink:href="jnj-20221002.xsd#jnj_A0550NotesDue2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A0550NotesDue2025Member_952e88b2-c937-4898-bf60-c6dca9509ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_1ec7fe24-918d-4c94-a4f3-56df953862db" xlink:href="jnj-20221002.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2.45Notesdue2026Member_1ec7fe24-918d-4c94-a4f3-56df953862db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_a1a2219a-a0fc-4b23-9899-841d1a453b6e" xlink:href="jnj-20221002.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2.95Notesdue2027Member_a1a2219a-a0fc-4b23-9899-841d1a453b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_d3071828-b7fa-44fd-99c5-925e414b86f3" xlink:href="jnj-20221002.xsd#jnj_A095NotesDue2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A095NotesDue2027Member_d3071828-b7fa-44fd-99c5-925e414b86f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_e6c1fcd6-2bbd-4b99-8e68-ca67d1fb7c63" xlink:href="jnj-20221002.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2.900Notesdue2028Member_e6c1fcd6-2bbd-4b99-8e68-ca67d1fb7c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_967ec95d-0b31-441c-8245-1b21a99383b6" xlink:href="jnj-20221002.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A1.150NotesDue2028Member_967ec95d-0b31-441c-8245-1b21a99383b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_16430ef6-43e2-4b94-907b-607c3a2c4cd1" xlink:href="jnj-20221002.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A6.95Notesdue2029Member_16430ef6-43e2-4b94-907b-607c3a2c4cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_ec9f398f-7fa5-4266-927a-44746abe32bc" xlink:href="jnj-20221002.xsd#jnj_A1300NotesDue2030Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A1300NotesDue2030Member_ec9f398f-7fa5-4266-927a-44746abe32bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_d301a942-448a-4345-a505-46b4732144c7" xlink:href="jnj-20221002.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_d301a942-448a-4345-a505-46b4732144c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_4c93acc7-8b33-42ca-ab4c-bfc86eb4b39d" xlink:href="jnj-20221002.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A4.375Notesdue2033Member_4c93acc7-8b33-42ca-ab4c-bfc86eb4b39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_e252ab84-62ea-49d0-b521-098870f4315d" xlink:href="jnj-20221002.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A1.650NotesDue2035Member_e252ab84-62ea-49d0-b521-098870f4315d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_91f7ff6e-632f-461b-b62f-2670b257553c" xlink:href="jnj-20221002.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.55Notesdue2036Member_91f7ff6e-632f-461b-b62f-2670b257553c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_834b670a-ac15-4ea0-9082-add3c6670013" xlink:href="jnj-20221002.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A5.95Notesdue2037Member_834b670a-ac15-4ea0-9082-add3c6670013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_bd9a9bf9-8cea-46b6-8189-e13f3e499272" xlink:href="jnj-20221002.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.625Notesdue2037Member_bd9a9bf9-8cea-46b6-8189-e13f3e499272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_f7c864a1-6a4a-4e74-bb44-4579fc35b1b1" xlink:href="jnj-20221002.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.400Notesdue2038Member_f7c864a1-6a4a-4e74-bb44-4579fc35b1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_1ef80614-99bb-4b50-8a8a-3ddebc0662ff" xlink:href="jnj-20221002.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_1ef80614-99bb-4b50-8a8a-3ddebc0662ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_0666a3e1-268a-4006-b428-d85cfcd3275e" xlink:href="jnj-20221002.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_0666a3e1-268a-4006-b428-d85cfcd3275e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_480e6f88-4c93-44b2-98cb-4fc3c46abd3d" xlink:href="jnj-20221002.xsd#jnj_A210NotesDue2040Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A210NotesDue2040Member_480e6f88-4c93-44b2-98cb-4fc3c46abd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_b019efe2-4cb8-4c69-aa19-ef1fa726111e" xlink:href="jnj-20221002.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A4.85Notesdue2041Member_b019efe2-4cb8-4c69-aa19-ef1fa726111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_46b1c8f6-3d07-49ef-9dff-9af13bf3161f" xlink:href="jnj-20221002.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A4.50Notesdue2043Member_46b1c8f6-3d07-49ef-9dff-9af13bf3161f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_ad6c79b9-a3c4-403a-9afc-32293e03fc6f" xlink:href="jnj-20221002.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.70Notesdue2046Member_ad6c79b9-a3c4-403a-9afc-32293e03fc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_fd607e03-57ce-4d18-b140-cc5665c53584" xlink:href="jnj-20221002.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.75Notesdue2047Member_fd607e03-57ce-4d18-b140-cc5665c53584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_b097ebfc-edd8-4ca6-bfea-08598bb3fd93" xlink:href="jnj-20221002.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A3.500Notesdue2048Member_b097ebfc-edd8-4ca6-bfea-08598bb3fd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_ba07fab6-946b-4b6c-bcaa-fdb1efb2a4be" xlink:href="jnj-20221002.xsd#jnj_A2250NotesDue2050Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2250NotesDue2050Member_ba07fab6-946b-4b6c-bcaa-fdb1efb2a4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_789d448b-9b65-4150-9a61-8e4d33c2eaba" xlink:href="jnj-20221002.xsd#jnj_A2450NotesDue2060Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_A2450NotesDue2060Member_789d448b-9b65-4150-9a61-8e4d33c2eaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_34b01aeb-6941-41a6-86a5-f7fccef4b608" xlink:href="jnj-20221002.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7901bee6-4bab-4666-9ae1-34ed53731845" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_34b01aeb-6941-41a6-86a5-f7fccef4b608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_8172387d-4509-4871-a56b-2a4c4adfd4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_76980449-67af-46af-a611-75d544ebee6e" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_8172387d-4509-4871-a56b-2a4c4adfd4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_eef7ec76-0f30-4380-bea7-3664f520e14a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8172387d-4509-4871-a56b-2a4c4adfd4a9" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_eef7ec76-0f30-4380-bea7-3664f520e14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2fe2b2d1-4d43-4d25-b2c6-862598b941a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_eef7ec76-0f30-4380-bea7-3664f520e14a" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2fe2b2d1-4d43-4d25-b2c6-862598b941a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_f2935a70-611e-4e16-bb66-d8ce3f04a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2fe2b2d1-4d43-4d25-b2c6-862598b941a2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_f2935a70-611e-4e16-bb66-d8ce3f04a6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_06e88b1b-67f0-4813-9669-9e5108e43d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2fe2b2d1-4d43-4d25-b2c6-862598b941a2" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_06e88b1b-67f0-4813-9669-9e5108e43d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24c5ea2-2622-47dd-b79e-f174db801049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_76980449-67af-46af-a611-75d544ebee6e" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24c5ea2-2622-47dd-b79e-f174db801049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24c5ea2-2622-47dd-b79e-f174db801049" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_84dcafd7-8fef-4cf0-89f9-f64a61129017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_84dcafd7-8fef-4cf0-89f9-f64a61129017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_e589ea81-27d5-49b4-a33b-b8f89108a1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_84dcafd7-8fef-4cf0-89f9-f64a61129017" xlink:to="loc_us-gaap_ShortTermBorrowings_e589ea81-27d5-49b4-a33b-b8f89108a1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_5f3fc2aa-b8d7-41b7-a4e7-5dbf97de40bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_5f3fc2aa-b8d7-41b7-a4e7-5dbf97de40bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2bc7f919-4a97-4132-8d59-b93ef4e3b102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_5f3fc2aa-b8d7-41b7-a4e7-5dbf97de40bb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2bc7f919-4a97-4132-8d59-b93ef4e3b102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fcd257de-cb62-4523-a769-a30936a79bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fcd257de-cb62-4523-a769-a30936a79bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8c72d7fd-b8e9-419c-a591-3ab4aa802651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8c72d7fd-b8e9-419c-a591-3ab4aa802651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_b5dd2d47-680e-46f9-ad86-02ec8839ee3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_86a206ea-c14b-4c34-899d-b9fa29d44756" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_b5dd2d47-680e-46f9-ad86-02ec8839ee3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_324c2125-c08c-406b-b092-cbbb22361e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce322e9f-5ed0-4457-a5c1-928d237f9420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_324c2125-c08c-406b-b092-cbbb22361e98" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ce322e9f-5ed0-4457-a5c1-928d237f9420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8d2f859d-89bb-47a0-b7a1-320ca198cd89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_324c2125-c08c-406b-b092-cbbb22361e98" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8d2f859d-89bb-47a0-b7a1-320ca198cd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_7dd07bc6-329f-4e55-8c29-1c2848f5cbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_324c2125-c08c-406b-b092-cbbb22361e98" xlink:to="loc_us-gaap_DeferredTaxLiabilities_7dd07bc6-329f-4e55-8c29-1c2848f5cbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2c7acad0-911c-41c2-b009-dd47ec04222c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_324c2125-c08c-406b-b092-cbbb22361e98" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2c7acad0-911c-41c2-b009-dd47ec04222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_85355e29-9c53-4ba5-b68f-baf5c54933d3" xlink:href="jnj-20221002.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_324c2125-c08c-406b-b092-cbbb22361e98" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_85355e29-9c53-4ba5-b68f-baf5c54933d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e8c1162c-be1c-4d84-b4a9-211da047f624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_324c2125-c08c-406b-b092-cbbb22361e98" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e8c1162c-be1c-4d84-b4a9-211da047f624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_324c2125-c08c-406b-b092-cbbb22361e98" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e42f8fd4-3359-4b3d-8140-638d8626f226" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:to="loc_srt_LitigationCaseAxis_e42f8fd4-3359-4b3d-8140-638d8626f226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c21fb7ea-6c88-470e-afcb-619f315f1f71" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_e42f8fd4-3359-4b3d-8140-638d8626f226" xlink:to="loc_srt_LitigationCaseTypeDomain_c21fb7ea-6c88-470e-afcb-619f315f1f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_c514c123-e87a-4bb9-8919-a968a0bbd1af" xlink:href="jnj-20221002.xsd#jnj_TalcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c21fb7ea-6c88-470e-afcb-619f315f1f71" xlink:to="loc_jnj_TalcMember_c514c123-e87a-4bb9-8919-a968a0bbd1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_afdbd375-a88e-4945-a35b-a6005b732cf4" xlink:href="jnj-20221002.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c21fb7ea-6c88-470e-afcb-619f315f1f71" xlink:to="loc_jnj_RisperdalMember_afdbd375-a88e-4945-a35b-a6005b732cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_48f1aa79-d80e-4173-9481-99c0e4e0a4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_48f1aa79-d80e-4173-9481-99c0e4e0a4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_be3c9e0b-e906-421c-8b09-643a9b8d6554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_48f1aa79-d80e-4173-9481-99c0e4e0a4e2" xlink:to="loc_us-gaap_SegmentDomain_be3c9e0b-e906-421c-8b09-643a9b8d6554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_6000b78e-017e-418f-b6c1-9a650c6e3155" xlink:href="jnj-20221002.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_be3c9e0b-e906-421c-8b09-643a9b8d6554" xlink:to="loc_jnj_ConsumerMember_6000b78e-017e-418f-b6c1-9a650c6e3155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b81dabff-3655-4cd0-91f2-fc995612e0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b81dabff-3655-4cd0-91f2-fc995612e0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc6ee97c-8d7e-4e83-8ea7-dcfe39b97ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b81dabff-3655-4cd0-91f2-fc995612e0e6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc6ee97c-8d7e-4e83-8ea7-dcfe39b97ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_5741d63e-14f7-4ca4-86a0-c0950ea355f9" xlink:href="jnj-20221002.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bc6ee97c-8d7e-4e83-8ea7-dcfe39b97ec4" xlink:to="loc_jnj_AurisHealthMember_5741d63e-14f7-4ca4-86a0-c0950ea355f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_708ea334-a336-4ccf-9743-deee0f2ca839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_708ea334-a336-4ccf-9743-deee0f2ca839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f38297c-64f1-4fa7-95b5-21c147b84c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_708ea334-a336-4ccf-9743-deee0f2ca839" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f38297c-64f1-4fa7-95b5-21c147b84c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_6ee98f7b-825f-4f08-8adc-58df97cd0367" xlink:href="jnj-20221002.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f38297c-64f1-4fa7-95b5-21c147b84c69" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_6ee98f7b-825f-4f08-8adc-58df97cd0367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_8a162629-6264-4da5-bcee-8eb483dd5e70" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_57d0f201-4bed-4830-adf3-72b44fe2278f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_57d0f201-4bed-4830-adf3-72b44fe2278f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncrementalIncreaseDecreaseInTaxes_8b085bd8-3143-4587-bc6d-b6b0b6674aaa" xlink:href="jnj-20221002.xsd#jnj_IncrementalIncreaseDecreaseInTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_jnj_IncrementalIncreaseDecreaseInTaxes_8b085bd8-3143-4587-bc6d-b6b0b6674aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OneTimeFavorableTaxItemPercent_116bad73-bf69-4fd1-b134-777acfdf5844" xlink:href="jnj-20221002.xsd#jnj_OneTimeFavorableTaxItemPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_jnj_OneTimeFavorableTaxItemPercent_116bad73-bf69-4fd1-b134-777acfdf5844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_0ea186e5-08d3-4138-8081-3b307855f00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_us-gaap_LitigationSettlementExpense_0ea186e5-08d3-4138-8081-3b307855f00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_dba00106-b26f-4077-b227-70ea2d867878" xlink:href="jnj-20221002.xsd#jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_dba00106-b26f-4077-b227-70ea2d867878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9557625f-9519-4e3c-8415-add1f3018432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9557625f-9519-4e3c-8415-add1f3018432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_5e8becb9-8e7b-4067-88a5-88f2c43b1bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_58cc2d0b-6321-4cf9-887b-276cd8f92b61" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_5e8becb9-8e7b-4067-88a5-88f2c43b1bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fc400e92-a5ff-4b55-ac32-fb19dbf4d38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0faeaa94-8378-4cce-9ae5-e85934cbcf93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fc400e92-a5ff-4b55-ac32-fb19dbf4d38b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0faeaa94-8378-4cce-9ae5-e85934cbcf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_624f892c-32fe-4e27-acc9-6677f185a9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0faeaa94-8378-4cce-9ae5-e85934cbcf93" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_624f892c-32fe-4e27-acc9-6677f185a9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3593f32c-b971-42a3-9112-a1c12290e094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_624f892c-32fe-4e27-acc9-6677f185a9e6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3593f32c-b971-42a3-9112-a1c12290e094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_bbb563a1-bc6d-4b36-83c4-536a931d64db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3593f32c-b971-42a3-9112-a1c12290e094" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_bbb563a1-bc6d-4b36-83c4-536a931d64db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2e02da94-a048-48d9-9bcc-6302c0be7136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3593f32c-b971-42a3-9112-a1c12290e094" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2e02da94-a048-48d9-9bcc-6302c0be7136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_45f7670c-4ecb-43ba-ba3d-a82983ce691b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0faeaa94-8378-4cce-9ae5-e85934cbcf93" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_45f7670c-4ecb-43ba-ba3d-a82983ce691b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_45f7670c-4ecb-43ba-ba3d-a82983ce691b" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_dc46711a-3c83-4d64-9e6b-8af87d5dacd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_dc46711a-3c83-4d64-9e6b-8af87d5dacd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_930575ab-f5a8-405b-9f71-d134d3cfb2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_930575ab-f5a8-405b-9f71-d134d3cfb2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3214d9fa-24c8-45d2-989f-9c78a62c55d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3214d9fa-24c8-45d2-989f-9c78a62c55d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_7fed389d-eb3c-40da-bf6a-8d110b62a50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_7fed389d-eb3c-40da-bf6a-8d110b62a50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_18cb2f19-fd75-498b-8866-660c2bbdefec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_18cb2f19-fd75-498b-8866-660c2bbdefec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_532b65e4-7954-4363-9bc7-85fbbf6746b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_532b65e4-7954-4363-9bc7-85fbbf6746b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1af88eb9-4347-422b-8440-d567a1a6ebc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_81f174fc-1daa-424a-99da-274fbc857b26" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1af88eb9-4347-422b-8440-d567a1a6ebc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3f22deb7-9b23-419a-8a23-715afa819f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f96ef185-29e2-42f1-8b9e-72f7c3d25ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3f22deb7-9b23-419a-8a23-715afa819f53" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f96ef185-29e2-42f1-8b9e-72f7c3d25ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_84099d51-4e4e-46ae-a986-863a8d5ddaae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f96ef185-29e2-42f1-8b9e-72f7c3d25ec9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_84099d51-4e4e-46ae-a986-863a8d5ddaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5f362014-f2eb-40a1-89e8-7403a1ede6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_84099d51-4e4e-46ae-a986-863a8d5ddaae" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5f362014-f2eb-40a1-89e8-7403a1ede6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f7bf40b4-84ea-4601-9ff5-157e472abf07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5f362014-f2eb-40a1-89e8-7403a1ede6a8" xlink:to="loc_us-gaap_DomesticPlanMember_f7bf40b4-84ea-4601-9ff5-157e472abf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_22b99d7d-3c1e-4466-8e84-c2b228ad3f51" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_f7bf40b4-84ea-4601-9ff5-157e472abf07" xlink:to="loc_country_US_22b99d7d-3c1e-4466-8e84-c2b228ad3f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f31688a3-e9e7-4e92-bd37-5ba039120d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5f362014-f2eb-40a1-89e8-7403a1ede6a8" xlink:to="loc_us-gaap_ForeignPlanMember_f31688a3-e9e7-4e92-bd37-5ba039120d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_04dbb8bc-4f18-4b44-9198-2a085c3c666c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f96ef185-29e2-42f1-8b9e-72f7c3d25ec9" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_04dbb8bc-4f18-4b44-9198-2a085c3c666c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_f37f43c1-d213-42a0-b8dd-dc5f29597a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_04dbb8bc-4f18-4b44-9198-2a085c3c666c" xlink:to="loc_us-gaap_PensionContributions_f37f43c1-d213-42a0-b8dd-dc5f29597a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f56e436d-797f-46bf-95b9-887de1e9d840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e58f471f-8b54-40e3-a040-b38f2b2a5c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f56e436d-797f-46bf-95b9-887de1e9d840" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e58f471f-8b54-40e3-a040-b38f2b2a5c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cf1d62d2-37dd-4666-b3fe-26bcb030d074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e58f471f-8b54-40e3-a040-b38f2b2a5c8a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cf1d62d2-37dd-4666-b3fe-26bcb030d074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cf1d62d2-37dd-4666-b3fe-26bcb030d074" xlink:to="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e0c6f530-ec72-49d5-8e6a-a8ff8299ccf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_e0c6f530-ec72-49d5-8e6a-a8ff8299ccf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f6d6eb9f-d938-4592-894d-822cc95c0ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_f6d6eb9f-d938-4592-894d-822cc95c0ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c7b628f9-2d0e-4f12-b25e-1a8ab2972c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_c7b628f9-2d0e-4f12-b25e-1a8ab2972c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9049a0c6-b4ed-44c3-93bd-c41867a2f621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_9049a0c6-b4ed-44c3-93bd-c41867a2f621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cad70467-471c-44f4-b32a-d3a9134504a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_070c0ed5-5fff-43a2-ac67-56079685ee4d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cad70467-471c-44f4-b32a-d3a9134504a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14208de8-277b-4169-bc66-54380e1b4380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e58f471f-8b54-40e3-a040-b38f2b2a5c8a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14208de8-277b-4169-bc66-54380e1b4380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_14060afe-3067-4ea3-9b15-14375d93d7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_14208de8-277b-4169-bc66-54380e1b4380" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_14060afe-3067-4ea3-9b15-14375d93d7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ea2d10b-4932-4f9a-a3f2-e2fa6a639767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_14060afe-3067-4ea3-9b15-14375d93d7b1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4ea2d10b-4932-4f9a-a3f2-e2fa6a639767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3cd083ce-7c17-4d61-ad8b-8fa82e27f6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_14060afe-3067-4ea3-9b15-14375d93d7b1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3cd083ce-7c17-4d61-ad8b-8fa82e27f6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0ea6af9-d499-4a4c-a807-ecb1af5e976d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_14060afe-3067-4ea3-9b15-14375d93d7b1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0ea6af9-d499-4a4c-a807-ecb1af5e976d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_af6d0552-298a-4912-a451-fc05e79036e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_27d5c0fb-f2eb-4409-82c0-03a063f49440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_af6d0552-298a-4912-a451-fc05e79036e6" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_27d5c0fb-f2eb-4409-82c0-03a063f49440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b40b5cf6-e3cb-4533-ac07-09d06ab0e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_27d5c0fb-f2eb-4409-82c0-03a063f49440" xlink:to="loc_us-gaap_EarningsPerShareBasic_b40b5cf6-e3cb-4533-ac07-09d06ab0e54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88f5cf9f-dfeb-4fa2-b8d5-812e2d69c178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_27d5c0fb-f2eb-4409-82c0-03a063f49440" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_88f5cf9f-dfeb-4fa2-b8d5-812e2d69c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_12228ff4-a44f-4c90-93e3-08876bd3bf16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_27d5c0fb-f2eb-4409-82c0-03a063f49440" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_12228ff4-a44f-4c90-93e3-08876bd3bf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_778bef5f-dc26-454c-956b-a6426f0365f9" xlink:href="jnj-20221002.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_27d5c0fb-f2eb-4409-82c0-03a063f49440" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_778bef5f-dc26-454c-956b-a6426f0365f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6b6c05f6-a95b-4e67-b674-46f2cbefd002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_27d5c0fb-f2eb-4409-82c0-03a063f49440" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6b6c05f6-a95b-4e67-b674-46f2cbefd002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_589a4687-718a-4807-a4c6-365d4733d335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_27d5c0fb-f2eb-4409-82c0-03a063f49440" xlink:to="loc_us-gaap_EarningsPerShareDiluted_589a4687-718a-4807-a4c6-365d4733d335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_54615e0c-c5c2-4c60-9f56-a37bb3d8051b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_54615e0c-c5c2-4c60-9f56-a37bb3d8051b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d87648b5-b1bd-4b2b-a442-5153a92f0472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d87648b5-b1bd-4b2b-a442-5153a92f0472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4d44493-f699-42ce-9f67-216fccca5800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d87648b5-b1bd-4b2b-a442-5153a92f0472" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4d44493-f699-42ce-9f67-216fccca5800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d975c6c9-e0c7-4476-a40c-0a31ebfdd2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d975c6c9-e0c7-4476-a40c-0a31ebfdd2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d975c6c9-e0c7-4476-a40c-0a31ebfdd2a9" xlink:to="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_357c8ac4-9be5-400c-9fff-78a209ee0e37" xlink:href="jnj-20221002.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:to="loc_jnj_ConsumerMember_357c8ac4-9be5-400c-9fff-78a209ee0e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_91a9ebf0-cbd6-409f-b4e9-fcfbeab492d4" xlink:href="jnj-20221002.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:to="loc_jnj_PharmaceuticalMember_91a9ebf0-cbd6-409f-b4e9-fcfbeab492d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_43764cc3-6a21-4a6e-8a03-055c3e588c7a" xlink:href="jnj-20221002.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:to="loc_jnj_MedicalDevicesMember_43764cc3-6a21-4a6e-8a03-055c3e588c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b4b17338-b3e3-4821-8ee1-a7043aee451e" xlink:href="jnj-20221002.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_816ffb31-2046-487c-bbae-dadf64658f3c" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_b4b17338-b3e3-4821-8ee1-a7043aee451e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_36ebab44-7e01-45e7-8459-3ff1511722ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:to="loc_us-gaap_SubsegmentsAxis_36ebab44-7e01-45e7-8459-3ff1511722ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_36ebab44-7e01-45e7-8459-3ff1511722ab" xlink:to="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_28db8103-2b83-4b23-aa88-42789096820f" xlink:href="jnj-20221002.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_ImmunologyMember_28db8103-2b83-4b23-aa88-42789096820f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_df1adb2e-056e-4540-8799-03480d9ccc9a" xlink:href="jnj-20221002.xsd#jnj_InfectiousDiseasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_InfectiousDiseasesMember_df1adb2e-056e-4540-8799-03480d9ccc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_4330ee7d-9b56-4572-b759-6ba021d19234" xlink:href="jnj-20221002.xsd#jnj_NeuroscienceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_NeuroscienceMember_4330ee7d-9b56-4572-b759-6ba021d19234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_57e4e7e5-5f00-4511-9db8-5e734b078dcf" xlink:href="jnj-20221002.xsd#jnj_OncologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_OncologyMember_57e4e7e5-5f00-4511-9db8-5e734b078dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_7ef7ecf0-aaaa-4146-860d-c70c169fd5d6" xlink:href="jnj-20221002.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_PulmonaryHypertensionMember_7ef7ecf0-aaaa-4146-860d-c70c169fd5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_c4650c16-5bf8-44c2-921e-0915303e45e6" xlink:href="jnj-20221002.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_c4650c16-5bf8-44c2-921e-0915303e45e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_6a8e77dd-14b2-417f-b875-f2e30b6276e0" xlink:href="jnj-20221002.xsd#jnj_InterventionalSolutionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_InterventionalSolutionsMember_6a8e77dd-14b2-417f-b875-f2e30b6276e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_1e7f3152-8126-42c3-afdf-59872b627b61" xlink:href="jnj-20221002.xsd#jnj_OrthopaedicsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_OrthopaedicsMember_1e7f3152-8126-42c3-afdf-59872b627b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_b93cae8f-a3da-4a2e-afdf-0fe73c06c083" xlink:href="jnj-20221002.xsd#jnj_SurgeryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_SurgeryMember_b93cae8f-a3da-4a2e-afdf-0fe73c06c083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_82f61d4a-3ccc-4405-bd67-d2ba86ae7e04" xlink:href="jnj-20221002.xsd#jnj_VisionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5b94e979-c8b0-4371-b335-0451530ad7f3" xlink:to="loc_jnj_VisionMember_82f61d4a-3ccc-4405-bd67-d2ba86ae7e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_02eabe35-91fe-4e21-9a43-60eff813d616" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:to="loc_srt_ProductOrServiceAxis_02eabe35-91fe-4e21-9a43-60eff813d616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_02eabe35-91fe-4e21-9a43-60eff813d616" xlink:to="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_9b795038-bbda-4283-8751-392a213af885" xlink:href="jnj-20221002.xsd#jnj_OTCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OTCMember_9b795038-bbda-4283-8751-392a213af885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_f87513a8-d4dc-4580-ad81-eea5b6345757" xlink:href="jnj-20221002.xsd#jnj_BeautyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_BeautyMember_f87513a8-d4dc-4580-ad81-eea5b6345757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_b39c9cdd-010f-4b67-ad87-b95fa1bc4cb4" xlink:href="jnj-20221002.xsd#jnj_OralCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OralCareMember_b39c9cdd-010f-4b67-ad87-b95fa1bc4cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_feb8504d-c567-41c7-8c58-e5cbf0f59340" xlink:href="jnj-20221002.xsd#jnj_BabyCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_BabyCareMember_feb8504d-c567-41c7-8c58-e5cbf0f59340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_6693875c-0805-448b-8f50-542b0b2e7d6b" xlink:href="jnj-20221002.xsd#jnj_WomensHealthMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_WomensHealthMember_6693875c-0805-448b-8f50-542b0b2e7d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_f9361960-17b0-44ce-bb63-a502c6e81bb4" xlink:href="jnj-20221002.xsd#jnj_WoundCareandOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_WoundCareandOtherMember_f9361960-17b0-44ce-bb63-a502c6e81bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_11b3bec6-c59b-4537-a05c-3b62dd36147d" xlink:href="jnj-20221002.xsd#jnj_RemicadeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_RemicadeMember_11b3bec6-c59b-4537-a05c-3b62dd36147d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_3babae05-1bf3-44b7-a0ad-1572568087e0" xlink:href="jnj-20221002.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_SimponiSimponiAriaMember_3babae05-1bf3-44b7-a0ad-1572568087e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_4c04fe5c-6ef8-4eb8-ada5-ca989c8c5c22" xlink:href="jnj-20221002.xsd#jnj_StelaraMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_StelaraMember_4c04fe5c-6ef8-4eb8-ada5-ca989c8c5c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_4dea79ac-94ab-4550-a941-e48278a647ed" xlink:href="jnj-20221002.xsd#jnj_TremfyaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_TremfyaMember_4dea79ac-94ab-4550-a941-e48278a647ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_2aec88ca-24cd-4ed1-9dc5-37ec27c5dc79" xlink:href="jnj-20221002.xsd#jnj_OtherImmunologyMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OtherImmunologyMember_2aec88ca-24cd-4ed1-9dc5-37ec27c5dc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_d823e6c4-a479-4322-9117-c29c6d59b5b8" xlink:href="jnj-20221002.xsd#jnj_COVID19Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_COVID19Member_d823e6c4-a479-4322-9117-c29c6d59b5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_1de4da18-0228-40ae-96be-0f660c9625b1" xlink:href="jnj-20221002.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_EDURANTrilpivirineMember_1de4da18-0228-40ae-96be-0f660c9625b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_ee3b390b-440a-40a4-b7e4-b461a2d97305" xlink:href="jnj-20221002.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_ee3b390b-440a-40a4-b7e4-b461a2d97305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_c4449a71-154c-479b-92db-0a6f9b6fbc90" xlink:href="jnj-20221002.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_c4449a71-154c-479b-92db-0a6f9b6fbc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_db04c191-6835-4a13-9c8e-00d160fb2f93" xlink:href="jnj-20221002.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_db04c191-6835-4a13-9c8e-00d160fb2f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_3309fdd7-7b39-4b9a-b821-5f150d3a0dc2" xlink:href="jnj-20221002.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_3309fdd7-7b39-4b9a-b821-5f150d3a0dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_eff1b8cc-fe45-47fd-91ec-8d1f222183ee" xlink:href="jnj-20221002.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_RISPERDALCONSTAMember_eff1b8cc-fe45-47fd-91ec-8d1f222183ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_f12dd828-af16-4fcf-839a-e056488c3c45" xlink:href="jnj-20221002.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_f12dd828-af16-4fcf-839a-e056488c3c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_a478fa2a-b990-419a-b3ef-fb52e8ef0989" xlink:href="jnj-20221002.xsd#jnj_DARZALEXMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_DARZALEXMember_a478fa2a-b990-419a-b3ef-fb52e8ef0989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_85f8c1a5-c5c2-4f1d-a7ad-4069d5797350" xlink:href="jnj-20221002.xsd#jnj_ERLEADAMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_ERLEADAMember_85f8c1a5-c5c2-4f1d-a7ad-4069d5797350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_fa235ba4-e5a1-4368-951c-a5a5b9912d19" xlink:href="jnj-20221002.xsd#jnj_IMBRUVICAMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_IMBRUVICAMember_fa235ba4-e5a1-4368-951c-a5a5b9912d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_56261101-9fa2-482f-9fe1-60fffddcf422" xlink:href="jnj-20221002.xsd#jnj_ZYTIGAMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_ZYTIGAMember_56261101-9fa2-482f-9fe1-60fffddcf422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_94e2a531-3b1b-48f1-898d-02520c23f224" xlink:href="jnj-20221002.xsd#jnj_OtherOncologyMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OtherOncologyMember_94e2a531-3b1b-48f1-898d-02520c23f224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_4b9ccdd4-070d-4ded-bea0-69aa332008ec" xlink:href="jnj-20221002.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OPSUMITMember_4b9ccdd4-070d-4ded-bea0-69aa332008ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_ac29a4e8-efb5-409e-9741-bfd505601b33" xlink:href="jnj-20221002.xsd#jnj_UPTRAVIMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_UPTRAVIMember_ac29a4e8-efb5-409e-9741-bfd505601b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_1c46faf5-8d60-4233-9ca0-37d03ab5c5d2" xlink:href="jnj-20221002.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_XareltoMember_1c46faf5-8d60-4233-9ca0-37d03ab5c5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_96eb70f5-358c-4330-af41-e747382679b6" xlink:href="jnj-20221002.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_96eb70f5-358c-4330-af41-e747382679b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_41ad3425-7d93-4967-857f-602749aa2f6f" xlink:href="jnj-20221002.xsd#jnj_OtherMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_OtherMember_41ad3425-7d93-4967-857f-602749aa2f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_3bc890cd-420a-4a06-a10e-603363590151" xlink:href="jnj-20221002.xsd#jnj_HIPSMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_HIPSMember_3bc890cd-420a-4a06-a10e-603363590151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_fac765a6-0907-4502-9d9b-bf435672209b" xlink:href="jnj-20221002.xsd#jnj_KNEESMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_KNEESMember_fac765a6-0907-4502-9d9b-bf435672209b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_6c8557aa-2a81-4ad7-8978-6c207fd27280" xlink:href="jnj-20221002.xsd#jnj_TRAUMAMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_TRAUMAMember_6c8557aa-2a81-4ad7-8978-6c207fd27280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_8d39afd5-dcc2-4007-85fb-94231907c810" xlink:href="jnj-20221002.xsd#jnj_SPINEOTHERMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_SPINEOTHERMember_8d39afd5-dcc2-4007-85fb-94231907c810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_f0c3afd9-4440-4d5c-8d9a-affbe94d41ab" xlink:href="jnj-20221002.xsd#jnj_ADVANCEDMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_ADVANCEDMember_f0c3afd9-4440-4d5c-8d9a-affbe94d41ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_95703f41-358d-411e-a9fa-5cc480fb33b4" xlink:href="jnj-20221002.xsd#jnj_GENERALMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_GENERALMember_95703f41-358d-411e-a9fa-5cc480fb33b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_493659a4-dfa2-453f-a988-968122a004da" xlink:href="jnj-20221002.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_493659a4-dfa2-453f-a988-968122a004da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_c42da33c-80f2-4d8c-8583-40ff71891151" xlink:href="jnj-20221002.xsd#jnj_SURGICALMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7909444-1214-413e-90f1-9f233afdf4af" xlink:to="loc_jnj_SURGICALMember_c42da33c-80f2-4d8c-8583-40ff71891151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c3fc43c4-b621-4878-9378-1f4792b3ec04" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:to="loc_srt_StatementGeographicalAxis_c3fc43c4-b621-4878-9378-1f4792b3ec04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c3fc43c4-b621-4878-9378-1f4792b3ec04" xlink:to="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_815fbb05-aa3a-4539-be55-d64831532dd7" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:to="loc_country_CN_815fbb05-aa3a-4539-be55-d64831532dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2ba36e70-9c45-44f1-88b7-804a37f32832" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:to="loc_country_US_2ba36e70-9c45-44f1-88b7-804a37f32832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_f3fa4069-4f4f-44b4-b8f6-ba519ae08a92" xlink:href="jnj-20221002.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:to="loc_jnj_UNITEDSTATESExportsMember_f3fa4069-4f4f-44b4-b8f6-ba519ae08a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b5a09504-a66c-4f8f-8f2a-c4e22b6992db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a09fc289-f1a3-45a2-90d3-c625b20301b4" xlink:to="loc_us-gaap_NonUsMember_b5a09504-a66c-4f8f-8f2a-c4e22b6992db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_fd47a9a3-a99b-4454-aa22-0779900ace09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f820fc79-b926-4364-a3ef-ec6351227d2d" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_fd47a9a3-a99b-4454-aa22-0779900ace09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c8ae9a15-1238-4b8a-9cfc-0fe66f9d3e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_fd47a9a3-a99b-4454-aa22-0779900ace09" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c8ae9a15-1238-4b8a-9cfc-0fe66f9d3e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_633d47ca-b5fe-495f-9596-a8c12b658abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c8ae9a15-1238-4b8a-9cfc-0fe66f9d3e35" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_633d47ca-b5fe-495f-9596-a8c12b658abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_4cc4ae32-4aeb-4347-8d3f-5514ab1079a9" xlink:href="jnj-20221002.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_c8ae9a15-1238-4b8a-9cfc-0fe66f9d3e35" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_4cc4ae32-4aeb-4347-8d3f-5514ab1079a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_dbe2b17d-ac43-4e44-a3fa-29497890e079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_dbe2b17d-ac43-4e44-a3fa-29497890e079" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_1dc1a0cc-2491-47da-b477-1f1db241a43d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:to="loc_srt_ConsolidationItemsAxis_1dc1a0cc-2491-47da-b477-1f1db241a43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_478c2118-27d5-4061-ad73-dc238588392f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_1dc1a0cc-2491-47da-b477-1f1db241a43d" xlink:to="loc_srt_ConsolidationItemsDomain_478c2118-27d5-4061-ad73-dc238588392f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_6c60fd01-3b86-4ab3-9a48-6d716abf9d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_478c2118-27d5-4061-ad73-dc238588392f" xlink:to="loc_us-gaap_OperatingSegmentsMember_6c60fd01-3b86-4ab3-9a48-6d716abf9d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_2cc24c6b-6118-4393-ba76-e63363e33864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_478c2118-27d5-4061-ad73-dc238588392f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_2cc24c6b-6118-4393-ba76-e63363e33864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_08f16b4f-2186-460b-950c-638ed6dec307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_08f16b4f-2186-460b-950c-638ed6dec307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_08f16b4f-2186-460b-950c-638ed6dec307" xlink:to="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_8222190d-5871-419b-80c6-378c0bba4c23" xlink:href="jnj-20221002.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:to="loc_jnj_ConsumerMember_8222190d-5871-419b-80c6-378c0bba4c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_ea603a6b-4e65-4690-a455-80e669b7f897" xlink:href="jnj-20221002.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:to="loc_jnj_PharmaceuticalMember_ea603a6b-4e65-4690-a455-80e669b7f897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_a7e15a6c-1bf0-413c-af0c-5880e0fc83a6" xlink:href="jnj-20221002.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:to="loc_jnj_MedicalDevicesMember_a7e15a6c-1bf0-413c-af0c-5880e0fc83a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_abf70157-a2ef-4dba-bad1-acca8085dd98" xlink:href="jnj-20221002.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_83bc4b70-d153-4c41-b9f8-203edfcb0718" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_abf70157-a2ef-4dba-bad1-acca8085dd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8760f6cc-f922-4a00-8f5d-32b77302890c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8760f6cc-f922-4a00-8f5d-32b77302890c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27ef5750-a859-433b-b866-6e9320227070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8760f6cc-f922-4a00-8f5d-32b77302890c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27ef5750-a859-433b-b866-6e9320227070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_96b03d17-673e-4d56-b9c2-4b8e558ed0b6" xlink:href="jnj-20221002.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27ef5750-a859-433b-b866-6e9320227070" xlink:to="loc_jnj_BermekimabMember_96b03d17-673e-4d56-b9c2-4b8e558ed0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_600fd8d7-391d-4a1c-b5b7-b0e3d324e316" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:to="loc_srt_LitigationCaseAxis_600fd8d7-391d-4a1c-b5b7-b0e3d324e316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d9cd2f81-194b-42d3-8867-ab97558a6222" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_600fd8d7-391d-4a1c-b5b7-b0e3d324e316" xlink:to="loc_srt_LitigationCaseTypeDomain_d9cd2f81-194b-42d3-8867-ab97558a6222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_fc66db19-b60d-437b-bdc7-00d52bf2c0b1" xlink:href="jnj-20221002.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d9cd2f81-194b-42d3-8867-ab97558a6222" xlink:to="loc_jnj_RisperdalMember_fc66db19-b60d-437b-bdc7-00d52bf2c0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7f760724-8e6a-419d-93a4-0ce828037682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7f760724-8e6a-419d-93a4-0ce828037682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_520fc01e-952b-4fde-b90e-a816cc0632ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7f760724-8e6a-419d-93a4-0ce828037682" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_520fc01e-952b-4fde-b90e-a816cc0632ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_dfbb99bc-51ca-4050-b03a-7293a5277fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_520fc01e-952b-4fde-b90e-a816cc0632ff" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_dfbb99bc-51ca-4050-b03a-7293a5277fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_be0023af-8ca5-42a7-8fba-359638e298a2" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f2c0c2de-6809-4082-9e31-19d02265f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_OperatingIncomeLoss_f2c0c2de-6809-4082-9e31-19d02265f72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_28fcd59d-0726-432d-a6c6-fa1319c0dbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_BusinessExitCosts1_28fcd59d-0726-432d-a6c6-fa1319c0dbb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b406d508-0350-424b-96ff-f43335bacbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b406d508-0350-424b-96ff-f43335bacbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_f2454a39-8c7d-4a0c-bd57-f1e4cf491b8f" xlink:href="jnj-20221002.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_f2454a39-8c7d-4a0c-bd57-f1e4cf491b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_c4ffd201-6fae-4f96-9f55-394b624f8fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_AdjustmentForAmortization_c4ffd201-6fae-4f96-9f55-394b624f8fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_1d8b9227-f5c0-4a34-a720-7cfaa145d07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_1d8b9227-f5c0-4a34-a720-7cfaa145d07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_7e23f834-2c4e-46e4-a525-893fef570ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_7e23f834-2c4e-46e4-a525-893fef570ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_f21c9f9b-d1af-4600-90bb-acc7daabf401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_SuppliesExpense_f21c9f9b-d1af-4600-90bb-acc7daabf401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AmountPrepaidAndDueToManufacturers_711d2b17-b0c0-4c97-a311-e7afbf990ede" xlink:href="jnj-20221002.xsd#jnj_AmountPrepaidAndDueToManufacturers"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_jnj_AmountPrepaidAndDueToManufacturers_711d2b17-b0c0-4c97-a311-e7afbf990ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fcbb3aaa-0a3c-41f0-92ba-93f1cbb800c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_RestructuringCharges_fcbb3aaa-0a3c-41f0-92ba-93f1cbb800c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_deed8f7d-d4d0-4d43-b1b9-3bb75c7f8c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_LitigationSettlementExpense_deed8f7d-d4d0-4d43-b1b9-3bb75c7f8c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_473a7c31-66c9-4556-ad4a-75de70cf2e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_473a7c31-66c9-4556-ad4a-75de70cf2e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_afb51e5f-27a9-4ab0-bf05-446f2cdce3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_54a00857-1357-4a3a-984f-14def6962cac" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_afb51e5f-27a9-4ab0-bf05-446f2cdce3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_13fe252b-1e64-4013-98f3-3127e9452ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7ef0dd9b-7238-40ed-98b2-f0b9e49eec1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_13fe252b-1e64-4013-98f3-3127e9452ed4" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7ef0dd9b-7238-40ed-98b2-f0b9e49eec1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bdc0b03d-4727-4fea-8404-70937606c4e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7ef0dd9b-7238-40ed-98b2-f0b9e49eec1e" xlink:to="loc_srt_StatementGeographicalAxis_bdc0b03d-4727-4fea-8404-70937606c4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bdc0b03d-4727-4fea-8404-70937606c4e6" xlink:to="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c4907d7e-6439-4f0a-a0f7-b0156ff8eeb1" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:to="loc_country_US_c4907d7e-6439-4f0a-a0f7-b0156ff8eeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_c198768a-41c7-4c25-ab40-a804a1f9ef26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:to="loc_srt_EuropeMember_c198768a-41c7-4c25-ab40-a804a1f9ef26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_c4458988-1603-4488-9f8a-32132c69526c" xlink:href="jnj-20221002.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_c4458988-1603-4488-9f8a-32132c69526c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_2b6db516-618f-4aa5-b043-6fab9bd57ab0" xlink:href="jnj-20221002.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fc5d75d5-1c79-464d-9fab-94747aeac1a5" xlink:to="loc_jnj_AsiaPacificAfricaMember_2b6db516-618f-4aa5-b043-6fab9bd57ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bdef0fa4-aca2-4c61-a85f-73493776b384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7ef0dd9b-7238-40ed-98b2-f0b9e49eec1e" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bdef0fa4-aca2-4c61-a85f-73493776b384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_7605881f-a87d-4853-ae8b-d1a970b83add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_bdef0fa4-aca2-4c61-a85f-73493776b384" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_7605881f-a87d-4853-ae8b-d1a970b83add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_184acb39-cd31-4c94-a7be-a917ee1f8b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_7605881f-a87d-4853-ae8b-d1a970b83add" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_184acb39-cd31-4c94-a7be-a917ee1f8b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_cf0c48ad-625e-492e-bba1-7ddb681a906b" xlink:href="jnj-20221002.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_7605881f-a87d-4853-ae8b-d1a970b83add" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_cf0c48ad-625e-492e-bba1-7ddb681a906b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_6a0a6035-6660-40f9-931c-54c7a9a8d3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22735793-5e1f-4464-b716-1d4c3c97221c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_6a0a6035-6660-40f9-931c-54c7a9a8d3e1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22735793-5e1f-4464-b716-1d4c3c97221c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beace95b-d72c-4716-a20e-0b82ec182ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22735793-5e1f-4464-b716-1d4c3c97221c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beace95b-d72c-4716-a20e-0b82ec182ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_329ff6ff-f21a-48d6-ab5b-8a6ae0e44b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_beace95b-d72c-4716-a20e-0b82ec182ba4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_329ff6ff-f21a-48d6-ab5b-8a6ae0e44b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_099437c5-534f-48d1-aabd-9bfecfd8e199" xlink:href="jnj-20221002.xsd#jnj_EvraAndDoxilMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_329ff6ff-f21a-48d6-ab5b-8a6ae0e44b24" xlink:to="loc_jnj_EvraAndDoxilMember_099437c5-534f-48d1-aabd-9bfecfd8e199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_567eec53-8b0a-4251-baa6-557eb1865a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_22735793-5e1f-4464-b716-1d4c3c97221c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_567eec53-8b0a-4251-baa6-557eb1865a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfBrands_eb5ecd70-23bc-4821-9530-7e8f1ab5c7a6" xlink:href="jnj-20221002.xsd#jnj_NumberOfBrands"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_567eec53-8b0a-4251-baa6-557eb1865a87" xlink:to="loc_jnj_NumberOfBrands_eb5ecd70-23bc-4821-9530-7e8f1ab5c7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_47b596d7-20a1-4233-97dd-b8f51b7f140e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_567eec53-8b0a-4251-baa6-557eb1865a87" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_47b596d7-20a1-4233-97dd-b8f51b7f140e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#LegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e56a359-4288-42a8-96a0-4aa777864a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e56a359-4288-42a8-96a0-4aa777864a34" xlink:to="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d9616b38-b04b-401b-b21e-26b01c2df740" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_srt_LitigationCaseAxis_d9616b38-b04b-401b-b21e-26b01c2df740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_d9616b38-b04b-401b-b21e-26b01c2df740" xlink:to="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_2348d51f-fccc-47a3-8037-50f70fd02ff4" xlink:href="jnj-20221002.xsd#jnj_DePuyASRU.S.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:to="loc_jnj_DePuyASRU.S.Member_2348d51f-fccc-47a3-8037-50f70fd02ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_b39a4889-386a-4cf5-ae68-596496206b19" xlink:href="jnj-20221002.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:to="loc_jnj_RisperdalMember_b39a4889-386a-4cf5-ae68-596496206b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_9b22c391-caed-4a5c-9672-300dae8f2073" xlink:href="jnj-20221002.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:to="loc_jnj_BabyPowderMember_9b22c391-caed-4a5c-9672-300dae8f2073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_a12de088-e1d9-4919-8540-c05c63334e6a" xlink:href="jnj-20221002.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_a12de088-e1d9-4919-8540-c05c63334e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_e6314ce7-b8e3-4c62-b7f1-adadd7b09058" xlink:href="jnj-20221002.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a1184fe5-d3a7-4152-88f8-b5cbc0d1e2a8" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_e6314ce7-b8e3-4c62-b7f1-adadd7b09058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_48d8a18a-7829-47b8-931b-a0431d80b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_us-gaap_LitigationStatusAxis_48d8a18a-7829-47b8-931b-a0431d80b7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ea103dd6-d514-4529-baf4-1411226a6924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_48d8a18a-7829-47b8-931b-a0431d80b7a5" xlink:to="loc_us-gaap_LitigationStatusDomain_ea103dd6-d514-4529-baf4-1411226a6924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_d2dbbb9a-26e0-41cb-b80f-ceccd94d1987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_ea103dd6-d514-4529-baf4-1411226a6924" xlink:to="loc_us-gaap_SettledLitigationMember_d2dbbb9a-26e0-41cb-b80f-ceccd94d1987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_d24d54c6-b1e0-492f-a409-1a8000ad745d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_ea103dd6-d514-4529-baf4-1411226a6924" xlink:to="loc_us-gaap_JudicialRulingMember_d24d54c6-b1e0-492f-a409-1a8000ad745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f3838efa-a49e-487e-a494-35c5215dbbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_ea103dd6-d514-4529-baf4-1411226a6924" xlink:to="loc_us-gaap_PendingLitigationMember_f3838efa-a49e-487e-a494-35c5215dbbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4df5603-1749-4c4c-90bb-e6c7a5d99d37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_srt_ProductOrServiceAxis_e4df5603-1749-4c4c-90bb-e6c7a5d99d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e4df5603-1749-4c4c-90bb-e6c7a5d99d37" xlink:to="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_4413bf2b-cd03-43fc-ad5e-6b7e7ed03ecd" xlink:href="jnj-20221002.xsd#jnj_AsrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_AsrMember_4413bf2b-cd03-43fc-ad5e-6b7e7ed03ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_51b33b76-4470-4cea-b390-4ca0c3d04f24" xlink:href="jnj-20221002.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_51b33b76-4470-4cea-b390-4ca0c3d04f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_59d0f5b8-3cca-426f-b4b7-680a38383ac6" xlink:href="jnj-20221002.xsd#jnj_PelvicMeshesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_PelvicMeshesMember_59d0f5b8-3cca-426f-b4b7-680a38383ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_24494520-396f-4cf8-a383-d32abfea2e26" xlink:href="jnj-20221002.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_RisperdalMember_24494520-396f-4cf8-a383-d32abfea2e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_57a33001-aedf-49ef-8b70-4a5d6161a1ef" xlink:href="jnj-20221002.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_XareltoMember_57a33001-aedf-49ef-8b70-4a5d6161a1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_adc25290-971c-4399-925d-ba0e0823128b" xlink:href="jnj-20221002.xsd#jnj_TalcMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_TalcMember_adc25290-971c-4399-925d-ba0e0823128b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvokanaMember_2f0530e3-c7a8-4350-9d9f-1436973d9fdc" xlink:href="jnj-20221002.xsd#jnj_InvokanaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_InvokanaMember_2f0530e3-c7a8-4350-9d9f-1436973d9fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_5f120d0b-7557-4cc2-a2ff-2a0aa5cea514" xlink:href="jnj-20221002.xsd#jnj_PhysiomeshMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_PhysiomeshMember_5f120d0b-7557-4cc2-a2ff-2a0aa5cea514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_bb8d1622-af54-4407-b96c-3e34c4981dd7" xlink:href="jnj-20221002.xsd#jnj_OpioidMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_OpioidMember_bb8d1622-af54-4407-b96c-3e34c4981dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ContactLensesMember_67492c25-2f59-47d6-8a2a-fe2dfd9365e3" xlink:href="jnj-20221002.xsd#jnj_ContactLensesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_ContactLensesMember_67492c25-2f59-47d6-8a2a-fe2dfd9365e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember_e246d4db-e21c-4a15-a2e8-089d50f10211" xlink:href="jnj-20221002.xsd#jnj_ElmironMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3b3a7f77-e85b-488b-a89c-856cc21a1a2b" xlink:to="loc_jnj_ElmironMember_e246d4db-e21c-4a15-a2e8-089d50f10211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_3336cffc-c7ff-4a31-a645-bbfd6277a071" xlink:href="jnj-20221002.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_3336cffc-c7ff-4a31-a645-bbfd6277a071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_6bb83383-4c5c-481c-9b89-fc2621e5cd65" xlink:href="jnj-20221002.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_3336cffc-c7ff-4a31-a645-bbfd6277a071" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_6bb83383-4c5c-481c-9b89-fc2621e5cd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_233be48b-d2cb-40f9-945e-4cbfdd93e93d" xlink:href="jnj-20221002.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_6bb83383-4c5c-481c-9b89-fc2621e5cd65" xlink:to="loc_jnj_RisperdalMember_233be48b-d2cb-40f9-945e-4cbfdd93e93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_574ed954-4b39-4fe3-b3ea-24ac8c1097f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_574ed954-4b39-4fe3-b3ea-24ac8c1097f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_452d8c8a-1d6a-4485-946c-78ba0bbe62a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_574ed954-4b39-4fe3-b3ea-24ac8c1097f6" xlink:to="loc_us-gaap_LossContingencyNatureDomain_452d8c8a-1d6a-4485-946c-78ba0bbe62a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_51c1f350-9bb9-48bc-a4dd-d5f9a688beba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_452d8c8a-1d6a-4485-946c-78ba0bbe62a2" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_51c1f350-9bb9-48bc-a4dd-d5f9a688beba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6e8293e4-c7f0-4697-9b05-569723145fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6e8293e4-c7f0-4697-9b05-569723145fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c7bdc7c7-1b3b-4df7-a262-686ae28a21f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6e8293e4-c7f0-4697-9b05-569723145fbe" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c7bdc7c7-1b3b-4df7-a262-686ae28a21f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_4fa3ddc2-810d-4d9e-a3f2-23bb97cb83af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c7bdc7c7-1b3b-4df7-a262-686ae28a21f8" xlink:to="loc_us-gaap_SubsequentEventMember_4fa3ddc2-810d-4d9e-a3f2-23bb97cb83af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7f8c6ebb-48a8-4453-931d-f68f0595bc0c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_srt_CounterpartyNameAxis_7f8c6ebb-48a8-4453-931d-f68f0595bc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b17cff7-589c-49ae-baa3-f505458aeea4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7f8c6ebb-48a8-4453-931d-f68f0595bc0c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b17cff7-589c-49ae-baa3-f505458aeea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RasmussenInstrumentsLLCMember_537a444a-9725-4131-b3c3-e5aa7f3335ea" xlink:href="jnj-20221002.xsd#jnj_RasmussenInstrumentsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b17cff7-589c-49ae-baa3-f505458aeea4" xlink:to="loc_jnj_RasmussenInstrumentsLLCMember_537a444a-9725-4131-b3c3-e5aa7f3335ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5ad704c8-dbd9-4855-9a57-2a1b3322d6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1a673a61-9bea-4f09-89e9-29ccea1cab05" xlink:to="loc_us-gaap_LossContingenciesLineItems_5ad704c8-dbd9-4855-9a57-2a1b3322d6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:href="jnj-20221002.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5ad704c8-dbd9-4855-9a57-2a1b3322d6fe" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_7be8652c-fb1b-42fe-8572-dd3c12fc8b81" xlink:href="jnj-20221002.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_7be8652c-fb1b-42fe-8572-dd3c12fc8b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_2c7da553-f045-4856-b534-270c2375e369" xlink:href="jnj-20221002.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_jnj_Numberofpatientsinsettlement_2c7da553-f045-4856-b534-270c2375e369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_9daca0ad-3021-4698-a37e-db16f68b7692" xlink:href="jnj-20221002.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_9daca0ad-3021-4698-a37e-db16f68b7692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_68dae74d-e3a0-4644-808a-98c2ae00cc91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_68dae74d-e3a0-4644-808a-98c2ae00cc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_a6dff0ed-7d15-44ed-b958-adb52506d9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_a6dff0ed-7d15-44ed-b958-adb52506d9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_0d56493e-3c6a-4a0d-b1c0-9938d5868024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_0d56493e-3c6a-4a0d-b1c0-9938d5868024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_98ca6889-a11b-4c82-8789-8ca82a3a43ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_98ca6889-a11b-4c82-8789-8ca82a3a43ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_73ece054-2ba2-48a7-b6bb-a067043d9933" xlink:href="jnj-20221002.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_73ece054-2ba2-48a7-b6bb-a067043d9933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_29ea6a5b-60b4-4d27-b3ce-0ec8d928ec38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_29ea6a5b-60b4-4d27-b3ce-0ec8d928ec38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f07bcc8b-d56a-471e-bbb4-6cfdabef4804" xlink:href="jnj-20221002.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_242213de-77c3-4f9a-a18a-ef869d54776d" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_f07bcc8b-d56a-471e-bbb4-6cfdabef4804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a65b18d9-e3b7-4fe4-8854-dacd110aa72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a65b18d9-e3b7-4fe4-8854-dacd110aa72e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c1b8a55f-e890-4f62-b2c1-f3c042e618f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c1b8a55f-e890-4f62-b2c1-f3c042e618f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_598b145b-0a19-42fd-89cd-b5fcc4893517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c1b8a55f-e890-4f62-b2c1-f3c042e618f9" xlink:to="loc_us-gaap_SegmentDomain_598b145b-0a19-42fd-89cd-b5fcc4893517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_9e5b671f-30ff-43b6-9148-dcaa012d9498" xlink:href="jnj-20221002.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_598b145b-0a19-42fd-89cd-b5fcc4893517" xlink:to="loc_jnj_MedicalDevicesMember_9e5b671f-30ff-43b6-9148-dcaa012d9498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_423c2e42-56e4-4f6c-81c6-9b6e988ec066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:to="loc_us-gaap_RestructuringPlanAxis_423c2e42-56e4-4f6c-81c6-9b6e988ec066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d6da946f-c7de-4cea-a751-089169ff12e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_423c2e42-56e4-4f6c-81c6-9b6e988ec066" xlink:to="loc_us-gaap_RestructuringPlanDomain_d6da946f-c7de-4cea-a751-089169ff12e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_cc9a4b98-8716-43b7-8db1-724da4e810b2" xlink:href="jnj-20221002.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_d6da946f-c7de-4cea-a751-089169ff12e9" xlink:to="loc_jnj_SupplyChainMember_cc9a4b98-8716-43b7-8db1-724da4e810b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_be22e1f9-8ae7-4cb4-9ce1-4db4ffb7c44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_be22e1f9-8ae7-4cb4-9ce1-4db4ffb7c44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2768b1b3-866d-4528-a6dc-4f6194d7d55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_be22e1f9-8ae7-4cb4-9ce1-4db4ffb7c44d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2768b1b3-866d-4528-a6dc-4f6194d7d55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_6726cf12-f6c3-450e-825b-236c1baa945d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2768b1b3-866d-4528-a6dc-4f6194d7d55d" xlink:to="loc_us-gaap_RestructuringChargesMember_6726cf12-f6c3-450e-825b-236c1baa945d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_639d562b-a99f-4f59-8a98-94aae023cd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2768b1b3-866d-4528-a6dc-4f6194d7d55d" xlink:to="loc_us-gaap_CostOfSalesMember_639d562b-a99f-4f59-8a98-94aae023cd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_ce1bf650-7ae1-44f4-bd5c-2e81f5111af8" xlink:href="jnj-20221002.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2768b1b3-866d-4528-a6dc-4f6194d7d55d" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_ce1bf650-7ae1-44f4-bd5c-2e81f5111af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_645d95e0-a930-4200-a942-69338e6ef531" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:to="loc_srt_RangeAxis_645d95e0-a930-4200-a942-69338e6ef531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ae14ab6-1941-4197-81cc-af1212734a16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_645d95e0-a930-4200-a942-69338e6ef531" xlink:to="loc_srt_RangeMember_6ae14ab6-1941-4197-81cc-af1212734a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c065d941-c5d3-4452-997b-7629843c25f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6ae14ab6-1941-4197-81cc-af1212734a16" xlink:to="loc_srt_MaximumMember_c065d941-c5d3-4452-997b-7629843c25f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9a046559-730e-4f08-b1d7-9d3031aec28c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6ae14ab6-1941-4197-81cc-af1212734a16" xlink:to="loc_srt_MinimumMember_9a046559-730e-4f08-b1d7-9d3031aec28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9af4521-43cf-45e7-ac31-9fe9f08c89cb" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8242617e-4559-4629-8737-85be063638e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:to="loc_us-gaap_RestructuringCharges_8242617e-4559-4629-8737-85be063638e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3911e6dd-2b9c-407a-95bc-2c1e96490863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3911e6dd-2b9c-407a-95bc-2c1e96490863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_febed525-b6d0-4dc2-b10b-54913fb0d5ba" xlink:href="jnj-20221002.xsd#jnj_RestructuringandRelatedCostExpectedFutureSavings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:to="loc_jnj_RestructuringandRelatedCostExpectedFutureSavings_febed525-b6d0-4dc2-b10b-54913fb0d5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_3c339728-c7ca-478b-ba0b-c791a8d8c343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b70a6341-1a65-42a2-93ba-87f0dada41c4" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_3c339728-c7ca-478b-ba0b-c791a8d8c343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="simple" xlink:href="jnj-20221002.xsd#RestructuringScheduleofRestructuringReserveDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b56d13da-9f7c-4682-9ed7-2512d4b5e603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_365df539-e579-4569-9088-82f3762f295c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b56d13da-9f7c-4682-9ed7-2512d4b5e603" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_365df539-e579-4569-9088-82f3762f295c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_7f960aa6-beef-4f12-8c8e-7bd064907cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_365df539-e579-4569-9088-82f3762f295c" xlink:to="loc_us-gaap_RestructuringPlanAxis_7f960aa6-beef-4f12-8c8e-7bd064907cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_341c4df5-8742-46cf-90c8-22a9d7916b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_7f960aa6-beef-4f12-8c8e-7bd064907cc5" xlink:to="loc_us-gaap_RestructuringPlanDomain_341c4df5-8742-46cf-90c8-22a9d7916b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_78bad654-7fa9-4c7d-b178-ecf3a2419730" xlink:href="jnj-20221002.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_341c4df5-8742-46cf-90c8-22a9d7916b95" xlink:to="loc_jnj_MedicalDevicesMember_78bad654-7fa9-4c7d-b178-ecf3a2419730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_3348e447-372e-4eb0-b7d4-e11f7a23ce86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_365df539-e579-4569-9088-82f3762f295c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_3348e447-372e-4eb0-b7d4-e11f7a23ce86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_9c606bc0-6e42-4f82-8b12-36b67facb39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3348e447-372e-4eb0-b7d4-e11f7a23ce86" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_9c606bc0-6e42-4f82-8b12-36b67facb39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_9eb84957-e942-4662-becc-b7fbce643680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9c606bc0-6e42-4f82-8b12-36b67facb39e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_9eb84957-e942-4662-becc-b7fbce643680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_fad5a194-46f0-483f-acf5-e643a5c9df80" xlink:href="jnj-20221002.xsd#jnj_AssetWriteoffMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9c606bc0-6e42-4f82-8b12-36b67facb39e" xlink:to="loc_jnj_AssetWriteoffMember_fad5a194-46f0-483f-acf5-e643a5c9df80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_35546694-45ba-40a2-a208-f69cd723a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_9c606bc0-6e42-4f82-8b12-36b67facb39e" xlink:to="loc_us-gaap_OtherRestructuringMember_35546694-45ba-40a2-a208-f69cd723a7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_51946a3d-0e56-4d0e-9d7e-9610cfcfbbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_365df539-e579-4569-9088-82f3762f295c" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_51946a3d-0e56-4d0e-9d7e-9610cfcfbbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_51946a3d-0e56-4d0e-9d7e-9610cfcfbbab" xlink:to="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_049c6aa9-cd08-417f-927d-4fc3dbaf86da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:to="loc_us-gaap_RestructuringReserve_049c6aa9-cd08-417f-927d-4fc3dbaf86da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2e3e4dd1-ee75-4b79-9f75-00e4a608270c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:to="loc_us-gaap_RestructuringCharges_2e3e4dd1-ee75-4b79-9f75-00e4a608270c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PaymentsForRestructuringNet_9757c9b5-7766-4b91-b99a-acaad6a9525f" xlink:href="jnj-20221002.xsd#jnj_PaymentsForRestructuringNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:to="loc_jnj_PaymentsForRestructuringNet_9757c9b5-7766-4b91-b99a-acaad6a9525f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9e38ecf2-8c83-4b48-9cd6-67315c03d43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_9e38ecf2-8c83-4b48-9cd6-67315c03d43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_85f9e951-3ea5-449a-aae7-898fb2b67b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_44989329-41a3-4864-8097-b2ec5bbc35bf" xlink:to="loc_us-gaap_RestructuringReserve_85f9e951-3ea5-449a-aae7-898fb2b67b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>jnj-20221002_g1.jpg
<TEXT>
begin 644 jnj-20221002_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"*_>^CL9I-+MHIKE8F-O#/,8XWDP=JLX5BJDX
M!8*Q YP>E?FRW_!P;XOF_P""G=U_P29TO]A&>[^*%OJ=Q9QW*?$J!-+G,6FO
MJ7F+.]F'"M;)N&Z,-N(4@'./TKK^<#Q;XH\;^"_^#TS5O$WPX^&-SXRUJTUR
MY-CX:M-4M[*2^)\"LK*LURRQ)M4L_P S '9@<D4 ?L5+_P %"?VI? G[4GPT
M_9Z^/_\ P3JUCPMHOQ-URYTC2_B'IGQ!LM6TVUO(K*YO!#,D42RQL\=L^T.J
M!N=I)5@,[]AK_@K:_P"VG^W?\=OV)3^RCXM\'#X*:C+:CQ?J]QYEMJ_EW1M\
MM'Y*?96EQYT"[Y?-A#/E<8*_\$OOC)\<_P!M+PE\8/''[8GP4O/ ?BKPS^T'
M?V.B>"=1O5NYO"D5MHFEQVPBF ,;LT<TEQYL8,4C7;NF4<9^._\ @D+_ ,%'
MOV^OBU_P4]_;)_9B^+OQLU;XG>'_ (+IXE@^'OA_4-&TVVN)YK#6I;2V5I;.
MUA9Y)(XU0D\9<G:* /V)HK\)?^"3'_!6[XS_ /!02\T?P+XJ_P""A'B[P?\
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M_"[Z%X+^*_B;6M,^#EC):F%]5T>?4UN)]8,9 V),UM!Y9ZL6G/W=C/\ ,O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?Q3G^#7P2L/@]\6_$&F64'@7P78>-X;S6[:V%Q&=0:34T,=K!<S6YD2%(_\
M5;=QG\R4+!^67[3O_!&?_@L+\:/^"<?[-'PLT']@+PIH>L_"#Q'JCZWH&D?$
M6PFUG7I[^2"636+TR&.VA9S;HC*MQ<2Y;<PC10B_T<44 ?CO_P '"'[!7_!1
MS_@H1\9?V8/B#^S]^QA?:JOPPENM6\:K!X\T&.&WFNKC3)OL<#WEY;R3O&+*
M0,_E+&2R[689(_7_ $>^N=3TFUU&]T>YT^:XMTDEL+QHVFMF903$YB=XRRD[
M24=ER#AF&";-% 'S!\(M3_:3_P"'D'Q+\>>+/V-?%^B^!/$OP_\ "NA:'XTN
MO$?AZ6)[C3+O6Y[AY;:#4GN4C8:M&$(B9B89-RKE<_/W_!Q%_P $1M"_X*E?
M +_A:OP:T>UM?C?X$T^1O"]T=L?_  D%D"7?29W.!DDLT#L<1RL02J2R,/T@
MHH _,C_@XA_8C_;%_;E_X)F?#_\ 9:_9._9ZU#Q?XHMO%.CZIJRCQ!I6G0:?
M!:Z?<PNLCW]W 6<R3H%6,.,*Q)7 W>*_\%A_^"<G_!1/]L[_ ((Y_LO_ +'G
MP1_8XUNY\=_#ZVT0^--.OO&/AVWBTU]/T.33I$\Y]2V3;Y9-Z&(L-@)?8WRU
M^T-% 'XH?\%8/^"='_!2+]J_XX?L7?$KX,?L2:_?67P2T'2)O'D5UXU\-6\D
M%Q%=6,LMK$)-4 F=%M'^93Y9WIAS\VWK_P#@LA_P3E_X*">'_P#@IW\(_P#@
ML_\ \$Y/A&GC?Q#X7TZTL_&/P]N-5MK:\(B6>)\,\@22.:TN7M7\IG>,J'4.
MK$K^P%% 'B?['?Q7_:]^.VCW'Q._:8_9KA^#EE+:1PZ-X"O/$<&KZJTN2TMW
M=3VX$,*$;$B@7+C$CR$%DC3)_P""I'A[XU?$#]@WXH_!W]G[X%:MX^\5>./
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M\-0?#FZT^U\.Z]H_@W18M36[FDU6.!3*EFJK;$V@:<*@F<I$(Y85\P2>I?\
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M)(Q=OM&"OF#]OZ* "OQY_8?_ &)?VY?V#_\ @LO^T;_P42^('[*>O^)OAO\
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MB[]N31KGPC+X=_L*[O-.^#EK;ZU+8&'R"HFDO);)9#'D;A8[.XC'2@#\[O\
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MLXNTE@86-[-(DG[]&!*;" WS @ _K=110 4444 %%%% !1110 4444 %%%%
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MH'@5T=9+68-&&88 (8YX^%/^#EW_ )33?L(_]C=I7_J1V5'_  5F_P"5M_\
M9&_[%'P[_P"G;6Z /T*UC_@K:^D_\%C-,_X)*_\ #*/BV4:CX3;6?^%G+<8L
M8\6;W6?(\GFV^3[.;CS1BX81>6?O5]C5^1/_  WY^V]X1_X.I=(_X)U2?M+:
MOJ?P<U33+G49/!^HZ+IF(V?PO<WZQ+<1VJ7'EI<HKKF0MA0K,PSG0_9C_;T_
M:(_X*[_\%;/C_P#LO>"_VB/%7PO^$?P2T>[TSP]'X!%I!?ZMK$5\+,ZE<W,\
M$K21[X[ATMQLC*^5O#$/O /UFHK\@_\ @EC_ ,%@_P!I_P#;\_X)8?M+V_Q0
M^(S:/\:O@!X;OYAX^\-Z9:1/?JME>7%C=O;RPO;B0S6%Q'(BQA&100J%LCY3
M^%?_  4+_P""P7[0?_! SXK_ /!27Q!_P4=U?2M;^%WQ,@T_2K+1/!>E6]QJ
MJ/-H\,B7=PD  B07Y>..*-"6$GFM*K1K$ ?T45E^-=0\6:3X3U#4_ OAFVUG
M5[>V:33]*O-3^QQW<@Y$9G\N3R\] Q0C.,X&2/R*_;#_ ."Q?[;OAG_@W&^#
MW_!0+X<![?QSXYU73-'\?^+-%TV#S-*M!)>P75_"DD;PP2SRV<42LT9CC>\^
M500F/I#_ ()!?M3Z5^V5XQN_C;^SO^W3XF^*/PDD\#QVUUX&^(*V"^(_!'B'
M[2C-%=F""*6XCFAW^7(YE4&WE"2LK*  ?4W[)7[7_P )/VR/ &H>,OAE)?66
MH>'M=N=!\9^$];A6'5/#6L6S;+C3[R)68)*AZ,K-&ZE71V5@3ZG7X\_#;XO:
MM^RY_P '>OCGX"^%[AH/#?[0GPXM+S6M)C.V ZI9:,;J*\VCCS MC=+GO]KD
M)Y.1^PU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'EW[;W[/?_#67['7Q1_9F2\CMIO'?@+5=$L[N7.V
MWN+BUDCAE..R2,C'_=KX?_X-;/$^O^$O^"4%W\ ?%/A&_B\:_!GXB>)?#GBC
MPB3%'?07RW37OV?$KHBLQNMBL[JA93E@ 2/TQKRW3_V2/AGX8_::OOVK?AS=
M:AX9\2>(K&*S\>VNCO&MCXMB@C=+5[Z%T8&XM]Y\NYB,<VW]V[/'A  ?F?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]Y?.VJ7JD?H^2<?\+9[)0H5U&;^S/W7Z*^C?DFSZ4HHHKX\^S"BBB@ HHHH
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M^2W/ZDJ*_.;_ ()D?\%N-"^,TVG_  (_:\U*TTCQ9*RV^C^+MJPV>KN>%CG
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M*W6:YE7<S".)51!Z!0!0![]1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7Y1_\%@O^"P%S?7.K?LF?LH^)FBMHF>T\9>,;";#3L/EDLK1UZ(.5DE'+
M'*K\N6;[_P#VQ]$\6_$_X)^(O@U\-?B3=>%-;UO36MTU^RC#O:AL93U =<J2
MI#JK$J0<&OY\/V@?V=?BQ^S'\0[CX:_%WPT]A?19>VN$RUO>PYP)H), 2(?P
M(.0P5@0/U_PMX;RK,,8\7C9*4X:PIOK_ 'WWMT71ZOH?C7BKQ/FN7X-8+ Q<
M83TG473^XNU^KZ[+J</1117]&G\V!1110 4444 %%%% !1110 4444 %%%%
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MPO\  ;[%;VW@C1;*1X6M;6>.2/[(RSH+>5HHUMF9UD!C5.#L*. <#_P=R_\
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M;+.;%8).5+=K=Q_SCY[KKW/D&BBBOT,_/0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH TO!OC#Q/\/?%FF^.O!6MW&FZOI%['>:;?VK[9+>>-@R.I]00*
M_H>_X)W_ +9OA_\ ;@_9LTKXJ6[00:_:8L/%VF1''V6_11N95ZB.0$2)U^5]
MN25:OYSZ^K_^"//[9S_LC?M7V-AXGU0P^#_&[1:1XD#OB.W=G_T:[/8>5(V"
M3TCEE[XK\]\1>%X\09*ZM*/[^BG*/=K[4?FM5YI=V?HOAMQ5+AW/(T:TOW%9
MJ,NR?V9?)Z/R;[(_?6BBBOY5/ZS"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH R?&NL'1?#\TT;XEE_=Q'T)[_@,FO,:ZCXI:F9]5BTQ
M&^6WCW,/]IO_ *P'YUR]?4991]EAD^LM?\CXS.,0ZV,<5M'3_/\ KR"BBBO0
M/*"F7%O;W=N]K=0)+%*A22.10RNI&""#P01VI]% 'YM_\%$?^"036_V[XV_L
MC:"6C^:?6/ ULO*]VDLAW'<P?7R^T8_.6:&6WE:WN(F21&*NCK@J1P00>AK^
MCZOCK_@H7_P2L\(?M+17GQ8^"T%IH?CP*9+J' CM-</7$N.(YSVEZ,>'ZAU_
M4^%..Y4>7"9G*\=HSZKREW7GNNMUJOR[BK@6-;FQ>6QM+=PZ/SCV?EL^EGH_
MR$HKI+_X/_%+3/B=_P *7O? &JIXL.HK8+X?^QL;I[AB L:H!EBV001D,"""
M0<U^NG_!.K_@AM\-?@[I=A\5_P!KO1[/Q3XP=5GM_#$Q$NF:0>H61?NW<P[E
MLQ*<A0V!(?NN(^+<HX:P:KXF7,Y?#&.KEYKI;NWIZNR/B.&^$,YXGQKH8:'*
MH_'*5TH^3ZW[16OHKL_-_P#9A_X)J_MC?M;1Q:K\*_A+=0Z)*,CQ+KS?8K K
MZI)(,S#_ *Y*Y'>OL_X9?\&UNN3V<5W\9/VH[6UN.//T_P ,^'FG0?[MQ/)&
M3^,5?JW###;0I;V\*QQQJ%CC10%50,  #H*=7X3FOBQQ-C:C^JN-&/1)*3^;
MDG^"1^^Y3X1<+X&FOK:E7GU;;C'Y1BU^+9^<X_X-NOV:/LK(?CYXZ\[!VR".
MRVCTRODY/YUY[\2?^#:S5H;.2Z^#_P"U);W%P ?*L?$OAUH4)[9G@E<C_OT:
M_5JBO'H>(W&5"?,L4WY.,6O_ $G\CVJ_AMP57ARO")>:E-/\)?G<_G6_:@_X
M)F_MD_LD03ZU\4?A/<7.A0$[O$WA^3[;8!?[SN@W0#T\Y4S7@E?U12Q17$30
M3Q*Z.I5T=<A@>H([BOSW_P""C7_!#SX<?&C3;_XM_LD:19>%_&**T]SX9AVP
MZ;K!Y)$:\+:S'L1B)C@,%R9!^F<,>+5#%U8X?-X*FWHIQ^'_ +>3NX^J;7=)
M:GY?Q1X05\'2EB<GFZB6KIRMS?\ ;K5E+T:3[-O0_&6BK_BCPOXC\$^([[PA
MXOT.ZTS5=,NGMM0T^]A,<UO,C%61U;E6!!!!JA7[1&49Q4HNZ9^(RC*$G&2L
MT%%%%,04444 %%%% ']"'_!)O]J6?]J[]BSPWXJUZ_\ M'B'P\#H/B1V?+R7
M-LJA)F[EI(6AD)_O.P[5]*5^-G_!NQ\?YO!O[1WB3]GS4[_;8>,]#-YI\+-U
MO[/+84=MUN\Y..ODKZ<?LG7\A\>9-'(^)Z]""M"3YX^DM;+R3NEZ']C< YW+
M/N%J%>;O.*Y)?XHZ7?FU:3]0HHHKX\^R"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKPO\ :@_;X^%O
M[-OQ>\!_LT6?AG6?&GQ4^)KW1\&> /#1MUN9[>VB:6XO;B:YEBAM;6-$8F1W
MW-M81I(RE1Y7^QI_P5TMOVBO%?PP^&7QJ_95\9_#;7_B_P"'KS5_A_J<EQ;:
MKH&M1VL+S7,,5];N'BGCC1F,5Q!"2,%=VX9 /LBBO@C_ (*O_P#!P;^RK_P2
MMBC\+>)_AKXV\:>,K\3IH^CZ;H<]AIL\D)"R!M4N8A P1F"O]F%P\;$!T7(K
M[.^,7QB\#_ ?X5ZO\8?B/>W$&CZ+:":X6SLY+FXG=F5(K>"&,%YYY972*.)
M7DDD1%!9@* .IHK\J!_P= 6'PV_;5\,_LK_MB_\ !-OXI_!;1/&E_;V_AOQ;
MXVN%CNGCN)O)AN9[ P*$AWE1(T5Q,8SN!!*D5^J] !17R[^U#_P4S\/_  >_
M;'\!?\$[O@A\.K?QY\9_'VEW.KP:)J'B(Z3I6BZ7!%-(;K4+U+:ZDBW^1(L<
M<=O*[%<D("I;1_X)T_\ !2WX4?\ !0S2/'6AZ!X:O/"OCWX5>+KCPS\3/ FI
M727$NCZA%++%NCF0!;BWD>"81R[4+&%P44KB@#Z1HHHH ***KZO<_8]*N;O.
M/+MW8?4*:<4Y221,I*,7)]#R_7[[^TM;NKW=D23MM/\ LYP/TQ5.BBOM8Q4(
MJ*Z'YW.3G-R>["BBBJ)"BBB@ HHK2\):.-;UZ"SD7,8.^;_=';\>!^-3.<:<
M')[(NE3E5J*$=V[%GP9^SW\,)O'NG?'K7_ .F3^+[&PDM-*UN6T4W-K;2?>5
M7Z\C.#U4.P& [@^DT  # & .@HKY'$XJMBZG/4;=M%Y+LO(^[PF$H8*ER4DE
MU?F^[\PHHHKG.H**** "BBB@#\]?^"X?_!.73OC3\.;S]K?X2:"J>,?"]EYG
MB6UM8OFUC38Q\TA ^]- HW ]6B5EY*1@?C+7]44T,5Q$T$\2NCJ5='7(8'@@
M@]17\['_  4Q_9AM_P!DG]LGQ;\+=%L_)T*XN%U7PTH&%6PN<ND:^T;>9#GO
MY.:_H/PEXGJXNA/*,1*[IKF@W_+LX_\ ;K::\FULD?SMXO\ "]+!UX9QAHV5
M1\M1+^:UU+_MY)I^:3W;/!****_:3\0"BBB@ HHHH ]/_8L^+C_ C]K/X>?%
MEKLP6^C^++-]0D#8_P!$>01W S[PO(/QK^E6OY6Z_IK_ &8?'Q^*G[-W@#XE
M/-YCZ]X,TR_F8G)\R6UC=P?<,2#[BOP?QHP24L)C$M7S0?RLX_G(_?O!+'-P
MQF#;T7+-?.\9?E$[FBBBOPL_>@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _*?\ X.#?^"6W[<7QJ^-G
MP\_X*C_\$S?'5W;_ !?^$6AG3AX>M)TCN;VQ2:>=9+/S/W4LH^U7,<EM(-MQ
M%)L&XCRY/-O^#<?_ (+1?L]?M5Z)\-O^"<_[1WPP3PW\7?AC!<O\/-5N/GMM
M8FBM+J*X:+(#6MX+2>Z5HFW(Z>858'$8_0C]H?XN?MI_ 7]L;2/&7@/]F7Q+
M\3_@OK?@1+#Q)#X.U?3_ .TO#^MPWD[Q7<=E>7,!N(I89O+E\IB_[N,X/EA6
M_.?_ ()J_P#!,3Q[^U'^UI^RY_P4-F^!4OPV\(?"+X7I%K&O:I/:1ZCX]U<&
M[2V,=O;2R.D$"3(&GN?+D=8Q$J%%5U ./_X/C /^%9_LZ-CD:[XEY_[8Z=7[
MLO8V5_:0QWUG%,L;1RHLL88*ZD,K#/0@@$'J",U^/_\ P='_ /!/G_@H-_P4
MX7X4> /V.OV0-9\06W@2_P!:N=8UZ^\7^'K"VG^TI9I"L"W&HI,W^HD+;XTQ
M\N,Y./NO]MCXY_\ !1_PI^QG;?%C]A#]CW3]7^*46JV1U+X<_$75K/S$T[:Q
MNC$]C?\ D2S [%4"XY!=@'(5& /R<_X.%_VL_B9\-/\ @JG^SQ\4/^"@7_!/
MZ^;X$?"S7KRZ\)76E^*(KC_A*9I)K9Y;IY8X]J&'[+:R#3I=C/Y;;I-DN5_?
M3P[K^D>*_#]CXI\/WJW-AJ5G%=6-P@($L,B!T<9YP5(/XU^<7[9OP'_:'_X+
ML?LL>!/V9/C5^Q'XO^!UO'XZTW7?B)KGC;5-+G72X;6.43P:1]EN99[J>83&
M))988(U1Y&8[@(V[G_@H;K'_  69^'?[7O[/W@;_ ()I?#KP[<_!1+BVM?B8
MU['8L(($N422.X:Y830VZ6:[HWMOWA<.#N.Q& /A']GWQ1X@\8_\'JOQ%N/$
MLKEM,\/W=E81.>(K>+PY:)&%'8$$O[ER>]5_^" 'BOQ!9?\ !R]^W-X&LII!
MI&HZOXXOKV-2=AN;?QC#'"3VR%NK@#_>-?7?[3'_  3J^+OP(_X+F>#/^"QO
MP,^%^I^.?#&L^&;C0OBSX7\-R6W]KV=P-->RM=1MXKB6)+F(JEI')&K^8GDL
MX5PQ"Z/_  1%_P""7GQ5_9C_ &@/VB/^"A/[2OA1/#GC7X__ ! U/5-$\&O>
M0W-SX<T6XU*YOA#<RP.\1N)7FC+I&[J@MX_FW,RJ ?HU1110 5E^-9?)\+7K
M^L6W\R!_6M2L?Q__ ,BE=X]$_P#0UK;#*^(@O-?F<^+=L+4?]U_D>9T445]D
M?GX4444 %%%% !78_">T4O>7[#D!8U/UR3_(5QU=W\*<?V/<^OVG_P!E%<&9
MR<<'*WE^9Z>3Q4L?&_2_Y'4T445\L?:A1110 4444 %%%% !7Y1?\'*7PQLH
M-<^%WQEM8/\ 2+JTU#1;^7'5(FBG@&?K-<_G7ZNU^<__  <B^3_PS1X!W!?,
M_P"$Z;:3UV_8ILX]NGZ5]OX<UYT.,L*X]7)/T<9?\/\ (^%\2J%.OP5BU+HH
MM>JG'_AOF?CG1117]:G\@A1110 4444 %?T-_P#!)GQ!)XE_X)T_"K49"28_
M#[V@SZ07,T _2.OYY*_H!_X(MF8_\$S?ACYXPWDZMCZ?VO>X_3%?D?C)!/AV
MA+JJJ7WPG_D?L'@M-KB2O'HZ+?W3A_F?4=%%%?S>?TP%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %9?C6,R^%KU0,XBS^1!_I6I5?5[8WFE7-HHR9
M;=U ]RI%:49<E6,NS1E7CST)1[I_D>1T445]H?G@4444 %%%% !78_">\4/>
M6#'DA9%'Y@_S%<=4EAX^\/\ P\U2WU?Q'K$%I [>6_FO@NIP#@=6P2#QZ5AB
M<//%4)4X*[>R6]UJ=6"Q,,)BHU9NT5NWV>A[!12(Z2*'1@RL,@@Y!%+7QQ]\
M%%%% !1110 4444 %?E'_P '*7Q-LI];^%WP:M+G-Q:VNH:U?PYZ)*T4%NWY
MPW(_"OU:GG@M8'N;F9(XXT+222, JJ!DDD] !7\ZO_!2O]IY/VMOVQO%OQ3T
MJ]\[0X+H:7X993\IT^VRD<B^TC;YL=C,17Z?X3Y54QO$WUJWN48MM^<DXI?B
MW\C\L\7<VIX'A=X2_OUY))?W8M2D_P $OF>#T445_3I_+04444 %%%% !7]#
M?_!)K0)O#7_!.KX5:=.N&D\/O= 8[3W,TX_205_/)7]-?[,?@%_A5^S?X!^&
MDL1230/!FF:?,I'/F16L:.3[E@2?K7XUXS8A1RG"T.LIN7_@,;?^W'[5X*8=
MRS?%5^D::C_X%*__ +:=S1117\\']'!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!Y/K]B=-UJZL<8$<S;?\ =SD?IBJ==1\4=,-OJL6J(/EN
M(]K'_:7_ .L1^5<O7V.%J^VP\9^1\!C*+H8J<.S_  Z!1161XJ\=^%?!<'F^
M(-6CB<KF.W7YI7ZXPHYP<8R<#WKJITZE::A!-M]$<=2I3I0<IM)+JS7K,\2^
M,?#/A"V%UXBUB*V##,<;'+O_ +J#+'Z@8'?%>3^,OVC->U/?9^$;0:? <C[1
M* \S#V'W4X^I]#7G=Y>WFHW3WNH7<L\TAS)--(69CZDGDU]/@>&*]6TL2^5=
MEJ_\E^)\YC>)*%.\<.N9]WHO\W^!Z5XQ_:1U6]W6?@NP^QQ]!=W2AY3TZ+RJ
M]QSN_"O-]1U+4=7NVO\ 5;Z:YG?[\T\A=C^)J"BOKL)@,)@8VHPMY]7\SY3%
M8[%8V5ZTK^71?(^J?V1/CK!XJT*+X9>)KT#5-/BVZ?)(?^/JW4<+GNZ#C'=0
M#S@FO;Z_.6?Q,G@R/_A*GU22S^PL)8[B!B)%<'Y0F",L3TY'N0,D>\_LO?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME)XD3QE)X7TYM7CA\J/56LHS<K'_ '!+C<%Y/&<<T ?.O_!&C]FSXE_LA_\
M!+[X,?L]?&.!X/%&@^$5;6[*5]SV,]S/+=FU8C(W0^>(3@D9C."1@U]-T44
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M0?%[1/CYJ_PRTJ7QCX=M[R'1]?$&R>%+H1"<':0)"PACP7#%=IVE=S9[2B@
MHHHH IZWX=\/^)K1;#Q)H5GJ$"3+,D%]:I*BR*<JX# @,#R#U%7*** *VDZ+
MH^@VG]GZ%I-M90>8\GD6D"QIO9BS-A0!DDDD]R2:KV_@_P )6GB*;Q=:>%].
MBU:YC$=QJD=E&MQ*@P K2 ;F' X)["M&B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M!7QA_P"2N>*?^QCOO_2AZYRNC^,/_)7/%/\ V,=]_P"E#USE?TE@?]RI?X8_
MDC^9<=_OM7_%+\V?5_["G_)(]1_[&.;_ -)[>O::\6_84_Y)'J/_ &,<W_I/
M;U[37X7Q/_R/\1_B_1'[WPO_ ,D_AO\ "%%%%>">^%?"G_!4NVD_9L_:]_9E
M_P""@"7MW'X5TSXDKX(^*>GK>2+926>M0M::?JMS%N\LFRO?*Q*5+ 7 &?E7
M;]UUY%^WQ^ROHO[;?[&?Q(_95UN6*'_A-/"MS9:==S9VV=^!YMG<\<_NKF.&
M7C_GG0!\8_LI?'+P!^S'_P %A_VFOAEXKO+^R^'7BWP@OBSP)K>M7SRV%G)H
M<:P>)K&PWLWE0QW$XD>% JJUM, NU$Q[M\+?BSX*_8:_9T\ 6'C[3+'3/'OQ
MEU^_U:'0?$/B%-/M[&^O!<:K/:3W<Y86UG80,+1=BOM$4,<<3,X%<I\:O^"1
M$GQ=^%7[,OA>]^)+GQ)\&_%(O/'WB661O-\6:?J-K,OB:VD(7YO[3GDWRYP"
M)'Z$C'I/_!0O]EK]I'XP:_\ "[]HS]C7QOX9TOXH?!_Q)=W^C:;XX$XT77M/
MOK1K2_T^Y>W5I82\91XYE5]CQ#Y>=R@')^!O^"P_PB\;>$[))O"MIH7BN\^,
M]Q\,18^(?%$,&B?VQ%8SWZ3IJ\<<B36<]O 1;RI$9)9I(XO*5MQ6/X__ +=O
M[5O@OXL_LX> /#/[-$.D2?%'XD^(M$\4Z9K/B6(3JNF6.K21Q0-Y)4Q7'V.*
M[6X^7]UL0(3*63>^*'[/W[6G[1WP/TSP7^UA\(?@EX_MM?\ $#M\0?AE>ZA=
M?V/::2+1TA33[V6QDFFO8[KR[CSGB@&&9$,>Q)#Y7X4_X)@_M3?"#X;_ +/-
MM\,?B'X;UW5?@=\8?$'B#3/#_C?Q5J,UK8>&]2M=3LK?28=1^RRW%T]C;WL*
MHTL2"7R2NZ)=N #O?V@_^"P_P6^ J^(_%I\/VFO>$_ _CB+PMXUNM-\56W]M
M6MU]HBMKFXM-)P9;RVM9Y?+F;?'(#%,T<4J1[SLZ=_P4>^(_C']I[Q_^S-\*
MOV$O'GB2Z^&'BW2-)\9ZM#XBT6UBMK34+ 7L-_$)[M5G4QM&1"K^8 Q,@B.U
M7X[X6?LG_P#!2G]F7XY?$?P/\!_B)\+;_P"#?Q/^(.H^,4USQ&]_'XC\&WFJ
M2F?4XK2UCB>VOD-PTDT EECV-*?,WJH5O2OV</V:OCU\(?VS/VC_ -H?Q1;>
M$)M#^+>H:!>^$[2P\073W<#Z;I$6G&.[5[)4C$AB$FZ-I2@8KAL9(!YO\&_^
M"R%O\5O"WP6^+.I?LB^,/#W@+XT>.I?!NE^*=2UO3Y&T_6C/>PV\4EK%(TKQ
M2/8R(TPPJ.P \Q<2-Z)_P6'1H/\ @EK\?O$%G<36VH:)\)M=U/1M0M)VBN+&
M]M[":2&XAD0AHY$=00RD$<]B:\(^'O\ P3*_:_\ !O[$W[-_[-MW>_#:;7?@
MS\>[;QSX@O(_%.H"TO;&'4M0O/)MV.F[_.9;X)AU508L[CNP/J3_ (*&? OX
MF?M0?L1_%#]FOX1OH46N_$#P3J7AZUO/$>HS6UI:"\MI(#.[0P3.VS?N"!/F
MQC<O6@#\_?\ @H3^TW\.+3_@WKU#3O 6D?%#2/%FF_"30+O3/$W_  JWQ1IW
MV?4?]",MV-6DL8XE:0F3=<&?$OF'+MOY^V?B?^V)\./V8[O1?V</A]HWAFY\
M46G@)/$*Z'X@\:6V@6D6G[VAA N)U<O<7$T<ZQJ$*DP2M++$-K/PG[8/[#'[
M2W[1W_!'2X_X)\>&YO UAXVU+P!I'AJ]U2^\0WATNW-I]E$DZ2)8F:3<+<[4
M,2?>&6XI/CA^R_\ \% _"_[4WA3]M_\ 9!O?A?/XEN_AC;>!OBC\._'6NZA%
MI5Y:6UW/>6=Y97]M9M*L\,MU<J1);A7CE(P& - $G@7_ (+"^$?C#/\  VV^
M"_[,/CO6G^/?A'7M9\*B]GL+#[)<:08X[VQN1-/NBDBED"O(0(RH)B:9L(<4
M?\%F[FR^!][^T#XD_8O\8Z;X=\%?$Q_ WQANIO$.G,?"FIIJ\>ER>0JR;]3C
M26:"1I(E1?+E!4LRR(G;^*/V4OVKO&'[87[.O[2GBWQ+X)U6/X7:!XNM_&\B
M7UU9RW-SKB6@6.PMQ;2*8+;[*(U,TPD=-I8[@2WC_CO_ ()E?M?>+OV%?V@_
MV8K:\^&T.O?%SX_7OCO0;Q_%6H&SL[&XUNTU/R+AAIN_SE6U\O"(RDR;MPVX
M(!ZYXK_:@_9W^%'[>7Q?O_%W[/\ KFF^+OA[^SK:>*?$/CQ+B.<ZQX9AO-0D
MCM;6VCF;)2:&\(\Q8Y&;C!7:U2>+/^"ENI^ _P!ESQE^U]K'[/,VO^"O#/PV
MA\::5K7@#QE9ZI::Q9L)VFA2>46Z)/;K"'E5?,&V5?+,K J(O%_[+'[6US^W
M%\2/VNO <WP]L?\ A)/V;[;P-X4@U+6KNX>VUVVN]0O8;BYB^PA'M#-?!&VL
M7V0EMA+[%^7OVM/^"?&H_LK_ +''[8/QW\'>!?#/PL\*>-/V:M8M]<^$_@+Q
M-<W^AW/B)8+AY=8ABEM;:.S/D[( L42^:&+.D;*-P!]-^!/^"E,'Q!_:6\'_
M +)OQW_9+\8^ +#XR^%;Z_\ A9XFUO4[*XM?$R6UJMQ>6CQVLK2V,PMG,R1S
M!7:,'<(W!C'SK_P2-_;:U/\ 9P_89_9N^&/C3X ^(I/!WC[XA:UX,L?B,VL6
MK1Q:U<ZUK$MK&;5I#<R0N86B:X8+B3^%E(<_07PY_9L^-GQY\9?LZ_M"_%W0
M/">DVWP6\&W=_P"'M.T?Q%<7;:UK6H:0E@DDCO9Q?9;6.WDG; $KM),G"B#,
MOF7P]_X)D?M?>#?V*/V</V;KR]^&TVN?!KX_6_CO7[R/Q3J M+VPBU/4+WR+
M=CIN_P XK?!,.JJ#%G<=V  >E?&O_@L/\$_@[=ZCXFCT&TUWP;X>^(H\&>*-
M2TOQ5;-K-G>+>BQN+N'2,&:XLK>[)AFDWI*/*E=(9(U$C:F@?\%,O$?BK]H'
MX@_!C0_V//%ZZ5\)O&EOHWQ+\9ZCXBTFWL]"L)M+345U4J;@M/%Y4B$Q0EY5
M0[G5&*QMRGP1_90_X*1_LN?%[QU\)/@Q\0OA??? [QQ\1-5\6:7K^NRWR^)_
M!_\ :MV]YJ%E;6J0M:W@%Q+,UO)+*FPREI%E"B)NN^#W[$?Q0MOB]^U;?_&Q
MO#8\'?M"ZE;/IJ^'=<N9K^TM5T&WT:5)TEM(HT=D@\T%'<*7V\[=Q *GPN_X
M*R_"_P"(_P </AA\+?\ A#H5TKXRZ?=7/@77-'\46VI3VDD-L+I;?6+2$;M,
MDF@RT?SS+N7RW,<GRUO?\%!?C[XE\(>,O@I^R9\/]:N=,USXZ_$C^Q+O5;&=
MH;FQT*RLI]2U62"12&BF>WMQ;)(N&C^U&1"KQJ:YW]@+X*_\%0/@9X>\*_LZ
M?M-^/OA3JG@+X<Z='IFD>-/"CWYU[Q58VT)@LHKNUGA6"Q<((GFDCEF+M%M4
M .TE6_\ @I%\)M63XL?L\_MK:/:R3V_P.^)\UWXK6-"QM_#^JZ=<:7?WF!R5
MMC/!<2'^&&*9_P"&@#5_:(_;V^&'[*VK:[\%OAKX1\.ZGJWP_P#!5OKVK^&[
MKQA9Z$L=C)]H%M9V0E5OM-Y(+68K  D:J$,DL9EB#\UXG_X*^?"?PC;_  =^
M('B/X::QI7PV^-OAV:_\+?$/6)O(M[&_2P>\71[Z!8WE@OI?+>.*-0XE='6-
MG<!#%\9?V;/V\?AK^V_J_P"V/^P1XA^&.NZ+\3/"6E:/\1?!GQ-U.^LHHKC3
MFG^Q:K8W5E!.2?)N7CDA9 &"J0Q)&S;_ &H?V'OBO^VCX#_X4/\ M%>+]-N_
M"=EX0:[L];\.ZS<Z;J4WC3K;ZB(D@9;2WLW+2VRB><B0HTB2-"C4 ?0?PD\6
M>,?'GPVT;QGX^^'%SX0U;5+".YN_#-[?QW-QII<;A!-)%^[,J@@.$+*&R S
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M **** "BBB@#D]1^)_\ 9^H3V']A[_(F:/?]IQNVDC.-O'2H?^%M_P#4O_\
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M)VFE&ZUMH%**6VHK*?+C2.-2$15'D7PO_P""6/PO^$7P;^,GP&\)_'[XE_\
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MG_"6^*M1UK^S?^$ \[[)]JN9)_*\S[>OF;?,V[MJYQG SBN5_P"(9K_J]?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>jnj-20221002_g10.jpg
<TEXT>
begin 644 jnj-20221002_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHKAO$/[2?P5\*ZW<^'-?\:>1>6<ICN8?[.N7V,.HRL9!_ U
MT8?"8K&2<:%.4VND4W^1SXG&83!Q4L14C!/2\FE^9W-%><_\-9_L_?\ 0_\
M_E*N_P#XU1_PUG^S]_T/_P#Y2KO_ .-5V?V)G7_0-4_\ E_D<7]N9)_T%4__
M  ./^9Z-17G/_#6?[/W_ $/_ /Y2KO\ ^-4?\-9_L_?]#_\ ^4J[_P#C5']B
M9U_T#5/_  "7^0?VYDG_ $%4_P#P./\ F>C45YS_ ,-9_L_?]#__ .4J[_\
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MM[*]CUJBN+^-W[1?P*_9L\-P^+?CS\5]$\*:?<S^3:3ZS?+$;B3&2D:GYI&
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MBOG.BC_4WAO_ )\?^33_ /D@_P!=>)O^?_\ Y+#_ .1/HS_AO[_JDW_E>_\
MM%'_  W]_P!4F_\ *]_]HKYSHH_U-X;_ .?'_DT__D@_UUXF_P"?_P#Y+#_Y
M$^C/^&_O^J3?^5[_ .T4?\-_?]4F_P#*]_\ :*^<Z*/]3>&_^?'_ )-/_P"2
M#_77B;_G_P#^2P_^1/HS_AO[_JDW_E>_^T5Z_P#!;XI?\+@\$KXQ_L+^SMUU
M)#]F^U>=]W'.[:O7/3%?"E?7W[%G_)$X_P#L*7'_ ++7S'%W#V3Y9E/ML-2Y
M9<R5^:3T=^[:/JN#^(\YS3-W1Q57FCRMVY8K56[),]:HHHK\Q/U$**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KX9_:$_Y+9XE_["C_ -*^YJ^&
M?VA/^2V>)?\ L*/_ $K] \//^1E6_P '_MR/SOQ&_P"191_Q_P#MK.-HHHK]
M</Q\**** /F__@K!\'OC3\;OV*]?\*? ;2UU77;+4]/U5O#KGY=;M[6Y2>2S
M(R-^X(&V?QE O5A7F7[%7QZ_9Z_X*0:?\2='U6R_L#Q*OQ2T;Q/)X(UQ$75=
M&GTW3M$B\U8VPQ1;NPFB\Q0#M.'"%]E?4/Q]_:%\!?LWZ/H'BGXFZC!I^BZS
MXIMM$N=6N[D10V#W"2^5+(S# 0RHB$DJ%$FXG"D'X!_X*!_";P9J/Q-\4_M'
M?L]ZLME^T!;?';0K#X97&@7?^DZY#)H&A&:WD1"1-:K%)/,[D;54.&;;(P/S
M&;OZMB?K,&I6LIP?56G9Q\]6DMI/31GU.3KZSAOJLTX7NX5%T=X74O*ZBV]X
MK75'WO\ &'2_V;_ $E_^T-\>?^$?M([#1_L4NN>)S&T5G:AG=HHA+D(9"QW!
M!NEV1@[MB ?/'_!&W0?@?-X%^*OQ9_9Z\;Z7=>%_''Q4U#4](\+Z2Q1/#]J,
M1PQ20$ V\LB*)?+P L;1*/NU]'ZY^TU^SMX=^*4GP,\3_&CPSIWBQ=/2\;P]
MJ6K107#0/G:P60C=D G R<<D8YKY\_82^"'@_P -_MN?'SX\_ :QMK+X:>*!
MHUGIQTE%33M3U>".1KZ>U"?(\:/)L,B90RR3J#E& [,0HO-*$Z?+))R3M\2;
MB[NZ>VEFFMVNMCCP[DLJKPJ\T6U%J_PR2DK))K?6Z:>R?2Y]+?&WXK^'/@3\
M'O%'QH\7[SIGA70;O5;U(R \B01-(47/\3;=H'<D5\$_L9?M>> /A]\.)/\
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MD]A_1_FS^?N+O^2CQ'JO_24%%%%?0GS@5'=W=K86LM]?7,<,$$;2332N%6-
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M"HT<K]H_XBFD^RO%NUNZMKYZ=-??Z***]8\@**** "OK[]BS_DB<?_84N/\
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M5KY>7S.QHKCOCA\-/%WQ5\)6OASP9\7]9\$W4&LVEY+JVAQQM--#%(&>U82
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M?^"7YH]:HHHK\7/VT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKX9_:$_Y+9XE_P"PH_\ 2ON:OAG]H3_DMGB7_L*/_2OT#P\_Y&5;_!_[<C\[
M\1O^191_Q_\ MK.-HHHK]</Q\**** "BBB@ KY__ .';?[.'_#1__#0W]@?]
M/'_",^4OV#[?NS]JV?KY?W=WS>U?0%% !1110 4444 %%%% !1110!^@G@?_
M )$O1_\ L%V__HM:U*R_ _\ R)>C_P#8+M__ $6M:E?S3B/X\_5_F?T]A_\
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M>C_]@NW_ /1:UJ5_-.(_CS]7^9_3V'_W>'HOR"BBBL38**** "BBB@ HHHH
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M1./_ +"EQ_[+7Q?'O_(B_P"WX_DS[?P__P"1\_\ !+\T>M4445^+G[:%%%%
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MS-_T/_Q3_P##CWO^-'_#H?\ 9F_Z'_XI_P#AQ[W_ !KZ[_B(_P#U"_\ D_\
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M][_C1_PZ'_9F_P"A_P#BG_X<>]_QH_XB/_U"_P#D_P#]H'_$-?\ J*_\D_\
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M?\:/^'0_[,W_ $/_ ,4__#CWO^-'_$1_^H7_ ,G_ /M _P"(:_\ 45_Y)_\
M;GAM%>Y?\.A_V9O^A_\ BG_X<>]_QH_X=#_LS?\ 0_\ Q3_\./>_XT?\1'_Z
MA?\ R?\ ^T#_ (AK_P!17_DG_P!N>&T5[E_PZ'_9F_Z'_P"*?_AQ[W_&C_AT
M/^S-_P!#_P#%/_PX][_C1_Q$?_J%_P#)_P#[0/\ B&O_ %%?^2?_ &YX;17N
M7_#H?]F;_H?_ (I_^''O?\:/^'0_[,W_ $/_ ,4__#CWO^-'_$1_^H7_ ,G_
M /M _P"(:_\ 45_Y)_\ ;GAM%>Y?\.A_V9O^A_\ BG_X<>]_QH_X=#_LS?\
M0_\ Q3_\./>_XT?\1'_ZA?\ R?\ ^T#_ (AK_P!17_DG_P!N>&T5[E_PZ'_9
MF_Z'_P"*?_AQ[W_&C_AT/^S-_P!#_P#%/_PX][_C1_Q$?_J%_P#)_P#[0/\
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M#,A(#1.%=<C(% '4T5X)\4/^"I?_  3F^"GQH'[._P 6?VU/ASX?\:"=()]
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M<RFRN/$=Q<W%Y<P1S9V/]FM;N19]I/E.8T;!R  =[^W%_P $W/\ @G3\-O\
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M 4_$6NZ=X6\/WWB;5Y"EIIUG+=73@9*QQH78_D#7YA_\&VWB'6OVZM(^+_\
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M1_#;PUX&T?3O#D5HUK%H%CID4-DD# AHA BB,(0Q!7&#D\<UL44 <!_PR?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>jnj-20221002_g11.jpg
<TEXT>
begin 644 jnj-20221002_g11.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M%%% !1110 4444 %17]_8Z58SZIJEY%;6UM"TMQ<3R!$BC4$LS,>%  ))/
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MX_:9\ M5^'S:#XMFT.?3KW5AJ$%R5ABF66&Y$,._Y9E#IL!1N,L"#7T;\/\
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MXET/Q9_PA_Q3^%GB:'Q+\)OB!%9B=M'U.)T?RIHLJ9[.;RHUFAW#<$4YR@H
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M%+&P974C(((X((YS3Z* "BBB@ HHHH **** "OD#_@OQ_P H;/VA/^R?S?\
MHZ*OK^OD#_@OQ_RAL_:$_P"R?S?^CHJ /XPJ*** /W^_X--O^4IG[7?_ &\?
M^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH **** "BBB@ HHHH *
M*** "BJ/B;Q-X=\%^'-0\8>+]=M-+TG2K*6\U/4]0N%A@M+>)"\DLDC$*B*J
MEBQ(  )-?%&L?\'#/_!.OPRW@SQ5XNU+QQHWP\^(>MWFD^"OB[JW@V:#PUJM
MS:RB&8I.S>>D2R';YTD*Q_*YW;4=E /N6BO'?VD?VZ_V=_V7?%/A'X:^//$5
M[J?C7X@SRQ>!/ GA?37U#5]=:*,R2M##'PL2("S32M'$H!RX/%<!^R'_ ,%=
M_P!D?]L7]H3Q9^R-X8/BGP=\5?!7F-KGP]^(6@?V;J0B0J'EB"O)%,HWHWR.
M6VNKXVG=0!]0UE>*?'7@GP-;Q7?C;QCI6CQ3N4@EU74(K=9& R0ID8 G'85\
M]_$?_@JY^S?X(_:'\5?LQ^$?!WQ"^(/B7X?:9;W_ ,1Q\./!LNK0^%89UWQ"
MZ,;!WE9,L(;=)I< _)E2!\E_\'!?QS^"/[:7_!N1X[_:C^$L9U7P[JTV@W_A
M+5-3TPPSH!XEL[1IT20;X2Z>:N"%?9(0P!)6@#]0=!\0:#XITF+7O#&MV>I6
M-QN\B]L+E)HI,,5.UT)!PP(.#P01VJY7XD?\$=/^"W_["G_!.;_@B[\!?!7Q
M]U;Q==W*76MV6N7?A3PC<:A9Z%//K^ISPQ7MR-L44SP$3"W5FG,163R]K(6_
M9SX;?$;P/\8/A[H?Q7^&7B:UUKPYXETFWU/0M7LF)BO+2>-9(I4)P<,C*>0#
MSR!0!MT5YW^U-^UC^SW^Q7\';_X]_M-_$NS\+>%]/ECA>^NHY)9)YY"1';P0
MQ*TL\SD';'&K,0"<8!(\&C_X+6_LC^'OVK_#'[&?QS\)?$7X5^,O'$4+^"3\
M2?"/V"SUPRR&.)(9TED".\BF,+*(SOPAPS*I /KVBO)OVO\ ]MO]G3]AGP!8
M>/\ ]H7QI)8+K>L0Z1X9T73;&6]U/7M2F.V*SLK6$-)/*Q(& -JYRQ4<UY[^
MRW_P5H_90_:H_:7\6?L8Z2/$_@WXM>#(S+K/P^\?:*+&_:$*C&:$QR2PS*$E
MC?"2%MD@?;MR0 ?3=%?-OQ4_X*F?LU^ ?VF+K]C7P!HWB_XG_%'2M(;5?$?@
MSX9Z&NH7&A60V?OKR626*" GS(\1&0RGS(\)^\3=#^R'_P %=/V%OV[/C#+\
M"OV8/BC=^(O$=CX.?Q'KED^AW-H='A2ZBM6M;H7"(8KH2RX,."5"$L0"FX ^
MF**^3_@+_P %GOV*?VC?VN-=_86^'][XNA^*/AJ&_?6?#&L>$KBT>!K/'GQ^
M8_[MF!(VX8AL@@D'-6/V0/\ @L=^Q/\ MO\ [3OBS]COX(Z]XF'Q!\#V%_=^
M*-"U_P *W-@;$65[#97,;/*-OF)<3QH5!S]X]C0!]$V7Q6^%VI?$.\^$6G?$
MG0+CQ9IUDEYJ'A>'6('U&VMFQMFDM@WFI&=RX<J =PYYK?K\@?V.= _X)3>*
M_P#@XO\ &_QF^''QD^+<'Q_OK;54U3X9^)_#CVNGZ;=K9K%>.9RF9$\E=T<9
M<H"X9690@7Z]UC_@N?\ \$]_"'[8NJ?L*?$KQWKOA+X@Z)%>3ZQ;>)_#<UI9
MV5O;:;)J<EQ)=-^Z6(V<9F5]V&4KCDXH ^P:*^6/V"_^"R7["?\ P4=TSXE>
M(/V</B'?_P!E?"EH)/%FK^)M*;3+:.TF2X>.]1YB,0%;6X):38R",EU4$$X.
MA?\ !<W]A+6H?"GC2YO_ !AI?PW\=>+9?#'@SXQZSX5DM?"^L:LC2(;>.Y=A
M+&K/%*JSRQ1PL8I,281B #[%KG-2^,7PCT;6G\-:O\4_#EIJ,<HBDT^YURWC
MG5SC"E&<,"<CC&>17E'[??\ P4J_9*_X)J_#W3/'O[47CJYLY?$%\;+POX<T
M73WO=5UNY&W=';6\?+;=Z;G8JBET!8,Z!OP=_P"#C+]H;X0?M(?\%)/V9?&7
M@CX6^)O!?B6"2TA\7^'?'7@R71-;MR=6@>V:XBE4>;&R,YCE1I(S^\4-N1U4
M _I0L/$7A_5=3OM$TO7;.YO=+DCCU.TM[I'EM'=!(BRH#F,LC*P# 95@1P:N
M5\!?\%[H/B'^RW^SS!_P57_9:N(])^)WP6U/3Y=7>)2L7BOPU/>1VUWHVH*N
M!<6X,ZSINRT+1.\11V)/UM^R#^TY\/\ ]L[]F'P-^U/\+F<:'XY\.V^J6D$K
MAI+5W7$MM(1QYD4HDB;'&Z-L4 >CT444 %%%% !1110 4444 %%%% !7R!_P
M7X_Y0V?M"?\ 9/YO_1T5?7]?('_!?C_E#9^T)_V3^;_T=%0!_&%1110!^_W_
M  :;?\I3/VN_^WC_ -/D]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1
M110 4444 %%%% !1110!^=__  =0>)_B+X7_ ."*?Q.E^'TUS%'?:CHMEXAG
MM20R:=+J4"R D<A7?RHV[%9&4\$UYW_P2M_9%_80_P""PW_!!S]G_P"%_P"T
M/X$C\2:7X +VTUG8:O/97&FZO9S3P2J[VSJZ^;#()&0G#).CX#;&'Z7_ !B^
M#_PU_: ^%?B#X)_&+PC:Z]X6\4:5-IVNZ/>J?+NK>52K*2"&4\Y#*0RL RD$
M C\\OV8/^#8']F/]E#XBZOJ'PV_;(^/T'P_UVY\W6_A59^/3I^E:RG06U^;.
M.)[N#:63:2K,AVL[ L& .%_X+02_\$]/ 7_!1W]E_P 5Z5X(\4>-OVH;272+
M'X+>!/#?C!-*T(VHU!SI]UK$QAE,=FER\S#R/GF6.1'#1CCY/_8_M?BII7_!
MYCKEE\9O$FBZGXH>VU Z[>>&M,ELK!Y6\((^R"&66601H-J NY9MFX[2VT?I
MK_P4%_X-^OV*_P#@HE^T3X)_::^(/BWQYX+\1^"-)M-+LS\.]9@T^.>TM9GF
MM4^:"1H'B>1@LD)C8*0.JH5S/#/_  ;H?L.?#_\ ;WT7_@H%\+O'WQ2\,>(]
M(BC\[1-'\;R"UU*9;;[-)+<W$B->RF>/)GS<9F9F9C\[A@#\X?\ @J[^RS_P
M4<_X);?M\?$/_@M%_P $R/B5+XF\">(?$-U/\2;73/\ 31HURD@%_8ZM9Y_?
M67G(["9<& 'DQ%(Y7]J_;U_:Z^&G[</_  :/>-OVAOA?\*8/ ]OJVI::-8\*
M6<K/;V&J_P#"9V;WOD,W_+&2=Y)D7HBS*F!MP/N_Q_\ \$FKS6]:^,%Y\+OV
MY/BGX+TKXZZA=W'Q#\+6,&D7VFN+FU2TF:RCO+*1[*=H$V-,CG=D%E)2,JOQ
M5_X(I_LH?$?_ ()P:1_P2N\.^+_''@KX4:9]G-W;^$K^P%_JS178O=]S<7EG
M<99[L"=VC6,E^.$^2@#\@/C1ING6W_!E!\++BVL(8Y)_'\LTSQQ &23_ (2C
M5DWL1U;8JKD\X '05^OW_! B>:Y_X(V_L]23R%V'P_A4%C_"LLJ@?@ !^%<-
MXD_X-ZOV8_%7_!.SP_\ \$O-5_:>^-1^%GAKQ)-K.GP1ZGH(OF>2>6X^SO<?
MV1\T*W$\\RC:'W2D%V141?IW]AS]C[P?^P7^S/X=_95^'7Q&\5>)O#OA2*2#
M0KOQE-927MO;,Y<6^^SM;='169BI9"_S8+$   'R9_P<LV7_  3>N?V!+&__
M ."DFJ^,ET73O&,%WX*TKX>ZA%!K&J:RMO.BP1>>CP^687F\QY5VHO((<H&_
M)W_@MAJ?[0.M?M:?L,^-?C=X:T'PJFHZ%HTW@_P3HMW<7UQX=TH:G:?9H+[4
M9GS?WFS89)4CB16^4!\&5_W1_P""I_\ P2=_9N_X*W?!K1?@_P#M"ZUXDT<>
M'-<_M30]<\*WD45U;2F,QR(1-%+&\;H>04R"JD$8.?G/XN?\&LO_  3U^*WA
M/X9Z'_PM#XPZ5J_PS"Q67C&'QPMWJVHVZM&T4,LMW!*D*0F(>2ELD,<6Y]J9
M;- 'QS_P<>_'[4_@I_P< _L<^-/BS>O!\-?!*>'M?$MP?]&MI3XCF_M&X&>
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MYI6:25MH7,CLS,3EB22: -+_ ()VJT?_  >+_'177!/_  DY /O%;$?I3?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OD#_@OQ_P H;/VA/^R?S?\ HZ*OK^OD#_@OQ_RAL_:$
M_P"R?S?^CHJ /XPJ*** /W^_X--O^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F
M?M=_]O'_ *?)Z_?Z@ KPG]MGQ!^PS^SS!X;_ &__ -M+5M,T'_A3AOQX5\7:
MA<71?3)-3A6TN(H;>W)-U)-&JH(_+D;@E0"":]VKXT_X*R_M+_LB_LK>-?@'
M\5OVW;PQ>"M)^(&H7U@6\/W&J)'K4>D74=G,;:WBE=FC6:X9&V'8^U\@J" #
MX+^/7BS_ (-._$&A7?[;_B'X37'QEUGXS?$+5;I=,\)66L2:TVH*D,^H;K S
MVWV:-#.DS%U0M]I#+Y@.:_2'_@D;X&_X)_\ AG]D.W\:?\$SK5;3X5>-]=N-
M=L--2:Y;[#>&*&TNH"MTS31.LEH=\;D[7+[?E*U\0?#G_@MC_P $(_ W_!1O
MXD?MCZ5XVN["]\6?#'PWH\?B:V^$NMK+=WL-]K#ZAE5L?,#M"=(#R, )%AA
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M]KO_ +>/_3Y/7[_5^ /_  :;?\I3/VN_^WC_ -/D]?O]0 5\Y_M_?MO?$/\
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M"VMVGB7PQ^R]\.M-U+3[E+BPU"P\$V$,]M,C!DDCD2(,CJP!# @@@$5Z+10
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MVM[236GWG\N7]GWO_/NU']GWO_/NU?T[?\*0^"W_ $2'PO\ ^""V_P#B*/\
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M""V_^(H_X4A\%O\ HD/A?_P06W_Q%'_$9<]_Z!Z?_DW_ ,D'_$%<A_Z"*O\
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M]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1110 4444 %%%% !1110
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MAY-.O(I'@NK5F &XQ3Q2H'P-X4,  P%?"7['_B7_ (*!?\$5?^"<_C/]G/\
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M3XJ^%+RU^-.I>*=2M/%7A:WN0^E3ZU (VC:VG4"5(7'F!A*"X.PJ/OU^@%%
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MMXKUJ/1K$VNFV5W?S"0V=C S,T5K!&L4,88DD1ER%+;1]#T4 %%%% !1110
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M]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ
M_P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%?B#_Q&\_LL_\ 1CWQ _\
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M%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\ "C_B-Y_99_Z,>^('_A16/^%
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;U;4-<M)(;5V=&WNJ#<1\O0>M 'X6T444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>jnj-20221002_g12.jpg
<TEXT>
begin 644 jnj-20221002_g12.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
M'_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_X
MA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;
M_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*
MF?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_
M $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)
M=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_
M ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*
MAKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y
M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M5^(/_![S_P FL_ __LH&H_\ I"* //\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\
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MAQ>> /%NK>$G\6:)\/\ 6_$>@C3;+3KK3-8CMH]4U-[4-(\8MDG411(0]Q/
M#M3<R@'[DT5^3_Q/_P""H_\ P4O_ ."2?_!('6/CY_P51\/^&/$'Q\UGXCW.
M@?#32;(V8M)[>6!9()[T::5C*1"&]D(CVLZ"WC=D>1F7B_VK?^"GW_!23_@F
M/^Q;^S1_P4@^+_Q[M/BQHWQ;DTT_$GX:ZGX/TW3;?3EU'3CJ44>E7-E#'/$\
M422Q;KE[@.ZJQ !*T ?LI17Y5_\ !P3_ ,%;OVF?V(?V1O@O^V?^P?\ $_21
MH?Q.NH(TLM>\-07D-S9W-@;ZVNT+8>-RF R[F4@K@*02W@/_  5 _P""K/\
MP6F_8$^!7[.G[>>H_'[X=2Z#\4["VFU;X0Z;X!B>V@'V*"Z43ZC*S7$\DT<C
MF0P?9DA;"H) -Y /W2HK\0/^"P/_  5E_P""P'_!/&R^!7[;5E\8/ *>!_BP
M\EY+\$++P;%-%IEJD5M<QVUQJ\V;F[FDAG(DFA6U1)%.Q'7!K]KO"/B2R\9>
M$]+\7Z:C+;ZKIT%Y;J_W@DL:NH/OAA0!C_&_XU?#/]G+X0>)/CO\9/%-OHGA
M;PGH\^IZYJ=R?E@@B4LV .7<\*J#+.S*J@D@5X]_P4D_;ZD_X)\?L8:K^VW!
M\'I?&WAWP_\ 8)=;TVWUU;"[CMKNXAMHI8@\,BR$2W$6Y"4(4LP)Q@_E#_P>
MP>-_VC?"7@WX2>"[7XYO%\-/&-[J)NO .GZ2;?S;VP6U=;F[NO.8W8S<_)#L
MC2,QAB'?#+],?\%G?A_^T?\ #_\ X-W?C?:?M'_M&:9\1KVZTKPS-I%YIG@2
M/05L+;^V=*'D,B7,_G'.3YA*]<;: /M;_@F9^W=X>_X*5?L8^%/VR/"OP]O?
M"UCXIGU".'0]0ODN9;<VE]/:$F1%4-N,!88' 8#M7O5?S>?LW_M2?\%3_P!B
M'_@VV^''[87[+WQ^\%^"_!?A#QE?:?%X:;P;%JNH^(XKK7[Q9;FXN;O=':*E
MP_E+;Q1%V1&E-P"RQ+^GGCO_ (+B6'PA_P""%7A;_@K#X\^'UG/XF\3^&;.'
M3/"=K.\=K>>(9I'MS&K$EDMQ)#/.027$,3*"6P2 ?H/17XT_&O\ X+ _MG?L
M"_LY?LN?M_\ QY_:4T/XC^'_ (S75F?BU\,;3P[IMM!X;M=0M%OH7TJ2UC6[
M22V@WHZW<UP)73 ,><C]D[:YM[RWCN[299(I4#QR(V592,@@]P10 ^BBB@ H
MHHH **** "BBB@ K\0?^#WG_ )-9^!__ &4#4?\ TA%?M]7X@_\ ![S_ ,FL
M_ __ +*!J/\ Z0B@#S__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\
MV\?^GR>OW^H **** "BBB@ HHHH **** ,;Q]\1?A_\ "GPK<^.OBAXYT?PW
MHED%-YK&O:E%:6L&2%&^65E1<D@#)Y) K^;7_@V!^-'PK^''_!;;XR>.OB1X
M[TWPYHOC'P7XDMO#.JZ_=+96^H7$WB#3KF*&.28JID>&*1U7.2$.!FOZ8Z*
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M]OI&F6]K')*TLB6T*QAG;JQ"@9)[GJ: /YLK'4/AY_P1*_X.#OBUXB_X*1_
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M2=<F\1Z=J<&DZG=I;W$UE':3"2X2.0AGC0@[W (3(W$9&?/O^"#'Q1^&B?\
M!SI^U'X^O/&FEQ:-XZG\=P^!]6N+Q$M];FN?%ME<6Z6DC$+.TL"22($)+HI(
MR*_H=HH _+[_ (.P/V#/C/\ MI_\$[M,\4_ /PO?>(-?^%_BU=>N_#VFP--<
MWVFO;2P7)AC4%I)8R\4NT9)1)< G /Q-_P %<?C!X1_X*3?\$EOV*?V'_P!B
MC6K/XA?%74Y=!DU+P)X9NDN=0T22PT)]/NA?Q(2;%8KBX*L\^Q0(W?.U"P_H
M:JO:Z1I-C=SZA9:7;PSW+ W,\4"J\I'0L0,M^- 'X&?\'47PRT;]G/\ X)2_
MLH?L16_BNTU;Q/X"&F6$UE9R;[BXM;#1#8O>^5]]8FE4 ,0!DXZ@@<+_ ,')
M?Q6^&_Q2_P""1O[%'AKX;>-],U[4O^$:L[R33](O$N)X8(M'@M97DC0EHPMP
MDD+;@,212(?F1@/Z-:* /YRO^#HKXN?#'XO?\$]?V,M"^%GCK2_$5]_PC#ZA
M)9Z)>)=2PVPT^SMC)(L9)C'GQ30_-C]Y!*GWHW _?/\ 9,\:^$?B+^S!\/O&
MG@3Q+8ZOI-]X.TYK34-.N5FAEVVZ*P#*2,JRLI'4,I!P017H5% 'X??\'M?P
M>^)?C#]GGX)?%OPMX,U#4/#_ (1\1:U;^)-2L[9I(].-Y#9_9VF*@^6CFVE4
M.<+NVKG+*#[)_P %K/VQO@9^TG_P;K?$3Q7\,M;OCIOB.P\-:9X0NM8TR6P;
MQ)<)J.EW,PL(;@)-<K&BR[W5-N;>8@LL;,/U=HH _FJ\4?%#X>/_ ,&:_AOX
M-Q^,M.;Q:OQ(ELF\,K=*;]9QXDN+XH8,^8"+5TFZ?<=3T(KU_P ;_LO>.?V^
MO^#0[X8>!?V;8&\3^+?A9JBZYJGA71V\Z^:2TN]1CN;0PKEQ.MM??:%B(WNJ
MIL#%T#?OM10!^'O_  16_P""E?\ P33^-'['/@+]DOQ#^Q%HOB;]I/PMH</A
MJ/P-'\(TN)/$$EJH@AOY]2%H\%I#Y:QM=3W3HT3+,VV3"[_V^M(5M[2*W2WC
MA6.-5$,/W$ &-J\#@=!P/I4=KI&DV-Y/J%EI=O#<71!N9XH%5YB.A9@,MCWJ
MQ0 4444 %%%% !1110 4444 %?B#_P 'O/\ R:S\#_\ LH&H_P#I"*_;ZOQ!
M_P"#WG_DUGX'_P#90-1_](10!Y__ ,&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM
M_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444 %%%% !117SQ^WG_P5$_9
M*_X)TQ>&=,^/OB75KSQ-XWU!;+P7X%\(Z/)J6MZY.72,+;VT>.-[H@9V569@
MJDL0* /9&^,7PC37_P#A%'^*?AP:I]K^R_V:=<M_M'G[MGE>7OW;]WR[<9SQ
MBI/&'Q6^%WP]UG1?#OC[XDZ!H>H>([S[)X>L-8UB"VFU2XX_<VR2,&GD^9?E
M0$\CCFOYS_\ @J_\;/A#\??^#E']DCQ[\+O 6L^%[[^W_ %OXS\/^)_"DNC:
MM9:J/%MPY6]MY55C*;>2V<2@NKQ-$5=EQ7VC_P %\-!_X)3?$_\ X* ? K2_
MV\/C)\6_ OC+PS<VS>%K3PQX<>;3?$EK+>Q.J)<!'$++<+Y;R*5=02".(W !
M^OU%>!?M-_\ !1OX"_LQ?&_PG^S#J&A^*_&?Q-\::=/J6A_#_P  Z(+_ %(Z
M="'\V]E#R1Q00 QR -)(I<HP0,5(&3X9_P""JG[+_B_]FWXE?M5:#I/CI_"_
MPA\07>C_ !"M[KP/>6VI:/<V=C;WM[YEC.J3A+>.Y42-LX,<A7<@#D ^DZ*^
M +'_ (.5_P#@F=XG^!6K_M _"^X^)GC31O#M])#XEMO"?PTOKJXT6W2.)S?7
MN56.SM3YRJDTTB"1TD5-QB?;]8?LF?MD_LX_MO\ P#TW]IC]FOXDVFO^$-26
M0?;]C0/:2Q_ZV"XCD >"5/XE<#@AAE65B >GT5\4W_\ P7Q_8,C\*>)_C#X<
MA\?^(?A5X*\2IH/BWXS>'?!4UWX9TR^9HTVF=6\^= TT0,L$,D?[V,[B)$+>
MW_M ?\%!?V1?V:/V2S^W!\3?C)IO_"M9K"VNM*\0:0QO5U87./LR6BQ9,[RY
M&T+T&YF*JK, #V>BOGCX.?\ !2GX._%CX]Z'^R]K7PI^)W@3Q]XA\/W>N:7X
M=^('@B73S-IUMY7F3K<!GMWYF13&DK2H<B1$XSF?&;_@J]^S/\+/&GC[X;^"
MO#GCCXH>(/A3IL=]\3-*^%OAAM3;PU"Z2.@NI6>*$2E8I6\A)'F B?*#% 'T
MCJ^L:1X?TR;6M>U2VL;.V3?<7=Y.L442_P!YF8@*/<FL_P *?$7X?>.WG3P/
MXZT;66M@IN1I6IQ7!B#9V[O+8[<X.,]<'TKRC]BK]NG]D7_@I_\ L^R_&+]F
M[Q;;^*?"]S<2Z9KFEZKIQCGL[@(IDM+NVE'RDHZG!W(ZL"I8'-?C9_P9,6T%
MG\7/VI+2UB"111>&DC11PJBXU< #\* /Z Z*1W2-2[L%51DDG  KXNUC_@O1
M^PE;:+XS^)/A"W\?>+OAM\.M=31_'?Q;\(^#);[PYHUVS(I5IU82W*J9(RTE
MM%,@61&W;74D ^TJX;5/VG?V:]#^)4/P8UO]H;P-9^,+B58K?PG=>+;./4Y7
M;&U5M6D$K,<C "Y.17A7_!1O]OSPQ\)/^"7/C7]KW]G/5]<\51Z[\/-5F^'_
M (J^'WA^XUF"SNGTJ[GM=2N&MD<6MG$\(,ES-MBB;:KE2<5^1/\ P;M?L4_L
MM?\ !5S]A*]^!W[6/AKXJW&M>$OCYJGC^'QKHMK>6EA?S-8Z3 ]I/K#0O%+<
MNQ,C0+(MR$_>JR@EB ?T2454U[7=$\+:'>^)O$VL6NGZ;IUI)=:A?WLZQ0VT
M$:EY)9'8A415!8L2  "37Q9\4?\ @X _84^%/PMT?]HW5_#_ ,3M0^$.NZ\^
MCZ?\8=*\ 3R>'Y+E)9(F(=V6X>,20S*)$@97,;!"W&0#[>HKQC]H'_@H-^R/
M^S-^R4O[<'Q0^+]BOPVNM.M+S1]=TQ6N_P"UUNPIM4M(XP6G>4,"J@<#+,55
M688'P;_X*3_!WXL_'S1?V7-9^%7Q.\">/]?\/7>NZ;X<^('@B73S+IUN8@\Z
MW 9[>3YIE4QI*TB$$2(G&0#Z&HKY)\2_\%HOV0=#\6_$;2=!\/\ Q%\4^'?A
M!J$EA\4/B!X.\"W.IZ)X<NXU+30320;II3$%8RM!#*D0!+LH!->H?%+]O[]E
M;X&?L?Z=^W/\:OB7#X6^'FJ^'[#5K'4-4A;[1-'>PK-;P1P1;WEN'5QB*,,W
M#'HI( /9J*^=/@9_P4[_ &>/C/\ M"P?LG:YX?\ &7P\^).I>&(_$?A[P=\2
M/#XTV[UO26W_ .E6A621)-OEOOA++.GER;HQY;[?SR_: _X.'+[7O^"X?PR_
M9*\#_#'XGV'PS^&^H:U-XYT_3? >IRZ]XLOWT"^6VV:4D7VIK*+SHYU#1_/D
M7!4)%&U '[,45\S?$[_@JS^SG\-_&/P[^$MGX*^(?B3XA?$[PO\ \)'X>^&7
MA_P=)_;]MI00NUU>VURT(L57:Z%)F5R\;HJLRD#T']D7]L_X+?ML^%O$_B[X
M*#Q!'!X/\83^%O$-IXF\.7.E7=GJL%M:W$]N]M=(DJ-&+I(VW*/G5]NY=K,
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M"TA*QXW ,00#XD_X(M:U\0]5_P"#3/\ :<LO&LMPVFZ=X>^(]MX1$^=JZ<=
M25Q'G^'[9+>].-Q;WKVG_@RY_P"44WC#_LNNK?\ IIT>OO;Q;_P3B^ NH?L&
M3?\ !.+X4ZKKWPU^&MQX8G\/3P>"'L_M<FFW$<D=S"9;^VN06G\Z1I)MOFL[
M%MX))/-_\$OO^"4?P:_X)-?#76O@W^SO\9_B+KOA;6]:EUB;1?'%YI=REO?R
M100O/%):V%O*"8[:)=C.R<$A0Q)H ]3_ &UM/^ .K_L@?$[2/VJ]=.F?#6\\
M":I!XZU!;EX6@TI[61;EE>,%P_EEMH4%BV  Q.#_ #O_ +56I>&M=_X-UO%-
ME^Q)X/U/PW^S-H'QFMK?PY>_$K4O[3\7>+]2:Y!FO&^S^5:Z5:1DA%A6.5Y6
M1F)B^8R?T;?M,?L\?#7]K3X >+OV:OC#8W-QX9\:Z%/I6L)97'DSK%*N-\;X
M.V13AU)! 91D$9!^ /!/_!J1_P $Z/"?[*_BC]EG5?B1\6]=LO$=]'?6>LZM
MXQ0OH5VCHPN+*TC@6R25EC6-Y9())&C+('56P #QH?\ !/B3_@I]_P &P_[.
M/[,V@_%+3/#?C4VEEJOPZ&MW)CMM6U:UM]3/V"0@%L/9M>,"H;88@Y!"$5YQ
M_P $,_\ @H_^VC\/?^"AG@__ ()(?\%8_A'J-]X\\,66IVWPO\9>(4/]M:+B
MPDFEMI;A6*ZA97%M;-Y<^7RT<7SR+L,7Z+^%O^")WP.\%?L4^ OV(?"W[1_Q
MALM)^'GC6V\4^'O&$7BZ-M;L[ZW2985MI'@:"UA1ILB&.$(0"&#%W9NG^#__
M  2U\&^%OVT[;_@H/^T!\=/%'Q9^*FC>$!X8\):UXDTW3;"#0M-S,7\FWT^V
MA1KB3[3<!YGS\L[JJH#B@#\2_P!J'X5_\%)?^#>G]J/Q;^WC^QCXI@^(_P"S
M9\3/$]Q=ZN2#?Z/=PSW4G_$NUB '-O/&\CP1WBX#$[=P9Y(*V?\ @XV_:JT'
MXK?L;?\ !/[XK?!+PC<>%?A+J6BW6L6'A>Z1[N#39K*/2H(;24;E-Q]FB,\2
M$LID5I""-QQ^KGB[_@B)HGB;X+>-/V7;/]NCXO67PJ^(_B6^UCQEX$9='N8=
MUWJ#W\]O87$UBT^GPO(V&1'8<%@%9Y&;T;]K;_@D#^Q%^V+^Q1H'[!GQ"^'U
MQI7@KP=9VD/@>X\/70AO_#S6T/D12V\TBR!F\LLK^:KB3<2X9L, #P?XI_\
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M_P"GR>OW^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J "BBB@ HHHH **** "BBB@
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M/]H?Z/\ 9MG^J^;9C]]0!]X4444 %%%% !1110 4444 %%%% !1110 4444
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M^3U^_P!7X _\&FW_ "E,_:[_ .WC_P!/D]?O]0 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\0?\
M@]Y_Y-9^!_\ V4#4?_2$5^WU?B#_ ,'O/_)K/P/_ .R@:C_Z0B@#S_\ X--O
M^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=Q\1- @N-3:7Q[=ZDMY+XBU)]1N7U+4'G3Y)6FOVNI"R?(2WR97% 'L5%%%
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M]YC[_P ^Z@#U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME))NR[DS;C!M*[['6?\ #S_]@'_HZ?PO_P!_Y/\ XBC_ (>?_L _]'3^%_\
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M-IG[1?\ #S_]@'_HZ?PO_P!_Y/\ XBC_ (>?_L _]'3^%_\ O_)_\17XN_\
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M#'U,CQ,<#?VSA+DL[/FMI9Z6=S\N?^&A_CK_ -%@\3?^#ZX_^+H_X:'^.O\
MT6#Q-_X/KC_XNO5?^'4G_!0/_HU_Q-_X#I_\71_PZD_X*!_]&O\ B;_P'3_X
MNOWW^TO"+^6C_P""W_\ (G\^?V;XQ?S5O_!B_P#DCRK_ (:'^.O_ $6#Q-_X
M/KC_ .+H_P"&A_CK_P!%@\3?^#ZX_P#BZ]5_X=2?\% _^C7_ !-_X#I_\71_
MPZD_X*!_]&O^)O\ P'3_ .+H_M+PB_EH_P#@M_\ R(?V;XQ?S5O_  8O_DCR
MK_AH?XZ_]%@\3?\ @^N/_BZ/^&A_CK_T6#Q-_P"#ZX_^+KU7_AU)_P % _\
MHU_Q-_X#I_\ %T?\.I/^"@?_ $:_XF_\!T_^+H_M+PB_EH_^"W_\B']F^,7\
MU;_P8O\ Y(\J_P"&A_CK_P!%@\3?^#ZX_P#BZ/\ AH?XZ_\ 18/$W_@^N/\
MXNO5?^'4G_!0/_HU_P 3?^ Z?_%T?\.I/^"@?_1K_B;_ ,!T_P#BZ/[2\(OY
M:/\ X+?_ ,B']F^,7\U;_P &+_Y(\J_X:'^.O_18/$W_ (/KC_XNC_AH?XZ_
M]%@\3?\ @^N/_BZ]5_X=2?\ !0/_ *-?\3?^ Z?_ !='_#J3_@H'_P!&O^)O
M_ =/_BZ/[2\(OY:/_@M__(A_9OC%_-6_\&+_ .2/*O\ AH?XZ_\ 18/$W_@^
MN/\ XNC_ (:'^.O_ $6#Q-_X/KC_ .+KU7_AU)_P4#_Z-?\ $W_@.G_Q='_#
MJ3_@H'_T:_XF_P# =/\ XNC^TO"+^6C_ ."W_P#(A_9OC%_-6_\ !B_^2/*O
M^&A_CK_T6#Q-_P"#ZX_^+H_X:'^.O_18/$W_ (/KC_XNO5?^'4G_  4#_P"C
M7_$W_@.G_P 71_PZD_X*!_\ 1K_B;_P'3_XNC^TO"+^6C_X+?_R(?V;XQ?S5
MO_!B_P#DCRK_ (:'^.O_ $6#Q-_X/KC_ .+KWO\ X)@_&CXN>)OV\OAGH^O_
M !-U^\M)O$D:S6USK,[QR#8_#*SD$>QKF?\ AU)_P4#_ .C7_$W_ (#I_P#%
MU[5_P3M_X)V_MH_"3]M'X>_$'X@_L]Z_IFC:9KZ3:AJ%S"@C@C"."S$,>,D5
M\]Q5CO#:KP_7AEJI>W:7+RP:=^97L^56TOU/HN$\#XFTN(<//,G5]@F^;FFF
MK<KM=<SOK;H?MG1117X8?O(5^(/_  >\_P#)K/P/_P"R@:C_ .D(K]OJ_$'_
M (/>?^36?@?_ -E U'_TA% 'G_\ P:;?\I3/VN_^WC_T^3U^_P!7X _\&FW_
M "E,_:[_ .WC_P!/D]?O]0 5\=?MF?M%GX7?MG^&-+^+&O>(] \$:'X!O=:T
MR&S^)>G>&]/\17HN8!<R7,MQ?6SSI91K#^YW;3]N=G5UVU]BUQGQP_9R_9]_
M::\*P^!OVC?@?X2\>:-;W:W5OI7C#P[;:E;Q3J"!*D=PCJK@$C< #AB.A(H
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M3Q/X+B\+^.O!OBS4/!_Q.\*P3F6+2]>L'5;A(G;YFA=7CD0GD"382Q0DT/\
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M1_\ 2$5^WU?B#_P>\_\ )K/P/_[*!J/_ *0B@#S_ /X--O\ E*9^UW_V\?\
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M_!+;P=_P5=^!?@'P#^T$UGX=UWP=X^T_7C>:!>2W0%HDP2_LHIVCAD"W-H6
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MVG?"NB06>28;:.![.*RC8GKB&&89/8-[T ?1?Q3_ &MOVDO^"?WQN^"WA_\
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MD;@2Q@X'OG[DHH ^6/V$/^"6W@G]D+XL^-?VK_BA\6M8^+'QR^)&U/&/Q/\
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M7X@_\1O/[+/_ $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\
MQ&\_LL_]&/?$#_PHK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]7X@_P#![S_R
M:S\#_P#LH&H_^D(H_P"(WG]EG_HQ[X@?^%%8_P"%? ?_  7T_P""^GPB_P""
KPGPB\ ?#?X;_  !\2>#I_!WB2ZU*YN=<U.WG2X26W$011$,@@C.30!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>jnj-20221002_g13.jpg
<TEXT>
begin 644 jnj-20221002_g13.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
M< &" P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ ^/?V'_V'_P!N3_@KK^W)\=_A1\*/V[O$'@C_ (0CQ!J%^[ZM
MX@U.6*6)]3FA6*-891MVX^F.*^P/^(3;_@J9_P!)=O\ RH:Y_P#'J/\ @TV_
MY2F?M=_]O'_I\GK]_J /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_T
MEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O
M_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH
M:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?
M_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZ
MOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_
MJ* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@
M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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MP7X_Y0V?M"?]D_F_]'14 ?QA4444 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^
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MQFU_X:OO$/PH?7;Z2XDBBMI-,\N"UGN"&:".6!D5HI/.D(< H7_I15510B*
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M"]GX<N+BZU60:Q(X:,JOEI"T4JS"XD=(!$&D,@12U?T-T4 ?A/\ L^_!A_\
M@E%_P=%_$OXR?M4:W:^%?AK\<M,\2ZCX(^(OB&Y6TT>XNM2NX-3DLWNY2(H9
MHY(IX?+=E8XC(!$J;K__  0X_9A\>?M(_P#!=W]H[_@JWX?TJY'P@'B3Q+8^
M!/%;PLEMXHGNKT1QRV;, )[=;>.21I%R 9(AU+;?W"U'3--U>S?3]6T^"ZMY
M/]9!<1!T;ZJP(-2Q11PQK##&J(BA411@*!T ':@!U%%% !1110 4444 %%%%
M !1110 4444 %?('_!?C_E#9^T)_V3^;_P!'15]?U\@?\%^/^4-G[0G_ &3^
M;_T=%0!_&%1110!^_P!_P:;?\I3/VN_^WC_T^3U^_P!7X _\&FW_ "E,_:[_
M .WC_P!/D]?O]0 4444 %%%% !1110 4444 %%%% !1110 5C>*OB+\/O CP
M1^-_'>C:,UR&-LNJZI%;F4+C<5\QANQD9QTR*^:/%7_!9/\ 9)\/_$/XB^"_
M#_AWXB>+=*^#]V;3XJ^-?!7@:XU32/"]RJLTL-P\&9I6B".9?L\4PBV-O*[3
MCX@_X.P_'?PW_:*_X(@?#;]I+P9I8GT_Q-XW\-ZYX7OK^S5+J&RO]+NYT'<Q
MEHW3<H.,CG.!0!^Q&EZKI>N:=!K&BZE;WEI<QB2VNK699(Y4/(964D,#ZBIZ
M_([]@W_@OA_P3N_8@_X)Y_LR?!GXX>+/%:M<?#G1]*U'Q3H_@^YNM$TJ]2UB
M\VWFO0 DDL09?-C@\YXLX=58$#])/VD?VQ_V:/V1_@3+^TK^T!\6]-T'P8H@
M^RZO\]Q]N><9@BM8X%>2YDD'*)$K,P!;& 2 #TVBOD.#_@M9^R/H/[67AG]B
M_P"./A/XB?"OQIXWBA?P4/B3X2^P6>N&60QQ)#.DL@1WD4QA91&=^$.'95.[
M_P %!_\ @KO^QU_P3!U+P]9_M=ZCXHT:V\513-H6J:;X6GOK6Y>$KYL7F0@[
M9%#HQ5@,AP1GG !]/T5\A^&_^"Y/_!.[QI^W9HG_  3M\$_%._UGXA:VLB(V
MFZ0\FG6EVELURUE-<YPMP(T;<JAE1P8W97!4;?QL_P""N7[*GP=^)GCCX1Z)
MIOC+X@:U\+=!_MKXJ1?#KPY_:47A"QVEO,O93)&@DV*[_9XC).%C<F/"F@#Z
M.\4^-?!O@>SCU'QKXMTS1[>67RXI]4OX[='?!.T-(P!. 3CK@&IO#WB7PYXN
MTM-<\*>(++4[*5F$=YI]VDT3D'! ="0<$$'G@BOSQ_X+N?%_X!_M??\ !O7\
M4_V@?@WXETGQAX3UGPYI>J>&-<@BWKN76+--ZAU#PRHWF1LK!71@Z, 0PKY(
M_P""('_!:;]B3_@FY_P1B^&>@_'W4/%NH72>)]:BUG_A#O"<^HPZ&;C5;IH!
M?7 VPV[R("Z0ES,R#>(RI4D _=*BN"\/_M1?L^^)OV<+;]KO2OBQI'_"M;KP
MP/$,?C"XN/)M$TWRO-,[M( 8P%SN5@&4@J0&!%?,^C_\%\/V#;OPGX7^,/BB
M'Q]X8^%GC?Q%)H?A#XQ^*/!<UGX:U2]1I%V"<L9H$8PRXEGABC_=2$L CE0#
MZZ\4_$SX;^!KJ*Q\;?$'0]'FFCWPPZKJT-NTBYQN42,"1GC(K5T_4+#5["#5
M=*OH;JUNH5EMKFWE#QRQL 5=6&0RD$$$<$&OQT_X/5-(\-:E_P $T?AKXUAT
MZRGOD^-MA;V>JI$K2"VET;5Y'1)!SY;M'$Q ."44]A7V;^RI^UK^S[^Q#_P1
M(^ ?[1?[3GQ&M?#'A31O@#X+6YOKA'D>:5]%M!'!#%&&>:5SPJ("3@G@ D '
MU-XG^*?PQ\$:@ND^,_B/H.D73PB5+;5-8@MY&C)(#A9&!*DJPSTR#Z5LV%_8
MZK8PZGIE[%<VUS$LMO<02!TE1AE75APRD$$$<$&OYYO^#H[]OK]F[]NC_@GO
M\*/&W@'X0^.?"VNWOQ#MM2\,W?Q$^'\VDW&M>'Y--OMUU87#!DN;4R-:LRI)
MD>; S(!(C']>_P!D?]H3X+_LJ_\ !'?X+?'S]H3XAZ?X6\(>'/@)X2N-7UK4
MG(CA4Z1:*JJJ@M)([,J)&@9W9E55)(% 'U'17S#\%O\ @K5^RY\7_C-X/^ F
ML:-XT\!>(_B1X=_M[X96_P 0_#9TZ/Q;I^TN9+)Q(XWA,/Y$WE3[2#Y>"*R_
MBY_P6G_88^ O[9VF?L%?&/Q)XC\._$+6;VV@TR#4_#,R6,\=PQ6*Y%W_ *H0
M':V9"P"[6W8*D  ^LJ*^.OV8?^"\?_!-7]KGQ=\4O#?PA^,]RUC\(?#TVO>*
MO$^JZ1+:Z9)I<+%9KRWF;YI(T; .54MN4H'!S5OX:_\ !:3]E?XE0_#W5T^'
M'Q7T/1/BWXCL]%^%OB?Q!\/;B#3/$UQ<S>7$T-PK.L"E0\H%UY#O&C-&KXQ0
M!]=4444 %%%% !1110 4444 %%%% !1110 5\@?\%^/^4-G[0G_9/YO_ $=%
M7U_7R!_P7X_Y0V?M"?\ 9/YO_1T5 '\85%%% '[_ '_!IM_RE,_:[_[>/_3Y
M/7[_ %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444 %%%% !1110 4
M444 %%%% '\V7[8OP?\ ^"E/_! ?]K_QQ_P4A_83\9Q>/_V??B/XQO;SQ&8\
MW^EDRWTPDTS6;=3NB>*X>:".\0@Y.W>CR/"??/\ @OA\=/A/^TG_ ,&Q_P $
M?C+\#/A^WA/PEJOB?PS%H?A4RF0:+%;V-_:_8E<\R)"T+1*^!N5%; S@?>7C
M3_@BGIGB;X8?$?\ 9]T3]NGXN:3\-?BYXJU?6_'/@94T:ZMP=1U"2]N;?3IK
MBQ>;3XW,A1E5V!P7P'=V;?\ VRO^"*'[*7[9O['?@3]@O6_&OCKP-\+OA[):
MOHOA[P#?:?"9VMH'@@:>:]LKF1RJR2DE67>\C,^]L$ 'Y _\%I]-T[3O^#7O
M]B*/3["&!3?:%(5AB"@O)H-_)(W'=G)9CW))/)K['_X*@1?\$X]2_P"#?S]G
M;6O^"EFL>-&TNR\%>$+WP;IGP^U**#6-6UD:"J^1'YZ/#Y9A>8R22KA%Y!#E
M%;W_ /:#_P"#>K]F/]IO]C;X8?L)_%7]I[XU3^ OA*^_PQ#9ZGH,5U*5B>&'
M[1*-(/F>3#(\:;0ORN2^]L,-[]K?_@A'^RU^VA^Q!\-OV'/C/\5OB'>:9\)D
MMH?!?C%+_3TUB&W@MQ:I!,8[)+>9/(6-"3 ')B1BQ;<6 /QL_P""U6I_M!ZS
M^V5^PUXT^./AS0?"W]HZ)H<WA'P5HEW<7T_AW2QJEM]GM[W49GSJ%YLVF25(
MXD#?*H?!E?Z9_P"#X7_DB/[/W_8U:]_Z36E?57Q<_P"#6;_@GM\5?#'PSTD?
M%#XPZ3K/PR"Q6/C&#QPMWJVHP(T;10RRW<$J0K"8QY*6R0QQ;GVI\V1ZO_P4
MB_X(9?LU?\%1?#W@'P;^T/\ 'CXNV.C?#BPDM] T[P]XBL&,LDB1I)=7-Q?V
M%U<W,[+#&"[RD<$XW,Q(!ZY^RQ^QO^S'\./A-\)/%OAWX!^#V\4>!?AW9:7X
M7\53>'K8ZG90O:*)ECNS&94\TO(TA#9<S2%LEVS^'O\ P:[7/[2/[2WB#]K'
MX+Z9^T9X1\'^,O&TEMJ/CNW\9_#J?7-0U=9VU&"[FC9-4L_*,,UR0^]9?GNT
MZ<@_T+?"'X>3?";X9:'\-)O'6L^)?[#TZ.RCUOQ"MJ+VZCC&U#+]D@@A+!0%
MRD2YQD@G)/P-\=/^#:K]EOQ[^V=>_MS_ +.W[2/Q9^!?C/6K^:\U]_A9KT-F
MEQ/.<W,L)>)GMVF)8R+N:)BQ/ECD$ \$_:L_X)R6G_!*_P#X-I_VE?V2;#]I
MK_A9\-CK4&I"\?1DL'T8W-YHSFP:%;F?;T%R,LI(NP=N"&/RQIVFZ=;?\&2M
M_=6]A#'+<?$!9IY$B :60>+8XP[$?>;8JKD\[5 Z 5^T/QV_X)3? CX[_L*W
M_P#P3[U#XG?$/0_!^NW$=QXMUW2];MKK7O$<XN$N9)KZ^U&UNFEEEGC21Y %
M<[%12L8\NO)%_P"#>G]F-/\ @G4W_!+I?VGOC5_PJM_$O]LM;_VGH/V[?Y_V
MG[/Y_P#9'^I^T 38V[]PQOV?)0!^:?[4GB7XFZ?_ ,&7/P;B\&7-U]AU#Q-;
MV?BUX6./[,&N:HR*Y'\'VJ*R7GC.T5U/_!2"UT2R_P"#._X#PPI%\R>%7@P!
MQ.S7+2$>_,F?J:_6/]GO_@E/^S5\"?V +C_@F=KNL>)OB+\*9[*\LETSQ_/9
M2W$5K<SO<O"LUE:VQ^6>1I8Y"#+&^TJXV(%\2F_X-ZO@CXH^!G@?]C;XN_M5
M?%#QA\"/AUXF.M^&?A;J;Z; KR;IFCMKN_M[2.ZN+:/[1<!8PZ,!(!N^1, '
MYI?\%A=:^(?B#_@T^_8[U7XHRW+ZL_C30$22[R9'LTT774LV)/)!M5@(/<$'
MO7._\'%GB'QU;?\ !%3_ ()T>%=/EG'AF]^%&FW6KHI/E&^A\.:.EH6[;A'/
M>[?8M[U^TG_!2?\ X(^?L[_\%0/@[X2_9[^,GQ+\=^$O _@N_AO=&\,?#J?2
MK*V%Q#;RVT#L;C3[AU$<$TD:QHR( W*D@$0_%[_@C/\ LL?M ?\ !.SP]_P3
M6^.7B?QAXK\(^#M/LK3P9XFU6ZL8]<T06<'V>T>&:VM(H2T4&8LO"V]&82;R
M<T ?GQ_P=SP>&#_P1O\ V?Y_"L-O_9Z?$'1%TIX%&U;4^'M0V!".BE0G3C@>
M@KQS_@XS\3>/M/\ ^""'[#'A?2)[A/#>I>%?#DNM^62(Y+J'PQ;_ &17QU^6
M2Z8 ]TSVK[N^(_\ P;&_ 'X\_LY>"?V:OVCOVW/CGXTTCX?7\/\ PB=U?:[9
M(^D:9%;R0C3K:+[*T2(P:(M+(DLN+:)$9$7:?I/XC_\ !(_]D_XR?\$^=._X
M)K_&&7Q1XI\ Z'I]K:>'-1UG6$DUC2/LJ>7:2V]RL2A)(4_=H2C*4+1LKHS*
M0#Y;^*W_  3)^)O_  4GM_V8?V^/B%_P4=\$:/H_PF&G^+/ -YX,^$+Z;#-!
M=/IURD4\\^N3C'^B0QK@+@NX*MD ?$__  7%^&_A;XP?\'47[.?PR\<Z;'>Z
M+K5MX*MM7L)EW1W=J=7O/-@<'[R2(&1AW5B.]?I3_P $_?\ @@I\)?V#[[2K
M*3]KSXS_ !&\*>&-4&I>#_ASXQ\5C_A'-)O5D\U+O[! B1S3QR?O8RW[M)?W
MHC\P*ZZ'[2G_  0:_9W_ &HOV^="_P""C_CC]ICXQZ=\1/"U]I]QX831-0T)
M-/TM;*4S6\*0S:3(9(P[.3YKR,V\Y8\8 /2/VYOV /V3?B_^RU\:?!$GAOPA
M\--1^+?A==)\4_$?3- M;6ZDE#*ME+>3(J/<)',8_D=^5)7*YR/Q$_9!_:2_
MX*&?\$+OVL? 7_!,/_@IO\+CXS^">L^/=,F\&37+O<VVF7$6I0RVVKZ'>C#&
M.&Y\F:2S?! )!CB:5M_]"7[3_P"SAX5_:N_9H\7?LO\ Q#\0ZI!I/C/PY-H^
MJZII[QI>)'(FUI8SLV+)W!V;0?X<<5\\ZE_P1Q\'?$SXH_"KQK^U+^U=\2/B
M[HGP2U3^U/AQX9\:QZ4!%?#R_*N+^ZM;.&?46C\J,KYK#<4!D\TE]P!]DT44
M4 %%%% !1110 4444 %%%% !1110 5\@?\%^/^4-G[0G_9/YO_1T5?7]?('_
M  7X_P"4-G[0G_9/YO\ T=%0!_&%1110!^_W_!IM_P I3/VN_P#MX_\ 3Y/7
M[_5^ /\ P:;?\I3/VN_^WC_T^3U^_P!0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %?('_!?C_E#9^T)_V3^;_T=%7U_7R!
M_P %^/\ E#9^T)_V3^;_ -'14 ?QA4444 ?O]_P:;?\ *4S]KO\ [>/_ $^3
MU^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\ 4 %%%% !1110 4444 %%%% !1110
M 4444 %%%?G_ /\ !97]J:V_9]_:7_9>\%_M">+M7\,?LZ^-O%NMV7Q6\0Z9
MJ4]C VH)91G1K._NH&22*RDG>:25-X218#YN8HW5@#] **^'/@'?W?A+_@KG
MJGP>_8_UJZO/@O9_!I+[XHZ9;:K->Z'HOB:6[C?3!9L[NEM>363222P0E4>'
MR973<R,WVEXO/BM?">J-X$CL'UP:=/\ V,FJ.ZVS7?EMY(F* L(]^W<5!(7.
M 30!HT5^5O[2W_!&GPW^S/\ LP^./VI?CO\ \%E_VV;ZY\'>$K_Q!XBFT3XV
M)IMG>7$,+S-';6QM)?LZR2 )'%O?;O503Q7VK_P2V^#OQ9^ W_!/CX3_  W^
M/?CWQ%XE\<0^$8+WQ?JWBO6)[^_;4;LFZN(9)YV:1Q"\S0KD\)$H  &* /?:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BO/_BS^U/\ L_? _P 267@K
MXF?$^PL-=U*S>\L?#\"27>HS6J-M>Y%K;J\WDJWRF79L#$ MDXKH?AE\4_AK
M\:?!-E\2?A'X\TGQ+H&HJQL=8T2_CN;>;:Q1P'0D;E965EZJRE2 010!OT51
M\3^*/#/@CPY?>,?&?B*QTC2-+M)+K4]5U2[2WMK2!%+/++*Y"QHJ@DLQ  !)
M->/_ +-W_!2?]@?]K_QG>_#K]F7]K;P-XTU_3XFEN-&T378Y+DQ*<-*D9(:6
M,$C,B!E&1D\C(![=1110 4444 %%%% !1110 5\@?\%^/^4-G[0G_9/YO_1T
M5?7]?('_  7X_P"4-G[0G_9/YO\ T=%0!_&%1110!^_W_!IM_P I3/VN_P#M
MX_\ 3Y/7[_5^ /\ P:;?\I3/VN_^WC_T^3U^_P!0 4444 %%%% !1110 444
M4 %%%% !1110 5\1?\%3?$VA?M&?M _!K_@D1XK\+6,WAGX[QZUJGC_5M1LH
MYGBT71X$N6M+$2 K'=W$S1)]H7]Y;1J\D>V4QNGV[7E_[2?[(GP@_:BE\+Z]
MXZBU/3/$W@75VU3P+XT\-Z@;/5O#]V\9BE>WFPRE)8R8Y8)5DAE7 DC? P ?
M ?\ P3T^%'Q]_P""-7_!2/1?^"5EMXUNO&_[.WQ?T#7?$OP;NM453J7A.^L=
MD]]8S2*!YD)65/FQM9YHF4(QF5OU,KR_X;?LI^"_ _Q5D^/?BWQAXA\<^/&T
M5M'M?%OB^:V,]AIS2+*]K:P6<%O:VR/(D;2-%"LDICC\QW\M-N3^SG^PG\$O
MV7OCO\7OVB?AK?>))=?^-FO6FK>,8]8UU[JUCGMXY$C%K$P'DKB5\C+'&U00
MB(B@'E'_  5+3_A>GC;X$_\ !/FT'FP?%?XF0ZUXWMS]UO"OAW9JMZCXY"S7
M2:;:GL1=$5]>UYX?V9_A_+^U8/VPKR^U2X\4P^ /^$0L+:>XC-E8V#7OVR9X
M8P@=9II%@$CER"MM$ J[26]#H **** "BBB@ HHHH **** "BBB@ HHHH **
M** /RK^/G[9%[_P1B_X*\_%/]H7]MCPEJMS\"_VDM-\/0>$_BGI5@]Y_PBVH
MZ3I[PMI%S'&"ZQR$SSJ$!Y?>%?\ ?M']0_\ !)?X(?$#P-X+^*?[1GCK['IL
M/Q]^*]_\0O#_ (1TW5(;R#1--NX(([</-;L\$ES/'"MQ,T+O'OE 5WVEF\G^
M'7@SP/\ M9?\%7/VI_V??^"@/@[2_$$%KX/\/Z;\'_!7BF$/:3>$+FV:34;W
M3XWP)));]$%Q<1_O(GM[=-R^6@JA_P $1_ ]Q^Q'X=_:?^#D?Q8O-:_9P^%/
MQ(F?X3^*]8NS<165BM@+O5[6*;GS8+*=O)9D^4SQ7/&_>  ?;G[1/[./PY_:
MC\(Z;\-OC#IRZKX5M_$%MJ>M^&;J,/9ZZMN'>&UNXSQ+ +CR)S&<J[6R*X9"
MRGX!_P""K'[$/PAL/V_/V)O&?[(GPOT3P?\ %I?CC%)?WOA'2HK![CP;8P&Y
MUAKD0*HDBCC\J$;^/],,0/[[!^J_&?\ P5L_8&\'?L+V_P#P48;X\V-[\+=3
M25/#NK1026]QK5VDTL'V*VM[I8I#<&:&5-CJFW8SN4C5G'S+\!O^"OG_  2N
MTKQKJG[4OQ<_;/\ !WBWXR>+["'2-+\*^#?M.I2Z/8&7=:^'-*41*9G>=E::
M<[/M-PP=O+AB@CA /TKHI$8L@9D*DC)4XR/;BEH **** "BBB@ HHHH *^0/
M^"_'_*&S]H3_ +)_-_Z.BKZ_KY _X+\?\H;/VA/^R?S?^CHJ /XPJ*** /W^
M_P"#3;_E*9^UW_V\?^GR>OW^K\ ?^#3;_E*9^UW_ -O'_I\GK]_J "BBB@ H
MJOJNJZ7H6F7&M:WJ5O9V=I"TUU=W<RQQ0QJ,L[LQ 50 223@ 4S0?$&@^*M&
MMO$7A?6[34M/O(A):7]A<K-#.AZ,CH2K#W!Q0!;HHHH ***^.O\ @L3^VM\;
MOV*?ACX0\6?!&]TZ"ZUC6Y[:^.HZ>MP&C2$. H)&#GO6M"C5Q-:-&FKRDTDN
M[;LE]YE7KTL-0E6JNT8IMOLDKM_<?8M%?AM_P_W_ &^?^@WX9_\ ";C_ /BJ
M/^'^_P"WS_T&_#/_ (3<?_Q5?7_\0\XS_P"@1_\ @4/_ )(^._XB-P5_T&1_
M\!G_ /(G[DT5^&W_  _W_;Y_Z#?AG_PFX_\ XJC_ (?[_M\_]!OPS_X3<?\
M\51_Q#SC/_H$?_@4/_D@_P"(C<%?]!D?_ 9__(G[DT5^&W_#_?\ ;Y_Z#?AG
M_P )N/\ ^*H_X?[_ +?/_0;\,_\ A-Q__%4?\0\XS_Z!'_X%#_Y(/^(C<%?]
M!D?_  &?_P B?N317X;?\/\ ?]OG_H-^&?\ PFX__BJ/^'^_[?/_ $&_#/\
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M4%%%% !1110 4444 %%%% !1110 4Z'_ %J_[PIM.A_UJ_[PK#%?[K4_PO\
M(Z,)_O=/_$OS/Z*O^"8/_)@/PK_[%:/_ -&/7O%>#_\ !,'_ ),!^%?_ &*T
M?_HQZ]XK^&C^\ KY _X+\?\ *&S]H3_LG\W_ *.BKZ_KY _X+\?\H;/VA/\
MLG\W_HZ*@#^,*BBB@#]_O^#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7
M?_;Q_P"GR>OW^H *H7OA?P_J7B&P\57^EQRZAI<,\6GW+Y)@6;9YFT= 6$:C
M.,XR 0"<WZ* "LW0_#OAG1-2UC4=!L((;K5]26[UJ2)LM-<BV@@#OSPWD0P+
MV^5%/?)_)3QC\0?V2?B+^T7\88OVU/\ @X4^)GPS\6Z'\5M:TS3O!/P\^.EE
MX<TC2M'BG(L;=+80,6GCA(BN&<[_ +1%*", ._VG_P $D[']G^R^#'CEOV;/
MVS/%?QY\.S?$J>1_B#XR\5#7+V:Y_LK3!);F_556X2,!0I"@(#Y?/EY(!]54
M444 %?F__P '(/\ R0KX>?\ 8S7?_I,*_2"OS?\ ^#D'_DA7P\_[&:[_ /28
M5Z^0?\CW"?\ 7VG_ .E(\CB#_D0XO_KU4_\ 2&?CW1117]JG\/!1110 4444
M %%%% !1110 4444 %%%% !7[L_\$'O^4?>F?]C-J7_H:U^$U?NS_P $'O\
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M#=R"6>6) #,VQ4#L1]X[%1<GLH'0"@":BBB@ K\W_P#@Y!_Y(5\//^QFN_\
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M]H3_ +)_-_Z.BH _C"HHHH _?[_@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\
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M !%'_"D/@M_T2'PO_P"""V_^(KJ** .7_P"%(?!;_HD/A?\ \$%M_P#$4?\
M"D/@M_T2'PO_ .""V_\ B*ZBB@#E_P#A2'P6_P"B0^%__!!;?_$5N:#X<\/>
M%M/&D^&-"LM.M0Y86UA:I#&&/4[4 &35RB@ HHHH R?$?@'P)XPGCN?%W@K2
M-5DA0K#)J.FQ3LBDY(!=3@9]*S?^%(?!;_HD/A?_ ,$%M_\ $5U%% '+_P#"
MD/@M_P!$A\+_ /@@MO\ XBC_ (4A\%O^B0^%_P#P06W_ ,17444 <O\ \*0^
M"W_1(?"__@@MO_B*/^%(?!;_ *)#X7_\$%M_\17444 <O_PI#X+?]$A\+_\
M@@MO_B*/^%(?!;_HD/A?_P $%M_\17444 <O_P *0^"W_1(?"_\ X(+;_P"(
MH_X4A\%O^B0^%_\ P06W_P 17444 <O_ ,*0^"W_ $2'PO\ ^""V_P#B*/\
MA2'P6_Z)#X7_ /!!;?\ Q%=110!R_P#PI#X+?]$A\+_^""V_^(H_X4A\%O\
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MS]H3_LG\W_HZ*OK^OD#_ (+\?\H;/VA/^R?S?^CHJ /XPJ*** /W^_X--O\
ME*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "B
MBB@ HHHH I>)?$>B>#O#FH>+O$VHQV>FZ592WFH7<I^2"")"\CM[*JDGZ5\,
M_"G]J[_@H%^V7^PYJ/\ P4>_9C\4>$=!LKR#5-7^&7PEUOPFUW_;6DV4\T<<
M6HWJW"R1WEVMN[(;<+';^=$K+-M=F^UOBA\/]%^+/PS\1?"OQ))*NG>)M"N]
M*OV@;#B&XA>%RI/0[7./>OS-_8_\2_\ !0+_ ((J_P#!.?QG^SG^T?\ LMZ?
MXI\)?!32M<O_  ;\9K'Q_IEIHVI:07GO(X[NVDD?4(;@22M$D<=K*'+1Q@\;
MV /NW]@#]L[X>?\ !0C]C_P-^U]\,;&6RTWQCI1FFTRXE#R:=>12/!=6K, -
MQBGBE0/@;PH8 !@*^=/^"[O[;7[=?_!/7]GG0_VAOV-;'P7XBEN?$PTO4_"/
MBCPM<W4CP+I]_?S74,\%["04CL6S&4;()(.0%:I_P;+_  "\=?L]_P#!&OX5
MZ)\1=/FLM2\2#4/$B6-PI#06M]=R36O!Z;[<PRX[>;BO8?\ @HM86.J>+OV;
M=,U.SBN+:Y_:,L(KBWGC#I*C:#K@964\,""00>"#0!Z7^QI^U'X _;7_ &6/
M G[5?PQE!T;QQX=@U*&#S [6DS#;/:N1P9(9EEA;'\435\0_\%4_^"P?[1O[
M-O\ P4,^!G[!G[)&@^$G'CKQIHV@?$7Q=XLT6XOX='GU:ZCCM+>".&ZM\W"6
MZS7+HQ(V36W*;\GR[_@FI\=O"?\ P17_ &I?VG/^"7O[06NS6'PZ\':???%W
MX)W=RQ9IO#<J&2[L(-Q!EDC951(UYDFANR!S7"_MZ_!GQS\+_B=_P3U\=_&K
M3A;_ !)^*/[8UGXV^)$1;<;74[ZYTTIIX;NEE:):V">J6:GN: /VKT6WU6TT
MFWMM<U..]O$B N;J&V\E97[L$W-M'MD_6K5? G[6_P ;M1^//_!:GX2_\$OO
M%&KWMM\.X/A'J7Q%\8Z+:WDEO'XKN?M$UE96%T8RK2VL)AEN&@SY<K;!('5-
MM<%\3$U?_@FG_P %M/@7\$_V>[J^TSX-_M1^']>TSQ)\-+*\E&G:/K.F6XF&
MJZ=#NQ8.ZS6Z2+#L1E#N5+!2H!^G%9'Q \?>"_A5X&UCXF?$?Q-9Z+H&@:;-
MJ&M:OJ$PC@L[6)"\DKL>BJJDGZ5^4G_!.W]B[X?_ +57[7_[<GP(_:'^)OQ,
M\4^ _#OQBL[.P\+7_P 3M8 F1K65H_M%XMR+VY6%3MCBDG,0^\R.ZQLGG7P7
MTN?X[?\ !LA^TG\./CUKNI^,X?@SK?CS2?!E]KVIS2W$46E*TE@TKAP9S"TI
MV"3<J[(P /+3 !]E_P#!5?\ ;P_: \#?\$8+W_@H[^P_X[TWPI=77@C0_$^G
M#Q)X634+HV>IR60C5 \WDP3)'=[B9(KA25V[1]ZOLGX/:]JWBGX2>%O$^O7?
MGWVI>'+&ZO9_+5?,EDMT=VVJ !EB3@  =A7Y-?M>? [X6_"/_@THU#Q'\/?"
M_P#9][XL^ 'P^U#Q!-]MGE^U7);2&+XE=@GS2.<(%'/3@5+_ ,%*/V>-&_8\
M^$?[*O\ P4$^%'Q*\=?\+9_X7'X'T;7_ !/?^-+V2/5](O866XTU[+S1:0VI
M5$010PQJ%W9R7=F /V#HK\R/^"K/QTU7]D?]NJP^/G[;_P"R%K_Q;_98O?AM
M;:7;:OHFEC5;?X?ZZMY</=:A<V#':IFB>U7[8=KHL2K$Q;>C_6W_  2\D_9\
MF_8H\+W7[*_QP?XA^ ;S4];O_#/B2>^GN)_LMWJ]Y=I:3/<,9S+;"<6S>=B3
M,'S@'( !] T444 %%%% !5+Q+XCT3P=X<U#Q=XFU&.STW2K*6\U"[E/R001(
M7D=O954D_2KM87Q0^'^B_%GX9^(OA7XDDE73O$VA7>E7[0-AQ#<0O"Y4GH=K
MG'O0!\4_"G]J[_@H%^V7^PYJ/_!1[]F/Q1X1T&RO(-4U?X9?"76_";7?]M:3
M93S1QQ:C>K<+)'>7:V[LAMPL=OYT2LLVUV;Z1_8 _;.^'G_!0C]C_P #?M??
M#&QELM-\8Z49IM,N)0\FG7D4CP75JS #<8IXI4#X&\*&  8"OA+]C_Q+_P %
M O\ @BK_ ,$Y_&?[.?[1_P"RWI_BGPE\%-*UR_\ !OQFL?'^F6FC:EI!>>\C
MCN[:21]0AN!)*T21QVLH<M'&#QO;U?\ X-E_@%XZ_9[_ ."-?PKT3XBZ?-9:
MEXD&H>)$L;A2&@M;Z[DFM>#TWVYAEQV\W% %O_@N[^VU^W7_ ,$]?V>=#_:&
M_8UL?!?B*6Y\3#2]3\(^*/"US=2/ NGW]_-=0SP7L)!2.Q;,91L@D@Y 5OJ'
M]C3]J/P!^VO^RQX$_:K^&,H.C>./#L&I0P>8':TF8;9[5R.#)#,LL+8_BB:O
M-/\ @HM86.J>+OV;=,U.SBN+:Y_:,L(KBWGC#I*C:#K@964\,""00>"#7PW_
M ,$U/CMX3_X(K_M2_M.?\$O?V@M=FL/AUX.T^^^+OP3N[EBS3>&Y4,EW80;B
M#+)&RJB1KS)-#=D#F@#U'_@JG_P6#_:-_9M_X*&? S]@S]DC0?"3CQUXTT;0
M/B+XN\6:+<7\.CSZM=1QVEO!'#=6^;A+=9KET8D;)K;E-^3^D&BV^JVFDV]M
MKFIQWMXD0%S=0VWDK*_=@FYMH]LGZU^*G[>OP9\<_"_XG?\ !/7QW\:M.%O\
M2?BC^V-9^-OB1$6W&UU.^N=-*:>&[I96B6M@GJEFI[FOKK]K?XW:C\>?^"U/
MPE_X)?>*-7O;;X=P?"/4OB+XQT6UO)+>/Q7<_:)K*RL+HQE6EM83#+<-!GRY
M6V"0.J;: /ONBOS'^)B:O_P33_X+:? OX)_L]W5]IGP;_:C\/Z]IGB3X:65Y
M*-.T?6=,MQ,-5TZ'=BP=UFMTD6'8C*'<J6"E>%_X)V_L7?#_ /:J_:__ &Y/
M@1^T/\3?B9XI\!^'?C%9V=AX6O\ XG:P!,C6LK1_:+Q;D7MRL*G;'%).8A]Y
MD=UC9 #]6_B!X^\%_"KP-K'Q,^(_B:ST70- TV;4-:U?4)A'!9VL2%Y)78]%
M55)/TKXJ_P""J_[>'[0'@;_@C!>_\%'?V'_'>F^%+JZ\$:'XGTX>)/"R:A=&
MSU.2R$:H'F\F"9([O<3)%<*2NW:/O5\:?!?2Y_CM_P &R'[2?PX^/6NZGXSA
M^#.M^/-)\&7VO:G-+<11:4K26#2N'!G,+2G8)-RKLC  \M,=?^UY\#OA;\(_
M^#2C4/$?P]\+_P!GWOBSX ?#[4/$$WVV>7[5<EM(8OB5V"?-(YP@4<].!0!^
MLOP>U[5O%/PD\+>)]>N_/OM2\.6-U>S^6J^9+);H[MM4 #+$G   ["NCK\?/
M^"E'[/&C?L>?"/\ 95_X*"?"CXE>.O\ A;/_  N/P/HVO^)[_P :7LD>KZ1>
MPLMQIKV7FBTAM2J(@BAAC4+NSDN[-Z9_P59^.FJ_LC_MU6'Q\_;?_9"U_P"+
M?[+%[\-K;2[;5]$TL:K;_#_75O+A[K4+FP8[5,T3VJ_;#M=%B58F+;T< _3>
MBOG[_@EY)^SY-^Q1X7NOV5_C@_Q#\ WFIZW?^&?$D]]/<3_9;O5[R[2TF>X8
MSF6V$XMF\[$F8/G .0/H&@ HHHH *^0/^"_'_*&S]H3_ +)_-_Z.BKZ_KY _
MX+\?\H;/VA/^R?S?^CHJ /XPJ*** /W^_P"#3;_E*9^UW_V\?^GR>OW^K\ ?
M^#3;_E*9^UW_ -O'_I\GK]_J "BBB@ HHHH **** "BBB@!D[3K [6L:/*$)
MC21RJLV. 2 <#/?!^AKY?^/'[$?Q2_;WUO1_#?[;>N^'[#X4:'JL&IS_  A\
M%WMQ>P^*;V!P\#:OJ$\-NT]I&X$@L8[>-6D56EEE"J@^HZ* &6]O;V=O':6D
M"111($BBC4*J*!@  <  =J^>_P!M?X"_M/?';QY\*-6^"U]X&T_3/AM\2+/Q
M?>MXEO;PSZL8K2\M6LE6& K;*4O&83%I3N5?W> =WT/10!\E?ML_\$G_ (2?
MMX_M-?L^?M5_%>.VL-<^#>O27VL:;:9GBUJU,1FCL&E*H9(HK^."0;T >)KA
M2B^;QR/_  5$_P""=G[5O[='[1'P&^*_PK\=> /#6E? 7XCVWC'3H->:]N;C
M7KF*6UE$,HBB5;6/,#I\K2E@X;*D;:^XZ* /CO\ ;9_X)S_%3]H'X^?"+_@H
M%^S_ ..?#W@3X]_"5)K2--3\_4-"\0:1<!UN-(NY$2*81XEF,<Z1[D,TA\LD
MJR=+X3_8T^+7Q5_;$\+?MW_M=S^$E\2_#?PGJ&C?#'P1X.O;FZT[1Y]0"K?Z
MC+?7,$,MQ/-&B0*JV\:11A^)6<,OT_10!\8_L*_L.?M9_LD?M'?M%?'SQ3K'
MP\\01_'3Q>GB2STBPU2^M3HMQ%'+'';/*UJ_VA"CH&E"1D%"P0[MJ\;^R1_P
M2.^.'PL_X)]_'[]@?XZ?%7PI>6OQIU+Q3J5IXJ\+6]R'TJ?6H!&T;6TZ@2I"
MX\P,)07!V%1]^OT HH _.?XB_P#!+/\ X* _%S_@CU/_ ,$POB+^T/\ #"ZO
M9?"N@^%-.U[3M O;6TTK2-)DMVBE*,9);V\G2WC21RT$*!%*1$[V?KOV^O\
M@G=^U]^VI^R1\(?V=-+\7?#CPWJOPY\8:!XCU76Y[N_NX+^XTE'2.**$01M&
MDI979F=BG* /_K*^ZJ* /F_7/AQ^W_X>_:*U_P"+?@6;X8>(_!OBWPAI=CJG
MPU\4>(-0LQIVJ6XN!-=6U_%8W DBE29$>)[4%Q AW1_,&L_\$R?V"M%_X)W_
M +.M]\'=-UFQO+SQ!XUU;Q7K4>C6)M=-LKN_F$AL[&!F9HK6"-8H8PQ)(C+D
M*6VCZ'HH **** "BBB@ ID[3K [6L:/*$)C21RJLV. 2 <#/?!^AI]% 'RY\
M>/V(_BE^WOK>C^&_VV]=\/V'PHT/58-3G^$/@N]N+V'Q3>P.'@;5]0GAMVGM
M(W D%C';QJTBJTLLH54'U!;V]O9V\=I:0)%%$@2**-0JHH&  !P !VI]% 'S
MQ^VO\!?VGOCMX\^%&K?!:^\#:?IGPV^)%GXOO6\2WMX9]6,5I>6K62K# 5ME
M*7C,)BTIW*O[O .[D?VV?^"3_P )/V\?VFOV?/VJ_BO';6&N?!O7I+[6--M,
MSQ:U:F(S1V#2E4,D45_'!(-Z /$UPI1?-X^M:* /AS_@J)_P3L_:M_;H_:(^
M WQ7^%?CKP!X:TKX"_$>V\8Z=!KS7MS<:]<Q2VLHAE$42K:QY@=/E:4L'#94
MC;6_^VS_ ,$Y_BI^T#\?/A%_P4"_9_\ '/A[P)\>_A*DUI&FI^?J&A>(-(N
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MCJ-R=8.H6WG?-;?\)"GD",\<2/NZ_+7Z35^8/_!+_P#Y6$O^"@7_ %Q\%_\
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M'\0V=C\1?"OPYT>_M+_PM;W4JQ)-:7%RV;D+(RQ[I =[LBE$#[X_K+_@H/\
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M>G /J&D7<"2/$_[AXYX9DV'!,3*[;9&^>_V[[*_A_P"#FO\ 8?U'7E9=&E\
M^-(M(,@_=F^72M0,H';=L>W_ !V>U._X+9KJ=_\ \%8/^"<>C>&0S:H?BSK]
MR1%]\644>EM='CG;Y6[/; - 'J_[2'B+_@N!\;=>\4>-?V#+_P"#O@/PCX9U
M*\L/"VB_$?2KR[U?QE+9RO#-<2.A$-A:RRQNMOC+O'ME9T610OH'_!'_ /X*
M%ZW_ ,%+/V-[7XZ^.OAJ/"'C'1?$=]X8\>>'868P6FL6103>27);RV62-PK$
ME"S(6?9O;UK]J7]H$_L^_#4ZIX;\,OXD\9ZY.=+^'W@VVD"S:_K#HS0VX/\
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M32K:&:Z6%C;0W$YBCDDP=JLX5BBDX!8*Q YP>E344 ?"W[&?_!.[]KS]F_\
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MLI*.N=FUG>!/V*/B)\1_VW-&_;]_:[U#PTWB3P/X3NO#_P ,?!GA&>XNM/\
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M  HK'_"@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_T8]\0/_"BL?\*
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M  HK'_"@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_T8]\0/_"BL?\*
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::AKEI)#:NSHV]U0;B/EZ#UH _"VBBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>jnj-20221002_g2.jpg
<TEXT>
begin 644 jnj-20221002_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC>"OBW\&]<;3O'/@U]5%];O$7*Q7]A=^7$;JU? ^9H8I$+*'C3>A;XL_:_\
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MZ^4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^*G_!
MT;_P3/\ ^"BW_!3OXL?"NW_8^_9"U;7]+\ :9K$.IZ[?>,?#]A!=27<MH4$"
M7&HI,0!;,27C3[ZXSSC]JZ* ./\ AS:_\)M8Z#\4_&OPBU'PMXFLM&GL([#7
M+FSFN["&X:VDN(2]E<3P,'>U@)*R-_J1T[_EG_P4Q_8%_;]^.G_!P-\!OV]O
M@[^R#K>O?#+X5Z7H.GZ]K47B[P];RW1M]4U"ZGEM[>YU&.5D6.]0 .J,S(X
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MCQ?\4?$-]J6K^+M,\+ZA8+)=WD@:&UACGO+B"'RTMXH!\T@ =Y& ^8U^@%%
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MZ!+KB17ETIU/69+H:O+//?.CRRM.JO-NQY8!5 /W<HH **** "BBB@ HHHH
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MV"/"VAZ_\,O%NJW.NZ5IWQ$L9]<\1W&HL))-9O3(R6T1_=QQL/M4\QR&(B1
MB_T@44 ?CK_P<5?L&?\ !2'_ (*/^(OV9O$G[/7[%MYJ-S\.I=3U?QK!%X^T
M*."REO)-+=+**6[O+=[B5!92AW$8CR5V.X)(E_X+!?\ !.W_ (*%:5_P4O\
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M-ZUJWB:S\7:#:+J-O'K,>IO]DAO-0AF?$  !=$!8X!(^:K/QN_8&_;^\5_\
M!S-X%_X*3^&_V/\ 7+KX2>&;&#3+[71XN\/).X.D7=F]REL^I"8QI)=*2"HD
M*HQ"$[0?UTT71=)\-Z-:>'M TZ&SL;"UCMK*TMT"QP0HH5$4#@*%  '8"K-
M'Y"?L9?L"?M^_#;_ (./OBO_ ,%#?B'^R)K6D?"GQY8:EIFE:_+XN\/S2P!T
MLEBN)K:'47F$;_9&.%1G'F+E1\V. _9/_8N_X*L?\$0/^"F7Q?U_]F?]BVX^
M.WP.^,VIFZM/[!\76&FW%B1<S3V?FM=./*DMQ=3PN741RJX=7!7:/VZHH _,
M/_@OA^R%_P %%/\ @H!_P2[\/_ ;X>?L]6OB;XEZS\0+77M:T7PYXGTVVT[P
MY9PI<;+5KK4;FV-VZ+-%&98TQ+(DK[(D*)7S#_P5D_X):_\ !3G]K?\ 87_8
M@^!?P7_8EUF[\1_!#X?06/Q"MKWQQX:MX[2\ALM,L_)CD;4\3[C82RADRHCD
MBR0Y=$_=JB@#\G_^#E7_ ()P?MF_\% _#?[._P >/V3_ (+RZ_K/PL\07]YK
M_@*\UNQM-0$5\=-E&)'G-LQB>P,;A)7YE#)O4,1^FWP8\3_$_P 9_#ZS\5?%
M[X9Q^#=9OBTK^%_[6BOI=.B)Q''//#^Z>;: SB(M&K,45Y OF-U5% !1110
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M?$OB73YM;UJ6S@MVNGCUR\A0F.!$C7$<:+\JC[N>I)KA_P#@N#_RJQ?L5?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRZ[/6S/L6BBBOPP_> HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCQE\/=.\+W6K^(M5LH=&TRZDFCA@MKIHH\N_+.5 W$  G. !Q7P/_P %.O\
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M"*_:2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_C?HW@GQY\._$&E>*=/O/$>BRW^GZMY6E7NFW.G7212QND4\5]*&D0LR[?E
M8AU_$/&C")X;!XE;IRC]Z37Y,_=?!+%M8G&85O1J$E\FT_S1^(_[(W[</[=O
M_!LU^UUXJ_94_:1TZ+XB_ P_$6VTCQ3X@L+29DBO?['TN9)[&ZD4.MQ%I<^F
MEK*7<FR/RXRN/-K^A7]KW]K#P%^R'^SEK/[0/B:WGU;[/!'#X9\/Z6AEO/$>
MJW!$=CIMI&H+2SW$S)&H4'&XL<*K$? WQ _X)#_M7_\ !17XA_$'P%^WQ'X)
M\'_#.^_:(TCX@:O9>#)[G4;KQ8]GX0TC2DM[2XG6'[%9,8KA9'>-IRZR(@"*
MLTFM_P %<O\ @D?_ ,%0/^"AO[1_AKXC? 7_ (*#:3\(?!_P^A)\ Z-X<.IV
ME_:7<D)BN+Z6YM70F=U9X5VD+'"2@YDE+_@1_08__@EY_P $N_'G_!//_@F_
M\9=2^)=]:/\ M!?''PQK7B7Q=::?,I-E<?9)_LVGP[2?,%O)=L7=<KYUTRAF
M78Q_.G_@B8T2?\&T/[=#$\E=7!_'0[<#]:_4+_@C[_P2?_;9_8>^,_B[XV_M
MS?M_ZY\=M5U+PO%H?A*77-=U2_;1K=[D7%XJM?RR%!*T%ID)C/D\]!7#W'_!
M!_XR?!;X8?M%?LB?L<_%CP7HWP?_ &D-5CO+W_A);2[;4O RR_)>P64,*F+4
M(WBPD0DEMS$ H8RXW$ K_P#!G_9>(K7_ (([6,^M+(+:Y^).N2:07S@VX,"-
MM]O.2?\ '-?J*(85F:X6)1(RA6<+R0,D GT&3^9]:^ OVSO^",WQ#\2_\$H/
M!'_!-;_@G=^TM??"C_A!M4L9TUJ>\N(3KL$8N&NH[N6SQ(K37-Q]L8HI4RQ*
M-@4@K];_  H^&_QE^$'[)'A_X2O\3(_&?Q \-?#ZVTI?%WB=I$36=7@LEB%Y
M=%1)(%DG4.Y^=\,3\[<D ^1/V O^,OO^"P7[3W[=MS_I/A_X81V?P2^'5R?F
M4-9L+W7"O;/VV2)0R]5)!/:OT#KYU_X)4?L2ZS_P3[_8@\*?LY^-?$MEKWBV
M":]U;QSXBL&=H]5UF]NI+FYG#2(CN,R"-6958I$N0#7T50 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'X5_P#!;S5FU+_@HQXPLR3BPTW2
M8!^-A!+_ .U*^2Z^J?\ @M5&4_X*2>/V(^]!I!_\I5H/Z5\K5_;7"*4>%< E
M_P ^:?\ Z0C^&^,9.7%N/;_Y_5/_ $MA1117T1\V%%%% !1110!8TG3;C6-5
MMM(M<>;=7"0QY_O,P4?J:_IS\-:!I_A3PYI_A?28@EKIME%:VR 8VQQH$4?D
M!7\S?P_U"WTGQYHFJW;8BM=7MI9#Z*LJD_H*_IQK^?\ QQG/FP$.G[Q_/W/Z
M^9_0W@3"'+CY]?W2^7[S^OD%%%%?@9_004444 %%%% !1110 4444 ?%'_!7
M7P_&EYX'\4QQC?)%?6DSXYPIA=!_X])7QE7V_P#\%=;J%/#O@:R9OWDE[?NH
M_P!E4@!_5A7Q!7]8>&<YSX+PW-TYU\O:2/Y&\4(0AQOBN7KR/Y^SB%%%%?>'
MP 4444 %%%% !7ZC?L&7;7W[)/@V9VR5M+B//LEU,H_]!K\N:_3_ /X)]Q&+
M]D'P>I[QWK?G?7!_K7Y)XQI?ZMT7_P!/5_Z1,_7_  7;_P!9JZZ>QE_Z73/9
M:***_FX_ID**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#\0O^"[^@_V/^W_J&H;,?VKX6TRZSC[V(V@S_P"0<?A7QI7Z
M-?\ !QGX&_L_XV_#KXDB' U;PM=::7 ZFTN?-Q_Y.5^<M?V;P#B5BN#<%-=(
M*/\ X"W']#^*/$'#/"<:8Z#ZS<O_  -*7ZA1117UY\<%%%% !1110 5_23^R
MM\4K;XV?LU^!?BM;W(E;7/"ME<W)#9VW!A43(3ZK*'4^ZFOYMJ_7O_@WW_:<
MM?&?P3UO]E[7M1']I^#[Q]1T2)VYDTVX?,@4=_+N&<L?^GE!7Y#XQY1/&\/4
M\935W0EK_AGHW]ZC\C]B\%\XIX'B*I@JCLJ\=/\ %#5+_P !<OF?H;1117\P
MG]3!1110 4444 %%%% !115;6M8TSP[H]WK^M7B6]G8VSW%W<2'"QQHI9F/L
M ":<8RG)1BKMBE*,(N4G9(^#/^"KWC6/6/C%H/@>WE#KHNAF:8 _<EN)"2I_
MX!%$?^!5\KUU?QQ^)MW\8_BWK_Q+NU=!JNH/);Q2'+10#"1(?=8U1?PKE*_L
MWAC*Y9-P_AL'+XH15_\ $]9?BV?Q/Q3FL<[XBQ.-C\,Y.W^%>['_ ,E2"BBB
MO>/ "BBB@ HHHH *_57]B[2SH_[+/@FT*;=^BK/C'_/5VDS_ ./U^50!8A5&
M2>@%?L1\,/#;>#?AKX>\(/'L;2M#M+1E]#'"B$?^.U^,>,^(4<KPM#K*;E_X
M#&W_ +<?MG@GAG+-<7B.D8*/_@4K_P#MIN4445_/1_1@4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P?_P<$_"K_A+O
MV0]&^)MI;;KCPAXKA::3'W+6Z1H7_.46U?C/7](7[7/P4@_:+_9F\;_!:2%'
MFU[P]/#8;^B7BCS+9S_NS)&WX5_.!<6\]I.]K=0M'+$Y22-UPRL#@@@]"#7]
M.>#.9K%</5<&W[U&?_DL]5_Y,I'\N>->5O"\1TL:E[M:'_DT-'_Y*XC****_
M8#\:"BBB@ HHHH *]%_92_:1\:?LF?'C0/CEX'/F3Z3<XO;%I"J7UHXVS6[^
MS(3@X.U@K 945YU16&)PU#&8>="M'FA---/9IZ-&^%Q-?!8F&(H2Y9P:::W3
M3NF?TN? [XU?#W]HCX5Z-\8_A=K2WVBZW:":VDX#Q-T>*1<_+(C!D9>S*?K7
M65^"/_!-[_@I#X[_ &$_';V%_#<:SX"UFX5O$'A])/GB? 7[7;;B LP  *G"
MR* K$$(Z?N%\%/CC\*OVB/A]9?%#X.^,K36]&OE^2XM7^:)\ F*5#\T4BY&4
M8!AZ5_(?&W!..X3QS:3EAY/W)_\ MLNTE^.ZZI?V-P/QQ@.+L DVHXB*]^'_
M +='O%_^2[/HWUE%%%?#'W84444 %%%% !7QW_P4Q_:DMM/TEOV=O ^I[KNZ
MVOXGGA;_ %,7#);9'\3<,P[* .=Q ^E/B)\4+3P[$^DZ+*LU^00S#E8/<^K>
MWY^A^'?VGOV7K[5KZ]^*'P]BEN+FXE>XU?3,EWE=B6>6+/)).24_[Y_NU^D^
M'669=_;=/%9D^6,=8)[.71R[);KN[=-_S+Q(S3,O["J87+%S2EI-K=0ZJ/=O
M9]E>VNWS;1000<$45_49_*@4444 %%%% !1110!VO[./@A_B/\>/"?@T1;X[
MS7(#<KC/[A&\R7_R&C5^M]? /_!*GX:MXA^,.K?$JZ@S!X=TORK=R.ES<94$
M?2-90?\ >%??U?S5XO9DL5Q##"Q>E&"O_BE[S_\ )>4_ISP<RQX3ARIBY+6M
M-V_PQ]U?^3<P4445^4'ZX%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5^"O_!7G]F[_ (9R_;:\20:58>3HGBXCQ#HN
MU<(!<,WGQC' VW"S *.B%/45^]5?%O\ P7 _9._X7W^RL_Q8\,Z9YOB+X<M)
MJ,?EIEYM-8 7<?\ P%52;V$+ ?>K]$\,<_CD?$\(U':G6]R79-OW7\I:7Z)L
M_./%+AZ6>\+3E25ZE#]Y'NTE[R^<;NW5I'XDT445_7!_'P4444 %%%% !111
M0 5Z+^S=^U;\>?V3?&@\;_ WQ]=:3/(5%]9']Y:7Z#^">%ODD')P<;ER2I4\
MUYU16&)PV'QE"5&O!3A+1IJZ:\TS?#8K$X*O&OAYN$XZIIM-/R:/U[_9C_X.
M!_@GXSM;?0?VH?!-WX/U/:%FUO1H7O=-D/=S&,SP_P"Z!+TY:OL_X6?M4?LV
M_&V"*7X3_'3PMKKS8VVMAK4+7 )Z!H2PD0^S*#7\VM>Q_P#!/OPHGC/]LSX?
MZ3)%O6#7/MV,=#:Q/<@_G$*_(.(_"3AR6'JXO"3E1Y8N5E[T=$WHGJO_  *W
MD?LG#7B_Q)'$4L'BZ<:_-*,4_AEJTM6M'_X#?NS^B6F3W-M:IYEU<)&O]Z1P
M!^M?/4=Y=Q+LBNI%7T5R!37DDE;=+(S'U8YK\17#;OK5_#_@G[F^)E;2E^/_
M  #VG6?BCX+T96#:LMS(.D5H-Y/XCY?UK@_%?QAU[7%:STE386YX)1\R,/=N
MWX?G7(45Z6%R;!89\S7,_/\ R/,Q6=XW$KE3Y5Y?Y@22<DT445ZQY!XA^T=^
MRO:^-!/XY^'5JD&K\O>6"X5+T]V7LLGZ-WP<D_+5U:W5C<R65[;20S0N4EBE
M0JR,#@J0>00>U?HI7E/[0W[-.D?%>V?Q+X;6*S\01I_K#\L=Z .$D]&QP'_
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MW[B)1C'62,!1ED16_02BO9R#/<=PYFD,=A'[T=UTDNL7Y/\ !V:U2/$X@R'
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M?:#X8T+PU;_9]&T](<CYWZN_U8\FK]%>!BLPQ>,_B2T[+1?UZGT&%R["8/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAXK\*>%_'?A?4O
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M[;P[X^U)=/\ !VKRZ[$(=5N2Q5HHCG[R,K"3./**L)-FTXD^'?[<7[)GQ9\
M^)?B?\//CGHNIZ+X/U7^S/$MS"TBO87A\OR[=XG42&23S8A$H4F8R((]Y89
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MY&=%EF(\V0LH8D!0 ?<-%%% !1110 4444 %%%% !117\Y'[</\ R>I\7_\
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M(O%W[7UQXB\,Z3%\-M5%[J^G'Q'H]U%?01_9M\L7DVLSB0 A1'R02H/ZW44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>jnj-20221002_g3.jpg
<TEXT>
begin 644 jnj-20221002_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYJ'VMM4U&X19O[4$NU<K.,J(RH\KR/+&Y55V /NO]LK]KKX:_L1_ ?4OCO\
M$S2]:U:*WGALM&\-^&--:]U77M1F;;;V%E;KS-/(V<#@!59V(56(^ OV'_\
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MWOQA^#EMHEWK7P\\4ZZ]M<7MMY8LI!Y5[!%&+JW9;J106#*PCB=& +%^0_9
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M_M5-\ M9^')GU^]TO^P]6OOM:S?9]G^D6]QY4/GPMOV[O+7$D<J<[-Q^(O\
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MIMK*/'QM;C5-#URZO[BPBN;>Z@@B8PO,EMOAD#(HEE*!,*  ?JY17XQ?&?\
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MHEMIW@\W%U/Y,R&>\6V>.WM%MUCAA>0-,=TFX&0M^@-% 'X5_L=_"W_@ZO\
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M@?X<>'_!6M^))]9O='T2TLKS5[K/FWTL4*1O.^2?F=E+'D\M6W10!^1?Q?\
MV!OVW_!'_!R!=?\ !6GPO^SK?>*OA5X>LK+2KF#1-8LAJ]^EQX:>PFN;.UGF
MC\Y+>:1/,#,CL,B)9"& [3]AK_@F?\>OB?\ \%N/BQ_P6F_::^&EUX"TN_MU
MTKX3^"M8N[>757C73;;3#J5VEM)+';!K:"0+"7,A:Y8L%"#?^H%,N(5N8'MW
M=U$B%2T;E6&1C((Y!]Q0!^4?_!P__P $M/'/[6'[4'[+?[2_[./BBX\->/HO
MB;8^#-7UW2KD0WL&F2--?I?Q'JS62V]]+M&25F8D;4./U,\%>#O#/P[\&Z3\
M/_!>D1:?HVA:9!I^DV$ Q';6T,:QQ1*.RJBJH]A7R'_P3$_X(ZZ-_P $W$N=
M%;]J'Q9\1]#T_P 0ZKJ_@?1O$UC!&N@W&HK$EU.TB%GN;AHXM@E)15%Q=;8P
M;AS7V?0!\N?\%>/^"7GPR_X*R_LB7W[.7C?76T+6K*^35O!7BF.W\UM)U.-'
M16=,@R0NDCQR1Y&5;<"&12/%/^"8OQ!_;W_8 _9A\._L/_ML?L/^./$UW\.;
M/^Q_"7Q'^$\]AK6DZ]I41(M0Z/<PW-I)''MA EA566-6)0DBOT.HH _&G_@E
MI_P2G_;E\+_\%TOBG_P5.^,7P27P!\._%NJ>);O0-)\3ZW9/K<R:C-NA+6UC
M-<)$P&2X>52.V[-9&E?L0?\ !4/_ ()%?\%H/BA^V3^QY^R3-\=/@_\ '&^O
M;K6]%T;Q/9Z?=V,M[=?;&1OM+@Q26]RTNQRK1/!(5+(YS'^UM% 'YK_\%DO^
M"8W[5_\ P5X_X)JQ>'_%&A>'O"OQ@T+Q8OBKP=X+AUA9[:RA%NUNVC3ZAM6.
M:=XW:5IPJQ"?;&&,2^<WB7[;G_!.7]KW_@LKXR_9#^$?Q(_9D\2?"SP7\&M%
MDE^-&N>,;[3]LUQ(FFQS:?IJ6MS,]TS"PF"S[1$%N$8D$%#^RM% 'X>?\%TO
MV\/A;^R1_P %E/ ?BS]HO]D7QE_9OA3X8-=^ OB3\*M1&F>(]4O[B5HID>]R
M!+8P1/<0FU)R'N&=MR2JM>N_\$(?^"LW_!)_XJ?$GQ)^R?\ L=?LO^._AS\0
M_$JWOB?5U\9/'>ZAXUO8U:>=Y=2FNY)9[K#RR!;AHXP&<J0"PK[#\1?\$Z?%
MGA?]MSQI^WK^S)^TG-X2\6_$;0--TGQIHWBKPI'K^DW45A&([9[>,3VUQ:,%
M'S+'/Y;L2S(6YK?^'/[!EK'^U;8?MQ?M%?$J+QW\2]#\+3^'?"]W8>&H=(TW
M1+&>3?/]GMU>:9Y9/NF2>XEVH66,1AWW 'P=_P &]7_!/[]O7]B?]M?]I'XH
M_M5?LHZKX1\/?%_5EU'PWJS>+-!OTMPE]?W'E7$=GJ$LJ.RW48!5&7*MD@8)
MZ;_@X+_9._X*B_M0?M#?L_M^RG\&;?XH_!OPSXBM]6^(/PRN?%=KI=EK-[;W
MT4PCU/[1(@FM7@C,:X641DRDH2ZAOU/HH _'#]D7_@GG_P %._@[_P '%OBO
M]OCXH_LK^'%\#?$#PR8-0UOPWX]MY--T-9K2Q5XD\U([NYDA-JT0 M8Q*V''
ME1G*^!_L#?$WXF?"+_@Z>_:Z\;_#3X"ZQ\1VMM"\1C6O#OAO4K.#5/L1U?2-
MTUHEY+#!<2K*(087FBS&TC*S.JQ2?T%-NVG:0#C@D5\!?LC?\$2/&/[*?_!3
MGQ[_ ,%.K?\ :\L]=\0?$R/4+?Q9X9E^')M[,6MY=VUU)':N-19X65K6)4=_
M-P =RL30!X__ ,$1/^";?[5_PJ_;F_:1_P""M/[7/P:N?!FO?%B_U:/P1\-S
MJEI<ZE#I]WJ0OY!.R2^1'(3!:0H&D4DI(S^6I4MX]_P24_X)K?\ !2K]D;0O
MVWW^-/[$>NV=Q\<_"=R/A_:V?C;PU<-<W3'556UE*:H5A8_VC$V]B(P(I/FS
ML5_V_HH _&G_ ()*_P#!.W_@H9^R!_P0T_::_8>^,_['FM6WQ$\?2>)F\&Z7
M9>,/#L\.H_VKX?M=,B_?KJ7EP^7-;LTGFE?D92GF-E1@?L6?\$.OVP?'G_!
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MX'T^[6 I90#-QJ=]<,&%E8Q=&F*N[MB.&*:3Y*\>\8?\%;I?"/\ P6 \,?\
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MK)<V<A'+1O#%/&1Z7#XP3F@#]AJ* 01D'(/0T4 %%%% !1110 4444 %%%%
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MWMXM4NKP7/VDZGY;HZ3HJJI+AP^Y54!F_;:B@#\1_P#@IG_P33_X*1?M3?\
M!"W]F/\ 8.^%/[%VN3?$/X<7>C/XPLKWQIX;AM[)=/T>[L&*S'4]DOFR7".F
MPM\BMOV'"EW_  77_P"";'_!2+]OK]CO]E7X0?L\?L6:Y=Z]\-O#;'QM;:GX
MT\-VJ:?<?8[.V%N';4\3,6MI'W1[DV,GS;BR+^VU% 'Y:_\ !37_ ()N?M$>
M/?\ @I7^SE_P60_9[^"^JZW?>!)=/LOBC\+QJ-A'K,>GQ33/]IMB;G[+<3QQ
MW4Z/$L_S>7#L+98A?V7/^":7Q]^.7_!?#QU_P68^.GPQU'P!X/TG2X]-^%GA
MCQ!<VS:QJ<_]C1:5+>SPV\LJVT.S[6521A(3-&=H"DG]2:* /QZ_X)C_ +"7
M_!0;]FG_ (+D?M)_M[?%[]BKQ'8?#WXGZ7XE_P"$5N+?QAX:N+MY)M5M;ZVB
MD@CU0F-IH[9D!)VK)(@=D7<ZX7_!O]_P3Z_X*C_\$VOV</VJ=%^*7[,-YX1\
M<>+_  X-6^%=]_PDNA:K;W&KVUG?K!;NEM>RD/Y\\!'F((F 8,PX!_:*B@#\
M4?B[_P $@_B'^U%_P4M_9[_;#^"/[ _B;]G/QGH'C>U\2?M"ZJ^MZ4WA^5K6
M>"XWZ<;*[E-U<7#)-'NCBC#K*'N$1]^>U_X.7_@CK'[>7[5/['O_  3I\ VS
MWNJ>*?&^IZ[XG2 ;O[*T*W%K'<7LO]U/*:Z*DXW-"4'S$ _KS7EWPE_9*^&G
MPN^,?BC]H^]NM0\3?$3Q= EEJGC'Q"\<ES;Z9$Y>#2K18T2.TLHV8L(HU!D<
M^9,TLF9* /4:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6_U;-DK\U 'MM%?&'_!*;_@M9\#?^"NOQ%^+7A[]GOX8>(M(\/?"\:*L.O\
MB62**?67OS?@E;6/=Y")]AR"TA9Q+RD97!Y/_@JM_P %V]"_X)S>)]0^'OPM
M_8Z\>_&K7?#6FQ:CX_G\+PS6^C^$K:5/,B%_J"6UPL$SQD2B,I@1LKLRAER
M??=%?*W_  25_P""M/P#_P""NOP O?C)\'M"U'P_JN@:BNG^+O".L2I)<:7<
M,F^-ED3"S0R+N*284DHX*J5(KZBU/4M/T73;C6-7OHK:TM('FNKF>0*D4:@L
MSLQX  !))Z 4 3T5^+FJ_P#!X]\/O[>N;#PA_P $U?BAK-A]K>/2]2AU-4^W
M0[B(Y53[,2N]=K!<DC=C)K]CO VM:]XD\$Z/XB\4^%GT/4[_ $JWN=2T22Y$
MS:?.\:M);F10!(8V)3<  =N<#- &K1110 4444 %%%% !1110 4444 %%%%
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M?Q%\/[ZYWZOX5GGY@)/S7%HQXAE[E?N2=& .UU_=/X#?'KX5_M+?"_3?B_\
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M8R7N2_A-]);N'H]X^>G56_2BBBBOY_/Z&"BBB@ HHHH **** "BBB@ HHHH
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M5S8WUI,T5W9WD#12PR*<,CHP!5@>"",BJU?I"::NC\X::=F%%%%,0445Z'\
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MW3+R73M1LY;>X@D,<\$\91XW!P593R"#P0:BKZU--71\@TT[,**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT^.,X#'BOSO_ &B?VF/B-^TEXJ_MSQA=B"QMV8:7HMLY\BS4^G]]S_$YY/L
M /T'@[@#,N)*T:U>+IX;K)Z.7E!/>_\ -LO-Z'YUQGXA99PS1E0H253$](K5
M1\YM;6_EW?DM3X:_;F_:D^*/[77[1FM_%7XI64VG3+)]CTK0)&.-(LXV/EVP
MR!DC)9FP-SNS8&0!Y!7V'\;?@-X?^+VG&[B:.RUN"/%IJ.WY7QTCEP,LG;(R
MR]1D95ODSQ1X6U_P9KD_ASQ/IDEI>6S8EAD_1@1PRD<AAD$<@U_4.#P]#!8>
M&&HQ48P222VLNWZ]>_=_ROC,3B,=B9XJM)RE-MMO>[[_ *=.W99]%%%=1R!1
M110 4444 %?T2?\ !+3X-3_ O]@GX;^#-0M?*OKK0QJVH*RX82WKM=;6_P!I
M5E5#_N8K\*?V,_@%>_M/_M1>"?@;:PNT.N:Y$NIO'G,=C'F6Y?ZK"DA'N *_
MI3M[>WM+>.TM84CBB0)'&BX5% P  .@ K\.\9LT2HX;+HO5MU)?*\8_?>7W'
M[OX*95)UL5F4EHDJ<?5VE+[K1^\?1117X(?T"%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!#?V4.HV4MA./DFC*-[9'6O)K^SFTZ]EL;A</$Y5OPKU^N+^)
M^@%)$\06Z<-A+C [_P +?T_ 5ZN58CV=5TWM+\SP\[PKJT%5CO'?T_X'^9Q]
M,GG@M8'NKJ=(HHU+222.%5 .I)/ 'O7+>/?C#X5\#;[-I?MM^O'V*W<?(?\
M;;D)].6Y'&.:\6\;?$KQ5X\G_P")Q>[+96S'9096)/?'5CUY.3R<8'%??9=D
M6+QUIR]V'=]?1=?R/SK,,ZPN!O%>]/LNGJ^GYGHWC[]HC3[ /IG@:);J;E6O
MYE/E(?\ 87JY]S@<?Q UY)K.N:OXAU!]4UO4);FX?[TDK9P/0=@/0#@55HK[
MK Y9A,OA:E'7JWN_Z[(^*QN8XK'RO5EIV6R_KS"BBBN\X0K+\8>*K+P=H<FL
M701Y/N6ENQ/[Z3L..=HZL>..,@D9TIIH+:%[FZG6**)"\LC]$4#))QZ $UXE
M\0/&<_C376O%WI:0Y2R@8 ;4_O$#^)NIY/89PHKT\KP#QV(][X%O_E\_R/+S
M7,%@,/[OQO;_ #^7YF1J%_>:I?3:EJ$YDGGD+RR$ ;F)R>G ^E='\,OC;\5_
M@WJ!U'X:>.]0TEF;=+#!+NAE/J\391_^!*:Y:BOMJV&PV)HNC5@I0>C32:^Y
MZ'PU#%8G#5U6HS<9K523:=_5:GU7X'_X*P?%S1H4M_'?@#1M;"#!FM97LY7]
MR1O3/T0?2NYM/^"N?A%XP;_X*ZE&^.5AUB-P#]3&O\J^&Z*^.Q/AQP;BI\[P
MJB_[LI17W*5OP/M,+XE\:X6')'%.2_O1A)_>XW_$^T?$/_!75S$8_"GP0"R$
M';-J&N9 /^XD0S_WT*\=^)__  4*_:8^)<$FGQ>+(?#]G("&MO#L!@8C_KJQ
M:4?@P'M7B%%=>7\"\)Y9-3HX2/,NLKS_ /2F[?(X\PX]XOS.FX5\7+E?2-H?
M^D)7^8^XN+B[G>ZNYWEED8M))(Q9F8\DDGDFF445]:DDK(^0;;=V%<I\6?@_
MX6^+NB?V?K2>1>0J?L&IQ(#);GK@CC>F>J$^N"#S75T4I14E9CC)Q=T?#?Q!
M^'GBCX9>(I/#7BJQ\N51NAFC),5Q'GB2-L#<IQ[$$$$ @@8=?<?Q#^'7A;XG
M^'F\.^*;+>@):VN(\"6V<C&]&[=!D=#@9' Q\C_%GX0^*/A%K_\ 9>N1^=:3
M[FT_4HD(CN4'7_=<9&Y#R,@\J58RI-/EE_P__!+<4US1_P"&_P"!_7KRE%%%
M69A1172_!SX3^,?CK\5- ^#WP_T_[3K/B/5(K&QC.=JL[8+L1]U%7+LW95)[
M5%2I3HTY5)NT4FVWLDMV72I5*U6-.FKRDTDENV]$C]*_^#=']E=S+XI_; \3
M6!"A6\/^%C(O4_))=SC/IB&-6'K,/6OU4KBOV<_@5X/_ &9_@?X:^!?@2+&F
M^'-,2V24H%:YEY:6=@/XY)&>1O=S7:U_''%>>2XBSZMC?LMVBNT5I'[]WYMG
M]H\)9%'AS(*."^TE>3[S>LON>B\D@HHHKYT^D"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:T
MT*2K \JAW!*(6Y8#K@=\9%.H **** "BBB@ JKKFCVGB#1[K0[]I!#=P-%(T
M,A1U!&,JPY!'4'L:M45492A)2B[-$RC&<7&2NF? _P 3OA[K/PO\:7GA#6E)
M:!]UO/MP)X3]R0?4=?0@CM7/U]I?M'_!"W^,'A/S=-1$UO3E9].E/'FCJT+'
MT;'![''8G/QC>6=WIUW+87]L\,\$ACFAE4JR,#@J0>A!K]XX:SVGG>!4F_WD
M=)+S[KR?X.Z/P'B;(:F1X]Q2_=2UB_+L_-?BK,CHHHKZ(^;"BBN>^)/C=?!>
MB?Z'(O\ :-V"MFN>8QT,I'MT7/5O4*PK6C1J8BJJ<%=LRKUJ>'I.I-V2.7^-
M/CDRRMX(TN4A(G!U)U;[[@Y$7'93R<_Q # V9/GE*26)9B22>2:2OT'!X6G@
MZ"I0^;[ON?G6,Q=3&XAU9_)=EV"BBBNHY0HHHH **** "BBB@ HHHH *SO%?
MA/P]XXT"?PSXITU+JSN!EHVX*,,X=#U5QDX(]2.02#HT4FE)68TW%W1\=_&[
MX#^(?A!J8N07O=%N9=MEJ2I]UN3Y4H'W'P"1V8 D=&"\'7WQJVDZ7KVEW&B:
MYI\5W9W41CN;:=<I(O7!].0"",$$ @@@&OECX^?LXZK\+Y9/$WAH2WOA]W&9
M"-TED2<!9<=5)( DZ$D X)&83<':7W_YEM*:O'[O\CRZOU\_X(&?L$R> /!\
MO[9_Q0T,QZQXAM6MO!-M<Q8:UT]O]9> 'HTWW4/!\I202LM?'W_!);_@G'J_
M[;'Q=3QGX[TJ6+X;>%KQ'U^Y;*C4YQAUL(SWW?*9"/N1GJ&=*_>2QL;+2[*'
M3--LXK>VMXEBM[>",(D2*,*JJ.%    '  K\7\5.,(T*#R7"2]Z7\1KHND/5
M[ORTZG[;X3<&SKUUG>+C[D?X2?5]9^BVCYZ]-9:***_G\_H<**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KB/VF/'OCKX5_LX?$#XG_  O\*'7O$WAOP1JVJ>'=#$;/_:-];V<L
MMO;;5^8^9(B)@<G=Q7;UA_$_X@Z!\)/AKXA^*OBI;@Z7X9T.[U;4A:QAY3;V
MT+S2;%) 9MJ' R,G'(H _ S_ (),_M+?L[?\%;OBY\&_!/[1_P =/B+>_'B3
M2_B!)\1=:?Q[J>E7D%Q+)92Z5-HDEM-'#9Q1P(X6VME0![>4R1.I#/\ L;^S
M_P#L]_M9^'?V)-)_9\^*_P"UOX@3X@:7<:I8W/Q5M;*QO=4O;);^[%A<D7<,
ML G:T-HSF2.0@AU.6.\?D_\ \%Z?^",GP(^,?Q?\$_M6?\$YI]-\#^-?%W@7
MQ1\0;G4=!O'M]/UYM)@T^]BN;?RB!:74R73N)X\([A&8 LTH_0K_ (-Y_P!K
M#X^_MG_\$I/AU\;/VE+ZXU'Q0TNH:7+X@NX]LFM06EW+;Q7;\?,Y5/+=_P"-
MXG8\L: /A;_@T!^-7QS^._QO_:[\9?M"_&3Q#XY\11WGA&VFUWQ)J<MU,ZQR
MZ^H53(Q\M!_#&N%4<  5^X-?@W_P9:LK?%7]L(JP.=:\+$<]1Y_B"OV /_!0
M?]C$?MB?\, ']H'1/^%PG3?MW_"#XE^T>5Y'VG;YFSR?-\C]]Y._S?*_>;-O
M- 'YI?M>_P#!731/VPO^"J&L?\$Y;7]L_3/@'\ /A.MP?C+\11XQ@T+4_%>H
MP2)%)HEE?R.CVR^>_DOY!69E@NF#;56OU%_91^'G[)_@KX36&L?L=:3X0/A+
M6H$GMM>\(7,-W%K(7*B>2]1G:]?.X&621V)SEB<U^'O_  ;G?LY>#/%W_!1O
M]N;]DC]K?P%8:MKFI6U[8ZQ9:W8I+));G5;N&\D0R G:YN+=PZ]=T; ]#7K_
M /P9/7_Q8/[*/QIT#7[V[G\%:=\0[1/"[2,Q@6^:T8WXBSP/D%BQ XRX/4G(
M!^U]%%% !7B?[47[-W_"=P2?$#P/9@:S#'F]M$'_ !_(!U'_ $T _P"^AQU
MS[917?EN98K*L7'$4'9K[FNJ?D_^#N>?F>687-L'+#XA73^]/HUYK_@;'YT2
M1R12-%*A5E)#*PP01V-)7UE^T5^RW9?$/SO&?@6**VUP M<6W"QWWU/19/\
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MVF>"M;\":UHWQ*@L)?#EWI-S#K\6JLHM7LGB99Q,7PHC,98-GC;G/%?SC_\
M!1#_ ()9?M2?\$ /VQ] _;'_ ."2_P 2-5U71]1TC7=;/A2\L%O;C1-)L1:M
MJ$-R'R+ZR$=S&=X GC12Q.8C/7Q-:M6Q%1U*LG*3W;;;?S9]S1H4<-25.E%1
MBMDDDEZ)'[ ^/_V^?VE? W_!)J]_:;^)7PKT3PA\<;V6Z\):1X0:^']GIXM?
M69=#L]LER5#6IN1'<EG;:(-S%R@+U\F?LN:I_P ';OCKXW>"%^.NJ?##3/AM
M?>(;-O%OB#21X>NWCTGS5-P\"P2.TCF(.J;0?F(SQDUZ&GPR^'/_  =4?\$G
M/AGXX^)/C_Q-\+H8_$4][XCT/PIY$T+:U9B:S()N$8O;XD>6-<@@3*&)9,U\
M&Z]^PI_P40_X-AOVL_A=\9?@3^T?>_$;X$^/OB)I_AOQ)HJ6\EJEQ)=28-M=
MZ>9)(UG:)93!=Q,3OB(8(&$<F1J?T7U^5W_!0[]KC_@N!\6_VU_%'P5_X(X6
M_@&Y\*?#>WM=%\7GQ#?Z/]KN=>>W2^G\I+V59#%';W=I&2J[1*LJEMRD+^J-
M?B=^W1_P:&7OQG^)?C']JO\ 9S_;U\26GQ0\0^)+WQ&!XQTV/[//J$\S3E$N
MK,QRV8#M\KK'+L  "\9 !^A__!)^S_X*B#X ZMK'_!6#6?#[>/[OQ)(-(TCP
MW;62P6.EI%&$+R6A*2222F9CR=JA.A)%?45?FO\ \&T?[6W[9?QS_9V^)G[-
M_P"W=/J6H>/_ (#?$.3PE>Z[K$OFW=RBH?W%Q,"?M,T,D<B^?DF2-XB2QR[?
MI10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\3P> /%/AN/QOH_@R+P=XRUCP7>VEK=26FBS02O!<S0K'*;>X=,JK'GD9P2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(HH7"QQEC*R,#Y7R[P#[5HKGOAUXY\(?&[X4Z%\2O#D1NM \7^'K74[!+V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7RA^W7_ ,E<
MT[_L7(?_ $HN*^KZP/%7CG_A&=02P_LOS]\(DW^?MQDD8QM/I7N\.YC4RO,E
M7A3YW9JU^7?SLSP.)<OI9GE;H5*GLU=.]N;;R31\#5[3^PI_R5S4?^Q<F_\
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M_C%K;6UHCGH)+QD^_$X7ZMJOI6D:5H6GQ:3H>F6]G:P@B&VM(5CCC!.<*J@
M<DGCUH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[^*_$/P:LO$4"^%KS6I'$LMSY7V?[2B22J)9+9+A8)&&'C:/]W0!]1U\X_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>jnj-20221002_g4.jpg
<TEXT>
begin 644 jnj-20221002_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y1_X*0?\%>_V;_\ @G%JOA7X
M6^)M$USQU\4_']W%:^ _A7X,A275-4DEF$$3N794MX6F(C#L2SL&"(^Q]O)_
MM,?\%._VO?V%O@_!^TS^V3_P3HM;+X<6\UNOBK4?AC\6U\1:KX9BF=8UEO+*
M?3;&-D#NBLUO<3*I;.<<U^3/P8\3:[\??^#U"=OC)))<_P!A?$+Q#9:+:W>2
ML,&E^'[X6 C4\*!Y$4PQU8ENK$U^Y_\ P4X\-Z'XO_X)P?'WPWXC@C>RNO@S
MXF6?S!D)C2[@A_8J0&![%0>U &UX-_;>_9A^(G[)T'[;G@/XI6NL?#>YT4ZG
M;:YIT$LKRH&V>0L"KYS7/F_N1;!/-,V(@F\A:_/KQ5_P=&:=\$/VNO#?[/W[
M87_!-/XL_!WPGXOO8H_#_C;QQ(+>[>WDE$2W<NG-  L2,R>:([B5XP3\I8!3
MX9_P9'^/?&'BO]GGX[?![Q,'N_#'ASQAH6K:%!=)OBAO;J&Y\\INR 0;&T?C
MHV&ZG-<O_P '*W[3_P 5_ G_  4&_9^\9?MQ_P#!/V\O/V>_AIXKO+S1;[3?
M%,4W_"93R/ TA>5(R+4QI;1.+&3:TP63,FPYC /WWKX1_P""JW_!</0_^"<F
MN7/P_P#A?^R%X]^-GBC1='35_&=OX2MYHM+\*6$@8Q2:C?I;SK;/(J,ZQE#^
M[&]B@9-WVSX%\:>'OB1X)T?XA^$;[[3I.O:5;ZCI=SL*^;;SQ++&^#R,HRG!
M]:Y?XW_$?X)?LL?!KQY^T-\3DTS1/#NE:9<:[XRU 6T:&\\FV2(O)P//F:*&
M&! V6;;%&,X44 >#?\$A?^"P/P"_X*__  1U?XF?"?PUJ7AG7_"U_#9^,?!^
MK3I--ITDRL\$J3( LT$HCE"/M1BT,@*+M!/EOBC_ (+X^%=0\"_&7]H_]G_]
MF^X\>_!?X!^)8-$^('CF#Q>EG?7TYDC2YDT>P-L\=]# )4=GFN;7>IS&'&"?
MF_\ X(:_L%_&/_@GO_P22_:-_;.\9^%9_"GCOXN>"M4\2^'O"H0QS:)IECIU
M_-IB.I ,<SO<RR;."J&$-A@RK\G?\$AXHO\ B%7_ &TYF RWB?503]-*T@C]
M30!^WOQJ_P""GW[-OPH_8GT']N3PM_;GCSP_XUM;3_A7>@>"])>[U;Q1>74;
M206-K;##&?;'*TBM@Q+!*6&4(KY'_P"">?\ P<Z_"S]L']LV/]A3]H3]D3Q=
M\#O'.IW;VGA^U\2ZG]I$]VL9D%I=));6\MG.Z#**R.K,0NX%EW6_^#3BY?QO
M_P $=/ -[XOTFWN[CPCXO\1V7AB]N[=7EL[>2[:200NPR@+3RJ=I&1QTXKSS
MQ'^R/9_\%)?^#FZ+]K#P#I$4?PX_9?T'3=(\8^*+:,"+6_%]L;JXBL8I!Q+-
M;F\MQ.>?+%F(VVETH ^CO^"JW_!</0_^"<FN7/P_^%_[(7CWXV>*-%T=-7\9
MV_A*WFBTOPI82!C%)J-^EO.ML\BHSK&4/[L;V*!DW=Q_P2%_X+ _ +_@K_\
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M%XAYHD57A4 _)_Q-_P""IW[1G[*O_!9+]FKX!?"W]KS7OB%X2^+::#HGQ?\
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MZCX,M-,\:77AY]*U34X[N222"VM;@S!XT4!2+H+C&?D//->F?M^_\F(_&O\
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M\O[/'[=OPH_8ZU76OAY\*=-\/6OBC5;/QIH$1FDM]5O;RY:TBNK^&:6-([I
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M97Q?_;<_:B_8*_:L^.]]\2[7X2^)[N+PQXIUJP@AO0MMJES83*YA10R2;(I
MISY9#!3M.!^C/[>?_)C7QG_[)/XB_P#39<4 >6_\$@_^"I'A'_@KC^S'JW[2
M_@OX2:EX,M-*\:W7AQ]*U34X[N222"UM+@S!XT4!2+L+MQG*$YYKT3_@H1^U
MT?V#?V-/'O[7*_"?5O'!\$:5'>?\(OHDOESWF^XBAR9-C^5$GF^;))L;9%'(
M^UMN#^%G_!$+X=?M=2?\&_7QW_:'_9I_;;\5?#2]^&GC+Q)XCT/P_P"&='TY
MH-4O+'0]-NYQ?37,$LLJ20QK%'%$T*HV7D\X,%3Z3T?_ (++_M>?M0_\&T?C
M?_@H5X/^+%SX*^,OPI\26^@ZSKV@:18M;:M=+?:;&TCVUS!+&JR6>HQLRQA
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?X:?%CXF_!KQ-%XS^%'C[5O#NJ0_=OM'OW@D(S]UBA&Y3W5L@]P:^_OV1_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^4?\
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M0>(/ E^V?)2&Z.HV2G_:BN&\T_A,*^%/C[_P1N_:Y^ 7B: 7^CVWB'PK+/\
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M,?M%OX3GFQ#XCT>:W5">#-%B9#]=J2#_ (%7PWB/EBS/A*O9>]3M47_;N_\
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M^PG\$X/VB/VO? 'PBO[43V.I^(8I-5A*Y$EG #<7"_C#%(/QK^BU555"JH
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M_=M\,K15/J1J.H9_F*_3?"-)\9PO_)/\C\N\8&UP54MUG#\SX(HHHK^KS^2
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MTZ<JM10CNW9?,_7/X5Z6=#^&'AO164@V>@V<!![;($7^E;U)'&D4:Q1(%50
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M*-KI34GZ0]Y_?:WS/MRBBBOX\/[-"BBB@ HHHH **** "BBB@ HHHH ****
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MB#L/^^Y1/HQ/:OU.K\)\8\[3]AE5-_\ 3R?XJ*_]*;7HS]\\%\C:]OFU1?\
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M8\*0?T'PXXI7#.?)5I6H5;1GV7\LO^W7O_=;/SOQ*X4?$^0-T(WKT;RAW?\
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M9M-U*SEM[BWE:.>WGC*/&ZG#*RGE2"""#R*BK]P335T?A333LPHHHH ****
M.^_97\'MX]_:3\">$O(\R.\\5V(N4Q_RQ697E_)%8U^WU?DK_P $GO!Q\5?M
MH:)J3)NCT+3+[4)%QQ_J3 I_!YU/U K]:J_%_$C$>TS:E17V87^;;_1(_;?#
M3#^SRBK6?VIV^44OU;"BBBOSL_1PHHHH **** "BBB@ HHK5\+>#=;\77?V?
M2[?$:G][</PD?U/<^PYJ*E2G2@YS=DBZ=.I6FH05VRCIVG7VK7L>GZ=;---*
MV$C0<G_ >]>O_#[X=6?@ZW^UW)6:_D7$DH'$8_NK_4]ZN^#_  1H_@VS\JR3
MS)W'[^Z<?,_M[#V_G6S7QV:9O+%WI4M(?B_^!_3/M,KR>.$M5JZS_!?\'S^X
M****\,]T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.:X:Z\VZLT;9MLIO,B#(&)( 0=C^V)_P1F_82_;9^)7@[XU?$OP/KGA_QGX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUS]HSP]I6EZ7XH3PUJHUN5[&ZL=9=D5-/GM+A4N(;D^8A$3QA]K!L;3FNO\
M@7^T9\#OVH?!]_XX_9]^*.F>*=(L-:NM'O-3T>7?'#?6Y"S1988++N4YP5(9
M2"002 =O17R;_P $Y_VAOC]^T1\4?VD_"7Q=^(T=Y8_"WXT7W@GPG]@T6VMI
M!9Q6=K<I<SL$(EN/])VY 6/Y,^7SQ3_X)J?M@_$WXN_"CXU?%7]J_P"*^D+8
M_#CXZ>*_!EG??V?!IUK!IFDW8MXKB8CDSR9)8[@A)4*@/4 ^OJ*\KT7]MO\
M96UOPWXR\4CXS:;I]O\ #PQ#QU;Z_%-IEWH/FH'@-U:W:1SPB52#$60"7HFX
MUR'Q\_:Y\.^*OV3/C?XO_9A^*R6/C;X9>#=2O+NWU+09([[0[Z+3WO;876GW
MT<<B+*BJR&1 KHVY=P% 'T'17R)\'?\ @IKX)T?0OV8?@U\9M4U'4?B'\:OA
M19^(]1U6+0Y5MD*:5;37$Y,$/E&22YN(U\F/:$60LVQ0@?F?V*_^"F/A+3-4
M^)/PU_;:_:DT$>);+]ICQ#X&\#K>V$%B7L8)X+>PA=;>,)'OD9T668CS9"RA
MB0% !]PT444 %%%% !1110 4444 %%%?SD?MP_\ )ZGQ?_[*CX@_].4]?;\$
M<&_ZY8JM1]O[+V<4[\O->[M;XHV_$^%XZXT_U+PE&O[#VOM).-N;EM97O\,K
M_@?T;T5_+O7[*_\ !O!_R97XG_[*C>_^FW3:^@XN\,/]5<F>/^M^TM)+E]GR
M[^?/+\CY[@[Q2_ULSI9?]3]G>,I<WM.;;I;DC^9]YT445^4'ZV%%%% !17R%
M^VI\?OVF? ?_  4._9O_ &6O@W\6K+0?#_QFLO&)\0RWOAF"^FLGT;3K>[@:
MV+%,>8TS*X??P!MV\Y^<O'__  5,_;,M_@+\<-"NO&GAS2O&?[/G[1_A7P3J
MGCGPYX=C_LWQ1I.IZQ86S9@NWG6SND@NG$ZJ[A'"E2N<  _4JBO*OAO^W'^R
M)\7+#QMJOP]_:$\,ZA:?#B(3>.;HWXABT:W,3S+<S/*%46[1Q2.MP"8G6-RK
MD*<-T']N+]E#7],\3:N/C3IFF0^#=%M]9\3CQ)#-I,FG:;<*S6]])'>I$_V:
M4(^R< QN48*Q((H ]7HKY[TO_@J__P $X-95&T[]LCP0_FIH;P*VJ;&F&L#.
MG",, 9#,,\+DI@[PF#BQ=?\ !47_ ()_6>C>*-=F_:F\,F'P9>16WB.**262
M>U:6)Y8G$"H99HGBCDD6:-6C9(G<,51B #WRBO-?%7[8'[-OA#POX;\8W_Q4
ML[VP\8Z+)K'A5M MI]4EU;38X4GDOH(;..622V2*6)WG"F-!+'N8;US=NOVH
M?@%#\-_#GQ:L/B;8:KH/C&*.3P?=: DFI2:\LD+3K]B@M5DENSY*O*5B1R$1
MV("JQ !WM%>;Z1^UW^S?XC^$VC?&_P *?%?3]:\-^(KI[7P_=Z'%+?3:G=)Y
MGF6MO;0(\\UPGDS[X$C,B>1+N5?+;%+PO^V_^R=XUTSP=K7A;XYZ)>V?Q UF
M;1_!]S%(^S4=2A\SS;!25 2Z3R9=UN^V5?*?*C:V #U6BOG?]J3_ (*<?LP?
MLQ_L_?$OXZ7GBB37I/A?>)I?B#P[I5E<->0:O-&KVME.GEEK?S1)$WFNNQ8W
M#DD8SN7'[0'P\\8_M0_#OPAX/_:WL=.FU3PQK-\_PF;1H3>>)(5:%8[]FF07
M-FEJR2@ !5F,YSG8M 'ME%>:6_[8G[-%S\4=/^#<7Q:T_P#M[6-3N]-T:-X9
MEM=2O[4,;JQMKLH+>XNH0DGF6\<C2Q^6^Y!M;$?AS]L[]F'Q;\2K#X2>'OB[
M87&MZOJ.HZ?H:""=;;5KS3]POK6SNF06]W/;F.02Q0R.\1BD#*-C8 /3Z*^9
M?^"?/QT^-OQ:^+/[2O@;XQ^/4UZ#X=?'*3P_X3:/2;>T^R::=%TN\6 B%09"
M)+J4[Y"SG/7  'TU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%M)/$B3)YUK.N4)^X#]UE)^N*** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>jnj-20221002_g5.jpg
<TEXT>
begin 644 jnj-20221002_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU%><_P##6?[/W_0__P#E*N__ (U1_P -9_L_?]#_ /\ E*N__C5']B9U_P!
MU3_P"7^0?VYDG_053_\  X_YGHU%><_\-9_L_?\ 0_\ _E*N_P#XU1_PUG^S
M]_T/_P#Y2KO_ .-4?V)G7_0-4_\  )?Y!_;F2?\ 053_ / X_P"9Z-17G/\
MPUG^S]_T/_\ Y2KO_P"-4?\ #6?[/W_0_P#_ )2KO_XU1_8F=?\ 0-4_\ E_
MD']N9)_T%4__  ./^9Z-17G/_#6?[/W_ $/_ /Y2KO\ ^-4?\-9_L_?]#_\
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MJ]*4[;\L6[7VO9'+B<=@L%;ZQ5C"^W-)*]M[7:O:YZ-17G/_  UG^S]_T/\
M_P"4J[_^-4?\-9_L_?\ 0_\ _E*N_P#XU75_8F=?] U3_P  E_D<G]N9)_T%
M4_\ P./^9Z-17G/_  UG^S]_T/\ _P"4J[_^-4?\-9_L_?\ 0_\ _E*N_P#X
MU1_8F=?] U3_ , E_D']N9)_T%4__ X_YGHU%><_\-9_L_?]#_\ ^4J[_P#C
M5'_#6?[/W_0__P#E*N__ (U1_8F=?] U3_P"7^0?VYDG_053_P# X_YGHU%>
M<_\ #6?[/W_0_P#_ )2KO_XU1_PUG^S]_P!#_P#^4J[_ /C5']B9U_T#5/\
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M+;DY3G[R2DHR44KV;WLWOMK;76Q1117NG@!1110!]I?LE_\ )OWA_P#[>_\
MTKFKT:O.?V2_^3?O#_\ V]_^E<U>C5_.^=_\CK$_]?)_^E,_H_(_^1)A?^O<
M/_24%%%%>6>J%%%% !1110 4444 %%%% !1110 4444 %%%% 'Q;^UI_R<#X
M@_[=/_22&O.:]&_:T_Y.!\0?]NG_ *20UYS7]$Y)_P B7#?]>X?^DH_F_//^
M1WBO^OD__2F%%%%>F>6%%%% !1110 4444 %%%% !1110 4444 %?1G[ /\
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M $DAKSFO1OVM/^3@?$'_ &Z?^DD-><U_1.2?\B7#?]>X?^DH_F_//^1WBO\
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MP_\ ;BOF>,6UPY7:_N_^EQ/J."TGQ+03_O\ _I$CV#P7\#?A3\._@Y;?L_\
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MK^B<D_Y$N&_Z]P_])1_-^>?\CO%?]?)_^E,****],\L*^#_V@O%'[7_[)?\
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M]U^)/Q+\#?"#X>ZO\5OB/XABTSP_H.G27VJZE)&[K!;HNYGVQAF?CHJ@DG
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M?]NG_I)#7G-?T3DG_(EPW_7N'_I*/YOSS_D=XK_KY/\ ]*84445Z9Y84444
M%%%% !1110 4444 %%%% !1110 5]&?L _\ ,V_]N'_MQ7SG7T9^P#_S-O\
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M+_Y-^\/_ /;W_P"E<U>C5YS^R7_R;]X?_P"WO_TKFKT:OYWSO_D=8G_KY/\
M]*9_1^1_\B3"_P#7N'_I*"BBBO+/5"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#XM_:T_P"3@?$'_;I_Z20UYS7HW[6G_)P/B#_MT_\ 22&O.:_HG)/^
M1+AO^O</_24?S?GG_([Q7_7R?_I3"BBBO3/+"BBB@ HHHH **** "BBB@ HH
MHH **** "OHS]@'_ )FW_MP_]N*^<Z^C/V ?^9M_[</_ &XKYCC+_DFZ_P#V
M[_Z7$^IX*_Y*:A_V]_Z1(^C****_"C]["BBB@ HHHH **** "BBB@ K\YZ_1
MBOSGK].\./\ F*_[<_\ ;S\M\2O^87_N)_[8%%%%?IQ^6A1110 4444 %%%%
M !1110 4444 %%%% !1110!]I?LE_P#)OWA__M[_ /2N:O1J\Y_9+_Y-^\/_
M /;W_P"E<U>C5_.^=_\ (ZQ/_7R?_I3/Z/R/_D287_KW#_TE!1117EGJA111
M0 4444 %%%% !1110 4444 %%%% !1110!\6_M:?\G ^(/\ MT_])(:\YKT;
M]K3_ ).!\0?]NG_I)#7G-?T3DG_(EPW_ %[A_P"DH_F_//\ D=XK_KY/_P!*
M84445Z9Y84444 %%%% !1110 4444 %%%% !1110 5]&?L _\S;_ -N'_MQ7
MSG7T9^P#_P S;_VX?^W%?,<9?\DW7_[=_P#2XGU/!7_)34/^WO\ TB1]&444
M5^%'[V%%%% !1110 4444 %%%% !7YSU^C%?G/7Z=X<?\Q7_ &Y_[>?EOB5_
MS"_]Q/\ VP****_3C\M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[2_
M9+_Y-^\/_P#;W_Z5S5Z-7G/[)?\ R;]X?_[>_P#TKFKT:OYWSO\ Y'6)_P"O
MD_\ TIG]'Y'_ ,B3"_\ 7N'_ *2@HHHKRSU0HHHH **** "BBB@ HHHH \V_
M:1^-WQ#^"6B:;JGP\_9T\2?$6:^NGBN++PW-"CV:A<B1_-(!!/''>O(O^&^_
MVF?^D8/Q3_\  ZR_^*KZFHH ^6?^&^_VF?\ I&#\4_\ P.LO_BJ/^&^_VF?^
MD8/Q3_\  ZR_^*KZFHH ^6?^&^_VF?\ I&#\4_\ P.LO_BJ/^&^_VF?^D8/Q
M3_\  ZR_^*KZFHH _/#XM>/?VF?BC\0=0\=_\,!_%.Q^W>5_HOV>REV;(DC^
M]]H7.=F>@ZXKG-G[3/\ T8U\4_\ P7V7_P DU^F5%?14.+.(,-1C2IUK1BDD
MN6&B2LMXGS=?A'A[$UY5JE&\I-MOFGJV[O:5MS\S=G[3/_1C7Q3_ /!?9?\
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M^2:_3*BC_7+B3_G_ /\ DL/_ )$/]2N&?^?'_DT__DC\S=G[3/\ T8U\4_\
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M37Z944?ZY<2?\_\ _P EA_\ (A_J5PS_ ,^/_)I__)'YF[/VF?\ HQKXI_\
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M_M!^ _AW8Z#^RE\/M'\0?$/Q5K":3X</B>::+1M))AEGEU'47@!E^S0Q0O\
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MOE=IEV^0_P#!+S_@H'^V7X[_ &MOBI_P3/\ ^"C?@;PM!\5_ACH]KK^F>,/
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MCQ+XT\-?VCJZZ3:F"V65II5VQH68JH"@ %B>.237T%0 4444 %%%% !1110
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M)&H>$HO"VCV_AS3Y+?2_#>B+<&ZDM+?S7:6XEFN-LDUS)MW^3"J11+&0_N=
M'YR?\'&_[,-Q<?LRZ;_P4U^"7B5/"WQD_9DO8_$OA3Q''$3]ML!,@NM-GQ_K
M(G#;PK9&0\9PL\AKZ!_X)7:)K'CW]F_3/VY_B;<VUYX__:%T72_&?B&YM580
MZ=87%HDNF:-;[\LMO9VLJIC/SSR7,Q^:=JTO^"I'[+_QK_;9_8R\9_LD?!K6
M_#&BOX]TAM-U3Q%XEFN&&GPF6)B8K>&,^>S*KKEI(PAVG#Y('0_\$_?@E\8?
MV8_V1/A_^S-\9+_PWJ-Y\._!VF>&['6_#=S.8]2MK*V2WCF>&:)3 Y2-,J'D
M!.3E<[0 >SU^8/\ P:F_\F7?&S_LZGQ7_P"DNF5^E7C2?QI;>&;J7X>:5I=[
MK(0"RM]:OY+:V+$@$O)%%*X &3@(=Q 7*YW#XY_X(N?\$Z_VE_\ @F5\,_&W
MP:^+OC[P1XOTSQC\1-1\9?VSX?\ M=I<6=U=PVT<EMY$L;+)'FW#!_,5EW$$
M-Q@ \;_X.7^G[''_ &>!X7_]JU^GU?#_ /P5W_X)V?M4?\%#]?\ A)%\(O'O
M@#PKI?PD^)=CXVLKCQ&+V\FU:]M0#%#)%"D8@B!,@;$CLX*D%,$'K_CA^SU_
MP5$_:>^'EW\'/$7[5OPX^$^B:S;M;>(=>^&7A._O==FM7&V2&SN+VY2*P9U+
M+YWE3.F04VL,T ?''_!L+;MJ?[3_ .WQX^\!?-\-M6_:%E3P1+;_ /'JY2]U
M>23RB./^/>?3SQ_"4]J_7BO*/V*/V*_V?_\ @G[^SKH?[,/[-?A1M+\-Z(KN
M9+F42W>H74AS+=W,N!YLTAY+8  "JJJBJJ\K_P %'O@O^VS^T)\!7^$/[$WQ
MS\,?#K4]9N/*\1^)M>LKJ:X6PP-]O:&V96A>7E&F#!T0GRRKE9$ .!\1_#"R
M_P""@?[?/@7XSM;K-\*OV;M1U*;0]1(S'XH\:S)]ED: ]'M=,C613*O#WDK1
M@G[+(#X%^Q[9W]I_P=*_M<2^(PPDNO@SX5E\.^8/O6(M-+28I_L_:%8''\6:
M[;X9?L6?\%R=%3PO\+_%7_!0'X.:%\-],N;&TU;2/AQ\+&TR^318702V=C*2
M5M':!6B210&CW!E(*@U[E^T/^Q)XMU/]LGPA_P %#_V9-8T33_B5X>\*W7A+
MQ-I'B-YH=-\7>'IY1.MG// DDEK-!<JL\4ZQ2C[R/&P*E #Y91=2U3_@[8>3
MPPK&'3?V/@OB-H^@1M7R@?'^U);D ^@]*^I_^"D.M^,/BM\)M1_8,^!5W&WQ
M ^,6A76CSW93?'X7\/3@V^HZY<@?=6.&22.!"09KJ2)%^597CK_LY_L0_$'X
M/?$_XP_MH>-/$OAO7?CM\6K.W@6=;>=-#T"RLK;RM.TJ#/[^2!7 DGFPCSN2
MPCCVJH^</AW^P?\ \%_?ACXA\3^,?#__  4*^!$VM>,-7:_\0:SJ/PLNI[FX
M(R(+<.TGR6\$9\N&%<(B[C@N\CN ??WP&^"O@/\ 9P^"?A+X ?"[3FM/#G@O
MP[9Z+HL$C;G6VMH5B0NV!N<A06;JS$D]:^;/$?PPLO\ @H'^WSX%^,[6ZS?"
MK]F[4=2FT/42,Q^*/&LR?99&@/1[73(UD4RKP]Y*T8)^RR TOC'^R;_P50\7
M?L&Z9^SSX$_;=\+)\4]<O;F7XE_%#5]%N8Q-;RS,YL]+M[4Q_88_**6X=2KK
M'&S*1-(95X7X9?L6?\%R=%3PO\+_ !5_P4!^#FA?#?3+FQM-6TCX<?"QM,OD
MT6%T$MG8RDE;1V@5HDD4!H]P92"H- 'Z#4444 %%%% !1110 4444 %?#'_!
MRK8>-=2_X(B_'BW\!).UXNCZ5+<BWSO^Q)K-@]V>/X1;K,6[;0U?<]9OC/P=
MX5^(G@_5?A_XZ\/VNK:)KFFSZ?K&EWT(D@O+6:-HY89%/#(Z,RD'J": /!O^
M"0FI>&]6_P""57[.%WX4:(V8^"'AB(B+HLT>EVZ3*?\ :$JR!O\ :!KX;_X.
M)-.U36_^"EW_  3FTOX>(S>+A\;KB:U^S F2.Q2_T-[AWQSY01&9L\;5D]Z]
M1U;X:?MR?\$)_P!FS6-%_8?^";?M*_!C1=1N[_P_\-[S6Y=/\4^"[:=WFD@M
MKA(;@:O9)*S.L?E)<IYA&95RR:G_  2B\.?#/_@H]XXTG_@M)\6/BAIGB_XA
M-H$GAOPOX*TNQ:VL?A2@+"\TWRI7>63469W$UW+L,D<@\J-(F7(!]6_MM?##
M]K#XP? /6_ '['7[0^A_#+Q;J-A-#;^)]8\*/JCPEEPODE;B(6S]1YQCGVYW
M+&2HKYN_X-^_VA?BO\1OV2_$G[+_ ,?/A3H'A+QO^SIX\N_ASKUMX4M?)TV]
M^QQQM'=Q*. SB1BQ'$A'FC'F[5]9U'P]_P %<-(_:#\5W/AGXC? ;6/A?JER
MK^$H==T35K;6="38 4E6W<Q7H#9/+Q,_9HP=H[_]D3]E3PY^RAX#UK1;3Q%-
MK_B3QEXMOO%?C[Q5<VJP/K>MWC*9[@0H2L$2JD4,4(+>7##&I9V#.P!ZM7X]
M_P#!5?X<_%O_ ()N?\%6_A=^U[^PCXVTSPOJ/[7>N1?"WXAZ/J-BTUBNL73Q
M067B 0J0KS0M,DS+QN:W8'/VF8U^PE?#O_!53_@G7^U7^WI\:_@;X]^%'CSP
M#X8TOX%_$RR\:Z:-?:]NKC6[RWDMY4AD2*)5MHPT3J=K2E@P;*8VT ?6/[/W
MP,\!_LU?!KP_\#OAK;3II'A^Q\B*>\F,MS>2LQDGN[B0\RW$TSR32R'EY)78
M\L:^9O\ @X2_Y0P_M _]B4O_ *66]?7OAV;Q#<:);3^+--LK/4FB!O+;3KU[
MF"-_1)7BB9Q[E%^E?/G_  57_93^-O[='[%WC#]D'X-Z_P"%]"/CO3EL=5\1
M^))KA_L$*W$,I\JWAC/G,X1ERTB!.#A\X !N?\$O?^4:'[.__9"_"/\ Z9K2
MOC4_\K;X_P"S/_\ W+5]O_L(?![XO?LZ?LG> ?V=/C)=^';[4/A_X/TOPY;:
MSX;N9S%J4%E:1VR7#Q31*8'98P2@:09R0P!VCY=\6_\ !.O]OZY_X*SW/_!4
MGP)X^^$%E,WPU7P3:>"]875+M$L1,)S,US$D):8R GB,*%.W!(W$ ]C_ ."U
M.J>!](_X))?M&W?Q"D@6P?X/:[# ;D@*;V2SDCL@,_Q&Z> +_M%:X+_@W'T/
MQSX>_P"")_P"L/B''<+J$GAN]N;<7((;[#-JEY-9$9_A-I) 5_V<4G[2O_!,
M;]HO_@H_?Z-X/_X*&?M,:*GPETG5(-1O?@[\)M N=/@\17$+!X_[3U.ZN))Y
MH5;GR88H!T;=O577[1\/Z!H?A30;+PMX8T>UT[3--M([73M/LH%BAMH(U"1Q
M1HH 1%4!0H    % %3QWXZ\'?##P9JGQ$^(7B2TT?0]$L9;W5M4OYA'#:P1J
M6>1V/0  U\V?L*?L[>)=8_:#^*7_  4G^,7A2YT3Q3\7DL-,\)>&]2@,=WX>
M\)6"%;*&X0\Q7=TY>\GB/,1DBA.&B?/+_P#!13]DC_@I]^TU\:?"NO?LQ_M+
M_"OPCX$\'S1:C9>&/%_A*ZU-M2U=/FCO;M5=8Y!;L T$1!5) )CND2(Q;G[(
MG[/G_!630?CK;>._V[OVWO!/B[PAI6D7(TWPE\//!C:0+K4I-D:3W<CDM-%'
M"T^V'.TR/'(03$I !\\?\&E=G?Z=_P $MM6TWQ$&&NVWQF\1Q>)%E'[Q;Y3;
MB0/WW8VYS3O^#:==2NXOVQ?$-FK#P_?_ +8/BIM&(_U;.#$9"O;[C0#(]!Z5
M] >#?V&_VBOV1/BI\7?$'["'BKP-:^&/C3XC?Q1J&A>-X[M5\)>)9XEBO-3M
M$MD87T5QLBE:SD:WVR1G;.$?8E;3O^"=GQR_90_X)M6_[$O_  3<^-^C^%?&
M,\DSZS\4?&FG27-U<7-VTDM_J:QP\?:Y)6 C+$K"F -QC2@"3]ICX867_!1G
M]J_X?_"&V@6Y^%WP#\?V_C+Q]K &8M5\56D3C3-#A;I(+<SM=7AY52+:#EWE
M$7N/[;7_ "9E\7/^R8:__P"FZ>OBSX??L)?\%Z_A[\.]-^"G@W_@HC\$?"OA
M:S@%H'\,?">7[=;0,V9IHI+AI ]RVYW,LH=GE<NY9F+'[4_:B^&'Q*^(W[,/
MBGX'_!RXT@:KXC\+7>@1:GXLU*X,=I%<6DD!N7*1R27,B[E.PE-_),@/4 \)
M_P"#?W_E#1^SY_V(:?\ I1-7V'7SQ_P2U_99^,7[$'[%?@O]D?XO:YX:UJ7P
M'I?]G:;X@\.37"KJ$/FR2!I()HQY+*'5?E=PV"?DZ5]#T %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!QGQ/_9X^!_QFU73/$?Q-^%VCZMJ^AN7
MT'7IK0)J.DN007M+Q-L]JQ!(W1.IP3SS75Z5IMOHVF6^DVDEP\5M"L4;W=W)
M/*548!>25F>1O5F)8GDDFK%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5PK_LS? 9/B;-\:-)^&6G:3XM
MO'C.I^)- #Z=>ZF$.Y$O);5HVO(P22(YRZ<GCDUW5% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>jnj-20221002_g6.jpg
<TEXT>
begin 644 jnj-20221002_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **XOQ;^T/\ ![P+X@N/"WBKQ?\ 9;^UV>?!_9]P
M^W<@=?F2,J<JP/![UF_\-9_L_?\ 0_\ _E*N_P#XU7HPR?-JL%.&'FT]4U"3
M33V:=CS:F<Y12FX3Q%--.S3G%--;IJ^YZ-17G/\ PUG^S]_T/_\ Y2KO_P"-
M4?\ #6?[/W_0_P#_ )2KO_XU5_V)G7_0-4_\ E_D1_;F2?\ 053_ / X_P"9
MZ-17G/\ PUG^S]_T/_\ Y2KO_P"-4?\ #6?[/W_0_P#_ )2KO_XU1_8F=?\
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M .-4?V)G7_0-4_\  )?Y!_;F2?\ 053_ / X_P"9Z-17G/\ PUG^S]_T/_\
MY2KO_P"-5T?@#XM?#[XH_:_^$$\0?;OL/E_:O]$EBV;]VW_6(N<[&Z9Z5E6R
MO,\-2=2K0G&*W;C))=-VC:AFN5XFJJ=&O"4GLE*+;Z[)WV.CHHHK@.\****
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M&,DVNEQ2I5804I1:3V=M"_1115F84444 %?1G[ /_,V_]N'_ +<5\YU]&?L
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M1%R3_GW4^Z/_ ,F?:5%?%O\ PUG^T#_T/_\ Y2K3_P"-4?\ #6?[0/\ T/\
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M9?MM>&;+5_$">.9=*TW1-9P)+#P='#&^EW-EGYH$D=IYFFB()F&6.Y1CJ?\
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M.<)03M):N\6M>6Z3O9M)JS3\M3WWPUKUIXI\.:?XGT^.1(-2L8KJ!95PX21
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M"$#WKY>3]I_]I&X_8*/_  40LOB3X4GB'A,^*CX#CT;.GBQ5?,?3OM?F>?\
M;%0-$9ON>>#^XV_+6F(QM'#2Y97;2<G;I%;O_AM3/#8&MB8\T;).2BK]9/9;
M/\=/,^O:*^;_ (J?M:^,/$'QA^"'[/\ \)C_ ,(_>?%S1;W7]3UG4K!9[C1]
M-MK)+@11PN=AN)))$CW/N6,(YV,2N-_]@_\ :6\6?M%^ ?&.G?$>WLE\3_#?
MXDZSX*\0WFG0&*WOY["50MW'&S,8Q)%)&2NX@-NQ@8 FGF&'J8CV,=]K]+I*
M5O6TD^WS153+L32PWMI;:.W6S;C?TO%K>_R9[C17FOP,^)?BSXU^(==^)FG7
M447P_P!XT_P6@@'F:N8G87&J;SSY$C_NX%'#QQ&;++-'M]*KII58UH<\=GMY
M^?H^GD<M6E*C/DENM_+R]5U\PHHHK0S"OHS]@'_F;?\ MP_]N*^<Z^C/V ?^
M9M_[</\ VXKYCC+_ ))NO_V[_P"EQ/J>"O\ DIJ'_;W_ *1(^C****_"C]["
MBBB@ HHHH **** "BBB@ K\YZ_1BOSGK].\./^8K_MS_ -O/RWQ*_P"87_N)
M_P"V!1117Z<?EH4444 %%%% !1110 4444 %%%% !1110 4444 ?:7[)?_)O
MWA__ +>__2N:O1J\Y_9+_P"3?O#_ /V]_P#I7-7HU?SOG?\ R.L3_P!?)_\
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M@_)/;.DL9XZHP.,CH365:E"M2<)*Z?3H_7R[FM"K.C54XNS77JO->?8^5/\
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M7G/[)?\ R;]X?_[>_P#TKFKT:OYWSO\ Y'6)_P"OD_\ TIG]'Y'_ ,B3"_\
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M-_U[A_Z2C^;\\_Y'>*_Z^3_]*84445Z9Y84444 %%%% !1110 4444 %%%%
M!1110 5]&?L _P#,V_\ ;A_[<5\YU]&?L _\S;_VX?\ MQ7S'&7_ "3=?_MW
M_P!+B?4\%?\ )34/^WO_ $B1]&4445^%'[V%%%% !1110 4444 %%%% !7YS
MU^C%?G/7Z=X<?\Q7_;G_ +>?EOB5_P PO_<3_P!L"BBBOTX_+0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ^TOV2_P#DW[P__P!O?_I7-7HU><_LE_\
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M,:^*?_@OLO\ Y)HV?M,_]&-?%/\ \%]E_P#)-?IE16O^N7$G_/\ _P#)8?\
MR)E_J5PS_P ^/_)I_P#R1^9NS]IG_HQKXI_^"^R_^2:-G[3/_1C7Q3_\%]E_
M\DU^F5%'^N7$G_/_ /\ )8?_ "(?ZE<,_P#/C_R:?_R1^9NS]IG_ *,:^*?_
M (+[+_Y)HV?M,_\ 1C7Q3_\ !?9?_)-?IE11_KEQ)_S_ /\ R6'_ ,B'^I7#
M/_/C_P FG_\ )'YF[/VF?^C&OBG_ ."^R_\ DFC9^TS_ -&-?%/_ ,%]E_\
M)-?IE11_KEQ)_P __P#R6'_R(?ZE<,_\^/\ R:?_ ,D?F;L_:9_Z,:^*?_@O
MLO\ Y)HV?M,_]&-?%/\ \%]E_P#)-?IE11_KEQ)_S_\ _)8?_(A_J5PS_P ^
M/_)I_P#R1^9NS]IG_HQKXI_^"^R_^2:-G[3/_1C7Q3_\%]E_\DU^F5%'^N7$
MG_/_ /\ )8?_ "(?ZE<,_P#/C_R:?_R1^9NS]IG_ *,:^*?_ (+[+_Y)HV?M
M,_\ 1C7Q3_\ !?9?_)-?IE11_KEQ)_S_ /\ R6'_ ,B'^I7#/_/C_P FG_\
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M?_@OLO\ Y)K],J*/]<N)/^?_ /Y+#_Y$/]2N&?\ GQ_Y-/\ ^2/S-V?M,_\
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M?=MW>Q])0H4L-0C1IJT8I)+LDK+?78^6?^&^_P!IG_I&#\4__ ZR_P#BJ/\
MAOO]IG_I&#\4_P#P.LO_ (JOJ:BLC4^6?^&^_P!IG_I&#\4__ ZR_P#BJ/\
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M5O-*T2ZO4N?#YL;:>&&-&E@VW@=9$#$^3@J6&?N5]D4 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>jnj-20221002_g7.jpg
<TEXT>
begin 644 jnj-20221002_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4;PEL^:*_.29\_B^*<AP&)E0KUK3CNN63\]U%H^C**^<_P#AO[_JDW_E>_\
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M_AO[_JDW_E>_^T4?\-_?]4F_\KW_ -HH_P!3>)/^?'_DT/\ Y(/]=>&?^?\
M_P"2S_\ D3Z,HKYS_P"&_O\ JDW_ )7O_M%'_#?W_5)O_*]_]HH_U-XD_P"?
M'_DT/_D@_P!=>&?^?_\ Y+/_ .1/HRBOG/\ X;^_ZI-_Y7O_ +11_P -_?\
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M7OV\O^1WT/\ [!3_ /HTUX17N_[>7_([Z'_V"G_]&FO"*_>^%/\ DGL/Z/\
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M[HWS6LJ\82JQBJUY<W+9)K3E;4=%*_->UKI)VUNRBBBO7/'"BBB@#L?V??\
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M,EI$UQ%$\<4YC!=$<J64-U )1"1T)1<]!4M%% !1110 4444 %%%% !1110
M4444 =C^S[_R6OPU_P!A6.ON>OAC]GW_ )+7X:_["L=?<]?DGB'_ ,C*C_@_
M5G[!X<_\BRM_C_\ ;4%%%%?GQ^B!1110 4444 %%%% !1110 4444 %%%% !
M7DG[:O\ R11O^PK;_P#LU>MUY)^VK_R11O\ L*V__LU>SP[_ ,CW#?XX_F>)
MQ)_R(<3_ ('^1\A4445_09_.P4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'Z!^!?^1(T;_L%6__ **6M6LKP+_R)&C?]@JW_P#12UJU_-.(_CS]
M7^9_3N&_W:'HOR"BBBL3<**** "BBB@ HHHH ^7OV\O^1WT/_L%/_P"C37A%
M>[_MY?\ ([Z'_P!@I_\ T::\(K][X4_Y)[#^C_-G\_<7?\E'B/5?^DH****^
MA/G HHHH **** "BBB@ HHHH **** "BBB@ HHHH [']GW_DM?AK_L*QU]SU
M\,?L^_\ ):_#7_85CK[GK\D\0_\ D94?\'ZL_8/#G_D65O\ '_[:@HHHK\^/
MT0**** "BBB@ HHHH **** "BBB@ HHHH *\D_;5_P"2*-_V%;?_ -FKUNO)
M/VU?^2*-_P!A6W_]FKV>'?\ D>X;_''\SQ.)/^1#B?\  _R/D*BBBOZ#/YV"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _0/P+_ ,B1HW_8*M__
M $4M:M97@7_D2-&_[!5O_P"BEK5K^:<1_'GZO\S^G<-_NT/1?D%%%%8FX444
M4 %%%% !1110!\O?MY?\COH?_8*?_P!&FO"*]W_;R_Y'?0_^P4__ *-->$5^
M]\*?\D]A_1_FS^?N+O\ DH\1ZK_TE!1117T)\X%%%% !1110 4444 %%%% !
M1110 4444 %%%% '8_L^_P#):_#7_85CK[GKX8_9]_Y+7X:_["L=?<]?DGB'
M_P C*C_@_5G[!X<_\BRM_C_]M04445^?'Z(%%%% !1110 4444 %%%% !111
M0 4444 %>2?MJ_\ )%&_["MO_P"S5ZW7DG[:O_)%&_["MO\ ^S5[/#O_ "/<
M-_CC^9XG$G_(AQ/^!_D?(5%%%?T&?SL%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!^@?@7_ )$C1O\ L%6__HI:U:RO O\ R)&C?]@JW_\ 12UJ
MU_-.(_CS]7^9_3N&_P!VAZ+\@HHHK$W"BBB@ HHHH **** /E[]O+_D=]#_[
M!3_^C37A%>[_ +>7_([Z'_V"G_\ 1IKPBOWOA3_DGL/Z/\V?S]Q=_P E'B/5
M?^DH****^A/G HHHH **** "BBB@ HHHH **** "BBB@ HHHH [']GW_ )+7
MX:_["L=?<]?#'[/O_):_#7_85CK[GK\D\0_^1E1_P?JS]@\.?^196_Q_^VH*
M***_/C]$"BBB@ HHHH **** "BBB@ HHHH **** "O)/VU?^2*-_V%;?_P!F
MKUNO)/VU?^2*-_V%;?\ ]FKV>'?^1[AO\<?S/$XD_P"1#B?\#_(^0J***_H,
M_G8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#] _ O_ ")&C?\
M8*M__12UJUE>!?\ D2-&_P"P5;_^BEK5K^:<1_'GZO\ ,_IW#?[M#T7Y!111
M6)N%%%% !1110 4444 ?+W[>7_([Z'_V"G_]&FO"*]W_ &\O^1WT/_L%/_Z-
M->$5^]\*?\D]A_1_FS^?N+O^2CQ'JO\ TE!1117T)\X%%%% !1110 4444 %
M%%% !1110 4444 %%%% '8_L^_\ ):_#7_85CK[GKX8_9]_Y+7X:_P"PK'7W
M/7Y)XA_\C*C_ (/U9^P>'/\ R+*W^/\ ]M04445^?'Z(%%%% !1110 4444
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M^5EJ;E%8?AOXF?#OQCX!A^*OA/QSI.I>&;FQ:]M_$%C?QRV<ELH):99E)0H
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M_#7_ &%8Z^YZ_)/$/_D94?\ !^K/V#PY_P"196_Q_P#MJ"BBBOSX_1 HHHH
M**** "BBB@ HHHH **** "BBB@ KR3]M7_DBC?\ 85M__9J];KR3]M7_ )(H
MW_85M_\ V:O9X=_Y'N&_QQ_,\3B3_D0XG_ _R/D*BBBOZ#/YV"BBB@ HHHH
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MEDL\MO:P3.P,KS2"(-(7"+&[%6)7';?L'_M+>+/VB_ /C'3OB/;V2^)_AO\
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M_P B'$_X'^1\A4445_09_.P4444 %%%% !1110 4444 %%%% !1110 4444
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M "6'_P B?._ZE<,_\^/_ ":?_P D?F;L_:9_Z,:^*?\ X+[+_P"2:-G[3/\
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M?_@OLO\ Y)K],J*/]<N)/^?_ /Y+#_Y$/]2N&?\ GQ_Y-/\ ^2/S-V?M,_\
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M+_XJOJ:BO//1/EG_ (;[_:9_Z1@_%/\ \#K+_P"*H_X;[_:9_P"D8/Q3_P#
MZR_^*KZFHH JZ%J%UJVB6>JWNERV,US:QRS64Y!>W9E!,;8XRI.#CN*M444
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MNUT?QO#\$_#<#7GB#29+Y+.Y&F6X_P!(MUG@>5E'#+YJ'<#S7Q+^S[\9+_\
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M\=>'[75M$US39]/UC2[Z$207EK-&T<L,BGAD=&92#U!- '@W_!(34O#>K?\
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M>JNOVCX?T#0_"F@V7A;PQH]KIVF:;:1VNG:?90+%#;01J$CBC10 B*H"A0
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>jnj-20221002_g8.jpg
<TEXT>
begin 644 jnj-20221002_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN?\ MY^6^)7_ #"_]Q/_ &P****_3C\M"BBB@#YM_P""L?QL^*G[/W[%&O\
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M/X:?!GP]H*>)O 'Q!E\=ZD4-OJ'C?4_$G]KWEU)P9 9M[)""<'R8A'&O 5%
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MOSGK].\./^8K_MS_ -O/RWQ*_P"87_N)_P"V!1117Z<?EH4444 <9\=?@+X
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M%S5-/?XB?$S4H7UJ2*X'E6Z0PO\ 9-(M"VTR1V\"R'< &E<SS%5W;5ZOXV_
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MEW>U]#Z_HHHKVSP@HHHH ^TOV2_^3?O#_P#V]_\ I7-7HU><_LE_\F_>'_\
MM[_]*YJ]&K^=\[_Y'6)_Z^3_ /2F?T?D?_(DPO\ U[A_Z2@HHHKRSU0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ^+?VM/\ DX'Q!_VZ?^DD-><UZ-^U
MI_R<#X@_[=/_ $DAKSFOZ)R3_D2X;_KW#_TE'\WYY_R.\5_U\G_Z4PHHHKTS
MRSS?]J+]EWX?_M<_#?\ X5/\4==\16NAO>1W-W;>'M:>Q-VR<HDK(,N@;#;.
MFY5)Y48\5TO_ ((S?LC6&LV.JZCXD^).KQ6-_#=?V;K7Q!O+FTN&BD614EB<
M[9$)4 J>HR*^LJ*XJ^78#$U?:5::E+NU?8[J&99AAJ7LZ55QCV3MN>+?&/\
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MG_I)#7G->C?M:?\ )P/B#_MT_P#22&O.:_HG)/\ D2X;_KW#_P!)1_-^>?\
M([Q7_7R?_I3"BBBO3/+"BBB@ HHHH **** "BBB@ HHHH **** "OHS]@'_F
M;?\ MP_]N*^<Z^C/V ?^9M_[</\ VXKYCC+_ ))NO_V[_P"EQ/J>"O\ DIJ'
M_;W_ *1(^C****_"C]["BBB@ HHHH **** "BBB@ K\YZ_1BOSGK].\./^8K
M_MS_ -O/RWQ*_P"87_N)_P"V!1117Z<?EH4444 %%%% !1110 4444 %%%%
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M?BG_ .!UE_\ %5]345X1[Y\L_P##??[3/_2,'XI_^!UE_P#%4?\ #??[3/\
MTC!^*?\ X'67_P 57U-10!\L_P##??[3/_2,'XI_^!UE_P#%4?\ #??[3/\
MTC!^*?\ X'67_P 57U-10!\L_P##??[3/_2,'XI_^!UE_P#%4?\ #??[3/\
MTC!^*?\ X'67_P 57U-10!\L_P##??[3/_2,'XI_^!UE_P#%4?\ #??[3/\
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MF?\ HQKXI_\ @OLO_DFOTRHH_P!<N)/^?_\ Y+#_ .1#_4KAG_GQ_P"33_\
MDC\S=G[3/_1C7Q3_ /!?9?\ R31L_:9_Z,:^*?\ X+[+_P"2:_3*BC_7+B3_
M )__ /DL/_D0_P!2N&?^?'_DT_\ Y(_,W9^TS_T8U\4__!?9?_)-&S]IG_HQ
MKXI_^"^R_P#DFOTRHH_URXD_Y_\ _DL/_D0_U*X9_P"?'_DT_P#Y(_,W9^TS
M_P!&-?%/_P %]E_\DT;/VF?^C&OBG_X+[+_Y)K],J*/]<N)/^?\ _P"2P_\
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M5\-?V<?@]XE^//QB\31:/X7\(Z-/JFNZE,"1#;PH68A1R['&%1069B% )(%
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M[K3;OPWKMRZI:P213.1)"[..NYBB2-O4Q[) #].**^4OVI?VUOB*W[<_P_\
M^"9W[+]_I-AXY\4^%[SQAXW\6ZOIYOHO"WANWD\E)(K821B:ZN;G$,>]MD0!
MD=) 50K^S-^VUXYLOVU_B-_P3@_:DU72[SQIX.\*6GC/P=XNTO3C91^*/#$[
M>2\TMMO<0W5M<AH9/+;9*"KHD?S( #ZLHK\V?VH/C=_P<#:'\(]<_;L^!^@_
M!72/!>A:9+X@L?@9XATB^N/$%UH<2&8_;+L.B)J#0 R-;0E50_NP\CK\_P!A
M?L/?M=:=^W1^Q1X&_:^^'?A+^SSXW\+C4+?0M3O2JVUXI>.6V>=8V.Q9XW3S
M1&25 ?9SMH ]DHKXP_X)H?MQ_M3?M/\ [8'[4WP!_:5\.>#M)3X+>+-$TCP[
M9^#C<2QF&Z@NYFDEN+C:\[LJ0\^7$HP0$')/V?0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% &5X[A\17'@?68/"$FS5GTJ
MX72WW8VW!B81G/;Y]M?EO_P9TW&GK_P2M\1:(T31:QI_QIUJ+Q%!.")DN_LF
MGG]X#R&\LQCG^[CL:_5VOB'Q1^P7\<OV$OCC\3OVT?\ @F'I>BZZ?B0?[6^(
M?[/WB:]-AI^OZM'N;[?I6H*&&F7DFZ0.DL<D$S2?,8MJLH!P7_!UU)X;3_@B
M/\2TUPQ?:GUSPZ-&\S&?M/\ ;%H6V^_D"?\ #-?5_P"RQX:^.MO_ ,$\?A;X
M27Q-9:!\1(?A)X>MK[5/$>ARZC%::DNG6RW#36R7%N\I#B0;?.3YN23@@_!W
M[)WQ4C_X+]?'9M%_;R\+CX7_ /#/'C6/5IOV3;Z*5K^\U)$"VFL:K=7"1&\M
M(S)(D=O%;QIO),S.DD:O]P_M+Z#_ ,%+Q\;_  WXL_8]\>_!]_ D6DM!XK\'
M_$?2]0CNI[KS687-M?69<I\A1?+:/:"C$[MX\L ^2?\ @DU\1_VR_P!FG_@I
M=\:?^"9?[<5QX9\8^(_$'A]_B]H/Q=\.Z*+"7Q'9S7L.G.MW&. 8R8H(H_\
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MGPV\"?&3X>:Y\)OBAX7M=;\.>)-*GTW7-(ODW0WEK-&8Y8G'7#*Q'&".H(-
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M6\TK1+J]2Y\/FQMIX88T:6#;>!UD0,3Y."I89^Y7V10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q7Q)_9R^!GQ>
M\1:;XT^(7POTF_\ $&B@C0_$RV_D:KI@.=WV:]B*W%OG)SY<BYR<]:["PLH=
M-L8=.MWE:.")8T:>=Y9"%  +.Y+.W'+,22>22:EHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N%LOV9?@
M-H_Q+N?C'X9^&6G:'XHU"9)=8UOPZ'TZ?5F4Y7[<UJT?VX#)PMQY@&3Q7=44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>jnj-20221002_g9.jpg
<TEXT>
begin 644 jnj-20221002_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYST4?\0X_P"HK_R3_P"W#_B)7_4+_P"3_P#VA^C%%?G/11_Q#C_J*_\ )/\
M[</^(E?]0O\ Y/\ _:'Z,45^<]%'_$./^HK_ ,D_^W#_ (B5_P!0O_D__P!H
M?HQ17YST4?\ $./^HK_R3_[</^(E?]0O_D__ -H?HQ17YST4?\0X_P"HK_R3
M_P"W#_B)7_4+_P"3_P#VA^C%%?G/11_Q#C_J*_\ )/\ [</^(E?]0O\ Y/\
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M_P"W#_B)7_4+_P"3_P#VA^C%%?G/11_Q#C_J*_\ )/\ [</^(E?]0O\ Y/\
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M@ HHHH **** "BBB@ HHHH _03P/_P B7H__ &"[?_T6M:E9?@?_ )$O1_\
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MS^"? 7Q"G^,&L>(-<\5^,)M*72X_$WBF[CFN+6P#[_LL"0QQ0PH7PSE(P\A
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M >Q>VDY[U]M5G>$?"/ACP#X6T[P1X*T&UTO2-)LX[33-.LH1'#;01J%2-%'
M4   5HUT9?A/J.!IT+WY59ON^OXG-F.+^OXZIB+64G=+LNGX!11178<05]??
ML6?\D3C_ .PI<?\ LM?(-?7W[%G_ "1./_L*7'_LM?%\>_\ (B_[?C^3/M_#
M_P#Y'S_P2_-'K5%%%?BY^VA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?#/[0G_);/$O\ V%'_ *5]S5\,_M"?\EL\2_\ 84?^E?H'AY_R,JW^
M#_VY'YWXC?\ (LH_X_\ VUG&T445^N'X^%%%% !1110 4444 %%%% !1110
M4444 %%%% 'Z">!_^1+T?_L%V_\ Z+6M2LOP/_R)>C_]@NW_ /1:UJ5_-.(_
MCS]7^9_3V'_W>'HOR"BBBL38**** "BBB@ HHHH ^7_V\_\ D=-"_P"P6_\
MZ,->#U[Q^WG_ ,CIH7_8+?\ ]&&O!Z_>^%/^2>P_H_S9_/W%W_)1XCU7_I*"
MBBBOH3YP**** "BBB@ HHHH **** "BBB@ HHHH *^OOV+/^2)Q_]A2X_P#9
M:^0:^OOV+/\ DB<?_84N/_9:^+X]_P"1%_V_'\F?;^'_ /R/G_@E^:/6J***
M_%S]M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^&?VA/^2V>)
M?^PH_P#2ON:OAG]H3_DMGB7_ +"C_P!*_0/#S_D95O\ !_[<C\[\1O\ D64?
M\?\ [:SC:***_7#\?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]!/ _
M_(EZ/_V"[?\ ]%K6I67X'_Y$O1_^P7;_ /HM:U*_FG$?QY^K_,_I[#_[O#T7
MY!1116)L%%%% !1110 4444 ?+_[>?\ R.FA?]@M_P#T8:\'KWC]O/\ Y'30
MO^P6_P#Z,->#U^]\*?\ )/8?T?YL_G[B[_DH\1ZK_P!)04445]"?.!1110 4
M444 %%%% !1110 4444 %%%% !7U]^Q9_P D3C_["EQ_[+7R#7U]^Q9_R1./
M_L*7'_LM?%\>_P#(B_[?C^3/M_#_ /Y'S_P2_-'K5%%%?BY^VA1110 4444
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M_P!OQ_)GV_A__P CY_X)?FCUJBBBOQ<_;0HHHH **** "BBB@ HHHH ****
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M)L%%%% !1110 4444 ?+_P"WG_R.FA?]@M__ $8:\'KWC]O/_D=-"_[!;_\
MHPUX/7[WPI_R3V']'^;/Y^XN_P"2CQ'JO_24%%%%?0GS@4444 %%%% !1110
M 4444 %%%% !1110 5]??L6?\D3C_P"PI<?^RU\@U]??L6?\D3C_ .PI<?\
MLM?%\>_\B+_M^/Y,^W\/_P#D?/\ P2_-'K5%%%?BY^VA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %?#/[0G_);/$O_ &%'_I7W-7PS^T)_R6SQ
M+_V%'_I7Z!X>?\C*M_@_]N1^=^(W_(LH_P"/_P!M9QM%%%?KA^/A1110 444
M4 %%%% !1110 4444 %%%% !1110!^@G@?\ Y$O1_P#L%V__ *+6M2LOP/\
M\B7H_P#V"[?_ -%K6I7\TXC^//U?YG]/8?\ W>'HOR"BBBL38**** "BBB@
MHHHH ^7_ -O/_D=-"_[!;_\ HPUX/7O'[>?_ ".FA?\ 8+?_ -&&O!Z_>^%/
M^2>P_H_S9_/W%W_)1XCU7_I*"BBBOH3YP**** "BBB@ HHHH **** "BBB@
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M/?\ D1?]OQ_)GV_A_P#\CY_X)?FCUJBBBOQ<_;0HHHH **** "BBB@ HHHH
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MU\E9]=/2:***] \X**** /T$\#_\B7H__8+M_P#T6M:E9?@?_D2]'_[!=O\
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MA=7B\0RZ+ UZCJAC5Q,5WAE0L@;.0K%00"1755QY=E\\%*3E*]TEZV<GS/\
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M ,./>_XT?\.A_P!F;_H?_BG_ .''O?\ &C_B(_\ U"_^3_\ V@?\0U_ZBO\
MR3_[<\-HKW+_ (=#_LS?]#_\4_\ PX][_C1_PZ'_ &9O^A_^*?\ X<>]_P :
M/^(C_P#4+_Y/_P#:!_Q#7_J*_P#)/_MSPVBO<O\ AT/^S-_T/_Q3_P##CWO^
M-'_#H?\ 9F_Z'_XI_P#AQ[W_ !H_XB/_ -0O_D__ -H'_$-?^HK_ ,D_^W/#
M:*]R_P"'0_[,W_0__%/_ ,./>_XT?\.A_P!F;_H?_BG_ .''O?\ &C_B(_\
MU"_^3_\ V@?\0U_ZBO\ R3_[<\-HKW+_ (=#_LS?]#_\4_\ PX][_C1_PZ'_
M &9O^A_^*?\ X<>]_P :/^(C_P#4+_Y/_P#:!_Q#7_J*_P#)/_MSPVBO<O\
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MTU^SY^S-H]EKGQ]^,?A_PG#J=S]FTF/6=22*;49\9\FVASYES)CG9$K-CG%
M'<T5YA\#/VT?V5?VE-?U#P?\$OCKH&NZ[I4*S:IX<CNO)U.TB; 666SF"3QQ
MDG =D"D\ YK=^//[0_P+_9=^'%U\7OVBOBSH/@OPS92)'<:UXBU*.U@$CYV1
MJSD;Y&P=J+EFQP#0!V5%>=_LU_M;?LS?MB^!Y?B1^RY\<?#?CK1+>[-K=WWA
MW4TG%M. #Y4J@[HGVD-M< D$$#!!KM?$_BCP[X*\/7GBSQ;K5MIVF:? T]]?
MWDH2*"->6=V/"J.Y- %^BO)/@A^WQ^Q'^TOXI?P/^SM^UI\//'6L11&6;3/"
M7BZTU">- "=S)!(Q4?*>3@<5I?'']L?]D_\ 9DU?3= _:*_:/\%>!KW61G2+
M7Q7XDM[![WYMN(A,Z^8<\87)H ])HKQ?XD?\%&OV!?@YXK@\!_%K]LWX9>&=
M<N=/AOH-&U[QK96ET]M,F^*812R*^QT^8-C!'-<\?^"N_P#P2P%JUZ?^"BOP
M6$*2;'F_X63INU6_ND^=@'VH ^B:*\;^(W_!1#]@[X0:1H?B#XK?MB_#;PUI
M_B?3(=1\-W^N^,K.T@U6SEB26.XMI)9 L\;1R1N&0D%74YY%0>!?^"D__!/+
MXG>)+;P9\/OVYOA'K&L7I46.DV'Q$TV2ZN2QP/*B$V^3)X^4'J/6@#VNBBLO
MQOXX\%_#3PCJ/Q ^(OBW3-!T+1[1[K5M9UF^CMK6S@09:6660A(T Y+,0!0!
MJ45XO^S)_P %%_V%OVS-?U'PG^RW^U7X*\;ZMI41FO\ 2=#UI)+J.$$*9A"<
M.T0) \Q04!8#.2*[KXR?'GX-_L]^&H/%_P :OB1I7ANPN[Z.RL)-2N0KWMT^
M=EO;QC+SS, Q$<:LY"D@8!H ZZBN:^$WQD^%?QW\&Q_$'X.>/]+\2:-+<2V_
MV_2;M94CGB8I+!(!S'+&P*O&X#HP(8 C%>4>-_\ @J=_P3C^&OQQ/[-GC[]M
M?X<:1XX2\6TG\/7WBB".6WN2<""9BVR&4G \MV5\D#&2,@'OE% ((R#D'H:X
M[X8?M"_ OXV:]XD\,?![XN>'O%%]X/OX['Q1!H&JQ7?]EW3J66"9HR523 )*
M$[E[@4 =C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?-7_  6$
M_;%\2_L#?\$U?BU^U9X'2(Z_X;\/1P^'7FC#I#J-[=0V-M,R-PXCFN4D*GA@
MA!X-?2M?/G_!5;]C2[_X*!_\$]?BE^R+I&HP6FI^+?#P_L*XNFQ$NI6L\5Y9
MB0C)6,W%O$K, 2%+'!Z4 <%_P0M_9YT+X)_\$U?AIX\NWDU+QI\5_#%EX[^(
MGBW49#-J.NZKJL*WK2W4[9>5HTG2%<DX6,=R2?F'_@I7XVO/^"9'_!;W]F;]
MJ#X,8TO0/VF-7D\!_&CP_9CR[36)DN;2&SU2:,<-=1?V@K><!OV6NS.)'#?0
M7_!##]I_3?%O[#7@W]D_XPQGPC\8?@?X=MO!OQ ^'NONMOJ6GC3HA;VUWY3$
M&6VFMHHI4N$W1-EP&.TFO$?VQ?A_;?\ !7C_ (+$?L_^%/@C=1ZU\+/V4]:N
M?%?Q.\>:<XFTR37VFM)K30H)UREQ<HUC"TR(2(HYW#D.H0@'UC^VYJO_  33
M_9#^%WC_ /:,_;;T?P8FG^+;1D\2W'BNQBO[W7HXX%ACTZVBE#/,H0 );1#8
MK2/(0&DD<^??\&\7PE\$_!O_ ()._#?P[\/OC%I7C33-1DU'5X[S0M3-W9Z:
MUW>RSG38W;#!K??Y4@8 ^<LIP,XKW2^_;;_8*\<>*O&_P"\1?M*_#:ZU7PF)
M+/QYX4USQ#9H]FA3,B7$%PP#1[3AR04'*L<@BOG3_@@M^S!9_LY_##XWZ_\
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MTCXG?%U+=O[+O(%^U>%?#4 /]F:&6ZB548W%U@X:[N)5R4BBV^)_\%G/@?\
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M_@FW\)?VKO&D42Z[XG\.-'X@>"()'-J-G<S6-U*J#A%>>VD<*.%#@=J^=?\
M@M#_ ,% _!OQ5_9E\6?\$ZOV"-1MOC%\;_C%HDOAFU\,> KN/4DT/3;P>1>7
M^I3PLT5C"+=Y%!F=#ND5L;%=E^I_^":7['<'[ 7["'PR_9"35XM0N?!?AQ8-
M5O[<'RKC4)I'N;R2/< ?+:YFF*Y&=I&>: .A\<?L=? 7XK?'>/\ : ^,7P_T
MGQ?JNG^'(]&\-VGB73(;VVT.(S2RW,MK'*K+'-<%XEEE #,EK"F0%.[XI_X)
MO_LL>%/@3_P7'_:QUK]ECP[;^'/A%'X2\.6/B70-&B$.E)XOFC2[=+>),1JT
M5L[22(F!&U_C"A@H]N_X*1_\%9/V:?V(-;T7]G_Q#^T)X.\*?$;QE SV%UXH
MN=UIX:L.0^JWD2?/(%P1!;##7,H"[HXEFFBH_P#!//\ ;K_X)@>(-8TG]C?]
MAG]H*#XD^(KN'4?$/B34-*CEN[JXE+^;?:UJMTT:)YL]S-&I(^8R7$:I&L2?
MNP#QW_@V^\8R?M??L[_'/]NKXI6D6JZ]\;OCCK+WTU]&)?\ B1VMO;V]AIF&
M!S;P1M,B(<@+(V<Y-<S_ ,$0O"FC?M7_ +%WQ?\ ^"=GQUO[K6O!?P*_:1UG
MPC;:3<RF1-5\.65VMS9Z9<,Q+/;B<,C1G*O!$L!!C9EKH?\ @A?%X0_X)K_"
M#]H#]A+]HWQ;IWA.X^"_Q3U;Q!:7>N7B6\-WX.OHHIK#5T9R T+>5<(Y7(CD
MC*,0X*C'_P""0_BKP'_P36_X)N?%G_@HY^W+K#> ]/\ C-\7-<^(J66LQ&*]
M6PO7 TZT6 X:2YG6-YDB'S%;A<A<,0 3_P#!:?\ 86^"O_"V_P!DC7OV2/A)
MX?\ !WQI'[1>BVOAK4_!NCPV%P-!MXI[O4WG6W5?,M+>*".1MP(0'8.)F5ON
M[QQ^QU\!?BM\=X_V@/C%\/\ 2?%^JZ?X<CT;PW:>)=,AO;;0XC-++<RVL<JL
ML<UP7B664 ,R6L*9 4[OAWX-?\%DO^"4)\<:A^V?^T1^VQX+U#XD:AHS:;X9
M\': ]QJ<GA/2'D60:39I!$QN;VXD6)[J:,'SI4BC0F&WB)]T_P""B'_!7#]F
M[]C"Y\._ [Q/\=/"O@GXD^.;$3V?_"8W"M!X4LBO[S4K^*%F+E#E8;96S<S
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MOV ?'W[2/A3PYK6F> K'2?"&G>)M9AL;C5[:P@CM3,OFL%+NR9VYRS;MN<'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380710665872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  02,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Johnson & Johnson<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,614,483,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, Par Value $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes Due May 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.650% Notes Due May 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes Due November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Notes Due November 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24BP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes Due November 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes Due May 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380710835808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,355<span></span>
</td>
<td class="nump">$ 14,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">22,724<span></span>
</td>
<td class="nump">17,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, trade, less allowances $201 (2021, $230)</a></td>
<td class="nump">15,890<span></span>
</td>
<td class="nump">15,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Note 2)</a></td>
<td class="nump">11,675<span></span>
</td>
<td class="nump">10,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">3,592<span></span>
</td>
<td class="nump">3,701<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">65,236<span></span>
</td>
<td class="nump">60,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment at cost</a></td>
<td class="nump">46,681<span></span>
</td>
<td class="nump">47,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(28,529)<span></span>
</td>
<td class="num">(28,717)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">18,152<span></span>
</td>
<td class="nump">18,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (Note 3)</a></td>
<td class="nump">40,336<span></span>
</td>
<td class="nump">46,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 3)</a></td>
<td class="nump">33,383<span></span>
</td>
<td class="nump">35,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">9,392<span></span>
</td>
<td class="nump">10,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">8,625<span></span>
</td>
<td class="nump">10,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">175,124<span></span>
</td>
<td class="nump">182,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">4,424<span></span>
</td>
<td class="nump">3,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,153<span></span>
</td>
<td class="nump">11,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">11,953<span></span>
</td>
<td class="nump">13,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="nump">14,021<span></span>
</td>
<td class="nump">12,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee related obligations</a></td>
<td class="nump">3,006<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes on income (Note 5)</a></td>
<td class="nump">1,986<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">45,543<span></span>
</td>
<td class="nump">45,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note 4)</a></td>
<td class="nump">27,603<span></span>
</td>
<td class="nump">29,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">4,946<span></span>
</td>
<td class="nump">7,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employee related obligations (Note 6)</a></td>
<td class="nump">8,353<span></span>
</td>
<td class="nump">8,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term taxes payable (Note 5)</a></td>
<td class="nump">4,162<span></span>
</td>
<td class="nump">5,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">9,918<span></span>
</td>
<td class="nump">10,686<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">100,525<span></span>
</td>
<td class="nump">107,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</a></td>
<td class="nump">3,120<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss) (Note 7)</a></td>
<td class="num">(15,292)<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">127,917<span></span>
</td>
<td class="nump">123,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: common stock held in treasury, at cost (502,961,000 and 490,878,000 shares)</a></td>
<td class="nump">41,146<span></span>
</td>
<td class="nump">39,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">74,599<span></span>
</td>
<td class="nump">74,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 175,124<span></span>
</td>
<td class="nump">$ 182,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380704092144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">4,320,000,000<span></span>
</td>
<td class="nump">4,320,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,119,843,000<span></span>
</td>
<td class="nump">3,119,843,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">502,961,000<span></span>
</td>
<td class="nump">490,878,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380712361824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 23,791<span></span>
</td>
<td class="nump">$ 23,338<span></span>
</td>
<td class="nump">$ 71,237<span></span>
</td>
<td class="nump">$ 68,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SalesRevenueGoodsNetPercentToSales', window );">Sales to customers percent to sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 7,807<span></span>
</td>
<td class="nump">$ 7,250<span></span>
</td>
<td class="nump">$ 23,324<span></span>
</td>
<td class="nump">$ 21,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CostOfGoodsSoldPercentToSales', window );">Cost of products sold percent to sales</a></td>
<td class="nump">32.80%<span></span>
</td>
<td class="nump">31.10%<span></span>
</td>
<td class="nump">32.70%<span></span>
</td>
<td class="nump">31.80%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 15,984<span></span>
</td>
<td class="nump">$ 16,088<span></span>
</td>
<td class="nump">$ 47,913<span></span>
</td>
<td class="nump">$ 47,071<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_GrossProfitPercentToSales', window );">Gross Profit Percent To Sales</a></td>
<td class="nump">67.20%<span></span>
</td>
<td class="nump">68.90%<span></span>
</td>
<td class="nump">67.30%<span></span>
</td>
<td class="nump">68.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">$ 6,089<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 18,253<span></span>
</td>
<td class="nump">$ 17,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales', window );">Selling marketing and administrative expenses percent to sales</a></td>
<td class="nump">25.60%<span></span>
</td>
<td class="nump">25.70%<span></span>
</td>
<td class="nump">25.70%<span></span>
</td>
<td class="nump">25.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">$ 3,597<span></span>
</td>
<td class="nump">$ 3,422<span></span>
</td>
<td class="nump">$ 10,762<span></span>
</td>
<td class="nump">$ 9,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales', window );">Research and development expense percent to sales</a></td>
<td class="nump">15.10%<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="nump">15.10%<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 610<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentInProcessPercentToSales', window );">In-process research and development percent to sales</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (150)<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="num">$ (236)<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_InvestmentIncomeInterestPercentToSales', window );">Interest income percent to sales</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net of portion capitalized</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_InterestExpensePercentToSales', window );">Interest expense, net of portion capitalized percent to sales</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">$ 493<span></span>
</td>
<td class="nump">$ 1,850<span></span>
</td>
<td class="nump">$ 664<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherNonOperatingIncomeExpensePercentToSales', window );">Other (income) expense, net percent to sales</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring (Note 12)</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_Restructuringchargepercenttosales', window );">Restructuring charge percent to sales</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 5,822<span></span>
</td>
<td class="nump">$ 3,849<span></span>
</td>
<td class="nump">$ 17,524<span></span>
</td>
<td class="nump">$ 17,940<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales', window );">Earnings before provision for taxes on income percent to sales</a></td>
<td class="nump">24.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">24.60%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income (Note 5)</a></td>
<td class="nump">$ 1,364<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 3,103<span></span>
</td>
<td class="nump">$ 1,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_IncomeTaxExpenseBenefitPercentToSales', window );">Provision for taxes on income percent to sales</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 4,458<span></span>
</td>
<td class="nump">$ 3,667<span></span>
</td>
<td class="nump">$ 14,421<span></span>
</td>
<td class="nump">$ 16,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_NetIncomeAttributableToParentPercentToSales', window );">Net earnings percent to sales</a></td>
<td class="nump">18.70%<span></span>
</td>
<td class="nump">15.70%<span></span>
</td>
<td class="nump">20.20%<span></span>
</td>
<td class="nump">23.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (per share)</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="nump">$ 5.49<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (per share)</a></td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="nump">$ 5.41<span></span>
</td>
<td class="nump">$ 6.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>AVG. SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">2,627.9<span></span>
</td>
<td class="nump">2,632.6<span></span>
</td>
<td class="nump">2,628.9<span></span>
</td>
<td class="nump">2,632.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">2,661.3<span></span>
</td>
<td class="nump">2,674.9<span></span>
</td>
<td class="nump">2,667.5<span></span>
</td>
<td class="nump">2,674.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CostOfGoodsSoldPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of goods sold percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CostOfGoodsSoldPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_GrossProfitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross profit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_GrossProfitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeTaxExpenseBenefitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax expense benefit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeTaxExpenseBenefitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InterestExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InterestExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InvestmentIncomeInterestPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment income interest percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InvestmentIncomeInterestPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NetIncomeAttributableToParentPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income Attributable to Parent Percent to Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NetIncomeAttributableToParentPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherNonOperatingIncomeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non operating income expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherNonOperatingIncomeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense excluding acquired in process cost percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentInProcessPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>research and development in process percent to sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentInProcessPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Restructuringchargepercenttosales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring charge percent to sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Restructuringchargepercenttosales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesRevenueGoodsNetPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales revenue goods net percentage to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesRevenueGoodsNetPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling general and administrative expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SellingGeneralAndAdministrativeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380710870352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 4,458<span></span>
</td>
<td class="nump">$ 3,667<span></span>
</td>
<td class="nump">$ 14,421<span></span>
</td>
<td class="nump">$ 16,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation</a></td>
<td class="num">(1,252)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
<td class="num">(1,957)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) arising during period</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Employee benefit plans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax', window );">Prior service cost amortization during period</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax', window );">Gain (loss) amortization during period</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="nump">822<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Derivatives &amp; hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) arising during period</a></td>
<td class="num">(204)<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to earnings</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="num">(576)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="num">(309)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(586)<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1,449)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="num">(2,234)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 3,009<span></span>
</td>
<td class="nump">$ 3,352<span></span>
</td>
<td class="nump">$ 12,187<span></span>
</td>
<td class="nump">$ 15,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380710638304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign Currency Translation</a></td>
<td class="num">$ (181)<span></span>
</td>
<td class="num">$ (86)<span></span>
</td>
<td class="num">$ (859)<span></span>
</td>
<td class="num">$ (315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Employee Benefit Plans</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives &amp; Hedges</a></td>
<td class="num">$ (82)<span></span>
</td>
<td class="num">$ (43)<span></span>
</td>
<td class="num">$ (155)<span></span>
</td>
<td class="num">$ (167)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380706603648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Common Stock Issued Amount</div></th>
<th class="th"><div>Treasury Stock Amount</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jan. 03, 2021</a></td>
<td class="nump">$ 63,278<span></span>
</td>
<td class="nump">$ 113,890<span></span>
</td>
<td class="num">$ (15,242)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (38,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">16,142<span></span>
</td>
<td class="nump">16,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(8,241)<span></span>
</td>
<td class="num">(8,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="num">(699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Oct. 03, 2021</a></td>
<td class="nump">70,272<span></span>
</td>
<td class="nump">121,092<span></span>
</td>
<td class="num">(15,415)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,525)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jul. 04, 2021</a></td>
<td class="nump">69,580<span></span>
</td>
<td class="nump">120,154<span></span>
</td>
<td class="num">(15,100)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,791)<span></span>
</td>
<td class="num">(2,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Oct. 03, 2021</a></td>
<td class="nump">70,272<span></span>
</td>
<td class="nump">121,092<span></span>
</td>
<td class="num">(15,415)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,525)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jan. 02, 2022</a></td>
<td class="nump">74,023<span></span>
</td>
<td class="nump">123,060<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(39,099)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">14,421<span></span>
</td>
<td class="nump">14,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(8,728)<span></span>
</td>
<td class="num">(8,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="num">(836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(4,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,715)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(2,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Oct. 02, 2022</a></td>
<td class="nump">74,599<span></span>
</td>
<td class="nump">127,917<span></span>
</td>
<td class="num">(15,292)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(41,146)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jul. 03, 2022</a></td>
<td class="nump">76,357<span></span>
</td>
<td class="nump">126,216<span></span>
</td>
<td class="num">(13,843)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(39,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">4,458<span></span>
</td>
<td class="nump">4,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,970)<span></span>
</td>
<td class="num">(2,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1,449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Oct. 02, 2022</a></td>
<td class="nump">$ 74,599<span></span>
</td>
<td class="nump">$ 127,917<span></span>
</td>
<td class="num">$ (15,292)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (41,146)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707187312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="nump">$ 3.32<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380712136704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 14,421<span></span>
</td>
<td class="nump">$ 16,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and intangibles</a></td>
<td class="nump">5,198<span></span>
</td>
<td class="nump">5,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">925<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="nump">787<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Net gain on sale of assets/businesses</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision</a></td>
<td class="num">(2,488)<span></span>
</td>
<td class="num">(2,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses and accounts receivable allowances</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(1,591)<span></span>
</td>
<td class="num">(1,818)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(1,877)<span></span>
</td>
<td class="num">(1,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accrued liabilities</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in other current and non-current assets</a></td>
<td class="nump">4,563<span></span>
</td>
<td class="nump">2,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in other current and non-current liabilities</a></td>
<td class="num">(4,008)<span></span>
</td>
<td class="num">(1,938)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH FLOWS FROM OPERATING ACTIVITIES</a></td>
<td class="nump">15,844<span></span>
</td>
<td class="nump">17,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="num">(2,422)<span></span>
</td>
<td class="num">(2,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from the disposal of assets/businesses, net (Note 10)</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note 10)</a></td>
<td class="num">(522)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(31,163)<span></span>
</td>
<td class="num">(18,843)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales of investments</a></td>
<td class="nump">26,324<span></span>
</td>
<td class="nump">16,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities', window );">Credit support agreements activity, net</a></td>
<td class="num">(305)<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other (primarily licenses and milestones)</a></td>
<td class="num">(208)<span></span>
</td>
<td class="num">(414)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED BY INVESTING ACTIVITIES</a></td>
<td class="num">(7,974)<span></span>
</td>
<td class="num">(3,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Dividends to shareholders</a></td>
<td class="num">(8,728)<span></span>
</td>
<td class="num">(8,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(4,715)<span></span>
</td>
<td class="num">(2,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term debt</a></td>
<td class="nump">7,099<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term debt</a></td>
<td class="num">(4,808)<span></span>
</td>
<td class="num">(821)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(2,133)<span></span>
</td>
<td class="num">(1,452)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits', window );">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities', window );">Credit support agreements activity, net</a></td>
<td class="nump">1,678<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED BY FINANCING ACTIVITIES</a></td>
<td class="num">(10,571)<span></span>
</td>
<td class="num">(10,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(431)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease)/Increase in cash and cash equivalents</a></td>
<td class="num">(3,132)<span></span>
</td>
<td class="nump">3,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash equivalents, beginning of period</a></td>
<td class="nump">14,487<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">11,355<span></span>
</td>
<td class="nump">17,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed and noncontrolling interests</a></td>
<td class="num">(98)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net cash paid for acquisitions</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380714293056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October&#160;2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended October&#160;2, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. </span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal third quarter of 2022.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Not Adopted as of October 2, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) &#8211; Disclosure of Supplier Finance Program Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity&#8217;s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707877296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">INVENTORIES <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707948928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,572&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,406)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The change in intangible assets with definite lives is primarily the result of currency translation effects.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, subsequent to the fiscal third quarter, additional information regarding efficacy of the HS indication became available which led the Company to the decision to terminate the development of bermekimab for HS. The Company will record a charge of approximately $0.2&#160;billion in the fiscal fourth quarter related to this impairment.  The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of October&#160;2, 2022 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:39.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at October 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.0 billion and $1.1&#160;billion for the fiscal third quarters ended October&#160;2, 2022 and October&#160;3, 2021, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $3.2&#160;billion and $3.6&#160;billion for the fiscal nine months ended October&#160;2, 2022 and October&#160;3, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380702425616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October&#160;2, 2022, the cumulative amount of cash collateral received by the Company under the CSA amounted to $0.8 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $47.1&#160;billion, $36.2&#160;billion and $10.0&#160;billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion,  $37.4 billion and $10.0 billion respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;2, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $922&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2022 and 2021, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2022 and 2021, net of tax:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.493%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  October&#160;2, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2022 and 2021: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:24.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.620%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal third quarters ended in 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal nine months ended in 2022 and 2021</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:24.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair  </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"/><td style="width:26.470%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.009%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(607)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity investments without readily determinable market values, there was a decrease of $29 million in the fair value reflected in net income as a result of impairments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal third quarter ended October&#160;2, 2022, the Company sold all its equity investments in argenx SE for proceeds of $0.6&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of October&#160;2, 2022 and January&#160;2, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration for each of the fiscal nine months ended is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $507 million and $520 million, classified as non-current other liabilities as of October&#160;2, 2022 and January&#160;2, 2022, respectively.  Includes $18 million and $13 million classified as current liabilities as of October&#160;2, 2022 and January&#160;2, 2022, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of October&#160;2, 2022 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:30.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/( Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the fiscal year ended January&#160;2, 2022 the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of October&#160;2, 2022 are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October&#160;2, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 0.9712)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500MM GBP 1.0908)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.550% Notes due 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 0.9712)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 0.9712)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is 3.06%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the estimated fair value over the carrying value of debt was $3.2 billion at January 2, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of October&#160;2, 2022 includes $3.9&#160;billion of commercial paper which has a weighted average interest rate of 2.88% and a weighted average maturity of approximately three months.</span></div>Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707877296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal nine months of 2022 and 2021 were 17.7% and 10.0%, respectively. This increase in the consolidated tax rate as compared to the prior year fiscal nine months is primarily due to the Company reorganizing the ownership structure of certain wholly-owned international subsidiaries in the second fiscal quarter of 2021.  As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with the applicable local regulations. Accordingly, the Company recorded a local deferred tax benefit of approximately $2.3&#160;billion which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $1.7&#160;billion. The net impact of this reorganization was an approximate $0.6&#160;billion net benefit or a 3.4% decrease to the effective tax rate of the fiscal nine months of 2021. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Additionally, the following items had an unfavorable impact to the Company&#8217;s year-to-date effective tax rate as compared to the same period in the prior fiscal year:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">as part of the planned separation of the Company&#8217;s Consumer Health business (for further information see Note 1 in the Company's Annual Report on Form 10-K for the fiscal year ended January 2, 2022) the Company has recognized approximately $0.4&#160;billion in net incremental tax costs which increased the rate by approximately 2.0% for the fiscal nine months of 2022 </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">certain one-time favorable tax items that occurred during the fiscal nine months of  2021 and resulted in an approximate 1.0% benefit to the effective tax rate, but were not repeated in fiscal 2022 </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.53pt">In the fiscal third quarter of 2021 the Company had accrued additional Talc expenses of $1.4&#160;billion at an effective tax rate of 23.5% and $0.8&#160;billion for the Risperdal Gynecomastia settlement at an effective tax rate of 16.4%. (See note 11 to the Consolidated Financial Statements for more details)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">in the fiscal third quarter of 2021 the Company recorded a partial IPR&amp;D charge of $0.9&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of 22.4%</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during the first three fiscal quarters of 2022 and 2021.  The Company&#8217;s 2022 tax rate benefited primarily from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022, the impairment of bermekimab for AD IPR&amp;D (for further information see Note 3 of the Consolidated Financial Statements) and changes in the fair value of securities in the Company&#8217;s investment portfolio, both recorded at the U.S. statutory rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of October&#160;2, 2022, the Company had approximately $3.8 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016.  In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707956128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pensions and Other Benefit Plans</a></td>
<td class="text">PENSIONS AND OTHER BENEFIT PLANS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:32.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.962%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal nine months ended October&#160;2, 2022, the Company contributed $82 million and $15 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707995408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE INCOME<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,974)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707903056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">EARNINGS PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:53.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The diluted net earnings per share calculation for both the fiscal third quarter ended October&#160;2, 2022 and October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock. </span></div>The diluted net earnings per share calculation for the fiscal nine months ended October&#160;2, 2022 and October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707941632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments of Business and Geographic Areas</a></td>
<td class="text">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA / INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:44pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Approximately $0.1&#160;billion in the fiscal third quarter of 2021 and $0.3&#160;billion in the fiscal nine months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Previously referred to as Medical Devices</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:36.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.904%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*The 2021 fiscal third  quarter and nine months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">**Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.3&#160;billion in both the fiscal nine months of 2022 and 2021. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Litigation expense of $0.1&#160;billion in the fiscal nine months of 2022. Litigation expense of $1.4&#160;billion and $1.5&#160;billion in the fiscal three months and fiscal nine months of 2021, respectively, primarily for talc related costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $0.6&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal third quarter of 2022 and 2021, respectively. Intangible amortization expense of $2.2&#160;billion and $2.5&#160;billion in the fiscal nine months of 2022 and 2021, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A loss of $0.2&#160;billion and a gain of $0.1&#160;billion related to the change in the fair value of securities in the fiscal third quarter of 2022 and 2021, respectively. A loss of $0.7&#160;billion and a gain of $0.2&#160;billion related to the change in the fair value of securities in the fiscal nine months of 2022 and 2021, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine supply network related costs of $0.4&#160;billion and $0.7&#160;billion in the fiscal third quarter and fiscal nine months 2022, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Litigation expense of $0.8&#160;billion and $0.7&#160;billion in the fiscal third quarter and fiscal nine months of 2021, respectively, primarily related to Risperdal Gynecomastia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal third quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.5&#160;billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $0.2&#160;billion in  the fiscal third quarter of 2022. Litigation expense of $0.5 billion in fiscal nine months of 2022, primarily pelvic mesh related costs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.2&#160;billion in the fiscal nine months of 2022 and 2021, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.3&#160;billion in both the fiscal third quarter of 2022 and 2021 and $0.8&#160;billion in both the fiscal nine months of 2022 and 2021.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes an in-process research and development expense of $0.9&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amounts not allocated to segments include interest income/expense and general corporate income/expense. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,587&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,960&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,018&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707877296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">ACQUISITIONS AND DIVESTITURESThere were no material acquisitions or divestitures in the fiscal first, second or third quarter of 2022. During the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707935520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text">LEGAL PROCEEDINGS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of  October&#160;2, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; XARELTO; body powders containing talc, primarily JOHNSON&#8217;S Baby Powder; INVOKANA; and ETHICON PHYSIOMESH Flexible Composite Mesh. As of October&#160;2, 2022, in the United States there were approximately 180 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; 1,400 with respect to the PINNACLE Acetabular Cup System; 9,400 with respect to pelvic meshes; 1,500 with respect to RISPERDAL; 600 with respect to XARELTO; 40,300 with respect to body powders containing talc; 5 with respect to INVOKANA;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> 4,800 with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; and 1,900 with respect to ELMIRON. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp; Johnson (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. Prior to 2019, several adverse verdicts had been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia  and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. In September 2022, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia, pending Federal Court approval. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of October 2022, there are approximately 154 active cases subject to these orders which are being reviewed and evaluated. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%">Claims have also been filed against Ethicon and Johnson &amp; Johnson alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and Johnson &amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp; Johnson; and JPI&#8217;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp; Johnson announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and Johnson &amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No. ED 207476 (Mo. App.), reducing the overall award to  $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. The briefing and oral argument on the appeal were completed in September 2022. While the New Jersey Bankruptcy Court&#8217;s order effectively stays all of the Company&#8217;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that J&amp;J fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by Johnson &amp; Johnson&#8217;s then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In July 2022, Imerys filed a motion in the Imerys Bankruptcy to stay the Edley Class Action, which was denied in August 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#8217;s insurers (the Mediation Parties) agreed to engage in mediation. The term of the mediation ended in September 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC)  (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#8220;talc-related claims&#8221; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against Johnson &amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, and that purchasers of Johnson &amp; Johnson&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiff&#8217;s motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#8217;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record.  In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action. Plaintiff has appealed the Bankruptcy Court&#8217;s order.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Baby Powder, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2020, a report was delivered to the Company&#8217;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In re Johnson &amp; Johnson Talc Stockholder Derivative Litigation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp; Johnson&#8217;s motion to dismiss pending a decision on Plaintiff&#8217;s motion for discovery. In July 2022, the Court denied Plaintiff&#8217;s discovery motion. In August 2022, the Court reopened Johnson &amp; Johnson&#8217;s motion to dismiss. In lieu of opposing, Plaintiff made a motion to voluntarily dismiss the case, which the Court granted in October 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp; Johnson Savings Plan against Johnson &amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp; Johnson stock as a Johnson &amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#8217; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#8217; motion was complete. In February 2021, the Court granted Defendants&#8217; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument. In September 2022, the Third Circuit affirmed the dismissal of Plaintiffs&#8217; amended complaint.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. The appeal continues to be held in abeyance, with the Company being required to file periodic status updates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp; Johnson, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON related product liability litigation.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of Johnson &amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MedTech</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos.  6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447);  and 9,452,276 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(&#8217;276) based on Auris&#8217; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the  &#8217;056,  &#8217;447, &#8217;276 and &#8217;906 patents.  In December 2019, the USPTO  denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the  &#8217;447,  and &#8217;906 patents and denied review of the &#8217;276 patent. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris appealed, and  in April 2022, the United States Court of Appeals for the Federal Circuit vacated the decision that the &#8217;447 patent was not invalid and remanded the decision  to the USPTO for further review.  In May 2022, the United States Court of Appeals for the Federal Circuit confirmed the ruling that claim 53 of the &#8217;906 patent was not invalid, vacated the decision that the remaining claims of the &#8217;906 patent were not invalid and remanded the decision  to the USPTO for further review. Auris filed a request for reexamination of the &#8217;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in September 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 (&#8217;234) and 9,713,537 (&#8217;537) by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. Trial is scheduled to begin in December 2022. In June 2022, DePuy filed potentially dispositive summary judgment motions that the &#8217;234 patent is invalid as anticipated and the &#8217;537 patent is not infringed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 (&#8217;180) and 10,517,583 (&#8217;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#8217;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#8217;180 patent, and awarding damages in the amount of $20&#160;million. DePuy challenged the verdict in its post-trial motions. In July 2022, a hearing was held on the post-trial motions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company&#8217;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#8217;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2019, Janssen Inc., Janssen Oncology, Inc., and BTG International Ltd. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#8217;s Laboratories Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision. The appeal hearing took place in September 2022. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In April 2021, July 2021 and April 2022, respectively, Apotex, DRL and Pharmascience initiated Statements of Claim under Section 8 of the Patented Medicines (Notice of Compliance) Regulations against Janssen seeking damages in respect of those parties generic Zytiga tablets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> Trials against Apotex and DRL are scheduled for June 2023. A trial date for the Pharmascience action has not been set.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#8217;310). The following generic drug companies are named defendants:  Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. In August 2022, after receiving a second notice letter from Mylan regarding the same ANDA, JPI and Bayer filed a second patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan. In September 2022, Mylan moved to dismiss the second lawsuit. In September 2022, the MDL panel transferred the second lawsuit to the District of Delaware. No trial date has been set for these two lawsuits. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Partes Review (IPR) with the United States Patent and Trademark Office (USPTO), seeking to invalidate the &#8217;310 patent. In August 2022, the Patent Trial and Appeal Board issued a decision instituting IPR.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022, InvaGen Pharmaceuticals, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#8217;310 patent. Also in September 2022, Teva Pharmaceuticals USA, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022, JPI, Bayer, and Bayer Intellectual Property GmbH (BIP) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against USV Private Limited (USV), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg, 10 mg, 15 mg, and 20 mg) before the expiration of the '310 patent and United States Patent No. 9,539,218 (&#8217;218). JPI, Bayer, and BIP are seeking an order enjoining USV from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent, and its generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, JPI, Bayer AG, and BIP </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mankind Pharma Limited (Mankind), who filed an ANDA seeking approval to market generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. JPI, Bayer AG, and BIP are seeking an order enjoining Mankind from marketing its generic versions of XARELTO before the expiration of the &#8217;218 patent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Sandoz stipulated to infringement of the &#8217;770 patent.  Trial against Sandoz on the issue of validity concluded in February 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Sandoz appealed the decision. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Apotex stipulated to validity of the &#8217;770 patent.  Trial against Apotex on the issue of infringement concluded in March 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Apotex appealed the decision.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of United States Patent No. 9,439,906 (&#8217;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#8217;s favor. Teva has appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. A trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. The action has been consolidated with the November 2020 action for trial, which took place in July 2022. In August 2022, the Court issued a decision finding the claims of the&#8217;335 patent are not invalid. Pharmascience appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#8217;s filing of an ANDS (original ANDS) seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Janssen Canada initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex in response to Apotex&#8217;s Notice of Allegation of invalidity with respect to the original ANDS and in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of United States Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(546 mg). Trial is scheduled to begin in November 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. The trial is scheduled to begin in July 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SYMTUZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of United States Patent Nos. 10,039,718 (the &#8217;718 patent) and 10,786,518 (the &#8217;518 patent). Janssen is seeking an order enjoining Lupin from marketing its generic version of SYMTUZA before the expiration of the &#8217;718 and &#8217;518 patents. The trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ERLEADA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of United States Patent No. 9,481,663 (the &#8217;663 patent). In August 2022, Janssen and SKI filed a first amended complaint against Lupin adding U.S. Patent Nos. 9,884,054 (the &#8217;054 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">patent), 10,052,314 (&#8217;314), 10,702,508 (&#8217;508) and 10,849,888 (&#8217;888) to the suit. Janssen and SKI are seeking an order enjoining Lupin from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents. In August 2022, Janssen and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Janssen and SKI initiated a patent infringement lawsuit in United States District Court for the District of New Jersey against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited (collectively, Zydus), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents. Janssen and SKI are seeking an order enjoining Zydus from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Janssen, The Regents of the University of California (UC), and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Sandoz Inc. (Sandoz), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663 patent and United States Patent Nos. 8,445,507 (&#8217;507), 8,802,689 (&#8217;689), 9,338,159 (&#8217;159), and 9,987,261 (&#8217;261).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, Janssen, UC, and SKI filed a first amended complaint against Sandoz adding the &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents to the suit.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Janssen, UC, and SKI are seeking an order enjoining Sandoz from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;689, &#8217;159, &#8217;261, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">District Court for the Districts of New Jersey and Delaware against Eugia Pharma Specialities Limited, Aurobindo Pharma USA, Inc., and Auromedics Pharma LLC (collectively, Eugia), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the &#8217;663, &#8217;507, &#8217;689, &#8217;159 and &#8217;261 patents. Janssen, UC, and SKI are seeking an order enjoining Eugia from marketing its generic version of ERLEADA before the expiration of the &#8217;663,&#8217;507, &#8217;689, &#8217;159, and &#8217;261 patents. In September 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Hetero Labs Limited Unit V and Hetero USA, Inc. (collectively, Hetero), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507,&#8217;054, &#8217;314,&#8217;508, and&#8217;888 patents. Janssen, UC, and SKI are seeking an order enjoining Hetero from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">UPTRAVI </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022, Actelion Pharmaceuticals Ltd, and Janssen Inc. (collectively, Janssen) and Nippon Shinyaku Co. (Nippon Shinyaku) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. in response to Sandoz&#8217;s filing of an ANDS seeking approval to market generic versions of UPTRAVI before the expiration of Canadian Patent Nos. 2,731,370 and 2,764,475. In this lawsuit, Janssen and Nippon Shinyaku are seeking an order enjoining Sandoz from marketing its generic version of UPTRAVI before the expiration of the relevant patents. A trial date has not been set.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Other Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#8217; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#8217; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in response to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution. The parties exchanged opening briefs in July 2022 and responsive briefs in September 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp; Johnson and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, Johnson &amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Johnson &amp; Johnson, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#8217;s judgment and directed entry of judgment for Defendants. In October 2019 Johnson &amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#8217; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of  $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement is expected to be paid by the end of fiscal year 2022, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022. Also in April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions. In September 2022, the Company also reached a settlement agreement with the State of New Hampshire and its participating subdivisions. Consequently, by September 2022, the Company had settled the opioid claims advanced by all states except Washington.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There are approximately 60 cases remaining post-settlement in various state courts. There are approximately 860 remaining federal cases against Johnson &amp; Johnson and JPI coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2019, Johnson &amp; Johnson received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp; Johnson has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020.  By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted Johnson &amp; Johnson&#8217;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state court&#8217;s dismissal order.   </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">denied. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#8217;s dismissal of the case to the First Circuit. The briefing on the appeal will be complete by the end of October 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2012, Johnson &amp; Johnson was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp; Johnson&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp; Johnson and Ethicon settled the Washington case. In October 2019, Johnson &amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for May 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $302&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company&#8217;s petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. The Company plans to petition for review by the United States Supreme Court.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#8217;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp; Johnson and JJCI&#8217;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#8217;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting as barred by the stay arising from the LTL Bankruptcy Case, referenced above, while the State argued that the stay did not apply. In January 2022, the Court granted the State&#8217;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. The temporary stay expired in May 2022. LTL thereafter moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#8217;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#8217;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#8217;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexico&#8217;s discovery obligations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to mediation of their claims in the LTL Bankruptcy Case.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, Johnson &amp; Johnson and Janssen Products, LP were served with a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April and September 2017, Johnson &amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, Johnson &amp; Johnson received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#8217;s investigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div style="margin-bottom:10pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. This case was settled in March 2022. The Court approved the settlement in October 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022, subject to Court approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The complaint seeks damages and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#8217;s decision. This case was settled in January 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022. Genmab has moved for early disposition of the arbitration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In February 2022, defendants petitioned for rehearing en banc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. In September 2022, the Court granted in part and denied in part plaintiff&#8217;s motion for class certification. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#8217;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, Johnson &amp; Johnson received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (&#8220;EBSI&#8221;) with the American Arbitration Association, alleging that EBSI breached the parties&#8217; Manufacturing Services Agreement for the Company&#8217;s COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> In July 2022, Emergent filed its answering statement and counterclaims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequent to the quarter, in October 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Merck Sharp &amp; Dohme Corp. with the American Arbitration Association pursuant to the Parties&#8217; agreements relating to production of drug substance and drug product for Johnson &amp; Johnson&#8217;s COVID-19 vaccine. Also in October 2022, Merck filed its answer and counterclaims.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in May 2021, multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">putative </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">class actions were filed in state and federal courts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(California, Florida, New York, and New Jersey)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the affirmative promotion of those products as &#8220;safe&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; and, in at least one case, alleging a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strict liability manufacturing defect and failure to warn </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">claims, asserting that the named plaintiffs</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> suffered unspecified injuries as a result of alleged exposure to benzene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Johnson &amp; Johnson or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707931040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">RESTRUCTURING<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal third quarter of 2022, the Company recorded a net pre-tax charge of $123 million, which is included on the following lines of the Consolidated Statement of Earnings, $82 million in restructuring, $13 million in cost of products sold and $28 million in other (income) expense, net.  In the fiscal nine months of 2022, the Company recorded a net pre-tax charge of $323&#160;million, which is included on the following lines of the Consolidated Statement of Earnings, $237&#160;million in restructuring, $46&#160;million in cost of products sold and $40&#160;million in other (income) expense, net. Total project costs of approximately $2.1 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In total, the Company expects the Global Supply Chain actions to generate approximately $0.7 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.2 billion to $2.3 billion by the completion of the program in December 2022. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:32.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, October 2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380703965536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts the Company&#8217;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October&#160;2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#8217;s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company&#8217;s consolidated financial statements as of and for the quarter ended October&#160;2, 2022, the Company&#8217;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#8217;s consolidated financial statements in future reporting periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New and Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. </span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in the fiscal third quarter of 2022.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Not Adopted as of October 2, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) &#8211; Disclosure of Supplier Finance Program Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity&#8217;s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707906784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380803762128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,572&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,406)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The change in intangible assets with definite lives is primarily the result of currency translation effects.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, subsequent to the fiscal third quarter, additional information regarding efficacy of the HS indication became available which led the Company to the decision to terminate the development of bermekimab for HS. The Company will record a charge of approximately $0.2&#160;billion in the fiscal fourth quarter related to this impairment.  The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of October&#160;2, 2022 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:39.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at October 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Intangible Asset Amortization Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,800</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380702654272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2022 and 2021, net of tax:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2022 and 2021, net of tax:</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.493%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal third quarters ended in 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal nine months ended in 2022 and 2021</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:24.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  October&#160;2, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Effect of Derivatives not Designated as Hedging Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2022 and 2021: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:24.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.716%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.013%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.620%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Activity Related to Equity Investments</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"/><td style="width:26.470%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.009%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.451%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(607)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Financial Assets and Liabilities at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of October&#160;2, 2022 and January&#160;2, 2022 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration for each of the fiscal nine months ended is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $507 million and $520 million, classified as non-current other liabilities as of October&#160;2, 2022 and January&#160;2, 2022, respectively.  Includes $18 million and $13 million classified as current liabilities as of October&#160;2, 2022 and January&#160;2, 2022, respectively.</span></div>           (6)    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents and current marketable securities as of October&#160;2, 2022 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:30.762%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.462%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/( Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. sovereign securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available for Sale Securities Maturities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of October&#160;2, 2022 are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Financial Liabilities not Measured at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October&#160;2, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.838%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73% Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 0.9712)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500MM GBP 1.0908)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.550% Notes due 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 0.9712)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 0.9712)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707956128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:32.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.962%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380708059184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,957)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,974)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380708093424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"/><td style="width:53.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,628.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707778672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SalesBySegmentOfBusinessTableTextBlock', window );">Sales By Segment Of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA / INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:44pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Approximately $0.1&#160;billion in the fiscal third quarter of 2021 and $0.3&#160;billion in the fiscal nine months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Previously referred to as Medical Devices</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operating Profit by Segment of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:36.362%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.904%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3,<br/>2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*The 2021 fiscal third  quarter and nine months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">**Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.3&#160;billion in both the fiscal nine months of 2022 and 2021. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Litigation expense of $0.1&#160;billion in the fiscal nine months of 2022. Litigation expense of $1.4&#160;billion and $1.5&#160;billion in the fiscal three months and fiscal nine months of 2021, respectively, primarily for talc related costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Divestiture gains of $0.6&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal third quarter of 2022 and 2021, respectively. Intangible amortization expense of $2.2&#160;billion and $2.5&#160;billion in the fiscal nine months of 2022 and 2021, respectively.  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A loss of $0.2&#160;billion and a gain of $0.1&#160;billion related to the change in the fair value of securities in the fiscal third quarter of 2022 and 2021, respectively. A loss of $0.7&#160;billion and a gain of $0.2&#160;billion related to the change in the fair value of securities in the fiscal nine months of 2022 and 2021, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine supply network related costs of $0.4&#160;billion and $0.7&#160;billion in the fiscal third quarter and fiscal nine months 2022, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Litigation expense of $0.8&#160;billion and $0.7&#160;billion in the fiscal third quarter and fiscal nine months of 2021, respectively, primarily related to Risperdal Gynecomastia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal third quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.5&#160;billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $0.2&#160;billion in  the fiscal third quarter of 2022. Litigation expense of $0.5 billion in fiscal nine months of 2022, primarily pelvic mesh related costs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.2&#160;billion in the fiscal nine months of 2022 and 2021, respectively. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.3&#160;billion in both the fiscal third quarter of 2022 and 2021 and $0.8&#160;billion in both the fiscal nine months of 2022 and 2021.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Includes an in-process research and development expense of $0.9&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021.</span></div>(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.503%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Third Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 3, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,587&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,960&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,018&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesBySegmentOfBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesBySegmentOfBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380707877296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:32.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, October 2, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380706470832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 1,730<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Goods in process</a></td>
<td class="nump">2,106<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">7,839<span></span>
</td>
<td class="nump">6,508<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 11,675<span></span>
</td>
<td class="nump">$ 10,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380712300080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 27, 2022</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,424<span></span>
</td>
<td class="nump">$ 16,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets - net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,336<span></span>
</td>
<td class="nump">46,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,648<span></span>
</td>
<td class="nump">6,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember', window );">Purchased In-Process Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,776<span></span>
</td>
<td class="nump">9,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,132<span></span>
</td>
<td class="nump">38,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,116)<span></span>
</td>
<td class="num">(20,088)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,016<span></span>
</td>
<td class="nump">18,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,302<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,406)<span></span>
</td>
<td class="num">(11,925)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,896<span></span>
</td>
<td class="nump">$ 11,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | bermekimab | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380706519296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Goodwill By Segment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">$ 35,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(2,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">33,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">9,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(1,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">8,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">10,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">9,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">14,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">$ 14,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380710814352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of amortizable intangible assets</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380704076336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 4,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">4,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380703772416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2022</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Accumulated other comprehensive income on derivatives, after tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss', window );">Reclassification of foreign exchange contracts into earnings, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">next 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Maximum length of time for hedge exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate on non-current debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt', window );">Excess of the estimated fair value over the carrying value of debt</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,424<span></span>
</td>
<td class="nump">$ 3,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral already posted, aggregate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,100<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,200<span></span>
</td>
<td class="nump">37,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember', window );">Equity Investments without readily determinable value | Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentImpairmentLoss', window );">Equity, fair value adjustment, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess of fair value over carrying value of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfFairValueOverCarryingValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380702969168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="num">(322)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(1,094)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(83)<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(205)<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061172-113977<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380706508736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Derivatives, Balance Sheet Location (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">$ 3,833<span></span>
</td>
<td class="nump">$ 1,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term Debt | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">8,668<span></span>
</td>
<td class="nump">9,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability</a></td>
<td class="num">$ (1,430)<span></span>
</td>
<td class="num">$ (142)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380702426720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain/(Loss) Recognized In Income on Derivative</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="num">$ (50)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380712279872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">$ 208<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract | Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380702117856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 8,625<span></span>
</td>
<td class="nump">$ 10,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, end of period</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments with readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, beginning of period</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">(607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="num">(755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, end of period</a></td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, beginning of period</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, end of period</a></td>
<td class="nump">531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investment [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380703616000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">$ 4,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">3,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">22,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total Gross Assets</a></td>
<td class="nump">4,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(4,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,285)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total Net Asset</a></td>
<td class="nump">213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total Gross Liabilities</a></td>
<td class="nump">3,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(3,636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,855)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total Net Liabilities</a></td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue', window );">Changes in estimated fair value (6)</a></td>
<td class="num">(85)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable Securities, Noncurrent</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">4,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">3,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">22,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">2,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">2,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">1,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380702384832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">$ 22,124<span></span>
</td>
<td class="nump">$ 19,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">11,355<span></span>
</td>
<td class="nump">14,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">22,724<span></span>
</td>
<td class="nump">$ 17,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and current marketable securities, Carrying Amount</a></td>
<td class="nump">34,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss', window );">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue', window );">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</a></td>
<td class="nump">34,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">11,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">11,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">9,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">4,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">4,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">4,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Non-U.S. sovereign securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | U.S. reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">2,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">2,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">2,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">1,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">1,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">1,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Time deposits(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">22,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">22,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">19,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">21,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">21,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">2,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 19,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380703803984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Cost Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 22,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total debt securities</a></td>
<td class="nump">22,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">22,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total debt securities</a></td>
<td class="nump">$ 22,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380696635120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 4,424,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,766,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">27,603,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,985,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">4,424,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">27,603,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">4,422,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 24,232,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73% Debentures due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 256,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 802,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 797,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 0.9712)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">0.9712<span></span>
</td>
<td class="nump">0.9712<span></span>
</td>
<td class="nump">0.9712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 0.9712) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 722,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 0.9712) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 702,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500MM GBP 1.0908)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">1.0908<span></span>
</td>
<td class="nump">1.0908<span></span>
</td>
<td class="nump">1.0908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500MM GBP 1.0908) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 544,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500MM GBP 1.0908) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 548,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 749,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">721,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">922,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 826,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,996,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,868,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 877,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 829,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,396,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,185,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,379,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 0.9712)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">0.9712<span></span>
</td>
<td class="nump">0.9712<span></span>
</td>
<td class="nump">0.9712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 0.9712) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 724,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 0.9712) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 649,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.95%<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 298,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 342,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,606,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,276,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 498,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 507,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 855,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">820,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 0.9712) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">0.9712<span></span>
</td>
<td class="nump">0.9712<span></span>
</td>
<td class="nump">0.9712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 0.9712) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,181,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 841,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 726,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 993,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,074,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,334,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,154,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 992,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 822,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 697,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 747,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 506,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 827,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 551,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 297,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 291,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 457,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,976,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,626,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 811,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 668,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 743,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 593,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 809,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,054,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">619,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380702395344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Worldwide effective income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.70%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax benefit, net</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent', window );">Decrease in effective tax rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Incremental tax costs related to restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_IncrementalIncreaseDecreaseInTaxes', window );">Incremental change to income tax rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OneTimeFavorableTaxItemPercent', window );">Favorable tax event (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health | Purchased In-Process Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Effective income tax rate, impairment losses, percent</a></td>
<td class="nump">22.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_TalcMember', window );">Talc | CONSUMER HEALTH (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent', window );">Effective tax rate for legal expense (percent)</a></td>
<td class="nump">0.235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_RisperdalMember', window );">Risperdal | CONSUMER HEALTH (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent', window );">Effective tax rate for legal expense (percent)</a></td>
<td class="nump">0.164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncrementalIncreaseDecreaseInTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental Increase (Decrease) In Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncrementalIncreaseDecreaseInTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OneTimeFavorableTaxItemPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>One Time Favorable Tax Item,Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OneTimeFavorableTaxItemPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380710622272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">$ 953<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">685<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(683)<span></span>
</td>
<td class="num">(661)<span></span>
</td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(1,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380709732512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 02, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380702928752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">$ 76,357<span></span>
</td>
<td class="nump">$ 69,580<span></span>
</td>
<td class="nump">$ 74,023<span></span>
</td>
<td class="nump">$ 63,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(1,449)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="num">(2,234)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">74,599<span></span>
</td>
<td class="nump">70,272<span></span>
</td>
<td class="nump">74,599<span></span>
</td>
<td class="nump">70,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Foreign Currency Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(11,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Investment Gain (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(2,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(13,843)<span></span>
</td>
<td class="num">(15,100)<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(1,449)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="num">(2,234)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">$ (15,292)<span></span>
</td>
<td class="num">$ (15,415)<span></span>
</td>
<td class="num">$ (15,292)<span></span>
</td>
<td class="num">$ (15,415)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380702372832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Reconciliation of basic net earnings per share to diluted net earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings per share</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="nump">$ 5.49<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average shares outstanding &#8212; basic</a></td>
<td class="nump">2,627.9<span></span>
</td>
<td class="nump">2,632.6<span></span>
</td>
<td class="nump">2,628.9<span></span>
</td>
<td class="nump">2,632.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Potential shares exercisable under stock option plans</a></td>
<td class="nump">140.1<span></span>
</td>
<td class="nump">138.3<span></span>
</td>
<td class="nump">141.1<span></span>
</td>
<td class="nump">139.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod', window );">Less: shares which could be repurchased under treasury stock method</a></td>
<td class="num">(106.7)<span></span>
</td>
<td class="num">(96.0)<span></span>
</td>
<td class="num">(102.5)<span></span>
</td>
<td class="num">(96.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average shares outstanding &#8212; diluted</a></td>
<td class="nump">2,661.3<span></span>
</td>
<td class="nump">2,674.9<span></span>
</td>
<td class="nump">2,667.5<span></span>
</td>
<td class="nump">2,674.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings per share</a></td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="nump">$ 5.41<span></span>
</td>
<td class="nump">$ 6.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380684910992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 23,791<span></span>
</td>
<td class="nump">$ 23,338<span></span>
</td>
<td class="nump">$ 71,237<span></span>
</td>
<td class="nump">$ 68,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 12,453<span></span>
</td>
<td class="nump">11,963<span></span>
</td>
<td class="nump">$ 36,064<span></span>
</td>
<td class="nump">34,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 11,338<span></span>
</td>
<td class="nump">11,375<span></span>
</td>
<td class="nump">$ 35,173<span></span>
</td>
<td class="nump">33,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,795<span></span>
</td>
<td class="nump">3,812<span></span>
</td>
<td class="nump">$ 11,186<span></span>
</td>
<td class="nump">11,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,659<span></span>
</td>
<td class="nump">1,625<span></span>
</td>
<td class="nump">$ 4,903<span></span>
</td>
<td class="nump">4,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,136<span></span>
</td>
<td class="nump">2,187<span></span>
</td>
<td class="nump">$ 6,283<span></span>
</td>
<td class="nump">6,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | OTC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,519<span></span>
</td>
<td class="nump">1,484<span></span>
</td>
<td class="nump">$ 4,462<span></span>
</td>
<td class="nump">4,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | OTC [Member] | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 695<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="nump">$ 2,028<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | OTC [Member] | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 825<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="nump">$ 2,434<span></span>
</td>
<td class="nump">2,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Skin Health/Beauty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,126<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
<td class="nump">$ 3,264<span></span>
</td>
<td class="nump">3,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Skin Health/Beauty | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 591<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="nump">$ 1,764<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Skin Health/Beauty | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Oral Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="nump">$ 1,135<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Oral Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Oral Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">$ 664<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Baby Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">$ 1,105<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Baby Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Baby Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Women's Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">$ 684<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Women's Health | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(22.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Women's Health | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Wound Care/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">$ 537<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Wound Care/Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Wound Care/Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(11.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 13,214<span></span>
</td>
<td class="nump">12,882<span></span>
</td>
<td class="nump">$ 39,400<span></span>
</td>
<td class="nump">37,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 7,438<span></span>
</td>
<td class="nump">7,221<span></span>
</td>
<td class="nump">$ 21,229<span></span>
</td>
<td class="nump">20,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 5,776<span></span>
</td>
<td class="nump">5,661<span></span>
</td>
<td class="nump">$ 18,171<span></span>
</td>
<td class="nump">16,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 4,287<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
<td class="nump">$ 12,817<span></span>
</td>
<td class="nump">12,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,876<span></span>
</td>
<td class="nump">2,771<span></span>
</td>
<td class="nump">$ 8,230<span></span>
</td>
<td class="nump">7,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,411<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
<td class="nump">$ 4,587<span></span>
</td>
<td class="nump">4,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | REMICADE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 558<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">$ 1,868<span></span>
</td>
<td class="nump">2,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(26.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | REMICADE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="nump">$ 1,099<span></span>
</td>
<td class="nump">1,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(27.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | REMICADE | U.S. Exports</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(16.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | REMICADE | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(27.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 545<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">$ 1,682<span></span>
</td>
<td class="nump">1,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | SIMPONI / SIMPONI ARIA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(10.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | STELARA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,449<span></span>
</td>
<td class="nump">2,378<span></span>
</td>
<td class="nump">$ 7,336<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | STELARA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,655<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
<td class="nump">$ 4,766<span></span>
</td>
<td class="nump">4,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | STELARA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">809<span></span>
</td>
<td class="nump">$ 2,571<span></span>
</td>
<td class="nump">2,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | TREMFYA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">537<span></span>
</td>
<td class="nump">$ 1,916<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">35.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | TREMFYA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 530<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="nump">$ 1,303<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">40.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | TREMFYA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">24.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Immunology | OTHER IMMUNOLOGY | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,295<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">$ 3,908<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">679<span></span>
</td>
<td class="nump">$ 1,266<span></span>
</td>
<td class="nump">1,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(42.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 905<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="nump">$ 2,642<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">29.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 489<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="nump">$ 1,490<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | COVID-19 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | COVID-19 | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">$ 1,370<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(27.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | EDURANT / rilpivirine | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">$ 691<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 485<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="nump">$ 1,450<span></span>
</td>
<td class="nump">1,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">$ 1,096<span></span>
</td>
<td class="nump">1,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">$ 354<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(17.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES(</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(22.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(46.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(17.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,681<span></span>
</td>
<td class="nump">1,680<span></span>
</td>
<td class="nump">$ 5,156<span></span>
</td>
<td class="nump">5,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 919<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="nump">$ 2,658<span></span>
</td>
<td class="nump">2,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 763<span></span>
</td>
<td class="nump">845<span></span>
</td>
<td class="nump">$ 2,498<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">19.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | CONCERTA / methylphenidate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,031<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">$ 3,132<span></span>
</td>
<td class="nump">2,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 684<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="nump">$ 2,036<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 348<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">$ 1,097<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | RISPERDAL CONSTA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(24.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 374<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="nump">$ 1,174<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">57.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Neuroscience | OTHER NEUROSCIENCE | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(17.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 4,064<span></span>
</td>
<td class="nump">3,665<span></span>
</td>
<td class="nump">$ 12,056<span></span>
</td>
<td class="nump">10,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,812<span></span>
</td>
<td class="nump">1,525<span></span>
</td>
<td class="nump">$ 5,073<span></span>
</td>
<td class="nump">4,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">18.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,252<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">$ 6,983<span></span>
</td>
<td class="nump">6,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | DARZALEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,052<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
<td class="nump">$ 5,894<span></span>
</td>
<td class="nump">4,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">29.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | DARZALEX | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,097<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="nump">$ 3,071<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">30.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | DARZALEX | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 955<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="nump">$ 2,823<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">29.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ERLEADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">$ 1,340<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">42.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ERLEADA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">$ 693<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">19.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ERLEADA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | IMBRUVICA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 911<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">$ 2,918<span></span>
</td>
<td class="nump">3,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | IMBRUVICA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 353<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">$ 1,072<span></span>
</td>
<td class="nump">1,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | IMBRUVICA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="nump">$ 1,847<span></span>
</td>
<td class="nump">1,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 456<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(16.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(33.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | ZYTIGA / abiraterone acetate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="nump">$ 1,446<span></span>
</td>
<td class="nump">1,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(15.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">$ 403<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">23.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Oncology | OTHER ONCOLOGY | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(32.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="nump">$ 2,547<span></span>
</td>
<td class="nump">2,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 604<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">1,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 441<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="nump">$ 1,322<span></span>
</td>
<td class="nump">1,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="nump">$ 827<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | OPSUMIT | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">$ 986<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="nump">$ 824<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | UPTRAVI | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">14.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(22.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(29.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Pulmonary Hypertension | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(15.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,034<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">$ 2,916<span></span>
</td>
<td class="nump">3,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 837<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">$ 2,266<span></span>
</td>
<td class="nump">2,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">$ 651<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(17.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="nump">$ 1,806<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="nump">$ 1,806<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | XARELTO | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(18.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(25.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | INVOKANA / INVOKAMET | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Cardiovascular / Metabolism / Other | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(20.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6,782<span></span>
</td>
<td class="nump">6,644<span></span>
</td>
<td class="nump">$ 20,651<span></span>
</td>
<td class="nump">20,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,356<span></span>
</td>
<td class="nump">3,117<span></span>
</td>
<td class="nump">$ 9,932<span></span>
</td>
<td class="nump">9,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,426<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
<td class="nump">$ 10,719<span></span>
</td>
<td class="nump">10,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,060<span></span>
</td>
<td class="nump">957<span></span>
</td>
<td class="nump">$ 3,202<span></span>
</td>
<td class="nump">2,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Interventional Solutions | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 547<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="nump">$ 1,566<span></span>
</td>
<td class="nump">1,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">23.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Interventional Solutions | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 513<span></span>
</td>
<td class="nump">513<span></span>
</td>
<td class="nump">$ 1,636<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,095<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">$ 6,440<span></span>
</td>
<td class="nump">6,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,309<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">$ 3,936<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 785<span></span>
</td>
<td class="nump">843<span></span>
</td>
<td class="nump">$ 2,504<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | HIPS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">$ 1,129<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | HIPS | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">$ 693<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | HIPS | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(15.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | KNEES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">$ 1,005<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | KNEES | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">$ 620<span></span>
</td>
<td class="nump">579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | KNEES | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">$ 386<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | TRAUMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 717<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="nump">$ 2,161<span></span>
</td>
<td class="nump">2,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | TRAUMA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | TRAUMA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | SPINE, SPORTS &amp; OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 708<span></span>
</td>
<td class="nump">706<span></span>
</td>
<td class="nump">$ 2,144<span></span>
</td>
<td class="nump">2,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | SPINE, SPORTS &amp; OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 406<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">$ 1,211<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Orthopaedics | SPINE, SPORTS &amp; OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="nump">$ 933<span></span>
</td>
<td class="nump">952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,422<span></span>
</td>
<td class="nump">2,405<span></span>
</td>
<td class="nump">$ 7,306<span></span>
</td>
<td class="nump">7,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 984<span></span>
</td>
<td class="nump">948<span></span>
</td>
<td class="nump">$ 2,897<span></span>
</td>
<td class="nump">2,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,439<span></span>
</td>
<td class="nump">1,457<span></span>
</td>
<td class="nump">$ 4,410<span></span>
</td>
<td class="nump">4,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | ADVANCED</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,158<span></span>
</td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">$ 3,460<span></span>
</td>
<td class="nump">3,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | ADVANCED | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 457<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">$ 1,328<span></span>
</td>
<td class="nump">1,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | ADVANCED | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 701<span></span>
</td>
<td class="nump">705<span></span>
</td>
<td class="nump">$ 2,132<span></span>
</td>
<td class="nump">2,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | GENERAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,264<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="nump">$ 3,846<span></span>
</td>
<td class="nump">3,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | GENERAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 527<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">$ 1,569<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Surgery | GENERAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 737<span></span>
</td>
<td class="nump">752<span></span>
</td>
<td class="nump">$ 2,277<span></span>
</td>
<td class="nump">2,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,206<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
<td class="nump">$ 3,704<span></span>
</td>
<td class="nump">3,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 517<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">$ 1,534<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="nump">$ 2,170<span></span>
</td>
<td class="nump">2,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | CONTACT LENSES / OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 908<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="nump">$ 2,712<span></span>
</td>
<td class="nump">2,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | CONTACT LENSES / OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="nump">$ 1,179<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | CONTACT LENSES / OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="nump">$ 1,533<span></span>
</td>
<td class="nump">1,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | SURGICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">$ 992<span></span>
</td>
<td class="nump">910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | SURGICAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH(3) | Vision | SURGICAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">$ 637<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember', window );">CONSUMER HEALTH and PHARMACEUTICAL [Member] | OTC [Member] | CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesBySegmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesBySegmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OralCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OralCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BabyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BabyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_StelaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_StelaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_DARZALEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ERLEADAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ERLEADAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_IMBRUVICAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ZYTIGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_UPTRAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_HIPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_HIPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_KNEESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_KNEESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TRAUMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPINEOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPINEOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_SurgeryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_SurgeryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ADVANCEDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_GENERALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_GENERALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_VisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_VisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SURGICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SURGICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380702308432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Worldwide income before tax</a></td>
<td class="nump">$ 5,822<span></span>
</td>
<td class="nump">$ 3,849<span></span>
</td>
<td class="nump">$ 17,524<span></span>
</td>
<td class="nump">$ 17,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">51.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AmountPrepaidAndDueToManufacturers', window );">Amount prepaid and due to manufacturers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH (1) | Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL(1) | Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 6,182<span></span>
</td>
<td class="nump">4,046<span></span>
</td>
<td class="nump">$ 18,614<span></span>
</td>
<td class="nump">18,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">52.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CONSUMER HEALTH (1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 809<span></span>
</td>
<td class="num">(577)<span></span>
</td>
<td class="nump">$ 2,279<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business Exit Costs</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">619<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | PHARMACEUTICAL(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 4,249<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">$ 12,593<span></span>
</td>
<td class="nump">13,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on disposition of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Unrealized gain (loss) on securities</a></td>
<td class="num">(200)<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supply network costs</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">1,124<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">$ 3,742<span></span>
</td>
<td class="nump">3,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">$ 652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AmountPrepaidAndDueToManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Prepaid and Due to Manufacturers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AmountPrepaidAndDueToManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage change in operating income loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380703552000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 23,791<span></span>
</td>
<td class="nump">$ 23,338<span></span>
</td>
<td class="nump">$ 71,237<span></span>
</td>
<td class="nump">$ 68,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 12,453<span></span>
</td>
<td class="nump">11,963<span></span>
</td>
<td class="nump">$ 36,064<span></span>
</td>
<td class="nump">34,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 5,524<span></span>
</td>
<td class="nump">5,587<span></span>
</td>
<td class="nump">$ 17,633<span></span>
</td>
<td class="nump">16,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember', window );">Western Hemisphere, excluding U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 1,562<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">$ 4,580<span></span>
</td>
<td class="nump">4,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember', window );">Asia-Pacific, Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 4,252<span></span>
</td>
<td class="nump">$ 4,288<span></span>
</td>
<td class="nump">$ 12,960<span></span>
</td>
<td class="nump">$ 13,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesByGeographicArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by geographic area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesByGeographicArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380712234672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Narrative (Details) - Evra and Doxil<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($) </div>
<div>brand</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_NumberOfBrands', window );">Number Of Brands | brand</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on disposition of assets | $</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NumberOfBrands">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Brands</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NumberOfBrands</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380700695040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 22, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 02, 2022 </div>
<div>claimant </div>
<div>patient </div>
<div>claim </div>
<div>cases</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>cases</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>claimant </div>
<div>cases</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jnj_RasmussenInstrumentsLLCMember', window );">Rasmussen Instruments, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_AsrMember', window );">ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember', window );">Pinnacle Acetabular Cup System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember', window );">Pelvic Meshes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RisperdalMember', window );">Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_XareltoMember', window );">XARELTO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_InvokanaMember', window );">Invokana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OpioidMember', window );">Opioid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ContactLensesMember', window );">Contact Lenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ElmironMember', window );">Elmiron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss', window );">Loss contingency, estimate of additional possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement', window );">Number of claims within settlement agreement | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member', window );">DePuy ASR U.S. | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_Numberofpatientsinsettlement', window );">Number of patients in settlement | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyReserveEstablishedWithinTrust', window );">Reserve established | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Judicial Ruling | Damages from Product Defects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Litigation contingency | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember', window );">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember', window );">Surgical Mesh Products Marketing | Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="nump">$ 302.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalProceedingTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Proceeding Textuals Abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalProceedingTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Additional Possible Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyEstimateOfAdditionalPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Claims within Settlement Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyReserveEstablishedWithinTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Reserve Established within Trust</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyReserveEstablishedWithinTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Numberofpatientsinsettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patients in settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Numberofpatientsinsettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityContingencyNumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product liability contingency number of claimant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityContingencyNumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jnj_RasmussenInstrumentsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jnj_RasmussenInstrumentsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_AsrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_AsrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PelvicMeshesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_InvokanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_InvokanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PhysiomeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OpioidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OpioidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ContactLensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ContactLensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ElmironMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ElmironMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380709394144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring charges recorded to date</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Cost savings expected</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring estimated cost</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_RestructuringandRelatedCostExpectedFutureSavings', window );">Cost savings expected</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring estimated cost</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RestructuringandRelatedCostExpectedFutureSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Future Savings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RestructuringandRelatedCostExpectedFutureSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140380703561296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Schedule of Restructuring Reserve (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Oct. 02, 2022</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech | Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech | Asset Write-offs/Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember', window );">MedTech | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PaymentsForRestructuringNet', window );">Cash settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PaymentsForRestructuringNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Restructuring, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PaymentsForRestructuringNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>jnj-20221002_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jnj="http://www.jnj.com/20221002"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jnj-20221002.xsd" xlink:type="simple"/>
    <context id="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3d1079dea4094854a0d8215a7b7bee77_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia5474370380a497b82e6a430f952af34_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i12fdbd4684c2453789af8d70324bc71a_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4072dbe684f043559e6b3816abcc50e8_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i414d244f8d08480fb66a8026c8d80ad4_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4a83e7272e834e8fae6c7fe265b3be1b_I20221021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-10-21</instant>
        </period>
    </context>
    <context id="i88a45c1864b841c3bd10c2ba6038465e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i6295bb2d9d624931bd4df9123d80c9d2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i00b96c9b90b442fab76aafa9fe0f84c0_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i4b472a7b024e4350a7efccb19639fe5d_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i897e4f04cc0743dab9335bb279413316_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i761acbf210e54d4fb1c6163ec297f3bf_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i58e73c0430be475c963749b0d5dfc1f0_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="i69a1c834e78d4ae6845c115cb37b55cc_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4e381efb52944e08881f1e2b2dbd0e62_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia001762d1dae4d37bc5d624881fae1f7_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i46a1b195ff7d410ba97f45f6c00f9cdb_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i3a9083e68f134a6b959f8e81ba70dca0_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i17402ff8071d436f8f5e04dfd2b0c961_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="if3af518980d74cf485a8c59539fbb189_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i2ceeba3817c74be08a112b20898f78ce_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib60c35086bcc4c329bbe423674e693a9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i04a23e81d62c4182843a25a386d3c871_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i0a4a604382b3438899182204e090fce2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i71751112fea74037b276e2ca1d6230b8_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i67d8e299561a467d8fbca5be63ecf1db_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6d3b5d7c62914a7d86c97bf6c03bc15e_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if04a9117c60243599ca157246ed62b82_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i2841ce9e4bda45d8adf1dbed8d0ebb98_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="icc527a1e93694a149099814a6a780f3f_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i627a7e7e8917482ea7ed3fcf4e5c6e7c_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="if42495605efa42b5bb22a39f20c44adb_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i922b7adff7f14b97a51ffc13b9d0eb2d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic763a721f63241119bc153b39881a917_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic42e25ee27d54341885e6febcb82d781_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie4184dedf017492f81476885b7412820_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i58afd10b08ae473ebc46006082b2cec6_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i50585c37981c4ff18094df49a0252cde_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ib4a790e2ad784bd7ad2cc7889a2256a0_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i4e846d19941748ce9cbcf17a4f318405_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="i7466db7fb3de4e73b837ebe5f0b10609_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0c66231e52f741d58eefd24bb80b245b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5d5a9d98b51145fda780e8e3cb899d96_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5af1680d3ee24b0db79fec7b602aee32_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i360f555817294c969083b2da5b0c7012_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia39a746470bc4c38bb1c35c5afbcd727_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i784f48887ba4406090c0c953b964f651_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iba060ae7e2bf4658880cd1a19b71adf6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i543c0b5db3074157b1c389cc2cb0ab48_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i15558a3176fc43799fe21d45d80bca2a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic2612dc9b393420aae1223b600b75635_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i2af979d2806348c99fb689ce6819de96_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i0536181aa78447d784d738349332b35e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i661087c5259246cfa115e122efa6dcaf_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i235a103d58c546b8837d113d0020a52e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ica2f1087d4384fb0b48f876aae358e67_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i813f5728d4834e4081f50346c8257c32_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9cb8f0f0413e458aa5d67d5e5470970a_D20221001-20221027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-27</endDate>
        </period>
    </context>
    <context id="idcf057d296c84d089ec6d58708ea1502_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if32850109bc44a7fbb02840853387b1a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4fbdf34d70c14edbb7715d0150857e3d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7787b0e8db0d4969ac6e93a11454dd47_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i470f1742dc564aceade9de615023f5d9_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i522547423bad464f84afd2d37c47a86d_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i21aa856799804b82aa87e91511e1349b_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id36c39c3a9764cb68cde96d61776f981_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i6dbbb67dd9c940368c9c692b2970e944_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i957a0b8f238643b5a7f04ec25dd1ade7_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i1c547b36424143b69e5081413c4fdc53_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i717dee1c18bf45e493386905d911c3e8_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i62511374dce64f139252ff8bd59a8db6_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i8a64086e3de14779a155947b262f6215_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib1c84b4bb409475ca45e6496196a8bfe_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7879ef9eb79f474c8938fb5e9a08e0c1_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iefd146d7e5a948cb9bea7e9644188230_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0995bad590ed43e0bd73dc14bc4125a2_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i28d9447c402644708f5027054c7c807d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5f7c9ef50ebc4fa19a9a1d74ac4d6b69_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i888f5820c4ce448da471f2eeb67baf91_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie5a1bf6a5e0a43f89bd6a0e1d76c50bb_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5ee5060692494cee9c6f548b6e07c2a1_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ica35d2547f134655985b599491b5d2de_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i027b98ae63404a32b51e156b3616bcf5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ieceea25b4808416c866a84c9e93d2bc5_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4346ff30c79f4cb6889ccfc5de69e800_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic14f778c18a3446c9134ffdea15dbf34_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4dc12c5833b246768b8eb8a92f87ba5b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i07d3d9443f8444bbaf8ea1e69ddb15bb_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i72dbeff9573f40a5b9ba376ad81d5398_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idb87a9281a92433d81c4a3ab6ffcf38e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6f92be1d7860435ab1166cf51a2c9ada_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i699ea2f9280641c6a2c2ca9ae65c2e9e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9571f8c7ed824bd7907d0dc67ac2cbfc_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i78647d618ebb4323997e495ab6b689d1_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6804eaf6e9a2498bb21b278580ca9ca0_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i132eac11468e4392b097dc2bcb6b935b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib7950a50b27c4ebdb91385e119fda9f5_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i89a2ff3d08834c418a9d5c5493adff6e_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibcc16a1145204ef7b053987f85b7f51d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i98263d9f7f8641fd9e965fa50bc0532a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i82b29d715d9741d3abce2df4d39b309e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if4f312e218c94f0da6a1676afa932315_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5fde6866da6845ffa717894b879f8c97_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7366275be3ae410893ecf9408865b9c7_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9c0b992f36af4511aa5daeaab0f6fbab_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8378ff8e008a4098af1366d8ed328c04_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0757ae310f7c40a68adf9115fdf4e04f_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i773b6479d1f84dd099a271d67f39d97b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0f6aac49f1e34f848da45a55d588af8d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i98dd0e4104d64d1e9e04143dee5c8d7b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i30c2531c320b4c429410121c99424073_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if365333f1f9d4429b45bb40e00408696_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i02b8db1fe34e46ee8c685ab4da2008f5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8e443c797bce44b8904549f48d8fc7a7_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i425df44efbe4432dafc49cc44a80a0c5_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibc5be715bb3247109709d1a846e794a0_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i971a920aa5d64f5992b34b4dddba6c81_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7500ee5f78d14a669d9868e1d786c583_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i64a948b4810449dda6fec2b6273bb8cb_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1eecf9b0d2d34ad7af622fbf637bcea6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3ac33f410fd64a498d0320619c400fc0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if68cb6de6b7547ddbd0a239ef2261809_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idd364fbacd784c248996002106d412f1_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5e79e3afda2d4ff4b9c9715fed272c0d_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="idced9fd0a0dc40e2962f7034fb149e25_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5cfd0ec8b28f4d61aef0be150644a052_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iaa79f363437b49b18f54f6dfea462a0c_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id3f939a4ef544f199f0a9ba9f0486f0e_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i29be9feba45c4fbf8a5331a5258734dc_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id20d1c20c564471ca693f0dbf7e3e2b7_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i531bee53a47b496db85de6734c8b4ba1_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i35ef3a7f91694f4784dabed8656e3e52_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i891a31716b3c4d33862563ef6041c58c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i234b580d2ab945b7a1da2967b50f2f0b_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0c2c6e50b3414bb7b581acb7b2ddf236_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie4b5f475cfa74c208c0321112d12da5e_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ide20e84875b34943bcfaf3c9ae95202b_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i29b950c0556549258d0b61b677f0b680_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="icbe5347877f646f8a69accb4b750d574_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic472125573384b52b4aa88304af5b630_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7ff0963b4e07465bbef6c78a5da86146_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7792ddd751e74a3fa36de680b670123a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i42bf0720b1074baa96eb44f6c995dbfc_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7912b942d37f465fb3e53088b7761ba5_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2000357e194a441e9534374b54cbc72a_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia6c24b49746b4613b703772fdfe9f6eb_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibd7f9d1ac03a4e2ea6d1d353ef976c71_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0bb2d4354806473f89aeaf974654c5d0_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i370583126d5b4bab94e9ead51c975ebf_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4ee255d90708413cb5622bce2a34a5eb_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iba8c6cab16ef4288b07b2a65d72b7ca7_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8e59de01264548d093d60627efe88e9d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i10d2e79904b6488a85d7505ca382bbc1_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i487741e9485f4d4989b2d9bdd6959f03_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i1f8bb4709c5441d49ce49132893c52de_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7eba85641ea146e5bc22ff998e193635_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i185112cfdae241938bc5001036d374c8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5777045ad8034f0ba971fbea4fe60d05_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib8c1c1667b484cd296b17f3e255a344c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if65ea7c0fbd54a3d9557ee7eb1a25b7c_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie6bb3d370ef04b7d8291df862fee2c4e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id2db0b7f18904840b6133ca100157ba1_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i97ce603cf39f42638ed7c1c786b7b5cf_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iedd9f71bda284795aea57b0e3717a2fd_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i09ae709d11a747f5bcc44c920b026868_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i995da9ebcbab4f4db89d58d96f77b4f5_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7bd6461d92f04ed69ce2217f18942c36_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9b27f2a754554e6dafba78c082f6f40b_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if177366e6dce47ec8b19785b5a66cc57_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i606547907f3f4875acafd89bf36f7292_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i47c3297a283649f18a41e3b7ce1b4275_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4a1fe51dbd41434cacb992b4b627a3a1_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5794f5fa77224cff877efb7f11be88a9_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8788e8f33a374f91990206b3e2c99555_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id8ae9a8d6d144029b31ac56599a2c97d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2b0e63e41f6a4d339367644bfc21181c_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib372927ab7a04736879231296a9857fc_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ibe72fcc581ba4b3aa24c4cf87da552b5_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ic9edf61dadd24a7a89bfd4eb35fdb595_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ie5ec42981eb24a7b8f39e90fcfcb3b97_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i7787c920b4fa4851a091b1d05760f26c_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="if9abd0ce724b48d1878bcaa4742736aa_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i13455fb6580c486fa719cf5f9b78801a_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i17df52d9c169494fb0dbcfa0f99740fa_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="iaf68b60de7014cf2a3fbb8410bc3a9bd_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i4f13cabfbd6e4267a7040e78e38ec939_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i91092ba038134ef4a95f7a6d01647908_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2e55b859d5454474b61a342f2ab11b53_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i01e0e3590e6e48db894610a47ecd29c5_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i57a26835dc1c47168bfb6605e72bd3bf_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i38e80c564ea64f3fbe9520902829f8e1_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i12c14427081a4db2aa89c55987a2b503_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i0dab1f127dfc4cc180ee120f93e8d77b_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i4a3800ae61df48de8d071ba58133741a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id965e9daba4e49939bc440149dcc9a39_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="if15f41a6eac24347aff0d98e523e6a33_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i298d351dbfee46d79686114bc7415cde_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i8bfc8f6514464a3799d65367ae9e9037_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="iacffb22cdad9443a846f401be599d84d_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i07d551fd651b44dc8ea8cbf5d62affe2_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ia3f1d898f0d04ab99472e9d1769191c9_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ic52ecafdfee4446badc41ecd13c9f2a2_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i980e7f0f06314813b0a382c339d86df1_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i9006cebe9baf49098f28b71ba8b0b364_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i7e6b7c5e255f431184d25955b77d4780_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i0157c2d40621415cb530f8b4f529c1d8_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i09041d6f39a84ccea0a739091619c846_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i262548be13894c1896c025888251703e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i5de5b6e1d4334a008a1d9c060b09147b_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i870bf42cc2f24c9ca6e75df10312d19f_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i94e04502c4854e9099be4395f58835e5_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ie9d2496e033944a6858188b916c2ec78_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i2b4f83eb2b694aaebcf4695cd84e55b9_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i70cc3db8241b44bdadd5529cad658578_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i030634cc2bab40ba860c6310273384f3_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ida226c289b3d44c98e6aca58fd729233_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i1ed802dd203a43d3afa9f1915bf381d2_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i38954d1e3098492e806481f25cf864c8_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i8507feada10d4116ae4715be0f83f61b_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ic33663885e724dba955223059c45014c_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i3220255239e4430e8bc071481c23af70_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id2ac596ef8054dd9bec84c0c13239c57_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i463dccc9a3684c049eac0a5bb39ebf77_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i5f76f6e1c7584e90bdce33b5939f49fe_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id4e881a6337c48eba78aa5737f820648_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ibf9913e7637b4fefad4d9411b1e57dda_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i2c801bf0bfb74c4fb7e197403e0c19da_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i7e9ef1c58573413fb263475037c7df0f_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="iec007660d14f41158b78244410752ef6_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ib01c6007919844dc8a0fff621af91ba7_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i1cefb1e606b8454bbae8580ad29ba4e9_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="idd59161e160443be992c19c3e552de73_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i46bc9af826d04e288de22182a64ee453_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i0955f4509fed4180a52c8b18fe4c4b13_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i5267d6a76fd344b9aae4d32ffcdb89ea_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ib1f362e68c5546b8b0891c1e060d692e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ib7a74be7a73c41d79f6e2392d1d60ea0_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ib1bec1f0d9314920bb56531e382e7cdc_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id3efd972e13344cdb42226b639f85eea_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i60f419a473f34fb29199544a2c8cb16f_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i81460a08681c4e40ab454eff67450960_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i78f4c5055c844c61bdbada64f0290039_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="iaa22322ad88f4cfebf3bdcb75ad25975_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i06fdae26fcfd4a60b871ade74a542ac4_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i32266ba4f72e43a792a31e7faa9148b2_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id940c82927a641158fe648918accafc9_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="if847a21b92f348a0b7a4025c882fc0e2_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i8d6a26673c434118a68c645642b3fbc4_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i3f89bf72f2ba4b478472d343bdeec569_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i29078fb071994051bd63d8f4587eb909_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i8851eff20e5145c5bca1a1ee92617a5e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i477c86f7309842dfb55248451d3efa39_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i2ca4d871cf6b437582cda14e89bb594b_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i9c7dc65157e44d3aba2a140b03b946b1_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ib89592a0e11e4753b648c5e3cc03ee9e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i36742f2d0f1f4ab8a7597150249a02bf_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i733cb704b7674b0e9a24cc4ab884180a_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="iae69d4e77db7465fb0571ca12ef0fff2_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ic4ff5147e1a54074a2362ad5feee7c65_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ia452af2ce27e4af2a660f83bf6fbda90_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i6b7612a89a5a4d3e9fddec30bc11ee22_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i8534a543c9964871863c7e4c16232cb4_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i6a53e2b415aa46dba827a399ff3c0318_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i23e399c422d04b4c9802c29f75c01f77_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i515258d897424d1d91d0dd5e6ba17edb_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i57ec40d315b946f2b9c6a729deef3a36_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i1f6e82e7b82a4263986c8f5f799e01aa_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i331180abea9a4581bd4f74309a491129_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i2a76440ea8554d14aface7459e0c118e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id71489b63d304114b1ee5ae439e5265d_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i3f32d63a3ac54710b81b92f90e389147_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i04beb44383334787802dafc265394766_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ic8ab907b696a4139a072f00b70bbda49_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i725d5d1c65b54fe9961ae484ef90be5e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i165e3f370fbf46ed93bf4cce9e54727f_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i428e006eac404991b3e3d872ddd1c1f7_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i9b9310bb6dc4450490632d0116946ede_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id11fe423cd3a474cb70088616178415a_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ia36a4cef5d4f402fbd7eac9f85a18b17_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i86512b1f50de4ad88f542164448d26c1_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="iff6bcf8520fa4057a7f4a5589d4684d2_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ia2b9b9e93ec74f2b850cf4cacc8bbe2b_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i12550a2b68084f8b9214b4faeb85013d_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i5c6f68f74915492181e040fe2b309c71_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ic72911776cd542c5852cd1d5ca05062f_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i4e72ec4950db4ec699a1131d9548a556_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ic668dba37a974482a824018731b483bc_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i955013ec18f9497e9a9c99fee52c731e_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i2fe780e81ace4f5c8b98dcf4b0ac0e21_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i7deba806ae124861960bbc06843762d7_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i0861e096ce334fdfae380bc7f0d69b72_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ibbdbc1ee962e45f7901626232a02576c_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="iffbcba0a9b874fb6b9472d4fa8d72638_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i333dd5feeee74afbb5ad0dc46eb323e0_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i0422e59a7ebf4c4cbf75f1140ecc88d0_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ic8ebbcfaca4140c38e6ed48542fbd4de_D20220103-20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-07-03</endDate>
        </period>
    </context>
    <context id="i017db5ac595541f0b302582a410ea26d_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i0dd1b1fcff0145219d7fb406847ea584_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7d211681392d483b8f62c60a8d8a4dc2_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if235130eab4e408b92fb2c43ccb98f42_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5d60d3f4537d4080a89795d512b26b9e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if38fd805a6f8420da833524d3340a063_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i04fab62da2c141f888b893afab6164da_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i332809e8f61c44149c2e4659a135fe38_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iff704175779c4e83903efe4bb1b1eb21_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i206b36fcd5884efc8e2d9f8f10a5a918_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i096b7900f5fe4d45964781506fef7cd4_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i8d64a67a236a4c7e9d6dae0c1d2fd34a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i944bc08bbd494170a723fa335d775693_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i0857a3c31a28448189abbe9edefd142c_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="icfb9d5a6b7ad47d78a2e5ef496f4cbb9_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ib49ea28b1f6a4233b9e391f4fe2d7695_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i08ec2d8a0db84c62aeaf6386e449a7e3_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i7cde6a52268347428b5037069103d820_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia74220ebf81e4065a938588bde5498e7_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i78fcb0fd89d14eb6b29ffdbd3720e7ce_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i54a459b3600145d3b4107cf4bdccf257_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i941ed2c1db534253af22569d7910ede8_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i1f1d220f585f4dec831f31a5f9ce8adf_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9aeb275ad1f442feafbe9c4c30a972b6_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iec58864a102d428fba3c283afdd1c086_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i63196f90176a4d4c89a11a247847a7d2_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib10849b3cb49478ebbdfac543124e1cb_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i343ce984f8d243c99d19169f2ce469e8_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie94a7099ba6b469abec25cbdb9df79c3_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7c7b7f8b4fa541888ad11c59317e305b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i110338127fd4477e9581eeb21a88403b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iba3692bbfa0746ad97c0e05cf2f74b81_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib155353bba1e4367acb4afc65093ac17_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id8c11083b6fd4c70b63123ebd3184bcc_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i59bf5576de564479ab33549d72205efb_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i92b06f4a72c54053ab762b36aa11132f_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie061b083973e42d4885e9f9780a30d24_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id127890eb1d746d2b41f02aec9b35a5a_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i028f7b0cc1fe4417b3829de872b9bff7_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i20bbf2239aa6444fa5e65541167d42d9_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia6217c9284834a96aba0480663c6c29a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4fc1b31fec9043679c9a24c4e7d7eb15_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i728ae91795a049659be1d1a2f8f086d6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i197d29cb3728490aa880fe1b2febaf85_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ifc8a1658b7674fd480d2da4366870996_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8200dc57bcf946c89ace0088bd07514a_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie4c3e6ddd1e342c29393fe34fb925065_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icaf3eefd4fdc4df398da4efb9abc13be_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie31d505d43664fc6a37a1a6f7390b6d9_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id1f6eab93c9b4d1fb2d19580cedc8b4c_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia4fadfd175984a22b86dc24c89dc4bc0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i15720a18344e469886257608fa371d4b_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8a609c570d4247459662c095f2834797_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5be2488acb464b53b616386ec7557fd2_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="idbb0f442da954722b1c33088aa5d0bc2_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9b5a875d8089486c8f44852cabb6ecfd_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i211cbd1cb10f4ee7839006b5eaa4a2bd_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i258122d0b65d4169b5b5519e4d8d5074_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i29c2eb559dcd4387b1033c88491e2a2e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie0235b711c804ebfa7876a02dd285bb1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iec063ee8c3a4470694b6e73255290c52_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i04db1cf7ec4e45bba56bc0d72ea66e02_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9f2286d04e2f4ee5b108615874070bf9_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5dd220bba8484f9ab20dffe40805100c_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4ebc82e0cc7a43579e7cb5d5261ff68b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie05209c75c064c149e32ca91f101c128_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i60597d445fdd471dbefd75d06e9d49b6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie59769c19cc641d08a4a75d12515d22c_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iadaaf79391e243ce9580a4a5f82c3c1e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie40537dd17e641f18a84d3dae0e1e91e_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id74e23c5a1ea4a3fa4324f3cbebba2ec_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i57dad0479d5f408586720d9c4f156c48_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6571e3bbe1c5478088cde974f1a794ff_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7cf927e34f9e49f0abbbe3cd9b236507_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iaa1da1546f194c1fb0e2caecfe484dff_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if82e78c4579b4156b6cdbcf7c3cee740_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id0699f62151e4b32a947734f89b31cdd_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i117745a3dd684de8974772ece9648d65_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4b9a0c60f81b457091ed4cdfdfcafa87_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i85433357f9bb4fba8f50ce185075b2a3_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i76af37281c8f42adacabdb80e1047e01_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2f4bdb37dc4b4d47be92fde1fbb37bab_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia378214014c14267bb7dedcdfdfa66ce_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5fa62c7427744e21ad6b4c38c6a07153_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie59345d38f1c4186b66ae8cc16f7a721_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0e80efcfa77b44a5b447cd4080557081_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie501da18e9c84dbdb77d1e9fce501b01_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic34261d9fecc4b469fbfc7320a06ad74_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i38e077f4d7ef4d1ba0449d563d1247a0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if8bba328151b4f589a73606eb0809caf_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4b41c4b48d4d43e0a26a3b93522fd773_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7c2d3a271be74fd9aea5facb617f9860_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic4f833113f7041289bb2eb913b130ebf_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i20e5cf3b01a84cb493dc2721b5a74b79_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i320bb566db254466ba9c6a695628a6b0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3e5886c2fb184bac9cd7ffe1b974ffb7_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i755b8f931470497ba00724a368f9cdbe_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1c1d5e55ddc144bc825a5b127870993d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i44a1dbe5705741b68a24e0e337ef63e8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icc8e23dcc91d417896dc4ffb5479cb12_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i11459a5bbd884b9cbcefb0dd8cc442ec_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if3cc1f7e1fa54ceb9ccc93da93684bef_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i676de123fa744973b1d51400eabfad36_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i58528c896007432da65d8fa36f867e8e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i050bad26138643da94080c24dc214a0b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i1ebea684bc144c3ab6b069f307243b39_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if9ab2943111a45ddb4c3689d0f23f0b8_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2c86dfc4bbb843088a0478dacfdda4eb_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie710509f29a84a6798f07d16fdf4bc25_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if36c2d2204694bd1b65beb048a38a087_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i27e0991470e3476189d1336285252c30_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id9da5926e9f140999d1bba65c342a33e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i601cd15753894e97b054f81a710b6ce8_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8f5d0786855c4f85a8c2679f03a458e6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2fb4bb0a29804fc68f9bc363715532c3_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id807a25e86074bc39f2d148f8a84be6e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i14c31eac278e41a1ba118b6c025d1f7a_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6e7e206e166a4e58afbaf397873c5618_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iab929e3264374872bb7f54c68dd062ca_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4eab22cd2cda488aa69b38e14ab9166f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib47f7963286445b1827fe6925d9837a5_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i29e7b4c0a8e04fc7a1fb4736a9fc92a4_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7967609999b541f2b29b2c6ce68ddbc8_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9ac3cb68f0c34215a382d7031670ff23_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia6bd3d8de975456d820b150c1d106f90_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7b4fc3995b69496ca407948b3dea092c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic73b319201054f529e8ccf164554f568_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4cf4f4567b834309abf4b2ff42315882_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8b43ed5dbcd543d9ae7b7fd7bb075ab7_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5c16c4c7023f4f0790700efabacf60f9_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i35f027f36faa4af1b4f6e944c1417488_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0afbd5dc3a754753a394dd6670fce509_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifc5345a5249f40379024f3ef934dd3db_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3d2ca59e69a743e88208410ceda1bcba_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib294a903194d4a7187902c709f695b44_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i67974f0f7a1245e7809b5204fc2509b6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib3db40e6bab3440fbc146528ac4ef7a0_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6202780aca5740c78cbc6ab6252f4036_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifff14a1f8c334b9aadadb7babbfdd924_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia0a6027ed50842c6972d5eee3da4c9c6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie5b800af44314d97bc6e07ab8f06ffb3_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id938e01bb77e45deb2dd767caac9cdff_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i60bca8e9e03447268cf3bf5aee0f765e_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9c5c096bdb6c47b695ac4b997e09e315_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iea479d1c88df4fae9e4ce67cffee6742_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i618dbaeeb2c24741aa3cbe519fe58c50_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8086f446324048e2a9c8937b0ced6d84_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5b22d7a7eb564fce9cb4052d7a41c913_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i059e1b1f3a53490db3d19ba632df2180_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id0008e6798c040f696f04e80c67a9f1f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iec6ee4cea0654427bd1841c05b22220d_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7db6efcbef124e2cbfa8b06aaf5015e1_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4ab89cc409f64d07bce8e87a8fdf95c7_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0c6fc771e5cf47a7964910a8424d9aa6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if9b5a3ff0712432c9a8b2bec26f39b4d_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic969d91a8c6340d49f4ca9c6d0a168bd_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i611a544e7fed48459222bd6dba1e2fff_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i532f597a8ed14fc5aaa5997db648cfba_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib5a81309c93e40bbb6520a059a567fc9_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i75bc3e4b7f0f4bebbec4aa452e444d00_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i045bb0bb60d64408bc746a0b601e9798_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i73cbadc80e7d49bfab612db1296213d4_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i02219b77430640bcb4d575751528f347_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if0e29062c8fe44fd9b3dc53b1dcfddc0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iade60d9fbc69468ea53b4630449ae23d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i48d8585ed15e4dd9b2a5802f367ad706_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1f6578cdec5d474fb61356ea6723f969_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i539ed9db6fc4408cb8bf66316e3d162b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i113f00d20dd64c9c8ec5149aaec8e0e2_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i14d2acd0bff348a696db84de99c97bfb_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i438b4b2bfa6b4080af4749683d1d6535_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9e88b65375c744c690cb9f2531ad1947_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i777a5ad66b154207965e26b2bac930d7_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i20227083c87e481eacfb2dd925179f5b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5446bf9970a24b6b937fb2036be6ff7c_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic4543179c68d4c82a76af5e632f3aa8b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id59930ef089148a392af915228263641_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8c253c52c7ee4f25a276574c0adf9fe3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if48bf4caae12427a934bf19365269a73_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0e97e36903074830b97a3f886bbda733_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i94fa08b8cbd0498cb485bc7b48711e3b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iff2bdce36f584334bc4721f3d6131a87_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5acf2a6ea8034d3e9b7d7074924ada01_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i14747989f826463ca3488654f17be9f5_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4a1127e192c04223a462719cdaa10ae0_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i55656c2263544ef8b6e0bad424c168b7_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6f0d1ddf2bf748eb9fb05773730d69a5_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if490f8f38569467da82013ec07af4dc0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9fcbba0ef29f4f6fbad46f21014a1b89_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibd0faf0da5f04c0992e10094b3f8e97c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6191e64a17bc461c9838efdd458364cf_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="idc6597880ac74bf48cc5795eaf19e569_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idf91d92c233a4dbfa5243a026f870176_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="icddabaad4cf84f18995b0dfd4ec27309_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia1a722add33f4a4e970219beb9128bbc_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="icbb9d283788741abb9be248c18d56115_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iba72ecd0fd3b47c6b352e266260fc5cf_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib213aac39dd14e45914c3a0c2bf6713c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia8d296b6dadd4d958ffe5990c80d6a0c_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i83db602d21fc49c098bf5479b3b020f9_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icf51711c9fc9401ea85ff7dab87f84e2_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i413c6a3f140542e58e400aa2f983c6e5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i67e44ed2293b4d0ca08120085f5e960d_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic4b33e65c46b4a568b37f7326d33ae1e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4345727efc2f4029a0ed4bd19dcf7bfd_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i054f2ca9d0cb4fb8b157c2706a23ca76_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i76df4b1c1d904841a08d373dc471035c_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i46fb64831ae740e8819f320229d29799_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i374469fd1fe84b23986b0e14cfccfc49_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3bbe137b43fd4b918335c8497edf70c1_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i32c68d6e42284bbfb401b21b31fe0f06_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ife8189ee4e82488592a6e11bb1a45d3a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i84e3265b7db3479d856ade508a46ed66_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7faac73e2f23406cb8eb7dbe1944acdf_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2b2795880e984fa283bc3a164283cb1c_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2e3eb5daefce43a7ace1a8549cc00d5c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i53e3c10757fd42b993341c8066c8b790_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia4d204cb63f34d5f990c71beecdb6abb_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifef1f530ace84a29a6481dcddde7acf2_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ifb1aab6ee7734aaa9c1c053a59b47312_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7aea2bc286e74c24ab2637ca0d209a3c_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i58f24b47415f48b0885b0d7c10967969_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic305652d07704e98ba5feacfb2d5f00d_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i33a0efdb63c04fa69e366975a05bb13f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i177dc85392db469a8c1db91c948cdd05_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ied3e8bd6206b4ee5a70504f5d9b66667_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9610be906255476eab03ae58f21e9645_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8979440d00f14555833df82de8200c08_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5af5e8ef63074a068a23d526b83f8c0f_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if7a94a1625b94c1e93bba0b6e6b48f6e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibe25061e631e414e92da52fa72c80da1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i976e2778a2084719a4234e95ad13c666_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iecbfb31a552f4de39c19d87cb748cc94_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6c1202469d66404db95107a79c2868a0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3dd1abaa86844d559d8ce0f5cf23ff7c_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ieaa1aba1c6e8477da278328f0b8c7659_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iaa25cbf4d9754df6ba84b4ef2d383458_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iedfbfd4bd41c4c5187cf6e182e899660_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1612b190f4f14f649d1d8aaf00cdd1c6_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i968f6b90e0d24fbf8745420b22f191a9_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iaec7a45f95d444fc9c23636a25fc71b4_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie877d3091b2a412cada21c76c157025a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i823acd2fea2640ddb3d3f3ab09a21a0a_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iac2c5b49a0b14b7886ce8b9cb93667c8_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ieba37868d4ab40a494a8932e5c195ce0_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib0705f1796374a95b4f177ad23d8fa53_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id5b2ee0a4ccb47b689fde9e511d136bc_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id289d5f0f10e4ee799a2e6ea8bd1d88f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0cd7004acb80425580aeab7c75bcb925_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9b2cb42ee1f24a339b3c00347bb66920_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idf202bcc43b74c6e97e4400e94a50ef9_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib390ee20bcf14042acab18119fdcb669_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i11dfd015a75b4884aaf7606edf7f9f0a_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i45a4897765d040e2aef60f9e024a65d8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0ead4e3e50cf4bfeba22c28a2397048c_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ifa16021f57ab4f1caa859b2705fd46a2_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia0e31c64d572445bb6085f0d2c49ea4b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="idd460e77c2eb4aa3be50b1cdf64ac81d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icca3698a549d4feda795428aba1c8625_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i49a96dfb6d88408fb4483ed241d5e788_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i137cde1513484ea6a0ba43bca08f33f7_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibab5433d88374b8f9bd823c575a7a039_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7d7a58a2310f449cafcd3b8351c93cfe_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6e55ac0a94064596be5e7888ac1c9bec_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie09bdbc4c576474ba2cece696d19cb68_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iedf94af89fe14fea8f4a33af0a883c1a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i79c0238a6fff4c91bf6b829e1e0e6892_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0ad2fa156fe5432eb82a37c862ef94fb_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i45a7b092ca9844859eac9399e8268977_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i62f741d423224f489272cc2103a2be77_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2ac7374616114d02b1ef9e3af61e8c95_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4365f12a95234c7dbbcbde1b929baee3_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibe1eed427e824c31a74eb9fd41fbaa1e_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie11b64a00633401683a6ce25e6f615fb_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9968c0bccd0448c9a01e166ab918a984_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4b46d64b60414934aca49f64ba9e5f60_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib1580db90b0e48cc893c81fb2540cb41_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i22a0e4c73916450babe25165d391d6bc_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ide5f51b2ac144660a667a5fef9ab26d4_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3a52f1a99905452fb46ab62760965f86_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8a2a628c1fc440eca687de37f708aa8c_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i52da69a2389c48eb9e42c1a2ea47bd75_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i66a7d12f22764dbb8759a742d94eb8a2_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i93952a8fa3ba416a91d3216edf3a66f8_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id3e8caf499784ae398f716cde9975425_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i451f3c5eff7745599f90d0af11f4f4cf_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia582797f6e464aa9a43e5e6175ed4fdc_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8801d5f445ea486381246f9557e84830_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i08dd8fcd4d2a45b99b04b6d5af0eb436_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i78d8a32d310f4f73ad47b98c02d07725_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1eccfe1cbc774b868af74e3ecf7e96d1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iab744bf1ae1c4732bff2f6dbcb6177c9_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i983dfa5746394727b4076b1302b725e3_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i524e2edfc08f4a5580c142b4fbe47bdf_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib1b57f9e060b40b7a959c01f75f2cdb8_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6e84d1337fdb4905ba98011e4e8bd221_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0e5b869f0296461f9fd2b132c207af88_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i76cd338bc7d045b684ffef7f072eb708_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7f93a1e291fb4f21aa74bf605526f3d4_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i57185a1089ea4d859905b073688fb56b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i122d085eabad46eb96a300589fd4bb3d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i89657990d309468383c0be47dae23813_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i59754740b9fc4cf0ae2c2c849165f4c0_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic879ca2153fb4a0088c7ee21b8bb666f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibae451029e5d4bd580e6089d7352e564_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iedf29bc608704deab5ec4bfc9c1166f5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9f1ff4ca321f4e6fa0ef4ae8850e39b3_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i70cf1523502f4cf5ba39389cb696eb37_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3b56bacf950743f084cba59a7fa25e7a_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i081f0f428e784cab8f9d016f92effd83_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2c5cd7d0017649089af560975f3138e1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i475fdfe52a874f96855bebe87d3bcdf4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i87898be332414773b484d0dc62a17a36_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia552b1bea3ed45ea9d9428a49f4aa36d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6dc593f363ef47a58da8ed226cc81f6d_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia5273b9790a9456bbdf4c45498aaef2f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i47cb84e4eff645bc93a43e37e94a9db3_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic6dde9f39bec4bea8b20aa1d494c72cf_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i01a4a90d5035473fbeccea2782bd2c3b_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i42adb27c042b423eb963af60ecdd4f28_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i027553a8069f4b20b245dc5aa1b7f00d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4f6c8c3e6d5948d28dd9796e3ca9f2a0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i72692a16cfbd4625a23c6c13e5c4a89a_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5b6abfbb54c2428e827e225364933220_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i55a933b2468c47028feef151e8eca9a6_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i09e27f9730db43f6a2ad23e6cf8a28d5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i77060b346f464d5d94e95a340469f8c1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i272627f13bc84d4cbe6effb2975aca80_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1544200114ae4509a452b21c7cda8113_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i37417b84faf544e388d7fbea6710dde8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibcd68e44359f480b9c73e8e0717f39b5_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i60c2e5afe5f447d98cdb95e255a91e36_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia610c33820924e2887785db9deee9d33_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id90c807d7bb242bdb981d10b3fe54eb6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i694546fb28354b728eb7a664114dcc64_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0c8924e9eaec4b2dbfbc45f97506d991_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4d326425f4074d3aa5f72ef541b7d36a_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id3a634db09b3472284861b507d5c1114_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibba42e341ee7416abbbe3661f587439e_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i13b890bcafd74f788a55c0ebe94e5632_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i505a0ebef84644338a169d2b6209fbd0_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i38ddfba15a2041d88d410a99ac1e926a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i033591a445a5468693248831071b5242_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7da56618ab654c42b05e7ce3d95c93fb_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5c5a4918db2e4440a13d121f8cffb4d5_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5604fe07056d43b898f627ac12fe4ae3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i400f6ad312e1418a8315ea7c4ca60914_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i80d4fa554f9c42f2b2dbef32f68ab0dc_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0eecfc49d16b42a8a21357eaf2267e33_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7cb87af3cab043ca8decf206c6b249b3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9cfd9c7ab83c419bbf61049f45186a29_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i028ed305b9b440838647dbf947fce3c2_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5014237d9c1c451999919bf6eec12ab2_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i63b1476e16fc4757b5fe6b377ec00a8b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5b55351b3e714b4196d956f493f5fbfe_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i494b3dcc71a9471bbb64838967bf211f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2d1982faddbe4e81a502b33e94996bba_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i1677f52df4334218aa0a0cb8d77df066_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idf32b8dec40e4c26a1275c9cbeb2cab9_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0075c921c1a3418087cbff16476429bb_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i642b7fdb6d7141198e59206a87715ca1_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iaec24b62e56f4c749ad066b0f5814893_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie9a58f759a804eeea68e4f6cf19f54cc_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic8d2e948664e48509acc9a46d147acd6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9034ae3630be4f90ac8759f73c9d84ee_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia01a0e267e3d49408ae383c295013155_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7b9230ef516443ccad9d26677a66975e_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i900204896d434dda8fac86bae0cf2c69_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id112e58fd1da4992aaabcf75b671635a_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i69daef85a2cd4f0698981e2468d08268_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i77a8f26f579b45d49451e22987cfe043_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia6a917baf2b146579258ed0bd76a5682_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i70ffc7cf3c884b2296b9598791625833_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3c8f9a3dd9c847dc8c25bf43d101da5a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i01ddcdd029114904a3d37f67d1a5375f_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8e00716790544c2aa2782fbaa642b291_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4d366ba8634843b7952c594a0298644e_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i80589dad11a143ef83bed73c9c636e0d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8a27bbab26194f368e984c6efeac7dbf_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id541227fbffe4cb58cbf08c74d640a31_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i35536d5c87534fd7904edf6033b8d2fb_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibab3102676df483cb94d5771c3340715_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i61e739cf89e04a2ab85cbf458333e420_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7a347180bf99437b8e59ccf9b456e939_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib7c91bc046b54947b056276f205609b5_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i76d1d755fe864e0aa2bc11b07fb588d5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i861cea3736ba431ea19399c9d74f4a1e_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0643a60ebf034a56a19d98183b76d940_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie0d3bc436e1940458257e25f0366f0fd_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iaee986d724e44b098461eac0f89dfb0a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie3461941dfba467a82a64d0fe6a92726_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i27b82c53a0dc4b3abae2328362331d7b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib052e84cde5f4591ac72582a42239b41_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8bd7ffd7738b4d259f17a9f3eed5fe8f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i847dce3495ea4ca1a4c5ecbdcdeb9266_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id846e2e0c92e48e1a68009c7f0c3ec3d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id7e140ec784341c3bdaa6b9e35a220ad_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib9bdd1c6bdaa4f278e3d75778bc8098e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic62f68f5cbaa47839c0b6b490a8f2c4f_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i03b53f572aa44e899c6d9df9aab6646f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9bba86c6d32b4bb1a8652b8dd4c5851d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i09aa7aa2a79a46fe942e1eab7057a546_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3c58cf190dba4d119b64a72bea44dee8_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib35fad42d0e6463995e0600e17c5c1b5_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5565a9f7ec554e8cabd71fcaee639311_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0f344311b3cf48939c39240aac35200c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iefa33272c8bd4721a74234b17b990694_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ib87579025231469fb10ceb2f4c7cfdcb_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if99ca9d34e85413ab54b2210dcdfb7fd_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic9e7cfafb6474ef2948dd5e06029902a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia860b7d96f0447f392f5eeac7875c1a1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie2cef51b9a6c41d794a7883c2331934f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2605c867ea164850b491768230077fdb_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i73ebd1cbb69f4706bf7449a515a56452_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i67b836292a904483a2495cd84486214a_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8ae4efec9bc24e5c832eb9b323983513_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i881f037a08664e86b329cb3e8bac41e3_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i876e020ffc28486eb2cba4c856c63d96_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7cad11a8c56443738c97c90053bcf485_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="icad2abe11b5d441f84340fceedeecb5f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i10b4ecc9ffe3480b8f5dd56a9cd5aa6a_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="icca30d47d5784736873c33392dc4ae62_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iea669ae399404c9ca5423bd557cf0873_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3b3c8d3f2fb24fcf990880e0ff513c1f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i244e58e9444a4e3d9e577108f15d8bd8_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i82e4b71f563c40d697c20b57f2ac67af_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i13674b49cf2b434d99ece35b1733ccb9_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i90a01e2a70a145dfb1adbbc859b6dd82_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iea4a942c29b64296a578054f8bb63c6e_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i838ec4506aac4839afabb56c89fe75de_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i43cb13f6753d4651a135658fc71c6eff_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie4942e0be0534752a71e7f1ada41cc70_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i05be66fafb444a8080fecb6fcd302e95_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ida875fcca159482f83502993ab5d5e4e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i34bb5f16f5ad400fbb4ffb0ed9d46048_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia07c17c915a040be98c96fe359fecfd2_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2cdaa89f4a1441e29f7642f5b666eb27_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7de0a5cf540d4fee9c40859ef3796bdc_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8138f8e21ac94faf9fe88ce25877aed5_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie5898c52cfe945779c5143c8df491534_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i68c5d8ed136a4c20816e313a4c90b13b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if3e5afc3d50e4e4ca0a187ad6b9f1a6c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie37eb67f7b144c5eb518c4948cf96145_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i85dda44763ba4414829f3605a73753e0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5e9b58f0b50e427692c9798179519c8c_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iaf9944934bf44f41a5d848a08016534f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8a4e187060bf4b56af8469e2457ad148_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i53914db7b6994764b67ebd82cd5d70b1_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i29e6c0eadbf94d859fbb92d57ca15229_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ifbec97fb95be414cb2b89e264202246c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0297066eac1245ce913a0df991220e7d_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i1e5b7a4bbda24f7f9fcc5b69ed4a9435_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i722ea23e5f924f16a6e6c00652075eba_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if177d277829c4cf39e15833c514ec56f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i29aa768ec65741dc949cd342666e4f34_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ife790b9884ac4cabbd776e36f99b03af_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8ad125a62b6946b1b33566216a51ed56_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie42b6679085b4580b95eb6119e492e4c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if6e27d7094e94cc8af96f23c67b17244_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2fbc058d591f475e80e0b7c6171f743d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i305a29aa90b04a249642618470269a81_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i065d4da56934430d83b7760ca1e819d3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i564acf556d06473886229ffaf87f0863_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia8bde317222d4d88bda353d061dbd018_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3ceeea82fd7e49d6a825cf5247584a5e_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8a5ce8f1fae8494f9167e95a0acaaeb6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i03f7fb6c7a194120a4df7e29ac654467_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2bb546e3766343bf9f6063a3941899a5_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6f10cfdf4b7c497b8b6044b5b86bf524_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i818389fdcd8e4be3bf8813b2e25a407d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1f381374d0cb4d7d863372ef4c0e1356_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia8d82aed0673478d9b0ab5456d859fc6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i680f6194af6c4f068b01fc50ebebf2bc_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i95e4a4d3e8ab4d7eb48f7cc386ceeb8c_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i499f24d8dbf843af8dd118f4348d0ab6_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib458d25a886746158cfacde3445cd6fc_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0430caf022a942bdb0f6cdbd46b04bac_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia7ef391ad36744e5a7cca822a0d2390d_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8778f377a1564158aa09c4c776f50a1e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idc078949f249451895be35c4a94e683e_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i577a1cff490044bfa62a9e2f3af70a8a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifa3a87266183456fa1a996407ff90f9d_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7df5dd26fd074767b958cd1516adf6ea_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2fe5ed9c09394a3ead9cf56afedcc350_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i392724c4d2c743918e9611261847ffc2_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iff24f989dc2649e0a841bfefa2388270_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia5f74ff91d6b439183caba093e33753e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3bd824b5eee841079ac4190b0b4c2ded_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id063a0459cf44210877c1484ef7c45a0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6cbfd51374014b128d8615d36bec5484_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7aa376f5433c40de98c137cab1b41421_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i038004c2490c4105b96321ee95665011_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic5f92f7db04a4642b0601560adc62b41_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iffe31a46ec13474db2f9953a95a8ebf1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i24e24057824445669dc06fd3fa613c19_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9bf3746768844207b9687743172b8829_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4b31eb5bc05146f6bd4d2d78e8fda6ff_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie4170b6c793743a092f6c56a49529637_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i092927032fbf41288117417bd83c8d33_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2847269390c248719305140d646fb64d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="id7be44d585f94dd1b4e8bdccd9f72fcd_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8cd97ec22af24e1aaafd19a24d6e9286_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iaa0dde31e99e496dbedc1e0f945ca70e_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib9417a55ca564c889c26bac785e05477_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6ae91066041f4be1b8f92b78864de25f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i974d64a21e4f41528433f1336946ceed_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6f9110d30d29404584bef97cc4a24dd1_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic9cd6cfa9d6a40558ceef771622f76b4_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ifbc22c2972644793b32196e789568db5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic7c3c999eaef4151b4669dc63eb4030a_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic3e2207be87140cab8ceaa62aa0d6044_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id9429a289df048cfa5ab4fdd10126b5b_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5cd65d3eab964c75adc84d3231cdbf0d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5cae4423d64f4d4bbfe2cbf8df84e736_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia6a87b0c3795491d8cb754d008abe491_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i26b3f7fda8dc45a4acd129a76f977cd3_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7efc4792ae7f465ab37467091fef4a2d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i97fdcab14626459db0701cecead7f119_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i855d5f8389ac44e5abf80391fa0ee110_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0d6094b282dc44208ebf68078e1e3b34_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic907c783f0ed4d86bdb6abb9d2580af7_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3281cef57f094b31b7cdacddcdaf74a8_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic1d05e3bda784d0d9ae066ae87e26eae_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib707a9c98f6b4c618112fba387110572_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic13deb7b513e4e2281a5b9c7dcd54fb8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ief2452e5e77d4264a2a230717da020d1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i95095593fff6463d893fd017b40967ea_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id0ce74ed131d46019830ea323390afd8_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="icb897375b8384ad0bed6f189fe441473_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id7368c2116cf4338b2809934b019406f_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i372b1bcd430544318ad85558939c89df_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5ec4f3ba11ea4d6b88b6d131ffd28198_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibe322b23cff240edbba0ccd9e2b833c8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i34035b45a76f4ade91be1a7e5f2dd59f_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic700316f668447918923186ca5e57289_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i58690ca930484006850c26e283195c51_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i6a3ef38541d04372a83ca49403db6011_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8a94b325e9bc4923bb6d5064b162cbb1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia30996795fa94ea6b9c7db00253f7c7c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="icbc66fc1dfb74e039295ae639e9205c3_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i47a2e3c8bb504b308a68c7504052a8cc_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8b794e63d907423bbad6d7dfdc91be50_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i33bcbb3a06994413a39168066fba21c0_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i391427c923714920834b2e9cb41cb698_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5b326613e99b4043bfe3af2bbeeaf963_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i37b0ad3859c844e399e58cadb8404920_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i2b0f540aabca4cbb8e8011d5ced8cbfb_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i7c8bf7911a294fd5a9711bf309527dd7_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic13b79cce02e4ae4924831ae4711540f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i19ef6dc106bc4d7d871aedead8e03203_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie3d9e613aba94a1f9b967f1b8b04148b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i51efdf97f2214c34a66a193a4ee00409_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i99f710c786d345ffab2ccc1e077da0e5_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i0b737de8e7ed48e9a0f1e473c0fd11b0_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iaa68cd0ebbc649f8b1944c6452cf157c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6e651723831f48ba8112b343beaff0d3_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ic19353844d9d42988aefc5611b61c81a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idc3559fd0b124045a8fa153a444ef33e_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i38c4456bb5034d83b9f17294fc378c0a_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia5d3558da8644e909594aa8c7e4e0083_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i00b3e8006e23428f8b7ee7417c102c09_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1039c0aa59334e18b5a49bf9c2b74e02_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8b1416bbe0bf416081fe7ae31939518b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib3d4e80547494117a247653eb23d938e_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8c7c7b4a1930485390375e2d3bbb3a2f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i76779eb2bfad4ee1a6a2508e4e75218c_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i09bb019661ae4ed0a5e67d8131209bf2_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i70c0711b6e2e4a6087c73758e3f91243_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i28e3fcd890c242319befd0f7388bfe2e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ic42e396c0efc43a3ba71cd4831b384c8_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4d0c0d174e1e465a968649b402f5cea1_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3ac832e9cf5c414d856dd7230794b701_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ida2ad956ed734c17a0b3ce03be3fff11_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i2d9be1e0153f4553b7b041b59504358d_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i17d8758d185d4148b85cbe1809fe78e2_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib7e826c2f1324a59aedd22ebe1aca2e6_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i89b09107775e49eaa9df473cb669c97e_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iad0196cb82f94a8ea79748ba42931837_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i02b2071e56d747afbf128fec4a955609_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6af84b75578249b38eb94570b45c8bcf_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i366a7d5e35604a52910d0f6633b551b3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i640f5e27e4594136be6910021459b067_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7d78c321af554254b32b1e3a8a1d3694_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iaff737262fdb484bbf75e5931817a490_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8c366e52f34f4c939ba9bb069bc96cea_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i49dade5fbc6447ae87c04ac20252f3ee_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3b9c2927f6ad471d81601e63f54fc36f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5d94242030db4c6e972f72cfbfe05464_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i158baf5a07fa408c826b2c8d54778c21_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i358c3cd12c24472787b2a36a2550e8c6_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3a772c8416cf49df88d756da5e9a094d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i02c59bee76a743e19c22b2e772f8d973_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i201e6e46d1c74819a9acfb688922322f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6b398a883ec74c3eba875c513b5d8cd2_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ifafc57d6cd754d72bbe14c0919d17e1f_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i623b6ae349b44bf9b2853ebb6769281d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i123867d1543d46d9afd6cedaa87c7ed3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia200d3ae9c054b709c7195a311b6c9e3_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie23f74e989df418392f516e411c8ba59_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i9146e1200a7f49d3ac965e4dc89a064c_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i17622e1e5cdf4287a5ce27533de69c09_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i15889f3752b64ea98aa7f132f768a0d1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3e93bc594b454595aa61c0a479afcfcf_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i40e55fe351984553bed44ba01eed5ad0_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie132afb6984b4e4d956e2c5e87394126_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i04d49f0375714f51b3b624836cc6d325_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i8f897a88b0e9498e84e0922c6ac778a3_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibba76952fd2b4a519af20462218629da_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="idae82913ec44462fb96a4ca814d6a702_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i8eba42d826fe467a9b5e86014b866bdb_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i71ec2459bfe446ec8682b17c888295b8_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i529501a1b6e049f08c8a55b366fc992d_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ibf01c838f2074a85932e153dd373f7b0_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1a2e6ad455cb48d9b9bb5b16d05ff610_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if60b072dec854b1e8dfb55dd85a8118b_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i647abea8193b4b739d73a6331f0863b4_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie7de7cde1f8a4671978be90e6b0c20b6_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i57af817119fa4ecd8f610dbcbd0f3ac1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i63c3910a76f84ce297ae66994c95a35c_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib4cfbdab95a0435dbfa671be6d271f63_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i643bc69b32254fa0bbda0732674f0a17_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i3e56281ecec14a7c80ff8779c1ca8f17_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i25009198d573425d8e230b1a71881f95_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id8fe8d12a2fd4f01b02c290b548244b4_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9452da93d10a4670896f05edcac90904_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iba3e034faa2643de9e74a65652cc9170_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i38bfe15254ae44efae8441525503c832_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifc4c09ce590a442181ad6662947c8fe7_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i90e9c507ad5b4f6c9505f100acae883a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i4a34e43a1f6446ecbcaa76509bae0457_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i074ce9c3c7514a87bf8e13428ff46900_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="idd2f05005c0f428383f2f6685296745f_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i353ce076e41d4fed82b475f2741cafd1_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i0f05af96e15a40369cfe4cd4140d6449_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if5ffe02d809844979135aec3c5ba4751_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="if191b6e468a3476aa02636eb2412f60b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i331c19f370344f7baf99003b536c4f3e_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i96d61b35824144f9bcdad8d927f11908_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i68cff4026c6244d2acead47809054223_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="id982a81309df49e9b1b002ff1ac41cae_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ie667e5b01edb4ec3a359b1a4b8416940_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="iadb11728d759451d965568df87db85d8_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iaf94b8f123d04272bb4b90c496e51b83_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i815bc18a28fc42afa083e798ae8e6b32_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i1f9b9a440e17401eaa071454d7751a0d_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i5f75366413fe46b586eb415473747dec_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="idea81eebb8464de781937770e40b4cf8_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="idf724f9760f04a4d97e3362a30a8c490_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia5394d3d3ed644aaadfbfd8d6956ee4a_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6bb2fc4834df4cee928c01c8ffe451e8_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i29f562eb61574b4a8135f7a6ff000d61_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="iffded04d2e5b4de28d6c73c949492aa9_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3a2695569614474a9334e8de4bd04385_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ibfb750d153444cfbb2321cb34524ef38_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ied1e8cdc798340419a8c42b1446f8a47_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ifadac292feaa4f469fb02f86ff949995_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i072ffc473a074bf6b2765979c610418b_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ied5e809531a04e8ebd37dbed6ad36ab8_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="idc46250604114f8e80b3e470ae4babdb_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia4268f03b6cf41eb89ecb7ae077eb9e3_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i72c1a76dec8d49eaa40c1cca89c0bc8d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="if3c67e57cd4f489992a696a230aaba42_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5c08f0957c7d4b9e8e627867718f4458_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i990e1ccf4a544e3caa982783ffee28fe_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5068794590a54e5988087731a2a8b4d4_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i6c47fac364494aed96246540e7b4f7c7_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i3aa4e83b89284abc892194a08d7295b2_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia79ea739fc2a40d89f2755e7e4a01102_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i5891042222334a28a0bb7a5e271806af_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i21a2cce4e35d4c1297c84a76cb27a899_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i66d27784d12d4bb18f3912c082fcae16_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1b3d5cdd413d4757984bddf6f14322bd_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i751be87313594bb993858ae3c749f84d_D20210104-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i1cf347773ad54fb88be2e997e4827221_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="idc76602e6fb84b0a862455dca71e8bba_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="i7ed71c93d9694050bbc60255c39761e2_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id4a164f8c9e84a87a27b9958b9f63142_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i5eea6ea68542417790d4a54103e549ae_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ie08773cd5b344ed58f2677261b44e9de_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i6eb4e32762af4828a35d4453122c0f42_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i7c421f92c4fe44b480312cbb61c76537_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i494bb8f36e6b4d348f07972031b000b3_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:InvokanaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ida7fb50fd03e447e8bfba4781b1f21c6_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="id34d8d00dc95419c9bd7f8538f501612_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ElmironMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i20d66d03f67b4697b74d7d5b092b023a_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="icdd65a25b656477ea5bb46da7f0655dc_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i57f785ad2f34433aa2271007ab8726b8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5bc38c671bd94c1891fa4b65bac8ec0b_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i6e63d8a7e74e42f6a4a9d28176f31ee4_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i135a75e1eac047bcb5100f4e1292998c_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i699c1217087e4147b4a39954f40ee65c_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="icf7c3ce8a2b94702bf75c6781069843d_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4b18def56e5244478a2952bec11e5335_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c83f6e3f6e543809b38536c601fde43_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="icb28f8306622475282cfa3ad654e30a5_D20220301-20220322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jnj:RasmussenInstrumentsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-22</endDate>
        </period>
    </context>
    <context id="i5473d8ddcca64b71b3e429a13c5bf85d_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i533d6a68961b4cbc8e82491aa88f91f5_D20191230-20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="icf0bc69e2f514d4f8022cfc52f98c981_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i54e00e15c6a4438da0eb288d0b6da9f6_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i0cc5049a65cc4fe3b6242125d5b8d5c0_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i438940227a2a4ff395f3e492e755ecde_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="id67cae946c154573ad2500e94ad849da_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i1d2b36aba9e54f04a044b6f392d0eac4_I20150430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ContactLensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-04-30</instant>
        </period>
    </context>
    <context id="icacdc0678d9f4679bbb4b670b539eae6_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia9e691f551214439bf1ee3b313e022c3_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i9ca0be8b6078437fbd42287a1c403587_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ife72459bccf34924aabd0acb8e60d652_D20220704-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-04</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i690d9c2e2c884662976264e7af01ba35_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ia93e937c11c7436bacd6ccaeacdf0cb6_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i28209dc3607348dbb3171ab6afdd3dea_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4fe9fcf4dbc843569a9d49299bde3c5a_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="ie51585f5aa3d424c9d17456abcf75390_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i6262632abd6a46d5a6a2555c388ca348_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ib3d9ff58f127499cb7a03cc08f3f4dbf_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i6bfabbf7068d43948d05ef08e73d9679_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4425d96eacb04e7696f85e7eaea16821_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i72c4525bf37f4e2aa7ae0c4f54cbf866_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i57839c019e9745718882687e73ce9e18_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="icb01ffbc16f648fb954f806b9df10064_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i339ac2517af5425bb6f6bd7a62b270be_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i4ea736a79ff947c586d1da1d7bcb9f18_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i923ad899b5ec4870933079c36fc15f9a_D20220103-20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-10-02</endDate>
        </period>
    </context>
    <context id="i7802b4bc08714bbfa6723a15254942f7_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i199a6c4996a1468e956555f0edbf4206_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="i8caf79efe14c4c99b6b144f88b0704f5_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <context id="ic114825b023e4671a3b06ef6426697c5_I20221002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-02</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="brand">
        <measure>jnj:brand</measure>
    </unit>
    <unit id="claimant">
        <measure>jnj:claimant</measure>
    </unit>
    <unit id="patient">
        <measure>jnj:patient</measure>
    </unit>
    <unit id="cases">
        <measure>jnj:cases</measure>
    </unit>
    <unit id="claim">
        <measure>jnj:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80L2ZyYWc6NjBiZDQ5MjM1ZmM5NDcxODhlMjE1YmFmM2E0YjY4YTUvdGFibGU6ZDIxZDE0NWY0NjM1NGNlNThkMjA0MmU3NTFiN2I1OGMvdGFibGVyYW5nZTpkMjFkMTQ1ZjQ2MzU0Y2U1OGQyMDQyZTc1MWI3YjU4Y180LTEtMS0xLTc3NDA3_4e0bdbc1-6386-4ea3-80c0-a863172e8863">0000200406</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80L2ZyYWc6NjBiZDQ5MjM1ZmM5NDcxODhlMjE1YmFmM2E0YjY4YTUvdGFibGU6ZDIxZDE0NWY0NjM1NGNlNThkMjA0MmU3NTFiN2I1OGMvdGFibGVyYW5nZTpkMjFkMTQ1ZjQ2MzU0Y2U1OGQyMDQyZTc1MWI3YjU4Y181LTEtMS0xLTc3NDA3_0f269ab4-e9e8-4b18-931d-056d439b83c5">--01-01</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80L2ZyYWc6NjBiZDQ5MjM1ZmM5NDcxODhlMjE1YmFmM2E0YjY4YTUvdGFibGU6ZDIxZDE0NWY0NjM1NGNlNThkMjA0MmU3NTFiN2I1OGMvdGFibGVyYW5nZTpkMjFkMTQ1ZjQ2MzU0Y2U1OGQyMDQyZTc1MWI3YjU4Y185LTEtMS0xLTc3NDA3_6bbd45ea-a228-4c3f-9657-66e94d9147b7">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80L2ZyYWc6NjBiZDQ5MjM1ZmM5NDcxODhlMjE1YmFmM2E0YjY4YTUvdGFibGU6ZDIxZDE0NWY0NjM1NGNlNThkMjA0MmU3NTFiN2I1OGMvdGFibGVyYW5nZTpkMjFkMTQ1ZjQ2MzU0Y2U1OGQyMDQyZTc1MWI3YjU4Y18xMC0xLTEtMS03NzQwNw_ff6a6dc1-5088-499d-bdb4-f4f012ebb010">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80L2ZyYWc6NjBiZDQ5MjM1ZmM5NDcxODhlMjE1YmFmM2E0YjY4YTUvdGFibGU6ZDIxZDE0NWY0NjM1NGNlNThkMjA0MmU3NTFiN2I1OGMvdGFibGVyYW5nZTpkMjFkMTQ1ZjQ2MzU0Y2U1OGQyMDQyZTc1MWI3YjU4Y18xMS0xLTEtMS03NzQwNw_6f531b40-a31a-4576-8b56-376a4b916fe8">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDY2_1557fbb8-924d-44bb-95d5-6db2f8f771bb">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6ZDU2MGNiZjI5ZWVjNDgzNWFlM2Y2N2Q4MGY4NGRhZWQvdGFibGVyYW5nZTpkNTYwY2JmMjllZWM0ODM1YWUzZjY3ZDgwZjg0ZGFlZF8xLTAtMS0xLTc3NDA3_21afd2b6-f2e9-4e05-910c-53a0bc4be673">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8xMjI_14650054-42b4-4ed2-b8fe-c559ee608c9d">2022-10-02</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6ZDI4OWQyZmFlZDc3NDZkOGJiNzA3YjFjNjRhMDUxNmYvdGFibGVyYW5nZTpkMjg5ZDJmYWVkNzc0NmQ4YmI3MDdiMWM2NGEwNTE2Zl8xLTAtMS0xLTc3NDA3_d6473cff-2261-40cb-8da3-766b5d42dcd8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDU4_bb81f31d-3ad3-4f6f-9290-c9d8d5431597">1-3215</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDU5_a7cb4631-e7b6-422d-a062-50371df33000">Johnson &amp; Johnson</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6ZGI3Y2EyYjA0OTZiNDIwMmJlYWI1YTI2ZDc1MWM1YmQvdGFibGVyYW5nZTpkYjdjYTJiMDQ5NmI0MjAyYmVhYjVhMjZkNzUxYzViZF8wLTAtMS0xLTc3NDA3_9fc746a2-8244-478c-8cf6-48fa25eecaba">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6ZGI3Y2EyYjA0OTZiNDIwMmJlYWI1YTI2ZDc1MWM1YmQvdGFibGVyYW5nZTpkYjdjYTJiMDQ5NmI0MjAyYmVhYjVhMjZkNzUxYzViZF8wLTItMS0xLTc3NDA3_ea51dded-70d5-4fac-8db6-b93a624fad4a">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDYw_3a92e286-b9d6-4abc-b65f-95856ca90bf0">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDYx_f670e3ef-0c65-4d9d-9cb7-7396eae6b9fb">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDYy_4b51fc6e-7b3c-4995-9519-0cbd44fca0bd">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDY3_470692a4-d513-49d7-aec7-7bfb951aac0d">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDYz_7075e8ec-0397-4a82-b59b-22430e6e7a93">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDY0_00fd9958-534a-4f53-8b24-8bfd45bf675a">524-0400</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDU3_0d130ac7-33f1-4397-879a-390beaf67fc9">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDY4_e514cc87-04ae-44f1-a4ff-70a8dc21309c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MjNkMDgwYzZiODZiNDBmMWI1OWYwMjBkMGJmNmRlZGEvdGFibGVyYW5nZToyM2QwODBjNmI4NmI0MGYxYjU5ZjAyMGQwYmY2ZGVkYV8wLTEtMS0xLTc3NDA3_4c24e7a2-6f45-4ba6-a6db-dbba0d40e45d">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MjNkMDgwYzZiODZiNDBmMWI1OWYwMjBkMGJmNmRlZGEvdGFibGVyYW5nZToyM2QwODBjNmI4NmI0MGYxYjU5ZjAyMGQwYmY2ZGVkYV8xLTQtMS0xLTc3NDA3_d55204be-fd2c-49e7-868c-55f90e92b447">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MjNkMDgwYzZiODZiNDBmMWI1OWYwMjBkMGJmNmRlZGEvdGFibGVyYW5nZToyM2QwODBjNmI4NmI0MGYxYjU5ZjAyMGQwYmY2ZGVkYV8yLTItMS0xLTc3NDA3_144a0534-7133-4403-b362-6cd1b4eeba8f">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8yMDY1_b82be262-3ff4-4eb3-91bd-6a00024b6f69">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="i3d1079dea4094854a0d8215a7b7bee77_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8xLTAtMS0xLTc3NDA3_83557c98-e8ec-4521-b2e2-103f32a707d9">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3d1079dea4094854a0d8215a7b7bee77_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8xLTEtMS0xLTc3NDA3_89a01ea6-6459-4684-89fd-44785be11465">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3d1079dea4094854a0d8215a7b7bee77_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8xLTItMS0xLTc3NDA3_192ac3fd-f921-47a1-b557-189228c644e7">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia5474370380a497b82e6a430f952af34_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8yLTAtMS0xLTc3NDA3_801cd21d-1dae-4c6f-b645-337bfe8e45f4">0.650% Notes Due May 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia5474370380a497b82e6a430f952af34_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8yLTEtMS0xLTc3NDA3_6a6868c9-5dec-448c-b37f-2c52b5ecbf22">JNJ24C</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia5474370380a497b82e6a430f952af34_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8yLTItMS0xLTc3NDA3_61bf9641-1f78-4432-abec-e8c71f5a5059">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i12fdbd4684c2453789af8d70324bc71a_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8zLTAtMS0xLTc3NDA3_1ec62f34-3917-4efa-8497-215177cf2e93">5.50% Notes Due November 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i12fdbd4684c2453789af8d70324bc71a_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8zLTEtMS0xLTc3NDA3_8e745d2e-978d-4aca-9800-ec79e7a99e97">JNJ24BP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i12fdbd4684c2453789af8d70324bc71a_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF8zLTItMS0xLTc3NDA3_201ae211-5238-43fe-9821-7c3efdc1c526">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i4072dbe684f043559e6b3816abcc50e8_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF80LTAtMS0xLTc3NDA3_8c59902f-60dd-434a-8372-4b95e282955c">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4072dbe684f043559e6b3816abcc50e8_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF80LTEtMS0xLTc3NDA3_a850e828-c7a0-44b6-b1eb-409c6e175562">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4072dbe684f043559e6b3816abcc50e8_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF80LTItMS0xLTc3NDA3_3b6da2af-2240-4848-a52b-7ebe06dad884">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i414d244f8d08480fb66a8026c8d80ad4_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF81LTAtMS0xLTc3NDA3_ad797585-80d6-4139-8364-8b8e3cedd275">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i414d244f8d08480fb66a8026c8d80ad4_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF81LTEtMS0xLTc3NDA3_b31e70de-998f-45bc-bace-749d74e60bb2">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i414d244f8d08480fb66a8026c8d80ad4_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGFibGU6MGY1NDg1NjQ4OTA5NDEyMGFmZTBhODVlNWVjNGNmM2QvdGFibGVyYW5nZTowZjU0ODU2NDg5MDk0MTIwYWZlMGE4NWU1ZWM0Y2YzZF81LTItMS0xLTc3NDA3_ab512680-7909-494c-bef8-4f104464d5bc">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i4a83e7272e834e8fae6c7fe265b3be1b_I20221021"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xL2ZyYWc6YmUyNDQzODgyZDJiNGQzODg4ZjFlNzFjZDc3NjNjZGYvdGV4dHJlZ2lvbjpiZTI0NDM4ODJkMmI0ZDM4ODhmMWU3MWNkNzc2M2NkZl8xOTk2_e44b3ba7-e15c-4873-b269-869c0e410cff"
      unitRef="shares">2614483607</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMy0yLTEtMS03NzQwNw_87103184-e019-49ff-92cc-f2716cd6db40"
      unitRef="usd">11355000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMy00LTEtMS03NzQwNw_59835106-299b-450d-a3f8-3b4deb3d6ca1"
      unitRef="usd">14487000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNC0yLTEtMS03NzQwNw_9eddc708-d75f-4d2e-81d9-d5e9d7be3e67"
      unitRef="usd">22724000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNC00LTEtMS03NzQwNw_df457282-85da-4476-a7ae-d4729a580110"
      unitRef="usd">17121000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNS0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmE4Y2MyMDQ1Zjg2YjQ4NThiMjhjZmUzZjg3M2QyOGI1XzQ4_db0a988c-a9f0-48fc-b342-ae73ea582a48"
      unitRef="usd">201000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNS0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmE4Y2MyMDQ1Zjg2YjQ4NThiMjhjZmUzZjg3M2QyOGI1XzU4_c236d4c3-e9f4-46f5-a6ff-6c96422fff03"
      unitRef="usd">230000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNS0yLTEtMS03NzQwNw_166592de-6cf0-4885-854b-91b2fa77db96"
      unitRef="usd">15890000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNS00LTEtMS03NzQwNw_7de6833f-2cb4-4bfa-af78-cc7d2455d494"
      unitRef="usd">15283000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNi0yLTEtMS03NzQwNw_8fcfe02d-e954-4a93-89d2-fadd69c84553"
      unitRef="usd">11675000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNi00LTEtMS03NzQwNw_8ca633e4-f7c4-4a01-818d-66f7a8795189"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNy0yLTEtMS03NzQwNw_f3c91f56-3de4-4649-be69-cf01791a841e"
      unitRef="usd">3592000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNy00LTEtMS03NzQwNw_02cba2f9-1e58-460b-92cf-91b6dfc6bf4b"
      unitRef="usd">3701000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfOS0yLTEtMS03NzQwNw_f7b59207-a029-43d1-86a4-4dbc6c96d962"
      unitRef="usd">65236000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfOS00LTEtMS03NzQwNw_405dadee-e7cf-46b2-b016-5a3892ff5768"
      unitRef="usd">60979000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTAtMi0xLTEtNzc0MDc_c2a06ceb-4ded-4910-8828-812e63d225d4"
      unitRef="usd">46681000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTAtNC0xLTEtNzc0MDc_b97d8fc2-1666-4673-b1ae-0dd51aa565bd"
      unitRef="usd">47679000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTEtMi0xLTEtNzc0MDc_3a274bb7-cfa2-4b5d-bfee-419c082672ef"
      unitRef="usd">28529000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTEtNC0xLTEtNzc0MDc_04e00fe0-0cfe-4255-965f-ebf682f86bba"
      unitRef="usd">28717000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTItMi0xLTEtNzc0MDc_fe37fec7-5da4-47fc-9487-d218a61269bc"
      unitRef="usd">18152000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTItNC0xLTEtNzc0MDc_84044f85-e1eb-446b-ab6d-cf10395bf784"
      unitRef="usd">18962000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTMtMi0xLTEtNzc0MDc_135469e4-53c9-4c04-86d2-355cd267577a"
      unitRef="usd">40336000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTMtNC0xLTEtNzc0MDc_015a7663-8638-41ca-836c-d7191b80dcee"
      unitRef="usd">46392000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTQtMi0xLTEtNzc0MDc_dba52113-fa6a-4709-982a-bf3cc8f3bb7c"
      unitRef="usd">33383000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTQtNC0xLTEtNzc0MDc_f4af2b30-a432-4032-abdb-a5c1a19f6f8b"
      unitRef="usd">35246000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTUtMi0xLTEtNzc0MDc_a066e56e-476d-4e25-839f-8e28041232f3"
      unitRef="usd">9392000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTUtNC0xLTEtNzc0MDc_7439ecfa-799a-4c5e-8839-b92ff8847b98"
      unitRef="usd">10223000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTYtMi0xLTEtNzc0MDc_04140cb0-b802-4c90-ad7c-f159fee5f4ef"
      unitRef="usd">8625000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTYtNC0xLTEtNzc0MDc_39e37e67-9809-4f5d-ba2b-8dda461b921e"
      unitRef="usd">10216000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTctMi0xLTEtNzc0MDc_749f7a4b-d4bd-4642-90ee-ffe4d27f2845"
      unitRef="usd">175124000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMTctNC0xLTEtNzc0MDc_d950d475-eaa8-4982-a708-9d5593b9488c"
      unitRef="usd">182018000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjAtMi0xLTEtNzc0MDc_4f5a69c7-2ed3-4d28-bee4-9a169d70a49f"
      unitRef="usd">4424000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjAtNC0xLTEtNzc0MDc_876ec6c8-35bc-412c-8c19-faf9dbb44eb4"
      unitRef="usd">3766000000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjEtMi0xLTEtNzc0MDc_8bd9a4fb-5dfb-433d-b3d6-89a5a17bf781"
      unitRef="usd">10153000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjEtNC0xLTEtNzc0MDc_1e856972-33eb-4eee-8641-dcaee24efb9c"
      unitRef="usd">11055000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjItMi0xLTEtNzc0MDc_cadaf813-c621-40b8-b2ce-41d56f8d9161"
      unitRef="usd">11953000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjItNC0xLTEtNzc0MDc_829025f6-9a93-4a14-9d0f-a6f9b98898db"
      unitRef="usd">13612000000</us-gaap:AccruedLiabilitiesCurrent>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjMtMi0xLTEtNzc0MDc_a2b5129a-9bd7-43d9-8ede-167c125b1265"
      unitRef="usd">14021000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjMtNC0xLTEtNzc0MDc_2e47e8f4-1efc-4d63-a50d-0eca76016a50"
      unitRef="usd">12095000000</jnj:AccruedRebatesReturnsAndPromotions>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjQtMi0xLTEtNzc0MDc_668d4c33-33c3-4c85-9f6a-8a28c986c6d7"
      unitRef="usd">3006000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjQtNC0xLTEtNzc0MDc_053f6283-409b-45fe-b4fb-afa57b23c284"
      unitRef="usd">3586000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjUtMi0xLTEtNzc0MDc_d9f37115-7e45-4519-9bb9-5d4f036d0a50"
      unitRef="usd">1986000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjUtNC0xLTEtNzc0MDc_d5e299b0-46c3-4070-bbd9-4b0fff86a7be"
      unitRef="usd">1112000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjYtMi0xLTEtNzc0MDc_a108383d-d176-41ca-bfc8-afa8fd0038f4"
      unitRef="usd">45543000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjYtNC0xLTEtNzc0MDc_7b8de311-60bd-44e8-8981-6b41eba1a8c2"
      unitRef="usd">45226000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjctMi0xLTEtNzc0MDc_8edbbaf0-e601-4554-b54d-a5a4736f81e0"
      unitRef="usd">27603000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjctNC0xLTEtNzc0MDc_a34a94b0-c9db-49a6-8cf3-3c77d21efeb7"
      unitRef="usd">29985000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjgtMi0xLTEtNzc0MDc_81580457-3499-4fc2-ba9a-652ccf3f085a"
      unitRef="usd">4946000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjgtNC0xLTEtNzc0MDc_68b35dc9-fb82-4ee3-b2ac-bc3ef6151207"
      unitRef="usd">7487000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjktMi0xLTEtNzc0MDc_240859d2-6261-4e1f-878c-4480d837a102"
      unitRef="usd">8353000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMjktNC0xLTEtNzc0MDc_04eacb96-8b8a-424e-b906-06258e2a1436"
      unitRef="usd">8898000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzAtMi0xLTEtNzc0MDc_7f8da704-816c-433c-b35f-5902d844be1a"
      unitRef="usd">4162000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzAtNC0xLTEtNzc0MDc_bb55b820-67d0-4f18-9a21-f48041128418"
      unitRef="usd">5713000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzEtMi0xLTEtNzc0MDc_e3ead9bc-8f38-49d9-bf28-98f544cbd132"
      unitRef="usd">9918000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzEtNC0xLTEtNzc0MDc_834a8424-428c-4e93-99f5-8b19cb772d58"
      unitRef="usd">10686000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzItMi0xLTEtNzc0MDc_2d461f9c-d881-4725-a486-17740fae7c42"
      unitRef="usd">100525000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzItNC0xLTEtNzc0MDc_ce2e508e-1210-4879-8c8b-37a340e2fed8"
      unitRef="usd">107995000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzMtMi0xLTEtNzc0MDc_863fd9a3-5203-4203-80f7-f62980b7c3ec"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzMtNC0xLTEtNzc0MDc_ff805182-f9c5-43a6-a166-ddd1433924e9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl8yOQ_a6194ed0-5405-43d6-8151-38837ce4ce05"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl8yOQ_f0b9d193-96f9-4e2e-b2ed-b0ce923ff973"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl81NA_2259623f-e44c-41a2-8e0a-3822f851ca9d"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl81NA_5d64467d-b4d0-4af0-8c71-353a673700ff"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl83Mg_5d42feea-0e6f-4c72-b4b4-4ae29f48e828"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYTA5M2E4MjFlY2Y0OTc1OGQ4OTE3OTI5OTI5Mzg0Nl83Mg_b903eca1-d5a6-4506-93c3-1f2fc86c6bd0"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtMi0xLTEtNzc0MDc_71a55487-09a8-4104-9aea-3bde6e5d1d5d"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzUtNC0xLTEtNzc0MDc_70b7cc9f-0ff6-437b-b1d2-d170cf489373"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzYtMi0xLTEtNzc0MDc_f2a6f407-b57d-4ce6-9b87-3e0f4bcfc282"
      unitRef="usd">-15292000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzYtNC0xLTEtNzc0MDc_b61439ac-91a8-4fac-a8a1-56e8bb43a0d9"
      unitRef="usd">-13058000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzctMi0xLTEtNzc0MDc_38591a74-0544-40f6-b7a1-25da3a6e902e"
      unitRef="usd">127917000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzctNC0xLTEtNzc0MDc_cdfd2e67-bb96-4eba-b28e-49757d57303c"
      unitRef="usd">123060000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzgtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxMDFiM2M0YmU5NzU0NGVhODU0N2I1MmI0Mzk3M2FkMl81MA_bb84033f-fddb-4dd3-bd5c-4f790459aaa2"
      unitRef="shares">502961000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzgtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxMDFiM2M0YmU5NzU0NGVhODU0N2I1MmI0Mzk3M2FkMl81Nw_4e502b37-ee9d-4766-986f-8eabdb01be55"
      unitRef="shares">490878000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzgtMi0xLTEtNzc0MDc_29a1861b-5dc6-46cd-8ee4-85ef83bce80e"
      unitRef="usd">41146000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzgtNC0xLTEtNzc0MDc_2f588495-ba51-4042-9aeb-798e57aee85d"
      unitRef="usd">39099000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzktMi0xLTEtNzc0MDc_732360cb-5617-4c97-8d61-0f1c002ecb3b"
      unitRef="usd">74599000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfMzktNC0xLTEtNzc0MDc_23147768-22c7-4963-9c67-aa9371c0562f"
      unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNDAtMi0xLTEtNzc0MDc_21ff570f-8597-4fe2-a9e8-6c3f8b500556"
      unitRef="usd">175124000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8xOS9mcmFnOmFkODVmNDY4MmQxYTRlMjg5Y2IzMzMwNmZmYjQ5ZThmL3RhYmxlOjc5ZmI4OTkzMjQyYzQzZmY5M2YyYjYwOWNlNjJlNDBiL3RhYmxlcmFuZ2U6NzlmYjg5OTMyNDJjNDNmZjkzZjJiNjA5Y2U2MmU0MGJfNDAtNC0xLTEtNzc0MDc_5bc8d362-4041-410a-b8a3-79f448b7e741"
      unitRef="usd">182018000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMi0yLTEtMS03NzQwNw_e7669b04-6474-401f-9296-cb15f791ebcf"
      unitRef="usd">23791000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMi00LTEtMS03NzQwNw_52c10e84-3916-4fa7-8eb1-c5167d51dd08"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMi02LTEtMS03NzQwNw_59f130b2-a18e-4dc9-8568-85a6680c290f"
      unitRef="usd">23338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMi04LTEtMS03NzQwNw_a378741a-7b96-4a16-9348-b3c5f7bb5ffa"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMy0yLTEtMS03NzQwNw_91bb2ab7-1652-4524-a1e4-a2b19aae9d98"
      unitRef="usd">7807000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMy00LTEtMS03NzQwNw_2b50eec0-d653-4060-ab9e-7bf02991f0bc"
      unitRef="number">0.328</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMy02LTEtMS03NzQwNw_df82bc12-7f4d-47b8-93e4-65a0083aa18a"
      unitRef="usd">7250000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMy04LTEtMS03NzQwNw_e6d78e3c-f9a1-4729-b59d-c8b739614e53"
      unitRef="number">0.311</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:GrossProfit
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNC0yLTEtMS03NzQwNw_008c0253-7cc2-4d52-94fb-d6644c324400"
      unitRef="usd">15984000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNC00LTEtMS03NzQwNw_5a3f08ec-f631-4f03-8d58-59474bd34da3"
      unitRef="number">0.672</jnj:GrossProfitPercentToSales>
    <us-gaap:GrossProfit
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNC02LTEtMS03NzQwNw_b133490c-2358-4795-a2e8-058134964364"
      unitRef="usd">16088000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNC04LTEtMS03NzQwNw_1e7de4c4-3c6b-4eee-b7bb-a25a02170957"
      unitRef="number">0.689</jnj:GrossProfitPercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNS0yLTEtMS03NzQwNw_9f66543b-a186-4f8e-a1ee-1bfadada4e86"
      unitRef="usd">6089000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNS00LTEtMS03NzQwNw_8c3a5670-59f2-448e-a678-835bb5c7f6cb"
      unitRef="number">0.256</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNS02LTEtMS03NzQwNw_0ba0a223-b08d-47e9-850e-ba2b51dd8746"
      unitRef="usd">6000000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNS04LTEtMS03NzQwNw_5939f352-b128-4e0a-b78d-81a260653d1a"
      unitRef="number">0.257</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNi0yLTEtMS03NzQwNw_6fa74cba-f71d-4913-a0c4-27f2bbaf9baa"
      unitRef="usd">3597000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNi00LTEtMS03NzQwNw_2b622228-5811-40fc-a99c-ddf706f705d4"
      unitRef="number">0.151</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNi02LTEtMS03NzQwNw_a0f854b9-6215-4d3e-8d43-9acdd3c05454"
      unitRef="usd">3422000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNi04LTEtMS03NzQwNw_442311df-3285-4ee5-8ee9-a6e8c54a80a4"
      unitRef="number">0.147</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNy0yLTEtMS03NzQwNw_d6e26cfa-091e-4836-8ff8-73a8827b593e"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNy00LTEtMS03NzQwNw_fa36dbf1-e04b-468e-90ef-14f600995a37"
      unitRef="number">0</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNy02LTEtMS03NzQwNw_12d909b0-981f-4334-a17d-166ad9119dfa"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfNy04LTEtMS03NzQwNw_e4672b65-e46f-4276-b14d-a634c143eb16"
      unitRef="number">0.039</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOC0yLTEtMS03NzQwNw_b65067aa-f27a-4a68-acd3-6abcef660606"
      unitRef="usd">150000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOC00LTEtMS03NzQwNw_6e97430b-4e7e-4e00-a6a2-012ffb0aee6a"
      unitRef="number">-0.006</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOC02LTEtMS03NzQwNw_3131b186-861a-45ce-bfd9-61ea73b349ed"
      unitRef="usd">13000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOC04LTEtMS03NzQwNw_23e811e5-2259-4871-aa18-7e325e0655c1"
      unitRef="number">-0.001</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InterestExpense
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOS0yLTEtMS03NzQwNw_99d77481-2a6a-40fe-b80f-19234ecea244"
      unitRef="usd">51000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOS00LTEtMS03NzQwNw_66b1aa6c-1756-4dee-947d-1c46decf1316"
      unitRef="number">0.002</jnj:InterestExpensePercentToSales>
    <us-gaap:InterestExpense
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOS02LTEtMS03NzQwNw_f334f432-3b73-406f-9f83-031e54491ce7"
      unitRef="usd">20000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfOS04LTEtMS03NzQwNw_30821169-ee6e-40b5-af85-218c3503a24f"
      unitRef="number">0.001</jnj:InterestExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTAtMi0xLTEtNzc0MDc_4c074f55-0479-4df4-bb86-96c588213115"
      unitRef="usd">-493000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTAtNC0xLTEtNzc0MDc_ed05f75e-a475-4252-add3-b704084faf06"
      unitRef="number">0.021</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTAtNi0xLTEtNzc0MDc_93b07f1b-8dbb-46f2-af55-623982eb1c22"
      unitRef="usd">-1850000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTAtOC0xLTEtNzc0MDc_3c565883-9fa4-4ecb-8091-bfdd83f44df4"
      unitRef="number">0.079</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:RestructuringCharges
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTEtMi0xLTEtNzc0MDc_d8ece78a-c54e-4098-a4b3-c187dd2273e0"
      unitRef="usd">82000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTEtNC0xLTEtNzc0MDc_67ac033f-1635-49b7-80f8-45cad8bb5945"
      unitRef="number">0.003</jnj:Restructuringchargepercenttosales>
    <us-gaap:RestructuringCharges
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTEtNi0xLTEtNzc0MDc_f0fb4a6d-540a-4178-a689-4aa6093d50b2"
      unitRef="usd">60000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTEtOC0xLTEtNzc0MDc_51ee9268-9bbf-4a18-ae65-dde5b9533b22"
      unitRef="number">0.002</jnj:Restructuringchargepercenttosales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTItMi0xLTEtNzc0MDc_ffc1b3f1-f2fc-4f46-bb97-5e9164e3b1f1"
      unitRef="usd">5822000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTItNC0xLTEtNzc0MDc_4f4e4e15-7264-4c3d-82ba-7ad1936d718d"
      unitRef="number">0.245</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTItNi0xLTEtNzc0MDc_b3e1bfb8-6cbd-4e20-ac43-10e76d4b9645"
      unitRef="usd">3849000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTItOC0xLTEtNzc0MDc_1d49ad83-df2e-42f8-bcae-f8da6401d4d0"
      unitRef="number">0.165</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTMtMi0xLTEtNzc0MDc_cad8236b-a1ab-4173-9978-a42cf2eed74e"
      unitRef="usd">1364000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTMtNC0xLTEtNzc0MDc_6ee5fc51-5f9b-43ab-9cf4-829a8c977721"
      unitRef="number">0.058</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTMtNi0xLTEtNzc0MDc_b297863b-f219-4d54-94b7-ee6bcdc1e016"
      unitRef="usd">182000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTMtOC0xLTEtNzc0MDc_5b1f8c29-6d2a-43b7-b6d4-57c8d4576bcb"
      unitRef="number">0.008</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTQtMi0xLTEtNzc0MDc_b7474ca7-cc8c-4e4b-b7b6-1e1256c59f61"
      unitRef="usd">4458000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTQtNC0xLTEtNzc0MDc_72c9609b-7c50-4948-b18b-18d9d6d4d220"
      unitRef="number">0.187</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTQtNi0xLTEtNzc0MDc_fb744b19-805d-40b5-8de5-0d15a4d3d54c"
      unitRef="usd">3667000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTQtOC0xLTEtNzc0MDc_e12e7e76-f0aa-42e0-853b-02e84e14419a"
      unitRef="number">0.157</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTctMi0xLTEtNzc0MDc_f9012076-c601-4018-8e27-b21858348250"
      unitRef="usdPerShare">1.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTctNi0xLTEtNzc0MDc_698c2e6c-250b-443c-8484-36156cbd03a8"
      unitRef="usdPerShare">1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTgtMi0xLTEtNzc0MDc_04d648b3-0408-4560-8459-5d8f13cbfc34"
      unitRef="usdPerShare">1.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMTgtNi0xLTEtNzc0MDc_ae2cd20b-779c-4e6f-a380-f23638a5ecb5"
      unitRef="usdPerShare">1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMjEtMi0xLTEtNzc0MDc_7e7da13a-2a06-4713-9999-036e9b8f956a"
      unitRef="shares">2627900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMjEtNi0xLTEtNzc0MDc_b0583c0a-7e7a-4260-809c-1f60c8b591fb"
      unitRef="shares">2632600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMjItMi0xLTEtNzc0MDc_612fcda8-71ce-41bd-8691-d8eb524f5111"
      unitRef="shares">2661300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yNS9mcmFnOjRkZjgxN2I2NWIwMDQyMzVhYTFjZDJjYzEwMWRjZjVlL3RhYmxlOmZhMjAzMWJkMGUyMTQ0YWNiNjk5ZGQ0OTZhYzk5NDkxL3RhYmxlcmFuZ2U6ZmEyMDMxYmQwZTIxNDRhY2I2OTlkZDQ5NmFjOTk0OTFfMjItNi0xLTEtNzc0MDc_cfccc64b-6147-4a37-98b7-18a11c7a18f6"
      unitRef="shares">2674900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNC0yLTEtMS03NzQwNw_f5a2ec24-f815-4ed4-9851-11c79c8c3ada"
      unitRef="usd">71237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNC00LTEtMS03NzQwNw_8ec4b547-eede-4745-819b-f10e2b8d3ed9"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNC02LTEtMS03NzQwNw_e5b866e2-b172-4658-8178-2914c5852061"
      unitRef="usd">68971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNC04LTEtMS03NzQwNw_445626d7-05b7-425a-89d8-1dc0c95dc68c"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNS0yLTEtMS03NzQwNw_8897d550-3c21-41ce-91bb-f6cd4be75cdf"
      unitRef="usd">23324000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNS00LTEtMS03NzQwNw_46ccf2bb-b353-44f9-a725-879969389750"
      unitRef="number">0.327</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNS02LTEtMS03NzQwNw_900fd153-87d0-4b49-911c-66e7b71c78cd"
      unitRef="usd">21900000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNS04LTEtMS03NzQwNw_7603cd11-1946-4e1b-9b7a-e8e9ba96e0a5"
      unitRef="number">0.318</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:GrossProfit
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNi0yLTEtMS03NzQwNw_47e44759-d38e-48ce-978f-6e10d7e74d70"
      unitRef="usd">47913000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNi00LTEtMS03NzQwNw_cd108292-7b5f-4aae-84ad-8aef632976cd"
      unitRef="number">0.673</jnj:GrossProfitPercentToSales>
    <us-gaap:GrossProfit
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNi02LTEtMS03NzQwNw_a6772f8e-0748-4c71-9b13-343fb76ffbe4"
      unitRef="usd">47071000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNi04LTEtMS03NzQwNw_a21a4d55-a7c2-4edb-b0e6-bcd1048e723e"
      unitRef="number">0.682</jnj:GrossProfitPercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNy0yLTEtMS03NzQwNw_bb6193c7-ba6b-4df7-a39a-e1a27f332ede"
      unitRef="usd">18253000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNy00LTEtMS03NzQwNw_ee0f9227-9c9c-4da2-ae45-b2fcc960ae8e"
      unitRef="number">0.257</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNy02LTEtMS03NzQwNw_5ea13cd2-9328-452a-818e-01e99a24f382"
      unitRef="usd">17505000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfNy04LTEtMS03NzQwNw_625d5796-90de-49c3-a427-749f8a6cd36c"
      unitRef="number">0.254</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOC0yLTEtMS03NzQwNw_c9505f97-fab0-4446-b53f-c4d0f7cff0ce"
      unitRef="usd">10762000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOC00LTEtMS03NzQwNw_2569f713-362d-4705-b28e-e0a7efd07659"
      unitRef="number">0.151</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOC02LTEtMS03NzQwNw_0828cad7-c7d4-45eb-896a-5ac2bfb04f98"
      unitRef="usd">9994000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOC04LTEtMS03NzQwNw_0482be19-1070-45bb-a74f-0ba97fd794d9"
      unitRef="number">0.145</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOS0yLTEtMS03NzQwNw_ba8b3b88-7c90-4fb9-87a7-1cbede5fb593"
      unitRef="usd">610000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOS00LTEtMS03NzQwNw_78a683ec-906b-4f7b-b0cc-a2b7e838225e"
      unitRef="number">0.009</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOS02LTEtMS03NzQwNw_d13a1e74-5745-4b6d-b3ef-8c6bf9745869"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfOS04LTEtMS03NzQwNw_f449112c-7a05-470e-a86d-18cccc66932f"
      unitRef="number">0.013</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTAtMi0xLTEtNzc0MDc_e6a318f7-b651-4c8b-a950-bec1bd675c1d"
      unitRef="usd">236000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTAtNC0xLTEtNzc0MDc_5bb5fb16-9248-4b56-bdd1-8f027b0fbee7"
      unitRef="number">-0.003</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTAtNi0xLTEtNzc0MDc_22f027af-aca3-483c-b2fb-2faa65219719"
      unitRef="usd">40000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTAtOC0xLTEtNzc0MDc_227579b0-51d8-4143-94cb-25d8a24ad3b0"
      unitRef="number">-0.001</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InterestExpense
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTEtMi0xLTEtNzc0MDc_50c391d2-97da-42f4-afad-1b191f658ecd"
      unitRef="usd">99000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTEtNC0xLTEtNzc0MDc_f24ea554-2b27-4b46-b534-77af4dc2a5f0"
      unitRef="number">0.001</jnj:InterestExpensePercentToSales>
    <us-gaap:InterestExpense
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTEtNi0xLTEtNzc0MDc_ee882c2d-a591-44f1-adec-9e70f416c0e1"
      unitRef="usd">123000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTEtOC0xLTEtNzc0MDc_b93b7144-2bb0-4e20-af9e-a75acc9a52be"
      unitRef="number">0.002</jnj:InterestExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTItMi0xLTEtNzc0MDc_3d266828-ca78-43bd-a549-fe1dec0990b3"
      unitRef="usd">-664000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTItNC0xLTEtNzc0MDc_2b297fa7-4ffa-498e-abfe-8ac5573b2a79"
      unitRef="number">0.009</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTItNi0xLTEtNzc0MDc_2f00dd84-3824-40c8-9402-05ca56a6f201"
      unitRef="usd">-480000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTItOC0xLTEtNzc0MDc_8c73213a-392e-490e-844c-b5673a099660"
      unitRef="number">0.007</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:RestructuringCharges
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTMtMi0xLTEtNzc0MDc_0a020613-fa1b-461a-9395-23bd2c9cce43"
      unitRef="usd">237000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTMtNC0xLTEtNzc0MDc_bd66958f-5bd2-4dfb-adbb-183e536ef0d2"
      unitRef="number">0.003</jnj:Restructuringchargepercenttosales>
    <us-gaap:RestructuringCharges
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTMtNi0xLTEtNzc0MDc_ffdb22f1-98af-4c43-9a7e-a807902d182a"
      unitRef="usd">169000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTMtOC0xLTEtNzc0MDc_e745979b-c91f-4032-8032-d98bf48e0c1d"
      unitRef="number">0.002</jnj:Restructuringchargepercenttosales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTQtMi0xLTEtNzc0MDc_8ff1c250-5417-4a37-8c8f-6844cd067d8d"
      unitRef="usd">17524000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTQtNC0xLTEtNzc0MDc_948f914b-ddcc-4508-8c13-b34a20627f31"
      unitRef="number">0.246</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTQtNi0xLTEtNzc0MDc_fdf1d23d-f750-49d6-aa7e-a01e7d506a2f"
      unitRef="usd">17940000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTQtOC0xLTEtNzc0MDc_2da939e4-76dc-45ee-ab19-886303f42570"
      unitRef="number">0.260</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTUtMi0xLTEtNzc0MDc_c4100f43-c18c-4cfa-a5d7-0cf246ea8c5a"
      unitRef="usd">3103000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTUtNC0xLTEtNzc0MDc_4e7c1248-cb28-4d6b-b45a-d868058d74e0"
      unitRef="number">0.044</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTUtNi0xLTEtNzc0MDc_1b6fff84-ae67-428e-832b-e64538ec710d"
      unitRef="usd">1798000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTUtOC0xLTEtNzc0MDc_cd9af93b-7763-4c41-a4be-e1220c042e79"
      unitRef="number">0.026</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTYtMi0xLTEtNzc0MDc_75037e60-c6da-4b97-86c6-7b536a9d9306"
      unitRef="usd">14421000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTYtNC0xLTEtNzc0MDc_05a4386e-5c7c-44ff-9f35-f4c38377e474"
      unitRef="number">0.202</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTYtNi0xLTEtNzc0MDc_6a03cc3c-8486-46fd-8b12-4552698747b2"
      unitRef="usd">16142000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTYtOC0xLTEtNzc0MDc_27896a8c-7a49-4a65-8850-04977ea12c3c"
      unitRef="number">0.234</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:EarningsPerShareBasic
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTktMi0xLTEtNzc0MDc_72032aae-227c-468e-90f8-3ba688e2399e"
      unitRef="usdPerShare">5.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMTktNi0xLTEtNzc0MDc_c0143160-ef21-4091-8e43-caec981347d7"
      unitRef="usdPerShare">6.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjAtMi0xLTEtNzc0MDc_298e37c3-4c61-4e98-9e79-bfa727b12766"
      unitRef="usdPerShare">5.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjAtNi0xLTEtNzc0MDc_6bbf739b-0e2e-4712-b377-0a869bf98cea"
      unitRef="usdPerShare">6.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjMtMi0xLTEtNzc0MDc_2b7b7575-df7e-4cd2-bc1e-0ed3b3a52411"
      unitRef="shares">2628900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjMtNi0xLTEtNzc0MDc_709486ab-d7c5-4ab1-8733-ff96d5e71a9e"
      unitRef="shares">2632200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjQtMi0xLTEtNzc0MDc_d632d07c-28f7-4be1-acbc-9f8fb0acc3a0"
      unitRef="shares">2667500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8yOC9mcmFnOjcxMWZhNTQ4ZTJhMDQ3NzE4ODY2ZWU1NTFhMjYwNzYyL3RhYmxlOmNlZmZkN2E0MzBiZDQ2NjZiN2NiNzU0ZmE3YmVkZDRjL3RhYmxlcmFuZ2U6Y2VmZmQ3YTQzMGJkNDY2NmI3Y2I3NTRmYTdiZWRkNGNfMjQtNi0xLTEtNzc0MDc_d6fc6f2f-1347-4276-a0b2-ac8e3213bfb2"
      unitRef="shares">2674600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMy0xLTEtMS03NzQwNw_110560c9-a79d-4d68-941c-3c0cbaac40d7"
      unitRef="usd">4458000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMy0zLTEtMS03NzQwNw_700b268b-7d22-4fd0-9e88-367918aa8419"
      unitRef="usd">3667000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMy01LTEtMS03NzQwNw_0a9c1e71-74fa-4abd-9c1d-a89ce6d3b602"
      unitRef="usd">14421000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMy03LTEtMS03NzQwNw_836dfb9a-6fa5-454e-a294-38c85b147fc1"
      unitRef="usd">16142000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfNi0xLTEtMS03NzQwNw_b82184fe-beb3-4ec7-a5bd-09389826e487"
      unitRef="usd">-1252000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfNi0zLTEtMS03NzQwNw_72144488-f179-47b9-9259-48ec48053837"
      unitRef="usd">-382000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfNi01LTEtMS03NzQwNw_02136c81-8bc5-46fd-b9d1-888dcfb33c4f"
      unitRef="usd">-1957000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfNi03LTEtMS03NzQwNw_28704fa4-6b2a-4ae8-a84f-f2c24357dcf9"
      unitRef="usd">-241000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfOS0xLTEtMS03NzQwNw_c8c8d7c4-de35-46a0-be4f-e9dbea7bf221"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfOS0zLTEtMS03NzQwNw_6bf01c41-3889-4c96-9f9e-840d374da1ea"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfOS01LTEtMS03NzQwNw_4ca80f36-7318-4c5a-8a14-2526735dfd03"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfOS03LTEtMS03NzQwNw_35ccf82c-4a14-4127-a24a-4857a0785ec1"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTAtMS0xLTEtNzc0MDc_5e0947e7-61a0-418b-b449-96699b9b1126"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTAtMy0xLTEtNzc0MDc_5e2a0b0e-c78e-485d-a555-e294902c5dfa"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTAtNS0xLTEtNzc0MDc_ecbd9a70-cd50-4451-a7b5-c43bee25841e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTAtNy0xLTEtNzc0MDc_f9b1cc33-180d-4d25-b58d-021cbe0a7f83"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTItMS0xLTEtNzc0MDc_c417de3c-31ee-45a9-8da1-3e5469f485e2"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTItMy0xLTEtNzc0MDc_9174a654-830f-436e-9101-308a13324f2b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTItNS0xLTEtNzc0MDc_42e6895a-e8ea-49c4-bc22-e7de6e823630"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTItNy0xLTEtNzc0MDc_9e1f9bb2-e9af-4695-8f27-772b4ef6dcf6"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTUtMS0xLTEtNzc0MDc_83f98b5c-16e1-4e67-bb85-6cf33e5e88c5"
      unitRef="usd">37000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTUtMy0xLTEtNzc0MDc_1bda04de-b68c-4e79-967c-40accd1136ba"
      unitRef="usd">40000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTUtNS0xLTEtNzc0MDc_7c09e143-066d-4935-927d-0b833de3b201"
      unitRef="usd">110000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTUtNy0xLTEtNzc0MDc_c9cc537c-4f75-4385-afca-ada814340e56"
      unitRef="usd">122000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTYtMS0xLTEtNzc0MDc_9bee777a-74ac-4428-bc98-8674530886b8"
      unitRef="usd">-151000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTYtMy0xLTEtNzc0MDc_bd824ef0-ab90-46ea-982b-52101fd1f63f"
      unitRef="usd">-273000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTYtNS0xLTEtNzc0MDc_72e06459-1837-4e5a-aa50-a63e6f0302ba"
      unitRef="usd">-454000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTYtNy0xLTEtNzc0MDc_b8b6751f-884c-4ec4-ad84-7641fd0a3079"
      unitRef="usd">-822000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTgtMS0xLTEtNzc0MDc_a026f745-e032-49f6-9f53-54c131d3d4b5"
      unitRef="usd">-114000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTgtMy0xLTEtNzc0MDc_d0eaccdf-5ee9-415f-8aae-0c644e3812ee"
      unitRef="usd">-233000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTgtNS0xLTEtNzc0MDc_62100389-3d69-489b-822f-221dd731b421"
      unitRef="usd">-344000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMTgtNy0xLTEtNzc0MDc_aaaab364-16c2-4b88-b08b-08eab07493f3"
      unitRef="usd">-700000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjEtMS0xLTEtNzc0MDc_58cc26a1-6c3f-48ab-a177-041f057d08c5"
      unitRef="usd">-204000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjEtMy0xLTEtNzc0MDc_115cdd30-e9dd-4ab6-a278-6a94ed778e99"
      unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjEtNS0xLTEtNzc0MDc_dc94b9ea-b95a-4606-af1c-5d49e36e8463"
      unitRef="usd">-254000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjEtNy0xLTEtNzc0MDc_0e157cc5-7b09-4c64-9d63-32a81e6efdee"
      unitRef="usd">-55000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjItMS0xLTEtNzc0MDc_939408bf-98af-4a7a-b4f2-49fd4b33567b"
      unitRef="usd">105000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjItMy0xLTEtNzc0MDc_9ba8821a-cb68-46d8-a45a-ab8e7784279d"
      unitRef="usd">233000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjItNS0xLTEtNzc0MDc_3cf73413-78ae-48b6-bc7c-1f6f8b910737"
      unitRef="usd">332000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjItNy0xLTEtNzc0MDc_bcf5b53d-0c71-4d5b-8de0-aab1a60c0bf4"
      unitRef="usd">576000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjMtMS0xLTEtNzc0MDc_da59a21b-3ba8-4793-9edd-388dd3ee80a7"
      unitRef="usd">-309000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjMtMy0xLTEtNzc0MDc_dc2fca47-aef4-405b-8145-8109707a8e70"
      unitRef="usd">-166000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjMtNS0xLTEtNzc0MDc_4c53123c-1ef4-4d08-a969-8e7966359dda"
      unitRef="usd">-586000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjMtNy0xLTEtNzc0MDc_617ed074-5c38-420f-9648-7195058dbe93"
      unitRef="usd">-631000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjUtMS0xLTEtNzc0MDc_10efc6f1-826f-400a-aeef-251d4170bf7b"
      unitRef="usd">-1449000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjUtMy0xLTEtNzc0MDc_9e20df94-8f55-4f4b-90fe-d49544c23bbd"
      unitRef="usd">-315000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjUtNS0xLTEtNzc0MDc_8101384f-c5da-47cf-b219-7d3f6ce1fd37"
      unitRef="usd">-2234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjUtNy0xLTEtNzc0MDc_099db2f6-61f2-4932-aef7-b9f319d337bc"
      unitRef="usd">-173000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjctMS0xLTEtNzc0MDc_88c3e5a2-b438-44d0-8d51-54f3fe639c54"
      unitRef="usd">3009000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjctMy0xLTEtNzc0MDc_9f49de67-6216-4848-a513-e0a6ca152b30"
      unitRef="usd">3352000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjctNS0xLTEtNzc0MDc_91db4f11-13e8-49cd-bded-b43c15ac8146"
      unitRef="usd">12187000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjUxOWIwMmU3ZTQ0MzRlMDBhZjQxMDk5YzYzMjI2NGU5L3RhYmxlcmFuZ2U6NTE5YjAyZTdlNDQzNGUwMGFmNDEwOTljNjMyMjY0ZTlfMjctNy0xLTEtNzc0MDc_30a737cb-acc2-46c0-bbe1-85738bcd56d8"
      unitRef="usd">15969000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzE2MA_c28bf0c1-2384-40bf-8778-d8ee2814908e"
      unitRef="usd">-181000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzE3NQ_ca01e69a-53c9-48f1-9f0f-94e16b8d7f76"
      unitRef="usd">-86000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzI0NA_14bebd82-371a-46d2-8c3a-2e354b6bf03a"
      unitRef="usd">-33000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzI2MA_d3472a9b-911a-4860-953c-3c78bbe47c78"
      unitRef="usd">-65000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzI5NQ_c164548f-3a49-401d-bb2c-7eee168f3632"
      unitRef="usd">-82000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmJjYTQ4OTIzZjYxNTQ0YWFhM2VhZDdkY2I1NjI3MWI5XzMxMQ_e0736f9e-a586-4e8e-bcb0-74e9929957d0"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzE1Ng_1dfb214e-9691-4932-b735-75b15c2cc516"
      unitRef="usd">-859000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzE3Mg_2d64fa4f-cba3-4c53-978b-b42ea20d3d30"
      unitRef="usd">-315000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzE5Nw_16fec028-03e5-43fa-9744-23654cd0f8a2"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzI0Mg_b900b322-dc59-44ae-8ac0-a51a609de560"
      unitRef="usd">-98000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzI1OA_f22a90b3-f014-4d55-90ad-f68e893ef043"
      unitRef="usd">-197000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzI5Mw_d4c70296-4122-4102-b758-52b9ce957296"
      unitRef="usd">-155000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zMS9mcmFnOjAwODYyYzk0YmUwYzQyODc4Y2RkMTZlMzBhMDViNTU0L3RhYmxlOjBiMjVkNjNmNTc0MzRkMWJiN2Q0N2FjYWI4YmU2NGRiL3RhYmxlcmFuZ2U6MGIyNWQ2M2Y1NzQzNGQxYmI3ZDQ3YWNhYjhiZTY0ZGJfMi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjI3OThjNzI1NjFiODQzNGJhOTNkN2E4ZmQzMjMyZTBiXzMwOQ_5b133280-05cb-4a4c-a4d6-f4fef5645bb8"
      unitRef="usd">-167000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i00b96c9b90b442fab76aafa9fe0f84c0_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMS0xLTEtMS03NzQwNw_b60eb3fa-f435-43f2-babe-fe7d6a3c2f9e"
      unitRef="usd">76357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b472a7b024e4350a7efccb19639fe5d_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMS0zLTEtMS03NzQwNw_33dda6d0-b7ab-490a-8047-f269b29760d9"
      unitRef="usd">126216000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i897e4f04cc0743dab9335bb279413316_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMS01LTEtMS03NzQwNw_2d718c72-5494-47be-9494-967ec42ab1fe"
      unitRef="usd">-13843000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i761acbf210e54d4fb1c6163ec297f3bf_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMS03LTEtMS03NzQwNw_85aaf8bd-69b7-47f5-84a4-5b01db4883c0"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58e73c0430be475c963749b0d5dfc1f0_I20220703"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMS05LTEtMS03NzQwNw_5cd09265-8938-437b-b748-07a1216260f6"
      unitRef="usd">-39136000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMi0xLTEtMS03NzQwNw_a363907b-7bf8-4e6c-8171-10be47d123f3"
      unitRef="usd">4458000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i69a1c834e78d4ae6845c115cb37b55cc_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMi0zLTEtMS03NzQwNw_cefdba05-0f4a-4d10-98cd-5f6c355ebfa1"
      unitRef="usd">4458000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMy0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjFkMGRmNTA3MzkwZTQzYmJiOTU0MDdkOTU5YmIwMmI1XzI2_eb64f03c-5c4f-4f81-907e-ef844ab7e7bc"
      unitRef="usdPerShare">1.13</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMy0xLTEtMS03NzQwNw_d059f147-a6cb-4023-8cec-c77636748eb6"
      unitRef="usd">2970000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i69a1c834e78d4ae6845c115cb37b55cc_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfMy0zLTEtMS03NzQwNw_cef42521-5be4-4725-83b5-0176af07a933"
      unitRef="usd">2970000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNC0xLTEtMS03NzQwNw_a66bfd5f-7ad4-4e0e-a55a-b952cac1f975"
      unitRef="usd">368000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i69a1c834e78d4ae6845c115cb37b55cc_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNC0zLTEtMS03NzQwNw_91c15446-5ce0-4ea0-acf2-28a651b16b44"
      unitRef="usd">213000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i4e381efb52944e08881f1e2b2dbd0e62_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNC05LTEtMS03NzQwNw_952aa9f5-c840-49cb-be70-72c7f2754665"
      unitRef="usd">155000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNS0xLTEtMS03NzQwNw_224ba15c-6311-40a9-aa3a-4f56e673b1e7"
      unitRef="usd">2165000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4e381efb52944e08881f1e2b2dbd0e62_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNS05LTEtMS03NzQwNw_5d08aa82-aef7-4771-bef3-fe869ff25fa6"
      unitRef="usd">2165000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNy0xLTEtMS03NzQwNw_4ccb0dfa-eb7d-41e5-b940-3ee15a9b010c"
      unitRef="usd">-1449000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia001762d1dae4d37bc5d624881fae1f7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfNy01LTEtMS03NzQwNw_4198631f-cfd7-414b-8dee-f93163bcdab2"
      unitRef="usd">-1449000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfOC0xLTEtMS03NzQwNw_ef95f7c1-2a6a-4d84-b495-5b598bb25371"
      unitRef="usd">74599000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46a1b195ff7d410ba97f45f6c00f9cdb_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfOC0zLTEtMS03NzQwNw_eaf2cc51-15ca-4744-bd9b-5e3ca42afc63"
      unitRef="usd">127917000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a9083e68f134a6b959f8e81ba70dca0_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfOC01LTEtMS03NzQwNw_ca397452-07f1-4a2d-926a-6db23d5e1ea4"
      unitRef="usd">-15292000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17402ff8071d436f8f5e04dfd2b0c961_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfOC03LTEtMS03NzQwNw_040906d5-435e-45f9-83f7-5476bcad6607"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3af518980d74cf485a8c59539fbb189_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjE4ZjZjODQyMzBhZjRmZjVhNzBlNzRiNjg4MmNiMGM2L3RhYmxlcmFuZ2U6MThmNmM4NDIzMGFmNGZmNWE3MGU3NGI2ODgyY2IwYzZfOC05LTEtMS03NzQwNw_ead86e1f-85f4-4813-8d66-410325d1b8a4"
      unitRef="usd">-41146000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMy0xLTEtMS03NzQwNw_9a9e10fc-b1f0-48d7-9d96-87cea1c23610"
      unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ceeba3817c74be08a112b20898f78ce_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMy0zLTEtMS03NzQwNw_e03ccdce-c330-4a68-8caa-b7c790a15d75"
      unitRef="usd">123060000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib60c35086bcc4c329bbe423674e693a9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMy01LTEtMS03NzQwNw_97f1be44-533c-4b65-9714-d8aa9a1446a6"
      unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i04a23e81d62c4182843a25a386d3c871_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMy03LTEtMS03NzQwNw_8a6db7ee-8ca9-4dd4-b6a6-9b13f549c355"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a4a604382b3438899182204e090fce2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMy05LTEtMS03NzQwNw_5bc089b4-8ee3-4c50-a806-66b4012aac01"
      unitRef="usd">-39099000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNC0xLTEtMS03NzQwNw_aaabac85-0dca-4278-93af-1eba5a3ece27"
      unitRef="usd">14421000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i71751112fea74037b276e2ca1d6230b8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNC0zLTEtMS03NzQwNw_41709fb4-14b9-41bf-95d1-d56673f3753b"
      unitRef="usd">14421000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNS0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjFiMDlhYjc5NTRhMTQyYmRhMWJiODI4MjcyN2Q1NjJiXzI2_0baee691-25fa-4bb8-a2fe-1f1eb50b0d38"
      unitRef="usdPerShare">3.32</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNS0xLTEtMS03NzQwNw_383a967d-ce41-42b2-9233-9a274ded4566"
      unitRef="usd">8728000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i71751112fea74037b276e2ca1d6230b8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNS0zLTEtMS03NzQwNw_642d558a-0c81-406f-9e34-cd2352d9dcd3"
      unitRef="usd">8728000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNi0xLTEtMS03NzQwNw_a086730d-9be0-4d5f-8540-04fcee732143"
      unitRef="usd">1832000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i71751112fea74037b276e2ca1d6230b8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNi0zLTEtMS03NzQwNw_b7f58f14-e066-4a97-a08d-17546152ab51"
      unitRef="usd">-836000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i67d8e299561a467d8fbca5be63ecf1db_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNi05LTEtMS03NzQwNw_a3a23227-81ca-4af1-b7ab-d5e2c9498ecb"
      unitRef="usd">2668000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNy0xLTEtMS03NzQwNw_0a1fa4ae-560d-4b30-8fc8-d50414838314"
      unitRef="usd">4715000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i67d8e299561a467d8fbca5be63ecf1db_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfNy05LTEtMS03NzQwNw_c1ff493a-682d-4a8f-a6fa-22767a53a73a"
      unitRef="usd">4715000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfOS0xLTEtMS03NzQwNw_59ebd771-21f2-44ee-a2c9-94fb2442a8f1"
      unitRef="usd">-2234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6d3b5d7c62914a7d86c97bf6c03bc15e_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfOS01LTEtMS03NzQwNw_25d20126-5b61-4e26-80e3-8f146bdd0827"
      unitRef="usd">-2234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMTAtMS0xLTEtNzc0MDc_de20bd48-0964-4cdc-87a2-fe5e8b371bf6"
      unitRef="usd">74599000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46a1b195ff7d410ba97f45f6c00f9cdb_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMTAtMy0xLTEtNzc0MDc_a48223bb-0840-440b-8b9b-6e0b6cfb4e67"
      unitRef="usd">127917000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a9083e68f134a6b959f8e81ba70dca0_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMTAtNS0xLTEtNzc0MDc_e012660f-da08-4695-9f8c-5263de88aba3"
      unitRef="usd">-15292000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17402ff8071d436f8f5e04dfd2b0c961_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMTAtNy0xLTEtNzc0MDc_3f3ffabe-861a-49b2-87ee-346607f89ef0"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if3af518980d74cf485a8c59539fbb189_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmUxNDA2YTRmM2YyZjQ2ZmRhYzMxNmUzMGVmMTFjN2EyL3RhYmxlcmFuZ2U6ZTE0MDZhNGYzZjJmNDZmZGFjMzE2ZTMwZWYxMWM3YTJfMTAtOS0xLTEtNzc0MDc_605ab8e3-4381-4b97-8eac-3e1186c2a0fc"
      unitRef="usd">-41146000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if04a9117c60243599ca157246ed62b82_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMS0xLTEtMS03NzQwNw_e6abf1c9-7d43-48fd-b53b-c1414b844aa6"
      unitRef="usd">69580000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2841ce9e4bda45d8adf1dbed8d0ebb98_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMS0zLTEtMS03NzQwNw_f896e826-a67e-4cad-8610-4d5e0fea9ea4"
      unitRef="usd">120154000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc527a1e93694a149099814a6a780f3f_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMS01LTEtMS03NzQwNw_28bdd847-38ba-4192-a0af-d858fd011297"
      unitRef="usd">-15100000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i627a7e7e8917482ea7ed3fcf4e5c6e7c_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMS03LTEtMS03NzQwNw_55acaac4-fd0b-456f-bc8e-a06a66dc73aa"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if42495605efa42b5bb22a39f20c44adb_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMS05LTEtMS03NzQwNw_11eb6088-4512-4533-b6cb-5c2e262b1a51"
      unitRef="usd">-38594000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMy0xLTEtMS03NzQwNw_1a2838e2-d89b-4611-9187-6a4250be9505"
      unitRef="usd">3667000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i922b7adff7f14b97a51ffc13b9d0eb2d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfMy0zLTEtMS03NzQwNw_07a55c4b-1107-45f8-a23a-41e6efd42542"
      unitRef="usd">3667000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmRiYmY1ZjM3YTgzNTRiNTE4OTM5MzEzZjYyOGZiMTVjXzI2_4c0c0fe1-6c07-47a9-97dd-e7c9ed6dfd37"
      unitRef="usdPerShare">1.06</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNC0xLTEtMS03NzQwNw_c4322b5e-66fe-4f30-9a2e-6cd450d92c31"
      unitRef="usd">2791000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i922b7adff7f14b97a51ffc13b9d0eb2d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNC0zLTEtMS03NzQwNw_254c7b3d-577a-45e4-b972-e7b3f5dee9f5"
      unitRef="usd">2791000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNS0xLTEtMS03NzQwNw_13a86886-981d-4d84-92c2-7ff92a245090"
      unitRef="usd">522000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i922b7adff7f14b97a51ffc13b9d0eb2d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNS0zLTEtMS03NzQwNw_03598dd8-21cf-487a-b848-be4310c1c34e"
      unitRef="usd">62000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ic763a721f63241119bc153b39881a917_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNS05LTEtMS03NzQwNw_e6df1df4-751c-436a-aa50-bb8a1128c703"
      unitRef="usd">460000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNi0xLTEtMS03NzQwNw_651f72d4-5a89-4930-b924-980a483b2fbf"
      unitRef="usd">391000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic763a721f63241119bc153b39881a917_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfNi05LTEtMS03NzQwNw_bdc45345-5579-4541-b33e-4fa41f541ef2"
      unitRef="usd">391000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOC0xLTEtMS03NzQwNw_1a659c88-2c84-470b-8ec0-aa1f9cf226a6"
      unitRef="usd">-315000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic42e25ee27d54341885e6febcb82d781_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOC01LTEtMS03NzQwNw_6eb141b8-7530-49da-a8b4-74d2982930c0"
      unitRef="usd">-315000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4184dedf017492f81476885b7412820_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOS0xLTEtMS03NzQwNw_c73ddf12-b975-4fcc-b225-e14918a0a51f"
      unitRef="usd">70272000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58afd10b08ae473ebc46006082b2cec6_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOS0zLTEtMS03NzQwNw_1df9b6b2-4500-4928-b8d8-45cb9e5b3107"
      unitRef="usd">121092000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50585c37981c4ff18094df49a0252cde_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOS01LTEtMS03NzQwNw_5e951084-bd89-4585-9708-2c7299b02cb3"
      unitRef="usd">-15415000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4a790e2ad784bd7ad2cc7889a2256a0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOS03LTEtMS03NzQwNw_ea8aed71-ee74-45ca-bec7-ccda69962527"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e846d19941748ce9cbcf17a4f318405_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOmMzZDNmYTlkZjkwNTQ3ZmRhYTYyOTQzODlkMjZlNzhiL3RhYmxlcmFuZ2U6YzNkM2ZhOWRmOTA1NDdmZGFhNjI5NDM4OWQyNmU3OGJfOS05LTEtMS03NzQwNw_93de1509-9bc1-4fc5-9228-b3b2df7c02d5"
      unitRef="usd">-38525000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7466db7fb3de4e73b837ebe5f0b10609_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMy0xLTEtMS03NzQwNw_24ce7470-8260-4d6b-b315-839d717f3491"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c66231e52f741d58eefd24bb80b245b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMy0zLTEtMS03NzQwNw_93f41593-c31f-4c7e-b911-3ef69bb87194"
      unitRef="usd">113890000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d5a9d98b51145fda780e8e3cb899d96_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMy01LTEtMS03NzQwNw_ca683c5c-4849-4711-830e-5ffafe810654"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5af1680d3ee24b0db79fec7b602aee32_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMy03LTEtMS03NzQwNw_e504a033-8b8e-4fa1-9cda-426ea2178fdb"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i360f555817294c969083b2da5b0c7012_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMy05LTEtMS03NzQwNw_cd9a3420-8897-4099-ba3a-ce49ab75c310"
      unitRef="usd">-38490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNS0xLTEtMS03NzQwNw_077ca4ea-f352-4c33-87f4-191e72cd281e"
      unitRef="usd">16142000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia39a746470bc4c38bb1c35c5afbcd727_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNS0zLTEtMS03NzQwNw_a64b9063-20e7-48aa-8abc-d9a6676ffb76"
      unitRef="usd">16142000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNi0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOjdkY2M4M2E2MTFmODQxYjFiODMxZWY0MTMzYmFiYTJiXzI2_317aea22-5e9d-46b7-adf3-3ee0c19d1171"
      unitRef="usdPerShare">3.13</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNi0xLTEtMS03NzQwNw_69e642e4-5464-426e-8380-f85e02a01d77"
      unitRef="usd">8241000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ia39a746470bc4c38bb1c35c5afbcd727_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNi0zLTEtMS03NzQwNw_f8667112-f0cc-4f02-9f45-76c416277e7d"
      unitRef="usd">8241000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNy0xLTEtMS03NzQwNw_d9831973-49cb-4e47-82e0-40d61ecca7dd"
      unitRef="usd">1726000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ia39a746470bc4c38bb1c35c5afbcd727_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNy0zLTEtMS03NzQwNw_aae8aeac-6b06-4f98-bf1d-543786e45966"
      unitRef="usd">-699000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i784f48887ba4406090c0c953b964f651_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfNy05LTEtMS03NzQwNw_79bd4418-d796-431e-b575-524ba1560e26"
      unitRef="usd">2425000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfOC0xLTEtMS03NzQwNw_5e7dc7f0-c0b3-424d-993e-f3d81e9f44da"
      unitRef="usd">2460000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i784f48887ba4406090c0c953b964f651_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfOC05LTEtMS03NzQwNw_5494f380-90db-46d1-82ba-a341f6b3b021"
      unitRef="usd">2460000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTAtMS0xLTEtNzc0MDc_ee7d3f39-1076-4a92-ab57-48e00c9da7e8"
      unitRef="usd">-173000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iba060ae7e2bf4658880cd1a19b71adf6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTAtNS0xLTEtNzc0MDc_17ad68f5-2ba3-434a-ace3-e547e6447ad1"
      unitRef="usd">-173000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4184dedf017492f81476885b7412820_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTEtMS0xLTEtNzc0MDc_2f4d6965-a0fc-4032-b51f-b52caa1e9b60"
      unitRef="usd">70272000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58afd10b08ae473ebc46006082b2cec6_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTEtMy0xLTEtNzc0MDc_29135590-59b8-428e-9084-c6815806bb95"
      unitRef="usd">121092000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50585c37981c4ff18094df49a0252cde_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTEtNS0xLTEtNzc0MDc_e737f642-273d-4f2b-a0ed-2c95c645fa97"
      unitRef="usd">-15415000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4a790e2ad784bd7ad2cc7889a2256a0_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTEtNy0xLTEtNzc0MDc_51f68bc7-db25-4e99-bdd1-637b02d3804d"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e846d19941748ce9cbcf17a4f318405_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl8zNy9mcmFnOmExMzlkYjEwYjA3YzQyNGU4YzJjZGNiZDBhNDE5NThhL3RhYmxlOjUwYWFhNjJmZDE5YTRmY2M4MjUxZTliOTVkMmU3OWU4L3RhYmxlcmFuZ2U6NTBhYWE2MmZkMTlhNGZjYzgyNTFlOWI5NWQyZTc5ZThfMTEtOS0xLTEtNzc0MDc_d36b1e6b-4aa3-42f3-a715-df3a7910c61c"
      unitRef="usd">-38525000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMy0yLTEtMS03NzQwNw_d77ae4a8-cbb0-441a-99a9-b339b2590c87"
      unitRef="usd">14421000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMy00LTEtMS03NzQwNw_f0a20d36-1767-42fa-8091-4d9f3e764ee9"
      unitRef="usd">16142000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNS0yLTEtMS03NzQwNw_4239dc7d-73b2-488c-8ae9-1fd1e61015ef"
      unitRef="usd">5198000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNS00LTEtMS03NzQwNw_df124ac5-d52a-462e-b453-22c0b84f2389"
      unitRef="usd">5547000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNi0yLTEtMS03NzQwNw_be652b45-27dc-414f-b4e6-c718eb9ef56a"
      unitRef="usd">925000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNi00LTEtMS03NzQwNw_9bb28ad1-115c-46f4-8162-c0b937846756"
      unitRef="usd">920000000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfOS0yLTEtMS03NzQwNw_01634787-8cf8-40c5-ab0f-a05926ae8bb6"
      unitRef="usd">787000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfOS00LTEtMS03NzQwNw_30076e63-6b86-42b5-84df-50ddf28190ef"
      unitRef="usd">964000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTEtMi0xLTEtNzc0MDc_013e1a28-be40-4106-b350-33462d23440f"
      unitRef="usd">213000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTEtNC0xLTEtNzc0MDc_0b3c2ca7-52c4-4b5d-a71c-c7ee8c0a8261"
      unitRef="usd">601000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTMtMi0xLTEtNzc0MDc_5bed5f71-6286-4199-8b23-3cf14dbdaaa5"
      unitRef="usd">-2488000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTMtNC0xLTEtNzc0MDc_5a1c5942-f792-4cd3-b901-518a6b5b76fb"
      unitRef="usd">-2564000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTQtMi0xLTEtNzc0MDc_853d4d83-d2bc-4853-8096-b04562bb097c"
      unitRef="usd">-14000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTQtNC0xLTEtNzc0MDc_99bb2354-da9e-4c27-a2ac-8cdbacee8bcc"
      unitRef="usd">-60000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTYtMi0xLTEtNzc0MDc_01297cc6-332a-45e1-addc-c1857b56125d"
      unitRef="usd">1591000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTYtNC0xLTEtNzc0MDc_c32c1ca1-66f3-44c1-9201-f105041fbe85"
      unitRef="usd">1818000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTctMi0xLTEtNzc0MDc_a11524f0-66bc-47be-b967-2b59bd8987e1"
      unitRef="usd">1877000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTctNC0xLTEtNzc0MDc_6b5fef3b-dd61-49b0-8793-a6292efa754e"
      unitRef="usd">1178000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTgtMi0xLTEtNzc0MDc_ec06f2cb-92ab-4821-879b-4d22011e7104"
      unitRef="usd">141000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTgtNC0xLTEtNzc0MDc_f77e944e-c3e6-405f-a823-e0668b41abe4"
      unitRef="usd">182000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTktMi0xLTEtNzc0MDc_de669004-52b4-487f-818c-bfda666b193f"
      unitRef="usd">-4563000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMTktNC0xLTEtNzc0MDc_2854eaee-9629-4f49-a3cc-1adeb0257734"
      unitRef="usd">-2082000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjAtMi0xLTEtNzc0MDc_a39ee4e1-3ba2-4cb3-96e1-52ffa97d6d32"
      unitRef="usd">-4008000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjAtNC0xLTEtNzc0MDc_d08b996f-3ecf-43ae-98b6-8ce8f67db110"
      unitRef="usd">-1938000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjItMi0xLTEtNzc0MDc_a226c4c5-d71f-4356-bf26-816da0b42b92"
      unitRef="usd">15844000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjItNC0xLTEtNzc0MDc_30c550cf-6f65-4ac4-a12d-c1bf45f4eeaf"
      unitRef="usd">17678000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjUtMi0xLTEtNzc0MDc_e8b579f8-3d0f-4cfd-8d6a-f43ecc081c95"
      unitRef="usd">2422000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjUtNC0xLTEtNzc0MDc_024399f4-6a55-4c09-9f73-9087a32436a5"
      unitRef="usd">2237000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjYtMi0xLTEtNzc0MDc_0e4678a8-009d-44ed-94bc-b4def033cb05"
      unitRef="usd">322000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjYtNC0xLTEtNzc0MDc_ca025bd3-01af-4bd3-8adc-d3358a8ed60a"
      unitRef="usd">666000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjctMi0xLTEtNzc0MDc_dbb05eb3-167f-4d0a-a693-c1d761e7ad83"
      unitRef="usd">522000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjctNC0xLTEtNzc0MDc_be49d969-98e3-48ae-91db-2f7fa5d4b8cd"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjgtMi0xLTEtNzc0MDc_a7d849c3-7135-4e32-921c-0f3733e1927a"
      unitRef="usd">31163000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjgtNC0xLTEtNzc0MDc_add9ecbf-c223-4572-8d48-cab344188c7e"
      unitRef="usd">18843000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjktMi0xLTEtNzc0MDc_f5a68bc6-7529-472e-a9d9-710a8c2c3539"
      unitRef="usd">26324000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMjktNC0xLTEtNzc0MDc_7e46d6a7-e1a2-4af0-b60c-3aaaad7aa9d3"
      unitRef="usd">16809000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzAtMi0xLTEtNzc0MDc_5b8e0c50-f19d-4813-9280-6a087ee34172"
      unitRef="usd">-305000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzAtNC0xLTEtNzc0MDc_af07be19-f734-4373-8a4c-179092485e3d"
      unitRef="usd">696000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzEtMi0xLTEtNzc0MDc_f245e816-320b-4090-b1fd-4b6a520a5288"
      unitRef="usd">208000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzEtNC0xLTEtNzc0MDc_d10241e4-e77e-4aff-86b4-c0f939c6ddab"
      unitRef="usd">414000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzMtMi0xLTEtNzc0MDc_593db909-57fd-4d35-94bf-953ecb5ef604"
      unitRef="usd">-7974000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzMtNC0xLTEtNzc0MDc_ce9ea83c-71fc-46ce-a927-4e860369b80a"
      unitRef="usd">-3323000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzYtMi0xLTEtNzc0MDc_aecf976c-1aee-4695-a179-c47febe354b8"
      unitRef="usd">8728000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzYtNC0xLTEtNzc0MDc_0cbc91b1-0103-4a46-8c60-ed8173b2f005"
      unitRef="usd">8241000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzctMi0xLTEtNzc0MDc_d6b2ef40-1741-4fd4-ab3e-2408d71381c7"
      unitRef="usd">4715000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzctNC0xLTEtNzc0MDc_d1a16085-c6a8-491c-b71b-e98f1f943da8"
      unitRef="usd">2460000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzgtMi0xLTEtNzc0MDc_57dcd356-acd8-4025-a14c-4ef7de8a421b"
      unitRef="usd">7099000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzgtNC0xLTEtNzc0MDc_3231a6ac-9ea9-4e38-bb1a-1f1adf266f31"
      unitRef="usd">1283000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzktMi0xLTEtNzc0MDc_35717fb1-1e2b-4ba7-84ef-4fc5adc10c92"
      unitRef="usd">4808000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfMzktNC0xLTEtNzc0MDc_bec73b7a-d88a-499c-80e2-96c618d14154"
      unitRef="usd">821000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDAtMi0xLTEtNzc0MDc_8889a16a-793b-4b4a-904d-e163f950ea78"
      unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDAtNC0xLTEtNzc0MDc_1da4b78f-ce4d-4fc9-a11d-fb8517cb88bc"
      unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDEtMi0xLTEtNzc0MDc_7a060f8d-9e43-4b3a-81a7-75f4885d926a"
      unitRef="usd">2133000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDEtNC0xLTEtNzc0MDc_0ed92207-e8ed-4c67-93ca-23a812b9ae32"
      unitRef="usd">1452000000</us-gaap:RepaymentsOfLongTermDebt>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDItMi0xLTEtNzc0MDc_1a1b796c-0eb4-4692-97e8-c37318b47d80"
      unitRef="usd">907000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDItNC0xLTEtNzc0MDc_f77339ce-2e74-48d7-931b-1912e232070b"
      unitRef="usd">808000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDMtMi0xLTEtNzc0MDc_18107803-efc3-4942-91c9-857c685cb61b"
      unitRef="usd">1678000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDMtNC0xLTEtNzc0MDc_e5ce003b-3fc9-40cc-aac2-dcff6b68b75c"
      unitRef="usd">168000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDQtMi0xLTEtNzc0MDc_9acc224c-c3bb-4569-92d2-f322615e3356"
      unitRef="usd">128000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDQtNC0xLTEtNzc0MDc_dbc0b915-0af8-4768-9dbe-d0cb17f52ee9"
      unitRef="usd">101000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDYtMi0xLTEtNzc0MDc_1561ac3d-1493-4fb2-8457-0e4d2185a157"
      unitRef="usd">-10571000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDYtNC0xLTEtNzc0MDc_b819f7a2-0156-440e-b36f-6fb6f44c449d"
      unitRef="usd">-10611000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDgtMi0xLTEtNzc0MDc_23967340-a438-4284-81ab-fb7da664afd6"
      unitRef="usd">-431000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDgtNC0xLTEtNzc0MDc_f2d3836e-f851-4336-aa97-69a0550882b3"
      unitRef="usd">-125000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDktMi0xLTEtNzc0MDc_d4e2f038-1b0e-4993-8fa4-876a5851c535"
      unitRef="usd">-3132000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNDktNC0xLTEtNzc0MDc_79aab141-1ee6-47ef-8566-0a5e110168cf"
      unitRef="usd">3619000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTAtMi0xLTEtNzc0MDc_b4db5bd0-8a44-49cb-9d0c-7b26e7aaa1ac"
      unitRef="usd">14487000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7466db7fb3de4e73b837ebe5f0b10609_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTAtNC0xLTEtNzc0MDc_f22a585a-5086-4a7c-a230-1da646609a7e"
      unitRef="usd">13985000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTEtMi0xLTEtNzc0MDc_c86c259a-d954-4976-9bb9-0f25c211bee3"
      unitRef="usd">11355000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie4184dedf017492f81476885b7412820_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTEtNC0xLTEtNzc0MDc_ae6706f2-9f0c-4f40-aec3-3668c5e470aa"
      unitRef="usd">17604000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTgtMi0xLTEtNzc0MDc_75f04ea6-31a8-41db-87bf-1f921327f324"
      unitRef="usd">620000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTgtNC0xLTEtNzc0MDc_7491c08f-2485-4562-8041-aae42b101c88"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTktMi0xLTEtNzc0MDc_60115e45-9538-4725-b75b-ec63ad9e0590"
      unitRef="usd">98000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNTktNC0xLTEtNzc0MDc_38d92255-b650-4cb6-90fa-63d8f284b17b"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNjAtMi0xLTEtNzc0MDc_35315050-79f3-43b8-b7ed-ddc93b27e551"
      unitRef="usd">522000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80My9mcmFnOmZiMTk0NjA2M2MxYTRmNWNhODQ0NDljNGM1NDJmYjUxL3RhYmxlOmYwMmZhYWZkMTUxZDRhNzc5YzIzZTZiZWRhYWQ3MWVkL3RhYmxlcmFuZ2U6ZjAyZmFhZmQxNTFkNGE3NzljMjNlNmJlZGFhZDcxZWRfNjAtNC0xLTEtNzc0MDc_5734cece-0717-4ede-83eb-dfc06b96bff8"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80OS9mcmFnOjUzNjYzMGY1OGIwZTRjZDZiNGQ4MGRmNDFmMzc0ODA0L3RleHRyZWdpb246NTM2NjMwZjU4YjBlNGNkNmI0ZDgwZGY0MWYzNzQ4MDRfMjczOA_853d0cec-7463-4576-a10d-74a421dbf33a">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp;amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October&#160;2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the quarter ended October&#160;2, 2022, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the fiscal third quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Not Adopted as of October 2, 2022&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) &#x2013; Disclosure of Supplier Finance Program Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity&#x2019;s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80OS9mcmFnOjUzNjYzMGY1OGIwZTRjZDZiNGQ4MGRmNDFmMzc0ODA0L3RleHRyZWdpb246NTM2NjMwZjU4YjBlNGNkNmI0ZDgwZGY0MWYzNzQ4MDRfMjcyOQ_07e51840-3ed6-4264-8ff2-12456321ca63">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which COVID-19 impacts the Company&#x2019;s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the extent to which it will impact worldwide macroeconomic conditions including interest rates, inflation, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of October&#160;2, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company&#x2019;s allowance for credit losses, inventory and related reserves, accrued rebates and associated reserves, and the carrying value of the goodwill and other assets. While there was not a material impact to the Company&#x2019;s consolidated financial statements as of and for the quarter ended October&#160;2, 2022, the Company&#x2019;s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company&#x2019;s consolidated financial statements in future reporting periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80OS9mcmFnOjUzNjYzMGY1OGIwZTRjZDZiNGQ4MGRmNDFmMzc0ODA0L3RleHRyZWdpb246NTM2NjMwZjU4YjBlNGNkNmI0ZDgwZGY0MWYzNzQ4MDRfMjczNg_12f62725-e8d5-4e79-a7e9-4b49c38a38bb">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in the fiscal third quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Not Adopted as of October 2, 2022&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) &#x2013; Disclosure of Supplier Finance Program Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity&#x2019;s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl80OS9mcmFnOjUzNjYzMGY1OGIwZTRjZDZiNGQ4MGRmNDFmMzc0ODA0L3RleHRyZWdpb246NTM2NjMwZjU4YjBlNGNkNmI0ZDgwZGY0MWYzNzQ4MDRfMjczMA_2f4ec82a-586d-4136-aa3e-f4d8d0026ad4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RleHRyZWdpb246OTljODVmZmE4OWQzNGQ5ZGIwYjNiZTQzNDNiODYzNDBfMzY_64cc3147-39d7-4831-b94b-c09a8bf0a559">INVENTORIES &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RleHRyZWdpb246OTljODVmZmE4OWQzNGQ5ZGIwYjNiZTQzNDNiODYzNDBfMzE_c2c20f35-df21-4e41-b2d4-91a903a43518">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMS0yLTEtMS03NzQwNw_f017fc8b-1ca7-4c03-a103-2e1f7cf15a60"
      unitRef="usd">1730000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMS00LTEtMS03NzQwNw_32edaca2-d4af-47e5-9b91-056aec4e9729"
      unitRef="usd">1592000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMi0yLTEtMS03NzQwNw_4174c7c7-bc25-4138-bdb2-939540c4d921"
      unitRef="usd">2106000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMi00LTEtMS03NzQwNw_633a912f-2f18-4c97-9307-0065efc21aaa"
      unitRef="usd">2287000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMy0yLTEtMS03NzQwNw_88160913-5ee0-4ae3-b87d-55bcfaa361a2"
      unitRef="usd">7839000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfMy00LTEtMS03NzQwNw_ee0eeeda-e937-4a10-9e27-aa58eff4c8bc"
      unitRef="usd">6508000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfNC0yLTEtMS03NzQwNw_51b2b64c-25e2-4fc7-8675-f308263b1101"
      unitRef="usd">11675000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81Mi9mcmFnOjk5Yzg1ZmZhODlkMzRkOWRiMGIzYmU0MzQzYjg2MzQwL3RhYmxlOmFkNTY0MDU1ZTdkYTQ5ZTJiYjcxNDYxZGY0NTAyNzRhL3RhYmxlcmFuZ2U6YWQ1NjQwNTVlN2RhNDllMmJiNzE0NjFkZjQ1MDI3NGFfNC00LTEtMS03NzQwNw_fb797332-7aa1-4fb0-861b-36d93822a4a0"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMjA2MQ_9f6f37bf-ed33-4705-969d-8a22e22fe45b">INTANGIBLE ASSETS AND GOODWILL&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2021. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The change in intangible assets with definite lives is primarily the result of currency translation effects.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;      &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2022, subsequent to the fiscal third quarter, additional information regarding efficacy of the HS indication became available which led the Company to the decision to terminate the development of bermekimab for HS. The Company will record a charge of approximately $0.2&#160;billion in the fiscal fourth quarter related to this impairment.  The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of October&#160;2, 2022 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.0 billion and $1.1&#160;billion for the fiscal third quarters ended October&#160;2, 2022 and October&#160;3, 2021, respectively. The amortization expense of amortizable intangible assets included in cost of products sold was $3.2&#160;billion and $3.6&#160;billion for the fiscal nine months ended October&#160;2, 2022 and October&#160;3, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMjA1OA_7aa14ccb-dbf1-41c4-8a66-774855fb7c4f">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The change in intangible assets with definite lives is primarily the result of currency translation effects.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;$0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD. The remaining reduction was driven by assets that reached commercialization and are now classified as having definite lives.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;      &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2022, subsequent to the fiscal third quarter, additional information regarding efficacy of the HS indication became available which led the Company to the decision to terminate the development of bermekimab for HS. The Company will record a charge of approximately $0.2&#160;billion in the fiscal fourth quarter related to this impairment.  The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020.&lt;/span&gt;&lt;/div&gt;</jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i543c0b5db3074157b1c389cc2cb0ab48_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMi0yLTEtMS03NzQwNw_3af32b75-3ee2-492f-97ad-0968cf179608"
      unitRef="usd">35132000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i15558a3176fc43799fe21d45d80bca2a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMi00LTEtMS03NzQwNw_e38a9e1d-e598-4b3f-aa92-ab021036e98a"
      unitRef="usd">38572000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i543c0b5db3074157b1c389cc2cb0ab48_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMy0yLTEtMS03NzQwNw_7827fc05-ea07-47df-ad76-4e27090234cb"
      unitRef="usd">20116000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i15558a3176fc43799fe21d45d80bca2a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMy00LTEtMS03NzQwNw_07d5f736-42bf-41a7-90cf-4a5809327872"
      unitRef="usd">20088000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i543c0b5db3074157b1c389cc2cb0ab48_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNC0yLTEtMS03NzQwNw_f18eff10-af44-4013-b99d-23a1cba7daa8"
      unitRef="usd">15016000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i15558a3176fc43799fe21d45d80bca2a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNC00LTEtMS03NzQwNw_930efde1-8e8d-4a85-b418-fdee75a05c1c"
      unitRef="usd">18484000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic2612dc9b393420aae1223b600b75635_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNS0yLTEtMS03NzQwNw_d89d44af-11f5-4d91-b9af-d9b9b83c9ffc"
      unitRef="usd">22302000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2af979d2806348c99fb689ce6819de96_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNS00LTEtMS03NzQwNw_e534b5a0-18e2-4da1-a147-eeb5c3a6954b"
      unitRef="usd">23011000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic2612dc9b393420aae1223b600b75635_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNi0yLTEtMS03NzQwNw_5439ed32-2d81-406d-9ec6-bfb5b82971b2"
      unitRef="usd">12406000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2af979d2806348c99fb689ce6819de96_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNi00LTEtMS03NzQwNw_22b860be-00d2-4d2d-866e-06a50f3a1023"
      unitRef="usd">11925000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic2612dc9b393420aae1223b600b75635_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNy0yLTEtMS03NzQwNw_0da9c2ef-244d-4bd2-a5ca-194eff090299"
      unitRef="usd">9896000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2af979d2806348c99fb689ce6819de96_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfNy00LTEtMS03NzQwNw_40128cd4-880f-40e2-a89f-c23a3ea704b5"
      unitRef="usd">11086000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i0536181aa78447d784d738349332b35e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfOS0yLTEtMS03NzQwNw_db04d4ab-6921-4803-8fd6-7b3a83c8f0bf"
      unitRef="usd">6648000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i661087c5259246cfa115e122efa6dcaf_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfOS00LTEtMS03NzQwNw_4ecc8abd-2953-489b-8081-7503a788d2ad"
      unitRef="usd">6985000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i235a103d58c546b8837d113d0020a52e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTAtMi0xLTEtNzc0MDc_0a76b79a-8e5d-4a5a-afe4-3ab059e43636"
      unitRef="usd">8776000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ica2f1087d4384fb0b48f876aae358e67_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTAtNC0xLTEtNzc0MDc_e1d64ac0-c513-4692-b9c5-9b16904d983f"
      unitRef="usd">9837000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTEtMi0xLTEtNzc0MDc_24a4627b-1817-4d20-92bf-3a5739f0fcc5"
      unitRef="usd">15424000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTEtNC0xLTEtNzc0MDc_7d83def3-551f-476c-badb-9dc9d4ee56e4"
      unitRef="usd">16822000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTItMi0xLTEtNzc0MDc_20121d8d-8006-48f9-898e-c0fc5c7b06be"
      unitRef="usd">40336000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjIzNDY1MWE1ZGU1MjRiNzY4YjJkZTEyMTg1NzZiODZjL3RhYmxlcmFuZ2U6MjM0NjUxYTVkZTUyNGI3NjhiMmRlMTIxODU3NmI4NmNfMTItNC0xLTEtNzc0MDc_68b7e9a6-3090-46c5-99cd-79e5c9726bd7"
      unitRef="usd">46392000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i813f5728d4834e4081f50346c8257c32_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfNjE1_63d60b12-b1f5-4649-bfdb-691b944fcde7"
      unitRef="usd">600000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i9cb8f0f0413e458aa5d67d5e5470970a_D20221001-20221027"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMjc0ODc3OTA3MTk5OA_f8b4119f-cc9d-47ce-82cf-87836b727d21"
      unitRef="usd">200000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMjA2MA_61625a08-f90a-4841-be12-a1fcdf543987">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of October&#160;2, 2022 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="idcf057d296c84d089ec6d58708ea1502_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMS0yLTEtMS03NzQwNw_67bfc192-cbb3-4e6d-9409-8f3d227dd64b"
      unitRef="usd">9810000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if32850109bc44a7fbb02840853387b1a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMS00LTEtMS03NzQwNw_7ba241bc-1df8-415a-98e3-b5fe55f19fe4"
      unitRef="usd">10580000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4fbdf34d70c14edbb7715d0150857e3d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMS02LTEtMS03NzQwNw_d028fcd1-102f-4809-b7b2-3a3ea8c1f40d"
      unitRef="usd">14856000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMS04LTEtMS03NzQwNw_cfced1ea-1783-4f60-8df6-8517c44f3735"
      unitRef="usd">35246000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i7787b0e8db0d4969ac6e93a11454dd47_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMi0yLTEtMS03NzQwNw_ac8f88e8-b22d-4468-a547-329c435888c3"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i470f1742dc564aceade9de615023f5d9_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMi00LTEtMS03NzQwNw_69ac9856-ae2d-49ab-b925-7709f1164ece"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMi02LTEtMS03NzQwNw_3c294d00-315e-4a4e-a0da-16ed829ad79f"
      unitRef="usd">195000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfMi04LTEtMS03NzQwNw_3bc7d5c2-efc3-4273-a563-fa72452b2575"
      unitRef="usd">195000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i7787b0e8db0d4969ac6e93a11454dd47_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNC0yLTEtMS03NzQwNw_86aaf039-ec33-4f5d-aead-a3f25259ef9f"
      unitRef="usd">-1037000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i470f1742dc564aceade9de615023f5d9_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNC00LTEtMS03NzQwNw_5ce6ef15-ec6a-4e47-b2a3-4efe358dcef5"
      unitRef="usd">-920000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNC02LTEtMS03NzQwNw_262954d4-5c95-4529-9ac8-2c199dd40f86"
      unitRef="usd">-101000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNC04LTEtMS03NzQwNw_f4f5ded5-1e65-43a3-9373-fb11f23d8a02"
      unitRef="usd">-2058000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i522547423bad464f84afd2d37c47a86d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNS0yLTEtMS03NzQwNw_2aaa6f11-0b11-45fd-bda4-f08b3e4eb3f7"
      unitRef="usd">8773000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i21aa856799804b82aa87e91511e1349b_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNS00LTEtMS03NzQwNw_11672cc6-9b75-4769-b4d9-dc8aec8631fd"
      unitRef="usd">9660000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id36c39c3a9764cb68cde96d61776f981_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNS02LTEtMS03NzQwNw_5cc6c9e8-0b4a-4b29-8650-18bbaa1f37cc"
      unitRef="usd">14950000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjNkZDAzNWYyNDc1YTQxNjQ4MTM0Yjk1YjJmMmM2ZTA4L3RhYmxlcmFuZ2U6M2RkMDM1ZjI0NzVhNDE2NDgxMzRiOTViMmYyYzZlMDhfNS04LTEtMS03NzQwNw_507a2262-6f26-41e2-a897-5a6a04b3bd22"
      unitRef="usd">33383000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6dbbb67dd9c940368c9c692b2970e944_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTMzMQ_30e7e4cb-9331-4693-8977-dc8559f21d2e">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i957a0b8f238643b5a7f04ec25dd1ade7_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTQ0MA_a8fb9773-5e06-4cc2-90ca-16f218bb76d8">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTU0Ng_81a88ca1-13c5-4b6a-b550-188cd02e8772"
      unitRef="usd">1000000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTU1Mw_dc3432a5-bec1-4c22-90fc-92f968c76f70"
      unitRef="usd">1100000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTY4OA_5c1a18ea-d034-4d91-8c94-6b6d5510f9ee"
      unitRef="usd">3200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMTY5NQ_0d46a2e7-5a0d-4afa-9072-04c541945b55"
      unitRef="usd">3600000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RleHRyZWdpb246YmYyYTFmY2RhZDEyNGI4MTk0MmZmZTNjOWU5ZmU0OGNfMjA3OA_dd642aef-5e3a-4a37-8785-968dfc46507a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,100&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,800&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjBlODA0ODA2Y2RjNjRjYjY5YzYwMmY5NGRiMTU0NjcwL3RhYmxlcmFuZ2U6MGU4MDQ4MDZjZGM2NGNiNjljNjAyZjk0ZGIxNTQ2NzBfMi0wLTEtMS03NzQwNw_442d7336-c985-4d02-8515-bc9be502156c"
      unitRef="usd">4300000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjBlODA0ODA2Y2RjNjRjYjY5YzYwMmY5NGRiMTU0NjcwL3RhYmxlcmFuZ2U6MGU4MDQ4MDZjZGM2NGNiNjljNjAyZjk0ZGIxNTQ2NzBfMi0yLTEtMS03NzQwNw_b5ee6294-192e-46fa-b611-435ae6ec6a5e"
      unitRef="usd">4300000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjBlODA0ODA2Y2RjNjRjYjY5YzYwMmY5NGRiMTU0NjcwL3RhYmxlcmFuZ2U6MGU4MDQ4MDZjZGM2NGNiNjljNjAyZjk0ZGIxNTQ2NzBfMi00LTEtMS03NzQwNw_67dc700d-69d3-4828-96e6-56ad3f67749c"
      unitRef="usd">4100000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjBlODA0ODA2Y2RjNjRjYjY5YzYwMmY5NGRiMTU0NjcwL3RhYmxlcmFuZ2U6MGU4MDQ4MDZjZGM2NGNiNjljNjAyZjk0ZGIxNTQ2NzBfMi02LTEtMS03NzQwNw_facb7df8-2214-4507-be33-9a601ca631c8"
      unitRef="usd">3400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl81NS9mcmFnOmJmMmExZmNkYWQxMjRiODE5NDJmZmUzYzllOWZlNDhjL3RhYmxlOjBlODA0ODA2Y2RjNjRjYjY5YzYwMmY5NGRiMTU0NjcwL3RhYmxlcmFuZ2U6MGU4MDQ4MDZjZGM2NGNiNjljNjAyZjk0ZGIxNTQ2NzBfMi04LTEtMS03NzQwNw_be466696-b5d6-4be9-9026-66f8d1ad1bf5"
      unitRef="usd">2800000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2MzY_89e6cb3f-5df0-4c14-9652-4a5911294f51">FAIR VALUE MEASUREMENTS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of October&#160;2, 2022, the cumulative amount of cash collateral received by the Company under the CSA amounted to $0.8 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of October&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $47.1&#160;billion, $36.2&#160;billion and $10.0&#160;billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion,  $37.4 billion and $10.0 billion respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of October&#160;2, 2022, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $922&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net investment hedge&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2022 and 2021, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2022 and 2021, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of  October&#160;2, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal third quarters ended in 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal nine months ended in 2022 and 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="33" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity investments without readily determinable market values, there was a decrease of $29 million in the fair value reflected in net income as a result of impairments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In the fiscal third quarter ended October&#160;2, 2022, the Company sold all its equity investments in argenx SE for proceeds of $0.6&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#x2019;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following three levels of inputs are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; Significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014; Significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of October&#160;2, 2022 and January&#160;2, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration for each of the fiscal nine months ended is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $507 million and $520 million, classified as non-current other liabilities as of October&#160;2, 2022 and January&#160;2, 2022, respectively.  Includes $18 million and $13 million classified as current liabilities as of October&#160;2, 2022 and January&#160;2, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents and current marketable securities as of October&#160;2, 2022 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain/( Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. sovereign securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the fiscal year ended January&#160;2, 2022 the carrying amount was approximately the same as the estimated fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of October&#160;2, 2022 are as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October&#160;2, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73% Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 0.9712)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500MM GBP 1.0908)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.550% Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 0.9712)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 0.9712)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average effective interest rate on non-current debt is 3.06%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the estimated fair value over the carrying value of debt was $3.2 billion at January 2, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The current debt balance as of October&#160;2, 2022 includes $3.9&#160;billion of commercial paper which has a weighted average interest rate of 2.88% and a weighted average maturity of approximately three months.&lt;/span&gt;&lt;/div&gt;Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTY1MQ_28e7241f-fb86-4186-ab0c-d980552d672d"
      unitRef="usd">800000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjMxNg_e3b8cc74-4d11-48c5-ada6-03838e4b59ad"
      unitRef="usd">47100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1c547b36424143b69e5081413c4fdc53_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjMyMA_f931adee-54fc-43e7-b90f-bc26849df999"
      unitRef="usd">36200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i717dee1c18bf45e493386905d911c3e8_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjMyNw_455c82f5-27a6-4a4f-aa0d-6ac5d284671d"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i62511374dce64f139252ff8bd59a8db6_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjUwMg_96920d38-906d-4e89-b41c-651133bd3ffa"
      unitRef="usd">45800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8a64086e3de14779a155947b262f6215_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjUwNw_8be9d7c3-e5b4-46cf-a958-abbc70db6d34"
      unitRef="usd">37400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib1c84b4bb409475ca45e6496196a8bfe_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjUxNA_cbd46eb2-e80f-402d-b5af-795d2fc192a2"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfNDY0NA_1a2a2ba5-c27e-4981-a9da-346ec8c1fd7d"
      unitRef="usd">922000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfNDkwMg_0a29a671-e772-4dbb-bbe7-edf3cb5b1a73">next 12 months</us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfNTA2Mw_076c82b7-058a-4b29-bfad-02ce50db6ed6">P18M</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2ODA_3fb1d9aa-86bf-43f7-9eaa-2c72e23a8562">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2022 and 2021, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2022 and 2021, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.302%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal third quarters ended in 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal nine months ended in 2022 and 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="33" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i7879ef9eb79f474c8938fb5e9a08e0c1_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy0xLTEtMS03NzQwNw_8223593a-6e47-4639-9028-654b94311d4a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="iefd146d7e5a948cb9bea7e9644188230_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy0yLTEtMS03NzQwNw_253f87fc-f5ba-4e92-9dc5-d05418742c13"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i0995bad590ed43e0bd73dc14bc4125a2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy0zLTEtMS03NzQwNw_ec197f8e-d1c1-42a5-90ef-4e376968cb53"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i28d9447c402644708f5027054c7c807d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy00LTEtMS03NzQwNw_01927ff9-9fd1-43b0-90ab-21ae448acfe7"
      unitRef="usd">-322000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5f7c9ef50ebc4fa19a9a1d74ac4d6b69_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy01LTEtMS03NzQwNw_8e7f1d90-0e57-470f-ab38-df04162dce71"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i888f5820c4ce448da471f2eeb67baf91_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy02LTEtMS03NzQwNw_07f2244b-1e90-4057-94b2-364a108cf80c"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ie5a1bf6a5e0a43f89bd6a0e1d76c50bb_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy03LTEtMS03NzQwNw_f968fed9-47ec-4c70-a9dd-7cc8b5d31cab"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5ee5060692494cee9c6f548b6e07c2a1_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy04LTEtMS03NzQwNw_3b5b6c79-d28e-4040-b1c0-ee494155ebe8"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ica35d2547f134655985b599491b5d2de_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy05LTEtMS03NzQwNw_ea83f3ec-5b54-4578-854e-39be072edfd7"
      unitRef="usd">-62000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i027b98ae63404a32b51e156b3616bcf5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfNy0xMC0xLTEtNzc0MDc_5079ea2a-b278-4c5a-8542-76816925a968"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7879ef9eb79f474c8938fb5e9a08e0c1_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC0xLTEtMS03NzQwNw_8ed1dc86-e9f7-48b7-bcc1-cff021a69319"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iefd146d7e5a948cb9bea7e9644188230_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC0yLTEtMS03NzQwNw_c528ca0a-6180-469e-be1c-7f8ca3bbd99a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0995bad590ed43e0bd73dc14bc4125a2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC0zLTEtMS03NzQwNw_d8131e72-b32d-44ef-9133-a96ce9818e94"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i28d9447c402644708f5027054c7c807d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC00LTEtMS03NzQwNw_e579948c-84b2-4c44-a43e-9241c07ccb27"
      unitRef="usd">322000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5f7c9ef50ebc4fa19a9a1d74ac4d6b69_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC01LTEtMS03NzQwNw_71f2c5a7-7c4b-4142-9519-800cd1a111d2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i888f5820c4ce448da471f2eeb67baf91_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC02LTEtMS03NzQwNw_04abbb7f-7d25-4443-8a2d-63290bb94005"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ie5a1bf6a5e0a43f89bd6a0e1d76c50bb_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC03LTEtMS03NzQwNw_5d8c3f9e-9372-4846-acc7-3047b0418083"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5ee5060692494cee9c6f548b6e07c2a1_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC04LTEtMS03NzQwNw_c8335e74-4416-477f-a000-9095fb1bf574"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ica35d2547f134655985b599491b5d2de_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC05LTEtMS03NzQwNw_e22ee133-96a9-4d3e-88e7-287b3d401721"
      unitRef="usd">62000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i027b98ae63404a32b51e156b3616bcf5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfOC0xMC0xLTEtNzc0MDc_3a3a85b6-b9fd-498b-b515-86418b154420"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ieceea25b4808416c866a84c9e93d2bc5_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItMS0xLTEtNzc0MDc_d2915ef4-577e-4499-9831-94c982abfe7d"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i4346ff30c79f4cb6889ccfc5de69e800_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItMi0xLTEtNzc0MDc_0118b64b-c54d-428f-a7b6-ecdd2aea360f"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ic14f778c18a3446c9134ffdea15dbf34_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItMy0xLTEtNzc0MDc_f9a565e9-44fc-409c-9329-4e7de8dca57c"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i4dc12c5833b246768b8eb8a92f87ba5b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItNC0xLTEtNzc0MDc_4afeceee-72f0-4419-bb5d-4ef600d33cc0"
      unitRef="usd">13000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i07d3d9443f8444bbaf8ea1e69ddb15bb_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItNS0xLTEtNzc0MDc_53452e43-19b1-45c2-b4a1-47b8c9b5fd03"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i72dbeff9573f40a5b9ba376ad81d5398_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItNi0xLTEtNzc0MDc_772dec44-cf62-4d03-828b-a6f3fcbeb43e"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="idb87a9281a92433d81c4a3ab6ffcf38e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItNy0xLTEtNzc0MDc_7ecb050d-8abf-4da9-b311-b8c7533baa8c"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i6f92be1d7860435ab1166cf51a2c9ada_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItOC0xLTEtNzc0MDc_a5969ab6-c2cd-40e7-b7f5-993b6f017811"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i699ea2f9280641c6a2c2ca9ae65c2e9e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItOS0xLTEtNzc0MDc_9eb9cccc-eb69-487a-b906-c0809d956989"
      unitRef="usd">34000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i9571f8c7ed824bd7907d0dc67ac2cbfc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTItMTAtMS0xLTc3NDA3_21c6af1d-54f5-4e88-b37c-c670694dd854"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ieceea25b4808416c866a84c9e93d2bc5_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtMS0xLTEtNzc0MDc_99b0b57d-3eb5-4e87-a89e-80d34509567c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4346ff30c79f4cb6889ccfc5de69e800_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtMi0xLTEtNzc0MDc_18542194-2944-448d-9a1c-315db14a9ffb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic14f778c18a3446c9134ffdea15dbf34_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtMy0xLTEtNzc0MDc_ef59538d-db03-4283-aa74-3b462e4712a5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4dc12c5833b246768b8eb8a92f87ba5b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtNC0xLTEtNzc0MDc_789ede97-25b0-4e64-9e2d-1956ae330d45"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i07d3d9443f8444bbaf8ea1e69ddb15bb_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtNS0xLTEtNzc0MDc_92164361-2f93-4292-8841-9519bad8f936"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i72dbeff9573f40a5b9ba376ad81d5398_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtNi0xLTEtNzc0MDc_97aeec12-84fa-4f2d-a557-c9922b338254"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="idb87a9281a92433d81c4a3ab6ffcf38e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtNy0xLTEtNzc0MDc_2df63db5-d322-42ba-a33e-8f0dba817c92"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i6f92be1d7860435ab1166cf51a2c9ada_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtOC0xLTEtNzc0MDc_887eaa22-4d5e-4320-9ef7-619b5bc7535f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i699ea2f9280641c6a2c2ca9ae65c2e9e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtOS0xLTEtNzc0MDc_eca66ad3-fc6d-427b-bd97-ba2410cfedba"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9571f8c7ed824bd7907d0dc67ac2cbfc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTMtMTAtMS0xLTc3NDA3_eb4b4e56-8b63-4a00-a735-4529c27ba8d3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i78647d618ebb4323997e495ab6b689d1_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctMS0xLTEtNzc0MDc_32157a9a-f22a-43cc-b763-92009ac63ee0"
      unitRef="usd">-20000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i6804eaf6e9a2498bb21b278580ca9ca0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctMi0xLTEtNzc0MDc_c9c321ea-31fa-40ee-97f5-0d64ebc8a7a2"
      unitRef="usd">-83000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i132eac11468e4392b097dc2bcb6b935b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctMy0xLTEtNzc0MDc_2ae2c51d-8293-4f29-be52-a0cab97bcd5d"
      unitRef="usd">53000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ib7950a50b27c4ebdb91385e119fda9f5_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctNC0xLTEtNzc0MDc_6b60fcce-203d-47f2-b6a5-87a9b9e08970"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i89a2ff3d08834c418a9d5c5493adff6e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctNS0xLTEtNzc0MDc_00987ae9-3f1e-4c3b-a5d5-0579dde3d320"
      unitRef="usd">22000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ibcc16a1145204ef7b053987f85b7f51d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctNi0xLTEtNzc0MDc_5c82757a-8835-4050-8ff5-feefe14c2f81"
      unitRef="usd">-3000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i98263d9f7f8641fd9e965fa50bc0532a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctNy0xLTEtNzc0MDc_7c67528c-e0b9-4e57-ab87-1723e756d3d5"
      unitRef="usd">58000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i82b29d715d9741d3abce2df4d39b309e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctOC0xLTEtNzc0MDc_295a4983-e1dc-432d-8ef2-4a9c6990a3a8"
      unitRef="usd">8000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="if4f312e218c94f0da6a1676afa932315_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctOS0xLTEtNzc0MDc_50e83a23-41cb-4fa3-9748-5a8759993bd8"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i5fde6866da6845ffa717894b879f8c97_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMTctMTAtMS0xLTc3NDA3_0d971727-74e2-4c81-902c-ebcca56a3a5b"
      unitRef="usd">19000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i78647d618ebb4323997e495ab6b689d1_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtMS0xLTEtNzc0MDc_80b43298-16f4-41e6-88e0-c0c494b6acf8"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i6804eaf6e9a2498bb21b278580ca9ca0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtMi0xLTEtNzc0MDc_67ce7382-c60c-40f9-a111-f37c654011be"
      unitRef="usd">-94000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i132eac11468e4392b097dc2bcb6b935b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtMy0xLTEtNzc0MDc_c7dc21e0-2e6c-4bc4-b402-a03990d0d9de"
      unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ib7950a50b27c4ebdb91385e119fda9f5_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtNC0xLTEtNzc0MDc_b983987e-017d-4bbf-a2b8-e941a240139a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i89a2ff3d08834c418a9d5c5493adff6e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtNS0xLTEtNzc0MDc_19ac987a-18fd-42bb-8676-6b08ed9339f0"
      unitRef="usd">36000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ibcc16a1145204ef7b053987f85b7f51d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtNi0xLTEtNzc0MDc_1e989e3d-95c1-42a2-a147-41e110780d78"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i98263d9f7f8641fd9e965fa50bc0532a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtNy0xLTEtNzc0MDc_81abddd1-40a6-4e25-b64e-f85152d95525"
      unitRef="usd">-155000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i82b29d715d9741d3abce2df4d39b309e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtOC0xLTEtNzc0MDc_26babf0d-8511-48e6-8622-dc70acaf4415"
      unitRef="usd">37000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if4f312e218c94f0da6a1676afa932315_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtOS0xLTEtNzc0MDc_8ec6bb73-40bd-4e7d-8db1-22af5cd8d33d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5fde6866da6845ffa717894b879f8c97_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjEtMTAtMS0xLTc3NDA3_092a07bf-3ba3-4ceb-95d0-fc74138b3690"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i7366275be3ae410893ecf9408865b9c7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtMS0xLTEtNzc0MDc_025b5214-0ee2-4dc0-8b3f-38cc6c1180e0"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i9c0b992f36af4511aa5daeaab0f6fbab_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtMi0xLTEtNzc0MDc_0afffff8-17eb-4e45-b3e6-f4b4becc723f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i8378ff8e008a4098af1366d8ed328c04_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtMy0xLTEtNzc0MDc_1015aa2f-9122-4381-91dc-edd1f2c86679"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i0757ae310f7c40a68adf9115fdf4e04f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtNC0xLTEtNzc0MDc_66c4c53e-a66e-41e4-bb9a-79d82d285ad6"
      unitRef="usd">120000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i773b6479d1f84dd099a271d67f39d97b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtNS0xLTEtNzc0MDc_f7c870cd-def5-4696-88d0-c7df3d00b757"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i0f6aac49f1e34f848da45a55d588af8d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtNi0xLTEtNzc0MDc_a2918abe-78ee-4f73-b2ab-6fa0d7402af6"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i98dd0e4104d64d1e9e04143dee5c8d7b_D20210705-20211003"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtNy0xLTEtNzc0MDc_30d13d53-5b77-481f-b944-5dbacc38c00a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i30c2531c320b4c429410121c99424073_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtOC0xLTEtNzc0MDc_54a97734-31a1-4d95-9664-21bdba1aee49"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="if365333f1f9d4429b45bb40e00408696_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtOS0xLTEtNzc0MDc_800f2a78-02b2-4175-b720-01513f8d9dd0"
      unitRef="usd">117000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i02b8db1fe34e46ee8c685ab4da2008f5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjQtMTAtMS0xLTc3NDA3_e0fb1252-52c3-40c1-b62f-62930049066d"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7366275be3ae410893ecf9408865b9c7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtMS0xLTEtNzc0MDc_cf651b1c-edb9-4df6-8815-370bd4b53fca"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9c0b992f36af4511aa5daeaab0f6fbab_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtMi0xLTEtNzc0MDc_fa47fb8e-5443-42c5-870f-72c3e77e3a86"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i8378ff8e008a4098af1366d8ed328c04_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtMy0xLTEtNzc0MDc_f2f29b61-372a-4927-b251-4713bfd1c9b0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0757ae310f7c40a68adf9115fdf4e04f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtNC0xLTEtNzc0MDc_29784c4f-53ae-493d-bd41-7068d0351015"
      unitRef="usd">-205000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i773b6479d1f84dd099a271d67f39d97b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtNS0xLTEtNzc0MDc_de27e918-d3ad-4693-985f-05a117df09c6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0f6aac49f1e34f848da45a55d588af8d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtNi0xLTEtNzc0MDc_b575a435-ccfe-41c7-ae08-808f72d7dce0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i98dd0e4104d64d1e9e04143dee5c8d7b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtNy0xLTEtNzc0MDc_f2ec6a60-6b33-44d2-a8d8-de480e988abb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i30c2531c320b4c429410121c99424073_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtOC0xLTEtNzc0MDc_2fd4a2ae-f3d2-4058-adcb-3d58398adbcf"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if365333f1f9d4429b45bb40e00408696_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtOS0xLTEtNzc0MDc_18af4b3b-5c1a-49b8-b474-f5156c319c4c"
      unitRef="usd">144000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i02b8db1fe34e46ee8c685ab4da2008f5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjczNWQ4ZjY4NmEyMDQzNjk5MjhjMDFiMzNkYzAyOTMwL3RhYmxlcmFuZ2U6NzM1ZDhmNjg2YTIwNDM2OTkyOGMwMWIzM2RjMDI5MzBfMjYtMTAtMS0xLTc3NDA3_e3e6044a-6fad-4df2-ae32-830c84192e9d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i8e443c797bce44b8904549f48d8fc7a7_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy0xLTEtMS03NzQwNw_89670d35-9e1c-4dfb-a3ea-96d88f68c02c"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i425df44efbe4432dafc49cc44a80a0c5_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy0yLTEtMS03NzQwNw_5c6e558c-8dd3-4195-b7fb-4bf91e410bfe"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ibc5be715bb3247109709d1a846e794a0_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy0zLTEtMS03NzQwNw_f2a96ed4-1d86-4f64-9e00-273f7217f6c7"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i971a920aa5d64f5992b34b4dddba6c81_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy00LTEtMS03NzQwNw_f929399c-8aba-4aa9-8665-5c0a2a32964d"
      unitRef="usd">-1094000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i7500ee5f78d14a669d9868e1d786c583_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy01LTEtMS03NzQwNw_5c909717-d114-484c-9502-9b6a898173c1"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i64a948b4810449dda6fec2b6273bb8cb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy02LTEtMS03NzQwNw_6a8f7471-3445-4218-bbdc-6361c79aaad2"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i1eecf9b0d2d34ad7af622fbf637bcea6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy03LTEtMS03NzQwNw_301b3546-abc6-49dc-adbd-334efa7ae29f"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i3ac33f410fd64a498d0320619c400fc0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy04LTEtMS03NzQwNw_3e82efcd-ab4d-4f27-9037-192449b95456"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="if68cb6de6b7547ddbd0a239ef2261809_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy05LTEtMS03NzQwNw_f9832778-f0d3-4419-b4fb-56820ac87658"
      unitRef="usd">-56000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="idd364fbacd784c248996002106d412f1_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfNy0xMC0xLTEtNzc0MDc_b6cbbd5c-831d-4470-ab5b-0354fa64f9d9"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i8e443c797bce44b8904549f48d8fc7a7_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC0xLTEtMS03NzQwNw_88009eea-d429-4b8c-ba81-f2a1f18caa48"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i425df44efbe4432dafc49cc44a80a0c5_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC0yLTEtMS03NzQwNw_75296205-b481-40e0-a4ff-b77bb024ba77"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ibc5be715bb3247109709d1a846e794a0_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC0zLTEtMS03NzQwNw_de1a0322-9baa-41ce-a445-f2b5546167b1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i971a920aa5d64f5992b34b4dddba6c81_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC00LTEtMS03NzQwNw_0b459bf5-a536-4c29-8618-4300701be1fa"
      unitRef="usd">1094000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7500ee5f78d14a669d9868e1d786c583_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC01LTEtMS03NzQwNw_ef8ee1b9-2519-4aea-afa4-0ac9f6221623"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i64a948b4810449dda6fec2b6273bb8cb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC02LTEtMS03NzQwNw_adcee368-a3b5-408e-91ef-c41670c972f6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1eecf9b0d2d34ad7af622fbf637bcea6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC03LTEtMS03NzQwNw_f9efe592-bca7-42a9-a575-c5b7ef3f43be"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i3ac33f410fd64a498d0320619c400fc0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC04LTEtMS03NzQwNw_18f57eb9-b5dd-4fb4-b089-a6e934c09f6b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if68cb6de6b7547ddbd0a239ef2261809_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC05LTEtMS03NzQwNw_68e42078-6a5f-451d-ad7b-d68dce091074"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="idd364fbacd784c248996002106d412f1_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfOC0xMC0xLTEtNzc0MDc_e7b40d6c-ff76-478e-b001-562e1b6b7c63"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5e79e3afda2d4ff4b9c9715fed272c0d_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItMS0xLTEtNzc0MDc_6bd90fe1-0296-4951-b800-d1de3d866663"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="idced9fd0a0dc40e2962f7034fb149e25_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItMi0xLTEtNzc0MDc_e8a471dd-7647-46f9-a52f-6c9a197c231a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5cfd0ec8b28f4d61aef0be150644a052_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItMy0xLTEtNzc0MDc_99c56c21-5431-4161-9605-b48ecd7ca9de"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="iaa79f363437b49b18f54f6dfea462a0c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItNC0xLTEtNzc0MDc_e03d242f-df30-42ca-8efa-358ec987dbe0"
      unitRef="usd">102000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id3f939a4ef544f199f0a9ba9f0486f0e_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItNS0xLTEtNzc0MDc_e8a2cd69-303d-4b2e-9487-f1134538ac92"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i29be9feba45c4fbf8a5331a5258734dc_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItNi0xLTEtNzc0MDc_34e9331c-0c91-4c8f-992c-fd50f224e3d6"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id20d1c20c564471ca693f0dbf7e3e2b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItNy0xLTEtNzc0MDc_d6334635-7c48-4581-af8e-8d2bf345c479"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i531bee53a47b496db85de6734c8b4ba1_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItOC0xLTEtNzc0MDc_449b0d90-4db7-452a-af53-5ba9e1109be2"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i35ef3a7f91694f4784dabed8656e3e52_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItOS0xLTEtNzc0MDc_2f792b40-1645-48dd-ba74-deb16e69bd47"
      unitRef="usd">115000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i891a31716b3c4d33862563ef6041c58c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTItMTAtMS0xLTc3NDA3_93fdd91c-a811-4826-832d-913bf9194552"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5e79e3afda2d4ff4b9c9715fed272c0d_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtMS0xLTEtNzc0MDc_217050dc-fd55-4faf-b68d-45e13ec653e6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="idced9fd0a0dc40e2962f7034fb149e25_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtMi0xLTEtNzc0MDc_176cb356-ea16-4296-a0ce-517eac1b2fbe"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5cfd0ec8b28f4d61aef0be150644a052_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtMy0xLTEtNzc0MDc_cbb167c8-2c3b-459f-b8e5-7fafa5da272f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iaa79f363437b49b18f54f6dfea462a0c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtNC0xLTEtNzc0MDc_68381f6a-946a-4517-b701-93aeaf821500"
      unitRef="usd">102000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id3f939a4ef544f199f0a9ba9f0486f0e_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtNS0xLTEtNzc0MDc_0954ab03-88c8-46c5-afd2-c2037e118847"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i29be9feba45c4fbf8a5331a5258734dc_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtNi0xLTEtNzc0MDc_0b880418-eaad-4c7d-9d41-5b858f97dd86"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id20d1c20c564471ca693f0dbf7e3e2b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtNy0xLTEtNzc0MDc_08281b0a-044f-4b49-b4b9-66bf36e54c0a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i531bee53a47b496db85de6734c8b4ba1_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtOC0xLTEtNzc0MDc_1fb9b33a-64c0-4b14-99a6-61eaf5fbcff4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i35ef3a7f91694f4784dabed8656e3e52_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtOS0xLTEtNzc0MDc_38e8647c-e022-4430-a306-12002cc43e3c"
      unitRef="usd">115000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i891a31716b3c4d33862563ef6041c58c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTMtMTAtMS0xLTc3NDA3_0d4af285-af98-4e73-88a1-1ed806667c88"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i234b580d2ab945b7a1da2967b50f2f0b_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctMS0xLTEtNzc0MDc_9ef30bde-216f-4f74-8a28-1f777042f51c"
      unitRef="usd">-54000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i0c2c6e50b3414bb7b581acb7b2ddf236_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctMi0xLTEtNzc0MDc_dac552b6-dfca-45d7-bdb2-ae12f13563c0"
      unitRef="usd">-141000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ie4b5f475cfa74c208c0321112d12da5e_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctMy0xLTEtNzc0MDc_84a83dc2-032d-4ab1-94da-50c1012d4c21"
      unitRef="usd">118000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ide20e84875b34943bcfaf3c9ae95202b_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctNC0xLTEtNzc0MDc_14f602ee-8618-4a25-a917-e8ae6573ba13"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i29b950c0556549258d0b61b677f0b680_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctNS0xLTEtNzc0MDc_23db3eb4-9cfb-455f-8396-bfc890595402"
      unitRef="usd">-35000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="icbe5347877f646f8a69accb4b750d574_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctNi0xLTEtNzc0MDc_6dc5a955-2282-4f91-989e-f59fea778da0"
      unitRef="usd">25000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ic472125573384b52b4aa88304af5b630_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctNy0xLTEtNzc0MDc_071441c2-159d-46ce-9b05-b1a835b9d323"
      unitRef="usd">106000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i7ff0963b4e07465bbef6c78a5da86146_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctOC0xLTEtNzc0MDc_5e1a8503-765d-4b73-8e83-124aa6b157ce"
      unitRef="usd">-1000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i7792ddd751e74a3fa36de680b670123a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctOS0xLTEtNzc0MDc_a0484325-7bb8-4331-b045-82e9d7271b0d"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i42bf0720b1074baa96eb44f6c995dbfc_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMTctMTAtMS0xLTc3NDA3_162f66b5-5a09-4e08-aecd-6a08c6150cb2"
      unitRef="usd">24000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i234b580d2ab945b7a1da2967b50f2f0b_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtMS0xLTEtNzc0MDc_59efcf37-1389-445f-a114-1df247f974d4"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0c2c6e50b3414bb7b581acb7b2ddf236_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtMi0xLTEtNzc0MDc_4349c131-0103-49d2-bc19-de6f16b52498"
      unitRef="usd">-153000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ie4b5f475cfa74c208c0321112d12da5e_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtMy0xLTEtNzc0MDc_9fefdc5f-6b0b-4f05-bcec-73c301be377c"
      unitRef="usd">193000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ide20e84875b34943bcfaf3c9ae95202b_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtNC0xLTEtNzc0MDc_af913719-4a66-40b9-9681-4531b30f7798"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i29b950c0556549258d0b61b677f0b680_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtNS0xLTEtNzc0MDc_309ca1b3-6b4e-4931-b879-06ef35208b03"
      unitRef="usd">-75000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="icbe5347877f646f8a69accb4b750d574_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtNi0xLTEtNzc0MDc_8cc5ce6c-0ab5-4d53-bc8c-d0e38acffeb3"
      unitRef="usd">-41000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic472125573384b52b4aa88304af5b630_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtNy0xLTEtNzc0MDc_d87319c0-1325-4f41-b78f-4a2eda90fc5b"
      unitRef="usd">-398000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7ff0963b4e07465bbef6c78a5da86146_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtOC0xLTEtNzc0MDc_9aa51e5c-35ae-4135-997b-e120d6f19cb7"
      unitRef="usd">80000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7792ddd751e74a3fa36de680b670123a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtOS0xLTEtNzc0MDc_b50b7007-8cc3-4174-b14e-fe794b6bb08f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i42bf0720b1074baa96eb44f6c995dbfc_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjEtMTAtMS0xLTc3NDA3_8cc8e338-04d7-4250-a87a-90eac1365248"
      unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i7912b942d37f465fb3e53088b7761ba5_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtMS0xLTEtNzc0MDc_3fd926c1-99e1-409e-877f-2f0b022ff7c0"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i2000357e194a441e9534374b54cbc72a_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtMi0xLTEtNzc0MDc_1ddf0bfa-ec02-4a73-9aec-713b921ac2ca"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ia6c24b49746b4613b703772fdfe9f6eb_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtMy0xLTEtNzc0MDc_21390b4d-06f8-4660-924f-e57b36fc1314"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ibd7f9d1ac03a4e2ea6d1d353ef976c71_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtNC0xLTEtNzc0MDc_6ff7077d-9dba-4ef4-96a5-0ba1bbfb1772"
      unitRef="usd">342000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i0bb2d4354806473f89aeaf974654c5d0_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtNS0xLTEtNzc0MDc_116294df-c98a-41b2-b799-3973fb690077"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i370583126d5b4bab94e9ead51c975ebf_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtNi0xLTEtNzc0MDc_be40fa52-52a9-4206-8bd4-9390630dbb44"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i4ee255d90708413cb5622bce2a34a5eb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtNy0xLTEtNzc0MDc_64628083-a56b-465f-bb1d-e1415425d7c1"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iba8c6cab16ef4288b07b2a65d72b7ca7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtOC0xLTEtNzc0MDc_746a07a5-3421-4149-b1e3-dda3c1887fc5"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i8e59de01264548d093d60627efe88e9d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtOS0xLTEtNzc0MDc_652cabc4-e904-4ef1-a92b-12ff29b87f71"
      unitRef="usd">307000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i10d2e79904b6488a85d7505ca382bbc1_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjQtMTAtMS0xLTc3NDA3_6ffab85c-a388-4478-86a3-0c71d0a72231"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7912b942d37f465fb3e53088b7761ba5_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtMS0xLTEtNzc0MDc_a60b318c-4bc7-4f04-978b-1684ae5c5f08"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2000357e194a441e9534374b54cbc72a_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtMi0xLTEtNzc0MDc_a584aca1-429d-4349-833b-5f3f47ea4ed0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia6c24b49746b4613b703772fdfe9f6eb_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtMy0xLTEtNzc0MDc_fb0d2801-cc3c-4349-b0d4-8195f5d959f8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ibd7f9d1ac03a4e2ea6d1d353ef976c71_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtNC0xLTEtNzc0MDc_3ab4af8c-e3de-4ea0-8940-d218a106e0cd"
      unitRef="usd">-273000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0bb2d4354806473f89aeaf974654c5d0_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtNS0xLTEtNzc0MDc_1d2f435d-35f2-45d7-889c-f8df33e93633"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i370583126d5b4bab94e9ead51c975ebf_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtNi0xLTEtNzc0MDc_27251cfc-5457-4983-8edd-15b2ca065bca"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4ee255d90708413cb5622bce2a34a5eb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtNy0xLTEtNzc0MDc_20abeabb-4e65-4c67-9e1c-53dc49a6b3b1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iba8c6cab16ef4288b07b2a65d72b7ca7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtOC0xLTEtNzc0MDc_470e3d00-1042-4079-89ee-4bb69df3d35f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i8e59de01264548d093d60627efe88e9d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtOS0xLTEtNzc0MDc_48eefb3a-1e88-423d-b0f2-bef1ade82d39"
      unitRef="usd">122000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i10d2e79904b6488a85d7505ca382bbc1_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI2MDUzOTI1OGMzYjQwM2RhMDkyMmI4YWRhZDdjOTBlL3RhYmxlcmFuZ2U6MjYwNTM5MjU4YzNiNDAzZGEwOTIyYjhhZGFkN2M5MGVfMjYtMTAtMS0xLTc3NDA3_59d4a89e-db23-4e4a-aeb9-30d6df8d8651"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2Mzg_9c35d5a1-6efe-43b7-b4a5-3c48d6066deb">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of  October&#160;2, 2022, and January&#160;2, 2022, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i487741e9485f4d4989b2d9bdd6959f03_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmQ1NmRiZmVhOThkOTRhYTk5Y2VhZmZiODFmMDUyZjFlL3RhYmxlcmFuZ2U6ZDU2ZGJmZWE5OGQ5NGFhOTljZWFmZmI4MWYwNTJmMWVfNC0yLTEtMS03NzQwNw_0fb4bee9-5151-4e24-86cc-2a781cc40261"
      unitRef="usd">8668000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1f8bb4709c5441d49ce49132893c52de_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmQ1NmRiZmVhOThkOTRhYTk5Y2VhZmZiODFmMDUyZjFlL3RhYmxlcmFuZ2U6ZDU2ZGJmZWE5OGQ5NGFhOTljZWFmZmI4MWYwNTJmMWVfNC00LTEtMS03NzQwNw_931d53d2-14ea-43a9-bee1-0d7c1f6a18d9"
      unitRef="usd">9793000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i487741e9485f4d4989b2d9bdd6959f03_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmQ1NmRiZmVhOThkOTRhYTk5Y2VhZmZiODFmMDUyZjFlL3RhYmxlcmFuZ2U6ZDU2ZGJmZWE5OGQ5NGFhOTljZWFmZmI4MWYwNTJmMWVfNC02LTEtMS03NzQwNw_b35745d3-f126-492b-969c-641d7cdad854"
      unitRef="usd">-1430000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i1f8bb4709c5441d49ce49132893c52de_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmQ1NmRiZmVhOThkOTRhYTk5Y2VhZmZiODFmMDUyZjFlL3RhYmxlcmFuZ2U6ZDU2ZGJmZWE5OGQ5NGFhOTljZWFmZmI4MWYwNTJmMWVfNC04LTEtMS03NzQwNw_21861e01-7ab5-44fc-be22-49e4f247e06e"
      unitRef="usd">-142000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2ODE_4aaad050-8a03-41fc-877b-b7bbcacf5e92">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of derivatives not designated as hedging instruments for the fiscal third quarters and fiscal nine months in 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.414%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i7eba85641ea146e5bc22ff998e193635_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjJhOWY5MGQ0ZWE3NTQ5ZmJhYjBkN2I5NDA5ZDdjZDE3L3RhYmxlcmFuZ2U6MmE5ZjkwZDRlYTc1NDlmYmFiMGQ3Yjk0MDlkN2NkMTdfNC00LTEtMS03NzQwNw_2b3e1867-1313-44df-a386-eceeb61d4f85"
      unitRef="usd">109000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i185112cfdae241938bc5001036d374c8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjJhOWY5MGQ0ZWE3NTQ5ZmJhYjBkN2I5NDA5ZDdjZDE3L3RhYmxlcmFuZ2U6MmE5ZjkwZDRlYTc1NDlmYmFiMGQ3Yjk0MDlkN2NkMTdfNC02LTEtMS03NzQwNw_32e797fd-c8c9-46f3-96bf-58320094c520"
      unitRef="usd">-13000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i5777045ad8034f0ba971fbea4fe60d05_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjJhOWY5MGQ0ZWE3NTQ5ZmJhYjBkN2I5NDA5ZDdjZDE3L3RhYmxlcmFuZ2U6MmE5ZjkwZDRlYTc1NDlmYmFiMGQ3Yjk0MDlkN2NkMTdfNC03LTEtMS03NzQwNw_5b49c984-2759-4050-9e04-809b251af658"
      unitRef="usd">211000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ib8c1c1667b484cd296b17f3e255a344c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjJhOWY5MGQ0ZWE3NTQ5ZmJhYjBkN2I5NDA5ZDdjZDE3L3RhYmxlcmFuZ2U6MmE5ZjkwZDRlYTc1NDlmYmFiMGQ3Yjk0MDlkN2NkMTdfNC05LTEtMS03NzQwNw_1409d59e-e470-4b18-a1ab-5522f21b9d75"
      unitRef="usd">-50000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfMy0yLTEtMS03NzQwNw_dbd3e2a8-2a54-415d-86de-3732f7730724"
      unitRef="usd">208000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfMy00LTEtMS03NzQwNw_dfb20e11-bbb9-49e8-9aaf-63545e09c6ed"
      unitRef="usd">115000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="if65ea7c0fbd54a3d9557ee7eb1a25b7c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfMy04LTEtMS03NzQwNw_6e6cb5ea-26ef-4a73-adae-41e4eef6d580"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ie6bb3d370ef04b7d8291df862fee2c4e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfMy0xMC0xLTEtNzc0MDc_a2bb3a9e-33dd-4d73-a5fd-33e88b450fc0"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="id2db0b7f18904840b6133ca100157ba1_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfNC0yLTEtMS03NzQwNw_70b05344-9f06-4ee6-ba1a-3731752cf6ce"
      unitRef="usd">261000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i97ce603cf39f42638ed7c1c786b7b5cf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfNC00LTEtMS03NzQwNw_41590c0f-06a0-4f2e-9eb4-dca228338a3a"
      unitRef="usd">141000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iedd9f71bda284795aea57b0e3717a2fd_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfNC04LTEtMS03NzQwNw_76ef9c81-074d-45ae-bbd4-704a156334c8"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i09ae709d11a747f5bcc44c920b026868_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFkMjZjMDNlYzViMjQ0OWRiOWMzYjRiYWM3YjYwNWQzL3RhYmxlcmFuZ2U6MWQyNmMwM2VjNWIyNDQ5ZGI5YzNiNGJhYzdiNjA1ZDNfNC0xMC0xLTEtNzc0MDc_fdd6cfef-636d-4e91-9338-ae1ca5bd7b75"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfMy0yLTEtMS03NzQwNw_06a37b2d-9cc8-4b9a-89c6-9c0b54b5c946"
      unitRef="usd">478000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfMy00LTEtMS03NzQwNw_c6706464-0c0b-4da9-bb42-d2e509c3dbdc"
      unitRef="usd">279000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i995da9ebcbab4f4db89d58d96f77b4f5_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfMy04LTEtMS03NzQwNw_8ab446c4-3df4-493b-b6fc-878036f2e05b"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i7bd6461d92f04ed69ce2217f18942c36_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfMy0xMC0xLTEtNzc0MDc_8c86c43a-63b4-465d-b9e0-ebdd0a2e3d14"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i9b27f2a754554e6dafba78c082f6f40b_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfNC0yLTEtMS03NzQwNw_b47a9da8-4982-4d00-af27-87e54310c57a"
      unitRef="usd">1134000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="if177366e6dce47ec8b19785b5a66cc57_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfNC00LTEtMS03NzQwNw_f0d0d0a8-1047-498a-81f7-3900a0cbeee2"
      unitRef="usd">432000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i606547907f3f4875acafd89bf36f7292_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfNC04LTEtMS03NzQwNw_68f3064a-962c-47a4-9abd-c646c3121852"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i47c3297a283649f18a41e3b7ce1b4275_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjkyZmYzYTRmYjMxMzQ5YjY5MWJmOTIwNjkwMDk2MGFlL3RhYmxlcmFuZ2U6OTJmZjNhNGZiMzEzNDliNjkxYmY5MjA2OTAwOTYwYWVfNC0xMC0xLTEtNzc0MDc_71eb4cc1-8713-4984-88f6-4e9099cc208a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2NTI_4e9d233a-96a0-4d5d-9578-211ed269134b">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i4a1fe51dbd41434cacb992b4b627a3a1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfMi0yLTEtMS03NzQwNw_14702c63-99b3-4c2b-a2b5-83655e5da57b"
      unitRef="usd">1884000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i5794f5fa77224cff877efb7f11be88a9_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfMi00LTEtMS03NzQwNw_e6c1edd4-04e7-4a94-88d6-652f8c1613e9"
      unitRef="usd">-607000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i5794f5fa77224cff877efb7f11be88a9_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfMi02LTEtMS03NzQwNw_79821abb-3a81-4ec8-8d09-1e5c76612c4d"
      unitRef="usd">-755000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i8788e8f33a374f91990206b3e2c99555_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfMi04LTEtMS03NzQwNw_3858bfcd-e3d5-47ad-a94d-b9ffab185878"
      unitRef="usd">522000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8788e8f33a374f91990206b3e2c99555_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfMi0xMC0xLTEtNzc0MDc_181e9897-17d1-4864-8c60-2197fdcb29a0"
      unitRef="usd">522000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="id8ae9a8d6d144029b31ac56599a2c97d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfNC0yLTEtMS03NzQwNw_4b73fc8e-64c1-4398-bd45-e38830aabcb5"
      unitRef="usd">500000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i2b0e63e41f6a4d339367644bfc21181c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfNC00LTEtMS03NzQwNw_b7377f30-9317-49f6-8961-ac90aeebcaf6"
      unitRef="usd">-29000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i2b0e63e41f6a4d339367644bfc21181c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfNC02LTEtMS03NzQwNw_bde3057a-da0f-45a0-bb72-29b69740e2e5"
      unitRef="usd">60000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ib372927ab7a04736879231296a9857fc_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfNC04LTEtMS03NzQwNw_8c31e282-4141-4b26-a3ea-3c5ed16434bd"
      unitRef="usd">531000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib372927ab7a04736879231296a9857fc_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjI1YWMxMjA5YzJiNDRhM2I5ZTFiYWM1MWVkNWNiODY1L3RhYmxlcmFuZ2U6MjVhYzEyMDljMmI0NGEzYjllMWJhYzUxZWQ1Y2I4NjVfNC0xMC0xLTEtNzc0MDc_693d83b8-51d3-4f98-902f-c93e9f101644"
      unitRef="usd">531000000</us-gaap:OtherAssetsNoncurrent>
    <jnj:EquityFairValueAdjustmentImpairmentLoss
      contextRef="i2b0e63e41f6a4d339367644bfc21181c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfNjcyOQ_e6cdce8e-a4b4-4452-b3e7-43f3cfafee06"
      unitRef="usd">-29000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ibe72fcc581ba4b3aa24c4cf87da552b5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMjE5OTAyMzI2ODEwNA_525450c3-7852-4188-9fd5-276960ec50dc"
      unitRef="usd">600000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE3MDI_da5537d5-82f9-4a21-98d8-ef608997b713">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of October&#160;2, 2022 and January&#160;2, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration for each of the fiscal nine months ended is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2021 assets and liabilities are all classified as Level 2 with the exception of equity investments of $1,884 million, which are classified as Level 1 and contingent consideration of $533 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $507 million and $520 million, classified as non-current other liabilities as of October&#160;2, 2022 and January&#160;2, 2022, respectively.  Includes $18 million and $13 million classified as current liabilities as of October&#160;2, 2022 and January&#160;2, 2022, respectively.&lt;/span&gt;&lt;/div&gt;           (6)    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ic9edf61dadd24a7a89bfd4eb35fdb595_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNC0yLTEtMS03NzQwNw_34522b34-9f71-4692-9736-067171efb28f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ie5ec42981eb24a7b8f39e90fcfcb3b97_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNC00LTEtMS03NzQwNw_482827d1-9241-4bd1-a6f3-4956c6e752ec"
      unitRef="usd">1942000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7787c920b4fa4851a091b1d05760f26c_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNC02LTEtMS03NzQwNw_3f3a8500-e869-499e-afdc-08e58bccbf2e"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNC04LTEtMS03NzQwNw_f12a67ff-1bf7-41f8-88e5-05a0b4350fb1"
      unitRef="usd">1942000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="if9abd0ce724b48d1878bcaa4742736aa_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNC0xMC0xLTEtNzc0MDc_51ac9ce7-23ab-4fb4-8e21-2711ce3b16d1"
      unitRef="usd">540000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i13455fb6580c486fa719cf5f9b78801a_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNS0yLTEtMS03NzQwNw_a503a8e2-f829-46ef-ac2c-9bfc619f9657"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i17df52d9c169494fb0dbcfa0f99740fa_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNS00LTEtMS03NzQwNw_5fd9007f-eff8-4125-a0b2-1bfbb5fcf1a9"
      unitRef="usd">2533000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="iaf68b60de7014cf2a3fbb8410bc3a9bd_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNS02LTEtMS03NzQwNw_33ad4657-f165-43ce-a0ba-2a57ca306506"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i4f13cabfbd6e4267a7040e78e38ec939_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNS04LTEtMS03NzQwNw_fa3e2256-54dd-48c9-a2cc-1f1fc93c11ab"
      unitRef="usd">2533000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i91092ba038134ef4a95f7a6d01647908_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNS0xMC0xLTEtNzc0MDc_1016411b-d08d-476c-9725-975bd94710db"
      unitRef="usd">796000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i2e55b859d5454474b61a342f2ab11b53_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNy0yLTEtMS03NzQwNw_95eed028-6cc6-46ee-aaeb-ba7a4d77a92a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i01e0e3590e6e48db894610a47ecd29c5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNy00LTEtMS03NzQwNw_88a7360b-6c36-4e0f-8474-23a90d8532cd"
      unitRef="usd">4475000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNy02LTEtMS03NzQwNw_49d45a08-a64f-4aa0-b97e-6ff9f839b6bf"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNy04LTEtMS03NzQwNw_9db7a870-6934-473e-a88e-0c268a7abc4b"
      unitRef="usd">4475000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i57a26835dc1c47168bfb6605e72bd3bf_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfNy0xMC0xLTEtNzc0MDc_a5d8773e-a352-46ed-abb9-e9de5f3c594a"
      unitRef="usd">1336000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ic9edf61dadd24a7a89bfd4eb35fdb595_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfOS0yLTEtMS03NzQwNw_023560ad-bdc8-47eb-b1db-7ec7156e2892"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ie5ec42981eb24a7b8f39e90fcfcb3b97_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfOS00LTEtMS03NzQwNw_20cfdaf5-3b3b-4cc2-be47-0999d6649b02"
      unitRef="usd">1881000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7787c920b4fa4851a091b1d05760f26c_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfOS02LTEtMS03NzQwNw_7b680ad8-2658-4ba0-8669-1b1f50a8479c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfOS04LTEtMS03NzQwNw_ed158d29-f350-4839-8d2f-9a7caa9f4fb0"
      unitRef="usd">1881000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="if9abd0ce724b48d1878bcaa4742736aa_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfOS0xMC0xLTEtNzc0MDc_eead4f55-d7ba-4ec0-bc39-9ebe4d6dc06d"
      unitRef="usd">881000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i13455fb6580c486fa719cf5f9b78801a_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTAtMi0xLTEtNzc0MDc_c461be11-678e-4d4e-89f9-8081c2cf3b9a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i17df52d9c169494fb0dbcfa0f99740fa_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTAtNC0xLTEtNzc0MDc_5c608119-8c88-4d65-bd09-5b400e8dc1d2"
      unitRef="usd">1884000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="iaf68b60de7014cf2a3fbb8410bc3a9bd_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTAtNi0xLTEtNzc0MDc_d059c771-27ec-4d2d-9c30-1ab0cb09ca53"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i4f13cabfbd6e4267a7040e78e38ec939_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTAtOC0xLTEtNzc0MDc_f65976cf-9bb3-49ff-ba74-259d0429ef75"
      unitRef="usd">1884000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i91092ba038134ef4a95f7a6d01647908_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTAtMTAtMS0xLTc3NDA3_cd781155-1cf2-4578-97e5-6207fef46763"
      unitRef="usd">979000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i2e55b859d5454474b61a342f2ab11b53_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTItMi0xLTEtNzc0MDc_f04f5d06-932a-4369-bd78-189f77cc7e37"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i01e0e3590e6e48db894610a47ecd29c5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTItNC0xLTEtNzc0MDc_c6b1623b-3b19-48cd-80f6-67c56e380baf"
      unitRef="usd">3765000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTItNi0xLTEtNzc0MDc_41a4c69f-23e3-4f51-9b49-458f180d0e18"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTItOC0xLTEtNzc0MDc_f68c242b-0406-4c2a-a9a4-d3881910b57f"
      unitRef="usd">3765000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i57a26835dc1c47168bfb6605e72bd3bf_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTItMTAtMS0xLTc3NDA3_77684a4d-5db4-4d71-8305-77ac88d592e5"
      unitRef="usd">1860000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ic9edf61dadd24a7a89bfd4eb35fdb595_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTUtMi0xLTEtNzc0MDc_6bbf0de3-670b-44bb-b60f-81fd88e3b42b"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ie5ec42981eb24a7b8f39e90fcfcb3b97_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTUtNC0xLTEtNzc0MDc_0776a2de-e7da-49d9-a0d0-30049070a7a8"
      unitRef="usd">178000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i7787c920b4fa4851a091b1d05760f26c_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTUtNi0xLTEtNzc0MDc_6ecdbf39-6f2f-41c4-8374-3d97e3ed3434"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTUtOC0xLTEtNzc0MDc_70908b88-d206-4ddd-93c6-927b30744dce"
      unitRef="usd">178000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="if9abd0ce724b48d1878bcaa4742736aa_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTUtMTAtMS0xLTc3NDA3_f6de4d8d-08cf-460e-91f8-805c37540a01"
      unitRef="usd">24000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ic9edf61dadd24a7a89bfd4eb35fdb595_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTctMi0xLTEtNzc0MDc_4906dba3-6cb4-4697-b619-92856f1f6dbf"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ie5ec42981eb24a7b8f39e90fcfcb3b97_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTctNC0xLTEtNzc0MDc_d336cf42-6d81-4d7d-811c-bed968895ff0"
      unitRef="usd">68000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i7787c920b4fa4851a091b1d05760f26c_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTctNi0xLTEtNzc0MDc_091c1f91-4537-402a-b8c8-090d4fc09ef4"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i2344f1a9eb1848e58cb6fe9b9a3e708b_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTctOC0xLTEtNzc0MDc_a3eb0089-a90b-410f-9b10-8eb5303e940a"
      unitRef="usd">68000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="if9abd0ce724b48d1878bcaa4742736aa_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTctMTAtMS0xLTc3NDA3_7ab98916-5694-4dbf-bfc9-fd4d82315cc5"
      unitRef="usd">28000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2e55b859d5454474b61a342f2ab11b53_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTktMi0xLTEtNzc0MDc_5819d7d6-d778-4bd5-954e-99be18413b3e"
      unitRef="usd">522000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i01e0e3590e6e48db894610a47ecd29c5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTktNC0xLTEtNzc0MDc_1a81273c-b389-4aae-ad88-5568ac3a902f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTktNi0xLTEtNzc0MDc_9a370408-95fa-4006-9c5a-fab590ec1338"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTktOC0xLTEtNzc0MDc_cdc5f7c4-a72c-4dbd-8c17-14ed156dc6a3"
      unitRef="usd">522000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMTktMTAtMS0xLTc3NDA3_55a99c1b-b28b-4979-9257-02442f9a9d1e"
      unitRef="usd">1884000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e55b859d5454474b61a342f2ab11b53_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjAtMi0xLTEtNzc0MDc_2109db0b-9b55-483c-b05b-7c0b7637a9f2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01e0e3590e6e48db894610a47ecd29c5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjAtNC0xLTEtNzc0MDc_75a0a63b-993e-415c-b4d4-49ade5414f83"
      unitRef="usd">22124000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjAtNi0xLTEtNzc0MDc_bb9503ad-2f13-4332-808e-0518e4d5791f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjAtOC0xLTEtNzc0MDc_cffeb7d5-c84d-4721-8663-5f6aeaa2ccff"
      unitRef="usd">22124000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjAtMTAtMS0xLTc3NDA3_eb9cc727-1005-4f07-8271-ebe7b41eb8d8"
      unitRef="usd">19727000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2e55b859d5454474b61a342f2ab11b53_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjItMi0xLTEtNzc0MDc_26e7571a-5674-486a-9210-01395f16723a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i01e0e3590e6e48db894610a47ecd29c5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjItNC0xLTEtNzc0MDc_98bf727c-78af-47d9-84eb-0daaefd4204e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0145a4a0e4324a37a4caf33ea96b45a6_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjItNi0xLTEtNzc0MDc_12bc1c19-abda-4bb1-89c8-e53de8bd9809"
      unitRef="usd">525000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjItOC0xLTEtNzc0MDc_f925e83c-9afe-48ce-8dfd-02baf8226f5b"
      unitRef="usd">525000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNmODRiZGRmYTA0NTQ4Zjk4YmY0MzgwOGI3OTM1MDQyL3RhYmxlcmFuZ2U6M2Y4NGJkZGZhMDQ1NDhmOThiZjQzODA4Yjc5MzUwNDJfMjItMTAtMS0xLTc3NDA3_11cad7d6-bbb2-4040-8c9a-b5d2b698b197"
      unitRef="usd">533000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfMi0yLTEtMS03NzQwNw_125a2ac5-63b3-4016-8db7-cd546006e368"
      unitRef="usd">4653000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfMi00LTEtMS03NzQwNw_4e6d2cf7-ccc4-4445-a550-dd24571b0b9d"
      unitRef="usd">1360000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfMy0yLTEtMS03NzQwNw_b3b4ba01-953a-449d-94c7-72806d52783c"
      unitRef="usd">4440000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfMy00LTEtMS03NzQwNw_702fb190-85fe-44ac-b338-529c17ea73a7"
      unitRef="usd">1285000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNC0yLTEtMS03NzQwNw_7431bfe0-ec8e-41ba-8384-b4a92be0362b"
      unitRef="usd">213000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNC00LTEtMS03NzQwNw_8c03a22d-0757-4e49-bdaf-6d7db0c3c486"
      unitRef="usd">75000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNi0yLTEtMS03NzQwNw_143c784d-ace3-4140-bee0-8b1b1e13eb0c"
      unitRef="usd">3833000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNi00LTEtMS03NzQwNw_9263177f-78a1-428f-a150-7f7a6e2189ac"
      unitRef="usd">1888000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNy0yLTEtMS03NzQwNw_f6af8a52-c092-400f-8e47-c27f77838f78"
      unitRef="usd">3636000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfNy00LTEtMS03NzQwNw_d646bc49-2632-4775-9b6e-db53b6f17fa8"
      unitRef="usd">1855000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfOC0yLTEtMS03NzQwNw_e11e2435-924c-4c01-9a50-c3e5fd2fdfec"
      unitRef="usd">197000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjc0ZDU0YWIwOTAxMzRjZDM4YjQwZTdlYzdlMTQ3OTBkL3RhYmxlcmFuZ2U6NzRkNTRhYjA5MDEzNGNkMzhiNDBlN2VjN2UxNDc5MGRfOC00LTEtMS03NzQwNw_a1e36792-d3bf-4b1c-a0b8-bbbf7d12dd38"
      unitRef="usd">33000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6295bb2d9d624931bd4df9123d80c9d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfMy0yLTEtMS03NzQwNw_29862f22-4b89-47c2-a388-951d937a3723"
      unitRef="usd">533000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i7466db7fb3de4e73b837ebe5f0b10609_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfMy00LTEtMS03NzQwNw_cba9b616-656f-43de-ba04-aea470bf428f"
      unitRef="usd">633000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNC0yLTEtMS03NzQwNw_d4a53770-cd40-4523-a208-afea61fa6ac7"
      unitRef="usd">-85000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNC00LTEtMS03NzQwNw_287d4364-3b49-4709-bc7e-cfc66506596a"
      unitRef="usd">28000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNS0yLTEtMS03NzQwNw_c507c220-6c70-4e14-ad37-4cbfad7c977b"
      unitRef="usd">89000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNS00LTEtMS03NzQwNw_61620eb2-f5a6-4c22-9ecc-310183ab00d5"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNi0yLTEtMS03NzQwNw_d1e7bf02-8b58-4832-a1ad-0b2d93ab55a6"
      unitRef="usd">12000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNi00LTEtMS03NzQwNw_15c89d91-fca9-42fc-9410-b431377d9663"
      unitRef="usd">48000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNy0yLTEtMS03NzQwNw_756db0ed-63e1-434f-9be0-cb3ad7f45cee"
      unitRef="usd">525000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie4184dedf017492f81476885b7412820_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjYyNWYzOTczMzgyNzRlNjU4OTAyYzA0Yjk4ZmQyN2I5L3RhYmxlcmFuZ2U6NjI1ZjM5NzMzODI3NGU2NTg5MDJjMDRiOThmZDI3YjlfNy00LTEtMS03NzQwNw_e84809b8-9da9-4809-81c6-29df01de783b"
      unitRef="usd">613000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i38e80c564ea64f3fbe9520902829f8e1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTA4NA_b78ef0f0-c346-4448-a630-9081f50c4c0c"
      unitRef="usd">1884000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i12c14427081a4db2aa89c55987a2b503_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTE1Mg_41b9bab7-8f2b-400d-b383-5606c5522568"
      unitRef="usd">533000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0dab1f127dfc4cc180ee120f93e8d77b_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTQwOA_91da519b-883c-496c-a26c-0cd7c50be8b7"
      unitRef="usd">507000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4a3800ae61df48de8d071ba58133741a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTQyMw_0f839a28-68ae-4144-a004-a56eb2061bde"
      unitRef="usd">520000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id965e9daba4e49939bc440149dcc9a39_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTUyMA_baa95c2d-f089-4beb-a6db-8d57a77de24c"
      unitRef="usd">18000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if15f41a6eac24347aff0d98e523e6a33_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfOTUzNQ_88a9a0e2-2515-4767-aa1b-c375f6af0d3f"
      unitRef="usd">13000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2ODk_0f1693f4-4939-4043-bf78-b7487218fc54">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents and current marketable securities as of October&#160;2, 2022 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.664%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain/( Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. sovereign securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMS0xLTEtMS03NzQwNw_e89f47c4-6107-4293-a4be-d4ed2965131f"
      unitRef="usd">4037000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMS01LTEtMS03NzQwNw_17ab715c-09cc-4d62-92dd-1947b0c39f69"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMS03LTEtMS03NzQwNw_0baa273b-1bed-48a6-8e5d-111b72cff342"
      unitRef="usd">4037000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMS05LTEtMS03NzQwNw_587c8e12-0102-41d8-bcf2-cf34f3e03deb"
      unitRef="usd">4037000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i5015e22f0f7e4b9694c5c8aebd63cf7a_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMS0xMS0xLTEtNzc0MDc_8d10fca8-8aac-4461-90ec-d75cf55a4a3d"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMy0xLTEtMS03NzQwNw_d8c110af-274f-4388-92f7-56f26ff9ff9a"
      unitRef="usd">389000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMy01LTEtMS03NzQwNw_2e1a433d-8435-4a43-8edf-4a91301dbad5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMy03LTEtMS03NzQwNw_c53f4eca-8d4d-42ec-af1e-ed3d1339f303"
      unitRef="usd">389000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMy05LTEtMS03NzQwNw_b5fe09c9-f7e7-4a12-986e-3b5acdddcf43"
      unitRef="usd">89000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3b4d4f767aec442ca5bed7ef94f8c6a0_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMy0xMS0xLTEtNzc0MDc_14bb8e13-6a44-4e8a-a672-27d95a069b0a"
      unitRef="usd">300000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNC0xLTEtMS03NzQwNw_7816c183-fba0-47eb-851e-91e6efaa1681"
      unitRef="usd">2541000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNC01LTEtMS03NzQwNw_b18707be-c286-42d4-b1e9-0fdbda918cab"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNC03LTEtMS03NzQwNw_d9ccfd88-7fba-4ce5-bb1e-314004cf5539"
      unitRef="usd">2541000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNC05LTEtMS03NzQwNw_76df08a3-e3fc-4c2f-8f72-8d866790d05c"
      unitRef="usd">2541000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i1b7d8b1c4a81478a85a6d5e1f84bcb5d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNC0xMS0xLTEtNzc0MDc_b35d74e4-5d03-4d04-a2aa-2403ae6d7c0d"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i298d351dbfee46d79686114bc7415cde_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNi0xLTEtMS03NzQwNw_b6d4ed92-9e06-41d6-bb33-d9b329de6c89"
      unitRef="usd">2544000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i298d351dbfee46d79686114bc7415cde_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNi01LTEtMS03NzQwNw_accef0d4-0b12-42a2-8fe7-a04d2bca897e"
      unitRef="usd">5000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i298d351dbfee46d79686114bc7415cde_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNi03LTEtMS03NzQwNw_155dd513-1657-47bb-8da1-29bee7d0ef47"
      unitRef="usd">2539000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i298d351dbfee46d79686114bc7415cde_I20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNi05LTEtMS03NzQwNw_c986dcc6-04dc-4db7-9968-e27c24e0c73e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i298d351dbfee46d79686114bc7415cde_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNi0xMS0xLTEtNzc0MDc_16b81e7b-0ff1-4db8-8fad-a8926334bc1e"
      unitRef="usd">2544000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNy0xLTEtMS03NzQwNw_dce57bb0-a7ed-449e-a8ff-5a9cdee1c152"
      unitRef="usd">1516000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNy01LTEtMS03NzQwNw_7632e851-866a-4447-a3e4-6b30f5bfd888"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNy03LTEtMS03NzQwNw_754ccd6b-1efa-4519-bcb8-7113baae0e46"
      unitRef="usd">1516000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNy05LTEtMS03NzQwNw_4107175b-66ef-48ea-8235-7ac9c3817e70"
      unitRef="usd">1516000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8a66031bc9654340b1ee5fbc2fda0a19_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfNy0xMS0xLTEtNzc0MDc_b0b2fe73-5562-4b8c-bf6d-f2f940a0a003"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i8bfc8f6514464a3799d65367ae9e9037_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOC0xLTEtMS03NzQwNw_97f9c578-6e34-4175-baf7-6e0bc5e44f1a"
      unitRef="usd">928000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i8bfc8f6514464a3799d65367ae9e9037_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOC01LTEtMS03NzQwNw_9835c1ef-b6f1-45da-958b-37321d8ab130"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8bfc8f6514464a3799d65367ae9e9037_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOC03LTEtMS03NzQwNw_9e14080d-e17f-4851-a4a6-034beeaa2e90"
      unitRef="usd">928000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8bfc8f6514464a3799d65367ae9e9037_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOC05LTEtMS03NzQwNw_b79eaf7e-2966-4301-b49b-a25792ff4bd5"
      unitRef="usd">928000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8bfc8f6514464a3799d65367ae9e9037_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOC0xMS0xLTEtNzc0MDc_5c797441-b77c-4c03-ad00-c5fcf4775940"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="iacffb22cdad9443a846f401be599d84d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOS0xLTEtMS03NzQwNw_67c90087-1ac6-438e-92ad-0f3db5f45ffc"
      unitRef="usd">11955000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="iacffb22cdad9443a846f401be599d84d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOS01LTEtMS03NzQwNw_8a0dfae0-3753-4d89-b544-160b64953099"
      unitRef="usd">5000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="iacffb22cdad9443a846f401be599d84d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOS03LTEtMS03NzQwNw_8ff23838-764d-4950-a09c-34741c2f1aa9"
      unitRef="usd">11950000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iacffb22cdad9443a846f401be599d84d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOS05LTEtMS03NzQwNw_48d7adc1-1ca0-40dc-bbcf-437d57e028c2"
      unitRef="usd">9111000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iacffb22cdad9443a846f401be599d84d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfOS0xMS0xLTEtNzc0MDc_745959d9-1647-4fc5-b1d0-28c50a09a731"
      unitRef="usd">2844000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i07d551fd651b44dc8ea8cbf5d62affe2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTItMS0xLTEtNzc0MDc_18db9e1b-e39c-48ab-983c-a4bb43250956"
      unitRef="usd">21930000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i07d551fd651b44dc8ea8cbf5d62affe2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTItNS0xLTEtNzc0MDc_ebffa19b-b785-4d56-a245-971ea4108bc6"
      unitRef="usd">48000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07d551fd651b44dc8ea8cbf5d62affe2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTItNy0xLTEtNzc0MDc_9792bfe5-18fb-4347-9ab7-f0ab7b7501e6"
      unitRef="usd">21882000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia3f1d898f0d04ab99472e9d1769191c9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTItOS0xLTEtNzc0MDc_44cd1be3-2628-4054-8257-b9994ef26d87"
      unitRef="usd">2189000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ia3f1d898f0d04ab99472e9d1769191c9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTItMTEtMS0xLTc3NDA3_4a4677ff-5bb1-4a82-9aa2-643190e6ca75"
      unitRef="usd">19693000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic52ecafdfee4446badc41ecd13c9f2a2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTQtMS0xLTEtNzc0MDc_8233e231-c836-4a0d-a5eb-af755047b7c7"
      unitRef="usd">243000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic52ecafdfee4446badc41ecd13c9f2a2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTQtNS0xLTEtNzc0MDc_8a7332fd-6068-4c2a-9085-37c9e53482e1"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic52ecafdfee4446badc41ecd13c9f2a2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTQtNy0xLTEtNzc0MDc_e092b877-665b-408c-88bd-0aaf14df5c1a"
      unitRef="usd">242000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i980e7f0f06314813b0a382c339d86df1_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTQtOS0xLTEtNzc0MDc_c4dabbb2-a4b3-4cff-87f8-d70b3f99e803"
      unitRef="usd">55000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i980e7f0f06314813b0a382c339d86df1_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTQtMTEtMS0xLTc3NDA3_58cb0a09-1097-4173-a063-248cd9d62c38"
      unitRef="usd">187000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTUtMS0xLTEtNzc0MDc_ee60af32-b3a9-4501-85e9-f0c5593ea9e7"
      unitRef="usd">22173000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTUtNS0xLTEtNzc0MDc_4cf75330-294a-49cd-acca-207984bb37cb"
      unitRef="usd">49000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTUtNy0xLTEtNzc0MDc_1a606e16-8878-424b-955c-6da9ad2975c8"
      unitRef="usd">22124000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTUtOS0xLTEtNzc0MDc_2f7761a1-56aa-4914-aefe-175c07ff4e88"
      unitRef="usd">2244000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ibbf76f62eaed4310a7b7bb55a1cf6917_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTUtMTEtMS0xLTc3NDA3_a0d99d95-1002-4cd9-82b4-0df30f49ed28"
      unitRef="usd">19880000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTYtMS0xLTEtNzc0MDc_71b3848e-83b4-44c1-b783-7b2cd4e18c24"
      unitRef="usd">34128000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTYtNS0xLTEtNzc0MDc_f2533de6-128d-4253-a335-2b375ecaa24a"
      unitRef="usd">54000000</jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTYtNy0xLTEtNzc0MDc_e1b92c3a-2cde-4d46-af7a-1e52288e2b24"
      unitRef="usd">34074000000</jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTYtOS0xLTEtNzc0MDc_67bca0da-1309-46ab-b55f-c4e783f8b8e9"
      unitRef="usd">11355000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjNhMTQ2Mzk2NmY3ZDQ4MjFiYTBhMDM0YmVmZDY2YWJhL3RhYmxlcmFuZ2U6M2ExNDYzOTY2ZjdkNDgyMWJhMGEwMzRiZWZkNjZhYmFfMTYtMTEtMS0xLTc3NDA3_d2415f8d-c67f-42e4-9ee5-6b3b9bda313a"
      unitRef="usd">22724000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2NTA_0d7f2ab6-b2a1-49be-ad21-e85e0b931c62">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2Njk_e023e9c2-c7e4-4717-bd5c-5d9de6a86226">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of October&#160;2, 2022 are as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMS0yLTEtMS03NzQwNw_452d2632-ae94-4591-9c61-c414e3916681"
      unitRef="usd">22153000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMS00LTEtMS03NzQwNw_fb414c27-241b-4bc5-a8ba-a8e79b0cb253"
      unitRef="usd">22104000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMi0yLTEtMS03NzQwNw_135850c4-0dec-410c-b26c-1320748bdedc"
      unitRef="usd">20000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMi00LTEtMS03NzQwNw_8e8798d1-480a-4cba-b57f-bcb33f46c758"
      unitRef="usd">20000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMy0yLTEtMS03NzQwNw_04f2b6a9-d0b9-466c-a6be-93e3c06d5421"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfMy00LTEtMS03NzQwNw_d9e8ca81-0970-4cff-9010-8040dc911c64"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfNC0yLTEtMS03NzQwNw_d9aa4266-f7ec-4af1-93ae-015db0c600af"
      unitRef="usd">22173000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOjFmNDllZTRjYTRlYTQ1ZDk5YWIzMjlhZDViOThlYmI3L3RhYmxlcmFuZ2U6MWY0OWVlNGNhNGVhNDVkOTlhYjMyOWFkNWI5OGViYjdfNC00LTEtMS03NzQwNw_029f56d2-e737-4521-aead-e1c15dd90634"
      unitRef="usd">22124000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE2NjA_6b0245e9-222a-48aa-be2e-ee7f8503e1eb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of October&#160;2, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73% Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 0.9712)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500MM GBP 1.0908)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.550% Notes due 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 0.9712)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 0.9712)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="i9006cebe9baf49098f28b71ba8b0b364_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNC0yLTEtMS03NzQwNw_3dfc95c4-ded7-4198-a519-30052389b7f8"
      unitRef="usd">4424000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i7e6b7c5e255f431184d25955b77d4780_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNC00LTEtMS03NzQwNw_07a45922-9a04-4475-944d-541590340d05"
      unitRef="usd">4422000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0157c2d40621415cb530f8b4f529c1d8_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNy0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmI5ZjcxMTMxZTJmODQwMzk4NWQ1ODE1NjhjMDMxYmUxXzQ_15bf2977-b8ed-4ce8-b141-809654e46626"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i09041d6f39a84ccea0a739091619c846_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNy0yLTEtMS03NzQwNw_8520ba88-8133-4478-a724-5aeef0894128"
      unitRef="usd">250000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i262548be13894c1896c025888251703e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNy00LTEtMS03NzQwNw_036ecc0f-e93a-4b1b-985d-17352e8a4d67"
      unitRef="usd">256000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5de5b6e1d4334a008a1d9c060b09147b_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfOC0wLTEtMS03NzQwNy90ZXh0cmVnaW9uOmZmZTc3NzMzNGM4YTRiYTRiYTRkY2E0YjhiMTk5ZjcwXzQ_b0b7ee92-ff5d-48af-800e-01b410f7ecf8"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i870bf42cc2f24c9ca6e75df10312d19f_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfOC0yLTEtMS03NzQwNw_3c47e0b4-659e-4398-aa74-58c609eb1a91"
      unitRef="usd">802000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i94e04502c4854e9099be4395f58835e5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfOC00LTEtMS03NzQwNw_d068f133-d5a1-43b7-a207-6154264488f7"
      unitRef="usd">797000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie9d2496e033944a6858188b916c2ec78_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo4MDU1Y2ZlZTJkMjY0ZTdhOWVlMWVmOTJkYjY1YzIzZV80_7b0cebc7-c1f5-4878-aa3f-39178af5b813"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie9d2496e033944a6858188b916c2ec78_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo4MDU1Y2ZlZTJkMjY0ZTdhOWVlMWVmOTJkYjY1YzIzZV8yMw_9d12f485-1729-4866-b7ba-239435dfacdc"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ie9d2496e033944a6858188b916c2ec78_I20221002"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo4MDU1Y2ZlZTJkMjY0ZTdhOWVlMWVmOTJkYjY1YzIzZV8zMw_f0fba65a-b82b-4126-93de-e1fa8e807d60"
      unitRef="number">0.9712</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2b4f83eb2b694aaebcf4695cd84e55b9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTAtMi0xLTEtNzc0MDc_a9cfcc38-b4df-41ed-bc8c-7ac442e95d85"
      unitRef="usd">722000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i70cc3db8241b44bdadd5529cad658578_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTAtNC0xLTEtNzc0MDc_a2a6b76d-880e-4b5c-9a37-4e94b733a7f9"
      unitRef="usd">702000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i030634cc2bab40ba860c6310273384f3_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTEtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjowZDI1ZjdlMGE5YzQ0NmU0ODE5NWU3MTdiNDFjZWM2NF80_be68491a-82f5-481c-91f8-772d46324dbe"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i030634cc2bab40ba860c6310273384f3_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTEtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjowZDI1ZjdlMGE5YzQ0NmU0ODE5NWU3MTdiNDFjZWM2NF8yMw_04fbe35a-f093-4770-891e-9cef1e817af0"
      unitRef="gbp">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i030634cc2bab40ba860c6310273384f3_I20221002"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTEtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjowZDI1ZjdlMGE5YzQ0NmU0ODE5NWU3MTdiNDFjZWM2NF8zMg_b5514766-46df-4971-9004-a39ac7c2e020"
      unitRef="number">1.0908</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ida226c289b3d44c98e6aca58fd729233_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTEtMi0xLTEtNzc0MDc_c2dca628-9e07-42e0-bb6d-bfdd29fdb9b8"
      unitRef="usd">544000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1ed802dd203a43d3afa9f1915bf381d2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTEtNC0xLTEtNzc0MDc_1309b618-69ca-4204-9657-386288b06925"
      unitRef="usd">548000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i38954d1e3098492e806481f25cf864c8_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTItMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxMTdhN2JlYTA4YTA0ZTI5YjNmNTQ1MGIwM2Q2NGQwY180_8a1f866d-fa2c-4a3b-ac1f-2dfa99d9a254"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8507feada10d4116ae4715be0f83f61b_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTItMi0xLTEtNzc0MDc_cc42b064-4982-46a0-b50e-7b6d585f1fc0"
      unitRef="usd">749000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic33663885e724dba955223059c45014c_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTItNC0xLTEtNzc0MDc_4682649c-d047-44e7-b329-452b63d9666d"
      unitRef="usd">721000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3220255239e4430e8bc071481c23af70_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTMtMi0xLTEtNzc0MDc_b83ccf56-7368-4772-98d1-b60bdaae18fe"
      unitRef="usd">922000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id2ac596ef8054dd9bec84c0c13239c57_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTMtNC0xLTEtNzc0MDc_1c3654a8-8902-4f46-88b9-faf8e078c969"
      unitRef="usd">826000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i463dccc9a3684c049eac0a5bb39ebf77_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjowMGYzYWM5YzEwNzM0YjEwYmEwN2JkMjk4ZTk5ZGM5Zl80_a32a1c83-1438-4e13-abe9-96445284a9b0"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5f76f6e1c7584e90bdce33b5939f49fe_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTUtMi0xLTEtNzc0MDc_5b14d7c3-69f4-492d-883f-02893e81696c"
      unitRef="usd">1996000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id4e881a6337c48eba78aa5737f820648_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTUtNC0xLTEtNzc0MDc_ce1d3b03-41c0-481b-9914-b588dc90f738"
      unitRef="usd">1868000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibf9913e7637b4fefad4d9411b1e57dda_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTYtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjplZDVhZWY1MWJhMWM0NmE1YThhYWIwOTZmMDA3MmIzMV80_e2c3082d-bb63-4844-8efa-691ab08e6489"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2c801bf0bfb74c4fb7e197403e0c19da_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTYtMi0xLTEtNzc0MDc_68040224-2629-4741-9a9a-3c64d11e7826"
      unitRef="usd">877000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7e9ef1c58573413fb263475037c7df0f_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTYtNC0xLTEtNzc0MDc_c568f926-574f-442e-8542-5ac69b46f571"
      unitRef="usd">829000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iec007660d14f41158b78244410752ef6_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTgtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo2OWJmYWFkODg0MGY0NjI1YjBiZWMxNTYzYzk1ZTJkYV80_d52a9e55-4e14-4371-abc0-c4a562aa7804"
      unitRef="number">0.0095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib01c6007919844dc8a0fff621af91ba7_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTgtMi0xLTEtNzc0MDc_23d3fc82-3140-44f6-830b-cc3cfb8074c9"
      unitRef="usd">1396000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1cefb1e606b8454bbae8580ad29ba4e9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTgtNC0xLTEtNzc0MDc_9b4f477f-4a58-42d3-b194-3a4cfd22ceb8"
      unitRef="usd">1185000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idd59161e160443be992c19c3e552de73_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTktMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo3YTQwZDIxNDg2YWU0Y2I3ODVmNWVkYmI5MTkzNTA2M180_a8f5931d-d4b0-4dff-85e3-2f87c9ce271b"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i46bc9af826d04e288de22182a64ee453_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTktMi0xLTEtNzc0MDc_7fa321ab-e5c5-4036-a398-cd1c87a648ab"
      unitRef="usd">1496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0955f4509fed4180a52c8b18fe4c4b13_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMTktNC0xLTEtNzc0MDc_3c07f727-63b4-4999-9de8-3f13d1cb3111"
      unitRef="usd">1379000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5267d6a76fd344b9aae4d32ffcdb89ea_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjplOWY1MTQ3Y2I3ZDk0Y2VmYjNkMjg0MDY2OTU0MDJjY180_1a9ad378-7a14-4432-a326-75536399c4a4"
      unitRef="number">0.01150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5267d6a76fd344b9aae4d32ffcdb89ea_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjplOWY1MTQ3Y2I3ZDk0Y2VmYjNkMjg0MDY2OTU0MDJjY18yMw_a71e0de7-8500-4c19-9081-8406b9c9bc63"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i5267d6a76fd344b9aae4d32ffcdb89ea_I20221002"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjplOWY1MTQ3Y2I3ZDk0Y2VmYjNkMjg0MDY2OTU0MDJjY18zMw_b022d3ec-2310-4e86-9a8a-b5ed2cc09bea"
      unitRef="number">0.9712</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib1f362e68c5546b8b0891c1e060d692e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjAtMi0xLTEtNzc0MDc_b08c0748-54e0-4dee-aa4a-8f4532f52105"
      unitRef="usd">724000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib7a74be7a73c41d79f6e2392d1d60ea0_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjAtNC0xLTEtNzc0MDc_57c5a3f3-d722-4dd1-b7e9-1a33f88260d1"
      unitRef="usd">649000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib1bec1f0d9314920bb56531e382e7cdc_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjEtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo0NDViNjY4M2M2NjQ0MDE5YTU2MTA2YzkzYTA1N2Y2ZV80_4f43af8e-6189-4689-bd9b-60005e28e53c"
      unitRef="number">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id3efd972e13344cdb42226b639f85eea_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjEtMi0xLTEtNzc0MDc_0c98503d-d48b-4d4f-a16a-a8115a9f5900"
      unitRef="usd">298000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i60f419a473f34fb29199544a2c8cb16f_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjEtNC0xLTEtNzc0MDc_471e23f1-c9da-4908-b9d5-c22059367723"
      unitRef="usd">342000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i81460a08681c4e40ab454eff67450960_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjItMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpiNWJkZDgxMWM0OTI0MTdjYTBlOWEyMDUxNzhiZGJlM180_86293598-ae61-4dfa-8e9f-dfd059a5408c"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i78f4c5055c844c61bdbada64f0290039_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjItMi0xLTEtNzc0MDc_f9f61326-2f22-48e3-9704-cc093ba0127f"
      unitRef="usd">1606000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaa22322ad88f4cfebf3bdcb75ad25975_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjItNC0xLTEtNzc0MDc_8843941b-73f0-4907-86ee-9635d70f6046"
      unitRef="usd">1276000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i06fdae26fcfd4a60b871ade74a542ac4_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjMtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo4ZTg2ODk0MDVmNjI0ZjRhYjNmODg0NDMwNDVhNGFhNV80_362bedf7-b1a0-4464-b37b-1d31f54ada1d"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i32266ba4f72e43a792a31e7faa9148b2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjMtMi0xLTEtNzc0MDc_35e400d2-ea39-4643-9e59-1622524b365a"
      unitRef="usd">498000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id940c82927a641158fe648918accafc9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjMtNC0xLTEtNzc0MDc_47c6d73b-c8f9-4f6b-ae02-4df31986143a"
      unitRef="usd">507000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if847a21b92f348a0b7a4025c882fc0e2_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjQtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo5NDUyN2U3NTMxMjE0ODY2ODc4OGM3M2JhZTMzMDU4OV80_73d65011-4875-4b18-9465-0feba2c43dff"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8d6a26673c434118a68c645642b3fbc4_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjQtMi0xLTEtNzc0MDc_b07c01f5-0aee-4d55-90c3-8e02cdb23338"
      unitRef="usd">855000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3f89bf72f2ba4b478472d343bdeec569_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjQtNC0xLTEtNzc0MDc_e5d5d048-3870-4ee2-8441-5d8746213d5c"
      unitRef="usd">820000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i29078fb071994051bd63d8f4587eb909_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoyZThlOTk0MThlMWU0NWY0YmUxZmU0YWM4ZTY1MDkzZV80_8c1e40c4-f2ee-4c5e-906f-8ec1a3eb880f"
      unitRef="number">0.01650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i29078fb071994051bd63d8f4587eb909_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoyZThlOTk0MThlMWU0NWY0YmUxZmU0YWM4ZTY1MDkzZV8yMw_37c1dbdd-d621-47e5-a629-458e4771b55a"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i29078fb071994051bd63d8f4587eb909_I20221002"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoyZThlOTk0MThlMWU0NWY0YmUxZmU0YWM4ZTY1MDkzZV8zMg_049baf8a-f1a7-4060-a424-39519f91058b"
      unitRef="number">0.9712</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i29078fb071994051bd63d8f4587eb909_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjUtMi0xLTEtNzc0MDc_6e432337-169f-4b5c-ba77-1b9eeb6c37a9"
      unitRef="usd">1450000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8851eff20e5145c5bca1a1ee92617a5e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjUtNC0xLTEtNzc0MDc_aa05ab9f-848e-4ea1-b29d-e0f2f420132e"
      unitRef="usd">1181000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i477c86f7309842dfb55248451d3efa39_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjYtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxYTk1ZTAyMTJmMTA0N2E3YWY5Nzk4MjI2Yjc2YTQ1Ml80_efc8e399-c0a5-42b7-a93e-926226160777"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2ca4d871cf6b437582cda14e89bb594b_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjYtMi0xLTEtNzc0MDc_0849ef83-c939-4ee8-8695-230b6731bd79"
      unitRef="usd">841000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9c7dc65157e44d3aba2a140b03b946b1_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjYtNC0xLTEtNzc0MDc_7adcf267-63e0-42f7-b377-1b1af8257417"
      unitRef="usd">726000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib89592a0e11e4753b648c5e3cc03ee9e_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjctMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxYjFhMDQ1OGFkNDE0NjBhYjY1NzA1ZGZjNGM1ZGMxYV80_8e5e7f5c-4a9a-4641-a375-84f628655e85"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i36742f2d0f1f4ab8a7597150249a02bf_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjctMi0xLTEtNzc0MDc_72632a99-c00f-4d62-9722-514056af4e3a"
      unitRef="usd">993000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i733cb704b7674b0e9a24cc4ab884180a_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjctNC0xLTEtNzc0MDc_ca72fe71-2358-4d57-baae-c41b60151acd"
      unitRef="usd">1074000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iae69d4e77db7465fb0571ca12ef0fff2_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjgtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoyOGIxMWQ4M2Y1Mjg0NGM5YWNkOWFhNmQxN2U0OTJkMF80_8def504b-3f23-46c2-92f4-fb33f4c5ae12"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic4ff5147e1a54074a2362ad5feee7c65_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjgtMi0xLTEtNzc0MDc_3ab64fdb-902f-46e2-9c7b-c85efed0ba86"
      unitRef="usd">1334000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia452af2ce27e4af2a660f83bf6fbda90_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjgtNC0xLTEtNzc0MDc_c6f30371-2cbf-4011-8796-5aace8fb229f"
      unitRef="usd">1154000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6b7612a89a5a4d3e9fddec30bc11ee22_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjktMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjozZWNiYWUxMjlhYWY0ZGFmYjc4NzcxNzU0ZDhlMWJhZV80_ac5e3ba3-8312-4c45-90aa-74e09859ee29"
      unitRef="number">0.0340</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8534a543c9964871863c7e4c16232cb4_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjktMi0xLTEtNzc0MDc_3b90a500-edcc-49a1-869c-d69ccb948358"
      unitRef="usd">992000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6a53e2b415aa46dba827a399ff3c0318_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMjktNC0xLTEtNzc0MDc_aa29a10b-2743-4f4d-ad97-298e4216b0ab"
      unitRef="usd">822000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23e399c422d04b4c9802c29f75c01f77_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzAtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo5OWJmZjA3ZWMwN2U0NzhlYjQwOTFhOGY0YTZiMzM1MF80_0fcd1d26-cd74-4ec9-97f4-1c5b55594b8c"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i515258d897424d1d91d0dd5e6ba17edb_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzAtMi0xLTEtNzc0MDc_0e3bde78-fe2a-42e0-adcc-0193135abe74"
      unitRef="usd">697000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i57ec40d315b946f2b9c6a729deef3a36_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzAtNC0xLTEtNzc0MDc_54391f99-603b-422b-ac4a-d8bbdf02ba92"
      unitRef="usd">747000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1f6e82e7b82a4263986c8f5f799e01aa_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzEtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpiZThhMTk0YjlkMGU0NzQ5OTBlNTVmOGVjMjIwNGNhYV80_3f523171-7895-4c2f-bb25-484187d1600d"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i331180abea9a4581bd4f74309a491129_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzEtMi0xLTEtNzc0MDc_c3807ad1-ea79-40c6-a157-2b668240e3c0"
      unitRef="usd">540000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2a76440ea8554d14aface7459e0c118e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzEtNC0xLTEtNzc0MDc_c6ee3c6c-94ab-43fe-b9aa-0b1e97417b86"
      unitRef="usd">506000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id71489b63d304114b1ee5ae439e5265d_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzItMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjplNDY4M2Y5NzI0MGQ0N2RhOWY1OTkxZWZjMzFiZjQ5N180_20854e30-1f1f-419a-8f59-306a86389133"
      unitRef="number">0.0210</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3f32d63a3ac54710b81b92f90e389147_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzItMi0xLTEtNzc0MDc_fac2a18b-2ef6-454d-9e50-e940e4b0434b"
      unitRef="usd">827000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i04beb44383334787802dafc265394766_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzItNC0xLTEtNzc0MDc_7b27940d-2c61-42bc-bf54-6dddb4e7e768"
      unitRef="usd">551000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic8ab907b696a4139a072f00b70bbda49_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzMtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo3NTBhZTExYjMyYWQ0OTBhOTBjMjljMmRiNWRhMjU3ZV80_05e28d5c-984d-4a42-9011-da56f20ff9d3"
      unitRef="number">0.0485</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i725d5d1c65b54fe9961ae484ef90be5e_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzMtMi0xLTEtNzc0MDc_52f79f06-bbca-410f-8d31-0f1a73f27eeb"
      unitRef="usd">297000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i165e3f370fbf46ed93bf4cce9e54727f_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzMtNC0xLTEtNzc0MDc_f2603218-0d7a-4304-ae29-571991b87020"
      unitRef="usd">291000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i428e006eac404991b3e3d872ddd1c1f7_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzQtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo0YTk0NjQxM2MyMzU0ZDkyOTA0MTJhNTQyMDJhMjljZl80_1dc53928-f6b0-4dd7-b324-1134c791c9ee"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9b9310bb6dc4450490632d0116946ede_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzQtMi0xLTEtNzc0MDc_e114f258-1121-457f-b5bb-91c826263ece"
      unitRef="usd">496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id11fe423cd3a474cb70088616178415a_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzQtNC0xLTEtNzc0MDc_25050221-e82b-438b-8a5c-ff37377bd378"
      unitRef="usd">457000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia36a4cef5d4f402fbd7eac9f85a18b17_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzUtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjo4NmQ5Zjk3MmE4ZGQ0ZTZjOTAyOGQ0YTA3ZTA5MzY5YV80_9a7df79b-ff71-4482-9a93-f9c26e6f631b"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i86512b1f50de4ad88f542164448d26c1_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzUtMi0xLTEtNzc0MDc_3d86ada1-c94c-45ec-a35a-3a58576293d6"
      unitRef="usd">1976000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iff6bcf8520fa4057a7f4a5589d4684d2_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzUtNC0xLTEtNzc0MDc_ae0d5bff-e0f1-4a90-a318-634920c28510"
      unitRef="usd">1626000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia2b9b9e93ec74f2b850cf4cacc8bbe2b_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzYtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpmZTg2OGRkZjM3OGI0YjdkOWYxMDNlZjNkNzZiNTU5Yl80_5d7bdedf-cfc2-4119-8c37-2387fb53a767"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i12550a2b68084f8b9214b4faeb85013d_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzYtMi0xLTEtNzc0MDc_2e065bbf-4a03-4e32-b666-54a95c798a38"
      unitRef="usd">811000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5c6f68f74915492181e040fe2b309c71_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzYtNC0xLTEtNzc0MDc_4d71d918-255c-4ba7-a348-3022579382dc"
      unitRef="usd">668000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic72911776cd542c5852cd1d5ca05062f_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzctMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoyZmNhMGE5OTYzM2M0NmFhYjlkOGU1MTczOTFhYTU3Zl80_78762afb-a544-4ace-8835-2bc945b7309a"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4e72ec4950db4ec699a1131d9548a556_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzctMi0xLTEtNzc0MDc_6affa024-256a-4f31-9708-e9e782aa87d7"
      unitRef="usd">743000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic668dba37a974482a824018731b483bc_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzctNC0xLTEtNzc0MDc_c00541ca-6c26-44fe-8fb6-0c207239ac28"
      unitRef="usd">593000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i955013ec18f9497e9a9c99fee52c731e_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzgtMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjoxZjRhOTMzNzg0MTQ0MzQ0ODA0ZWNlZDI2ZWI4MzkyNF80_7d34eeed-687a-400e-b56b-892f58f99727"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2fe780e81ace4f5c8b98dcf4b0ac0e21_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzgtMi0xLTEtNzc0MDc_502b4678-241a-48b2-85e0-97c577890e5d"
      unitRef="usd">809000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7deba806ae124861960bbc06843762d7_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzgtNC0xLTEtNzc0MDc_b99db3b4-4079-4b08-a16e-5c1bba8bfa1b"
      unitRef="usd">500000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0861e096ce334fdfae380bc7f0d69b72_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzktMC0xLTEtNzc0MDcvdGV4dHJlZ2lvbjpjYmJkOTVhYjUwNzE0NWY2OTk5NTE5NDE1Njg0YTNmZl80_a1a68f78-c51e-4889-a534-5513629b3b91"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibbdbc1ee962e45f7901626232a02576c_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzktMi0xLTEtNzc0MDc_8444d36b-e7c7-4945-abc0-e15f81fd9bd1"
      unitRef="usd">1054000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iffbcba0a9b874fb6b9472d4fa8d72638_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfMzktNC0xLTEtNzc0MDc_54ddc3c0-5e0a-49dd-bf79-7d1bdb953757"
      unitRef="usd">619000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i333dd5feeee74afbb5ad0dc46eb323e0_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNDAtMi0xLTEtNzc0MDc_1cc03be9-1435-4a25-b901-ebeafeda39d6"
      unitRef="usd">8000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0422e59a7ebf4c4cbf75f1140ecc88d0_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNDAtNC0xLTEtNzc0MDc_d465494d-aa47-48aa-8c01-68158e852bc2"
      unitRef="usd">12000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9006cebe9baf49098f28b71ba8b0b364_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNDEtMi0xLTEtNzc0MDc_04bc1b3e-1306-4d5e-b3e4-8512bac37a17"
      unitRef="usd">27603000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7e6b7c5e255f431184d25955b77d4780_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RhYmxlOmNkMDE3MDI2ZGY0NTQ0OWY4YThlNmEyMTU5NzZiZTMwL3RhYmxlcmFuZ2U6Y2QwMTcwMjZkZjQ1NDQ5ZjhhOGU2YTIxNTk3NmJlMzBfNDEtNC0xLTEtNzc0MDc_d3d140db-f244-49c8-a41a-c79cb98ea602"
      unitRef="usd">24232000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTExOTE_572ec12f-2d1d-4c62-9f8a-9aee0af3f741"
      unitRef="number">0.0306</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <jnj:ExcessOfFairValueOverCarryingValueOfDebt
      contextRef="ic8ebbcfaca4140c38e6ed48542fbd4de_D20220103-20220703"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTEyNzE_abc507f5-1c67-4d11-af11-84c8b4a9fa32"
      unitRef="usd">3200000000</jnj:ExcessOfFairValueOverCarryingValueOfDebt>
    <us-gaap:ShortTermBorrowings
      contextRef="i017db5ac595541f0b302582a410ea26d_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTEzMzg_78827c3f-bbb4-4581-9f6d-b96c7704bf75"
      unitRef="usd">3900000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i017db5ac595541f0b302582a410ea26d_I20221002"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE0MDc_dc530ec7-f7b0-416a-b403-682652aeb41a"
      unitRef="number">0.0288</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentTerm
      contextRef="i0dd1b1fcff0145219d7fb406847ea584_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82MS9mcmFnOjc5MjZiMDdiMDI4YTRjYWRiNjI5YmViMTg3ZjI3YjBmL3RleHRyZWdpb246NzkyNmIwN2IwMjhhNGNhZGI2MjliZWIxODdmMjdiMGZfMTE0NTk_5120d5e0-00e0-48f2-8556-ace8c5dd932d">P3M</us-gaap:DebtInstrumentTerm>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMzA4Nw_8455da33-12db-4c01-bcf1-dd79a2652a0c">INCOME TAXES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The worldwide effective income tax rates for the fiscal nine months of 2022 and 2021 were 17.7% and 10.0%, respectively. This increase in the consolidated tax rate as compared to the prior year fiscal nine months is primarily due to the Company reorganizing the ownership structure of certain wholly-owned international subsidiaries in the second fiscal quarter of 2021.  As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with the applicable local regulations. Accordingly, the Company recorded a local deferred tax benefit of approximately $2.3&#160;billion which was partially offset by a related increase in the U.S. GILTI deferred tax liability of approximately $1.7&#160;billion. The net impact of this reorganization was an approximate $0.6&#160;billion net benefit or a 3.4% decrease to the effective tax rate of the fiscal nine months of 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Additionally, the following items had an unfavorable impact to the Company&#x2019;s year-to-date effective tax rate as compared to the same period in the prior fiscal year:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt"&gt;as part of the planned separation of the Company&#x2019;s Consumer Health business (for further information see Note 1 in the Company's Annual Report on Form 10-K for the fiscal year ended January 2, 2022) the Company has recognized approximately $0.4&#160;billion in net incremental tax costs which increased the rate by approximately 2.0% for the fiscal nine months of 2022 &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt"&gt;certain one-time favorable tax items that occurred during the fiscal nine months of  2021 and resulted in an approximate 1.0% benefit to the effective tax rate, but were not repeated in fiscal 2022 &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.53pt"&gt;In the fiscal third quarter of 2021 the Company had accrued additional Talc expenses of $1.4&#160;billion at an effective tax rate of 23.5% and $0.8&#160;billion for the Risperdal Gynecomastia settlement at an effective tax rate of 16.4%. (See note 11 to the Consolidated Financial Statements for more details)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt"&gt;in the fiscal third quarter of 2021 the Company recorded a partial IPR&amp;amp;D charge of $0.9&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of 22.4%&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company also had additional tax benefits received from stock-based compensation that were either exercised or vested during the first three fiscal quarters of 2022 and 2021.  The Company&#x2019;s 2022 tax rate benefited primarily from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022, the impairment of bermekimab for AD IPR&amp;amp;D (for further information see Note 3 of the Consolidated Financial Statements) and changes in the fair value of securities in the Company&#x2019;s investment portfolio, both recorded at the U.S. statutory rate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of October&#160;2, 2022, the Company had approximately $3.8 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016.  In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTIz_7939717d-a06b-4d21-a643-8d93415c85a5"
      unitRef="number">0.177</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTMw_93391cb6-62f4-4973-b0f9-8dfebf5aa290"
      unitRef="number">0.100</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ie4184dedf017492f81476885b7412820_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfNjI4_d30cc084-c0af-4e3c-b6b1-8fa6d86550c0"
      unitRef="usd">2300000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ie4184dedf017492f81476885b7412820_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfNzM4_4fb45e3c-594c-422e-ba3f-60879bfbaaf1"
      unitRef="usd">1700000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ie4184dedf017492f81476885b7412820_I20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfNzk4_26e01f16-d95c-4f25-b52b-329ff6ef640e"
      unitRef="usd">600000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfODE4_6a390a63-9f2e-41a3-92e0-c6545e63c1e3"
      unitRef="number">-0.034</jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent>
    <us-gaap:IncreaseDecreaseInIncomeTaxes
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTY0OTI2NzQ1NTk0MA_8ac47b0f-4241-4918-9283-11af1049306e"
      unitRef="usd">400000000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <jnj:IncrementalIncreaseDecreaseInTaxes
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTY0OTI2NzQ1NTk1NA_18febf4a-2a5b-474c-8aa6-ca884d09af2f"
      unitRef="number">0.020</jnj:IncrementalIncreaseDecreaseInTaxes>
    <jnj:OneTimeFavorableTaxItemPercent
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTY0OTI2NzQ1NTk2MA_74518c5a-94d1-4bc3-93c3-62969baab1a8"
      unitRef="number">0.010</jnj:OneTimeFavorableTaxItemPercent>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7d211681392d483b8f62c60a8d8a4dc2_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc0Mg_4adec178-8de3-4229-8dbb-befc4312b8a3"
      unitRef="usd">1400000000</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent
      contextRef="i7d211681392d483b8f62c60a8d8a4dc2_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc1Ng_fcf629b8-b99b-495c-a058-84974c808b87"
      unitRef="number">0.235</jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent>
    <us-gaap:LitigationSettlementExpense
      contextRef="if235130eab4e408b92fb2c43ccb98f42_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc2Mw_20174b9f-82e6-4094-9228-72afabc3a518"
      unitRef="usd">800000000</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent
      contextRef="if235130eab4e408b92fb2c43ccb98f42_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc3Nw_6c91ec85-4a92-45b5-952d-3230dfd265eb"
      unitRef="number">0.164</jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i5d60d3f4537d4080a89795d512b26b9e_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc4NA_177f703e-5b9d-4e6e-9e72-3b59bb75693a"
      unitRef="usd">900000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i5d60d3f4537d4080a89795d512b26b9e_D20210705-20211003"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMjc0ODc3OTA4Mzc5OA_ba8abdec-c100-4f60-b187-c1d79dc29cc6"
      unitRef="number">0.224</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl82Ny9mcmFnOjM5NDg2ZWM5ZmE1MDQ4OTI4YTcwZWJmZTRhZDZiOTFmL3RleHRyZWdpb246Mzk0ODZlYzlmYTUwNDg5MjhhNzBlYmZlNGFkNmI5MWZfMTk4Mg_1a5e6b30-65e7-4afd-98b8-3c03aee950bf"
      unitRef="usd">3800000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RleHRyZWdpb246ZGYxNDUyZDI2M2Y1NGEzZjlhOTljOTNiNDlmY2NlNGJfMTAwNA_47dcc6e6-cdad-4c80-8631-53b9fbf605d3">PENSIONS AND OTHER BENEFIT PLANS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of Net Periodic Benefit Cost&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.962%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Company Contributions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the fiscal nine months ended October&#160;2, 2022, the Company contributed $82 million and $15 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RleHRyZWdpb246ZGYxNDUyZDI2M2Y1NGEzZjlhOTljOTNiNDlmY2NlNGJfMTAxNg_62a9c25f-7815-4883-8cbf-324fe03b940c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.962%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy0yLTEtMS03NzQwNw_1dca604d-ffc8-4825-b2a1-5b6433e875b5"
      unitRef="usd">313000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy00LTEtMS03NzQwNw_81d03e0f-959d-4fd0-9996-10e5bbc25c49"
      unitRef="usd">339000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy02LTEtMS03NzQwNw_fe3ea17e-686d-4356-be0c-c5c83828e7de"
      unitRef="usd">80000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy04LTEtMS03NzQwNw_4766061c-f29f-4bea-8e9a-b9bb040deef7"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy0xMC0xLTEtNzc0MDc_7354d9b5-ef13-412d-b065-b3b5406246a6"
      unitRef="usd">953000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy0xMi0xLTEtNzc0MDc_e912c6d6-0568-4614-9ffd-680e8a983c07"
      unitRef="usd">1019000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy0xNC0xLTEtNzc0MDc_567ec81c-2262-4fdb-b1bd-36b2191e4d8a"
      unitRef="usd">240000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMy0xNi0xLTEtNzc0MDc_5eaaa277-cbac-4d40-884e-a5a1859448fc"
      unitRef="usd">232000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC0yLTEtMS03NzQwNw_313c247b-b361-41f3-b6e9-9426d657997d"
      unitRef="usd">226000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC00LTEtMS03NzQwNw_ce2c4ef6-4ef3-4490-bcb0-df1174cba705"
      unitRef="usd">192000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC02LTEtMS03NzQwNw_00ffb3ad-febb-4bf1-9ed2-a6a603ad98d5"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC04LTEtMS03NzQwNw_63a20f24-adad-47c0-abaf-7731c547bafc"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC0xMC0xLTEtNzc0MDc_b327d9b6-54db-4a29-88f5-d5278a9f0ede"
      unitRef="usd">685000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC0xMi0xLTEtNzc0MDc_19aa52ce-ec5c-4e78-8a71-8ec878ee1739"
      unitRef="usd">578000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC0xNC0xLTEtNzc0MDc_23361908-7c50-4f78-aaf1-24b5326cc200"
      unitRef="usd">79000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNC0xNi0xLTEtNzc0MDc_e9e79bc4-1833-42d3-93e8-ebd126cacdcf"
      unitRef="usd">61000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS0yLTEtMS03NzQwNw_110c5e08-1f1a-47e8-8314-b5d9aabe8cd8"
      unitRef="usd">683000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS00LTEtMS03NzQwNw_d5a6c5a3-7695-46be-bc2e-c7f00d227a7c"
      unitRef="usd">661000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS02LTEtMS03NzQwNw_5fa38641-f7bf-4456-99c6-6041648daae5"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS04LTEtMS03NzQwNw_3d5c08b0-54f7-489d-ab01-9adfff742356"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS0xMC0xLTEtNzc0MDc_ada40638-fb2f-45bb-9c53-8881a723337f"
      unitRef="usd">2075000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS0xMi0xLTEtNzc0MDc_c070c080-8358-47a2-b8fd-0c47778306ae"
      unitRef="usd">1988000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS0xNC0xLTEtNzc0MDc_2fae021b-f289-4e63-add8-47c6d2812cc2"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNS0xNi0xLTEtNzc0MDc_52747841-cecb-4579-b8e3-441ff8b2ef62"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi0yLTEtMS03NzQwNw_2da52b26-7426-425b-855d-4696eaf7f680"
      unitRef="usd">-46000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi00LTEtMS03NzQwNw_cd12e8d9-6058-4f39-bc33-c9baed4dabfa"
      unitRef="usd">-46000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi02LTEtMS03NzQwNw_28771d16-8a87-4578-bd41-18e03b537567"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi04LTEtMS03NzQwNw_6bb42ead-7301-4479-a77c-b615b21c0543"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi0xMC0xLTEtNzc0MDc_0bf56a18-e908-48db-b626-739661015d86"
      unitRef="usd">-138000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi0xMi0xLTEtNzc0MDc_dfb119ee-7318-4feb-add2-b0ef3ec2b787"
      unitRef="usd">-136000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi0xNC0xLTEtNzc0MDc_4d6882b8-3a7d-45c1-9499-d6aa2fd7a26c"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfNi0xNi0xLTEtNzc0MDc_f6450eb5-163d-4fab-945c-36a0873af351"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC0yLTEtMS03NzQwNw_47571c9c-b332-4fd5-8ba4-f14db207dab6"
      unitRef="usd">-163000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC00LTEtMS03NzQwNw_57adbb03-c6c8-46e1-9923-c6d3f4a1f4f3"
      unitRef="usd">-314000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC02LTEtMS03NzQwNw_be22b183-f703-4111-95eb-da82ffbff562"
      unitRef="usd">-30000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC04LTEtMS03NzQwNw_c5588e31-2a52-4a60-9732-9f5cb9a76288"
      unitRef="usd">-38000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC0xMC0xLTEtNzc0MDc_906bfc16-e799-48d3-9254-61cfba034a00"
      unitRef="usd">-492000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC0xMi0xLTEtNzc0MDc_dad822b8-bc4e-42cc-8e5c-8f8f4af33b8d"
      unitRef="usd">-944000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC0xNC0xLTEtNzc0MDc_fd1a080e-4b1a-487d-9ec0-cfa69e8d5620"
      unitRef="usd">-91000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOC0xNi0xLTEtNzc0MDc_7bd4e1b2-789b-4db0-8ebd-9ad6f3d39ffe"
      unitRef="usd">-113000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS0yLTEtMS03NzQwNw_b45d9277-a249-445b-836a-a0d9ee67e208"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS00LTEtMS03NzQwNw_a6ce0cb0-f2d1-4b36-a160-2291d3dc5542"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS02LTEtMS03NzQwNw_8ef0bb4b-a345-4f49-8aef-5a60edf744cb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS04LTEtMS03NzQwNw_7d02cb42-5ae8-4f61-ad47-f2c75b6e041c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS0xMC0xLTEtNzc0MDc_e86cec9c-c8db-42f7-9663-4b4e796169ed"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS0xMi0xLTEtNzc0MDc_762c2ea8-875a-4317-94d6-ca66bc221603"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS0xNC0xLTEtNzc0MDc_f490b084-2d72-4ea2-952d-4fa3030d5f7e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfOS0xNi0xLTEtNzc0MDc_467eb590-ad97-4b1d-a86f-4fdafa48baac"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if38fd805a6f8420da833524d3340a063_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtMi0xLTEtNzc0MDc_8cadabdc-4544-49e5-98e8-8b92d78f5f67"
      unitRef="usd">-27000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i959f7612fd3245f0b9811069228ce71f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtNC0xLTEtNzc0MDc_c1819070-3819-4231-943e-102a468c1aab"
      unitRef="usd">138000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i7d898aeba7b640eeb7e21b75a0923318_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtNi0xLTEtNzc0MDc_025e8c6e-8243-444c-9aa8-470e583bee70"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i04fab62da2c141f888b893afab6164da_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtOC0xLTEtNzc0MDc_2c0a7dd4-9730-4157-b609-906bca8b2213"
      unitRef="usd">127000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i85c55dc9b42b422fba1756b99bcadcc3_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtMTAtMS0xLTc3NDA3_22430dac-0267-4919-9e76-c681b4b458f4"
      unitRef="usd">-82000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i064a9bd006b8416c873cb3f4b8b3c322_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtMTItMS0xLTc3NDA3_769fc4be-df2c-46ff-9310-d618295665a5"
      unitRef="usd">418000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="icfa9a07ffdf442f4940452b31c4a79cd_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtMTQtMS0xLTc3NDA3_c5867b62-9758-455f-ba7c-5b69c11bba2c"
      unitRef="usd">400000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i6ba550e02f7d42ac9f2fb08cbc5fe7c0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RhYmxlOjdlY2IyMzYxMjkxZTRiMjBiZTU5NzEyY2MxZThlNjBmL3RhYmxlcmFuZ2U6N2VjYjIzNjEyOTFlNGIyMGJlNTk3MTJjYzFlOGU2MGZfMTAtMTYtMS0xLTc3NDA3_58182d51-f616-44ce-b97d-32b3eca066e1"
      unitRef="usd">378000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:PensionContributions
      contextRef="i332809e8f61c44149c2e4659a135fe38_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RleHRyZWdpb246ZGYxNDUyZDI2M2Y1NGEzZjlhOTljOTNiNDlmY2NlNGJfNzQy_b8de06c1-68bc-4e5d-9cba-c386dbd4a24d"
      unitRef="usd">82000000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="iff704175779c4e83903efe4bb1b1eb21_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83MC9mcmFnOmRmMTQ1MmQyNjNmNTRhM2Y5YTk5YzkzYjQ5ZmNjZTRiL3RleHRyZWdpb246ZGYxNDUyZDI2M2Y1NGEzZjlhOTljOTNiNDlmY2NlNGJfNzQ5_39c29ef7-afef-4330-a749-426a0534a7df"
      unitRef="usd">15000000</us-gaap:PensionContributions>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RleHRyZWdpb246MmNiZWE3YmExMmQ2NDJhMDljNDI3Y2FlMTViNzk4N2RfOTMy_802221b7-a344-4a1a-a388-0a38041f25a2">ACCUMULATED OTHER COMPREHENSIVE INCOME&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details on reclassifications out of Accumulated Other Comprehensive Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Derivatives &amp;amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RleHRyZWdpb246MmNiZWE3YmExMmQ2NDJhMDljNDI3Y2FlMTViNzk4N2RfOTMw_edcf0a04-c448-4bb6-b3c0-7af18a2719a7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i206b36fcd5884efc8e2d9f8f10a5a918_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNC0yLTEtMS03NzQwNw_e3d23e1b-fec6-47e1-a177-061a95a66fa1"
      unitRef="usd">-10017000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i096b7900f5fe4d45964781506fef7cd4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNC00LTEtMS03NzQwNw_e354f69b-0e0c-4a2f-8671-12d1651652ab"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d64a67a236a4c7e9d6dae0c1d2fd34a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNC02LTEtMS03NzQwNw_7ae94870-7339-4f62-ab7e-8281e3ec5df5"
      unitRef="usd">-2702000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i944bc08bbd494170a723fa335d775693_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNC04LTEtMS03NzQwNw_fbd7767d-9fd8-45e4-b36b-806664831a2d"
      unitRef="usd">-336000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib60c35086bcc4c329bbe423674e693a9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNC0xMC0xLTEtNzc0MDc_788c3654-d35f-4a5e-b5ce-fd5bfeaf6b99"
      unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNS0yLTEtMS03NzQwNw_02136c81-8bc5-46fd-b9d1-888dcfb33c4f"
      unitRef="usd">-1957000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNS00LTEtMS03NzQwNw_42e6895a-e8ea-49c4-bc22-e7de6e823630"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNS02LTEtMS03NzQwNw_62100389-3d69-489b-822f-221dd731b421"
      unitRef="usd">-344000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNS04LTEtMS03NzQwNw_4c53123c-1ef4-4d08-a969-8e7966359dda"
      unitRef="usd">-586000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNS0xMC0xLTEtNzc0MDc_8101384f-c5da-47cf-b219-7d3f6ce1fd37"
      unitRef="usd">-2234000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0857a3c31a28448189abbe9edefd142c_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNy0yLTEtMS03NzQwNw_dc397e7a-12c3-4461-b78d-a00655dfca79"
      unitRef="usd">-11974000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icfb9d5a6b7ad47d78a2e5ef496f4cbb9_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNy00LTEtMS03NzQwNw_d4cdde95-87d0-4fbf-8582-56196220dd35"
      unitRef="usd">-38000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib49ea28b1f6a4233b9e391f4fe2d7695_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNy02LTEtMS03NzQwNw_2794d45e-3ef4-4828-a96a-43db10d0deec"
      unitRef="usd">-2358000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08ec2d8a0db84c62aeaf6386e449a7e3_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNy04LTEtMS03NzQwNw_7a8ae12b-e25e-4bab-9ef4-6500a82d6d4e"
      unitRef="usd">-922000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a9083e68f134a6b959f8e81ba70dca0_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83My9mcmFnOjJjYmVhN2JhMTJkNjQyYTA5YzQyN2NhZTE1Yjc5ODdkL3RhYmxlOjY2ODY5YTNlMjlkMDQ1YjBhZmJhYTRiMWE2MWU1NjU3L3RhYmxlcmFuZ2U6NjY4NjlhM2UyOWQwNDViMGFmYmFhNGIxYTYxZTU2NTdfNy0xMC0xLTEtNzc0MDc_309534e3-4b1d-45be-a6e2-cf565b76dd18"
      unitRef="usd">-15292000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RleHRyZWdpb246ZjRjMThlYWYxNjNmNDYzZDk2ZjE0NjE3NWJlZDk4NWFfODA0_9f746c6b-25be-4cc2-9b63-c4b93a3681a1">EARNINGS PER SHARE&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,628.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The diluted net earnings per share calculation for both the fiscal third quarter ended October&#160;2, 2022 and October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#x2019;s stock. &lt;/span&gt;&lt;/div&gt;The diluted net earnings per share calculation for the fiscal nine months ended October&#160;2, 2022 and October&#160;3, 2021 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#x2019;s stock.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RleHRyZWdpb246ZjRjMThlYWYxNjNmNDYzZDk2ZjE0NjE3NWJlZDk4NWFfODIx_8b01bc34-ea25-42b2-9666-f2ab524e22e0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,628.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMi0yLTEtMS03NzQwNw_f9012076-c601-4018-8e27-b21858348250"
      unitRef="usdPerShare">1.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMi00LTEtMS03NzQwNw_befd3460-b7bb-47bd-bb58-fd64f8af4adf"
      unitRef="usdPerShare">1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMi02LTEtMS03NzQwNw_c2de6305-39f2-4d47-af45-976cb7be90fc"
      unitRef="usdPerShare">5.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMi04LTEtMS03NzQwNw_6f17ac4b-4655-4cff-9daf-f2698c2dba32"
      unitRef="usdPerShare">6.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMy0yLTEtMS03NzQwNw_7e7da13a-2a06-4713-9999-036e9b8f956a"
      unitRef="shares">2627900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMy00LTEtMS03NzQwNw_b58a4c69-0a8e-4d5e-9908-e250f853225d"
      unitRef="shares">2632600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMy02LTEtMS03NzQwNw_21f4461c-44b1-4800-bbe9-20c35b5a91c5"
      unitRef="shares">2628900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfMy04LTEtMS03NzQwNw_d71b869c-3b47-4327-a9b5-acc94742c3cc"
      unitRef="shares">2632200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNC0yLTEtMS03NzQwNw_01f3f65e-b157-4007-b3d8-14891b278750"
      unitRef="shares">140100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNC00LTEtMS03NzQwNw_75638a4b-82df-4487-93d1-ab8f84063ea2"
      unitRef="shares">138300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNC02LTEtMS03NzQwNw_0dffcb94-164d-47b4-88d7-9f21dfb42867"
      unitRef="shares">141100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNC04LTEtMS03NzQwNw_d33a5482-b96d-459f-ad42-f342b6fee314"
      unitRef="shares">139100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNS0yLTEtMS03NzQwNw_32b0027a-13ad-4fee-a410-43cd86d6f2de"
      unitRef="shares">106700000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNS00LTEtMS03NzQwNw_0e4e70d5-51f3-4471-a7ce-10ab7a7051d4"
      unitRef="shares">96000000.0</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNS02LTEtMS03NzQwNw_82ad045a-d6c3-45c0-89d6-d23bd429e62b"
      unitRef="shares">102500000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNS04LTEtMS03NzQwNw_d1ff37f6-3992-4f2f-890a-35e28dde5f26"
      unitRef="shares">96700000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNy0yLTEtMS03NzQwNw_612fcda8-71ce-41bd-8691-d8eb524f5111"
      unitRef="shares">2661300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNy00LTEtMS03NzQwNw_8576be8a-46fc-448b-a0ab-aa1d39dcaf0d"
      unitRef="shares">2674900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNy02LTEtMS03NzQwNw_2f0d206b-c5e4-430c-bd9b-2d28c427f01f"
      unitRef="shares">2667500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfNy04LTEtMS03NzQwNw_4d04a57d-ac9d-4ea8-895d-a50d61114329"
      unitRef="shares">2674600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfOC0yLTEtMS03NzQwNw_04d648b3-0408-4560-8459-5d8f13cbfc34"
      unitRef="usdPerShare">1.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfOC00LTEtMS03NzQwNw_309612bd-7dfc-478e-a31b-b1664696b854"
      unitRef="usdPerShare">1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfOC02LTEtMS03NzQwNw_f53ed9e2-2b9c-476c-8228-0495c015f18a"
      unitRef="usdPerShare">5.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83Ni9mcmFnOmY0YzE4ZWFmMTYzZjQ2M2Q5NmYxNDYxNzViZWQ5ODVhL3RhYmxlOmI1MDJlMjBhOGExZjQxODhiMGVmMDhhNzBkOTcxMjNkL3RhYmxlcmFuZ2U6YjUwMmUyMGE4YTFmNDE4OGIwZWYwOGE3MGQ5NzEyM2RfOC04LTEtMS03NzQwNw_f4cd8903-b7e2-4222-8265-cb9ac6064684"
      unitRef="usdPerShare">6.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzU4OA_39778cbe-64ee-4e31-b28a-1c7eccebc75a">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;REMICADE  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX /&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;            REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA / INVOKAMET&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDTECH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Approximately $0.1&#160;billion in the fiscal third quarter of 2021 and $0.3&#160;billion in the fiscal nine months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inclusive of  PROCRIT / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Previously referred to as Medical Devices&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Consumer Health separation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*The 2021 fiscal third  quarter and nine months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;**Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.3&#160;billion in both the fiscal nine months of 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Litigation expense of $0.1&#160;billion in the fiscal nine months of 2022. Litigation expense of $1.4&#160;billion and $1.5&#160;billion in the fiscal three months and fiscal nine months of 2021, respectively, primarily for talc related costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Divestiture gains of $0.6&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal third quarter of 2022 and 2021, respectively. Intangible amortization expense of $2.2&#160;billion and $2.5&#160;billion in the fiscal nine months of 2022 and 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A loss of $0.2&#160;billion and a gain of $0.1&#160;billion related to the change in the fair value of securities in the fiscal third quarter of 2022 and 2021, respectively. A loss of $0.7&#160;billion and a gain of $0.2&#160;billion related to the change in the fair value of securities in the fiscal nine months of 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;COVID-19 Vaccine supply network related costs of $0.4&#160;billion and $0.7&#160;billion in the fiscal third quarter and fiscal nine months 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;Litigation expense of $0.8&#160;billion and $0.7&#160;billion in the fiscal third quarter and fiscal nine months of 2021, respectively, primarily related to Risperdal Gynecomastia.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal third quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.5&#160;billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Litigation expense of $0.2&#160;billion in  the fiscal third quarter of 2022. Litigation expense of $0.5 billion in fiscal nine months of 2022, primarily pelvic mesh related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.2&#160;billion in the fiscal nine months of 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.3&#160;billion in both the fiscal third quarter of 2022 and 2021 and $0.8&#160;billion in both the fiscal nine months of 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes an in-process research and development expense of $0.9&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Amounts not allocated to segments include interest income/expense and general corporate income/expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <jnj:SalesBySegmentOfBusinessTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzYwMg_55361f1d-bb2b-4d3b-a749-98594f3d8b6a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;REMICADE  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX /&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;            REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;* &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA / INVOKAMET&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDTECH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Approximately $0.1&#160;billion in the fiscal third quarter of 2021 and $0.3&#160;billion in the fiscal nine months of 2021, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inclusive of  PROCRIT / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Previously referred to as Medical Devices&lt;/span&gt;&lt;/div&gt;</jnj:SalesBySegmentOfBusinessTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cde6a52268347428b5037069103d820_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS0yLTEtMS03NzQwNw_59413411-829c-47f7-ae4b-aac3f5332e92"
      unitRef="usd">695000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia74220ebf81e4065a938588bde5498e7_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS00LTEtMS03NzQwNw_9f004705-6b38-4eaf-b14b-d69cce79949e"
      unitRef="usd">686000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7cde6a52268347428b5037069103d820_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS02LTEtMS03NzQwNw_42a71c50-5438-4a40-9870-b0062aad3542"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78fcb0fd89d14eb6b29ffdbd3720e7ce_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS04LTEtMS03NzQwNw_e2d67109-f7de-4a12-9df8-b05dadf04b83"
      unitRef="usd">2028000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54a459b3600145d3b4107cf4bdccf257_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS0xMC0xLTEtNzc0MDc_ef8b9ceb-91f4-4535-a428-e3bca447d41e"
      unitRef="usd">1960000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i78fcb0fd89d14eb6b29ffdbd3720e7ce_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNS0xMi0xLTEtNzc0MDc_f9470d28-83b5-4f3e-bfb1-3eb0766be26e"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i941ed2c1db534253af22569d7910ede8_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi0yLTEtMS03NzQwNw_fdb1bef5-06e9-4237-96e9-ced9cfc8933c"
      unitRef="usd">825000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f1d220f585f4dec831f31a5f9ce8adf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi00LTEtMS03NzQwNw_7b23c3d2-c23d-47c6-83f3-b0c8428003e3"
      unitRef="usd">798000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i941ed2c1db534253af22569d7910ede8_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi02LTEtMS03NzQwNw_7a52a8b9-3e4f-45d6-8c63-a309d8bd0967"
      unitRef="number">0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9aeb275ad1f442feafbe9c4c30a972b6_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi04LTEtMS03NzQwNw_1db87aea-5f2d-406c-9542-ed8051d585bc"
      unitRef="usd">2434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec58864a102d428fba3c283afdd1c086_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi0xMC0xLTEtNzc0MDc_228d8f2f-6be3-4878-a0d0-79bcc6f91662"
      unitRef="usd">2223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9aeb275ad1f442feafbe9c4c30a972b6_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNi0xMi0xLTEtNzc0MDc_739a5433-0b9d-49cb-967f-0d372b87c2e5"
      unitRef="number">0.095</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63196f90176a4d4c89a11a247847a7d2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy0yLTEtMS03NzQwNw_c0b12b4e-801c-49f4-beef-2a64ed9a36d2"
      unitRef="usd">1519000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib10849b3cb49478ebbdfac543124e1cb_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy00LTEtMS03NzQwNw_2b860998-6891-4fe8-b107-7f26415d9dc8"
      unitRef="usd">1484000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i63196f90176a4d4c89a11a247847a7d2_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy02LTEtMS03NzQwNw_ed8a513a-631f-4351-8a25-bc9e0eb4405b"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i343ce984f8d243c99d19169f2ce469e8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy04LTEtMS03NzQwNw_9da5adf0-3eaf-447b-8280-f7469db9efca"
      unitRef="usd">4462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie94a7099ba6b469abec25cbdb9df79c3_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy0xMC0xLTEtNzc0MDc_f0048b70-6b4a-4ac1-b3be-493a2f788898"
      unitRef="usd">4183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i343ce984f8d243c99d19169f2ce469e8_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNy0xMi0xLTEtNzc0MDc_58fc3880-a7a8-4e12-91e7-a4ae9d2a421b"
      unitRef="number">0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c7b7f8b4fa541888ad11c59317e305b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS0yLTEtMS03NzQwNw_1a4e5c64-6942-4614-85c1-436c22b63f6d"
      unitRef="usd">591000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i110338127fd4477e9581eeb21a88403b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS00LTEtMS03NzQwNw_d5e4f6a1-5e45-44e4-9d99-79405fbc1124"
      unitRef="usd">569000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7c7b7f8b4fa541888ad11c59317e305b_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS02LTEtMS03NzQwNw_49278a8c-db08-46bc-bc6c-781825ae067b"
      unitRef="number">0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba3692bbfa0746ad97c0e05cf2f74b81_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS04LTEtMS03NzQwNw_0fbfbdd8-bb49-4fb3-a161-195524e2847c"
      unitRef="usd">1764000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib155353bba1e4367acb4afc65093ac17_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS0xMC0xLTEtNzc0MDc_b3af86f2-6374-43b4-9db7-145d31d000bb"
      unitRef="usd">1862000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iba3692bbfa0746ad97c0e05cf2f74b81_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOS0xMi0xLTEtNzc0MDc_60b82335-384d-4f48-8824-e6aa67ff20cf"
      unitRef="number">-0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8c11083b6fd4c70b63123ebd3184bcc_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtMi0xLTEtNzc0MDc_bbccca33-32a2-47f2-8253-8e133f256fc5"
      unitRef="usd">535000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59bf5576de564479ab33549d72205efb_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtNC0xLTEtNzc0MDc_aef9d247-9d52-43ca-a9dc-b0f861d6555f"
      unitRef="usd">555000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id8c11083b6fd4c70b63123ebd3184bcc_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtNi0xLTEtNzc0MDc_90e893db-e185-4280-9ddf-fc04512a9add"
      unitRef="number">-0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92b06f4a72c54053ab762b36aa11132f_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtOC0xLTEtNzc0MDc_97a4f5e9-8075-4fd9-a848-37e4440b3971"
      unitRef="usd">1500000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie061b083973e42d4885e9f9780a30d24_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtMTAtMS0xLTc3NDA3_6e20173b-1f8e-4389-9bf4-79f47eeaf652"
      unitRef="usd">1595000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i92b06f4a72c54053ab762b36aa11132f_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAtMTItMS0xLTc3NDA3_471e7678-d4af-4fff-97c2-8c746c1c3f2c"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id127890eb1d746d2b41f02aec9b35a5a_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtMi0xLTEtNzc0MDc_8d0202cf-7814-407f-9f74-dae132db1f83"
      unitRef="usd">1126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i028f7b0cc1fe4417b3829de872b9bff7_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtNC0xLTEtNzc0MDc_d41fb1ea-c45c-4ca3-ba02-f2f1b385b1a4"
      unitRef="usd">1124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id127890eb1d746d2b41f02aec9b35a5a_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtNi0xLTEtNzc0MDc_9f0d28c1-c2f3-45dc-b18b-51f0444ae30a"
      unitRef="number">0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20bbf2239aa6444fa5e65541167d42d9_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtOC0xLTEtNzc0MDc_3a3e9671-052d-4f57-88c2-e9ccf0154850"
      unitRef="usd">3264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6217c9284834a96aba0480663c6c29a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtMTAtMS0xLTc3NDA3_e09177ba-ee10-43d8-b464-0460de19fe89"
      unitRef="usd">3457000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i20bbf2239aa6444fa5e65541167d42d9_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEtMTItMS0xLTc3NDA3_799abeb3-71c5-4cf0-91f9-a271406eaaec"
      unitRef="number">-0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fc1b31fec9043679c9a24c4e7d7eb15_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtMi0xLTEtNzc0MDc_a48e9090-5d45-4507-b683-a2cc970a8e0a"
      unitRef="usd">158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i728ae91795a049659be1d1a2f8f086d6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtNC0xLTEtNzc0MDc_bb950bbc-8cd6-49c0-a15d-8fe02f68c1bc"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4fc1b31fec9043679c9a24c4e7d7eb15_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtNi0xLTEtNzc0MDc_cfddb3c5-5742-4360-8584-785dc066e8cc"
      unitRef="number">0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i197d29cb3728490aa880fe1b2febaf85_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtOC0xLTEtNzc0MDc_f6e40d46-5207-40c9-8786-c918aa976d8b"
      unitRef="usd">471000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc8a1658b7674fd480d2da4366870996_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtMTAtMS0xLTc3NDA3_854e2157-10da-4e26-b367-bab2900d7150"
      unitRef="usd">478000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i197d29cb3728490aa880fe1b2febaf85_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMtMTItMS0xLTc3NDA3_84f292da-cb92-400e-81d6-dd7daaafab30"
      unitRef="number">-0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8200dc57bcf946c89ace0088bd07514a_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtMi0xLTEtNzc0MDc_e1147286-b09c-49d4-bdfb-79cf2e59a8f9"
      unitRef="usd">217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4c3e6ddd1e342c29393fe34fb925065_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtNC0xLTEtNzc0MDc_a15945f9-3d6a-43fc-b0d9-e9aee683c298"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8200dc57bcf946c89ace0088bd07514a_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtNi0xLTEtNzc0MDc_fcbb6fd8-7829-4e58-8f1e-7c5cdce83e55"
      unitRef="number">-0.124</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icaf3eefd4fdc4df398da4efb9abc13be_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtOC0xLTEtNzc0MDc_6f4b24ab-293b-4be2-a953-9421c74e1a55"
      unitRef="usd">664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie31d505d43664fc6a37a1a6f7390b6d9_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtMTAtMS0xLTc3NDA3_6f74d880-e86b-4891-b4b5-c4d201e934c2"
      unitRef="usd">762000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icaf3eefd4fdc4df398da4efb9abc13be_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQtMTItMS0xLTc3NDA3_ae879925-04bc-4a25-9995-9af62fd1841d"
      unitRef="number">-0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1f6eab93c9b4d1fb2d19580cedc8b4c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtMi0xLTEtNzc0MDc_babb0ded-1ff0-429c-b5b8-3b00f860c2ce"
      unitRef="usd">375000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4fadfd175984a22b86dc24c89dc4bc0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtNC0xLTEtNzc0MDc_c95dd050-a8b9-450c-b81c-684eda001353"
      unitRef="usd">398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id1f6eab93c9b4d1fb2d19580cedc8b4c_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtNi0xLTEtNzc0MDc_e603d4a0-2398-41a1-9445-aaa12e5df721"
      unitRef="number">-0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15720a18344e469886257608fa371d4b_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtOC0xLTEtNzc0MDc_ae10b3e3-bc08-4337-8bfa-95191a04b844"
      unitRef="usd">1135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a609c570d4247459662c095f2834797_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtMTAtMS0xLTc3NDA3_11e12e2f-6e98-4627-853c-b7eed80e790d"
      unitRef="usd">1240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i15720a18344e469886257608fa371d4b_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUtMTItMS0xLTc3NDA3_e9b1a0c6-432c-4d66-8305-29153602b945"
      unitRef="number">-0.085</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5be2488acb464b53b616386ec7557fd2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctMi0xLTEtNzc0MDc_74219e21-c734-49e2-b469-b2871b4bd366"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbb0f442da954722b1c33088aa5d0bc2_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctNC0xLTEtNzc0MDc_9774b12e-7ae8-4190-92b6-506953826ffb"
      unitRef="usd">95000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5be2488acb464b53b616386ec7557fd2_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctNi0xLTEtNzc0MDc_41e07552-5f3b-44e1-8d5b-f98aa0e8214d"
      unitRef="number">-0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b5a875d8089486c8f44852cabb6ecfd_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctOC0xLTEtNzc0MDc_9e627362-f253-4c8b-b0d9-06543c2b8e4c"
      unitRef="usd">264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i211cbd1cb10f4ee7839006b5eaa4a2bd_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctMTAtMS0xLTc3NDA3_e898c9b7-b97c-45fe-a04f-e7836028c527"
      unitRef="usd">288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9b5a875d8089486c8f44852cabb6ecfd_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTctMTItMS0xLTc3NDA3_8e5362a9-8832-4d56-a17e-1a1992da2fa4"
      unitRef="number">-0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i258122d0b65d4169b5b5519e4d8d5074_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtMi0xLTEtNzc0MDc_cdcafa1f-42ab-4e58-af22-d4969211cd13"
      unitRef="usd">283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29c2eb559dcd4387b1033c88491e2a2e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtNC0xLTEtNzc0MDc_530d6762-d52a-4051-aaf3-3b3f9b802507"
      unitRef="usd">296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i258122d0b65d4169b5b5519e4d8d5074_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtNi0xLTEtNzc0MDc_74cd8681-9464-40e7-b7e0-d9d4a89bb853"
      unitRef="number">-0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0235b711c804ebfa7876a02dd285bb1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtOC0xLTEtNzc0MDc_6be96a6b-0c7c-4114-aecb-fb0f4ff7bd72"
      unitRef="usd">840000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec063ee8c3a4470694b6e73255290c52_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtMTAtMS0xLTc3NDA3_258a888c-cf23-4204-add2-16d3bdf57dfb"
      unitRef="usd">879000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie0235b711c804ebfa7876a02dd285bb1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTgtMTItMS0xLTc3NDA3_0a283013-1641-4c16-8dd8-f64b89d72567"
      unitRef="number">-0.044</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04db1cf7ec4e45bba56bc0d72ea66e02_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktMi0xLTEtNzc0MDc_342a9295-e9da-420c-b205-dfe85d1f4a8e"
      unitRef="usd">375000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f2286d04e2f4ee5b108615874070bf9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktNC0xLTEtNzc0MDc_6bbdf6fa-070e-4b43-bc6b-ef38f5993f78"
      unitRef="usd">391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i04db1cf7ec4e45bba56bc0d72ea66e02_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktNi0xLTEtNzc0MDc_27839314-58a4-471f-a3cd-72e4e3b7f8c3"
      unitRef="number">-0.043</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5dd220bba8484f9ab20dffe40805100c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktOC0xLTEtNzc0MDc_040e47c0-f840-49a2-be0e-d5b70c622e96"
      unitRef="usd">1105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ebc82e0cc7a43579e7cb5d5261ff68b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktMTAtMS0xLTc3NDA3_e9039079-ecf2-468c-a2ad-a446ac6afc70"
      unitRef="usd">1167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5dd220bba8484f9ab20dffe40805100c_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTktMTItMS0xLTc3NDA3_7bfb3d80-1c30-431b-bbb7-41125465a56c"
      unitRef="number">-0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie05209c75c064c149e32ca91f101c128_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtMi0xLTEtNzc0MDc_3ccc7044-c7d7-42b4-87db-c2c51300b6b1"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60597d445fdd471dbefd75d06e9d49b6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtNC0xLTEtNzc0MDc_e3865dc8-2975-4b27-9311-683b25e214ae"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie05209c75c064c149e32ca91f101c128_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtNi0xLTEtNzc0MDc_0b32d4b3-fe25-4e62-9424-e0d335b9c384"
      unitRef="number">-0.220</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie59769c19cc641d08a4a75d12515d22c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtOC0xLTEtNzc0MDc_87f82f8e-58a7-4847-89a2-a5cee3e528be"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadaaf79391e243ce9580a4a5f82c3c1e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtMTAtMS0xLTc3NDA3_95ad487e-96d0-4a81-9616-a37e83a757fe"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie59769c19cc641d08a4a75d12515d22c_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEtMTItMS0xLTc3NDA3_c0cc72f7-b729-47cb-8942-be51aa121b8b"
      unitRef="number">-0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie40537dd17e641f18a84d3dae0e1e91e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItMi0xLTEtNzc0MDc_314037b5-455a-4fa4-b625-4a86b2f1c47a"
      unitRef="usd">222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id74e23c5a1ea4a3fa4324f3cbebba2ec_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItNC0xLTEtNzc0MDc_3126b015-a2b2-400f-b1c2-9d594ffd43bf"
      unitRef="usd">229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie40537dd17e641f18a84d3dae0e1e91e_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItNi0xLTEtNzc0MDc_c1b4ed39-a872-4fd4-8544-c4409b18a124"
      unitRef="number">-0.027</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57dad0479d5f408586720d9c4f156c48_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItOC0xLTEtNzc0MDc_efbfbf2b-4de3-4641-bf58-f307cc389755"
      unitRef="usd">674000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6571e3bbe1c5478088cde974f1a794ff_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItMTAtMS0xLTc3NDA3_e3c3dc46-d410-47f1-8d46-3a527d60fc3a"
      unitRef="usd">675000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i57dad0479d5f408586720d9c4f156c48_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjItMTItMS0xLTc3NDA3_a4a3d232-58b2-4e40-ba0d-f6efe9956e75"
      unitRef="number">-0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cf927e34f9e49f0abbbe3cd9b236507_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtMi0xLTEtNzc0MDc_5c042d3e-8b84-467a-8b6a-a57138b3a6e5"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa1da1546f194c1fb0e2caecfe484dff_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtNC0xLTEtNzc0MDc_ffa5fb2e-4c67-4ea8-aea3-94625172899a"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7cf927e34f9e49f0abbbe3cd9b236507_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtNi0xLTEtNzc0MDc_04afb899-58b7-43df-85dd-db24ecb64cd7"
      unitRef="number">-0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if82e78c4579b4156b6cdbcf7c3cee740_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtOC0xLTEtNzc0MDc_e3478ab8-0522-4a38-aa19-14cc4859c0f9"
      unitRef="usd">684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0699f62151e4b32a947734f89b31cdd_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtMTAtMS0xLTc3NDA3_a6560930-33e0-4033-ba3b-200f316b3288"
      unitRef="usd">684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if82e78c4579b4156b6cdbcf7c3cee740_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMtMTItMS0xLTc3NDA3_e28636cf-605e-47d5-a9d5-0ba2cab0220b"
      unitRef="number">-0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i117745a3dd684de8974772ece9648d65_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtMi0xLTEtNzc0MDc_f3268367-3737-4965-9011-25b9e0721c32"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b9a0c60f81b457091ed4cdfdfcafa87_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtNC0xLTEtNzc0MDc_f1cc2c81-862c-4651-b3c0-d5e634cef9c5"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i117745a3dd684de8974772ece9648d65_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtNi0xLTEtNzc0MDc_0d8930fb-e79e-4aa8-9679-dadba48f79f7"
      unitRef="number">-0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85433357f9bb4fba8f50ce185075b2a3_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtOC0xLTEtNzc0MDc_815c2d1e-2528-43bc-8a4a-5c4c753b96a7"
      unitRef="usd">366000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76af37281c8f42adacabdb80e1047e01_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtMTAtMS0xLTc3NDA3_3572a242-c48e-4ff1-9d1f-5d1c0778b0ce"
      unitRef="usd">390000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i85433357f9bb4fba8f50ce185075b2a3_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjUtMTItMS0xLTc3NDA3_84071c53-0b24-4f3c-94ce-86f2508e40a0"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f4bdb37dc4b4d47be92fde1fbb37bab_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtMi0xLTEtNzc0MDc_e60c679f-d7c4-4ed3-8b0f-f4b3b3c0616e"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia378214014c14267bb7dedcdfdfa66ce_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtNC0xLTEtNzc0MDc_caca1ea8-18cb-4ac5-a45b-1ecd30d11fee"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2f4bdb37dc4b4d47be92fde1fbb37bab_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtNi0xLTEtNzc0MDc_1026add4-4662-45f2-9b07-0d8d14b92180"
      unitRef="number">-0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fa62c7427744e21ad6b4c38c6a07153_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtOC0xLTEtNzc0MDc_f26efdfe-4634-42bf-8fd2-3a94e8735832"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie59345d38f1c4186b66ae8cc16f7a721_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtMTAtMS0xLTc3NDA3_86dba171-5256-43aa-ba30-b956320551bd"
      unitRef="usd">186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5fa62c7427744e21ad6b4c38c6a07153_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjYtMTItMS0xLTc3NDA3_4367beb7-2700-484c-b89f-d7b46414e7e5"
      unitRef="number">-0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e80efcfa77b44a5b447cd4080557081_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctMi0xLTEtNzc0MDc_73c86cc1-7adf-43eb-b79b-caf8fafb2a6d"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie501da18e9c84dbdb77d1e9fce501b01_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctNC0xLTEtNzc0MDc_4acef47a-36f5-4413-9078-e47b2e2c5dc2"
      unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0e80efcfa77b44a5b447cd4080557081_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctNi0xLTEtNzc0MDc_6c29965d-5433-4cf5-8a8d-f09c0df5c6c5"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic34261d9fecc4b469fbfc7320a06ad74_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctOC0xLTEtNzc0MDc_ca43f135-afbd-49b2-8519-976eea5e5a54"
      unitRef="usd">537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38e077f4d7ef4d1ba0449d563d1247a0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctMTAtMS0xLTc3NDA3_48ffae35-1520-4513-8593-e89c5ef6e69f"
      unitRef="usd">575000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic34261d9fecc4b469fbfc7320a06ad74_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjctMTItMS0xLTc3NDA3_b3d96eaf-51ff-4c06-920e-b68cafe232df"
      unitRef="number">-0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8bba328151b4f589a73606eb0809caf_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktMi0xLTEtNzc0MDc_eee7fce0-8b52-4f4e-8096-e6beec03f8eb"
      unitRef="usd">1659000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b41c4b48d4d43e0a26a3b93522fd773_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktNC0xLTEtNzc0MDc_54f6e8b2-de92-43cb-97b9-a29b22d7e9f3"
      unitRef="usd">1625000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if8bba328151b4f589a73606eb0809caf_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktNi0xLTEtNzc0MDc_f0d4ec57-7d89-4273-8d84-11f29a802f1b"
      unitRef="number">0.021</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c2d3a271be74fd9aea5facb617f9860_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktOC0xLTEtNzc0MDc_b76a9afe-1d83-4e90-93db-7471a961df1e"
      unitRef="usd">4903000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4f833113f7041289bb2eb913b130ebf_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktMTAtMS0xLTc3NDA3_50b6734e-1f46-4726-83ad-35fb20bfab17"
      unitRef="usd">4987000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7c2d3a271be74fd9aea5facb617f9860_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjktMTItMS0xLTc3NDA3_8b686e19-751d-41fd-a429-cfd97a787437"
      unitRef="number">-0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20e5cf3b01a84cb493dc2721b5a74b79_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtMi0xLTEtNzc0MDc_2e89c608-498c-4779-bded-ccf11a2fcb08"
      unitRef="usd">2136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i320bb566db254466ba9c6a695628a6b0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtNC0xLTEtNzc0MDc_5833723b-5cf2-468f-832b-8a241ba54f54"
      unitRef="usd">2187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i20e5cf3b01a84cb493dc2721b5a74b79_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtNi0xLTEtNzc0MDc_91b1aff2-d506-46f3-af83-41b2cc7c72c1"
      unitRef="number">-0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e5886c2fb184bac9cd7ffe1b974ffb7_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtOC0xLTEtNzc0MDc_bdc0a319-21ff-4d1d-8484-3a920bfa94c7"
      unitRef="usd">6283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i755b8f931470497ba00724a368f9cdbe_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtMTAtMS0xLTc3NDA3_e664e9b8-400d-4c31-9a02-b67afd237119"
      unitRef="usd">6320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3e5886c2fb184bac9cd7ffe1b974ffb7_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzAtMTItMS0xLTc3NDA3_63161ca3-7c32-4a96-93a7-9300152cdc94"
      unitRef="number">-0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c1d5e55ddc144bc825a5b127870993d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtMi0xLTEtNzc0MDc_d7ad69de-6e0c-48ad-8a2f-8d32959408e9"
      unitRef="usd">3795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44a1dbe5705741b68a24e0e337ef63e8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtNC0xLTEtNzc0MDc_4010399e-40fc-44fb-9ed2-8ecbcdd7b2c1"
      unitRef="usd">3812000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1c1d5e55ddc144bc825a5b127870993d_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtNi0xLTEtNzc0MDc_7f5248ff-cf1d-4217-9ea9-3d457770367a"
      unitRef="number">-0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7787b0e8db0d4969ac6e93a11454dd47_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtOC0xLTEtNzc0MDc_9507c010-8439-4b52-b985-1836e2d95c8b"
      unitRef="usd">11186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc8e23dcc91d417896dc4ffb5479cb12_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtMTAtMS0xLTc3NDA3_bbf99355-12e4-432f-ab59-3930eb7d5c1d"
      unitRef="usd">11307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7787b0e8db0d4969ac6e93a11454dd47_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzEtMTItMS0xLTc3NDA3_236d866e-4f23-4a1b-a8c6-eafe60da4ea4"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11459a5bbd884b9cbcefb0dd8cc442ec_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtMi0xLTEtNzc0MDc_a837e592-24eb-4fef-af89-0d97abe1b90d"
      unitRef="usd">2876000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3cc1f7e1fa54ceb9ccc93da93684bef_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtNC0xLTEtNzc0MDc_95c5dce4-6e98-4041-8bd5-73b8bfdbcca2"
      unitRef="usd">2771000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i11459a5bbd884b9cbcefb0dd8cc442ec_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtNi0xLTEtNzc0MDc_c686bee2-6ee4-44c6-88e2-628cec507bcd"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i676de123fa744973b1d51400eabfad36_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtOC0xLTEtNzc0MDc_b1389ada-1de3-49a9-9a2c-6c63d8914c28"
      unitRef="usd">8230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58528c896007432da65d8fa36f867e8e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtMTAtMS0xLTc3NDA3_7e983e16-0b0b-4e1f-a165-d2ec300a85b9"
      unitRef="usd">7932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i676de123fa744973b1d51400eabfad36_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzYtMTItMS0xLTc3NDA3_99fdb9b9-91b2-4274-80d3-4e92a4969a80"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i050bad26138643da94080c24dc214a0b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctMi0xLTEtNzc0MDc_9e9be918-d635-441d-97a4-fcc184cade99"
      unitRef="usd">1411000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ebea684bc144c3ab6b069f307243b39_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctNC0xLTEtNzc0MDc_839a7b16-57ca-4fec-9908-8bd4c7a13d76"
      unitRef="usd">1480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i050bad26138643da94080c24dc214a0b_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctNi0xLTEtNzc0MDc_7f2df336-94a9-4020-9d13-407390dee5ea"
      unitRef="number">-0.047</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9ab2943111a45ddb4c3689d0f23f0b8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctOC0xLTEtNzc0MDc_f5dc9dbe-8081-467a-8510-672358d9b8c9"
      unitRef="usd">4587000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c86dfc4bbb843088a0478dacfdda4eb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctMTAtMS0xLTc3NDA3_95a47a86-de54-4bf5-83d4-5099e7b9628e"
      unitRef="usd">4464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if9ab2943111a45ddb4c3689d0f23f0b8_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzctMTItMS0xLTc3NDA3_981962d8-2634-47b1-8313-814a4ce3b089"
      unitRef="number">0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie710509f29a84a6798f07d16fdf4bc25_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtMi0xLTEtNzc0MDc_5b4210fb-dd1d-4d48-ba59-6a906e6f3f26"
      unitRef="usd">4287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if36c2d2204694bd1b65beb048a38a087_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtNC0xLTEtNzc0MDc_0c780254-b978-4433-9a13-1e28079247b2"
      unitRef="usd">4250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie710509f29a84a6798f07d16fdf4bc25_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtNi0xLTEtNzc0MDc_bb659963-7858-4e70-8067-a1ced1bb981e"
      unitRef="number">0.009</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27e0991470e3476189d1336285252c30_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtOC0xLTEtNzc0MDc_8aa6c302-342b-423d-a218-7393ef9e7422"
      unitRef="usd">12817000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9da5926e9f140999d1bba65c342a33e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtMTAtMS0xLTc3NDA3_50c0fed8-eeb4-4b6a-98d4-11f9b2cc31f1"
      unitRef="usd">12395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i27e0991470e3476189d1336285252c30_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMzgtMTItMS0xLTc3NDA3_290d9523-b6fe-4158-b0ac-2bf3617c023c"
      unitRef="number">0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i601cd15753894e97b054f81a710b6ce8_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtMi0xLTEtNzc0MDc_6ab38b0a-7745-4a8b-bb27-c67addaf781a"
      unitRef="usd">350000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f5d0786855c4f85a8c2679f03a458e6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtNC0xLTEtNzc0MDc_a5bc51c8-ba8f-4c8d-9447-4d1037269f7a"
      unitRef="usd">480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i601cd15753894e97b054f81a710b6ce8_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtNi0xLTEtNzc0MDc_a807058d-dfa7-429a-88e8-628104fff1ce"
      unitRef="number">-0.270</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fb4bb0a29804fc68f9bc363715532c3_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtOC0xLTEtNzc0MDc_63436432-8ed0-44cb-ab8e-4601d5758862"
      unitRef="usd">1099000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id807a25e86074bc39f2d148f8a84be6e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtMTAtMS0xLTc3NDA3_07a534c9-e359-42c0-b030-e8d69edf28af"
      unitRef="usd">1508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2fb4bb0a29804fc68f9bc363715532c3_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDAtMTItMS0xLTc3NDA3_7712e95a-4e2a-4ccd-af69-6dffa11803e1"
      unitRef="number">-0.271</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14c31eac278e41a1ba118b6c025d1f7a_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtMi0xLTEtNzc0MDc_7b0235b8-aaf5-45ef-82e5-d15da1584c44"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e7e206e166a4e58afbaf397873c5618_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtNC0xLTEtNzc0MDc_f0640957-2582-440e-a7fd-0c73a6d24e6b"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i14c31eac278e41a1ba118b6c025d1f7a_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtNi0xLTEtNzc0MDc_985b4f05-16c7-47b1-a87e-7baab1c48154"
      unitRef="number">-0.169</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab929e3264374872bb7f54c68dd062ca_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtOC0xLTEtNzc0MDc_f44ea88a-0726-4697-9641-af53bb8c4319"
      unitRef="usd">163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4eab22cd2cda488aa69b38e14ab9166f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtMTAtMS0xLTc3NDA3_fa85c70a-5262-4b3e-a834-979b0c5063ab"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iab929e3264374872bb7f54c68dd062ca_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDEtMTItMS0xLTc3NDA3_a2254e24-dc7b-405d-aa5f-331300ce5a49"
      unitRef="number">-0.172</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib47f7963286445b1827fe6925d9837a5_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItMi0xLTEtNzc0MDc_4764cd7b-0ff9-46fe-bede-6458fa718a56"
      unitRef="usd">169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29e7b4c0a8e04fc7a1fb4736a9fc92a4_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItNC0xLTEtNzc0MDc_1310f2a2-1b10-46e2-b859-fe5a7528a784"
      unitRef="usd">234000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib47f7963286445b1827fe6925d9837a5_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItNi0xLTEtNzc0MDc_eb56d570-92d7-4d21-8dba-c156dee1bbfa"
      unitRef="number">-0.278</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7967609999b541f2b29b2c6ce68ddbc8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItOC0xLTEtNzc0MDc_2f40955c-5cab-4636-a987-9abd794f60d1"
      unitRef="usd">606000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ac3cb68f0c34215a382d7031670ff23_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItMTAtMS0xLTc3NDA3_754b161b-d169-414b-ac16-22455773cd3d"
      unitRef="usd">721000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7967609999b541f2b29b2c6ce68ddbc8_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDItMTItMS0xLTc3NDA3_d2a44334-0174-48b5-b358-4f1e1e32ad85"
      unitRef="number">-0.160</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6bd3d8de975456d820b150c1d106f90_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtMi0xLTEtNzc0MDc_580407f6-3235-449f-ad43-196bd77d72c8"
      unitRef="usd">558000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b4fc3995b69496ca407948b3dea092c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtNC0xLTEtNzc0MDc_724db83f-ab4b-458a-9b06-ee3442f26212"
      unitRef="usd">761000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia6bd3d8de975456d820b150c1d106f90_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtNi0xLTEtNzc0MDc_9b4b21f0-3413-4ed5-bd86-9eff8910610a"
      unitRef="number">-0.266</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic73b319201054f529e8ccf164554f568_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtOC0xLTEtNzc0MDc_1ce92dd4-fb7f-490b-acdb-e71a25638d89"
      unitRef="usd">1868000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cf4f4567b834309abf4b2ff42315882_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtMTAtMS0xLTc3NDA3_b97e2ba5-a36a-4f44-a5d4-cd9915128743"
      unitRef="usd">2426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic73b319201054f529e8ccf164554f568_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDMtMTItMS0xLTc3NDA3_18348597-bd9c-4b6a-b3c2-0d1ef15412ad"
      unitRef="number">-0.230</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b43ed5dbcd543d9ae7b7fd7bb075ab7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtMi0xLTEtNzc0MDc_defe4e0e-78d3-4640-a280-33ddfea29328"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c16c4c7023f4f0790700efabacf60f9_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtNC0xLTEtNzc0MDc_de9c122c-5bed-460d-a3a6-71e786453a0a"
      unitRef="usd">295000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8b43ed5dbcd543d9ae7b7fd7bb075ab7_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtNi0xLTEtNzc0MDc_d8a5e396-61aa-45bf-96a1-1c3533dc0ffa"
      unitRef="number">0.009</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35f027f36faa4af1b4f6e944c1417488_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtOC0xLTEtNzc0MDc_b43657aa-1e70-4986-996c-9acf48d345d2"
      unitRef="usd">886000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0afbd5dc3a754753a394dd6670fce509_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtMTAtMS0xLTc3NDA3_1a1bf7a5-657c-4cc7-8133-ba5e3f864728"
      unitRef="usd">840000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i35f027f36faa4af1b4f6e944c1417488_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDUtMTItMS0xLTc3NDA3_42a84120-d5df-4103-914f-b1c76eb1a32b"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc5345a5249f40379024f3ef934dd3db_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtMi0xLTEtNzc0MDc_d81b63ed-effa-4e68-b244-25c488ed4d16"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d2ca59e69a743e88208410ceda1bcba_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtNC0xLTEtNzc0MDc_6280f48d-43ce-4e19-99a8-b88840af4004"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifc5345a5249f40379024f3ef934dd3db_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtNi0xLTEtNzc0MDc_fa3b738b-4571-4501-b8ff-3daec54242ca"
      unitRef="number">-0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib294a903194d4a7187902c709f695b44_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtOC0xLTEtNzc0MDc_46e1b6ef-234b-4f83-b42d-778af207dbec"
      unitRef="usd">797000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67974f0f7a1245e7809b5204fc2509b6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtMTAtMS0xLTc3NDA3_2e925e51-f81c-473f-9f40-9a76068f1550"
      unitRef="usd">877000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib294a903194d4a7187902c709f695b44_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDYtMTItMS0xLTc3NDA3_4465ca52-9c63-4723-87e7-b581df07e98d"
      unitRef="number">-0.092</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3db40e6bab3440fbc146528ac4ef7a0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctMi0xLTEtNzc0MDc_fa42dc83-651a-4eb2-bb8d-bab8a817ef75"
      unitRef="usd">545000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6202780aca5740c78cbc6ab6252f4036_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctNC0xLTEtNzc0MDc_7e6b31d4-d023-41ed-98cd-83721c74d46c"
      unitRef="usd">571000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib3db40e6bab3440fbc146528ac4ef7a0_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctNi0xLTEtNzc0MDc_54dd8940-95bf-46e6-bd43-ce637829f35b"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifff14a1f8c334b9aadadb7babbfdd924_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctOC0xLTEtNzc0MDc_ff3c0c87-bea1-4c62-bf9c-eb740f079f38"
      unitRef="usd">1682000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0a6027ed50842c6972d5eee3da4c9c6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctMTAtMS0xLTc3NDA3_27cc52d5-a9d8-4ec5-b6d3-e4ea4a8d322a"
      unitRef="usd">1717000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifff14a1f8c334b9aadadb7babbfdd924_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDctMTItMS0xLTc3NDA3_ae907ef5-def6-4ed4-9625-f92ba70b31f9"
      unitRef="number">-0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5b800af44314d97bc6e07ab8f06ffb3_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktMi0xLTEtNzc0MDc_5ae1e1d8-1efc-4fd3-8f53-23e5fcc88a46"
      unitRef="usd">1655000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id938e01bb77e45deb2dd767caac9cdff_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktNC0xLTEtNzc0MDc_eb5dd764-166b-47a1-9c57-4ba274819899"
      unitRef="usd">1569000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie5b800af44314d97bc6e07ab8f06ffb3_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktNi0xLTEtNzc0MDc_a0985353-228a-4ae6-abc9-d7acc4f6a056"
      unitRef="number">0.055</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60bca8e9e03447268cf3bf5aee0f765e_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktOC0xLTEtNzc0MDc_8c3480a0-f954-4720-9a12-8e7e88c71ca6"
      unitRef="usd">4766000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c5c096bdb6c47b695ac4b997e09e315_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktMTAtMS0xLTc3NDA3_8d4ef654-e481-40da-a208-d722a341be43"
      unitRef="usd">4396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i60bca8e9e03447268cf3bf5aee0f765e_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNDktMTItMS0xLTc3NDA3_d27162cb-3157-4297-a81f-95bd6c447bd3"
      unitRef="number">0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea479d1c88df4fae9e4ce67cffee6742_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtMi0xLTEtNzc0MDc_cda29a62-b4d4-418f-b6cb-299e832be683"
      unitRef="usd">794000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i618dbaeeb2c24741aa3cbe519fe58c50_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtNC0xLTEtNzc0MDc_30e30dcd-4acd-402c-b05f-cddc833eacc2"
      unitRef="usd">809000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iea479d1c88df4fae9e4ce67cffee6742_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtNi0xLTEtNzc0MDc_7e551b6e-1ad0-4e3e-8850-6633b8f6f7e1"
      unitRef="number">-0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8086f446324048e2a9c8937b0ced6d84_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtOC0xLTEtNzc0MDc_0d8a293e-3e8e-4026-9e45-afdba5a6aad0"
      unitRef="usd">2571000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b22d7a7eb564fce9cb4052d7a41c913_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtMTAtMS0xLTc3NDA3_528e4874-6258-4b8b-99e2-d726d1fb8239"
      unitRef="usd">2404000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8086f446324048e2a9c8937b0ced6d84_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTAtMTItMS0xLTc3NDA3_a991d0e7-9c4b-4b7b-b81e-ebfb01df6e83"
      unitRef="number">0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i059e1b1f3a53490db3d19ba632df2180_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtMi0xLTEtNzc0MDc_d6d4e47e-c35c-4b41-b6ad-2372a7d4f9c2"
      unitRef="usd">2449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0008e6798c040f696f04e80c67a9f1f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtNC0xLTEtNzc0MDc_4292bd4b-d834-4ef1-b293-834e7991bab7"
      unitRef="usd">2378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i059e1b1f3a53490db3d19ba632df2180_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtNi0xLTEtNzc0MDc_e8998345-365a-4f3d-94a8-398e1fbaf73c"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec6ee4cea0654427bd1841c05b22220d_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtOC0xLTEtNzc0MDc_6839f0a2-e247-414f-9a48-a649fa640b97"
      unitRef="usd">7336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7db6efcbef124e2cbfa8b06aaf5015e1_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtMTAtMS0xLTc3NDA3_9f5f0e26-d754-4ba0-bad3-7f9fe9a84813"
      unitRef="usd">6800000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iec6ee4cea0654427bd1841c05b22220d_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTEtMTItMS0xLTc3NDA3_756b4260-e9b0-4b43-a530-86ac32435e60"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ab89cc409f64d07bce8e87a8fdf95c7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtMi0xLTEtNzc0MDc_40fc483c-f1ab-4507-8893-b7fa09f4e87e"
      unitRef="usd">530000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c6fc771e5cf47a7964910a8424d9aa6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtNC0xLTEtNzc0MDc_a98f745f-048c-4145-87b0-628d1ede27a2"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4ab89cc409f64d07bce8e87a8fdf95c7_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtNi0xLTEtNzc0MDc_1c2816ae-0b3c-4f5d-8192-c2111f55a47d"
      unitRef="number">0.407</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9b5a3ff0712432c9a8b2bec26f39b4d_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtOC0xLTEtNzc0MDc_7b8b801f-ac90-4d6e-9b03-ae16b5195c1e"
      unitRef="usd">1303000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic969d91a8c6340d49f4ca9c6d0a168bd_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtMTAtMS0xLTc3NDA3_02adb906-808e-4861-bb15-bdea206eaece"
      unitRef="usd">975000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if9b5a3ff0712432c9a8b2bec26f39b4d_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTMtMTItMS0xLTc3NDA3_c4fa9928-5e53-45a2-abd9-f3de5a85a48e"
      unitRef="number">0.336</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i611a544e7fed48459222bd6dba1e2fff_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtMi0xLTEtNzc0MDc_96df341a-4d82-48ed-b95a-50bedfef1589"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i532f597a8ed14fc5aaa5997db648cfba_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtNC0xLTEtNzc0MDc_02f282e2-20cc-4e5f-abe6-02fb5b1e76a1"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i611a544e7fed48459222bd6dba1e2fff_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtNi0xLTEtNzc0MDc_5d66b278-31b7-4d64-9e6c-bb3a3447efd7"
      unitRef="number">0.246</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5a81309c93e40bbb6520a059a567fc9_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtOC0xLTEtNzc0MDc_4d7c5f70-e788-4c46-9f61-e514c6cd79b9"
      unitRef="usd">613000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75bc3e4b7f0f4bebbec4aa452e444d00_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtMTAtMS0xLTc3NDA3_07e25301-183b-47cf-84c8-45ec9b4e411b"
      unitRef="usd">459000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib5a81309c93e40bbb6520a059a567fc9_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTQtMTItMS0xLTc3NDA3_83c42ee2-1e9a-4132-8d07-961c5a566b5a"
      unitRef="number">0.337</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i045bb0bb60d64408bc746a0b601e9798_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtMi0xLTEtNzc0MDc_4dcde3da-5e81-4022-b2e8-1df9d80d7ebf"
      unitRef="usd">729000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73cbadc80e7d49bfab612db1296213d4_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtNC0xLTEtNzc0MDc_02516780-cbf3-4d54-9194-d3c8b53d01e4"
      unitRef="usd">537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i045bb0bb60d64408bc746a0b601e9798_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtNi0xLTEtNzc0MDc_c2ab594d-cb99-4e2e-bab3-4c3c157caaa6"
      unitRef="number">0.359</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02219b77430640bcb4d575751528f347_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtOC0xLTEtNzc0MDc_f6b25e07-cb9a-4990-be1f-69e7baee6319"
      unitRef="usd">1916000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0e29062c8fe44fd9b3dc53b1dcfddc0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtMTAtMS0xLTc3NDA3_7b1f02ea-cb42-4877-9e1f-f209defbef6a"
      unitRef="usd">1434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i02219b77430640bcb4d575751528f347_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTUtMTItMS0xLTc3NDA3_a14680d0-58e8-4460-b624-cd09af6a66ba"
      unitRef="number">0.336</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iade60d9fbc69468ea53b4630449ae23d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTctMi0xLTEtNzc0MDc_45b6c98e-ae16-485e-9878-2bc49f2ad7f8"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48d8585ed15e4dd9b2a5802f367ad706_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTctNC0xLTEtNzc0MDc_ebcb1f7b-b8b0-4df8-a42b-4f5570bffd26"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f6578cdec5d474fb61356ea6723f969_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTctOC0xLTEtNzc0MDc_a5dd101d-de5f-4b7f-8b7f-fca50b922c3f"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i539ed9db6fc4408cb8bf66316e3d162b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTctMTAtMS0xLTc3NDA3_c751bf29-eb6e-409f-9859-4cbbaeea96ea"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1f6578cdec5d474fb61356ea6723f969_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTctMTItMS0xLTc3NDA3_3bdd1c77-28fb-4d63-be72-18af7c2fd38b"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i113f00d20dd64c9c8ec5149aaec8e0e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTgtMi0xLTEtNzc0MDc_f70dcbc5-1d03-44a0-88cd-116724f26d54"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14d2acd0bff348a696db84de99c97bfb_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTgtNC0xLTEtNzc0MDc_c45eece1-3e2a-471e-9a5a-7477b298d5db"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i438b4b2bfa6b4080af4749683d1d6535_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTgtOC0xLTEtNzc0MDc_c984d639-6e30-4ce7-a66c-89fd0904bba4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e88b65375c744c690cb9f2531ad1947_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTgtMTAtMS0xLTc3NDA3_fe32225e-f811-4157-9db0-746e501e92cd"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i777a5ad66b154207965e26b2bac930d7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTktMi0xLTEtNzc0MDc_f6b868c4-c3bf-4867-8c54-d705b20bcee0"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20227083c87e481eacfb2dd925179f5b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTktNC0xLTEtNzc0MDc_fd8e1245-868b-4226-8b03-e7c262796247"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5446bf9970a24b6b937fb2036be6ff7c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTktOC0xLTEtNzc0MDc_730f31f0-706c-4570-867b-dfbeeaca0f02"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4543179c68d4c82a76af5e632f3aa8b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTktMTAtMS0xLTc3NDA3_3795aa56-8daf-46fb-b80c-19c08d372adf"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5446bf9970a24b6b937fb2036be6ff7c_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNTktMTItMS0xLTc3NDA3_e470e269-21d7-4414-98f0-39529d4e5914"
      unitRef="number">-0.193</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id59930ef089148a392af915228263641_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItMi0xLTEtNzc0MDc_47368de9-84fc-4338-980b-9dad9d191bf1"
      unitRef="usd">390000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c253c52c7ee4f25a276574c0adf9fe3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItNC0xLTEtNzc0MDc_b2825b21-7a08-4448-aec8-86511d9833b5"
      unitRef="usd">679000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id59930ef089148a392af915228263641_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItNi0xLTEtNzc0MDc_d24f025b-fa03-49be-b78a-f3f310100fcc"
      unitRef="number">-0.427</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if48bf4caae12427a934bf19365269a73_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItOC0xLTEtNzc0MDc_316772e8-17ce-4a59-8119-4cbdb0c20781"
      unitRef="usd">1266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e97e36903074830b97a3f886bbda733_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItMTAtMS0xLTc3NDA3_5e367d68-88b4-4cc4-a995-6f84953096cc"
      unitRef="usd">1635000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if48bf4caae12427a934bf19365269a73_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjItMTItMS0xLTc3NDA3_7c807d2e-e262-4302-81a7-c643a346a415"
      unitRef="number">-0.226</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94fa08b8cbd0498cb485bc7b48711e3b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtMi0xLTEtNzc0MDc_53be8a00-0096-4fae-bcd7-0a767a8b57cc"
      unitRef="usd">905000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff2bdce36f584334bc4721f3d6131a87_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtNC0xLTEtNzc0MDc_a46f9a62-29ab-4d9c-9503-eec7ff8e6ff7"
      unitRef="usd">698000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i94fa08b8cbd0498cb485bc7b48711e3b_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtNi0xLTEtNzc0MDc_f74cdf86-9c39-4246-a8f0-076a01cc2bf6"
      unitRef="number">0.297</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5acf2a6ea8034d3e9b7d7074924ada01_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtOC0xLTEtNzc0MDc_6015893c-9657-4dc2-b7af-ed54f6852083"
      unitRef="usd">2642000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14747989f826463ca3488654f17be9f5_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtMTAtMS0xLTc3NDA3_a40d8d39-bd65-44c3-b2c1-904ad7901e87"
      unitRef="usd">1758000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5acf2a6ea8034d3e9b7d7074924ada01_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjMtMTItMS0xLTc3NDA3_bc0c6489-65e7-420e-82fc-679664619290"
      unitRef="number">0.503</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a1127e192c04223a462719cdaa10ae0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtMi0xLTEtNzc0MDc_01695cc6-13a9-4f07-ba28-a97f0d8cc7b7"
      unitRef="usd">1295000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55656c2263544ef8b6e0bad424c168b7_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtNC0xLTEtNzc0MDc_b9028e9c-92e8-4a81-abc2-e1e7ff1b12f7"
      unitRef="usd">1378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4a1127e192c04223a462719cdaa10ae0_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtNi0xLTEtNzc0MDc_29ba9019-4769-413c-b3eb-753320f014bf"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f0d1ddf2bf748eb9fb05773730d69a5_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtOC0xLTEtNzc0MDc_96898518-30bd-4278-ad09-421e7b8bc22f"
      unitRef="usd">3908000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if490f8f38569467da82013ec07af4dc0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtMTAtMS0xLTc3NDA3_253d5bd4-900e-4ac6-ae61-03e58773c940"
      unitRef="usd">3394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6f0d1ddf2bf748eb9fb05773730d69a5_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjQtMTItMS0xLTc3NDA3_67c76d88-b2af-4adb-8382-f519019dafcf"
      unitRef="number">0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fcbba0ef29f4f6fbad46f21014a1b89_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjYtMi0xLTEtNzc0MDc_8b6ce3a5-604b-4052-b892-75e5893674fa"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd0faf0da5f04c0992e10094b3f8e97c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjYtNC0xLTEtNzc0MDc_8231d942-6654-4a10-a648-96064e38f568"
      unitRef="usd">270000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6191e64a17bc461c9838efdd458364cf_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjYtOC0xLTEtNzc0MDc_4797a437-1a20-4d30-b557-29dfb0242e41"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc6597880ac74bf48cc5795eaf19e569_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjYtMTAtMS0xLTc3NDA3_58b10de5-69e9-426d-b67d-4604269f54af"
      unitRef="usd">421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6191e64a17bc461c9838efdd458364cf_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjYtMTItMS0xLTc3NDA3_e29450b7-1a3f-45c0-992e-b7598f65ceae"
      unitRef="number">-0.715</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf91d92c233a4dbfa5243a026f870176_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjctMi0xLTEtNzc0MDc_888821c2-5622-4d53-b041-a65e849ddf45"
      unitRef="usd">489000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icddabaad4cf84f18995b0dfd4ec27309_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjctNC0xLTEtNzc0MDc_5ed94443-07a4-4247-9ff1-581705cccade"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1a722add33f4a4e970219beb9128bbc_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjctOC0xLTEtNzc0MDc_8aeef6be-5f94-4f39-8175-8bc2d00887cd"
      unitRef="usd">1370000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbb9d283788741abb9be248c18d56115_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjctMTAtMS0xLTc3NDA3_a4a7de14-d29a-4cfc-8d71-b0f6c7af866c"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba72ecd0fd3b47c6b352e266260fc5cf_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjgtMi0xLTEtNzc0MDc_aece5654-f77e-4d16-809d-67e8d7b5ef4b"
      unitRef="usd">489000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib213aac39dd14e45914c3a0c2bf6713c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjgtNC0xLTEtNzc0MDc_4509bc1c-cf94-4e14-99d2-8ab4710bd408"
      unitRef="usd">502000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iba72ecd0fd3b47c6b352e266260fc5cf_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjgtNi0xLTEtNzc0MDc_33376d9b-3755-4d39-b84e-d647a25c65a7"
      unitRef="number">-0.027</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8d296b6dadd4d958ffe5990c80d6a0c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjgtOC0xLTEtNzc0MDc_0c21881b-4bdc-4f87-b649-9765fca826f0"
      unitRef="usd">1490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83db602d21fc49c098bf5479b3b020f9_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNjgtMTAtMS0xLTc3NDA3_61b5dc6b-5828-4d9f-b3c4-a3a258a57c12"
      unitRef="usd">766000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf51711c9fc9401ea85ff7dab87f84e2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtMi0xLTEtNzc0MDc_29aed3a1-c8a0-44d4-8824-e2026525e6ae"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i413c6a3f140542e58e400aa2f983c6e5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtNC0xLTEtNzc0MDc_3a629e62-a970-4c2a-99b7-a49cbfef05ab"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icf51711c9fc9401ea85ff7dab87f84e2_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtNi0xLTEtNzc0MDc_64fc13de-a325-4e3d-8dad-45c3f5b53382"
      unitRef="number">-0.271</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67e44ed2293b4d0ca08120085f5e960d_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtOC0xLTEtNzc0MDc_1140684e-46a7-420d-b6f9-0e257a6457e2"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4b33e65c46b4a568b37f7326d33ae1e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtMTAtMS0xLTc3NDA3_89589aac-a892-41d1-99fd-03bf9ec53d00"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i67e44ed2293b4d0ca08120085f5e960d_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzAtMTItMS0xLTc3NDA3_33b60f80-5a5c-477c-83a4-2c15e0be2b90"
      unitRef="number">-0.145</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4345727efc2f4029a0ed4bd19dcf7bfd_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtMi0xLTEtNzc0MDc_6a2a6626-96cc-4ba1-8d1f-cbd9dcbc9fda"
      unitRef="usd">237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i054f2ca9d0cb4fb8b157c2706a23ca76_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtNC0xLTEtNzc0MDc_b0aa9c6d-2bce-43ac-8379-68346a1f4caa"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4345727efc2f4029a0ed4bd19dcf7bfd_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtNi0xLTEtNzc0MDc_10a53e5b-8094-4c4a-9b2d-a17cbd716ff5"
      unitRef="number">-0.042</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76df4b1c1d904841a08d373dc471035c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtOC0xLTEtNzc0MDc_a69f9606-97b4-441c-86fd-4588e4ee7c3f"
      unitRef="usd">691000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46fb64831ae740e8819f320229d29799_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtMTAtMS0xLTc3NDA3_140c268d-0a3c-4d8f-b2f1-e1535100ee28"
      unitRef="usd">733000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i76df4b1c1d904841a08d373dc471035c_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzEtMTItMS0xLTc3NDA3_95dd87ab-042f-484c-967a-c4745be902a7"
      unitRef="number">-0.057</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i374469fd1fe84b23986b0e14cfccfc49_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItMi0xLTEtNzc0MDc_5e2c23ce-a6a9-454e-abdf-c9571c2a1375"
      unitRef="usd">245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bbe137b43fd4b918335c8497edf70c1_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItNC0xLTEtNzc0MDc_f5cb3dd3-2fa4-47d0-a529-f69ca9172b8e"
      unitRef="usd">259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i374469fd1fe84b23986b0e14cfccfc49_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItNi0xLTEtNzc0MDc_55c23dda-5ea9-440b-a641-7b53a9150591"
      unitRef="number">-0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32c68d6e42284bbfb401b21b31fe0f06_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItOC0xLTEtNzc0MDc_e10e61a4-848b-42f8-882b-edad1ced569a"
      unitRef="usd">718000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife8189ee4e82488592a6e11bb1a45d3a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItMTAtMS0xLTc3NDA3_95bcbc52-71a7-4f4e-af05-4cffb4367ef0"
      unitRef="usd">764000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i32c68d6e42284bbfb401b21b31fe0f06_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzItMTItMS0xLTc3NDA3_bd0d84d1-f947-4395-b06d-4bb642052226"
      unitRef="number">-0.061</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84e3265b7db3479d856ade508a46ed66_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtMi0xLTEtNzc0MDc_1256cbaf-a2f7-4873-b75b-6e11a1c3d31d"
      unitRef="usd">372000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7faac73e2f23406cb8eb7dbe1944acdf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtNC0xLTEtNzc0MDc_d18a9d54-3f08-4a18-aad8-35eae62fb6fd"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i84e3265b7db3479d856ade508a46ed66_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtNi0xLTEtNzc0MDc_b8f89818-48fc-433c-9f85-1d771edb1feb"
      unitRef="number">-0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b2795880e984fa283bc3a164283cb1c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtOC0xLTEtNzc0MDc_da50c09c-890f-4e48-8558-ecf4bf8a827a"
      unitRef="usd">1096000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e3eb5daefce43a7ace1a8549cc00d5c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtMTAtMS0xLTc3NDA3_6a280055-c372-46b1-b522-9860287f63ce"
      unitRef="usd">1128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2b2795880e984fa283bc3a164283cb1c_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzQtMTItMS0xLTc3NDA3_4f3ddd2e-d60d-40f2-9e8b-d3831475e7a0"
      unitRef="number">-0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53e3c10757fd42b993341c8066c8b790_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtMi0xLTEtNzc0MDc_d3fda435-0492-4fda-8b09-f932b96cf509"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4d204cb63f34d5f990c71beecdb6abb_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtNC0xLTEtNzc0MDc_7ac67ad9-ada9-4edb-8461-1005a8b6b9d0"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i53e3c10757fd42b993341c8066c8b790_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtNi0xLTEtNzc0MDc_3289ec07-f42f-42c0-8992-b56cd397fb63"
      unitRef="number">-0.179</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifef1f530ace84a29a6481dcddde7acf2_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtOC0xLTEtNzc0MDc_a3eedb7d-82c3-4a6e-a0ec-8b6fbbb5ecf2"
      unitRef="usd">354000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb1aab6ee7734aaa9c1c053a59b47312_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtMTAtMS0xLTc3NDA3_ad2b657e-5c80-4204-9b0c-9a1f174d2a2d"
      unitRef="usd">440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifef1f530ace84a29a6481dcddde7acf2_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzUtMTItMS0xLTc3NDA3_1c2d7e8e-dd15-4c2d-8ef6-899a579a0079"
      unitRef="number">-0.195</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7aea2bc286e74c24ab2637ca0d209a3c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtMi0xLTEtNzc0MDc_bbb1f125-0833-45c5-9876-aa658d931ac2"
      unitRef="usd">485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58f24b47415f48b0885b0d7c10967969_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtNC0xLTEtNzc0MDc_e7732a68-812d-45f8-bb76-b00bf1260567"
      unitRef="usd">517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7aea2bc286e74c24ab2637ca0d209a3c_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtNi0xLTEtNzc0MDc_d5bb0e8a-5781-4f4b-8915-73938387e548"
      unitRef="number">-0.064</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic305652d07704e98ba5feacfb2d5f00d_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtOC0xLTEtNzc0MDc_04dc15a4-47ef-484f-beb9-c2dcdddaef20"
      unitRef="usd">1450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33a0efdb63c04fa69e366975a05bb13f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtMTAtMS0xLTc3NDA3_30e2e8f5-1540-4e57-afca-99ec96322f76"
      unitRef="usd">1568000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic305652d07704e98ba5feacfb2d5f00d_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfNzYtMTItMS0xLTc3NDA3_0ff2f79e-fea5-4484-af83-c405b3d9ca3e"
      unitRef="number">-0.075</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i177dc85392db469a8c1db91c948cdd05_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtMi0xLTEtNzc0MDc_f489b4e6-6f4a-432b-b1af-ecbd1a606e8f"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied3e8bd6206b4ee5a70504f5d9b66667_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtNC0xLTEtNzc0MDc_e2c2b124-58ef-4ced-9c42-bd47f0fc795c"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i177dc85392db469a8c1db91c948cdd05_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtNi0xLTEtNzc0MDc_c545c1c4-704d-4ea8-8e13-791d53bad3f0"
      unitRef="number">-0.464</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9610be906255476eab03ae58f21e9645_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtOC0xLTEtNzc0MDc_6d3e93bb-67a9-47cc-9338-6e0564354001"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8979440d00f14555833df82de8200c08_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtMTAtMS0xLTc3NDA3_3834d242-7a17-4c1d-8ffc-1e8249c79c71"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9610be906255476eab03ae58f21e9645_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODAtMTItMS0xLTc3NDA3_ecb6bb25-88b6-4cf4-b0d4-67d310a6c268"
      unitRef="number">-0.572</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5af5e8ef63074a068a23d526b83f8c0f_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtMi0xLTEtNzc0MDc_6b69c364-b219-4eef-9ca1-34dbb96a0740"
      unitRef="usd">68000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7a94a1625b94c1e93bba0b6e6b48f6e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtNC0xLTEtNzc0MDc_43c9d68d-b773-4612-bba7-2af9b52ae5e7"
      unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5af5e8ef63074a068a23d526b83f8c0f_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtNi0xLTEtNzc0MDc_a7d9d6b9-a76e-42a1-a935-40088a7b58d1"
      unitRef="number">-0.171</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe25061e631e414e92da52fa72c80da1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtOC0xLTEtNzc0MDc_e4fa116b-118d-46c2-b5c2-ff1b8f3d8e05"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i976e2778a2084719a4234e95ad13c666_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtMTAtMS0xLTc3NDA3_ca7a3f55-9d5c-4706-b714-5c010db1d520"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibe25061e631e414e92da52fa72c80da1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODEtMTItMS0xLTc3NDA3_2211dd7a-ccca-43bb-8d14-527ec329a83d"
      unitRef="number">-0.050</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecbfb31a552f4de39c19d87cb748cc94_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItMi0xLTEtNzc0MDc_f6949069-dc98-4cff-b340-9d88c991a821"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c1202469d66404db95107a79c2868a0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItNC0xLTEtNzc0MDc_eda126e3-8efe-463e-bef0-214c8493f4d6"
      unitRef="usd">99000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iecbfb31a552f4de39c19d87cb748cc94_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItNi0xLTEtNzc0MDc_8eb67f87-973d-4222-98b9-03dd3fd5b17f"
      unitRef="number">-0.224</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dd1abaa86844d559d8ce0f5cf23ff7c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItOC0xLTEtNzc0MDc_1c8d0d93-da31-4041-aa94-4fd675d26719"
      unitRef="usd">251000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaa1aba1c6e8477da278328f0b8c7659_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItMTAtMS0xLTc3NDA3_c9df8f2e-0057-41a4-a693-e8ee3744485d"
      unitRef="usd">295000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3dd1abaa86844d559d8ce0f5cf23ff7c_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODItMTItMS0xLTc3NDA3_68168bc5-0d73-4fba-90f2-ae6fc6b179ae"
      unitRef="number">-0.148</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa25cbf4d9754df6ba84b4ef2d383458_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtMi0xLTEtNzc0MDc_808358a3-7ff4-4324-bf80-e30387986627"
      unitRef="usd">919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedfbfd4bd41c4c5187cf6e182e899660_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtNC0xLTEtNzc0MDc_93326aa5-3669-47a9-bc12-0c2a24e25941"
      unitRef="usd">835000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaa25cbf4d9754df6ba84b4ef2d383458_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtNi0xLTEtNzc0MDc_ff337655-8c07-4939-ad7b-5b877e839527"
      unitRef="number">0.100</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1612b190f4f14f649d1d8aaf00cdd1c6_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtOC0xLTEtNzc0MDc_f84a56b7-b1d0-45fd-ac8a-b8427efa3704"
      unitRef="usd">2658000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i968f6b90e0d24fbf8745420b22f191a9_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtMTAtMS0xLTc3NDA3_2bb08870-2e25-4457-b49b-c8e860d24d9a"
      unitRef="usd">2448000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1612b190f4f14f649d1d8aaf00cdd1c6_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODUtMTItMS0xLTc3NDA3_48e43ccc-5b0b-4812-86da-72c1ec5e907d"
      unitRef="number">0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaec7a45f95d444fc9c23636a25fc71b4_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtMi0xLTEtNzc0MDc_22f5cd97-1912-40a4-a09f-9d0bf3d57252"
      unitRef="usd">763000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie877d3091b2a412cada21c76c157025a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtNC0xLTEtNzc0MDc_22725b53-eb28-48f9-b867-4853d882fc8c"
      unitRef="usd">845000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaec7a45f95d444fc9c23636a25fc71b4_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtNi0xLTEtNzc0MDc_869491bd-eca1-4228-ae5c-747532224e79"
      unitRef="number">-0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i823acd2fea2640ddb3d3f3ab09a21a0a_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtOC0xLTEtNzc0MDc_5c77b5d1-b47e-4574-bea9-b6de56dca8ba"
      unitRef="usd">2498000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac2c5b49a0b14b7886ce8b9cb93667c8_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtMTAtMS0xLTc3NDA3_444692fc-9fa9-4254-93bc-9c7323ecc9f7"
      unitRef="usd">2751000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i823acd2fea2640ddb3d3f3ab09a21a0a_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODYtMTItMS0xLTc3NDA3_4550e0ae-0198-4886-815d-d8e054370b72"
      unitRef="number">-0.092</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieba37868d4ab40a494a8932e5c195ce0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctMi0xLTEtNzc0MDc_12dff2e9-ad91-47d5-b860-d87ce60e1be9"
      unitRef="usd">1681000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0705f1796374a95b4f177ad23d8fa53_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctNC0xLTEtNzc0MDc_b6510c5d-646e-4821-8be2-e46ef9f02862"
      unitRef="usd">1680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieba37868d4ab40a494a8932e5c195ce0_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctNi0xLTEtNzc0MDc_40e92951-f719-4ee8-96a3-9016a6a9f33b"
      unitRef="number">0.0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5b2ee0a4ccb47b689fde9e511d136bc_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctOC0xLTEtNzc0MDc_df7324c4-0e27-4936-8f57-b1dd22ceb1b6"
      unitRef="usd">5156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id289d5f0f10e4ee799a2e6ea8bd1d88f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctMTAtMS0xLTc3NDA3_acebab13-d5ac-4fb2-962c-5067a4fd0fa2"
      unitRef="usd">5199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id5b2ee0a4ccb47b689fde9e511d136bc_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODctMTItMS0xLTc3NDA3_929bdf37-8b40-4013-b6af-8143adf84357"
      unitRef="number">-0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cd7004acb80425580aeab7c75bcb925_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktMi0xLTEtNzc0MDc_333954a5-b672-4e15-9586-ff7ae79280e6"
      unitRef="usd">41000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b2cb42ee1f24a339b3c00347bb66920_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktNC0xLTEtNzc0MDc_e28b2e7a-a2bf-4f9d-831e-931236729932"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0cd7004acb80425580aeab7c75bcb925_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktNi0xLTEtNzc0MDc_eb3735c7-b1a4-4160-8eae-7d087ef0f976"
      unitRef="number">0.193</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf202bcc43b74c6e97e4400e94a50ef9_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktOC0xLTEtNzc0MDc_41ace2e4-00cb-4617-84fe-5dd148e32e0e"
      unitRef="usd">114000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib390ee20bcf14042acab18119fdcb669_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktMTAtMS0xLTc3NDA3_d1298dd1-7b24-4119-86bf-728d16695a18"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idf202bcc43b74c6e97e4400e94a50ef9_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfODktMTItMS0xLTc3NDA3_b23565f8-90f8-4f55-9496-0757e3005d1c"
      unitRef="number">-0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11dfd015a75b4884aaf7606edf7f9f0a_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtMi0xLTEtNzc0MDc_788b1e76-0b16-402b-9112-a8f5e97f4e24"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45a4897765d040e2aef60f9e024a65d8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtNC0xLTEtNzc0MDc_388945ca-27bc-4d38-9be1-33fe53dcced2"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i11dfd015a75b4884aaf7606edf7f9f0a_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtNi0xLTEtNzc0MDc_d6f3eac1-5ede-4605-a793-a230718548ea"
      unitRef="number">-0.044</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ead4e3e50cf4bfeba22c28a2397048c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtOC0xLTEtNzc0MDc_52b32043-256c-483c-9415-eb844493ec44"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa16021f57ab4f1caa859b2705fd46a2_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtMTAtMS0xLTc3NDA3_1f76a271-58d7-4902-8146-1b8613dd09b3"
      unitRef="usd">372000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0ead4e3e50cf4bfeba22c28a2397048c_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTAtMTItMS0xLTc3NDA3_449074a0-cc5d-48f9-9b98-af9a2661b112"
      unitRef="number">-0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0e31c64d572445bb6085f0d2c49ea4b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtMi0xLTEtNzc0MDc_835d2d21-7cac-4145-a472-b505bf57abc1"
      unitRef="usd">158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd460e77c2eb4aa3be50b1cdf64ac81d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtNC0xLTEtNzc0MDc_5fb72534-981b-4188-80ea-8c3aa5b9a996"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia0e31c64d572445bb6085f0d2c49ea4b_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtNi0xLTEtNzc0MDc_58d1a9b7-3c80-4090-8685-ab26285f1447"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icca3698a549d4feda795428aba1c8625_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtOC0xLTEtNzc0MDc_64341a2b-0557-4c24-8d93-b37d43fe896e"
      unitRef="usd">476000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49a96dfb6d88408fb4483ed241d5e788_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtMTAtMS0xLTc3NDA3_a52ce96b-019d-4dbe-97d4-f2a2fcb90062"
      unitRef="usd">489000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icca3698a549d4feda795428aba1c8625_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTEtMTItMS0xLTc3NDA3_7755f128-2a1c-4fd0-a304-44d58fa7d028"
      unitRef="number">-0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i137cde1513484ea6a0ba43bca08f33f7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtMi0xLTEtNzc0MDc_c7f243be-14ce-4082-9099-30d79881a505"
      unitRef="usd">684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibab5433d88374b8f9bd823c575a7a039_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtNC0xLTEtNzc0MDc_89d5ce76-e101-4dc4-9226-6c95644e4723"
      unitRef="usd">648000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i137cde1513484ea6a0ba43bca08f33f7_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtNi0xLTEtNzc0MDc_258d2f27-82d7-4253-8a36-76ef48a93a4b"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d7a58a2310f449cafcd3b8351c93cfe_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtOC0xLTEtNzc0MDc_b5b2d816-f010-4efb-a553-d60afe6401b6"
      unitRef="usd">2036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e55ac0a94064596be5e7888ac1c9bec_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtMTAtMS0xLTc3NDA3_2757dea4-9ffc-430f-aa27-644341e30a3e"
      unitRef="usd">1882000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7d7a58a2310f449cafcd3b8351c93cfe_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTMtMTItMS0xLTc3NDA3_c91f4295-e737-4c30-8ded-eeace5ca5e52"
      unitRef="number">0.081</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie09bdbc4c576474ba2cece696d19cb68_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtMi0xLTEtNzc0MDc_62b82a76-ebaa-4a26-bb8d-8f0bc972dbb8"
      unitRef="usd">348000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedf94af89fe14fea8f4a33af0a883c1a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtNC0xLTEtNzc0MDc_3466a044-dbb6-4ab8-8b4f-215570584248"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie09bdbc4c576474ba2cece696d19cb68_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtNi0xLTEtNzc0MDc_f13b102a-4601-444b-bdd5-845df9ca2255"
      unitRef="number">-0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79c0238a6fff4c91bf6b829e1e0e6892_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtOC0xLTEtNzc0MDc_cd0f1d01-682f-49a2-82a1-9ced9735df9c"
      unitRef="usd">1097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ad2fa156fe5432eb82a37c862ef94fb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtMTAtMS0xLTc3NDA3_a5d8a634-7494-41b0-8a4b-c193cfb94416"
      unitRef="usd">1111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i79c0238a6fff4c91bf6b829e1e0e6892_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTQtMTItMS0xLTc3NDA3_12c6a435-2a3a-46fd-8ff2-cff4564c45ee"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45a7b092ca9844859eac9399e8268977_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtMi0xLTEtNzc0MDc_e280ccd5-ecd5-4407-874f-9cbd5ddb9ccc"
      unitRef="usd">1031000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62f741d423224f489272cc2103a2be77_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtNC0xLTEtNzc0MDc_b4498783-1e86-4734-9ae2-7cb6fff1188d"
      unitRef="usd">1004000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i45a7b092ca9844859eac9399e8268977_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtNi0xLTEtNzc0MDc_f0bd6415-e8ea-4ae6-8087-120841df53d1"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ac7374616114d02b1ef9e3af61e8c95_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtOC0xLTEtNzc0MDc_2741a272-2e05-4f48-b308-223c25e2da6f"
      unitRef="usd">3132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4365f12a95234c7dbbcbde1b929baee3_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtMTAtMS0xLTc3NDA3_9ef81c1e-e8d6-4828-bac6-46b3685e648b"
      unitRef="usd">2994000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2ac7374616114d02b1ef9e3af61e8c95_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTUtMTItMS0xLTc3NDA3_329c6dd2-af7d-4526-a739-757b8d94ce6e"
      unitRef="number">0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe1eed427e824c31a74eb9fd41fbaa1e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctMi0xLTEtNzc0MDc_701b5593-cc67-47d1-94e6-ebc0499e26a2"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie11b64a00633401683a6ce25e6f615fb_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctNC0xLTEtNzc0MDc_21afcaf4-5a2b-4849-815d-aab94e7ffc1a"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibe1eed427e824c31a74eb9fd41fbaa1e_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctNi0xLTEtNzc0MDc_7ed676c0-b375-4d94-8354-e0cadef89638"
      unitRef="number">-0.061</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9968c0bccd0448c9a01e166ab918a984_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctOC0xLTEtNzc0MDc_460e7383-612e-4ec1-8562-d05073f2830d"
      unitRef="usd">195000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b46d64b60414934aca49f64ba9e5f60_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctMTAtMS0xLTc3NDA3_ff1ec17a-ae1a-4903-954d-f21d927ec842"
      unitRef="usd">210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9968c0bccd0448c9a01e166ab918a984_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTctMTItMS0xLTc3NDA3_43796aba-6920-4bef-b974-0f4100e860f8"
      unitRef="number">-0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1580db90b0e48cc893c81fb2540cb41_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtMi0xLTEtNzc0MDc_9b36aa4b-c96f-4c9d-a39f-fef74cd21e0e"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22a0e4c73916450babe25165d391d6bc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtNC0xLTEtNzc0MDc_a75a2202-d335-4abe-bea5-8f14bf7b31de"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib1580db90b0e48cc893c81fb2540cb41_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtNi0xLTEtNzc0MDc_22deb5a8-6bd4-4336-b2d7-c76c30f5d895"
      unitRef="number">-0.242</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide5f51b2ac144660a667a5fef9ab26d4_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtOC0xLTEtNzc0MDc_126fb367-6ae0-48d6-b14a-6b745df1c42b"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a52f1a99905452fb46ab62760965f86_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtMTAtMS0xLTc3NDA3_1d21f116-90b8-4b17-8106-0b0f3db722e1"
      unitRef="usd">242000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ide5f51b2ac144660a667a5fef9ab26d4_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTgtMTItMS0xLTc3NDA3_19330906-0457-46ec-8400-6cdd53998e55"
      unitRef="number">-0.263</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a2a628c1fc440eca687de37f708aa8c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktMi0xLTEtNzc0MDc_71ec06e7-abc3-4076-a13d-6894a05fc1e5"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52da69a2389c48eb9e42c1a2ea47bd75_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktNC0xLTEtNzc0MDc_90a46f9e-53a8-4cb9-b573-842b84d1a45f"
      unitRef="usd">140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a2a628c1fc440eca687de37f708aa8c_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktNi0xLTEtNzc0MDc_5bd0151d-ff35-444f-82ce-b3d9385daa1a"
      unitRef="number">-0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66a7d12f22764dbb8759a742d94eb8a2_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktOC0xLTEtNzc0MDc_21bfd868-37b1-4c2d-ace2-0bdc84d65f25"
      unitRef="usd">373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93952a8fa3ba416a91d3216edf3a66f8_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktMTAtMS0xLTc3NDA3_ce3e271b-0223-4d5e-a6b6-caa65dd9d871"
      unitRef="usd">452000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i66a7d12f22764dbb8759a742d94eb8a2_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfOTktMTItMS0xLTc3NDA3_96934a77-5965-4a04-870e-4d08accdd6bd"
      unitRef="number">-0.174</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3e8caf499784ae398f716cde9975425_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTItMS0xLTc3NDA3_48673073-917f-483c-aa33-def7924d7c5b"
      unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i451f3c5eff7745599f90d0af11f4f4cf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTQtMS0xLTc3NDA3_ffe6b00c-7f5f-43d1-895d-5fa60412d07f"
      unitRef="usd">81000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id3e8caf499784ae398f716cde9975425_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTYtMS0xLTc3NDA3_88e23ce5-d2bf-4439-9760-2bbede28a0af"
      unitRef="number">0.572</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia582797f6e464aa9a43e5e6175ed4fdc_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTgtMS0xLTc3NDA3_3af971b8-bb78-42a6-af45-219e2e2d090f"
      unitRef="usd">313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8801d5f445ea486381246f9557e84830_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTEwLTEtMS03NzQwNw_28e11162-fb92-4851-bcfb-e4eb8ed7a4ff"
      unitRef="usd">239000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia582797f6e464aa9a43e5e6175ed4fdc_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAxLTEyLTEtMS03NzQwNw_8b028469-25d6-4aec-9572-b62a82e3baa7"
      unitRef="number">0.311</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08dd8fcd4d2a45b99b04b6d5af0eb436_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTItMS0xLTc3NDA3_fbe3eb00-9051-4ef2-9e56-42f63434b99f"
      unitRef="usd">246000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78d8a32d310f4f73ad47b98c02d07725_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTQtMS0xLTc3NDA3_bfef3121-2151-4ee2-bb7e-92ef04cfdcfe"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i08dd8fcd4d2a45b99b04b6d5af0eb436_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTYtMS0xLTc3NDA3_b48232e2-0d3c-4954-a1e0-dd9be5c9277b"
      unitRef="number">-0.179</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1eccfe1cbc774b868af74e3ecf7e96d1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTgtMS0xLTc3NDA3_855eeca2-3fc2-491c-a027-1d4af3cf06bf"
      unitRef="usd">861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab744bf1ae1c4732bff2f6dbcb6177c9_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTEwLTEtMS03NzQwNw_d696a5fe-445e-4874-954f-e66f8b03ed31"
      unitRef="usd">1026000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1eccfe1cbc774b868af74e3ecf7e96d1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAyLTEyLTEtMS03NzQwNw_dfd84226-2bb1-4260-b820-9e2191987683"
      unitRef="number">-0.162</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i983dfa5746394727b4076b1302b725e3_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTItMS0xLTc3NDA3_37c34a36-fc15-48ce-b77f-abfda35fb74b"
      unitRef="usd">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i524e2edfc08f4a5580c142b4fbe47bdf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTQtMS0xLTc3NDA3_e6971af1-eae6-4dda-af61-4380a3670ce4"
      unitRef="usd">379000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i983dfa5746394727b4076b1302b725e3_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTYtMS0xLTc3NDA3_684291d8-6f42-4a3f-85f9-fb5050c9bd18"
      unitRef="number">-0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1b57f9e060b40b7a959c01f75f2cdb8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTgtMS0xLTc3NDA3_b689dae6-6ba7-4d41-b5e8-5c2714591092"
      unitRef="usd">1174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e84d1337fdb4905ba98011e4e8bd221_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTEwLTEtMS03NzQwNw_21c758af-d7dc-46f2-a614-f5c913903ab8"
      unitRef="usd">1265000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib1b57f9e060b40b7a959c01f75f2cdb8_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTAzLTEyLTEtMS03NzQwNw_956c8cf6-5353-4de0-8241-cb6f27dc4c02"
      unitRef="number">-0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e5b869f0296461f9fd2b132c207af88_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTItMS0xLTc3NDA3_d214af7d-4e88-4fdc-81bf-8c4fd7ddf8ed"
      unitRef="usd">1812000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76cd338bc7d045b684ffef7f072eb708_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTQtMS0xLTc3NDA3_8167dfef-993f-41c2-a515-6148ca65d237"
      unitRef="usd">1525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0e5b869f0296461f9fd2b132c207af88_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTYtMS0xLTc3NDA3_16c3e3eb-301c-4519-b53c-4ec17e1d95fa"
      unitRef="number">0.188</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f93a1e291fb4f21aa74bf605526f3d4_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTgtMS0xLTc3NDA3_3aeeb45a-40ec-4c81-aacd-ce1cbcc44619"
      unitRef="usd">5073000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57185a1089ea4d859905b073688fb56b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTEwLTEtMS03NzQwNw_7c4636a9-9e27-4c82-a251-6a67fee584ac"
      unitRef="usd">4364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7f93a1e291fb4f21aa74bf605526f3d4_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA2LTEyLTEtMS03NzQwNw_9e1d2eeb-2d73-4c92-b86f-22fd86ce80a8"
      unitRef="number">0.162</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i122d085eabad46eb96a300589fd4bb3d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTItMS0xLTc3NDA3_6533568b-230c-44d5-b75b-75a9787dd620"
      unitRef="usd">2252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89657990d309468383c0be47dae23813_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTQtMS0xLTc3NDA3_de527da9-c737-4ac5-a91d-c098d4f04533"
      unitRef="usd">2140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i122d085eabad46eb96a300589fd4bb3d_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTYtMS0xLTc3NDA3_27d0c423-304c-48ad-9cf0-712c69df04f4"
      unitRef="number">0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59754740b9fc4cf0ae2c2c849165f4c0_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTgtMS0xLTc3NDA3_27c9666f-1475-4705-a1c3-30290963e8ca"
      unitRef="usd">6983000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic879ca2153fb4a0088c7ee21b8bb666f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTEwLTEtMS03NzQwNw_fea86ad9-c0f3-4881-83c8-a4623e44c0a2"
      unitRef="usd">6406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i59754740b9fc4cf0ae2c2c849165f4c0_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA3LTEyLTEtMS03NzQwNw_9202e584-a112-48c6-8425-2feb89bc1132"
      unitRef="number">0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibae451029e5d4bd580e6089d7352e564_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTItMS0xLTc3NDA3_98be3939-c0e0-4a8d-ab14-954241c02eea"
      unitRef="usd">4064000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedf29bc608704deab5ec4bfc9c1166f5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTQtMS0xLTc3NDA3_ca46f7f3-f5be-49fd-be9f-e66592cee528"
      unitRef="usd">3665000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibae451029e5d4bd580e6089d7352e564_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTYtMS0xLTc3NDA3_06a1738b-f655-4f69-99b6-a78c10d3d1df"
      unitRef="number">0.109</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f1ff4ca321f4e6fa0ef4ae8850e39b3_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTgtMS0xLTc3NDA3_c3905425-e31c-4ff0-837a-df6a10f25fa8"
      unitRef="usd">12056000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70cf1523502f4cf5ba39389cb696eb37_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTEwLTEtMS03NzQwNw_28b709af-2d42-44b4-b615-6330e08029a6"
      unitRef="usd">10770000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9f1ff4ca321f4e6fa0ef4ae8850e39b3_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTA4LTEyLTEtMS03NzQwNw_50d036af-c305-4661-9483-0bdce0b18f37"
      unitRef="number">0.119</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b56bacf950743f084cba59a7fa25e7a_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTItMS0xLTc3NDA3_03d3f669-1492-43c3-a9cb-5900aa0f71a7"
      unitRef="usd">1097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i081f0f428e784cab8f9d016f92effd83_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTQtMS0xLTc3NDA3_bde6be23-13ca-4874-9ec4-47b584d66741"
      unitRef="usd">841000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3b56bacf950743f084cba59a7fa25e7a_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTYtMS0xLTc3NDA3_8ecaf0c6-4e43-4620-ac5c-dae1a3d273df"
      unitRef="number">0.303</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c5cd7d0017649089af560975f3138e1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTgtMS0xLTc3NDA3_39c46373-4d28-49e1-bb0b-6cff1247892b"
      unitRef="usd">3071000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i475fdfe52a874f96855bebe87d3bcdf4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTEwLTEtMS03NzQwNw_8e39a05d-0be4-4943-a123-6a4de6e52e64"
      unitRef="usd">2302000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2c5cd7d0017649089af560975f3138e1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEwLTEyLTEtMS03NzQwNw_6ce8e65a-782e-4c4b-9599-de5c2f15cbb5"
      unitRef="number">0.334</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87898be332414773b484d0dc62a17a36_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTItMS0xLTc3NDA3_23314db0-e01a-4dc4-8ae0-8130f724c1a1"
      unitRef="usd">955000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia552b1bea3ed45ea9d9428a49f4aa36d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTQtMS0xLTc3NDA3_5fb90ada-8ec1-4c1a-b27b-6941052c0104"
      unitRef="usd">739000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i87898be332414773b484d0dc62a17a36_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTYtMS0xLTc3NDA3_708dde4d-6199-48ee-8ebf-6b94ee19b1c4"
      unitRef="number">0.293</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6dc593f363ef47a58da8ed226cc81f6d_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTgtMS0xLTc3NDA3_2612f869-e935-4c49-ad1e-40244aab656c"
      unitRef="usd">2823000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5273b9790a9456bbdf4c45498aaef2f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTEwLTEtMS03NzQwNw_3afc5a25-0d40-4ca5-8dfb-3349db3e98da"
      unitRef="usd">2076000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6dc593f363ef47a58da8ed226cc81f6d_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTExLTEyLTEtMS03NzQwNw_3d62dee7-7cb0-4315-9620-fe9a17a6436c"
      unitRef="number">0.360</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47cb84e4eff645bc93a43e37e94a9db3_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTItMS0xLTc3NDA3_8e75c137-9852-4fde-9d61-e89a2d5908b7"
      unitRef="usd">2052000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6dde9f39bec4bea8b20aa1d494c72cf_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTQtMS0xLTc3NDA3_3a61e633-fc61-429a-94b9-0b729667f803"
      unitRef="usd">1580000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i47cb84e4eff645bc93a43e37e94a9db3_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTYtMS0xLTc3NDA3_696014d7-df05-45dd-9865-c2950e78cdfc"
      unitRef="number">0.298</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01a4a90d5035473fbeccea2782bd2c3b_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTgtMS0xLTc3NDA3_f80eee1c-2149-458c-b474-2d1de51b91ab"
      unitRef="usd">5894000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42adb27c042b423eb963af60ecdd4f28_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTEwLTEtMS03NzQwNw_f60af198-5fbe-445c-905e-bbf5b742dfd6"
      unitRef="usd">4378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i01a4a90d5035473fbeccea2782bd2c3b_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTEyLTEyLTEtMS03NzQwNw_2d30d891-c3b4-49e6-aaa8-b9b625840489"
      unitRef="number">0.346</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i027553a8069f4b20b245dc5aa1b7f00d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTItMS0xLTc3NDA3_287f142b-7f35-4ec5-bdb0-0e2b90a14056"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f6c8c3e6d5948d28dd9796e3ca9f2a0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTQtMS0xLTc3NDA3_211f067f-7f58-465f-80b3-9411e23b76ce"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i027553a8069f4b20b245dc5aa1b7f00d_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTYtMS0xLTc3NDA3_f7bb5c41-e0ed-4df8-805d-55997268d18e"
      unitRef="number">0.191</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72692a16cfbd4625a23c6c13e5c4a89a_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTgtMS0xLTc3NDA3_ac4a8dd8-f7db-4ee4-a7ab-52956cdeae6f"
      unitRef="usd">693000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b6abfbb54c2428e827e225364933220_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTEwLTEtMS03NzQwNw_f2782d0e-8461-4d4e-9841-c5ab12cd1c97"
      unitRef="usd">578000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i72692a16cfbd4625a23c6c13e5c4a89a_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE0LTEyLTEtMS03NzQwNw_e807403e-396f-4c87-9e5a-e212875d9263"
      unitRef="number">0.200</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55a933b2468c47028feef151e8eca9a6_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE1LTItMS0xLTc3NDA3_5e09de0f-4206-4087-895f-da474b8f9078"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09e27f9730db43f6a2ad23e6cf8a28d5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE1LTQtMS0xLTc3NDA3_c64141db-737c-43b1-9971-498295b50c9d"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77060b346f464d5d94e95a340469f8c1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE1LTgtMS0xLTc3NDA3_8aacf51e-bffc-4b42-b072-dea5badff64e"
      unitRef="usd">647000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i272627f13bc84d4cbe6effb2975aca80_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE1LTEwLTEtMS03NzQwNw_02417707-2282-4ac3-95d4-c90cad35f187"
      unitRef="usd">329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1544200114ae4509a452b21c7cda8113_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTItMS0xLTc3NDA3_c22f5687-6fb2-43cb-8bdc-f58f574a72f3"
      unitRef="usd">490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37417b84faf544e388d7fbea6710dde8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTQtMS0xLTc3NDA3_bcf94185-eb52-46f1-a302-b5c4b7b6756f"
      unitRef="usd">344000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1544200114ae4509a452b21c7cda8113_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTYtMS0xLTc3NDA3_d87ece80-d296-4576-9d3b-c604ebcd3202"
      unitRef="number">0.422</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd68e44359f480b9c73e8e0717f39b5_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTgtMS0xLTc3NDA3_98cc1356-3f79-4aa8-8910-58e458eca8b9"
      unitRef="usd">1340000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60c2e5afe5f447d98cdb95e255a91e36_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTEwLTEtMS03NzQwNw_3a99b534-daad-496a-a79c-9b5bed46228a"
      unitRef="usd">907000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibcd68e44359f480b9c73e8e0717f39b5_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE2LTEyLTEtMS03NzQwNw_cd7cb7f1-8789-4bcd-a0da-4a659c9c9a37"
      unitRef="number">0.477</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia610c33820924e2887785db9deee9d33_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTItMS0xLTc3NDA3_0234758e-347d-40ca-b683-049239750663"
      unitRef="usd">353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id90c807d7bb242bdb981d10b3fe54eb6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTQtMS0xLTc3NDA3_be799c6e-85cf-458b-b538-66d54118db28"
      unitRef="usd">413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia610c33820924e2887785db9deee9d33_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTYtMS0xLTc3NDA3_c062cd81-7af4-4a34-bc57-691fa4c1b149"
      unitRef="number">-0.146</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i694546fb28354b728eb7a664114dcc64_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTgtMS0xLTc3NDA3_dcbb3bd6-5c2d-4e87-bc9b-5cc40ed9b855"
      unitRef="usd">1072000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c8924e9eaec4b2dbfbc45f97506d991_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTEwLTEtMS03NzQwNw_416ebf96-c735-4384-96a5-bff5f2084d42"
      unitRef="usd">1311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i694546fb28354b728eb7a664114dcc64_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE4LTEyLTEtMS03NzQwNw_b30733b8-be6c-4f74-b5e8-890f8c7ba811"
      unitRef="number">-0.183</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d326425f4074d3aa5f72ef541b7d36a_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTItMS0xLTc3NDA3_d78cf9e2-aa47-4d8e-982c-c4bae48714bb"
      unitRef="usd">559000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3a634db09b3472284861b507d5c1114_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTQtMS0xLTc3NDA3_a1c7a277-be6b-4452-bb68-a2c961ddc66a"
      unitRef="usd">654000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4d326425f4074d3aa5f72ef541b7d36a_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTYtMS0xLTc3NDA3_55d25271-a8b1-4117-8ef4-d9ab2c12891a"
      unitRef="number">-0.146</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibba42e341ee7416abbbe3661f587439e_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTgtMS0xLTc3NDA3_4d8cd4e7-b1ae-4e67-baed-c46b7f7537bf"
      unitRef="usd">1847000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13b890bcafd74f788a55c0ebe94e5632_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTEwLTEtMS03NzQwNw_3612d35b-c93b-4fda-9a90-312bc79fe64f"
      unitRef="usd">1996000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibba42e341ee7416abbbe3661f587439e_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTE5LTEyLTEtMS03NzQwNw_26eaa90e-5751-4129-8340-7d46c688cb76"
      unitRef="number">-0.075</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i505a0ebef84644338a169d2b6209fbd0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTItMS0xLTc3NDA3_2576fffa-8034-4e79-a4fd-4d9d417acb17"
      unitRef="usd">911000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38ddfba15a2041d88d410a99ac1e926a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTQtMS0xLTc3NDA3_fe03e4b8-1df3-4912-9228-da26ac0b6b23"
      unitRef="usd">1066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i505a0ebef84644338a169d2b6209fbd0_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTYtMS0xLTc3NDA3_ee504c8a-78f1-47ee-82dd-7388425ca8d7"
      unitRef="number">-0.146</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i033591a445a5468693248831071b5242_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTgtMS0xLTc3NDA3_508135d0-1f2f-439d-8ba7-86cda0f377b8"
      unitRef="usd">2918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7da56618ab654c42b05e7ce3d95c93fb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTEwLTEtMS03NzQwNw_f4f8a39b-33d6-412e-a847-354532a71e92"
      unitRef="usd">3307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i033591a445a5468693248831071b5242_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIwLTEyLTEtMS03NzQwNw_c4066696-d018-49f2-86f3-d99de4e8cbf9"
      unitRef="number">-0.118</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c5a4918db2e4440a13d121f8cffb4d5_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTItMS0xLTc3NDA3_e545b6f8-2b4d-455a-b99d-180d319ac5ef"
      unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5604fe07056d43b898f627ac12fe4ae3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTQtMS0xLTc3NDA3_86d2a40b-8df6-4238-825f-6e0312219a85"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5c5a4918db2e4440a13d121f8cffb4d5_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTYtMS0xLTc3NDA3_e6dc1394-7707-4d7b-bd89-ae0c1e6f82be"
      unitRef="number">-0.331</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i400f6ad312e1418a8315ea7c4ca60914_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTgtMS0xLTc3NDA3_f77e75a0-7f42-4e30-b7ac-7f65f7807d45"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80d4fa554f9c42f2b2dbef32f68ab0dc_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTEwLTEtMS03NzQwNw_5bfa69dd-2c1d-46d1-886d-b44e4c957733"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i400f6ad312e1418a8315ea7c4ca60914_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIyLTEyLTEtMS03NzQwNw_b1577bff-4f53-4dae-8733-588ba1b6622e"
      unitRef="number">-0.434</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0eecfc49d16b42a8a21357eaf2267e33_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTItMS0xLTc3NDA3_cbdc47fd-6c4d-40a3-b5c3-81068826cfe4"
      unitRef="usd">440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cb87af3cab043ca8decf206c6b249b3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTQtMS0xLTc3NDA3_3fd574a9-9e22-471e-a01c-85c32a7d8de8"
      unitRef="usd">523000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0eecfc49d16b42a8a21357eaf2267e33_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTYtMS0xLTc3NDA3_6cafda5e-5747-47ac-ac59-dc241b4fcfcc"
      unitRef="number">-0.159</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cfd9c7ab83c419bbf61049f45186a29_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTgtMS0xLTc3NDA3_ded03fa5-407c-4a6c-8a06-1f8f3380ab01"
      unitRef="usd">1446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i028ed305b9b440838647dbf947fce3c2_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTEwLTEtMS03NzQwNw_be42f362-ded4-448c-bf1d-436bb13a5810"
      unitRef="usd">1653000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9cfd9c7ab83c419bbf61049f45186a29_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTIzLTEyLTEtMS03NzQwNw_3dcad1c0-cce6-4dbb-9418-39bca020373d"
      unitRef="number">-0.125</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5014237d9c1c451999919bf6eec12ab2_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTItMS0xLTc3NDA3_acda469a-4753-461f-b094-41eed4869b66"
      unitRef="usd">456000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63b1476e16fc4757b5fe6b377ec00a8b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTQtMS0xLTc3NDA3_f7be6355-fb9c-4998-8c79-98f102c14138"
      unitRef="usd">548000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5014237d9c1c451999919bf6eec12ab2_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTYtMS0xLTc3NDA3_e8d8d080-283d-4aeb-85cf-d3584eb6f4e6"
      unitRef="number">-0.167</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b55351b3e714b4196d956f493f5fbfe_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTgtMS0xLTc3NDA3_578c338a-f210-4790-9f1a-ac2b7680ca21"
      unitRef="usd">1500000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i494b3dcc71a9471bbb64838967bf211f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTEwLTEtMS03NzQwNw_d0902220-d9c0-4656-938e-4a452be8bda3"
      unitRef="usd">1749000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5b55351b3e714b4196d956f493f5fbfe_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI0LTEyLTEtMS03NzQwNw_ab8ba990-5c79-4b42-a4cf-c0dc091f1ba0"
      unitRef="number">-0.142</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d1982faddbe4e81a502b33e94996bba_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI3LTItMS0xLTc3NDA3_e3a14ccb-6865-4d23-a48e-e14908056178"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1677f52df4334218aa0a0cb8d77df066_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI3LTQtMS0xLTc3NDA3_c14cb655-ef00-4d3e-b072-466c0bc19fba"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf32b8dec40e4c26a1275c9cbeb2cab9_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI3LTgtMS0xLTc3NDA3_e340695d-9537-4580-8a22-fe46afaf9f60"
      unitRef="usd">183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0075c921c1a3418087cbff16476429bb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI3LTEwLTEtMS03NzQwNw_11eca9c6-c206-407d-95df-bfc1ac27fd71"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i642b7fdb6d7141198e59206a87715ca1_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTItMS0xLTc3NDA3_244eaea4-67e4-40bc-8f19-fc7c5f9bbb5e"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaec24b62e56f4c749ad066b0f5814893_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTQtMS0xLTc3NDA3_c7115bdc-9eec-44c1-92c3-191e39d4c257"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i642b7fdb6d7141198e59206a87715ca1_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTYtMS0xLTc3NDA3_a98fc5b6-43fa-4af9-8aaa-914b005c9d38"
      unitRef="number">-0.321</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9a58f759a804eeea68e4f6cf19f54cc_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTgtMS0xLTc3NDA3_c866ac00-8fd5-4550-a5ed-3ca856679c1e"
      unitRef="usd">220000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8d2e948664e48509acc9a46d147acd6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTEwLTEtMS03NzQwNw_37332820-7e5e-4690-964b-13c1ceec07c7"
      unitRef="usd">352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie9a58f759a804eeea68e4f6cf19f54cc_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI4LTEyLTEtMS03NzQwNw_8fa0c22c-713b-4831-886b-29cfed3e886f"
      unitRef="number">-0.375</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9034ae3630be4f90ac8759f73c9d84ee_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTItMS0xLTc3NDA3_f91aa134-d844-459b-b87b-0d2a11c217cc"
      unitRef="usd">155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia01a0e267e3d49408ae383c295013155_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTQtMS0xLTc3NDA3_7a823a65-edef-4359-8079-dd4227445437"
      unitRef="usd">126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9034ae3630be4f90ac8759f73c9d84ee_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTYtMS0xLTc3NDA3_bd740b6d-bd0e-4ba3-8385-ff398d27601b"
      unitRef="number">0.231</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b9230ef516443ccad9d26677a66975e_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTgtMS0xLTc3NDA3_14172523-c3c0-4e9b-b79f-f9f4c1003637"
      unitRef="usd">403000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i900204896d434dda8fac86bae0cf2c69_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTEwLTEtMS03NzQwNw_e979e815-c2d0-41b0-97e5-d01f8a03c160"
      unitRef="usd">428000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7b9230ef516443ccad9d26677a66975e_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTI5LTEyLTEtMS03NzQwNw_38a7dc33-3315-413c-851b-669c6af55694"
      unitRef="number">-0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id112e58fd1da4992aaabcf75b671635a_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTItMS0xLTc3NDA3_3511f5ee-dd7f-4c17-b845-38e773e59ac6"
      unitRef="usd">604000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69daef85a2cd4f0698981e2468d08268_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTQtMS0xLTc3NDA3_b46bd0f0-41a8-4865-8107-d298d1515695"
      unitRef="usd">610000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id112e58fd1da4992aaabcf75b671635a_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTYtMS0xLTc3NDA3_0c3c3efe-48e7-4b31-951e-197455468209"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77a8f26f579b45d49451e22987cfe043_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTgtMS0xLTc3NDA3_ddf15e6c-ea0a-4e54-9d68-771f7da8ccca"
      unitRef="usd">1736000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6a917baf2b146579258ed0bd76a5682_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTEwLTEtMS03NzQwNw_9245d2e1-9d97-46da-90e8-eb2156864507"
      unitRef="usd">1778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i77a8f26f579b45d49451e22987cfe043_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMyLTEyLTEtMS03NzQwNw_ccde8a03-b75b-4031-ac1b-2404c045b747"
      unitRef="number">-0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70ffc7cf3c884b2296b9598791625833_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTItMS0xLTc3NDA3_3938836d-477a-4202-9771-859e2f863feb"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c8f9a3dd9c847dc8c25bf43d101da5a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTQtMS0xLTc3NDA3_c54c9968-c3d3-42a0-a994-b8c9c04b6de4"
      unitRef="usd">258000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i70ffc7cf3c884b2296b9598791625833_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTYtMS0xLTc3NDA3_114dbbf2-aea0-44d0-b490-01bec53f2994"
      unitRef="number">-0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01ddcdd029114904a3d37f67d1a5375f_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTgtMS0xLTc3NDA3_f3d76392-afda-48b6-880b-222ebce54cf0"
      unitRef="usd">810000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e00716790544c2aa2782fbaa642b291_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTEwLTEtMS03NzQwNw_305ee796-2803-49be-98b0-c4355d667943"
      unitRef="usd">821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i01ddcdd029114904a3d37f67d1a5375f_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTMzLTEyLTEtMS03NzQwNw_e1658095-92b1-4e84-983d-77ae77b63195"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d366ba8634843b7952c594a0298644e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTItMS0xLTc3NDA3_392adf84-2e4d-4a19-bc7f-34f00990ccf4"
      unitRef="usd">852000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80589dad11a143ef83bed73c9c636e0d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTQtMS0xLTc3NDA3_3045cced-73b6-4df6-abdd-ab69c913288a"
      unitRef="usd">868000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4d366ba8634843b7952c594a0298644e_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTYtMS0xLTc3NDA3_d6a3a0ee-c230-4e1c-807d-afa27eb5556f"
      unitRef="number">-0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a27bbab26194f368e984c6efeac7dbf_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTgtMS0xLTc3NDA3_ada063bb-ad5c-43fd-9be0-d031010e8c83"
      unitRef="usd">2547000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id541227fbffe4cb58cbf08c74d640a31_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTEwLTEtMS03NzQwNw_283a79cc-f8d2-41eb-b8dd-11d685193b2c"
      unitRef="usd">2599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a27bbab26194f368e984c6efeac7dbf_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM0LTEyLTEtMS03NzQwNw_fb9a5d5d-eda3-46bd-914d-60a042a4587a"
      unitRef="number">-0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35536d5c87534fd7904edf6033b8d2fb_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTItMS0xLTc3NDA3_e761b49e-4eb5-4900-8bfb-857f84de24a6"
      unitRef="usd">289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibab3102676df483cb94d5771c3340715_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTQtMS0xLTc3NDA3_9bd28808-e53a-4e9f-b8a1-ddab81281ee5"
      unitRef="usd">299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i35536d5c87534fd7904edf6033b8d2fb_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTYtMS0xLTc3NDA3_4dbfaeca-369e-429a-bf33-b567d34547bd"
      unitRef="number">-0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61e739cf89e04a2ab85cbf458333e420_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTgtMS0xLTc3NDA3_2bc1bbf9-c80e-472e-a075-6d1f2a79983f"
      unitRef="usd">827000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a347180bf99437b8e59ccf9b456e939_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTEwLTEtMS03NzQwNw_72434eff-9e67-46df-8e8c-e34f035aa965"
      unitRef="usd">861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i61e739cf89e04a2ab85cbf458333e420_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM2LTEyLTEtMS03NzQwNw_5daebafe-bd0f-4c55-aa32-c23b04644619"
      unitRef="number">-0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7c91bc046b54947b056276f205609b5_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTItMS0xLTc3NDA3_0613b1d3-0cc1-42b9-96a1-ae5fef344c91"
      unitRef="usd">152000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76d1d755fe864e0aa2bc11b07fb588d5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTQtMS0xLTc3NDA3_cab83dad-0471-41d9-8c5d-90a2d70bd9cd"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib7c91bc046b54947b056276f205609b5_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTYtMS0xLTc3NDA3_d33885c0-69ac-488f-8ff8-285954e9afe4"
      unitRef="number">-0.047</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i861cea3736ba431ea19399c9d74f4a1e_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTgtMS0xLTc3NDA3_e4195035-91d1-49e7-a00f-be8ab91512e2"
      unitRef="usd">495000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0643a60ebf034a56a19d98183b76d940_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTEwLTEtMS03NzQwNw_bbb13930-8869-4ff1-ae99-a2ccef1be885"
      unitRef="usd">510000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i861cea3736ba431ea19399c9d74f4a1e_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM3LTEyLTEtMS03NzQwNw_7f084ced-c4a1-4bc1-b88c-1a5867dd73ed"
      unitRef="number">-0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0d3bc436e1940458257e25f0366f0fd_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTItMS0xLTc3NDA3_7241e281-c8c9-4c12-8eb4-6a9453ca1035"
      unitRef="usd">441000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaee986d724e44b098461eac0f89dfb0a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTQtMS0xLTc3NDA3_5eae7404-9c11-4ca5-aa09-45128e57a8a2"
      unitRef="usd">458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie0d3bc436e1940458257e25f0366f0fd_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTYtMS0xLTc3NDA3_a4157344-d8ea-4cfe-a237-1f7daab7b707"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3461941dfba467a82a64d0fe6a92726_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTgtMS0xLTc3NDA3_daca405b-e0dc-4167-9999-7ede50bacd38"
      unitRef="usd">1322000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27b82c53a0dc4b3abae2328362331d7b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTEwLTEtMS03NzQwNw_a86add6f-cda7-480b-a1d0-5303880eee12"
      unitRef="usd">1371000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie3461941dfba467a82a64d0fe6a92726_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTM4LTEyLTEtMS03NzQwNw_638012cb-848f-4f82-9e19-72f0589b893a"
      unitRef="number">-0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib052e84cde5f4591ac72582a42239b41_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTItMS0xLTc3NDA3_dc228651-234a-4d8e-90b9-8cda101577e5"
      unitRef="usd">283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bd7ffd7738b4d259f17a9f3eed5fe8f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTQtMS0xLTc3NDA3_6deba91d-4c53-4fb2-9a47-1e7cd8ceee72"
      unitRef="usd">265000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib052e84cde5f4591ac72582a42239b41_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTYtMS0xLTc3NDA3_364ef25e-f32a-486c-8655-187b77c7a5b5"
      unitRef="number">0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i847dce3495ea4ca1a4c5ecbdcdeb9266_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTgtMS0xLTc3NDA3_f41ffb41-70a1-481b-87d2-4a7b2b9aed51"
      unitRef="usd">824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id846e2e0c92e48e1a68009c7f0c3ec3d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTEwLTEtMS03NzQwNw_6461d6a2-450d-4aff-b467-b8a0830e2be5"
      unitRef="usd">792000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i847dce3495ea4ca1a4c5ecbdcdeb9266_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQwLTEyLTEtMS03NzQwNw_e51184ea-a268-4de4-85e2-680af4b35963"
      unitRef="number">0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7e140ec784341c3bdaa6b9e35a220ad_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTItMS0xLTc3NDA3_2d8e9b06-e3be-4ddb-b4b5-8672c55c1e4b"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9bdd1c6bdaa4f278e3d75778bc8098e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTQtMS0xLTc3NDA3_efb19cbe-e43f-4c96-b3fd-4aab6df40105"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id7e140ec784341c3bdaa6b9e35a220ad_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTYtMS0xLTc3NDA3_e1e26adc-6321-4357-8b08-45978d4a9b68"
      unitRef="number">0.142</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic62f68f5cbaa47839c0b6b490a8f2c4f_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTgtMS0xLTc3NDA3_f817a614-6369-4e47-89b2-022132315c34"
      unitRef="usd">162000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03b53f572aa44e899c6d9df9aab6646f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTEwLTEtMS03NzQwNw_71c565ad-f339-438c-8b20-330e2634b7dc"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic62f68f5cbaa47839c0b6b490a8f2c4f_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQxLTEyLTEtMS03NzQwNw_cef64399-9474-4d5b-bde3-df1b8fa4b03c"
      unitRef="number">0.204</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bba86c6d32b4bb1a8652b8dd4c5851d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTItMS0xLTc3NDA3_e1cd5d82-e08b-4f75-ab59-eddfe72053cd"
      unitRef="usd">333000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09aa7aa2a79a46fe942e1eab7057a546_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTQtMS0xLTc3NDA3_d531da8d-27a3-47ac-bc2c-e1ac95ed335a"
      unitRef="usd">309000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9bba86c6d32b4bb1a8652b8dd4c5851d_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTYtMS0xLTc3NDA3_4140bb6a-c20e-4c33-b451-e5026879d07c"
      unitRef="number">0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c58cf190dba4d119b64a72bea44dee8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTgtMS0xLTc3NDA3_5c23778a-ad52-4f00-a202-b36b0ba4048d"
      unitRef="usd">986000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib35fad42d0e6463995e0600e17c5c1b5_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTEwLTEtMS03NzQwNw_05de47d6-eed3-45bd-b2e6-35e966d9546b"
      unitRef="usd">927000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3c58cf190dba4d119b64a72bea44dee8_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQyLTEyLTEtMS03NzQwNw_4325afc0-1a0a-46a9-b0cd-bf8c334fd112"
      unitRef="number">0.063</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5565a9f7ec554e8cabd71fcaee639311_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTItMS0xLTc3NDA3_caf402d7-4639-4ded-8e6b-ba03aec291ed"
      unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f344311b3cf48939c39240aac35200c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTQtMS0xLTc3NDA3_2b5567e7-3c8a-48a9-a55e-b2af1cab17bc"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5565a9f7ec554e8cabd71fcaee639311_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTYtMS0xLTc3NDA3_4becd5d5-974d-465b-8fd5-3cac01f0b023"
      unitRef="number">-0.295</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefa33272c8bd4721a74234b17b990694_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTgtMS0xLTc3NDA3_17185166-fcde-4c9e-915f-dddc091bcacf"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib87579025231469fb10ceb2f4c7cfdcb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTEwLTEtMS03NzQwNw_4db9d07b-a803-43aa-9993-1d520875a6b3"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iefa33272c8bd4721a74234b17b990694_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ0LTEyLTEtMS03NzQwNw_fd965fff-05fd-4519-aea3-809902e6dc75"
      unitRef="number">-0.313</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if99ca9d34e85413ab54b2210dcdfb7fd_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTItMS0xLTc3NDA3_fdd7205a-3ebb-485b-b24e-fe3b1b130169"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9e7cfafb6474ef2948dd5e06029902a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTQtMS0xLTc3NDA3_653bc627-e3e1-467e-bff1-12ee11182aa4"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if99ca9d34e85413ab54b2210dcdfb7fd_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTYtMS0xLTc3NDA3_25691fd5-21e0-46b1-85b6-4ebcd27239dd"
      unitRef="number">-0.157</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia860b7d96f0447f392f5eeac7875c1a1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTgtMS0xLTc3NDA3_549f1649-5c77-4446-8097-8015105a7e59"
      unitRef="usd">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2cef51b9a6c41d794a7883c2331934f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTEwLTEtMS03NzQwNw_adb468f6-1d89-4a52-842e-6bc6c4fde406"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia860b7d96f0447f392f5eeac7875c1a1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ1LTEyLTEtMS03NzQwNw_d2d7e20a-310c-48a2-8f52-00dab75bb075"
      unitRef="number">-0.130</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2605c867ea164850b491768230077fdb_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTItMS0xLTc3NDA3_bce076f7-4bcf-49a5-833e-8c73fd3b20a7"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73ebd1cbb69f4706bf7449a515a56452_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTQtMS0xLTc3NDA3_bb7ce1c4-7321-4a44-b63a-8165b25a8f86"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2605c867ea164850b491768230077fdb_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTYtMS0xLTc3NDA3_12f680f4-842c-4538-9eff-6ccf87de50c9"
      unitRef="number">-0.221</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67b836292a904483a2495cd84486214a_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTgtMS0xLTc3NDA3_120fc276-f680-4bc5-97ab-3ebc614a8337"
      unitRef="usd">239000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ae4efec9bc24e5c832eb9b323983513_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTEwLTEtMS03NzQwNw_da43cb3a-66f8-4391-af83-9cc01a5ddf9b"
      unitRef="usd">301000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i67b836292a904483a2495cd84486214a_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ2LTEyLTEtMS03NzQwNw_76370a1f-27d4-4dd8-93b8-e06c773d324b"
      unitRef="number">-0.205</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i881f037a08664e86b329cb3e8bac41e3_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTItMS0xLTc3NDA3_5c768719-7d0e-43f6-82ec-df6508130207"
      unitRef="usd">837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i876e020ffc28486eb2cba4c856c63d96_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTQtMS0xLTc3NDA3_e95cdfc6-0894-4834-87fc-6503ad535300"
      unitRef="usd">800000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i881f037a08664e86b329cb3e8bac41e3_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTYtMS0xLTc3NDA3_0a646aff-c97f-4806-a226-c9c8a46f3caf"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cad11a8c56443738c97c90053bcf485_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTgtMS0xLTc3NDA3_24fc8f65-f233-4ae5-8b97-9fa9d7901456"
      unitRef="usd">2266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icad2abe11b5d441f84340fceedeecb5f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTEwLTEtMS03NzQwNw_51efd61a-914a-48f4-bb47-ad5eb20f6bbf"
      unitRef="usd">2379000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7cad11a8c56443738c97c90053bcf485_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTQ5LTEyLTEtMS03NzQwNw_4c88fe83-1d6d-432d-a9c3-931baf01eabf"
      unitRef="number">-0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10b4ecc9ffe3480b8f5dd56a9cd5aa6a_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTItMS0xLTc3NDA3_4f8299fb-8e08-427a-a07f-7094c514591b"
      unitRef="usd">198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icca30d47d5784736873c33392dc4ae62_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTQtMS0xLTc3NDA3_9f7cdd5c-7743-4409-a4e5-adfa70e9c8c6"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i10b4ecc9ffe3480b8f5dd56a9cd5aa6a_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTYtMS0xLTc3NDA3_68274191-fd36-43ac-a30d-2a1458dedbea"
      unitRef="number">-0.175</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea669ae399404c9ca5423bd557cf0873_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTgtMS0xLTc3NDA3_d7aa8853-8dc7-4868-9de9-21fc7bb03ed7"
      unitRef="usd">651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b3c8d3f2fb24fcf990880e0ff513c1f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTEwLTEtMS03NzQwNw_2b132ee5-539e-499b-a63b-ed24df92ba41"
      unitRef="usd">727000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iea669ae399404c9ca5423bd557cf0873_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUwLTEyLTEtMS03NzQwNw_1efe1136-8242-4411-8adf-a72bafeb9aba"
      unitRef="number">-0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i244e58e9444a4e3d9e577108f15d8bd8_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTItMS0xLTc3NDA3_517c518f-f206-4b08-8d9d-584fff8d2896"
      unitRef="usd">1034000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82e4b71f563c40d697c20b57f2ac67af_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTQtMS0xLTc3NDA3_8f839337-a6b7-45f6-a429-48cf78d63c84"
      unitRef="usd">1041000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i244e58e9444a4e3d9e577108f15d8bd8_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTYtMS0xLTc3NDA3_e1415e55-1510-49a6-8630-9789904b4e6f"
      unitRef="number">-0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13674b49cf2b434d99ece35b1733ccb9_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTgtMS0xLTc3NDA3_9ef79ea3-a9a6-4226-ab81-48770c34ae3a"
      unitRef="usd">2916000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90a01e2a70a145dfb1adbbc859b6dd82_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTEwLTEtMS03NzQwNw_79652551-2c80-41db-bfe1-69777dcbbddc"
      unitRef="usd">3106000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i13674b49cf2b434d99ece35b1733ccb9_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUxLTEyLTEtMS03NzQwNw_383116c8-aa53-436d-80b6-eaa899a9226d"
      unitRef="number">-0.061</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea4a942c29b64296a578054f8bb63c6e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTItMS0xLTc3NDA3_6302ca0d-1870-4566-9261-44de90b5056c"
      unitRef="usd">689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i838ec4506aac4839afabb56c89fe75de_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTQtMS0xLTc3NDA3_fb31f829-13fe-423a-b2e2-9f7b30e6c26c"
      unitRef="usd">636000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iea4a942c29b64296a578054f8bb63c6e_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTYtMS0xLTc3NDA3_bd1341ae-a1e4-480c-8412-51567796d9f6"
      unitRef="number">0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43cb13f6753d4651a135658fc71c6eff_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTgtMS0xLTc3NDA3_cd55ceab-a4b2-4195-ae3d-dbbeb3ccd196"
      unitRef="usd">1806000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4942e0be0534752a71e7f1ada41cc70_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTEwLTEtMS03NzQwNw_b51feedc-6008-4062-9cf2-23e331c59150"
      unitRef="usd">1794000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i43cb13f6753d4651a135658fc71c6eff_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTUzLTEyLTEtMS03NzQwNw_2faed52e-996e-4d51-bab2-a241593d7c7d"
      unitRef="number">0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05be66fafb444a8080fecb6fcd302e95_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTItMS0xLTc3NDA3_0c9becb0-9bf9-42ba-b26f-5537cd579930"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida875fcca159482f83502993ab5d5e4e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTQtMS0xLTc3NDA3_88643bdc-9f4f-40d5-827e-7a26b714f8ed"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i05be66fafb444a8080fecb6fcd302e95_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTYtMS0xLTc3NDA3_5e711fd2-fe5e-4b10-9f14-f66fb5f76b76"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34bb5f16f5ad400fbb4ffb0ed9d46048_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTgtMS0xLTc3NDA3_f9cbe219-ce06-4ff9-bb42-6187073833f1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia07c17c915a040be98c96fe359fecfd2_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTEwLTEtMS03NzQwNw_3e58969a-8383-47db-aa59-9d1e8e7501f8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i34bb5f16f5ad400fbb4ffb0ed9d46048_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU0LTEyLTEtMS03NzQwNw_5866727e-55c7-46bc-8f10-3ea584e8efa9"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cdaa89f4a1441e29f7642f5b666eb27_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTItMS0xLTc3NDA3_04ab2642-05a7-4094-839d-4dee942e3324"
      unitRef="usd">689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7de0a5cf540d4fee9c40859ef3796bdc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTQtMS0xLTc3NDA3_648973f2-f967-426e-a13d-8f5d990e6097"
      unitRef="usd">636000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2cdaa89f4a1441e29f7642f5b666eb27_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTYtMS0xLTc3NDA3_90fe365c-b7af-462d-b022-13cc631dcbde"
      unitRef="number">0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8138f8e21ac94faf9fe88ce25877aed5_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTgtMS0xLTc3NDA3_279bc62e-2b1e-4fbf-bda4-b2321267a99b"
      unitRef="usd">1806000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5898c52cfe945779c5143c8df491534_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTEwLTEtMS03NzQwNw_e11644aa-6751-4f5a-b570-041bd2560493"
      unitRef="usd">1794000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8138f8e21ac94faf9fe88ce25877aed5_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU1LTEyLTEtMS03NzQwNw_e29c9627-15f7-46d5-9665-c61db1cbc6b8"
      unitRef="number">0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68c5d8ed136a4c20816e313a4c90b13b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTItMS0xLTc3NDA3_4ed1fefc-8fb3-4549-a686-63a3554aa6d3"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3e5afc3d50e4e4ca0a187ad6b9f1a6c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTQtMS0xLTc3NDA3_b31756bb-4a91-4165-94dc-07a42628cc3c"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i68c5d8ed136a4c20816e313a4c90b13b_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTYtMS0xLTc3NDA3_bb7001f2-888a-4151-b7ca-e97993ed55d9"
      unitRef="number">-0.258</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie37eb67f7b144c5eb518c4948cf96145_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTgtMS0xLTc3NDA3_ce2b778b-0ca3-4b0a-8daf-5fd72ddc8492"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85dda44763ba4414829f3605a73753e0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTEwLTEtMS03NzQwNw_7c547968-084d-42bb-9d7d-2476c9c6d48a"
      unitRef="usd">249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie37eb67f7b144c5eb518c4948cf96145_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU3LTEyLTEtMS03NzQwNw_e290d45c-c166-421a-b237-5ad520aaf6eb"
      unitRef="number">-0.341</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e9b58f0b50e427692c9798179519c8c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTItMS0xLTc3NDA3_56e7f97b-8c71-489c-a5c7-02ad4c7d171f"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf9944934bf44f41a5d848a08016534f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTQtMS0xLTc3NDA3_60c4a047-ce44-4dc3-a2c3-52088461dbbf"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5e9b58f0b50e427692c9798179519c8c_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTYtMS0xLTc3NDA3_4d70f9a8-edc0-4e62-88e4-3415270fedd1"
      unitRef="number">-0.110</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a4e187060bf4b56af8469e2457ad148_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTgtMS0xLTc3NDA3_d8092904-78e2-40c5-925d-a37570c250bf"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53914db7b6994764b67ebd82cd5d70b1_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTEwLTEtMS03NzQwNw_d0d89fb7-ce76-4fd1-bf6b-bc7226040e1f"
      unitRef="usd">194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a4e187060bf4b56af8469e2457ad148_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU4LTEyLTEtMS03NzQwNw_31569bdc-5795-4ce7-97fe-7ed0f81b912e"
      unitRef="number">-0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29e6c0eadbf94d859fbb92d57ca15229_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTItMS0xLTc3NDA3_948e08a9-a2e8-4984-ac58-fb361df640d3"
      unitRef="usd">109000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbec97fb95be414cb2b89e264202246c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTQtMS0xLTc3NDA3_5aae144a-d10e-4b5d-aed9-05bf14f6ef59"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29e6c0eadbf94d859fbb92d57ca15229_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTYtMS0xLTc3NDA3_37c4bc9b-1d0b-4543-88e0-9736e1008c8d"
      unitRef="number">-0.184</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0297066eac1245ce913a0df991220e7d_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTgtMS0xLTc3NDA3_6bfe21e1-2d7d-481e-a6a3-bf07fe7601dc"
      unitRef="usd">357000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e5b7a4bbda24f7f9fcc5b69ed4a9435_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTEwLTEtMS03NzQwNw_cfb577af-68c6-47e3-b972-b020a7244dc7"
      unitRef="usd">443000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0297066eac1245ce913a0df991220e7d_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTU5LTEyLTEtMS03NzQwNw_45a2ebf1-6857-4740-8956-558fd2d7226c"
      unitRef="number">-0.195</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i722ea23e5f924f16a6e6c00652075eba_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTItMS0xLTc3NDA3_6b4f5241-f65d-4023-aa59-a109483a6a45"
      unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if177d277829c4cf39e15833c514ec56f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTQtMS0xLTc3NDA3_7ee684cd-377c-405f-b474-4d7db431ea2a"
      unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i722ea23e5f924f16a6e6c00652075eba_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTYtMS0xLTc3NDA3_776e7f55-123e-4ec7-a2ad-7e97a48d344c"
      unitRef="number">-0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29aa768ec65741dc949cd342666e4f34_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTgtMS0xLTc3NDA3_b3903ef0-7aaf-4bb8-ab0f-1fbeb33a8325"
      unitRef="usd">295000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife790b9884ac4cabbd776e36f99b03af_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTEwLTEtMS03NzQwNw_6c8fc756-ec09-4715-9400-58ca866fc88d"
      unitRef="usd">336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29aa768ec65741dc949cd342666e4f34_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY1LTEyLTEtMS03NzQwNw_881b739e-18e4-43b5-b987-89d2a9440ea8"
      unitRef="number">-0.122</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ad125a62b6946b1b33566216a51ed56_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTItMS0xLTc3NDA3_982e70ba-98a1-4111-936d-161ffd7d4702"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie42b6679085b4580b95eb6119e492e4c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTQtMS0xLTc3NDA3_3f5ab6a8-7108-411a-87cf-3e3f7d687134"
      unitRef="usd">173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8ad125a62b6946b1b33566216a51ed56_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTYtMS0xLTc3NDA3_237d6184-999b-4131-8690-13a2fd9c96cd"
      unitRef="number">-0.200</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6e27d7094e94cc8af96f23c67b17244_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTgtMS0xLTc3NDA3_c14e7ce8-9114-4fc3-8e25-f328c6e254b7"
      unitRef="usd">458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fbc058d591f475e80e0b7c6171f743d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTEwLTEtMS03NzQwNw_2a96f201-d388-4834-a107-b51d63cc3976"
      unitRef="usd">533000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if6e27d7094e94cc8af96f23c67b17244_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY2LTEyLTEtMS03NzQwNw_78c8c6a1-b717-433e-9b48-1b0322a3186d"
      unitRef="number">-0.140</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i305a29aa90b04a249642618470269a81_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTItMS0xLTc3NDA3_9f6d6125-c8ff-4bc5-bb72-94533cac0023"
      unitRef="usd">236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i065d4da56934430d83b7760ca1e819d3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTQtMS0xLTc3NDA3_310a0ae6-4411-4e59-bdaf-8d268a2eee45"
      unitRef="usd">271000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i305a29aa90b04a249642618470269a81_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTYtMS0xLTc3NDA3_695c22f2-9519-4a5f-9599-2251d8e8eb3e"
      unitRef="number">-0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i564acf556d06473886229ffaf87f0863_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTgtMS0xLTc3NDA3_f2b18eb4-cfc3-4326-8afd-a58929d6f7c9"
      unitRef="usd">753000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8bde317222d4d88bda353d061dbd018_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTEwLTEtMS03NzQwNw_366b1f59-d009-4e30-a0bd-1162f0d8378b"
      unitRef="usd">869000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i564acf556d06473886229ffaf87f0863_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTY3LTEyLTEtMS03NzQwNw_8c172611-c6a4-4f0c-aa48-f1e95c860ee1"
      unitRef="number">-0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ceeea82fd7e49d6a825cf5247584a5e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTItMS0xLTc3NDA3_468f30d8-4c4d-4e16-b087-dba79f7b0c70"
      unitRef="usd">7438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a5ce8f1fae8494f9167e95a0acaaeb6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTQtMS0xLTc3NDA3_0c3a6499-b4e4-4796-9085-9ce34da713ca"
      unitRef="usd">7221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3ceeea82fd7e49d6a825cf5247584a5e_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTYtMS0xLTc3NDA3_6b1a0b57-6dd5-449b-900b-b10fcd4faadd"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03f7fb6c7a194120a4df7e29ac654467_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTgtMS0xLTc3NDA3_4a9c197d-9e38-49d1-93cb-f07329ba3998"
      unitRef="usd">21229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bb546e3766343bf9f6063a3941899a5_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTEwLTEtMS03NzQwNw_d4fa4b6e-35a8-4c85-8f35-8b792c129818"
      unitRef="usd">20536000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i03f7fb6c7a194120a4df7e29ac654467_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcwLTEyLTEtMS03NzQwNw_336c24d9-c73d-4294-b53d-4c41871758bc"
      unitRef="number">0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f10cfdf4b7c497b8b6044b5b86bf524_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTItMS0xLTc3NDA3_359980ba-fe71-4a52-abf0-08655e170e8b"
      unitRef="usd">5776000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i818389fdcd8e4be3bf8813b2e25a407d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTQtMS0xLTc3NDA3_6eeb4330-672d-49c9-a209-1746c3e12b5d"
      unitRef="usd">5661000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6f10cfdf4b7c497b8b6044b5b86bf524_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTYtMS0xLTc3NDA3_ddadbc47-dd0a-43c1-9175-069505637450"
      unitRef="number">0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f381374d0cb4d7d863372ef4c0e1356_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTgtMS0xLTc3NDA3_26f6e2e5-2494-4d88-a6e8-ee4836ec2297"
      unitRef="usd">18171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8d82aed0673478d9b0ab5456d859fc6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTEwLTEtMS03NzQwNw_9969d362-8df0-475f-a9be-739057125396"
      unitRef="usd">16927000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1f381374d0cb4d7d863372ef4c0e1356_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcxLTEyLTEtMS03NzQwNw_882551d9-17ef-4c81-844a-601bca10fd20"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i680f6194af6c4f068b01fc50ebebf2bc_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTItMS0xLTc3NDA3_d11b99a6-415b-46d4-b841-4a6672aa9447"
      unitRef="usd">13214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95e4a4d3e8ab4d7eb48f7cc386ceeb8c_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTQtMS0xLTc3NDA3_bbe1691e-1011-492a-930e-3a8506fe5fc8"
      unitRef="usd">12882000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i680f6194af6c4f068b01fc50ebebf2bc_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTYtMS0xLTc3NDA3_fa0ac1c6-8c37-429e-9019-5f6b609bc4ea"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i470f1742dc564aceade9de615023f5d9_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTgtMS0xLTc3NDA3_7c390e92-87f0-401b-aef2-931db7f9279e"
      unitRef="usd">39400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i499f24d8dbf843af8dd118f4348d0ab6_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTEwLTEtMS03NzQwNw_5f9988cf-636a-4a27-a525-52a6dd5a0a7d"
      unitRef="usd">37463000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i470f1742dc564aceade9de615023f5d9_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTcyLTEyLTEtMS03NzQwNw_14f04e7a-b33e-4fe7-9f0e-6f8b18ded687"
      unitRef="number">0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib458d25a886746158cfacde3445cd6fc_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTItMS0xLTc3NDA3_735039ea-04d6-47d5-8627-5330bf5ef52a"
      unitRef="usd">547000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0430caf022a942bdb0f6cdbd46b04bac_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTQtMS0xLTc3NDA3_3d88f6a1-d97f-41d9-8d76-5c26bb44009d"
      unitRef="usd">444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib458d25a886746158cfacde3445cd6fc_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTYtMS0xLTc3NDA3_c938e0ee-dc78-4091-ac0c-8811d3ba30f3"
      unitRef="number">0.232</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7ef391ad36744e5a7cca822a0d2390d_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTgtMS0xLTc3NDA3_b2a002ed-f7fb-444c-9286-5155950c51a4"
      unitRef="usd">1566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8778f377a1564158aa09c4c776f50a1e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTEwLTEtMS03NzQwNw_ee19f447-6a93-4cec-8e9f-8c4d20e91225"
      unitRef="usd">1353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia7ef391ad36744e5a7cca822a0d2390d_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg1LTEyLTEtMS03NzQwNw_8c48d3e1-fa25-4af3-972c-b9cb0cfdd2ca"
      unitRef="number">0.157</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc078949f249451895be35c4a94e683e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTItMS0xLTc3NDA3_0442f9c8-9c4d-4508-b94c-b1d0b3380816"
      unitRef="usd">513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i577a1cff490044bfa62a9e2f3af70a8a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTQtMS0xLTc3NDA3_25ed1f9a-ad48-4a0d-8dce-0a4581fee68e"
      unitRef="usd">513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idc078949f249451895be35c4a94e683e_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTYtMS0xLTc3NDA3_48a76f98-e913-4fff-9aa0-ce9ae56dbf20"
      unitRef="number">0.0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa3a87266183456fa1a996407ff90f9d_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTgtMS0xLTc3NDA3_7c38dfe4-ebcf-45b5-af8b-0a4fa9666547"
      unitRef="usd">1636000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7df5dd26fd074767b958cd1516adf6ea_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTEwLTEtMS03NzQwNw_35a013dd-21d8-4019-8396-30e45443fa6d"
      unitRef="usd">1599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifa3a87266183456fa1a996407ff90f9d_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg2LTEyLTEtMS03NzQwNw_ce8eebdb-c334-49e4-b7d5-6fe47ec07271"
      unitRef="number">0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fe5ed9c09394a3ead9cf56afedcc350_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTItMS0xLTc3NDA3_8532c240-20b7-4c5f-9a27-6b47ff54d410"
      unitRef="usd">1060000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i392724c4d2c743918e9611261847ffc2_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTQtMS0xLTc3NDA3_ebd5dfd8-6dba-44e3-ae42-d3a197d6e7c7"
      unitRef="usd">957000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2fe5ed9c09394a3ead9cf56afedcc350_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTYtMS0xLTc3NDA3_766c4779-5f5f-4563-a669-121940604f3a"
      unitRef="number">0.108</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff24f989dc2649e0a841bfefa2388270_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTgtMS0xLTc3NDA3_e7af085f-0f28-481c-ad04-afa92e868459"
      unitRef="usd">3202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5f74ff91d6b439183caba093e33753e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTEwLTEtMS03NzQwNw_e379c65a-0254-4b69-b2a8-8d47028e3650"
      unitRef="usd">2952000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iff24f989dc2649e0a841bfefa2388270_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg3LTEyLTEtMS03NzQwNw_3fdd1a73-d7c1-4d58-ae87-a3504775eaed"
      unitRef="number">0.085</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bd824b5eee841079ac4190b0b4c2ded_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTItMS0xLTc3NDA3_15d584d4-dcda-464e-9b03-69c0e1cf9d78"
      unitRef="usd">1309000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id063a0459cf44210877c1484ef7c45a0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTQtMS0xLTc3NDA3_0301ee3b-249d-49ad-bb07-c4c888dce78e"
      unitRef="usd">1249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3bd824b5eee841079ac4190b0b4c2ded_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTYtMS0xLTc3NDA3_c2da1b79-bb2b-438c-8fd5-83ed30d91aaa"
      unitRef="number">0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cbfd51374014b128d8615d36bec5484_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTgtMS0xLTc3NDA3_44699a29-0719-4657-9626-f2c8975976a5"
      unitRef="usd">3936000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7aa376f5433c40de98c137cab1b41421_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTEwLTEtMS03NzQwNw_cf4ad064-c03d-4564-8765-239eb7aff4a8"
      unitRef="usd">3821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6cbfd51374014b128d8615d36bec5484_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTg5LTEyLTEtMS03NzQwNw_7098b416-3fe4-4c26-82b6-3c9ba2bcb4b1"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i038004c2490c4105b96321ee95665011_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTItMS0xLTc3NDA3_a24f60b7-a19b-4fa5-a568-7d53b819cdc7"
      unitRef="usd">785000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5f92f7db04a4642b0601560adc62b41_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTQtMS0xLTc3NDA3_0948852e-cc32-4f93-a987-ba1a7de0ad8b"
      unitRef="usd">843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i038004c2490c4105b96321ee95665011_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTYtMS0xLTc3NDA3_0753a207-561d-43e8-98d7-f0115fbb71b2"
      unitRef="number">-0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffe31a46ec13474db2f9953a95a8ebf1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTgtMS0xLTc3NDA3_5b0fd4f9-bd13-4211-8e6e-ee358ac9ced3"
      unitRef="usd">2504000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24e24057824445669dc06fd3fa613c19_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTEwLTEtMS03NzQwNw_d06bb938-c23f-4971-91e4-f219d1607f26"
      unitRef="usd">2611000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iffe31a46ec13474db2f9953a95a8ebf1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkwLTEyLTEtMS03NzQwNw_7178ecee-a6d9-4605-b1ec-c2e3189a3c55"
      unitRef="number">-0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bf3746768844207b9687743172b8829_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTItMS0xLTc3NDA3_a51a46d6-1cae-44aa-bfc7-7346dc1eef85"
      unitRef="usd">2095000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b31eb5bc05146f6bd4d2d78e8fda6ff_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTQtMS0xLTc3NDA3_e3c4ac7c-f222-496e-9d7e-1b2ca6e224d4"
      unitRef="usd">2093000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9bf3746768844207b9687743172b8829_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTYtMS0xLTc3NDA3_bee470b8-3cbc-470e-acb2-b6db50f320f5"
      unitRef="number">0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4170b6c793743a092f6c56a49529637_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTgtMS0xLTc3NDA3_318422ef-0832-4684-bcd1-3364a4651359"
      unitRef="usd">6440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i092927032fbf41288117417bd83c8d33_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTEwLTEtMS03NzQwNw_f4c419c6-bf2a-4adf-98f7-e9c488f823d0"
      unitRef="usd">6433000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie4170b6c793743a092f6c56a49529637_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkxLTEyLTEtMS03NzQwNw_3b3544a6-faa4-4922-bf36-9a6acf51b724"
      unitRef="number">0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2847269390c248719305140d646fb64d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTItMS0xLTc3NDA3_5d98d112-932b-46fe-bc45-411cb76eb3ae"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7be44d585f94dd1b4e8bdccd9f72fcd_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTQtMS0xLTc3NDA3_6ef1adb2-86c8-4d39-bf73-43bbf6f46ce2"
      unitRef="usd">209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2847269390c248719305140d646fb64d_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTYtMS0xLTc3NDA3_09ef40b2-186d-45de-87ee-fc152ce5b807"
      unitRef="number">0.091</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cd97ec22af24e1aaafd19a24d6e9286_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTgtMS0xLTc3NDA3_a39fe74e-c0f2-48b1-ab54-9f6297dfdb64"
      unitRef="usd">693000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa0dde31e99e496dbedc1e0f945ca70e_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTEwLTEtMS03NzQwNw_5d959bb7-5c1e-4e0f-a14c-db3b881cb3f4"
      unitRef="usd">651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8cd97ec22af24e1aaafd19a24d6e9286_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTkzLTEyLTEtMS03NzQwNw_db2b5215-fa1a-4aef-b2ea-e66b76c10bb1"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9417a55ca564c889c26bac785e05477_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTItMS0xLTc3NDA3_573ec7b4-e53a-4def-932a-e8715a772764"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ae91066041f4be1b8f92b78864de25f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTQtMS0xLTc3NDA3_75633c37-8fad-44e3-bd66-fc02000856ae"
      unitRef="usd">146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib9417a55ca564c889c26bac785e05477_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTYtMS0xLTc3NDA3_5adb204e-e500-485c-97c7-d8ce001f7283"
      unitRef="number">-0.151</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i974d64a21e4f41528433f1336946ceed_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTgtMS0xLTc3NDA3_03c289e7-d780-452a-a668-7853f0a412af"
      unitRef="usd">437000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f9110d30d29404584bef97cc4a24dd1_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTEwLTEtMS03NzQwNw_4e7ac24f-02cd-487f-a2de-9e60b3524a5f"
      unitRef="usd">451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i974d64a21e4f41528433f1336946ceed_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk0LTEyLTEtMS03NzQwNw_6b37614d-af77-4c23-b104-ae71c60473e5"
      unitRef="number">-0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9cd6cfa9d6a40558ceef771622f76b4_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTItMS0xLTc3NDA3_2084a9e1-173d-408d-9b09-4d51d018803e"
      unitRef="usd">352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbc22c2972644793b32196e789568db5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTQtMS0xLTc3NDA3_0536de5a-6d20-4407-8bd9-3c233dd45776"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic9cd6cfa9d6a40558ceef771622f76b4_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTYtMS0xLTc3NDA3_e5bd93ca-5174-4e66-94bd-79984e4fd807"
      unitRef="number">-0.009</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7c3c999eaef4151b4669dc63eb4030a_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTgtMS0xLTc3NDA3_1793e12d-a2a9-4203-8179-60bc9c00540e"
      unitRef="usd">1129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3e2207be87140cab8ceaa62aa0d6044_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTEwLTEtMS03NzQwNw_eeba0878-b84d-4c4c-9716-367e5eab513b"
      unitRef="usd">1102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic7c3c999eaef4151b4669dc63eb4030a_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk1LTEyLTEtMS03NzQwNw_282533c4-0d88-49e2-b3f3-2309949a67f4"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9429a289df048cfa5ab4fdd10126b5b_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTItMS0xLTc3NDA3_27ca44e4-be71-4c43-9f54-05a2e6e8a8cf"
      unitRef="usd">203000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cd65d3eab964c75adc84d3231cdbf0d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTQtMS0xLTc3NDA3_71da9903-bd01-4f1e-8d09-129ed260b85f"
      unitRef="usd">184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id9429a289df048cfa5ab4fdd10126b5b_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTYtMS0xLTc3NDA3_cb9ed2f2-7d02-4fe1-93c0-960df50f39c7"
      unitRef="number">0.098</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cae4423d64f4d4bbfe2cbf8df84e736_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTgtMS0xLTc3NDA3_1d699ee8-11e3-4e0a-b1ce-ebcc27229cf5"
      unitRef="usd">620000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6a87b0c3795491d8cb754d008abe491_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTEwLTEtMS03NzQwNw_00bf82c3-3e14-4324-8964-9b62ba74ba97"
      unitRef="usd">579000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5cae4423d64f4d4bbfe2cbf8df84e736_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk3LTEyLTEtMS03NzQwNw_b2071c6e-dc8d-4159-a3d7-dc263943d54b"
      unitRef="number">0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26b3f7fda8dc45a4acd129a76f977cd3_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTItMS0xLTc3NDA3_fcace501-bb51-4b0b-a865-e916d52f5cdc"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7efc4792ae7f465ab37467091fef4a2d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTQtMS0xLTc3NDA3_536d3199-f1c2-487e-bae2-770e49a77cc0"
      unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i26b3f7fda8dc45a4acd129a76f977cd3_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTYtMS0xLTc3NDA3_cacfcb1d-bb4e-41ba-b0c8-1f0b8d2bb8a0"
      unitRef="number">-0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97fdcab14626459db0701cecead7f119_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTgtMS0xLTc3NDA3_0051e27f-4adc-4dad-adf3-b96967d90b4f"
      unitRef="usd">386000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i855d5f8389ac44e5abf80391fa0ee110_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTEwLTEtMS03NzQwNw_c777d6ef-533d-4da8-9446-10b770915950"
      unitRef="usd">403000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i97fdcab14626459db0701cecead7f119_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk4LTEyLTEtMS03NzQwNw_01e51fa6-7dcc-4a30-bffb-b2bf823bfedd"
      unitRef="number">-0.044</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d6094b282dc44208ebf68078e1e3b34_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTItMS0xLTc3NDA3_968a7298-f731-431a-8f91-8d4e3658465c"
      unitRef="usd">317000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic907c783f0ed4d86bdb6abb9d2580af7_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTQtMS0xLTc3NDA3_6ab17021-b72e-45df-b74b-f84994abbaa7"
      unitRef="usd">316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0d6094b282dc44208ebf68078e1e3b34_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTYtMS0xLTc3NDA3_de5b641b-e5fd-49de-b435-62afaf1ec73a"
      unitRef="number">0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3281cef57f094b31b7cdacddcdaf74a8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTgtMS0xLTc3NDA3_3b05cfa2-9b1f-4965-ac58-7dbfa748ea7a"
      unitRef="usd">1005000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1d05e3bda784d0d9ae066ae87e26eae_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTEwLTEtMS03NzQwNw_05639c6c-180a-43c9-83c6-e5e3d86b500b"
      unitRef="usd">983000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3281cef57f094b31b7cdacddcdaf74a8_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMTk5LTEyLTEtMS03NzQwNw_f6e198b6-588d-462f-b35b-0edb7ce2ffaa"
      unitRef="number">0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib707a9c98f6b4c618112fba387110572_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTItMS0xLTc3NDA3_d72dddaf-bbf9-4166-b264-f7a37db61e34"
      unitRef="usd">473000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic13deb7b513e4e2281a5b9c7dcd54fb8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTQtMS0xLTc3NDA3_31f2592e-dfff-4d7f-b0ac-537e67dc2072"
      unitRef="usd">455000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib707a9c98f6b4c618112fba387110572_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTYtMS0xLTc3NDA3_6d04bfb4-5b8c-4d3d-89af-90392489793c"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief2452e5e77d4264a2a230717da020d1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTgtMS0xLTc3NDA3_84c7a1f1-e5cd-4b3a-b3b1-3c0960b45e55"
      unitRef="usd">1412000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95095593fff6463d893fd017b40967ea_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTEwLTEtMS03NzQwNw_2d790786-1fd0-40a4-9542-a9878b7004be"
      unitRef="usd">1352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ief2452e5e77d4264a2a230717da020d1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAxLTEyLTEtMS03NzQwNw_c677d293-7fd0-4eba-82b9-222ba4e8ed46"
      unitRef="number">0.044</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0ce74ed131d46019830ea323390afd8_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTItMS0xLTc3NDA3_d1f1a0d2-e126-45f4-8f61-5fccd975f163"
      unitRef="usd">244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb897375b8384ad0bed6f189fe441473_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTQtMS0xLTc3NDA3_c8892014-50e0-4c0c-9c63-62b6b22b639e"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id0ce74ed131d46019830ea323390afd8_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTYtMS0xLTc3NDA3_42ac3194-dd30-4d08-a311-b5f755720dbd"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7368c2116cf4338b2809934b019406f_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTgtMS0xLTc3NDA3_92619ad5-92e9-42e5-b311-aa3e6866de26"
      unitRef="usd">749000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i372b1bcd430544318ad85558939c89df_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTEwLTEtMS03NzQwNw_3f11a529-b49d-4959-8b0c-bb697cb18c74"
      unitRef="usd">805000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id7368c2116cf4338b2809934b019406f_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAyLTEyLTEtMS03NzQwNw_c009be18-8b48-4b5d-8934-aec62c5d1be4"
      unitRef="number">-0.070</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ec4f3ba11ea4d6b88b6d131ffd28198_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTItMS0xLTc3NDA3_a167598c-9215-4048-865d-b84e9d45d2f8"
      unitRef="usd">717000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe322b23cff240edbba0ccd9e2b833c8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTQtMS0xLTc3NDA3_e4fcc5b7-5ed4-46c6-86bc-0dfc4bee707e"
      unitRef="usd">715000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5ec4f3ba11ea4d6b88b6d131ffd28198_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTYtMS0xLTc3NDA3_e0c00f7e-8240-4ee3-9346-497673c93608"
      unitRef="number">0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34035b45a76f4ade91be1a7e5f2dd59f_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTgtMS0xLTc3NDA3_ddbc4127-1d21-4a0d-a77c-9b8344871396"
      unitRef="usd">2161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic700316f668447918923186ca5e57289_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTEwLTEtMS03NzQwNw_648c16b7-96a1-49c6-b387-60d2748c7867"
      unitRef="usd">2157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i34035b45a76f4ade91be1a7e5f2dd59f_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjAzLTEyLTEtMS03NzQwNw_2741b38e-3eec-4a44-be6f-b2431053cb28"
      unitRef="number">0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58690ca930484006850c26e283195c51_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTItMS0xLTc3NDA3_4fe66eb7-6ce2-47ed-bd9d-c9cce3b9cdb0"
      unitRef="usd">406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a3ef38541d04372a83ca49403db6011_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTQtMS0xLTc3NDA3_ef22f886-a7a4-4069-bd2d-586023897de2"
      unitRef="usd">401000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i58690ca930484006850c26e283195c51_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTYtMS0xLTc3NDA3_cba10df8-4304-4c1e-b09d-2a0a53fb6041"
      unitRef="number">0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a94b325e9bc4923bb6d5064b162cbb1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTgtMS0xLTc3NDA3_73b9ffae-4516-4a00-970e-37801fc879f1"
      unitRef="usd">1211000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia30996795fa94ea6b9c7db00253f7c7c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTEwLTEtMS03NzQwNw_b481aa32-62c6-49e0-a211-59439a455062"
      unitRef="usd">1239000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a94b325e9bc4923bb6d5064b162cbb1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA1LTEyLTEtMS03NzQwNw_530c917d-01a4-4d06-91d5-9f27d6a277e9"
      unitRef="number">-0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbc66fc1dfb74e039295ae639e9205c3_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTItMS0xLTc3NDA3_9f658e3c-63db-470a-9db6-22f4fcc6ea22"
      unitRef="usd">303000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47a2e3c8bb504b308a68c7504052a8cc_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTQtMS0xLTc3NDA3_85809c7c-a94e-4e90-9d40-7af8112f7035"
      unitRef="usd">306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icbc66fc1dfb74e039295ae639e9205c3_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTYtMS0xLTc3NDA3_0989e131-3b2f-48cf-97ba-641369622531"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b794e63d907423bbad6d7dfdc91be50_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTgtMS0xLTc3NDA3_9bca8211-819a-4820-aa1c-03378c5909d1"
      unitRef="usd">933000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33bcbb3a06994413a39168066fba21c0_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTEwLTEtMS03NzQwNw_35c91964-25cb-43eb-9dcb-47772767b31d"
      unitRef="usd">952000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8b794e63d907423bbad6d7dfdc91be50_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA2LTEyLTEtMS03NzQwNw_cc0a0b97-95e8-439d-bb3d-206519073e3a"
      unitRef="number">-0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i391427c923714920834b2e9cb41cb698_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTItMS0xLTc3NDA3_18cf1fdf-d27e-4c9d-b740-9b6fffd26aef"
      unitRef="usd">708000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b326613e99b4043bfe3af2bbeeaf963_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTQtMS0xLTc3NDA3_0a5d433c-5829-4b59-ba04-51ba4a278113"
      unitRef="usd">706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i391427c923714920834b2e9cb41cb698_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTYtMS0xLTc3NDA3_132de5f6-61ed-4e83-88b2-347af736e560"
      unitRef="number">0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37b0ad3859c844e399e58cadb8404920_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTgtMS0xLTc3NDA3_b1f85878-0d2b-4f8c-a6ae-ae7510d31f9f"
      unitRef="usd">2144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b0f540aabca4cbb8e8011d5ced8cbfb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTEwLTEtMS03NzQwNw_def3e8d5-f9bd-4a1d-8d4b-fa7f31e7e437"
      unitRef="usd">2190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i37b0ad3859c844e399e58cadb8404920_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA3LTEyLTEtMS03NzQwNw_aca8562e-ff1d-47ec-847a-05e1eeda0ad2"
      unitRef="number">-0.021</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c8bf7911a294fd5a9711bf309527dd7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTItMS0xLTc3NDA3_589527b5-cc26-4525-8b8d-114f59e4e8b1"
      unitRef="usd">984000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic13b79cce02e4ae4924831ae4711540f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTQtMS0xLTc3NDA3_902dc25a-b865-4cb4-9b91-2108dbfb72ac"
      unitRef="usd">948000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7c8bf7911a294fd5a9711bf309527dd7_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTYtMS0xLTc3NDA3_3c705cb9-8df4-41b6-a33a-5e06aee4c507"
      unitRef="number">0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19ef6dc106bc4d7d871aedead8e03203_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTgtMS0xLTc3NDA3_133df480-0d48-4945-a637-88ad2a0dbf20"
      unitRef="usd">2897000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3d9e613aba94a1f9b967f1b8b04148b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTEwLTEtMS03NzQwNw_3a6cfb3b-4f9d-4ed3-ab1c-786ee8fc4eca"
      unitRef="usd">2881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i19ef6dc106bc4d7d871aedead8e03203_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjA5LTEyLTEtMS03NzQwNw_d54cd679-2982-4545-b711-736278d8ff43"
      unitRef="number">0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51efdf97f2214c34a66a193a4ee00409_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTItMS0xLTc3NDA3_81982296-b61c-400d-b7e0-d4de0b41bff9"
      unitRef="usd">1439000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99f710c786d345ffab2ccc1e077da0e5_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTQtMS0xLTc3NDA3_7c22415f-a99b-4073-b5ad-d64a6f167b4f"
      unitRef="usd">1457000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i51efdf97f2214c34a66a193a4ee00409_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTYtMS0xLTc3NDA3_564c3c11-5a8c-4653-b49a-ce8a7eca2686"
      unitRef="number">-0.012</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b737de8e7ed48e9a0f1e473c0fd11b0_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTgtMS0xLTc3NDA3_67a7d3de-a67a-49e0-95c3-695bc82b29a4"
      unitRef="usd">4410000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa68cd0ebbc649f8b1944c6452cf157c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTEwLTEtMS03NzQwNw_293d1269-2c37-40c9-85a7-05e38cc5ed18"
      unitRef="usd">4418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0b737de8e7ed48e9a0f1e473c0fd11b0_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEwLTEyLTEtMS03NzQwNw_8dd54ffa-5f71-4107-9869-b404246ec0a9"
      unitRef="number">-0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e651723831f48ba8112b343beaff0d3_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTItMS0xLTc3NDA3_5fe918b6-73f7-4084-ab4c-a2e38404e1b8"
      unitRef="usd">2422000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic19353844d9d42988aefc5611b61c81a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTQtMS0xLTc3NDA3_b60bc6ce-d77c-454f-88b0-f9319f0d28a5"
      unitRef="usd">2405000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6e651723831f48ba8112b343beaff0d3_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTYtMS0xLTc3NDA3_3d9fde95-0f52-41d8-8120-4d607519cd0d"
      unitRef="number">0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc3559fd0b124045a8fa153a444ef33e_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTgtMS0xLTc3NDA3_d3b630c8-353a-4b1d-ae0f-f5e4d2fd522b"
      unitRef="usd">7306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38c4456bb5034d83b9f17294fc378c0a_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTEwLTEtMS03NzQwNw_d753d475-2933-48ff-b4b0-d90e34e7e321"
      unitRef="usd">7299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idc3559fd0b124045a8fa153a444ef33e_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjExLTEyLTEtMS03NzQwNw_b8087cd3-36db-4ad5-b20d-6226eb326aec"
      unitRef="number">0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5d3558da8644e909594aa8c7e4e0083_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTItMS0xLTc3NDA3_732ee62a-d1a2-49bc-80b5-0cd7f3d2585c"
      unitRef="usd">457000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00b3e8006e23428f8b7ee7417c102c09_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTQtMS0xLTc3NDA3_54e2f815-ec97-49d6-ab79-7d5d0cec9db8"
      unitRef="usd">440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia5d3558da8644e909594aa8c7e4e0083_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTYtMS0xLTc3NDA3_f6af0c82-afe7-4fbb-a271-f7b8322df038"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1039c0aa59334e18b5a49bf9c2b74e02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTgtMS0xLTc3NDA3_6d320bb8-ca46-40d0-8a08-a31c166ff845"
      unitRef="usd">1328000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b1416bbe0bf416081fe7ae31939518b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTEwLTEtMS03NzQwNw_90a20301-79d6-4572-8ef2-6427f467b155"
      unitRef="usd">1304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1039c0aa59334e18b5a49bf9c2b74e02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjEzLTEyLTEtMS03NzQwNw_7f6121ff-b60b-4bdf-b730-f32d1b4f1084"
      unitRef="number">0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3d4e80547494117a247653eb23d938e_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTItMS0xLTc3NDA3_432354da-eb72-433f-b97e-a79cb0b73f4d"
      unitRef="usd">701000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c7c7b4a1930485390375e2d3bbb3a2f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTQtMS0xLTc3NDA3_22eafc17-32d1-4724-bfbe-a997f4ba2279"
      unitRef="usd">705000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib3d4e80547494117a247653eb23d938e_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTYtMS0xLTc3NDA3_fc2bf70b-d1a6-4ada-a256-b3cd8be8a03c"
      unitRef="number">-0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76779eb2bfad4ee1a6a2508e4e75218c_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTgtMS0xLTc3NDA3_a21db887-422e-45e5-963f-65b30085c957"
      unitRef="usd">2132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09bb019661ae4ed0a5e67d8131209bf2_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTEwLTEtMS03NzQwNw_abc107ec-0b78-4dfe-b80a-a29e87d7165f"
      unitRef="usd">2126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i76779eb2bfad4ee1a6a2508e4e75218c_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE0LTEyLTEtMS03NzQwNw_4e2e2bb3-bfee-4fb5-86a5-47d1be0d0808"
      unitRef="number">0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70c0711b6e2e4a6087c73758e3f91243_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTItMS0xLTc3NDA3_a4df08a6-7e76-44a1-9d0d-1ccc1bc7f22a"
      unitRef="usd">1158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28e3fcd890c242319befd0f7388bfe2e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTQtMS0xLTc3NDA3_d2861147-a246-4fc7-b39d-796362a231b3"
      unitRef="usd">1144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i70c0711b6e2e4a6087c73758e3f91243_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTYtMS0xLTc3NDA3_fb34db29-bf93-4ea8-9f84-b154f0e21346"
      unitRef="number">0.012</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic42e396c0efc43a3ba71cd4831b384c8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTgtMS0xLTc3NDA3_866e50f5-6b73-47a2-a6a6-31277cca7c54"
      unitRef="usd">3460000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d0c0d174e1e465a968649b402f5cea1_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTEwLTEtMS03NzQwNw_800bfd4a-6e49-42d2-aa1b-04a4367fad23"
      unitRef="usd">3430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic42e396c0efc43a3ba71cd4831b384c8_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE1LTEyLTEtMS03NzQwNw_feaa171d-149a-4b25-995e-ab9b778fcd89"
      unitRef="number">0.009</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ac832e9cf5c414d856dd7230794b701_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTItMS0xLTc3NDA3_63511e63-349d-4f8f-9563-ac99ae99708d"
      unitRef="usd">527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida2ad956ed734c17a0b3ce03be3fff11_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTQtMS0xLTc3NDA3_3925248b-6406-435c-9cfb-9d657856d2e6"
      unitRef="usd">508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3ac832e9cf5c414d856dd7230794b701_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTYtMS0xLTc3NDA3_2b1679f0-4755-4584-bf20-66c80d800a9c"
      unitRef="number">0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d9be1e0153f4553b7b041b59504358d_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTgtMS0xLTc3NDA3_33ba11fa-daef-44dd-aa9d-4941378c85b7"
      unitRef="usd">1569000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17d8758d185d4148b85cbe1809fe78e2_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTEwLTEtMS03NzQwNw_19f17a8b-faf0-4028-b90d-83004cac17b3"
      unitRef="usd">1577000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2d9be1e0153f4553b7b041b59504358d_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE3LTEyLTEtMS03NzQwNw_ce0ac28f-b791-4770-8de9-65ffd483abdf"
      unitRef="number">-0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7e826c2f1324a59aedd22ebe1aca2e6_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTItMS0xLTc3NDA3_7cce9b42-5d89-4915-9378-dd70d93b2f43"
      unitRef="usd">737000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89b09107775e49eaa9df473cb669c97e_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTQtMS0xLTc3NDA3_4d3eb1b9-6044-43a0-b474-8f392144c087"
      unitRef="usd">752000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib7e826c2f1324a59aedd22ebe1aca2e6_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTYtMS0xLTc3NDA3_fba80c76-d779-4a32-84e8-ec057bf3c49c"
      unitRef="number">-0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad0196cb82f94a8ea79748ba42931837_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTgtMS0xLTc3NDA3_6f5008af-6e03-4916-bbeb-fe475050b8a9"
      unitRef="usd">2277000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02b2071e56d747afbf128fec4a955609_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTEwLTEtMS03NzQwNw_fead43dd-93ae-48d3-96a6-fe0dec40a1a2"
      unitRef="usd">2292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iad0196cb82f94a8ea79748ba42931837_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE4LTEyLTEtMS03NzQwNw_7d60187e-d650-4cd2-8152-a9198e412995"
      unitRef="number">-0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6af84b75578249b38eb94570b45c8bcf_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTItMS0xLTc3NDA3_4542a229-016d-4df9-b325-b1d8793828e0"
      unitRef="usd">1264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i366a7d5e35604a52910d0f6633b551b3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTQtMS0xLTc3NDA3_702c68f5-40f6-4150-b4a4-cdd557a6d22f"
      unitRef="usd">1261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6af84b75578249b38eb94570b45c8bcf_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTYtMS0xLTc3NDA3_5bb8135b-0992-4898-9adc-d38ed856aaef"
      unitRef="number">0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i640f5e27e4594136be6910021459b067_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTgtMS0xLTc3NDA3_6dcaf866-bf59-4bf3-adb3-652ae1061ca0"
      unitRef="usd">3846000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d78c321af554254b32b1e3a8a1d3694_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTEwLTEtMS03NzQwNw_fb4925a9-4304-4a25-b047-207df35b7bc5"
      unitRef="usd">3869000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i640f5e27e4594136be6910021459b067_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjE5LTEyLTEtMS03NzQwNw_f9a72543-f77d-4d3e-ab75-7d2fc0043302"
      unitRef="number">-0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaff737262fdb484bbf75e5931817a490_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTItMS0xLTc3NDA3_b4d39a0a-c606-4ff1-b9b5-3187bdaebac8"
      unitRef="usd">517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c366e52f34f4c939ba9bb069bc96cea_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTQtMS0xLTc3NDA3_94aa6c5e-f13f-4f4e-8209-b10f31d866fe"
      unitRef="usd">475000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaff737262fdb484bbf75e5931817a490_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTYtMS0xLTc3NDA3_cf729e36-e84d-4cc2-926f-37eb65b03218"
      unitRef="number">0.088</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49dade5fbc6447ae87c04ac20252f3ee_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTgtMS0xLTc3NDA3_00496c5f-9b60-4bf1-a68c-41bd36fcc496"
      unitRef="usd">1534000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b9c2927f6ad471d81601e63f54fc36f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTEwLTEtMS03NzQwNw_b31bedc7-4bca-4c84-b656-bec05b075e14"
      unitRef="usd">1414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i49dade5fbc6447ae87c04ac20252f3ee_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIxLTEyLTEtMS03NzQwNw_d2dbe143-c509-4cfd-8c15-850d3e46f1be"
      unitRef="number">0.085</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d94242030db4c6e972f72cfbfe05464_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTItMS0xLTc3NDA3_dc98364a-a3f4-44b1-bbd4-cee2b61b5363"
      unitRef="usd">689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i158baf5a07fa408c826b2c8d54778c21_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTQtMS0xLTc3NDA3_f61f1977-71fe-4acf-853d-457a245f4813"
      unitRef="usd">714000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5d94242030db4c6e972f72cfbfe05464_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTYtMS0xLTc3NDA3_d0dc4731-ad11-4967-869d-66ee27e7482f"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i358c3cd12c24472787b2a36a2550e8c6_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTgtMS0xLTc3NDA3_1d82ae60-b668-4798-8cae-dfb45c6c4805"
      unitRef="usd">2170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a772c8416cf49df88d756da5e9a094d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTEwLTEtMS03NzQwNw_74f79d01-2f11-4d7e-a55f-b3f63b15e825"
      unitRef="usd">2103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i358c3cd12c24472787b2a36a2550e8c6_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIyLTEyLTEtMS03NzQwNw_214d0de1-b3d5-4d4e-898f-00462e64568f"
      unitRef="number">0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02c59bee76a743e19c22b2e772f8d973_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTItMS0xLTc3NDA3_fec98f45-f794-495b-987b-1382578a5deb"
      unitRef="usd">1206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i201e6e46d1c74819a9acfb688922322f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTQtMS0xLTc3NDA3_aa2c7583-06fa-4d5d-9f04-a915b532beaa"
      unitRef="usd">1189000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i02c59bee76a743e19c22b2e772f8d973_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTYtMS0xLTc3NDA3_07810b2d-b596-4e40-a4e4-090886951a34"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b398a883ec74c3eba875c513b5d8cd2_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTgtMS0xLTc3NDA3_b6b78c76-897a-4abb-a360-c7e9a45410ee"
      unitRef="usd">3704000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifafc57d6cd754d72bbe14c0919d17e1f_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTEwLTEtMS03NzQwNw_acd15deb-9033-4be3-bef6-8fd7b82bd010"
      unitRef="usd">3517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6b398a883ec74c3eba875c513b5d8cd2_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjIzLTEyLTEtMS03NzQwNw_430f1b19-6534-4654-b84b-225bf75cfb37"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i623b6ae349b44bf9b2853ebb6769281d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTItMS0xLTc3NDA3_f141a941-6fae-40e6-845f-354db5f454ab"
      unitRef="usd">405000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i123867d1543d46d9afd6cedaa87c7ed3_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTQtMS0xLTc3NDA3_119228a1-a2b9-4835-8ec4-d61fa9d7216f"
      unitRef="usd">359000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i623b6ae349b44bf9b2853ebb6769281d_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTYtMS0xLTc3NDA3_59cdba0d-cc15-4272-87f9-a810719c0c85"
      unitRef="number">0.126</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia200d3ae9c054b709c7195a311b6c9e3_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTgtMS0xLTc3NDA3_47540613-c85d-4f95-b5c6-a1aeaa0459d9"
      unitRef="usd">1179000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie23f74e989df418392f516e411c8ba59_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTEwLTEtMS03NzQwNw_91289273-4f97-4a82-b029-7c53cdaff945"
      unitRef="usd">1082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia200d3ae9c054b709c7195a311b6c9e3_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI1LTEyLTEtMS03NzQwNw_9fa42715-a6ef-4dbc-bad1-c3d141169ebf"
      unitRef="number">0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9146e1200a7f49d3ac965e4dc89a064c_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTItMS0xLTc3NDA3_8147fa6c-8d5d-4f29-bcd3-2355b2b22b3d"
      unitRef="usd">503000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17622e1e5cdf4287a5ce27533de69c09_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTQtMS0xLTc3NDA3_f990ab97-29a8-4b36-910b-81302b45bd60"
      unitRef="usd">522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9146e1200a7f49d3ac965e4dc89a064c_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTYtMS0xLTc3NDA3_5e124fbd-23b8-4eb7-8788-2cbc7314e3a3"
      unitRef="number">-0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15889f3752b64ea98aa7f132f768a0d1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTgtMS0xLTc3NDA3_74641b74-21af-4e8e-baa7-b8ef5ecc56ac"
      unitRef="usd">1533000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e93bc594b454595aa61c0a479afcfcf_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTEwLTEtMS03NzQwNw_f6f994d8-486c-4c71-8397-beed00afd6c8"
      unitRef="usd">1525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i15889f3752b64ea98aa7f132f768a0d1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI2LTEyLTEtMS03NzQwNw_a5b07beb-5372-46d8-b5ea-a38565a809ae"
      unitRef="number">0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40e55fe351984553bed44ba01eed5ad0_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTItMS0xLTc3NDA3_f218c5df-39d5-43c7-8b36-6f52efcfd207"
      unitRef="usd">908000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie132afb6984b4e4d956e2c5e87394126_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTQtMS0xLTc3NDA3_260e347f-f85d-4265-b868-adcd622783f0"
      unitRef="usd">882000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i40e55fe351984553bed44ba01eed5ad0_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTYtMS0xLTc3NDA3_8c9232fb-66d1-4d6d-ad0e-da82be6daeb4"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04d49f0375714f51b3b624836cc6d325_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTgtMS0xLTc3NDA3_39636d8b-5cf1-4d32-9e40-60386f5b1603"
      unitRef="usd">2712000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f897a88b0e9498e84e0922c6ac778a3_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTEwLTEtMS03NzQwNw_f593fd93-045a-4609-a02a-d00d770765a4"
      unitRef="usd">2607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i04d49f0375714f51b3b624836cc6d325_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjI3LTEyLTEtMS03NzQwNw_15d90354-8dad-4746-a57d-5393404f0be8"
      unitRef="number">0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibba76952fd2b4a519af20462218629da_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTItMS0xLTc3NDA3_1c3072c7-ddda-4a9a-abb1-72e942392317"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idae82913ec44462fb96a4ca814d6a702_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTQtMS0xLTc3NDA3_1b84f543-f918-4928-8d34-cbb3c1471268"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibba76952fd2b4a519af20462218629da_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTYtMS0xLTc3NDA3_397974ce-a3a6-4225-a5b1-ad3ffad3057a"
      unitRef="number">-0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eba42d826fe467a9b5e86014b866bdb_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTgtMS0xLTc3NDA3_0608606f-c606-49a9-898b-4a3a659e399f"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71ec2459bfe446ec8682b17c888295b8_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTEwLTEtMS03NzQwNw_c390aa6e-cf46-496b-a1fd-1183efebd1a8"
      unitRef="usd">333000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8eba42d826fe467a9b5e86014b866bdb_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMwLTEyLTEtMS03NzQwNw_3a7cddec-99ef-497a-a4a0-276f190ec0c6"
      unitRef="number">0.068</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i529501a1b6e049f08c8a55b366fc992d_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTItMS0xLTc3NDA3_03d31dff-ac9a-4967-a79c-aefcac9735d0"
      unitRef="usd">186000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf01c838f2074a85932e153dd373f7b0_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTQtMS0xLTc3NDA3_7f98afdf-d143-42ea-bfcb-3c97f74d939f"
      unitRef="usd">191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i529501a1b6e049f08c8a55b366fc992d_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTYtMS0xLTc3NDA3_ce4ec366-62eb-4750-b55c-839baf74af76"
      unitRef="number">-0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a2e6ad455cb48d9b9bb5b16d05ff610_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTgtMS0xLTc3NDA3_64bab64f-6c85-47df-9563-a03002a44ccf"
      unitRef="usd">637000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if60b072dec854b1e8dfb55dd85a8118b_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTEwLTEtMS03NzQwNw_72c54545-88ed-4a14-9d7c-e0ee268ac0b1"
      unitRef="usd">577000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1a2e6ad455cb48d9b9bb5b16d05ff610_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMxLTEyLTEtMS03NzQwNw_38758470-3258-4dff-a154-5cdd4a59c882"
      unitRef="number">0.103</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i647abea8193b4b739d73a6331f0863b4_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTItMS0xLTc3NDA3_5fdbd7c4-fb25-4a0b-8690-774063dfa662"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7de7cde1f8a4671978be90e6b0c20b6_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTQtMS0xLTc3NDA3_6d910608-010f-44ff-9817-e43dbfd74b24"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i647abea8193b4b739d73a6331f0863b4_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTYtMS0xLTc3NDA3_f5bce298-7d17-4638-999d-e033d2d1ba4d"
      unitRef="number">-0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57af817119fa4ecd8f610dbcbd0f3ac1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTgtMS0xLTc3NDA3_72b42ae8-1af0-4c5d-923f-f15bdab116de"
      unitRef="usd">992000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63c3910a76f84ce297ae66994c95a35c_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTEwLTEtMS03NzQwNw_bab3dbf1-ad3a-45a5-aa43-3424f1378790"
      unitRef="usd">910000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i57af817119fa4ecd8f610dbcbd0f3ac1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjMyLTEyLTEtMS03NzQwNw_0e0d0fcd-2ad8-4d7b-b119-f8769ea1a700"
      unitRef="number">0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4cfbdab95a0435dbfa671be6d271f63_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTItMS0xLTc3NDA3_6d5afd70-6383-4676-b5d1-5ce606e84b02"
      unitRef="usd">3356000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i643bc69b32254fa0bbda0732674f0a17_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTQtMS0xLTc3NDA3_92c0931f-3304-47ea-a11b-682e4129f029"
      unitRef="usd">3117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib4cfbdab95a0435dbfa671be6d271f63_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTYtMS0xLTc3NDA3_e9336e9d-e9cd-40f0-980e-8c64236dc684"
      unitRef="number">0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e56281ecec14a7c80ff8779c1ca8f17_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTgtMS0xLTc3NDA3_76ad3076-73dc-4875-9b99-212e32819055"
      unitRef="usd">9932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25009198d573425d8e230b1a71881f95_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTEwLTEtMS03NzQwNw_1a68d5e9-2928-4740-b8be-45058458d609"
      unitRef="usd">9470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3e56281ecec14a7c80ff8779c1ca8f17_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM1LTEyLTEtMS03NzQwNw_7e951af0-ec4b-409b-a2e0-5d115044a5ce"
      unitRef="number">0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8fe8d12a2fd4f01b02c290b548244b4_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTItMS0xLTc3NDA3_40e62fad-9bef-4b40-ba75-6a192afa924e"
      unitRef="usd">3426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9452da93d10a4670896f05edcac90904_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTQtMS0xLTc3NDA3_a5a1f79a-642f-47a8-a927-fef088cda6a7"
      unitRef="usd">3527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id8fe8d12a2fd4f01b02c290b548244b4_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTYtMS0xLTc3NDA3_e14f3a81-514a-4225-b71e-8e9f2fdf428f"
      unitRef="number">-0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba3e034faa2643de9e74a65652cc9170_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTgtMS0xLTc3NDA3_b802a6a8-f340-4247-bc2f-e48ac6667455"
      unitRef="usd">10719000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38bfe15254ae44efae8441525503c832_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTEwLTEtMS03NzQwNw_3b60d84b-6405-4d36-8ea5-0f3fc66f213d"
      unitRef="usd">10731000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iba3e034faa2643de9e74a65652cc9170_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM2LTEyLTEtMS03NzQwNw_d3f45b19-b2dc-4472-b557-5673e1510b69"
      unitRef="number">-0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc4c09ce590a442181ad6662947c8fe7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTItMS0xLTc3NDA3_3a336d22-eab0-43fb-bbec-34fb45349935"
      unitRef="usd">6782000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90e9c507ad5b4f6c9505f100acae883a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTQtMS0xLTc3NDA3_33cf323c-4d4c-473c-8f7f-32a72daaf2dc"
      unitRef="usd">6644000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifc4c09ce590a442181ad6662947c8fe7_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTYtMS0xLTc3NDA3_c6600fae-8a1b-4b41-9b3d-568624d6b1e7"
      unitRef="number">0.021</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTgtMS0xLTc3NDA3_6f7fec80-a804-4f22-bfd7-2612873922bc"
      unitRef="usd">20651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a34e43a1f6446ecbcaa76509bae0457_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTEwLTEtMS03NzQwNw_bb074d11-0d38-4e01-afcf-b04961fa6442"
      unitRef="usd">20201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjM3LTEyLTEtMS03NzQwNw_a1b32d37-8055-437c-907c-bf969a208647"
      unitRef="number">0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i074ce9c3c7514a87bf8e13428ff46900_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTItMS0xLTc3NDA3_0d8595b8-38d7-493c-8bae-26a98ee8755c"
      unitRef="usd">12453000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd2f05005c0f428383f2f6685296745f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTQtMS0xLTc3NDA3_c620747b-16d8-41c0-b558-99cf02a75496"
      unitRef="usd">11963000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i074ce9c3c7514a87bf8e13428ff46900_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTYtMS0xLTc3NDA3_476878fa-166c-43ec-b434-5e78b560a1ab"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i353ce076e41d4fed82b475f2741cafd1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTgtMS0xLTc3NDA3_b36b98b8-8e6f-414e-8cf4-ed8106a74488"
      unitRef="usd">36064000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f05af96e15a40369cfe4cd4140d6449_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTEwLTEtMS03NzQwNw_ac938dfa-0b51-48d9-9b8e-a3350f371257"
      unitRef="usd">34993000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i353ce076e41d4fed82b475f2741cafd1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQwLTEyLTEtMS03NzQwNw_3bce7cfb-f0d3-45d7-a70d-3f06a2b99aa4"
      unitRef="number">0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5ffe02d809844979135aec3c5ba4751_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTItMS0xLTc3NDA3_928a7b8f-fe25-47b9-ab53-f6880a1ec2bb"
      unitRef="usd">11338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if191b6e468a3476aa02636eb2412f60b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTQtMS0xLTc3NDA3_80a0c12d-7769-41eb-8106-3975390413c4"
      unitRef="usd">11375000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if5ffe02d809844979135aec3c5ba4751_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTYtMS0xLTc3NDA3_8c099f03-5b13-4e19-adb7-3fa07740cbc7"
      unitRef="number">-0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i331c19f370344f7baf99003b536c4f3e_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTgtMS0xLTc3NDA3_e2cfc12b-a846-4821-8d01-748254f3b2f3"
      unitRef="usd">35173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96d61b35824144f9bcdad8d927f11908_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTEwLTEtMS03NzQwNw_9e525c48-ee45-48cd-91b3-3c08f7b91794"
      unitRef="usd">33978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i331c19f370344f7baf99003b536c4f3e_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQxLTEyLTEtMS03NzQwNw_1702f11b-9afc-42d1-8633-37bca21d4ec8"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTItMS0xLTc3NDA3_7e81da3e-ecd4-460f-baa8-8bbacbfe3bf9"
      unitRef="usd">23791000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTQtMS0xLTc3NDA3_3e7bf816-cc0d-43c5-b45a-afed8da4d0a9"
      unitRef="usd">23338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTYtMS0xLTc3NDA3_81d50106-d8f0-49cc-a9fa-7bde49fff754"
      unitRef="number">0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTgtMS0xLTc3NDA3_7212cc7f-b7b5-4436-94e4-470cf7fbae40"
      unitRef="usd">71237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTEwLTEtMS03NzQwNw_d88e4a0a-3620-4e37-ba3e-d06170ce4eec"
      unitRef="usd">68971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjQyYTNmOWNiYjgwYzRlNGVhNzAwOGE2NzdiNjNiMDI1L3RhYmxlcmFuZ2U6NDJhM2Y5Y2JiODBjNGU0ZWE3MDA4YTY3N2I2M2IwMjVfMjQyLTEyLTEtMS03NzQwNw_917de753-caba-4a07-ab98-71cf22e55bab"
      unitRef="number">0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68cff4026c6244d2acead47809054223_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTU2_3a2eac7c-236a-4bc6-810a-3737ca16d27e"
      unitRef="usd">100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id982a81309df49e9b1b002ff1ac41cae_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjAw_fcfac2c3-4997-4744-bd4c-eb945f9c3f05"
      unitRef="usd">300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzU4MQ_bb944dd9-50fb-4125-adfa-ab1475a7f5cf">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT*  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Consumer Health separation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*The 2021 fiscal third  quarter and nine months earnings before provision for taxes has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;**Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.3&#160;billion in both the fiscal nine months of 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Litigation expense of $0.1&#160;billion in the fiscal nine months of 2022. Litigation expense of $1.4&#160;billion and $1.5&#160;billion in the fiscal three months and fiscal nine months of 2021, respectively, primarily for talc related costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Divestiture gains of $0.6&#160;billion in the fiscal nine months of 2021 related to two brands outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal third quarter of 2022 and 2021, respectively. Intangible amortization expense of $2.2&#160;billion and $2.5&#160;billion in the fiscal nine months of 2022 and 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In the fiscal nine months of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication became available which led the Company to the decision to terminate the development of bermekimab for AD.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A loss of $0.2&#160;billion and a gain of $0.1&#160;billion related to the change in the fair value of securities in the fiscal third quarter of 2022 and 2021, respectively. A loss of $0.7&#160;billion and a gain of $0.2&#160;billion related to the change in the fair value of securities in the fiscal nine months of 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;COVID-19 Vaccine supply network related costs of $0.4&#160;billion and $0.7&#160;billion in the fiscal third quarter and fiscal nine months 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt"&gt;Litigation expense of $0.8&#160;billion and $0.7&#160;billion in the fiscal third quarter and fiscal nine months of 2021, respectively, primarily related to Risperdal Gynecomastia.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In fiscal 2021 and 2020, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. In the fiscal third quarter of 2022, amounts paid for services to be delivered and contractually obligated to be paid to these contract manufacturing organizations of approximately $0.5&#160;billion are reflected in the prepaid expenses and other and the accrued liabilities accounts in the Company's consolidated balance sheet. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Litigation expense of $0.2&#160;billion in  the fiscal third quarter of 2022. Litigation expense of $0.5 billion in fiscal nine months of 2022, primarily pelvic mesh related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1 billion in both the fiscal third quarter of 2022 and 2021 and $0.2&#160;billion in the fiscal nine months of 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.3&#160;billion in both the fiscal third quarter of 2022 and 2021 and $0.8&#160;billion in both the fiscal nine months of 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Includes an in-process research and development expense of $0.9&#160;billion related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019 in both the fiscal third quarter and fiscal nine months of 2021.&lt;/span&gt;&lt;/div&gt;(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie667e5b01edb4ec3a359b1a4b8416940_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMi0yLTEtMS03NzQwNw_0d0c6d94-2dea-4606-8455-3bceb8ae8903"
      unitRef="usd">809000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iadb11728d759451d965568df87db85d8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMi00LTEtMS03NzQwNw_99b087a2-dcc7-4bb5-b379-6cbe3327fffd"
      unitRef="usd">-577000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaf94b8f123d04272bb4b90c496e51b83_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMi04LTEtMS03NzQwNw_5ce7bcfb-70da-41ec-af0f-00dc2ed18f28"
      unitRef="usd">2279000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i815bc18a28fc42afa083e798ae8e6b32_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMi0xMC0xLTEtNzc0MDc_93e610e7-5281-4ab9-bdda-b495d1306b85"
      unitRef="usd">1131000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy0yLTEtMS03NzQwNw_44e23931-ff1b-4bf8-9a3c-894c13542da4"
      unitRef="usd">4249000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1f9b9a440e17401eaa071454d7751a0d_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy00LTEtMS03NzQwNw_a1e83c5f-4584-47b5-b49d-c1cf24014ffd"
      unitRef="usd">4200000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy02LTEtMS03NzQwNw_6f6deb1e-217b-4322-b0b2-afd9d3f2b315"
      unitRef="number">0.012</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy04LTEtMS03NzQwNw_5f71b284-bd8d-4159-9a07-1a0dd6bdc6d0"
      unitRef="usd">12593000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idea81eebb8464de781937770e40b4cf8_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy0xMC0xLTEtNzc0MDc_8b566601-5178-4aa6-8853-876e517f96a7"
      unitRef="usd">13663000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfMy0xMi0xLTEtNzc0MDc_2269d154-397c-4c8d-8653-578a796b7857"
      unitRef="number">-0.078</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idf724f9760f04a4d97e3362a30a8c490_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNC0yLTEtMS03NzQwNw_2ccc212a-8a3d-41b2-bbc1-3ed20e8940f0"
      unitRef="usd">1124000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia5394d3d3ed644aaadfbfd8d6956ee4a_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNC00LTEtMS03NzQwNw_38b62ca6-c570-4cca-89c3-cc35ebfd3362"
      unitRef="usd">423000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6bb2fc4834df4cee928c01c8ffe451e8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNC04LTEtMS03NzQwNw_261826bb-614e-4e75-b08e-2ad7a77cd6f7"
      unitRef="usd">3742000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i29f562eb61574b4a8135f7a6ff000d61_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNC0xMC0xLTEtNzc0MDc_14830d07-6778-48f0-a924-5a1c2f6dbd07"
      unitRef="usd">3798000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i6bb2fc4834df4cee928c01c8ffe451e8_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNC0xMi0xLTEtNzc0MDc_df88b7d8-f0ef-4aa1-83c8-f512b26c255a"
      unitRef="number">-0.015</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iffded04d2e5b4de28d6c73c949492aa9_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS0yLTEtMS03NzQwNw_47cb199b-f46b-4077-bb1b-a4399d6f7cc4"
      unitRef="usd">6182000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3a2695569614474a9334e8de4bd04385_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS00LTEtMS03NzQwNw_db1210cb-3697-441f-829f-14f290730c58"
      unitRef="usd">4046000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="iffded04d2e5b4de28d6c73c949492aa9_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS02LTEtMS03NzQwNw_fe85f93e-bb55-45a5-a3c3-363094a0d2ac"
      unitRef="number">0.528</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibfb750d153444cfbb2321cb34524ef38_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS04LTEtMS03NzQwNw_b10c4b8f-8831-4c5f-af33-c2474ab6570d"
      unitRef="usd">18614000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ied1e8cdc798340419a8c42b1446f8a47_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS0xMC0xLTEtNzc0MDc_762cfeea-d95e-42b6-9d1d-28f23825ed81"
      unitRef="usd">18592000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="ibfb750d153444cfbb2321cb34524ef38_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNS0xMi0xLTEtNzc0MDc_0f43fa08-8f4a-46b7-bd14-a2bce4aa8f00"
      unitRef="number">0.001</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifadac292feaa4f469fb02f86ff949995_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNi0yLTEtMS03NzQwNw_74e745ea-6af8-421b-8899-333e0e244fec"
      unitRef="usd">111000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i072ffc473a074bf6b2765979c610418b_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNi00LTEtMS03NzQwNw_06fac315-d71a-403a-9f08-7fbc68384eed"
      unitRef="usd">197000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ied5e809531a04e8ebd37dbed6ad36ab8_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNi04LTEtMS03NzQwNw_aabf5515-e2c3-4e15-b89e-0e5555a91a51"
      unitRef="usd">471000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idc46250604114f8e80b3e470ae4babdb_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNi0xMC0xLTEtNzc0MDc_a332a9f2-dd41-48c6-92d0-2d2172fa1113"
      unitRef="usd">652000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:BusinessExitCosts1
      contextRef="ie667e5b01edb4ec3a359b1a4b8416940_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNy0yLTEtMS03NzQwNw_16f36248-376d-4987-a252-18917b305113"
      unitRef="usd">249000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="iadb11728d759451d965568df87db85d8_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNy00LTEtMS03NzQwNw_688db27d-67c3-41ac-b5d0-a8c6615f311d"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="iaf94b8f123d04272bb4b90c496e51b83_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNy04LTEtMS03NzQwNw_0f3e8ba0-5dc2-4f68-b496-814930aa5e6f"
      unitRef="usd">619000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i815bc18a28fc42afa083e798ae8e6b32_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfNy0xMC0xLTEtNzc0MDc_420d666b-de79-4ed9-acd7-7d6137f8468b"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC0yLTEtMS03NzQwNw_e623c46e-3d9e-4e2f-aad3-8e7d478eb90a"
      unitRef="usd">5822000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC00LTEtMS03NzQwNw_62272d25-0194-43b4-920f-cd3a1eb4bdc2"
      unitRef="usd">3849000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC02LTEtMS03NzQwNw_19fd099e-8a0a-447b-922d-1ee4f05782fc"
      unitRef="number">0.513</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC04LTEtMS03NzQwNw_6896312d-021c-4028-a49c-c05a5a99ca7c"
      unitRef="usd">17524000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC0xMC0xLTEtNzc0MDc_f971c5af-bd98-4612-ab0f-579d47fea24e"
      unitRef="usd">17940000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOmM3YzQyMDczMjIyODQ1YjFiY2FkOTgxOWJmZGIxMTRlL3RhYmxlcmFuZ2U6YzdjNDIwNzMyMjI4NDViMWJjYWQ5ODE5YmZkYjExNGVfOC0xMi0xLTEtNzc0MDc_662ce76b-17b5-4846-8df4-9ee171da6588"
      unitRef="number">-0.023</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="ie667e5b01edb4ec3a359b1a4b8416940_D20220704-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfOTIz_6e0edee6-ac74-40af-9a60-a74f987f7637"
      unitRef="usd">100000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i815bc18a28fc42afa083e798ae8e6b32_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfOTYy_177d1333-c7ca-4f89-9cf8-4c15725682d2"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="iaf94b8f123d04272bb4b90c496e51b83_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfOTYy_5969c358-81d7-47e6-b32d-e67ed808c360"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:LitigationSettlementExpense
      contextRef="iaf94b8f123d04272bb4b90c496e51b83_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTAyMQ_f13e0418-588c-464d-83d7-41420e689f71"
      unitRef="usd">100000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="iadb11728d759451d965568df87db85d8_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDQwNg_35c84ec8-cc90-4ad3-8c6e-1b332929bbed"
      unitRef="usd">1400000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i815bc18a28fc42afa083e798ae8e6b32_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDQyMA_3d4cd530-36f6-4e9e-bcf8-9de3d54b7822"
      unitRef="usd">1500000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTE4Ng_85caabfa-013b-4fec-92d5-37ecf84394f9"
      unitRef="usd">600000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AdjustmentForAmortization
      contextRef="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTI5Ng_f2de774a-7d7f-421d-92ba-a5bf888ff18c"
      unitRef="usd">700000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i1f9b9a440e17401eaa071454d7751a0d_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTMwMw_a6d08831-ec96-4068-aaff-261f0e2d0750"
      unitRef="usd">800000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTM4Mw_2def5e4c-cd3d-40b0-8a9d-1f652e06b29b"
      unitRef="usd">2200000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="idea81eebb8464de781937770e40b4cf8_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTM5MA_4235d194-b60d-4bbd-b206-2b08803eb1a8"
      unitRef="usd">2500000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i813f5728d4834e4081f50346c8257c32_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTY0OTI2NzQ0NjY3NQ_63d60b12-b1f5-4649-bfdb-691b944fcde7"
      unitRef="usd">600000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTkxNg_4e5ce5af-7e5d-4dba-a261-33dc135ff8ec"
      unitRef="usd">-200000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i1f9b9a440e17401eaa071454d7751a0d_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMTkzMw_10fd8a05-11d8-4810-8e2a-d3abd7948671"
      unitRef="usd">100000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjA0Mg_aa8c636c-dee9-440b-9eee-57c0be2756a6"
      unitRef="usd">-700000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjA0Mg_bc50538d-b337-43b8-8b2b-42f5ee8a3c69"
      unitRef="usd">-700000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="idea81eebb8464de781937770e40b4cf8_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjA1OQ_53099f78-9c37-47b8-b4b1-0763eb33541d"
      unitRef="usd">200000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:SuppliesExpense
      contextRef="ib94fe14157fd4a319a180f98138effcd_D20220704-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjIwNw_b3a22ed7-2f8e-409f-b089-f2f85a957ace"
      unitRef="usd">400000000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i5f75366413fe46b586eb415473747dec_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDM2NA_d7825f34-997d-4739-9590-b835462d5749"
      unitRef="usd">700000000</us-gaap:SuppliesExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="ia4268f03b6cf41eb89ecb7ae077eb9e3_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDM3OA_158c6d5b-44fc-44b3-bb93-4c4cc98144c7"
      unitRef="usd">800000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i72c1a76dec8d49eaa40c1cca89c0bc8d_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDM5Mg_2f2c409d-ec37-4e57-a391-7124b7f80e47"
      unitRef="usd">700000000</us-gaap:LitigationSettlementExpense>
    <jnj:AmountPrepaidAndDueToManufacturers
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjgyMQ_e75e6913-58b6-4d27-aeef-03c485580615"
      unitRef="usd">500000000</jnj:AmountPrepaidAndDueToManufacturers>
    <us-gaap:LitigationSettlementExpense
      contextRef="i6bb2fc4834df4cee928c01c8ffe451e8_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzEzNw_25e58bea-a425-43c6-ab65-0b04bc6a6460"
      unitRef="usd">200000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="idf724f9760f04a4d97e3362a30a8c490_D20220704-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzEzNw_5b3a19e7-b716-4b21-93c6-f16a52cf0be0"
      unitRef="usd">200000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzI3Ng_685f4c52-69ce-4e91-8d0d-23210a84d4a9"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4a34e43a1f6446ecbcaa76509bae0457_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzI4Mw_061bdfb2-ffe5-49ce-ad81-265f78331bdb"
      unitRef="usd">200000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4a34e43a1f6446ecbcaa76509bae0457_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzI4Mw_a09db157-68bc-4beb-b745-d86005d64774"
      unitRef="usd">200000000</us-gaap:RestructuringCharges>
    <us-gaap:AdjustmentForAmortization
      contextRef="ia5394d3d3ed644aaadfbfd8d6956ee4a_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzM2NA_65ba53c9-4169-48d6-98a9-1a5a74d5d15a"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="idf724f9760f04a4d97e3362a30a8c490_D20220704-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzM2NA_c617d353-959e-4867-88f8-ffd98cc3f558"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i1a6c592da39e46dab193ae7d66fab4f7_D20220103-20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzQwMw_5fb45733-a071-4668-90a7-63d198fbb563"
      unitRef="usd">800000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i4a34e43a1f6446ecbcaa76509bae0457_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzQwMw_927c9d7a-7046-4a96-9870-40f6d5528d84"
      unitRef="usd">800000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia5394d3d3ed644aaadfbfd8d6956ee4a_D20210705-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDQzNA_22fe40b1-b00a-4a1b-bc5b-c75e32023c75"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i29f562eb61574b4a8135f7a6ff000d61_D20210104-20211003"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMjc0ODc3OTA3NDQzNA_ddd32f36-bdc6-4541-8955-4c82d4f8c9fd"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RleHRyZWdpb246NzI1Yzg4NWI2OTFjNDJlOGE0OGVhZGM2OTE1YjA3MzFfMzYwMQ_7d0b7900-bb3b-45e1-8d3e-9ea9cca15029">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Third Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;October 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i074ce9c3c7514a87bf8e13428ff46900_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi0yLTEtMS03NzQwNw_5db1b413-0e98-47c2-b03e-509997306ccf"
      unitRef="usd">12453000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd2f05005c0f428383f2f6685296745f_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi00LTEtMS03NzQwNw_52dc14cd-ce30-4acf-bf34-2ba4fbc5e02c"
      unitRef="usd">11963000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i074ce9c3c7514a87bf8e13428ff46900_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi02LTEtMS03NzQwNw_3149c0f3-282d-42b4-b2f3-9b7c5d61895d"
      unitRef="number">0.041</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i353ce076e41d4fed82b475f2741cafd1_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi04LTEtMS03NzQwNw_f087ea79-304e-4bef-87a0-6e62b42dbb56"
      unitRef="usd">36064000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f05af96e15a40369cfe4cd4140d6449_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi0xMC0xLTEtNzc0MDc_ee35cdd7-1e20-497a-97c0-7181a7d1b712"
      unitRef="usd">34993000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i353ce076e41d4fed82b475f2741cafd1_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMi0xMi0xLTEtNzc0MDc_c33ba4cf-d799-44f4-993f-3b9a861946ed"
      unitRef="number">0.031</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3c67e57cd4f489992a696a230aaba42_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy0yLTEtMS03NzQwNw_34f27675-a396-46b3-baae-d8bd98eb48b0"
      unitRef="usd">5524000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c08f0957c7d4b9e8e627867718f4458_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy00LTEtMS03NzQwNw_3702beb3-0605-486f-98b9-95cf321d4518"
      unitRef="usd">5587000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="if3c67e57cd4f489992a696a230aaba42_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy02LTEtMS03NzQwNw_3614204c-8e73-4c36-9699-e27354efe537"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i990e1ccf4a544e3caa982783ffee28fe_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy04LTEtMS03NzQwNw_f7db8fb0-7e63-4a89-ba8c-18941b367cc0"
      unitRef="usd">17633000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5068794590a54e5988087731a2a8b4d4_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy0xMC0xLTEtNzc0MDc_064b07ac-698a-4025-846e-aaf5a2ebbd15"
      unitRef="usd">16669000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i990e1ccf4a544e3caa982783ffee28fe_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfMy0xMi0xLTEtNzc0MDc_92d85196-bb1e-4b91-b97a-09a9271b4d68"
      unitRef="number">0.058</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c47fac364494aed96246540e7b4f7c7_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC0yLTEtMS03NzQwNw_854cecb4-f60b-4226-99fd-bdf253c61026"
      unitRef="usd">1562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3aa4e83b89284abc892194a08d7295b2_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC00LTEtMS03NzQwNw_957db391-8aee-4ad8-8610-24285c043b10"
      unitRef="usd">1500000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i6c47fac364494aed96246540e7b4f7c7_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC02LTEtMS03NzQwNw_1ec9b3c1-0ccd-4240-bac7-71db8bb66eed"
      unitRef="number">0.041</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia79ea739fc2a40d89f2755e7e4a01102_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC04LTEtMS03NzQwNw_2c649352-30d1-48b0-89df-8b24f2245c3d"
      unitRef="usd">4580000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5891042222334a28a0bb7a5e271806af_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC0xMC0xLTEtNzc0MDc_85e8bac0-e8b3-4a10-a087-33f50e5e4d87"
      unitRef="usd">4291000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ia79ea739fc2a40d89f2755e7e4a01102_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNC0xMi0xLTEtNzc0MDc_7833e27a-3ca5-46f3-b8a3-8b675524fbcf"
      unitRef="number">0.067</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21a2cce4e35d4c1297c84a76cb27a899_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS0yLTEtMS03NzQwNw_e6f5848a-52a2-411d-873f-997870be8137"
      unitRef="usd">4252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66d27784d12d4bb18f3912c082fcae16_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS00LTEtMS03NzQwNw_1bfead8d-2d81-493f-a20e-95b921b8c4f6"
      unitRef="usd">4288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i21a2cce4e35d4c1297c84a76cb27a899_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS02LTEtMS03NzQwNw_107adf4e-251b-4de2-8a97-56d3d2208533"
      unitRef="number">-0.009</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b3d5cdd413d4757984bddf6f14322bd_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS04LTEtMS03NzQwNw_c9eb3823-8d4c-4985-adff-136c9498abaf"
      unitRef="usd">12960000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i751be87313594bb993858ae3c749f84d_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS0xMC0xLTEtNzc0MDc_82bc4fbe-95fb-4ee5-b16b-99809109ae41"
      unitRef="usd">13018000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i1b3d5cdd413d4757984bddf6f14322bd_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNS0xMi0xLTEtNzc0MDc_1d87bed9-0362-4208-8b6d-cc2f3d206892"
      unitRef="number">-0.004</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi0yLTEtMS03NzQwNw_86680c64-86b4-4189-be86-2561f0e75c9a"
      unitRef="usd">23791000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18f6a284cf62429a97583de4bdcd4907_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi00LTEtMS03NzQwNw_82febc5b-2974-4001-8e70-05a382ef8288"
      unitRef="usd">23338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi02LTEtMS03NzQwNw_cd4005c9-4bc2-4b74-a918-f36908251cf4"
      unitRef="number">0.019</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi04LTEtMS03NzQwNw_7d491886-ffcc-4dae-9870-9e1f6b0ec408"
      unitRef="usd">71237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f20acb128764111a16ed39b33ca22b7_D20210104-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi0xMC0xLTEtNzc0MDc_8d9f6e1e-0e74-42c6-8ec2-3757279bd35e"
      unitRef="usd">68971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl83OS9mcmFnOjcyNWM4ODViNjkxYzQyZThhNDhlYWRjNjkxNWIwNzMxL3RhYmxlOjEwMGRhZjI0NjM1MzQzNDA4NjBiYjI1MjczYWI2MjAzL3RhYmxlcmFuZ2U6MTAwZGFmMjQ2MzUzNDM0MDg2MGJiMjUyNzNhYjYyMDNfNi0xMi0xLTEtNzc0MDc_79cc2d8a-d297-4407-bd29-69788d4bbdd7"
      unitRef="number">0.033</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84Mi9mcmFnOjFiNjEzYjZhNGZlMTQxOTliYmFhYTZiM2U0MmYyYTRmL3RleHRyZWdpb246MWI2MTNiNmE0ZmUxNDE5OWJiYWFhNmIzZTQyZjJhNGZfNDE4_adad86d3-529d-4100-b7c7-95863b660f89">ACQUISITIONS AND DIVESTITURESThere were no material acquisitions or divestitures in the fiscal first, second or third quarter of 2022. During the first fiscal quarter of 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion.</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <jnj:NumberOfBrands
      contextRef="i1cf347773ad54fb88be2e997e4827221_I20210404"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84Mi9mcmFnOjFiNjEzYjZhNGZlMTQxOTliYmFhYTZiM2U0MmYyYTRmL3RleHRyZWdpb246MWI2MTNiNmE0ZmUxNDE5OWJiYWFhNmIzZTQyZjJhNGZfMjUw_5a7fc2d0-7e16-4cd3-930c-b4e4326e5f29"
      unitRef="brand">2</jnj:NumberOfBrands>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="idc76602e6fb84b0a862455dca71e8bba_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84Mi9mcmFnOjFiNjEzYjZhNGZlMTQxOTliYmFhYTZiM2U0MmYyYTRmL3RleHRyZWdpb246MWI2MTNiNmE0ZmUxNDE5OWJiYWFhNmIzZTQyZjJhNGZfNDA4_c8ccbe33-f53b-4024-894d-f22141bca6e2"
      unitRef="usd">600000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfOTkzNTI_2c45093d-657a-4fd9-89eb-668392ff2c0a">LEGAL PROCEEDINGS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of  October&#160;2, 2022, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Company&#x2019;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#x2019;s balance sheet, is not expected to have a material adverse effect on the Company&#x2019;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#x2019;s results of operations and cash flows for that period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;PRODUCT LIABILITY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; XARELTO; body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder; INVOKANA; and ETHICON PHYSIOMESH Flexible Composite Mesh. As of October&#160;2, 2022, in the United States there were approximately 180 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; 1,400 with respect to the PINNACLE Acetabular Cup System; 9,400 with respect to pelvic meshes; 1,500 with respect to RISPERDAL; 600 with respect to XARELTO; 40,300 with respect to body powders containing talc; 5 with respect to INVOKANA;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; 4,800 with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; and 1,900 with respect to ELMIRON. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson &amp;amp; Johnson. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson &amp;amp; Johnson (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. Prior to 2019, several adverse verdicts had been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson arising out of Ethicon&#x2019;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#x2019;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#x2019;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia  and class actions in Israel, Australia and Canada. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In March 2020, the Court issued a decision and entered damages awards to the three Lead Applicants. The Company appealed the decision to the intermediate appellate court, the Full Court. The appeal was heard in February 2021 and, in March 2021, the Full Court entered a judgment dismissing the appeal. An application for special leave to the High Court of Australia was filed in April 2021, and the High Court heard oral argument on the application in November 2021. Special leave was refused. In September 2022, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia, pending Federal Court approval. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#x2019;s pelvic mesh products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson &amp;amp; Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, one multi-plaintiff lawsuit pending in Oklahoma state court and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of October 2022, there are approximately 154 active cases subject to these orders which are being reviewed and evaluated. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:102%"&gt;Claims have also been filed against Ethicon and Johnson &amp;amp; Johnson alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Ethicon and Johnson &amp;amp; Johnson also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#x2019;s accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson &amp;amp; Johnson; and JPI&#x2019;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and Johnson &amp;amp; Johnson announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp;amp; Johnson Consumer Inc. and Johnson &amp;amp; Johnson arising out of the use of body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham v. Johnson &amp;amp; Johnson, et al., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;No. ED 207476 (Mo. App.), reducing the overall award to  $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Ingham&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#x2019;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, Johnson &amp;amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#x2019;s direct parent, Johnson &amp;amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#x2019;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#x2019; compensation statute or act (the Talc-Related Liabilities). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, notwithstanding the Company&#x2019;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp;amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. The briefing and oral argument on the appeal were completed in September 2022. While the New Jersey Bankruptcy Court&#x2019;s order effectively stays all of the Company&#x2019;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that J&amp;amp;J fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by Johnson &amp;amp; Johnson&#x2019;s then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In July 2022, Imerys filed a motion in the Imerys Bankruptcy to stay the Edley Class Action, which was denied in August 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2019, the Company&#x2019;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#x2019;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#x2019; Committee (TCC), and the Future Claimants&#x2019; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#x2019;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, and certain of Imerys&#x2019;s insurers (the Mediation Parties) agreed to engage in mediation. The term of the mediation ended in September 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#x2019;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC)  (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#x201c;talc-related claims&#x201d; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2021, several of the Company&#x2019;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2018, a securities class action lawsuit was filed against Johnson &amp;amp; Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson &amp;amp; Johnson violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder, and that purchasers of Johnson &amp;amp; Johnson&#x2019;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiff&#x2019;s motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#x2019;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record.  In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action. Plaintiff has appealed the Bankruptcy Court&#x2019;s order.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2019, December 2019, and January 2020, four shareholders filed four separate derivative lawsuits against Johnson &amp;amp; Johnson as the nominal defendant and its current directors and certain officers as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Baby Powder, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. In February 2020, the four cases were consolidated into a single action under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2020, a report was delivered to the Company&#x2019;s Board of Directors by independent counsel retained by the Board to investigate the allegations in the derivative lawsuits and in a series of shareholder letters that the Board received raising similar issues and demanding that suit be brought against certain Directors. Four of the shareholders who sent demands are plaintiffs in th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;e &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;In re Johnson &amp;amp; Johnson Talc Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The independent counsel recommended that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of the derivative lawsuits. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report. In October 2020, the shareholders filed a consolidated complaint, and in January 2021, Johnson &amp;amp; Johnson moved to dismiss the consolidated complaint. In March 2021, Plaintiffs filed a motion for discovery. The Court temporarily terminated Johnson &amp;amp; Johnson&#x2019;s motion to dismiss pending a decision on Plaintiff&#x2019;s motion for discovery. In July 2022, the Court denied Plaintiff&#x2019;s discovery motion. In August 2022, the Court reopened Johnson &amp;amp; Johnson&#x2019;s motion to dismiss. In lieu of opposing, Plaintiff made a motion to voluntarily dismiss the case, which the Court granted in October 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson &amp;amp; Johnson Savings Plan against Johnson &amp;amp; Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson &amp;amp; Johnson stock as a Johnson &amp;amp; Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder. Plaintiffs are seeking damages and injunctive relief. In September 2019, Defendants filed a motion to dismiss. In April 2020, the Court granted Defendants&#x2019; motion but granted leave to amend. In June 2020, Plaintiffs filed an amended complaint, and in July 2020, Defendants moved to dismiss the amended complaint. As of October 2020, briefing on Defendants&#x2019; motion was complete. In February 2021, the Court granted Defendants&#x2019; motion, and granted Plaintiffs leave to amend. In April 2021, Plaintiffs informed the Court that they did not intend to file an amended complaint, and the Court dismissed the case with prejudice. In May 2021, Plaintiffs filed a notice of appeal with the Third Circuit. In July 2021, Plaintiffs filed their opening brief in the Third Circuit and in September &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2021, Defendants filed their response brief, and in October 2021, Plaintiffs filed their reply brief. In January 2022, the Third Circuit heard oral argument. In September 2022, the Third Circuit affirmed the dismissal of Plaintiffs&#x2019; amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#x2019;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#x2019;S Baby Powder. In that lawsuit, the plaintiffs allege that Johnson &amp;amp; Johnson violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#x2019;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. The appeal continues to be held in abeyance, with the Company being required to file periodic status updates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#x2019;s accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson &amp;amp; Johnson, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with ELMIRON related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;INTELLECTUAL PROPERTY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain subsidiaries of Johnson &amp;amp; Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#x2019;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;MedTech&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos.  6,522,906 (&#x2019;906); 6,800,056 (&#x2019;056); 8,142,447 (&#x2019;447);  and 9,452,276 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(&#x2019;276) based on Auris&#x2019; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the  &#x2019;056,  &#x2019;447, &#x2019;276 and &#x2019;906 patents.  In December 2019, the USPTO  denied review of the &#x2019;056 patent. In February and March 2020, the USPTO instituted review of the  &#x2019;447,  and &#x2019;906 patents and denied review of the &#x2019;276 patent. In March 2021, the USPTO ruled that the challenged claims of the &#x2019;447 and &#x2019;906 patents are not invalid. Auris appealed, and  in April 2022, the United States Court of Appeals for the Federal Circuit vacated the decision that the &#x2019;447 patent was not invalid and remanded the decision  to the USPTO for further review.  In May 2022, the United States Court of Appeals for the Federal Circuit confirmed the ruling that claim 53 of the &#x2019;906 patent was not invalid, vacated the decision that the remaining claims of the &#x2019;906 patent were not invalid and remanded the decision  to the USPTO for further review. Auris filed a request for reexamination of the &#x2019;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in September 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 (&#x2019;234) and 9,713,537 (&#x2019;537) by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. Trial is scheduled to begin in December 2022. In June 2022, DePuy filed potentially dispositive summary judgment motions that the &#x2019;234 patent is invalid as anticipated and the &#x2019;537 patent is not infringed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 (&#x2019;180) and 10,517,583 (&#x2019;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#x2019;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#x2019;180 patent, and awarding damages in the amount of $20&#160;million. DePuy challenged the verdict in its post-trial motions. In July 2022, a hearing was held on the post-trial motions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes lawsuits the Company&#x2019;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of Johnson &amp;amp; Johnson prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#x2019;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#x2019;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ZYTIGA &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in January 2019, Janssen Inc., Janssen Oncology, Inc., and BTG International Ltd. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#x2019;s Laboratories Ltd. and Dr. Reddy&#x2019;s Laboratories, Inc. (collectively, DRL) in response to those parties&#x2019; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#x2019;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#x2019;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision. The appeal hearing took place in September 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt;In April 2021, July 2021 and April 2022, respectively, Apotex, DRL and Pharmascience initiated Statements of Claim under Section 8 of the Patented Medicines (Notice of Compliance) Regulations against Janssen seeking damages in respect of those parties generic Zytiga tablets.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%"&gt; Trials against Apotex and DRL are scheduled for June 2023. A trial date for the Pharmascience action has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#x2019;310). The following generic drug companies are named defendants:  Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#x2019;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. In August 2022, after receiving a second notice letter from Mylan regarding the same ANDA, JPI and Bayer filed a second patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan. In September 2022, Mylan moved to dismiss the second lawsuit. In September 2022, the MDL panel transferred the second lawsuit to the District of Delaware. No trial date has been set for these two lawsuits. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#x2019;310 patent. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Partes Review (IPR) with the United States Patent and Trademark Office (USPTO), seeking to invalidate the &#x2019;310 patent. In August 2022, the Patent Trial and Appeal Board issued a decision instituting IPR.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2022, InvaGen Pharmaceuticals, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#x2019;310 patent. Also in September 2022, Teva Pharmaceuticals USA, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#x2019;310 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2022, JPI, Bayer, and Bayer Intellectual Property GmbH (BIP) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against USV Private Limited (USV), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg, 10 mg, 15 mg, and 20 mg) before the expiration of the '310 patent and United States Patent No. 9,539,218 (&#x2019;218). JPI, Bayer, and BIP are seeking an order enjoining USV from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#x2019;310 patent, and its generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#x2019;218 patent. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, JPI, Bayer AG, and BIP &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mankind Pharma Limited (Mankind), who filed an ANDA seeking approval to market generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#x2019;218 patent. JPI, Bayer AG, and BIP are seeking an order enjoining Mankind from marketing its generic versions of XARELTO before the expiration of the &#x2019;218 patent.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;before the expiration of Canadian Patent No. 2,659,770 (&#x2019;770). Sandoz stipulated to infringement of the &#x2019;770 patent.  Trial against Sandoz on the issue of validity concluded in February 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Sandoz appealed the decision. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the &#x2019;770 patent. Apotex stipulated to validity of the &#x2019;770 patent.  Trial against Apotex on the issue of infringement concluded in March 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Apotex appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of United States Patent No. 9,439,906 (&#x2019;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#x2019;s favor. Teva has appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent. A trial is scheduled to begin in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#x2019;629) and 2,655,335 (&#x2019;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#x2019;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#x2019;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#x2019;335 patent and that the claims of the &#x2019;335 patent are not invalid. Teva Canada appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#x2019;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. The action has been consolidated with the November 2020 action for trial, which took place in July 2022. In August 2022, the Court issued a decision finding the claims of the&#x2019;335 patent are not invalid. Pharmascience appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#x2019;s filing of an ANDS (original ANDS) seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022, Janssen Canada initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex in response to Apotex&#x2019;s Notice of Allegation of invalidity with respect to the original ANDS and in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA TRINZA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp;amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of United States Patent No. 10,143,693 (&#x2019;693) relating to INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(546 mg). Trial is scheduled to begin in November 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(819 mg) before expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of United States Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of United States Patent No. 10,213,386. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. Alvogen has appealed that decision. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#x2019;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;capsules before the expiration of Canadian Patent Nos. 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. The trial is scheduled to begin in July 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of United States Patent Nos. 10,039,718 (the &#x2019;718 patent) and 10,786,518 (the &#x2019;518 patent). Janssen is seeking an order enjoining Lupin from marketing its generic version of SYMTUZA before the expiration of the &#x2019;718 and &#x2019;518 patents. The trial is scheduled to begin in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ERLEADA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of United States Patent No. 9,481,663 (the &#x2019;663 patent). In August 2022, Janssen and SKI filed a first amended complaint against Lupin adding U.S. Patent Nos. 9,884,054 (the &#x2019;054 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;patent), 10,052,314 (&#x2019;314), 10,702,508 (&#x2019;508) and 10,849,888 (&#x2019;888) to the suit. Janssen and SKI are seeking an order enjoining Lupin from marketing its generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents. In August 2022, Janssen and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, Janssen and SKI initiated a patent infringement lawsuit in United States District Court for the District of New Jersey against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited (collectively, Zydus), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents. Janssen and SKI are seeking an order enjoining Zydus from marketing its generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, Janssen, The Regents of the University of California (UC), and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Sandoz Inc. (Sandoz), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#x2019;663 patent and United States Patent Nos. 8,445,507 (&#x2019;507), 8,802,689 (&#x2019;689), 9,338,159 (&#x2019;159), and 9,987,261 (&#x2019;261).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2022, Janssen, UC, and SKI filed a first amended complaint against Sandoz adding the &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents to the suit.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Janssen, UC, and SKI are seeking an order enjoining Sandoz from marketing its generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;507, &#x2019;689, &#x2019;159, &#x2019;261, &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;District Court for the Districts of New Jersey and Delaware against Eugia Pharma Specialities Limited, Aurobindo Pharma USA, Inc., and Auromedics Pharma LLC (collectively, Eugia), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;the &#x2019;663, &#x2019;507, &#x2019;689, &#x2019;159 and &#x2019;261 patents. Janssen, UC, and SKI are seeking an order enjoining Eugia from marketing its generic version of ERLEADA before the expiration of the &#x2019;663,&#x2019;507, &#x2019;689, &#x2019;159, and &#x2019;261 patents. In September 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Hetero Labs Limited Unit V and Hetero USA, Inc. (collectively, Hetero), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;507,&#x2019;054, &#x2019;314,&#x2019;508, and&#x2019;888 patents. Janssen, UC, and SKI are seeking an order enjoining Hetero from marketing its generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;507, &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;UPTRAVI &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2022, Actelion Pharmaceuticals Ltd, and Janssen Inc. (collectively, Janssen) and Nippon Shinyaku Co. (Nippon Shinyaku) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market generic versions of UPTRAVI before the expiration of Canadian Patent Nos. 2,731,370 and 2,764,475. In this lawsuit, Janssen and Nippon Shinyaku are seeking an order enjoining Sandoz from marketing its generic version of UPTRAVI before the expiration of the relevant patents. A trial date has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#x2019; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#x2019; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in response to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution. The parties exchanged opening briefs in July 2022 and responsive briefs in September 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;GOVERNMENT PROCEEDINGS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Like other companies in the pharmaceutical, consumer health and medical devices industries, Johnson &amp;amp; Johnson and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Average Wholesale Price (AWP) Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and several of its pharmaceutical subsidiaries (the J&amp;amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;amp;J AWP Defendants were ultimately dismissed. The J&amp;amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), Johnson &amp;amp; Johnson and ALZA Corporation. All other cases have been resolved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Opioid Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in 2014 and continuing to the present, Johnson &amp;amp; Johnson and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children suffering from Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including Johnson &amp;amp; Johnson and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in the following states: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The Government of Puerto Rico filed suit in Superior Court of San Juan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Johnson &amp;amp; Johnson, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, Johnson &amp;amp; Johnson and JPI were contacted by the Texas and Colorado Attorney General&#x2019;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against Johnson &amp;amp; Johnson and JPI in the amount of $465&#160;million. Johnson &amp;amp; Johnson and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#x2019;s judgment and directed entry of judgment for Defendants. In October 2019 Johnson &amp;amp; Johnson and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against Johnson &amp;amp; Johnson and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#x2019; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of  $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement is expected to be paid by the end of fiscal year 2022, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022. Also in April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions. In September 2022, the Company also reached a settlement agreement with the State of New Hampshire and its participating subdivisions. Consequently, by September 2022, the Company had settled the opioid claims advanced by all states except Washington.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There are approximately 60 cases remaining post-settlement in various state courts. There are approximately 860 remaining federal cases against Johnson &amp;amp; Johnson and JPI coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio. In addition, the Province of British Columbia filed suit against Johnson &amp;amp; Johnson and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against Johnson &amp;amp; Johnson and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In August 2019, Johnson &amp;amp; Johnson received a grand jury subpoena from the United States Attorney&#x2019;s Office for the Eastern District of New York for documents related to the Company&#x2019;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#x2019; and distributors&#x2019; monitoring programs and reporting under the Controlled Substances Act. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;From June 2017 through December 2019, the Company&#x2019;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2019, one of the shareholders who sent a demand filed a derivative complaint against Johnson &amp;amp; Johnson as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that Johnson &amp;amp; Johnson has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020.  By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted Johnson &amp;amp; Johnson&#x2019;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state court&#x2019;s dismissal order.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp;amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#x2019;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#x2019; motion to dismiss with prejudice, unsealed the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint, and denied the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators&#x2019; request for leave to file a further amended complaint. The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#x2019;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#x2019; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#x2019; second amended complaint; the District Court denied DePuy&#x2019;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#x2019;s July 2021 ruling. In November 2021, the District Court granted DePuy&#x2019;s motion for reconsideration and dismissed the case with prejudice. The District Court&#x2019;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;denied. Following the District Court&#x2019;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#x2019; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#x2019;s dismissal of the case to the First Circuit. The briefing on the appeal will be complete by the end of October 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2012, Johnson &amp;amp; Johnson was contacted by the California Attorney General&#x2019;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by Johnson &amp;amp; Johnson&#x2019;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against Johnson &amp;amp; Johnson, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, Johnson &amp;amp; Johnson and Ethicon settled the Washington case. In October 2019, Johnson &amp;amp; Johnson and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for May 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#x2019;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#x2019;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $302&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company&#x2019;s petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. The Company plans to petition for review by the United States Supreme Court.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp;amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#x2019; use of talc contained in JOHNSON&#x2019;S Baby Powder and JOHNSON&#x2019;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. Johnson &amp;amp; Johnson and JJCI moved for summary judgment on the grounds that the State&#x2019;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted Johnson &amp;amp; Johnson and JJCI&#x2019;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#x2019;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting as barred by the stay arising from the LTL Bankruptcy Case, referenced above, while the State argued that the stay did not apply. In January 2022, the Court granted the State&#x2019;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. The temporary stay expired in May 2022. LTL thereafter moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#x2019;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#x2019;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#x2019;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexico&#x2019;s discovery obligations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#x2019;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to mediation of their claims in the LTL Bankruptcy Case.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2016, Johnson &amp;amp; Johnson and Janssen Products, LP were served with a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Daubert&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April and September 2017, Johnson &amp;amp; Johnson received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, Johnson &amp;amp; Johnson received a subpoena from the United States Attorney&#x2019;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals. Johnson &amp;amp; Johnson and DePuy have produced documents in response to the subpoena and are fully cooperating with the government&#x2019;s investigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp;amp; Johnson do Brasil Ind&#xfa;stria e Com&#xe9;rcio de Produtos para Sa&#xfa;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp;amp; Johnson to cooperate with these inquiries by producing the requested information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GENERAL LITIGATION&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In March and April 2015, over 30 putative class action complaints were filed by contact lens patients in a number of courts around the United States against Johnson &amp;amp; Johnson Vision Care, Inc. (JJVCI) and other contact lens manufacturers, distributors, and retailers, alleging vertical and horizontal conspiracies to fix the retail prices of contact lenses. The complaints allege that the manufacturers reached agreements with each other and certain distributors and retailers concerning the prices at which some contact lenses could be sold to consumers. The plaintiffs are seeking damages and injunctive relief. All of the class action cases were transferred to the United States District Court for the Middle District of Florida in June 2015. The plaintiffs filed a consolidated class action complaint in November 2015. This case was settled in March 2022. The Court approved the settlement in October 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re REMICADE Antitrust Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022, subject to Court approval.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, Walgreen Co. and Kroger Co., filed an antitrust complaint against Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in the United States District Court for the Eastern District of Pennsylvania. The complaint alleges that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The complaint seeks damages and &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;injunctive relief. In March 2019, summary judgment was granted in favor of Janssen. In February 2020, the United States Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decision. This case was settled in January 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#x2019;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022. Genmab has moved for early disposition of the arbitration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp;amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#x2019;s decision. In February 2022, defendants petitioned for rehearing en banc. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#x2019;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In May 2019, a class action antitrust complaint was filed against Janssen R&amp;amp;D Ireland (Janssen) and Johnson &amp;amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#x2019; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#x201c;Opt-Out&#x201d; complaints containing allegations similar to the original complaint. In September 2022, the Court granted in part and denied in part plaintiff&#x2019;s motion for class certification. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#x2019;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#x2019;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#x2019;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, Johnson &amp;amp; Johnson received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp;amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp;amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp;amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp;amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp;amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp;amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against Johnson &amp;amp; Johnson, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#x2019;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#x2019; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (&#x201c;EBSI&#x201d;) with the American Arbitration Association, alleging that EBSI breached the parties&#x2019; Manufacturing Services Agreement for the Company&#x2019;s COVID-19 vaccine.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; In July 2022, Emergent filed its answering statement and counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Subsequent to the quarter, in October 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Merck Sharp &amp;amp; Dohme Corp. with the American Arbitration Association pursuant to the Parties&#x2019; agreements relating to production of drug substance and drug product for Johnson &amp;amp; Johnson&#x2019;s COVID-19 vaccine. Also in October 2022, Merck filed its answer and counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning in May 2021, multiple &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;putative &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;class actions were filed in state and federal courts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(California, Florida, New York, and New Jersey)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; against various Johnson &amp;amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and the affirmative promotion of those products as &#x201c;safe&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; and, in at least one case, alleging a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;strict liability manufacturing defect and failure to warn &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;claims, asserting that the named plaintiffs&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; suffered unspecified injuries as a result of alleged exposure to benzene.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Johnson &amp;amp; Johnson (subsequently substituted by Johnson &amp;amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Johnson &amp;amp; Johnson or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i7ed71c93d9694050bbc60255c39761e2_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDM4Nw_3d0adc07-e42b-4b9c-81b5-663bfc812dff"
      unitRef="claimant">180</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="id4a164f8c9e84a87a27b9958b9f63142_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDU0OQ_2a375b64-ad9f-4160-a8ef-52dcc967eec3"
      unitRef="claimant">1400</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i5eea6ea68542417790d4a54103e549ae_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDYwNA_29c139b6-1fb1-44e8-bb33-b1495aae69a9"
      unitRef="claimant">9400</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ie08773cd5b344ed58f2677261b44e9de_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDYzOA_a0f9dafe-bc22-44cb-b4f5-6087be5487c8"
      unitRef="claimant">1500</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i6eb4e32762af4828a35d4453122c0f42_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDY2OA_6121b1f8-1954-48ca-b04c-7b7ee0c6b0c8"
      unitRef="claimant">600</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i7c421f92c4fe44b480312cbb61c76537_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDY5Ng_247c2f0c-db6a-4422-a989-ba96f6ff8d93"
      unitRef="claimant">40300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i494bb8f36e6b4d348f07972031b000b3_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDc0NQ_19919991-261b-4d02-b569-0568bbd92514"
      unitRef="claimant">5</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ida7fb50fd03e447e8bfba4781b1f21c6_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDc3NQ_ba46afb7-761a-4094-b5e4-bf3b594aacf9"
      unitRef="claimant">4800</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="id34d8d00dc95419c9bd7f8538f501612_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDg0Mg_8e7a47b0-ab1c-46fa-b9e7-b90170950f48"
      unitRef="claimant">1900</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:Numberofpatientsinsettlement
      contextRef="i20d66d03f67b4697b74d7d5b092b023a_I20221002"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjE4OQ_4db8cee7-7f71-47c3-8698-4a45a0a50b7e"
      unitRef="patient">10000</jnj:Numberofpatientsinsettlement>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="icdd65a25b656477ea5bb46da7f0655dc_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTIzMDQ_37083326-e47a-43d1-8df2-29747c365f3c"
      unitRef="cases">3600</us-gaap:LossContingencyPendingClaimsNumber>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="icdd65a25b656477ea5bb46da7f0655dc_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTIzNDg_67deaa2f-5724-4500-919a-514a60a4f24e"
      unitRef="claimant">4300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement
      contextRef="i57f785ad2f34433aa2271007ab8726b8_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTI0ODg_a4c7c768-a1c3-4829-a264-9a01222d99d3"
      unitRef="cases">3729</jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5bc38c671bd94c1891fa4b65bac8ec0b_I20221002"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfOTkzNDg_03cb8227-e560-422f-a439-79d72c16c123"
      unitRef="cases">154</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i6e63d8a7e74e42f6a4a9d28176f31ee4_D20191001-20191031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTQ3ODI_cde3de10-c9f2-45bc-8b10-cfc307a9cb9f"
      unitRef="usd">8000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i135a75e1eac047bcb5100f4e1292998c_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTQ4NjQ_6f24f4d0-c4e1-40f7-ba1a-2447ea338d7e"
      unitRef="usd">6800000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i699c1217087e4147b4a39954f40ee65c_D20180701-20180731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTcxMTI_420d2d8b-59f6-4cbd-ae37-3740e8a2808b"
      unitRef="usd">4700000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="icf7c3ce8a2b94702bf75c6781069843d_D20200601-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTcyMTI_5ebaf890-c17d-44b8-8026-7decaebea20f"
      unitRef="usd">2100000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i4b18def56e5244478a2952bec11e5335_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMTc1MzQ_bfc6ce51-3488-425e-84ee-a27b4363a5da"
      unitRef="usd">2500000000</us-gaap:PaymentsForLegalSettlements>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="i8c83f6e3f6e543809b38536c601fde43_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMjE0MTM_a94e63a5-33b9-4857-89ce-6db6757f73a3"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="i8c83f6e3f6e543809b38536c601fde43_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfMjE1MTA_326c2105-4efb-47bd-8cd3-b719d4747f64"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="icb28f8306622475282cfa3ad654e30a5_D20220301-20220322"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNDEzNDA_4adac001-14e9-42af-b192-adbec78e1a3c"
      unitRef="usd">20000000</us-gaap:LossContingencyDamagesAwardedValue>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i5473d8ddcca64b71b3e429a13c5bf85d_I20221002"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjYwNDI_b923734e-cb9e-4bfc-afcb-9945330a2945"
      unitRef="claimant">3500</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i533d6a68961b4cbc8e82491aa88f91f5_D20191230-20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjg0MDY_81af66d6-1de0-472d-9ef1-ce5b1677c30e"
      unitRef="usd">465000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="icf0bc69e2f514d4f8022cfc52f98c981_I20191031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjk0MzI_c6fa804d-5ccb-48de-a644-7ed845b2671a"
      unitRef="usd">4000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <jnj:LossContingencyEstimateOfAdditionalPossibleLoss
      contextRef="i54e00e15c6a4438da0eb288d0b6da9f6_I20201031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjk1NzI_5ce93c39-8b7c-4873-a4a3-3256f095a511"
      unitRef="usd">1000000000</jnj:LossContingencyEstimateOfAdditionalPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i54e00e15c6a4438da0eb288d0b6da9f6_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNjk3MzM_671d4e05-456c-4b3f-b03e-3a967782025a"
      unitRef="usd">5000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i88a45c1864b841c3bd10c2ba6038465e_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNzEzODI_c2dc7e4b-a22e-4964-8fb6-252c132b3848"
      unitRef="claim">60</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i0cc5049a65cc4fe3b6242125d5b8d5c0_I20221002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNzE0NjY_ceab4332-9458-4fd1-845c-5c931cdcc4c6"
      unitRef="claim">860</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i438940227a2a4ff395f3e492e755ecde_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNzk1ODM_0a87bc30-4dd6-46d3-b6a0-55f1c5d563cf"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i438940227a2a4ff395f3e492e755ecde_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNzk3NDc_46f6b19b-a4eb-4d69-847d-a4f23e8919c2"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="id67cae946c154573ad2500e94ad849da_D20220401-20220430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfNzk5MTk_6781da46-ae45-4baa-88b5-c4f3c4def073"
      unitRef="usd">302000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i1d2b36aba9e54f04a044b6f392d0eac4_I20150430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84NS9mcmFnOjBmZjhkM2RlZDkxZTRjOThiZDJlYzZmZTRkMmYyYThjL3RleHRyZWdpb246MGZmOGQzZGVkOTFlNGM5OGJkMmVjNmZlNGQyZjJhOGNfODgwNjU_4a138fe7-aae3-4256-92fc-494d2e01f5da"
      unitRef="claim">30</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMjU5OQ_7962f0f3-b900-4282-a3fd-9bc8d00cc579">RESTRUCTURING&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In the fiscal second quarter of 2018 the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In the fiscal third quarter of 2022, the Company recorded a net pre-tax charge of $123 million, which is included on the following lines of the Consolidated Statement of Earnings, $82 million in restructuring, $13 million in cost of products sold and $28 million in other (income) expense, net.  In the fiscal nine months of 2022, the Company recorded a net pre-tax charge of $323&#160;million, which is included on the following lines of the Consolidated Statement of Earnings, $237&#160;million in restructuring, $46&#160;million in cost of products sold and $40&#160;million in other (income) expense, net. Total project costs of approximately $2.1 billion have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In total, the Company expects the Global Supply Chain actions to generate approximately $0.7 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by the end of 2022. The Company expects to record pre-tax restructuring charges of approximately $2.2 billion to $2.3 billion by the completion of the program in December 2022. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization.&#160; &#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, October 2, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents gain on sale of assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continuously reevaluates its severance reserves related to restructuring and the timing of payments due to the planned release of associates regarding several longer-term projects. The Company believes that the existing severance reserves are sufficient to cover the Global Supply Chain plans given the period over which the actions will take place. The Company will continue to assess and make adjustments as necessary if additional amounts become probable and estimable.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="icacdc0678d9f4679bbb4b670b539eae6_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfNjY0_d7c94527-b77e-4bd9-80a8-1989dba1ea06"
      unitRef="usd">123000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia9e691f551214439bf1ee3b313e022c3_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfNzUy_cc96ba85-747c-40d9-a6ce-83fcab407002"
      unitRef="usd">82000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9ca0be8b6078437fbd42287a1c403587_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfNzcz_48930e17-cf6f-4790-95da-d1d0c5d7db3c"
      unitRef="usd">13000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ife72459bccf34924aabd0acb8e60d652_D20220704-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfODA1_6e26083f-b4ff-4950-83b6-64af444775c5"
      unitRef="usd">28000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i690d9c2e2c884662976264e7af01ba35_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfOTA1_1b80022d-2704-4c01-b7db-01e9816b0aa5"
      unitRef="usd">323000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia93e937c11c7436bacd6ccaeacdf0cb6_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfOTkz_2788e860-5d6e-411e-b611-095a089df7f6"
      unitRef="usd">237000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i28209dc3607348dbb3171ab6afdd3dea_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTAxNA_7042a77d-1050-4262-aabb-2cd1b8362b53"
      unitRef="usd">46000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i28209dc3607348dbb3171ab6afdd3dea_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTAxNA_734b103c-86d5-45e9-a40b-f12a7905febb"
      unitRef="usd">46000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4fe9fcf4dbc843569a9d49299bde3c5a_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTA0Ng_6c613ae8-9f40-4f39-906e-cc73dc245d3e"
      unitRef="usd">40000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="ie51585f5aa3d424c9d17456abcf75390_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTExOA_a64932df-dca0-4578-9c28-9f3156c34cf4"
      unitRef="usd">2100000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="i6262632abd6a46d5a6a2555c388ca348_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTM0Ng_3c2fabcd-684f-4f80-80d6-8f1619b0bc57"
      unitRef="usd">700000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <jnj:RestructuringandRelatedCostExpectedFutureSavings
      contextRef="ib3d9ff58f127499cb7a03cc08f3f4dbf_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTM1Mg_1128f430-2dca-460c-98d3-a1422e234d71"
      unitRef="usd">800000000</jnj:RestructuringandRelatedCostExpectedFutureSavings>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i6262632abd6a46d5a6a2555c388ca348_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTUyMA_470dcde2-e45a-43c1-a8e4-cf093e43d5fe"
      unitRef="usd">2200000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ib3d9ff58f127499cb7a03cc08f3f4dbf_I20221002"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMTUyNg_a5dad99c-51d6-47bc-97b2-3daf0078e3ec"
      unitRef="usd">2300000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RleHRyZWdpb246MWUxYWFhMGQxZDdkNDYxZDk4ZWEzMjhmNzAyOWFhYTZfMjYwNQ_eeb87794-4fd9-42eb-b099-7fff7256ca94">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance related reserves and the associated restructuring expenses through the fiscal third quarter of 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, October 2, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash outlays for severance are expected to be substantially paid out by the completion of the program in December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents gain on sale of assets&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i6bfabbf7068d43948d05ef08e73d9679_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfMS0xLTEtMS03NzQwNw_bc87d09f-fe17-4e7a-9af3-0dc4637f4640"
      unitRef="usd">112000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i4425d96eacb04e7696f85e7eaea16821_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfMS0yLTEtMS03NzQwNw_f09548b0-36ae-4d83-ae40-0aaa41b2712b"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i72c4525bf37f4e2aa7ae0c4f54cbf866_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfMS00LTEtMS03NzQwNw_5b98ce1d-3543-4ed7-be1e-918e1cc4112d"
      unitRef="usd">25000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i57839c019e9745718882687e73ce9e18_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfMS01LTEtMS03NzQwNw_ab98a15d-e8a8-40a0-a73c-19a5583f8730"
      unitRef="usd">137000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="icb01ffbc16f648fb954f806b9df10064_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNC0xLTEtMS03NzQwNw_f8238d89-3f1c-4449-9cd9-99251a7d84f6"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i339ac2517af5425bb6f6bd7a62b270be_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNC0yLTEtMS03NzQwNw_08c40136-6d30-406a-ab72-b2c0664ae535"
      unitRef="usd">-4000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4ea736a79ff947c586d1da1d7bcb9f18_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNC00LTEtMS03NzQwNw_ea133571-63f1-415d-a8ea-4262859ecfac"
      unitRef="usd">327000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i923ad899b5ec4870933079c36fc15f9a_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNC01LTEtMS03NzQwNw_9573001d-4e96-4e1a-9ddf-766f52aac4c2"
      unitRef="usd">323000000</us-gaap:RestructuringCharges>
    <jnj:PaymentsForRestructuringNet
      contextRef="icb01ffbc16f648fb954f806b9df10064_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNS0xLTEtMS03NzQwNw_37cf2a59-7675-49ec-807a-1391feaeb615"
      unitRef="usd">28000000</jnj:PaymentsForRestructuringNet>
    <jnj:PaymentsForRestructuringNet
      contextRef="i339ac2517af5425bb6f6bd7a62b270be_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNS0yLTEtMS03NzQwNw_901db085-d384-461a-847a-08b6aa486705"
      unitRef="usd">-35000000</jnj:PaymentsForRestructuringNet>
    <jnj:PaymentsForRestructuringNet
      contextRef="i4ea736a79ff947c586d1da1d7bcb9f18_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNS00LTEtMS03NzQwNw_32b1e306-8ee5-4667-8fc2-acbfdadd0a1b"
      unitRef="usd">317000000</jnj:PaymentsForRestructuringNet>
    <jnj:PaymentsForRestructuringNet
      contextRef="i923ad899b5ec4870933079c36fc15f9a_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNS01LTEtMS03NzQwNw_fb04d5a8-fb70-410b-a8b5-e4e3d6fa0056"
      unitRef="usd">310000000</jnj:PaymentsForRestructuringNet>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="icb01ffbc16f648fb954f806b9df10064_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNi0xLTEtMS03NzQwNw_ab1a26db-988f-4dbb-8d4a-86b27c1af8c8"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i339ac2517af5425bb6f6bd7a62b270be_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNi0yLTEtMS03NzQwNw_610cfa35-bc3a-45be-aca2-bffb6577b012"
      unitRef="usd">31000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i4ea736a79ff947c586d1da1d7bcb9f18_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNi00LTEtMS03NzQwNw_be982d82-df62-4404-a3b9-4bbe5f63ebd2"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i923ad899b5ec4870933079c36fc15f9a_D20220103-20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfNi01LTEtMS03NzQwNw_d9aaeef4-acec-4cac-ba8f-d9ef8bf2596c"
      unitRef="usd">31000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve
      contextRef="i7802b4bc08714bbfa6723a15254942f7_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfOS0xLTEtMS03NzQwNw_fb63fe06-7c57-413f-a899-bc523597c24f"
      unitRef="usd">84000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i199a6c4996a1468e956555f0edbf4206_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfOS0yLTEtMS03NzQwNw_4cf8639b-a42b-4534-a160-48b998c3fc17"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i8caf79efe14c4c99b6b144f88b0704f5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfOS00LTEtMS03NzQwNw_7c17eab2-4d2a-47ef-bcd1-2366b7cc2f6b"
      unitRef="usd">35000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic114825b023e4671a3b06ef6426697c5_I20221002"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDk0ZTZiZTg0YjQ2N2E4ZDdhMTE4OGU1NDUxMmFiL3NlYzo1YTQ5NGU2YmU4NGI0NjdhOGQ3YTExODhlNTQ1MTJhYl84OC9mcmFnOjFlMWFhYTBkMWQ3ZDQ2MWQ5OGVhMzI4ZjcwMjlhYWE2L3RhYmxlOjNlMDBjMGY1ZjdmYjQ2OTFiYWQyOTRkOTMxNWEzMjA4L3RhYmxlcmFuZ2U6M2UwMGMwZjVmN2ZiNDY5MWJhZDI5NGQ5MzE1YTMyMDhfOS01LTEtMS03NzQwNw_6fa7f4b2-4dd8-4eb9-a3ab-decf6954944d"
      unitRef="usd">119000000</us-gaap:RestructuringReserve>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M6^VJ)D!.5!5@?;B5H]S*Z<JM:H*J)BJX[%"^X<Y=#]E7R_G-( GRLE]4%C=
M;%_=WG!RF=]F,52K%W>K?"#9-],)"NE<EAK')]*">'$#2+$@V"J_A^*!"<&B
M_.F2$I_R; 7Y_IS)GELN9!^PO0UG_!]02P,$%     @ 6H!;59Q4JY(F!P
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M-8#O;S4LW.%-^R#Q\.!X_7]02P,$%     @ 6H!;58QA0&'F @  Z@@  !@
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6RM5N]OVC 0_5>LK-JHU#4_@91!
MI)9IVB950V7=/IOD(%:=.+4=:/?7[YRD$91 6ZE\ -NY]_S>'?9EO!'R3J4
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MCMZA+XLY.GOS%N6;,&,YBA+T,8ICT=#Y.7K3?KP<<5&IPO5H65=@6E6 :"I
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M(!AV'3D\L#=9FA% !@^)JXE.HT*)687>&:-190L'3A:J5L14SO<S""7GE#D
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M;()BMJ8/B;X13[^S2I"7\T4B4<4O>BJQ4S)!T8/2(JV"S16D/"NW]+F:B(,
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MFG\O[K7CC:7B;Y;3M%V6 ,CM%"8 PKA]VX$HTF/ \/Y)  ^ZV.5OATWUQR;
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MXVMCS;$SVVVW?X_MI*$=637!OL2^\SW/^<Z7N^%.JAM= !AT5W*A1T%A3#7
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M.A?H&'U?GJ-/OWQ&OR"1HV\B3<T:%*=];2#8B?IQ];JOY>M(R^O&Z)O,];I
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M]4:'KX^8/XWH<!!C*\P+XDVJ5D5]>FDJOHYU+"$R.AOP'LT\M6UVIYJC5B(
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MOO?-:=)E8]@O3&U(1TK]0O<QK/(,O(:Q\%P$@J%S(,^'Z_]?4T;ILG&+260
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MEU\\KH:=ET)7R@;MK/!J?CHX'[]Y=T#K><$_M5J%WF]!.YDY=TL7E\7I8$2
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MLU2R4)X6X/G<0;R:"PK0?<0Z^R]02P,$%     @ 6H!;57_[9\0&!0  F@L
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M O1^J8E^M?$&]M]>P[\ 4$L#!!0    ( %J 6U4)#P*$J ,  &0(   9
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MJ)T"[6\5<;P3G(/^QV+Q'5!+ P04    " !:@%M5GQ(]  X6   @-P  &0
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M!@*CH]H]"@!K(5D!/,LT>Q5;6P(B2(#B"JS;TMJ14D\C&2-;:-OR,.)N7O,
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M@F%&I_P#F[S/_0+F<.U72\CK$_EM%M,'_*OZ =/JV]7/O]K5KYZ>FE>_';L
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M6.V"H*&_O443(;MYV6%NJR7==HD0ER7#>(=L(<56@$^7!<7RG(EPEB!Z80X
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M?(/[=B7,/_=S'XP8DNK[&SDO^[9J$1S/<_YT"_Q^HZHO=;=JLTTO ,6.RWX
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M<X2YO'G4(7<<W@7"^LQ=1X2LI ]NFQ)P=]T\:/%Q5XWDBNZQ8LC0JS\-UBP
MG<O0=OK91M1#6A'#)KYCYOJN,9L":5&5YH#/]C-6(C T,O/*BBTJ (:;]D12
M?ZM=CYIP*XHQF'4P.C5O8.N9G-%PX^$BE<O.CC#9]44C54U860?"PI8(:=N[
M61001)TBT"S:82!X*[? D2,5L]Q(+YFV'7>S&JRFU>)MS8;48LE9.KY/*Q\T
M)1R'=[[LV!9_:1)O %V_0R?#:)5-F,#N^ZG(; SR#<YNIB2IA/4Q!Y9SV^^\
M]7M,9_6:)4[E WLE;)/;;7C5,X,A1B_Q-W+%GYM(G#MEQ>1T&U+C&E7X8C::
M3VXCN5\WY+XJ3KJ;-;<#6:=  F,38[[M\<_'+HP'[-Y0=E%.ZI+%LTUI@+
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M5E]<$=V!*,A<\]H)69:*.PW.E!2DTGX-Z*Y*N+5PLD[I9=]WL\C!,1;A!TR
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M2#UA_HV;)Y5CIZ7SOLM"Z:?$XTVU;'7KX[;JPW"=K%7)5 5@EB78'2ZI ?-
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M62(/ESS =IP&X/XBPUK+$V)0_[#I[+]02P,$%     @ 6H!;5>-%#/"< P
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M/TX= !089ZY/M[$BA]#+1"'C#<:G"+7^^?G5Q>!L\.%S(P'PYK5R />"YSM
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M8-7P680Z-(+4ZSH[JM! %B;!)IQ"(ZME\D2BU9M\$E >M"D(Z@H\@5.?2X/
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MI5-^R=5U@97@Z;(J&;_L+-3FCSE*L*E#5M/?3R,>;;ZIMLYW34Y:MC&Y?M:
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MGVB+:-M1O+9U:,&5KFJVN=;O#@@3H.>7G*OGCBEM_4N6_P%02P,$%     @
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M#Y"-D.IZ7N!NHY/N@=[]"\Y.N;>B<>H)=0H\Y_D)Q>6$[F*QDE,FDR'.8D%
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M]5 .*[)E^DE4GZ')$]IZF6#*/5'5K T\E&V5%D4C-@X*RNLWV3?[<"3 ^(P
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ML&!9K._%YB.4 SHW>(&(5?Y+-D7=R:A'@DQID93&V(.$I\4_VY9$- P0I]N
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MST=?\VW?:H^PW^Z-_7IO[/=[VSADB.0A0_12K?9(<Q.NWRZ178P?M&LD]$@
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MA<CFHF@ ]=^O\[S:_])T\) 7?VRG<_5_4$L#!!0    ( %J 6U55/P,%Y (
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M[,O2Y%S@I0)=%@53OXXPE_.!%WJ/"U<\FQB[X _[4Y;A-9J;Z:6BF=^PI+Q
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M8/<#V:NJ'J.:&#EUC^B=-/0DN^&$VC)45H#VQU*:QXE5T#1ZP[]02P,$%
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M&@-7!G@_84S>#Y2#Y@!T_C]02P,$%     @ 6H!;512.)XDQ!   .14  !D
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M'V/=>T"8!?K]FG/U-# .JMO2Q;]02P,$%     @ 6H!;5<C*9?,Y"P  O&T
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MCE1?2S$(5S@=:_+TF-&T8\TM.+A7]+0WB^IK* 8]"N=D38P><QI-.XB1+B>
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M_+EDB>"R_H'X]X>BX"\?Z@#[%[9=_0M02P,$%     @ 6H!;517ZY]5D"0
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MQ%!-"&P0&04DHPN[N=@01C7!L %E#*",:4/9L%S<V&^?]>[<"7IG/>Z%KDK
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MVUR\GC8\@\N=8ZIMRP9A>4!8GGY-[!-YFZ7\8]- 1VYVZ5K=LFJTG<R4M6Y
M - \N^UDGM$:F2EKW6  XGF6V\D\13N91_U^-[,-6O. UCS;W62>7%+KPSKN
M@ZY&@##O2S23>8IF,L5T6FFV;W7;/TDOF6>T8F;*6C=& '*>P5XR3^8UU:S;
MX#4/>,TSU$OF'2^"X4/I2@&L\DYI)/LMWE3?J;=9$9>/?9G&!QA]KMH +@^
MR[/;5.89K8B9LM:]0P=XS;?<5.;+5;*%=',+[H2N2& PWW9/F7^\>H;[H*L1
MT,K_$CUEOLQ7BMFT@5<^X)7_)"UEOM$:F2EKW1@!GOD&6\I\F<(4DVX#PGR
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M]I%>U9=>W3%RY2Z:N31X;;EFCC\*H.P$_)Y):;8=>W?Y7X_D+U!+ P04
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M6UP(@8SQ;%NM%AJ=#31&]:X/M#1O:76,E%Z0SVZ65(>[VK<9TB@,0>]YB*^
M"&L@&(7TQ9YX7C@J]LLE9V3#U5^%<U&K#)+FJ:]B<L7J*D V'%C,T.P4FZ.*
M%<Y>J764Y5)#,"F;/RE;,!5;OQZ=<X;6_^79X*26>E(V?U*V8"JV?HTZ6PU'
M?>%9Y]:$GZY45]H#9<Q<VA9DC&D;XK:@ %GFP+;0>5,X;D[/FK<FOM>M>(ZK
M,-)&+V/FGBA1QCA#6WWG3N&X/;W<OD'91%Z;HF0%1C1O*HPC2E9@9@.2.\,*
MQQWK3UHWJ/*3HGX%1IK6"HPMZE<Y7&L@ 9UUA>/>]4+O!F7_:$GK6(&1!,L8
M3W(S,@;"(<&=5X7C9O5B\R9;2$GP68A_'A*,0OH7<)U3-<>=ZD7FK>'J_>2U
M1&.N HD.SU> ;$/4JP!9T@]0_>2V-D5T5UV3%US"(6/UY5O;VE[%WU47T$+[
M/;Q=0T6[#V^#^J*]HZ_O_1]"NL-9 1*TY5T9-W->&5I?I=<OC.357?$S88RD
MU>,>A3&B)8!_OR6$O;V4';3_T%C]"U!+ P04    " !:@%M5I+-/Q(4"  !
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M+:U;P^]2+J.7?[!"JI?^;<+L[]3Y#$H+0&DA%$VM'&XKAY]/LZB?!:JJD+0
ME!9"T=2JMO+1,:J9?BW#S#BY&J#*KZ:I"J"[YOT,1>>TDLXQ:[H>+</3!#'N
M]@NCEY/SUL-E".5235RK#QVS0#QL%@%=RG=C-*>Y?"70M4QF\6/*PNSUY.D,
M20M :2$43:U?*WZ=T3-J&48E?G)5(6D!*"V$HJE5;96^8Y;Z_5H&J'P'I04U
M3?T]R+=Q=_'[&=+<:;6Y8Y2*?;K&6!.'.SSJ&Z!BN9_3$,JIFKQ6"#MF)=R5
M&8?:8LE9AA:D6*-WJ>2^I_&*%J>T#U %#4H+0&DA%$W=YFFE-K:?3_O D&I\
M 4H+0&DA%$VM:OL+ #;_ M"K?9@9)U<#5-77-/6;LSOJ+(!0/M4LMVH=&W5C
MC^Y1 Y0P)KC3!!=F-R>GKH_/$,JGFKI6$F.S)*Z6G?[MP$P[>:J"BF-06@A%
M4^O2RFCL/:-V "FV%Z"T )060M'4JK8:'YLU?K]VH-N;=<>>VUVM=..&CMW=
M]-;S[*-OL7H>]A[8+,6M,L;F?6'SUC<^WJ+5[7WKAAUO?NM&:7:_M3X?VO[&
MK5C$9K'8HP_Y1V<+RAQ/CCJ1=IQW'&\_7O@X;Q^R=7!H*Z-\59V6*U#$MKG8
MG]-I[C8G\BZJ<VB=^W/G;.%H[@?.6;@_;]?B]\?_K@B7'XX"I70I7=EO?5D=
MOC]1M[\0;%,=&;MA0K"L>KFF)*:\'"#?7S(F[B]*!\VYQMG_4$L#!!0    (
M %J 6U5,;TBYO@,  $ -   9    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM
M;*U7;8_B-A#^*U:N.K727=X)A .DY>742ET=VE7;SR89B+5.G-H&]OY];2>D
M$ S:]O8+B<TSS\P\'MN3R9'Q%U$ 2/1:TDI,G4+*>NQY(BN@Q,)E-53JGRWC
M)99JR'>>J#G@W!B5U M]/_%*3"IG-C%S:SZ;L+VDI((U1V)?EIA_GP-EQZD3
M.*>))[(KI)[P9I,:[^ 9Y!_UFJN1U['DI(1*$%8A#MNI\Q",5ZG&&\"?!([B
M[!WI3#:,O>C!;_G4\75 0"&3F@&KQP$60*DF4F'\W7(ZG4MM>/Y^8O]J<E>Y
M;+" !:-_D5P64V?DH!RV>$_E$SO^"FT^ \V7,2K,+SJV6-]!V5Y(5K;&*H*2
M5,T3O[8ZG!DH'KM!V!J$?8/XAD'4&D1O]1"W!O%;/0Q: Y.ZU^1NA%MBB6<3
MSHZ(:[1BTR]&?6.M]"*5KI-GR=6_1-G)V0KSBE0[@=; T7.!.:"?ER QH>(7
M]!G]A#PD]*PX/4B%'@FE:I'%Q),J LWC9:VW>>,MO.$M0H^LDH5 JRJ'W&*_
MO&^?WK'W5.9=^N$I_7EXE_!;)EWDAY]0Z(>A)9[%6\PC8Q[8TODQ[ZO_[?U"
MC*BKA<CP13?XGB!C548HP68/LZW>@B1#E3JNX%0GM:H34PI(,I03NI>0WT#8
MZJ.)(+9'H _%L:AQ!E-'G7H"^ &<V<</0>)_L2W.>Y(MWY-L]4YD%\L8=\L8
MWV.?S>\LFFU)&K;4L.EKY3 +W.'$.YPK;<-$Z25H>0T:N'$/M+H&)6X0=:"+
MC ==QH.[&3\<@*M+[71$J>M02%SE*G7T\<,H#,(O327;LF^8 _\LH# )AVXO
M[H45%X5NTA/!SC?J\ZUN\85V*9).BN2N%&LFH9($TY,8\ H\(P)O**"].C55
M(4B6O2!6FTU>4VP_R)/K^(+8=X.>+#98-'*CGBI6MJ#/MK*RI6>P"TV&G2;#
MNYK\#D*,3WH<"Y(5*&-[FJ,-J%:GWO.L4*U&WLHC5;LE]OQ[JU,)LF"VJVH^
MO [V<^ G5WNGP0W.86F_:NQ<H3OH"63#I><N+P0:=0*-?G3_M">]38>1K9*3
MH%\#"RMN&/=WQM+.-[S2XA9?8A<C[<1([XJQ_,]W6FHY')-1+WL;*.J5RO(:
MI$[0_B:Y!B6N'_>2]LY:PA+XSO3B0M=])9N.H)OMVOT'T^7VYN?!>!%8YI?J
M\Z#IYO^E;[XM'C'?D4H@"EOERG>'JO1YTZ\W \EJTY!NF%3MK7DMU"<.< U0
M_V^9.L3:@7;0?33-_@%02P,$%     @ 6H!;55ESS+MX1    GT# !D   !X
M;"]W;W)K<VAE971S+W-H965T-3$N>&ULM9UKDQPW<J[_2H>.CT\[PB8+ET)5
MK;6*&#6P$L/B)3BDO+L.?QA1+9&Q)(=G9KAK19P??WJH*78B,P$,9E[N!YN2
MJAZ@D.@D7KRX?/V/\XN_7;[>[Z\V__/N[?O+/W[U^NKJPQ\>/KQ\]7K_[NSR
MP?F'_?O#?_GE_.+=V=7A'R]^?7CYX6)_]O.GE]Z]?6B'(3Q\=_;F_5???/WI
MWSV[^.;K\X]7;]^\WS^[V%Q^?/?N[.*W;_=OS__QQZ_,5^N_>/[FU]=7U__B
MX3=??SC[=7^ZOWKYX=G%X9\>?J;\_.;=_OWEF_/WFXO]+W_\ZL3\(04[7[_Q
MZ9$?W^S_<4G^O+G^EI_.S_]V_0^/?O[C5\-UE?9O]Z^NKAEGA__W]_UN__;M
M->I0D?][0_WJ<Z'7+](_K_0_??KZP]?\=':YWYV__<\W/U^]_N-7\U>;G_>_
MG'U\>_7\_!_?[V^^:+SFO3I_>_GI_V[^<?/L\-7FU<?+J_-W-R\?:O#NS?O?
M___9_]RT!'GAP-%?L#<O6/Z"+[S@;EYPMRW!W[S@;UO">//"IT]_^/NW?VJX
M>'9U]LW7%^?_V%Q</WV@7?_A4^M_>OO07F_>7_>4TZN+PW]]<WCOZIO3_:^'
MN%]=;LY_V7S[\?+P7R\O-V?O?]Y\MS__]>+LP^LWKS8GARYXN?FWS>G9V_WE
MYMO?-C<O;9Z2=[9Q?W7VYNWEOQP>?'D:-]M_^I?-/VW>O-\\?O/V[:%+7'[]
M\.I0W^M2'[ZZJ=NWO]?-%NKF-H_/WU^]OMRD]S_O?U;>C_7WE\K[#P_M]+FQ
M[-I8W]HJ\.FKJP>;P?[KQ@[6*O79W>9U]^EUHWW._4I/=RX]:PSWN>>X3SQ7
MZCF?>L-/OVTN;WK#H0?]=-,;M%C_3O,Z[3HA_N'RP]FK_1^_.F2\R_W%W_=?
M??//_\N$X=^UAD;"(A*60+ L)/YS2'R-?A.2J_.;Q+&_4 /Q.R-\8ES_1?+W
M;ZR;ED.7^#MM8>TIY^;\J2B?FLR!EC^5Y%-A7J9CB=G'CI\_=JQ^[+/]Q:OK
M;K=[??;^U_UF>TA19YL/O__+?]&^^W?<3&HQ/!C,PKZ[6FAOSU*+=(XU#ZC(
MK!7#YU8,U59\^>#T@=98U;=Z?ZU(6$3"$@B6-?WTN>DG: *=D"%!PB(2ED"P
M+"3SYY#,@ 0ZBW1FK!_9KWKW^U,C?<HL@3T5)<N%(7B6(23+^65Q>@)=/G_L
M@DV@BY;-//^+HUIH;\]2BW2LR 0J,FM%,QQ'T$.U'1^]O]I?O#^[UCUG;]51
M;O7]WE\NE!:AM(2BY9$@6L9 ,^H-#A48)"U":0E%RP-CCX&Q@+QZ \D2JQ%C
MSMW-8WEF==/(,JM"<Z.9^.!+H3FW3+.>6\U1'9GJ2+\_NS9XV^&!&_ZW]N:N
M_F9WQW-JSAUYNWT)H6..2L?4I<[NZ9/3EX_3\\WWZ>2'%]]OMD9OU"JE^Q>.
MI$4H+:%H>3R.8LR,V-2+U%D[*"U":0E%RP-SU'>F+O!NF7J#3);3,O+,&V2N
MG(WEB5>RC#%SX E$P@YI?)@*B?>HJDQ5(=PA\=9YA\3K2XD7JJ):]3 /C%Z/
MA*I'WN)'T63JJDG)Q9O_MRG-+-1AW;]\)"U":0E%R\-RE'=FP:9DI'+;06D1
M2DLH6FXB' 6CK0O&VZ7D&TB61L/(IRMOGLJR:+!\+*RP_#+PH;#"\LM<2,CV
MJ,IL55ST)^0;'AN!6C[14"^VMX<U/N*0?:="]D75(V_>H[:R=6VE9]_FI$2=
MVOMKA](BE)90M#P^1R%HL3Z9A1IE4%J$TA**E@?F*"$MPBVSBA%F7."YR(O4
M:<T\\32L&&%V%FE8LH*S0R$-'Q6:!?ME#=[6%B<DZF]V=[I&/88'H929OX3T
MLD?I9>O22\_,3U_L-O_U>/_NI_W%?ZO-#K7>H+0(I244+0_/42A:K/]FH08<
ME!:AM(2BY8$YZDF+<.&L8L.-PLZWB@WG9\\3LV1Y'RQ/S)+ES5QPX>Q1IUFP
M#V=55XP/^G?U8KM[F%IHX$L]4(7F2Y*.TLK5I54[Y59F)NKL[B5*4)\.2DLH
M6AZEHR)T6)_.07TZ*"U":0E%RP-SU)(.X=,YZ:P%,5?LI*\6^!QP5$AVL,SP
M2PK*+*$P('9D_2+8H7.J,V8\_W+LXL3;V7&H0O.V/&HIUVW'R;S;G).H%]+]
M.X>Z=5!:0M'R<!VUH,.Z=0[JUD%I$4I+*%H>F*-D= BWSDF';1;#/R?]M6GA
MZW<5DO6.+S]34-;:PL#7'068 SMU-SR>"T4"ADHKO5#^]UU"%9JWY5$SN;MX
M<*=_>_-^\_W^[.W5ZX??[L\^7OVF-BO4D8/2(I264+0\2$>EY[".G(,Z<E!:
MA-(2BI9OFSC*1H]PY+SBR!G+IX*]XL@9RV<<%):S8MVOPG)^+#AR_JB_/-B1
M\ZHC-X@](U!EU?B([5B<]T75(V_>HXKR=W'D9"ZN3$742^C]Y4-I$4I+*%H>
MJZ,(]%AWSD/=.2@M0FD)1<L#0[:R(=PY+QVU46YEDX;:&!:>D"7)3#(A2Y29
MR41Q_K%'/>;!WIS7=Y9-_,NA2JOQ$8>$7# $$ZH>>?,>596_BQ&G)N3F'$6]
MJ.X$ +7GH+2$HN5!.ZI#C[7G/-2>@](BE)90M#PP1ZGI$?:<EY;:R&<M=UXZ
M:N/(%Z\I)#,. \_,BM$W$I6>?^Q1LGFP.=?@;5UIU+JKO]G=Y1KU"(?Q>R%9
M?PDM-AZUV'@G"^_B[.UF=W:QU]J\3NS]Z4-I$4I+*%H>FZ-P'+'&W0@U[J"T
M"*4E%"T/S%%RC@CC;E2VQ/%]<[M1V1 GYHT5DC'"E%)0QOJ"<3<>-=L(-NX:
MO,/ =2[DY/J;W5VN48_YP5C(R:AZY"U^%&/CG>R]-2=7)C+JX.X, +7TH+2$
MHN4A(J>A8"V]$6KI06D12DLH6AZ8H_@<$9;>J&R:&_G.YU'9,C<./#5+DI_X
MB0D*R9?V/(]'R3:"#;U1]=9&R[\;*L8:'[$UY2S\)837>!1>XUT\/IJ%F[,7
M]1*Z?_50JP]*2RA:'JNC;ARQ5M\(M?J@M BE)10M/^[J*"\#PNH+TIZSAL^N
M!NG.6<]'R@HIB&EEA3259I7#4:T%L,W7X&V-+6Z%KK_:V^-N49'"B#VA*I*W
M^5&(A;MX?]^>'3)!:?:B3NS]Z4-I$4I+*%H>FZ-N#%BO+T"]/B@M0FD)1<L#
M<Y27 >'U!>G0R=F+( TZQPW!J)",&?CLA8(R)A067X2C4 M@KZ_!V_KB/KSZ
MF]U=KFG_%?YR2*AZY"U.CKB\B_WW.2=79B_JX.X,@#T'$WL0YI<P^\)1.0:L
MV1>@9A^4%J&TA*+E@3EJSH P^X*TZ,0JC" -.KZ(-BH<N2A. =FY,'<1CH(M
M@(V^!N^0E@L&VZ[^9G=W:]1C?F!+:?E+*+'IJ,2FNQA]-"TWIS/J)?2F 2@M
M0FD)1<MC=922$];XFZ#&'Y06H;2$HN6!.>K-"6'\3<H^.W[NQ&Z2;IU=^(X]
MA31[OA9#(<W3HF?HZ2C?)K#MU^ =,G1AHG=7?[.[PS7K41HXH^J1M_A1ETUW
ML?W^\]#-WO^?RYNE<VK#0TT_*"U":0E%RP-TU)(3UO2;H*8?E!:AM(2BY8$Y
M2LX)8?I-RNX[L8]O4C;?.7[FID(*_)2+I)#H0_FGDEL,P*9?@[=UQ8%S_<WN
M#M<\][-TWB:J'GF+'S79=!<?,$_+E4F-.KT["4 ]0"@MH6AYG(Z2<L)Z@!/4
M X32(I264+3\DH^C\IP1'N"L>(#\C@]E?QZ_X$-2V-:3I% *@^7Y*-AFL/?7
MX&VM+:;E^JN]/:U9D:+UAZI'WN1'*3;?Q?H3:;DYJ5$OIC<-0&D12DLH6AZP
MHZ"<L7[@#/4#H;0(I244+0_,47?."#]PEBZ>M2)#2Q//6K[W3R&%2=S!)$EA
M*NPOF8\*;@:[@0W>(3T6SBG>U=_L[G#-4SE+HV=4/?(6/TJS^2YNX'^>?WS_
M\Z=YYX=/KU[O+]2FA[J!4%J$TA**EH?H*"EGK!LX0]U *"U":0E%RP-#KL>#
MW(^G;-B;^#$9L[)?;^;3&@II%+>+*J2QF)B/XFT&^X$-WM8]6$J)&:K46O4(
MQ8/L4?7(;R,\JK+E+GX@3\R5B8TZOS<-0&D12DLH6AZIH[A<L&[@ G4#H;0(
MI244+0_,48(N"#=P43;OB8'SHNW=X_E9(;G +WI22&XI; )<CN)M ;N!#=YA
MP%I8)[&KO]G=X1KU*&_,1M4C;_&C*EONY@:*_-R<X:@7U)T/H/X@E)90M#QD
M1W6Y8/W!!>H/0FD12DLH6AZ8HPA=$/[@(ET]<<WTHIAZ?+VSPC$37[2A@.BE
M??F''J7< G8'&[RM,<4]*/57N_M;HR+E=76H>N1-?A1I2UVD/?O^Y/GCDUUZ
M^>+1[N2'PL6H=4;W+QUJ D)I"47+HT$N6<>:@ O4!(32(I264#1V;3N]MQUA
M ZZ4+'LZ*XY]7Y_+1\RSF-/0>&[QXD CC><F'PK'+IN!7),^@,W!%<BO'.&3
M.HV">_M;H5B^/SS!BF4M:DF+UH67R+FU"U#KK-Z?.!87L;@$P['0D'O8!ZS+
MM_)@X<'>S@[%)1B.A8?<XSX@O+Z50I/FY!T_(&-]+-M(;?G-H5&C62-\P:3A
M[#"ZPJC8#.2Z] 'L^ZW *<^%7 XTRNWO;OI!H]P<A17+&I1<<S[4%966@9L3
M$0UH_V\=ZNEA<0F&8S$B-[,/6%]OY<'"@[VO'8I+,!P+#[G&?4"X>RLEFY68
MA+^W/I:?NBRF)C2:F8TXL$C#F;#8PG9L,Y!KT@>PT[<"62KF,^B-<ON[FWH#
MW\2OCX45FS>H(;K*U'65FHK?O?OX_OSM^:_J#20-8O</'8J+6%R"X5B B/XS
M6/]NY<'"@U6)4%R"X5AXB)@T"!=OI60'O5E^Y_1N?2P[ZLV*4^,TFK$S/_,H
M:3AC7>F@96.(4#-@1V\%\FM)YB7_GV@1K"+3:R&'R*AB60,3J67J4JN>EVLS
M%G5P_^\?ZMAA<0F&8W$BVM!@7;N5!PL/5D)"<0F&8^$A2M,@O+N5DN^YEL-D
MHVSOF_CP-VJTV3HQ9ZS0IL453I(SAD@W _;Q5B!/BV+*IEYP?V^[5;$)5BQK
M4:*V3*=-Q[-Q>_:B7D+_[Q[JXF%Q"89C 2,ZT6"=O)4'"P]63D)Q"8;+PV.)
MZK00-\\J;IXW_+"B];%LF.MG,6I6:'[D8_"DT;P/A:W7QA(E9]%.7@.X]<7]
M(XU7NSN@U3U%D:E1Q;)&)GK,]IM[6:9^GAX?_DM,>H-CW3XH+F)Q"89CL2(B
MTH+=/HMU^Z"XB,4E&(Z%ATA0"W'[K/3G1G$:_OI4?FJR&#DK+#,'F644J\_;
MDM-GB9JS:*>O =S:4+Q#JO%N?_]K5:5X6$>"586U/!%J]@Z6H):W:U,?]3+Z
M\P/6(83B$@S'0D9DI@4[A!;K$$)Q$8M+,!P+#]&L%N(06NGI.3[CO%N?R@;%
MR@A;\0<'/J>;-)@9A\*IH,82U6?1[F #N+53\22-QKO]_:]=E=(N;5A5\I9W
M1-"Y^]B(,GUOTO]\.+^XTKMDO:SN/ '%12PNP7 L=$26.K#!Z+ &(Q07L;@$
MP['P$$'K( :C4W;W"3/-*?;BQ).X0C)!+%Q04&8I+?!P1!,ZM+'8 &Y-*&[F
M;KS;W_=:59F*^U!@56$M3^2>NZ?C2%)X>[J[7EA_DL"ZD%!<@N%8[(AN=6 7
MTF%=2"@N8G$)AF/A(>+605Q(IVS]"S*):V>,>I'%E4-&![[;6V--9 4V^V B
M#1W:@6P KT>_I7M?&^_V][[6KL;RKF]855C+$]7G[NE4GCYZ_.SIDT>;AY__
M=/+\T8D>$ZQE"<5%+"[!<"QR1+PZL&7IL)8E%!>QN 3#Y>'Q1.%ZB&7II<DX
M>GY,]/I4?@R2F U76";P/8I)@YG)E,;BGBA#CS8L&\"M+T^&UU_M[GZMFA1/
M2$VPFK!V)Y+/W]/#U'-X;6:\7F)WKH#B(A:78#@60")B/=C8]%AC$XJ+6%R"
MX5AXB-+U$&/32S/2+L+8](H7*>[*TECS+(;C"HM>V,(^F,A#C[8UO;J5L+E:
MNUZ/_HZGUF(4J[51Q;(&)@+/W].]+&;L]DQ*O>C^W( U-:&X!,.Q2!+EZL&F
MIL>:FE!<Q.(2#,?"0^2MAYB:7KF;D-_VO5N?RI=S\TNT--:TB%6#"FN>BF-P
MH@H]VM)L +=F*![*U'BWO_<UJK*4I\-1-<D;?B1Z;[RGHWGZ(OUP\ER?.:FS
MNY,"%!>QN 3#L5 1G3J"'<P1ZV!"<1&+2S <"P^1LR/$P1R5>P^]%T/,4;GY
MT$TSS]H*;7).C+@56IB'TI![)!)P1/N8-\#6F2'U<OL[F[HA<A)K=E#%L@8E
MHFV\ISUYDX]KLR#U(OI_]UA3$HI+,!R+&%&=(]B4'+&F)!07L;@$P['P$,TZ
M0DS)43,E1S&C/2HGDH[<O(P:S4_B%&J-YMU26N ]$GDWHHW)4=VCJ#0 5KCI
MQ<Y^H/\3!Z^@*L':E^BS\;[VX^<LW9[YJ)?5GP^P_B,4EV X%CJB-$>P_SAB
M_4<H+F)Q"8;+PQ.('@T0_S%(SW!:Q/&G05J&\R"2M<*RPJ9,&LSZH;1A,A!=
M%]#^8P.X->6E@/57N[M?4#=,AJ6>OU&58$U.M%JXI_7XXGEZ_*>_Z+,>=79W
M0H#B(A:78#@6*J(P ]AD#%B3$8J+6%R"X5AXB%X-$),Q2&-PXF>;[M:GLO4B
M_&ZMJ+',8L3@6H$9[XKYF@B^@+89@V;PN5%^/U;*Z<7*V2%4L:Q%B48+]_05
M;])Q;=*C7D3_SQ[K'T)Q"89C$2,",X#]PX#U#Z&XB,4E&(Z%A^C3 /$/@W:7
MH=@4&:3GYZ1_J+",X_.Z28,MI9L132"R+J -Q*"=7>H'<5AAO>#^KJ85JR7E
M+Z+$)J+$IGLZ@\>DW)[CJ)?5_?.'XB(6EV X%CJB*">P4SAAG4(H+F)Q"89C
MX2'J<X(XA9/B%/(K67;K4_DAU&*-M<(*1B1GA>7)*)5],-%P$]HEG#2_SGIQ
M5&&]X/Z>IA7KQ/6^L&)9BQ+9-=W3)GSZXOOT?//H\>.73Y[^\/2[O^BMC#4*
MH;B(Q248CL6,Z,8);!1.6*,0BHM87(+A6'B(")T@1N&D7( HLI+T]9S(R(KA
M*%;\*B!3.D!D(NIM0MN#=6!_5\3*M\;G;LWRP)56X*&JPH)!M-IT3R^1I_+:
M+$B]K/XX8;U$*"[!<"QT1'1.8"]QPGJ)4%S$XA(,EX=G)@IVAGB)L[)+D6=T
MY1F1T6?M&%>>T160*4U_S$3QS6@/L0[L[HI07&Q][M8]&$L)'543%@LB[^9[
MFHM*0F_/H-0+[8\7UG6$XA(,QV)(%.L,=AUGK.L(Q44L+L%P+#Q$_LX0UW&6
M%J"8/VD_$]=G0OF9I'%*U^+.1#/.#:]1O4+PE_VK0Z;X>+F);R[W9Y?[PM=C
MY2,4%[&X!,.Q2!'Y. =PQL :EE!<Q.(2#,?"0R3O7-> M\T8DQS#B7W.N_6Q
M;!2G[,Y0:&X9Q#G/"LVYI;1282;2<FY(R_Y181VX+9X)M&N\VM\!9V4JULA[
MME'%LD8F(G!N.(^W2]$UU5XOH3\58&4A%)=@N#Q@"Y&%RX#-U O6O(3B(A:7
M8#@6'B)EE[JVNV6FOJ&PW,H3]<U3V<8WONLK:BQCY78-!6:"*ZGWA2C&I:$8
MN_-T [CUMGQG2OW=_O[7J(JUI=.0$JPJK.6)SEL:SN2MDW=;H=>+ZD\36 D(
MQ248CD6.2,#%@[,XUNR$XB(6EV X%AXB7)>Z<+UM%A]%YET&,=R^>2K+XOR(
MHJBQ;/!BP*C S#267+6%*,"EL8JU/XL';94#/W5CURBXOZ]IQ8YRK1ZJ6-:B
M1+0M#9_RUMEY]_3'1_'?S*(W,]:\A.(B%I=@.!8T(CJ7&9R8L9XE%!>QN 3#
ML? 0N;K4Y>IM$_,BDJF?Q8:%FZ<RZVRP(C%+EO%\K)XT&-TSG7VQ'8YZ[_K/
MT+S< F[+@^O&J[V]#XM+,!R+A2&Q:/B4W1F],F_2**PW<V!Q$8M+,!R+G26Q
ML]#$OO)@X8'J5BPNP7 L/(Z$IRYE;Y?85TK%R]JMS^0GQG%73",9R[.ZQO*E
ML_?MX,GG-E; ]F=UJ #$XF+K<[>3*2YY@%6%!6,DP8#8E'E:;\ZH-$KMCQC4
MP<3B$@S'@AA($+$.YLJ#A0>J<K&X!,.Q\$PD/ @'<Z7D5QCR@;OVE'5\1=OZ
M5+ZGC_]%D#28\\6!^TR^^ XK8]6LDN++YR=/7FP>;B[>O/WPYN]O+@XHO7F@
M8A.+BUA<@N%8!!<20>P"V94'"P_4"<7B$@R7A\<096P0"V172GYD)9^D79_*
M4@H_XB!JK,GP%1$::PJ%!1'6$/EIP,MD6\#M6#K;=]=XM;OSM6H2BO>FPFK"
MVIU(1W.');&WS^2U.8!ZR=T9 XJ+6%R"X5@@B<@TV'6Q*P\6'J@IBL4E&(Z%
MAXAB@U@7NU(RUTVD<[F>U?"970UD^699C>1*$P"&:$X#/H:G!:Q</;UKO-O?
M\1I5,;ZL]E%582U/A**YPW$]7=F\+?WK5>C/&UAM"<4E&(Y%E&A+@SW.9^7!
MP@.U5+&X!,.Q\! A;!#'^:R4+!OSLPMVZU/Y.9;\D#6-%19^D*/&FEQAVX,U
M1#<:\&D^+>#65\;I6)'8JLE8,@\3K"9YNULB".T=SOQ1,_NSY^FOCTY?G!Q2
M^_4?=T^_??3GPY\/?WSZP^__^O0OCU^\_*MZA&:C&MWI XJ+6%R"X5A4B>JU
MV.. 5AXL/%@A#,4E&(Z%AXACBS@.:*7D*S+$+(R51_B,1F1WA67\*"9V%9@9
M0V&IG+5$1EKP@4 MX#84;WMJO-K?_1HUF<HC=U1-6+L3?6@;IBD^O]?F9NJU
MZ<\C6,<5BDLP' LN$<06>[[0RH.%!RN1H;@$P['P$-5L$><+K91L7\MD19I7
M3AB:Q0H-A66&A>]KT6#&V&*:)[+2@L\9:@&WMCR,K[_:W_V:-2F<L9]@-6'M
M3O2B11FG/6F^/6E3KU9_0L&:JU!<@N%8E(E(MF!SU6+-52@N8G$)ALO#XXB6
M=A!SU2FG!O&)]MWZ%-MPSO.]PG+B&FF-Y4O7;UM'9*9#FZL-X-9,Q8M,&N]V
M][YF59;RL!Y5%=;R1$$ZE+UZ<_30DS^EW8M'3U^>;N*CTW1RFDZW>H"PYBH4
M%[&X!,.Q,!)5[,#FJL.:JU!<Q.(2#,?"0\2S@YBK3GJBDYB$=](37<1:&85D
M1S$'KZ#HB27L<XF<=&A_M0&\W@E>G*2IO]O?]]K^ZEQ,YU]$*3JB%!W*7RVG
M\]JT3+WX_K2!]5:AN 3#L6@2$>S WJK#>JM07,3B$@S'PD.TLH-XJTZYWD3L
MFW'2#N5K&Z-&LG*,+DEC,:<3R>C0OFH#N/65B??ZN_T]KV6L3J7)H02K2M[R
MGJA!CW)6JSF]/0=3KT=W]H#B(A:78#@65J)Y/=A:]5AK%8J+6%R"X5AXB##V
M$&O5*[>CS#RY>VF&SF)!I$*R5BQO5U"V. /CB8#T:%NU ;R>@2DNB:R_V]_W
M&E492T</)EA-6,,3:>C[?=4G^X\7YY>OWNS?O]*W(M69_:D ZXY"<0F&8R$B
M<M:#W5&/=4>AN(C%)1B.A8=H7@]Q1[WB:(;9B%RM.)I!^J,*;32C\$<5VFB6
MPKU8UA-IZ-'^Z UP(E41*J1>:']/:QBA0WDF!543UL!$W/E^(Y3FY=HL21W=
M__O'FIE07(+A6*2(,O5@,]-CS4PH+F)Q"8;+PS,2^3I"S,Q1&I"+$5N+1FE
MSF[DR5EAV3"*L;0".PPV2HM71B+M1K2=>0/,DO,#\7=3O=CNGG:#RP_S&^9Q
MR?XG6NV+*+.1*+.QW[)DF;D]UU$OHSL'0'$1BTLP' L949<CV)X<L?8D%!>Q
MN 3#L? 0#3I"[,E1L2>#$TE*FHHSW_(?-=;AKRJ9HA6'<AI+6T!'HNE&M$79
M &Z7\H*3^JO]W:]9D^)D-JHFK-V)6!O[#4J6O'=/G^S2\T\K"-_MKU[_]O;#
MZ_W[-S^?7>ES(?4"^U,%UI*$XA(,Q^)'=.<(MB1'K"4)Q44L+L%P+#Q$M8X0
M2W)4+$D^/MZM3^5[>,3*087E)S$1HK#HV5+L@XGX&]&VY V0C7KYU3J[1L']
M/:UA0=KR(D%43?)&#D3"A7X'\M9)NS914B^W.SE <1&+2S <"R.1I0'L. :L
MXPC%12PNP7 L/$37!HCC&)3-G&*F($B;4$Z3*"0CKIW54(9L"V6?2S1A0#N.
M-T!VK]<B%$B]X/Y^UG 7BQN+$JPFK)&)L@OW<Q=;F;L]D5*O0'^.P%J14%R"
MX5@\B6P-8"LR8*U(*"YB<0F&8^$AZC9 K,B@6)%\I_UN?2H_1DLL&U%8+O";
M:S06W1K*/IC(P8"V(1O K2\O"JR_VM_YFMLT2Y>/P6K"VIWHO'!O=_+1DQ_3
M=R>;TY>G+]*3)]?I_<_IV0^/GCXY_.GFO[UX_NC)7Z__RXOGZ<='NQ?ZB2OU
MJO2G$*R;"<4E&(Y%E@C: '8S ];-A.(B%I=@N#P\$Y'"$\3-G)2MF8,3P_1)
MV9LY#)[G>(7FC!-)7J'9I709L)V(<)S0?N:D6HLVB ; 2D*]6"]FHU#%LA8E
M6F^ZOX=YA_Q=FVNIUZ@[3T!Q$8M+,!P+,%&W$]CQG+".)Q07L;@$P['P$%T\
M01S/2;J48?8BB4F3,GBQ>4=AV<')U"1A9IY+0_6)2,<)[7C> %DV'<5\2[W@
M_KZF%LM7:B98L:Q%B=J;[NUEWC&)MZ==ZE7K3Q=8UQ.*2S <BS21N1/8]9RP
MKB<4%[&X!,.Q\! U/$%<STDZE8[GZ=WZ5#YU+N;.%989^/6[28.9P_]*V9S(
MQ GM>S: 6_O E29>ZJ_V=[]&34RI)@E6D[S=9Z+_YGM;H<\?G3Y+S^/)#]=3
MZZ>%295Z,=T) HJ+6%R"X5C4B("=P<[GC'4^H;B(Q248CH6'J.$9XGS.FE\I
MEHC/BE_IQ?X=A>4F?HVYQO)C:2P^$W4XH[W/!O#Z5)+B\L/ZN_V]K[WQLS"%
MGV!582U/A-]\;T.4Y^_:I$J]M/X\@74_H;@$P['@$0D[@]W/&>M^0G$1BTLP
M' L/T<,SQ/V<I6,9A/DY2\-R,B*)*S[J,HHD+E'6E+;,ST04SFCOLP$LW\.V
M:[S:W_4:-2GNW4^PFK!V)VIOOK?WJ:3P]I1*O=C^9('U.:&X!,.Q*!(!.X-]
MSAGK<T)Q$8M+,%P>GH7HW 7B<R[2F1S%";2+]"6#.+%0(9E)[ =24-:7!N0+
M$8@+VN%L +>V<FU0_=WNOM>L2BA/J*"JPEJ>:+_EWD[H[\=:/4DOGS\]W3U*
M3W9)CPC6X(3B(A:78#@6-R)A%[#!N6 -3B@N8G$)AF/A(3IW@1B<BS0EW20,
MSD5ZDFZ2&5RRC.&PI,&,#:43"A>B#A>TP=D ;DUY3J7^:G_W:]1DJF3P+R+[
M%B+[EGO;H#*#UR95ZN7U9PJLMPG%)1B.A8_(V 7L;2Y8;Q.*BUA<@N%8>(C:
M72#>YJ+XD?P^Y=WZ5+8W7\RJ*"AGQ-2X@K*NM*%S(;IP01N;B[:A<Y07']4+
M[N]H6K'.B&4JJ&*S%G7#4<I=__E+Y.?FC$FCX-Y,@,5%+"[!<"R.AL01:V*N
M/%AXH*H5BTLP' N/)>%!F)@K)3_XA*^+7I_*EW+S)84::PX\ 6DL0Y=BLR]V
MY(O!+F8+6+NUI_%N?_=K5244MW7"JL):WI.6[W<QG[Y_=?[V_-??](:'^I18
M7,3B$@S'PC.2\&!]RI4'"P]4G&)Q"89CX0DD/ B?<J5D&^V'P"='UL>RR9$0
M^()!C6;L($Z,U7!FF*:"7^F&B7PVV*]<@6S#_<"7W#0*[N]O:K%\I4^"%<M:
M="8MVN]$KFFX,L'1P/;_W*%.(Q:78#@6I85$">LTKCQ8>*"Z$XM+,%P>'D/D
MJ4$XC2LERY^SN.UR?2P_L\J*;*S0QD&L_]-HWH7"CLJ#]B<?#?8;5R!+BC-?
MOMXHN+NWZ<6* P9@Q;(6)?++]/N()!>W)S/J_.Y?/107L;@$P[%P$>UHL/;A
MRH.%!ZLFH;@$P['P$(%I$/;A2LGOK!$+0-;'\A5X8DVV1@O++).RI(7#P+R4
ME(EL,V #<07R'9*R ;""[ :7GQ;.A^4)5BIK4"*T3+\S2')R/'G^UY,?TI_U
MIH6:@%A<Q.(2#,<B1;2AP9J *P\6'JR"A.(2#,?"0X2F09B *R7?8JYD(^U<
M5W'%C48;YX6OY]!HWDV%6Q2<(;K-@)W %9BG8S%OOFL4W-_;5"=0G#H"*S9O
M44NDENUW I5\7)NZJ)?0_;N'XB(6EV X%C B$RW8\K-8RP^*BUA<@N%8>(CF
MM!#+SRK[%L5>\=WZ6'YQ E^=H<'<P+?&) UFW5!8*>TL$6X6;?I9[=A6-_!C
M1!H%]W<VM5@G_OY"%<M:E&@M>W<S+\_*[4F,>E']OW^LSP?%)1B.18X(1@OV
M^2S6YX/B(A:78#@6'B(_+<3GL]*96_B!'[OUJ6Q#HN-KH#66G:V8PE!@=IA*
M4QB6Z#B+]OBL9K99<:AVH^#^OJ;<1OE G(8%*Y4U*%%>]EX67WK^0SJ)ZA$?
M#7+_CQWK\D%Q"89C@2)JT8)=/HMU^:"XB,4E&"X/CR/2TT%</B=].;_P:VK7
MI[(E%YZ?FJJQC..SSDF#+4/A?@/GB'9S:(O/:5Z;YT=^[QH%=W<UO=B)GV4%
M*Y:U*)%;[EX6WTTNKLU>U OH_LU#<1&+2S <BQ>1B@[L\3FLQP?%12PNP7 L
M/$1W.HC'YQ2/;Q2KX)QJ\8F4K#E\8G2LL,;BA+(C<LVA_3VG^7MFX>=X-PKN
M[VF:OR>67* *9>U)])6[E[UWS,?M>8MZ2?V_?*S;!\4E&(X%CJA$!W;['-;M
M@^(B%I=@.!8>HCD=Q.USBMO'+_G:K4]E9I\37I_""EZ. )6C46UASY]S1+NY
MAM/76+OU^-OG+W\\_">]&; Z#HJ+6%R"X?)0>:+C_(!-'1YK&$)Q$8M+,!P+
M#Q&=OBXZ;YDZ;BC9E"??N;I;G\JW(H3 <X<"LXOA1_=HM(/V+@EM3V2A;\C"
M[F%= WA]F&;AZJ==X]W^#MBJBGDPE[:AH:K"6IX(/-_P F^9MVN2O%Y$?W[
M:CXH+L%P+&)$\WD/3M]80Q&*BUA<@N%8>(A"]76%>MOT/<HU .):CO6I;&$6
M/\<A:BPS\,,3D@8SKG20O?-$1/J&B.S/WG5@/7MCA6&S*G/QW!Y855C+$Q7H
M&U[A[;-W6\#7R^K/$UB%",4E&(Z%CBA$/X/3.-:+A.(B%I=@.!8>HF=]7<_>
M-HTO(O6.H]A<>_-4MMV!S[]&C65FJ> 5F%F6TL*#D>C"L;&TM#N--X#5-%Y_
MM[O_M:HR/1A+61Q5$];P1/&-#9NQGL7_^I<7C[Z[OEWJ[*<W%V>'+'[^?K\Y
MU.?J\&<]+-@5I%!<Q.(2#,>B1[3K:+&)?,0ZF%!<Q.(2#,?"0P3N6!>XMTSD
M-Y1LU0(_V6&W/I796N*:0(UEQD&L6E!@9O*EN=B1*,2QL1JU/Y'7@=<GZ4S%
M1([5@\VJ% ]E3K"JL)8GXF]LV)-WS^2U"99ZJ?T9 VMU0G$)AF-!)')V#."$
MCG4^H;B(Q248CH6':-ZQKGEOF] GF81E/I_DD@=QT(1"XH/WI)'*8W*B$L?&
MVM7^5%X';ITKWE#2>+>_YS6JXEWQEBE855C+$P$XWLO0;*3R]FQ+O?C^I('U
M/*&X!,/ET0Q$VP:PYQFPGB<4%[&X!,.Q\! %'"">9Y VI>>K@7?K4]D@G>_?
MB!K+>+GA5X&90";JV2<3V1C0EF<#N#5C^>3-^KO]_:]5%5N>;D%5A;4\483A
M7I;G[P<I/WVR>_K#T^_^HD<":WA"<1&+2S <BQ>1LP%L> :LX0G%12PNP7 L
M/$3S!HCA&1234F[1"XI':<5R%87E^6;DI+&\+:U!#D0?!K3=>0-D&_2<6*U3
M+[B_IS6LS>+?%PE6$];(1.6%>SF;>9*NS9W4R^E/!EA7$XI+,!P+&]&K >QJ
M!JRK"<5%+"[!<"P\1-0&B*L9I!.YB"UL0?J0SHI,K7F:,E-+5'$G]41$WW2O
MLW)$#FF+]GJ!W;T5BHM87(+A6/R(*IS 1^=,6.,3BHM87(+A6'B(@IT@1^=,
M\K0;>0+[),^ZX<>418UDK;#5%)0;2Z?F3$0V3NA3<QK K;/EJ=CZN_U]KU65
MROH(5%58RQ,!.#7\3"6//_OX]MTA35_\MOG^MT,0KO;O+P]I6P\#5@Y"<1&+
M2S <"Q:1@Q/X0)T):VY"<1&+2S <"P\1KQ/D0)U)'H(SRU,H)WD&SAS$<@B%
M94>YKDV!V7$I+8>8B)2<T ?J-("52T4;K_9WOT9-[(.AF+:_B!:<B!:<^L_=
MT=-V3;_7"^E/#UB!",4E&([%C C$"7P$SX2U,:&XB,4E&"X/STP4[0PY@F>6
MQ^:$08RY9WEJ3C!B6['",I,\Y4N!F:EXXL-,1.",/H.G 3QD[^*HN_YJ=_=K
MU<26US^@:L+:G:B[N?^DGF+V;L^<U$OKSA-07,3B$@S'@D>TZ@P^MF?&.II0
M7,3B$@S'PD,$[5P7M+=-XUX.G/FX>;<^E8^;Q2!<8<T\V2>--=O2#L&9B,(9
M?6Q/ [AUI3W5N\:K_9VO41-3WA^(J@EK=Z+VYO[C?8I)_.FSTY>/'[W0PX%=
MX@K%12PNP7 L;$2QSN##?6:LR0G%12PNP7 L/$38SI##?69Y((_GA\'OUJ>R
M50I*^I8LX_BQDDF#&3<5$SC1A3/Z(H\&\)# BW,H]5?[NU^S)H5-B@E6D[S=
M%R+XEGX+LY7 :[,I]>*Z$P44%[&X!,.QZ!'MNH -S 5K8$)Q$8M+,!P+#Y&X
M"\3 7!3;<19[O!?EMHY%'"ZOL&8KIL(5UAQ*67PALG!!6Y@-X+:X@V/7>+6_
M\S5JXLLSX:B:L'8G>F]!&9A9%F_/JM3+[<\76&L3BDLP' LC4;$+V-I<L-8F
M%!>QN 3#L? 0L;M K,U%VI%&6IN+=",-/]@C:BR_C"*=2]9(YE[8!Q.9N*"-
MS0;PD$2+V[SKK_9WOD9-7"6=?Q']MQ#]MR"-S6<OGI_\^$@/!];;A.(B%I=@
M.!8VHF$7L+>Y8+U-*"YB<0F&R\+CAZ/4O?[S_=/W2LD.SG/\X+SUJ6P1(+]=
M.6JL9>;6IL9:;.'04S\8\L%@9W,%LKNJ^34?NT;!O3VM4&S@R[AAQ;(6M:1%
M@9[E36*NS)8TBNM- %A<Q.(2#,>BYTCTL*;ERH.%!RI8L;@$P['P>!(>A&FY
M4O+9$IF?%=,R\),W--9L^=$;&FM:"@N^_3"2#P:;EBN0)TI^[$BCX/Z>IA;+
M;S9,L&)9BP;2HD [\IB?F_,@C7+[,P'4GL3B$@S'PCB1,&+MR94'"P]4BF)Q
M"89CX9E)>!#VY$K)CC7B9VFL#V7N)-^7HY%,X-ZDAC+DKA/VN0OY7+ UN0+9
ME5">SP$U"N[O9UJQEJ_+3+!B\Q8U1(D9I.EX]7I_H39SO93N7ST4%[&X!,.Q
MH!$U:;!>X\J#A0>K.:&X!,.Q\!!I:A!>XTJAJ72:>5XRTAXT@^%964%9.294
M6&XH6(W>$#%GP%9C"[BUY=V2C7?[.U^K*D-QMR2L*JSEB4XS2+/Q.GO7ID#J
MA?5G":C#B,4E&([%CDA.@W485QXL/%AA"L4E&(Z%A^A7@W 85TH^12V2N#0%
M^=KNJ)'D_+1",K8TL#9$YAFPO=@";NU2RIN[QKO]7:_E+Y:7;<.JPEJ>*#@#
M-!C7%-Z>):F7VI\LH'8C%I=@.!9$HDL-UFY<>;#P8-4K%)=@N#P\EHA<"[$;
MK;0(^2&AN_6A_%H GLL5DA'G2&LH4SH+R5LB#RW:;&P KX\;+2T6:;S;W?>:
M52FO%H%5A;4\47ZVWY3<G5W\_.;\[V>7KSZ^/;O8/-P\WE^=_73^]LWEN\,_
ME*=4ZD5UIP@H+F)Q"89CD2,:UH(-28LU)*&XB,4E&(Z%APA="S$DK301S>#X
M;OCUL7Q2A6_7B1K-+OQB@:31G!F*>9PH1(LV)1O [5"\HZOQ:G\';-0DE"9X
M$JPFK-V)]+/]UN4MLGAM:J5>8G^VP)J64%R"X5@ B9JU8-/28DU+*"YB<0F&
M8^$ADM="3$LKK<;9B?5O5EJ-,[]_*VHL:_EBC:3!K)L*YU)Y2P2B11N75G,0
M!\]/T6X4W-_7&ALH??%^<UA-\D9V1.:Y?B_S=GF[/9]2+[H[0T!Q$8M+,!R+
M)%&P#FQP.JS!"<5%+"[!<"P\1.8ZB,'II"MI%N%P.F4SI1R+*ZPP&IZ_%=94
M7+[MB#IT:(>S =R:XB&LN\:[_;VO596A>#05K"JLY8GP<_T.Y^UR^I]/GJ<?
M7CS5HX-U.J&XB,4E&([%D.A8!W8Z'=;IA.(B%I=@.!8>(G<=Q.ETTI\,8FO\
M^E1VT" _03!J+#,/8CBNP,Q$S@IGGTP$HD/;G3= -AR?_4#_QP]\:52CO^>I
ME1CXF0*P8EG[$H7G^DW-KJQ=FTNIE]V?';#6)A278#@62J)<'=C:=%AK$XJ+
M6%R"X?+P>*)Y/<3:],HIL3)Y>^646)F\%9:6O!58)7E[(@X]VM[TZJ;&5O*N
M5Z.[Y^F5D,D;52QK7Z+N_!<Q,;/DW9Y0J5>B.TU <1&+2S <BRD1L!YL;WJL
MO0G%12PNP7 L/$3E>HB]Z:4A*7;Q>.E&BMGP-B?5.>Q#B13T:$OS!CA5OQDK
M\-I%)EB1K"6):O-?RJ1\].3'I_]Q\N3Z0O/?__@XJ0?!-FK0GP.PIB44EV X
M%E"B23W8M/18TQ**BUA<@N%8>(BD]1#3TBO[(_EA)+OUJ7Q_)+^V7&.Y48X7
MM6V;A4O+O2?"SZ,MRP9P:^;B"8*-=_M[7ZLJQ=7I"5:5O.5'HNG&+^9C*JF]
M-I52KTAW"H'B(A:78#@65R)<1["K.6)=32@N8G$)AF/A(;IWA+B:HW0BO4CP
MHS0B^6J3J)$,ORXS:2CK2TM21B()1[2GV0!N[5B\J*'Q;G_?:YU5Z\OK"U%5
M82U/U-[XI3S-0GYOS[;4:]2?2;"&)Q278#@68*)R1[#A.6(-3R@N8G$)AF/A
M(=)YA!B>HV)XBJF'4?$[Q=9.A606<:2>@C+%^?*1",L1;78V@%MC2GMP=HUW
M^_M>HRK%%>T)5A/6\$0RCE_*!2WO"JH7V9\IL.8G%)=@.!9!HH%'L/DY8LU/
M*"YB<0F&R\,3B% .$/,S2,/2<EMSMSZ5C;,GL0Y184VC2.4*:PZE,7L@"C*@
MK<\&<&ML><Q>?[>[]S6KXLK;]%%582U/Q&'X4J9H<V]0O>3NG '%12PNP7 L
MD$3V!K 3&K!.*!07L;@$P['P$&T<($YHD ZF7%D>I(7)'XH:R8IK'324<Z4M
MGH$HQ8#V0QO PX"X>')6_=7^KM>Z+-,^L,5\_D4T8" :,'PI^_3V>X;J5>C/
M'%C_%(I+,!R+*)&Y >R?!JQ_"L5%+"[!<"P\1 P'B'\:M,LO9697_--)^*<*
M2URWF336Z$K^:2#:,:#]TP;P^BC"XK1+_=W^WM?R3\M7L,&JDK?\1&3A5)>%
MCU-\D7;?;YW>S/6WNW_W4%S$XA(,QX)!).L$-CTGK.D)Q44L+L%P+#Q$UTX0
MTW-2ME].LSA%>])L3WF(N$*S@[*=4\'9P1:/K)V("IS0YN<-D"W?MF+5>+W@
M_OZF%RM.7$<5RUJ4"+>I+MR.2;<VUU&']/^XL3XD%)=@.!83HBXGL \Y87U(
M*"YB<0F&8^$A&G2"^)"3=L3L*.:O)VD?.F.$%ZG0EL7)?")IRV$P4<J\1*9-
M:#=R4G<]RIO0Z@7W]S:U6+[4)\&*92U*E-545U99YFW/2M1I_;]QK(,(Q248
MC@6'J, )["!.6 <1BHM87(+A\O#,1"K.$ =Q5BZB]%:DX%FYB7+D5[Y'C6:&
MR8C,HN .S[G2\'<FHFQ&^X@-X-8^6$I3$_57N[M@JR;%"? $JPEK=Z*VYKK:
MDJGZ[X<6_Y2K-Z?G;S]>_['0 [$F(107L;@$P[$X$7DX@TW"&6L20G$1BTLP
M' L/T9HSQ"2<I;5G!KF$;U9L0K[-)FHP9P<Q;E9@=AE+-U3.1,O-:*=PUJZ*
M-(.83*\7W-_9U!LJY[&VV3[!*L':EXBQN2[&;I6::U,;=7Y_"L"Z?5!<@N%8
MN(B,G,%NWXQU^Z"XB,4E&(Z%AVC2&>+VS<J]E/QFG-WZ5+[#44PJ*RPSRB->
M%9AQ8\GOFXG2F]%^WZQ>$LGG8G:-@OO[FGHEIMQ8BBHV;]&%B+/EMCY>/26W
MYSSJ!77_^*&XB,4E&([%C:C+!6SY+5C+#XJ+6%R"X5AXB A=();?(DVZT8BK
MS19IT8FGHL8RXF2II,',N)3632]$SRUHN^\&6#UVI%YH?S_3K3ZQN!Q5+&M-
M(K^6#JOOZ<75Z_,/9_N?W[PJ]".LY0?%12PNP7 L-D0F+F#+;\%:?E!<Q.(2
M#,?"0U3F K'\%FG2V8&O2MZMC^7K(_C&PJC1@O?B2".%%GQQ)=Q"M-J"MOP6
M_:!3L=BB7G!_;[M5L0E6+&M1(J^6#LN/9N#:!$6=V?]+QQI_4%R"X5B(B!Q<
MP,;?@C7^H+B(Q248+@O/.!RUY?6?[Y^(5TJ^'%F<Y[0^EE_+RY<*1(WF%C$,
MUFANM@7;;QP,^6BP[;<"^2((/H?<*+BWMZVX*2^6CX1AI;(&M:1!._P\EH>;
MLQ(->.\O'HN+6%R"X5BL'(D5UM-;>;#P0-4B%I=@.!8>3\*#\/162K;_>N8#
MX_6I;/^UY^-BC64/_U)D&<72"Z:8CD?RR6!+KP7<AN(JC,:K_=VO49/R^4NP
MFK!V#Z3=.ZP^EK6_?_3L5&]ZJ+V'Q44L+L%P+$03"1'6WEMYL/! A246EV X
M%IZ9A =A[ZV4_ !3;F^M3^6KYD:1K!5[SUB^9DZ#&3,4UE^,PT(^&6SOM8#;
MH9*LH>)MQ?&99;[+'59LWLB&J#+3X?@IF;DRO=% =V< *"YB<0F&8Y$B4M)@
M/;Z5!PL/5G!"<0F&8^$APM0@/+Z5DE^+*\2]T;;AB<D-A17$(7<:BV[\8Q],
MU)T!.WPKD"7%A<\Q-PKN[VEJL4'D8E2QK$6)(#-W=/F.N;@]Q5$OH_]7#S7_
ML+@$P[&0$4%IL.;?RH.%!ZLQH;@$P['P$-UI$.;?2LE&NM:+M*2<%NKY$=,:
MR_,[U)/&\N6D3%2< 1M_+>#6C,7CC1KO]O>^1E7*I]7!:L(:GN@S<W=_\#^>
MI*1/<=2A_=D :A!B<0F&8S$B@M)@#<*5!PL/5F-"<0F&R\-CB12U$(/0*I8>
MWW2]6Y_*]V:+9*VPS#"(D:$"6^;",HW1$DEGT>Z@U:\T%']7U0ON[FIZL6*A
M'*Q8UJ)$A=F[VX.?TG!M/J/.[OZY0W$1BTLP' L5T8\6[ Y:K#L(Q44L+L%P
M+#Q$C%J(.V@51X\O&]BM3V5#YYGO)]%8P?)%<QIKG HKED=+I)Q%>X-6W7<G
M3D5M%-S?T]1BPU+=[@>K!&M?HL7LW3W -36WIS?JA?0G :PI",4E&([%C,A)
M"S8%+=84A.(B%I=@.!8>(CHMQ!2TFI$G5G!8;9L>/XU?8[E9K*=36'XH#IB)
M@K-H2[ !K)W&WWBWO_<UJN)+=S4F6$WRAG=$F[F[VX0OGI^\?'RBMGZ=VIT.
MH+B(Q248C@6)R$D'=@@=UB&$XB(6EV X%AZB31W$(732U9OD_(:3KM[$<WK4
M6-8$,3948)9N3V:?3#2>0WN$3C7K^*D?NT;!_7WM5L4F6+&L18DL<W?W"']/
MQ+49CCJ\_P>/-0>AN 3#L5@11>G YJ##FH-07,3B$@S'PD,$J8.8@TXQ]/C)
M][OUJ=S0D_E8,1J]D5E&<1I=Z4BCT1$]Y]#VH%,WZ(G[ 1H%]_<U_2A0L5(<
M52QK42+!W-U]O\_YN#VM42^E_Y>/-0*AN 3#L: 1&>G 1J##&H%07,3B$@R7
MA\<3L>DA1J!7+AGD&6*W/I7O)1EX8E98DSAX6&/-Q"UD'TR$FT?[@ W@-A3O
M+6F\VMWY6C69BM>6P&K"VITH,G]WM_#TV:,GZ5\/_^_I\Q>GFW\^>_?AWS=/
M7WR?GNOQP%J'4%S$XA(,Q^)&9*4'6X<>:QU"<1&+2S <"P_1J!YB'7II]TWB
MK,SUJ6RB8Q +.126-7*XJ,"L60IG[(^>2#V/-@^]ZN))Z[1><']?:^PBM.5=
MA*B:L$8F@LW?W4$LINO:=$B]O/ZT@#43H;@$P['P$?'IP6:BQYJ)4%S$XA(,
MQ\)#E*R'F(E>N>*/Y^/=^E1N  HS46$9:\3TM (SUI66?'BB SW:3O3JOCYQ
M2%^CX/Z^UKJGL'CO*ZPF>2./1,V-=[<.:UF[/6E2+[@[/T!Q$8M+,!R+(Q&I
M(]A='+'N(A07L;@$P['P$"T[0MS%43J"3@XZ1VD(.CGH5EB+$VN"%5;Q>/YQ
M)")P1'N+#>#6E'>ZU%_M[WR-FMCRI FJ)JS=B;H;.QS(TX\7O^XO?M.;&VLV
M0G$1BTLP' L+4: CV&P<L68C%!>QN 3#L? 0[3I"S,91.8;4\[M'=^MCV3R&
MY_M6HD:;1!Y/&FVRI4.@QY$HOA%M-X[Z>:!B^4N]X/[>=KMC2&'%LA8E(FWL
ML!MODF]MAJ..Z_^18WU%*"[!<"PZ1$^.8%]QQ/J*4%S$XA(,EX<G$"4:(+YB
MD%[@PC>K[-:G\NM:9YZ!%9:=%[$=7('9>2[M!P]$M 6TLQC4K7Y\!_NN47!W
M7].+E5LQ4<6R%B4Z*W1XAL<,W)ZMJ'.[?^M07,3B$@S'PD3480!;A %K$4)Q
M$8M+,!P+#Q&1 6(1!FGK&>_$8=!!VGK&BPL%-9KW1FPP5&B'Q^92,B82+:!-
MP@9P:TKSOKO&J_T=L%&3H3P#C:H):W>BO4*';WA,V2?QQY,GNQ3UEL=:@U!<
MQ.(2#,<B1(1B %N# 6L-0G$1BTLP' L/49T!8@T&=9^A6-$1M -#Q>V"&LUY
MOG(O:33G76E)1R!B+J#-P:";@V+VIEYP?V]3BQWF)?^?:+@O(L<F(L>F#F-0
MIN7:M$:=W/WSA^(B%I=@.!8H(B(GL/,W89T_*"YB<0F&8^$ABG2".'^3=.O$
M&'FW/I4/?L5R:85E'#_&-&DPX\AA1>R3B;J;T-[?I&[PD_M8Z@7W]S6U6"-;
MZHL(LHD(LJG?U<N3<7N&HUY$_\\>:_A!<0F&8Q$C:G("&WX3UO"#XB(6EV X
M%AXB.B>(X3<I%IVX=6]]*E\$+>P^A64-O]PZ:3!K;"AE9:+B)K3=UP!NA]*1
M&+O&J_W=3W< Q6H65+&LD8D6F^[D 'Z7GJ3G)S_HK8PU :&XB,4E&(X%B.C&
M"6P"3E@3$(J+6%R"X?+PS$1USA 3<%9.!K5!N("S=@TA/V C:C0W\[.CDT9S
M<R@MQ)B)@IO1-N"L^W%BI6"]X.[>UOB.PU\(H33-C*H):V2BP^8[.8,WF;DV
MG5$'=V< *"YB<0F&8W$BXG$&6X,SUAJ$XB(6EV X%AZB1&>(-3A+,V^T8CIC
MEE[>R/<81HUEQB!F3!68.0P(2^F92+D9;0S.ZNY!?K'MKE%P?U]KNH!C,3U_
M$4$V$T$VW\D%/*;G]@1'O83^1( U!:&X!,.Q@!$Y.8--P1EK"D)Q$8M+,!P+
M#Q&B,\04G*6--\G59+-T\29^;V'46-9.8C6= K-V*6TYF8FTF]&68 -8WNBQ
M:[S:W_V:=R.61]9?1+,M1+,M'4[ACV\N#QE:;>TZICL!0'$1BTLP'(L*$94+
MV!9<L+8@%!>QN 3#L? 0.;I ;,%%L?*LW-"]*%:>F<65A K-3?*";X7F1E,:
M22]$VRUH8W#1'3HQTU,ON+^WJ<6.8KX952QK42+'E@YC\/?<6YO*J-/Z?^-8
M#Q"*2S <"PX1C@O8 URP'B 4%[&X!,.Q\!#)N4 \P$7Z=J,\\7E13AB=A >H
ML,SH9 +6[C(TI949"Q%M"]H#7%3G;9YJJ]=VC6KT]SR]$F/]3A54)5AK$PVV
M=)B!GY-S>R*CCNU/ UA'$(I+,!R+$I&-"]@17+".(!07L;@$PV7A"<-175[_
M^?Y9>J5DMU/Q ?!N?2H_EY^O;=98UDQ\;;,&LZ9TCTH8#/EDL!_8 FY=:>9W
MUWBUM_NM.#[US9>YP(IEC6Q)(W?X@9^3\^[IDQ<GNQ>;']*3TW2Z>5@^5+3!
M[TT#6%S$XA(,Q\+E2+BPMN#*@X4'*C"QN 3#L?!X$AZ$+;A2LLW;XE#1]:GL
M(.>93S=K+#N)T_HUF U#83(C#"/Y9+ MN (GEAO%YT-E6Z%4KCE@I;+V#*0]
M.QS 1D*NS'$TBNG_X4-M0"PNP7 L:A.)&M8&7'FP\$"5)A:78#@6GIF$!V$#
MKI3\V%!^!^'Z5#XOS">9-98Q$U^NH<',,!=LP# LY)/!-N *S,>L=,WU^OU0
MI;;B6&*6#?5%%)@A"LQT^WNUQ-R<WVB4UYT"H+B(Q248CH6/J$F#-0)7'BP\
M6($)Q248CH6'Z%"#, )72C8++8>.1CIW(S^?+FHL,XJC0368&6WA0I5@B)8S
M8!NP!=RZTO*(7>/5_NZG7T7(3T*"%<L:F2@R<Q=G\/3E\^\>[?2=* UB_P\?
MZ@YB<0F&8P$B^M%@W<&5!PL/5F9"<0F&8^$A<M0@W,&5DLU"+&)&PTA#SXF%
MSAIK6<2$AL):3.%$C6"(DC-@;[ %/&1E6\S*6-EV@VL-I5&ELC8F<LS<Q1%<
MDW)M5J,.[O_Q0SU!+"[!<"Q.1$,:K">X\F#AP2I-*"[!<'EX+%&D%N()6F67
MH#CO9WTJ7SO'3Z?36([?()LTEG,E1] 2#6?1CF #6,O-]5>[.Y]5'<' #]F
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M2M,R:MA6O8?FLWDS!^#,DQP:7:CFH)J+:AZJ^:@6H)I -8EJ8:-I7S!PMG,
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M[=WF2K6X_W34/[*N%U6UF*\OWF7I-%NN[E#__&:QJ%ZNK"9X7"R_KQ_VQ7\
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MT@.[KM\_$5DU<%C5&:)J1Y0F>]6NF8R2/&LV3^ :@_).4NK<$CYVIX2SF6#
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 6H!;5=H<*PYI!   !28   \
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M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VCM.PT 4A>&M1%X
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MMW'U"E!+ 0(4 Q0    ( %J 6U4'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 6H!;50%H1N3M
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ 6H!;59E<G",0!@  G"<  !,              ( !RP$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " !:@%M5SFY)FDT'  "2,P  &
M            @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ 6H!;59Q4JY(F!P  1!X  !@              ("!CP\  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %J 6U6,84!AY@(  .H(
M   8              " @>L6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " !:@%M5'KG&(KL'  !X*   &               @($'&@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 6H!;5<]1"EXU
M!0  K!D  !@              ("!^"$  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( %J 6U49[4VG- ,  ",+   8              "
M@6,G  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !:@%M5
MQ[/+-L$&  !0+0  &               @('-*@  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ 6H!;5727ONFK @  ZP<  !@
M     ("!Q#$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M %J 6U4QQ$6WK @  '\E   8              " @:4T  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " !:@%M5\[#EYF$'  !%$@  &0
M            @(&'/0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( %J 6U7N51!6> (  %T%   9              " @1]%  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 6H!;5<@([!=\!P
M,1,  !D              ("!SD<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " !:@%M5$MU"(JT7  !75   &0              @(&!
M3P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %J 6U7
M<"HHO0<  - 2   9              " @65G  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ 6H!;57_[9\0&!0  F@L  !D
M     ("!66\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %J 6U55!5%B72<  #Z&   9              "
M@4:6  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 6H!;
M5=?9,%[3!@  CA   !D              ("!VKT  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " !:@%M59S4Q>#4'   :$P  &0
M        @('DQ   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( %J 6U5IFNA;?0(  &4%   9              " @5#,  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 6H!;511W#D ]!@  DP\
M !D              ("!!,\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " !:@%M5'%QYX-X-  #D-   &0              @(%XU0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %J 6U7C10SP
MG ,  #L(   9              " @8WC  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ 6H!;5=M0>1CY @  8@8  !D
M ("!8.<  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !:
M@%M53TJ\@SH#  "%!P  &0              @(&0Z@  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( %J 6U5,0^YT5!8  .TW   9
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M970S,RYX;6Q02P$"% ,4    " !:@%M5SH,8AI4#  #!$0  &0
M    @(&P% $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M %J 6U6$/:E55P(   ,&   9              " @7P8 0!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ 6H!;50^(OX<6!@  %B0  !D
M             ("!"AL! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " !:@%M5L2-H>FD-  #MH0  &0              @(%7(0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( %J 6U55/P,%Y (
M .0(   9              " @?<N 0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ 6H!;5;OHC&80 P  ] D  !D              ("!
M$C(! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !:@%M5
M@BBQ61D$   ,%0  &0              @(%9-0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( %J 6U44CB>),00  #D5   9
M      " @:DY 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ 6H!;5<C*9?,Y"P  O&T  !D              ("!$3X! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !:@%M5%?KGU60)  !960
M&0              @(&!20$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( %J 6U4NCOQJMP(  (8(   9              " @1Q3 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 6H!;5="Z:HDW
M'0  XL ! !D              ("!"E8! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " !:@%M54&T3PFP%  #1'P  &0
M@(%X<P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( %J
M6U5%L>MVZ@0  -P8   9              " @1MY 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ 6H!;5:2S3\2% @  0 <  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( %J 6U59KL/0&P4  "<?   9
M  " @8K8 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M6H!;54DJADUT @  9P4  !D              ("!W-T! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " !:@%M5D[^)*6P1  "2/ $ &0
M            @(&'X $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( %J 6U4DI3MZ6 4  /XJ   9              " @2KR 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 6H!;56B)*>^T!0
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M2P$"% ,4    " !:@%M5\R"+>>D!   2(@  &@              @ '0!@(
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !:@%M5LFA)
MV-4!  "_(0  $P              @ 'Q" ( 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     00!! +X1  #W"@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1041</ContextCount>
  <ElementCount>311</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>185</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEarnings</Role>
      <ShortName>Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1008009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124105 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Pensions and Other Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlans</Role>
      <ShortName>Pensions and Other Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Accumulated Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</Role>
      <ShortName>Accumulated Other Comprehensive Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133108 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - Segments of Business and Geographic Areas</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</Role>
      <ShortName>Segments of Business and Geographic Areas</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2141110 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2146112 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Inventories</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2307302 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</Role>
      <ShortName>Pensions and Other Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2334306 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables</Role>
      <ShortName>Segments of Business and Geographic Areas (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2347308 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Restructuring</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/InventoriesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Goodwill By Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Derivative Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails</Role>
      <ShortName>Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2425416 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - Pensions and Other Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShareTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/LegalProceedings</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="jnj-20221002.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails</Role>
      <ShortName>Restructuring - Schedule of Restructuring Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="jnj-20221002.htm">jnj-20221002.htm</File>
    <File>a20223qex311ceocertificati.htm</File>
    <File>a20223qex312cfocertificati.htm</File>
    <File>a20223qex321ceocertificati.htm</File>
    <File>a20223qex322cfocertificati.htm</File>
    <File>jnj-20221002.xsd</File>
    <File>jnj-20221002_cal.xml</File>
    <File>jnj-20221002_def.xml</File>
    <File>jnj-20221002_lab.xml</File>
    <File>jnj-20221002_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>jnj-20221002_g1.jpg</File>
    <File>jnj-20221002_g10.jpg</File>
    <File>jnj-20221002_g11.jpg</File>
    <File>jnj-20221002_g12.jpg</File>
    <File>jnj-20221002_g13.jpg</File>
    <File>jnj-20221002_g2.jpg</File>
    <File>jnj-20221002_g3.jpg</File>
    <File>jnj-20221002_g4.jpg</File>
    <File>jnj-20221002_g5.jpg</File>
    <File>jnj-20221002_g6.jpg</File>
    <File>jnj-20221002_g7.jpg</File>
    <File>jnj-20221002_g8.jpg</File>
    <File>jnj-20221002_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1761">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "jnj-20221002.htm": {
   "axisCustom": 0,
   "axisStandard": 35,
   "contextCount": 1041,
   "dts": {
    "calculationLink": {
     "local": [
      "jnj-20221002_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jnj-20221002_def.xml"
     ]
    },
    "inline": {
     "local": [
      "jnj-20221002.htm"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20221002_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20221002_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "jnj-20221002.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 650,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 44,
   "keyStandard": 267,
   "memberCustom": 111,
   "memberStandard": 61,
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20221002",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.jnj.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Inventories",
     "role": "http://www.jnj.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Fair Value Measurements",
     "role": "http://www.jnj.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124105 - Disclosure - Income Taxes",
     "role": "http://www.jnj.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Pensions and Other Benefit Plans",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlans",
     "shortName": "Pensions and Other Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Accumulated Other Comprehensive Income",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome",
     "shortName": "Accumulated Other Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133108 - Disclosure - Earnings Per Share",
     "role": "http://www.jnj.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - Segments of Business and Geographic Areas",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas",
     "shortName": "Segments of Business and Geographic Areas",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141110 - Disclosure - Acquisitions and Divestitures",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestitures",
     "shortName": "Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Legal Proceedings",
     "role": "http://www.jnj.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146112 - Disclosure - Restructuring",
     "role": "http://www.jnj.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Inventories (Tables)",
     "role": "http://www.jnj.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307302 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327304 - Disclosure - Pensions and Other Benefit Plans (Tables)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables",
     "shortName": "Pensions and Other Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Accumulated Other Comprehensive Income (Tables)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables",
     "shortName": "Accumulated Other Comprehensive Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334306 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.jnj.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - Segments of Business and Geographic Areas (Tables)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables",
     "shortName": "Segments of Business and Geographic Areas (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347308 - Disclosure - Restructuring (Tables)",
     "role": "http://www.jnj.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Inventories (Details)",
     "role": "http://www.jnj.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i6295bb2d9d624931bd4df9123d80c9d2_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
     "shortName": "Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails",
     "shortName": "Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "if65ea7c0fbd54a3d9557ee7eb1a25b7c_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
     "shortName": "Fair Value Measurements - Summary of Derivative Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i5e79e3afda2d4ff4b9c9715fed272c0d_D20220103-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
     "shortName": "Fair Value Measurements - Derivatives, Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i487741e9485f4d4989b2d9bdd6959f03_I20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i7eba85641ea146e5bc22ff998e193635_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i7eba85641ea146e5bc22ff998e193635_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Earnings",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
     "shortName": "Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:SalesRevenueGoodsNetPercentToSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
     "shortName": "Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i4a1fe51dbd41434cacb992b4b627a3a1_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421413 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422414 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails",
     "shortName": "Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423415 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i9006cebe9baf49098f28b71ba8b0b364_I20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425416 - Disclosure - Income Taxes (Details)",
     "role": "http://www.jnj.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "if38fd805a6f8420da833524d3340a063_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "if38fd805a6f8420da833524d3340a063_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i332809e8f61c44149c2e4659a135fe38_D20220103-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - Pensions and Other Benefit Plans (Details)",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
     "shortName": "Pensions and Other Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i332809e8f61c44149c2e4659a135fe38_D20220103-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i00b96c9b90b442fab76aafa9fe0f84c0_I20220703",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Accumulated Other Comprehensive Income (Details)",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i206b36fcd5884efc8e2d9f8f10a5a918_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.jnj.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesBySegmentOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInOperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesByGeographicArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i1cf347773ad54fb88be2e997e4827221_I20210404",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfBrands",
      "reportCount": 1,
      "unique": true,
      "unitRef": "brand",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Acquisitions and Divestitures - Narrative (Details)",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
     "shortName": "Acquisitions and Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i1cf347773ad54fb88be2e997e4827221_I20210404",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfBrands",
      "reportCount": 1,
      "unique": true,
      "unitRef": "brand",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Legal Proceedings (Details)",
     "role": "http://www.jnj.com/role/LegalProceedingsDetails",
     "shortName": "Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88a45c1864b841c3bd10c2ba6038465e_I20221002",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Restructuring - Narrative (Details)",
     "role": "http://www.jnj.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "icacdc0678d9f4679bbb4b670b539eae6_D20220704-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Restructuring - Schedule of Restructuring Reserve (Details)",
     "role": "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
     "shortName": "Restructuring - Schedule of Restructuring Reserve (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i57839c019e9745718882687e73ce9e18_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i7466db7fb3de4e73b837ebe5f0b10609_I20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Equity",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i0c66231e52f741d58eefd24bb80b245b_I20210103",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i8738bdb5c38f40649ffb885e32e5c546_D20220704-20221002",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1008009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20221002.htm",
      "contextRef": "i88ecccd3dbfb48b7923618e99ef7af02_D20220103-20221002",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 185,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "CHINA"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "jnj_A0.650NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.650% Notes Due 2024 [Member]",
        "label": "0.650% Notes Due 2024 [Member]",
        "terseLabel": "0.650% Notes due 2024 (750MM Euro 0.9712)",
        "verboseLabel": "0.650% Notes Due May 2024"
       }
      }
     },
     "localname": "A0.650NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A0550NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.550 Notes due 2025",
        "label": "0.550 Notes due 2025 [Member]",
        "terseLabel": "0.55% Notes due 2025"
       }
      }
     },
     "localname": "A0550NotesDue2025Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A095NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.95% Notes due 2027",
        "label": "0.95% Notes due 2027 [Member]",
        "terseLabel": "0.95% Notes due 2027"
       }
      }
     },
     "localname": "A095NotesDue2027Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.150NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.150% Notes Due 2028 [Member]",
        "label": "1.150% Notes Due 2028 [Member]",
        "terseLabel": "1.150% Notes due 2028 (750MM Euro 0.9712)",
        "verboseLabel": "1.150% Notes Due November 2028"
       }
      }
     },
     "localname": "A1.150NotesDue2028Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.650NotesDue2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.650% Notes Due 2035 [Member]",
        "label": "1.650% Notes Due 2035 [Member]",
        "terseLabel": "1.650% Notes due 2035 (1.5B Euro 0.9712)",
        "verboseLabel": "1.650% Notes Due May 2035"
       }
      }
     },
     "localname": "A1.650NotesDue2035Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1300NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.300% Notes due 2030",
        "label": "1.300% Notes due 2030 [Member]",
        "terseLabel": "1.30% Notes due 2030"
       }
      }
     },
     "localname": "A1300NotesDue2030Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.45Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes due 2026 [Member]",
        "label": "2.45% Notes due 2026 [Member]",
        "terseLabel": "2.45% Notes due 2026"
       }
      }
     },
     "localname": "A2.45Notesdue2026Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.625Notesdue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.625 Notes due 2025 [Member]",
        "label": "2.625 Notes due 2025 [Member]",
        "terseLabel": "2.625% Notes due 2025"
       }
      }
     },
     "localname": "A2.625Notesdue2025Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.900Notesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.900% Notes due 2028 [Member]",
        "label": "2.900% Notes due 2028 [Member]",
        "terseLabel": "2.90%\u00a0Notes due 2028"
       }
      }
     },
     "localname": "A2.900Notesdue2028Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.95Notesdue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Notes due 2027 [Member]",
        "label": "2.95% Notes due 2027 [Member]",
        "terseLabel": "2.95% Notes due 2027"
       }
      }
     },
     "localname": "A2.95Notesdue2027Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A210NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.10% Notes due 2040",
        "label": "2.10% Notes due 2040 [Member]",
        "terseLabel": "2.10% Notes due 2040"
       }
      }
     },
     "localname": "A210NotesDue2040Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2250NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.250% Notes due 2050",
        "label": "2.250% Notes due 2050 [Member]",
        "terseLabel": "2.25% Notes due 2050"
       }
      }
     },
     "localname": "A2250NotesDue2050Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2450NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.450% Notes due 2060",
        "label": "2.450% Notes due 2060 [Member]",
        "terseLabel": "2.45% Notes due 2060"
       }
      }
     },
     "localname": "A2450NotesDue2060Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.375Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes due 2023 [Member]",
        "label": "3.375% Notes due 2023 [Member]",
        "terseLabel": "3.375% Notes due 2023"
       }
      }
     },
     "localname": "A3.375Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.400Notesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.400% Notes due 2038 [Member]",
        "label": "3.400% Notes due 2038 [Member]",
        "terseLabel": "3.40%\u00a0Notes due 2038"
       }
      }
     },
     "localname": "A3.400Notesdue2038Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.500Notesdue2048Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.500% Notes due 2048 [Member]",
        "label": "3.500% Notes due 2048 [Member]",
        "terseLabel": "3.50% Notes due 2048"
       }
      }
     },
     "localname": "A3.500Notesdue2048Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.55Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.55% Notes due 2036 [Member]",
        "label": "3.55% Notes due 2036 [Member]",
        "terseLabel": "3.55% Notes due 2036"
       }
      }
     },
     "localname": "A3.55Notesdue2036Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.625Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.625% Notes due 2037 [Member]",
        "label": "3.625% Notes due 2037 [Member]",
        "terseLabel": "3.625% Notes due 2037"
       }
      }
     },
     "localname": "A3.625Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.70Notesdue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes due 2046 [Member]",
        "label": "3.70% Notes due 2046 [Member]",
        "terseLabel": "3.70% Notes due 2046"
       }
      }
     },
     "localname": "A3.70Notesdue2046Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.75Notesdue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.75% Notes due 2047 [Member]",
        "label": "3.75% Notes due 2047 [Member]",
        "terseLabel": "3.75% Notes due 2047"
       }
      }
     },
     "localname": "A3.75Notesdue2047Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.375Notesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Notes due 2033 [Member]",
        "label": "4.375% Notes due 2033 [Member]",
        "terseLabel": "4.375% Notes due 2033"
       }
      }
     },
     "localname": "A4.375Notesdue2033Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Debenturesdue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Debentures due 2040 [Member]",
        "label": "4.50% Debentures due 2040 [Member]",
        "terseLabel": "4.50% Debentures due 2040"
       }
      }
     },
     "localname": "A4.50Debenturesdue2040Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Notesdue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Notes due 2043 [Member]",
        "label": "4.50% Notes due 2043 [Member]",
        "terseLabel": "4.50% Notes due 2043"
       }
      }
     },
     "localname": "A4.50Notesdue2043Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.85Notesdue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.85% Notes due 2041 [Member]",
        "label": "4.85% Notes due 2041 [Member]",
        "terseLabel": "4.85% Notes due 2041"
       }
      }
     },
     "localname": "A4.85Notesdue2041Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.95Debenturesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.95% Debentures due 2033 [Member]",
        "label": "4.95% Debentures due 2033 [Member]",
        "terseLabel": "4.95% Debentures due 2033"
       }
      }
     },
     "localname": "A4.95Debenturesdue2033Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.50NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Notes Due 2024 [Member]",
        "label": "5.50% Notes Due 2024 [Member]",
        "terseLabel": "5.50% Notes due 2024 (500MM GBP 1.0908)",
        "verboseLabel": "5.50% Notes Due November 2024"
       }
      }
     },
     "localname": "A5.50NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.85Debenturesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.85% Debentures due 2038 [Member]",
        "label": "5.85% Debentures due 2038 [Member]",
        "terseLabel": "5.85% Debentures due 2038"
       }
      }
     },
     "localname": "A5.85Debenturesdue2038Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.95Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes due 2037 [Member]",
        "label": "5.95% Notes due 2037 [Member]",
        "terseLabel": "5.95% Notes due 2037"
       }
      }
     },
     "localname": "A5.95Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.73Debenturesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.73% Debentures due 2023 [Member]",
        "label": "6.73% Debentures due 2023 [Member]",
        "terseLabel": "6.73% Debentures due 2023"
       }
      }
     },
     "localname": "A6.73Debenturesdue2023Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.95Notesdue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.95% Notes due 2029 [Member]",
        "label": "6.95% Notes due 2029 [Member]",
        "terseLabel": "6.95% Notes due 2029"
       }
      }
     },
     "localname": "A6.95Notesdue2029Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ADVANCEDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADVANCED [Member]",
        "label": "ADVANCED [Member]",
        "terseLabel": "ADVANCED"
       }
      }
     },
     "localname": "ADVANCEDMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AccruedRebatesReturnsAndPromotions": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.",
        "label": "Accrued Rebates Returns And Promotions",
        "verboseLabel": "Accrued rebates, returns and promotions"
       }
      }
     },
     "localname": "AccruedRebatesReturnsAndPromotions",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AmountPrepaidAndDueToManufacturers": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Prepaid and Due to Manufacturers",
        "label": "Amount Prepaid and Due to Manufacturers",
        "terseLabel": "Amount prepaid and due to manufacturers"
       }
      }
     },
     "localname": "AmountPrepaidAndDueToManufacturers",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AsiaPacificAfricaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asia-Pacific, Africa [Member]",
        "label": "Asia-Pacific, Africa [Member]",
        "terseLabel": "Asia-Pacific, Africa"
       }
      }
     },
     "localname": "AsiaPacificAfricaMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASR.",
        "label": "ASR [Member]",
        "terseLabel": "ASR"
       }
      }
     },
     "localname": "AsrMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AssetWriteoffMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Write-off [Member]",
        "label": "Asset Write-off [Member]",
        "terseLabel": "Asset Write-offs/Sales"
       }
      }
     },
     "localname": "AssetWriteoffMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AurisHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auris Health",
        "label": "Auris Health [Member]",
        "terseLabel": "Auris Health"
       }
      }
     },
     "localname": "AurisHealthMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Care [Member]",
        "label": "Baby Care [Member]",
        "terseLabel": "Baby Care"
       }
      }
     },
     "localname": "BabyCareMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyPowderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Powder [Member]",
        "label": "Baby Powder [Member]",
        "terseLabel": "Baby Powder"
       }
      }
     },
     "localname": "BabyPowderMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BeautyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beauty [Member]",
        "label": "Beauty [Member]",
        "terseLabel": "Skin Health/Beauty"
       }
      }
     },
     "localname": "BeautyMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BermekimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bermekimab [Member]",
        "label": "bermekimab [Member]",
        "terseLabel": "bermekimab"
       }
      }
     },
     "localname": "BermekimabMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONCERTAMethylphenidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONCERTA/Methylphenidate [Member]",
        "label": "CONCERTA/Methylphenidate [Member]",
        "terseLabel": "CONCERTA / methylphenidate"
       }
      }
     },
     "localname": "CONCERTAMethylphenidateMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONSUMERHEALTHAndPHARMACEUTICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONSUMER HEALTH and PHARMACEUTICAL",
        "label": "CONSUMER HEALTH and PHARMACEUTICAL [Member]",
        "terseLabel": "CONSUMER HEALTH and PHARMACEUTICAL [Member]"
       }
      }
     },
     "localname": "CONSUMERHEALTHAndPHARMACEUTICALMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONTACTLENSESOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONTACT LENSES/OTHER [Member]",
        "label": "CONTACT LENSES/OTHER [Member]",
        "terseLabel": "CONTACT LENSES / OTHER"
       }
      }
     },
     "localname": "CONTACTLENSESOTHERMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CardiovascularMetabolismOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular/Metabolism/Other [Member]",
        "label": "Cardiovascular/Metabolism/Other [Member]",
        "terseLabel": "Cardiovascular / Metabolism / Other"
       }
      }
     },
     "localname": "CardiovascularMetabolismOtherMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "negatedTerseLabel": "Total cash, cash equivalents and current marketable securities, Unrecognized Loss"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Estimated Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ConsumerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer.",
        "label": "Consumer [Member]",
        "terseLabel": "CONSUMER HEALTH (1)"
       }
      }
     },
     "localname": "ConsumerMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ContactLensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contact Lenses",
        "label": "Contact Lenses [Member]",
        "terseLabel": "Contact Lenses"
       }
      }
     },
     "localname": "ContactLensesMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CostOfGoodsSoldPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of goods sold percent to sales.",
        "label": "Cost Of Goods Sold Percent To Sales",
        "terseLabel": "Cost of products sold percent to sales"
       }
      }
     },
     "localname": "CostOfGoodsSoldPercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_DARZALEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARZALEX [Member]",
        "label": "DARZALEX [Member]",
        "terseLabel": "DARZALEX"
       }
      }
     },
     "localname": "DARZALEXMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DePuyASRU.S.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DePuy ASR U.S. [Member]",
        "label": "DePuy ASR U.S. [Member]",
        "terseLabel": "DePuy ASR U.S."
       }
      }
     },
     "localname": "DePuyASRU.S.Member",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EDURANTrilpivirineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EDURANT/rilpivirine [Member]",
        "label": "EDURANT/rilpivirine [Member]",
        "terseLabel": "EDURANT / rilpivirine"
       }
      }
     },
     "localname": "EDURANTrilpivirineMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ERLEADAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ERLEADA",
        "label": "ERLEADA [Member]",
        "terseLabel": "ERLEADA"
       }
      }
     },
     "localname": "ERLEADAMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent",
        "label": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent",
        "negatedTerseLabel": "Decrease in effective tax rate (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent",
        "terseLabel": "Effective tax rate for legal expense (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "jnj_ElmironMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elmiron",
        "label": "Elmiron [Member]",
        "terseLabel": "Elmiron"
       }
      }
     },
     "localname": "ElmironMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityFairValueAdjustmentImpairmentLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, Fair Value Adjustment, Impairment Loss",
        "label": "Equity, Fair Value Adjustment, Impairment Loss",
        "terseLabel": "Equity, fair value adjustment, impairment loss"
       }
      }
     },
     "localname": "EquityFairValueAdjustmentImpairmentLoss",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment [Roll Forward]",
        "label": "Equity Investment [Roll Forward]",
        "terseLabel": "Equity Investment [Roll Forward]"
       }
      }
     },
     "localname": "EquityInvestmentRollForward",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "label": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "terseLabel": "Sales/ Purchases/Other"
       }
      }
     },
     "localname": "EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentswithReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments with Readily Determinable Value [Member]",
        "label": "Equity Investments with Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments with readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityInvestmentswithoutReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments without Readily Determinable Value [Member]",
        "label": "Equity Investments without Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments without readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithoutReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EvraAndDoxilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evra and Doxil",
        "label": "Evra and Doxil [Member]",
        "terseLabel": "Evra and Doxil"
       }
      }
     },
     "localname": "EvraAndDoxilMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExcessOfFairValueOverCarryingValueOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of fair value over carrying value of debt.",
        "label": "Excess Of Fair Value Over Carrying Value Of Debt",
        "terseLabel": "Excess of the estimated fair value over the carrying value of debt"
       }
      }
     },
     "localname": "ExcessOfFairValueOverCarryingValueOfDebt",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "terseLabel": "Changes in estimated fair value (6)"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_GENERALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GENERAL [Member]",
        "label": "GENERAL [Member]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "GENERALMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GrossProfitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross profit percent to sales.",
        "label": "Gross Profit Percent To Sales",
        "totalLabel": "Gross Profit Percent To Sales"
       }
      }
     },
     "localname": "GrossProfitPercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_HIPSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIPS [Member]",
        "label": "HIPS [Member]",
        "terseLabel": "HIPS"
       }
      }
     },
     "localname": "HIPSMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IMBRUVICAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMBRUVICA [Member]",
        "label": "IMBRUVICA [Member]",
        "terseLabel": "IMBRUVICA"
       }
      }
     },
     "localname": "IMBRUVICAMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "label": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "terseLabel": "INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA"
       }
      }
     },
     "localname": "INVEGASUSTENNAXEPLIONTRINZATREVICTAMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVOKANAINVOKAMETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVOKANA/INVOKAMET [Member]",
        "label": "INVOKANA/INVOKAMET [Member]",
        "terseLabel": "INVOKANA / INVOKAMET"
       }
      }
     },
     "localname": "INVOKANAINVOKAMETMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percent To Sales",
        "totalLabel": "Earnings before provision for taxes on income percent to sales"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_IncomeTaxExpenseBenefitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax expense benefit percent to sales.",
        "label": "Income Tax Expense Benefit Percent To Sales",
        "terseLabel": "Provision for taxes on income percent to sales"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitPercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_IncrementalIncreaseDecreaseInTaxes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental Increase (Decrease) In Taxes",
        "label": "Incremental Increase (Decrease) In Taxes",
        "terseLabel": "Incremental change to income tax rate (percent)"
       }
      }
     },
     "localname": "IncrementalIncreaseDecreaseInTaxes",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infectious Diseases [Member]",
        "label": "Infectious Diseases [Member]",
        "terseLabel": "Infectious Diseases"
       }
      }
     },
     "localname": "InfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterestExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense percent to sales.",
        "label": "Interest Expense Percent To Sales",
        "terseLabel": "Interest expense, net of portion capitalized percent to sales"
       }
      }
     },
     "localname": "InterestExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InterestIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income Expense Net Member.",
        "label": "Interest Income Expense Net Member",
        "verboseLabel": "Interest (income)/Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterventionalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interventional Solutions [Member]",
        "label": "Interventional Solutions [Member]",
        "verboseLabel": "Interventional Solutions"
       }
      }
     },
     "localname": "InterventionalSolutionsMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InvestmentIncomeInterestPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment income interest percent to sales.",
        "label": "Investment Income Interest Percent To Sales",
        "terseLabel": "Interest income percent to sales"
       }
      }
     },
     "localname": "InvestmentIncomeInterestPercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InvokanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invokana [Member]",
        "label": "Invokana [Member]",
        "terseLabel": "Invokana"
       }
      }
     },
     "localname": "InvokanaMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_KNEESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KNEES [Member]",
        "label": "KNEES [Member]",
        "terseLabel": "KNEES"
       }
      }
     },
     "localname": "KNEESMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LegalProceedingTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Proceeding Textuals Abstract.",
        "label": "Legal Proceeding (Textuals) [Abstract]",
        "terseLabel": "Legal Proceeding (Textuals)"
       }
      }
     },
     "localname": "LegalProceedingTextualsAbstract",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Axis]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesAxis",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Domain]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesDomain",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LossContingencyEstimateOfAdditionalPossibleLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Additional Possible Loss",
        "label": "Loss Contingency, Estimate of Additional Possible Loss",
        "terseLabel": "Loss contingency, estimate of additional possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfAdditionalPossibleLoss",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Claims within Settlement Agreement",
        "label": "Loss Contingency, Number of Claims within Settlement Agreement",
        "terseLabel": "Number of claims within settlement agreement"
       }
      }
     },
     "localname": "LossContingencyNumberOfClaimsWithinSettlementAgreement",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyReserveEstablishedWithinTrust": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Reserve Established within Trust",
        "label": "Loss Contingency, Reserve Established within Trust",
        "terseLabel": "Reserve established"
       }
      }
     },
     "localname": "LossContingencyReserveEstablishedWithinTrust",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_MedicalDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Devices [Member]",
        "label": "Medical Devices [Member]",
        "terseLabel": "MEDTECH(3)",
        "verboseLabel": "MedTech"
       }
      }
     },
     "localname": "MedicalDevicesMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NetIncomeAttributableToParentPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income Attributable to Parent Percent to Sales",
        "label": "Net Income Attributable to Parent Percent to Sales",
        "totalLabel": "Net earnings percent to sales"
       }
      }
     },
     "localname": "NetIncomeAttributableToParentPercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neuroscience [Member]",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NotesDuePeriodFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes due period fifteen.",
        "label": "Notes Due Period Fifteen Member",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "NotesDuePeriodFifteenMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NumberOfBrands": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Brands",
        "label": "Number Of Brands",
        "terseLabel": "Number Of Brands"
       }
      }
     },
     "localname": "NumberOfBrands",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_Numberofpatientsinsettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients in settlement",
        "label": "Number of patients in settlement",
        "terseLabel": "Number of patients in settlement"
       }
      }
     },
     "localname": "Numberofpatientsinsettlement",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_OPSUMITMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPSUMIT [Member]",
        "label": "OPSUMIT [Member]",
        "terseLabel": "OPSUMIT"
       }
      }
     },
     "localname": "OPSUMITMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTC [Member]",
        "label": "OTC [Member]",
        "terseLabel": "OTC [Member]"
       }
      }
     },
     "localname": "OTCMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTHERNEUROSCIENCEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTHER NEUROSCIENCE [Member]",
        "label": "OTHER NEUROSCIENCE [Member]",
        "terseLabel": "OTHER NEUROSCIENCE"
       }
      }
     },
     "localname": "OTHERNEUROSCIENCEMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "label": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "terseLabel": "Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI"
       }
      }
     },
     "localname": "OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OneTimeFavorableTaxItemPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Favorable Tax Item,Percent",
        "label": "One Time Favorable Tax Item,Percent",
        "terseLabel": "Favorable tax event (percent)"
       }
      }
     },
     "localname": "OneTimeFavorableTaxItemPercent",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_OpioidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid",
        "label": "opioid [Member]",
        "terseLabel": "Opioid"
       }
      }
     },
     "localname": "OpioidMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OralCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Care [Member]",
        "label": "Oral Care [Member]",
        "terseLabel": "Oral Care"
       }
      }
     },
     "localname": "OralCareMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OrthopaedicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orthopaedics [Member]",
        "label": "Orthopaedics [Member]",
        "terseLabel": "Orthopaedics"
       }
      }
     },
     "localname": "OrthopaedicsMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "negatedTerseLabel": "Prior service cost amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "negatedTerseLabel": "Gain (loss) amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "OTHER IMMUNOLOGY"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense Net [Member]",
        "label": "Other Income Expense Net [Member]",
        "terseLabel": "Other (income) expense",
        "verboseLabel": "Other Income Expense Net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Infectious Diseases [Member]",
        "label": "Other Infectious Diseases [Member]",
        "terseLabel": "OTHER INFECTIOUS DISEASES("
       }
      }
     },
     "localname": "OtherInfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherNonOperatingIncomeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non operating income expense percent to sales.",
        "label": "Other Non Operating Income Expense Percent To Sales",
        "terseLabel": "Other (income) expense, net percent to sales"
       }
      }
     },
     "localname": "OtherNonOperatingIncomeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "OTHER ONCOLOGY"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "label": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "terseLabel": "PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA"
       }
      }
     },
     "localname": "PREZISTAPREZCOBIXREZOLSTASYMTUZAMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents And Trademarks [Member]",
        "label": "Patents And Trademarks [Member]",
        "terseLabel": "Patents And Trademarks"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PaymentsForRestructuringNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Restructuring, Net",
        "label": "Payments for Restructuring, Net",
        "negatedTerseLabel": "Cash settlements"
       }
      }
     },
     "localname": "PaymentsForRestructuringNet",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_PelvicMeshesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pelvic meshes.",
        "label": "Pelvic Meshes [Member]",
        "terseLabel": "Pelvic Meshes"
       }
      }
     },
     "localname": "PelvicMeshesMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PercentageChangeInOperatingIncomeLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in operating income loss.",
        "label": "Percentage Change in Operating Income Loss",
        "terseLabel": "Percentage Change in Operating Income Loss"
       }
      }
     },
     "localname": "PercentageChangeInOperatingIncomeLoss",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesByGeographicArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by geographic area.",
        "label": "Percentage Change In Sales By Geographic Area",
        "terseLabel": "Percentage Change In Sales By Geographic Area"
       }
      }
     },
     "localname": "PercentageChangeInSalesByGeographicArea",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesBySegmentOfBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by segment of business.",
        "label": "Percentage Change In Sales By Segment Of Business",
        "terseLabel": "Percent Change (as a percent)"
       }
      }
     },
     "localname": "PercentageChangeInSalesBySegmentOfBusiness",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical.",
        "label": "Pharmaceutical [Member]",
        "terseLabel": "PHARMACEUTICAL(1)"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PhysiomeshMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physiomesh [Member]",
        "label": "Physiomesh [Member]",
        "terseLabel": "Physiomesh"
       }
      }
     },
     "localname": "PhysiomeshMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PinnacleAcetabularCupSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Acetabular cup system.",
        "label": "Pinnacle Acetabular Cup System [Member]",
        "terseLabel": "Pinnacle Acetabular Cup System"
       }
      }
     },
     "localname": "PinnacleAcetabularCupSystemMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "label": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "verboseLabel": "Proceeds from the exercise of stock options/employee withholding tax on stock awards, net"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProductLiabilityContingencyNumberOfClaimant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability contingency number of claimant.",
        "label": "Product Liability Contingency Number Of Claimant",
        "terseLabel": "Product liability contingency, number of claimants"
       }
      }
     },
     "localname": "ProductLiabilityContingencyNumberOfClaimant",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_PulmonaryHypertensionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pulmonary Hypertension [Member]",
        "label": "Pulmonary Hypertension [Member]",
        "terseLabel": "Pulmonary Hypertension"
       }
      }
     },
     "localname": "PulmonaryHypertensionMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PurchasedInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased In-Process Research And Development [Member]",
        "label": "Purchased In-Process Research And Development [Member]",
        "terseLabel": "Purchased In-Process Research And Development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RISPERDALCONSTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RISPERDAL CONSTA [Member]",
        "label": "RISPERDAL CONSTA [Member]",
        "terseLabel": "RISPERDAL CONSTA"
       }
      }
     },
     "localname": "RISPERDALCONSTAMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RasmussenInstrumentsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rasmussen Instruments, LLC",
        "label": "Rasmussen Instruments, LLC [Member]",
        "terseLabel": "Rasmussen Instruments, LLC"
       }
      }
     },
     "localname": "RasmussenInstrumentsLLCMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member]",
        "label": "Remicade [Member]",
        "terseLabel": "REMICADE"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense excluding acquired in process cost percent to sales.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost Percent To Sales",
        "terseLabel": "Research and development expense percent to sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ResearchAndDevelopmentInProcessPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "research and development in process percent to sales",
        "label": "Research and development in process percent to sales",
        "terseLabel": "In-process research and development percent to sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessPercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RestructuringandRelatedCostExpectedFutureSavings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Expected Future Savings",
        "label": "Restructuring and Related Cost, Expected Future Savings",
        "terseLabel": "Cost savings expected"
       }
      }
     },
     "localname": "RestructuringandRelatedCostExpectedFutureSavings",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_Restructuringchargepercenttosales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring charge percent to sales",
        "label": "Restructuring charge percent to sales",
        "terseLabel": "Restructuring charge percent to sales"
       }
      }
     },
     "localname": "Restructuringchargepercenttosales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RisperdalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risperdal.",
        "label": "Risperdal [Member]",
        "terseLabel": "Risperdal"
       }
      }
     },
     "localname": "RisperdalMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SPINEOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINE &amp; OTHER [Member]",
        "label": "SPINE &amp; OTHER [Member]",
        "terseLabel": "SPINE, SPORTS &amp; OTHER"
       }
      }
     },
     "localname": "SPINEOTHERMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SURGICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SURGICAL [Member]",
        "label": "SURGICAL [Member]",
        "terseLabel": "SURGICAL"
       }
      }
     },
     "localname": "SURGICALMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SalesBySegmentOfBusinessTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales by segment of business.",
        "label": "Sales By Segment Of Business [Table Text Block]",
        "terseLabel": "Sales By Segment Of Business"
       }
      }
     },
     "localname": "SalesBySegmentOfBusinessTableTextBlock",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_SalesRevenueGoodsNetPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales revenue goods net percentage to sales.",
        "label": "Sales Revenue Goods Net Percent To Sales",
        "terseLabel": "Sales to customers percent to sales"
       }
      }
     },
     "localname": "SalesRevenueGoodsNetPercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "label": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "label": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "terseLabel": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SellingGeneralAndAdministrativeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling general and administrative expense percent to sales.",
        "label": "Selling General And Administrative Expense Percent To Sales",
        "terseLabel": "Selling marketing and administrative expenses percent to sales"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.",
        "label": "Shares Which Could Be Repurchased Under Treasury Stock Method",
        "negatedTerseLabel": "Less: shares which could be repurchased under treasury stock method"
       }
      }
     },
     "localname": "SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_SimponiSimponiAriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi/Simponi Aria [Member]",
        "label": "Simponi/Simponi Aria [Member]",
        "terseLabel": "SIMPONI / SIMPONI ARIA"
       }
      }
     },
     "localname": "SimponiSimponiAriaMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_StelaraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stelara [Member]",
        "label": "Stelara [Member]",
        "terseLabel": "STELARA"
       }
      }
     },
     "localname": "StelaraMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SupplyChainMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Chain",
        "label": "Supply Chain [Member]",
        "terseLabel": "Supply Chain"
       }
      }
     },
     "localname": "SupplyChainMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgeryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgery [Member]",
        "label": "Surgery [Member]",
        "terseLabel": "Surgery"
       }
      }
     },
     "localname": "SurgeryMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgicalMeshProductsMarketingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Mesh Products Marketing",
        "label": "Surgical Mesh Products Marketing [Member]",
        "terseLabel": "Surgical Mesh Products Marketing"
       }
      }
     },
     "localname": "SurgicalMeshProductsMarketingMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TRAUMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRAUMA [Member]",
        "label": "TRAUMA [Member]",
        "terseLabel": "TRAUMA"
       }
      }
     },
     "localname": "TRAUMAMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TalcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Talc [Member]",
        "label": "Talc [Member]",
        "terseLabel": "Talc"
       }
      }
     },
     "localname": "TalcMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfaya",
        "label": "Tremfya [Member]",
        "terseLabel": "TREMFYA"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UNITEDSTATESExportsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES Exports [Member]",
        "label": "UNITED STATES Exports [Member]",
        "terseLabel": "U.S. Exports"
       }
      }
     },
     "localname": "UNITEDSTATESExportsMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UPTRAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPTRAVI [Member]",
        "label": "UPTRAVI [Member]",
        "terseLabel": "UPTRAVI"
       }
      }
     },
     "localname": "UPTRAVIMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_VisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision[Member]",
        "label": "Vision [Member]",
        "terseLabel": "Vision"
       }
      }
     },
     "localname": "VisionMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WesternHemisphereExcludingUSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Western Hemisphere, excluding U.S. [Member]",
        "label": "Western Hemisphere, excluding U.S. [Member]",
        "terseLabel": "Western Hemisphere, excluding U.S."
       }
      }
     },
     "localname": "WesternHemisphereExcludingUSMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WomensHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Women's Health [Member]",
        "label": "Women's Health [Member]",
        "terseLabel": "Women's Health"
       }
      }
     },
     "localname": "WomensHealthMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WoundCareandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound Care and Other [Member]",
        "label": "Wound Care and Other [Member]",
        "terseLabel": "Wound Care/Other"
       }
      }
     },
     "localname": "WoundCareandOtherMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_XareltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xarelto [Member]",
        "label": "Xarelto [Member]",
        "terseLabel": "XARELTO"
       }
      }
     },
     "localname": "XareltoMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ZYTIGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZYTIGA [Member]",
        "label": "ZYTIGA [Member]",
        "terseLabel": "ZYTIGA / abiraterone acetate"
       }
      }
     },
     "localname": "ZYTIGAMember",
     "nsuri": "http://www.jnj.com/20221002",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r132",
      "r186",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r206",
      "r210",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r336",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r132",
      "r186",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r206",
      "r210",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r336",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r55",
      "r58",
      "r130",
      "r131",
      "r345",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r317",
      "r319",
      "r320",
      "r321",
      "r344",
      "r365",
      "r463",
      "r468",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r653",
      "r706",
      "r709",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r317",
      "r319",
      "r320",
      "r321",
      "r344",
      "r365",
      "r463",
      "r468",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r653",
      "r706",
      "r709",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r213",
      "r319",
      "r320",
      "r375",
      "r376",
      "r654",
      "r705",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r213",
      "r319",
      "r320",
      "r375",
      "r376",
      "r654",
      "r705",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r299",
      "r317",
      "r319",
      "r320",
      "r321",
      "r344",
      "r365",
      "r404",
      "r463",
      "r468",
      "r471",
      "r472",
      "r473",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r653",
      "r706",
      "r709",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r299",
      "r317",
      "r319",
      "r320",
      "r321",
      "r344",
      "r365",
      "r404",
      "r463",
      "r468",
      "r471",
      "r472",
      "r473",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r653",
      "r706",
      "r709",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r57",
      "r58",
      "r130",
      "r131",
      "r345",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r214",
      "r215",
      "r375",
      "r377",
      "r708",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r375",
      "r377",
      "r708",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r620"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r219",
      "r220"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, trade, less allowances $201 (2021, $230)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r23",
      "r665",
      "r691"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Accrued taxes on income (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r25",
      "r665",
      "r691"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term taxes payable (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r68",
      "r74",
      "r83",
      "r84",
      "r85",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r15",
      "r295"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r74",
      "r83",
      "r84",
      "r85",
      "r86",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r74",
      "r83",
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Accumulated Net Investment Gain (Loss) Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r71",
      "r73",
      "r74",
      "r693",
      "r714",
      "r717"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss) (Note 7)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r70",
      "r74",
      "r83",
      "r84",
      "r85",
      "r133",
      "r134",
      "r135",
      "r524",
      "r616",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r62",
      "r74",
      "r83",
      "r84",
      "r85",
      "r524",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r116",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net earnings to cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r32",
      "r221",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r116",
      "r280",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense of amortizable intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "negatedTerseLabel": "Accumulated other comprehensive income on derivatives, after tax"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r116",
      "r293"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset write-downs"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r19",
      "r126",
      "r194",
      "r201",
      "r208",
      "r248",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r337",
      "r339",
      "r340",
      "r521",
      "r525",
      "r589",
      "r618",
      "r620",
      "r663",
      "r690"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r39",
      "r126",
      "r248",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r337",
      "r339",
      "r340",
      "r521",
      "r525",
      "r589",
      "r618",
      "r620"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r226",
      "r259"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Available-for-sale Securities - Carrying Amount"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r229",
      "r232",
      "r685"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r229",
      "r231",
      "r684"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r229",
      "r233",
      "r686"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r229",
      "r233",
      "r682"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r229",
      "r230",
      "r683"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r225",
      "r227",
      "r259",
      "r668"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale Securities",
        "verboseLabel": "Available-for-sale Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-Sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r537",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits(1)"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r459",
      "r464",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r459",
      "r464",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r514",
      "r515",
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Business Exit Costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "verboseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r13",
      "r118"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Carrying Amount"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r112",
      "r118",
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "periodStartLabel": "Cash and Cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r112",
      "r596"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease)/Increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r124",
      "r126",
      "r155",
      "r159",
      "r160",
      "r162",
      "r164",
      "r172",
      "r173",
      "r174",
      "r248",
      "r326",
      "r331",
      "r332",
      "r333",
      "r339",
      "r340",
      "r363",
      "r364",
      "r367",
      "r368",
      "r370",
      "r589",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral already posted, aggregate fair value"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r48",
      "r671",
      "r697"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock Issued Amount",
        "verboseLabel": "Common Stock, Par Value $1.00"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value per share (per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r620"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock \u2014 par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r79",
      "r81",
      "r82",
      "r92",
      "r675",
      "r701"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r91",
      "r101",
      "r674",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "verboseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r405",
      "r453",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities(1)"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate, Non-Segment"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r97",
      "r654"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r405",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross Currency Interest Rate Contract",
        "verboseLabel": "Cross currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DamagesFromProductDefectsMember": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk of loss arises with respect to product defects and recalls, or improperly performed services which actually or allegedly resulted in damages suffered by the injured party, excluding major product liability matters.",
        "label": "Damages from Product Defects [Member]",
        "terseLabel": "Damages from Product Defects"
       }
      }
     },
     "localname": "DamagesFromProductDefectsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r21",
      "r23",
      "r24",
      "r125",
      "r132",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r611",
      "r664",
      "r666",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r341",
      "r359",
      "r360",
      "r609",
      "r611",
      "r612"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r45",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r46",
      "r125",
      "r132",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale and Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Available for Sale Securities Maturities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r127",
      "r492",
      "r501",
      "r502",
      "r503"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r479",
      "r480"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax benefit, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r480",
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r381",
      "r420",
      "r447",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Recognized actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r381",
      "r421",
      "r448",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Amortization of prior service cost/(credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r381",
      "r419",
      "r446",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r381",
      "r386",
      "r418",
      "r445",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r416",
      "r443",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "verboseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": {
     "auth_ref": [
      "r382",
      "r423",
      "r450"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment",
        "negatedLabel": "Curtailments and settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r384",
      "r417",
      "r444",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r116",
      "r189"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization of property and intangibles"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r52",
      "r60",
      "r541"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r53",
      "r54",
      "r58",
      "r586"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Total Net Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "auth_ref": [
      "r547",
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "terseLabel": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r51",
      "r58",
      "r59",
      "r541",
      "r635"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total Gross Assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r51",
      "r58",
      "r59",
      "r541",
      "r635"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total Gross Liabilities",
        "verboseLabel": "Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gain/(Loss) Recognized In Income on Derivative"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]",
        "verboseLabel": "Financial assets and liabilities at fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r58",
      "r538",
      "r542",
      "r549",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r535",
      "r538",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r535",
      "r538",
      "r549",
      "r556",
      "r557",
      "r562",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r568"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Amount of gain or (loss) reclassified from AOCI into income"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Assets, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r53",
      "r54",
      "r58",
      "r586"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Total Net Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r52",
      "r56",
      "r60",
      "r541"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r529",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r528",
      "r530",
      "r531",
      "r535",
      "r536",
      "r545",
      "r549",
      "r560",
      "r561",
      "r565",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.",
        "label": "Description of Reclassification of Cash Flow Hedge Gain (Loss)",
        "verboseLabel": "Reclassification of foreign exchange contracts into earnings, period"
       }
      }
     },
     "localname": "DescriptionOfReclassificationOfCashFlowHedgeGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r459",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r458",
      "r462",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan [Member]"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "NET EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r93",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r153",
      "r155",
      "r162",
      "r163",
      "r164",
      "r168",
      "r169",
      "r572",
      "r573",
      "r676",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (per share)",
        "verboseLabel": "Basic net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r93",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r155",
      "r162",
      "r163",
      "r164",
      "r168",
      "r169",
      "r572",
      "r573",
      "r676",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (per share)",
        "verboseLabel": "Diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "verboseLabel": "Reconciliation of basic net earnings per share to diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Worldwide effective income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r482",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Effective income tax rate, impairment losses, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and employee related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r670",
      "r698"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Employee-related Liabilities",
        "verboseLabel": "Employee related obligations (Note 6)"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r83",
      "r84",
      "r85",
      "r133",
      "r134",
      "r135",
      "r139",
      "r147",
      "r149",
      "r171",
      "r249",
      "r370",
      "r371",
      "r474",
      "r475",
      "r476",
      "r494",
      "r495",
      "r571",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605",
      "r616",
      "r710",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity, Fair Value Adjustment",
        "terseLabel": "Changes in Fair Value Reflected in Net Income"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r9",
      "r22",
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Available-for-sale Securities, Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r244",
      "r689",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r350",
      "r359",
      "r360",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r577",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r577",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r577",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "verboseLabel": "Financial Liabilities not Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r350",
      "r359",
      "r360",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r453",
      "r578",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Fair Value, Hierarchy"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r350",
      "r359",
      "r360",
      "r577",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r350",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r350",
      "r405",
      "r407",
      "r412",
      "r453",
      "r578",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted prices in active markets for identical assets and liabilities Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r350",
      "r359",
      "r360",
      "r405",
      "r407",
      "r412",
      "r453",
      "r578",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant other observable inputs Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r350",
      "r359",
      "r360",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r453",
      "r578",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r350",
      "r359",
      "r360",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r453",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r537",
      "r545",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r237",
      "r240",
      "r245",
      "r246",
      "r247",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r358",
      "r369",
      "r569",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Liabilities"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Finite-Lived Intangible Assets, Weighted-Average Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r17",
      "r286"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Intangible Asset Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r281",
      "r283",
      "r286",
      "r290",
      "r655",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r286",
      "r659"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r281",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r286",
      "r655"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Intangible assets with definite lives:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Foreign exchange rate"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r58",
      "r405",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Forward foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r458",
      "r462",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan [Member]"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Gain (loss) on disposition of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Net gain on sale of assets/businesses"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r16",
      "r266",
      "r267",
      "r274",
      "r278",
      "r620",
      "r662"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill End of Period",
        "periodStartLabel": "Goodwill Beginning of Period",
        "terseLabel": "Goodwill (Note 3)"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r268",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, related to acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Currency translation/Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r96",
      "r126",
      "r194",
      "r200",
      "r204",
      "r207",
      "r210",
      "r248",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r335",
      "r337",
      "r339",
      "r340",
      "r589"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r558"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r535",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r222",
      "r234",
      "r252",
      "r256"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "totalLabel": "Held-to-maturity Securities - Carrying Amount"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r236",
      "r239"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
        "negatedLabel": "Held-to-maturity Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesClassifiedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesClassifiedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r235",
      "r238",
      "r668"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Held-to-maturity Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldtomaturitySecuritiesMember": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as held-to-maturity.",
        "label": "Held-to-Maturity Securities [Member]",
        "terseLabel": "Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r116",
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r89",
      "r194",
      "r200",
      "r204",
      "r207",
      "r210",
      "r660",
      "r672",
      "r680",
      "r703"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings before provision for taxes on income",
        "verboseLabel": "Worldwide income before tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r459",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r297",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]",
        "verboseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r484",
      "r486",
      "r488",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r483",
      "r487",
      "r491",
      "r499",
      "r505",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r129",
      "r148",
      "r149",
      "r192",
      "r481",
      "r500",
      "r506",
      "r704"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for taxes on income (Note 5)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxes": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.",
        "label": "Increase (Decrease) in Income Taxes",
        "terseLabel": "Incremental tax costs related to restructuring"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Decrease in other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Decrease in other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r164",
      "r470"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Potential shares exercisable under stock option plans"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r282",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets with indefinite lives:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r282",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r279",
      "r284"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Total intangible assets - net",
        "verboseLabel": "Intangible assets, net (Note 3)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r87",
      "r188",
      "r608",
      "r610",
      "r678"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net of portion capitalized"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r58",
      "r405",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r33",
      "r264"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r38",
      "r620"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories (Note 2)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r38",
      "r264"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "verboseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r34",
      "r264"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Goods in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r99",
      "r187"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r126",
      "r202",
      "r248",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r335",
      "r337",
      "r339",
      "r340",
      "r522",
      "r525",
      "r526",
      "r589",
      "r618",
      "r619"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r126",
      "r248",
      "r589",
      "r620",
      "r667",
      "r695"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r44",
      "r126",
      "r248",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r335",
      "r337",
      "r339",
      "r340",
      "r522",
      "r525",
      "r526",
      "r589",
      "r618",
      "r619",
      "r620"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-Current Debt",
        "verboseLabel": "Long-term debt (Note 4)"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities [Abstract]",
        "terseLabel": "Non-Current Debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.",
        "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted average interest rate on non-current debt"
       }
      }
     },
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "verboseLabel": "Product Liability Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r315",
      "r316",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r315",
      "r316",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Litigation contingency"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r317",
      "r319",
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss contingency, estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r316",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period",
        "terseLabel": "Marketable Securities, Noncurrent"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Maximum length of time for hedge exposure"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r6",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "verboseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH USED BY FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH USED BY INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r112",
      "r114",
      "r117"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r77",
      "r80",
      "r85",
      "r90",
      "r117",
      "r126",
      "r138",
      "r142",
      "r143",
      "r144",
      "r145",
      "r148",
      "r149",
      "r161",
      "r194",
      "r200",
      "r204",
      "r207",
      "r210",
      "r248",
      "r326",
      "r327",
      "r328",
      "r331",
      "r332",
      "r333",
      "r335",
      "r337",
      "r339",
      "r340",
      "r573",
      "r589",
      "r673",
      "r699"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net earnings",
        "terseLabel": "Net earnings",
        "totalLabel": "Net earnings"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r2",
      "r136",
      "r137",
      "r140",
      "r141",
      "r150",
      "r151",
      "r152",
      "r223",
      "r224",
      "r250",
      "r251",
      "r496",
      "r497",
      "r498",
      "r570",
      "r574",
      "r575",
      "r576",
      "r590",
      "r591",
      "r592",
      "r613",
      "r614",
      "r615",
      "r617",
      "r656",
      "r657",
      "r658",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New and Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r120",
      "r121",
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "totalLabel": "Net cash paid for acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r120",
      "r121",
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "verboseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r120",
      "r121",
      "r122"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Fair value of liabilities assumed and noncontrolling interests"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r194",
      "r200",
      "r204",
      "r207",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "verboseLabel": "Total Segment Operating Income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Non Current Other Assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]",
        "terseLabel": "Employee benefit plans:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]",
        "terseLabel": "Derivatives &amp; hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r61",
      "r71",
      "r593",
      "r594",
      "r597"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r65",
      "r66",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r63",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Derivatives &amp; Hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r63",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r71",
      "r75"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "auth_ref": [
      "r64",
      "r71",
      "r546",
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "verboseLabel": "Amount of gain or (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r64",
      "r71",
      "r546",
      "r551",
      "r564"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain/(Loss) Recognized In Accumulated OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r61",
      "r72",
      "r595",
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r78",
      "r81",
      "r83",
      "r84",
      "r86",
      "r91",
      "r370",
      "r598",
      "r603",
      "r605",
      "r674",
      "r700"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Net change",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r69",
      "r72",
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r71",
      "r75",
      "r76",
      "r243"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r65",
      "r71"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r66",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Customer relationships and other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of items that represent other investments not readily marketable, including description of investment, fair value, and value as measured by quoted value method.",
        "label": "Other Investment Not Readily Marketable [Axis]",
        "terseLabel": "Other Investment Not Readily Marketable [Axis]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Investment Not Readily Marketable [Line Items]",
        "terseLabel": "Other Investment Not Readily Marketable [Line Items]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the investment category or actual investment title.",
        "label": "Other Investment Not Readily Marketable, Name [Domain]",
        "terseLabel": "Other Investment Not Readily Marketable, Name [Domain]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableTable": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the information about other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.",
        "label": "Other Investment Not Readily Marketable [Table]",
        "terseLabel": "Other Investment Not Readily Marketable [Table]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r379",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r431",
      "r434",
      "r438",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "verboseLabel": "Other Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r302",
      "r303",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r103",
      "r106"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other (primarily licenses and milestones)"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired (Note 10)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r404",
      "r406",
      "r412",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r453",
      "r455",
      "r456",
      "r457",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pensions and Other Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Payment for Pension Benefits",
        "terseLabel": "Contribution to pension plans"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r378",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r431",
      "r434",
      "r438",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "verboseLabel": "Retirement Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "verboseLabel": "Proceeds from the disposal of assets/businesses, net (Note 10)"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "verboseLabel": "Proceeds from short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r14",
      "r294"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r296",
      "r620",
      "r687",
      "r696"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r94",
      "r254"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Credit losses and accounts receivable allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Repayment of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r301",
      "r303",
      "r306",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r302",
      "r305",
      "r309",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring charges recorded to date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r302",
      "r305",
      "r309",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Restructuring estimated cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r116",
      "r300",
      "r307",
      "r309"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring (Note 12)",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r307",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r302",
      "r303",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r303",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Reserve balance ending",
        "periodStartLabel": "Reserve balance beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r303",
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Settled non cash"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r371",
      "r620",
      "r694",
      "r713",
      "r717"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r133",
      "r134",
      "r135",
      "r139",
      "r147",
      "r149",
      "r249",
      "r474",
      "r475",
      "r476",
      "r494",
      "r495",
      "r571",
      "r710",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r434",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r458",
      "r462",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r434",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r458",
      "r462",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r431",
      "r434",
      "r438",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r378",
      "r379",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r431",
      "r434",
      "r438",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r185",
      "r186",
      "r199",
      "r205",
      "r206",
      "r213",
      "r214",
      "r217",
      "r374",
      "r375",
      "r654"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Sales",
        "terseLabel": "Sales to customers",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r74",
      "r603",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Equity Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r437",
      "r438",
      "r441",
      "r442",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r538",
      "r549",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Derivative Activity"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Financial Assets and Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r281",
      "r285",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r35",
      "r36",
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r548",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule of Effect of Derivatives not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r309",
      "r310",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r303",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r95",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r88",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r194",
      "r197",
      "r203",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r194",
      "r197",
      "r203",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Operating Profit by Segment of Business"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities that an institution sells and agrees to repurchase at a specified date for a specified price, net of any reductions or offsets.",
        "label": "Securities Loaned or Sold under Agreements to Repurchase [Member]",
        "terseLabel": "U.S. reverse repurchase agreements"
       }
      }
     },
     "localname": "SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r217",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r278",
      "r305",
      "r312",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]",
        "verboseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r194",
      "r198",
      "r204",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r216",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segments of Business and Geographic Areas"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingInformationRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]",
        "verboseLabel": "Sales by segment of business"
       }
      }
     },
     "localname": "SegmentReportingInformationRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentsGeographicalAreasAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments, Geographical Areas [Abstract]",
        "verboseLabel": "Sales by geographic area"
       }
      }
     },
     "localname": "SegmentsGeographicalAreasAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, marketing and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r20",
      "r620",
      "r664",
      "r692"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Current Debt",
        "verboseLabel": "Loans and notes payable"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Non-U.S. sovereign securities(1)"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r4",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r217",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r278",
      "r298",
      "r305",
      "r312",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Statement, Business Segments"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r124",
      "r126",
      "r155",
      "r159",
      "r160",
      "r162",
      "r164",
      "r172",
      "r173",
      "r174",
      "r248",
      "r326",
      "r331",
      "r332",
      "r333",
      "r339",
      "r340",
      "r363",
      "r364",
      "r367",
      "r368",
      "r370",
      "r589",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r50",
      "r83",
      "r84",
      "r85",
      "r133",
      "r134",
      "r135",
      "r139",
      "r147",
      "r149",
      "r171",
      "r249",
      "r370",
      "r371",
      "r474",
      "r475",
      "r476",
      "r494",
      "r495",
      "r571",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605",
      "r616",
      "r710",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r171",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r27",
      "r28",
      "r370",
      "r371",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Employee compensation and stock option plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r84",
      "r126",
      "r133",
      "r134",
      "r135",
      "r139",
      "r147",
      "r248",
      "r249",
      "r371",
      "r474",
      "r475",
      "r476",
      "r494",
      "r495",
      "r518",
      "r519",
      "r527",
      "r571",
      "r589",
      "r598",
      "r599",
      "r605",
      "r616",
      "r711",
      "r712"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r606",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r606",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r606",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r677"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supply network costs"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r237",
      "r240",
      "r245",
      "r246",
      "r247",
      "r358",
      "r369",
      "r569",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r49",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock Amount"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r49",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "verboseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r49",
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "verboseLabel": "Less: common stock held in treasury, at cost (502,961,000 and 490,878,000 shares)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r302",
      "r303",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringScheduleofRestructuringReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r405",
      "r681",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Gov't securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r478",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r154",
      "r164"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Average shares outstanding \u2014 diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "AVG. SHARES OUTSTANDING"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r153",
      "r164"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Average shares outstanding \u2014 basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6284393-111563"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r746": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r747": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r748": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r749": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580"
  },
  "r750": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r751": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r752": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r753": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r754": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r755": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r756": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r757": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r758": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0000200406-22-000086-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000200406-22-000086-xbrl.zip
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M[Y_3S6#K&YBE8Z"L56F_N7;A@5&RL-LNG_ELICSZCWC<YT2G?P!02P,$%
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M2VDA5Z=\YZI9]2POONDK>*/_ %!+ P04    " !:@%M5[_EK*_<%  #&)P
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M=7Q8!84(HXBS$+9X0I* DQ@F8<@#EH$($3U*I$A@?:W>[I5O52!&V_=(EJT
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MSMC7!<^8WFY)7>6*^HE%]C5Y<U(\6;#(<(^($\?'0422 U964+=3;V U[/2
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M?GHZ /YTL^U\]*WQZ2?'>F<,0N^^\RS:QCO\>/:!CM_<>CS>]M$MY94"KZ5
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MR >$9WGO\.&$T)**#3@]0"Z%K$K&6%EZ+\'P@.",[\5+>.)!XAE!$\ (R8"
MP:56QI!J1QT)6 \IW<;+Z3:7@\23,5M+LYR5P=#9:F]NJ1;)8E'^_ODS&%/<
M ^GXK 9]]O(.I/CRA9X_\MONP/GQYMG7WS[B(;%??K/'QMOS4_OP.0 7#[YX
MB1>/O?AYOL:OJ'*&TB-6$(38LPRUV9-P'1(%:K$7=W0OQ/C/[^A/G/J==_3\
MPMM<OF7/YW(^^.;^G3>^FS51$4E*6A/0L'8*ZA13'NFFDZ9G=W/DF[V[FS.8
MK^!N?F6G]R<17WX]W?PP/M:KEUX86#X[.?V=-_X7SY^_O&/')X\WQ__N97]K
M>%QZB?<O?_K71E'+*"JE9_0!")"[(!;+R4HO4)^/,RW /GO;=BO 6\_G+]ER
M?#X'HE_)9D_&/]\X^B)ZY32DN(_H2\34"F8U$.T*%)XYY6&F0YDHQ(%"WC<4
MX@4*Y;>@$"]0R+\/A<OWS5/@+C%AJQ!CY%A-,TG.G5.2%_<M/F/OOMZW^!O9
M>W7W+02AVDDH"$!REE:9G<DM^&!A>)[MVU[<KLO9OKUR!]XLVU_68P(M<9-A
M!VWXI<#-O \F4<WC+A2]OCOPAV7U)_\\GQ/1)X^?G!R/'[>7RU)?VQEOCDT_
MX=/CS?'#[=6+Z[>"#U*S:65[#PVRLE#.4Z T@IASK >#ST>]GS\^/YHKF[X\
M>V2G\[I3>S1?[0?[_+B?/+:%0-9J'+G81[ZU @HNL==8L_5$S;/XP4#V5BN]
M;P6:@M9R#Y"#&+321Y9K0!*TJ/?HUYCOWS(T#TXO)-?3)8%3B6.?58&&"CQ+
M>,/6QM(E-RFE]QU(\,6/23LQ")<%AF6,YE(2 5A Q.C1TK#8HL%J.CQ4WW+L
M[1Y2#B&VFC0J&^B(SEYFM60BRQ:]'1ZD.Q$GNP<:*L=A!8I[4XA!AA]W*%Y[
M"$Y=Y?I*BXM/Q%=5^+R\L( I8!XCI<<,7(4*.1I&X1:T<S@8?'9O#JX*LM@@
M)'<,+2KDZNC% JAKDC#D:#P8R*[/'%P5-)[92T3"H VZ Q;&7JAD<I'Q^X.!
MYCK-P56!D[J9\)"2K3>0H2,YQB$BPX#+&W:[OGF9PQJ*_L"LT25\I(:>2\ J
MO4//B60X[)1K ZLTQJF#P6?W0]%501: 4QYJ86CW#A$30N941HQ5S1U;/!C(
MKK%.=570\)!S 3(FR>-/)!KXI##\,P7O=HVST <T%%T5."VV$L?HX\9#S W[
MFUJUU'D&4@ZRR"5FNQZ3=K\PJ39%2T2E1H;Y@TOG(C8+]QZ'USTX5*^Y3K4#
M2#5+T=9KH@@\(*V=FLSR198>BQT>I'M1I[I^H'U(&8K#&M20(!>BD8Q+2U!M
MI&3!9\/E7#8"^S6-'R\7]?Z(/9I+_XSF2AF&HL@Z<Y8I:C 1PNN[ XL?BMX*
M/KV7U#@:Y4K $2@0X4A*E1L&SWXP^.S:'ET=9'4 UJP94FR :8@]T^S=P4JO
MUOK!0'9=]NCJH'%(,(1:*.8,2>9ZF,29/(4.P,_G)0X!FNNS1U<'#LT%AV/\
M\>81A!J7Z-YC%IIC4=(=K.%<_)BT^Q6FO=7,+46O.<T5IC05=)9,B'%HKUVL
MS%UV[.T!I) L%;/4M$"&.)>[5S?I0S%KPWAXD.[>'NT$:!O8@IIZ&$J&D@_A
MV>I 6QK$A.G9-/&^+ J_-"9=N@-_:-T?N\8@ =F@Y<%QJ"'4@$E2MUZO[PXL
M?BAZ._B$@J7G-CQ1!_>(@4 =B$,JJ:L=##Z[MT=7!9D -PJ6> P5(#H47^J]
M(1*G5"I?8U(Y&'MT5=" (52-1#"=:S?JTCTV!L]C( CE8*"Y3GMT5> TJ%6E
MN<Q];=:R8&XF5CQ('",2/?>N<?\&XTN%W3\RN=EK33E:23X$B!8T<TT@@D$2
M%+F^.W!8@_%5X5.T,"FAE!BAN,X2I:'EX0MH_+X>##Z['XRO##+V6#%H'FX.
M)(S\0FZ]20V)S7(Z&,BNL59Y1=#D&KR4@K$E@DYUKMB5I%PD]!;BX4!SK;7*
M*P*',_$8D*$%F:O64"3V7/H()^G:TB[V32]^3-K]KNYA2!P0L0D#3$T5>NA4
MLE %KR4>'JK77*N\?DB%!XYLS9(XU#+ #5TC1Y(66;T>'J1[4:N\?J +Y!ZD
MJ.0PS$%I,R$C]9ZZ!!; _5^$_^GF>'-F7PR4]//C,3 ]W,B1?;3=VMGVXZ=W
M^?N3TXO^7S\U_OJ*SR[@/]8'IZSVF$__L90-2'$J&\ZQ5>^0&PW5F:+.!2AC
M0.7$^[].=0EH7=7"U9YJ3-I),F5(@=EB2GF8A""MU%P.++9>/.DB??[\\H4$
M6&*G1IHPU S81X!)'>G0*D92HWI@ ;9+R*YL[7Z97;$C\Y"AT&9U7%O&#)1S
MDGR=_?A^+V3S$!?_/; M;ORJ-09LO:1""6IWCK',I&@^>_BS[W]X[3]65Q57
M*1>.(6O!V8]/$'/3&+/.N\HE'6)<7>B-\]/^B+?S\J].3[IMMU_;UGC\<DB0
M._:#'9T\F9]C(1$W5*'/F%/(PZ5+&)+><79=LUS0:CO B-LC%*\J%C%F+RVA
MPNS7 P&CEY!'!L546L^[. GB]\+Y\?EV<SSP^*@/.[[=S(/C?H+M8SM];/_8
M/&9Y#3!O5PY=.VEVOZ6#NJ '#Q"SP?"87+0V+5:@!6KA>5O^0:SXG&&IK0Q[
M5E\ZEZW]\WP6F'X8?\SS!B^SZ6<7W&AF3[K&W\SLU*Z V=H]E*:)1K8$#4C6
MZQ U+:!Q+&%)>WM?,/O^LY=X9;R[?7*\G5V>%S*>>4Y8QBTGF1L(FHN$A&-8
M*SECD[B .M9OP.2K1WSZF+N=GPT5=K009(9&5,_#0H<>P52DM5@TC$#!TBSK
M02!SUW1",A+?9N3"A2#3V@B-8*@2=!X,S;T:99YK1D 5%GFJU2X2VNZUUI!4
M'ALD[:7"2!"L1FIU#D9#YBL=%I)O.PWN'L_(M1=*RID,JK+$$9?6M%9G 3^P
MR'S;R7/W>):4YJ%S*0LK5' $=DV:6X?&6'7_*U_[HQBO;&(F,F.IC0@#"*;Q
M4S.*)4:+&6A)K3'W1#%>%3*::\_4,U.KT*5BGQ-E6F-KU0F7U&%Q3Q3CE<VV
M#/DNM:E2)PAY($.]4I)$+1C!DLYRV]-E [L?JZ@T#H*>,E;(4H:9#F ]%=4X
MOO>2M,<^SUSO'NB4 3PRF40$M((CU;J1$&=K 1<P -X97_8'/KM83K<].SV?
M3_]ZL_W9<<:?GIS:YN'Q)S_V1P-3&S+E[)3[4J;;8A_*47*%!'&$8R4K 2/$
MW,&'W<N'@M+MTY/M]O;YZ3S+_.D(/SNU[=G7@]H+PZO%IF:Q1Q2'8G/1"%8*
MPX3'V+,M8/GC;\/K58CN_XN?+ 2>FH; SPVTV_!A,5,JLYFW:"%&E04LQ]KG
MI'=EL]-<(6"UK!:A->)8"HTTF&KRFF(Y%)1VG?2NK'=T[ @"(A!HGLK$(_-5
MH!JI\LB#"^CMO9=)[\H*_=C(? B]1@X-.E)&EV+$ 2WTN*#C7I[MFWCIK[\X
MZ?S3=/Q+^\U'K[74?X@9V\]X<_S%B-V/G_[%].'F^.'7=G3Q0;:/-D]^EHEY
M<_K??'1NSZ]\FY]K%XS]N9&Y_D-NS#5"U6:%"8:+(9FM_JC"[(B4<E@0O?>5
M;+\I[&Z?;,^^]+<>?#>3Y(&H" ^9&DPA6Q!M67L$Z1!3X26=PK9HDO_[94Z?
M_/ADO-KK]O.MM']CVB=4 F@=0AKYO 7T$E(+!7KK&)HNB/;_D5ZSPOP"SV<7
M/J?4/;NR]7W[&G<KVU_.$WOK0ZF7,/O;.4?B87VU 7?0*I4.B>W/Z^PKU6\F
MU1%'*L?9[[D; "I#BY[,I#9AIR7U+ET]Z5[3>S<=6PM'\<K% D-V)-'*P48R
MK[T$D071>U_)MGK279.\F)500Z4$--*X4:]> *5::#WQDG+XHDE^<SWI;MJN
M<RXZ%W3.0YMK*81%"A%0E/%[M071?O6D*]M?5WA,30C9:H8 G).4:+%4R356
MZ5X.B>VK)[W15+>A83@5 0P(L7:LE1$Z&65-TLNAE%^NS9/^DD8CGCX__F'P
M:#Y\#41^DP#['9]MD:47&*K%/8<^EP/,]?6S/9_WHE;),"QIOG2_/>!*]MV3
MO4?PUK!'Y Q0.PW-[JYSI[Z*9U@0V7=/NOUVHRO]_TVNUQY3+YBS)*BMHJ )
M\CQ#J@D761#]]]*KKDE_'UD?FN:Y;B [ H (^VS-,N2-JL0B!\7Z:_>L*^7W
MD?(MJ9@[E98=PLCL))Q;9<6H)1,>2IEF]:[[0O.=E&A4L WU,H^L39"SSN,&
M.;,,0]L]X\'4WE?ONI)]4YV2S#4#6 /DPA)CK=U+Y-2)E1=$]MV3;O6NBZ,_
MD7$:,8"A0NQUL#YU)K9:>C(ZF%R_>M>5]9?Z;T3'WDPQS6-Y:9C9H+TVGD?H
M>#\DUJ_>=:7\Q?[4"DUK1!.!G#)1,Z"A=^H\*T77_:F[Z@=P;4R_S=M'GQZ=
M_.N "S05 QA[->($A"(I2FI8, Q-TWE)LZY[0;E]LL\KU2_W+,K)N,<(%0WR
M\+"!FO8D?21TRHN:=%H.U1=A76\ ^:51"5S"2.X=3%0H9BP6([DR^<$L(ML?
MU[IJFUUS'H>F<<\:$#-TB,BDI1>@S.I#\AP2Y_? LZZ$WS7AI?=8+TY*2$/5
M>Y,PYUB;8Y'F)>JA%&E6Q[H?)-]-)1)3S4H^:%TANI)1+3ZE31]T3X<W_;0/
M,O[&.]:=4!UG#W.=!Q-1@ZB9I5M2!\TD.2QJJFDY5%\=ZWZ0W\%S3)8B=@(/
MRD/9U%;9F7+*\:!V^*V.=>7\LTY+:A5K'61'*.[<8D,"P48^PJ =$N=7Q[H2
M?M-RK:D5L<P&,2!EZTX0$&L1ZNU02C0[=*Q_M)OW@=)])P4:ZD&(DN<A8Z#$
M.(^?9F.6X-6%ES0%M4^V<27]/I,><T-WM!"0(1"RQY'U%4USPAX.;Z_KM9%O
M];,+"H/02F/+,?CL&SP$/JM3C$/R.U@ 7U 8+,3/KH/ _K"_M2P5&FET!-5
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MZFO_IOT@OUH*AH"MC$Q/D&5$@>=.;%3&&QV,F-F?_DVKMMDUYQ,)E=!#*;4
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M:?R32"/%2IZZ025;TM+1&T25W>@B FZ!2+C*X :+]52ZJ)!ZH^?[??9;%]U
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M2E'M$6#VUBM<)*:&+= 0.0O0-?N'Y&X*)<"SCU@98J)!E(J<P(+EW,QK-ER
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M=W.2N35+H5JLE<$*L@M[IH8M]U+C$K8=K"%QL"&Q$Y? 0HDLIPJY ;8DTKS
M< NJH:;.JTM80^*&&0<PEI2ZCO\8$)DK24:+,&)EC!Q+Z;6QAL1!AL1.O(1
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M4B'AFM=8:IT&V)"T)$X-^G'!!SB@'SL,[\V@@X?@PO"DK/*A/"U,3APX+O@
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MG_#N\46%^>6??IO?_5BW(A_DZN46FNW$7'.L0@ <7<R:M7!9S*L:/:'OR;'
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M=##G$=JYJ?=Q*]J!RHH"JY%XZQ6SI:?7\(_<B^R1#*(S<2=C2+%K'TE'*8X
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MO++/G:0L$;,L!?'Z]6P0 N,!F'.T<Q/O5%Q-DB.G[CT+1Y=NBXB&XDY8E?P
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M2]D:&6J>))0E",>$<WND4! J>X)$:/5Y4A/Z=D*+JS4B="03(642!Q'3).2
M\0)JDH"9V!8(BWE):+#1ZTCH!QTS_6LOM!!NJZ?A-Y-?F.OP;J=[WLF&QAR:
M"Y/;@G5+Y@EKGQ>R/$TP!>*#JR@#</LC'B7,%D\'YQ%%K*HR6?/$@WBBK%!7
MF/[7/.V;+$G6A!=BK C%5"9AG!"#A;!GRRF24*)DPJ)HS7CA+G%U$/[:W4^
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MN%8\8'%/EW[M?: GCU24XGLDKO:J#,NRE,X:H^VGELN]ZW)I!$5:&^W'@::
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M^ZO<W%P2SZ( MQ[9F%M@/L_ 0J?FENI9DZCY6!]/ZVZKB2=9UN5K1LOK)3.
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MJ$$")0-?L@ <+,7!U=*Q\A-$>6(,38A-BV6-"->GI+U@"5X4#*DE>.D2/(M
M '^$L8EBG[. ^R2QB>T"2Y]I+4B$ (C8RDT6@: 7&")9KX(HRRN$\F@O:N5F
M[/XGTMXTQ!>CF1=;UZ56Q8M3Q6H.3,6$)[$@TM=$:EM$#_L\,,9/$D,TCA/,
M"+5G0=$&J@]UJ^'4?4NZU$*[2*&=Q4^:TT"3F/I&".83SK O[+F,7%/*0\D)
M8RZ='C<"Q%9(:&\$4(@N]0BW4=M=D9^F/;^?G;^*KK>@ .^;_+FV4^]M_;WW
M8>]H;^?0VVIM>X?_;!WL_+/_87OGX/"__X-A%+_V=CY]WCLZON&XI-]AS:XJ
M#N5U4B'3CCLC\M52E^D>-W\E,SW-#+)[3>#-XEY/V<.F['>(/G_(X&&WN[&7
M]:'9<S&T!P0M(Q#]Z-#5RDW>_7V_FX;X8F#DHGR_PW:6]X],WOT[R_/L$B:J
MQI2+PY1G\^6S2$)%Q%7L8Z-#>[@W\Z4QQ.<"15S'@0!'<>,-:9#'NX%U5'UU
MY7=1;F MOTN6W[F-F7%D5*28'U*I?(*P\IE"'!@JX5I*0HPDKGQZ] )#ZBN-
M#,;'>3\&3]5QK&<Z\?9C2;2Z1O'"==A\P2LF-1<DD3[5\(>$H?9EJ".?<4$%
MBNWF<N36!1%=I<RD6H97%(34,KQ\&9[%(<@P&O$8^V%H"T088WS0Q<C72AB#
MB4DD5^ZDR("NTDF1OT-\!\0A'Q@]'4JMDPS7!(M8PGV8T*U690M79?-5JY30
M(F$H]%6$D4\"R7R)E:V_J6F4,,U1A)PJXX^'(W5,9'7%>(%PI!;CY8OQ7&0$
M\P#3)/*Y/;::"$1\KH/$%U'")6>,,RU!C,-&A.J25<^#2'(C1=\4#?C0'^35
M(M1YGG4S2X3Z&+:51BEGO;.1:CLHZ7A04G&KIS^.:5CKN,7IN/FB50)+BC 7
M/I<ZM@>S<9\9;7P4Q0IA*A&.;!H?:03XT8>?U)&3U97EQT*56I:?7I9G\0HV
M)#8L(3XRB?*)CD)?T$#[@5$BC@(4P3>09=P(>!U!>1Z\HK*N/27:E<HORX%W
MSSO9T!@ ,.6A*)F$WHI?1R^U<_;$,9:=BH(')0%K)VV92F^^UE44,4U4&/IA
MJ,!)4XSZ/(F$SP1FBK-(13JVR]=!L$K+U[4TKQA^J:7Y6:1YKN(F#9,(,Q#D
M@$N?T,3XTJ[KBD306.)08>:242A;)6G^G2(N=06L=08K%17'E7-JM;8$M39?
M $OS)(P1HGYL" 6UAKC/I>0^U20)PD@'I6?6X(]7:W60976E>,'K0;44+U>*
MYW9/4H,YEX%/(NMJ!''@2ZFY3V0 2()%(I:V^D0#/7XY:/7"*^M5?$+-;_ZK
MHRGK %!JAVN9.FV^)I9  0M9J'V-XJ@\XD FBEF'BR4Z .HEX' 1VJ"D3E5Y
MP?*[*&A2R^]RY7>N)J=DVH0(^5%@R[ 0PWS&&7R5!!DID& *._G%N(Z8//6N
MZ-ZIWS=Y%P1&CHY3(W6@9#UP"!#/[D+<!M+5U?V6H<OF2THQHZ442>";*$ ^
MH93XDA+M"RI('$8)0R;8>(/C!A!SA1RL6H97%8O4,KQT&9[%(R(D@A,9^$ H
MZ1,N(I^I)/1#%<<:(Y,8&8,,\P9G=0[*2SC$I/:PGOL0DRF7JSX"8:'J[70>
MHB#* D)C/R3<%B!6V)>""S^B6(&:2P)&[1FO#;Y21S35LKRB"*66Y2>4Y5FH
M$C$94JVXGTB&[8;CT)=8*%^JT"01H@@' %7B!F'Q"LGR[Q YV;DC*;9"*U$=
M1UD+M/+3?+JMGJY]LV4HO.]SX 43@"=@G?P(1P@4'DI\%C/E$\("S<)86'OU
MAC7"NDC*2Q;M)TN5K45[::(]ES=+C%"21SZ33/@$$^-+'D1^$&'*#!:(A)$5
M;<97OJSW"XNZ3%:!RK!+5<NM#KJL%8R9S[BK-=L2--N/^?*R<<*TB /B,Q0I
M6]H-'+20)C[E =:,$&F0B[B@:)5J,-2"O**@I1;DIQ+D68@B):62X<"/8AWX
M)$',YP(C/R'V#&B$03^SC3>T$:-52C3['<(MY>&QCTV5K?VOYSA!=CI@7"NR
M)2BR^6*S)C1"<ZE\EH3V$"7-?9E@T&8LH80H(&>([6GV?*6.4*K%>$4122W&
M3R/&<]7=0B(8P<0GV,9 #0]]SA/J,XFXDG&,-2U/LX]6:E/>;[F=9\G;>.I#
MA>I#A>Z[JZ%6RHM3RO.5<[$F$4JX\C5CR"<QIKX@+/)1'),@$296!%NE'#0H
M?G3^8!WO65W)7<)^I%IR%RFYLW!*&6QHP(R/0)_ZA,7<9XI)/XQ%2 *#$Z,=
MG(H;_/'5Y^H S\..0LVZW;3?-?8L(5MT[BT\ 7TW/05B4:U$(;3<C)I?:&,Y
M=OZJ2%_UTL[_;O3S@9E5%U,SM=73U^:IU@OWT OS!699%"::B]"G. C!UX(_
M+$AB/P$-SP(9J] HRR\S"F$-F? A)JMFPJ4RX:QQ2A(64,2P#]"2^B04D2]0
M%/E::T3"D&-P_V]EPM\A2^&P+7+3SCK:Y,7H]'#S[T':'_[:F=GWQ;F/F\;5
M0[B/.#.[GK)?/S/[D9A,IQ?/!\PR^]9,??><W.'7WKG(O0O1&1CO/^^R/A]-
M[J1V(8[37NO=358HZQW:KGT4^7Y^V+=9?E]LQR:OKIRFH+9+][!+G_O-ZW;I
M0N]^(?J?]YT3W+F09^=GQT=;\-X=TCQ[USG&Q\'^D4(P9NC;3KA_M$?M_YL_
M3H-6APWW/WT3$>+$Z,"G)+!FS9YXB"CR0\;"6!FB3$#OAC"W,-&OQ<UJ)EI'
M)DH"R36RJQ]1PGT";KPOL=&^#)3A.$P2'H?@N&\&P0WX:.8'[]SD7F&IZOTA
M!OUVEH,RU-ZM'.AN+9Z ^1RG%5OC+MTO%E1SY)-S)&IM?<.8\@@XSS>$V!.I
M!?:9"02H-8P31I$27-^AUFYDJF68Q9JIUHBIJ(X(B6+0:\2FG]DR(TS%8"LI
M>(-Q& =!DM@\TA '#0!]]O_WT'<EK[WVTJ(8/%C1_6*,._PI2^ZYWM3LN*+L
M&#9/@1T)3HP1?F"BQ"<JQL"8D@!C&LP3P@S#[*$Z[A=7.VM^>@'\)'D0&B60
MKZF(?$*#R.?V0 R4X$394S"D#FSA?(1X@Y'P0>IMLC#@'.5%1F8?G4*V<I&T
M^V=>W#3$U0[5/$/FQ90N<EYCO8B[4"4TN]D&"4H)B_V "P;(.R ^%V"D@'PF
M,E0C3;73(GA>>]2IK2]&>!>5?%$+[S*%=ZX4K%U-53SQP9,!"!#&TI=(8UO9
M.5  *7EH SFK)KR_P^K:EE*#[J J9>(VV]AS '/3-KTBO3#C.FR=K"C^K/(Q
MXGIG\,,G^H\G02@%C!,^W;"U<$1EE]/_=IK&Y8;##T#@ENGO)T?BJE:&BU.&
M\W7M$RRBA 2Q+VFLP;\VX ]) #:A"1(B5:(PLXFDM('Y_+[A.=&K4TC74<)_
M'<;4$KYZ$CZWGSA").1"^1Q97R6!3X()Y-/(,"E)* +-0<+#1D#G]^$]BX3_
M#JFF!Z8OX$?M&9'WH-/U7N*U"+.,R+9346U*TVV;)%5IO1EQ@<ILOO1]R"BH
ML9CX 27$)P$X<#(&98:I%J&(# ^P/5H,QPV.'EV-L@Z]K*Y +RKT4@OTTPKT
MW'88G6AL(O _;%4V8J3P)6;&)SP&AX3&81 J*]  3Z+?.1SS;*F7'TQ1O+)Q
MF$D"9MMTM)?VO'YN1#'(APU/].&.HN_=[G4L=2'VJ.K(U%)LO0B[.*D]_<DB
M;';5W'Z7-G$S@#'3UH_/06OW2WM_&_[%>ZC9W0N:/[Z'3?SN>[/#4'/KFP1R
M!V&8^(FVAU]H'?I24P7.2<P#0KD0 F^\H0%N\ C=N 3KMF<]3Q9)S6QKQ&RM
MRV_$ "/),/:-X=HG<13YG$6)SXR06@9(&DHWWA >-%C,;F:VQR_O_][!J&=P
MU*Y):;VHMG@AG2U(P 40#4F?:A79@Y\U")@A/J,F8:%4A@7@F!'40/6)'R]9
M?A?EE]7RNUSYG?7#<$(9(YSZ4E#DDX!@F]$B_9@S0V-A#',9+;P1<+Y"\KN@
M4/%Z57DJ;MV$6@>1UP&;.)U6T6_'T6VOISH#.W,?L]SV8JO?SU,YZ-L*Z$>9
MK70'_<BS#G3_= ]Z!&BTCDLM4!_.GP$2ASB, @5X)D*Q3Q2/?:8CY <)4D!@
MHV0H-][$I$$?KP_K.//JRORB\$PM\ZLG\W,8*$0DCB/F8ZQ YGD4^EQ%L2\$
M#V,0>QKAQ,E\@%?IX)_?O=*EBP5.8Z+_>0P:JDM@UB4P%U0"<ZNGY]5^K<(7
MI<);V_.GH&"4)#0.$I]10&PD,=@7W# _4F'") T"2J.--RBF#83)"OFQ=1QJ
M17%;+<Y/*<ZSB(Q*Q70881N00G:?E? E$Z$?\X00)F,3$P3BS' C>/PA HL.
M2_WEH/QHN0C^C%X]U98R%MD_O3AA5\S,&,_NH2B\?F9K7199)]5N\\6[M"=Z
M*@6<Y0K1N!)[UU>_IH93M4EPB1W/LR*UT__*'4J;7IC7EZGNMT<B//5@.6>O
M@LDC0D(?!OW;'UF5J4,S:X%3?VUOG;!303@QD32,2!+%@NE8(,28H80B+.0W
M;(L.E0^U\]$(SL6I\65NQ'=?)## 5Z)S*8;%QE_7YJ&;]OR9>9^=LN>9F"-W
M:%^6N-JI0*&;YND>]'SS+YG#B&]CN04_]M23]'[_G];A?LO[;]$]?^V-OFVU
MMKW#SW\?[FWO;1WL[1RN_##>[D._/^QM;QWM0,^/X)_F3NOHT-M_Y^UL';3V
M6KNK/X8_/O?$0*>@]%Y[VUFG(_*B(DN9VF'SG)III^..U-ZY4@8LPD>3EU>]
MK2X8D/YL9L"TG(K\%$2UGYV_H@ZI.9LP48 Y( EK?SKBO#"O1A]>Z[0X[XCA
MJ[3G>NP>>EVU56E-*_(S-LC-:7FYT@:<;Q)$K4*HX@/5BRM=L>ETQ8QA+*]1
MLADS?.OE8!/]XC4:TE]Z\J[.\LWH%UM]^KXRT-;UO"YG7J-[M?J3>-E*[")A
MBZVB^G-_$=UG_*6F7J49>)=:#\L[:J>Y]CX-1 []\W9ZVNB'%$I]0"W97[AU
M+29R7_4S"7.'&PY"6>=X$7RUIK,!%MYVRDT%^$:'X,3?9X/62YV.$7.$8^9
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M1>0F--:><@0@@P@2F*;'!5M@ AO05',@U'KB="(?1G.^?VG3O310?8@:]F]
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MI<S.O)5U,5V;73)_F@WRYC?A*W"_?[C7W;?>:69U,&!S0SXF4()[Q YX8O-
M15!,T"3/K\CT*_)\*:#^.*[; O4'@'I-LJ. N72.@[0H3Y$6#+07%"@Q"@<1
MHL\!6MZ0MIM/P=]6!DLVPO4P(VT5PIH+84T/ =!4,Z1L!*UR$U$CDY;"8I52
MYED24%Q(N[*.T2R,5:+*#<;VXSL;"K;GA>UZ@V!KE"+8@+-");O#*S LEQE9
M%:14C$CMK\X6*]A>"FP_Z.3'@NW[Q';=IT!=E)1A"E*9/-W5"K!..L!11&5U
M(FPJ5]8I;4A7EH+M!OH4"K8;@NUZO9^+W'+J 3F)@7EN0?F P!B+C4 .V<A6
MUKD4S<#V4\MG*/,#%RM;H>*E*;+J^T)5MZ6J]I3[P!NN#<$6:+(U@$E-00?O
M@2KE/0U!(9/5$*2;X? LH8T&N@\*SAN(\WKAF2/1&2;!A,B H:R28,;3#Z0E
MDD8%B5;6L9A%)2DX;S#.&Y2M4' ^/YQ/C0UTG&)"'> *YQXI,%IH2/C60E"N
MO3?)]% %YTN*\P:E*A2<SQ'G-7DNL P>20;90 -&4 0MF *)-4=<>1LT75D7
MM$P/+.=8]',\!?]41:[I[KYCUU:WHM>+<IOBJFJ8J^KJ<??]TV/P@S%<G+[(
MN5O)N>DI:!B%Z$3$H(B(R6Y%)EFP(0+AV#,LD8U5>LLJ8\5#M:3P?AP/56F"
M<%<$3TVY)LA'S4!%SH%%9D&C&"#M'6?,$6JM7UFGN"$IM06_R^%Y*N+Y/L!=
M=S<IC#!5+(+CW@"3+H(E6(/T- H7</0YBX6L$EIJ8Y84WH_C<"KB^:X(KA>\
M:.TMB0($KK+&*<DA(@E61XJUIU1:EQ3L*^9=%$=2.<=BG>,I.))>7.5"F@6I
M5XJLQMWV/V:ZQ69+X\<L]+I"_!;->OYRV4TYOI1R-'!#P+(<X&$>@?(< V>1
MQB"H3MN9S.95=$5J5NDRL32 GGMU5P'T0P&Z[@>+3/L@) B"!3#%%!B.*01D
MA#.8$TM1!C3E31H#,R= %X5C616.>5>H%7YZ('ZJN_(T]I9%C '3D!0.[3Q8
M'WS6/QSFQBG,JC'AJUB5OE;+K'',NRZM(/JA$%W3."@RDDIGP;C<?EPX!-8&
M#(IG*]%Y+GPU]'I5BR;9$,7%5\XQFXOO][&QO9#^]=V_U_\O_;@\UW</H@N)
M\X8/3\<DT_%N"*W.8!RJ_D4O!OW1H-?U9AQ\ZV6W;_JN:WJMW7%Z(8]C^-;8
MZ":W4]WZU[4;#'T8YG7KF9-1>';YR_/+P83=?G5QU8>>'YOAQVX?)FA\EO!6
MQVGU?9/#SS]W_?CPF99KA) L8"[<JA=?/#F*URK94R./BT^J-8VN/XS6\/^L
MW,QM>U?O;+6:CR&,]PY#:VR^M-)#'-QXU.KV6X/KT_^2A&REHZW8S>(P_=H=
M^M9_3\TP[7?K<QB&EAFE-_5Z@\^CZLU9SVZ9OL^_X-76,(Q.TM>D,Z8;:;T<
M#-.E]%LO3H?#T'=GK;UANI->E9K]K/6/QF?=75S_Y>5_=_7?YI<L3UCPCV[[
MZ*]/G:/.<6?/9=WA4_O]G]T.>8,ZY.71_OMMELZ5=(>WW;KNT'ZU?=9Y_X:T
MR3[NG&?=X<V7_>-M>K"9KO-]YW#_Z##=;](=7OT9VR_0YZPWM'<13>_]W#G3
MZ. _A\@=_]4W[_7ISO&?1^F>V<[>]OG!T?Z7=']H__W+PS;YZS"MTZ=]LHT[
M1]NT_7Z;_^=\B[0W/CBB;$0. Z$JEYO9"$I*!5Z%0)(EH9$*2?50T^GIK02X
M7G[T\A-\F^?Q<=+$RO/8^.>1=MY\< ;A(+0!3ET>P!4QZ)AK)EC PBHOHTS&
M[15549>/X_/6UO%);W"6!/?%T*16-35I$3CSQB.@RH/ZF ]J6H^-#YC98+TB
M0"7.K88] >6H 1(H9U8D4J4FMP5:=-XLS^1B/)-9F'O*)#':@L;YF50"@4X\
M"M1)96U@,OV[LBZF$WB_D>?TT*1_388F+0!]WKRVL3RKC_JL\BSHL6 \R7>@
MAB5!C[ ':XD#&4*2]"I204D2]-,AM@7CS_)0+L9#V?[2?O,A($E%U $,5P)8
M4 &LLP@D"UH3K?-(H)5U=KU07_O1!?03-ZGZB9?T+CEQ3\NYTD^G:QVG[S@<
M/:IKY5$J)HHI>P]DTOT%F22BV-D[/.J<9])XV=VIPCQ_'N[L=3Y5:W7\YKQ]
MU#X[V/NCFTQ9W/GX ?MH"68!M-!XDK!M)>4@N<7<$><XSJ8LGP[IW%W$/4J*
M?WD>&_\\TO;'#\0+%DTN ;*&0NX_ SK9!6 9"8:@Q&)57M,5]7W?S(/=X$Z'
MW7'WU@;!@Q/EMUF8_QKTLF2\U+UV^M]N8F,R&7.S&HSYNIJ+61[41WU0>>?S
M!RR21H"( D0#!T:C20\J2Y1%!6?.HZA,,@U^0IM)E<A/T9Q<@8\BXXO;92&>
MUVV4B-5JA"PE!+SCR91E)H R#N6L42.0]H&+1*Q:+;J<+\_D8CR3>&?C0R3$
MZ/140D0XMY?C'#0R'J)006D:(F)T91WKZ0S!N?L"&][/L#RLC_JP\O;G#YXY
MB8@6P'!B4891MI2X DZL=D%SF8[E_+?K-=,%8=#R5"[&4]G^O//F0S+3*24*
M >+. C/,@6%>0&0Q1"X8MS9G95XQ//B7WL"IO+?'R6YK79NP=O$V1M9D3B\[
M&8RZE7=L&'J50+C(*KO(6?[N@Q<Y:>C;1XP=#7JGX^L_TI1</U;;K>]^YJNM
M(,@-TRP(&Q2S3$BCO#08)Q''&<?$V ^YB\;%APZ'WWRS'P/89(]^ I/!_LST
M/INST<KO/ZS#<;</M76O+]GC+,Q>E:DXB#D!<IQVZ*IU:N!^_KGSK\[N3N=B
MH$2EOUR\U-KH;+9VW_VQN[VYO?%V>VOW5HF;CW$O+W;2=?][>W-C;RM=^5[Z
MI[W5V=MM[;QL;;UYM[VWW_@[^.U=WYSZ[CCXI%CF[-9AY?)O3YCRN[:)-[V!
M]?^SPP2@9G_LH5?YY20\LE?EGKZYR#W=ZOO@6SMN/+!A.($#69V$2)J<L:S7
MN,!WR5BF:@TC>:.,Y=N<5JTIQ>]TUI]_HT3J25\KQFMJDIJ^ !>KUQ!=I&N]
M&0QN&%N^01'(3\+0$QYYF&H[76-+>74(>C VO6O[]2[__;\-XV2#!E_)MJU?
M3>=>_O78<.[T^+27ZWNJ):E,^>JW'^SYZI6)4?^$%RLMR?&@W]H=#]RGR8J,
M1J=)S]@X'IQ^9R,\O8792X;>Z'1X5BW*M^6Y8EUNW>;JZEF"#6F_</5J_&%Z
MIN_":NO/T]Y9BT[TSEF&)S:MZ\35MWWSKA-7W6)3:M2OOK=;N%D1LEHX;36R
MC)%HK!3&1*-C0%$QASYL7R0"_Z(TO8+1X:"73([1UG]/N^.SQ+^]T[QBKP?#
M*M5D/!YV[6EE;NP-.H-^OHYA,DK26[8S1831>#&JV#MG%^[6XZTO[?/>I_VC
MK<_[1QLTNUO3.=C^^9]'!Z\ZW8/-/])U;/'.WN'A-W=KNHZC@Z.=S3=GV1U[
M</3V^"!?[_D?O<[YVV[GZ"-K'W>Z[5=M,N5NW3L\[ARW66=S^[RJ7G]U<-QY
MOT7;K][1=,UD9_/CV3[9_KQ_?A OFV!]=;=^_F %"C;'ZB.C5=2>@#4V0 S2
M"T,=B3JLK$NQ2OFTQ_02+8^1B'C+ OHRJ[FY=,-L+H"0%A$6TE.(C S1.8NU
MH(ERN"]TL[!T<UZC&TJ]-\(CL-)88!H94(A)B$1H2[04R.O<!4>L$CQ=+5CX
MIO#-=7QSJY;Y6@86$7,.24:]L9I2;BV1FF%*L;B><*Z)'A?F:1SSX!KS$"^Q
M<I( 9YH!DTG'T?DW+61PC!B+8RZ9IZOJBD*11YD;7W _9SU#"FR<C02CP)EG
MT6(GL*#!)<$3J8U%SUA8M-,:VA5/!JNR'I):(1/:(P?%# -N4>[#IQ1U53=0
M3%#1,@K;W(N6P560Z3%C%.4B;NZ2.2.9MLAS'QV./_&B%"UC47B'UWB'.X\T
M$8EM=&XK3J5-E@Y3@*3!R:(A D61>$>O8CK+B.@YXOXI#&WHA'$K_"I0]N0[
MD\Y]N$%:]F])M(5VYD8[W2DOKJ&":I3(1MJ8:"<(!PI+#+@2/1X3&NG*.EME
M?+J<I?067AH$"VVP4Y0%J3PS02C&'<;<V22'.'>N(+@Q"*X[1EV(WAK$ 45F
M@'F,0"OG@4?A*.?!1H,+@A<3P?_[_Q3!Y'G9IK)-99L6?YL>.O_GT7K]Y+JW
M5OKVK@]]/VJ=F*YO_?;3<KW78;A[:(9AOI8%N6+DP?&@7[E#-B\O[_*K\T6_
M3E?Z52%!12'YM4)R]JLZO)>?VJ_>'G?V-FC[_-/G@[TWY_O'?W9W]MZA]J;_
ME/[E^\=Y#,,VSET-/P0K6$34 7<L HL*0[)/ H2H&#-6ALG8TS5\15.NDS!L
MC?)6_O.*0KQE<C'.8?;WO$WVKW#Z#F(9447WGR/4ZM:[1UQ'S"08D4M6$:&@
M7'#@I!142*82FO*4;RVG@Q4E,KD40)Z[Y5Z _ ! OL*(9X03#-R&G&- ."AJ
MDTV/I3 12:,I+4!>."#?S>(HVU2VJ6Q3 [?I*40\O[;0RVUY0W]4=:>IVNV,
MLB;0&IQ4+YSDOE\E(OI@YE6EADTJ[K[O7OF7Z9V&RP*TZCUO0[=Z5]'(;J&1
M=5Y,!T:%L-'S"-+XI)$%E)N$<P-6<^*,PU%+OK).10FJ+#&,YVY<%1C?,XSK
MAI7&#G/&!' 74(*Q06!<)$"4$1Q;+"QCR;"ZPIM88-QL&#]Z-*=L4]FFI=FF
MVQ1=!JIPB)83S9)>I)3"$0=BB;<>!4&*4&R:4*SG&B<5UA@=.3C%DE#4SH(-
M$H$D3D8BDWTB^-7]5Y].[/PQ0/@VG)P.W:$95=T7W:3A2F5VW\G27EQ/SZ-&
M,G^@G(J$-MQ_3[O#X%\,1N-V&!\.? F&S(V>ICM+$,*L2586"(HQ,&0T&$,-
ML,A%$)):'&0.AN K)AN68$AC0?WH[MNR366;RC:5;6JJ)C-WPZIH,@^LR4P5
M=7JDC%$$3(BYF%SB9&A%"C$HD?14PJ,1C=)D?F%E7?9Z3M<9?LX#Y9WW_\ZG
M$([>N7Y$[&^]P6CTS]56/XRSN3PV7YY8//J!K>0[S+_IA/%.K$;;%"$S)R$S
MG03,G+/(1P/!2@\,!PY6,P0T!,R-M@BCG#&_RMCT",6;"YGBD5\(!;]L4X-)
MV*"<STL\]B8P3Z5UW O"LIYO HZRD/#"D'"]21S#6@F*([CHDZ:/F07E0X"H
M*1;4.F\L*22\<.@N)%RVZ>E%)W_1V?]BLE2+E.;^3ZJYOU(FYS\JP:QBV%'K
MDV5!K!&(*B9XF+2ENV&^1^E&UQAU9F<Z^SE$S:-T&(@1N:F,8F"9YL MU\I:
MPJG$*^N2K7(]K<^4-I@E'C*/YO["8(O3<QBE9QA9HV5DN:L10E$[;PO=+"S=
MU+.T@XG$.8X!<Y?H1K)$-UY;X($ZPXB)3N3I]42N:ER&B12^N9^VN]1HI&@0
M*F+*C+":ZZB"PM9(Y)U!UQ-.:;N[*,Q3]]LX0[5DG "2$0,SQ(,F2>41WA+J
M><#!L)P*NTHT:4:(MN!^SGH&E@R1&!62V#,JHHH\(.:C)Q8Y+7#1,Q86[?7F
M_H@AC83/X\IX@*1,:E T2N!,"NN,%P+)TMR_L,U]:AF1FLBQT@IYR5QDBAOE
MN.941VO3ZT7+6'S>J>>!!>.5"#B"XI$!4YB"2F0#R:REA'ML5=8R&%[%K%G-
M_2^_Z_)IYQ6JYQV4*.<HY[B/<U0/\>\5[5VV@DP_+L\U-53Z0GBL5^.;?^P@
MV;B//: &0K*$>]G-$J#520=:[?3NPU%KJ^^#OPP&3324>D3H)G=3;<_7_1T,
MDQC+>]LS)Z/P[/*7YY?YC]U^=6W5AYX?F^'';A\FS/4L<5.=TZKOFQQ^_KGK
MQX?/M%[C F<#X2):=_'%DZ-XK;(=:D0[.4;5&D;RVL-H#5][[&>G56M*\3N=
M]>??*)%ZTM>*\9HB9$$N5J\E/6"!KO5F,+A&AV _T2%N(0K*6Q_PK7>H"_C%
M1^YP15>8@A,I\C"VH+Z1*;@W&)O>M8GHRW__;\/8I!=]I=9L_6ITUO*OQX9S
MI\>G/3.^6)(J4[/Z[8=TS>J52<[F$UZL2<OA5N71F*Q(U>^CM7&<5/[Q$UZ8
MRTJ^:E&^+<\5Z_*D,M'^-/U3,SPKF6A/+!--$)VGKGN=T^<UQ=8S'S4FU"OD
MM"<7 U)Q"=G,R75Z_.Y+9W.#[.^]/6Z3_;.#=&T'Q^G8>?M+Y_C=>?O57\?M
MO9='Z7K/ZJ[3@[TMU-X\..R\VC\_./KSN+-Y<'SPZN51^WR+'.RU/Q^\W__2
M?M].U_SG52,.M-$!H^C XHB *2]!>RU 21<,=H0*C*I,-$2F>_B5F$V)V<R!
M;DBZ26NHPM))9@-2!F-B"5):1:E<*'2SL'0SE8F&J'/>!7"4)KHQ0H%RQH!-
M6Z^1P=SGMK])TJPB46+$A6_N)T9L!7*4(R6L<\Q1HJT-C.2)/D%H:O3UA%-B
MQ(O"//5,-"TC3KO,@%/J@%G!04O,P"MCM,&,B=PK!"?BN6*0:\E$:RSN;P%[
MQ RA0>%DU3B&%5&,&L*3XB$\=4KBHF<L+-KKF6C*"&]E"%F[T,"\9V 3P$%;
M3"-G.H]N+IEHA6WN4\M )NFWB%%%+$T_E=:)<PAB >ED<(>?>%&*EK$HO#/5
MD<RZ9+9:!BH$"LQQ!$8A 4)8AC QQB&<>$>OHBL*^YK8DFPINEQUPK@5?A4K
M6\[2_5O5'P>7C'/J;;1,6:FS\T\%K4.4)J++_H@8T1OV1TS+_JU-2J&=>='.
M5=.4C$D/K>*0"ZF $:D@V;$1<+ F*;@A21N9C!NVR@AN4-/YTGUCSA"66'*,
M,8G!2(:HM$2*0)S))@]%5A4(-P;"=<\HPQ+I1+R F4T6"[81-/<8/!="TD@E
MI[9 >$$A_.@-=,HVE6TJV[2H[:BJ//_'6.D\F+[E+R?6MTY,U[=^^\?/%)+7
M8;A[:(9AOK8%J>LEDTRVRB&R>7EYEU^=+_IUNM*O&@DJ&LFO-9)=]/D'C>1,
MHX/_'")W_%??O->G.T<ON^W-WN'^D4O7]S:MRYNS_70=[?=_=G<VMUG[R)UU
MR!O<.?JS^Y_S;?(!61."T!AR%W9@UBHP22^%W'/?<F21IVIEG:[1Z;K_UDD8
MMD9Y*__Y8ZG+TCD9Y]!X>MY&^U<X?0>QC*BB_,\1:G7[G2IJM)#IV0T,)_O=
M$D@;24$;(ID/GB4C8&5=K4I28I-+"N2YF^X%R \ Y+H5+QCQG"L#R*D\6TTD
M*SY0!LX3RG-";:+J N2% W*9!E6VJ6S3TFS34XAY;AV?] 9G(53#?4)_9"H%
MQ/3S"B=-H#4XJ5XXZ:7O*#'1!S.O[C",NZAK<U+7NM-Q4Z2$I,B#M@$!\SRW
M$&(($(N);20EF.7&J*OJ"B]%\1(W&^4/;'S]+&?K=G@OD+X-I.L6F)61JX@9
M!)0[@!DM(:'<0]IA)C GQG*<+# Z2R.P@N6%T!C+-I5M*MLT6R6X]"H0K;G
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M\P>7@:SYY/("_#%:F]8 ?P: 3Y-(AKT0&/BC3%(@;CU'EE#8W,0E+A*/T28
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M 42(M4!>6HVX(1XY11R*1B>2#&?!ZK)0L<3+@>G7$%:Y7LRT?]3M#= @]DX
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MMP7";::JH@H>6&) T@2&N*8:&1DE$M(&EJ12W)1FCM1P>Q5P.^K%5W%?]\D
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M8\[+%%\?[K:3T4+9DSRPL?F;& KLX)A#$ 7LUFNPS@?(U5\^; T_7VFV^QR
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M-T?-DI>=LK>,PC!.CK<!YK-,3)#+C5DIGD"O(D>M$3O8'+5FDH?"=C>HEL*
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MAY(;I#V'-$0=LA4Z!"7!"NXM]TF@ Y.M!^0-TF%!^JD#:9'H34[ 1'*&03%
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M#=M.C*Q<=@9L9)E+R0 49ZBX84)R+F,$E55<28I;0W8@*6[- @\$Y:5<.)X
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M0JR,?CRF?GX03T?C,Z=I0D",IB?X\3I%67\Q([8^$U_K.;^59 H\V"*<Y^"
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M%#*C @T-1B<6?.8LAY0XRJR2@#X.#4-8L&B5<ZUR[KHN6Y"V2+0:M(9L$I:
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MJ"P4+[SGDIN@LHS>:ZWG3O5?YU?_E5/=*+T)I=WL9^6T"R4FEE72-?LY,3+
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MMI !!\Y<],B"3C(88MG"6T*P4C.$X(%;]A_'-0#WU<GWS7.Z\-_A\!\+/WH
MZ<O7^_KN@R*=JGQ(UQQ<Z-N-'QS2*:LWW<=/1_FWK]_\,VT??>KCZ6_;^P.P
M#-[TSST\_+B]S\YO[[<K_)*#SSO_\S\_;Z?CK0JO>7X.L0O/\L4G7_QY?O"G
MH>4\_QO(><_UM7_F\^*7_B;FO9>_^,[K;U;28WHW]LO:>>[L^&]6S2MQNYN]
M(28PFT&ZJV7\\N'!T5'G^("N=]RY[-;5^3V3?(\D8 ?"]A:1NSL$8'ZR/N>
MG,X*^=M%,>/Q0<B''?FB4U78,UZ)M[A_@H>G5Z[$HV[4Y6Z%E+\M535P>-39
MWN]TM_M]@L71WUNKKAEJ"?40\G/MX!C[G7,I.A@[-I$LAWM7H<[<NMT^YGC5
M(SX9NVE<CH]+S?VM8>9JN?SEX&0^ATRTR#>7WO.-]97/JVN+7[IGO^]L+G7)
M GKW>7,MT;VD?G?M'5E2+W>'K:C>V>^[O37ZW<ZB[BZ]/NLM]W:[9UO;O:67
M_9[\<Z<GWW_I+=$]+?]>NMO\M+I R(I2O;-WGWN?/PBI46+4S*B@R(82AKD4
M+(M)@^'<9&7<W *\,/K>5E0KF)]=/(_+#]+P/&4\\R$\0S9)QD( CA$8 &B&
M6G-6!QYI*P(//M7R>67X#.'Y4=/PV^:I'>:T?=SYX^33IX/#X\[BQ\.<:QO.
MSM]>_;$X64+^--V\?WM0OC(09=^$W(!(7Y,YT23</23<Z0AC"2I 0"Z8UPI)
MPOG$/$3+K'3<)"VM4[$R%H!1"3<"LQ:T>8QH'C];:6B>$IJ'^8KEL@3A.7.Z
M1F$!:W-,Y9B6/@J;T2JTE:](-QJ'?1 T/Q_G4/6L#W#19I(^+E?*N3^O2:8[
M2*;>JQ&>88$42\F<Y>AJ@XR S-&.L #H9<A<&1GF%J1H?I$G#,X),8T&SCN"
M<Y@VN,@52ID8M]HRR.!92%B8238%'E4$9^86[+USM\;OX_CZ61<GT@^ -RN1
MKZ=TC>=#U,ZC>-,J6'[V.F%*L:]F?XY?D5P1_P(5;>VL@C$K8GG 6<A$^EP0
M0611)TS&N07UPMT_B[#QO-G%])3B7PW3D\#T,#GTTBAA;:GU=8*!=(6AT)S9
M8M%D*9S'>-Y"NLV,;#&P9^,U'S]O^2;.?O2<MRC_>"7<: RL&"P.M621^UKY
MP MS&2R+DF2<=<H5ZRIK,<K,AM>\H7GV8V -S5-"\S!?209,B. 9\19"L[6:
M^6 R2T&K8(JP!=V K^@6 WN &-B$'2LM1[KE2-]10@_:<S:9>VN9NSH:W<M"
M9 F*)*V$R"#6?"(D&S&JK$N2)95<;41_[^:;S>LSNPB='(=J"+TS0H=9$8JL
MC"7S)JE0& 01&?+@:K%WL4G(E.JXS9ERR[80WP.$^'XLIK\X#+V3/<)D//\Y
M#CHQG PJ@F]?;G^Q>R#G;2V.'^WH^:TF_C_G?GCC144]OWP+AJ.#_LGQ]6^Y
MJK1_RK)3UGL2>JC_Z'=?M[Z=ZT_X,;-PF'&78:&;_0W[G_'T:.X?/SS3WO8^
M&UK#X<=_F(=<&_1,."B=VJ&#5ONJ1[Y/3X;KWC9T$L^5@DH@E$=O@.B(!4"9
MBHW9)0PI."'.-1:])Z?%:GV+ J)8E;+R"C(*)V+QV5CGM0F0T]PUGT/O42A1
M<< "KD07E(9D-)IL<R@X_#DJ%AF2XMI% 5$C2E*/0657-,E=8QYR _\XV=O#
M0WI#ZFSOG_LEZG-B.#@Y[L0MW/^8!]7._4ME7-T7%T]X1:?@^L>,<:L>BN.M
MW"G;575W]NF3.WOTIJVC3MY/]>...EBOU>\??#[Z;88[=5@Y[[C]I48=8EX:
M/_9&'7(>Q/4?^LN]+_2\X68"747@%Z]ZX\W>;F5O<+!\/26DZ/+/]>G]7GG+
M?B%W:!CQ>'I+W-+:> YM-NZX%&JP%.+I]-FXK?>^-=H8;XK>8]K\EYE4-!&&
MCYV7V,?]F.\A":YX_,?M^'V:_MUQ>8^^A=NZ&8].#@<)$>O;QUOO]P\"/<5?
ME0.N['\Z.3[ZL;E5_?'D\) 6]B4>;5_6JPVN]42\3QNGO?6-L]6U>-8]^WC:
M._N]W]MY#ZMKBZ<;9XMTK[NPN??NM"=7](CW:6=%;.YT=8_>N;JTHNK]]M8^
MZN[2VYWNTN_;JVM;>YM+]?/Z5U692N^,+%(R",XSL%$R5,XQKT7RRJ*R4OU"
M;\')N8&;,'G4PL2",2G8$LBTAVQ5<(KL\JP+#X*3V3 0)H*$B6K"9.:%R; K
M.P;TP0C#C#:% 6TQ"\B!84:P/)2:HCBW8!Y"F#R?,5&7?J%\=$SX.<ZI4P@M
MG;_J$7^,TZ+,WSM#OLN6:C69Q,D<8TPJA1+ !>NE,L)E[W.Q6+C\L'1!]!2[
M+J)_1 ],WWV5UCO[.U=*ZL^WD-0_"NKS8[VR__KKF?YVV2:T[R"TKZC_38!:
M6<M93, 9:*D82NX8EHQ&%#08[=S"K+0E:*@?,R$317*,04AG#0@A4)B<E ]*
M190RV 'H*R&#"GI!U[^&F36LSQ[6APD:;7("98"I -7:XYZ%:#.+)1JCN='>
MX-R"O'>YR/1R,!^3[VR1;G5@@XS#>RZO7(*G)Y_&0$K&8SE>8SC^^^0P;A%7
M?2IY4%.237^,\)"HN8VTD\Q$(B.0!=F-25D&,11,-GIK _$0/^N.J&>'T+$Q
MB,DC]$D/>IP:<H=9A1%&\APD*QH-X55*YDEH,T6;[A0&SI/^Q3F/C]'U\Q!P
M_3>>5I3\6N'&\[:5INPAF:BH^R,?'_<'%VETY$Y";;1A1A+9!MI2YH)V#)R2
M# 4FQFLDE(2:)EDWMR!D<XL\3:C/.JMI4/]EJ _S%Z&C\\D+5B)Z!K)$YD%P
M%D )96WRQJBY!1CUBLQB4>IC8BVO]U/+)'I&P?]Q58JVX/^#2]'13"*K30J<
M3&JCLF"@H# ?,F<Q*$RVT,;G_ MSAELF41,F5PJ3#,)!RJEP8<'+X@18XYP.
M%HBT27Z>230Y7M:$R1B%R3 ERPX<]\$QGRHEH^^9$]$PZ>M^IVR="G,+YJY-
MJ1]XLO'%Q[,J.7X3[JLXV=Y/=.9^8_4WX\;=+3)SY*]GYHB_3R2=Z%;U<?_\
M<37Y/*BZ?!7T'1PTG^[@?OJA. X/<P?[_4[LTPNVRW9.M<SM?_)?N=^1G1JH
M'I3%Y2\Q?QJ(GX/2R?]W0J#N;.__E8^.!^96_>U_W$%0*9<=C]I 1@-%E9"]
MEMQS$E*^N"QNFS_]>G G?U2I,WB<-W_UMI]TOZ)^_M?OIYOKZ5.08'IGNZ>]
MO97/)&P^=W>VMGK+O:W-Y179W>EO;ZZOT&>FO>X.77=YLY" @M[BAV!=+KS4
M9A=@ZHPPQ] HSCQWHF@>(?*+_H@P(D8Z>^>5+2\ZG[>VX];@Z%QU;,3@D%U;
M<7G'HR)D% #2T@TBI" 1G8]:>V=1!LW5;8_*RY,C0LO1T:N#O;"]/[B55]]N
M\=7W=_A=I\YG>UA>B^['#R""#Q@L<T6&VFHNL:"<8MIP0UL@I:X#(J]*A+\\
M*E<=$#7_?-2!_'NG_N_A=,+<0F=E/_9/$ETP#KJ%5XJ6]V,5X,?YD$1XA\Y]
M[AQ]QD_G^N&*WX_NV&/:A<[E__ZF_GY.AT:_/N0>O?H!)@0E=KY+QYT#4K^'
M%]I[OO.HM^%O\(#<:&[ANGW_;NTKW]G>[T0\VAJPG+](_.]?L*:O&[*'A[OY
MHJ3_&_%X1A)-S^0F?I-Q=^$6/&$014B;"C&?*!S/F3ZF>)5=LC;<UOG6N,5=
MN,6[SZN+'[Q(J(4/S#D5&7@3&4KZPF.R4?.07;#$+?AH$[:OW&( RKOL-J!R
MG&,V(A5PB;:86Q%0.Z&4!8&-24YDMT^[GS_PXI1'Z9AQ6 =J 3#DM0I*FQPD
M-R*D@2-T=&SG=4QR5$7^8-4.+-*+K@3G N*B2\/@U+S%_1,\//WA#R\Z1'D^
MY5@%8?]TOM/Y)8F2O-'9DUC!.IC(*Q\B !?@4XP>E6\291)G[/UIETQ;1*^C
M3*SP6K8;<B#3-I& 2=JBM2E+J*;M:,CREP5*$;J0W# 9HP0%%DOAR;NLI<H&
M53--)[/99[UW'YQ#CSQ+)K70#*RQ#%$$%I75M4,Z3ZK09E]OF0Z)DZ^B9+Q"
M9*A$[_I^=(^#^EW3QNRF=F$C;<RB%CE7QP( 0G R^<*M%DYE#0Y^--?,WZ]8
MMP?DGU>OP>V>:77_XT$-[G]7>HIIY^3<A]K!O8.3@:UQF#N?#K=KF[/^*9VG
M6!N&5:.\\WL^RGA8/6]T_):J*^7@T^"M^<NGO'^4YT>7:M1@O-8N>:"^@]>9
MM->TT;ML\#B&-,0?Q? ?<2NGDWY>+:_(_JO_O;XT 1?WTQ];!X?':_EP;^72
M\3UH*+A&=_&R?Q!WGYDLIGN6JTN[Q.Z$\:H T7A%FI>#8J%8QP@,SDKA"!PP
MU\FDL3[1<A\?GN0'[0&YE3ND:>F33__K:&#JO_@%@_]GVB'2U0^WCW*ZODW@
M15^_*G7U>8_8J?8(='X>K/J5'H&*SULCQ]X@3_!Y8V "W?RDO77KP4ETV[O]
M LAY^,5U'=L"//QN:6_'?[-B'MROW= #K*R8)TDRCD:1,Y'TZ";:/>]Q]4A\
MA8>'IY7^+0Z(WGC;14ZB+>CC6MYEW-[_Q]\Z_W-P=*>S\^1:<7[K$-"I65R=
M0>K5<UZ/RN,[_P_W/OVS,_CV.T[_K)?E@MQV+\GM91K-_?JW/L*)3_5DW&MR
MT:-.AGUFPYDT%SI+67BQ&8(W'J*.#G-(1L5B\;8^^G_E?EH[Z.)Q1<UW26A/
M.@'M(@NV1_?P3G;/=F5O;T-M+KV#[LZ;[8VUEUO=I2ZG]^UM+FW(C?6W6\-9
ML%WY^DMOJ6;0;LC-G;3;6_IXVJ77=9=??^Z>_;Z]N;ZYV]O9I/>\*=T_^)>1
M+%A?P$9@1G#+0'K%$$)F"7*2WFBA1)E;@!=</>7Q39,@?L]^)-2DY<)BC"=[
M)_W*S=[O5[_NQ_TZR.)?!_VZJ)6X/O%N#%,3&F*XFM%BL$)'QGV,#)*1S,N4
MF/!@ X_*%^-_L1O#HQ(;#>(3AOAW7=D:!Q@;G-40G'E E%8%)@()2'!HF,N:
MX"Q$L#*6HD ^?0[0P#PF,%?C;W$_#0?\CK\Z[!J@QPUH/01H[6QT64A6<V48
MB.18B$6R2$@N*G.5<FB ;H"^): O?5J7FOG"W]48]IC,\J^F>>\L\NY2_."2
MX"6B8PZ1*#88P3S/D26K8]$: 56:18H](^/6VBL?ZI7/9@I"[V"?O9__8[YS
M=$#W1G_9_RZ=Y1&.0+@LM+YF L+3;-AUERKK  F*-19S!) 1-=E+-A</Q46#
M_/Z.[J8T;Z\T3T=\V<E%(3@6)BW4V3!UQI0LEFE3I"G%T_]Q;D'=M;_OH^JJ
M-UF!?^O[F@RHOHW^^'*T_=O^=O\B^7&,_N(&P+L <-@O++- 4"HQ!THSH.^9
MRXF@B%XH+E+ VJ5W!'VMO^2C5%=/;63&U& S['^-6A7($9E+D!A(,O.PB,QR
M4DDHY8OBZJGKK8;6,:'UEM[7AMB[(';8P1ITR=Q'SXK-EM2;D,P[DYD*&F-*
M*190=Q\DT0#[' '[4^]J@^F=#,)A+ZJ $%P6BAD$8) =,C16DH&8O$9N?.#5
M(N2C=?(S.XWJ2>2'#OQFAYENZ2C3OY\NQJ=T\.-ASC^?,O'LHSHBV.2"B("U
M':E#I]$DG45Q$&+0J:5;SHI$ZKT:<5%9)TP43K$2D#.P.3"GB>I[D4TNB,(X
M,;<@7V@0,Q34:>F632ZT=,NI"8UAMUH0SG(;,HO2&08R 0LB>\9+"@F]<!'#
M+,:"6T+'(X-X2[><!)R'W7W)QUB2<\P2"6 0LV:!\,R4H ,"-;M#^:?/ 1J8
MQP3FEFXY;4 />P.M284[5"RK$NMPRL)<L9*YY(RQGB>N8P-T W1+MYP5!(\X
M"H/2R4(&IA-7#%+MI2D1F02N,)MD(V_IENV5L_?*9Y-N^>K@\-/!H(%^RN&X
MI5H^;5TJO4M*BQ1*SD#BUQMGA" ]:D'HF&X]QJ\YN2>N3;='G-S!U.X!OHYH
MYZ:6'QDR<)5BR0<E?<HFN@L#=W0HSM,)D$_;R?UXY<)=9B9/6C"T)-%Q2X=A
M;S;202T\ >-!2 82R5 NV3+DD&2(Z+RMO>MG8Q)RRYIY9(J]N; G@>%A%[;0
M.B4M%!-&6P8VU+$ *)CT(6>;>"Y@!QI>/>44N(G61=P%*#\MAV@)H1, Q+ +
M.'IG4HR&D1*K'7&"99YVC&5IHX3,HU6Y53X\-B5S:T]L4R_W,R!'\C9-<"+;
MP'@IHL+)$4?$Q(@<2J,4[:3(LV=!/H?,S2Y9IJ<7+?P[A9ZE96I>*X8<&L.5
M"-$;#0K(WLE9EQ!E2<A1W'IX57-B35P&75%,'+,F7LL9VMH4"WPFZ5,*T^A)
M@V01A99ULK,69H;B02U3L\F%EJDY-:$Q[-NR1LGLM&#.&*SCX"U#E8&9H'C1
MH69]N5D,([=<D$<&\>;FF@2<A]U<5D.,R00F<B$X:^%9B&2+6"%40,R<K,NG
MSP$:F,<$YI:I.6U #[OI0' KK [,F%P8N(S,2:69Q>BC<L)FRQN@&Z!;IN:L
M('@T4Y,'6;)53&LC&00762@FL2*+!T[;QVNSE-FCV,\F4:]>C% S2(UKR7E/
M4GR&$ETQ6@ 80&6]3T:KV@C#9\^5;7T0IR@C5T>+S+TM/FKKF,D*&!#A80&+
MI1]YB#H#%(%S"UZZ&8J=M.R[!OSFN)R:R!AV7'JG=!1D$P53 ZXZ(?/:!::L
MDB(Y#$+QL;&J&18;#>(3AGAK&OF+B!WV3?HL@#N>6!:VNC*T8 AH&%<0<D:4
MM%U/7<DWM(X)K2U'< *('6D::7TF&IZ9],8P4%RP #XPE-IZ60J$VAVY(;8A
MMKD>9P&_(ZY'':VW  1;:VN?!ZX8)LY9U"46L%9[F$F2_!SR$L]7]_NO?YR$
MXX-C['=:@N)UP@AC*4'*F#!Y (4.3 $N0M8DEART5I*S(XY&)W<;&SWGSC*!
ML=()EYF7F!@O*@5=0)<2YQ:$>.'U:#'=TPEFM@S%29393EHRM#+;<8N'88^>
M0YX*9LZ4U;6CC?,L: !&N \&O%;<^_N5V<ZP4'B: )XA_+;\PTE@>-C'YTJ1
MRBG'K*F#8;SF#+F/3($%$641B/Y"Q=^[@WU#\]-'<TM G#:B1Q(07;*8HF B
MUO[O/$460JS#"FW2-G/IHIQ;\"^$:*TB&Z!;@?*,P'C$%6A!>^V3)SH-ED&)
MF@61."/\:DXZ&JT:S'%P]R]0'G\.XM?/NCB]?@#2&6B.\6@2@6;OV=HU[G.-
M^SK(?^F&'N8:TP'!S0&$2"HJ'\Z4_JZ.*+J-LYPZU0%U;=A@]C;U^5YCVEGU
M#W(NZ["TY8.__NNJKK<MPC[,K3E94EJ49+0( "FZC"Z&HI.16$J6M^76BW_A
M=K]2ZS<'AW\065[*X?@[!_;> :T.R8I7!T?'+_%HNP6[QC?)<6WE>*0CD$O!
M9Q%85CXR<!B8=RHRA!! 2<V]-D2XQ0NO9FF8XV-@LT]38MPEVC4ED7$9\UH^
M)()QR3<JW7B927SD-?S21,4=145O2%3D4 H*'UBP3C-(VC"4H)FW(B,([D(D
M40&C:7:MP^S,HGD&P'P)Y!]AW?3^6,%\^B.8O?4RE*R9<"4P4&"9QV!9X?0U
M6,U%/M?[SLDGK/>?/:I1%9&<=X4G#AB\!RNS3\(:+[R(K0?'[$)Z=4@_ \0D
M0E9,&ND8< W,26T9;:J'7*1);M \6KBGW#RZ(7I,B&XQL&F9Y.>A;,)R5+VE
M1?4!$(RUM2=F"((!.DFZ&24SH(3GV42T>FY!^!?&JQE"<IN9]LQ?^1SJ(6X<
ME]:2,H854M0R1RRI-HT', %3!)&)JZCHB\0).HZ;(KJ#(GHWXAMV4JDLE6#1
M*4-ZB">&.@>&Q6K-@<S$6 DEW%L)S7!*52N#F(1C>$HBH3F&)R(GAAW##JU2
MLB1FN'%U3C<RSYUFRD:?M0(GLR"^VDHB'@^89P#+U_N%&USO!M<AUV_F7@9G
M+3-&!P;<1>9<2(PC%@&IZ%C;F$FXM]^WH79V4>L=S[;PPHT2X(0*')6342F?
MG$E%M XG#PG98==NA(0A!%G3,A1IV%*8L\6Q9'E0Q?OL:G/6)UV/W! [)L3^
MU*_;<'HWBWG8=:M=#+5.@0GN;6T1JAC2AC$)+B:?#.V7(RKL[ PA]=ET4/Y)
M+Q/\2CYK9*-S1" 8^/<>89ME>4V;Y7L'Q6;.%?L?]PERW $D,ZX70BC6%",S
MY@1*<+3!AJ UBEB,%[?N?-7R<A].D[P?\;WF;#@6)5E0Z!EH+IC3V;/"H]9>
M9?2Y^E[E"U(Q,Q0#;'FYC\'].B61T=RO$Q$5P^Y7,@>M5HHSZ0$9^)@8QHA,
M<NL=A*!L#',+,)KTT_)R9Q;-,P#FEI<[%3 /.6<%&FZR,,PYZQA(",QK'9E)
MZ#%);W5TYWI?SM*([H;J&45UR\N=.J2'G;>R6&L$"J8-5OTL@&$NF0G",K>E
M0*[#:^4+>?^>%@W13Q_1+2]W6B;YL',7>?(^><WJ)C&(R3,G S">BN(%?$[2
M#?)RG9NE6MGGD):Y-O#B1M)R+P9?._E2V75PGQ[\'"&=O6_H^4GNYKT#33.W
M/K?WE5[UB$]&!CN'H*-P!H(#$55(@D<9B',K!T;GN["J84JUG_[8.C@\7LN'
M>RO[?^6CX[WZZR:2QR>2-T:\I%8$VCB7F5,DAP%BG2'@%+-!Q@19N"AA;D$!
M64OWGOXQP['QEJ0Z"2_I?87%SO[.'03%S[VE35+<45(,.TF+U$JE;!A)@L2
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M]P?&ZYKO>?+J$DR('HN3)G'(TKF4"91.HH&<0=^[X+^IRS&"=8CQVH**3)/
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M $9EVB:M2%"&>? @38:U#3/?N: :P"N+X>6F'U3D+@FY.Q>1JY7- 7PB,?-
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MK*P-M2MWN"7N4!"_^8_K]8M&A*SB)2+X2^Q],QZ>C">ESA4%Q%YN.$ %^75
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MIT9)>P1-R*^V'=?/P'WH.R&:G6!U)RI-?),F'D-^_F_?LG-JMOYCS];_5CK
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M]?K"*DMM?[72,%_0)U!AOCHPG_,D2.,@*,2U,PG-$ID0YM240CZ:C12<R]C
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M7MN(I@?HK<?1BP$UM%*S9\2,<;3ZEV3]SF8=QS+\^BR;I=Z\K@ZB0>0!>L+
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M26"+$H:4>4NQC1IE>BN7+WW8H^S')5FAYPC-L(P"O8ZU<9B2N;=NJ&:[&G!
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MA>E-3Y0S>2M9E$M_>*QOSE'> MY;P/OFSK>7=/0V&U:2UGF@0?<B+4EG:D;
MK0GL9/[ASK>/SUOS44 B2NA->)4K1[ "<3HNS$TD*>?T\$A;]?>.0<:6)J"
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MU?J:8SJ(?L*F^%W+C4:O*&VP>"!-\_S.S0:M(41T2F'/,1V2XK.B9K(6S89
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M1..A9 $GPBF\L+[O_3&\6_*W%MF-7!4Q4R[3/\%D9!;G)SD9]TXM<XX[EW_
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MLUJK?19EN#7/!R9Y@!<=#7J)CHY-HR8F[=5D)*U;\SPFR2>:IT&B4LT"JJ2
M:19E@KV%2(JY9FX-EN?:WD>]-Y+?T<C^RKB\C>QO3_*I^9I1C&GDP,PZ25X>
M#]0TN*S^9N^E='EZSN4U'\/'?F/\ON40(+=*@RPAMN)6$C>4-3%0:L(;"9\[
M(+\CQJ?>:IZ-B"W$IK!&O&K@KB.4T2GWWA@E/SVGNM6.!T:92^^*2!5L_E]"
MSC*@KA.F0 7\1LYJ&^5W1/E\4E0K2%(Y1,:^C$<L2*<>\KRU35KMR&LJW"Z4
M[P[F=TROKXS-.[W^ #!?$#%CQ])"2W6->$S+10@H%.TE1]51W9Z> ?]:!T4=
M;SM_&ZC=+&,I+E9XK($;CIFJY#;K3DXD)4GCMO?UC[?(X=F^?JE.0\@"-UJS
M:Z4%7?V;,6O'1CU1&D_/-1ZH87.3_+Z-%X8(H@#:0!R8M'2>:6KDF&H!''M?
M_Y DG_8RQ88:D4)SQ("]0= \_YB9"C.N8U>V2+[ZP-4F^=B%QY5Q>1<>MR?Y
M9%\?.\4ARL%[BP&]KAU^QP"82IY?\M[3TW-*K\^C\@\O.S;&QPW(K.C+_:K&
M&9&M5!US 1?/6$A[NI7AV0[([XCQR;Y^YRA9YC)+[#E@;"5(+CTH4*'8<HDK
M(">!'9$?%^4"DK ;69TY-E6T2FZ=<^MEKO*6]K[^(5$^V]?OL;,,6]DU+9?"
MGH*-:L$:Y5PC1D\O,%\MTFV8CYU>7QF;=WK] 6 ^W=>'5*HLV_ RBZ* $^D@
M-#R0]S@XF:3LJSGI_ S<!\FO]RG][5!V*X<R\=JB:[<AV+G,D&>2>Z$U0"%G
MV9OZQUOARMFFOB![9)6@V3F@, 9MA<,PJ*F/BG$=UD]Q'T)X8)2'>9M1S:28
M8\)FV7CF*147N+A/ZQ\4Y9-=_:+J"5%#3W$-05C[!]XEQ&(CX:@^BDR4X>I-
MA(WRL>N.*R/SKCMNC_+)MCY00VMB(?5HJX4.UK9^G*4'5)_WBQOWB?(EL[)]
M7/^P&+_+R,$L%&MU;2EC:2X)-/8AL]S,T:GO;?U#8GRRK5]M>$Z>0E[G>I&3
M!ZT*P4:DX51CZNWI&<J1G$TVRN\9Y>3%2-&L:\9!0T9KQ:IX1Q6$LK?U#XGR
MV;9^&U9H68=6;C4@^>18*"\3T:B4$7NCIV?$G5[?&\SOF%Y?&9MW>OT!8#[=
MUL>BV6=9/&$N-&'&&%A*#:7PZ#-:YUS;TNA>EV,DV/_#OGY_\\U77^@?UOOT
M_Y[]_9V/_IW[4=G?N1^5_9W[4=G?><1'97NC?CAOU%]\_K//?OFCO+/RFLL/
M>7-???G-FY=W];5_,=_>;_V3;[_\ZN, K]/Z\=-;K-_XVS?^-_EOMX?KOL:^
MQE77V*?#MH?KCS[M+F?7#%Z&9!RI:EUB=*PE1RINNH^%'6Z'[/\['UQ9#4?)
MF,*HI0>,&=X.X-84!1FT*I:G9SEWB]M[W0]#\DA$/1-QEH9M@'@J#+#FZ'@K
M=?=Z'Y/DDU-AY%X96P] U";)901#6EW?U TAS<5:-\EW2/([JE97QN6M6MV>
MY)-#843+@*64D.9M#',-IC#9[8%<2)$[(+;5BG(0AZE-\7MON%"ERMYJ(4R]
M"4J;-SVOP;,XOIMHM\^$'8WB7Y]ZJDL$'S&0KC&T9AS4X@AIF!N ,N2966<Y
M%YYW0'X8E(>31!-FU)E:JUE?BSO4(6(1=.PS88=$^>Q,6&T\&I4:O$4)2&D-
M2(@Q%&[*M8[&ZYPV[*'P=P?S.[=<7!6;=W;] 6 ^/1/&G(Q /*3EH(1@)<PE
MF@)+SRJ(T96?GE-^G8^18&\+UVWA>D.?J9YRT9JM"E9+,U4MM>94M23OI>YM
M_>,M<OF\VYNS4S0-PKH&.J44!&H/J:8Q.G6DN.9'P-6[@=N:YK@H.TZ(ZRQ
MN!@6GG5(<:LIB:-DQ]WM?4R43_;U812UJAPH15XH:V!J(X##H%Z9$N!$F;9E
MW+VA_,XN4U=%YEUZW![EDXW]#!/8Q!A$Q";*D )7B2&!YM&E26W]Z3G';>)Z
M3QB_RW9@]4R=HJ +ML8ZI(X,K9*EU5FX=_8/B?'I<+:$3LTY2$H8<#0([+F$
M 9G;O,,%;36(EIU</S#*>5B+A7N1-)"*<_1HU.H:CD$(?>_L'Q+ELYW]K&L)
MCBETX)E>,^ Z^T;!2NH56@.A^O1<KC=3VC ?.[V^,C;O]/H#P'RZLT_<9@36
M-?,X44  #V+((5F$G!42UV6GA$=)L/<Y_>WB>J-\!6+1)5Y*M(B:42KF58M2
MS%64T][7/]X2!^?[^J/VFF:MT7BL0T6M!#/*07!F*$W;O&OP])SW.81'1CG6
MTK%KJ0*($#N#$=78-#DGZ;#W]0^)\NF^?HH:U6M 3"F@%PFV1KQSSY4UN_OJ
MO,ET?LIWHWQLE-^Q\+@R,N_"X_8HG^SK5RDMYS'#<$D24,N8KT1"SB5U=G8#
M?SE0=+XCN$_L'Q;C=YGH5%';**7V6)& N>8L8^A@&I$K['W]0V)\LJ\_LJ7)
M*H:VMO01<@VLHP<M+%EZ'=3DZ9G*-GY\8)25K3LDRCG/))OG?RD4F%RG;CTF
MWOOZAT3Y;%\?:K4T9E+=XSJQ[Q"#1NLAI9K'JIF([>F9ZYYW<F\PO^OLX^MB
M\TZO/P#,9R?VVUR0ZRR36]6EN,<65)'#2#Y3;Z[1?4T_AM?GH?E#GMC__M_Z
M_O$M+Y@>Q21H7V-?XZ_E&G<MM)V: =+%L/CY+S[_]!\^^J>???K+?_STIY_]
MG\___J>?_L./*JG=R\?W3CKE_L3N]1/;U[B#:^Q6QK_8F/"O^S#7NYQTF,^?
M*^?1R5%ZG2]+6R9W5!BU^&U..HPOO_XW_7:^G=]_^_&L2T/_\L6K=_TC>WOG
MG2K"]KNS8Q!8>2SA.V##'M!3#1:90C<E&62Q47QZIE>X&QP?F736TIQ'&NJ,
M@D-2)9>B49NJ6[W-08A-^OLD_>241&R@%46"X?)J(*EA];,&:0[8E1(T7:3/
M=7R3_BBD7SXF<5U8A[U]>RN$3T]'6-)HA4+MO01$L8EPM& ICM9QZ'QRGY[A
MPIGL#?"= GSAS"(,&E8;:1),.2KV09Y%6RV(E6YS0F*'ZO?)^<GQ"51I2:@'
M<9B9N?3E.=(LC$B0Q11$^.DYIQFKKQ9=-^K'13V;%:P.5"L@V)!18X5Y^S&Q
MB-YH#NY&_7VB?G:\8L5MM.H!BJXR?*;DLR2??QA);BD+IP5[?%6N[T78L!\%
M]LMC<J\+[3LQOQW%I^<J &K+V"4T@AXP"P8KZU6;:S6E65G9FEO_&@^$\%U+
MN0=Q0_SK/D#V#KE,'2FVT0<:-10RMAH1K1A76WL/6TNXLU7P]V=: I19ERRK
MQ.&45O-&#FHCALBU%$\4?1T4+:^(=E/E Y,^\U5@&;UU=C2?=0MS LN>BV*D
MOK6$^R/]1$NH[H8 ,53*,\>1)D%SE) (:P-/V4I?I->Z>RX?AO2+)<N587V7
M+#=#^$1+Z%V[-:30>]2 T%*06::$6*7$4H&PQ*?G?+V6L $^"L#GH3H-F*&9
ML,=F:[H=5P#*/K!%3_!'(]2M)=P1YR=:0J[+CLMGKH6R1A@R!ZW.P1T9JK><
MA9Z>$[]*VQ_AD5%7[IS5>ZP$2-S%HEK!4CL7&:UN+>'^4#_3$D2J=*@Y<)]U
M-U(90<4\$$@LE'(!J1/V^DHR;=@?!?:+B?F5H7TGYK>C^'RJ4BXE]55.^UB*
M8 J,J*'&9$U3'#VO,[D76C0_',*['>%:_\4ME/Y0)8'CJ$E01VTX8F6+:;02
MW=Q&MK:5A#M; _]PIB3TE$Q$:\!4+&#M&(QQ:0JU4M8U6FX5+? JIR,)JAOU
M]XRZ%$?%#LZZDA@WY$&M =<9N8QO-'=IH_X^43^1$LP\54D>9NTY 9>L02!Z
M .42Z_ RVLL(R5<S*]JH/PKJE[6$ZP+[+EENQO")EC!6GUAJ-7 #6H>?/$A,
M$LJH5J-80]>E)>SSBP\#\'FL1HHC$>;>7GRB7+M+]YI*S#!*EZTEW!_G)UH"
M-9#HDL,R_ H8DP7U9=8*J1L-R23^] SR:CY,&_4'1EUD9.S<;3""#NZS8..!
M@-RCVM82[A#U,RVA#!'F-D*%JK/RSA2TY!)*UM5^.$,^K69#>H5U3W1Z&-@O
M)N97AO:=F-^.XE,M(<U""ITTV!KAA,,IR)CE=1ULB;NOL<=/S^7UD6KK]^+Y
M> \>3OL:^QKW<(W+0")N$]9]C7V-#V7"^I-OU;[PYY? O=*U-[_Y]Y=.MHM_
MT]_\]OE_S3].&<ZO:<;53[[Z\ILWZSL__MJ_F#_R6__D=V_ZM__R?;;X)S_X
M-E1_'/_S1]2^^?*+?__VS__(GT3_E?K-]/+F26]>[RF7/V8S+Q_'G_[Y+W]<
MW;Z:J6FPKUW_->B8;_9C_>)W^H=OGG[R7WZG?WOSFW#R&9[^^A_FE_Q\/10?
M?3D^6H7T_+0O_<I_^GOHU[^>O\JW7W[U\=O\ZN31>9MXDV8 X#BT ,[LWUJO
MF>=K+Z/,Q/)MO3!_QONGJR(G%*M=H;<.:'E^/W0>'O-(+<M(?^[?D<H]"AB/
MG! 45*45XAQ'+8IJI__.O/3HW7&^FX'03;-7<!@Y=_6V-IW_UPLD__GP?MW]
MZT78%_K5-_[Q]R\^Z6^^^>H+_</';W[S\HF^_- GWWTVWSWQZQ:?I*TO#_;;
M+__GW7\=WSX!WQV&^>Y?_N[+KU^^=)),O_T:X&LN?_[+\77Z"[^&S'_13_YW
M;U9>EUCOY+VF^!H@W\F;Y==2RMV\UTJRW^M[?Z_T.M$/>S^W[N!__U'MASFR
M_^-G?_?Y9S_]V?>Q[+V^@S*7W1_P)BZD2"MH!GB=+D0&TV]\7>'I^6_@;T]"
M\)$JNWV-?8U[N,;_L-!]G[[]YLN%W'_WS^[O?/3OW(_*_L[]J.SOW(_*_L[]
MJ.SO//)W[D=E?^=^5/9W[D=E?^<1'Y4[:]N^O'G\8O+Z6__-6Y?7CWZUQ.KY
M\IL?M4M[7V-?XY&OL;VC_^+QD]O%Y@>VF1@6[KDH<R6LJ7 ;VKH#8FF]CAL9
M/>Q.DG<X@_[K=.;E0% BB&N(V&M ZB5PS10*0+11?)2L3\\%MR'5 Z,<$6+3
M,2E5P6S=XJBM6\=J$>=G<ALCAXWR.Z)\XM4 G7E43:$+C8#+HHH[U5!:KF8X
MGQ+I3\^(5WNR;)2/@O+%?K K S/L?K!; 7QBU- $V*-[Z(TX8)04M,46F%/J
M8 IQP--SANO;P3;!1R'X@A4L^0!)VF'BBUZ46E.>H3GV#!+[=FJX/]!/G!IL
MWLR8O8<U4"S,B-R"9)Z1.I4B);:2%)^>TZM2]RB6!R:=B7@ D:92<<9IU2@-
M&U$=)6KR;=1P?Z2?&36X)QF(%*H*!&P^X[G+"-RPY^B2<BZ+=2A',HS=K+__
MO/S*P+[S\MM!?.;YW) [>)J/42X!=4 0RBV8-%L#=GIN.B$NKX^T3?98ZN&'
M&2"Y?6A^8"[36R067,Y3@B6Q%',H#570*X-O->!X*UT^4P,B8A[2.,P\M <L
MD><2-ZL32SW::C'F5)^>2]J64@^,<ED521L#):YA<4-K5O$\0 =%9=UJP"%1
M/E$#<O&>AFC0CCQ3EM@#]^8A*A9.P^>J[(^.\KLF._#=^[Y?FB\6'E?&YK^X
M\-C@_B!P3U0 9*4ZA(-+@H#S(0VB&D-S42^UVUCS9>*%T8\[P_TQP^)04*9<
M:V+ 4H<F%:D8:0R)0_:^_!VB=^Z@S'TX!K<V9OIK)>A@6S%SJ-1:R\M@DU<5
MME?Z Y-.?93><QT]$E(ED\*MIY*J]E%=][[\_9%^MB\/16."WD-.?8GM20*#
MU #1L2#"+'OZBP8GLEE_%-8OIL=7!O:]+W\[B$_WY9NSNW4+#0 #R@S=MHZP
MUAG$R6?9DRFMT29'*G+WV?QK9S%NT?$')C)Y>/$N+0H(*KC.UZ-4'=Y;@Q+W
M+,8[6P/A;,>>"^26,<X;:!2PE;5;D"E4PQF_"G9,<:4QL5X]\V4?+S@NZ2"9
M,JXC)8T0)+%+32G/E&8]!BWO/?M#PGRR9S]3F=+'+$=J-PV(#D$=<^B@2:A7
MIT9/SU*.=,I@H_S^*Y(KX_:N2&X&\,G>/=7:D&C-5BQK [%.@&N5D'(2G"$8
M!ZQS0O$U;X(?A> +2L'(.(2EMUQG31J5,=GPH1F8,\6M%-P?Z"=*@9..R)/Q
M.#('Y-2"]KD<ZU#)SI6QR-,SO)KW=Y/^N*1K&81C2.JSWEII-S0UG6'; :C
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M92""M%[;4.E5,9;"ZY<F2C7G0=5P;^L?;X5+9]OZ.3*J> J)UARVR'T-0I>
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M*'E6*IT#IQP#]AJI)&D]]E6I[!/+#P/P>:CN#4J9ST&TE&>"5I2'I@**B#X
M?(L)]\?YB9C0P2K$QF'F9!K04@_J<811''L>O>1L3\_TZCT,$]ND'Y=TX(98
MZAH+"-AYS;&?85MPM#7 )NH6$^Z/]',O,RK0D69=)0 !>8Q@.-/R+M$!G1QR
M6JQGV2/+'X;UBVGYE8%]I^6W@_A40C".3*U#@+K&^&HOP7+LH>9<??G J[>5
MF!^IO>C6O0G]S6_?,X7R'K2$[S_YF[^QMY_;Q/?+KU^Z(SZ>G[1_O;[KZ?G3
MO_OG3W_^T\_^[H^/Q<MG=RASJWV-?8U[N,962[<)VX]^Z*OTF;EQ5ZZXYGY+
M$53E1HX>(]]()MVEV+MD<?]QIH029/>:-?2D.:!8"QRMA-@Z#>BY<)DYW'OH
MM]AEV'%1CM' .<;J&3#S8"-WPD0MQ=R^Z[78)FQ'0_E$ZBSH>7 JP9O01+G7
MH$82J)<>V_S+O@XU(&YW^(=!^>*.RI6!>>^HW S@$Z%S5!VQ<0XZ? (\S()F
M2F&0,>3<1P1>)FS;1?%A +Y@PA9!6E0M H">V(K.K&Q(RT:3W[R%SOOC_+1K
MJD..9AR:8@T8>PRLD8-":JG6,1C+ZG*&O$E_8-+9$J9JYM'&?!$YS65?'9*
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MFA@1O^RL+!WA2":(]^^@5EYS^2%>95]]^<V;%Y.RK_T+_?;-;_V3;[_\ZN,
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M#UTYF]>N;KA$@".=0-H OV^#8^PH(P(52CA*,K":D:&V5CODLI6 ^^/\1 D
MJ5 [6RAM+,XA!UG&B34"S[S;)LNPYC10VJ'Z@4GGL;STF"VZH+ S>I2<6]5&
MQ I;";@_TL^5@"(PND"(6#1@C1(T9@T]QDX4J1;%Q7J-VTOM85B_;'%\76#?
M:?GM(#Y5 E+I$J%@X*ZSLB:L00OU4$  (XYHSD_/>*C$_#LEX/M_Z[L'-^,+
MH$?Q,-K7V-?X:[G&"Y _^5;M"W]^62=6='CSFW]_Z5VY^#<OWGCSCQ.&,;^F
MY1)X[B'XNS?]VW_Y/CC]R0^^71D^CO_Y(VK??/G%OW_[YW_D3Q:;%6EF-+MY
MC,WK/>5Z8A7X)W_^RQ]7MZ]F) SVM>N_!AWSS7ZL7_Q.__#-TT_^R^_T;V]^
M$TX^P]-?_\/\DI^OA^*C+\='*VV?G_:E7_GD\7@;RPG%:E?HK0-:=FO0>7C,
M([4L([U-0>;/>/]TY?A2S7,3F5]$)#6N':VDS "2AK>G/_/OS$N/WAU[S0.A
MFV:OX#!R[NK-];\^._^F7_]Z?M3+T;*\#3<OO]\?'\:ONW^]B/E"O_K&/_[^
MQ2?]S3=??:%_^/C-;UX^H9<?^N2[:WWW!%\PQWQY4-]^^3_OYNOX]HY^IX1_
M]R]_]^77+U\ZB<5OOP;XFO\O>V_:U$:RK0O_E0K>?>[;O8.D<Q[:.XB@;>RF
MKP$/=/>QOSARA'(+B:W!&/_ZN[)*$D(2!EF )5S[],&@H2HK<SUK/6O(E>+Z
MM_$6^<;WN-;?],VO#=9L"2S79*P$;S%&UV2P>LL(L39CE<HT8[WSL:HMHFXW
MGH<NN6F:%M]_T^*W?[YYL?=TY^42;8IO&QIIKM%<XS%?HVE1\,UMBILZZUMF
M4IRS2AI!4Z".6T&,330?ETR)EM0$VY0BKER<=?]\IA21>(85]0J%$/(14\8B
MZQQ!BD;#*3.4$;6Q399/BC9;)E87RL%&30UAT7,."$[.2,N]U80':16F32GB
M2D)YNDVQTSP)SE R1"-NJ$8Z,(Z\<\P3K@B5>?_3\N='-5!^8"@OV)E@2<O<
M="9X>"B_FRY64D9Q'Y%E5B).J4!6@%6V@:4$/[!0-A<ESEKEIC/!RJ)XD2JE
MZ"RG05.9(I?*&B>BEIAPIZ5TP3U,/6)CD!=$\53)(988%DTFY.$G&&1KD#;:
M <L&5 L3F3'5N0&KM)>Q@?(=0UF1Z"D7Q@&2N8Q>2TT=45YKH-S"Z8<I.&R@
MO""49VH*/3/86AF13SR#63ID20J($,UBBBX0"^R:-7U$'@^8YY+K)4US4U'X
M<!">KBAD5OD 2X&,R<V&\YGJEEN,J)*)&!P]]G)C6VXMO>VVZ2VP4LV&FX+I
M6W(5 8P$$TN<C#B736NOK1".29F\,;0Y>7 %%=WGF9 ^9H&1D!*RWMC,5!2R
MRGAD8_+PDF(BX(UMHIO#CAXQE%W"Q&NF$\"56RT,HY$(%@)3+"F'FY#^2D)Y
M*J2ODM$VA80"X0QQ&BURR3O$ ,9)\6!8CB 00QHHKQF4%PSI+VF9FY#^PT-Y
M*J3O(X\>U@M)&AWB2F#DA/"Y1:&S@&7X?YE#^K/Q@]N']!L4KZY!)KE\WP8.
M:^ZX#L89Y_*N\X!%2I+@)J2_DBB>"NE+[JR3/"'IM0 4@VDV0C)D,8,%LYQ[
M#P99LF9?\2.&<I+8844!G%IP1Z(."51Y"%I838AV34A_):$\$])7U(O<#QII
M'0/BEG!D@O(HXABIU-9C1S:VA6K _&C /+]=\'*FN0GI/QR$9T+Z6@G-%4:,
M"HUX%?4B@B/A0^!6&*\U!0<9SZ'5W[U+P ]<G;]LO^ F87E+JB+SAN,(M,0P
MQYUB8-^8E8R1A+6$EYJ(_NKIN8N9B+Y(P0$QX2@Y"EZ'S<>-28.14AQ+%I*5
M$K0<-:N4N&R@?-?]@E6(RH=(DK9<*F*4=M'@*!WV%+NF7_!J0GDJHB^#(;DN
M$ &=3(AS("Q&$X5B[O"0@N*.YG:CR[?^;J"\VA'])2US$]%_>"A/1?23<#Z"
MT44J ("Y9!H98P**F+%  W&6AZ9(?\U0O$BUC+()5#<A^1#[Z(/.L8+@O LX
M,>L?Z/C QB OB.+I$P*IX]1&C8A-&'$O C*4)92(<,$Z0F2(&]O&-!M@'S&4
M)?,,>)E5,FF>E;JR44ICN#?",N&;B/Y*0GDFHN^LRS2ZVBAG$1=6(&LY0XQ3
MG@A36AD,8"9+]PQMP+PJ8)Y?+K.<:6XB^@\'X>F(/HX8%LD'1&T^RC,HA\ (
M&Y2TDB9:8A7.$%Z^[>_=%^F/[C5N,[E0V]]UZ"O47*.YQCI<8ZTS;--]]-1<
M@WAT>+3SLMC??7:T^_3W>TVBK<N\+929;&9L76=L5:[1K%PS8P_?R_Z'W@KZ
MS4T=FVJXVVX;XS[EL*<1%G,F@DM6*I+/0:2*),D>IEZD.1[KSEQL,E-,(H.P
M*2B,)-,,<:DD<B(0)'R46$;-':SI-MMDHMD@^HB1+CES7AK'*!4\6>P ]E@Q
M*A5/V!+U,.4D#=+O$NE3M2:&>FP828@QT-=<18LL(0Y)32,GU"1,34;Z';2$
M;)"^*DB?WQ%R.;/>Q,,?#,)3-2;1,"9C+BHQ/B".$T9&XXBTEYPR&;S4?&-;
M;34 ?C0 GC75+ I)-8D^>L*M\AJGI)4RGGBKT]!4-Z=3KQ7.IZM09.[J"E1<
ML> 1UTH@XXQ!E-#(8.T-%F)CVVP:UIQ._8B13@7&AA@=A&*<BJ C9=@1JXC6
M)!G1G$Z]?DB?*5(A5L("1P!W;M'.%<?(:1<1%UAH+G20V&2L<[5*1]LV6+][
M6KZD86]H^<.!>+I,144CJHK1Z+D#8FX<LC1B) (A G-NA8_Y=&JS0A!>ZZSX
MBO22;*KP;GNFC$Y1!T(M38$G3!RFGAKL!->4\X?:>=I0F3O3@G0FD\!QE#39
M *Y*[J?K,I&QX+E(2PRUR1K*8XXO<KIT)J&IMUU=I!LN:+"&!8+SQE2LC4Q8
MQ)";C6*#>9-)6#^D3V42K+ D*6.1Y!20KJQ&@&Z%4DQ8:Q^LM"HC7=#F<*EU
M0_J"^U:7M.O-OM6'!_-T3H'PQ*PF2(#361\NY12)2$>38%$3ISIM;-,YKDNS
M;W5E4;Q(C8]E$3.>K*62LQ!-5-Q*(07UWA#U0)TH&WM]EQ"?2B<XC2G89(T2
M U+.*5?(>;#<D6OKI92*YW0"P9N*+!V@:*"^NE!GVJ5(!!7<1LYCLE%SGO\6
MF'G-:)-/6#^HS^03F),X:.Z G(.+Q0.38,JM0#BQ!&!/E+!0@YTMW2>^ ?MJ
ML_,E;7O#SK\#GJ=3"X$E+APQR-%<"\ 5S9WB%1)2,5#F!#MI-K;QUBR8OPL_
M;[8E+-O-LDF9WK;QMN<>&Q^%P99S2C2Q =@L-5QYG:)J<@IKIO[83$Z!6<9D
MH!1%Z\!S8<DAYZ)'8-,<%XP;P\!SD9M*-X50CQCI!D?C!58V",>3]$9@D> J
MUH,+HYEM<@KKA_2IG )C/C'*@.$$#C\4_*:32HA1JVBP-@'[R4B7G#=(?RQ(
MG^NT+&G6FS*H!X/P])E64F*<;$3:$I<+  @RC@7P5+2D/$A'HLJ9A.9XND<#
MX'D'6TDO#&AL9B*7N66B838J0'"R8+N;W0EKB//I4Z_ +D>O,;(Z;R1,0,]S
MKVI$):%:,4.I U--\:84#=0?,=2Y93QR9DD"4B:C=]Y:)04VSD;,A6K2">L'
M]=D>F@XK'@A!.#"->,0$V>03<I@;29*%I:<5V$&G-V!_+&"_YF"LI4Q[0\P?
M#L73200@Y(P&II#&0B#.E$<&PP^7C#268BUY1<U7*8HVOXVF7JB+YHHV"VNN
MT5QC[:ZQUIF]VW71_/OPS<MG?^\]V[W7Q-VZS-G]]\AK9JR9L6;&FAEK9NRQ
MS%BSJ?B;NY+^V)6-"\0=L>(^&L^\REM6M'))1\+R/I7$I<&XJ?M9KXC%Z_.9
MNA\<M##":<1T4(B;7 W@;$146J-CU$H(O[%-Z"872Q_EW10QKR[40Z )"XR%
MQWDC&M,LT22E%M3D72NI*?Q9/ZB_GJX: %7-E4-$YA-^B,>YOCD?GND3IE8)
M;B1 G6P:V4#]T4!];H)A2</>)!@>#,-3E3]<2:UTLH!AZ1%GT2/'&4<B*NV$
MQ)98E]L?-1N.'@V Y^PN%,Q'K&3D)/ 4@Z:.*Y&H IUN4WB@ W ;6WV7.)_>
M2,RD,QIHN8XR@:WFN?5PX@@6FV!I%>=:;VPSN8GETE6Z#=17%^H82+E-1D8B
M+,=, E6+W <0"!PDYZ:I_%D_J,]4_EAOP/L&HXZ=((CK8)!Q.B++F,")*4)%
M[O+#-XUIB/FC ?O\SJ3+F?:&F#\<BJ<K?YCS4?GD4,*!(2Z"0E;A@%@"@TV=
M,=9R0/%*4?.UKC18D<ZD36'C;7<1BY0BID%CHX&Z*$.8L-$S+YP%)4>:;,*:
M:<'/,]D$0[553B>4(A6(*V>0=8*A)+7&ED1/G:M"C(SI%2J ;*!^UU GAC@@
M,5);QI6T%E/)9'24$YHD=DTV8?V@/I5- #QC3VA 2DF#.(D.Y= $8D8)9C G
MS/,:ZDHT4%\SJ"_8_6A)R]YT/WIX-$_E%;3'QB3P*H4CX+Q$ H8[. 7.B\5*
M<>R=5[GWT6S\X?:]CQH4KZ[!9HQX8A)3F'&>E+/)&##*P-VDYXG%)J6P?A"?
M2BE$ZA,8;(>LYA)Q30G2 1.DX%<!:^QH8AO;3&P2M724L8'ZZD+=R"")8T(#
M&0>L&^>##3H8JA(A!NLFI;!^4)])*9@HJ/!<HQ@Y..+:!P0>&4/,8PWJW1!E
M<C"2;1K5..*/!NSS4PK+F?8FI?!P*)Y.*1"%:<HGAQN;/.(T@,F6#%"LG+>4
M!!Y]K@+86B4'N]F7L&Q;TAORI4OG2%=N.O^U3.IK ?E<*5T]2\RT8MH%)SS3
MB6/)34I.:Q$9C<(++IO\R)JI](N9_(B*F@3+(HH^<,0E3LA9JY%V(.LN1>:2
MV=BF;%.954H3-Y4>=]V[32=IJ>8^2<JIL48)S4+D+H!<&*R:_,CZ07VZS6K,
M5?5$(N]Q0)QY@1P7%ME<U1,L#]C64+^#5&@#]56!^EP/;$G#WGA@#X;AZ:P(
M"0+GI&;0"2-NO$?6)(N4 UT-JYB4R#G.Y0^;OAL ?P\D_$_CXC0NSNU='!V]
M]X$%EQS73AG*)-'1F)B439@V::;UTYE3:29%"?5>@6.CG$"<,XD,C^#L*.R3
M2LY&CC>V%=FDK#FS]M'PGCDN3J(8?-K<J%AR0H@E,@9F'&/>4NJ:GK5K"/69
M-%, A<XMMHA)"@0I,H7R26@H8$D [Y''F,^2T)M&-?&,1P/V^4[.<J:]<7(>
M#L73:29#5(A*,.2MLPCPK)!U1B-%?*+@HPJ7-Y6S.<5?/ZB;4^6X?NE;UXKP
M;R@_;?^G^G&OC31G!D;SP/Y]B97BN!MM/W:+/H"FR.,N.MVBW>D7I]&V8<+3
MX'*'RW<=]#@O=J?WEEOB%G=_<M;IE5EX?^W&ENV7G^*3?N?L5\2J;T_+G.W%
M?(&-[9_(S_<RZ%M.V,[96;?S&71E/[8NBG\MP,.D]BEQ3*67E/- K8\V<*6Q
MP8)3RE8GU&S64X.WXN]O+M[_'<X<Y?+@RQYY]^68P_OT\.CY1]#.+=#@^!"T
M^?L7^_#:+GGW<8?M?WF>]H_^I!^8I=%ZY1&82]"]SLM<1@^$2C'E@3,'JN+\
M0T=KW>O*5BM+0-D&V,<BE7DRX=>R&XK_#FPWZX-.*O+2%K8=%A*=8#2UFC!L
M0N(F&D<<6.V4B/5Y.VI<'0K_PXG.QYWS#\DGZZEGB!NCP+_F'+E\I%MTAHMD
M/$M8S*_9_IKH@*&(Q2FLSDEO)#B;^1</FM&6^=,3&R:+PZ.G!6BF,/#]WB;\
M!JO2!>V7K_GTI&S;S>(\=F/1C;YE>[TRE3$4"9:_NN.K$PM+Z^.@4KE%KR9W
M1;]3O0L2TAN 5!2_1]OJGXS?SCHY%##NSEGLCL;A*Y[8:\S;MYHW>C_F36SI
MY49-OCKL^YGIVZWR7ANT50^&FM%1O'IS^/3-WE'Q2['[ZLWN_S:3N=ADGI^4
M_J0XMSW0(?%3V1GT0(D$T$BM3D9[+Y[9;L5]&H1_*\+9=R6PKRZ7M1M3['9A
M54'1PX+OQU"I_V?P 3^MPK/ERIRD; \J53^QY-O_<=U?MJ]^O+9S!]ELE/X.
MXA-7Z<M;?Q+#H!4/TS .\2:>=6"ZV\=[[9JEP C'08HCN/5OK8[_YT?C)E_^
MY/NO/SA@(3P$@P1.#G%"!;*YQXUUA"MA51(^U7P3UC:&G<SP#%$*<^Z"]H1S
MY@W5AGG*8DQ.2@[\- )'.8,EZ7<'(-/W@/^;XP&5/._NO#G8.WCQMOAM]_GA
MF]VL_O_:>[MW>%# G\71SO_NPEOOBK>[+_9W#X[^/5$).M);HQ$#83HNVRA#
M6-0G[N2PPCB&TNF&V,WQDY8]Z\5?1[\\ =UXUK(7OY;M:G#5EYX,KU5'2GZ=
MHPZJ&$O]]I/S,O1/?C5JRPB6HWW#FMWAC>MWR585")P*[-3O,;G%)+WV;7!9
MOO$]P>4W??-K@U5@.L6:C-5L$:/79*QZBXM&!GYT&3"8W_:J<_(N(U4&ECNN
MVR=OV.VP$IL:]-T>RG%C-HR(VSQ_#EK'[BK-P/,Z ')4Q<Y>#V-GN^T00S,K
MQ4$."^W78:';SLDW &:UMP?=;L9^>I9)6K>7@V#[=8RM-],EX4[SS\O-W^K)
MW*'O=QR CVY6/E[VQYKY^X;Y8^/Y(\W\+3!_PYQJ-7EU!4(S?0U\&_BNR?Q]
M$WQ7S[>X1U*U9!O7[Q%VJU9V.B?XO<+P^"[J2(81[COL>['(>C^V?1/S'G&U
M:\H6J,2(4JHH'"8Q.!X]LTP81RQWFA-I^.('\1W6N?.<N?"=T_BR,U%*N=;U
MT*?[+']N_YG_LO]Q[^+PV6OR[N/S\AU]_L_AT?'GP[__.'W_8N_S_M&;UG0E
MY;LOX>/!L^IZ%_!=?@#WW?_[CX_O_GXM#I_MBG>G[_]Y]W'W\\&+O])^B:>K
M*'' 7@8#*Q"BS7N[)=)<")3[@CMMHS:8;6QKO/1FL:;?S@,#]?INF+-(M<$1
MHJ@.2A@N2#!2"*E#TBHX+8*^1;G=5"_,!K)W!ED\7?AL'-;*4A2\5X@[)Y!C
MRB#I762,*F"^86-;J-F-2H^BZ^6B#)$-Q[WR@/WWO^^CDW_#KAXIN[+) )-*
MA+* .574.>X,]MS(*(C3;.%=J7-5]:/?BO9P>IQ/Z7'AHW+YZ!6%@\V]R#VR
M"2>$<? T!J(3U1O;=).JAGRM&_E:9'<Y$<X3;:E.GE.;+-8L*I.Y=Y2.T87K
MU1L<WR^./^\_S3O'=_L'7SR&^WTP+$J"HT*":H*X=0:Y )!VW(A &); H3>V
MR29A2V\G76$@_]B\;/7"J]^]'.2[Q5NO[M!8PV@K72;:VFS_OJ7A=8:G2#@1
M*@5N&3&6:)R,)DR#LO+A;L*3C>&](\-[,1.[Y#Q29AA!*1&'N$L:&<L\TH9[
MP@2G(9]=R#<I7Y%65PV.[Z=GBW'&<HXC41R3:"U6A L>E!+$XK#P7N$&Q_>+
MX^F IB51,R\2XD+GEDLYH,D-"''NY  KRJN )N 8XP;'CP7'<]NQ+&F2;VC'
M\K5<Q'IW8GDX[-(I[,HD0W0D(DH4V&!&*7+84613,($EZAC)ON\6;9#[6) [
M:X%%4H))R0E+D4LGM(P.0,P54UP!/)M0](JA>"84G11Q5.=6##H@6#H#3!HK
ME.E3D"YX&3"@F&X*LR+ME!H@WP>00[2:Q.B<YI*'J#0Q3"F%(\>.^[3X*5L-
MD.\7R#.Q:.V$E!(3)(C2B%LKD=:"(:UR6E E(ZT")+--*1LDKQN2%SS@=DFS
M?-L#;AM:?1<X+J_BF%)I JQ5/IG:(^[!+&L).!9*6V6D4UH CM76["D,MR_R
MN7?\KEZJHZE.GU$J^S$<17^RAFD2=H]%Z4U]PI@3)D5Y,DKBA+GEP:C(F*26
M8:L]-W=4Q=UPPKNQ)0=/9](DU'M/";5(6Y:=.T>1<YX@%@/%41L."UN5)U#^
MB,L3?G@<6\$,#RS LDL.CH$-R25P]Z41,D9N[R9-TD!U$:A.9T*8=I)Z\-F\
M4!A8GP?0&L^0]TQ$6*VL>#>V.7W,1YW_V'5$C8+[9@4GG:/)<\UX2!P>V%#M
M,?$Z@?<K2-1-%'K%M-]T%)I*HBFL(I*$1\2C$LAA'1&U05FE?) )?%ZVJ?C2
MV:05UG\_/(ZI24+2Z"01BCN>>WF+I*Q,"888)&F"T"N&XYD@- $EC -62*H<
MA,['$%I#.1*6>)ID</!>!62S]"&B#9!7.P:]I%%N8M /">.I&'1(6CL5-$HX
MIIQ+(D@S#W\*0AV5G@IA<VV'6.6-IJL76?Y!VL[=4I\,^TX7T7;S:3^]PD4P
MS3&?S_"I[&4% W\6??MYHLEVDS&\!]J54H@!\T"C<#Q$JH/TBGG#X?^HM::)
M\ZZ4OGX[6PZOO"/&.)2X=(ACI9!SQ"'+F3'9=_*>;VS+37"RFLS_X\4QLU0:
M(:0!+YHK;@UC/.H0.;!NSK1HRN%7#,?30>#@"*R/=XC)?$(2)PEI\(D1X8D:
MK!CV0N=R>,QE@^/'@N.YSM.2)KDIA[]W[$Z7PZ>H13(L@N45 G%A!;+,,X R
MPX9;G$\RW-@6=$[=3@/=-87NG)VER2F! Q&,<^Z3<Y11XAWC@O*86).)6#48
M3V<B'-C?W%P':<T(XGEOFDV,(4\SHW)2*!PVMHG>!([5 /GQ CD&$K4/7AG-
M..;$Y)(GZH!8RZ0M5TTJ8L6 /).*4)+Z%*-%P8B(8.TD,H$$1'6B3%,1@R85
MDH5IO.)'@^3YFTN7L\H-FWX ]$YE('#B+#?$0CKQW)W6*>0"X<A2YR.W5B>,
MOW;.].I =_62"TTI_(P^>1E[O5^+W<]GL=V+1;O3+VRKU?&V7Q_[.3S+N;=^
MI?+%3[RIE7^('(H-UE-#4[26)RY-<I@F+5,RW!@CFH[G#VU49CN>*QX5%\ (
MI4T:&"%QX.49@QAC$4?*>8H>&"%YS+WZ?GB@8D53\EPQBQ5W23JJI##*> F^
M'-&N*89_>*!.YT&P3-8S(E!0!,@?9A:9!%Q0)>>E9IK'F(,P9K;/^>,!ZG(L
M:_4@>NOS.AO=MD302D2-C6#$8AYU=(&IX&*0-C!IW1U%GQO=MHANFPXP6^N2
M$*#;(O4,\0B_.6TBPE' _ZPA5I"-;:X:$O*(@1H\EU1@"8R#\*0!M(Y%KK"-
MW%D7W-U$EQN@+@+4F0"R98Q:DR@*@1/$M9?(T( 1#90 B;3@*+"-;2D>\Y:4
MN[W&Z@6XFHK<V2C8]*&%O7AFLW(!E>8[O7ZO:*IQU^KLO-\&/1A/K[?[N>P_
MS0M(&M.PB&F8;3]-9&*2<HV8D@%QHQ6R5%!$M"'*,2PJR] TGW[4.+V#D_-N
MQNED@4 J/\> OL1NI\'O8OB=CB])K8.C*B"IL@]&K$=. +.SP/$D$8D1$G+$
M0E-"GSQB#*_*-1I=<M<GNC4V?UF=,1VWP8E%[2Q&(GB*>)(ZMZJ72!-N&+96
M1)G &R2-S7_$.+WS$]L:FW]?^)T)YW"*@Y32H0 KAG@,!ED?%%)!$J:2YE*[
MQN@O>HW5"]2L;G73]U!N?W>ZK7!>AEB4561XM,FZ;S\W9PXW9P[?WO(IIEUP
MPC.=.);<I.2T%I'1*+S@<N&HU&6BXGFW<_H4[E6V!S!OPTQ&I]W[K9+4^G-'
MN0O [N=^UW:Z,+NV>['7CZ>]@TX[C[+;:;6JW$<_=F.OW]35WY4=/9SM*1HE
M99[+B%@PN5473<C:P)".*G"E(_@M=F-;;&KZF/,B/WP&D^@D@09SGR3EU%BC
MA&;55G,?N,%JX>A7HP_60Q_,Q-(H5310@3 Q'''F.#(4)^0#LR2Z+! T=_S2
MRT?#&WVP*OI@[BZ;)2E"L\OFWK$[O6>=F!2P 3.N+;:(<^4 NS0@$B-/6"A-
M4]ZS3K96I.OP]\# _S1N4N,FW=Y-TM%[,'W!)<>U4X8R270$C"5E$Z8+!_(;
M6K0>JG4Z72"UD8R +@7RZQ''5"/+C4<>"RNL,=ZJO-=$;8KF[(7'PXOF'5%-
ML?6.4*TD)X18(F-@QC'F+:5N\3X"C4)8#X4PDW](1A$O;$(N&(VX)!19!XZ2
M4"9PE:*E/%8:P?"E#[MN-,)J]T9>DB8TO9$?$L=3G0FDI#XJZ1#)Q]5SS272
M(7%D8B2*!"N%UAO;=([/]-"]D5?575J]3."".<-?^M:UXFA#_=TW+;A%1P#Z
MS1T!_GUT$HO,-8I49EU0]$_*;BB*_PYL%WA 8=NA:,,GBU.X_TGO-NV9BQ.;
MWX[MHAM]R_9Z92IC*.!%#Z.P9;LH,\5H5_P$[GAX]#1?)@Q\O[<)OX%:Z\+T
MP*>*IR? 4C:+<R D5R^6@.W 4&/QZL0"2?%Q4#W>J#5#[M*0WYTM7J_?SL\?
M"AAT9\23X+N^TI.]J_T1UFTY_WVI]XOC;K1Y#?OP8$4&9 %+E+M9G$:;%S$-
M6FO]L#^1G^^E!<?-RHUFY38C767;MP8A]GZ=F=71T(8J'.6 S:],CGA,V0ZP
M9+\BHBN6], /0\3_U)4N5#[Y3O,)0WAR96X(STN_L0W."("R!/U:V-,.R,&7
M>NM)'/9FZ:3B7P^XFT)/^U\[X>.@U\\ZY7FGNS,QPMMY3V8]65<K_O[FXOW?
MX<Q1+@^^[)%W7XXYO$\/CYX#F_JC=?AB%Q^^^.OD_8M]>&T7V-@.V__R/!T>
M[7WY("..(4:)K%<<<0Q.D+$2(ZMX,EHE)9F:W\RI<"6XJ)UL0 K@-2>5CK]B
MMT9F"^0B+V!EOBKKEG]91%*6K>UK)&5927EW\8$H%0C+_3:5MX@G;9#QN5F+
M)T)1(34-]$$KJYM5O8-5%48:SX1&F@2%N )- ( **()N#AIKSV35S&W69;HF
M$/(5K3!)7:=UPE;1V.F[LM,O@;X=+V6:[QR:ET-Z&_O]5LP@';9T:\ Y#YS[
M1SL7^Z\_),)B[GV$A-8><<D#TBP#E7"*H]0F*?*U7HL3:/PZ$+>*.Y":);?=
M-5*SM-1\]/CPF6>'1SOLX-GK\X/C#TQX#>Q:(^\-1KRJ!_0R(N(8HX8:YZJ&
M35O7I;I&$O3=.5LC#,L)P\7^S@<6N ^"8<1DDHA'$Y'+',Z$R(+@3H$]FW]X
MW-?42?^D&\?Z),O)M6J&;!;=V#N+/H<56A>3 :8Z8M7R115UB*%N:+!UWS&1
M6UKZ8I:>K%5PAG[?X,Q48'!-8S,4?W?.5XG /,[W#$2AUR_[@VXLCFW9[BUJ
MO$52@DG)"4N12R>TC(X3P1537($J79CRO8!1Y+368?M9V1N)[6':Z?7BS%ZZ
M1F6/6-\N!YNMA<^]R"S"A#F4>Y_F]D8",15!6W-F>#*9]5UWU-1M61\9*]L<
MHC_O%*X+ZAO>'?1[>5]2_O*?6V]GE7 #TV^$Z1V'4!U(0B0 4Y4"MXP82S1.
M1A.F8TH^-"'4^\;KG@"\)AJB4MPB%53*W8L#X-599(5+6NN4B/89K]<U1?U6
MCDV2<<9RCB-1')-H+5:$"QZ4$L3BL+##U2S_@LN_?[Y__L'*@*LSB:(WP*JQ
MU,C:E!"5).%( U:BBJ%==[S8=:SZ:S'TJT1ZJ[ACQ7+G;*"1K$4EBX-D@5Y)
M(G*?M^P$D"R'D;8F()*DH!%+!_Y[+FBY;C_?MRJ6$*TF,3JG<\@I*DT,4TKA
M"$/@0$&:A,N]+[\ =YU3)D+>N^4DAN5W+B!'L434@;[!+#IBJWJFQ=SUKX7A
MI]7*FD7E5YOZW; (F\,JF5,8\$6NL.ET0R[5J4ITQLH]NT]%"9\INU7UC ?7
M^KC2[_;LK-OY#+CIP](M&*MC2>3 +=>, \8U20(S+KVF0GEVX]:(&;COC<=W
MF"XM4^WZ[7[.SC],SXM.)YR#A#8J8+X*>(</C_;HP9?7,*YW[.#U!\F"Q(Y0
MY&!]<C+ ()>"0](0< 0X\/VH;N,63CA]E7 AD!L?>[V,_6B[_J12!R&""NB<
M54)62=UFX2*LZ3^P+*[XZ8_V'P@XK^)<TI\WZPM5(8CC40E7Z Z.Z[ >B'4_
MES]5UP))W>EWSDI?/(MYV<M^V2M^VGGV<W77W\O0M:!"JE??#L[.!KDD[),M
M?OK][<];Q0X :WCYLEV+3?U$QS87T1\7X/:4WOJ+?)M\WYUG\,$ +U6?<]&#
MG!;VDRU;N4ZP.#\IX7%;>3(FL#<L6,LB6%73Y;]AK&4;IFWXSN7<P(TFYB4_
M[\ZS*8]YN!P'N3ZI]/7?OMX>8.M<ZH1B'2H23K=4CNG-!OS.R] _&6UWF/AB
M75SZ*[[\BG6]3FO0O_XK$_6JN4XM=K^3RJ9J:L(F?IYT+TW.<40.!.D?9!,,
M]E?;.K<7O8U?KCP3+!.:FL/IQ_\^#WE421R(2]X9 K,][Y&G!*-6>4:Z2+TQ
MG@+*E75:!NX$H9HQ0ZJ#<:[Y'@'*QKD+VA/.F3=4&^8IBS$YX/9#*P#?B6$G
M:]]<@P538 -7D5.CP)OTWDKI.!728+?1$(!E",!.T>KT%H[+WD&(9VI#PLA(
M[]ON/[$JEWX;_: +*B/VWD30!E]B& 5O&]L\WS;#=8X_\"A\S-N&5!1 ST..
M^(#/CQ@+GC"1DHY5V.<VWIFMHO:+"L>=!X :F5A")KZ QTYP"MK"?!,2-.*:
M@,<>J46!61>4X5K>KF!C,C /A*,NAQ\[<D"NBT^V-:C,26^\4DM%D+Y-/=U!
MH*A13W>>^-_!^\<?;.Z9S*2'^8@&@9)P>2-41.#282 42D@K%RK8;-9Z9=?:
M>8$%TP$YQE1N]:.1=M0A3I.(45OFI9F?@;@WVW3G,<1&2)80$G+X^H-@V)BD
M-#(^"XERN4^R(P@KR2((CN"YM_K-?.4N;-,"0<@F!'E7'LC3P[_VGB%BBK^L
M]WD!>H.SL]9%T8[]\T[WGZNE5]\]%YVC/ZTR]TAHBOR^ NV]W-/$,4MI# I1
M<#H0QR8AA[5!"?X6U@AE?<S0ONLJSSO/$S:+OG!EYSX]V/D0E*8B,8Z,4>"+
M*F:0$08CIT&M2QJ$XM<0@-OGH*\I[:QS%VNLL@G][BH;AG!O>SDXE3IAYJ1/
MG,1\HJ5WRD:L5'0FLJ8J_X'AR@YW/A !OED00-!Y\O##,>2<88A[[CW83,Z]
MNDW)R*+Z6E%/K)*P(CIP$ZWEV!/OK3;@$\)K357^ PN# .>-)NK!9 <4*UX>
MA4*6&8(4H=RII,%E4O>DNV\LRY_@^F]*^$@WP!5>7+2C!WW7ZY?VN@K][?^X
M[B_;*U"^GY7[7GOT\./]Q_ +OIIQKQ)@\*AE.R=&BWRK6,U0U8\+9KR <0P2
M_ (N3?NXL-UN=GRRQ/>JO-^G(:L>]L_(2W)>5EL@\TJ<P4)<7'>M3O?8MH<E
M,;VMXN@D@J*_<H.JM\>P)G<TXNKJ:5 5?5=4OOIL[I[1.3V-75_F7^V9]67_
MXKH1YKDXZ^1\%'P:%AQ&U^ZEV*V25543FUY>_-[ GTQ^K4R75RY[52.+;OSO
MH(0)S,5H-X8A-W.9VJ!Z,%N&:G PX9]*'ZO;N9QC;8$T=JL*B#">MT$UR(YK
M9:U3RR5\MKI&[8["O-UFCI<LF%BREZ2>; ZU4TW$JV[,3['3#L\&\:BS/QYZ
M[#91C6LTZ7'>(AF5B-(0AH1V$O% 07O&F!!FGFLA-)9$9.UY4Y&4K=K:I!9H
MP4H)5")\5J_*B'O5VYLZ\$ZM4?-' %+= 7RC55JX5!WK@-=JX1Y>9@C8_[^7
MQ:C7:96A$EYG6[;M ;LG,?8GBQNR#IX$>F[B<T4]C9KWC  ]69"0O7>XI)U5
M4I6^..X JMK5)T?*?4K[?%>-?HM]4!59_K9]4.SGXOLQ_(WM_1B.HE_;YC2K
M'-M:WE&2SM'D<PE<2-S':*CVF'B=4N2"1-UL>K]WC?YE]\O!^0<J(NCR:!&X
MK@)QYB6R3@J$'>;.2RMY[DFQ2"HB*<J341(GS"T/1D7&)+4,6^VY6;S34+.R
MW[:RPC%+3%3(*0*VVE&"3%[>1*05U"?L(IZ?@;C9];F1<E[;X@"XP60SHZ]5
MZ%XZ1F>Q!6RU *UV<M.6Y4:G?W/%5.Y]W!V,&/QXGL<USPL5RUCIA:$!?.O(
M9;".&&:C"E(FZWA2"^OW-Y.#>UJ-J:'JU\!_CQT<?Y!:@&45%$GC\P%5AB =
M<$"4P6Q;S0.WYKLW&^,VU\"#GDJ2<QF]\]8J*;!Q-F(N;FP+WHC),F*2=SV!
MQ^9"<A0!\P+[GV7%!DT0E2(IS1B\ZQ:R_\V2?N\EM=@$1X1"4CL/AC\ZH !<
MH* EQB)(KA3_5L/_C5N;&C.]HIO:K6"&!Q98!+G@UEK0!2GH((V0,7+;[&J^
M;\A6&64I'*R$-RAW8T4<YA\9;0TB5EC%@PA$V._KA37K^BWKZB51@0F6ZP.
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MJ3!3!C51R;<.;M)-[L4EWY[C8\SQIJYU.XJ?X)'R9CF0C=;%D"3_7%?M#U7
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MT?;P<J /:Y,.+I[@A0!6*_B:51S+HIBL$&C 3)F4EK8_= _W:+54GJ-=!H,
MK&7'MH@0H:^D:+AQ1MLC?,AC.HGU9;^;#,5 #D(9=B9]$8I1TAFV!_U)MRUE
MB-UQVB.PE]M-_L./*S9']_B?>PPT&"/.0"8?P N2+Z.;V-\?R?FM>[)W\$><
MR&XBVZUF/)ITFF$OBIO#"/\YB;NM@1C%T6CRP\_#G6I$T6LH1J70)?Y>HZQ
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M6*)50<!\[#G$N]37L[7"#;94@4TGOMX+_@;TY&7B'E8WY5?7NSLHJS%J=_8
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MQ886(E41]EL"G)-MX(:XJ9@,W GX6;:DDC,?7/4891)&[2%8,[V^['7",!R
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M'R67ERNPY3/=*X"H!;/5LL "E;HV;H';ST/EDO2@4!'24IK<G^Z$9C 4#TK
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M8 IEV!D&W;9-K\#?RAZR<2K]P 2--SMD<NE+Z?$?&P^S+!]B@J*M^E/C<+6
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M:'>)TLM![J\Y.5PXQ',_'2S&C$^'VH3]6Z4G+W*1N &UQM;;B]UMRX&S ?H
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MN]]V:H^><E,;H[QN$$\^<VMA%.F\!AB@:C6?<CJWW':8JK OH)M_S/+KP!"
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MJ$E<U&+!YS:9B%@".\<& 1I<;9-$<PGW+?#PQ:8\%@/ E_$ TV5AW"0DC9J
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M-@V3@C=B*%ZSK0+2KF*VJ>>]^6A83R3[95%?CXUJM*G;]MM&X/G@KIB62]P
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MVX0/:+;ANKYG$S X?,5IZVQ9;R,+U,@"ZD7G3] .3MO0E:8&:KAI6(K?=)U
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M^B*=7%V>GM^5]]R<W7[]<L=ON;H^NVFQ"[>"-X/-5]9='3CO;\+T]PEH:]#
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M&VUNI'BXLYFR[ <^6$<VU,U4.M_$6$UK,Q7D-S%66]/74>E<B!VQS18TKU#
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M/.QTCT_B7G#\N3?D%P<T"$D&STAM&&;";@X#&OE $WCM ^WU^/" ;SIQ\LC
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M;PYT-NAY=@O\^8E$R)*T"]#= 55ZC)B91'\,P@3\Z1DB,UH4$L;F!^8FH^:
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MZ3H!CRYB_XV!_'T6&R*Y+]&F0#ZFL=C,(FZ9#HJ;$OKW, ^@L3D"--&P#3C
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M\'YX7Y\D,'4I2$ .(LE[Y-]IQ[U>_,#TFW06!;$_S.#M$MSZG68@H7Y\S]Y
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M[H6#H+=CIJ[)#Z8Y4]KA"@( ](8I/ /J8:;2QV0AE@>FZ5F-#UZ6(UU<E$.
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MH#V7W/!2%0]I(SD92_:7N4[".,F;A3[M"=HE+%^=L@Z3?H^D:=@.:<#:QYS
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M.8QZBGY\OF5TBUE(<)"=-X2 -</+]V<P4#;20?)?'EHT09&4HB#_V/+YU^?
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MP *UK(->%@JL1#,KH]JK?55#/,(A#U,$(?^>MUV=*,GSRY!;R]M>,>VHKK5
MX=:A="LN_M4B"LN ="J>8K$A$M+X1-RAZ9YM%_5+DEO'5:^8%J6U -FO.A(-
MK)"FY_\R2KS:2-IZ'X@/LS9!WMX%O"5H03S";XA!X9[GF092MQBI=71:O6(B
M5[5U[,O.NIN9XBT49KE?32-I.GX&D__CW><!>?PC:+D[Q+Y! X%S/L-.Q$0+
M/M,XZA<D-X]VKZV=<-$01TU_B0^<9A001G)0P3KH\&H@Q=6 _0 -PMMI2=D,
M91&[0^'+&,G3"I,;"H]B/&T-LM?! B4LKD760@YZO!I+80;(C+RPPD](W!\P
MU6@7)#>2;J]="&'J3#;9&8:[,JD"K]--]N!BG6AU@4D.W$6O70A09H\QGF33
MRQ+E>(84]>,T$G"M)N"+4Y<X"4F?!C4V!U^F'#G X$(6HI3*G+V&=2@^]2%3
M#?:D7(=7\\C!]C+@ZT$+_E\A#JE.QSQ!P#1R*/5QJR%,"E^7>_!/S<@\01#S
MF97ZB%5QRN&Y !=:)RGS!*'02:3DR_U@G]HRWE/JP_82I<@A?@MN\-/S.!O"
MI0FR*37C#,^K891#-MYBOLGMKR:,PK2T2,&C/\A$],N3&\L5N,+/,9:]'E:L
MB+4XV U]M1MU5]_'-J;X ?L1YJ^T#!Y#S'SD]:,@A(F1B: I]5>W,%FZ<21S
ML3L(0IX0]<)CT,LK)K7$7@O\[6<-6YD83:)R_.1-JK2UUSH. X/>#:%X$AS^
MA=MN5ODTL_T$35=RI\ 3<H[J2),;"?@'A;"=],:"D\\_2KL-K+@7Q$=E&!RZ
M.HSA_%4A-,5!Y-79&GR)4N3(=WN=0BQN/R1DBRTS@>S8 *5;HG@K*?\DS2)_
M5X4^U%6<<OC [RA$Y J779PD$D<G>9XPN,KYY:B JU (HQV?+#KUX?.H-;)K
MHLS'\ =F3X9,3Z@<1UC%*TZ(Y=='V>^2HO[;\?WU_/C!J?COHT>I^)-4R>MZ
M GU [5\3S!Q>OQ7NKY&_PD._RCT_L] "VA4YX?NS)?+XZSK\@2T>6M47X1-/
M["Z^/P.$^/L\_'G"=UL1IIZ+)W3<B F%SZP@6HA)CO_UD=%H^_XL)B<AWIQ9
M\8L[^_<*N1"NQA"^Y)(.+W/EJVRWF^V+UHB&.+B)<*?5>7N'-PO^*,^A@K%V
M<?VJZ7]@;5RZ0<175V;L.]2CJYV\"GDJ Q2_!1M?B2)F. SC+Z]W/'**?+[/
M+<14U4>3V81J4KYL%-?X8-_9)8/1(.#)%R2 ,>L+"=?$GS/PWBI[6#TA=6H=
M?[>(,YS?GSD,EBJA9F/$GVRH#^,JVZF;XFA8=M;\'<^DSX8T0.)X<47]-3A-
M&%B&=]?3^\_#OBWOC 4R \PTSB3<)Q#8[A]1G%$XA"Y%&/^-&V$E0MK\SS!.
M%R]^F&T.;NZG]FC.B+<E#P3,#,LQK*8W $P^/B#FK&UP4?$#]NA6(.$+7R0(
MDOEZ3F>J3E='B@D=4.R^:<Z(9:0&8#=X8(BW.'TDGL($2R@-J, $>P_$N<,P
M+07%"N06CD52 VIP!W,@K-[!Z(E35H<L".6T!E1B,AW\/IS-;?ZS/[X>?H6?
MXUOX8/;/N_G][XHI2I?;@(K>V-/?[=O!5WF%\E0&*!ZG!?!9\0.CFWAY%\'Z
M)MESHGYPS1-!<28];$3A=S\$Q\\3YYA"#-YIJ#F>_[#R3!CY^^-1?S"=@V&&
MZYVW76-?O+XC-PH%DP$V8M]\MD''&X6#FJ,R0'%8)+BP8$]317<9[V44<2W'
MR[Z'R ;YU5Y/+1GJ.L<OQM=;0!(P^15F&D!=--]>W. %?,:#\BZ/$W15<04I
MCP$@SB)PM)AB(94C,D#MW_\Y'WY43'#'- 8H/4&[.,F;LN.0-Y9T$!F/J5&
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MC5$4*E;NQS0&* V#Y/V=XLSI,8T!2HMCOID$7?76:#FY 57ICT>S^[O!]-/
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M(2OI#:A,[D;KH_O<@O@VZ\/-WOO-*-T+LK7%_<4!Q)S:Z7F>\=)V71)O'DR
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M-Z,>?_OU'%H@  O=H-]^^C]02P,$%     @ 6H!;5<'0FW,C)   KF0! !0
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MG]T4[^0\C%H*^-ZC&Z!=/ C.\3SBM"746\^]@7,%\B["^LA_C?_U0YJ<_[A
M]G+RN0LB^C=0MU'.F%B\>?GO;KR1J!V-1W6W>$._O/S']14[O1N_S'&<,7__
MW2C__?L1UYJC3)Y)GU20/$86=%!2L<B+U^YD^8B*8H7C;))N/?&L[F&3J]><
MA8AGB]\]R3@Z^7D\'\V_OAZ7R?0\7(+'UW,\GYU8FWPPW !FC*"<1' !!=@L
MT#..T>4UM,U6:C##],/'R><?Z2T_5LG5GRQ$N"1NZ[N7<GW<BE;'Y ?ZNR=,
MR"BXT, ,G6S*Y@P!T4(L]-L.?0XI]5K#S;?=1GVM#R^F*_R7G\,COY=ZR#=G
M;CYI(+HE+P3^^^\FTXS3OW_/6E#X_UR$Z1RG9U_?X:?)='YBDY+:" /61%8A
M%8C>2T =HO#T20COFK!YY\5'0VP?@=[GF+?@^'><CB;YYW%^13;MB2^$ALQ2
MX%E94)IGLC-S(AUD2'\2,8?<A.%;KST:?A\OS/OLBB:;\#20)5$7>:EQJ&-
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M-E:=#2B_-65J0=8 ?MAVH9RDXNC\3@Y(%A$4-^2.T$D.5AE?;# L;VT/U_X
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M3X'W(0H_AEJ?259QK0,$G>MU!C+PIC;4$QBLD4G3.?%-Z_-#I23/2YUWH7L
M-5[:%>_K(HB:JPX</"FO4ZX!-EM'C[L$GL0'0DB18\2HFQ<<K$=R@%J#)\'T
MVHOR7C0-FO-[':E]-YK]L1RQ*0*9\S: SK4#/<L(P='7QEQ-T-<VI.8W8=OP
M'(.1UTS> R3;76-[.1G/IR'=G$;0!=M MMHV7(>QM]JQN%$]&E$PP'FS%6.4
MUC*N,FA;VS^;VDQ3"05".9&$2"'EUI.A]J\>#Y@OA]&.720_A#&]3 ']^4LZ
M#>./5P!7A9DR*^-RA"Q,)G"I0,2D017)D[8^MK]!V0KHD)>K?;F[:]8V$_P
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MBK1\_/%WG(XF^41S2[MB"H"^Y&5SL(C)@M-U<*@S2'0]PAS9%<?S5I&],S'
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M<&G[S-1Y%[KW$.M<S2M!IC5W%FSQ@5!)!%<=):\%XR$X8P</9![J3OAI,/U
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M9*LZ#_3UV[H#^&SW,E5L(\*GT?FE#\==6E^T(6A?O5M6:&_L[3<A9^]#Y*Q
MXH'\GY+I T."C-&00R1ST'*X+MN=87Y;BM6 J@$B7Y?=H5>%RVM7\-O-*8QK
M)H4NOYE;GXQ HYAU8+,1M"A._C<C+\<JI[R3WBO7NE?J( LY.@T]/-T#-'AN
MLJC5Y_GUYL)DD#QQ<NK88M:BEDBB+AFL+$7[HJT0K?.@!UO,7[H\".T#)-/>
MO6G[Y?-OHQ-N!#<&.1C!(JA@ MG,P@)J53-'T5K=.H5V'8ZCTZ+>PKZO +JO
M KSX3*M;Y.-.IC73^QK=*XSSZU^=.)%<"$E#5*K4^UQ3VR9[J/G6*41FG&O=
ML:,KMJ-3E$%(N:\\IJ_R_'0Q(T=[-GLY.8^CY=2SVH*&MCV2!_UL-J+WA&6H
MZW+O.Q'&%R-E <TUZ;ME'CQG&9AE='2S%+%YJX5'P#PZE1J:J@$RNZ\E<G5<
MOKTQL7UA&IY(GXN(,D+42/9@T $BEP(DJF"C*DS:UN9_%US'&09KQ,.@D8L%
MG"N@_Y@NNIA>:700+" M7BE2:R59;;@5!#B#2>M$YE=L/?NI&[+CU)=F7 PZ
M87 9ACLQ4INDG09;FR<KE!J\#F27&9=$R37WJ'46Q%T,1ZP%N\EW ,_]@5WL
M6B]E"-GH@F"+HD77AGG>. :6L621.X?-T_>Z8CM._6C(QP >\AI(MW>TY?G'
M,#)1$@==5*VOYP5",A%,85IGJ5)N7FG8#=EQZDPS+@9PJ>^CK*X:S](S;AE(
M%VG[RTE!S((DX*-AL:12['#W)#> '+<^["KI 9SB=:D2M0SZ7@K]['8._>QV
MQOV5AJ_BWD%S7L=R1I=!%4N&D@X*6,J:&1/)7&K=>7F0A1R3^AV>Z89>=\T2
M6[>@/SLLZ/9Z7BZ&O[X>7XTJN8YV&Q6SE2*#05Y[#+H:N0H9I-:EU/%=M+H.
MN7U#XSP&)7UR?-[757>HK7;#]_?[Q32=AAD=(;4)%WDH"HK+]9:1(3C+#80<
M&!>2_)7F20U#K>48=/E)\7U?C_T3T^/W.)\O>QZ0,:2-EJ%8P"3(%G9&@G,Z
M031"%\\EL_A4[(:'5_.7+C?G?$TLMG=6XC!V42P\)>YJZ8(W=62XA>BM!I%,
MHD7EE$7KY,4]6,"[2_>A_E<B.Q\S \RU'8])&3Q+#C@N8O"R8&R=%?Q4>G@.
M_]$VE/V:#Z]_AMUJM3<&:<Y^"F=AG/#]*>+::1$WAY-<S9Q89;+0WUU6YD8I
ME4M,0G HR95&5D>5))!)9D<?IH^ZM5H-MYK]S]8;[/0X+--/I273NI4O!\4+
M9KG#.H6I7DOR&@JT(8!**G'!BV*E]?7P)BR'*KY_*JIR-R&A!64#W"2OP[5J
M:=$!V4#%^)M1':;RO@U['52BA^CWK!Q>:?0)":'/=< 2816TFRO+A F&[-7F
M>>C[5HH'*N;WKA,[2'RH'@O7QM^-&XC5\)-D&3(3H&A1+@>J>)O <9.]8=D$
MUSK9Y"%,^[?%6_&WKG-"*^$/U2OHY29P=&Q*+J("$00G!YV\="=D;:C,+7TB
MR6O6VIC>"NBXU**)V ?8,-Y,QA\_X/2\YO!>(G(LN(R1 W>UFH6[Z@+01FFU
MQ2 Y8URV3H:]C^)HV.\IX &2S%99MS?:J2_'Q(H4LD<+5H9:YZDB!",U8 Y<
M(EK%0^O[A0U0_O)*FA.V)SVJ/YWBU?3H#@"'\DT> G<@%Z4%E1W4HS\/0S@J
M#P(-6N:2% >C!6VTW@8(I1B(R?CH4)ELQ7$HRD-NRT'T9!?Q-V[F]>)B.IK]
M!X:S^>GE*8DQQ%2"@U#G3BF7R5C6*8,,)7-ABBYW/96U:1GW'GP RZ*MX">M
MI#;(>.U5,Z=Z'"Y[T?D4=4P<"J/S;F'@AF 2:+0IVE#):EU#?!_%7Q9%2YH&
MR(2_C>AEF./'R73TWXOU7JIV%X2##<Y^"-VAIF?WXW&K6C0C89#)V0\B#9D%
MS6J.(A;:"=%Z<(5<+:F=P)@BB[K]^.S#J,F#,[3WK26[R'Y_'=4%BRX::4'[
M;&NK;@->Q0*(.ALFK!>JM77Y5#JJM^:L6V_T702^IT9D[T:S/Q9?@ X^H$ZD
M]YQ'4*(H\#YY8$Q+79@NUNVC4=T*SU\&RC#4#5I\=5,.JX'U'; -9*1LPW48
M\Z0=BQO5HQ$%@U9_K\&8A3;1U [(:#PHQNDK\9:.8^<SUSPQ'EL[1?M7CP?,
MDL-HQRZ2'\1PG>.4CN)W= 2OT*TFB0CE0J #."L60*E$3GQ@&1P6DD84+IOV
MCO(F-(=,D.S+VCU[M8G(!S!0+CMX_?PE+:I9[H!C 5WQP4)R1H.*6H+CF@&F
MS)D5*I 86F<W;@-T1"K13O #;!$O:]'PJJO;%N7-EL=L%-G4L:0Z-362=9UK
M%P-="+3-FK5.[ND([8@T90@RAFAC>CUQ[>JG_S'"*;WD].L;_(QGBU-59"8B
M$JR<:K)!]AHBUPZ25B9*Q6/4K3W@;LC^<G^&IG. G@+K^^_?PWOY%78!._2P
MT"Y #SX!M!GC'8J[VM(UP&&X&VC/4O B""BB]G"J#1:"D@H,;<U2&RYT&FS6
M\>%TJ_LTSJ>A6KNP-*1*+:OD%A+@J^L-BSH8,OADD;1IN\C Q2C!&U.*1"Y3
M&$R![L,YX.3-]D1N4IF>+ SAEJV!)E;IFE8)SK@ O2CX](R6C)EL#>X4TI'.
M'6]]J[0%SK>F((]A84\[B+R$9E5R5M*2?:@=!),/$)A 2"([Y#P&&?>A(/+;
M5)#'L#!H'\<;K=;_00M^0][DE<OP#L^6E=FGHT_+6]DLA4J*7$=KZBQA)\ Q
M<AX,3S+1KL>+'VY>U"Y(_W+7]DWW #W!UL!:#8SM &P@5VTCJ*=S@]6:V<F0
MM QP^FT&F!)S28A(>SC2;EZ[=#M6 N1"!IVRHC;)>-[Z\H@KK8.IRRYL#&DD
M72)<!4I3$#D'!)<7'7>Y@R UX2N13FDK_(#VT2TD^S>-&E&UR0QZO)R']*%^
M^KKH?_KR+,QFRSA#S+[V9:]90 I44 *B(^,OY.10\<*<;=V4=B.8O^R8 4@;
M8.K"%;!EV^Y+UR*_O=-XZEX+I-L=D&ZN:A7E[+"NH8/2C==T\/AU']79I)!/
M@?<AS\C6ZY-.F<@, ZVD 55/%:=8@JB$8R&X;)GZIO6Y>\S\.:CS+G3O+]\Z
M2FN]$1YTJ55-H39B]62,.!XM_<\+U*T+BI]*OO738+I;EO8N-&VT%/_MQSNR
M?4._O)XO7V7W#LMW];__?/=ZQZGR+\/LM/Z_+N!S.*N_%<9Y7=^[M7/E9Z/S
M3V=W4N?NU0HV>O&/UVN^+8O+M]_2LKVL'K_,<9QK<\U1_OOW(^U39$Z5)+DA
M7\#2+XI'R0OICU)>KP_@[HZA9PX4O>O%.-]YY9NK-G4R>&\B+X"RR-I.GY'#
M)#2(VJ8N!:P_MLY]V@ZI?U3E+'^8_!KF58XW/M+%QS\J(\Q7(]><T\[3:0/!
M8P$EO(5@8QV9["*FB-R(UED\W='M?Z]MJ2OWHRN#L#* P[T)Z0GGFM88:/DI
M!EI^T>"9SY"9D\*8HA/;E[8<(N0R#'\=U60GX0\2JEV/ZT5*%^<79[5O_C_'
M4[(Y/HY'_XWY/R9GF4R3&JP\*:%>MAL%R6H'RM74:%40T <5.>-,-I_M\7BT
MWYQB-29P@"O03<BOYS1X[V/6(0/7F9%<F".34S(H*+*3,3#ZU9XT[(!#-@ZL
M2(^C8X & )O'"U^MGP414=D"S-2\_"2JUTV>N+,*8XDB:];ZZN!A5,=E[S1F
M88 C[2["V\.G7YQ/IO.Z$[Z<S.8+%_LDUNKE.CR#Q^!!1<(;0[ @R&4NG@=E
M9>N4OETQ[E^'6O/\@!HU)6G_2G5]V"X&^M43-YS5!2RN=;%,IO@A?#F),@@4
M0I!"F B*T?X<,0C0"4,T61M?6M]L-0'^K:G? '0.8$!MEM'MY9QH+V+,OH!D
MBYM>$I)WKDX,XHDL!6?0M8[U=\5V])K5A)0!K*D[&G\'-5D/M^W!*]D$1MZJ
M\ JR3036D+\0G<(Z2@V1)^&R:JU+CX1Z7';7/O@:8(]:+Y(7\Y=A.OU*CNBE
M9U$#S5$ET,*1WU)\!(>*0?).\,R-CJ;U/5 G8(<H4]T#S7<K6)MS-( !MNXF
MX;)E]DE.4A@N3,V+(L<4<ZDM#35PF>D0=B%RW=JLV@+GVU":5GP,M.?<5>9Q
M?G]*/D7MLWW=Z6IVXFF%AID",:E,$A 90DADQ@DKK><Q6M4Z8- =W;>A2 .Q
MU=!DJGU4NZ/<[CR<*(-:6QF YYI]5RLIHTX2G"?9J1I_->6!B^B6>(Y;QP[&
M7,.F8KNM8<VTXQQ=8G5@&[.*#FY)D$/V"7Q"B]S*[.^FT_;4N*<QF?JI:EE/
MA@;HTO ^G6*^.,.W9;TEN$P;-C88Z9F$%"V"XA(A%!(4V85&L52TQM#XJ.P$
M;%]3$8=T[MHSL,X"/\2(P]?C,IF>7^:J7785_?JVW/@\ORZ2)C&*5%3.H%%:
M\BX6_<F13,9@';/HK&S>RJHCM$-5  R@$_?:GK7G9JB)91].P_@#GG^:3,/T
MZ^OS3[1W5O5\.<4\FM?C&1?#C)>7W*_'/X?IF#S7V:J/+<[>EAM[\&6J9)>%
M#93;/]BB#M5F? !56C<EZ\GHP;-2]*"#1F,R2*MK-P0R;4*J_0RY*3($D9-J
MG4CQS!3\P0;ISUF_=Z%_H!RS.2&YFUERU<O%,QZS (R*D?7+62UR)'28>%'!
M, Q#I!]N1K1_;^6)4+\F(Z@1;P.DLU[Y=/1ESFY=M*U:MP85@M0"I&8)E$8!
M]'4&R%$YZ73Q!EMWRWT(TU^:-0!W@P\/6<[5HGV=\Y# :4^&MM0U]I@-)%TB
M#\KG4%KO4D]G2-$^?)%>$A_@%J'#0(PN"/^:-[03C[M/DGD,"8>9-V2%$BH)
M!.D"!Q5X B^B)'*5Y\'3;[)AYYP]Y7E# VO)+K(?HF,W[9>KWN$J\^R"A&P+
M(8FUCK*$""%GE;PTR'7KLHGKMS_)N4([<;/F]O 1@AW 'GT_^8R+GO&WKQY6
MQG).27(GP!97AWB39@=%"),O)6A2?&=:YQAO!71TBM!._ -\_M=XWDS"&//;
MZ?O)6?[GF)[^XN,4EQ6T'R;O\-/%-)V&&:[.-F2>-#=6"]B"$E*3,54BZ,"X
MSR4EY5O';1X)]?CT:0^4#9'[,IE6-V^.:S\#;E%ZK"5>K#:])/G4@?6$4 F6
MH@^"-Y^>O!70T6E-._$/D/+[ZV2,7Y=Y6[]<C//5WNA$EE98J"G'H)!^<$CK
M3=6#QR1)H5LG7ZY'<G3:T$#@ TRG^RF,__A IOHK_#29C>;733X\;5::?'8,
M-8C'&,2@#;!<I%7(N8JMSYKU2(Y.#1H(?("LCW^^_S!=]._X^F*<_U&MIW&5
MP"4X%X-2,6LHJ=8DZ.AHJR*83DB?O2<J;6FL#5L!'9U2M!/_ (U_?QF-PSB-
MPMEUD]+E]5;(9#KK %G[F@+G(D3A-.2:'45_6#*V;JJR <KQ1D);R'X X^'#
M-(QG!:>+M#:<?AZET?CCV[(&[:Q^+[/U?[2Z<.^PEH$"IRW7<:!&BBT49/+$
MV!W Z6ZZ)I]"B:)(R(;7%FBI;O5!0+*&%2Z3I75]<YKZ4(O$IZZHNY Z@()N
M-P%0:R9<L9"#)?-0N 118H',F?&1&Z5<ZXS()V:!'8[KG6RU78C:>]S9&"LE
M#PR*4HHL$;))(@8'Y( FHE\JWKS Z8G%G9^,%K4C:H@+JJV!*V6-EW6:DLNA
M=I^O*LYS 6&=H#\( IOO14\L;OADM*@=41NCSX-V:KT2RYM1B*.S!?CQ9+[J
M?QOF5_^J<:?6W5\\0*?6GJN_VZE5"J:2MY[(5JXXYVJ)MHE$M",/U&\8M;4S
MAE:#'FZ,+_C'='+QB3ZA*S#OYZ33BZRT\&DQ^^+-565-%BKIVE=%&"% V9PA
M6H]0N%4Y.L:9:CW&NB_F 0(PU[PM.T:O0W;=PL29()C! (FK2#:V5."\)\'Y
M$D2MH[6Z]:"=OI@/V(-['YK9(<XS',5#S&_9AO_&UO+ (E2FPS!;<*5V+$R%
MT2**AV)4,)P+S]I/RVP!_ #*NE=]V459!R%[B"R,537N3Y/I=/)GA4;.F_-D
M9G.RD#(93#XJ"%)&B'2<>LY<X-C:LET#XXEITS"$WG6'>K(Q@(*\F8P_5D35
MM/YM,D[+=B97J]5%EB1"(#BT9,6CK04/%G2.Q=N,BL786%>V(WIB:C/T)M20
MG@$R;]:C.Q$QV>*Y)S?/5U2R^F;:TX(E%H4R\N;-U=<CV;^RM.2KDRKL).P!
M]H^*YOK#>#V>XQ1G\W=D/BYLR/P[3A/]0?B()R5EH6F1D**I%[Q"0B#?G;8[
MYJ4)UL?2NIM"=W3?V+XR$&T#-6V\1OI+2/CB?')!BN^2%=D66J]#TG[N$P3M
M.<@050B.":-;FS&;L'S3RO-(2@;(\OIELH@U+UNRI:\_?TFG8?P1JU8O8IG+
M":/\).J<1586C&-8&]Z0,F=G@ E,SDF/*%MO1!VA?6.*- 1A Z2-W9A[MTX6
MR_P7VA(7LZ+ V$!^@:$?JC\ 5F>M%$9$T[K2J0NN?;4*.FQ<J35!3Z65T.V=
M=I%)X'PJ.<8 TM5&S1$S>!<1F!>6BV"28:T;?]Y'<? 1P<V(WGJT[2SPP0WL
MW\(Y7MZH=<$U4$+9)DR'20[KR]E6%>@I\'TJQ*(W!2DW00MT$AMCP <DZTMA
MUM)*[E3K>KO]*L(#N5?[TH-=Y-R0_]IR\87YP4H"1H NR&'+%TB4R*N+\(+!
M%5JG(MM(91D@%B>!*Y:<D4PKO).OM[;IY;9W'*:I97\6)@.(L.']T@*7_$%:
M_=MD?A<3JV.F##E5VA4R?E,F_UMY2RJ=H[;*6?2F"ZT;GG\,E+807>LOE?U@
M-%M@>K7 I"XQ^41N, L,.*\EVUD;B'61P:F0LM<E9-^%S@W//P8Z6XBN8;1[
M@4G_L!:24U8JF0P(Z6I!D['@(O>U'$8SQ[)GH4MKZPV//P8R&PBN<5_S%^('
M(VYN%_H2$[F9 I$<AYB5HX72.1 22V"%,R(DQ<O=JM#U9&YX_C&PV4)TC1N%
MOV#ZEH:M('DMT+DH(/G:E]!Y1V>Y89!,3L%KYE/J9 ZM?_PQD-E < VC;9?Z
MI6ZJEUE5D6,BRTPH\-QE.LB]JF-;)6B3B]=DW(L<NWV9ZQY_#%PV$%S#HLI+
M2/XF)'L)*?! M/@ @954IQI*\LF\!Z=XYD%I&>\&2C=QN>[QQ\%E;\'=Y]+V
MVV,O$;VZA2A+9KD3M#_80H>X(DO;^Z3!"XV*J^A,D9VVV'5//P8F^XOM/I&N
M[T?)V WE<JN*'I-X29GLL1AIHXA5K] X2,'8S$NTR72B<L/SCX',%J*[3Z?O
M12?_@=\ZPU>8O+&8O,[ HB172?$$3B@-/ H>O)>.-HLN=&YX_C'0V4)T:X(&
M_8) YO;6[U?'N%&28:G3Q5!4%:,#G=D(AMDD@T@J9=Z%SO6//P8V&PAN#9G]
M0D!<LAL*)MEJOTB^2.\*T.ZO08FZ1E'+*)55AAXA14R=OLVUCS\&,AL(;@V9
M_0) BA3L3MA8RNL#G;8&)6K8F.!(VBV"9@311&6EX$HEVX71+>\X!EI;B7 -
MM_T"0NIV_/@*5.VA&5*JH2DI2>$2V=YU'&@LR1F,*DK?*82PX?G'P6E_T:WA
MLU]$B-\.(,M59 .%%B$Z!4;4IOT^,XA:<&#>.<N*DO?ZT&ZRBM8^_QCX;"&Z
M-7SVBPK)'_1-'5L%-SPOMA2#8*2HB1X\0C3T,V$LBT);K66G@W3]XX^!S0:"
M6T-FO["0OF6IR953[*2*]'K:)A*G;1\#(TO-B=K*6"9#?\)X)P=T_>./@<P&
M@EM#9K^XD+Q]'W %*F8??"SD":>Z79AHP''G ;DL$I4GNTUT^S37/O\8Z&PA
MNC5\]@L/R1_4S1B'7#G%Q=*QK0('$U2]KK,*8JQ-.[3U)4D=>>SD@&YX_G'P
MV5]T:_CL%Q_2/[A[)O<*&,?BF.'D$?M(*XV:@0MD?,N<,29FZ$3H>'>]\1W'
MP&LK$:[)2.@7*U(_:'8'F%JYRO1J$R0M3YCJ3C%F("KA(#N=2LI26-WIDF7+
M.XZ!VU8B7,-MO] 1T7!MA%]!4HZA*<[5BSQRJE04X%VB%=,^DFH(),M._LO:
MIQ\#G_W%MH;)OG$C=^.45WQURC->VZ(+PA0KL%I0%SB=\H678(7AG'?\0-<]
M_ABX;""X-63V#13I&T>\N@IVF,B3*X;V?6;).<8"/A?Z(10N8Y'<\$XGZ?K'
M'P>9O06WALQ^42+Y@[V):>4<AVR2];$6N":RTI@,%4X"*827=8I!,IW(7/_X
M8R"S@>#6D-DW1'0S#*E6SE3)AEEZ-VB;$%3F#B)7#%+2QNBDI7:J(YEK'G\D
M9/85W!HR^X6().T6-S7,7>W]WF(DE<*<Z]X?R"0KY"0SI[V+499\=S;0QH#?
MNN<?!YW]1;>&SWY1(B%NQI3URBZ+@=D2(BU-U>%!T22(*00H.9)C%450L5LF
MV-K''P.;#02WALR>&43J)B:SPF1=+?9V$7RLI5:<7&$?# >'*DN9!(88.I&Y
M]O%'069_P:TALU=\: 7G=YR.)OF749DCKB9]2$6F=L (QBM.N&C'<"9H*+:D
MA(6TCG7)AM_RBB,@M94 UY0X].]6>%TL?:,7ZD]A-IHMBR.Y%=+9#*27'I2S
M'(*F_82VCZ1J2WH5ANLQNA;2T9:5MZ1B@#Y>OT^F"S%?M\&][H<[FM6&!X1X
M==W4 >I 9><[P#S0F)*6-$_VR]$ E>IK -9>'\MF05>34[!83-8 *Y+5]MT,
M(@8+TAA5M&#(5?-F/!UP'69ZR(#ZTYR, 11F%QT7!444N=:!*DD_" U1I'K$
MBNK1T)$;6C<9/-#^LV-CYV;\]MB =B%G@#[-+\-T^I4.[G?XB4!C7@IA,]PB
MO-3!,J#S'$$A)^<XD@F874)9F H&6\^!W!'B_O5I,+KO33,?CJL!MJB?9_/1
M>9CCV])!+LS40DI.'H M]+DY+L$;X\&CYHS\.YEUZXXLN^ [7J4:C*7!!XB\
M'M-/\4/X0F[EHX>!K'E(O\$>#Z&Z,Z2#O-R@@E;H,"GO?(R!9,B*]SP+5LS)
MFN?U^RRO'OAR,I[3;E+;";ZYZBVG74HBLUCS'7GMV>W!.4MVDS4IN^)%-*U;
MA6X%U'<3HH?7X5SX"I?_?3V^(= 3;3,K@O%EOR/EZ*0GVU""%5$I^JB$=:WG
MV&X%=(@YMJVTX>[&TD[RC=L'+8!5;Z%V\KR+<8G.1>9TS XDKQNJ=A9B,AFB
MB8Q.4*M"Z!*A??A-QT#X #)MW&'H[1CKA.U?PN?)M :H"%!=[F7GYA/.#>VZ
M5M;>#>0K%CI((Y<*K+4AE5RT4UUN/K>_Y5B8;BC+(=KLDTP_+EKAOL?Y?-EB
M].<OGW \PQ.&@3N#&IC+LK9_=^"8XR"C9-9I71AK'3[9 N<8]*&UU!MW+_JY
M%$SST6>\6GEME_P.TV2<1F>CL+3K[D-?Z7*.@3%>DQF%*:"8I1V+#B:PM":1
MG;'.=KG6Z0GC&!1EWVP,T#']]?DG<HLJH+?E-9USXX\CVOV6;;]__I+.+C))
MZA^32?YS='9VXK6VY'P5\+K.FT"9:N\172M->)&,.R5;A]QV G@,2C4\,P,T
M2._R%?PVJ0[B!?TU6L?E/GJ]R#<36AE)#%W$%&L##9*38K4KG N:?B@B*4E.
M>G&--:P5]F-2OH/PV;#]U#8)+2]S7>!&&.&!?E2@ZN38F! )9R2W+6>-MG47
M]8U@]M6B?U"ON(&<#]UT?S:=WS#Z7I*7M[AT0R6**UF!E)KVUB@SN)H)::2C
M YJ.;2$ZC16EQ]]0$_K5M8JL?_.ALB$:L3EI)M6&CO-]-'5T]>IVK .F75(;
M=F+\&L=^<Q=:\+.1ZI["W1?Q2=0V71C I%HE1,8WA))H*^2^2*X++[93?/A)
M$;XAUV!??.\BT\:1L0_A+%W>[23-5>)" KK:*"A64Z0.RPO>N,!BS+Q3?^;K
M)^[/S&LGW4EOT30.5K\;S>@\RN%L53E2<LS2DK_B'(+RM?F/U!&"84Q'*T4J
M76*5=Q[[S*GJ(Z0!+KZO1C?]=#$CHW$V>[^TMI:92<H5'H+UD!<3NKB5X)7C
MM:\E0X4L*&P=&M@*Z#ALI_:R'R Z?8GE4MN[@!DH/?06D,,D@#8DZJX*]);R
M$'O"+5 19?)('B1Z9D")VC@S,E)X)8./+ANMU?.C_(&4S7TQOHMP&YM3M)7-
M+LYQ>GD.T7'#HJ4CB'%;U^0*1)-X+5K1+!FD,TUW.*QO/W7_T;,>XITTD<T
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M)T4DQ==QY5;'6.#4I423:#(*\?&J>XMY;"/>81795(R;S@(LUX '3TC322]
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M9L]3C4ZZB*B^388:;/+,PU> 3J7<P:#W):P($MWD23K+G_ _E*8=Y2]<<9=
M@_)$4R^)C!Q!BI (3<%&QVT*HO88DT; #E]?NN.AXDCX%4I]#_#^;N@1U$R-
M#Z'4R:IRZ!E6REH1M XYXLI96BHWWSU>>NSA*T37LNYB(OR3B.X\'8.!-@(T
M(\XG*.4D>,:YY AW(21@ 3QM5&/5)E*_TS2MRI'MBN+==RK6F@:HT6E6"II+
MKCN:0A3M(<]1>[GVE 4>LY&-NKD?3 /H&E0^W^-Y$Y'NKM7ORYA^E![/&_'3
MK.?OYL+=%?'HX5B9DR)1H%TKF4)7QV:$JH(/-++$H9'=^*H(WZS'<W6^-Y%I
MY0NL=^G3]/O1Q?GGOUS\95&W)*2-BF620R@)/2!(Z?Q(%,VFC.WE.3<Q\YZN
M_$HZ/6\D[6$U456^A%[N.^U%&:%L'1&V&(PA*P))6Z*<EDYSJCUK<MGX.IMS
M;TM9&R'5GG4"_ONGX1_Q;HBB\YP'X1@)D$JG>!6(TX8306F$9#.GIDDL9GG=
M V>LE9@J7_^>_:,/U_@Z1Q/\.X/T_9<T2"/H_W;QE_\87@_&*--!?/"K3^\7
M,]P8CXE:2Q(KCH%C:/HI24F@*F@AA$P:&C"[Y>,/7 %V(?2*5[\%\L5T]&4^
M97-\?9NW,OX(HW^DXA,L1F]JP61(AGB;RM1 S4FISR(0(4;CJ:.JR83$!H\Z
M</YK"[.+*]R[=R[)U=-Y&C0: G86"3*6H_X9;XD3K 1]I6#14F^:=9_9)#*R
M L<;\(*KB;F#UGK+F&Z5O0FJCFII5B/:3ZE,>\9>4($6XNZ@;F4-.M1K*F+4
M!#T#2:1"B!ZR)$PRQKD&[>K?S>]0"5ZH.MF5#FPBY2Y*GV>WO_$>W*(G/8_>
M>P>$ZU1&-8<RUH]F$E((T<E8VOA4)G\-E#UD@5=@ZDDWY_9B[J CPG],8R_T
MH'\^[=];)9'+J- 8(9X53(YG A(// :64@K12%6[Z?<J'&^"]]8"[N"3OTTF
M?**+65AA\;!!,"X1:4TJOY)$J* X4ZBH4'OLS!HH;X+Z&F*N:/D5)^?6#SD;
M7:31MUZ81X&3C%F5%EW,2%?FP ?BJ/<DZ8"G670NBD8[_0N!\%7/?@-&?A6Q
M5O3C'^ IK71O$=WI<P-0%6^[U@+9_757>XZ>$EY)P)5OO-:#$UZ R<:09)7'
MG<>BX6I=(%;I$#@#!MP?'NO/W'GMB/1-Y%HY&G\T7L27I63"9^Y)B*7=HLB!
M0%2):&^22?AG*30IR;Q;<+?AMTK"';:53.T*R]Y@ *&?CD*:@)_V870\_7KQ
M?3Q)-[?@5,FQ\483*0W:@GC.$"]<^170("*5>=G)7EU7^=*##IW.NI*L/K&D
MC^]8(KUIO$#C(LW*6R)"F>G&=29>>D.TI5 ,0 &A25? IRL?/)'M9%7Y:FSY
M8I5+-,45IT0X1"%#+H5W5I H./B<@*?E]LZO[_:Y/F=MI%3YCNIO,$*K8[C0
M' -"4,H(I(A 7,K$^O+UXT&NF<8W2KD!78\6/72RMI=0Q2NF N02^F%QJ1D#
M1^>9$F=8P"/8.>*XBNA,TT0M%XS;)J.:[E<\=)*VE$W%&KV"XOW@V_ ?,+AK
M])RI$C0)@H:P120*,467"9-".R/PE[%)]_/'JQXZ4RUD5+%@;G9R7G]'C^<&
M3\[%MYT9IY%Z8I0JO?0#)\!S)APH@$(#2+%&MN/2NH?.6"LY5:YJ._O:&_;B
M(FO+V\@TQZ=G)=%,I89XIP,12: ;ZBR+T33@Z^&:A\[5UO*I6&]6<)1H((3)
MAS08WYFEVDC'RX *GE6Y[(N:6.! <N(Q1R>T2DT2VU8L?>BLM956Y?JOD_Y-
M;W077T]<ZBBC)XF7\Q28PJ\]64*MBXIF1CEKTJGHT:*'3MCV$JI9DS6K'[N_
M:+FK._[I^_'PYBL,>FE^RRZ$T"'G@&=L+@,G!%JO6BKB?8Z:&P/4-&&PP:/>
MP 5$%T*M[ B\ &^AVPT KKZ;V(;]?=Q#=$)5<S5H(>?*\;)F0#7: Z*$%610
M95H$[E7.6T=RX)JSI$+4ZG4KPIJKB=>A!YN(MS+_3^))0O@D2Y$P#Z40*:,+
M+,O$X8!OBK9#<J+)W<7>HFX="?VY"-P&$NL@;^C)^?73]U,H,X7.\H/B\)D2
M*R-3=,6>][/!?>@Z>X&G&Y<0;&#4F=QH8%Z;2NNUZ-[ ^=\Q)=UWA9JCO/T^
MFD#K*@%Y/:P]92%WQ.CS[3U:T]%%@O(S$*7BT08+A,52"B>MPIU0!V*L!^I]
MTAPZ;C+7O::\E*J\?T79A(4N)B_,.YN5@>*WSO.[E%.IN%G<#0>69[%:[TN+
M"Q\(R!A)5-F5AE<^>:BL)"] VG=OZQ;T+<\^J"C[#DR5BZD?I_^9HC5V\@U_
M*)5=LR]!)\O13I+%N"[M,YU!@%01A;_B@DF5?>WV<FN@O"$CI(:P.V@SN +6
MPAYO *PC>V,MJ/U8&U6H>UD=6LB]B^J7M0"#\3&88 CS AVLF T!=-&(MAH2
MM\!9KMU6;L<*\8)1L5M]V$3<W>O!(G$P@X@Q<&(9C0C*)0(B\S*]U#L3T).O
M7A"Q$LCN;85*1#U/_Q92KF@?E(N6X^%T,$FCKS":?"]#@&8*;K(-.OERO5)N
M^*42I<8ODJQMILHI'VBCV9XO9$FO>O8;L 2JB+7B)7S!<YZ^3D?ANK0]6G38
M7X9XJ]U-0%:LCV@,;/?U$NTY'.Z*@,KU$\W!"L],R+@#JG('*QVD,MU6D*RH
MDLI"2LVFJKYN+7FFOF)/2K*)W&O?7,#X9CH>I\'[P7@RFLZZ9G_X<+QP=84!
M*240-(44D4RPT@-7D*0 3!9"J-2D8<ZS#]EM*D)'I R[D.A:XZ#6$+WS5!"&
MR72$!^4IC,KXP&]I^U%ZSZ_7;J#>!EB7QNI9Z:/S.EJ=I#2BS.L&%9PVUOOL
MI;AZ?NEVAOBCM8^'XS+A\[9)^8>[AK7>4-!",H(&"BH%!XX[C =BT2.)$$&R
M4+LQ11-<;9V0Q\^XAM&7-+ZR7'+-3")2E;0JS=$&,\(0JWRB6FAA4Z,VM%N_
MZQS'[EV0ZIJP[(VT%G<'P<I'F&8OW(=)BN7UR__?#\)T-$KQ<O@._YA="<=8
MTC$2[LN>2PWNDWB^$AY8*IT J=6B2^5X$>%;5YNZ%-6V51XBA4=(3_[\F@+^
M^N=IN02X@&]E/.I53CY%A><L[OX4/7'TR3VCGBCIF,B>1K5\2[+:?-GPN6](
M23H7>P>MP)Y1Z 7>\FM4Y2 $FF&6!%/*]- >*#4J'G_K&-AH@Y [W&T>87M#
M*M0I+16+\>Z">N$ZQ6D_G>5G$-\&E,!!EJI,-!0AXQ&;#(& )KW+R65J WH.
MC1H0;!)0;0YO5Z,8.E>=KBC9]Z2&N_>;X$O,\NNF8Q38>'PQ7W>>-1F8MZ!4
M)LF6ZN]<FFKB:4NR"%3RI)G-KK:2/0=H7T'=SK1@6=NJL=%)>[L9EL7E10,P
M7=WV/@2RIQO>>D0]Z6[75LJ=4Z^<]4PJ3R@P5V9K1X)*'8E7.01IG5"L?C_#
MSBE_Z0YW1XQO(MS*3L['%$N7Y7=I5B:UZ+6>E->&92)H29P77A/'I"4Q %#&
MHY.N29/J56OOX2YV>U$/*\JIZVC'ISX,YCU6N0@\24Z43K*H92"6!43F=7+6
MID!U[83QE4#>^KG=7OI=.Z,%U")!L0&LCD[N-9#V<X97(.TE-6@A\0Y.\77P
MHH[@I,[HYL8T[_8$1K%2P\JTRYGQ5-O*WZDBO'"R[TX/-A%TY;/]8OKU:__[
M\37"N#VP0G @O;/H!C-=#BQ#;/2,&"[1)4Z64<\;'.Q/%MYS_&A;<0]KR:J#
MP_W]( QOTIT%^J'\@R+1HJ<^<9Y8=L1"*@TYO"0N)#S%HI<Y>Q.DK-UA^ADX
M;_V@K\5$!\'#-=!NOX4FX#HZ])\%MI^COQJ-S=2C!0<=F '/@^1&HU?D!;%:
MQ]*FVQ+0,903D#D93535.];O04%>, GVHQ^;B+YK\_#V$O^N(0W7 <]+@F:0
M0&0T$<O1<>9"!^8!3]GJ2K$>S>X-C(JT-4B<V$+F'=@<Y< \RQ?0OP<D7%2:
M>P+.X;E96A-90)O(28!$T5R.HE$R]P9*\ 3$6^*^G80K^P=GD^LTFK]KN1(=
MC--I6E05X.[FLU:4&"C[G,R2^*@"X6CX9L48@^7ZG=6]UM8_XBW06E.*E6=5
MG,/@RVW%$6X:3B6*&B8HD9R67Z&3JYT0-NF4E6!-ON&7TJP7#WRK_L#V4JW8
M#^H.Q&+[: "C9L7%_:-W7U.QI?"7Z6LAN=JE$@_AX XAP6N"FPVJ)7.FQ)X"
M 30'&#=" FL4MM\W@<^4.U3F;P.!5>;M(_S9NYDN&N<'JO%M$$-0492"#4Z<
M,YX8S9W%_86K9AUZ7F#NT4-W7,6PK=B'-616N6CQ(XKJ'H@#*G7)538"C6V)
M>S_Q+!KBHJ""00K<UJA6?/30 R1O:YFM_?(Z*2I9F ##QR; ;798I4J39@^I
M6'ZRQ5LMU:0XSP5NMS[):&5FVB+3D5JDFZ(5FNW5%L_;0:&*0C75("*A26DB
M(VJ;BP9_T(R&'++W4#O?<>>%*K>+GP_[_9^'HS]@%*^D=-:),B"5 6Z.5DMB
M*7ZJGJ>@O ]"^=IU\R] >J7YP9OHQ[-1F)8D=)W;<0OOBDH7-( KDY@L C.9
M.&[06<U!1(^^I(ZUVS"MPK%G;6A+5@-%V$C2.PK+7O$D</^.C*1D%)'>.'17
M\5>4)@F:6FZ:-58X[%*V+MG?1M*5!RI]@N^S#$-\M\=UHFERY8PRP7E%C-&X
MW7G'B'<." 2 J,$IM)H;Q.2>><3;X+:F'#NXM%WURK?SK7_O3:Z'T\DQC*_Y
ME4OH"X?,B0VEX:V7EK@0-=%&,!6HB%+4[K#6$-K;4),N^:@8\7OVG+(JN^04
M(R(![E2R:'&YHK3.9L^]-IYV:B&OM @V?[=-0K="JYB5<"0IW)>ETK@Y4VN)
MY5D8S3-WJO8Q>*A%4&WLXZXH>2U%4*LS $UVF@)HXE,JMW%L]K4G8GRDI=K8
MA*"Z_)X.*7EZ(]8;)4]O(OT=YLHV@?7C)D]O1%K#I-EM)+Y#A1"E>A1UGU@C
M.9$ZH'=(@R6< ^ZOCFGO.M\E7EWR=!=ZL(F@=U$85?HY1ZTD,1G*[',3B6?&
M$C0+!? 23Q=+W61><6%4%:&_5"*UB<2Z#J,]-I-N1\1(6]HT$6%X(C)Y2KR)
MDB3&L@$N0K*=%DL]A?1#G?PM&>F@@*JT:ET2P=W<IY>!=60%K 7U"NR MA0.
MNY1_!S;!>H N:*I]H$27$B*9+1Z 'D]!H=$/SQ"\<+7C-3M6C$WL@IWIQ29B
M[T ?3FZ^]H??4[I(W]((!F%QU>Z2M](I0Y*;G:*E.CR%@&^<?4A:"FUK-YY;
M V7WED4ELH;U)5W1Q"@FS]%XG":_CWJ3-,SY%DZ&J( YB4A*@W<K,H& UE1!
M4AI!QKQ,_$H;<<72ATYD#8EU\ 7/$G@?O>,M+J$4:E/!I3P02:',O::69.U"
M-%R \;5K9-=A.73JJ\IZK=FW)J?H]H_+#Q[&Z?_]G_\/4$L#!!0    ( %J
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M<C_S /_@K&$ H2PJQ6(L063DT_O05#.Z[/W;N,%&WDU+=SI.&33@29S]WNS
MF*:E]:?6ECO<^OD##!RZ5%^=">*W5U=7C.I6:7W7W809P^Y<NV4-PW;9;\($
MA+EE&&'V18P)M[ %L0EK.U*+$_4GR43T%JC;@PDEF./5WXGC[A\KWJ+XC34N
MZ%;5] 2S3[[9,1N@Z2JV_".()T+>A-7A%RG,<98FHAJ7@MEM)1)H1,8IS*^K
M^M01?DTJ8XC8,_>R7_44;%_.[7MH_"LLAL2P7T[%[]Z$A1@(8ZXQ>Q:3&!=7
M6[$'&/V+@H#72[3VA0_N#<W[Y>J27O4$JSWA4ZZQ-<E5#;[6I>[15'*A&VL!
MV>@$)*LM"45(03*<*./:K!M@$[/&&2R@0>_-T5VM5$'@_ !Q/"AIYMW(*V*=
M<\[7$?DHC733$XZ*M^XDP[A)+TG" #4+SG!>3MV$,<[;]\%;6PY !S]$-[5M
MPH@/$?+A[&4ICA%3+ST71</+@X%'/851)I5ZGJ-?:MZG=VDZQ%P(4U?_^;G:
M^.0:LHL"[A/LVH21^WFB)=!\IY$/\;M,<0E8(0;\_I(I(?'()BQ.H#%(:>8E
MZY&#>+&"<=>^NGC-YKH[AJ\SQC0OCM_<Q_>W)9DSQ'V*50/:6A&P31CUR29L
MMS:WF"?Q W,*I%$KK[@C8R_FIRB&6CK<\-S7-U'E=KIL7](5NR*;E=DGVCF]
M30(M!MP&@%I!JC=8$(]D'^ X)["JF/JOF.:=C"=  #P&J_=AT&#A[Y]'P>,?
MT;HA-Y2N9E8,57>*]"H)W?[<\(CO+Y(GD@M%Q>LA$C6'I,*3Y^P%'[#-/-%%
MCF MFM6B.AJ.D^T1=>^59;W[JAUSVNI\R9+\Q;?C#Q#AJ2X3M:#')DSPWB;L
MTRBO$V"9_4%N()^[+*7!L%[8*3SCEE\\@OJ44N>1L)#%]L3V'!DI$/AK=B45
M:\2@I.X=#D':OG]*9]\Z$4+/3C9QVA$7T_+;59]Z(7\1("NPWC2!86SU0*!.
MH=5Q1P @0Q0W;K\(OKC^CGEB;!,6$&!(KAW(^XI4<YVYDQIZR4OI'0(X)/C+
M -P'<&34J22.G,OT)JP'-S9+?QCV(T@2HP#>BZ8"\IKOH_ZJG ^T,A0V^FL@
M<^_3C8\['U+C+T5PRJ!0B(9BS*[%'-KK8N#,99Y0)&0:3;N_T=NH!&E7M* 3
MZ7'S%?U2*_S-@7&-A.6Y]5<CI[WA!S[M.S1N;'(-7DVIS^7( 73!!;Y-&/_<
MP"8LM#]Q$U;5_:(R\.[7LI)QH%WX.9KP5<G;I8I89KKXNT9'Z'R+>W"R]6IQ
M$M\C=L_P)HR/IP5/0P@T[V6F@K:7&/^8?G%_N7YL0?>$W@]#V.\A4!+YOG>D
MY1UEJT0;92"? 8R;ZXL1;&=>.\"P)\13B)$+"<SURPS;1*?.//V4NW5YGOA(
M5'1 6,G$Z?93S76Y.PDH1><3S?+\NU.C'#GRXSR1P^PHWN>M$(:/!;%ZN7C(
MNESW#JPI<R27]@=0=-P9]^KJ\3>?HFBLECP:_3WQD:UV@;QM=A7LCO+=:WRL
MP&2.";<*@0+ _;,+BFPTK[M0FYFP6'E[.D1P^D-)QB9,N.<^0).KKAY8+"J<
M^2I,K[UTTNR.1[Q;P9="[^@DJ?I,DBUD\C-0 I1[[F?4<^0Z:((<Z:9VY*Y2
M,("FXG0ZMQ.I8'FOQ%TC+ZM5#Z6O1RQW1A>S#V4ME,V<3?3N^ASLSS*C2@Q]
M7D&-^[&2F82%7+8Y2&!E,.K;@U"*;FB=XTTC$8M[FVVY!;=&[C 5O<U^5?ZR
MTQ"JN&-A<[#94$/DGS%/J)=]!_N-HDSR7R;SL4Z 8V_0L5T\9? V_4XC:,NT
MO_KMRDA(]+&<J M["B_'[WOK\U#(T.AU '^Z^U(,-AT*GHI-V&<CA#^"K6ZE
ML0D;"OZ[C09GG,:!!HAV Q J-%TH.$:X&E1YBS%CYMY?*&K&'V/N+)/K''TD
M3)[Z]5AM[TG^J3-'WOTY$CW]C41]BV<X.R;@&7:HF"..720%S('OS:BH\D '
M62Q\ %54ER.JX3^=Q[/3<!85NSTQ=@RM\2E*<LD!>QRRI*/)AY,\H<M0:JJ
MZCP109J%8@5/">-."D%V7KC2C2E)_Q7WEH0B A495RZ1+L_-."JLHS?L>:+<
MJ%+> , X"Y"C6=^('^(W8<=BG1F4^U:[IH[O0?L,A6_"I-WJRN[)[!1J^"[V
M3EK8!7>Z[F;4<XEO *A9RI$514)VR.-]N8M<#+O.V&\I0]/#TE=4MBM39%/^
ML.-K&Z,#/$]GCJDG67XL%L%T>]5DPV*1]BX_#3C2?*R/@U  X/&,P/0T]O7
MN]+S:=1*\\Z:N0WO],OZRR5,T\7:8OV.;)N&0KD;AT7L=H]F@OD\$0DH0]5
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MK?VE+/63DA.!\NOB8DVW;[7NRS1SC35J?DFR>?U<X@L<U.S$,\(0:0@H, ,
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M1=2&N\GO$T%\'M,TOX^]/X#,03!<"6EX!A(?1Q+"^+']L9^PYN!MQC@MH6-
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M(C*Z69-<D(!I7\I;W/>+T8O.TGW]NOS(L++;\0O&=S&4>X_)98?ZGRBL;B1
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MG/+9FI:?27CZX7J7RN=YZQ C)=OE@>7ZRF:P)=:4X'?YNY%M3X5XG)!F9-:
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MA9;UEK4(VD?ZXW]E,<8/<DDBO>JC);?W.S?Z*O3F!%E,B#BM#,03P&R=R)I
MNQ.^/\<-MWY-=?W4]BQ[Q/=\=Q]HH^0#SBIMR-@@$?O'_)]]N$?ME<8<W_\
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M$5ZX=[^?[+POWI7#GAC#$#/$1PM^EAW3?\B/Q7L"4N_(*$H3L$?N/,?B$V+
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M# I2A5F=HJHVIWF3<41&\L=E<7I7,F&-UTP\S-HA@Q$R-G85X_]LNE#0S\B
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MU,#6G&>P\9"*F!>Z%ZGJAOEF9!.B]:M*:\&E3%RLVXEO2^G:E<D=AT/.7'<
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M"V_&G@)"+M[]<V^.L\]H1V%G)PN(A3-\Y2O2GIV+YBFG%\9>7(E>7N$L$SB
ME/UHM+.JM_.YZ;?9C9>Z.7*]8RISI3;>>:M@H:(WOQSX)O 2]Y_<!#&(4^ ^
M)/<!VMT7V3:"P2*;$1@3KZJ,]#JU_I *F^1"FY>WF2;';X)^_:(A!KAFCYM-
M&NXRC!9E@OL34&^_(CM@#5?-EO4"<X=Z_!\^U(8VHJ.\!][7_3(H3X._M;Q.
MLNP0E83'@*>P+J)JCI4V4.(X ^^FW-A6S(I%[ZGLPD8AJ!.[CXH*5K9>TF@E
MZ\X2P#D5T$APF4<2_HJ(C+7:+9Y&[J)=Z0605E6)O #'<6,Y&4;$MX@^=*A\
M <1U=M?#8W\I\8RN&-RBYZL<,;3^(RN%^#SK%N$@84JL**(& "_F?<"]5F!N
M3U\RIM[(/,/22&3C6'+>B$P)13S.>7?/NE&FT,3PGG.RQC 7*=S#Z?)5X273
M:2HX^KQI!CXXBIO=J@5<%Q\YB7:L:%VIS'>%G9P=T-'>@8'35=^^*_-4WGW2
M[NLTWA589+LDEZI2MW"SG(&PMGHUR[:.VY;!@D _9^,&3,F"C6Z029"<JD+1
MKMV+LHJ$&_?YC:(:O+;@B-!BQ,*?+2?/\1RE.K!G]+MG%3_H!J7IQ/@$GW_I
MG>"--7'W9+F^N_0IZLZ92"D%I9L6OG3Q]DT0-TER"LL)5>:PVPA#2,BZCPMK
MH\?R0M^L(B\OC_]@JOA>U3/C:50/V?E$0R"E:&7B8)^NO'7NSBZ[J1_ZDS"^
M#E=F&1LU_Y4 P]OP\EO!#'WH#*[N8BO/]\6!*:\PY:.E(09*J=#P]%N#CX9-
M<+*0+2X2=6LG]!@36_4)S/$!HL?7J(B:01:4I' )R'7B[?<JN9\(438A<[#2
MO6;:Q\O:[+(#*1D7(4>&KVDFWKYIX<&_+TH6*@L<A#& M\ :*&!3TM=]4"QY
M4MPSX%P_?2WT6\B$J<G"5%#Q-=V%>*G3 X_DG\AH^#^W(ZVD"C1P,/X@X(SF
M4GI+#'BP9*UA_/DJ()?>J<DM_FBPI&K74.VC^;YJ5 OW]&[:V22XQK7*/;W7
M[6N'K&%:OS/V]BZ3[7UDFDJ]E3[^3^#^/)R8^2LV5SFS;*+U6R ,.U)VSQSC
M.K$\/I18LN+<LEN/^;%WZ!;D?-F1&]C?OILGUA/UYUS2Q3OQCJ):L1[^5#N/
M<J>:V[.1@0]M]/P81E9U&C)R]9X*;W8,N5^W1^.]5#]<.O2 \.7M1!5;$)[3
M0.PR(ZBA?0\ >UC5P QOZRQL<FEA?+'+T'NP"MM>.-OK;&7:,>-WIM*K7^.,
MG;I,1/@U^J[9@Q*TCL6#>90>SGV4DE@=/7N8MQ^I*MP5S(+M!RZXE8P(]'ST
M)O5<(7=LPW,9<SX?B\41)PHLW4P$8Y M:[#71$"+7RHPQA\;LX ^%8\QH4(L
M'RGC\T5-NH#1J?.B<*T[-M+F<\W()<R3E)DCGN/F133C#X>?Q&14>OR 36JS
MLGI@=XC-P?<Z]^%10&DCKHYQTN<Q=Y"-5&#:QCWKW^4"]T:,=?<^BXJ"R,FZ
M.BGH-IT9I"STW/"!;%ED-M.6?_H+S'$H3^Y,,H.T!U?N',>8NM=!K 6JZ@M7
M&CG:H570!LP3US3O,+C.ZOS9>5=%)?MLO/YO"R^A/F#+Q<YKO\;N$!( "=!L
M9_:N!'B/63@&1L14*C[U">NZ*PCMBO[L'9A]^9:*?.I&GEMJP/H/R; I0G,B
MZVL3 +Y*,,.?ZEOF'#:]=75MO6'"W&AAQ)JZ"4HE<I(G-7*.-_=KQX=_WY+L
MS';YIX!5FBY1X[0I#D-\E/<'O[H&;UCTVD,,>67B4OXQ9.1RXE//677,8G,+
M-7_M158!%$<**+]IY2DJ),[EEFZG!36 Q4ICU7V#:6)]KGQ1]>P_N.,L9CK5
M3:FW@(7VK@F\?;9!UL VXJ"G=N'V#,;(OHK(/:$_:PNZ2@$-9#<GR5<=@+/1
MV*F$^6WMIJ_-H3/ZK'75V5?5\09?)A1.R? O_XWU5R[::H_=OCO"7'KG:ML?
MMK^&__=?((G1FZ!KM)^6S'0BW^VW26DU/&VU380'))MNV]HFJ'L)F)G73R_E
M3I1.EG+S@;KSX[1F(@NTUODWO^XO[57J((7T%^7=='O8HLKK 7C>)B@EB+;T
M8Q.T!MT$;?32GC5M@A0!PWM;\TZP&X[TZ@CR3!VT^>#/^^GT<R:DK#K7?=Z]
MKKDH:G4SAD2^01)"<S=!6K;L4L%1"O,79@3.F>*" 6WMY>.;('DQH%XKE'1[
MMV(3M /++TVK'J>UT%Y8=7W^F3_^(=X756H2P<=,4V0YO=L,$\6TDI?-!^Z^
M [+VI-$="Q]_CEX>&RNPRQ4,B92[S61]/>B>E_6T+%H/08VCE[__>CKQL3OM
M"*G$*OWW-_B9./SO$JEB4:HPABVSM\V67\!3I@^%72A^KE<5]?2??DSX .&\
M1C_6+".JX-@#0QSI)?HQ4,=-8)GVN<B\YV[,>] 14CU3LJN535]F-8</=9)#
M%3YKK"ZX^RS%N_=>7-UNM&6!J/(#+A?,'P<0<^\-5T^T6NH-,KSX9<'0),V.
MF\W>A\QOO:USB=FM@\1][XTE&Q"O=4CQ542-G5NUEWF"/W'5+F,6\'F8FBW+
M,='CS$1YIH\RXT5\T_3=MHPU=/Q^OMB5A%AXD]VFE)W?@67)+*]PH7PBN;,5
M4.<FT D0U8K>7Y6%>[.46@K>W:PU^IZF>J7VK.NG!_+;_KCP4I1'##(?W+ED
M]0=55"Q4-$FNQ]U;]!U;#Z7"0_@%4PVO_2,2C;0L<SXZ=%#>OFZ^=D+KII6E
M*,,8-9W U_F=W ^%<<\1I_3GNX71W-_IW*5.=2"*!_5J\A2ZL:83X$5G YO&
M*IWN/[H\N-WQ*;W_L-_Z/Z6Q@'EOB3R0RBIR4<4C>4%_-7Z9NA.X;(Q1%9O7
MH?-D+[9$]E[:?U7Q@<O!S+$!H9[H,3+XMQ^D:L9B-^SVK#)W]!<UHJ?V\I<V
MC;VK,WUJ'+T3!R#'RZ_YI3A<E#U]4RX<;P2@N--S?;=:)!((N1V_I0+G3;_A
MA%$K>()+<$H;&!A2F9R\<D_SHK7/7YF@OZ_<R+6&MOP'S_Y_^[_=B)N3_P90
M2P,$%     @ 6H!;55-="P_=.P  ]TX  !0   !J;FHM,C R,C$P,#)?9S$P
M+FIP9^V["SB4?]<_>DLBD?,IAY%#2"@EA4PEA!\B9S&5G',JQQHS#CF'G$-,
M.20YY7PV.9,D9T:,&20A,V@:YK3O?N_SOOO9S_/L]WW^__WN?;W[NIZO:]V7
MN>:^UW>M]5WKL];ZWM]AS# 6 6Y#/0,]@.D $W ;_ ,8/X"C5^[YW'4&G %P
M,#'F !W@ -/O\?MZX/<XR/S[RG+P(//!0RR'#OU)K(?90&(]=(CM"-MA]M\#
M_(_C"#O'[P^_F?S;HP=8F)E9V%D/L;+_+P_&>X"'C<F-:9>920HXP,/$S,/$
MZ $@H(PL?XK'!/QE,!U@/LARB!44XPAX0STW*#XS,R@T"R@Q^&TH^#UPD(>%
M]_B9*X?XS.ZP2OGQJX:GO&*3OEK=*6 ^2I Y>_=!Q&%V02%AD6.R)^3D%4Z>
M4SNO?N&BALXU73W]ZP:&-RTLK:QM;.V<[CF[N+JY>SST#P@,"@YY%/DD*CHF
M-BX^-2T](S/K>79.06%1\>N2-Z5O:VKKZAL:FYI;NKI[>OOZ!P8_C(U/3$Y-
MS\QB</BEY96OJ]_6OA.W=W9_DGZ1]_9_Z\4$,#/]^_B'>O& >AWXO0:LO_5B
M.A#T^P:>@RS'SQSBO6+&>L>/3THUG(W_:LJKZL[#TF?-"0)W'XRR"\J<P\D2
M?ZOVIV;_G&(1_UN:_8=B_Z=>&("#F0E</&8>  K0J 7Q\L"_Z%_T+_H7_<\@
M7)L.Q8 J0*AL?(@;1O;EZZZ\>*WY'%E;"7,Z6J@HPDI0&XWINEN=ZO?*Y*9G
MT4UDRDA<WYW3?N8]%D_YQK;=$:X/=4-&J&JH#1H#T&$ =/-*!D">A!"FD+6_
M:%P,8,^PE0$L6<[2XO*0G]5,J0=@RWY([WNH70%3!L"<O)>?^,\\;X&\ZPK;
MY;S) ("L/5;25P,&<,6" 1 N,(#L;Q/6+QA MRU]!+L+90 K)[<80*(9 ^!T
MI4"1GQD  T@O0]/5]$DG AC Y4DHX3#RV;\D^.^7P,)*O0&3D:Z1F-Z*:XJ[
M%T=*:;:Y)R:AS]INY.ADK'EVPEC-G]],]W@4O]EEEO]N@I^E7$4.WB>JT*(@
M^]9?)@DCFX<9@&QM#YK$CUR#O0P.80#2)[&+#& N90\;B]T^54B'TNI?>/&;
MP2HAR7_*) "SGCJ'XEJSUOC1_M;>9F;V_8ZCHZ-)M>Y!P\.N07</O %2#=X?
M:&O$,8#-48H<U9B8,1+6IDA$7PDU5#(^=4JJ>4(Z*L#=;N%(V/WL 2&C&ASK
MCVT#SC"]PQ^*'YTK*KPHLS#].&>\>[I,2%ZWKK&F/=FNH F=B*V#O:^:K>WV
M)3<NC?2&\G7EA'ZD&Q?M#V_W>,OT&>J5?$T)6XYB94[K=:<JD>L)_4O(B$V$
M%/4X\6L&WIC]EV_#Y+G'/?E"SA><OQ3APA=+.UDC6-3L$LHVTK/.DSH:MKPZ
M/Y>7GJQ4R?*<Q="JJC^/ZCY$<7>HP$^3305>H'BH(:_=MDI-;H]M5GEGN':D
M<SQ?3-CZ1%Z]YS&<Y&>IT,?S-:U&BOO%RI! T+*_OV6HW,WZJ;H!M<<">7>:
M8PVXF^M31<ZGI+1<%'#@J@7TBVW>@NML9*QY^B\8P[S+]YX!;,M^8P"D(XT,
M8-33+B-K$;G'NXNDL,PQ@&_U%89T]QZD!*)J!UKRC@'\(.S"GIGI"L2],]/E
M!_Y"3"L,0 +I#B&;:TPF)3, -E<2:L[+SN<L17]P-GKN:8@7JDJ@$PP!)'+R
M! /X\(L!N)6CYT;H^L9'Z)T^#*"0,_@2HKF;>B9EJ<9#;7VT;3D/>R[+&F,
M2?83XE^=X?A>SRY0P5;O/"0T>NF+O?93!A!-9P!OC1E QA9]5)^J_HMF[D.M
M0I+B]S[%DY 3"Z(,  79.P<&AW0O W (SJ4C&< RJ,"R:2$4AT9_3T.N/&8
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MGNQ@F<?6$8C/UY$>7)$H/OHE#^:/!)4G<&:\)C*:-/S!HQ$[.WWZR_H3_WO
MH(_'(_ZS']5/C0IL0A<ST-M)R9$HDM0LZ+\G7F>JUM\:F:W"-9UO;350W-=<
M6ZER.-G GBA6A8'B%8HHBKVM]BT-'8_\I['?"N)_)DO^F3G7MV9JZ==?($G\
M30Q@UG/YV#Z%= K,^7(06I0RE&1'[K@$AHD0#0T91/F A3<U&466W2O\,S/?
MHM7]?Y29J]ZN:5BUEA@7KN<XMV\6=_$WU;=&W4NRO&29$<YQ*=$/=03JXA.&
M/4@UJ"0WXER[*EAUT$2![7D/OK6<:]P"4@ML6DT?W8JEI5@>1$9*#]!N30?I
MNIZT6%53T#W?$)HH;54NN21R+G^]^6/P^&))9U7<L?H.-)$/)Q>M1J%<[[)S
M7+?C;)_X_$8SHO##TP^J!N\O&?MG3DV1 HD8N\LINKP'X^4G3A:$AP%B *MP
MR:C%*[;!NOI[S9_,S'QTJW-Q6-9@_2Z(%P-X8M35XIU%*T;*D@II>4YB$(\6
MN$^^<9A/RCO5S<P+(FJZ=%[JR;2^)?Q]% =5:T&&G3\XO,Z&DP#<YH*Z9C_U
M^]5B?457SH13UOGEI&%<8] ;$.SN_7L3!GF9SPK:3T4?M*T#FIY@-U&.9F8
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MD0^O_Z3"7R4:)N(#YWRC4XYQ&"F;6?.=;R.-&K38FZ=27SG#TIM6'J: MCY
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MGRP(3S70 E@?$:O(P:L;8%K5+R&T,H CN1"ZIF,>4?1]#K0'5/D[^FB;KE^
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M_Y,L]/^*P^5_,?CO9_!_S20AJ'\&AQ-0?DC2 NOWA>XTBZWAT*KQC* ?CU]
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M>B=2KNVYA+21.)NJ1\#:N],B )VX($Q[AKY=13Z1U9?,?6O>$R:B+4F&=#&
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ME&QZ?D'8!0<=$HR6H^83&X.GEU$TR8+KO:^=T\D%2UU6IF^R^8$J4AI/EB\
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M2G<8?!-^\U(.\LE'DIJZ?'/R1.65^,[MR5_M=TGNTSXLV[TA/PI^_VD[$I2
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M@37F]N'2SVG/P.:VAV,=.UMF#C3_KN[7\M61S"JDF/7"BJ$8:Y?FF'(?PQ7
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M'L7^XB_9>78> 9[]RV^[/R=IY0&CD.5A%5!*BJ1P0EP\Y:!F=#_ [KELN^@
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MW[Y\NN'JWK>'MMY%J'C8>XBZ>[2H!CC.]FL7N-X5-+Y\9E-WY/Q+I^L1NFK
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M1#J/V34V3)GN6T'+;MMUY4G##V>7[QWF9B/TK-6J'N3,%&4X#:?$^?-M++?
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M5%&("$J)B 4&AQ8<I,DH125 A(R5-AA0D2 A09$N1$! 00Q5+&#H08@)572
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M PY>!AP_-M',W2 8?WMDU/J>Y:3YD7UYJ*G7H[/6N0.'E.7\<C5?D+Z=R80
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MA0C'CQYQ4!$_5\T+6+@:XP:V%7V#^ZB7O+6;56NW([.KXC==]-&[90686?7
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MB22[Q^93"UG#.S[N&7:IUZ=O[AF9C/YU0I=B45- '+R4F_PJ\V#7:[G;4$/
M4GA9,N%D 3KQ'3 L4?K!S^IV4AAUT"T3J:#U07*8?6IZ-N34P)Z:\(CLF,MV
MAYU\)F0'/$ZH=1;B]PE:\%<!38E_,;]??"^6)*F*1GXJ^%]_?[J,T(NBF3)$
M=N^LZ<GCQ5K%XKFJVX&>;/O7Y<V44#=?^(]]'E^B3&"[HZ;WVY*#?ER6*)+
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MT>ZTSLV G>4O0JZ_P)R@/3_E^IJB9#)5B9G1>^?Q6\=+6U)3V'_C-V$_',&
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M>"R.L@392B"%I?WC)K:&AB,>4SE-_T#JJ71IS.?+.;*FX.'6U]':,;G7]IL
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M\$Z]-<_..N]&JF;\QZ?<*]A9.)S-SX(R2F<SKDYP48EU\)<DV$USF6M]&JP
MB/Q54%!>O;/A6S:C8#__'HB]7+6[Q\RQ\DV!RB$GK0V]2OI/99?&8L,:5-ET
M?[1%4M$W=3?M= N!\_N/K#V5^$[@BLY"0J5QRMM%H!EV$BYMPF39%B-&41P/
MYG5Z-1'9XUFO2/RVJ-WJXY/2GJJN4T-NB?<D'CGHI7EU6Y74!N2B?.\A_]S
M#A+HI[*%T0>@-"?$504'3X.XZ+!0@B3[< CE<>)HVUZ;VU&Q5B4+!G:-[A]W
M:A_XX&V\,IX1SOI=];/%_D'I4>:&?0$J;$=N?:U.O;YB4$2US>W<V*+R6XC'
M^JJVE.]L*7WN]NU@ ]4(W 7OV!DUF(!0- F/6#[*./&:PC]><[Z10/"U(7+Y
MT:3/:)6HZI^*^PW7%?4ON!/L"!'XVU#X ^3G)+H#D.6W Y+W*G: R54=9EM?
M>+;@MVV\!J,"B<WF'G[LTI:UX;J[SQD=N"*B98W:TWF\SDGCC.>X]N._I-,C
MQH6A,]YA%KYO9YPU6WJCMKTKOOWN\EXM];^'*WMA6!C0R8<@EY+H+B0Q[OL6
MAT4M*(7T2X4BX1B5%Z00;[UD*FC$J:I"M\;UU-ENWX35[6UZD_KN/-#0MJ^D
M)VN$A^"/(--PMS9A<D   .[$+4(EC=^O!31F$B3:) 03:S"^9: WHL$+#/WC
M,)ZY]F5\Y.#X!7392O'%G"J5&XKGDO"DYW\S=55/N(0:&,ZB=.\X&! [2CRL
MAYW]M26.CS693DPV+H?$1.3V:CZ HGE_2]'3A$Y9'O87H', :(1WDJ;O,5LY
M#[F:W ^V?HR*I/HJGX+S#,,'E*K!NM LHR7M1_HFZ F?O"3WHW=2W?Q<]^R[
MGG/Z;S175$J"+2/!G&=,)@'^R],K"PB!GVI:X'5+-WHI+6DHSJ1>W,;YA7K>
M1&S&?<^EW.")J3R5NZ\_^$<=O&_C\#.N$7?ATO.\&R=[-%/M%-/5BR6ONV7=
MNGF]Y->)T67_//UIQ4 OZDJ%UT4Q[1/8LX-N[\F,]ZM/)?HV8:!Q+ 6^)$JW
M@1,/41Z0>BH8*9WB@OVO?Q+$,%[A!):^;UM\V#L\ZN^GGA?QGA/#3TKWR^]J
M>)ABLG&/%<BVH1M!Z'7*E:J0P=5"=[L,_7V#47UAO[91LV"M\)!9N]M>Z1W_
M5*J[VX TC.^)1YF/C\_4=%G9,V%9M^>>M$R;RN<_8#MX7)]*="' _?G]12+T
MZ$Y"%E*B#4E]BW":U&6H%;[H?+80'8**-+E_XYZPH;2Y4%"FT*&9;3):D4I*
M?Y9!]?Y>>'(:E!XML&-8JS9&>;Y\)NT%.UKB]FI81H]S7$083G[JG$_9LSLV
MGT<Z<AUO"QNF.[[#_[B1#F.W0_GH%>+\X)U-6"..+=-ZG.':@1 EH1.0()(Z
M/OF2?;B\8_0<*00?OD=!5W%,/M=SH-=P.-=-IT,/QG:!'"L2[*3 P5UF;&D?
MYJZM?;^+F:&#5(5>WQ.^ B[.'45*+<Z%MD=SNVWBK'X@>Q(?RZ53R566+%FA
MV3\-HA(_0JN(4&[)G-E(RLM'B:WM$?_(.%*YDC/TFM< '!(D![%5[>@#]IPG
M4/Z[3ZA-6;1#45M=?'JXVY0#$B?.7D6]>=/P:E@\8VX=&7<QY RLA^=>UM/;
M6VSB/2#7KL+>XA;VW%XU93"<%G? ;XQ 4:YKN^<Z8B1-19_/<(B?\,@UUBD5
MO9)K,WVK)\<Q9=Z>=\,$RK=/\*"%/O5[-SR#1'=%?AFP ;UH-48]'B3Z':MB
MG:(T=/ZI[LO&K$/^VAE*NON^]QHC3!$Q?"_62J\@,)NP2X/*H /5:+&3SNHK
MXF,89.&?D="'3H2YV)YH]BK.#V_1AWUP_%!;FS.V_^X5:[D?9TX*4M;8:I/T
M6"KR#B((%X^49QN0/]F>A,!K(L:NQ@>\=ZJN,41K-/.K*1 4DI[PK?1QR!GS
MKM_$YH&=5E#FY*_FO&X7P(X ](BF'E<Y]OZ)Y:S'U$,2XB%%DBT3QN\OJ_3D
M"S__&7U 5"ABF\O5UR4#;\=-Y^<NBNZYW+T*N0$WM,V-84NA0>OVB*L"FL'O
MU,\S0MF.>>_;]C<=0TU$4ITSJ,EBZ[<R/)Q:XOI/#Z6O;L)4N -SYEL<=&@Y
M68V?\_@\2@9LH@0^;YE_0?%5;?LUGSNR[)8U/]35'&DQC8PKOJ@56UG>T3MD
MMMP@RP/&0CG_+&2=!]"<QEQC;+_5-DXNVY8E%=RN"]$W@^)NRG.V.+S+^,V]
M'FGOY_$JZZL:P71OVV_5X5&'1TN/#AP(OR=*8&Z,R#75I\\:T)+\,\_82LP<
M$3#%\]X>NF+U0/5ESK,O<Z[/O4)NT&=\)2."TOD]'F8E/11K/+S0"Y-UL_M7
M3>X?\05^>H%M#47('/!U BL(1?F1,>!OXDE!'"1T.6GE_B!QF3N'^+M^&+L)
M\R!+L)7#-V&[CG->;L*6H+5TO3>YO/KO9I)U0UIBYP#Z&=<I?:[PJ$+R]<'L
M=IUQO*4++<[Z<IL"&2GT8R74>Z[9_/H=@[?U:%ILB< -]\#SE<Z2.WFG5&@*
M7<:3FS"*+)".W:%<0>0.<!Y%#0#U,:S&&#\_SO0:IC7R"2/]7A]<KET!<WCB
M.G([R**>N%V\H*;5QM)+J3;)O"@:TN"<A;AV.7=OR-?U_&]'7+6RPM8'(6/@
MV9=!6\8:=[L;)]<REM[:X3V8M$QH8O.@: @)$->5^X/8D%=IZ7/E&RK\F[O_
MKJ;<J9ZG+6TN4AX!O7%;988^!)#ODR#B2'X*WU9/F.ZFZ?42MH$#W6:FGRAA
MKF+HR/E1C%.8P>*)Y_D\.VP&KK3[O"OSM5;/TKK"L\&Q0RLLF4&CJ("BK'T8
M%!VWV/T\&*O/P/60E$-&%[SA$,:'_8C?A)VRN*[!GIZR?;_CY!&QJ[ 1Q[(/
M>X_T.BI9*4%*5&('N$:<QU@=[+CW]GNT"CJA"R[I^V,3)EGSNTTB)OQ%\)KI
M#=.UIO: .POW$INROAW-K$O8D12MOOV(U;V2=AA$W1,@KR07S.F!<E7<(83H
M;RM=]*@]?>GO73!ON@L0-WKYTMCG>I:>V62S>];GL?4/+XQ'U'-&[%SZ]*97
M4Q8+6)>XGQ&-F[".PV;,AYQ'7&UB&%=R+,^:R<GD)3K#-[X8:MT5C#_#U;ER
M4"/9_4&J8,4P4I8$^10&./^.O8L*W+':D=+/U0#=R7CI\@0JZ<Z<*OW,)%9I
MU*B@U*4\"F5U'2+K WS['5A?/E.U;>9(K"- IS5P"3E5RG1&- GVD.X\0K'U
MO:H-7M;C)4/$4!YG%0ZR]GOO\3K0UJQB\U>E(+VR#B815-*.!LVA!=\%'F+X
MT^926$9A2!&L'EJF?TZ#SIEK+@.CJ8+Q.J,?B5%-#^9/-/$4S:X7R/;EUC^_
MJGV49HY3VMJ JD-T#2JC611"?)LY+3M=31T\7=X?QSAP#/2A)(]-=Y]L<?QA
M6!:4+K7+LPREH1US*VTE09;G;Q:^.D0-/JH[T;!TBMCW><ILQG?NQ&L[Z4U8
M3$&JR.'WU5O8W Z,HS456DK0:E2\PLZ7?PWQ?N(AH#XUW3K@WW3PX. Y^+&5
M["]5S)^<'(AU0U!HD:!("%R6GP8KNM;,I'\^FL^O_-EGOOA[VZ[<D=]$MY7<
MK K!JQ:O=GONF*0%L97VA?/C>@>)N2,3ZCEV"LFYQFY=S]^,=_#2GTK\V)[N
M<#W3N97?74G["4R?NN3/%1UF"?L$MQ\ [U%$ 3BZE=+471-E#*BR?>C9"3KM
M]/G,&Q_3W2O.2L]4%F@9Z-2?5O>2:@J/TN9=VDUI<"5&,\.&N#JV='\?3G&;
M>!!--.VL/B \BV[\?/B$Q^5P]X80ONI^+9CA"3NT!UL6Q633^[M<09W!3"",
M-#7H,6GIKM9*_^/^&*)=Z>UP-);F%?_YY]^JYJ4H_>1&!_G&2$OU]]=,OY2$
M5WYSZL4>A=RI%?G:=7%K9^P<)Q&/%<1.6"F#59$U:&?:_ L:B DK(<YY>R(_
M3E@<EPBQ>C74=FJF54;K2*W!.]>YJITZJ8)_G>S.3#;,RG0159?3VERJO7]N
M1!2&Z$P4 [$6O>+U4B]B='*^)!UUY\^0AL'N(>4Q$%E+N(6XX)J$$+T.T6P/
MJ'[U+-E2MK?BK;(KV!=&VG@LB^"YWW1R=35F\R@T:=O]:=("'OM>V<Q<XEU:
MT.]#!,/!G6:+V:P#V/?.K"N8DR#A(D'\9?TOYT]PWU$Y**\V3"SN:G!VI/%7
MQ-ANJQ3DW=/K[I4LV$D =R$Z21D(N#%RZIH7Z,XXU%&$F&0?CG[YLWT'>)N<
M=OV/86'$10F+&8'8&*N0!\=#]!T3I33UE& ;RNGK>CT$NK?1E* M ]43KF>]
M)352%HRF"!3KI/1*I*IMIQM\KBA!7_UM8F LXR3PLVP?O[^^M=@+2;[6G7R3
MSS&G. 1" .HV[C6WD'6-'0KF2R2UJX6VPU^-5T>)GY)G'1V>ZZKSZ=PAA8J)
M4#UW<6>WF=C-7>J\4\_QA58"0.>)35A0-@3 ZO? :V\T0^95PEB"]UZ@+R*D
MP-A.DK2EE?'T6Y035%M^GDVZE*,]_:T==-[S\]O[EGW?VDF#1D1>[O8=[9,$
M\AM C' )S\O>!^(NT <I[<4U+K1"A M=K<+P+75@;<@H;SKP?D[<B^J2/Z6%
MM@Y_OIZ3$Y8-/P*OD_7X2)*!8AE1A^L&%-F'0.<@,CX5JPTF,0Y!8(J> \92
M\E/8JGI,3N-]R59?O^ES]9J]'F'%3@7GVB+2JS\<^0N?4F .@@:LRR"$S@S!
MG9;6.]0D&(E<>89X15J;^;4RWZF%5S[>,ZX1S$G'W%)[PUS3F=+O'M/--^I@
MT=^I9MW##"&,MM6A80)%WV+?>'\RHD&3.V2!SG]OA@N<G8]1"Y%:;[V!6K]6
MI!_8K@BE^0 X& ),$Y@OH,^W_: "[()2]L'L!&,.K,@XT3>DXO88#)>\&7NI
MA\D23L@J0%P;XK&3/?FO&C(508\=9#\:[-B$L78J9W/OIG/:\3UP\/!WKDL0
M&>#<%W?8A#G:P6(V8?]4V[&P?\ !)__]-(/?E[Y3Q5%>4'2\YVX/0<I>"AR^
M_CA;?!IT,1S\/:'[*B^8W<;8A&D(!_8ALN<(3RW 9:X(-!^?!^<1@EQ>=( >
MU(>31P_V^L' Q_0--*Z+(&4I&BUK1M<^O<ZPTWN8I>TY__%U3@/MQL6:Y(#S
M$A_AX$%I12UHPJ> _R[--+EG" GOL^Y;M2UQ!-P6AX;%\2.XVR':?C^?^VX3
M!F6+T4\-<0,,,ZYX-2>__2!WU$J2@[<RP8[C=IALPN#@B0^=*6GP7OE(WU#E
M!V4S^9(DQZZA5-.(=./DJ0N9\K/;1?.#EK;J/HYNC9KJYXJX,%J[D&KM".X(
MH+BX"O"&T+U![\ENB_(,%.JB?T[ @8OAN[VT<[ZY:2FI)J-/5B7!X'!H.7O@
M=!?\M',_O.%WQG_;TT>RCQ.:P1?TUB[3O>C2SJ(=;7U-0<$Z;6%A+,<LNX]7
MBUN2G4])/'KUZDS^]51#;!><?AJBZOQ&4%=M+!&[#TRB/W:A#_;Z2E" U/Y>
M48Z\8/IDCX<K)62IID%+1N;KY_.O/+7O7!&O?=5Q)6V#AW& *SR)1U<Q'Z0P
MWX)AK!#,<;I'MA8878&VVEAV27!\\VHBW, 0'W%T<N+ E+',\<&;7RW#)/+K
MUF+=9WWZN7J0&H>V MN<0,X&&H#$=KF%FXUUU>A!2E"6I0.-H(3.<O3>A/F.
MZPWCQ>XY?>W?X::NG9AN?.:(*W]!P2VK_9#=3EJ:45117*$XEAT17>72$&O@
MVN^G73>A_4B'LUK!UO*^$CQ3]%S>"6TIOK001EL&-0?O<!'!"/H1%+A3#+$]
M:$SZPZC3Z*51OR^OI#@EPB43JD(_[.*/>F:E\RSY?=^$";SC=MQL6H)0&U\E
MV/ 4'<3L!!_0FS$.C$.GZ:2,)4N5J""3EW7/VK/+963O^EGO;,I?^V-$#+^S
MO];1C6AW1IBUC[6U:6]*"$"">M\7GR'\";?G1,-PPK,9^0P5,"WW-ZU'9L9>
M\\VCOXMG'CS+/+N_6&Z;YM.3 CMY&2RN\&I(B0_0^02NHINC:743_<CYSFTN
M8<GTEY+5)FP/>D.DAQ./N""1BJ2?(8&F6MU [40-X]1H-U:['B15^K$EK33>
M!"^9>"V%_RX+M[PK>ADP\U!_'IXIO_1,0VY#0X&M,DQWZ";PM 6P%#!&G"JK
MG: /V2@;<[+E>RI6/F0EI&ZW4[N2VL3DR:+AWT\;;S0E7 ^83;V3N0D[]'V6
M:P1T&A&""*E [?=NTI0,I:^)BDR:DX4XL2K"BQXPV)UI9V B;CK_7D^R[=JG
M'23SW!NY#E$W<C)0>K'2/.M0'>0SA=POBTL$Q %R<9'X%@^%%LO+2FI!8<Z<
M_NEE63B]M<]*PR:J4#+3RDF[,?>;L*]-'Y4XV]:\LGXI=3G'1K$5F1S.,O2$
MNKDAPHQXH7>=Z[-0L>BW6$Z.^K5,%*6Z9J\VM=%)*5,O_9P'#L-/I'QXM/';
MN2_@C^X36QXG4X4C_L 0(1%)=W85 (.88_60% G8(80JQHT11"U*@8B[O:5&
M-7C/9?2R^E ]-=#P0M/HTE/[-_>6S'CF,>RZELJG!]6,R#C0%,45_D;&3_/V
M(1IZK#3!>U<LPV-B(ZM!&+J#^..:://Q2?F5FOK(F7,^QCBSJ6\%U(/$A048
M#*X.=&:/O ."EK/OYA]2Z+,XL/O[+9>R/M<?B-TT!/D#?'T/H<&!U;YC$S:2
MZ4=PA!+($QS=!IB:Y@I'ZV67<QX"P:X9>4NTYVT-+LX]IM<Z2Y=FOWWB?UW/
M,IX44JP<N";[Q0^F%#X"+<Y>J',2LLZ#+1U&-4OC:F(_(=6L]!< >H&WK6#:
M=912Z".[V;*?267!EW3%395RALOOQ^?N//29W+WMUJ%E<,]\*P/>C:0?0Q!%
MSX&N.A]OSA*ZWI[K-BG0]#QONFAXR<;\K*=8M=#7\'=?/;ZNL:6M1H\V08$*
MF37DQ3/'[*(BDUR:.H!7]BWI<R4,R"-$.'_'C=\>.#=J>-TW[$3\RN<5P?C?
M(PL:VJ=[%MQSQF^+/9,6LI2,1&Z#&*8 B)&B YV$5&2M1R><^)B*NMTNR#[%
M@(U#X++5P>(RHU]CI>W+97Q$N'9S0[Q[TVU54<=C_9D=^_AXJ:Z@YD0#0\(=
M$N8X),R D?+ %6)$(64YE3DG)?,]]&?_$:=S#C@*ZU+3VX,S/G-O*[ABS5#F
M/XWNY@Z\K-F$E1>JM3,9*+9,!MFPF"7@ GDO%3Q=^8LDCE6>05\$)%P%X]4&
MEZZ&-$F]5_VHZ\,*N^L-6-CGAK>''9*?$];^ ]"=ET$=>"<>U)[L]@TCDQ:7
M&3BJ82LE'.6=[_G8CM$[GW\U;VW%CL_(\I3W%Y\/PEE$G2^?WW=JV$H'\XYM
MPL+#$>3M>)8ZYL0((O3M]9\X<92E<*4UK<8ZPD\^X5BLE_RW!S3^[O6 QB3^
MC/.P'C(4IA 8/%M&J8GFBD\P7/(7G<@<UVZ@SO0VXQ&1U)U/D&XP6D(HH FG
MPNX&MJ'JUL^VN#^[E.AYUMSOK/W%B^MW<,--2_M8EA@33HT5#-W*# 6[_:]%
M4G#*/T[_].[R.A=SH/K42[,^\-"ETRFGK'GN7Y*ZBX717=G*.=#R_("X*9Z:
M/17D#N8P4+ZU#-6_T1,W/]?09(V*?4M+13/T'<D^V@_R3#*_Y0IK!P^H1YWM
M@#&*H9[@/:Y('&3P;H@BUIDF,)R/TTF9+F5Y5?0?8=&ZA\)]SC8TC0U^T5:7
M[YYJH&TK;E1,N&LCY1<)=3T A6\VEXB0V,HH$M _CD"G)U=JP6S.DMZ;5Q%.
M)_3Y:=AR&DJH74YEC7D4SY?% 9'AE^?.K6/J(S$KAMT*/PA)!'(:B;=-CB4+
MBC(UZ$U+<$;R@!,80_-!R8*Q?5+H%M.)Q>6:D8"D\&=H95%/M_)WR0=M)(7.
M]\X^K@ 1D!0-=%02(?P05&402SR,T5ZX/'9W\)RDFB(]KX'J8N;R*L%F]-H^
M0)?DVIBD3'6MGQ$L^+/R>:'R%O46 B)WH? D@'X*"9I5,$L9J"4:2Q$LETB%
MJ%M0SZ#,C._"UP2@=+;[\!B.83BA+FCZIV_%4FK.D%>FZ4I0KL@4Y.*9A- :
M06K3XA8\XH(U=.<N,S4YT/E%<)-W;TK2[YS?Y-' VNQC\2I.]M_,X(&I@]+2
M'RZ=O1MOM@/[$MW*%4HK03\F-V4B J81TZ74U?PN?"I7IWW",H!L[ZLVKSIY
M,X$TB+H0:9+A6M&U8JHD]>6*)W]0SN-A0A@*U)98M&-=Y/8J"RXJ,40IJWT/
MR'A!+Z(M.39;PE<(Q;:<&%J7<D899Z@'K@SHKU=277K>!';#) 1!B)SR58,O
M6">Y1!S/UA-B!0*YM&A[#%9I-J06'8PVH_C\O(%5?]7<XN%\.M*JZ=JGH3=[
MM7::LX[P[+@KT;5Q4(LK4=S,%WUO$^;^%GL?Z+2$#$F RLKY@GK7)5?B $VP
MUP71^2W[%L8 @J=R2M<18JU:>KB0BIXJR2?:N;M;(Z325 ;.!.[Q84'5J5-X
M$Q8()[HRUX8!\C,+O=Y-6!I.'*L7,M2_O:**;3Y)KK,H*7M1)[9DTH:731[C
M%#S2]1T6.V\V> 0.@>].*$^ZD*9]>H%&-4@B?BCMQ/M"**T%+*8/=.7M1==U
MMN]HA4_?,/VPYH**"Q-^UY+N^:GGE/==3*<,OU/3NXQ1H!."E>16"Z 7!VI7
M+.FQPME'0(\RM ]ULONZF=_!YI'SP8ML-[Q+>?>%9W/K)USO&7\*"0O3ME57
ME$O9+H6E,?K9,O93A&!G)#&,&<.I;-=@&S#$\[OC]#LE?Q)%/4.5W2?R+YC,
MO.*\G'1K>C+SP6K"YH/O)9<G9LO:$M^Q<I#(DMB/7"%.X65$$$("8\/8,W$S
MO^^M&=6CUP#EGD4,(ZDAB3.<YT2_F,A^65/\_A[,&S<;(7"]</;6X0RN\ 66
MP2RW#Z"[ DF(NL]-,IDH1_HS,ZO=,2?\7 +I#?-//_;GZ?Z.6;<DBVQL^]='
MR?ZE_0/1P)+^5Q]:^V]M78\K&L.ZB!V"Q!T$]5!W")=Q4Q]^=2U7@[M_.1_X
MZ;=G:/YM(R%Y^73#J]UB9GN-CY=__RB>)Q@X<^TNSVK#59PR5I"MQRGAJI(P
M.N L.18AC0X[#0OUUBU1G)[=R562E7H;=^:K&K5-GRO4SPK$;&WMQD..8F*E
MS)TDJ/Q]*SW0JV;D<FXA;VY'?9ZH-LOP=6P0/']'[8=?#VMH>H93%WO.2PJ.
MR?)\!>H\%I58:MA^L^A)7"UID0,1XFVJ;J8+^]!7!9K2OS]8+]H[K90\SI,Z
M(P@C/UK]L//IMG1]\A_64:#3'Z" "/K3E,7I<J![%W A!D=_# 1EX:;:442K
MJ?F@)001_@/R_"ENU?Q4-NFDX-R_WYW]'YN?. L)*6%C)8SM)TEC9=@RC/#%
MFRF9$*> *"!],LG2!(5^@7APN,LA\KE3MUP\W^7O<,L[.?&M&4\%VX;M9&%N
M_]#^R<8$5-4_/?@^H@9 M>(Q\.$T(HS 0D,L[>LJBX.\A:"'-+'+#C!;-V%-
MV1PK5R1A[)^G@H ^6Q4:;^<ND+9*'^0^VW#'WO+H@S@]<GF*0/-8BH(24SY8
MQC+G?N;RO6$8W6ESC:*\,_95)GK20J8L[<H_:2GD/)"2WODUI_#A[LI]>MMN
M(79QA;"]?WX!]-"72:P(M"WS+EA3C+&F"V36_"H2N6<+)L1>J A^-8U^M!K4
MF/QYBI:Z7EEW;/1-"'M*0$>JY.CA.LHR6U:&MKST'M*N"F/+*<.J8TXR3 L9
MMI2<9@C,4<SIDZF&]56LJH%=2]XJC7DCCE,%-1$CYM8ZEZ[\MG?L)6WG#@+T
MDT "1#?%;;E"+X)8XN"H._@6P4Q)N=QF7>X<R)5O'L6O-D<)CIUX/EH=J3D]
MXP1_H.[5UJMT9+O#,'([E'[2B_: 4"(0X* )$-XD(Z5^MN3WP&70A]Q:QE:M
M-;(^LWK,Q)JVF=R 56N4)$]=.K_]W?B4M39,(M%2"0I#9B8#R5:6H1*(^=Z<
M,JX.H0<00Z\B'1AM@&2#XZKCA*NTIY<EZNJ]-)WL=V\>\$5XV9./\&T[[-.)
M:)!8^J[ 5OI5QAU&"K3KH?M]P0*#ER]-2"K.53-^O_):3C+"V0H>3I%:QM,E
M#2>+SA\J3O,:P]]7PIRF."R&;9T?' /()%(JCGY,',$5?H'_25RTVIMRLF42
M8TT]I!+Y8AH(]YP3C;. FQTX46OC^_6&)Y^4XUG[G-([' C\\=% "(7PJW)2
M$>1$+ S4(9.F5+SOT?2Z"2K:WBG=LU  G\A"2(5$M^_.6_A]\.6=9;[@RT:7
M!#P"5N;V.VI@STM Q3Q>'CM.J!5<&F XDV^4L1#L($9%-S)M$R9>_!:5 0BP
M3S-4W DC[!CA(?QE"*\MEC8_<GQI6-J<I_2^Y^JS<"LZ]> S2WP\UP032X>S
MU4X0:@.36$?9]D!R2/0U"U#&C<&MB"D3>-RQ/W2[U2?+926W**UCE?9CYUN/
M$-_\LE2"%,&Z0NB!?@Z12&J<7+P&P8E?3("NEZ3:L G+V O6?IYTJ0_WPG0T
M>@?4*TBG6=+GSO7Q,D\F%:AH5XW#7SLL41'DGYLP\*8>>U]0)H%R$H(HG'Q6
MV)(R"O<-Z-+@I#!Q=1S\QQ7N,.NC/Y#_>89=S_,=U_@]BQ "(L@+<''L.Z00
MA& E,M0$Z:B,9>/F57%]!\:G169CW_=C,1&9;\L^UOH<'4S9]7!*,R>A$E,<
M9LN4!I,8CYE&$)QYB8$R#!^3[K DRA#LP8E;6O./1;>X9K4AHZK:LN:4?<-U
M@]X$ZE["717&;L+R%I\5]A_N7S)A26+GU/9!_1^Q]2 [2D!X-(RFL@E+4E.<
M,&X]-"AE%U5>Y2*K'.OM'+5#_(9V<$+SA0?;/SQ+^KKMD> B@H7V!CK'S!#T
MTZ*$+Y-]3O3DN, P'88@L7Y4/17T_#$0_564<."]&0SA0M5JC; GPH; XJUY
M4--:W.W2#(?%TXP!;\8?C#"H3VD=5KC%5?NA/%_"U9WT=_;\^F;,X*]C0/.C
MG64M]\Y'?M6;NJ@GKB40O1C%L@$ZO;ARW/>D)L$._':,%CALDM_])JK0F>G!
MP/7@^'[);R1]SHJ(H#FJWSMS6[<U3^5,TYMX)=YC2@4B=^4$#[&@=-5Y&""7
MP:&R"QJP@$X_!!F'J&N8[%T6 MLI+RU]R!Q-AO22,G4J?'GQJPWF4VTMIWP7
MS4G>?*_JE5M.&S)Q##Q7))+AP;0"LQEK]IR'_=U(Y6[*!;VN[,0UXMN7%95S
MH5(RN_)/%IAV"SU)O&WPH$Y96,U!7/.9.OP!DGZ4,(U@7N0T5&.E,%+WF E@
M KV?^8">WV.@=9:Q9TX;Q%6?@TJ,XIZ:5;DW;?&4@$)JWF+WO.45)\4+>X)?
M-V<^D_K]+Z>ZR*5-\-KO; 7:.3J2+=O?B9., J;^@ON[!BCCV8EL]^<_(W^*
M1O+7Y_YB_@RRA(<5&N:M"(9W>7:L"^\M:?)B^0.=VFP[5@S0>83+SQV"$+0'
M6^9[/U#W/6N1'8*JX0XI_ZZ$:/UB;SW]7%SY2)A/2A9W]9F3C7-HZ:<]^+WV
M,P.K1FS9:Y03!)8GNI06M#C+@EA&IQD[AH&@G(G.BT9NPVJQ+5^]:AZ_'ML_
MM&@WWK9OG3%[A/_'@PERE<\[/\_R0YJP6U> ^DW8TC@5#NJLL27U3W&>(@()
MQ#+N/B2ZJ2^:"0A;[0JSJ&]I&/59(!;.?MP_YW35S"DZY+)>9J[U;9.6E".\
M]E8!C/Z>;.(]BMFB+6LG%T+Y]!.N8MA10+K]<'U+1 .C*,0*#DYP^_O.6F2F
M3!M=;'TT/S3E-[V'>E #K12OE9)(WW'3HR,;-&MEEC&,V"KY+[F=2(4&Y\-:
M5(B3O<>JHSULVL=.^<3)+YT2*AG5R=O_KMSS(NZ:AOZ._,3<&Z:Q)% KI0\.
M&DQVXJ;JMLY-HC#>T&MXJ(5N#?F-C_T0]P!8T7-V^ ?1/K\Y\:H+7\#G4IW:
MPM=VX;IZ[FE>Q3SSZFI;)Z%+MR@:&L?TA]Y'01T@8CD9D#0!ILI_47JKBW;0
MRQ.HHDL[:GI').H76@WF4Y;,)D91B=W:Z?XN23?VG46-28#:)A6W(A"!!C[]
M"$%$F*HSS>RVI0_M,0?5T6XXV68;_6+A2L@]NPB%$V_SEM<&#E>_,%;1UNG2
M#J!_>X#)8'+H@JE ,#P-(44(-)J.Y@K_I+G>(<#P]>&&?SK:#])=,C/[:IZ&
M!8Z7MCAJR-A=3[SO)#\O=\DCU_'K1U0#]@PG'B#CH/7WQ(.Z#FQ)&O5&!FLW
M.KRZW0P<I6J&M2O1H]A,!8\6M:R!<)16XH-''Q<DQ'2(^[W<36^)54K"L).3
M\]_9J@[435@J4@0@/VC)[P,2$7*62/*R+!KH4SX6TC*8P/:**SNN]>:)G?%5
M%2]_Z=)=+/R;;3R*EI,O@$Y!0BAN6H99PTE=7G6=[G?*DDB;XP>S:\ #/=&O
MB=-=J/G1KYG:#R8FUU1&/'(%]MY6"KOJ</H<BKVC@F6!'28U++-EKOYAAG+R
MV@7"L <9KJF6[N4S9>T/3*K=O#K#]CYRTLV=#^X03#K9FJ;W%/8(QB[EM/P%
MB+9= !U%6B1!5M0? U"(S$>XGB6'7N8CC,)^]I'6])$/?7;CJNZ:F0F'.V(/
MGIL]MJR?V_'*6MEAS8@M=X KJL)RP'XDT5'+'22B;8>:KCQ.OOT@Z-S=>!HL
MTK\N43$0^2P.?Y*0%-D0H".B!]=X,V-N[6?$"H!"#@$1>H02@3QK!+D^5WB-
M#'PI[3N-<:5'9^;2>HB6DRT7[0+"P]2>62X?G%V,-)I^^D7VWLK &\/.UBG@
M,@!JNRZILK! 9SN<'T*.LPC*6U(BUQBC,%1_HY;>E!:Q5,(=:GD]2NQ;&'+=
M@1>I?C?O^&R/;%MDU</.BT_5KC%4(#Q8CUBL88@R;4&H&/(-@F&L$^#&V?KD
M;F9>]ADPG!;V&"'O=;S1<"-I-/1LO%*$J!.@';U/YE7M^?702@S$+D195F@'
MJ'@F/.>*L ^W,%!WL.]I;VV[)F\V+&(/$)RG'9K'7I9>>MWL=;11JD0S=43
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M=!#S[F/JZIV;?6^90)J'V?#,>SQO#5+FD(O"[V_JN4DTSO3E#YBR8-[I?WO
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M EEH\[M[D=K.B_TTIP_6;,+X=1@2;-D__3@QHS8I$;9& Z1 #>^Y%?NJY]Y
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M@OTQI"C@WD'7V4*+[JXQ./F%;;(3=(PV$J(:=5C"+6.Q)CVR1XYT?VI]_\'
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MQJCGV[GD=0#)#QW(70?G%&$NR<0+34 ^W<,CEZ5DO4;A:N;)E)FFIV<3XZ=
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M5!>VT_E29"!=UU[H?4XH36A3N_XO.;Z.VIE%2+1>OI!H&G0#E;)6[37F)CW
M2="X\2U;==Y$=LU/O)M<W#X=?K;Q#F<3VIVM7A10]I5<2;\Q,W?NB]/LAEFB
MCJ_JLUV)2FIJ)P4/.PI(7Q 1< _^/W\6E72:]![_^ZPQ/SL*SL(L<,=HIC\_
MU(M!B2-MG&[$PS]9QDXLM;L-<*H/-_]BL1\-B##S>B":*U+H5^.PNH8[</,D
M.$B%]O" :$,HIP6WRLJP@-3-)HC4F_( <3,_*S5HOOFG2^A" YYCL-M6)[VP
MQ[0AY\B1==V]-SQDV$DSYHZ'J>;6:^"?J$CW!$A+F3R=A"7N=1CDW"3N&;#6
M.$-7^%4:NGZ]E?]$ER3>H2]Q:O0;NX9V36MO6?W)F;E;N].VSS\^=4>I<18;
M8N+*67F4R,=JZT%DZ1.NL5;NT"]4]ZC@(.(0!EXT)CS-*BQKUJ+%+.\N?WP0
M>--;*]@IJ,7_O?,W=47H&,K> J>BB%8\H#Q[C@<X19%NN6-L#E&-Y %:!LPO
MW,1A<'FWP?!K_%08!MP4+&06"JZJ[L#"7)7 O?:8!Q08LW[$ZU)F]\.A_Q;O
M_QWV+_JB(MMX@"ZG'S]S>H"Z8$II/LL=Q:27 CNM%WHX2M5&7$E_EI0R^/&9
M=R7RD/2-D<(9-T<V(E/AF79R[@R'A;5+3E@^DD+L61B0-!HBVQ*:&LT&JPIR
M6MP-3:Y=R5\O]F46.'7S>'KR9ZH%GIF'8A#>>XQECDH]Q<,O.1QT)38^K0[Z
M@K8E4+AZ\DMDPGO2:@AUR(+&RA):; JX!7<^R7TL4S/%WR?NFUB_J#_AXR <
M=W]+V)8Z>Q>#6L-+"Y9&\!DPF;K@8>6"V>U["KHAY1^_>$XS6'#]91D%?A4C
MHT#*._SP'D,,UJ:IL,I_:+0N#]C_W!V]CMF5(?+?@_^A;P:>ICB9[UA"VAB:
M(X!5(&N_D[$).B_AO[MSF1X3H?BH_)@<#_T0)V[4R)AD^Q'W];LU6-7G:)R@
M%]S5&#<RO7QTOQ?W)FGU-&WH4?#5R_CHDWX_ @O]M%)KJ>O?.NE\]Y[TEL(X
M$,:XTOE@=QYPH@I<WO1]W "&T2ZQ)7Y4' L^W7/<//P,N9L'Y#^D4+[_E=9<
MQR?J8[L+#U(9_4%+NWQG0[!T@ELFYE+!4D@8E33#RJ9"TC#(QB8K>O-]<1FK
M(Y\:=>"J\$WD:!Z@B$A!LNWHUHB6-OJJ/056,@_?!!E8/^:2 VL5<P[O?7@U
M>/.+\:Y[S NA#Z1231- V"!F5I)UL5W=D!M/](7\&44MDI8=GH7WSXSK0H_:
M:Y_ C6CSIP7.&.?N9-J6LF-79]4T1,8O%M@X:%Z[L1 R<W&2J@;7[6"EQ* F
MH5[-UT):7<5#6_T(TH%6,NO+"L]F?G'N_Y%7?W./U=>6D0\CD:IUV6:VZDOR
M"@[(-/<EWM\5UB;'X,\8*84:,1<1Q?0)]YGO3VTG_%];KX7%6ZX=_#A.5B^N
MJ/C8%:36%IFC5Y >]IH]?W6?8_NQJ(_WT3<8"%C""6P<2WBFK+B#(X#L'T9
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MW-H 5+S%_S+1ZOAE\Y99RU:CXN;W>;7S$PWM+:JIS]:I7:A,LPTX H028GC
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M"N27J%@ 8H7?&S'X*A;+IG0T7>S7O-22.A/_?1;/U5-WD 9?QRABT5<"?I-
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MKQ#W%^J"YD )J),3./R&Y(;/M#J!#:G!_YK&W\-H%&7 M?./;.KO>+W?[^\
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MM@26_3R?\=VT*W^5F4M 9]";^3E8NZ@C""LHF[ *]"R!=A$5#>/L\*_T(%I
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M^LT"&&/*Y:6$O:Y[]G:LFZOI@6\"W1=RT0I8#@5 ,X*!7(HZV?1R!+_J$/]
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M]^\;/I5::^%!;WR:+P >I&A.L<$#GRW7MH&N=WC'S9@ NLG;?H\TA6 ;.QR
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MT18=C-755^;KD X$$M=!>)S[AR/=P7^^N4CWO*58H*IW35Y8H)S>05=/[*"
MYS0[L.ERX""7*D)Y<GRNTG]7/1WZ"OF<OY@0>WF;YNTE'N'SF^[7!=O<OWL\
M?:)/XC$\PTL5L6GZ:A_(:T%VET1VA(P'> IS:)>FAF<C31[VQZ8/NZB6?WH5
MWWY-@7:VOCOJ[YNI7XM.-$,4 )PY,B!!!H0?BE@L*M@3:IRQ8)0V\/GN^GW4
M+]T&+QNOD^MIYUZ,/XNX7W8%LQWVIC'\BA@Z!KY:,4Y- :?06>-V8%[6SSI[
M/_I0(U4%2I@OI=C;U*;)1=Z_]F#5M?0WJBFOJ,4?:F9W[5F8>%SBM65L_:,B
MC>WO/ATXF>NQ-:9FAZ])!4=#GKGN7-P1V(^=['H8N=H$[>([<.Y5XG6!J 5=
M4C]WN*Z2'%UXP,NOR^%X]\_#4^<_FF1)9\5>J1N4I4G[NJ?4K]'J59\"P*/(
MT=X)>/:<!:9\W"P>3&=*4.!7:HY+UHR^$1]%LWE)T&OZJ7EB8W.:T\X8FH_E
M@%)ILTKFF@0O%P0YGX-/8H.^:'E)/QTMIC@Y\ED<8NJ7=R*[L+(]$_%(Z3.W
MFSZI[%G]_$EWV/EH1:/(:JW+N?SYZ6L['E$E<BMG>0] 9O!U"B1F<$!<1C15
MD\3J;1V,P*HF;B8U1-_QY5N6=H^^-#-99>!;L#??2F'2>O.M6ZRI5R92R>*J
M2[BQ;4R&5-,R8IWDI<06_)8FNIQ ^!(>M)%_/+4X)B[">M4C19B+ZO(U-ZO3
MO82>TMX^="3D(Y0&.I[CUTATC;MP:0SPH%62KX9PLF3B<#'7I_O-K\]?7@=%
MS&16Q=IKVKB_,7AIQ'M]>2)+; %[] 3,3YP2A^+>O#2&3'2.%._3.U$0I%1[
M-")H+93)4SC=:K^8O_?Z>$?UIH8V%KNG,DREH:$@M^5CTUT.;K2<9\P$6!==
MQ0P@XIESEQ</)P4=F.E:1BB2UW/7SULVKOP,YN,R C<4-#]I<JJE[:ZU+-/:
M#;7AD>%I&V2522GR[3+BG\D[K\1.A@PC,B\-H\,W>B(D)0XZN#'S-","&H&/
M==P$!>$VCX%+HV6K=VQLGCY-".)^N949IJ1:F/$',@9^>1N0-FLG/!K.!OWJ
MPB3R_@E4\JY(9"#DC[RR&;P4<'5QK&[VD,2LOSF[,$K5@^;*;K5^>+TC]AH1
M>_K]_^*)!-_CX8B!=5=RIV@EP5:Z9'8O(\*IF6A5S+J9$NN4'H>ODCN1D??8
M75*L]H#&[\4A)AUK=(/]IHQ%KC^$YBM]Y&3XCLZL7I&)E& I2[1G&9$Q#H12
MEJP7,M#0P:/+B*MHOD[_[).5;DH^7./(FZ'!4B1KVHPO(S&X+"X"IGKI&P"N
M2X@$!3")V(9^L=8B$RDRJ04ZKV")U50F&LKY)O!?1I3K0[ >OJJ>M_*#"Y5V
M21_V9PA;&0N6U<.#(L3T,H8RP+.G? R37(OGR4A0OEBNV_\;^?]&_M\TLN9_
M$,Z(__X($D6$NBA9-R NP4;VC\;R_&8I7.)'@Y[;^O<FJ$KT.X2:,]I?*ZZ/
MM3EL7SRBD_$[#AF $%FLM#DN?_PW4$L#!!0    ( %J 6U4LO9YO#7\  &>0
M   3    :FYJ+3(P,C(Q,# R7V<R+FIP9^R\"3A4__L_/$*RE'V7*4MV*EM)
M)ON6)BD[4Y9L(2%DFK$462=*BD\F(162/>O892DAA# S*H7)&3).9GN.[^_Y
M/\O_^OVOZUE^O]]S/=?U/Z[W89;SGON^W_?]NE^O,^=@?V$384)V5K96,(X]
M'+#+T ^,_1MVP-0OW,<?Y@^#-@[V',P<MH=C=]O=[]G=N#AW]]Q<7)Q<>[GW
M[OW7X.'=!PV>O7OW\>_CY=O=H+\$^/D$=A_L3O)OA^[AYN3DYN/9R\/W?WMC
M=\*$]^T1VG.-DT,!MD>8@U.8@]T+@T,V<O_+/ [8_[IQ[.'DXM[+ YG!#[VA
M00@RGY,3,IH;LAAZ]3;T.HQ+F%OD\#'3O:*.5W@4(L2.)^84[U,TJ^D2OS &
M*.GZW$CBY9.0E)*643ZBHJJFKJ=O8'CBI)&YA:65M8VMG=/%2\XNKF[NOG[^
M5P,"@X(CHZ)OQL3&W4J^<S<E]5Y:>NZ#AWF/\A\_*7A>4EKVHOSEJ]>U=?4-
MC4WOFENZ>WK[^@?>#PZ-3WR>G)K^,C-+(B]]^_YC^>>O%>K&YI\MVC;X=V?7
M+PX8)\=_V_Y=OX0AO_;LK@'/KE\<>V)VWR#,Q7WXV%X14T>>*Q&B"L<3]XF9
MY137=/$JZEX Q'UNC/%)*.F1E*F[KOW+L_]KCB7]/_+L?W/L?_=K%B; R0$M
M'J<P# %C,IZGJ\+^_SZJ1P5!C6F&9 .6B$,)M^D0US-1M0ZCZ5&+,K/>GF"
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M=+*-9XEBV(\1G([23[H24N&:?U2_KZK;V/#Z]X\^T<N<7)%%3DM-:_S4:MH
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ME#H\MPM_*Z0><<!]MR@*+U0JE/5S?$_W"!,D!3"$^4G3E&@5ANP6=9&6RBS
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M3^WG_8#IV;/O_4F>XO\2Z??O#L)A A&'Y]9'?=%E\:_2K["&6;H-(38FZK\
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MG['Z9I<8KF/&=H39G8M%>L#L[-Q<WVLO;WY\_5/D<%344_%+MM=)V^HO!3Y
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M0JS0LK%Z1'V];.='ZQ3]"X3M3PUS.Y,?=%E\NQ?D_9Q<INM74TZ^4(SX,/4
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MB]4JY" )E19_]Q__YGZ8LT'^*FSF#:$*$XL_AMK[-QG#!\:#@@*[PBC. F3
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MFF=;_OF9@F'/2*RJ+&#VF/!6G:Q%)U3.0C>&QR^S(+-;.]<X;HF96?S9B^Y
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MU7][+=W_&?\] \,:^[\ 4$L#!!0    ( %J 6U5(C$8'"XT  $6@   3
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M($$U,E.NDH*/Q\&#7A"I?*P,?7D9ZSBW(Y%'YWZ&94ZOS]I6]<\^NZO?_S+
MS29]3C4#Y7_;GH5Y W]>BP/55.*;5;%C;D90XG-?>WS"O TEQM0:7%XU4?%G
M:] FP8CS?;\;A4;H&L:24G^G?NH6)G9ESNB/V14*29M;, S9TR:*8#_C,EA
M1X)YC"-A>"HY"2--/1D0ZA3@?*6N<1"]LAJHL%]Y4/L-<N'9T627KPM<!0?-
M8H_<(*82 3OX6#I; ,J@W)50-,:##+9 -_2BL6G8V)I"CI6J\G,S& CR1ZP8
M5J>^,!BNRRNFU+83LJLNI+<9G99^[!,?@ZL@4J*1@"OA,1*PWX7%AKK)@^E
MY.@7,@)C1)6VG3^I\5*I<J0&7W-VT*#@^%3.X?6797/3?Q#W+E"Z:[@VYILC
MH)GQV)_U2, *-R[HQJHD8/<:)6X@!7XZJL3J3[J&WPXLB%]<E3U6&!.DJUEH
M=7>OE_*1P@J5_<BL75@M>67VWPH&<,ONC#/L/N@WO1T(*>P/G*2QVFPA$M;$
M4^3G=/'ZTH/SH7N5OF8&H+5^%*867!R8-DX2E%945;SF&5A-7V<1FI6PTSC
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M4T9TT>RUF:3/&_1^ETZ:MOA L>A"P(?PA)/C? (C)1\#$PUGQ!_YUZ:S!8E
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MI'DLCG2!?0Q'$C*!LA?)(Y 8"!?U08@9Z]$D C!:;WP:+D,P=,]JSMNRD9S
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M'RRIZ'U+.P]KC/H3M%#+0OSUYUVK"BL_G<LP2_DUL3^28V?)5/P*Q__;CH)
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M[:).>+JH9^1PJ>S+NV4<_J0,(VL:?KSNW'/OYP]S3R3>:C"L=4MS(J2?2BQ
M_KBG/CW(X72-?"TW941[@=G/DF=_PP-7=,9#Z;T#DK@GJ+WY)ZK.S;N%H>PX
MR;9U^W\?2<.TRT_K_M';JFZ/L,)I*<C3$+'&!\N=PO MV7/S+]]?_U'MZ"?S
ML/O<J:;X>_+R>[S<%T7\-T;9_-L0;J,-;W3GZ$0AZL58Y3UUK=XTSA^36WTA
MB( HOC4I=G:'D1#FZ[8V4G &+W#TQ9YNL>?U]H(.?#2"]?S&@-LEUN\H8V?2
M_+YD6:.+SZ?C_2G8SQY+I9C^G793&Z WCFDTBX*/@]6DG<W<]T6+DDNGH@N*
MITK[7,ZW'NP?>M;U\$S),+A1H/JMXV(/HMK,YM6U_-47-J;71FM_2K5,R*_%
M-5F4.(_Y3@079CELC=[?,U,?::"]?M)(X,.;-&L8IZ]0O2E&I0A'NJV#U5AD
M"]*0RR4,D;!=V(QYZRY,UA',7&J=5JX<UI\49#T@FV;N*2_7[S%9# J?U=%3
M3XBIRSRGL,_P:R^1J0LE[<?87I0$TF-%ECX-;-,NAAFYU.5:6NI1EI9>W[#D
MKCYG\&EPY5!VR$NE^I>.-LXL9\.+S"&.E1J'#@1P$0UJ>7^!R@VA#97@IL#*
M9>\/2[@ ;+70\DM/[,+B/./5-K.(1I2,VI309W%TN<@!R;LZ:M(N"M9L@7\'
M*9-]1,JK:94A$P6F%BNY*8)6X@J,Y$@6S&XS=81&=I!/RXJL=0_BWBG7MI#T
M.L[GZ[X0K6K4C79Y]'#+% ,-P)WQ[QR'R05=&YBPS^ W(.+L$ ;YX8],_ );
M&TBN5+>X6S2EBT[*/-_2(Y3PL?"%[<5CZD47".]J3UE:]P=-)GDX-,=/# SP
M92_.AW,6VKS3_/$]# :S4'DCSG%* OST 5KQLV0XL;[\MO%!:+YA,*]T[&'9
M[,"F:K"!=?VYC[%SUQA'-3Z'5+BD&7D<)GHT"9?Y3RL!EU-F=,1!QXU3EW=A
M%^L_#=58:)_O*?Y!*[$(]+S"'6VH; 3CF'PEU,=;]I].PAU^DYF2LFR!+_CJ
MZ)QPABZ[5V:F/H505K?4\+,QTO@45_G9O%T8OM@6*E&Y?N<>SGS<7+^4CFB3
M3CP2=F':.G1 HS3G3Q:3I^0"[>_47QWJ5%W8E&>91-62RH!:,!KX.7ZX^]_.
M.U0%->V?,+2T?G_!C?^@]SJ T=<ZWR]Z:HXTRW_]T[K:?7]!NJO8H7<*F8C5
MHQ4G8 ^!D+$[%8QIRJN$4K]089.\]WY2PIJC^Q1*O[>EX9[![!\.#_>L?,^J
MKX?K#QX/]\KHUJL\KFGQ*RV\1Y=8$H:*TOTA28K0/-%$;C>L36=)^6S\#?5>
MMY:X&^+;'D;VCPUYV[Q'9;4=2VAJV-8XD!^OL0C/^+^"6";_OND9@B-=81_!
MMB@H6_%/X$0QR.9/Y!+0/GS[4?I?%Z>C,](1&8RTH!LBHZB?R$=DA68)]@!9
M<(.<L OC,[XJ4I:_>'?^^-6X \\\,+K%U^=L[WP-EP_G%F-V.#3_VP)$HLGQ
MB IT^SNF'?7;VR&,SON+<3-$P9JQ^!W1SA<OJ2JG+<QW88]>E8BBLFCDF#$,
M^WGEQ_WO9NP)^>]_,2QK&E:T-$<77W'-'%:)6>SD24[/E/[3T(#U;XKH?$L;
M6=B%G=_\QGP GH/*VP2<XIUDPAE6M3Y/OD@C/MV4Y[KZL?I&M2DZW%^Y)O'I
MQHVJ??!WXD1NK"'&D)6/E5I [C?9!R9K73TW$O"TKEX4^/I WU;G6JJL^M=P
M;E$K<+L <YHF]84@ ^*HAOETK#H1R"Q"4W,^KF(RGUR)<)3\V89?_QYW4?YG
M9>XPL]<^PTG"ZW*ATW/7[ ?Z(PL%.Y$93G8+9F7'U<PL]$?>%U=;5R-SROAF
M=)CB5]G"#U@5;'GP)/T3T+8+$\/N^7,U+!(1H[>0]4V^9B0[P5EV^[:GEW?=
M1UY5Y0BU6.NCK]ZWO0UA1^W"W%.24=7F*SH,G3#T[-IRG+XP!;7_U"KAQK/)
M_4XG&W/&YYLM/)2V[R=T?OPKI<1O=",U$G<">1LMCQU&U&[VMI ?(VI^,_=-
M=A@A]@7K/,&:]!G@^'O?^USUR7Y;<M>_L%.>59Y'_RL>TM\C,R7U,+UU?=M7
M\9W*(AE4JE^VI,'9_">A--$-X)<7RGT<R'N;W-]^"W\//K$&DH;S^3XWOIP/
MT\IE1_@DWHU,18=:+1<!>15Z^LAC2$KW%:F9XI6G'X[PUE)O<^S"7)EG4%50
M\2:V6S]&5>DLS]'$Z%%@\5M?)URT?I+"FB/M.D/S@H'YWM((.0^Q'L.Q-U?&
MO0_K_WZ,RB(#M^N98DML 00DRRSXF08!Q]OPL=_7@?D<FOUOLT\#P24ZTF$1
M5^JK_"V"#Z>J6 :8SDM+?:LI1+/+JI/U!G$D7WTDJ&.^PL&X%N9@RHI%W@B
MMR$$3*07[_KM>$[KT0(?T9M51R7N2S!'[BT^(V;X7=\6O52P]>;[MT_NZU].
MD$&#+#9_ 4V%SL^*,R#$(^6:D-IQLSJ)#65UM7>IGYX5-IAE"5VN.W(IJ>O2
M^<&NKG#3EZ*/@MQ1*!S)IEF,/8A0V(7=^'>VS;D+\SQ>$XL)G[46_I;O6W]B
MOG D$W#^J=L:,G_-W M754,]8L+0.2"4DD.D9#O%,*5^=]BCI)I5H/5ET:P
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M5U;63SHISR2-H3.ZC:(N5&[S[05$5/@>; ?_%JED6 YN9\TN?=J>-'4<T0]
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MMR\I\L\/WVVQ<U(:?)<,WGFT^*U3\Q@<]K<05&A2,\0#3X:NCPM8,1J8@F#
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M:,PC7@&;X]GV;4QA-94[&\9^EPCYI^-L K]=06Q;?"H?(TS#0O=!#S OF&*
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MQDI2&3C=*YUSTL!ITO;= )Z9XG>&3/WR$3N%J8C8L0].3&&>72V535UT04B
M"7I>WB.@$+\!D7Z$?X ?!YO=K<6Q-3J-+?;-]";#O[T3&G2'5*2N.I.$V0:G
M5U>X IL80\( 73H!^EMA^TST][K8^J'4M8JAD?(+](S;YP"%A [FCH"%4T;Q
MI@4$HO/W_$ ^L%!RV82T#Q)Q%U.775=\VNVKM@]JL;+B9>PX]9(WF4<<R=IM
MGA(CV$;C8B#1M1/0C]'VVP<][[P5RF3"!H=@WQY(2E/0=S/0'U<&_W#D G3X
MKNJVEE\X2B+UHDHQS5BYR@N^J]*V#TK,0LYR J(T$=1A"J;3!,(V[B'&&:JC
MA"E;QHU2%:A1GH]6WW]*Q34IK,1]K*^_-(_7^B>#%)#3I NR,[ELB(?1:LSO
MF.K4-A7V@G9[B$0ODCP%/53[$9%KG-MW+R4EL*]K/+<^)<#BB8(QYUB(X>/8
MCS?/VV\K=(V[A=3@V1!VFNV%BC+DN:DD[V-XX0\]2D[=)->,6W N*=44GBR-
M!1W8)G8?=/#XW_PU]!".?)5W GR5\7$?-)VX#^*_Z @S'/*)\[/7%6RLL)^(
M$S#^*%Q:J/\4?&;OJZ&WZ!0H2]VB?5[J"NKVPY\?A21N5CY-FJR=P&@$]XD)
M/AY*OFQN'CTFG>@4!:[0A3":,1YP=DSKV7*,!SX*SK4%/8QZTI2R_,7.\*48
M@'$KB(';INI73<ATFPWG_S9\:COA'NHM<N[H2#>N<KYH'\3I!2S/^H6(S)85
MD=MN 9[!)'$-"C)2/6%FN0YKO&GY2^<H1_R 5N3E_!_H>Q<Z;P>*H=0 ;];[
M+#&MLKJBP"P)BJ7?)C><H!M<68_<@G %"%P;__DF[5N(%U_,!,DPY>+74[>R
MH^[WH<3+T5]P9'->0$.<6@4X4E*GH:O@((KX-!3;?,:#*4XY&YVR89?7GFIQ
M=\+QS[RQE.VXS.M6/P&!YC,G3CF??"N&ZP]&PS"M^G@$%E#F[,!/P#O !S'3
M\<+, _7D@K:@($>1CH5VS3W(^)KO0IW)'_K[IN3[JH9(/P]1^<_7B^53?KU7
M68I#RZ(GP61WU_5.3!1:E?%A'^0&F1AI3\$)ZNB33(A\+V8E-"!5A$+H!5-S
MY9)O3\>>KVXT="FW@(YV7N5<9 DM-(')%:D+6AKOH@N%VI)I_LSU]D0>*2/R
M9$UBJTO>>_.7*C+9<M*)-Q^X=(]G7^8W"#: I[$<@2=XU9/F2O=F9#:?1??M
M@^I\]E*R9UD3@'C\-SEY[7.)R?SDKYQL1D=["ZZZCSOA:S/:.%$S,K%+F9CW
M7WVL^O]Y-;\/Y09XNE'2IW=B='F7+F?46C,5R#^9V"LKJN%!/@UU_F(&=UKE
M3[[BY8@&CG;BR*900+ZYJ81E3)!RY@@:1%$.G<%&2"J08XDBRF@)$\ER#Y?"
M"1M[!4=;C:*YR2EU,[7WB]>=<U74O>QY]@P,0"A."IQY.'L6SX%NQ1S=![D@
M@;-=JV.SV!<BF*.^ 1<OZ>@7&&W@! AR?AE+)AROWNKW2AF)S$>R5WSI$7 K
MIFLQHB$>F.@&O[9-UDP]RWA'/TU1AH=/G:FE'(MPGB8>T(TYR*QY%)_2$/YN
MP/&[LJ2 E,E),T,$?V_-V/W1%^@\%N**(@%IWO9GK%G^"PLH0.D:#_#[H,,
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MMOSW/79R4<D<_S4U^%,GX>/RYS/KO%G!!$"7\IT)!BY/$'7/1N*?G/#F5'Z
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M$?I'*L6^(U6L/OEMOXI_E:(Y/\UJ/^+)@/9V]+'HA(A7W+ULT//MIG _ G#
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ME@-=^P-#3"@R:>NI+P_M-W"6T0[U"MG'HH.8@!%(Q;!W<*:$^C^U[!=["-:
MZDB=7+DZWJ:(.3R".>E/2;XVU)/-8^ZKN>D\TY]9F[#,WE>4K-QT2CBM:_#C
MY,5C%V!K9QF\H"D$$IY O?[2@BW8R^#!#I33$L'R)%:VIR&E1=JM<GH*Z2Q
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MZQ1J;T)P*;]2JU# V^N3YRO<S(33;R6<*C9U%)98,X05P!OPS&<3/3B&"OL
M!S+BU0T)13'%H&S!-#(,4$]=[2W%?F4+ 58E:)T1:UKY1"S,>DS/<'TAW5(S
MX*AP^[P9EV6S4,.^3^*Y_L-P4AZL;I@5A?- *+(GU*GX:[1VJGF&PB+SP(Y*
MV_6MG/4#L8=L4[^?RT7EJ.3(>=I]9#C?AI*]F:)"Y(FU8%6FW":-2(\%Z5H
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M8A_#[H;593$E+>A@$8_\A!V!4VTG<:3\Z?%H$I[+"8CP:1J=VSU\N\[%5"C
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MZ_':>4[GN<>(4K6F;E;F>AQ-8*MH\/XOA2C[E0VF>#';;I.JROY(C('_&0E
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M;1LVOR0,Z^RMG1P+F;>HZ )SR)A(O7-% H%'UV<>/QM_"N% RL=YEL(*.BH
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M9'O-$>=F_?W4BQ-#5YP<6WFG\%\B!B=.):XE9DK81F^XJ+V/V7699^SL_]*
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MQ+P@'&0+H\Y2$RJK:65W&!(I&KDO[3OIH3%:#YP34_QVEX4UOYR)]UN.70=
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M)LE"DSP)E\,NBE_U1WN?Z>AQ\W_=]_R@T!RCF PO31B$3"B5&WJ0#N!47>E
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M\CPJ;::,]XOK52=WC5M?-+)+%9%IRJ,N#2=DT@'W1LA7/^+*%TVI.6P4377
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M5?3$I)T;B"@_<_9 A(&8_F<F^HRXB]E570?3NTDL+?63?1SL\RZ6$E\!W=Y
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MWQP 7/MFI;Y_N!'Z2XD((M[+.MHW*'$6[8W*@]Z"[&8BUD!Q/&06SO71#!M
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M>=X>H\US4P/#0M7X\0B*6@)-$4K3QY!J880=6B,5NH[H3@"QA+;N/@P@6H5
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MQE3M<'U=QILGWB"+'DH/:!T5:D[]3'2)K;<X\]*U><8D-)*/"O 9 7C%)89
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M(K9*G$Q]_JY)2$G7GB9Y[7;/-BEE/;(*?6-JO\_L7YM8Y/_6S/YC8O_/O(B
M"#\?N'C\8@ ,X+#SX]6 ?\N_Y=_R;_E=:G%2W*\\0+!!F"*<(HPL;>4!'KBJ
MH>DF#N86*VAWX%K:H2+UC[30 01;'S//X0&F/(!K_X8',+^%'.Q<\GGK\$#1
M[YC#N72;8]GWC(E/OMA9^>]L<; QTIN6Z'-YB7W_L]_I*0_ 7^(22,LP'C"I
MOL #DNQXP'9/%@P-/ID'/"K%<?6=.'&YZ*_ZMNQ-\ ESQI0E#SAQG@?0#O.
M)_^B!G/&OD ></P;C":$?HCVOXY9EK3E ?PI:WE)9L&$OU@/I0V@*U8Y$!ZP
M9E7/ \;/HZ]YPI>W._  (&M-\-\6_$L6.)F/01+@D$8U#I:[PW9'6/V\"9R(
MZU%)N,$91@_LG3;:]3+$\4)Y V&[97_IR8#XD=I.E;Y[2<4WWKOM>U5TND%%
MM=P^ ?&FD^1>D!^O\=O"-K7\W_Z_$!,M3AEL8@QU@@?X8]8MMP=WAQA2O7F
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MBP<,QZ]]:4SD_(:>\@,C!L*IQ3X>UU[;-P=>P:U?MBT9PZ[M+T8/D]9/I12
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M^I-!W)=#@>B8?$S_F"!R+Z>=I2[X9-60W;@R^^7IK/L5XNJ5'#!"\A)^.?&
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M[AU6TK^7(V%W0APOXA,;+REV>E/$5[[O#J6#3M5%B=2P3?%J+W?_7X77V_X
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M]+4)(-<&6DP)W9)(!9X"26D *?&.^0.V[;B6+;G21),.P7?>[0Y8'LA#B_
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MJWNO1UF"L7$?=?3NS\;^7_=_7-;ILJ[6]SC_Y>MUK:0F"_M2QVH3]?,>7KA
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M,*?G>*&X%ROJ'#_'3O(:+(W!'#/TY'JJTFK&L!'A8MNMEO#GW"[/9O^8,?F
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MP7C" PKD-AP0R=+F6A9X;GCDM#X=3! !!IR=#G]YWNX?+8A9S\##EL;!W,*
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M?"^&DG3R>M;% ?91Z%F,H\<1>(U^J3EC[-"M&L4KLL9.@?_KL_WO%#1OZ'\
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M-S_1DCN)9^32ZV[%M[,WM1!/$N]^"[V<E[H[7OR>[K$[X%>]H^T6J5M!W4S
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MC*PF3)U^-_JL@:#-$>*_[3HZH51,2]R&T<.@>M(P@QR[B1GI9!B%\C(:S)A
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M_L]@L,P$_K+*="CG3&8W;<._8;M^.4&^)BG=CYF3AVKW;8&9_\CH_P3<_UW
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MJ^=2]8-+E?-$,TO$K]'1($ML14'^K;+NY4^7.1]O!(C[9-668%^:(V20)S=
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MHQYC_-H_I+DD0&9,6-?WE,B&&_9Y!Q05>?A3#K$-J\>>/7C#VE@Y?E__[OV
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M0W4*E'G8-A"T%$2!E3FCYJX<;8=#^W4H]J+^N0A_7004]A5Z%%;Q/2['?I9
M7L3$WJ,G]VBANJKLE>FQ(EIC=U_X%R'(! PDEC0[)"6[/89BO:XNM'8BY>F+
M[,5M9.OQV-@AF"(3: IE0*K'PZ"ED( T;]DYS;NYLYX]Q]$[*QP K:<0PM+\
M0NX4%O3%0VH_"=\1D[48#[Z%$W%, %I)0UY(]7W02I**YCWE6?]OC!S')L%%
M,1[8A.'1Q'(FL.\W6%@0&ONC:6KQ0R;:KLIO1OGT[^F/NG]G"&>&0,S:UWV2
M:O(V%=(?IN)HI*$U$"?\Y2[XW+;,<"UM)<.DTU4FZ>OHG]\I]A<'H9_(J84/
M*LO\RVEF^)9 )OTB$?O'<65(\F3XR<"_N)#:[;^XJ=?OCM@_L=C/!"P^NNV<
MT.Z%IOC/B)"TWAD#_^-0-"_C/+RO].#?#FE#[*37-/_J0X9_]E'\I=>Y]'LD
ML[\= F^"P)=W72$2LW-2&\ZX0/OV=T'4_5<O+>L])L\$KGY,^>,P.-0O3^K_
M_VL-IL%04MFPV^=L]5X=*.:XA2B7%ZBGEVY1-8=NIWQM\R:X:VV/#];\?=#8
M]O79/GDV_9$VD/,F%GOR8N?YBBV9D(,^ENE3@EDZ,J<L@^Y7EXXZ_A>R4?U:
M]W\E=QV;=8@8*,FQGZ^NO5IU\NIPF^* Y6/GT>=G5:NT.E+"$TDE_["D0 @A
M@S;6P0EJ(&,0 YG"%?N3UX:\$H62(-_;4BN+(1S4,<K5>WUKX!G./^MP^ZU(
MS61IL9C2@L#STNX1#4;7>"O=RQXQ <^5$=^-'2^YY,D0!-]0;X"]^F N6:PY
M^W#UCWKCB5"YQBCC011?T-TG;*-?CW^3$=E0M"IZUG/01>;:1?LK=![JE7E"
M%7M\A1*L ?]N.G]\]/":8U7RRA4P94+,7EU"V[B"1:>RNCS,;GAUVN7(Y!&#
M"'XY-\5+[N.2WPQ0FDQ@-XY>#O>!BS&@UDL</X[%5(_%$4T=6Z!*PZ5[74*;
M!'NP*%O9NUZB;1$S]<!T=_S8):*MU@%V?F7>U&GCC;*8)1T##'&A$\[A%3CL
M4RC#7:6YF;9G7EZ&(8(\_^2Y8-"5!:SY&9'9LN\J/]D9G*K4(#"%P9E+.<G@
MV-DC%!S B;F+$B(J;@[H21@15=B=[9/$/>)OC@9S;VJN[1Z")4^SV=XNZ4B#
MN=T+G=AH!;NHM_2I#B@E^G/X#:PX<L_P6K--^GU\LRLE*7RY4@4TJH?[-, K
M]$<(CB3C0O^J,';8IX#4IH@P"T O/P?GT>_/!$ HJ!)QNLBB\V3>5K.(,2XR
M>]2AWML56?K-6(X 'L<K%+8UNQ;=J8[@^RTOKHPHIBBZ&V68M)W@YPZ&JV(:
MCC.!VV6@@BU-L&W#'XR@)#7!)7!LH)DMV:V%QZ5A&/T$0_:RJJWJD^P0\^ /
MEC,-%F4Y]''X7-N1SS5B:[$ _60.7@T_GH,@F_."1XT6X\@J&S:4UD=H<7>&
M(CA$2N(!X23V*)K9N./"TQ\!1=0+P]->H1F/]MV();KM.GBB)3#I^+64943%
MOE?0"F: +.3Y-5)AHR\?BA\D*B?<'G1(:@)Q$O/9(GWK\BYBV=I<^*4X,'Z1
M943\W?@+8*CQ,6_I;!D6,PX% ]F\+ Q!ME(9"C*CY^.X1ISF"'/)'K@CY.\%
M'3Z_E2RD"AR-+Y()"KFY#S3SHN_D?5"QISK3C.DO:>SDY;:S]*<XF#M#"HPB
ME5Q7P^Z#"7Q3<]!(OG2B2SGW=3W0N>%^(X)Q@1'LBKQA46#:P3+?9SN-3J#>
MPS38P*]A1GJ)<HN#D KRF41LLUD41C*@\$>]] 0A<ENI-<OOU8(=0GF8Q&$7
M&?/\AU^R=5P,W)^"?0EWAX^8D!"Q$"Z^W/F*C# 7=,<V+C4?68!@O8HDD! )
ME:;'"661O]6RE$K&JZK6^&0_??SX!#CQ_L(-.C'1J0-@'Q"T;6<"'V:6"*0J
M>B%#%=V KU0?RX(G,OC=!W!'>G6,7\TE^?+&UJOX[??_Y&BZJF9[_ *ZZ_0A
M^1Y!]\:HGU@X>@ O"0E 5 EG GO65T8V&W"BX"&W\2[NN0_(,.C.D5>%SK^\
M'KNK'DHS]WNM4.S[V@A0D;FSE'#Q1&&&E>(#6(&:;><&OIJWI6M8>X,?=*4:
MH)OA'+=5:*Z4S,OO?;D\QD[4I*KA]]4/]%R].NIY[S/.Q7%$\43I89;"ITVB
MJ6OZ*M^V-9<@-=CLZ ^AYL[L$;8<01/,\8W$\.E)T(('L.?(24EHL=EJT8#O
M4277475>T;(W1(^XG?UN;*,L0^]M/0._]/</%KY#'T5=)L,:$)&U$#A#J*DG
M6]U=KTD,E9RQ&@QPS$'5F5R0]I!]\HY#ZG#* PY=0(;T0/-U60P3N*DR++(!
M]3UAV2AEL^$Z8E*BO^]#/.?ZPALF0'28"T+O,_5JOM\?;U%O\II@K+/@ZR%>
M')%;%2OG_4CU1:0#ELA+$]0D;3:8C<PW,3A2(,6 \*8RDN^!60LO&#M:'FEI
MEM9D2HFH=Z11%>*,79_]G.>+'HTM+A/,94-]Z,Y]$)IK@"JC(N8(9)N5F-/+
MU=Y4+G"0&-3T2;KI1T1/J9Z4^\GYZFRE^M4TP[;4PVV%]I&^,MHRY=IMTM[G
M?]Z$4M-N-/TCXS"FX3S\&H&3T<,$1/1$&X@(P5'G>5';:/\%'B;@DKS:NFQB
M?ZM*^>N89<7-)<61 Z=]0NNBV7N?VJ8S!C<(E74H[H%*^,]T!#FBNIF+ZZ"/
MORF\351F,$VT^'5$6O=739LEGYO2[IE^;(H<%BP[WP<S'@$GFR/B(#3 #\4Y
M4V:6)(J0@6TDWT<TI^"7R(7/#B*1,[VP)LWCG5*)IRQ(T\$R:]*<(]\_2QR)
MW^7B<@;F8XZ0IXF #51?VAUZ'5H&=&O$\.M)8A\0]JTKA!Y=5QT/*>BOU/6[
MEK9F$CE#U6\_ZI[$;^(WB25HGY,F".:C$!MY]'Q(CG>(#RLT@<)60O5*$D..
M)M*[0H._RO+I)#[%LP<89H\-FZ3:*966(:[&EWR.M/OZP!%(9C];=_ E;[>G
M I$0CA7$C)=@H53HAGA(J"Q(H3B.,X&8"HQD8;AZDA@HW$3<5^@:ZI8SWV.O
M3K4?X_$D.CNZ*]]\?%"*LY-+M55#4J$57X6E"89?@9RHYQ=42ZDP)&C.H%D>
M&( 3X)6P!W/M0=O0U\YML&&VFG+DQ(!W]W?:NZ="C>.WY3( ND@.'FI9O#$C
M! :G"F3-@IY%N#OO,)8XT[02CV45L*PNIT3%,@X@T=2F[<V(@6!AM=J,UN7M
M;;'701]>'E4[7R[O_7PWO9W<23)[B#N!.O4#K413I<CBWA.[!#R$MPLBW@ZK
MJHX.FXEV"A:]$#]QXL7^O5U2HL"O')P7_0/*%O+8_92VI)<@%S0YS6P7Z.!E
M*JQDVX(7T)/QV-1,J\KQ<$T<:VP<V*77[3]V/OGBZO$++JJHTEYEPB%(8V=,
MPQDHL> E& ,$(?C?L!G/BG3@A9".VS_$"7.)$O5@(E6M3, ]G3NZ>M<I8]4O
MHG:UWNPA1\^[/_O(/F9EVP)GPWCAA\,9G$<ITA,:KZABJ ODZK!Z5G)4JZ8>
M)WGC?2G2J=*-$A6]=-A8Y>:+&-*JVL\QNQOF>UR?GOPB>^F83>$BU":Q:5#:
MEH(@):A1&]$@._FT6%><!3(2L0>!.H7O>^ZMEB2DKQ4VIUQJ;6PB+Z*9)"7V
M[1V+54?'4Y8-(:&M8$K0!A'2IQDRX'&&+DV)(D<3%-TDBC1WA<.%4$%N1 DS
M*]#KE;/'((ZO;^5@?5B1]OL,;O;;51L!$4^?_2I\OHE9*J'H3T0UF UA6O$B
M&+<N#B3"G@*+1*ECWC:XD98NDX9_Y%<6E[^(0V9-W7#AE![=KQUS0OGX&5V+
MV*U-!H<EU01*4>\AE\Y&<.*AMC-NPDQ2EE(8B:\(".CQOB3<J6!Z;"F!2]6:
MY0SP7N>><=G+U__15X>QR*QQ>T_M%V/W\'F^6?8%*B!.EJP4PZ_[QJ.%*!_]
M*:58ZGE/R%YI+?Y^]XZ<]LFH2=%A B6)XWZTB^O;$PAA)"04G1*W84S/9QQB
MC$%#305RKBY@^8H'9DA!#;R"5]4+GDSPG)-8D5C/FK\Y=S]<Y.G)^GL-JL_C
MHMM/_& _!55CIXV)'R&-HO#B[#&7'$5'](5O7+H)18G/',.&$/J+\E-RJ P2
M(LP/&3)AD$3C+QKWC?19KW."M9)I N1?/,$DGB,FD^4UHJX0FPO5]N/!]D;<
M.$^)SVL(?D87_B 4,N-XC&09%+]=H#SL(6]#IN_#;,7J077$D#,3^)9I23G?
M7:I4*7%N^^8C)X_W%[[C;X7]4C@IW2XMW<@[BJ^4B\*/YRE1X(W.LO18G1!R
MH@JG@\,WWGB4+$7!&&^O<O6=ZC?OX)OV.<=JG")U7TYF;;&<T8-</LP'=8Y>
M!;^Y BH$M:B <IM+;6^0CFW54/.L<U(.<B,NVC7R3!03*"\-N/ R30*^:&N^
MJX'_P&,C0<?,+W9G>*6>"=&URKA!::H\6&1*SZE$C, WXBDV3TI1%_IT9$4B
M*D(P^SQ6'>?08MW"XZ/&'K[3=29W%0?%;F9,F];1GED?CG$Y1/_^ 'X*/CZ!
M&8HD36RX]F+&"_"[ZR]F"X/MU!/.;20$)S)1*X;J_> YVT"F'GS@/+$ZXG9\
M5#S1[?'@#SCYXI* '65ED5" ADPBX.-=IH.AGINM1<33]/T\BP_U%BLK\3N=
M-*PFI#F&:-M;JV*S@Y5OP=66'*#B*VD(,X%8*J<>1'9M7 #52T 7 XSD'$_!
M?/9ABN(@MQIXZ;VJJF/3P;6A5*=[/8;[E[10CT_#0+F5!I5X>#EL,8;,!#9N
M@>T8XB?#-0B(*[IX?BZ@Q6I>M+UQM'>4K??3.7F^@/VHJ*O^%X[VCAEW8.,^
MK8$)A%MB)CMQ&IBA/A RNK%_!_T8)8^A5D7^UH?G52M1WK3?RY:*J\3(5KZ_
M<49V,O;H5>#$G?W+4LJVVE%M<+)!%RB'6-H!V@[0;<(W'"&""AU/$IG+5@5C
M7H.=5#>H1_2J^%A>6Q<Y?$JI/L;%-5EG)))W6D&9M-?G.,L$AGR/"9C]G&!T
ML38R :H-WJP(@@U0 4\3*-]XO?,U20M,@.,P:#!! )"V)J Q1;FM=<!64EJD
M.L5SL.KE@5?)\A:JN\\\9[UAY,9VX6@8+X+2M'$?>F,.NI? J\S8AXS;* 'O
MDK'G![R'1YI/;S:I<!#&%LH=/H[(: 2)5!\5"C^=AM#N>-XK53  9;%$^/A/
MQ\ ^)@ !QLA$V]BN+9R8)Z%"\<UXC#<3F.CO<)Y?-9[B:Z.%=!5FPQ\55J+K
M;9^B6V#O$8L[/?%N.CW+'SX4M>%%SO6 /$WH5[N??-K*E=K'TXYUS^_H#.7I
MI'T&V*RM#:R=;1F<NF3$QA#]E=XN?"/L9^8$-E)/PO/^M[94$ES :\#6\JI2
MY!YJB/[MCA_U];F7#IP^I&=OJW 8N*,G#5Z'VF8V5CH.Q47)*AGPC4"4!^:^
M,7TU+W,++H@<N$E53&"9W:B]Z77XN6U4?6KN;GK:&137AFXYO@*R>3[&*P9E
M>, X@.S6^ $,^@J[W^S@X:%JMH'^4;P/'J<^@CI!CX./UYP^AD00,;'X\9=P
M=C65R&W7;PD%)7DH+=!NV'75_5TMQ^U%5YF2W K.;IE85J./)QY;B6ZJ#,,V
M9"@^A=2;H#Z#$T8]X25Z!$M1:!H3JB6GQU0D\=7_F,,IDW^OQ@Q\#QXWEJG,
MX$JU)V7=>!HZB?PI),^RVJ&<_Q;3,,(K%RD4?]IW$272[ T[DU TQ3I!?Z/T
MA?W'?=N^G6..$KZM,"&<@"?\G=OGHH\C)/96)<X%H^S% I"F0IQKJ.X+Z'RL
M-]_&G6RTBY][T.)\W&IQF01FJ&OC$!A.#B%A6F$C^JW9LN2Q.LH(J3^KGNOT
MR/<,R8>NKMY3'L-6!^FTQPH/9=:N2P;)/KJ[9 W30FG3PW? $<^-TB=A#H 8
M!J<0^;"W5ZMH'0(,M^]#"SN9^=TQ/"],'#9+'MO;E<ZM\,C@UQVGR2" 2AW7
M;$"P,+[#=M-DR:S$P!<#V>)D1-3MWT["'&)^)945"OPBMWF^GPO[UO\L^?[@
MM^S_+?MZH%SH*9CQMY+*]'#_KJ&9S]BJE8@44G9-B)]*,SY6%!?G=R!CS/[Y
MM^QT7T\7*C?:W.3.O/6 UM#3F+P395SDS@U%*&XF9]\0,1&,8]"?#VCB/W!B
M<^D:&AE53\@31!>/]/:<QEG9\O=/DZL2?RB<3Y;GD1SO.'O%G?6WZ%\_=L,=
M@!PM];:.UQM, Q]:QQ'DD/-JZ?[]QL< %T2/4<]DK]/![*VVCPL<%L7-%!,.
M@MJ->#X=V%L:G#(8M13@+7"UUZUW/4%YFT]&)*W<L+N3.Q9YT_^6!>\54P"I
M2>,7L""/E4 !]Y;^0IDFWRVF2M9OXN,3,<C051X]8LGXD7J3A_%#G4R@B1L7
M>F80:()U#(YO^30=0U\1WH1! 0?Z,P&9P*.85Y^:<*=6PZ1/NB44R7VZGUA"
M[MV8A'078'S+:(VC\M($?(=MQUOC7H\20 A:IZN5L20LV\CE%;7'CE=E-%EM
M/QC;9[FL)D_I-)X\-I5B^?\U;ZYA2>=9'"=UO"-EJ*2MF!?4<9.F+#53G#(S
M3=&<3=,2<;P;66:*-_ZNC>$EPTM)ZGJ9>=HRC' 4+T%Y01Q2,TO-"UH"II6&
M@C7(Q,7][[[>9^?MOCCOSIO?.=_SG,_W><Y/K7=<.'8=D(2L[T["2"*PI4BX
MRYB9\BA! PN5X_HCSI=&ABL=O<.CDGI^>+0QU-SN4?QH:2;VYO=+OA7[WVFN
M+,RE",EBO/2:P+)+ )M9E9%?JG<1NT)::RV G:N6\+P0X5^[<;9T[M'9KQ0W
MGM?\6OA0",X5Z.\%F.A!H&BA#5>, ;5#:=1/A^D1%V3ITJ6%@?KL.4YU3U!=
MCLQM,7%-%-*78/Q=C%LYQ>7'47Y/>[,\1ZTOO$MZ27)Z+!GCIN;S>1S5Z24<
M)WB5A:(3'GXXV:I126??87A?:(A"D481'B< A35IN&&WZM81'7IB9X-U'4YJ
M?^-)9)ZH%TFD+;^.SDN-?!)W8%XW^':!W0\EB)^_>=*-+POPT,Z _)ZLS 'K
MVZ)TEX/+70M<E 5TI;.* >"1%DD-9I- RM,T=&'O]B]YOH/W?CT?\U%4,,+5
M,-D3E1@16T,M&[W8]UY\P%SU$X,,2KU1$M3+9\B^R*<EKKQ>_2-9 J1A$J"A
M1ITE3@>:*Z+>G$O)K-Z('"Y_5N'30D DU@=-W6J-GCU%:((]!!+6_]Z@J:KM
M@1(!0>9 9-*$GT1%J8!O5NVZF&H7OQ^;>7G/<F3QO2Q4];&1(:=?E\IR1T$"
MTP.&$4 B4F%,W8($[%U=73 :%5F4&?,!TZ3.,]E5/M"ESOKLS7V^ZF*GP9UN
MFPZ]_G]\5NLS%(Y*@HJ%B5E'D)YAM'\'>>;#"5YVVLQ*CXW4=AHFTSTCVH6]
MG6J8\")!=Z2Z0N/2I3_Z(/\N#DA=PRZ8!$"QA[1C"S)Q\)^YR< 20;H%B0>V
M((^3%8!LN]Q3FB-+5U4]T50<SHUE2\2RGT$8Z/^*(^_M:(3.OXB9;&ICWIQU
MMG3\)52S[3<][W'#=]<A8J2SO$NM-ZT SH')9]< P0,O+>DFQ\"Q3DB3HR;Z
MLSDKU,1J:[Q[S:,8OX!3L5I21/#]BWH613H@5/<G7\5J?D1*3J+YA]9%\/*]
MUY26T_C\^7+XVZ$$VPSO!'G91)\9B&']0'_W5^3-7$^PV5CY-WBID4?AI*WD
MC7BT^[&6ZTS\:S2JS0;#(=CF,Q1NH 4%!'<6F#@EG+0%\94 2O@!V9U7H4+G
M*MKWS6^5?Y$'-IW[*"&6B$QA2%G#_:N7;3\?I8]5&08;E;&S6QA\+^1+%XQ^
MXJ$H4\EOE)3[2;6$NQFLC,8XC4$H<T>SGZ@,#BFB:11"(!"-_&^)Z[PH(SE>
M,!HJLN>BC2,2OUH6_[AWC4[#/;>Y/J4[V?[L4S9D&Z,.@\?.SG%9/+&.-$"M
MCY66<JB'[4M(:+OK-4(T="48L:;T%#II.<5!.98Q;%;:9A4WJV@(;@_=^1X4
M24$):0@I"5WGIRQB"Z^NSU)D5'F8$*E!]$KLL$ ;$GLY81%UR1&LW%=OW]!8
M/*NN:'/=HF\KMWWWQMHG9EY5@0%)W EU33HUQP.Z,L5/!8UFQ&/^X\Z^=4(T
MN<&08'4^^?2%,GMVQ5#2+S=-&R^X\V.)[ZSNW,J'-6 $XVP/E8=:C]"2U&-M
M>' N]<9;FU)NJ8-*M.#89:RSSK:X4INIM ABW9['=:*++KPFD]=!^XDT.73C
MQ-?.2S'[3<2;YMLJ/G@Z?8!IJP< 9MBG8FFH:+T(@X>9$,VG!Y#FN;YJATD7
MM 4OHT6(-AXS'LQZP+=KV]=3LAA[NN,?9:F=?B]F.5Y<^GV@W\/+G32,E 2V
M #-4M=YC:>\)">-&0F7"%,E!/A%4N;PB6A;?K=Z"A(8+%\5I_GV^X;<+]VDO
MF@=K-3)Y P9HN<.8& <J6PAE&ER1L 5(BE@9MRB.-ARDR6GC]N;Q9(/T\L@:
M_HID@W:<N9L];+V)G$M1GQH1O5=50<%Q"9R8'FR$]>+1<C1N8(&<G=J/U0:E
M[$/2E8=QIBX9>*L1<BQZCMX4_WSBN-V G^52ET=-G-&8$S7M^2"%W]AA-@ K
MQNWHC4?"E3"Y^^6[T# NR93]TGI2>?;!.838NIM9J9FV9%,94&.65O_3/?7)
M<LLFRYU;$&TU.,7F8"<5VR>V(/XH1NOJ>XK<CO&I'?2#5JH2I9G"1ADU?>0@
M/4#@B59X!$IUR*CNOTWN^1Q;[E(>B-@X>XRF?"1LQ0Z-]Y#_YWW3?\Y=#HB
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MNW&_FT]<49>H1-DV[2^6_3G#@OZ7+/M7P_Y_NT8  4X.</$XA0$8P&2\CS@
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M>ML[,%8P-GHG;62A=S9]99DA[E O*WB)B:W=GQW\\-<@AIC%4+WMDU!TXN'
M].+9ZX<G_:V_AGIY)W#O<QCUH?@RQ+%7NQ_&<*, J8)\S[L.U!1R:2/O],6F
M0_F$-W)M]-PO]\>YB&GO:W_8.YR?J0LZS&,D;"9H>KLB!?-@Y4;+%Z-L/L(&
M&]#5%+5U^3(9O)V ?\"(HX-_BR'[7-F XCB&[LL&K,+7C<38@)(>A![ !BQB
MUUQ%;>'!T)K@/^8T^L'@3#,XS/[<A^EP8'X!)\(FTA+8P$'\!IB_=T&XQY^#
M:?X%]3W90% AXRXMAPY#-TNQ@::8YZMS^DE"<XZ!M:6Y,Y20JE[=-B];K8+]
M7^5N"<=%3*%"K!EB._V[%C;(-XF8EDN4F):NH4G20)7$$$MSQN&Q/CZ+]I/E
MYQ-UZ&$,I#T \;BX@S3_6*^G/$T@1WOOA2S$ E32@\5?4EY"[HKZV9W/L'PX
M<E'<]X=_K,M7\K??7!?X7G:WJ@@VWD0J/L$<1FNBM"BM#)%)$K()-\I/U:%P
MNA,@#&.*G56W$8+L9>;;N\Y_K%/'(N5[R<YXF;H*_+T*^J=O$AMWNH]T_)XE
M4JSVV#[H<;34CA"_@.I>*:Z:7_J *US?JQ.MP$<N(2@YDPB-QRJTKOB/.\+<
M?KJ//IC'C!93JR@QC=!]?BK4LS2.C^X#!)%:)2N=^GR/PKS$-/'N"?N &L=;
M-\1/AL7Y6S0I&'E6O*QRZL&XP4*P7"CC=]GAU1P4+KC,G*E@;?IDH$T3=F0C
MZ<*]6UR>"R^#[J%>/_?&<=@>WU'K0'%HZ.+U:V7Q3Q9/8I_GZ:5JK4[P8.OU
MM_J3KSJ5=A@^O]Z@'O3A--<LY44!>>R>Q\9SEG@]_1@;J$?*DZ?K-&4UH0T$
MH=K=5OE^RXV55^75%2N#%B<B-MJ.B^B[78Z_!R3&W6Q[E&TC 9^/R[]@U$U-
MZU2?%WMOK>[DD!LP7!#1>;'^Q]:K.[U)&C5))5XCEG,C7AO==Q(';7(KM\JI
MJ;3Q#^A.;''7"Y;1'#7HMS:?WZ-Y6ZN3H^A>#>]XT:.+M=;A::.Y4Y'0':B+
MU6 473^RV'^DJ3. )7$VC1L9%NN71'>9.%T1-L?_(?\#&]A_1?J\)JNS^/IW
MAC_6. #/$.,GMH:A-3#U)K4:-(6&Q+BK'GO\3@:D(.Y<3'H]FO#ET,=]B=>%
MSQ^+V^5?C=ECI N;>/ZL];Q+,_42,]GD:^;!$2VS2"I<?7Z:M3SO^%NP2]K
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M3$?S^_%3ZVA)Q&5IFOHD)@Q#%)95Z4%I//0WTB/E**QJ$"_N^:9<6*FN<:8
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MY$-'G[0UC/D_N45Q[O\/6_N?*1SLX?\!4$L#!!0    ( %J 6U4L+X4&'DH
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M?>;JOM8-XVTNBA<C&G4 U9YZD P+UQ,+J&C:4_%LHW6C2,@>(9;IK^RT</)
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M@O'DHD(6$([YZYL/2#1='_X?[T1X-[@5W?_SO/_>+(E2+. _7H_@^A^ _V(
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M0^QFI38"8B9)@QI)AZ'*]J%?'90!(7#V[BS@NN<C'*F<!=R,#J9<H!H1P,!
MND-+G:(0A +SNBH==5'V,Q61P9]-9^U]X2J]$W)2+RIV[)9X')%DO[QR -4"
M9T/)(_TQE ?4)A)8C9!1>=G4^[KB#7ZI,GV'/I=W$T^:*'24%[?E%W?><Y))
MN,2N8E>?Q&:V$H;B1]?=Q$V^E&T1"UO"TLZAQB3Y^O6D;XN==*_=3_)[L"GV
M)E6H5]+@N;NZ^\Z+=SWO2MND+KC5K;V[D''V>D4XU@=4/QQ=YP"[M3)</]N
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MD<9&0E_I_ ]9E$'.JQ7 C7DZF"<[@AH6_9YYS(A_!LR?8$V+<O=O37SP>ZD
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M]BA]KLH@$@8IP3[D7"1$<3]6W"F(9.OY8S/M2O'>P$P6?V;S/\JP8]>#C"T
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MMI*>I/;ZLGG:@UHG-9KWKLY(O=$OS[4L;LJW(N7UOUYD>3%)$I6$5"KH\5!
MC$,*240D1%2(A#,<"(PFA7')[+95;0=VVAI=#M_?]WYM/J-:S$6:8]DZR3G-
MT0YWN[W-/M#L_;"]%!G4T@$C=)GY"!9R+W]E) ?O+N92I V!SFT2(YU ZRY#
MTF[8H5,EG<#8DS/I=K^[3?_YZN:N3EY#7 6!) D4)(X@ICR&B= _J4 I[E$<
M)'%@FRZY>NS8CF&,9/86VQH\QZW@=DKW3 E&J!8ICFN*V]N?[0 8R*BT \+)
M.-O5M\'B6KMX,#-J5\!UVVC/;]LV[E@SH<HF(>?\'R^I7EL,.]5N3.AQ'G"$
M(/88A5@E"A(B.>1A$J#8BT*BA,,^@,O8(W7]5Y:H<4KXFM/CVG+# GX[FZ<S
M-(<AMTU__&S1C&TA\UEEY1QQTULTS+ 'J;-&&!9##MS@PAZ$W<85#O>>U-5Z
M<92Y:'5K,I?6#C+]B0H#CTJ*H?)C!C%B$:0\0#"FGC)-@T(4.>5(6XX[-JMH
M$;6P[&YMLB%;-;8^BK@=$?6 8\]<M!/XL>QZ724^WEN$^[3M>FT+4[?]KX^.
M^B,Z8=M"<: GMO7M[6A)^V]5J,4R/H$+BB 2*($X5!+20'K0U&565& J@L!E
M_V?CZ6/<Y)%T/G,/_MT$#7.58 \)2#P90.QK8Y+$2,(@CB,6>EHGD6@[LN@+
MLJ6=6/PW 8RB,/2H:3?B>]KZ%IA PD@($QJIF*$8<6Q5__OTMVR A:PKT.Q6
MJ=90]+P6&10VXA+!>5'5["N/.(H,W% 3QM/=0K07B8Z6F\UG#[JH[%5K>^G8
M?]$ /=B_S19]@$U+X*WFW3Q20@9^ B7#IOV:YVD"D/K;ET(%*N:!<K-L.Y-L
M;)2QZL&>S:H6[,L.[*NF[#VV8&^<13L>^B%ST_M9QE MV#4@RR;L!I(?U(;=
M9EY^1!OV1KG&VX;=!LZ3VK!;#7!"4L].V>UJ.SX0.(@B+& 4Q!)B$FO[UXM#
M&$<^BX/("[CTW%(*&T9SX8-A$@D7&?]@+BN7+'],GZO8Y*S,SDA7!>IIJ4F+
MY)H#T-N1<4=P]DROB[YO6]7\.SPA<<"CRRR1 R,-G]S1K/+>G(PCM[3HS>N_
MCT*O['WYR?2^1.'BL)<E8:P\'Y(D)%#[U.:PEW HO0C[G'.9!-R.19J&&1]]
ME((NNJH:R^\K?0-&8(<>M(<P]1+*>"(8#(- 6]S$$Y"*((&(^L@72)#(H]8-
MCSM = CC>0//JDLM"L$[_WWX$5R^S#/@O3<%!QWZ:AV$MYE]NP*M9]K=>?]*
MO%HT0CZ$DD,GY [0&NCLOB5J;KV0C\#1U SYT*W#=4,^(OQ&.^1CUW85]7C^
ME,V+]+_*=^.;NIFGVJ@NV]1+<\Q7A9Y-*"'21TD()?$HQ A[,%$J@DAPO41%
M(0Z2T,V<;2?(^):J=:G+J&4C-\@KP<OPR _O^)'XO2YGRL[Z[1_]WO<=]L50
M;D]&J0:H]1@NF-(%R]Y"*ZV$^,&!EBY '0^[='I:RW)R+RR7_WC1:^GEJ_YC
M66^<AU[HD2""GE3,E-Z0D&(A88(#1!-$HQ@YG=X<&&=L=N5*3%#*>4(9]P/
MVM%9!W#US%>MD'(OH]:,0U?%T Z,,FQ)LV95=PJ3';F\V[(^YHAII^""^/M+
ME?MI2F.>?[NXJK<OOZG5!N:U++XI4]B%1'Z,/81@Y'/M^6.E#2[3&B)0C$>!
M8(B$I$4<9F\"NQW*#QB\N:E3;DY5VYT\]S?7#AN6/VSJ1E.Y9Z?PSDK7JA*R
MT;;L.6CT-4;@^NF4.7+7_S1(H9[.)J;GZCRGRSF*DCR=P6U;AZ>[ =UWC.L2
MC7G=8[.LMGR?52;NW<OSLS:$SQ_FLJRPF5=5!S3CU?5VM0@3C%CBQP&&V$^T
MP8H%A40B 6G PR@641AQ9KL+>JHP8[-J*\E!7HD.Z%)V0.N"Q0[='3N9K>.;
MJD/.0<^+P$(5\&ZAS$\5L[\KLI] /3FU3F"EU!E8J@56>@TX2?9[ND-.UD![
MO\-,FM-6<5<H-VPIGSS$8%O/78&QOD7=V3/;.5^FQD[Q9A;F;*9'J#J<3ZB0
MOJ_\$,I(ZM4M80J20'$8$$PHDDQ@A5QV8O:.,K85JQ(2+*4$OU=R.F["[$?4
MSCTY&:>>5Q5WB)P=@48(.C+B]X\QJ '>J.:V\=Q\L;OA:XSN587FM^L7<R;V
M35U,:?J4_RTM'M/9G2R*:4DZ2_:9A(1'0E+/A-EJ<U>Q #*/))!)A6(9"28B
M8FONMA-A;)11B5VFM):"@S]+R4&^%'UE^-H;42VGY[A]VS_H/?./46"M)+QV
M(58S<+$Q RL]5H92[S-@;[SV/Q,#F:P]S8B3C7H:F V6:<L'#V:/GJ;XNA5Z
MXI/<EZ!J25N5<KS-IM.?L_F?="XF*$8^XHK!Q$,^Q)11R!*.H!?$*/*3.(FX
MU3G@D7'&MIC4QM5*5O"[D1;4XCI$3#6!>WR5Z BR84S1GM&R9_2.4!N(MENC
MYT3,%I@TL&_3W8-1K(4*ZSQJ<WEG01.U:ZD4I8*2$ 8J,:G5"8$DEAZ,J(R(
M1[!0PFH7^NA(8R/, ^$ K;SVP_"V#IX8G??>$J\N BAZ<>,/C_.C@RB:W?GC
M-[3<RZN/Y&_DO*P%>BN-!NDTK4[56%[,*2\F)! 4>1A!140 ,0L9)%Q&D,4L
M(;Y(4!(*MS!4NX%=OH1APDXWY30N"Z-YRLVYU#*^P53KK&KGFJ@'D4Y?3++E
M_BL<-PKMILMRY[#S*>C;?EN@IR4&I<A@:SI^7TC=Y>ZB$TQ=;3?:#3KL_J,3
M$#L;DFYWN[N'W^X_7]Y>7_YZ^^WNXNKR^N*R3OE0C##.8@H53BC$A&*81"B"
M'N<A49Z,?,^W=0T/C#$V*Z<4$ZS+:>_:'(+QN!/8 3@]$\@N+BURBPX!9._W
M=0#40#Y?&\"<W+TC4#2X>H?N',S-.R+ZNHMW[-)VMMNM-/U]>5'6UB_C\$W@
M-@T)$D(1Z,4AAE@J"5F" Q@)[BFN!$+$<W'M]HXR-L+;$++,26D5#+\?43MK
MZF2<>N8^=XB<+:5&"#HRC/:/,:@=U*CFMMG3?''+YMJ;.^^7>9$^T4)^4S?Z
M%R8]OJS1I6*"*4\(E $U%8Y\#(E"">0R$0'RN9<(IZZT5J..C1C*LR:^?M8D
M:[FK3B>5Y&!JW<[-;0[LJ*-S9 <_4KU< W4A=$=MU5J!U%7';:LQA^VX[0+#
M3L=MIYM;1$<_ON5IIE^<Q]HFQK&'N5 Q])!09I]90D(9@YZ(8T_YW(2,64<[
M;SU\;%2SDL\A]G4;L.->UBDP],P+*]%:N%4[4#B$]9X R5!AN@[0N 7;'M"]
M*7AV^Y;A@F$/"+L1W'KH&G<ZJD(2,O6L)]>$PJ:S59#5A&/?D\(+H/*9-H\\
MSX-,_ZFMI9A12GBHO,B6FIH&&AM-K6)M%M*"C>@S^R^V$=[C1-85:#V3VD!X
MV;-=5[@-Q'RM\7.B01M0&BBQ\?;!Z-%&B76JM+J^CT*[J[]-I!^R$(4(AM(T
MKT'*G QZ/@R%+YF/@HAY5A:>Z\!CH]7-\JNY28%="=ME>=PU[)'R*0F9,HTY
M0NWA)PE, FUL8Q5(+_0"&GF.Q8'Z0'^@<D!-^ .X]%#%6E'<GJ;%SNGO ^J>
MET*+FL-#%0?>Q6>0VK]KPXZHM.\N&&Z5>_?<WV[5^"S%0SI[^"3S]&%6VA5U
M0!1+E%14:::BOC&V,8&)3 CDO@I"@4B B57SQ&,#C6U5J.4$:X*V##8["*T=
MVW0!6,_LT@HK9UHY!D1'-')PF$%IXYBRVS1Q]/H6)7:C]R0LJRD*4TTQ(/7N
MCA^&"F/IP\@/F#F=H)"$2GOCB4B2($)8"OMJL/O'&!L9&"DW:\$&Q*&DZ0$@
MCSO:'<#3\Z>_#YDV55\/0.10]/5TJ 9RJ]M!YE;RM1F,IHJO!^X<KN!KL^@;
M]5Z/7-JRP6(Z2POY)7V58KMJ^;4LEH&:E 74"V0(B3+=NJ@@^B?!8,0I4XS%
MV$>QFP=G-_#X_+>K[;X$90X@$*;8I%8(3+5&^5\=>R[:38*=!=4]L#V3:B4P
M+"7>[610E>3J(U[6#:BN>B[:#3ILRT4G('8Z+KK=W;8J]3Q]U2N5*:UEXE3*
M_*,T_Z.,>XI\'^,@(E!%QG-3F$-*,(4BP3%G"D6><(HD:QIL;+;:2E:P$K95
M3%DCQ';4TQ5PO6\/M<"L1=7GXV!T5MNY8:B!*S@?5WJW3K/%/2T3"^5#^31I
M2@UIA_%JIK+Y4VGQWLI7.7N1R\4UC%E"0XZAKW@(,2<^3))(EEO65(1!&!/+
M3BKN@X_/RC%[;SE@;R"OE"CSAU[R="9=X\\<IL".9/J!M6?*J84&2ZG!FMBF
M9FDI>%F5M+JD;/"YN*L/Z\<=QJXR&^T''C;5T1F0G=Q']R>T=-HVFUSO(]!<
M>XJ+[3$ISO-ZQVSM@M)$.R]6/2J)#$,O1 %$)#!FE$Q@X@D?<M_#.,081=1W
M]/'ZD'-\9+G2*P>SK-"^X$(?[2*"QWJ[.%VI!/Y:.S>.;F(OTV[I5?[HJ>S;
M":WT PL%P5XC,3<;6>#3QOPNC@/6KCJKIA?0PN80U]UQ[7,NNO)S>Y%Q6+>X
M3YAWO.A>!VNWS%QKG&C^^&U^0^=%_9=S_H^7-$_-FE8.\4U]22E+IU4_U3S7
M@@A_PGCB!UZ,H4)Z/<&$$\@4#B&/5! +'LM$QHOF!'9+26M9K#AFL^] S\M%
M20FO1F!C54]7(IL-12-SV05UIG7,9H66:UJM'H740K@N&>VGT&Y9Z'=:!@J<
MK,36GP8P6H#%W]?T.*LHW,S7FBZ@5J8[9C\9SH[8N[T<@S+TR7!ML_#I#VS'
MM+]DF?@SG4Z_: ?[JI!/^<1+B$\HB:'/?,V@'I.0(:1@2!)?>B0,)+**^CXX
MPM@V,A<"@M^-B*"4T7$'<Q=%.Q(["9N>R<D-%F?".:AZ1T2R^_Q!">*@>ML?
M_N$+W2-)KF:OV1]T1NM#?4X3&06)@@(E".(PBB%!"861[R74ER0246P;0++Y
MZ+%]P@OI[ ,AMJ!J_EQ/ Z#G[W0A6(MHD"T0[(- VH,Q4.R'/2A.\1[[]6X(
M\]BZ8;#HCOV"K@=U'+CB])JSN8E*N)54I%/M3.JO_RF=F3WETH19,%-(1,1C
M#\8HHA '<0!9B A4A+$X0<1G(6];B]9B_+'1UT[=T#JT8UYI <2:&I7_UKX.
MJ\WT'&?#GD'OF3(/X5TK -8UJ/TO=W)M WS[PK@=3\"/*IC;P42<5$O7 4:'
M&KLV3_UAM7<=5&ZJR>ORF)9'ZOIM+!/WOJD+[1W_/,W^S)<GN('G$RD"#WH"
M<[VBD A2Q81V705!/.:^I%;!TC:#C6WY6,I:M@<P&TBEN#:'M^Y 6QZ5=P1?
MWX?C[9%S/_:V@*2K@^ZFH88]VK90>N<PV^8>-PH1,IU<S@I-6.="Z!<H+\?X
M-K^99Z^I5F02(Y,6&D0P,G4O<8(3R 32_K(GJ.("*<JMFO <&VALU%')"FIA
MST I;KD?70MLQQQ'\6UFC2Y1Z]MT; V8-6'8HK&'+'+)WS]DKQ_T(RJ>T#^L
MZ.'H@P>A!EOU%K1@?;V[Z_HW;;O(^>RS?$KSYT<YEY??^?1%I+.'7^\625A^
MH@0F""H4((A]JDV*R*>0!C[2!H:/$$YL/=7CPXV-'FJ)P4KD,R 70H-?W]^]
MM_>'+, ^[G=V"V'/7'$<O19NI06,]EYDMW .Y#1V :N3DVB/4H-/:/&0P5Q
M>X76/3Z'NUH&%RZB1ZYFSR]%_D6^RJE?O],1"Q7UPQ J3#4/1[X/6:(BZ#,5
M^Y00H?T^QQ#!PZ.YO/3#!/K]/R^9"?IZGJ=<EM6!RG;?$CS1^1\F$\R$[Z9"
M?WLII]-%>I@)YE@/\BA5!+YCZ%_#I-CY@AT!W3-9K\+E3.-G(^C9 K .Z<0!
MDZ["X1I&&C:H[;C*.Z%I%K>THYIOA28PT_IU+A_E+"^CW7CV5%;WO);:\[RG
MWV_D/,V$_O>YI+G\)*O_+C="& H23W %HY@&$(M$PL3$,%//%\3#&)/$RC+L
M3J2Q68^E1H"OJZ2IR^@$WIERPC^=E1U?,@4*^MV-E3J8/SOR&G96>N:X:D(V
MM %7]81\J2;DNIH0K54OFV#=P=D1/78@T* LVAV VV3;X9-;!OW*PNSWE7Z]
MD.+CVZ^Y2>S]]BSGU"2UG!N3IZH?QI6O'\$QI"IDIC(IAR3AIG^-DERA,$D"
M-2FR@D[MN-=^:">.70K0WR=]?7D/+L[O/H.?OWS[VQWX^?;;5_#MYO+V_/[J
M^A=P?G%_]=O5_=7EG6/PKOU4V-%H/P#W3)>&"\M#@878)BWQG9%<+V,_@:7P
M8"5]AP&YSHAU%8%K/_"P(;?.@.S$V+H_H54,7GTB6M'G51T^KZF3F[:$69G@
M.F%"!@I1# F+M#^+60*)5#Y$E$<48X]*;-5>U'[(L5F'"RD7)N%S):WI!VAJ
M4UJF&SA ?GQWL7L@>V:HM4[#M1VW1+66&=QGX*X7.)VB!3N&=;@HP@6\]4NZ
M2(;9>5L/;X2[!A@Z0-4<>&CSH"$#$AT4VPI4=+GSU"HO57KLA'@\\L,P@$Q@
M4RZ8"DBBB$,<>1$./>8E)'*Q,+<'&)L=>6_&*+V_4KZV!5QJ].R,PE,PZ9E8
MUW)PF_$XH3C+IM*=%V2I'_^#BK!L*G>X\,K6=6V_WO4*O=N5?._-S_?R>_%1
MB_K'1"8\## )(8V9A#@(S4_2@[Y,],?M:W.,6F5%M!E\;#;8'7^4XF5:IA<N
M)2\/$^ZVRH-_I46K2NU.4V-+&_T WCNE'"T-#GXOI0=&?%#*WVE5*'?8.B,E
MAZ$')BQW4';)K,4S3CPA_2II_C(OH^3^EA:/O\XRELOYJQFK.BO9[!U]:\0S
M[14_TCS-%UFD;W?+7ACYQ$\4B;6Q SE"&&+B^Y"$L811I!(:) E%"BT2Y^_M
MV;$_B:T^[<WT^OLA>IS1MU*\EJ>LW4^LXR'MCYFGX<]XU_2L<@[6-:U/@,&F
MKJ9:5JTM*-4]6^;DOYV!-95[."?N;5JZ/F;N7M ?<TK=&^ '#[G[&_&$,_*5
M]WV=%75ZQ]<RZ,3(=:T_MKK)0J1$%$0,0X2X-JM#/X:,(0(EECZGB"4B<4K
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M >R9;)NPZZ&\N"TR7;:):AIN^#9/%LKO;=-D<Y][$N&A#E#FT/;&_$,VHW7
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MY$@S*+B4D6:1RK%7!%4W,<9&C^ZVXX7P.Y[\]0YJWT>"I0*PU !L50"E#E?
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M"!*=,AA%26)F/T%".5D4SCV.;?HWCJK%5FZ_^7\>9C<V" I>S]Q@904-8:]
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M"Y ^G8Z-%=:5P#9"@X;4%]S,=AH -_((#6O/5!( 46]J\8$H$-$X=3DH[?B
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M3G-KQ/VECI=%UJG0JX/"<O,/$T8X3PV]\LS81)QFD&5"0,8-!TN*$$.I7]C
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M#.8R1A#+)(4$F]5?D<P8!6F>,Y;X;%>X=#JVC8HJ%%_LA.(7=2B^K:OCF5S
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MQ_7^NU#K]:W^A<U6Q>G1[3?CW;'5ZG6V>"P_T.\4WSPHS16.DAA2:1OW,I1
MCIB 2B<)->8F2R*G.E8^@TZ.: JYBT[L7Q6PI:V?BIT.;?0 WZS<8&DT*?XJ
M*G7JSS601B-WQ\=Y8KJ]P2'@'IJ)2J1O-;!"E\?7P(H-:KGKSS1X-PRN[O[F
M$/B.Y([NOM''W^'SW]] OJLO8BVNK?.C1O-\?97;=XR][_5G_%]MDG)9;_JS
M,E^CQ>9^680G/E IXTQ0"B,J4^,@2PPI,[\2G"DI12PB@EUZL[>.XL7I(W1E
M+P2MZV]7HH+[)?",V&Q&M9N?@V U,"$/#I,[W0:!:R1^+6%[+F%[KF#;+,':
MRAN(3#OQ:&'/YGM'H\M.\??YL?OBGJDJ6BNQN=6&?[^:^5.V:,.M[5#[U?[O
M_3]?9N8U:$9;?S%6WVHFC-5G_W"]D(<?[%WY@"0UKG@>PSP1PF;Z"<B0SF""
M,LYU'J<X\FQ\,("4/FMFG(H-I9+6X%"5FF5-G_)G8ZLLC&VR_EJ$D18_J)TV
MGIDU TRZVT[F#Y[(H8WW[0S6^I4U;,HNVE^OBG_!GNQ78*=6=8F=W:,/#^^P
M)55FBQ=KH59M--HZ&OLG# TW0Z&2C0:0<-Q$I>$@/DER&G"HL#T@KK^QV=SN
M'>OERAH)=TJ\K&:;F5KORMU_4D:5>_;]LRW7L5Q<;XR$_*78<;Y??F:V'MVV
M>FV*N"1QI"!66$-DPX%8BCGD>9YPEL@,QTYQNB/+/;6=GYTZ_Q&F;43H>?8X
M09O6[(UR^-82A'0%MLI#HSVTUB38Z7_09<) 8-]J!H0K4,$ ]G&PEGV)Q"#5
MDD>>O8';5H26>A)=+0::"M>F%T,-W^\=][DJK69;;&S,N]2^/9\K$1YXS@B+
M:0)I2B.(<*XAU8F$7#.A1:0RCKC+9I/+8%/;<ZIEO2I2WS:%L:MJ>:_ 0GE6
MSFP%VNW-$ J^@>E\A]SG+7+O=\A]:D'.FVY=( G$D:U#C4IL+DH?LY'3/?X;
MU?;U7'IYC[:>IK'$U>J;>K^V5#5;?U7ROV:;K[/%_<H0VP/)1)*SF,,\SSA$
M+&60)ED$58Q)FMKR(E2['D_Z##PU0[42UAY.UM*Z[\YZ(=Z]KST4C@-SS,>B
M#.].[F)WH@!U3W3P5R$[*(0?"&'W+?&AD!YIESP@XEX[YWU@:]E,]WK<:/OK
M?93<WW+O=7_/.#=CJ)9),A+1E-!8P)SF.42"IY"G,K:[&%G*8TD4=DI@.GGR
MU/BZ%LXO\>@4L'8VO@B&H7>+71'PCRP[UK9_#-GV2>-&BQTK<!(7=G)!/T_M
MBWIFKY;HU[?ZXW+Q>*]63T40#.*Q66HH@3B7 J),VFHF6D,B128YB9(<H8>%
M>K1A4&Y^6M-03M](6GXC]P<<TI2J)+5[/G,C*C2$\.01QM6)KIMK=A%BXZSA
MG8@6*RLDM%*VAV9Y.V1=0 1RQAJ'&=41ZU+VV GKO+Y'-A[ZF6+S#//0EU55
M&S=-JW2L7 MEEC^%,6$$HE@FD%![Q)U%B,5*X1BY5W1K&6AJ+VPKZM_ 3MBJ
M^G*:>N2TM>':[5:%0FM@3F@$JD\68!MB'HF!@9 ;R2VZ $&_3$('6-J2"]MN
M'R_?T$&)@Q1$E^O].?-_?WK__J[Z8L8IHTH(#16*)$0Y32%+\A1BK/,DSU3*
M4V>*W'ONU!BQ$,U]+>\CU$UV/?4>F-L*J7KPV+[N[K35$X.16,H1"R]&.J-Q
M"P'M7ST:WYP1<9]>SOTY;*2(W9?9E9AY_UW,7Z22]L+EPLRZN<C6@5/O5/G?
MM_9,4.V. =?7VI##/?O^@!#.:)9SF-!<&Q\O22')C(^7"V5L/()1QN,>;5H'
M%-EG%8P3M'C]9+.QK//SR&8+FRSW9EZ4.%DIL7Q<S/ZE;',I<'U[\R%,_$BP
MV7?S0:<THP-SNT/$R$[C*U#K#+9*7X%:;?"F5MS<Q O=]^))UE> 6?5M/,GP
M02*A9VK@Z)!@XDXB+"0T^*[Q(,'']3>([]3<_.7Q5[50*V:;D5_+I]EB9@-,
M2IEL86!UG RBT\B8XQ&,.8H@XFD*>9[ED+-$2YIQA(A3J8Z^ DS-Q*YT $]%
M:0'[4]'*\$ 1H$I-UB=Y)N[V::_)ZC;BAYZ"@=\(-?J5_.#:MC8\Q+Y2X8+,
MJ'[KQ-F'&'H*1G(VZJEXK*:B>1D,E6UU"9 M/DROQX[F[%RB]+Y7=-%S>I:\
M-:_!]68F;'!2W8*-8J(1TU#3%$,4Q^;%8FO+H9RP3$1)FG"OZIBG0TSM_5%+
M6$3->>Y;M #IYCM<!L_ W.Z)C'\9W$;E0U7"/1U@W&*XC0J>U,-MOK+?TCXH
M=%\DQS^0+(I$A&.(<)::I2TTY()(B%,=*163B"'EMY=Q.LCT=A\^JO7Z/VR3
MC:?EHFJM\57-BQV'326^\34WYHKU!KS!47)%L_@JBJ+B_8EH=$5R4OR^_LJ,
M8#_Y,<.9>7!CALNP'9@9#GME5"TTPA%#L^Z!B.', *,20[."Q\30<F4_8M@_
M_ZY>550(\W*7$<QDRFVE>PQIQE*H49ICG0JM.?=YYY\.,;5W_L=MQ(I[@9P6
M -U6]&6P#+RB#^-2!GC9-VL?:$V?&6#4-=VLX/&:;KDR_#'(9_M!T<*^N.JS
M><VMU&:V4M8C?6N<#5LNPC:9.LV">HB5,B@C":5MU852XQ&PW/"$T%G*LBQ)
MC31UA-N]>SK20.(ZK:;#*+G[$1*:;&)DF5D=[G3CDDF]_%!CZ#GZ<6<9;THE
M?P)637N6H6<+)4&E4^$'U0<37Y28L_5ZIF>B;-VVGPP[\ME%@ D9X<CB$BDG
M<U(1 &J? XH0PUW:#NG#P@Q:;&"N/RS^H>2C6A<=)=?7FVTIM@?&I4X299S+
MA-N45:DAB7,!>8IE*C!.<*3]G$L_ :;G>.[D7P.IUK/'15$/DZV-_RD?[4;M
M;*<7^ ]0JM2WZ9+3)#GN20T&_-#[5;N637N26T^_E/VJPKCP]W>U,X?HZ^2#
M7/"V3TZ#_Z"N4#[ -#>-\GI*SYY2\_GR+]OS^Y?EZMWRA6_TR_Q:"!O*LC;O
M?F4DX7-U\[*R10$>4DD$99Q!R96 B)(,DDQ2F*1*)QE1"">><4)>XT^/_;;B
MKX%>KH"L- "L4L&SB9379+C1W&  #\QRM8Q@)Z0AMEJ9 NV;E9+&7"V-V$J#
M@(VD^@ 7JI.4U]CCMI+J \M)+ZE>#[E@U^#3<K$L2\0M'DNSLSIH?,AIKE"<
M*DBBS%ATL1:0"B)@3)#*&5-$<;QU_CV+9#6.VL>''ZTES)M9Y1U6Q^@]JI%T
M8.[AFU\&X9@N]KZDVVC!2MCFTY1^#G(G*B']W.;!QG=7.Q4_ZW5VW]6/6MZR
MN26QNZ]*;3XNRPV2LC5V)G(<$6;3/A1$+(X@553!1"'$4LGSA#AU2N@::&H'
M#I6<H! 4U))Z]<GNQ-:-/$(@-C!M] /+FS"ZD A$%8W#C$H27<H>TT/G]>%/
M*K8%VHSM<]=1H.U!"QK'3":&/M(4(AX+R)G04.-8&C,%J4C&/B720@GF13S_
MEYX^>$W4Y<<-0\$_M/%S\^&J/$S="7RNH.85^-6FQ=3Y$^71P4ZS(@QEM).$
M/EB/<'3@)=9DS@KZ@.ES.-#K^7V+H-@--[$QSU\\%J6?BW['UV(S^U:,^&ZV
M%O/E^F6E[M7WS5L#T9\/9HD86R]ED&54&XXF,20BEU!3E) H5B0G3CF^EP@Q
M-4/P0 ??4BD]YL"-?H=&=F"J/1"_*H]?]EG?:0!V*H _K!*@T"*@/7D)B,'*
ML_008>32+?U!.BWK<L&S^O'@31%'6@3CW17AH-<OFZ_+E<UA?6")2 F+$AC)
M+(-(98;X<DH@(Y%,4ZH01]3O#*!EM.GM^-_LA=A>5<&R@&T%MKMG_4)HVS!W
MH[= . [,8A6 54AM*2C821J.J!S@",1';2.-2CL.*A^SB\LM_4BD:%%JC;-;
M794F7\AS!<OK_@64X32CJ8 9IPPBK)GQ>O,<)EK&*,MP@J+8QX[R'']J)M16
M?%M2X&PNND.#@2 3X\8^ \(],",%0=J;GGKB%8BR?$<?E<9Z0G-,;7T?TS.2
M0HC5BY+E,XTKJM;U03W5FJ0:<UOU24 DLP@R)E)(E,@496F:">$9-=$TUO3L
MI4I4L+%2VOY?L^IH[--RHP#V-)*:078CJ2# #4Q'-6(5]Q12#A'?T 5%J%B&
MQG'&C5OH4O<D1J'S!C^>6*\V#[^Q[[.GEZ<JGT9SE6"21U#0/($H9ABR.$(0
MQ[G*M18)D4Y)R"=/GIHI4PGGMM1/<6I?VA=I/_!2KN0*F&?4J&W;:C4W[:U4
M\]MNE9X^;Y15V:A&O0J;+^C]=GYY>BDV3MKVFK?G.4KCG.0\ASGB$B*:"\@2
MD<$TBQ-I7MMY*KGW.]M'@DF^R6L%P+((>1$'MG+]8B^KGI7O]]S__>XU3<YO
M_:&@']X6V&+N4)5LUYTNJ)W0![QPUH/7Z&/;%'V@.6-I]'I,SVT9\57)E[FZ
MU6]?UK.%6J^OQ3]?9NM9T3[W[>O>;V5?B91R+ 62,,^,K8)R8Z%PC#&4+$]0
ME.7&<"%>^S*> DS-FJGEMRNMU@#LJW %^.O^!WZ-/7K/D^,VS8#H#[U/$QQX
M_TV;GNB%VK7Q'7[<;9N>X)SLV_1]SJ6$6+#O7D*;,6'>;5/:KM?_*!/:]K)R
MMCM,ZUO]RVS!%F+&YI_52B]73S:N['HA=Q\O2Y'K,+-"]-T)=B15A+D4D*/4
M.(,YRR")XQA*HA#B<4(T=NI>-RFMIDS=NQ;U^RF,B^4&O#M(8ZSPV<^UZTOD
M/_+[Y?MV^+_D6S/P*V?_J_')Y:M1O7+ (*$7DYJ=X*^T'ZG3#WI/3F :FU^^
M4Q"N9_@*6W^U9SWF/[81[3<V+RH9;V[8:O5J9"[3Q)&*,5.)@#2V?HVM-4PB
ME,%$8>/9$,U0C#P#65S&G=[&CI6W""<3]@>UD]PS@,4)]021',>:0*85A4CF
M"22)YI Q)73*4RW2U,?."8[Y&';(%O'BA_?#(N[VY@^.X\!OYD8(B[('M=2A
M2Q]XH10JNLAIS''CC'Q@.(DX\KJYYW9_42:A/AMF,L,2"6;XO:SQJR')8@U5
M@K# +,E)*GVR: Z>[L4M(Z3"%,6^@"B%,U:J?[F50_ <M]C[0C+T!GI5"B7\
M\?DYA4-M>A\\>]PM[7-JG6Q8G[VH;P&F%I.R.@".6*:R#$EKJ2&(M$XA83&"
M>1RS5 K$"'/J!>$QYM0LAB['T[>@4C?H;NL^,)2#N_/M* Y1_=L=H& 5DKI'
M'+DLDC,$I[60W&_U;TSS>;64+V+S<<;X;#[;O.[UN/_T8I]]JV_F;&:<U\T#
M$CSAL<XAC_(,HB1.($TQA2I/%1$)BA.)7?O1>(P[-1ZJ1 ?S6G8@=L)?@44A
MOMU4%94"'OU/?*:CG9T&!'E@AJKQW8H-]N0&I>#@5H-:]&'0=6\J,Q#*(_62
M:?TVG_DR!VH@TP.TEKXQ/D\;K5U,#Q7WN\3TN;V?_?G!?,D6CS,^5Z55^TEM
MRB9IMDG-<BG_FLWGNQ05R;3,I891I#A$*<HA0XF &<52$84)3CRCPGR&G][.
MX4[ZRM$L=F1JN?UL4J^)<#-.AP)WX'? 'JJU^VH#N]YL9=\B_-,@F2E]8 MD
MNWH-/:H1VP>48VNVUS/ZT=IG]EJ<Q/RR7'U4CVQ^IS:;>7DX\Z!Y(A(1V]WW
M3$,4IQ@2:\^F-!.2,<%SMZ;D#F--SGRM1"WJ1\ZML&"]D]:/L-H@=N.G0, -
M;9+N8U;(">X<,/.F'0<T K%,VTBCDHJ#RL<<XG)+SSBHXDGRXVPS>RSL[FHC
MB/ 8,24R*$DD(>)"0IYR 37G#"NI,,V]>N4UC#,UJJC$!#LY/<-^&N!THX8
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MMB1PG/,X3G7B5 /XS+.G9L-LQ7/?\#U&JWLO_ (,!J:1K60]-KZ/<7#?\+X
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MG)O[U^__^3+;O#Y$6!)%.(=4I)'A+AMJ1,U/FG*54IJ)+"4/F^6&S=V8JVM
M+\MH.^QP:^O>C@'F.ZF+()CU5[92E=S_"ZA"<C_NZ@3>C;!"PCDP2WT\PO!]
M.VK>5.0*12#^Z1QN5-)Q5?Z8:9SOZVLE\<VN%I0M[/*08YXG#",H49+:BO("
M<D0ES#"*N,9$&,+Q:[5S/,34G"LKDZ]A<P*;J_UR"1B#FRE\LU=6[@JT M/#
M%&G2/9C%<3+ R(9%DX*G]D/CE3WWH(TS]?[[LUJLU6=EO@[FH<NB ,I#QD06
M*6K;Y$38+&>.(*%F32N5T2P6"4ZD4U'+SI&FMJIK88$JI;T"BS+NH]C]-R:W
M8,\S8SL4?LYSJ8JMV+-VKQO3C;[C)G4(3,?8I+9P5H*"2E)POP0>I7:Z(?/<
MI X!W9B;U'O?R)-OW<\!=ZF[<.G:I6Z\?]Q=ZBXU3G:I.V^X,&#Q"_OK-V;&
MF;%Y89&]/#_/C7%V&%''=:;3F$909C*!2"D"&;=5T62F),:$JSSM&;KH,O[T
M#@.-U."I%KOTT"K!>X8S.DV#^X;V(-".L+==A3A:>'\[@+<6?HQH1Q_<0L<]
M.HW]8R(@?6!IC(7T>HB_[5@$62JYMG6^WG\WA#E;JUM=N)FW96M7,^C[[S80
M\YY]K_:[S#LZ%T02B2#BN;$L42(A)UD&S8<$ZUQP&7'WP(9^0DR/Y&H]RCIY
MFZ_*O.A+;>P"7%M]P+)4Z._JZ7F^?%6JJ*)G/7H;$;1AWVVG^O)*]A=;R75A
MM;J;5CWGL]M,'7Z.!F;+[>18#<"]F9Q:#7"K0:$(J#0!UW;WJ]#%EC"LM^T]
M+-R^R\K9]!U^.D:RB8><%B^C^3)$6ZSIG@\>S<R^3/%]^_O")_4SS&UZS%^S
M^?S+<C[_9;FRI/E 8LX2$D60)(F"B&8(4IHD,*6QF1H2BQCE/EN89\:8VFY'
M+2+XPPH)*BD]8T3.8>EF0U^(T,#<[PN.MRG<HGX@@_?<"*.:M2TJ'ANO;9?V
M/*9@3^Q1%<1B2$:^B,T[I978U(&-E',ALR2'F!#;@2Q)(<$H@BK)E&V,&Z$\
M]CJS:!]O:HN_$K>T.RN!026QY\%&!]".IQSAX!OZR*,%N0$JN#@"$^H\I&.T
M<0]'W%0_.2EQO*WOKIY8J<+*G=\LGYZ6BSL;-["^WFQ6,_ZRL760[I?%9V_9
M6LG/[-5>?+U:F>]0<=_Z(8J1BC&/84Z%+1ZG)*2)X% 8-SB/.<T9\TH;O%RD
MJ;'3Y^7&1@ZS>1F5L:Z]XJ+*U,O"S-:!;PR>S=W>VX(7SZ/K7N&8LS/X!N)6
M&5!J TIUP+X^]G3BW<Q&?'\SSIFVB\]N9Q17PD)+4*D)]O4,N<\8"O-@FX\7
M"S3RCF0H $^W*8,]N1^!?UHN?J]M$Z9HBKCAWX3B%**8)9!SCF$LD&2"YQG/
M/5L$[#U]>KN-Q6E7F>#*' M_GT/-C?=Z(C$P@1FIS'\'L-/.J!N(._:?/"H)
MG%'I>#6?NZ1GIK0]<:V^8)KG)+*'GQ3A!"*J<LACVU4UUUJ**(VH1G[+<N_I
MTUN6EW9^VH?.;6WVA&/@M5GB$'YIGM$V5%+SWI/'S6,^5>DD=?G,);WS8M1J
M533LL;U[-NM?5\OU^D&H*%8R32 1D:U8::MAYRB%$F68*,XBY+=E>GZ8J;DF
MM93%R1NS<GHGN)P#TW&7Y&*(AMX<J=&QIRVEB%>@$#)H?DH+".%24<X-,G;6
M28NB9Q),VJ[N;2Q+M9X]+FP.6?6*2>,,Q[G,S-N91V;=2V,T1SR#B<X(%[&4
M:>JU<WIFC*DM^D]+N\57RVB6/?B'DH_V_'T7DNMM3Y\ ZVQ77P+7X/9U-U+#
M6-]-H(2SPD]&&-L:;U+QC%7>>&E/$V"V?EZNV;SH[+TV/GS9RL]\;*3?S!8O
M2MX^JU59.^F3^7Y4;:0EPC2R^2 L);8@8RHA(4K#/%-Y3//<\(5?9D@_.:;&
M)[4:H- #6$%[YNCWG1A'>V-XN(<V2/H@[6^27(93*)NEIQ3C&C67075B]5SX
M./_XQ^OD9XK-:TZMY8LR<Y!7;^\XS0RK10CJQ+:UYBJ%-(YB*&.>)CI.$HTB
MUZR9AC&F1F-6RK^!0DY@! 564O>(MR8@VZDI$#P#T\XY9'K49FJ"R#WJ+P!4
M(X7U]8/,*V"O XR6B+RF.T<+N>L0?3^FKNO2GCW1RH.8]?WR6OSS9;92==7,
M*K+\AJV_5G^1#VFN:9Q1#95F&*(\2R"+4 2URA1F68H1QW[547R&=_IRCUH>
MI9!L/2M>0MND0F%$!JR2&;RQ,P;BJ+F0Q^73XF;T!8=ZI&CM2FR[D5Z)!W:2
M;Y-:K/3UWV7 ]FP]0 O5L\UGZ'$;N?4 Y:2[6Y]GA&OYEFRM.X*)3B1441Y#
M)*B"G%,"HUS&6"4LRZ, +=^2R1Y1[;5\6VZ^JA5H:ON67-[V+?':#PN$X\#L
MU-SV+1FI[5LRR+98VT@_O.U;TKY-YG)+(&-IKZC@@[&$1)I1"26B%"*)$*1*
M1# F6B4Z12I+Q(7&T=YPTS.&/IL'?66&O^WK>+:3]$+#9Q_BGH:.+VP_SK#Y
MX #;Y3;,&3R&LEGVA_JQ-LH9I3MMDG/W].CY_K):F4?\,EL+-O]OQ5;O%_*=
M69 /6B-.;7 :274&D4I22$EB:P.(G IN& 2YMW]O&&1J>TN5G* 4%%A)@1$5
M6%D]NL(W0=K.$*& &I@9>F'DUS>^ X1^+>2;'CI>-_D.M0X:RW==V\]$^(VM
M_E1%N.NN55HUU$.*TUSD+(8))CE$W!@'/,L41'&"&(E4FC&O7K M8TUMV>]$
M!>NMK'Z601NR;H9!(+P&7OU[4.UW2:P$#6<6.* 1R"IH&VE4H\!!Y6.;P.66
MGML2L\5LHS[.OBGY8;$QWX"9&:0,\?DX6Z@/&_6T?DA2*3"C&.8HM<%X-(<$
M"V+MA"S*I61">-6[=QET:MQ1R@P+H<%.ZBH.#?QA!0>%Y)Z'[$XSX+A;$1C7
MH;<M D#JOWOA@5&H;0R7(<?=S_  X61CP^?>?J3TGJT6L\7C^K-:%<DZ1;J7
MD@\(:Z+MEH;2#!D>PC'D6#"H)4T5PHP1YM4)NF&<J5%/)19X\VQ3$ZV@GN<X
M37BF.-<XYQG4"$N(,LPA(X;AHUS$F<):QT+Z[3L'0'2</><:4WM<IBJAP1;?
M,/"ZD78 R ;FZ5I"6V*SS+.\ I64X7BY X9 5-PTRJCLVZ'J,>%V7=XWU?R0
MNS^IS?OO58!373#C0<89XAF3,,L8A2B*"&2)\1H%E0111*CYQ+=N9/>PTV.+
M/>.$57D'ECC*8_74DXV=D-=)A&*1*!C1W+91H ED+$<PR4F6IU20A'J]ZD+C
M/DH=]**5PNP8>P#=:]!Y8>[&UZ&1')B\3^SJ,ECAS59F4 L=L,N+#T;!DN =
MAAPYS=T=A--$=H][_<-,;Y]GRUF=&4(CFC!"&;0&-$289H9J: 0-!4G,1!KK
MS#FV=/_!4Z.34C;W^,@#D-JYX1+5!U[_RT*L'N&A!^J[QX3VA6&D0-".+X%7
MQ.<Y55O"/ \N'RVV\YR0^P&=9__>)W =X:B("WUGXT*S:!O:9$Q%AB*(N74Q
ME3 N)B,)C&.&C$&39+%VRN-M&6-J/)/\C(YBC;/()RK[/)#=!!0 GH&YR"(3
M'4/3*W+]/$8^D>L78S5:Y/H9S$)%K+>"T!JQ?O[.$2/66T4_C%AOO[1G11'Q
M5<F7N;)5S[^IQ8NJJLP6-7#F-W6MC>N%_+A</!:[I:4E=V]/<1YB3+*(8PXQ
MBC/CW@EI:)'GD*99A+,HQL;#]G'O+A-G:@Q::U/V"2CU*4LBUAJ!K4I%=P&K
M5'6.4!\>%(IY'L5<.*EN_N-X4S4PFX\P2_[56(* &ZJ RV7"C%OS)0AP)V5B
MPCS5CZ+7J\W#S7*Q7LYGLG@Y%T=2U]]GZP>=T$10I:"FL;%&>4PAP4K G*0Q
M2PA3&#EEC#</,34J/9"R/$P%?UA!':FQ!<QVN@L#T< 4U@,=9TKJ!J"-9LS=
M>Q1C?MO12\N#1Z&,;L5J&G"XLH>GB7XF>QF(**XKQT2$"(T1C*G4ML<5AH1&
M J:8222S*")9ZNQIGA]C:HO;2GGH&J#8PXMJ -+!T[P<GH$7]CED^CB:#1!Y
M.)J70S62H]D/,C^'LQV,-H>SX<[Q',YVT0\<SHY++VZ\7L>;9IHC+5(,.4$1
M1+9J%I-Y!J.$YC+F+"<*]VRUWB> =[3FZJ**3-]KLMZ[E[I?[.YE" W,>7O"
M#1"HVZQZ^/[H/R0LMUG!EA[H88)P;VW2ZQ=E2YB)S<MJMGBLWC.)6=X9SC&,
ME'%5D$($<L8DQ)(AQ!..BQ7NODW4--#4#)M"3K\UW8BAV\H.@<S Z[L0$1S(
M.$!V;Q<0@59[XS"CKODN98]7?N?U_=;_M1"K%QM.*Y9/ZIY]5^M/1O[JS:15
M*JF@"&I,,H@BD4."4@US15@F6822V*L2;MM@4^.!8L?0#/1D"^(:N_29O18I
M*67@%?8,O&J%V8TF0H$W,%548H)23E (>@5VHH:C"Q=  E%&ZU"CTH:+TL?4
MX71/CT@>RTC5FT[E&1(Q5S!3:0H181BR-$NAR*3 ,<Y3+ITR^XZ>.S52\# .
MCA'JWMKHJ?<HK_X>,3Q[NGN$\/3#8*P('C<L_")Y3C5N"^39NWJ\.)Y3$0_"
M>,[\N9\Q\OMBI<3R<3'[5U'N>]L,.,))HK.$0I4H#1$5'!(M&8PB3E#,,8N2
MS,<.:1AG:FRS+V91EI][=5_N0M7-[ B U< ,=0!3V&[(CB $LC*:1AG5P.A0
M]=BVZ+J\'Q$<^#DWR_7F>B'-9VKU37W<)J8B;0LNH@S&3&"(4I)#3J1Q4<RO
M62(I21'W80670:=&$8<NN16Z"'>HQ+X@-=AI!MP8)#2N ]-)"$B]"<8'HT!L
MXS3DJ-3C \(Q#WG=VS,U^)\OL\WKK@K"-LQ8$I)1 F-)#0WA.(,TRCC4.&$L
MXDQ13+TR@\\.,S7B*:7<*]#AF;=Z'DLW0KD<H8$IY 2< 39+VT$(E;-Z?I!Q
M4U9;%3W)6&V_VG^7H^@M:<BEW#UY__U9+=;JD]K4H1\4R3BB&<R3B$!$M(!4
M),Q8(KFA H'32"FW--7NP7R^X2,VWC3R@C>S0N*?_K[]1)7"7[DG3#J@W;V)
M$@[!@3EB"U2U45J)6F1(EL(&0\U]^R4<>B/MR'2C^'.8;1HW9%IV;CH>,-IF
MCILB^_L[CG?T,ZINEJOGY8IMU#O%-R?V !%Q@B3-86YKQ2$126A^2"!+$JI$
MIA*4>W64;QUM:B;65E@@C;1[9>/>Q)ZG3^T@NQE=P: ;F%=WJ%E!A[7!G# )
M9(JUCS6J1>:D]K%AYG;3A07NU^_4:O;-O'.^J?5;9KX70MU]56KST4ZE>1&]
M?=U=<+-<;%9,;.[-F&]?JVY^=8L_<VV96)/G*A$"(4,^(C7>71)!EJ<1S#'%
M*L$T5<JK*>1PHDZ-OG:5X==@3]<K4&D+"G5!K>\5X*][UX%:9V"5[I=3->#7
MPHTSIS'9 Q/NJ//<OV/ 8%,0NN% >$%_3+^"P0!O;'<PW(A]^XO7H]5AFZ];
M68LFQD7"V0/.(\)E)&!B%AA$N6*0,$JAS!2)LC2/1(KJO@GW/FW'749W(I+#
M-@KW8]B^*R5GQGI[>39&PP9</ZZ4*EKLOKFYN_:T?AVGP8W2 Z(Z5N?R+=5N
M);XRP/+_489T-TOP&UL;<\!ZS!M[X'&]6IG;"["OREQ9<*MU6SOX'HW.?3 ,
MUOC<:="1&Z'[ '':&-WK[I[QH?)_7LH.$+\L5]=/9C'._E7N(Q&4X=RFL2(F
M#6TIXY;3A!)(5&R^B2KF&69>P:%-(TW-L-V7S3,*M!%,-_() M' ?..$CG^L
M9Y?FH0(]&\<9-\JS2]V3$,_.&_Q//NZ_7/_^VW6U280ETI'6N2W52\P_F82<
M:@H%2HBPG9URX>0''S]X:HN[E,U]Z_T I.[CB;ZJ#[QH2[%Z1'D>J.]^SM 7
MAI%.%5SA\#I!.*=SRWG!P>6CG0Z<$W+_+.#LWR_UCK96RZW>?5@:Y3DE#,5I
M"KFB&B)$&&0VT"M"6 F**+4]Y3R,#)=!)T=)1>9I8=%5Q6OZ^C\M0/MZ/V'@
M&\_W*41S]GNXTLN5&M#QZ88ON-O3,N0/<GJZ06AV>1SN[9G1TG"(CA*N)$TX
MC'/*C0%$$*219% FQM%):(HD=RJ;UC'.U,BG3'FHPSOJJ [/-) &2''$\A1I
M 6-;20!A(2#'26I\R3@G.J51@B+WV)E H(X3.%/">AJT$ ;8;CLT$%@#\W<3
M2GW3D2Z.CPD$VZCI2GW@\\]@ZAT7TW;WN!E.[A$Q+I?[MTE]O]C,-J_74IKO
MP+KZS\?90L4/&L>"T3R'7$811#I!D CS*XHRGB0JSC*W$./64:;VYBD%!96(
M5_4/P H+;A<>S5*;@6TGRF!P#4R3O9'R:IG:B42OGJG-3QVM:6JG8OM=4[LO
M[AL'-Y\SLZS8_'J^4DR^?EX:]T1>/SZNBE.WK;W[P'*:IY(BJ 2Q[5E2"FFN
MM$V&U SG/,HSKX@4YY&G1A [P0$K)0?/A>A7@-7" VVC$[Y9\7U#YESGP\US
M'@3E@7EE#^!*:/"Y G@K-]B%?X2,J_,$*UB,G>NX(\?;><)Q&GOG^X!^)/9Y
MM11*R:+2;MU+_I?EJC"7?IDMV$+,%H_7PKCJ1>S?0TQEC#0UAHQ S/C4UJY1
MJ8(DTRKG/-5)YI4ZY3G^U BM1^DI7\3=R&I ' >FK%KRLACXFUIXH)>KGT#I
M#VT5 #L-PE%73^@"$9COZ*/26$]HCLFL[V-ZUKY<+A[OU>K)1BWOJN9<\W41
M/?9 C2N;*AG!/+.]\A!'D&6(0)E0+G(E5>1W/M$^W-0(RT@(JS*$1;2]9RG,
M=FC=J"H<8 ,S4U%/S$I:('4%=DWP:@1_8YMMJD*M0,!(6#>D0E74;!]LW.J:
M3HJ?5-ITN\N_/X#A+_DB-K>K.[7Z-A.J*&@?<8EEG%&H=1Q#I",,B<P8C%D6
MDS1*>9PZ]=QL&F!JS%')6%16J,3T[@UP%LAVU@@!S_ 6C"\R7GT!VM2_H"O
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MDSB'DJ2*\ Q3F3OMT!P\=6KFB1&LSUGZ%J1V0NFM^L!,<:G6'L$#?;0?*V[
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M3?7"A6?,&5MR47(ZGE]_ 9*2*(LB 0ADN,G#)H'O?" /#P[.H[6EV1UJ&93
M][NDP[[AJ19J9!UW4:V._C-H27)6>8<K8>J*NBUQ?NBZF'M]IUJ?B1R]Q]:)
M;-=I?=HZ6?EV?9#;X\X]:?C)/+@^2&@[;;V,YV8IZRG7K]LH.4D0S@@+0<(@
M4=MD*0&1::2WR5C A$0AL4K@WA]^;I^I&IUSU.$;[LPL8'=&1OX>F)-A;>-V
MR^S)JGTS^*1V;+=@;RW7(U?9VZKGR<\XN5JNQ8J_"!C&V:;9)Z&,066!)KK/
M)TJ0!+G@*8@C* 4EC.>Q40I!SQQS>W4URK\&%<Y  0TT4G-+Y!B1P\:?!WI&
M?H^[F''(ACQ&D;D=YH&JB4PL-\JL[*8!,GI,HF-W3F;M#$!O&S)#EWKSYFT_
MNC%)A:0(*3,%*M7'60((Q!"06&0LXC3.>&:7/75TKKFIP&XGE:,MT\>QLVMO
MAE:.*VD^_'HC&4!],_UHK]Z0:61RBVNWWSOR_9*KT;<!J%<OU1<LRL*((4I
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MKW@DGB?R'7ODV\J=[,!:CWO99K3)W,T.(K;=SRZW.Z2/+<1=\20^D6_+LIJ
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MYV)WYH1YKGUG,/$/*85G3LBQRG@6(YS0<W;7)./B@91?U68G94BB6$# <"H
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M45S+CZ1<Z %O1+G)YRR8=I44CR]JTCO=5^-.?9[>*VG_<Y]D,8E)% .1Q"%
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MQT S 8X/ _WGK4SXPM%)D8!KKFG/+>2@:2\AYR))6D'KJ'=!P?;'[P0"^1Q
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M.>\C*]*>JK5D#[*?5[O?/DC<9Z<>0L<=IR$.K33>U$1F%H3V!5Q,!516ED1
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M/__T[:\KS+_,W]"N2JJ:?WR1UK0D-GTMUP.BN$2GG(1 :XL66#&TOX<,Z$U
M(P-:U3H.W9_*;FS6<0C:DJD=4EU=1!+WLM'.QJ2" *&%JP-DR8<49(8Q"#+P
ML>146@_SZ>ANQZ'U_?1!P!ZB[R")=M-VNOJP>(<4D*3I#.^P]&&QKS2+<IBB
M=F!-+3)R5M8A6@(T;?Z\,&MIP;8N_1J CW&/JTZ,XM&!T(49?87T[C3=*)F^
MGN'E6)_;HWXG&9/7@AQ:Z5FIUY]GB"@S!,D<9L9#T:W[.G:A:URC.SY^[I^X
MM59E%P#=Q%<_A15NVOUPOKK@HYAD?2WK))^(@<JE-I,* T87YEP4U2ZT=K"W
M4C*NS>P.A W4U07L7JQ6),2SSV&ZK-)]26Q]Q-5$ZGIT'0-HF2F^9T&"R[Y6
MC0;M4!7)9?,:[ZV4C%LKT!WL&JBK ]_TUJ"(,,/5F[)A:U5M^';^?(G12\4@
M)\_J\%8/FU'\.67EF'31)ML8COO2.&Z)07= '53%_1PCO[I\^X68/X2OK[_6
MS0 O)T%,0K$E>B.(E\)!\6C .4\N/.T%2=L44_-"T>^0-&Z!0G<X;:G +C;T
MC>#JB)*?%\M7B_.X+N>S%RDMSDGD$Z%LQE 4,"]YG:0:ZCYA 464T?$Z[+YU
M_/X4/>,6,G2'Q6:JZP*(]Z]4N"6WE^'S=!UF-T-, AINLP*MBP4EO89@27)2
M.N=T;:3DK<L<=J=N7 _TQ,FB@936*2"O%A<M?IQ^V;3'E( EYWI4ZJ0A3YHI
M\-$R8"*9:(B_Y%I;R%WH&C<%-!0JO@N^(Q5TK)\X$.Q^F7\AH2^6M&@G45+<
MIM&#Q!1 J12)':ZA9!^<%R:5YAGU)PD:-\TS&M .54FG"+M:-V_#M[IH:M25
MTO*<WC<-<3K;[!<35%&@40%0UKZGA"1!CP:$S;8P)SWJUH7[AU$Z[@X\NO%K
MIL1.=^%-!?"-0[/)$TS(QM,ZTPR"EI)L/2=W5V@!J41F=(S*9SZ\2[B%LG'S
M/*.!\6@E=6HI[_)U>V45'F26M -@%A1PZ<3 \\*!!4\NAI?2GL \/DK>N&F<
M3F!XJ+HZ2('O'M=-L@Q*DQD'DI<B"=9D%!8/WO%8[X&(H?D1X.[4C6L.3U\0
M-(32.KBPY1'.JEN\>D202@2K0[*@4ZQWAM .$ +M "D$*[+EW(;629O]J>RD
M,?U$A8^MU-6%HTAN[V5N]K+ID+BEA;;^5L=KK\D;KC7OG^NO3*3BA@O%07(K
M0,5Z=L2,A"R95,8[H5CK4Y;=J>NR9+(94NZGL(=16A?.([&2$//J9Q)R/=1\
M4^B3?%X%B)<.L5<RE)3) ^:RGL,3=\[05YP11[5E(KG6/N/WJ>JRVG$P +95
M4I^6\*?SU72.Q,U%AVR5[U5C]H1K+TWPEMB)M<O09_*W2P04RI%_[%QDK2O$
M]Z&OR].4DUG#5HKKPQ[>Y^Y"C)O/)IESHC@'X-G2(N.IU'&4!;(I*DN7F&_>
M.O\4/5V&*2>#W:&*Z0-F]RSZ;V%=[Q;ZMKD88S;#5+6XJM=EW#!I;4K1,07:
MJ=KUJ#GYUC&#-\I&&WV2IG4A]P%DCIO#&7EC;JW&47?JO\__?LW@U>JKC'Y8
MO"0RINOWYY\_+Y;K%Q^7>-&TN47*DX0V&UWOX2;_%Y2IMPLKB@I33KSHJ$T4
M]XX"'_2@MJ!CW**<$Z'RY KK(.5XS>=B>7LQ;E*JV]@+FF5D,=;KV3PH%;'>
M=BTA)9(I1L?)BQYH"]^1Q'&GC(RTJP^AOBXV^MWE.3&"EIV+ D2]%EXI9<%S
MPR YR9*7Y"V7UE43NU.W$RK=?Q-4#J2T?E/B/T_G89ZV"S)XC,((!5@3N<KY
MS31^!TP6K@0M6:9/- O@"2H[F;YYHI1X*W5UE0AZ4]XL,S&V_'8]H66BM0FQ
MI RH,-:J)4N+N"YG=%'R:%(IK2>=/T%.ETGO9EAX9&<^5BU=[,*WW(QW^/E\
MF3Z%%;XIMZ8"36A7B+$4 \8J47MKR;.(-@-M%06UY($UOZ?\^U1UF>4>&G&-
ME-0'\&XG"#Y1\/4!EV>O,*XG5OB8T3$0JLZPY?0'"0_!.&D0/4]"MCYI?I28
M+O/7@\&LB4JZV#IIF5Q;Z;NL%%12HQ%0L%2['$,M4.+@7>3"6"9*:7UF]R@Q
M7::IAT)7&Y5T9[OJ9&Z2%YGC7Q?SC]<\1<:=I?BG1C_IXJ)F6D&,8B[#@M96
MDN\[H!';3E67&>A36+,&2NH@HW=[!=WA@^7B,+H$6="R40(SA"(S1(Z<\YB]
MXZU+!A^CI<MT\BE,VL$*&=6BW4Z,UX7R^BLNT[0ZEQNW\LWGS3%-+>3YFG"U
M^A"^7G9*KR:(,JNL-122%T7O14*06D!4Q7N7LB[WLQ]/GE_L]_8N4\&M878B
MY3ROH[0M0IXXFS,K@4RXK)V"Z,F..VX _68L5&9*-S]*VT)'EYG@(4%Y$H5U
ML/'>7H2W8O'-6<PV]NI-B2H$#UHG"I=\M?Q&> A9.J$TAJ*;9TSV(W$GJ/IG
M#M53J*\#=.XNS4DISJ20/!A6DY*^WA^L;0:31##"66],Z^!W=^IV2R*S_R:@
M'$AK'9RDO2X%T_I-(:_D4YA_Q'?DI;Z95V;K_VM%^)<PPTV;/\EQFLB'W51&
MSO/=#V[]YJ08(T4T ;C6F43@$'R]75T5FQQ#'Z1K79PP !N=W$O6^BQN;(5W
MD7$\BMV+*]T>]C]>7CMS6[ 7PIY$:R.7V8".0D+MO*4]*B*$:$ET])^PK4?D
MG9;#3FY6:[U6.H9)!UO'<38C!%LP6PLL^7IWJW+@;=2@N&3)&I:P>8OB\-O!
M\!>[=07QO938S?7,Q[&<@Y%%>P5Y,U=!, ].> /""\DL"B%%:^=F>-P.?]M;
M7[C=1XE-KWL[(G!<S!-Q\6;YEM;!Y3>;%I+5M"J3(A3Z\&PQ1UHGWRX'NEZV
M+]T:Q4 _.#_#?*T"4VP66H6+*^]4<G5B%^DAJLA*$"H;UKQ1? A&QLWF#5<X
M-[K2NW#7OR.&S>VWUU.,+_GG$V&+T((XE,77FY4-JTW,@GPJ8UR)#B-K[74?
M1.C(]7CC0VP_T#?0]C,"]4,9\TG2(BFC"@0I2+A(,;>GG0NT+\%KJWURS4N9
M#R5VY-*_9PKN8[7>1>%-4^'S2>295K'/H&K7H4(?P4NFP?KHF3(F"M5ZZEQ;
M#D8N3WQN2V%(?#3+GK2[]O3]^=D9\;DH[Z<?Y],R374FR\64R<U=UK-IJL<N
M=QC8Z>[3'1]\[ 6HA]#?Z!;4AZ^Y<;XY%U87 5;'6C26"Q :*.3#G+D4CIR"
MUA,W'J?F^+/#/VX]?+F8TY?IXMR^=FIOTHFKZ]FDF]^9SM.4(++Z0*+^:59K
MSZ,B-PFY!Y,B@F+>0LS"0F*V&!:XR[G]Q+KCZ1[YGK4V"'MXK'ABA79XW?/M
M^=;[&[<'T[&/L&"/4M+(3%T]_]NKZ2K-%JOS)5ZCR'IO0I$6G$RYH@@)1=Q!
M9*D.N>;&\M9%*$^0<_PHUP>/OL%KXIP[A0DTD00J<PM!8*%OC;?)<AO\"5CM
MQ+"TPL3#Z:R--- P5&YI,]9D&J=U\/;&+0SS_)?%(O\QG<T.LB&//^UXF[(C
MI8ULS-7#:?NX_^HM"/.)N]HJ!*58K CC%%QB .E%H1U%([K6(=5>!!Y]E]TN
M+[M9%]9$G[1+8)BRH(+AX(-7( (J:VTRLOG%BOM1.*ZM&@Y;#RZH&TYO7=JS
MG\-TN<G\_(:ALG8Q@6I_2[;].<?:L!VH:V2]KM]TH^4;1]L;H93W&KS1FG8M
MC!!RUN"8ECX;PIINO3J?HN=8V[3MV3>0SDB.O!.TV4M;C]-5G<P>-; 0(\49
M+)74^I3Y28+&M3S-<''?T+130I=VY?KBQ -CJYM_?;P?] @ES6*KR^=OV8ER
MD)%+\J,+J\.68JYW[V*&(FRP146G>.MSP"?(:7!-QOU'WR!6)1L)][3I2LY!
M*2$)NP%!6Z><2@FM'N!FED?I&3NV:H.)+3=?M-% ES;C+<[K-9<U4MGT7%QV
MJ=49X8<8D2<?=ZQ5V9W61F;F]GWRFP*C]?3"']H"L9*%D4$Y<-[4?@.KP"G/
M0$<G,(?:CM"ZJ7P/\H[NLKH0_8M+R;]=T&.O7W?5V;AM@3"CBQ-%@U&^EL-(
MVJF#=)"<\3F*H&/[64@'TCJN^1H*:P\:KDZAR0X3SR]2.C\[G]7C[@WC5=Y+
M_%2E\04O;/P!]FZ7IQYK]O:FO)'UJQ64ZV^W]M!8C& 91.+D'BLF2/\% 45P
MR2@L);9V-NY2<'0A\$.Y_;Y8WT)X*"%$X13$+&.]!J/09LX*9.F<"$%FUGQ4
MP_=H&M<F'8& !P6\+87?I2?U.BSGT_G'V@CR_A.)]P!K\N 1QYJ.IVEJ92?N
MO>3F1$,)]"*3-YPL ^4+N]BP>$KUK(/IHD1KB_$(+4?W3=Y[[JW3%6\92R9"
M-G6J8+WGSD66P#I31(I2RHP#,]F+M6B!@P?]BTT$WZ7!>(\?-[G51;FZBZ0>
M%^'BXS)\_C1-+VH#V2$%0+L\]NCRG[UI;V1L+E_\#NL@B]J*?04R;27//@0H
M/%&([XV$8$V!9!/+*8MH=>NTSV.T'&ML[C]WFS<>I8XI1U=[KQ2H7"2XE#F@
M]:HVM7B.K;VQ'<@:UP UP<9] ]1:&5V:HEMUF'4AOYIN1H:O:W[\H*#H\:<=
M'PSM2&DC>W-EWLA_C=-YN)CJ=(4K9FA#(\\43-&I7KI<1XDY 9P^#<(:%IQK
MO B?HN=8N_,;+C]2_'U;Q"^JB%>?%Y??;CTW,<)Y9D0!^C/7*PX4.+0&M. N
M8='*6=-8"H=1.JYU:H:D^Q;J!&KKTFC]BA_#[')^4'41#[!4#QYQK'EZFJ9V
M:>FSZ?JZ;G2QJ17%>:U3W9(L-$XB[7,&HN 2E-7TE?89/&>H"6U*N $2T[L3
M>*S5VHC\M["NJ</[;[M!NTO19YDD^,1JM, <!),->$7(YU%$DDEC*>Q$V.A)
MYX&0=-](M==2ES9ITX-^GNI]:O./!QBDN__^6&OT!#6-3-&=-VR.+39YZFWS
MN"3ZS'RB[:9.C+"LGEF@!!NR=]ZZ)&3K>P!W)N[XX;_?>=&VH,%+[JT7'H2J
M=]\F@GDD,0 W7L4< [.N_6#@_>D<UT -@Z^'LX('UE^'YV&[-7 -WHAVXH:T
MT1K30A(Y.@Y.NWIBJPHX&S0(PY+)R2#/K8<[#M>8]M<ZYO@UA=UGM$I6$V>,
MHI7 06I5I\::2"M/&.)2N%PB4\FUSKS=I:#?9K$]M'[?)ATAY"[FGC[:ZK:1
MTK>+/V^L*2;,:+, %>L908X%0HYDS0T&J0UZT_RL:%\:QYUM,!#,!E54!T!\
MNYPNEA>S^=YAFH75:K,W;+26_WY^<;WQ*UREY70SLGVB,5$HHRV8R +4H ,B
MCQ2'Z"*2"]$9U?RJU3UI''>RP$! '%11'0#Q<DC9_:F1]U:7L<QC-D@Q=2B@
MA(UU8160DE:=ULQ+U3Q9LPMAXT[''0AR[572H9]_J\WY0XBS8]NN+Y_1L/EZ
M&U4G:,'6UM>,%2=?RI%:D\K@(V[FAZ#P3,7V%\0.V(+]/GW"?#XCE_'Z)2_/
MEW5M;<1[&\U<1Z4Y:"[KW*P:)M.^#5R*%'42,37O--J5MK';!]I@Y<'Y\1":
MZ3+W^43S\Q&6YWO/'+!E>T#+M%]SK<LY*\\%Z$(;CZJ7UH;"(Q3OF'<)%;.M
M%^U)&K?K?34WZ^/GZ7RZQLT+,Y;--[].O^"#][_^>CE3^XK&G[[]%OZ^6+ZL
M3N.]117)"90V(\AD*%@.@<)FBE/ YH(2G4ZFY.] <' BGU.;]SY(O'TK43]:
M[F(8Y(TXKFW-K?;V)(T1$5A 7@?_:8@N<\@N%JDVO1VM"TJ?(&?<I,?PX&RM
MD2[@]?/CR^K%62UC^Z^-!E]_K1U'>-\/*4IK[QUH6E04[X@$P6  K]!9$8//
MS?MGCZ%WW&3(Z0!Z,IUV&,-N'4EQL$_YU-,&&9XQH!_YY*@$5H(WNN1:;1\V
MES2 M[HF,I*S!1GJV'K:^Y C-&Y,]"M<3K^08FHG43VYW4CY+V$Z_W6Q6OTR
MOS6?_?+*KC![B\NR6)[5BX9OEH7(&)FQ!C *!<IF1W%=Y+0L+%<D'G2L=>5B
M<R8Z'M6Q#_X>WX_'4'87N_@V$:QNR>":\]5VUFE/NOGXLA3TU\5%2OW>_L"-
M+<EF7RM/?>WL(P<Z*$%;%).1E<S;=SZ>CKMQ7=B3KI .X-'!4<N-9#;]TK?$
M\_NB'B%-/\XWY3VK_\#\D2+,8826E+ R)0TB. I*>;W>RR</0H3"6&;9Y=9'
M.5TP/JY#?H+E]EQ U=5*?/$E3&>5EY\7R_=AAN\QG2\WM77O,"V(]=ET*[^:
M:\Z#!.UJDX*3$FC/]A"TBM;PB!;98(OH,)K'/2H] ?Y/H,JNH+O5 7W$\;Q<
MO==:N,5^"CI(%+52=#,XO%Z=D 30!FJ*Q5*P^6CZQBR,>^OG6)'&H(KN+,[8
M<LL>[4WO/RV6ZP^X/*L'F!=U./<3\#IEVGM* )=0@RJT-P4A'3#/)>U(Q@O5
MNKC_>*K'O>+S!'@^B3H[,-6O,*YO-J'[V]/]5"ASSGL;(:8J6FT$<<D,9-3&
MH\_"^M;I[7WH&_?^SL% .9B*.H#?M=!^^O93F%6'_OTGQ/5?EHOSSQ0(W!IQ
MY'71RGHP+-0)_YH$Z).$HDE\LF JLO7)WJZTC7NAYF"P&T0U71;?/#4;\^"3
MDAT>.N1,SP'/3?:9MJB*R8$'"SF)2%Y=H<"%=D= U$7)R$5,0XR%.]%DSQMW
MX7>\FO_X<K%ZX!,(@SQEQL X'NJE:Z*V 2-(G@-C+ 62SF NWI.DC=Y"/0B2
M'G?KVNFI2TNVP[C+@PW:[L\^P=#. <W;O<&-VJ/E%@UPDQDH0[N;DRH#6N%B
MXMI9TWP07]/1G;>23]^7:ST7O%\@9E-(F7O()E)@KNOV7N^#%YEYC<9EKX>K
M>CZ(Y*X&?^Z#GR?RAH.KKDM[]F""X:'&ZY$'M9X1.J19>FQ"9'&<:ZX3(4HI
M4$$5B%87,%YXB@99O=ZUM8$::%+H#=[OO^&GL)JFS62FV3FM@?OI<4]>@*/E
ME4JI:4,*/D(Q"ABGU:=,<D$-5_:Y%ZF=3AG=!T./&ZGAE-:E<=IECN?!!FN/
MAY]B'NF ANW1R9/1&ZE9%L"\IYW3"@&.MD[:O6P1Z(+-[=NM&D\EW93O!Y+<
M3]\N'_WF6LCWEH,7W'N5/ 4;BKC5(=->7;DM)11OBA$R?@<SN[^MTUFC^VC\
M3H=$>Q%WD!N],:SW!?;+?%/^4/5US?7M?!S*C-*#=?7"GCK7)R 9UA*+9U$8
MI9K/%#F0U'&KRYK"\)1*Z^SD\QU^P?DYKGXF";^F/6$Y#[.7YZLUQ22;>76_
M+N8?-[7W%Q7W/WV[V5O"[&9WN76&H;@I-E3/P))G8)R&$ V'E*RMXL@8ARLM
M;LW-N"5= V-\5-5WV&QQ9QC:P;[?MJ<T'6<XH#>W^] Y$9#[% 4([3@H4<>/
M"![!Z,23"1IU;NW>G6RHX>T5<NN5] TNO^!/WS[0<]Z4FH*^@7XIWON$%J3P
M I3B!1RW#+A6W"N!JOT]I@>0^5Q&&NZ#KJ?LVQ#:Z]!PW9HI\@K783H[<M3)
MU4,:SCK92M<)AIWXI*)6Q0&&.C.NIBB\81)\+HXP)M';UN,'!QQV<OWH=^&/
MWVCM+*=AMJEL.O_\>492_AW7&]A7I&\FYQE,7D-4PH+*@D-PW("W,D=A$5EN
MG5O<B\!^QY[L@YJ'MZ8.I:,N(H=K]OZV6/[CE_EFXOOJ'E/*D!LHA*1PJ Z.
MDDF!$W(SGT"IP*+6MG5&=P>RQHU7!X=;(WWT!;+:^[VB_;QVF]]CRD:BW1=%
MZT5)4,D)\/5V/H\Y)Q11!M:ZQW<'LL8-& <'62-]] 4RXF/BBI6&2P<EJ0#*
M>PXQ>B0[')BL(E*R_=WI-^\?MW5F<-CL*^'#?>S%.LQ./>/K&)_[NP\=<,K7
MD#[Y?N-!A([:!51@3-V@ D5BKM1&$L9]\3I$JUM?)S7:F*^+C-IWIT ]&/HT
MT9ZDA*PV(]0V?HP2 J.ODF3)6^X%NS])?:>)7H?2\YR&=^V#KZ>&=YU$=QT<
M7CTQ<N<V;R^^3E>3R+2M1>)@HZDM\BJ3!Z =T&>E1-0YA-:-JGN0-PY*Q\/.
M[K.3CE)DWQB]8>SW<(:O%F=A.I]X(RQS+D+@NC:0IP)1R 3.1V%LY,;JYC.!
M]B-QY($V0T%E=T@>K;<185F7_-NPOFPU_+ ,&<_"\A^KW_ LXG(2(M?6^ 3%
MYCJ#QS#B0CD(@=9S8@X-IATV[\??T"UXCE?JHKF$.S!?FT+@![*Z9$7IG*7F
MX'4=6F>M!H=.@N""1X/9<]/Z"/T)<D:>(G0"9+7622?IC<M<8,W0$"UUX/\K
M_(*SQ>=:5'#)%EELJ23%XJ)H\HQY($N>:A):YLQ+0I:;S[_:B;"19^F<$'3M
M]=2!==O#R=TX%$99%2-YMEYE#DK[:K>=@QB#DYC)Z1W@J&HO$L>Q@MT$$D,J
MM'^\;E_T5B82IP)OC0,5"H=(JQ$*QD@60%IG6X_^.(#,L0]9!X3-?A ]6H<=
MP/2!T^NT5AJU &]<O<H\:X@L1N#,!4F"U"RW3K[T%7@,KO1%0PV,'9Z>DW<1
M5E5*N[@<43A445&0GY.I%\!$XBQYX,FAQ,*"#SN%K'N]=>Q#^M.@:6!M=&"I
MKIHX7J1_GD\O)H9M#+SUDFFG%6B;&"@5-/D@61 ;-CLMG2<WI+'!>H24<2*,
M;ARZ%@KJ%&?URR5>K<^B8U+2,M LT,))-M9Y.A)*$K18BY:A^=BK[Q(U[I[9
M1/4[P.EP/8R\4?Z$RS/\Q_0LQ$OC:PW9VL0S6%V0W%*1(%K:Y!4M0(=:!WN_
M2WOK5GC_N?W!X B5+1K)KP.C\OX\KO"?YR3#U[6 I5:,;Q9(ML8HJ1W0_N[)
MWDH+4=-7UCKA(NW)&INW-FTG99QZH6XVKQ8*ZA-GERO/2<51%0&6(SF52B+X
M8&G5E)2,D2&;T+IL_5%B1FXW;J'J[\/G +GW!Z!+:RNM2M$4VL)#*J!<H5#!
M.088G56:>?3-+_+>2DAWP#E$R4]#YP")C^S;[&6U?R4'X9<UGJTF,K'HM7(@
M@B>9B4P<DE-89Y0:G74.L; =/*##WC[._.W1=[L3J:L#.W:?D=]Q_> 6S.MB
M/JZ8ST9*L$$&\DJC!B^5!/J,>>D#"Z6U>=N'OO$JSDZ!E0<Y]X$4U\41^A/'
MP,3H33=^EK'4JQV*MA;J.$N(6#R4D%) J8GMUF'!;I2-G9H?"AN[5Y0=JJ;>
MX?>7Y6*UFK @;6:"-A4GZA@(-.!T*" ,L\BM+SJT+IO_'DW=EJ$=C(3=P;:_
M4GJ'V:W!E;>O6ITHZ57D*,#%0,&7*!9\O3!!RF \*ZS>#7PZX#U"9;=U:R>
M8@O%[0].?P'..7ZL+S[!%CQ)Q9&ODAR0]"(H7HL^R6L!JXPO-AB6FQ\G/4U1
MMW5K)P#=O@IIUN4W6-W/X_Z*S=%H15%<X36/K>O%D)XS,,(6="$K9=MW'Q]&
MZ]A'ZB?R D^BRBXV['TYG:@L7<Y2@$1B3DF=('*&8*4W(I;D2A@;K&.'*J?
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MQ6K#(*B1[#M T>W#_1LF: 'X*!,#:>JXSZ(UU(-:*$R5H$PPOGFMXU9"QBU
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MF(@NH0P1N,N1ED?J^:EOOO$^_MG"[0'A *5-:DFP ;NROB0I)OCN%8\-7OI
M(1.TL0LWSCD50"8=O'9%T;7K?IY3,:P3U.A9=J"RFH/;N9NGSY/IZ%\+^2PW
MD(O$2>($D)1Q R5MP63T#;DT+/G@B9?U.X[^C*JA.TL>IO<7872P$AJ U9;G
MTHQXXQ77(&W4Y;FT BM\AI1D5(1IRT1MEZC%%^ZU]=WMK?HNPF\ 0B]VS9?.
MNB0#[C%*/0B6!5@;+! BN<Q$9FV:&Q+>VS"W1@_':@IL"HP;NNM')I57Y2EJ
M4K;,M4-Q68TG@;&12AH(]?T-'3JI81<[:7V781>[J* !.+TP1B$S89Q#PQ]+
MCU\A @8NCD0P*:/T/#-1U7?V3W"DQ4X:?^9O51%_ T!Z>; Y<<EDZS0$HR0(
M+SD8*@FD$"G13#@46^UJFX.GRQ^AGVIE.-530A,]X;L.?(F:^J@$>I$^AU*X
MZ=&?C&C6D\S(IHZ2U*Y J#F)YPA=X2OCK _%-(&X!]WF[G_Y^RA-D:PO/]ZF
M[^EFX3VP2)A/R$@,Y3HS6@F>2@-!"N6YH-[+VM%C-\J&>3_2N/O?@U+; NNC
M$N5G'"[WNR7!6>889$;1^D<FP DN0.$&Y5)1)D-O+5*[$-A(^6!%C&R#875U
MM87&10O$V4)F='D.")VD4^AO\,QQ]QI/P'C/P2J5,T^4!]<;]IZ3TPC2ZL-@
M&^ .U$BS\&*KZB(M&"64@?2VM%TB**04$T1J1,*3@1I:^U[@!7(:J;48!%[[
M:*19>/$E,QIC;\U12-;Q#"*4<96$)0@LFD2I=]P? UZ\A9!B6'CMHY$FX+7[
M?*Z[J[S(F0@"HR:M2E-?P\ 0]'\5#3R@C:;9UF[WLA^EP[P6;CSN.(+2&TC\
M;6!CN?M#("8PYG'/)UD:M&=D)#N(&9T/H5G LZ$R>K<2TTK^N#\D3/I02P/X
M6A\N=QRM4DO!L1A= A-)22A1 XY+Y"=[/ XTLST>RH\H&199E=2\[>S=7^8M
M(>?9Z CFH[4QLU)Q($ XP< ;]%!<#"8)FHG1M?L@'#8NIGHOA,:/SCJJ:PF#
MM4=(<".4)XJ %!PCK++'C2 !O&"&.&>B)K4'X?Y/&S"S$]2.-6!F%[TW@/\M
M%6">:VT5LR!S*:IVIDRFQC/%4*_Q_RQ+LN].2"V<WFV@I%O1WBXJ:P!X#XZS
M>RF_O6]M[$WP7)9&BE&)\AZ[/#"+"8(6/AB6N-/]!=8;".H$0_,_S FHI\*F
M\+@. >_:!-VW2J'94Z.RP/.&$A!1&3QOA(1DT-^VEC&1CE%*^IBJ5@+G@R'0
M(3ES@#[:S3*^&9>]F69W1\S9NDG5-;':ZT@=6&W+8S>+X1PS%I3E&O^G;-2U
MFT7M1F$KV*N#D"[9P3K*:A^,#SH$/&02_6WG*<D0J-,@<L0-G9#)Y!57FD<G
M>6VW< \R6RD>/#XL*ZBM"6PNZR17%6P;>7XWF:^\F13/9DL'Y\$_6.S11UN4
M)26(-J!CZ5J0J09'- ,MC+"&6RNJ-T+JA9%6BA9[P??PJO_WV0$K<_#CH2BX
MXS10KX!8##B%Y F5DR-HGK.T66I6_8UP;\P,^YKJ%';"P1!H8C<\37G\^OW=
MZ)HJ1I5*%!0KMQU..8PNF(8D1>G[G+26M9O#;Z)CV)+>GC%XL. ;B.S/OJ,T
M%FW#)],R+V'-3>EHM/[=M6'!.!<D>"%RF?JLP#-FH?3 #\X398RO#*BNM U;
MO]$SR'I14 / 6_4N.9]\]:.[I%M)RJ&!1OGAKV8C5)N[ZWJ]M-+73-FLREVP
MI-*7]EP6+"41B";HHI#@<7=5QN >9 Y[)]HS'/M66P/(7$OPWBEXG]=_N'"?
MKWFY6_/<@Y>E)ZJ3#CSE#'@23GN1"=>UPZ4N=+42W?>7\*RDDZ9PMB#_GK'?
MRONT![O',>)2J4 5I5R4$P?.. 9&I2!E0 ?5UWY]VHVR5B+M_K!632^[H\W>
MH6V</I?@Y:HOT,VN%9<J2"-!RT59%)=@I4/W59G <BQ#=FM7$SVEH95 M6<@
M[2;K_0W49.YNCG$0KK<"=RXJF1/H+%!(*7BPRA#0A 2=J#$HIN,>AKL9J2,$
MH$<^$/?335.'XCT+CPWPW5%/DB<L!PHRBS*2M+2D#\J#RD3*R$6(U6=!=:.L
ME5BT/[Q5TTN+A^*#.Z)K&KDE5!/@QJ.UCD& +X^ A/6*^!QRUOW=YST@I)5X
MLG]([2KU!L[(34_*RFR^9U5OL\=E;[/'17+WFVIU(^,DI>A,>F\BB*S1K92E
MBUV(DBCET;F,E:'7"R/#5H;U!]WAM3[XG.W2)7B3&/[900R/I7"^:/?S9GPQ
MFX^^%L.^OHM1PD?-6025: "A2MFF<!&XE#D;X@G*Y/$^V-BVN6\Z.\'<G@[,
MF]-M X[IOEM^RX[_<#L-7]P,#SSA;<904$ VL=R^DP1&4P4N.D(9Q\"P>ME0
M7[QT*WDCI[,1FE+^O]\FN$SS^<W=*_QK*I7D+FM(@6'D8!0'8V0 KYC,EG*B
M4RLNS\^YZ;813K#PN!$ M!,Z]N,)^DQ#H(9!6'0@\4F#MUH""RJ@*&*(K+=)
MN$?W_^D)WD<-K_9&1K7_X:9_3_/"[KH4X<$,<?3OC/610(IEAK@*$2P)!FA:
MW,;QG'SM5R$O4]0-D2=X:U51$:<RS/W<S;Z4_Y4ZK._NIOR1&\=-@J@\SGWW
M#_<RT/U _H\QTIT)ETG.%J)D"#N/Q[L+@H%)2F7G14BVMUZC/8QTOPQ?4KR]
M2>]SD?O9.#X1_]VS0:6=XI9P-.,:F:8\@<M6@%5""1*RE*GV=5@GPAIY+GPH
M3IY:OOI*:2#2>C/.D^G7Y;O5Y6B3'^6&[[[F[\?BF7_R+&01(\C$R^N5Q8"N
M)($Z;=!C-II7[TW>D;1AT=8#*)YUOZ^OH0: MQB%>_7%C:_2UV^3J9O^>//U
M&V[=<N*<(SFC>6G[E!9^[>?QZ%\IOAE?N.D87=K9:@1/FKW/Z^$\L_M9=$[B
M=H[ M2QM%0/#/5ZF U"5N7,L!E$[J.F-F:$''_4 O4TCD0?'00,;XO=T$^=(
M^7PAUV>=)82VA/K((/ERX\TI*3VK7*FTH%DX19*K[>&\3-&PT&P$-L_ZR573
M80.(O'\2@%9@]NA)P&KZBA/.<<D @\GRA"DQ0$O@('IAN)'9JE3[%=O/:!JV
M,+E-5%;58P.XW##.,>#Y0ZD+8*1%!XO+"*4>#8+,GCIAH\NUK>.>,U=[P]XQ
M/-&#Y-X<<C9.<M1,,!$P..3&41".!K#,<]2_L-19_$/2[_3>DQB?NI/>=Q^?
MNHL2&H!5V6FK\5$BTF@<AZ@S4NY+[Z_L/+@81;!<)2IK7R^NO]X23 [7Z]-Q
M2OL)N0%X7$Z^I\4K\L<O*5=.80R!E\L8G0TM \\5.H7(4; Y+^JTC*H]]N-%
M@H8]Q7H&43U5M("K>_K?3MPXQ??3R\E-_#1&#9U]GJ:[Y/W5Y&/ZMJP#6;(9
M$K&X2WSQ]#!<9^5YB,H>I"/4QAR"L+43)'N2.NS3K[ZQ> 3U-8#2\\FTA$+S
MM''+49VX1<(@D?*Z#>4)O@R,LH*1X*UC5-=VW%\D:-@W8GT?H=54T0"N_IB,
MTX^[2\A?;\?QWH8;%KEFNKR/-" 2_F 2RB>4"#D%CING=IGC9DJ&?1'6,Y(J
M"+\!"+URX[]?C;[B=O@VF8WFZR:^%HVJQ,@XN9*<(P2\DPI(S%R+1*GPM<_'
MS90,^\BK9PA5$'X#$/IT>35=E$K\.!O'WXIW.2X26S)CO!/"1PDYH%<II#=H
M4I$MP[B-UB(,=.WN2"\2-.P3KYX!54\5#>#JU]'8C</(W:R[J]Q=M;F(88ET
M$&7I<!J,!\^,A)AH2OB7.:;:/;FWD#*L;]Y_MK.&!AH TM74C6?XY1G*Z#)-
MOX_":/SY?=[ W:SLRMGFOUJ-J@LN>Y8Y1$5+>_M0MJ=C$+0BF?*@D?_*Z*M)
M_\"%234 -6E$NPT@^V5[GZ0DS&0-T6GT(Y@)X'G*$"E1UE,EA*E=L'3XT=L;
M]H;#R4Z']"Y*:P"!+V<3E=*<4T<@B](1@^(QY),S@!%20.AP047M+G(-)W:;
M06 ]I36 P)<S.J(TO2\#ADUT9;I=V4XT9F#:,/P+QU)U&WAX<JTWE[$9!-93
M6@L(W.A^O[U_:\*=M<K3#(FCM$0,! QA$MD1/@27RH\]7(B^0-*P*=[^ Y>:
M&FD 8*6F[FKRQ[.:NL4DKU$>I7A?W6^,-#88E)5%IT$PJ\%I7T8L&)^"3U2Q
M/FHDNU$WK -8%10;JAY[T%##V+NF5*),'(HK>'148Y9@B8T0B>%,J2S163@2
MTH8>K=N/[CM";"=%--#&:1L?9R'<?KV]*6_&/XVG]]6AOT]N(CHII6CT.CMD
M)RN!+H8T($PPX$2YK;-.>$K04ZW>JVE_:H>--08&965E'MJ$H%?@KOOL6&M]
ME"X"E9&@)(D!0SD&4HE%P[TCAM:^-?LI4<,&' /#<#_5-'#J;A]%<"\O#(-\
M$CH#40J#I,#*P.&,,9,6R6-@%B6IG5OY.57#&KT^/;S*&FD08X]#\;.OD^F\
MV.SSR6R^Z*!Q[5GRH?1-HMY9$![Y\\YI8%ZP;*D3FM<NT]R5QF$]P=H8^0D$
MJRJL <_P)_RM78I%%]SB5[B;PG!Q)UZ5ESWIROUY[;ECB3&&8"H%@@3/$9\<
M QF2\RI*97/M?L55"!_6= X+W1Y4VX3+V'FBD+3,^V@S<+)H5X]BM<8L)@0&
M](=*+9DXVF&^Q\BGWAS((^.RBH*:&%7W9(<]X1.]I,<^\[TT'4G",2L@ZH#L
MJ5QF\HE46H>F1 ,S4=1&XIZD#@O,/GW-8^BN 0=TLPC/YN=N.OTQ&G]>1FY*
M9.]% ,D,QH79>C!)$ C6,!JIDE[5KF;N1-C00\>/ )%.MRJ'Z*L!$&[JX76^
M[.06 V>*,@6"<X)&/V8P,DB@/**S89RGLK8K^0(Y0P\<.S[@:NFF 9AM:"!7
M[N"_8,QVE:9?'W0[N+8H$454!A]$1(FQ\K XH*O+-->6>J^K%\UTIV[H263#
M6+T>-#<@)DO/^>Y<O1R<70N5I-3< 8VIE&XR"EX&#L:BK$7)Z*LG]?T;YP;4
MHF?H 6?'P^=@6AR^(_1NK&\8B!"]":1T?R6Z#/#ER*F+-H -22>J>;2:5 7M
MGH,L>IR6UBI0#]36J3347=5 3?+#UD2/4Q!+Z==OJKO?QWMIK%M!#L=HKNN"
M=$Y2 <J4=M$\N')9'4%K;JR14?O<6Y?X'IKKOISV6LO[T9W"NH-LL$GC#Y"Y
ME!CA10,^<0XJ)**,-M[WGF'?B>"&F_'N@JO=<I<UE=A _-25V3(98#1^/T[_
ME=ST$>?7-DNNB"\5)I2"D$Z#$=9"RJ@"+PWWM/8<\<.I;O5"LSK$]@1W)7V?
M$,+/,GX3&;[Z,IW<?O[RZ^C[@O?'.KC6E"0=M07-.1H6DM"A%_B#X<0*RF2*
MHK>^E#48:/4VM!7<UT?!J6V!PO*2^ZLTWL"\,=Y:HRRHTI>YU#H@\R5VT")Z
M*8.SIO;%054&6KUX;6H+5$7!"6V!R]'X\TU:Q>>O,6#>5/\C8\3][I%C:_ $
MM ILUAHP6,]96I9IK-U[HR;]P^;RVM\ U3'08 W8#KRO1$\5[OG@!7AMR[13
MPL%ZR8$D%+UV6;$PE.NSG>IA_9W!8]1*ZCPA _XH<%GG.ADGV6CG2G_\! +W
M*W);&HEYGHFC5-+@6PA2=\MC#QZ@UL)7C2AU/V6?$+2WQ29KQH5WT5++@2=%
MEM<(Y2X_2A^EU$RDZNU7JQ%_&I'IP("O"X%3P_Z&H&3-.'4$MSN3R#CUZ!GJ
M#"X; ]F)I))$]FCMCA35B#^-D+0%[%>#P EA_[G<KX7UVIE2K"\(0]]1:7#1
M>V"Q9*2(I#X.Y<X\I_8TXLV!T7V@DJN%F#W?S]_WO5G-C4;6QY/Y\I]$-U^'
M3'7OYG?_<"_W\@?R?XP[>8_(2EEHX#&6-KFQ] LJF0V5E)+$Q^Q.Z4[^?NU7
M/UZY&Q1^NOR2TOPW/$.^X9Z[:XJCE35$" ME.^,.QQ^<HA2TC%*(Y!,RWQ?/
M+]#5\ W[+BC9.GJ^EDH:.,R+-7_2?=/8D-%>.^"F/*#R*8(U/@&Q3%/F5%"D
M=CW'<RH:@5 U36]XTG. V)L#SCOW-2W[P"TF.B+OR()#'T I!=8E"APWF^2:
M4R-J/PO?1LOP;W(.T?&+D-E3X .7F9^I7S1'1I"!8I7C;4)=\OLV?SDYDU$N
MPB SD3OPV7"@@@2C.)'(3X<JW)>^T1(@]M7@I =Q#@T+_@O7\MUD_I0'4EJQ
MJ!Q!FIQ A,C!"8N'MXE>:F%TLJH+)+:L/_P3JKIPJ"'&H:% ?D$W;,'#ZP4/
M8LF##80IX@A06B;<1:G %Z$X(UR(5F87;1<H;%E_^(=,=:%00XQ#0T'^LI$%
M(S07/"A@W!077FDPGMHR$4,20Z(EKLL3HRW+#_]BJ"X0*@AQ:!RP7Q1[:-;D
MDH?H#4L)'7 ?1;DEP[/.!1) ,Z.8"X+FIX.M-@-AR_K#/\FIBX0:8AP:"D0^
M0O.*!2M9,L8S")9K$,8:]'44@:!B<%82&T(GUW'S\L,.G>KA;#A<B$/C@/TB
M'D)9K0;VI8!>+Q-@J8GHZ%A1:E,X2!6SE1ATL:?W"]LLPJ;EAYT5U8=!.%B(
MP^/ /F1!+UEPU*%*K0-'<BB=SCC&V=:"$312)R3W3_.BVW"P:?E..#"GA(.#
MA3@T#LB2@]>/.(B<:&H8VC&=T<DI56K6!@F6R22H\$8]?::WY5C8M'HG%-C3
M0<'A(AP:!(AC0AX V:QFZ*A <XCHZWJ/!LT7#"=E(#BE(\U>!]4)!EO6[Y94
M(J>#A!IR'!H+]!?ZR,E9\6"53L'*",1SC'\%#6"8D$ ]H\Y:;M"J=<'"EO6[
M8>&$,HPUY#@T%M3C\\VN_!PE.$FYM Q*K, 9/1ZB/2BB W<LB!!I%RAL7KX;
M$DXHN5A!BD,#@7+R ,N<K.Q:L)E;DP&/. F"%9&P,FU-:*%P"<Y\Z&03-B[?
M#0@GE%JL(,6A@2 0RT_N33A?>SQHP00K]R9(/4>CYB1!CI07FC,J1-!=T/#"
M-[I!XH22C+7D.3PN'EV@W/. 03!W(90<*>>([?+FI?0T]#D8E;SPW';*+VU9
MOQL>3BC56$..0V.!/KY!X:LT66*2.6\$*)80SS82\))1(-883;+@5';"PI;U
MNV'AA+*-->0X-!;X+_(AG%>9,DNSSEDE4)R5"B#JP2O\%5.:>":UE+R3X[!Y
M^6Y(.*%\8P4I#@T$^<@)YJLLB>'"([5HS0+%DRTY@DZP8>!BY$'AWY"GDWZV
M74EN6KX;$$XHX5A!BD,#@3^^3+OGP4?KK,\63"A637D%AAH+B?+,D[#H$K-N
M)F'C^MV@<$)9QQIR'!X+XF&^C*]R)%FC5R,<!>5$N6/7 KPO,Y2EMCEPZ:GO
ME&#8LGZWZJ43RCO6D./06)"_F&>1T(H/FK(AB@JPUJ-@O"1@',9$/,;D U%X
MZ'4L7-GZC6Z8.*'\8RUY#HT+\8LD3_@0J\P)4JH<1VDP52)D0A1XP0Q$(T,.
MD3,M.]U6OO"-;K@XH6QD+7D.C0M4X3HVNN= &))4>0): F80PI?Q,J&\#0T\
ME&Q:?#K9=,N-U:;5NV'AA!*2A\MP:!0(M'+K@T_0E1-$J$5J&++@"Q_*@G.T
MM"RDV6FF**4=#<.FY;OAX*2RD =+<7@@R <>D+C/FRE/@\D*CS:B092)J#9F
M_,%ERGWF5-%.GL/FY;L!X:32CP=+<6@@\%_T0Q96N1(75=#6(X+1AN'1QEVA
M/@!GS/)$> Z=QBML6;X;$$XH]UA!B@T X:%16\7'.2JBD520.B00D1KPM(Q5
M"E(I&2273R<$;@7"AN6[ >&D4H\'2W%X(,B'T;$P]\>;U<DC>E.,Y7ASZ.WF
MY( 8:8WW/,>GS9.V)J$WK=\-"B>4?*PAQZ&QP-C#*Q6Y<GF](SH[CY(0I?V&
M5P%\< YR]!@K>^:$[U;VNG'Y;D@XH=QC!2D.#@3QD 6U8D&;,GO*>+"^O#.F
MDJ!(%"V3]R+G@27G72<@;%R^VUNY$TH\5I#BP$!84?\A34>3^.LHSU,:+]G@
M B,@ESPH*RBR@8;-*"<AZQQ"R@APTN69U N?Z :(T\DZUI)F VT:'G2R>-#/
M9]$+^*XC =6,&QT!MX %830%)]'LH94+PL4<A:L]!>,G)#72^K:OSA\U%=(2
MOM;-=LK X[.OD]OQ?+;<AREEG8)60'(9SLD-*8/:-7"E1):,)"I<7R![@:YF
M>LP<#H1M(*NEE0:0]J'T,D?5K%N-;>!R::193LRS6!ZXBS)MFTGP+!1+S8HS
MCY;;L<J VX&\1G!7#1N3XRBJ 0RN1EM_3-^0R13OA+:=O<PLETX3P-,A@4@4
M8TJ/7D@T(?%,A%.I=D^Z'4D<%HN]0>79T-[^]+8W++^GJ9]4 N9J3.;[W$&2
M1)5WWA1=6)UQ<QO*P2IEP29)"08W/,K:';IVH6]8!_!8D.Q-8PV8R;5KL\&%
MOF\E>HE*7?@\Y^Y;$?GL[6B\.(IFUY&)()-CP!1C('2,I8=M@DS+F!Y#*!']
M127[T3QL Z$CABU'4&D+$%ZQM$XLK)O@GLUF:3[;)(EUHU&C',-MZR!0X4$$
M+L!8BTS;[%C)*VFI:D/X0)H;\4N/@K"G\#ZFNEN']X,>SS]A6L3@<M1@<D*#
M$O!L,C9;R$H4P\(LH?J8&.]*^,! /RK6=@%Z+XIO .WW@^5?3:;3R3\+*]=)
M&IN<H<!TE""L%^ X]^!--A:=*D=3[;D;&\AH&(G]@&%25S,-@.OM!/TKY*#<
M0KR;C,/MM(C^7CHR\QR8<T@^BDA0K\&)I$%&GZV.21!?>^3%RQ0-G%\?TOA5
M5%6SP+MF/NALJ07A;.&"EP[WTJ* >,HB<4])[=SG9DJ&M6TU==T)1CL)O@'X
M/+XU?3/&E=-L_A'=ZX6/'3^D:2@*^YRN<XA,HE @>(6>M61E7FXIH^7$<N6T
M];GV_4UWZ@8.O(>T9SVIL#EP_NI"NDO97IN@6=09Y6,2[C1J SAI*7#GA7.&
M,"5KNVW;:!FV4W!#P-M3/0W [-?)-(T^C\\7%CS\N/@S?''CSZGLH*NI&\]N
M%NJDBZG)+ H-RI!4IA/BQHE& 6$I&,-M2KSZ!78WTH9M4CQL*-N#\JIALMX\
MLC=C_&6Z<G^6T6O[SA;;L,BA<\)^1E>EF5_WGUE?BMRCAS,1&&42 C$!!%$8
M)!++\(SSGC&N:'K: /S@;?D".0??X>6<PGST/=U_HT#Y?#*>C\:WN&O>?TO3
MA8IFUR%QQI+-(%,D95(P>J\R4+#,1,;1"Q6L]HBF[M0-Z_?7PLNS^[I^M-/
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MWX=!FA!8Q.!8<4;+>V +QB!O3*L03;;,J]I/=%XDJ)&RFJKG:CT-M &G1Q5
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M$#)KI4G \R!@-,Z] ^]X!&>8Q1V7E*6U[5TGPH9%W?%\LOI::N"4?<[4YGS
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MO]Y,_OE[BI_3AX7@E^Q9(JQ#(P]>E$;5(G"PW$<(@AJE'<N*]6@ NY X[(.
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M6SKH)C>[=YMBIBYZEM!/0H])2$' :&N!<&%(M"$$V\75W+;^P"%&/=W7D-_
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M+P_LS!SQ_N] J3>%F2O\+U9/7FV(+!L*U J,XECD8$P9Q>ZM1MP[Q9XVM*V
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ML6?7CS/:'(VPS I?F 8PI.>TJBD_,=3<,8B\ S1>^/P81YH=BX<6'!Q!\/-
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MSI=5'?SU9E.K M._+>;KZR5]8F,6U'^SJ?3$?%_HN7ET0$@8#-T;3B:F*T-
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MJ?0]<-F!R@7/J+F:,GZ$0_E(,Z\6Z[1:+VC#/\.B3MK]CL>/A'O]>Z<.ACN
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MN4M6V_8OZB\1EOA?__'_4$L! A0#%     @ 6H!;50G?E/NJ!P  ^"   !X
M             ( !     &$R,#(R,W%E>#,Q,6-E;V-E<G1I9FEC871I+FAT
M;5!+ 0(4 Q0    ( %J 6U4.":2^J0<  *DD   >              "  >8'
M  !A,C R,C-Q97@S,3)C9F]C97)T:69I8V%T:2YH=&U02P$"% ,4    " !:
M@%M5P=4$"@4&  #=)P  '@              @ '+#P  83(P,C(S<65X,S(Q
M8V5O8V5R=&EF:6-A=&DN:'1M4$L! A0#%     @ 6H!;5>_Y:ROW!0  QB<
M !X              ( !#!8  &$R,#(R,W%E>#,R,F-F;V-E<G1I9FEC871I
M+FAT;5!+ 0(4 Q0    ( %J 6U7E75#F$T4$ #7,/0 0              "
M 3\<  !J;FHM,C R,C$P,#(N:'1M4$L! A0#%     @ 6H!;58O(5SN:%P
M//P  !               ( !@&$$ &IN:BTR,#(R,3 P,BYX<V102P$"% ,4
M    " !:@%M5P=";<R,D  "N9 $ %               @ %(>00 :FYJ+3(P
M,C(Q,# R7V-A;"YX;6Q02P$"% ,4    " !:@%M5']>LC4F$  #C>04 %
M            @ &=G00 :FYJ+3(P,C(Q,# R7V1E9BYX;6Q02P$"% ,4
M" !:@%M5(S,-@R66  !IJP  $P              @ $8(@4 :FYJ+3(P,C(Q
M,# R7V<Q+FIP9U!+ 0(4 Q0    ( %J 6U5370L/W3L  /=.   4
M      "  6ZX!0!J;FHM,C R,C$P,#)?9S$P+FIP9U!+ 0(4 Q0    ( %J
M6U7"H))Z[%D  !1P   4              "  7WT!0!J;FHM,C R,C$P,#)?
M9S$Q+FIP9U!+ 0(4 Q0    ( %J 6U4JO?AW^FD  #&!   4
M  "  9M.!@!J;FHM,C R,C$P,#)?9S$R+FIP9U!+ 0(4 Q0    ( %J 6U4U
M\+"QB5H  %EU   4              "  <>X!@!J;FHM,C R,C$P,#)?9S$S
M+FIP9U!+ 0(4 Q0    ( %J 6U4LO9YO#7\  &>0   3              "
M 8(3!P!J;FHM,C R,C$P,#)?9S(N:G!G4$L! A0#%     @ 6H!;54B,1@<+
MC0  1:   !,              ( !P)(' &IN:BTR,#(R,3 P,E]G,RYJ<&=0
M2P$"% ,4    " !:@%M5Z\&9IH5T  #0A0  $P              @ '\'P@
M:FYJ+3(P,C(Q,# R7V<T+FIP9U!+ 0(4 Q0    ( %J 6U6Z)_>\@DL   QB
M   3              "  ;*4" !J;FHM,C R,C$P,#)?9S4N:G!G4$L! A0#
M%     @ 6H!;58DV;G:N.P  -4X  !,              ( !9> ( &IN:BTR
M,#(R,3 P,E]G-BYJ<&=02P$"% ,4    " !:@%M5?8B(5-M)  #G7P  $P
M            @ %$' D :FYJ+3(P,C(Q,# R7V<W+FIP9U!+ 0(4 Q0    (
M %J 6U69[*9-*CD  !A,   3              "  5!F"0!J;FHM,C R,C$P
M,#)?9S@N:G!G4$L! A0#%     @ 6H!;52POA08>2@  [UX  !,
M     ( !JY\) &IN:BTR,#(R,3 P,E]G.2YJ<&=02P$"% ,4    " !:@%M5
ME4B1"5,T 0 ;< P %               @ 'ZZ0D :FYJ+3(P,C(Q,# R7VQA
M8BYX;6Q02P$"% ,4    " !:@%M5 TH>#<BV  !W_@< %
M@ %_'@L :FYJ+3(P,C(Q,# R7W!R92YX;6Q02P4&     !< %P %!@  >=4+
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
